PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Antelman, D; Perry, S; Hollingsworth, R; Gregory, RJ; Driscoll, B; Fung, YK; Bookstein, R				Antelman, D; Perry, S; Hollingsworth, R; Gregory, RJ; Driscoll, B; Fung, YK; Bookstein, R			Engineered mutants of pRB with improved growth suppression potential	ONCOGENE			English	Article						retinoblastoma; E2F; promoter repression	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; BLADDER-CARCINOMA CELLS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; TERMINAL REGION; T-ANTIGEN; RB GENE; DEPENDENT KINASE	We have constructed a panel of substitution mutants which affect one or more of the putative cdk target sites of the RB protein. We have examined the activity of these mutants relative to wild-type RB by both a transcriptional repression assay and by measuring growth suppression in vitro. We find that some phosphorylation site mutants of pRB can repress E2 transcription more strongly than wild-type RB. These mutants are partially resistant to phosphorylation by cdks and can arrest tumor cells in G1 in vitro. Our results indicate a functional correlation between the ability to repress E2F-dependent transcription and the ability to suppress tumor cell growth in vitro. In addition, we describe two classes of RB mutants: N-terminal truncated p56(RB) and a novel mutant of RB containing multiple substitutions near its nuclear localization signal. Both classes of RB mutants have greater activity than the mild-type protein. Because RB is a key regulator of cell cycle progression, expression of a more potent, phosphorylation resistant RB may have utility in both RB(-/-) and RB(+/+) tumors as well as in hyperproliferative disorders.	PHARMACIA & UPJOHN INC,KALAMAZOO,MI 49001; GENZYME INC,FRAMINGHAM,MA; CHILDRENS HOSP LOS ANGELES,DIV OPTHAMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	Pfizer; Sanofi-Aventis; Children's Hospital Los Angeles; University of Southern California	Antelman, D (corresponding author), CANJI INC,3030 SCI PK RD,SAN DIEGO,CA 92121, USA.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KITAGAWA M, 1995, ONCOGENE, V10, P229; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; OOKAWA K, 1993, ONCOGENE, V8, P2175; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; Xu HJ, 1996, CANCER RES, V56, P2245; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	64	8	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2855	2866		10.1038/sj.onc.1201465	http://dx.doi.org/10.1038/sj.onc.1201465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419977				2022-12-17	WOS:A1997YJ80300012
J	Afshari, CA; Rhodes, N; Paules, RS; Mudryj, M				Afshari, CA; Rhodes, N; Paules, RS; Mudryj, M			Deregulation of specific E2F complexes by the v-mos oncogene	ONCOGENE			English	Article						E2F; mos oncogene; cell cycle	MAP KINASE KINASE; CELL-CYCLE REGULATION; MURINE SARCOMA-VIRUS; TRANSCRIPTION FACTOR; XENOPUS-OOCYTES; PROTO-ONCOGENE; MEIOTIC MATURATION; TRANSFORMED CELLS; THYMIDINE KINASE; MAMMALIAN-CELLS	The product of the c-mos proto-oncogene is a protein kinase that is normally expressed in germ cells and functions during oocyte maturation, It has been shown, however, that inappropriate expression of either the viral or cellular mos gene can induce neoplastic progression in somatic cells. Furthermore, v-mos-transformed NIH3T3 cells will undergo arrest of proliferation in early G1 upon serum withdrawal but are unable to appropriately downregulate cell cycle regulatory proteins, such as cyclin and cdc2 proteins, that normally are down-regulated in quiescent, untransformed NIH3T3 cells. Since the levels of these proteins are partially transcriptionally controlled, me investigated whether there were alterations in the expression of E2F and AP-1 transcription factor complexes. Indeed, the putative G0/G1-specific p130-E2F complex that is normally observed during low serum-induced cell cycle arrest in NIH3T3 cells is not present in serum starved v-mos-transformed cells. instead, G1-phase arrested v-mos-transformed cells stably express two E2F protein complexes that are normally observed only during S-phase in untransformed cells, The elevation of these complexes in arrested v-mos-transformed cells may be the cause of the transcriptional activation of the E2F-regulated genes cdc2, DHFR, Cyclin A, and E2F1 seen in serum starved v-mos-transformed cells. In addition, there are high levels of AP-1 DNA binding activity in serum starved v-mos-transformed cells compared to very low amounts in nontransformed cells. This altered regulation of transcription factor complexes and cell cycle control proteins upon serum withdrawal may provide a mechanism for the uncontrolled cell growth associated with neoplastic transformation induced by certain proto-oncogenes.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27705; DURHAM VA VET ADM MED CTR,GRECC 182,DURHAM,NC 27705; CTR STUDY AGING & HUMAN DEV,DURHAM,NC 27705; NIEHS,GROWTH CONTROL & CANC GRP,RES TRIANGLE PK,NC 27709; UNIV CALIF DAVIS,SCH MED,DEPT MED MICROBIOL & IMMUNOL,DAVIS,CA 95616; MARTINEZ VET ADM,MARTINEZ,CA	Duke University; Geriatric Research Education & Clinical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California Davis				Paules, Richard S/0000-0001-9106-7486	NATIONAL INSTITUTE ON AGING [T32AG000029] Funding Source: NIH RePORTER; NIA NIH HHS [T32AG00029] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CANAANI E, 1979, NATURE, V282, P378, DOI 10.1038/282378a0; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LAMB EWF, 1993, EMBO J, V12, P2705; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LESTER SC, 1980, SOMAT CELL GENET, V6, P241, DOI 10.1007/BF01538799; LIU SH, 1994, CELL GROWTH DIFFER, V5, P447; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V246, P603; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RHODES N, 1994, EXP CELL RES, V213, P210, DOI 10.1006/excr.1994.1192; RICHTER KH, 1991, CANCER RES, V51, P6010; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHONTHAL A, 1990, New Biologist, V2, P143; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SINGH B, 1988, ONCOGENE, V3, P79; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	52	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3029	3038		10.1038/sj.onc.1201157	http://dx.doi.org/10.1038/sj.onc.1201157			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223666				2022-12-17	WOS:A1997XG10000005
J	Atanasoski, S; Schreiber, E; Fontana, A; Herr, W				Atanasoski, S; Schreiber, E; Fontana, A; Herr, W			N-Oct 5 is generated by in vitro proteolysis of the neural POU-domain protein N-Oct 3	ONCOGENE			English	Article						EMSA; transcription; DNA-binding; protease inhibitors	OCTAMER BINDING-PROTEINS; DNA-BINDING; TRANSCRIPTION FACTOR; IMMUNOGLOBULIN GENES; MOTIF; ACTIVATION; PROMOTER; EXPRESSION; ELEMENTS; CELLS	The neural POU-domain proteins N-Oct 3 and N-Oct 5 were first identified in electrophoretic mobility retardation assays through their ability to bind to the octamer sequence ATGCAAAT. These two N-Oct factors are detected in extracts from tumor-derived and normal neural cells. They are present differentially, however, in extracts from melanocytes and melanoma cells: N-Oct 3 is present in extracts from both melanocytes and melanoma cells, whereas N-Oct 5 is more evident in extracts from metastatic melanoma cells. We show here that a cDNA encoding N-Oct 3 directs synthesis of both the N-Oct 3 and N-Oct 5 proteins and that the N-Oct 5 protein in neural and melanoma-cell extracts is also related to N-Oct 3. N-Oct 5, however, is apparently not expressed in vivo: It is not detected if cells are rapidly lysed in SDS or if extracts are prepared with a cocktail of protease inhibitors that includes the serine-protease inhibitor 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF). These data suggest that N-Oct 5 is a specific in vitro proteolytic cleavage product of N-Oct 3 and is not directly related to melanocyte malignancy.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV ZURICH HOSP, DEPT INTERNAL MED, DIV CLIN IMMUNOL, CH-8044 ZURICH, SWITZERLAND; CALYDON INC, MENLO PK, CA 94025 USA	Cold Spring Harbor Laboratory; University of Zurich; University Zurich Hospital			Herr, Winship/E-6491-2012; Atanasoski, Suzana/A-3275-2011	Herr, Winship/0000-0002-3606-4546; Atanasoski, Suzana/0000-0001-7340-0775	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGUS J, 1995, ONCOGENE, V11, P691; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CLEARY MA, 1993, GENE DEV, V7, P72, DOI 10.1101/gad.7.1.72; DAS G, 1993, J BIOL CHEM, V268, P25026; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; SCHREIBER E, 1992, CANCER RES, V52, P6121; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	31	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	1997	14	11					1287	1294		10.1038/sj.onc.1200953	http://dx.doi.org/10.1038/sj.onc.1200953			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178889				2022-12-17	WOS:A1997WP10900004
J	Ligon, AH; Pershouse, MA; Jasser, SA; Yung, WKA; Steck, PA				Ligon, AH; Pershouse, MA; Jasser, SA; Yung, WKA; Steck, PA			Identification of a novel gene product, RIG, that is down-regulated in human glioblastoma	ONCOGENE			English	Article						glioblastoma; chromosome 11; differential expression	TUMOR-SUPPRESSOR GENES; HETEROZYGOSITY; ASTROCYTOMAS; LOCI; RNA; AMPLIFICATION; CHROMOSOME-17; TRANSCRIPTS; EXPRESSION; DELETIONS	Genetic deletions to chromosome 10 have been extensively documented for human glioblastomas (GBMs). To identify gene products that may be involved in malignant progression, a subtractive hybridization was performed between GEM cells and hybrid cells suppressed for tumorigenicity following microcell transfer of chromosome 10. One novel cDNA isolated from this subtraction showed consistent upregulation (similar to 4 to 10-fold) that correlated with the nontumorigenic phenotype of the hybrid cells. Subsequent analysis resulted in the identification of a full length cDNA (2,569 bp) termed RIG (regulated in glioma). RIG expression was either not detected or detected only at low levels in cultured glioma cells and primary glioblastoma specimens compared to normal brain cells. The 2.6 kb RIG mRNA was expressed predominantly in normal brain with lower levels in heart and lung. Sequence analysis showed no significant homology to known gene products, Genomic alterations of RIG were present in similar to 25% of glioma cell lines examined. Also, RIG mapped to chromosome 11p15.1, a region that is known to be altered in malignant astrocytomas. The differential expression pattern, tissue distribution and chromosomal location of RIG suggests it serves as a molecular marker for or may play a role in the malignant progression of GBMs.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BRAIN TUMOR CTR,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [R01 CA51148, R01 CA56041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051148, R01CA056041] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BIGNER SH, 1988, CANCER RES, V88, P405; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; DOWDY SF, 1991, NUCLEIC ACIDS RES, V19, P5763, DOI 10.1093/nar/19.20.5763; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FULTS D, 1989, CANCER RES, V49, P6572; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; HUTCHINS JT, 1991, CANCER RES, V51, P1418; JABER M, 1994, NEUROSCIENCE, V61, P245, DOI 10.1016/0306-4522(94)90228-3; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KHAN AS, 1992, NAT GENET, V2, P180, DOI 10.1038/ng1192-180; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P348, DOI 10.1002/gcc.2870050411; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Sambrook J., 1989, MOL CLONING; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SONODA Y, 1995, CANCER RES, V55, P2166; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WINGVIST R, 1993, CANCER RES, V52, P6646; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YUNG WKA, 1989, CANCER RES, V49, P1014; [No title captured]	36	8	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1075	1081		10.1038/sj.onc.1200925	http://dx.doi.org/10.1038/sj.onc.1200925			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070656				2022-12-17	WOS:A1997WM07000009
J	Ciossek, T; Ullrich, A				Ciossek, T; Ullrich, A			Identification of Elf-1 and B61 as high affinity ligands for the receptor tyrosine kinase MDK1	ONCOGENE			English	Article						MDK1; Elf-1; B61; RAP in situ; organogenesis; midbrain	GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; EPH FAMILY; GENE; EXPRESSION; HINDBRAIN; CLONING; CELLS; PHOSPHATASES; PROTEINS	Mouse Developmental Kinase 1 (MDK1) is a receptor tyrosine kinase of the eck/eph subfamily expressed in a variety of tissues during early mouse embryogenesis. To obtain further insight into the function of MDK1, we determined identity and localisation of its physiological ligand(s). Staining whole embryos,vith fusion proteins between the extracellular domain of MDK1 and human secreted alkaline phosphatase revealed areas of high receptor binding in the caudal mesencephalon, the frontal neocortex and the limb buds. This staining was sensitive to treatment with phosphatidylinositol-specific phospholipase C. Using Scatchard analysis, high affinity binding of Elf-1 (1.7 x 10(-10) M) and B61 (2.2 x 10(-10) M) towards MDK1 could be demonstrated. However, the transmembrane ligand Lerk2 displayed no measurable affinity for MDK1. Elf-1 and B61 bind to the three full-length MDK1 isoforms with similar dissociation constants. Slightly lower affinities were observed for the two truncated receptors MDK1-T1 and MDK1-T2. The activation of MDK1 with Elf-1 or B61 leads to the rapid autophosphorylation of MDK1 as well as tyrosine phosphorylation of an unknown 62 kDa phosphoprotein in Rat1 cells. These findings implicate MDK1 in patterning processes during early mouse embryogenesis and suggest MDK1 involvement in early organogenesis and midbrain development.	MAX PLANCK INST BIOCHEM,DEPT BIOL MOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society								BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen J, 1996, ONCOGENE, V12, P979; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CIOSSEK T, 1995, ONCOGENE, V10, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; ELLIS J, 1995, MECH DEVELOP, V52, P319, DOI 10.1016/0925-4773(95)00411-S; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; FRIEDRICH R, 1991, VIROLOGY, V183, P343, DOI 10.1016/0042-6822(91)90147-4; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; Holash JA, 1995, DEV BIOL, V172, P683, DOI 10.1006/dbio.1995.8039; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Kenny D, 1995, DEV BIOL, V172, P708, DOI 10.1006/dbio.1995.8083; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORI T, 1995, MOL BRAIN RES, V34, P154, DOI 10.1016/0169-328X(95)00154-K; Orike N, 1996, CURR BIOL, V6, P108, DOI 10.1016/S0960-9822(02)00435-9; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Patel K, 1996, DEVELOPMENT, V122, P1147; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; TAKAHASHI H, 1995, ONCOGENE, V11, P879; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UENO H, 1992, J BIOL CHEM, V267, P1470; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	49	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					35	43		10.1038/sj.onc.1200800	http://dx.doi.org/10.1038/sj.onc.1200800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010230				2022-12-17	WOS:A1997WB76000003
J	Qin, XQ; Barsoum, J				Qin, XQ; Barsoum, J			Differential cell cycle effects induced by E2F1 mutants	ONCOGENE			English	Article						restriction point; cell cycle withdrawal; E2F1; mutants; cell survival	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F-1; SUSCEPTIBILITY GENE; GROWTH SUPPRESSION; S-PHASE; DOWNSTREAM TARGET; FIBROBLASTS LEADS; BINDING PROTEIN; DNA-SYNTHESIS; EXPRESSION	Expression of two types of transactivation-defective E2F1 mutants in human Rb--/- tumor cells led to an increase in the proportion of cells in the G(1) phase of the cell cycle as determined by FAGS analysis. Experiments revealed two different mechanisms of action. One mutant type induced a G(1) arrest after the restriction point, with cells phenotypically at a cell cycle stage later than G(1). The action of this mutant was, at least in part, dependent on specific DNA binding and was over-ridden by coexpression of its wild-type counterpart. The other mutant type, which is defective in DNA binding, slowed the G(1) progression and restored a checkpoint for cell cycle withdrawal. The G(1) phase withdrawal of these tumor cells allowed the initiation of skeletal muscle cell differentiation. Thus, E2F1 appears to have two different functions before and after the cell cycle restriction point. This report also may provide a basis for a gene therapy approach for certain human cancers.			Qin, XQ (corresponding author), BIOGEN INC,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANERJEE A, 1992, CANCER RES, V5, P6297; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3028; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KOFF A, 1992, SCIENCE, V257, P1989; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lin SY, 1996, MOL CELL BIOL, V16, P1668; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1995, TRANSCRIPTIONAL CONT; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU HJ, 1991, CANCER RES, V51, P4481; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	8	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					53	62		10.1038/sj.onc.1200809	http://dx.doi.org/10.1038/sj.onc.1200809			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010232				2022-12-17	WOS:A1997WB76000005
J	Feo, S; DiLiegro, C; Mangano, R; Read, M; Fried, M				Feo, S; DiLiegro, C; Mangano, R; Read, M; Fried, M			The amplicons in HL60 cells contain novel cellular sequences linked to MYC locus DNA	ONCOGENE			English	Article						HL60 amplified DNA; c-myc; chromosome band 8q24; homogenous staining regions; double minutes; FISH	HL-60 LEUKEMIA-CELLS; ONCOGENE C-MYC; GENE AMPLIFICATION; CHROMOSOMAL LOCATION; HUMAN NEUROBLASTOMA; BURKITT-LYMPHOMA; TUMOR-CELLS; CARCINOMA; TRANSLOCATION; EXPRESSION	We have previously determined that the amplified DNA present in the HL60 promyelocytic leukaemia cell line contained 70 kb of continuous DNA sequences around the c-myc gene, In the work presented here we have further defined the HL60 amplicon and find it to be of the order of 160 kb and to contain a large region of DNA from chromosome 8q24 that is located at Least 260 kb telomeric to the c-myc gene, joined to the 70 kb of DNA from the c-myc gene region, The novel chromosome 8 DNA coamplified sequences are not lost during multiple passage of HL60 cells since the composition of the chimeric amplicon is the same in both early passage HL60 cells containing only double minutes (DMs) and late passage isolates containing homogeneous staining regions (HSRs) at different chromosomal locations, This shows that the HL60 HSRs found in late passage cells are not generated anew but are directly derived from the precursor DMs. The HL60 cells contain tao copies of chromosome 8, each with different polymorphic markers, Both these chromosome 8 homologues retain a c-myc gene as sell as the region containing the coamplified DNA sequences indicating that the HL60 amplicons were not generated by simple DNA deletion, The constraint to maintain the novel DNA sequences coamplified with c-myc gene DNA suggests that these sequences may play some role in maintaining the growth potential and/or differentiation capacity of the HL60 cells.	IMPERIAL CANC RES FUND,EUKARYOT GENE ORG & EXPRESS LAB,LONDON WC2A 3PX,ENGLAND; DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90128 PALERMO,ITALY; CNR,IST BIOL SVILUPPO,I-90123 PALERMO,ITALY	Cancer Research UK; Consiglio Nazionale delle Ricerche (CNR)			Feo, Salvatore/C-1333-2012	Feo, Salvatore/0000-0003-3877-2906; Di Liegro, Carlo Maria/0000-0001-7362-7814				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BAR AI, 1992, GENE CHROMOSOME CANC, V4, P314; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BRENNAN J, 1986, NUCLEIC ACIDS RES, V14, P9224, DOI 10.1093/nar/14.22.9224; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CORVI R, 1995, ONCOGENE, V10, P1081; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DONTI E, 1991, CANCER GENET CYTOGEN, V56, P57, DOI 10.1016/0165-4608(91)90362-X; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEO S, 1990, NUCLEIC ACIDS RES, V18, P4949, DOI 10.1093/nar/18.16.4949; FEO S, 1994, ONCOGENE, V9, P955; FEO S, 1986, P NATL ACAD SCI USA, V83, P706, DOI 10.1073/pnas.83.3.706; FRANCIS F, 1994, GENET ANAL-BIOMOL E, V11, P148, DOI 10.1016/1050-3862(94)90035-3; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; GALLAGHER R, 1979, BLOOD, V54, P713; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM SV, 1985, LEUKEMIA RES, V9, P239, DOI 10.1016/0145-2126(85)90086-4; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HEARD E, 1991, P NATL ACAD SCI USA, V88, P8242, DOI 10.1073/pnas.88.18.8242; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LEHRACH H., 1990, GENOME ANAL, P39; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P65, DOI 10.1093/hmg/1.1.65; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; TYLERSMITH C, 1981, J MOL BIOL, V153, P237, DOI 10.1016/0022-2836(81)90276-X; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VONHOFF DD, 1990, J CLIN INVEST, V85, P1887, DOI 10.1172/JCI114650; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P220; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	39	8	8	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1521	1529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875990				2022-12-17	WOS:A1996VL38400017
J	Little, MH; Holmes, G; Pell, L; Caricasole, A; Duarte, A; Law, M; Ward, A; Wainwright, B				Little, MH; Holmes, G; Pell, L; Caricasole, A; Duarte, A; Law, M; Ward, A; Wainwright, B			A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers	ONCOGENE			English	Article						Wilms' tumour suppressor protein; Wilms' tumour; transcription factor; Zinc finger binding	DENYS-DRASH SYNDROME; FACTOR-A-CHAIN; GENE-PRODUCT; DNA-BINDING; TRANSCRIPTION FACTOR; UROGENITAL DEVELOPMENT; PROMOTER ACTIVITY; POINT MUTATIONS; SEQUENCE; KIDNEY	All isoforms of the Wilms' tumour suppressor protein, WT1, contain four consecutive zinc fingers which facilitate DNA binding. The predominant WT1 transcript contains a 9 base pair insertion resulting in an additional three amino acids, lysine-threonine-serine (KTS), between zinc fingers 3 and 4. WT1 zinc fingers 2, 3 and 4 are highly homologous to the zinc fingers of the early growth response gene, EGR1. However, only WT1-KTS is capable of binding an EGR1 consensus site. In contrast, the previously described genomic fragment, +P5 (D1S3309E), is bound by both WT1-KTS and WT1+KTS. In this study, the region within +P5 to which both WT1-KTS and WT1+KTS bind was defined as 5-GGAGAGGGAGGATC-3'. EGR1 did not bind +P5. By creating zinc finger deletions, we demonstrate that zinc finger 1, but not zinc finger 4, is critical for +P5 binding; whereas zinc finger 4, but not 1, is necessary for the binding of WT1 target sites within EGR1, PDGF A chain and IGF2 promoters. Thus, zinc finger usage can vary with target and +P5 may represent a novel type of WT1 binding site, the physiological relevance of which must be investigated.	UNIV QUEENSLAND, DEPT BIOCHEM, BRISBANE, QLD 4072, AUSTRALIA; UNIV OXFORD, DEPT ZOOL, CRC, GROWTH FACTORS UNIT, OXFORD OX1 3PS, ENGLAND	University of Queensland; University of Oxford	Little, MH (corresponding author), UNIV QUEENSLAND, CTR CELLULAR & MOL BIOL, BRISBANE, QLD 4072, AUSTRALIA.		Little, Melissa H/A-6170-2010; Duarte, Antonio/V-1178-2018	Little, Melissa H/0000-0003-0380-2263; Duarte, Antonio/0000-0002-9255-3635; Wainwright, Brandon/0000-0003-0406-2092; Ward, Andrew/0000-0001-8311-5695				BAIRD PN, 1992, ONCOGENE, V7, P2141; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARICASOLE A, 1996, IN PRESS P NATL ACAD; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; HUFF V, 1991, AM J HUM GENET, V48, P997; KENT J, 1995, ONCOGENE, V11, P1781; KONIG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Negus K, 1996, CYTOGENET CELL GENET, V72, P306, DOI 10.1159/000134210; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; REDDY JC, 1996, IN PRESS BIOCH BIOPH; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; SZABO J, 1995, AM J HUM GENET, V56, P944; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Ward A, 1995, GENE, V167, P239, DOI 10.1016/0378-1119(95)00645-1; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	47	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1461	1469						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875984				2022-12-17	WOS:A1996VL38400011
J	Liang, YX; Robinson, DF; Kujoth, GC; Fahl, WE				Liang, YX; Robinson, DF; Kujoth, GC; Fahl, WE			Functional analysis of the SIS proximal element and its activating factors: Regulated transcription of the c-SIS/PDGF-B gene in human erythroleukemia cells	ONCOGENE			English	Article						c-sis/PDGF-B; K562; Sp1; Sp3; TPA	BOX-BINDING-PROTEINS; GROWTH-FACTOR; PROMOTER; EXPRESSION; FAMILY; PDGF; CIS; IDENTIFICATION; MEMBERS; CLONING	The SIS proximal element (SPE) is essential for the basal transcription of the c-sis/PDGF-B gene as well as the lineage-specific, activated transcription of this gene seen in megakaryocytes. In gel mobility shift analyses, the SPE element forms three gel-shift complexes; the t(op) and b(ottom) complexes were detected in nuclear extracts from both untreated and phorbol 12-myristate 13-acetate ('tetradecanoylphorbol acetate', TPA) treated K562 cells, whereas the m(iddle) complex was detected only in nuclear extracts from TPA-treated g562 cells. Site-directed mutagenesis of the SPE revealed CCACCC motif that was essential for promoter activity as well as the formation of all three SPE gel-shift complexes. Nested-deletion analyses showed that the SPE was required for TPA-inducibility of c-sis/PDGF-B transcription. Antibody supershift analyses demonstrated that the t gel-shift complex contained both Sp1 and Sp3, and that the b complex contained only Sp3. In vitvo transcription assays demonstrated that both Sp1 and Sp3 could support c-sis/PDGF-B transcription independent of each other in untreated K562 cells. However, overexpression of Sp1/Sp3 failed to significantly increase the c-sis/PDGF-B transcription in K562 cells.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, R37CA042024, T32CA009681] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA07175, T32-CA09681, R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1991, BAILLIERE CLIN ENDOC, V5, P595, DOI 10.1016/S0950-351X(10)80005-9; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKSRPH, 1995, NUCLEIC ACIDS RES, V23, P1119; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLEMING TP, 1992, ONCOGENE, V7, P1355; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; FRANKLIN GC, 1995, ONCOGENE, V11, P1873; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARTINET Y, 1987, NEW ENGL J MED, V317, P202, DOI 10.1056/NEJM198707233170404; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203	25	8	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					863	871						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761308				2022-12-17	WOS:A1996VD43300022
J	Pereira, DS; Kushner, DB; Ricciardi, RP; Graham, FL				Pereira, DS; Kushner, DB; Ricciardi, RP; Graham, FL			Testing NF-kappa B1-p50 antibody specificity using knockout mice	ONCOGENE			English	Article						NF-kappa B; p50; antibody specificity; knockout mice	SUBUNIT	Cell extracts from knockout mice can provide definitive proof of antibody specificity. Two NF-kappa B1-p50 antibodies, sc-114 (a commercial antibody) and NR1157, were observed to recognize proteins having distinct electrophoretic mobilities of 52-55 kD and 50 Kd, respectively, by Western blot analysis. In order to discriminate the specificity of these antibodies for NF-kappa B1-p50, whole cell extracts derived from NF-kappa B1-p105 knockout mice were employed. While the NR1157 antibody completely failed to recognize its 50 kD product in p105-/- knockout extracts, the sc-114 antibody still strongly recognized its 52-55 kD product. These data demonstrate that NR1157, but not sc-114, is highly specific for NF-kappa B1-p50 by Western blot analysis. In addition, these results highlight the utility of knockout cell extracts for discerning antibody specificity.	MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8S 4K1,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4K1,CANADA; UNIV PENN,SCH DENT MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,GRAD GRP MOLEC BIOL,PHILADELPHIA,PA 19104	McMaster University; McMaster University; University of Pennsylvania; University of Pennsylvania				Kushner, David B/0000-0002-6260-5094	NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29797] Funding Source: Medline; NIAID NIH HHS [5-T32-AI0735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Kushner DB, 1996, ONCOGENE, V12, P143; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; *SANT CRUZ BIOT, 9495 SANT CRUZ BIOT; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8	5	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					445	446						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710386				2022-12-17	WOS:A1996VA25200026
J	CAMUS, C; HERMANNLEDENMAT, S; JACQUET, M				CAMUS, C; HERMANNLEDENMAT, S; JACQUET, M			IDENTIFICATION OF GUANINE EXCHANGE FACTOR KEY RESIDUES INVOLVED IN EXCHANGE ACTIVITY AND RAS INTERACTION	ONCOGENE			English	Article						RAS EXCHANGE FACTOR; HUMAN; SACCHAROMYCES CEREVISIAE; ALAMINE SCANNING; 2-HYBRID	SACCHAROMYCES-CEREVISIAE CDC25; NUCLEOTIDE-RELEASING FACTOR; GENE-PRODUCT; SCANNING MUTAGENESIS; SIGNAL TRANSDUCTION; PROTEIN-KINASE; YEAST; RECEPTOR; GRB2; DNA	We have carried out a functional analysis of the human HGRF55 exchange factor in the yeast Saccharomyces cerevisiae. Twelve residues conserved among most of all known guanine exchange factors (GEFs) have been independently changed to alanine. Taking advantage of the ability of Hgrf55p to replace the yeast Cdc25p exchange factor, and using the two-hybrid system with RAS2(ala22) allele, we have identified key residues for the interaction with Pas and/or its activation. Substitution of arginine 392 to alanine leads to a complete loss of interaction with Ras, though the protein remains stable. Substitution of Asp266 or Arg359 to alanine results in inactive proteins at 39 degrees C, still able however to interact with Ras. The other charged-to-alanine substitutions led to no detectable phenotype when present alone but most of them dramatically increased the temperature sensitive phenotype observed with [Asp266Ala] substitution. Surprisingly, the cysteine to alanine substitution in the highly conserved PCVPF/Y motif proved to be without effect, suggesting that the sulfhydryl group is not essential for stability or interaction with Ras.	UNIV PARIS 11, INST GENET & MICROBIOL,INFORMAT GENET & DEV LAB, CNRS,URA 1354, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Camus, Christelle/A-3141-2009	Camus, Christelle/0000-0001-6590-1713				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CAMONIS JH, 1988, MOL CELL BIOL, V8, P2980, DOI 10.1128/MCB.8.7.2980; CAMONIS JH, 1990, GENE, V86, P263, DOI 10.1016/0378-1119(90)90288-3; CAMUS C, 1994, MOL GEN GENET, V245, P167, DOI 10.1007/BF00283264; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HOWE LR, 1993, ONCOGENE, V8, P2583; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Miller JH, 1972, EXPT MOL GENETICS; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; PART D, 1985, CELL DIFFER DEV, V17, P221, DOI 10.1016/0045-6039(85)90496-8; PETITJEAN A, 1990, GENETICS, V124, P797; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; VANAELST L, 1990, EUR J BIOCHEM, V193, P675; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8	47	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					951	959						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675454				2022-12-17	WOS:A1995RU79800016
J	JACOB, ANK; KANDPAL, G; PATANJALI, SR; KANDPAL, RP				JACOB, ANK; KANDPAL, G; PATANJALI, SR; KANDPAL, RP			MOLECULAR-CLONING AND EXPRESSION PATTERN OF GENES FROM A 470 KB REGION NEAR BRCA1 LOCUS ON CHROMOSOME-17Q21	ONCOGENE			English	Note						CDNA; HYBRIDIZATION SELECTION; BRCA1 LOCUS; EXPRESSED SEQUENCES	FAMILIAL BREAST; OVARIAN-CANCER; POLYMORPHISMS; LOCALIZATION; FRAGMENTS; SELECTION; SEQUENCES; LINKAGE; CDNA	We have used direct cDNA selection to isolate expressed sequences from a set of four overlapping YACs, spanning approximately 470 kb of the chromosomal interval 17q21 centromeric to BRCA1 gene. Thirty-eight nonoverlapping unique cDNA fragments were identified in this region. Twenty-two of the selected cDNAs showed complete identity with known genes and expressed sequence tags. Two of these cDNAs shared sequence homology with genes known to encode potential DNA binding motifs and hence could function in transcriptional regulation. The remaining 16 unique cDNA fragments showed no significant similarity to sequences in the databases and could potentially encode novel genes. Northern analysis of the novel cDNAs showed differential expression in various tissues, supporting the transcribed nature of these sequences. Our results place the gene for a G-protein coupled receptor (GPR2) previously mapped to 17q within a 400 kb region on 17q21.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yale University					NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC001682] Funding Source: NIH RePORTER; NIDCD NIH HHS [DC-01682] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; BRODY LC, 1995, GENOMICS, V25, P238, DOI 10.1016/0888-7543(95)80131-5; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1993, HUM MOL GENET, V2, P821, DOI 10.1093/hmg/2.6.821; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL AP, 1994, SCIENCE, V266, P120; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; FUTREAL PA, 1992, CANCER RES, V52, P2624; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JACOBS IJ, 1993, CANCER RES, V53, P1218; KRIZMAN DB, 1993, FOCUS, V15, P106; LANDSMAN D, 1989, NUCLEIC ACIDS RES, V17, P2301, DOI 10.1093/nar/17.6.2301; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; OSBORNELAWRENCE S, 1995, GENOMICS, V25, P248, DOI 10.1016/0888-7543(95)80132-6; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PATEL K, 1991, NUCLEIC ACIDS RES, V19, P4371, DOI 10.1093/nar/19.16.4371; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P6565; PELTOKETO H, 1992, EUR J BIOCHEM, V209, P459, DOI 10.1111/j.1432-1033.1992.tb17310.x; Sambrook J., 1989, MOL CLONING LAB MANU; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SULTSON J, 1992, NATURE, V356, P37; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; Zhao H. G., 1994, American Journal of Human Genetics, V55, pA252; ZHENG Y, 1991, CELL, V655, P817	35	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	1995	11	5					981	986						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675458				2022-12-17	WOS:A1995RU79800020
J	PRESS, RD; WISNER, TW; EWERT, DL				PRESS, RD; WISNER, TW; EWERT, DL			INDUCTION OF B-CELL LYMPHOMAS BY OVEREXPRESSION OF A MYB ONCOGENE TRUNCATED AT EITHER TERMINUS	ONCOGENE			English	Article						LYMPHOMA; MYB; ONCOGENE; B CELL	AVIAN-LEUKOSIS VIRUS; C-MYB; DNA-BINDING; MONOCLONAL-ANTIBODIES; V-MYB; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; RAPID INDUCTION; CHICKEN; DIFFERENTIATION	The c-myb oncogene encodes a nuclear transcriptional transactivator that is often terminally truncated in hematopoietic tumors. To directly assess the tumorigenic activity of full length and terminally-truncated variants of c-myb, we have overexpressed several structurally-altered forms of myb within an avian retroviral vector and have shown that overexpression of truncated (but not full length) myb transforms both myeloid cells in vitro and mesenchymal cells in vivo. In vivo infection with these truncated myb viruses is now shown to induce metastatic B cell lymphomas in a significant minority of animals. Evaluation of the lymphomas revealed two distinct mechanisms of myb-induced tumorigenesis. In most of the lymphomas, proviral DNA inserted into the endogenous chicken c-myb gene and promoted the expression of a 5'-truncated myb transcript encoding an amino terminal truncated protein. In comparison, some animals infected with a virus encoding a carboxyl (C) terminal truncated myb (T-myb) developed non-insertional B cell lymphomas that directly expressed the provirally-encoded T-myb gene. The lymphomagenic T-myb protein lacks 214 C terminal amino acids including all of the myb transcription inhibition domain, This novel lymphomagenic activity for a C terminal truncated myb suggests that a loss of regulatory sequences at either end of c-myb is sufficient to create a B cell-specific transforming gene.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	The Wistar Institute	PRESS, RD (corresponding author), OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201, USA.			Press, Richard/0000-0002-2103-5144	NATIONAL CANCER INSTITUTE [R01CA057516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-57516] Funding Source: Medline; NINDS NIH HHS [NS-01551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABA TW, 1985, P NATL ACAD SCI USA, V82, P213, DOI 10.1073/pnas.82.1.213; CHEN CLH, 1982, J IMMUNOL, V129, P2580; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V210, P249; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; ONG GLS, 1984, SCIENCE, V226, P1077; PINK JR, 1983, HYBRIDOMA, V2, P287, DOI 10.1089/hyb.1983.2.287; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1992, J VIROL, V66, P5373, DOI 10.1128/JVI.66.9.5373-5383.1992; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; VELLARD M, 1991, ONCOGENE, V6, P505; VEROMAA T, 1988, HYBRIDOMA, V7, P41, DOI 10.1089/hyb.1988.7.41; VORBRUEGGEN G, 1994, NUCLEIC ACIDS RES, V22, P2466, DOI 10.1093/nar/22.13.2466; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010	37	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					525	535						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630637				2022-12-17	WOS:A1995RN53000013
J	GRIECO, D; SANTORO, M; DATHAN, NA; FUSCO, A				GRIECO, D; SANTORO, M; DATHAN, NA; FUSCO, A			ACTIVATED RET ONCOGENE PRODUCTS INDUCE MATURATION OF XENOPUS OOCYTES	ONCOGENE			English	Article						RET/PTC; RAS; MPF	TRANSFORMING GENE; TYROSINE KINASE; PROTEIN-KINASE; RAS PROTEINS; PROTOONCOGENE; CARCINOMAS; EXPRESSION; MUTATIONS; FUSION	The RET proto-oncogene encodes a transmembrane receptor of the tyrosine kinase family, recently found to be the gene responsible for the multiple endocrine neoplasia type 2A and 2B syndromes, RET was found specifically activated, by gene rearrangement, in human thyroid carcinomas of the papillary subtype, In most cases the activation consisted of an in frame fusion of the RET tyrosine-kinase domain, at the carboxy-terminus, with heterologous genes at the amino-terminus. These chimeric oncogenes are collectively named RET/PTC, Two forms of these gene products, RET/PTC1 and RET/PTC3, have been tested for their ability to induce meiotic maturation in Xenopus oocytes, Injection of RET/PTC mRNAs into immature oocytes induced maturation-promoting-factor (MPF) activation and germinal vesicle breakdown (GVBD), The injected oocytes expressed polypeptides recognized by an anti-RET gene product antibody as well as by an anti-phosphotyrosine antibody, indicating activation of the tyrosine-kinase domain, The RET/PTC induced maturation was dependent on endogenous ras; in fact, the coinjection of RET/PTC mRNA with a neutralizing anti-ras antibody blocked oocytes maturation without interfering with the accumulation and tyrosine-phosphorylation of the RET/PTC protein.	UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,CNR,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	GRIECO, D (corresponding author), COLUMBIA UNIV,INST CANC RES,701 W 168TH ST,NEW YORK,NY 10032, USA.			Fusco, Alfredo/0000-0003-3332-5197; GRIECO, Domenico/0000-0002-7131-5742				AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; LANZI C, 1992, ONCOGENE, V7, P2189; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALLER JL, 1985, P NATL ACAD SCI USA, V82, P272, DOI 10.1073/pnas.82.2.272; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1994, ONCOGENE, V9, P509; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SPIVAK JG, 1994, MOL CELL BIOL, V4, P1631; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					113	117						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624118				2022-12-17	WOS:A1995RJ29500014
J	KHANDJIAN, EW				KHANDJIAN, EW			HEAT-TREATMENT INDUCES DEPHOSPHORYLATION OF PRB AND DISSOCIATION OF T-ANTIGEN PRB COMPLEX DURING TRANSFORMING INFECTION WITH SV40	ONCOGENE			English	Article						HEAT SHOCK; RETINOBLASTOMA; S-PHASE; T-ANTIGEN PRB COMPLEX; HSP71; PROLIFERATION	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; LARGE-TUMOR-ANTIGEN; MOUSE KIDNEY-CELLS; SIMIAN VIRUS-40; SHOCK PROTEINS; SUSCEPTIBILITY GENE; NUCLEAR COLOCALIZATION; IMMUNOLOGICAL EVIDENCE; TRANSCRIPTION FACTOR	The effects of heat treatment on key cell cycle regulatory molecules is currently unknown. Using primary mouse kidney cell cultures induced to re-enter S-phase by transforming infection with SV40, the effects of thermal treatment on the phosphorylation state of the Retinoblastoma gene product (pRb) and on its ability to bind T-antigen were examined. Time course analysis showed no detectable inhibition of cellular protein and T-antigen synthesis up to 180 min treatment at 42.5 degrees C, while a gradual disappearance of the phosphorylated forms of pRb was observed after 90 min. Dephosphorylation of pRb was shown to correlate with inhibition of SV40-induced DNA synthesis. Also, large T-antigen/pRb protein complex was affected since a gradual dissociation of the hypophosphorylated pRb from large T-antigen was observed concomitant to the inhibition of DNA synthesis. The effects of heat treatment were found to be reversible after shifting the cultures to 37 degrees C. Cells were shown to resume DNA synthesis concomitant to the reappearance of the phosphorylated forms of pRb and rebinding of the hypophosphorylated form to large T-antigen within 6-8 h after recovery at 37 degrees C. In addition, no evidence for a bona fide hsp71/large T-antigen protein complex was seen under the experimental conditions used. The data strongly suggest that inhibition of DNA synthesis by heat treatment might involve either an increase in phosphatase activity or the inhibition of a pRb kinase activity.	UNIV LAVAL,FAC MED,DEPT BIOCHIM,QUEBEC CITY,PQ,CANADA	Laval University	KHANDJIAN, EW (corresponding author), HOP ST FRANCOIS ASSISE,UNITE RECH GENET HUMAINE & MOLEC,QUEBEC CITY,PQ G1L 3L5,CANADA.							ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; ANGELIDIS CE, 1988, EUR J BIOCHEM, V172, P27, DOI 10.1111/j.1432-1033.1988.tb13851.x; ANGHILERI LJ, 1986, HYPERTHERMIA CANCER, V1; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CURRIE RW, 1991, BIOCHEM CELL BIOL, V69, P375, DOI 10.1139/o91-057; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EHRHART JC, 1988, ONCOGENE, V3, P595; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FORTIN CA, 1994, MOL CELL BIOL, V72, P239; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLOVER CVC, 1982, P NATL ACAD SCI-BIOL, V79, P1781, DOI 10.1073/pnas.79.6.1781; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HENRIKSSON M, 1992, EXP CELL RES, V203, P383, DOI 10.1016/0014-4827(92)90012-W; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; ISSELS RD, 1988, RECENT RESULTS CANCE, V107; KHANDJIAN EW, 1983, MOL CELL BIOL, V3, P1; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; KHANDJIAN EW, 1988, ONCOGENE, V3, P195; KOSKINEN PJ, 1991, J VIROL, V65, P842, DOI 10.1128/JVI.65.2.842-851.1991; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LASZLO A, 1992, CELL PROLIFERAT, V25, P59, DOI 10.1111/j.1365-2184.1992.tb01482.x; LATHANGUE NB, 1987, BIOSCIENCE REP, V7, P475, DOI 10.1007/BF01116504; LEE WH, 1991, COLD SH Q B, V56, P211; LIM MY, 1990, VIROLOGY, V175, P149, DOI 10.1016/0042-6822(90)90195-W; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LUDLOW JW, 1993, ONCOGENE, V8, P331; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MACEJAK DG, 1991, VIROLOGY, V180, P120, DOI 10.1016/0042-6822(91)90015-4; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; NIHEI T, 1993, CANCER LETT, V73, P181, DOI 10.1016/0304-3835(93)90262-8; NOVER L., 1991, HEAT SHOCK RESPONSE; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; ROBERTS AB, 1991, CANCER CELL-MON REV, V3, P19; ROSE TM, 1992, BIOCHEM CELL BIOL, V70, P149, DOI 10.1139/o92-022; ROTI JLR, 1992, CELL PROLIFERAT, V25, P89, DOI 10.1111/j.1365-2184.1992.tb01483.x; SALZMAN NP, 1986, PAPOVAVIRUSES, V1; SAWAI ET, 1989, J VIROL, V63, P3961, DOI 10.1128/JVI.63.9.3961-3973.1989; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STREFFER C, 1987, RECENT RESULTS CANCE, V104; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; STURZBECHER HW, 1988, ONCOGENE, V1, P201; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WHITE E, 1988, J VIROL, V62, P4153, DOI 10.1128/JVI.62.11.4153-4166.1988; WHITSON RH, 1992, J CELL BIOCHEM, V48, P305, DOI 10.1002/jcb.240480311; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1989, ONCOGENE, V4, P807; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803; ZHANG KR, 1994, BIOCHEM BIOPH RES CO, V200, P522, DOI 10.1006/bbrc.1994.1479	71	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					359	367						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838534				2022-12-17	WOS:A1995QC62400015
J	ADACHI, M; MIYACHI, T; SEKIYA, M; HINODA, Y; YACHI, A; IMAI, K				ADACHI, M; MIYACHI, T; SEKIYA, M; HINODA, Y; YACHI, A; IMAI, K			STRUCTURE OF THE HUMAN LC-PTP (HEPTP) GENE - SIMILARITY IN GENOMIC ORGANIZATION WITHIN PROTEIN-TYROSINE-PHOSPHATASE GENES	ONCOGENE			English	Note							MOLECULAR-CLONING; PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE SIMILARITY; MOTH-EATEN; EXPRESSION; MUTATIONS; DOMAINS; KINASES; FAMILY; EXONS	Recently, various cDNA sequences coding protein-tyrosine phosphatases (PTPs) have been reported and their extensive similarities in the catalytic domains clarified, but knowledge of the structures and organizations of their genes is still limited. In this study, a detailed structure and organization of the human intracellular LC-PTP (also called HePTP) gene is reported. The 13 to 18.5 kb genomic clones encoding human LC-PTP have been isolated. The LC-PTP gene is organized into 11 exons, including the 5'-noncoding first exon and the 3'-noncoding exon. Splicing sites for exons 4 to 10, which encode the conserved catalytic PTP domain, arise almost at the same position as for the CD45 gene. This elucidation of the LC-PTP gene structure provides insight into the domain evolution of intracellular LC-PTP and transmembrane CD45, which may be generated by gene duplications of an ancestral gene.			ADACHI, M (corresponding author), SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED 1,SAPPORO,JAPAN.							ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1992, CANCER RES, V52, P737; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; ADACHI M, 1994, FEBS LETT, V338, P47, DOI 10.1016/0014-5793(94)80114-2; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GOKKEL E, 1992, ONCOGENE, V7, P1423; HALL LR, 1988, J IMMUNOL, V141, P2781; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ISOBE M, 1994, ONCOGENE, V9, P1751; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAI C, 1994, ONCOGENE, V9, P877; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; STREULI M, 1987, J EXP MED, V166, P1548, DOI 10.1084/jem.166.5.1548; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3031	3035						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084610				2022-12-17	WOS:A1994PG82200033
J	CARTER, R; YUMET, G; PENA, A; SOPRANO, DR; SOPRANO, KJ				CARTER, R; YUMET, G; PENA, A; SOPRANO, DR; SOPRANO, KJ			TRANSCRIPTIONAL REGULATION OF C-JUN EXPRESSION DURING LATE G(1)/S IN NORMAL HUMAN-CELLS IS LOST IN HUMAN TUMOR-CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE; MESSENGER-RNA; G0/G1 TRANSITION; BINDING PROTEIN; DNA-REPLICATION; FACTOR AP-1; FOS; GENE; ACTIVATION; FIBROBLASTS	Previous results from our laboratory have identified a second peak in steady state levels of c-jun mRNA (in addition to the immediate early induction) which occurs at the G(1)/S border in WI-38 normal human diploid fibroblasts. The present studies were undertaken in an attempt to determine (1) the molecular mechanism responsible for the expression of c-jun in late G(1)/S, (2) the relationship between this second peak of c-jun mRNA expression and the induction of DNA synthesis and (3) whether this cell cycle specific c-jun expression is deregulated in transformed cells. Our results show that the second peak in steady state levels of c-jun mRNA is the result of new transcription during late G(1) and not altered stability of the c-jun mRNA transcribed during G(1). We also show that this second peak of expression still occurs even when DNA synthesis is inhibited by either hydroxyurea or aphidicolin. Thus, the second peak precedes and is independent of DNA synthesis. Finally, we find that while two other normal human fibroblast cell lines exhibit a second peak of c-jun mRNA during late G(1)/S, c-jun expression is not cell cycle-regulated but rather is constitutively expressed in a number of distinct transformed cell lines. Since events occuring throughout G(1) are known to regulate cell growth, our results suggest that the extent of regulation of c-jun expression during G, may affect molecular events which ultimately lead to altered growth control as a result of cellular transformation.	TEMPLE UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231	NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ANDEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COSENZA SC, 1994, J CELL BIOCHEM, V55, P503, DOI 10.1002/jcb.240550410; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; GINSBERG D, 1990, ONCOGENE, V5, P1285; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KUNZE N, 1990, EUR J BIOCHEM, V194, P323, DOI 10.1111/j.1432-1033.1990.tb15620.x; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MELVIN WT, 1977, BIOCHEM J, V168, P595, DOI 10.1042/bj1680595; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NOMURA N, 1993, J BIOL CHEM, V268, P4259; PHILLIPS PD, 1992, J CELL PHYSIOL, V151, P206, DOI 10.1002/jcp.1041510126; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAKAI M, 1989, CANCER RES, V49, P5633; SAUVE GL, 1991, DNA SEQUENCE, V1, P13; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SINCLAIR WK, 1967, CANCER RES, V27, P297; SOPRANO KJ, 1992, ANN NY ACAD SCI, V660, P231, DOI 10.1111/j.1749-6632.1992.tb21075.x; STEIN GS, 1984, RECOMBINANT DNA CELL, P107; TAKEISHI K, 1989, J BIOCHEM-TOKYO, V106, P575, DOI 10.1093/oxfordjournals.jbchem.a122898; TAVALI S, 1989, J BIOL CHEM, V264, P7466; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1990, ONCOGENE, V5, P1055; WOODFORD TA, 1988, ANAL BIOCHEM, V171, P166, DOI 10.1016/0003-2697(88)90138-8; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZULLO J, 1987, P NATL ACAD SCI USA, V84, P1210, DOI 10.1073/pnas.84.5.1210	48	8	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2675	2682						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058331				2022-12-17	WOS:A1994PC05400028
J	SU, ZZ; SHEN, RQ; OBRIAN, CA; FISHER, PB				SU, ZZ; SHEN, RQ; OBRIAN, CA; FISHER, PB			INDUCTION OF TRANSFORMATION PROGRESSION IN TYPE-5 ADENOVIRUS-TRANSFORMED RAT EMBRYO CELLS BY A CLONED PROTEIN-KINASE-C BETA(1)-GENE AND REVERSAL OF PROGRESSION BY 5-AZACYTIDINE	ONCOGENE			English	Article							PHORBOL ESTER RECEPTOR; ANCHORAGE-INDEPENDENT GROWTH; GENE-EXPRESSION; FIBROBLAST CELLS; CHEMICAL CARCINOGENS; TUMOR PROMOTERS; LEUCINE ZIPPER; DNA-BINDING; WILD-TYPE; PHENOTYPE	Protein kinase C (PKC) is a key component in signal transduction in eucaryotic cells and when specific PKC isoforms are over-expressed in immortal mammalian cells they can induce transformation-associated properties. In the present study we demonstrate that a cloned PKC beta1 gene can induce an enhanced expression of the transformed phenotype in type 5 adenovirus (Ad5)-transformed rat embryo (RE) cells (clone E11), a process termed transformation progression. Ell cells expressing the PKC beta1 gene, clone B1/PKC, produce PKC beta1 mRNA and display enhanced PKC enzymatic activity and binding of [H-3]-phorbol-12,13-dibutyrate (PDBu) to cell surface phorbol ester receptors. B1/PKC cells grow with increased efficiency in agar in comparison with parental Ell cells and anchorage-independence is further enhanced in both cell types by addition of the tumor promoting agent 12-0-tetradecanoyl-phorbol-13-acetate (TPA). A single-exposure of B1/PKC cells to 5-azacytidine (AZA), followed by growth in the absence of this demethylating agent, results in B1/PKC-AZA clones which display a stable reversion of the progression phenotype to that of the unprogressed parental Ell clone. Loss of the progression phenotype corresponds with a reduction in PKC beta1-induced biochemical and cellular changes. In contrast, progression-suppression does not involve an alteration in expression of the Ad5 transforming genes, E1A and E1B, or the endogenous PKC epsilon gene. TPA cannot induce the progression phenotype in B1/PKC-AZA cells, but it can reversibly induce an increase in the transcriptional rate and steady-state mRNA levels of PKC beta1 and c-jun and it increases AP-1 DNA-binding. These results indicate that the PKC beta1 gene can serve as a transformation progression-inducing gene in rat embryo cells previously transformed by Ad5 and progression may be mediated by the inactivation by methylation of an AZA-sensitive 'progression suppressor gene(s)'. The suppression process in B1/PKC cells is independent of expression of the Ad5-transforming genes but correlates directly with the reduced expression of the transfected PKC beta1 gene in AZA-treated B1/PKC cells.	COLUMBIA UNIV COLL PHYS & SURG, CTR COMPREHENS CANC, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, CTR COMPREHENS CANC, DEPT UROL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, NEW YORK, NY 10032 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Columbia University; Columbia University; Columbia University; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA035675, R01CA043208, R29CA052460] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA52460, CA43208] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BABISS LE, 1983, J VIROL, V46, P454, DOI 10.1128/JVI.46.2.454-465.1983; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BACHER N, 1991, MOL CELL BIOL, V11, P126, DOI 10.1128/MCB.11.1.126; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1992, J BIOL CHEM, V267, P12892; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; FISHER PB, 1984, MECHANISMS TUMOR PRO, V3, P57; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; HALAZONETIS TD, 1992, ANTICANCER RES, V12, P285; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P197; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRAUSS RS, 1989, ONCOGENE, V4, P991; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NICOLSON GL, 1987, CANCER RES, V47, P1473; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOWELL PC, 1986, CANCER RES, V46, P2203; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1986, FEBS LETT, V203, P111, DOI 10.1016/0014-5793(86)80724-4; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1990, J BIOL CHEM, V265, P22434; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PERKINS AS, 1983, MOL CELL BIOL, V3, P1123, DOI 10.1128/MCB.3.6.1123; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; REDDY PG, 1993, METHODS MOL GENETICS, V1, P68; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCOTT RE, 1989, P NATL ACAD SCI USA, V86, P1652, DOI 10.1073/pnas.86.5.1652; SU ZZ, 1993, ONCOGENE, V8, P1211; SU ZZ, 1991, MOL CARCINOGEN, V4, P328, DOI 10.1002/mc.2940040412; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SU ZZ, 1992, CELL MOL BIOL, V38, P27; SU ZZ, 1992, POLY ADP RIBOSYLATIO, P203; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; WARD NE, 1992, BIOCHEMISTRY-US, V31, P5905, DOI 10.1021/bi00140a029; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINSTEIN IB, 1988, CANCER RES, V48, P4135	68	8	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1123	1132						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510863				2022-12-17	WOS:A1994NC04800015
J	WILSON, BA; KHALIL, M; TAMANOI, F; CANNON, JF				WILSON, BA; KHALIL, M; TAMANOI, F; CANNON, JF			NEW ACTIVATED RAS2 MUTATIONS IDENTIFIED IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Note							GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; GTPASE ACTIVITY; PROTEINS; YEAST; GENE; PATHWAY; IRA2; P21; GAP	Activating mutations in RAS proto-oncogenes encode proteins with greater GTP binding. Such mutant proteins are responsible for many human cancers. Six new amino acids were discovered that can yield an activated Saccharomyces cerevisiae RAS2 protein when they are altered. These new RAS2 alleles were found among a collection of 35 random mutations that exhibit a dominant reduction of glycogen accumulation. The RAS2-P41S and RAS2-E99K alleles encode proteins that have lost responsiveness to GTPase activating proteins. They affect amino acids in loop 2 and helix 3 respectively and illustrate that GTPase activating proteins recognize a larger portion of the RAS structure than previously realized. RAS2 mutations E130K, S153F, A154T, and A157S alter amino acids proximal to the guanine binding site and probably influence nucleotide binding either directly or indirectly.	UNIV MISSOURI, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA	University of Missouri System; University of Missouri Columbia; University of California System; University of California Los Angeles				Cannon, John/0000-0001-6698-176X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030054] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30054] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CANNON JF, 1986, GENETICS, V113, P247; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARUTA H, 1991, J BIOL CHEM, V266, P11661; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; TAMANOI F, 1988, BIOCHIM BIOPHYS ACTA, V948, P1, DOI 10.1016/0304-419X(88)90002-9; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; THON VJ, 1993, J BIOL CHEM, V268, P7509; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; ZHANG K, 1991, SCIENCE, V254, P1630, DOI 10.1126/science.1749934	34	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3441	3445						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247549				2022-12-17	WOS:A1993MG78200031
J	SMITMCBRIDE, Z; PRIVALSKY, ML				SMITMCBRIDE, Z; PRIVALSKY, ML			FUNCTIONAL DOMAINS OF THE V-ERBA PROTEIN NECESSARY FOR ONCOGENESIS ARE REQUIRED FOR TRANSCRIPTIONAL ACTIVATION IN SACCHAROMYCES-CEREVISIAE	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; GLUCOCORTICOID RECEPTOR; BINDING DOMAIN; DNA-BINDING; C-ERBA; YEAST; PHOSPHORYLATION; TRANSFORMATION; SPECIFICITY	The v-erbA oncogene is a retrovirus-transduced and altered copy of a cellular gene (c-erbA-alpha) for a thyroid hormone receptor. In this paper we show that the v-erbA domains required for transcriptional activation in yeast and for oncogenic function in animal cells are closely congruent. We conclude that the behavior of the v-erbA protein as a transcriptional activator in yeast appears to closely reflect the same biochemical requirements that are necessary for v-erbA function in the neoplastic vertebrate cell. Intriguingly, parallel analyses of c-erbA-alpha and -beta demonstrated unexpected differences in the activities of the two thyroid hormone receptor isoforms in the yeast, perhaps reflecting different functions of these genes in vertebrates. Furthermore, results obtained by analysis of chimeric v-/c-erbA genes suggest that the basal and the hormone-induced transcriptional activity of the nuclear hormone receptors can be modulated independently by distinct structural features within the protein molecule.	UNIV CALIF DAVIS, DEPT MICROBIOL, DAVIS, CA 95616 USA	University of California System; University of California Davis				Smit-McBride, Zeljka/0000-0003-0275-8088	NCI NIH HHS [CA53394, F32 CA09050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394, F32CA009050, R01CA053394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BONDE BG, 1990, J VIROL, V64, P1314, DOI 10.1128/JVI.64.3.1314-1320.1990; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BOUCHER P, 1990, ONCOGENE, V5, P1303; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESBOIS C, 1991, ONCOGENE, V6, P2129; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORREST D, 1990, ONCOGENE, V5, P309; GANDRILLON O, 1987, EUR J BIOCHEM, V166, P63; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HALL BL, 1992, CELL GROWTH DIFFER, V3, P207; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MAK P, 1989, J BIOL CHEM, V264, P21613; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; PRIVALSKY ML, 1992, BIOCHIM BIOPHYS ACTA, V1114, P51, DOI 10.1016/0304-419X(92)90006-K; PRIVALSKY ML, 1991, J BIOL CHEM, V266, P1456; PRIVASLKY ML, 1988, MOL CELL BIOL, V8, P4155; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHENA M, 1990, METHOD ENZYMOL, V194, P373; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SIKORSKI RS, 1989, GENETICS, V122, P19; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	44	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1465	1475						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8099219				2022-12-17	WOS:A1993LE06400009
J	KLAGES, S; ADAM, D; EISEMAN, E; FARGNOLI, J; DYMECKI, SM; DESIDERIO, SV; BOLEN, JB				KLAGES, S; ADAM, D; EISEMAN, E; FARGNOLI, J; DYMECKI, SM; DESIDERIO, SV; BOLEN, JB			MOLECULAR-CLONING AND ANALYSIS OF CDNA-ENCODING THE MURINE C-YES-TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							SEQUENCE-ANALYSIS PROGRAMS; HEMATOPOIETIC-CELLS; COMPREHENSIVE SET; SRC FAMILY; GENE; CD4; EXPRESSION; P56LCK; VAX	The cellular yes (c-yes) gene is a member of the class of proto-oncogenes that encode non-receptor tyrosine protein kinases. In this report we describe the isolation of cDNAs that encode the murine c-yes gene product and analysis of the nucleotide sequence of the murine c-yes cDNA clones. The reading frame encodes a protein of 541 amino acids with a calculated molecular mass of 60.63 kDa that is reactive with anti-Yes antisera and possesses protein kinase activity.	BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Bristol-Myers Squibb; Howard Hughes Medical Institute; Johns Hopkins University			Adam, Dieter/E-9763-2010; Adam-Klages, Sabine/E-9761-2010	Adam, Dieter/0000-0002-5668-5032; 				BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GHYSDAEL J, 1981, P NATL ACAD SCI-BIOL, V78, P2611, DOI 10.1073/pnas.78.4.2611; HOLTZMAN DA, 1987, P NATL ACAD SCI USA, V84, P8325, DOI 10.1073/pnas.84.23.8325; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAWAI S, 1980, P NATL ACAD SCI-BIOL, V77, P6199, DOI 10.1073/pnas.77.10.6199; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KING FJ, 1990, ONCOGENE, V5, P337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; PYPER JM, 1989, J NEUROSCI RES, V24, P89, DOI 10.1002/jnr.490240113; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEELE RE, 1989, ONCOGENE RES, V1, P223; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; ZHAO YH, 1991, ONCOGENE, V6, P1725; ZHAO YH, 1990, ONCOGENE, V5, P1629; ZHENG XF, 1989, ONCOGENE, V4, P99	32	8	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					713	719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437854				2022-12-17	WOS:A1993KN00800023
J	KOSAKA, M; IWAI, SA; NISHINA, Y; SUMI, T; NISHIMUNE, Y				KOSAKA, M; IWAI, SA; NISHINA, Y; SUMI, T; NISHIMUNE, Y			C-MYC AND P53 GENE-EXPRESSION IN THE DIFFERENTIATION OF TEMPERATURE-SENSITIVE MUTANTS OF TERATOCARCINOMA F9 CELLS	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; INCUBATION TEMPERATURES; RETINOIC ACID; DNA-SYNTHESIS; STEM-CELLS; TRANSFORMATION; INDUCTION; GROWTH; SUPPRESSOR; INHIBITORS	We have previously reported the isolation of several temperature-sensitive (ts) mutants of F9 cells. Further investigations showed that some mutants were induced to differentiate at non-permissive temperature of cell growth, accompanied by changes in the expression of various genes, whereas others were not. During the differentiation induced by shifting up to the nonpermissive temperature, a rapid and transient decrease in both c-myc and p53 mRNA levels and rapid induction of c-jun mRNA were observed. These changes were specific in differentiation-inducible mutants and were not observed in a non-inducible mutant. In both types of mutants, the level of c-myc mRNA decreased in association with growth retardation at the non-permissive temperature. The p53 mRNA, however, showed specific increase in the differentiation-inducible ts mutants. These observations suggest distinct roles for p53 and c-myc from proliferation to differentiation in teratocarcinoma stem cells.	OSAKA UNIV,FAC DENT,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,FAC DENT,DEPT ORAL SURG 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			KOSAKA, Mitsuko/B-1603-2011; Nishina, Yuta/AHB-6194-2022	KOSAKA, Mitsuko/0000-0001-6146-5184; Nishina, Yuta/0000-0002-4958-1753				CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHANDRASEKARAN K, 1982, J CELL PHYSIOL, V113, P134, DOI 10.1002/jcp.1041130122; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KOSAKA M, 1991, EXP CELL RES, V192, P46, DOI 10.1016/0014-4827(91)90155-N; KURKINEN M, 1983, NUCLEIC ACIDS RES, V11, P6199, DOI 10.1093/nar/11.18.6199; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAMB AJ, 1986, MOL CELL BIOL, V6, P1385; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maniatis T., 1982, MOL CLONING; MORITA T, 1988, GENE, V68, P109; NISHIMUNE Y, 1989, BIOCHEM BIOPH RES CO, V163, P1290; NISHIMUNE Y, 1983, EXP CELL RES, V146, P439, DOI 10.1016/0014-4827(83)90147-7; NISHIMUNE Y, 1989, BIOCHEM BIOPH RES CO, V165, P65, DOI 10.1016/0006-291X(89)91034-6; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SABBAG KR, 1989, DEVELOPMENT, V106, P195; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SEJERSEN T, 1985, EXP CELL RES, V160, P19, DOI 10.1016/0014-4827(85)90232-0; SHERMAN MI, 1985, CIBA F SYMP, V113, P42; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; YANG-YEN H-F, 1990, New Biologist, V2, P351	31	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2455	2460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461650				2022-12-17	WOS:A1992KA85600010
J	PORIES, S; JAROS, K; STEELE, G; PAULEY, A; SUMMERHAYES, IC				PORIES, S; JAROS, K; STEELE, G; PAULEY, A; SUMMERHAYES, IC			ONCOGENE-MEDIATED TRANSFORMATION OF FETAL-RAT COLON INVITRO	ONCOGENE			English	Article							PP60C-SRC PROTEIN-KINASE; INTESTINAL EPITHELIAL-CELLS; C-MYC ONCOGENES; SUCRASE-ISOMALTASE; COLORECTAL CANCERS; MONOLAYER-CULTURE; GENE-MUTATIONS; HA-RAS; V-MYC; LINES	Short-term maintenance of fetal rat colonic tissue in vitro has been demonstrated using a collagen matrix organ culture system. The introduction of single (v-myc, v-ras(H), v-src) oncogenes or combinations of oncogenes (v-myc/ras(H), v-myc/src) into normal colon mucosal elements was established using retroviral vectors, resulting in enhanced proliferation and migration of epithelial cells from the lumen of tissue implants. Expression of a single oncogene in normal colon epithelium did not result in the establishment of cell lines. In contrast, expression of cooperating oncogenic elements resulted in cell lines in > 80% of experiments, revealing different morphological characteristics dependent upon the oncogene combination used. Confirmation of the expression of viral transcripts was determined using Northern blot analysis and viral oncoprotein expression using Western blot analysis (p21) and an immunoprecipitation kinase assay (src). Expression of keratin filaments was lost following passaging of cell lines but could be induced by the myc/ras transformants by growth on Rat-1 feeder layers. This induction phenomenon was not observed with myc/src lines, and although these expressed high levels of surcase isomaltase the epithelial origin of these cells is unclear. Karyotypic analysis performed on three myc/ras-transformed cell lines revealed a normal chromosome complement associated with transformation. In this report we describe a novel in vitro transformation system for normal rat colonic epithelium mediated by the introduction of oncogene elements using different retroviral vector constructs. The potential to generate cell lines representing different stages of neoplastic progression using relevant genetic components presents significant advantages for the study of cellular and molecular interactions underlying colon neoplastic progression.	HARVARD UNIV, NEW ENGLAND DEACONESS HOSP,SCH MED,CANC BIOL LAB, 50 BINNEY ST, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, CYTOGENET LAB, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Pories, Susan/AAB-1757-2019	Pories, Susan/0000-0001-7315-9993	NATIONAL CANCER INSTITUTE [R01CA042944, P01CA044704, R23CA042944] Funding Source: NIH RePORTER; NCI NIH HHS [CA42944, CA44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUTRUP H, 1978, IN VITRO CELL DEV B, V14, P868; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CATTERMOLE JA, 1989, J IMMUNOL, V142, P3746; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOPRA DP, 1981, IN VITRO CELL DEV B, V17, P441, DOI 10.1007/BF02626745; CHOPRA DP, 1987, GASTROENTEROLOGY, V92, P891, DOI 10.1016/0016-5085(87)90962-0; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; CZERNICHOW B, 1989, INT J CANCER, V44, P238, DOI 10.1002/ijc.2910440209; DANES BS, 1982, J NATL CANCER I, V69, P1271; DEMILIA JC, 1991, ONCOGENE, V6, P303; EMAMI S, 1989, P NATL ACAD SCI USA, V86, P3194, DOI 10.1073/pnas.86.9.3194; ERISMAN MD, 1988, ONCOGENE, V2, P367; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; EZZELL RM, 1989, DEVELOPMENT, V106, P407; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GIBSON PR, 1989, GASTROENTEROLOGY, V96, P283, DOI 10.1016/0016-5085(89)91549-7; HAHN U, 1990, GASTROENTEROLOGY, V98, P322, DOI 10.1016/0016-5085(90)90821-H; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KEDINGER M, 1987, DIFFERENTIATION, V36, P71, DOI 10.1111/j.1432-0436.1987.tb00182.x; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KONDO Y, 1985, EXP CELL RES, V159, P158, DOI 10.1016/S0014-4827(85)80045-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; MESSER M, 1966, ANAL BIOCHEM, V14, P376, DOI 10.1016/0003-2697(66)90280-6; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEGREL R, 1983, EXP CELL RES, V143, P427, DOI 10.1016/0014-4827(83)90069-1; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OVERELL RW, 1988, MOL CELL BIOL, V8, P1803, DOI 10.1128/MCB.8.4.1803; PAETAU A, 1985, ACTA NEUROPATHOL, V65, P190, DOI 10.1007/BF00686997; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; QUARONI A, 1985, J CELL BIOL, V100, P1611, DOI 10.1083/jcb.100.5.1611; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; QUARONI A, 1989, GASTROENTEROLOGY, V96, P535, DOI 10.1016/0016-5085(89)91584-9; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VIDRICH A, 1987, GASTROENTEROLOGY, V92, P1683; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; WIEHLE RD, 1990, ONCOGENE, V5, P787; WILTZ O, 1990, IN PRESS GASTROENTER; YEH KY, 1980, IN VITRO CELL DEV B, V16, P976; ZWEIBAUM A, 1983, INT J CANCER, V32, P407, DOI 10.1002/ijc.2910320403	53	8	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					885	893						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373876				2022-12-17	WOS:A1992HP64200007
J	GIVOL, I; GREENHOUSE, JJ; HUGHES, SH; EWERT, DL				GIVOL, I; GREENHOUSE, JJ; HUGHES, SH; EWERT, DL			RETROVIRUSES THAT EXPRESS DIFFERENT RAS MUTANTS CAUSE DIFFERENT TYPES OF TUMORS IN CHICKENS	ONCOGENE			English	Article								We have used replication-competent retroviral vectors to express avian and murine ras genes in cultured chick embryo fibroblasts (CEF) and in chickens. Since the viral vectors are identical, it is possible to compare the oncogenic potential of the ras genes directly. The normal (12 gly) form of chicken c-Ha-ras is not oncogenic in vivo, nor does high-level expression transform CEF. Expression of murine v-ras or modified forms of chicken c-Ha-ras with either lysine or glutamine at position 12 transforms CEF and causes tumors in birds. However, the oncogenic potential of the transforming ras genes is different, the viruses that express the genes with lysine and glutamine at position 12 cause a distinct spectrum of tumors.	NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, POB B, FREDERICK, MD 21702 USA; NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; WISTAR INST, PHILADELPHIA, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); The Wistar Institute					NCI NIH HHS [N01-CO-74101, CA39000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039000] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; WESTAWAY D, 1986, EMBO J, V5, P301, DOI 10.1002/j.1460-2075.1986.tb04213.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	16	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					141	146						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1632878				2022-12-17	WOS:A1992HC22700019
J	HAASE, VH; SNIJDERS, AJ; COOKE, SM; TENG, MN; KAUL, D; LEBEAU, MM; BRUNS, GAP; BERNARDS, A				HAASE, VH; SNIJDERS, AJ; COOKE, SM; TENG, MN; KAUL, D; LEBEAU, MM; BRUNS, GAP; BERNARDS, A			ALTERNATIVELY SPLICED LTK MESSENGER-RNA IN NEURONS PREDICTS A RECEPTOR WITH A LARGER PUTATIVE EXTRACELLULAR DOMAIN	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; ACUTE PROMYELOCYTIC LEUKEMIA; TYROSINE KINASE; SEVENLESS PROTEIN; TISSUE; GENES; IDENTIFICATION; LYMPHOCYTES; EXPRESSION; BRAIN	Ltk is a new member of the ros/insulin receptor family of tyrosine kinases that is expressed in murine B-lymphocyte precursors and forebrain neurons. We previously reported that lymphoid ltk cDNAs predict a 69kDa transmembrane glycoprotein, which uses a CUG translational start codon and has a 110 amino acid putative extracellular domain. We now show that the predominant ltk mRNA in brain is alternatively spliced and predicts a protein with a substantially larger extracellular part. The human ltk gene maps to chromosome 15, bands q13-21, a region containing the breakpoint of a recurring chromosomal abnormality in B-cell non-Hodgkin lymphomas.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET LAB,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV CHICAGO,HEMATOL ONCOL SECT,CHICAGO,IL 60637; CHILDRENS HOSP MED CTR,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Chicago; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Haase, Volker Hans/A-6758-2013; Haase, Volker Hans/AAJ-5061-2021; Teng, Michael N./I-5006-2012	Haase, Volker Hans/0000-0002-7051-8994; Teng, Michael N./0000-0002-0722-3659	NATIONAL CANCER INSTITUTE [R35CA042557] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42557] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BROOK JD, 1985, HUM GENET, V69, P282; BRUNS GAP, 1979, BIOCHEM GENET, V17, P1031, DOI 10.1007/BF00504344; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COX DW, 1989, CYTOGENET CELL GENET, V51, P280, DOI 10.1159/000132795; DONLON TA, 1990, CYTOGENET CELL GENET, V55, P189, DOI 10.1159/000133011; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LATT SA, 1976, CHROMOSOMA, V57, P135, DOI 10.1007/BF00292912; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LEVINE EG, 1989, BLOOD, V74, P1796; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARU Y, 1990, ONCOGENE RES, V5, P199; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROWLEY JD, 1977, LANCET, V1, P549; SCOTT AF, 1979, P NATL ACAD SCI USA, V76, P4563, DOI 10.1073/pnas.76.9.4563; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TAHIRA T, 1990, ONCOGENE, V5, P97; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	29	8	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2319	2325						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662793				2022-12-17	WOS:A1991GX73500021
J	KATO, JY; SHERR, CJ				KATO, JY; SHERR, CJ			A DOMINANT SUPPRESSIVE MUTATION IN A CELLULAR GENE RESTORES THE NONTRANSFORMED PHENOTYPE TO V-FMS-TRANSFORMED MINK CELLS	ONCOGENE			English	Article							FELINE SARCOMA-VIRUS; STIMULATING FACTOR-I; PROTO-ONCOGENE PRODUCT; VIRAL ONCOGENE; FLAT REVERTANTS; KINASE-ACTIVITY; GROWTH-FACTOR; WILD-TYPE; RAS; INHIBITION	A nontransformed revertant subclone (GVR17) was isolated from mutagen-treated populations of mink epithelial cells which had been transformed by the Susan McDonough strain of feline sarcoma virus (SM-FeSV). The revertant cells, although contact-inhibited for growth and unable to form colonies in semisolid medium, contained two copies of integrated SM-FeSV proviral DNA, expressed high levels of the v-fms oncogene product and its associated tyrosine kinase activity, and yielded rescuable viruses able to transform parental mink epithelial and mouse NIH3T3 cells. The transformed phenotype was suppressed in cell hybrids generated by fusing revertant and v-fms-transformed mink cells, indicating that GVR17 cells harbored a dominant cellular mutation that inhibited transformation by the v-fms oncogene. The revertant cells were refractory to retransformation by retroviruses containing v-fms or v-abl oncogenes, but could be transformed by v-ras-, v-raf-, and v-fes- containing retroviruses. Thus, the suppressing activity in GVR17 cells discriminates between transforming signals mediated by different tyrosine kinases and fails to block the transforming activity of two oncoproteins exhibiting either GTP-binding or serine/threonine kinase activity.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	SHERR, CJ (corresponding author), ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, DEPT TUMOR CELL BIOL, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA.		Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206	NCI NIH HHS [CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHATTOPADHYAY SK, 1981, J VIROL, V39, P777, DOI 10.1128/JVI.39.3.777-791.1981; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DONNER L, 1980, J VIROL, V35, P129, DOI 10.1128/JVI.35.1.129-140.1980; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRANKEL AE, 1979, J VIROL, V30, P821, DOI 10.1128/JVI.30.3.821-827.1979; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASS DJ, 1990, ONCOGENE RES, V5, P175; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; HENDERSON IC, 1974, VIROLOGY, V60, P282, DOI 10.1016/0042-6822(74)90386-9; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; INOUE H, 1983, VIROLOGY, V125, P242, DOI 10.1016/0042-6822(83)90078-8; JACKOWSKI S, 1990, J BIOL CHEM, V265, P6611; JOHNSON LV, 1982, CELL, V28, P7, DOI 10.1016/0092-8674(82)90369-5; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NORTON JD, 1984, J VIROL, V50, P439, DOI 10.1128/JVI.50.2.439-444.1984; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; RUSCETTI SK, 1980, J VIROL, V35, P259, DOI 10.1128/JVI.35.1.259-264.1980; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHERR CJ, 1979, J VIROL, V32, P860, DOI 10.1128/JVI.32.3.860-875.1979; SHERR CJ, IN PRESS ORIGINS HUM; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YANAGIHARA K, 1990, ONCOGENE, V5, P1179; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	51	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					687	693						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052353				2022-12-17	WOS:A1991GT82500002
J	TESTA, JR; PARK, M; BLAIR, DG; KALBAKJI, A; ARDEN, K; VANDEWOUDE, GF				TESTA, JR; PARK, M; BLAIR, DG; KALBAKJI, A; ARDEN, K; VANDEWOUDE, GF			ANALYSIS BY PULSED FIELD GEL-ELECTROPHORESIS REVEALS COMPLEX REARRANGEMENTS IN 2 MET ALLELES IN A CHEMICALLY-TREATED HUMAN CELL-LINE, MNNG-HOS	ONCOGENE			English	Article									NCI,DIV CANC ETIOL,MOLEC ONCOL LAB,FREDERICK,MD 21701; NCI,FREDERICK CANC RES FACIL,ABL BASIC RES PROGRAM,FREDERICK,MD 21701; LUDWIG INST CANC RES,MONTREAL H3A 1A1,QUEBEC,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research	TESTA, JR (corresponding author), FOX CHASE CANC INST,DEPT MED ONCOL,7701 BURHOLME AVE,PHILADELPHIA,PA 19111, USA.				NCI NIH HHS [N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; COLLINS FS, 1987, SCIENCE, V235, P1046, DOI 10.1126/science.2950591; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DEAN M, 1987, J PEDIATR-US, V111, P490, DOI 10.1016/S0022-3476(87)80106-3; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DELHANTY JDA, 1989, CANCER GENET CYTOGEN, V42, P263, DOI 10.1016/0165-4608(89)90094-0; Drumm ML, 1988, GENOMICS, V2, P346, DOI 10.1016/0888-7543(88)90024-9; ESTIVILL X, 1987, NATURE, V326, P840, DOI 10.1038/326840a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEMMILL RM, 1987, GENE ANAL TECH, V4, P119, DOI 10.1016/0735-0651(87)90010-0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JULIER C, 1988, AM J HUM GENET, V42, P45; KING HWS, 1988, ONCOGENE, V2, P617; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MICHIELS F, 1987, SCIENCE, V236, P1305, DOI 10.1126/science.3035716; PARK M, 1988, P NATL ACAD SCI USA, V85, P2667, DOI 10.1073/pnas.85.8.2667; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PERRY P, 1975, NATURE, V258, P121, DOI 10.1038/258121a0; RHIM JS, 1975, J NATL CANCER I, V55, P1291, DOI 10.1093/jnci/55.6.1291; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; ROMMENS JM, 1989, AM J HUM GENET, V45, P932; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P507; VANOMMEN GJB, 1986, HUMAN GENETIC DISEAS, P113; WAINWRIGHT BJ, 1985, NATURE, V318, P384, DOI 10.1038/318384a0	35	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1565	1571						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250912				2022-12-17	WOS:A1990EK50200017
J	HALVERSON, D; MODI, W; DEAN, M; GELMANN, EP; DUNN, KJ; CLANTON, D; OSKARSSON, M; OBRIEN, SJ; BLAIR, DG				HALVERSON, D; MODI, W; DEAN, M; GELMANN, EP; DUNN, KJ; CLANTON, D; OSKARSSON, M; OBRIEN, SJ; BLAIR, DG			AN ONCOGENIC CHROMOSOME-8-9 GENE FUSION ISOLATED FOLLOWING TRANSFECTION OF HUMAN OVARIAN-CARCINOMA CELL-LINE DNA	ONCOGENE			English	Note									NCI, MOLEC ONCOL LAB, POB B, FREDERICK, MD 21701 USA; PROGRAM RESOURCES INC, FREDERICK, MD 21701 USA; NCI, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21701 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, DIV MED ONCOL, WASHINGTON, DC 20007 USA; BIONET RES LABS INC, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University			Dean, Michael C/G-8172-2012; OBRIEN, STEPHEN/ABD-1346-2020; Dean, Michael/R-7501-2019	Dean, Michael C/0000-0003-2234-0631; OBRIEN, STEPHEN/0000-0001-7857-0757	OFFICE OF THE DIRECTOR, NCI [N01CO074101, N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102, N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIN W, 1987, CANCER RES, V47, P6040; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DEAN M, 1987, J PEDIATR-US, V111, P490, DOI 10.1016/S0022-3476(87)80106-3; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GALLI MC, 1981, CANCER-AM CANCER SOC, V47, P1297, DOI 10.1002/1097-0142(19810315)47:6<1297::AID-CNCR2820470611>3.0.CO;2-D; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; HAGEMEIJER A, 1982, CANCER GENET CYTOGEN, V5, P95, DOI 10.1016/0165-4608(82)90001-2; HAMILTON TC, 1983, CANCER RES, V43, P5379; HAYASHI S, 1978, HISTOCHEM CYTOCHEM, V26, P667; KONALCZYK J, 1983, CANCER GENET CYTOGEN, V9, P383; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LATHROP M, 1988, GENOMICS, V3, P361, DOI 10.1016/0888-7543(88)90128-0; LOENEN WAM, 1980, GENE, V10, P249, DOI 10.1016/0378-1119(80)90054-2; Maniatis T., 1982, MOL CLONING; MODI WS, 1987, GENE ANAL TECH, V4, P75; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; OHARA BM, 1986, CANCER RES, V46, P4695; PARK M, 1989, METABOLIC BASIS INHE; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; WHITE R, 1985, NATURE, V318, P382, DOI 10.1038/318382a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	31	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1990	5	7					1085	1089						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1973829				2022-12-17	WOS:A1990DP41500022
J	BLONDEL, B; TALBOT, N; MERLO, GR; WYCHOWSKI, C; YOKOZAKI, H; VALVERIUS, EM; SALOMON, DS; BASSIN, RH				BLONDEL, B; TALBOT, N; MERLO, GR; WYCHOWSKI, C; YOKOZAKI, H; VALVERIUS, EM; SALOMON, DS; BASSIN, RH			EFFICIENT INDUCTION OF FOCUS FORMATION IN A SUBCLONE OF NIH3T3 CELLS BY C-MYC AND ITS INHIBITION BY SERUM AND BY GROWTH-FACTORS	ONCOGENE			English	Article									NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892; NIAID,INFECT DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Yokozaki, Hiroshi/0000-0001-5276-3331				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COPELAND NG, 1980, J VIROL, V33, P1199, DOI 10.1128/JVI.33.3.1199-1202.1980; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1982, NATURE, V299, P61; DANIELPOUR D, 1989, J CELL PHYSIOL, V138, P79, DOI 10.1002/jcp.1041380112; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ENGEL JN, 1981, P NATL ACAD SCI-BIOL, V78, P4674, DOI 10.1073/pnas.78.8.4674; FALCONE G, 1987, EXP CELL RES, V168, P273, DOI 10.1016/0014-4827(87)90435-6; FERNANDEZPOL JA, 1987, BIOCHEM BIOPH RES CO, V144, P1197, DOI 10.1016/0006-291X(87)91438-0; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; RAY R, 1989, ONCOGENE, V4, P593; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; ROMEO G, 1989, TRENDS GENET, V5, P19, DOI 10.1016/0168-9525(89)90007-3; RUBIN H, 1989, P NATL ACAD SCI USA, V86, P1860, DOI 10.1073/pnas.86.6.1860; RUBIN H, 1960, VIROLOGY, V12, P14, DOI 10.1016/0042-6822(60)90146-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMINOVITCH L, 1976, CELL, V7, P1, DOI 10.1016/0092-8674(76)90249-X; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STUDZINSKY GP, 1985, CELL, V43, P243; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SYMONDS G, 1989, ONCOGENE, V4, P285; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEINBERG RA, 1989, CANCER RES, V49, P3713; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823; ZERLIN M, 1987, ONCOGENE, V1, P19	60	8	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					857	865						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2193293				2022-12-17	WOS:A1990DP55300011
J	BEIMLING, P; MOELLING, K				BEIMLING, P; MOELLING, K			TAX-INDEPENDENT BINDING OF MULTIPLE CELLULAR FACTORS TO TAX-RESPONSE ELEMENT DNA OF HTLV-I	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,ABT SCHUSTER,IHNESTR 73,W-1000 BERLIN 33,GERMANY	Max Planck Society								ALTMAN R, 1988, J VIROL, V62, P1339, DOI 10.1128/JVI.62.4.1339-1346.1988; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARYA SK, 1988, AIDS RES HUM RETROV, V4, P175, DOI 10.1089/aid.1988.4.175; BEIMLING P, 1989, ONCOGENE, V4, P511; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CHEN ISY, 1985, SCIENCE, V229, P54, DOI 10.1126/science.2990037; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GIAM CZ, 1986, P NATL ACAD SCI USA, V83, P7192, DOI 10.1073/pnas.83.19.7192; GOH WC, 1985, SCIENCE, V227, P1227, DOI 10.1126/science.2983419; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOSEPHS SF, 1984, VIROLOGY, V139, P340, DOI 10.1016/0042-6822(84)90379-9; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KALYANARAMAN VS, 1981, NATURE, V294, P271, DOI 10.1038/294271a0; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KIYOKAWA T, 1985, VIROLOGY, V147, P462, DOI 10.1016/0042-6822(85)90149-7; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; PARK RE, 1988, ONCOGENE, V3, P275; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; ROSEN CA, 1987, P NATL ACAD SCI USA, V84, P4919, DOI 10.1073/pnas.84.14.4919; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SAITO S, 1988, J VIROL, V62, P6444; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; SODROSKI JG, 1984, SCIENCE, V226, P177; SODROSKI JG, 1985, SCIENCE, V228, P430; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	56	8	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					361	368						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2314899				2022-12-17	WOS:A1990CW41500014
J	OHNO, S; MIGITA, S; MURAKAMI, S				OHNO, S; MIGITA, S; MURAKAMI, S			C-MYC-S-MU REARRANGEMENT IN A MURINE PLASMACYTOMA WITHOUT VISIBLE CHROMOSOMAL TRANSLOCATIONS	ONCOGENE			English	Note									KANAZAWA UNIV,CANC RES INST,DIV BIOPHYS,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University	OHNO, S (corresponding author), KANAZAWA UNIV,CANC RES INST,DEPT MOLEC IMMUNOL,13-1 TAKARA MACHI,KANAZAWA,ISHIKAWA 920,JAPAN.							CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DREAZEN O, 1987, LANCET, V1, P1402; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; MERWIN RM, 1963, J NAT CANC, V31, P998; MORRIS CM, 1986, NATURE, V320, P281, DOI 10.1038/320281a0; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; OHNO S, 1988, INT J CANCER, V41, P595, DOI 10.1002/ijc.2910410420; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; ROSENBERG SM, 1985, GENE, V39, P313, DOI 10.1016/0378-1119(85)90330-0; SAKANO H, 1980, NATURE, V286, P676, DOI 10.1038/286676a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STANTON LW, 1984, P NATL ACAD SCI-BIOL, V81, P829, DOI 10.1073/pnas.81.3.829; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; WANG HC, 1972, NATURE-NEW BIOL, V235, P52, DOI 10.1038/newbio235052a0; ZABAROVSKY ER, 1986, GENE, V42, P119, DOI 10.1016/0378-1119(86)90158-7; 1972, J HERED, V63, P69	20	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1513	1517						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687771				2022-12-17	WOS:A1989CB65900015
J	VANWARTHOOD, JE; LINDER, ME; BURR, JG				VANWARTHOOD, JE; LINDER, ME; BURR, JG			TPCK AND QUERCETIN ACT SYNERGISTICALLY WITH VANADATE TO INCREASE PROTEIN-TYROSINE PHOSPHORYLATION IN AVIAN CELLS	ONCOGENE			English	Note									UNIV TEXAS,PROGRAMS MOLEC & CELL BIOL,RICHARDSON,TX 75080	University of Texas System; University of Texas Dallas			Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712				AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Bonting SL, 1970, MEMBRANES ION TRANSP, V1, P257; BROWN DJ, 1984, J BIOL CHEM, V259, P9580; COLLETT MS, 1987, J VIROL, V61, P1593, DOI 10.1128/JVI.61.5.1593-1601.1987; COLLETT MS, 1984, MOL CELL BIOL, V4, P1213, DOI 10.1128/MCB.4.7.1213; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER JA, 1983, CURR TOP MICROBIOL, V107, P125; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; FAHRNEY DE, 1963, J AM CHEM SOC, V85, P997, DOI 10.1021/ja00890a037; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GSCHWENDT M, 1984, BIOCHEM BIOPH RES CO, V124, P63, DOI 10.1016/0006-291X(84)90916-1; HORN F, 1985, EUR J BIOCHEM, V148, P533, DOI 10.1111/j.1432-1033.1985.tb08872.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; LANG DR, 1974, BIOCHIM BIOPHYS ACTA, V333, P180, DOI 10.1016/0005-2728(74)90002-4; LEIS JF, 1982, P NATL ACAD SCI-BIOL, V79, P6507, DOI 10.1073/pnas.79.21.6507; LEVIN RM, 1976, MOL PHARMACOL, V12, P581; LINDER ME, 1988, J VIROL, V62, P2665, DOI 10.1128/JVI.62.8.2665-2673.1988; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; MOSS DE, 1978, BIOCHEM PHARMACOL, V27, P2693, DOI 10.1016/0006-2952(78)90044-8; NELSON RL, 1984, MOL CELL BIOL, V4, P1003, DOI 10.1128/MCB.4.6.1003; PONG SS, 1975, J BIOL CHEM, V250, P240; RICHERT N, 1979, CELL, V18, P369, DOI 10.1016/0092-8674(79)90056-4; ROSS AH, 1985, J CELL PHYSIOL, V124, P499, DOI 10.1002/jcp.1041240321; RYDER JW, 1987, MOL CELL BIOL, V7, P1139, DOI 10.1128/MCB.7.3.1139; SHAW E, 1970, PHYSIOL REV, V50, P244, DOI 10.1152/physrev.1970.50.2.244; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1982, J BIOL CHEM, V257, P7298; TONOKURA M, 1986, J BIOL CHEM, V261, P10749; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905	34	8	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1267	1271						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2552375				2022-12-17	WOS:A1989AU50800016
J	PONZETTO, C; WADEWITZ, AG; PENDERGAST, AM; WITTE, ON; WOLGEMUTH, DJ				PONZETTO, C; WADEWITZ, AG; PENDERGAST, AM; WITTE, ON; WOLGEMUTH, DJ			P150C-ABL IS DETECTED IN MOUSE MALE GERM-CELLS BY AN INVITRO KINASE ASSAY AND IS ASSOCIATED WITH STAGE-SPECIFIC PHOSPHOPROTEINS IN HAPLOID CELLS	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG, CTR REPROD SCI, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Columbia University; Columbia University; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Pendergast, Ann Marie/0000-0002-1250-6880	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD005077] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA027507] Funding Source: NIH RePORTER; NCI NIH HHS [CA27507] Funding Source: Medline; NICHD NIH HHS [HD07093, P50 HD05077] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DUGGAL RN, 1987, BIOL TESTIS EPIDIDYM, P112; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER RA, 1972, P NATL ACAD SCI USA, V69, P2965, DOI 10.1073/pnas.69.10.2965; LIPSICH LA, 1982, MOL CELL BIOL, V2, P875, DOI 10.1128/MCB.2.7.875; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; PONZETTO C, 1985, MOL CELL BIOL, V5, P1791, DOI 10.1128/MCB.5.7.1791; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WITTE O, 1986, CANCER SURV, V5, P182; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102; ZAKERI ZF, 1988, DEV BIOL, V125, P417, DOI 10.1016/0012-1606(88)90222-9; ZIEMIECKI A, 1986, VIROLOGY, V151, P265, DOI 10.1016/0042-6822(86)90048-6	24	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1989	4	6					685	690						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2660070				2022-12-17	WOS:A1989AA66000003
J	GRAND, RJA; LEVINE, BA; BYRD, PJ; GALLIMORE, PH				GRAND, RJA; LEVINE, BA; BYRD, PJ; GALLIMORE, PH			THE BINDING OF GUANINE-NUCLEOTIDE TO N-RAS P21 - A PHOSPHORUS AND PROTON MAGNETIC-RESONANCE STUDY	ONCOGENE			English	Article									UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 2QR,ENGLAND	University of Oxford	GRAND, RJA (corresponding author), UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CAMPBELLBURK S, 1988, 13TH P INT C MAGN RE; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; DALGARNO DC, 1983, BIOSCIENCE REP, V3, P443, DOI 10.1007/BF01121955; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FEUERSTEIN J, 1987, EUR J BIOCHEM, V162, P49, DOI 10.1111/j.1432-1033.1987.tb10540.x; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1984, NATURE, V309, P404; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAND RJA, 1987, ONCOGENE, V1, P305; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P502; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; NISHIMURA S, 1987, BIOCHEM J, V243, P313, DOI 10.1042/bj2430313; POE M, 1985, J BIOL CHEM, V260, P3906; ROSCH P, 1986, BIOCHEM BIOPH RES CO, V135, P549, DOI 10.1016/0006-291X(86)90029-X; SCHLICHTING I, 1988, BIOCHEM BIOPH RES CO, V150, P444, DOI 10.1016/0006-291X(88)90540-2; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TOKSOZ D, 1987, ONCOGENE, V1, P409; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	29	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					355	361						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2649849				2022-12-17	WOS:A1989U567600012
J	SORRENTINO, V; NEBREDA, AR; ALONSO, T; SANTOS, E				SORRENTINO, V; NEBREDA, AR; ALONSO, T; SANTOS, E			PREPARATION, CHARACTERIZATION AND PROPERTIES OF MONOCLONAL-ANTIBODIES AGAINST INTACT H-RAS P21 PROTEINS	ONCOGENE			English	Article									NIAID,MOLEC MICROBIOL LAB,BDG 4,RM 312,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Nebreda, Angel Rodriguez/R-9594-2019; Sorrentino, Vincenzo/A-4793-2014	Sorrentino, Vincenzo/0000-0002-8573-8631				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHANG EH, 1980, J VIROL, V35, P76, DOI 10.1128/JVI.35.1.76-92.1980; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CZERNIAK B, 1987, CANCER, V60, P2432, DOI 10.1002/1097-0142(19871115)60:10<2432::AID-CNCR2820601014>3.0.CO;2-1; DESTGROTH SF, 1980, J IMMUNOL METHODS, V35, P1, DOI 10.1016/0022-1759(80)90146-5; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAY NJ, 1983, NATURE, V301, P262, DOI 10.1038/301262a0; HARBOE N, 1973, Scandinavian Journal of Immunology, V2, P161; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; NOWINSKI RC, 1979, VIROLOGY, V93, P111, DOI 10.1016/0042-6822(79)90280-0; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; PAPAGEORGE AG, 1986, MOL CELL BIOL, V6, P1843, DOI 10.1128/MCB.6.5.1843; PINCUS MR, 1983, P NATL ACAD SCI-BIOL, V80, P5253, DOI 10.1073/pnas.80.17.5253; POLLOCK RR, 1984, ANNU REV MICROBIOL, V38, P389; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SANTOS E, 1983, P NATL ACAD SCI-BIOL, V80, P4679, DOI 10.1073/pnas.80.15.4679; SANTOS E, 1985, BIOCHEMISTRY-US, V24, P3006, DOI 10.1021/bi00333a030; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SRINIVASAPPA J, 1986, J VIROL, V57, P397, DOI 10.1128/JVI.57.1.397-401.1986; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; WARD JM, 1989, ONCOGENE, V4, P203; WARD JM, 1986, CARCINOGENESIS, V7, P645, DOI 10.1093/carcin/7.4.645; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	42	8	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					215	221						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2467247				2022-12-17	WOS:A1989U567500013
J	HUEN, DS; GRAND, RJ; YOUNG, LS				HUEN, DS; GRAND, RJ; YOUNG, LS			A REGION OF THE EPSTEIN-BARR VIRUS NUCLEAR ANTIGEN LEADER PROTEIN AND ADENOVIRUS E1A ARE IDENTICAL	ONCOGENE			English	Article									UNIV BIRMINGHAM,SCH MED,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND	University of Birmingham			Young, Lawrence S/B-7213-2009; Huen, David/F-3676-2014	Young, Lawrence S/0000-0003-3919-4298; Huen, David/0000-0002-9900-2297				BODESCOT M, 1984, EMBO J, V3, P1913, DOI 10.1002/j.1460-2075.1984.tb02067.x; BORNKAMM GW, 1982, J VIROL, V43, P952, DOI 10.1128/JVI.43.3.952-968.1982; DAMBAUGH T, 1984, P NATL ACAD SCI-BIOL, V81, P7632, DOI 10.1073/pnas.81.23.7632; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FIGGE J, 1988, NATURE, V334, P109, DOI 10.1038/334109a0; FINKE J, 1987, J VIROL, V61, P3870, DOI 10.1128/JVI.61.12.3870-3878.1987; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RICKINSON AB, 1987, J VIROL, V61, P1310, DOI 10.1128/JVI.61.5.1310-1317.1987; SAMPLE J, 1986, P NATL ACAD SCI USA, V83, P5096, DOI 10.1073/pnas.83.14.5096; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOUNG LS, 1987, J GEN VIROL, V68, P2853, DOI 10.1099/0022-1317-68-11-2853; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	17	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					729	730						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577878				2022-12-17	WOS:A1988R646000018
J	DANIEL, L; AHMED, CMI; BLOODGOOD, RS; KIDD, JR; CASTIGLIONE, CM; DUTTAGUPTA, S; LEBOWITZ, P				DANIEL, L; AHMED, CMI; BLOODGOOD, RS; KIDD, JR; CASTIGLIONE, CM; DUTTAGUPTA, S; LEBOWITZ, P			POLYMORPHISM OF THE HUMAN C-ABL-GENE - RELATION TO INCIDENCE AND COURSE OF CHRONIC MYELOGENOUS LEUKEMIA	ONCOGENE			English	Article									YALE UNIV,SCH MED,DEPT INTERNAL MED,333 CEDAR ST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT HUMAN GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,CTR COMPREHENS CANC,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University					NCI NIH HHS [IF32 CA07871] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA007871] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1983, CELL, V32, P1018; BRILL AB, 1962, ANN INTERN MED, V56, P590, DOI 10.7326/0003-4819-56-4-590; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CANAANI E, 1984, LANCET, V1, P593; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COLLINS SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4813, DOI 10.1073/pnas.80.15.4813; COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; COURTBROWN WM, 1955, LANCET, V2, P1283; DALLAFAVERA R, 1982, NATURE, V299, P61; DANIEL LN, 1986, P AM ASSOC CANC RES, V27, P8; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; EZDINLI E Z, 1970, Algerie Medicale, V72, P175; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HEISTERKAMP N, 1982, NATURE, V299, P747, DOI 10.1038/299747a0; HEISTERKAMP N, 1983, Journal of Molecular and Applied Genetics, V2, P57; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; KONOPKA JB, 1984, CELL, V37, P1034; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LYALL JM, 1978, LEUKEMIA RES, V2, P213, DOI 10.1016/0145-2126(78)90039-5; MCCARTHY DM, 1984, LANCET, V2, P1362; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUNDLES RW, 1977, HEMATOLOGY, P777; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SILVER RT, 1986, AM J MED, V80, P1137, DOI 10.1016/0002-9343(86)90676-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAM K, 1985, NEW ENGL J MED, V313, P1429, DOI 10.1056/NEJM198512053132301; THIEN SL, 1986, NATURE, V321, P84; THIEN SL, 1986, NATURE, V321, P85; VERBEEK JS, 1985, MOL CELL BIOL, V5, P422, DOI 10.1128/MCB.5.2.422; WINTROBE MM, 1974, CLIN HEMATOLOGY, P1500; XU DQ, 1985, P NATL ACAD SCI USA, V82, P2862, DOI 10.1073/pnas.82.9.2862; XU DQ, 1986, P NATL ACAD SCI USA, V83, P3447, DOI 10.1073/pnas.83.10.3447; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	39	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					193	200						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2894000				2022-12-17	WOS:A1987J635200012
J	LANE, DP				LANE, DP			MEETING REPORT - P53 IN PARIS, AN ONCOGENE COMES OF AGE	ONCOGENE			English	Editorial Material											LANE, DP (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SOUSSI T, 1987, ONCOGENE, V1, P71; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4	9	8	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					241	242						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3330773				2022-12-17	WOS:A1987J970500001
J	Xu, YF; He, XY; Wang, SZ; Sun, BF; Jia, RB; Chai, PW; Li, F; Yang, Y; Ge, SF; Jia, RB; Yang, YG; Fan, XQ				Xu, Yangfan; He, Xiaoyu; Wang, Shanzheng; Sun, Baofa; Jia, Ruobing; Chai, Peiwei; Li, Fang; Yang, Ying; Ge, Shengfang; Jia, Renbing; Yang, Yun-Gui; Fan, Xianqun			The m(6)A reading protein YTHDF3 potentiates tumorigenicity of cancer stem-like cells in ocular melanoma through facilitating CTNNB1 translation	ONCOGENE			English	Article							CONJUNCTIVAL MELANOMA; MALIGNANT-MELANOMA; HITS-CLIP; RNA; EXPRESSION; PROMOTES; DIFFERENTIATION; ACTIVATION; TISSUE; MODEL	N-6-methyladenosine (m(6)A) is the most universal internal RNA modification on messenger RNAs and regulates the fate and functions of m(6)A-modified transcripts through m(6)A-specific binding proteins. Nevertheless, the functional role and potential mechanism of the m(6)A reading proteins in ocular melanoma tumorigenicity, especially cancer stem-like cell (CSC) properties, remain to be elucidated. Herein, we demonstrated that the m(6)A reading protein YTHDF3 promotes the translation of the target transcript CTNNB1, contributing to ocular melanoma propagation and migration through m(6)A methylation. YTHDF3 is highly expressed in ocular melanoma stem-like cells and abundantly enriched in ocular melanoma tissues, which is related to poor clinical prognosis. Moreover, YTHDF3 is required for the maintenance of CSC properties and tumor initiation capacity in ocular melanoma both in vitro and in vivo. Ocular melanoma cells with targeted YTHDF3 knockdown exhibited inhibitory tumor proliferation and migration abilities. Transcriptome-wide mapping of m(6)A peaks and YTHDF3 binding peaks on mRNAs revealed a key target gene candidate, CTNNB1. Mechanistically, YTHDF3 enhances CTNNB1 translation through recognizing and binding the m(6)A peaks on CTNNB1 mRNA.	[Xu, Yangfan; He, Xiaoyu; Jia, Ruobing; Chai, Peiwei; Li, Fang; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China; [Xu, Yangfan; He, Xiaoyu; Jia, Ruobing; Chai, Peiwei; Li, Fang; Ge, Shengfang; Jia, Renbing; Fan, Xianqun] Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China; [Wang, Shanzheng; Sun, Baofa; Yang, Ying; Yang, Yun-Gui] Chinese Acad Sci, Collaborat Innovat Ctr Genet & Dev, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China; [Wang, Shanzheng; Sun, Baofa; Yang, Ying; Yang, Yun-Gui] China Natl Ctr Bioinformat, Beijing, Peoples R China; [Wang, Shanzheng; Sun, Baofa; Yang, Ying; Yang, Yun-Gui] Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China; [Sun, Baofa; Yang, Ying; Yang, Yun-Gui] Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences	Fan, XQ (corresponding author), Shanghai Jiao Tong Univ, Ninth Peoples Hosp, Dept Ophthalmol, Sch Med, Shanghai, Peoples R China.; Fan, XQ (corresponding author), Shanghai Key Lab Orbital Dis & Ocular Oncol, Shanghai, Peoples R China.; Yang, YG (corresponding author), Chinese Acad Sci, Collaborat Innovat Ctr Genet & Dev, Beijing Inst Genom, Key Lab Genom & Precis Med, Beijing, Peoples R China.; Yang, YG (corresponding author), China Natl Ctr Bioinformat, Beijing, Peoples R China.; Yang, YG (corresponding author), Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China.; Yang, YG (corresponding author), Chinese Acad Sci, Inst Stem Cell & Regenerat, Beijing, Peoples R China.	ygyang@big.ac.cn; fanxq@sjtu.edu.cn	Yang, Ying/GRO-4537-2022	Yang, Ying/0000-0002-8104-5985	National Key Research and Development Plan [2017YFE0196300]; National Natural Science Foundation of China [81772875, U1932135, 82073889]; Science and Technology Commission of Shanghai [20DZ2270800, 19JC1410200]; Clinical Research Plan of SHDC [SHDC2020CR1009A]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai(Science & Technology Commission of Shanghai Municipality (STCSM)); Clinical Research Plan of SHDC	We express our sincere thanks for all the patients participated in our study and wish them good health. This work was supported by the National Key Research and Development Plan (2017YFE0196300), the National Natural Science Foundation of China (81772875, U1932135, 82073889), the Clinical Research Plan of SHDC (SHDC2020CR1009A), the Science and Technology Commission of Shanghai (20DZ2270800 and 19JC1410200).	Angeloni V, 2015, SEMIN CANCER BIOL, V31, P43, DOI 10.1016/j.semcancer.2014.08.004; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Braun KM, 2008, CELL STEM CELL, V2, P406, DOI 10.1016/j.stem.2008.04.011; Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; de Waard NE, 2015, OCUL ONCOL PATHOL, V1, P182, DOI 10.1159/000371555; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Gao YF, 2019, CELL RES, V29, P767, DOI 10.1038/s41422-019-0210-3; Giraud J, 2016, CANCER RES, V76, P3618, DOI 10.1158/0008-5472.CAN-15-1497; Han B, 2020, EMBO REP, V21, DOI 10.15252/embr.201949229; Hsu PJ, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1336-6; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jia RB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1088-x; Jin B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01173-x; Kalirai H, 2011, INVEST OPHTH VIS SCI, V52, P8458, DOI 10.1167/iovs.11-7379; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Lai CY, 2012, CANCER RES, V72, P5111, DOI 10.1158/0008-5472.CAN-12-0624; Larsen AC, 2016, ACTA OPHTHALMOL, V94, P1, DOI 10.1111/aos.13100; Li A, 2017, CELL RES, V27, P444, DOI 10.1038/cr.2017.10; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li P, 2020, AUTOPHAGY, V16, P1186, DOI 10.1080/15548627.2019.1659614; Li ZR, 2018, CELL RES, V28, P904, DOI 10.1038/s41422-018-0072-0; Linder B, 2015, NAT METHODS, V12, P767, DOI [10.1038/NMETH.3453, 10.1038/nmeth.3453]; Liu L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1119-7; Liu LW, 2019, J CANCER, V10, P5447, DOI 10.7150/jca.35053; Mackiewicz J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0456-1; Meyer KD, 2019, NAT METHODS, V16, P1275, DOI 10.1038/s41592-019-0570-0; Missotten GS, 2005, INVEST OPHTH VIS SCI, V46, P75, DOI 10.1167/iovs.04-0344; Moore AR, 2018, CELL REP, V22, P2455, DOI 10.1016/j.celrep.2018.01.081; Moore MJ, 2014, NAT PROTOC, V9, P263, DOI 10.1038/nprot.2014.012; Murphy GF, 2014, MOL ASPECTS MED, V39, P33, DOI 10.1016/j.mam.2013.10.003; Newel F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11107-x; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rappa G, 2013, EXP CELL RES, V319, P810, DOI 10.1016/j.yexcr.2013.01.003; Shah A, 2017, BIOINFORMATICS, V33, P566, DOI 10.1093/bioinformatics/btw653; Shang QF, 2019, EPIGENOMICS-UK, V11, P787, DOI 10.2217/epi-2019-0029; Shi HL, 2018, NATURE, V563, P249, DOI 10.1038/s41586-018-0666-1; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Shidal C, 2019, CANCER RES, V79, P3622, DOI 10.1158/0008-5472.CAN-18-2659; Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P1497; Smit KN, 2020, PROG RETIN EYE RES, V75, DOI 10.1016/j.preteyeres.2019.100800; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Sun Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12733-1; Terai K, 2018, STEM CELLS, V36, P1154, DOI 10.1002/stem.2835; Tuomaala S, 2002, INVEST OPHTH VIS SCI, V43, P3399; Vu LP, 2019, CANCER DISCOV, V9, P25, DOI 10.1158/2159-8290.CD-18-0959; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Weyn-Vanhentenryck SM, 2014, CELL REP, V6, P1139, DOI 10.1016/j.celrep.2014.02.005; Yang J, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834018757175; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422-018-0040-8; Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yue YN, 2015, GENE DEV, V29, P1343, DOI 10.1101/gad.262766.115; Zhang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1070-7; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang Sisi, 2018, Yichuan, V40, P1044, DOI 10.16288/j.yczz.18-178; Zhang Y, 2019, P NATL ACAD SCI USA, V116, P976, DOI 10.1073/pnas.1812536116; Zhang Z, 2017, NUCLEIC ACIDS RES, V45, pD18, DOI 10.1093/nar/gkw1060; Zhao L, 2020, J CELL MOL MED, V24, P511, DOI 10.1111/jcmm.14758; Zhou JF, 2017, THERANOSTICS, V7, P1447, DOI 10.7150/thno.17451	66	7	7	4	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1281	1297		10.1038/s41388-021-02146-0	http://dx.doi.org/10.1038/s41388-021-02146-0		FEB 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35110680				2022-12-17	WOS:000749991400001
J	Li, MJ; Rao, XP; Cui, Y; Zhang, L; Li, X; Wang, BY; Zheng, YJ; Teng, LS; Zhou, TH; Zhuo, W				Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Wang, Boya; Zheng, Yijun; Teng, Lisong; Zhou, Tianhua; Zhuo, Wei			The keratin 17/YAP/IL6 axis contributes to E-cadherin loss and aggressiveness of diffuse gastric cancer	ONCOGENE			English	Article							HIPPO PATHWAY; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; YAP; MUTATIONS; ACTIVATION; CARCINOMA; GROWTH; CDH1; RHOA	DGC is a particular aggressive malignancy with poor prognosis. Recent omics studies characterized DGC with CDH1/E-cadherin loss and EMT-signatures. However, the underlying mechanisms for maintaining the aggressive behavior and molecular features of DGC remain unclear. Here, we find that intermediate filaments KRT17 is significantly lower in DGC tissues than that in intestinal gastric cancer tissues and associated with poor prognosis of DGC. We demonstrate that downregulation of KRT17 induces E-cadherin loss, EMT changes, and metastasis behaviors of GC cells. Mechanistically, the loss of intermediate filaments KRT17 induces reorganization of cytoskeleton, further activates YAP signaling, and increases IL6 expression, which contributes to the enhanced metastasis ability of GC cells. Together, these results indicate that KRT17/YAP/IL6 axis contributes to maintaining E-cadherin loss, EMT feature, and metastasis of DGC, providing a new insight into the role of aberrant intermediate filaments in DGC malignancy.	[Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Zheng, Yijun; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Cell Biol, Sch Med, Hangzhou, Peoples R China; [Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Zheng, Yijun; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Sch Med, Hangzhou, Peoples R China; [Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Zheng, Yijun; Teng, Lisong; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China; [Li, Mengjie; Rao, Xianping; Cui, Yun; Zhang, Lu; Li, Xiang; Wang, Boya; Zhou, Tianhua; Zhuo, Wei] Zhejiang Univ, Inst Gastroenterol, Hangzhou, Peoples R China; [Wang, Boya] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Pharm, Sch Med, Hangzhou, Peoples R China; [Zheng, Yijun; Teng, Lisong] Zhejiang Univ, Affiliated Hosp 1, Dept Surg Oncol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China; [Zhou, Tianhua] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University; University of Toronto	Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Cell Biol, Sch Med, Hangzhou, Peoples R China.; Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gastroenterol, Sch Med, Hangzhou, Peoples R China.; Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou, Peoples R China.; Zhou, TH; Zhuo, W (corresponding author), Zhejiang Univ, Inst Gastroenterol, Hangzhou, Peoples R China.; Zhou, TH (corresponding author), Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.	tzhou@zju.edu.cn; wzhuo@zju.edu.cn	li, mengjie/GRS-3931-2022; zhou, tianhua/K-4908-2013	zhou, tianhua/0000-0002-1791-2124; Zheng, Yijun/0000-0002-5064-8935; Zhuo, Wei/0000-0002-8251-4210	National Natural Science Foundation of China [31771540, 81972276, 82173040, 91740205, 31620103911]; Natural Scientific Foundation of Zhejiang Province, China [LYY19H310011]; Fundamental Research Funds for the Central Universities [2021QNA7004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Scientific Foundation of Zhejiang Province, China(Natural Science Foundation of Zhejiang Province); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Hai Song for providing pcDNA3.1-YAP plasmid. This work was supported by the National Natural Science Foundation of China (31771540, 81972276, 82173040, 91740205, 31620103911), Natural Scientific Foundation of Zhejiang Province, China (LYY19H310011), Fundamental Research Funds for the Central Universities (2021QNA7004).	Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; BECKER KF, 1994, CANCER RES, V54, P3845; Benham-Pyle BW, 2015, SCIENCE, V348, P1024, DOI 10.1126/science.aaa4559; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chivu-Economescu M, 2017, GASTRIC CANCER, V20, P948, DOI 10.1007/s10120-017-0712-y; Chivu-Economescu M, 2010, HEPATO-GASTROENTEROL, V57, P1453; Cho SY, 2017, GASTROENTEROLOGY, V153, P536, DOI 10.1053/j.gastro.2017.05.012; Choi W, 2018, CANCER RES, V78, P3306, DOI 10.1158/0008-5472.CAN-17-3487; Coccolini F, 2013, WORLD J GASTROENTERO, V19, P6979, DOI 10.3748/wjg.v19.i41.6979; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Corso G, 2013, J CLIN ONCOL, V31, P868, DOI 10.1200/JCO.2012.44.4612; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Eliazer S, 2019, CELL STEM CELL, V25, P654, DOI 10.1016/j.stem.2019.08.007; Enzo E, 2015, EMBO J, V34, P1349, DOI 10.15252/embj.201490379; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Fitzgerald RC, 2010, J MED GENET, V47, P436, DOI 10.1136/jmg.2009.074237; Ge S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03121-2; Ham IH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0972-8; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henson DE, 2004, ARCH PATHOL LAB MED, V128, P765; Hobbs RP, 2016, ONCOGENE, V35, P5653, DOI 10.1038/onc.2016.102; Hu H, 2018, J CANCER, V9, P346, DOI 10.7150/jca.19838; Huang CH, 2020, INT J CANCER, V146, P1937, DOI 10.1002/ijc.32609; Ide M, 2012, ANN SURG ONCOL, V19, P3506, DOI 10.1245/s10434-012-2437-9; Jiao S, 2018, J EXP MED, V215, P699, DOI 10.1084/jem.20171116; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kakiuchi M, 2014, NAT GENET, V46, P583, DOI 10.1038/ng.2984; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Khanom R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161163; Kim HJ, 2015, BIOMOL THER, V23, P301, DOI 10.4062/biomolther.2015.032; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Kurokawa I, 2011, EXP DERMATOL, V20, P217, DOI 10.1111/j.1600-0625.2009.01006.x; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lee JY, 2017, GUT LIVER, V11, P807, DOI 10.5009/gnl17033; Lee JH, 2018, ANN SURG, V267, P105, DOI 10.1097/SLA.0000000000002040; Lee KH, 2013, ANTICANCER RES, V33, P3765; Li D, 2020, CANCER MANAG RES, V12, P2087, DOI 10.2147/CMAR.S243129; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lim HYG, 2020, NATURE, V585, P404, DOI 10.1038/s41586-020-2647-4; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Liu Z, 2020, J PROTEOMICS, V211, DOI 10.1016/j.jprot.2019.103557; Mahmud N, 2015, J CLIN ONCOL, V33, pE19, DOI 10.1200/JCO.2013.49.1159; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Mun DG, 2019, CANCER CELL, V35, P111, DOI 10.1016/j.ccell.2018.12.003; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Oliveira C, 2015, LANCET ONCOL, V16, pE60, DOI 10.1016/S1470-2045(14)71016-2; Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013; Park J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10729-5; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; PROBY CM, 1993, AM J PATHOL, V143, P1667; Qi Yi-Jun, 2020, PLoS Biol, V18, pe3000825, DOI 10.1371/journal.pbio.3000825; Quinn JJ, 2021, SCIENCE, V371, P909, DOI 10.1126/science.abc1944; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rodriguez-Boulan E, 2014, NAT REV MOL CELL BIO, V15, P225, DOI 10.1038/nrm3775; Shen B, 2013, CELL RES, V23, P720, DOI 10.1038/cr.2013.46; Shimada S, 2012, GUT, V61, P344, DOI 10.1136/gutjnl-2011-300050; Shintani Y, 2016, J THORAC ONCOL, V11, P1482, DOI 10.1016/j.jtho.2016.05.025; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Tang Y, 2020, CANCER CELL, V38, P115, DOI 10.1016/j.ccell.2020.05.019; van der Post RS, 2015, J MED GENET, V52, P361, DOI 10.1136/jmedgenet-2015-103094; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang YB, 2018, CIRCULATION, V138, P48, DOI 10.1161/CIRCULATIONAHA.117.032398; Wang Z, 2019, CANCER MANAG RES, V11, P7485, DOI 10.2147/CMAR.S218926; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Weng YS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0988-0; Xu X, 2015, INT J ONCOL, V46, P2479, DOI 10.3892/ijo.2015.2966; Yang N, 2020, THERANOSTICS, V10, P5790, DOI 10.7150/thno.44789; Yimlamai D, 2014, CELL, V157, P1324, DOI 10.1016/j.cell.2014.03.060; Yoon C, 2016, CLIN CANCER RES, V22, P971, DOI 10.1158/1078-0432.CCR-15-1356; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yue T, 2012, DEV CELL, V22, P255, DOI 10.1016/j.devcel.2011.12.011; Zhang HS, 2020, CANCER DISCOV, V10, P288, DOI 10.1158/2159-8290.CD-19-0811; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhou X, 2015, J CLIN INVEST, V125, P2123, DOI 10.1172/JCI79573	80	7	7	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					770	781		10.1038/s41388-021-02119-3	http://dx.doi.org/10.1038/s41388-021-02119-3		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34845376				2022-12-17	WOS:000723571700005
J	Findlay, IJ; De Iuliis, GN; Duchatel, RJ; Jackson, ER; Vitanza, NA; Cain, JE; Waszak, SM; Dun, MD				Findlay, Izac J.; De Iuliis, Geoffry N.; Duchatel, Ryan J.; Jackson, Evangeline R.; Vitanza, Nicholas A.; Cain, Jason E.; Waszak, Sebastian M.; Dun, Matthew D.			Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies	ONCOGENE			English	Review							INTRINSIC PONTINE GLIOMA; HIGH-GRADE; THERAPEUTIC TARGETS; MUTATIONS; INHIBITION; ACVR1; PREDISPOSITION; SUBGROUPS; RADIATION; BREAST	Diffuse midline glioma (DMG) is a deadly pediatric and adolescent central nervous system (CNS) tumor localized along the midline structures of the brain atop the spinal cord. With a median overall survival (OS) of just 9-11-months, DMG is characterized by global hypomethylation of histone H3 at lysine 27 (H3K27me3), driven by recurring somatic mutations in H3 genes including, HIST1H3B/C (H3.1K27M) or H3F3A (H3.3K27M), or through overexpression of EZHIP in patients harboring wildtype H3. The recent World Health Organization's 5th Classification of CNS Tumors now designates DMG as, 'H3 K27-altered', suggesting that global H3K27me3 hypomethylation is a ubiquitous feature of DMG and drives devastating transcriptional programs for which there are no treatments. H3-alterations co-segregate with various other somatic driver mutations, highlighting the high-level of intertumoral heterogeneity of DMG. Furthermore, DMG is also characterized by very high-level intratumoral diversity with tumors harboring multiple subclones within each primary tumor. Each subclone contains their own combinations of driver and passenger lesions that continually evolve, making precision-based medicine challenging to successful execute. Whilst the intertumoral heterogeneity of DMG has been extensively investigated, this is yet to translate to an increase in patient survival. Conversely, our understanding of the non-genomic factors that drive the rapid growth and fatal nature of DMG, including endogenous and exogenous microenvironmental influences, neurological cues, and the posttranscriptional and posttranslational architecture of DMG remains enigmatic or at best, immature. However, these factors are likely to play a significant role in the complex biological sequelae that drives the disease. Here we summarize the heterogeneity of DMG and emphasize how analysis of the posttranslational architecture may improve treatment paradigms. We describe factors that contribute to treatment response and disease progression, as well as highlight the potential for pharmaco-proteogenomics (i.e., the integration of genomics, proteomics and pharmacology) in the management of this uniformly fatal cancer.	[Findlay, Izac J.; Duchatel, Ryan J.; Jackson, Evangeline R.; Dun, Matthew D.] Univ Newcastle, Sch Biomed Sci & Pharm, Coll Hlth Med & Wellbeing, Canc Signalling Res Grp, Callaghan, NSW, Australia; [Findlay, Izac J.; Duchatel, Ryan J.; Jackson, Evangeline R.; Dun, Matthew D.] Hunter Med Res Inst, Canc Res Program, New Lambton Hts, NSW, Australia; [De Iuliis, Geoffry N.] Univ Newcastle, Sch Environm & Life Sci, Coll Engn Sci & Environm, Reprod Sci Grp, Callaghan, NSW, Australia; [Vitanza, Nicholas A.] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA USA; [Vitanza, Nicholas A.] Seattle Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA USA; [Cain, Jason E.] Hudson Inst Med Res, Clayton, Vic, Australia; [Cain, Jason E.] Monash Univ, Dept Paediat, Clayton, Vic, Australia; [Waszak, Sebastian M.] Univ Oslo, Nord EMBL Partnership, Ctr Mol Med Norway NCMM, Oslo, Norway; [Waszak, Sebastian M.] Oslo Univ Hosp, Oslo, Norway; [Waszak, Sebastian M.] Oslo Univ Hosp, Rikshosp, Div Pediat & Adolescent Med, Dept Pediat Res, Oslo, Norway	University of Newcastle; Hunter Medical Research Institute; University of Newcastle; University of Newcastle; Seattle Children's Hospital; Seattle Children's Hospital; Hudson Institute of Medical Research; Monash University; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway	Dun, MD (corresponding author), Univ Newcastle, Sch Biomed Sci & Pharm, Coll Hlth Med & Wellbeing, Canc Signalling Res Grp, Callaghan, NSW, Australia.; Dun, MD (corresponding author), Hunter Med Res Inst, Canc Res Program, New Lambton Hts, NSW, Australia.	matt.dun@newcastle.edu.au	De Iuliis, Geoffry N./G-7042-2013	De Iuliis, Geoffry N./0000-0002-6978-6123; Dun, Matthew/0000-0002-9063-5370; Duchatel, Ryan/0000-0002-3651-7672; Findlay, Izac/0000-0002-3192-5888	Defeat DIPG ChadTough New Investigator Fellowship; NHMRC [GNT1173892]; DIPG Collaborative; RUN DIPG Ltd.; Strategic Group; McDonald Jones Foundation; Vinva Foundation; PNOC Foundation; Yuvaan Tiwari Foundation; Kiriwina Investments, Kids Cancer Project; Hunter Medical Research Institute; Isabella and Marcus Foundation Scholarship; Australian Communities Foundation	Defeat DIPG ChadTough New Investigator Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); DIPG Collaborative; RUN DIPG Ltd.; Strategic Group; McDonald Jones Foundation; Vinva Foundation; PNOC Foundation; Yuvaan Tiwari Foundation; Kiriwina Investments, Kids Cancer Project; Hunter Medical Research Institute; Isabella and Marcus Foundation Scholarship; Australian Communities Foundation	MDD is supported by a Defeat DIPG ChadTough New Investigator Fellowship and an NHMRC Investigator Grant -GNT1173892. The contents of the published material are solely the responsibility of the research institutions involved or individual authors and do not reflect the views of NHMRC. This project was supported by the DIPG Collaborative, RUN DIPG Ltd, Strategic Group, McDonald Jones Foundation, Vinva Foundation, PNOC Foundation, Yuvaan Tiwari Foundation, Kiriwina Investments, Kids Cancer Project, and the Hunter Medical Research Institute. ERJ is supported via the Josephine Dun Scholarship from the Isabella and Marcus Foundation Scholarship, a sub fund of Australian Communities Foundation.	Akamandisa MP, 2019, NEURO-ONCOLOGY, V21, P786, DOI 10.1093/neuonc/noz053; Ali NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0437-3; Antin C, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01056-8; Baker SJ, 2016, GLIA, V64, P879, DOI 10.1002/glia.22945; Brown ZZ, 2014, J AM CHEM SOC, V136, P13498, DOI 10.1021/ja5060934; Bruce DL, 2012, FEBS LETT, V586, P1897, DOI 10.1016/j.febslet.2012.02.001; Buczkowicz P, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00147; Buczkowicz P, 2014, NAT GENET, V46, P451, DOI 10.1038/ng.2936; Castel D, 2020, ACTA NEUROPATHOL, V139, P1109, DOI 10.1007/s00401-020-02142-w; Castel D, 2015, ACTA NEUROPATHOL, V130, P815, DOI 10.1007/s00401-015-1478-0; Chambliss AB, 2016, CLIN PROTEOM, V13, DOI 10.1186/s12014-016-9127-8; Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113; Chen ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01004; Cooper CD, 2002, J BIOL CHEM, V277, P44962, DOI 10.1074/jbc.M209427200; Corsello SM, 2020, NAT CANCER, V1, P235, DOI 10.1038/s43018-019-0018-6; de Leeuw R, 2018, CLIN CANCER RES, V24, P4201, DOI 10.1158/1078-0432.CCR-18-0410; Demma MJ, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00248-19; Duchatel RJ, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800479; Dun MD, 2015, MOL CELL PROTEOMICS, V14, P2316, DOI 10.1074/mcp.M114.046110; Fontebasso AM, 2014, NAT GENET, V46, P462, DOI 10.1038/ng.2950; Garner EF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25263-5; Georgescu MM, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-00992-9; Gillis NK, 2014, CLIN PHARMACOL THER, V95, P269, DOI 10.1038/clpt.2013.214; Grasso CS, 2015, NAT MED, V21, P555, DOI 10.1038/nm.3855; Gymnopoulos M, 2007, P NATL ACAD SCI USA, V104, P5569, DOI 10.1073/pnas.0701005104; Hanna C, 2020, NEURO-ONCOLOGY, V22, P1840, DOI 10.1093/neuonc/noaa104; Hart LS, 2017, CLIN CANCER RES, V23, P1785, DOI 10.1158/1078-0432.CCR-16-1131; Harutyunyan AS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09140-x; He B, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00830-3; HIRATA E, 2017, CSH PERSPECT MED, V7, DOI [10.1101/cshperspect.a026781, DOI 10.1101/CSHPERSPECT.A026781]; Hoeman CM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08823-9; Hoffman LM, 2018, J CLIN ONCOL, V36, P1963, DOI 10.1200/JCO.2017.75.9308; Hoffman LM, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-015-0269-0; Hong Semie, 2005, Cancer Res Treat, V37, P109, DOI 10.4143/crt.2005.37.2.109; Hopkins BD, 2018, NATURE, V560, P499, DOI 10.1038/s41586-018-0343-4; Jain SU, 2020, MOL CELL, V80, P726, DOI 10.1016/j.molcel.2020.09.028; Kluiver TA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00092; Koschmann C, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0033-y; Kostaras X, 2014, CURR ONCOL, V21, pE493, DOI 10.3747/co.21.1769; Lapin DH, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00057; Larson JD, 2019, CANCER CELL, V35, P140, DOI 10.1016/j.ccell.2018.11.015; Lee CH, 2019, GENE DEV, V33, P1428, DOI 10.1101/gad.328773.119; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Lin GL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw0064; Lobbous M, 2020, CANCERS, V12, DOI 10.3390/cancers12010114; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Ma XT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7604; Mackay A, 2017, CANCER CELL, V32, P520, DOI 10.1016/j.ccell.2017.08.017; Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268; Martin DDO, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25903-w; Marzluff WF, 2002, GENOMICS, V80, P487, DOI 10.1006/geno.2002.6850; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Menden MP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05811-3; Mu MD, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03105-5; Mueller S, 2019, INT J CANCER, V145, P1889, DOI 10.1002/ijc.32258; Murray HC, 2021, LEUKEMIA, V35, P1782, DOI 10.1038/s41375-020-01050-y; Nagaraja S, 2017, CANCER CELL, V31, P635, DOI 10.1016/j.ccell.2017.03.011; Nandal S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020448; Nikbakht H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11185; Nikolaev A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020490; Oh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17139-y; Oliver MD, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160258; Omar SI, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200769; Pajovic S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19972-7; Pal S, 2018, CANCER RES, V78, P4007, DOI 10.1158/0008-5472.CAN-17-3691; Paugh BS, 2013, CANCER RES, V73, P6219, DOI 10.1158/0008-5472.CAN-13-1491; Petralia F, 2020, CELL, V183, P1962, DOI 10.1016/j.cell.2020.10.044; Pfaff E, 2019, EUR J CANCER, V114, P27, DOI 10.1016/j.ejca.2019.03.019; Riba A, 2019, P NATL ACAD SCI USA, V116, P15023, DOI 10.1073/pnas.1817299116; Roden DM, 2006, ANN INTERN MED, V145, P749, DOI 10.7326/0003-4819-145-10-200611210-00007; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Rushing EJ, 2021, MEMO-MAG EUR MED ONC, V14, P188, DOI 10.1007/s12254-021-00680-x; Schettini F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00608; Sheppard KE, 2013, CLIN CANCER RES, V19, P5320, DOI 10.1158/1078-0432.CCR-13-0259; Sievers P, 2021, NEURO-ONCOLOGY, V23, P34, DOI 10.1093/neuonc/noaa251; Sillar JR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236003; Silveira AB, 2019, ACTA NEUROPATHOL, V137, P637, DOI 10.1007/s00401-019-01975-4; Sulman EP, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.659800; Szenker E, 2011, CELL RES, V21, P421, DOI 10.1038/cr.2011.14; Taylor IC, 2015, J NEUROPATH EXP NEUR, V74, P778, DOI 10.1097/NEN.0000000000000216; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; Velpula KK, 2012, TRANSL ONCOL, V5, P379, DOI 10.1593/tlo.12235; Venkatesh HS, 2019, NATURE, V573, P539, DOI 10.1038/s41586-019-1563-y; Vinci M, 2018, NAT MED, V24, P1204, DOI 10.1038/s41591-018-0086-7; Vitanza NA, 2021, J APPL LAB MED, V6, P550, DOI 10.1093/jalm/jfaa086; Vitanza NA, 2021, NEURO-ONCOLOGY, V23, P376, DOI 10.1093/neuonc/noaa249; Walker JA, 2018, EXPERT OPIN THER TAR, V22, P419, DOI 10.1080/14728222.2018.1465931; Wang HW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10299-6; Wang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161859; Wen PY, 2020, CLIN CANCER RES, V26, P1820, DOI 10.1158/1078-0432.CCR-19-2808; Werbrouck C, 2019, CLIN CANCER RES, V25, P6788, DOI 10.1158/1078-0432.CCR-19-0126; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wiese M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02800-7; Wong M, 2020, NAT MED, V26, P1742, DOI 10.1038/s41591-020-1072-4; Wu G, 2014, NAT GENET, V46, P444, DOI 10.1038/ng.2938; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; YU JR, 2021, SCI ADV, P7; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054; Zhang Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0463-7; Zhu XT, 2021, ACTA NEUROPATHOL COM, V9, DOI 10.1186/s40478-020-01107-0	100	7	7	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2022	41	4					461	475		10.1038/s41388-021-02102-y	http://dx.doi.org/10.1038/s41388-021-02102-y		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK9PJ	34759345	Green Published, hybrid			2022-12-17	WOS:000716867900003
J	Polosukhina, D; Singh, K; Asim, M; Barry, DP; Allaman, MM; Hardbower, DM; Piazuelo, MB; Washington, MK; Gobert, AP; Wilson, KT; Coburn, LA				Polosukhina, Dina; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Hardbower, Dana M.; Piazuelo, M. Blanca; Washington, M. Kay; Gobert, Alain P.; Wilson, Keith T.; Coburn, Lori A.			CCL11 exacerbates colitis and inflammation-associated colon tumorigenesis	ONCOGENE			English	Article							CHEMOKINE RECEPTOR CCR3; ULCERATIVE-COLITIS; BOWEL-DISEASE; COLORECTAL-CANCER; EOTAXIN-1; SERUM	CCL11, also known as eotaxin-1, is described as an eosinophil chemoattractant, which has been implicated in allergic and Th2 inflammatory diseases. We have reported that CCL11 is significantly increased in the serum of inflammatory bowel disease (IBD) patients, colonic eosinophils are increased and correlate with tissue CCL11 levels in ulcerative colitis patients, and CCL11 is increased in dextran sulfate sodium (DSS)-induced murine colitis. Here, we show that CCL11 is involved in the pathogenesis of DSS-induced colitis and in colon tumorigenesis in the azoxymethane (AOM)-DSS model of colitis-associated carcinogenesis (CAC). Ccl11(-/-) mice exposed to DSS then allowed to recover had significantly less body weight loss and a decrease in histologic injury versus wild-type (WT) mice. In the AOM-DSS model, Ccl11(-/-) mice exhibited decreased colonic tumor number and burden, histologic injury, and colonic eosinophil infiltration versus WT mice. Ccl11 is expressed by both colonic epithelial and lamina propria immune cells. Studies in bone marrow chimera mice revealed that hematopoietic- and epithelial-cell-derived CCL11 were both important for tumorigenesis in the AOM-DSS model. These findings indicate that CCL11 is important in the regulation of colitis and associated carcinogenesis and thus anti-CCL11 antibodies may be useful for treatment and cancer chemoprevention in IBD.	[Polosukhina, Dina; Singh, Kshipra; Asim, Mohammad; Barry, Daniel P.; Allaman, Margaret M.; Hardbower, Dana M.; Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.; Coburn, Lori A.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA; [Hardbower, Dana M.; Washington, M. Kay; Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Piazuelo, M. Blanca; Gobert, Alain P.; Wilson, Keith T.; Coburn, Lori A.] Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Wilson, Keith T.; Coburn, Lori A.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA; [Coburn, Lori A.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Coburn, LA (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37232 USA.; Coburn, LA (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Coburn, LA (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.; Coburn, LA (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	lori.coburn@vumc.org	Allaman, Margaret/GNO-9854-2022; /B-5647-2008	Wilson, Keith/0000-0003-4421-1830; Coburn, Lori/0000-0003-3249-9806; /0000-0002-3972-3914	NIH training grant [5T32DK007673]; Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award [1IK2BX002126]; Veterans Affairs Merit Award [1I01BX004366]; National Institutes of Health (NIH) [R01DK128200, R01CA190612, P01CA116087, P01CA028842]; Veterans Affairs Merit Review [I01CX002171]; Crohn's and Colitis Foundation Senior Research Award [703003]; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer [T32GM008554, F31DK10715]; NIH (Vanderbilt Digestive Disease Research Center) [P30DK058404]; NCI/NIH Cancer Center Support Grant [P30CA068485]; Vanderbilt Mouse Metabolic Phenotyping Center [U24DK059637]	NIH training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt Physician Scientist Development Award; Veterans Affairs Career Development Award; Veterans Affairs Merit Award(US Department of Veterans Affairs); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review(US Department of Veterans Affairs); Crohn's and Colitis Foundation Senior Research Award; Thomas F. Frist Sr. Endowment; Vanderbilt Center for Mucosal Inflammation and Cancer; NIH (Vanderbilt Digestive Disease Research Center)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH Cancer Center Support Grant; Vanderbilt Mouse Metabolic Phenotyping Center	LAC was supported by NIH training grant 5T32DK007673, a Vanderbilt Physician Scientist Development Award, a Veterans Affairs Career Development Award 1IK2BX002126, and a Veterans Affairs Merit Award 1I01BX004366. This work was also funded by National Institutes of Health (NIH) grants R01DK128200, R01CA190612, P01CA116087, and P01CA028842 (KTW), Veterans Affairs Merit Review grant I01CX002171 (KTW), Crohn's and Colitis Foundation Senior Research Award 703003 (KTW), the Thomas F. Frist Sr. Endowment (KTW), and the Vanderbilt Center for Mucosal Inflammation and Cancer (KTW). DMH was supported by T32GM008554 and F31DK10715. Additional support was provided by the Tissue Morphology Subcore of NIH Grant P30DK058404 (Vanderbilt Digestive Disease Research Center). The Translational Pathology Shared Resource was supported by NCI/NIH Cancer Center Support Grant P30CA068485 and the Vanderbilt Mouse Metabolic Phenotyping Center Grant U24DK059637.	Adar T, 2016, DIGEST DIS SCI, V61, P1915, DOI 10.1007/s10620-016-4047-z; Adar T, 2014, CLIN IMMUNOL, V153, P199, DOI 10.1016/j.clim.2014.04.012; Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; Ahrens R, 2008, J IMMUNOL, V181, P7390, DOI 10.4049/jimmunol.181.10.7390; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718; Chandrasekar B, 2013, J INFECT DIS, V207, P1556, DOI 10.1093/infdis/jit067; Coburn LA, 2019, ONCOGENE, V38, P1067, DOI 10.1038/s41388-018-0492-9; Coburn LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082300; Dahlhamer JM, 2016, MMWR-MORBID MORTAL W, V65, P1166, DOI 10.15585/mmwr.mm6542a3; Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Ferhat M, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.455; Forbes E, 2004, J IMMUNOL, V172, P5664, DOI 10.4049/jimmunol.172.9.5664; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Hardbower DM, 2017, ONCOGENE, V36, P3807, DOI 10.1038/onc.2017.23; Heidegger I, 2015, PROSTATE, V75, P1904, DOI 10.1002/pros.23086; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x; Karki R, 2019, NAT REV CANCER, V19, P197, DOI 10.1038/s41568-019-0123-y; Komura T, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/7436205; Levina V, 2009, CLIN CANCER RES, V15, P2647, DOI 10.1158/1078-0432.CCR-08-2024; Manousou P, 2010, CLIN EXP IMMUNOL, V162, P337, DOI 10.1111/j.1365-2249.2010.04248.x; Masterson JC, 2015, GUT, V64, P1236, DOI 10.1136/gutjnl-2014-306998; Olen O, 2020, LANCET, V395, P123, DOI 10.1016/S0140-6736(19)32545-0; Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451; Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052; Reichman H, 2019, CANCER IMMUNOL RES, V7, P388, DOI 10.1158/2326-6066.CIR-18-0494; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; Scoville EA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39232-z; Singh K, 2011, J BIOL CHEM, V286, P3839, DOI 10.1074/jbc.M110.176719; Vieira AT, 2009, AM J PATHOL, V175, P2382, DOI 10.2353/ajpath.2009.090093; Wagsater Dick, 2007, World J Surg Oncol, V5, P84, DOI 10.1186/1477-7819-5-84; Zimmerman NP, 2008, INFLAMM BOWEL DIS, V14, P1000, DOI 10.1002/ibd.20480	36	7	7	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6540	6546		10.1038/s41388-021-02046-3	http://dx.doi.org/10.1038/s41388-021-02046-3		OCT 2021	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34625710	Green Accepted			2022-12-17	WOS:000705760400004
J	Hua, QL; Zhang, BY; Xu, GJ; Wang, LQ; Wang, HH; Lin, ZY; Yu, DD; Ren, JH; Zhang, DJ; Zhao, L; Zhang, T				Hua, Qingling; Zhang, Biying; Xu, Guojie; Wang, Lanqing; Wang, Haihong; Lin, Zhenyu; Yu, Dandan; Ren, Jinghua; Zhang, Dejun; Zhao, Lei; Zhang, Tao			CEMIP, a novel adaptor protein of OGT, promotes colorectal cancer metastasis through glutamine metabolic reprogramming via reciprocal regulation of beta-catenin	ONCOGENE			English	Article							O-GLCNACYLATION; COLON-CANCER; EXPRESSION; KIAA1199; LOCALIZATION; TRANSDUCTION; TRANSPORTER; REVEALS; SLC1A5; GENE	Metastasis is the leading cause of colorectal cancer (CRC)-induced death. However, the underlying molecular mechanisms of CRC metastasis are poorly understood. Metabolic reprogramming is an intrinsic feature of cancer, which have complicated effects on cancer metastasis. Here, we find that a novel metastasis-related protein, cell migration-inducing and hyaluronan-binding protein (CEMIP), can act as a novel adaptor protein of O-GlcNAc transferase (OGT) to promote CRC metastasis through glutamine metabolic reprogramming. Mechanistically, CEMIP interacts with OGT and beta-catenin, which leads to elevated O-GlcNAcylation of beta-catenin and enhanced beta-catenin nuclear translocation from cytomembrane. Furthermore, accumulated beta-catenin in nucleus enhances the transcription of CEMIP to reciprocally regulate beta-catenin and contributes to over-expression of glutaminase 1 and glutamine transporters (SLC1A5 and SLC38A2). Combinational inhibition of CEMIP and glutamine metabolism could dramatically attenuate the metastasis of CRC in vivo. Collectively, this study reveals the importance of glutamine metabolic reprogramming in CEMIP-induced CRC metastasis, indicating the great potential of CEMIP and glutamine metabolism for CRC metastasis prevention.	[Hua, Qingling; Zhang, Biying; Xu, Guojie; Wang, Lanqing; Wang, Haihong; Lin, Zhenyu; Yu, Dandan; Ren, Jinghua; Zhang, Dejun; Zhao, Lei; Zhang, Tao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology	Zhao, L; Zhang, T (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China.	zhaolei8704@126.com; taozhangxh@hust.edu.cn		Hua, Qingling/0000-0002-4708-987X	National Natural Science Foundation of China [81874061, 81702392, 81903103]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work is supported by the National Natural Science Foundation of China (81874061 to TZ, 81702392 to LZ, and 81903103 to DZ).	Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birkenkamp-Demtroder K, 2011, BRIT J CANCER, V105, P552, DOI 10.1038/bjc.2011.268; Broer A, 2016, J BIOL CHEM, V291, P13194, DOI 10.1074/jbc.M115.700534; Chen C, 2014, INT J CLIN EXP MED, V7, P4253; Cheung WD, 2008, J BIOL CHEM, V283, P13009, DOI 10.1074/jbc.M801222200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Ding MC, 2020, INT J BIOL SCI, V16, P3100, DOI 10.7150/ijbs.48066; Evensen NA, 2013, JNCI-J NATL CANCER I, V105, P1402, DOI 10.1093/jnci/djt224; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gao SC, 2019, DNA CELL BIOL, V38, P286, DOI 10.1089/dna.2018.4447; Ha JR, 2014, EXP CELL RES, V321, P153, DOI 10.1016/j.yexcr.2013.11.021; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600; Duong HQ, 2018, CANCER RES, V78, P4533, DOI 10.1158/0008-5472.CAN-17-3149; Kasprowicz A, 2020, MOLECULES, V25, DOI 10.3390/molecules25194501; Liang GD, 2018, ACTA HISTOCHEM, V120, P56, DOI 10.1016/j.acthis.2017.11.002; Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Mafra ACP, 2019, CANCER RES, V79, P1302, DOI 10.1158/0008-5472.CAN-19-0313; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morotti M, 2021, BRIT J CANCER, V124, P494, DOI 10.1038/s41416-020-01113-y; Naka Y, 2020, ONCOL LETT, V20, P1171, DOI 10.3892/ol.2020.11665; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Sayat R, 2008, EXP CELL RES, V314, P2774, DOI 10.1016/j.yexcr.2008.05.017; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Schulte ML, 2018, NAT MED, V24, P194, DOI 10.1038/nm.4464; Sharma NS, 2020, J CLIN INVEST, V130, P451, DOI 10.1172/JCI127515; Shen YA, 2020, CANCER RES, V80, P4514, DOI 10.1158/0008-5472.CAN-19-3971; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stichelen SOV, 2012, AM J PHYSIOL-ENDOC M, V302, pE417, DOI 10.1152/ajpendo.00390.2011; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tiwari A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069473; Wei QY, 2020, ONCOGENE, V39, P6139, DOI 10.1038/s41388-020-01432-7; Yoo HC, 2020, CELL METAB, V31, P267, DOI 10.1016/j.cmet.2019.11.020; Yoshida H, 2013, P NATL ACAD SCI USA, V110, P5612, DOI 10.1073/pnas.1215432110; Zhang DJ, 2017, INT J CANCER, V140, P2298, DOI 10.1002/ijc.30656; Zhang P, 2018, FASEB J, V32, P3924, DOI 10.1096/fj.201701078R; Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00990-3; Zhao L, 2019, ONCOGENE, V38, P935, DOI 10.1038/s41388-018-0493-8; Zhou L, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152681	45	7	7	5	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6443	6455		10.1038/s41388-021-02023-w	http://dx.doi.org/10.1038/s41388-021-02023-w		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34608265				2022-12-17	WOS:000703526900002
J	Lebedev, T; Vagapova, E; Spirin, P; Rubtsov, P; Astashkova, O; Mikheeva, A; Sorokin, M; Vladimirova, U; Suntsova, M; Konovalov, D; Roumiantsev, A; Stocking, C; Buzdin, A; Prassolov, V				Lebedev, Timofey; Vagapova, Elmira; Spirin, Pavel; Rubtsov, Petr; Astashkova, Olga; Mikheeva, Alesya; Sorokin, Maxim; Vladimirova, Uliana; Suntsova, Maria; Konovalov, Dmitry; Roumiantsev, Alexander; Stocking, Carol; Buzdin, Anton; Prassolov, Vladimir			Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes	ONCOGENE			English	Article							GENE-EXPRESSION; IMATINIB MESYLATE; ERYTHROPOIETIN; CELLS; RECEPTOR; CLASSIFICATION; ACTIVATION; PATHWAYS; FREQUENT; MYCN	Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk NB, but their efficacy is likely impaired by the cancer cells' ability to adapt to these drugs through the employment of alternative signaling pathways. Based on the expression of 48 growth factor-related genes in 1189 NB tumors, we have developed a model for NB patient survival prediction. This model discriminates between stage 4 NB tumors with favorable outcomes (>80% overall survival) and very poor outcomes (<10%) independently from MYCN-amplification status. Using signaling pathway analysis and gene set enrichment methods in 60 NB patients with known therapy response, we identified signaling pathways, including EPO, NGF, and HGF, upregulated in patients with no or partial response. In a therapeutic setting, we showed that among six selected growth factors, EPO, and NGF showed the most pronounced protective effects in vitro against several promising anti-NB multikinase inhibitors: imatinib, dasatinib, crizotinib, cabozantinib, and axitinib. Mechanistically kinase inhibitors potentiated NB cells to stronger ERK activation by EPO and NGF. The protective action of these growth factors strongly correlated with ERK activation and was ERK-dependent. ERK inhibitors combined with anticancer drugs, especially with dasatinib, showed a synergistic effect on NB cell death. Consideration of growth factor signaling activity benefits NB outcome prediction and tailoring therapy regimens to treat NB.	[Lebedev, Timofey; Vagapova, Elmira; Spirin, Pavel; Rubtsov, Petr; Astashkova, Olga; Mikheeva, Alesya; Prassolov, Vladimir] Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Canc Cell Biol, Moscow, Russia; [Lebedev, Timofey; Vagapova, Elmira; Spirin, Pavel; Prassolov, Vladimir] Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia; [Astashkova, Olga; Mikheeva, Alesya; Buzdin, Anton] Natl Res Univ, Moscow Inst Phys & Technol, Moscow, Moscow Region, Russia; [Sorokin, Maxim; Buzdin, Anton] Shemyakin Ovchinnikov Inst Bioorgan Chem, Grp Genom Regulat Cell Signaling Syst, Moscow, Russia; [Sorokin, Maxim; Buzdin, Anton] OmicsWay Corp, Dept Bioinformat & Mol Networks, Walnut, CA USA; [Sorokin, Maxim; Vladimirova, Uliana; Suntsova, Maria; Buzdin, Anton] Sechenov First Moscow State Med Univ, Inst Personalized Med, Moscow, Russia; [Konovalov, Dmitry; Roumiantsev, Alexander] D Rogachyov Fed Res Ctr Pediat Hematol Oncol & Im, Moscow, Russia; [Stocking, Carol] Univ Med Ctr Hamburg Eppendorf UKE, Res Dept Cell & Gene Therapy, Dept Stem Cell Transplantat, Hamburg, Germany; [Stocking, Carol] Heinrich Pette Inst, Leibniz Inst Expt Virol, Hamburg, Germany	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Moscow Institute of Physics & Technology; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Sechenov First Moscow State Medical University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute	Lebedev, T (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Canc Cell Biol, Moscow, Russia.; Lebedev, T (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia.	lebedevtd@gmail.com	Mikheeva, Alesya/ABB-9826-2021; Lebedev, Timofey/ABG-3319-2021; Suntsova, Maria/O-2056-2013; Sorokin, Maksim I/P-1459-2017	Suntsova, Maria/0000-0002-0280-4446; Sorokin, Maksim I/0000-0001-7685-3446; Khabusheva, Elmira/0000-0002-2680-9356; Spirin, Pavel/0000-0002-0610-5079	RSF [19-74-00120]; RFBR [20-34-70119]; Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1660]; Russian Foundation for Basic Research [19-29-01108]	RSF(Russian Science Foundation (RSF)); RFBR(Russian Foundation for Basic Research (RFBR)); Ministry of Science and Higher Education of the Russian Federation; Russian Foundation for Basic Research(Russian Foundation for Basic Research (RFBR))	We thank Boris Fehse and Kristoffer Riecken (University Medical Center HamburgEppendorf, Hamburg, Germany) for providing LeGO packaging vectors. The creation and analysis of ERK-KTR cells were performed within the work funded by RSF project no. 19-74-00120. Cell viability measurement and drug-induced expression changes were supported by was funded by RFBR project no. 20-34-70119. The creation of cell lines with EPOR knockdown and automated microscopy work were supported by grant 075-15-2019-1660 from the Ministry of Science and Higher Education of the Russian Federation. Transcriptome analysis was financed by the Russian Foundation for Basic Research grant 19-29-01108.	Aikin TJ, 2020, ELIFE, V9, DOI 10.7554/eLife.60541; Andreotti AH, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002287; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Astels, 2017, J OPEN SOURCE SOFTW, V2, P205, DOI 10.21105/joss.00205; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Borisov N, 2020, METHODS MOL BIOL, V2063, P189, DOI 10.1007/978-1-0716-0138-9_15; Calafiore L, 2013, ANN ONCOL, V24, P1406, DOI 10.1093/annonc/mds648; Cangelosi D, 2020, CANCERS, V12, DOI 10.3390/cancers12092343; Chen ZH, 2017, ONCOTARGET, V8, P104090, DOI 10.18632/oncotarget.22011; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Daudigeos-Dubus E, 2017, INT J ONCOL, V50, P203, DOI 10.3892/ijo.2016.3792; Eggert A, 2000, KLIN PADIATR, V212, P200, DOI 10.1055/s-2000-9677; Eleveld TF, 2015, NAT GENET, V47, P864, DOI 10.1038/ng.3333; Foster JH, 2021, CLIN CANCER RES, V27, P3543, DOI 10.1158/1078-0432.CCR-20-4224; Goedhart J, 2021, MOL BIOL CELL, V32, P470, DOI 10.1091/mbc.E20-09-0583; Hartlieb SA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21247-8; He J, 2017, TRANSL ONCOL, V10, P936, DOI 10.1016/j.tranon.2017.09.008; Hirano I, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00105; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Vazquez-Mellado MJ, 2015, LIFE SCI, V137, P142, DOI 10.1016/j.lfs.2015.07.022; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Kocak H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.84; Korja M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-57; Lebedev TD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01046; Lord SJ, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001064; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Mlakar V, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0686-8; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Morandi F, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468953; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Petrov I, 2017, ONCOTARGET, V8, P83768, DOI 10.18632/oncotarget.19662; Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529; Rajbhandari P, 2018, CANCER DISCOV, V8, P582, DOI 10.1158/2159-8290.CD-16-0861; Regot S, 2014, CELL, V157, P1724, DOI 10.1016/j.cell.2014.04.039; Sartelet H, 2007, CANCER-AM CANCER SOC, V110, P1096, DOI 10.1002/cncr.22879; Scala S, 1996, CANCER RES, V56, P3737; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shohet J, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1863; Sokol E, 2019, CHILDREN-BASEL, V6, DOI 10.3390/children6020027; Spirin PV, 2014, LEUKEMIA, V28, P2222, DOI 10.1038/leu.2014.130; Stolze I, 2002, BLOOD, V100, P2623, DOI 10.1182/blood-2001-12-0169; Su ZQ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0523-y; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Todaro M, 2013, CANCER RES, V73, P6393, DOI 10.1158/0008-5472.CAN-13-0248; Uccini S, 2005, CLIN CANCER RES, V11, P380; Vagapova ER, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90701-w; Valentijn LJ, 2015, NAT GENET, V47, P1411, DOI 10.1038/ng.3438; Vitali R, 2009, INT J CANCER, V125, P2547, DOI 10.1002/ijc.24606; Wang C, 2014, NAT BIOTECHNOL, V32, P926, DOI 10.1038/nbt.3001; Wang K, 2011, NATURE, V469, P216, DOI 10.1038/nature09609; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	59	7	7	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6258	6272		10.1038/s41388-021-02018-7	http://dx.doi.org/10.1038/s41388-021-02018-7		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556815	hybrid, Green Published			2022-12-17	WOS:000698556400004
J	Di Giulio, S; Colicchia, V; Pastorino, F; Pedretti, F; Fabretti, F; di Robilant, VN; Ramponi, V; Scafetta, G; Moretti, M; Licursi, V; Belardinilli, F; Peruzzi, G; Infante, P; Goffredo, BM; Coppa, A; Canettieri, G; Bartolazzi, A; Ponzoni, M; Giannini, G; Petroni, M				Di Giulio, Stefano; Colicchia, Valeria; Pastorino, Fabio; Pedretti, Flaminia; Fabretti, Francesca; di Robilant, Vittoria Nicolis; Ramponi, Valentina; Scafetta, Giorgia; Moretti, Marta; Licursi, Valerio; Belardinilli, Francesca; Peruzzi, Giovanna; Infante, Paola; Goffredo, Bianca Maria; Coppa, Anna; Canettieri, Gianluca; Bartolazzi, Armando; Ponzoni, Mirco; Giannini, Giuseppe; Petroni, Marialaura			A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors	ONCOGENE			English	Article							N-MYC; HUMAN NEUROBLASTOMA; REPLICATION STRESS; EXPRESSION; CELLS; PROGRESSION; SENSITIVITY; DELETION; ONCOGENE; HMGI(Y)	MYCN drives aggressive behavior and refractoriness to chemotherapy, in several tumors. Since MYCN inactivation in clinical settings is not achievable, alternative vulnerabilities of MYCN-driven tumors need to be explored to identify more effective and less toxic therapies. We previously demonstrated that PARP inhibitors enhance MYCN-induced replication stress and promote mitotic catastrophe, counteracted by CHK1. Here, we showed that PARP and CHK1 inhibitors synergized to induce death in neuroblastoma cells and in primary cultures of SHH-dependent medulloblastoma, their combination being more effective in MYCN amplified and MYCN overexpressing cells compared to MYCN non-amplified cells. Although the MYCN amplified IMR-32 cell line carrying the p.Val2716Ala ATM mutation showed the highest sensitivity to the drug combination, this was not related to ATM status, as indicated by CRISPR/Cas9-based correction of the mutation. Suboptimal doses of the CHK1 inhibitor MK-8776 plus the PARP inhibitor olaparib led to a MYCN-dependent accumulation of DNA damage and cell death in vitro and significantly reduced the growth of four in vivo models of MYCN-driven tumors, without major toxicities. Our data highlight the combination of PARP and CHK1 inhibitors as a new potential chemo-free strategy to treat MYCN-driven tumors, which might be promptly translated into clinical trials.	[Di Giulio, Stefano; Colicchia, Valeria; Pedretti, Flaminia; Fabretti, Francesca; di Robilant, Vittoria Nicolis; Ramponi, Valentina; Belardinilli, Francesca; Canettieri, Gianluca; Giannini, Giuseppe; Petroni, Marialaura] Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy; [Pastorino, Fabio; Ponzoni, Mirco] IRCCS Ist Giannina Gaslini, Lab Expt Therapies Oncol, I-16147 Genoa, Italy; [Scafetta, Giorgia; Bartolazzi, Armando] St Andrea Univ Hosp, Pathol Res Lab, I-00189 Rome, Italy; [Moretti, Marta; Coppa, Anna] Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy; [Licursi, Valerio] Univ Roma La Sapienza, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy; [Peruzzi, Giovanna; Infante, Paola] Fdn Ist Italiano Tecnol IIT, Ctr Life Nano & Neuro Sci, Rome, Italy; [Goffredo, Bianca Maria] Osped Pediat Bambino Gesu, Metab Pathol Lab, I-00165 Rome, Italy; [Canettieri, Gianluca; Giannini, Giuseppe] Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy; [Colicchia, Valeria] Univ Tor Vergata, Dept Biol, I-00173 Rome, Italy; [Pedretti, Flaminia] Vail dHebron Inst Oncol VHIO, Vail dHebron Res Inst VHIR, Expt Therapeut Grp, Barcelona, Spain; [Ramponi, Valentina] Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Cellular Plast & Dis Grp, Barcelona 08028, Spain	Sapienza University Rome; University of Genoa; IRCCS Istituto Giannina Gaslini; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Sapienza University Rome; Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; IRCCS Bambino Gesu; Fondazione Cenci Bolognetti; University of Rome Tor Vergata; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Giannini, G (corresponding author), Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy.; Giannini, G (corresponding author), Ist Pasteur Fdn Cenci Bolognetti, I-00161 Rome, Italy.	giuseppe.giannini@uniroma1.it	Scafetta, Giorgia/AAB-9787-2022; Giannini, Giuseppe/B-5672-2013	Peruzzi, Giovanna/0000-0002-6517-9107; Giannini, Giuseppe/0000-0003-0299-4056; Belardinilli, Francesca/0000-0003-4966-7044; Infante, Paola/0000-0003-0682-3916; CANETTIERI, Gianluca/0000-0001-6694-2613	Italian Ministry of Education, Universities and Research-Dipartimenti di Eccellenza [L. 232/2016]; Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG17734, IG24329]; Italian Ministry of University and Research, PRIN projects; Istituto Pasteur-Fondazione Cenci Bolognetti; fondi Ricerca Ateneo La Sapienza; AIRC [IG17575]; AFM-Telethon grant [21025]; PhD Programme in Tecnologie Biomediche in Medicina Clinica, University La Sapienza; Fondazione Umberto Veronesi	Italian Ministry of Education, Universities and Research-Dipartimenti di Eccellenza(Ministry of Education, Universities and Research (MIUR)); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of University and Research, PRIN projects; Istituto Pasteur-Fondazione Cenci Bolognetti(Istituto Pasteur Italia Fondazione Cenci Bolognetti); fondi Ricerca Ateneo La Sapienza; AIRC(Fondazione AIRC per la ricerca sul cancro); AFM-Telethon grant; PhD Programme in Tecnologie Biomediche in Medicina Clinica, University La Sapienza; Fondazione Umberto Veronesi(Fondazione Umberto Veronesi)	We are grateful to Michele Cilli and Laura Emionite for technical supports in the animal facility and Antonio Daga for the luciferase transfection of IMR-32 cells. We are also grateful to Simone De Panfilis (CLN2S@Sapienza Imaging Facility of the Istituto Italiano di Tecnologia, Rome, Italy) for the acquisition of confocal microscopy data. This work was supported by: Italian Ministry of Education, Universities and Research-Dipartimenti di Eccellenza-L. 232/2016; Associazione Italiana per la Ricerca sul Cancro (AIRC) grant IG17734 and IG24329, Italian Ministry of University and Research, PRIN projects, Istituto Pasteur-Fondazione Cenci Bolognetti and fondi Ricerca Ateneo La Sapienza (to GG); AIRC grant IG17575, AFM-Telethon grant #21025, and Istituto Pasteur-Fondazione Cenci Bolognetti (to GC). FF and FB were recipients of fellowships from the PhD Programme in Tecnologie Biomediche in Medicina Clinica, University La Sapienza and Fondazione Umberto Veronesi, respectively.	Althoff K, 2015, ONCOGENE, V34, P3357, DOI 10.1038/onc.2014.269; Bendell JC, 2020, INVEST NEW DRUG, V38, P1145, DOI 10.1007/s10637-019-00873-6; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cash T, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.29065; Chayka O, 2015, J BIOL CHEM, V290, P2198, DOI 10.1074/jbc.M114.624056; Chesler L, 2011, SEMIN CANCER BIOL, V21, P245, DOI 10.1016/j.semcancer.2011.09.011; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Colicchia V, 2017, ONCOGENE, V36, P4682, DOI 10.1038/onc.2017.40; Cossu I, 2015, BIOMATERIALS, V68, P89, DOI 10.1016/j.biomaterials.2015.07.054; Daud AI, 2015, J CLIN ONCOL, V33, P1060, DOI 10.1200/JCO.2014.57.5027; Demuth I, 2011, NEUROGENETICS, V12, P273, DOI 10.1007/s10048-011-0299-0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng FY, 2015, MOL CELL, V58, P925, DOI 10.1016/j.molcel.2015.04.016; Forment JV, 2018, PHARMACOL THERAPEUT, V188, P155, DOI 10.1016/j.pharmthera.2018.03.005; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Giannini G, 1999, CANCER RES, V59, P2484; Giannini G, 2000, BRIT J CANCER, V83, P1503, DOI 10.1054/bjoc.2000.1494; Gu L, 2015, EBIOMEDICINE, V2, P1923, DOI 10.1016/j.ebiom.2015.11.016; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Hou HG, 2015, INT J CANCER, V136, P1688, DOI 10.1002/ijc.29132; Judware R, 1995, ONCOGENE, V11, P2599; Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095; Lee EK, 2019, TRENDS CANCER, V5, P524, DOI 10.1016/j.trecan.2019.06.004; Lowery CD, 2019, CLIN CANCER RES, V25, P2278, DOI 10.1158/1078-0432.CCR-18-2728; Lowery CD, 2017, CLIN CANCER RES, V23, P4354, DOI 10.1158/1078-0432.CCR-16-2876; Lupo B, 2014, BBA-REV CANCER, V1846, P201, DOI 10.1016/j.bbcan.2014.07.004; Lutz W, 1996, ONCOGENE, V13, P803; Mandriota SJ, 2015, ONCOTARGET, V6, P18558, DOI 10.18632/oncotarget.4061; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Olsen RR, 2017, ONCOGENE, V36, P5075, DOI 10.1038/onc.2017.128; Paquet D, 2016, NATURE, V533, P125, DOI 10.1038/nature17664; Pastorino F, 2003, CANCER RES, V63, P7400; Petroni M, 2016, CELL DEATH DIFFER, V23, P197, DOI 10.1038/cdd.2015.81; Petroni M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56057-y; Petroni M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0924-z; Petroni M, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1079673; Petroni M, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00141; Petroni M, 2011, MOL CANCER RES, V9, P67, DOI 10.1158/1541-7786.MCR-10-0227; Rickman DS, 2018, CANCER DISCOV, V8, P150, DOI 10.1158/2159-8290.CD-17-0273; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Russell MR, 2013, CANCER RES, V73, P776, DOI 10.1158/0008-5472.CAN-12-2669; Sanmartin E, 2017, CLIN CANCER RES, V23, P6875, DOI 10.1158/1078-0432.CCR-17-0593; Scott SP, 2002, P NATL ACAD SCI USA, V99, P925, DOI 10.1073/pnas.012329699; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Southgate HED, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00371; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Takagi M, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1409-7; Takagi M, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/.inci/djx062; Ubhi T, 2019, CANCER RES, V79, P1730, DOI 10.1158/0008-5472.CAN-18-3631; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Wehler T, 2017, LUNG CANCER, V108, P212, DOI 10.1016/j.lungcan.2017.03.001; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Yap Timothy A, 2019, Am Soc Clin Oncol Educ Book, V39, P185, DOI 10.1200/EDBK_238473	57	7	7	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6143	6152		10.1038/s41388-021-02003-0	http://dx.doi.org/10.1038/s41388-021-02003-0		SEP 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34508175	hybrid, Green Published			2022-12-17	WOS:000694774500002
J	Dong, CP; Cesarano, A; Bombaci, G; Reiter, JL; Yu, CY; Wang, Y; Jiang, ZY; Abu Zaid, M; Huang, K; Lu, XB; Walker, BA; Perna, F; Liu, YL				Dong, Chuanpeng; Cesarano, Annamaria; Bombaci, Giuseppe; Reiter, Jill L.; Yu, Christina Y.; Wang, Yue; Jiang, Zhaoyang; Abu Zaid, Mohammad; Huang, Kun; Lu, Xiongbin; Walker, Brian A.; Perna, Fabiana; Liu, Yunlong			Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma	ONCOGENE			English	Article							INTERNATIONAL STAGING SYSTEM; CHECKPOINT BLOCKADE; CELL; EXPRESSION; PATHWAY; FAMILY	Neoantigen peptides arising from genetic alterations may serve as targets for personalized cancer vaccines and as positive predictors of response to immune checkpoint therapy. Mutations in genes regulating RNA splicing are common in hematological malignancies leading to dysregulated splicing and intron retention (IR). In this study, we investigated IR as a potential source of tumor neoantigens in multiple myeloma (MM) patients and the relationship of IR-induced neoantigens (IR-neoAg) with clinical outcomes. MM-specific IR events were identified in RNA-sequencing data from the Multiple Myeloma Research Foundation CoMMpass study after removing IR events that also occurred in normal plasma cells. We quantified the IR-neoAg load by assessing IR-induced novel peptides that were predicted to bind to major histocompatibility complex (MHC) molecules. We found that high IR-neoAg load was associated with poor overall survival in both newly diagnosed and relapsed MM patients. Further analyses revealed that poor outcome in MM patients with high IR-neoAg load was associated with high expression levels of T-cell co-inhibitory molecules and elevated interferon signaling activity. We also found that MM cells exhibiting high IR levels had lower MHC-II protein abundance and treatment of MM cells with a spliceosome inhibitor resulted in increased MHC-I protein abundance. Our findings suggest that IR-neoAg may represent a novel biomarker of MM patient clinical outcome and further that targeting RNA splicing may serve as a potential therapeutic strategy to prevent MM immune escape and promote response to checkpoint blockade.	[Dong, Chuanpeng; Reiter, Jill L.; Wang, Yue; Jiang, Zhaoyang; Huang, Kun; Lu, Xiongbin; Walker, Brian A.; Liu, Yunlong] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA; [Dong, Chuanpeng; Huang, Kun; Liu, Yunlong] Indiana Univ Purdue Univ, Sch Informat & Comp, Dept BioHlth Informat, Indianapolis, IN 46202 USA; [Cesarano, Annamaria; Bombaci, Giuseppe; Yu, Christina Y.; Abu Zaid, Mohammad; Walker, Brian A.; Perna, Fabiana] Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; [Reiter, Jill L.; Wang, Yue; Lu, Xiongbin; Liu, Yunlong] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Jiang, Zhaoyang] Zionsville Community High Sch, Boone, IN 46077 USA; [Abu Zaid, Mohammad; Huang, Kun; Lu, Xiongbin; Walker, Brian A.; Perna, Fabiana; Liu, Yunlong] Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA; [Huang, Kun] Indiana Univ Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Liu, YL (corresponding author), Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA.; Liu, YL (corresponding author), Indiana Univ Purdue Univ, Sch Informat & Comp, Dept BioHlth Informat, Indianapolis, IN 46202 USA.; Perna, F (corresponding author), Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA.; Liu, YL (corresponding author), Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.; Perna, F; Liu, YL (corresponding author), Indiana Univ Sch Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46202 USA.	fabperna@iu.edu; yunliu@iu.edu	Abu Zaid, Mohammad/AFO-3625-2022; Reiter, Jill L/J-3335-2013; Reiter, Jill/AGZ-7331-2022	Reiter, Jill L/0000-0001-5460-2355; Reiter, Jill/0000-0001-5460-2355; Wang, Yue/0000-0003-4671-8547; Dong, Chuanpeng/0000-0001-5068-0495; Huang, Kun/0000-0002-8530-370X	Indiana University Grand Challenge Precision Health Initiative; NIH, National Cancer Institute (NCI) [P30 CA082709]; NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U54 DK106846]; NIH instrumentation grant [1S10D012270]; Leukemia Research Foundation grant	Indiana University Grand Challenge Precision Health Initiative; NIH, National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)National Research Council of Science & Technology (NST), Republic of Korea); NIH, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH instrumentation grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Research Foundation grant	The work was supported by the Indiana University Grand Challenge Precision Health Initiative. This study used the Multiple Myeloma Research Foundation (MMRF) CoMMpass Dataset. The authors acknowledge the efforts of the MMRF research consortium to provide the fundamental resource for our study. MM cell lines were provided by Dr. David Roodman, Indiana University School of Medicine. The authors thank the members of the Indiana University Melvin and Bren Simon Cancer Center (IUSCCC) Flow Cytometry Resource Facility (FCRF) for their outstanding technical support. The IUSCCC FCRF is funded in part by NIH, National Cancer Institute (NCI) grant P30 CA082709 and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant U54 DK106846. The FCRF is supported in part by NIH instrumentation grant 1S10D012270. F.P. is supported by a Leukemia Research Foundation grant and G.B. is a Kroemer Family Fellow in Myeloma Research.	Agirre X, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08679-z; Ahmad IA, 1996, AM STAT, V50, P324, DOI 10.2307/2684929; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Apcher S, 2011, P NATL ACAD SCI USA, V108, P11572, DOI 10.1073/pnas.1104104108; Bailey P, 2016, SCI REP-UK, V6, DOI 10.1038/srep35848; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Braunschweig U, 2014, GENOME RES, V24, P1774, DOI 10.1101/gr.177790.114; Brogna S, 2009, NAT STRUCT MOL BIOL, V16, P107, DOI 10.1038/nsmb.1550; Buchner M, 2014, CURR OPIN HEMATOL, V21, P341, DOI 10.1097/MOH.0000000000000048; Chabot B, 2016, J CELL BIOL, V212, P13, DOI 10.1083/jcb.201510032; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Chretien ML, 2015, BLOOD, V126, P2713, DOI 10.1182/blood-2015-06-650242; Cowan AJ, 2018, JAMA ONCOL, V4, P1221, DOI 10.1001/jamaoncol.2018.2128; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dufva O, 2020, CANCER CELL, V38, P380, DOI 10.1016/j.ccell.2020.06.002; Frankiw L, 2019, NAT REV IMMUNOL, V19, P675, DOI 10.1038/s41577-019-0195-7; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Gu SS, 2021, CANCER DISCOV, V11, P1524, DOI 10.1158/2159-8290.CD-20-0812; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hoyos LE, 2018, CANCER CELL, V34, P181, DOI 10.1016/j.ccell.2018.07.008; Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065; Jacob AG, 2017, HUM GENET, V136, P1043, DOI 10.1007/s00439-017-1791-x; Jensen MA, 2014, NAT STRUCT MOL BIOL, V21, P189, DOI 10.1038/nsmb.2756; Jimenez-Vacas JM, 2020, EBIOMEDICINE, V51, DOI 10.1016/j.ebiom.2019.11.008; Kadash-Edmondson KE, 2019, IRIS BIG DATA INFORM; Kawano Y, 2018, J CLIN INVEST, V128, P2487, DOI 10.1172/JCI88169; Lesokhin AM, 2019, CANCER IMMUNOL RES, V7, P1224, DOI 10.1158/2326-6066.CIR-19-0148; Liu J, 2012, ONKOLOGIE, V35, P335, DOI 10.1159/000338941; Lopes R, 2021, CANCERS, V13, DOI 10.3390/cancers13040625; Lu SX, 2021, CELL, V184, P4032, DOI 10.1016/j.cell.2021.05.038; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; Merryman RW, 2017, BLOOD ADV, V1, P2643, DOI 10.1182/bloodadvances.2017012534; Miller A, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.94; Mohamed A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227455; Nilsen TW, 2010, NATURE, V463, P457, DOI 10.1038/nature08909; Orenbuch R, 2020, BIOINFORMATICS, V36, P33, DOI 10.1093/bioinformatics/btz474; Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Perumal D, 2020, CLIN CANCER RES, V26, P450, DOI 10.1158/1078-0432.CCR-19-2309; Rahman MA, 2020, CELL, V180, P208, DOI 10.1016/j.cell.2019.12.011; Ren YX, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1744947; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; SCHEMPER M, 1992, STATISTICIAN, V41, P455, DOI 10.2307/2349009; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Sedgwick P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e509; Shen LH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50738-4; Shien K, 2016, LUNG CANCER, V99, P79, DOI 10.1016/j.lungcan.2016.06.016; Smart AC, 2018, NAT BIOTECHNOL, V36, P1056, DOI 10.1038/nbt.4239; Tan DJ, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-00159-4; Teoh PJ, 2018, BLOOD, V132, P1304, DOI 10.1182/blood-2018-02-832576; Walker BA, 2019, LEUKEMIA, V33, P159, DOI 10.1038/s41375-018-0196-8; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wong JJL, 2013, CELL, V154, P583, DOI 10.1016/j.cell.2013.06.052; Xie RH, 2019, CANCER LETT, V449, P31, DOI 10.1016/j.canlet.2019.01.041; Yang RY, 2018, BIORXIV; Yap K, 2012, GENE DEV, V26, P1209, DOI 10.1101/gad.188037.112; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zelle-Rieser C, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0345-3; Zhang D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16649-z; Zhang J, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0369-7; Zhao RH, 2013, P NATL ACAD SCI USA, V110, P9879, DOI 10.1073/pnas.1303524110	64	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6130	6138		10.1038/s41388-021-02005-y	http://dx.doi.org/10.1038/s41388-021-02005-y		SEP 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34504297	hybrid, Green Published			2022-12-17	WOS:000694570400001
J	Levine, AJ				Levine, Arnold J.			Spontaneous and inherited TP53 genetic alterations	ONCOGENE			English	Review							P53 TUMOR-SUPPRESSOR; STEM-CELLS; CLONAL HEMATOPOIESIS; CANCER; MUTATIONS; TISSUE; DOMAIN; POLYMORPHISM; METHYLATION; SELECTION	The p53 protein is a transcription factor that prevents tumors from developing. In spontaneous and inherited cancers there are many different missense mutations in the DNA binding domain of the TP53 gene that contributes to tumor formation. These mutations produce a wide distribution in the transcriptional capabilities of the mutant p53 proteins with over four logs differences in the efficiencies of forming cancers in many diverse tissue types. These inherited and spontaneous TP53 mutations produce proteins that interact with both genetic and epigenetic cellular modifiers of p53 function and their inherited polymorphisms to produce a large number of diverse phenotypes in individual patients. This manuscript reviews these variables and discusses how the combinations of TP53 genetic alterations interact with genetic polymorphisms, epigenetic alterations, and environmental factors to begin predicting and modifying patient outcomes and provide a better understanding for new therapeutic opportunities.	[Levine, Arnold J.] Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Levine, AJ (corresponding author), Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA.	alevine@ias.edu			NIH, NCI PO1	NIH, NCI PO1	The author thanks S Christen for help in the preparation of this review and Drs. K.C. de Andrade, M. Murphy and G. Zambetti for their critical reading and suggestions for the improvement of this review. The ideas, some of the experiments and results discussed in this review were supported by a grant from the NIH, NCI PO1- to A. J. Levine.	Amadou A, 2018, CURR OPIN ONCOL, V30, P23, DOI 10.1097/CCO.0000000000000423; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Barker N, 2013, DEVELOPMENT, V140, P2484, DOI 10.1242/dev.083113; Barnoud T, 2019, J MOL CELL BIOL, V11, P578, DOI 10.1093/jmcb/mjz052; Barnoud T, 2018, CANCER RES, V78, P5694, DOI 10.1158/0008-5472.CAN-18-1327; Baugh EH, 2018, CELL DEATH DIFFER, V25, P154, DOI 10.1038/cdd.2017.180; Belyi VA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001198; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Blokzijl F, 2016, NATURE, V538, P260, DOI 10.1038/nature19768; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bowman RL, 2018, CELL STEM CELL, V22, P157, DOI 10.1016/j.stem.2018.01.011; de Andrade KC, 2019, HUM MUTAT, V40, P97, DOI 10.1002/humu.23673; de Andrade KC, 2017, HUM MUTAT, V38, P1723, DOI 10.1002/humu.23320; Dubrovsky G, 2018, CURR OPIN PEDIATR, V30, P424, DOI 10.1097/MOP.0000000000000630; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Garber, LI FRAUMENI SYNDROME; Gnanapradeepan K, 2020, ELIFE, V9, DOI 10.7554/eLife.55994; Haigis KM, 2019, SCIENCE, V363, P1150, DOI 10.1126/science.aaw3472; Hainaut P, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026179; Harmeyer KM, 2017, TRENDS CANCER, V3, P713, DOI 10.1016/j.trecan.2017.08.004; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; Horvath S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1030-0; Hu DL, 2018, ISCIENCE, V9, P84, DOI 10.1016/j.isci.2018.10.012; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jaiswal S, 2019, SCIENCE, V366, P586, DOI 10.1126/science.aan4673; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jeong SI, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0867-4; Kakiuchi N, 2021, NAT REV CANCER, V21, P239, DOI 10.1038/s41568-021-00335-3; Lee MG, 2014, P NATL ACAD SCI USA, V111, P15532, DOI 10.1073/pnas.1411746111; Leu JIJ, 2020, P NATL ACAD SCI USA, V117, P26804, DOI 10.1073/pnas.2009943117; Levine AJ, 2020, NAT REV CANCER, V20, P471, DOI 10.1038/s41568-020-0262-1; Levine AJ, 2019, CANCER CELL, V35, P10, DOI 10.1016/j.ccell.2018.11.009; Levine AJ, 2019, ANNU REV CANC BIOL, V3, P21, DOI 10.1146/annurev-cancerbio-030518-055455; Levine AJ, 2017, GENE DEV, V31, P1195, DOI 10.1101/gad.298984.117; Levine AJ, 2015, COLD SH Q B, V80, P139, DOI 10.1101/sqb.2015.80.027631; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Mello SS, 2018, CURR OPIN CELL BIOL, V51, P65, DOI 10.1016/j.ceb.2017.11.005; Mizukami H, 2019, J BIOCHEM, V165, P335, DOI 10.1093/jb/mvy106; Murphy ME, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0007-9; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olivier Magali, 2004, IARC Sci Publ, P247; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Pinto EM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba3231; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Salk JJ, 2019, CELL REP, V28, P132, DOI 10.1016/j.celrep.2019.05.109; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Silver AJ, 2019, ADV CANCER RES, V141, P85, DOI 10.1016/bs.acr.2018.12.003; Singh KS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14151-9; Stacey SN, 2011, NAT GENET, V43, P1098, DOI 10.1038/ng.926; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takeda H, 2015, NAT GENET, V47, P142, DOI 10.1038/ng.3175; Takeo M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a023267; Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265; Victoria-Acosta G, 2015, SCI REP-UK, V5, DOI 10.1038/srep14838; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Weissman IL, 2015, P NATL ACAD SCI USA, V112, P8922, DOI 10.1073/pnas.1505464112; Welch JS, 2016, NEW ENGL J MED, V375, P2023, DOI 10.1056/NEJMoa1605949; Williams MJ, 2020, ELIFE, V9, DOI 10.7554/eLife.48714; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yi L, 2014, ONCOTARGET, V5, P8924, DOI 10.18632/oncotarget.2441; Yi L, 2012, CANCER RES, V72, P5635, DOI 10.1158/0008-5472.CAN-12-1451; Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x; Zhu JJ, 2016, P NATL ACAD SCI USA, V113, P9822, DOI 10.1073/pnas.1610387113	72	7	7	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					5975	5983		10.1038/s41388-021-01991-3	http://dx.doi.org/10.1038/s41388-021-01991-3		AUG 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34389799	hybrid, Green Published			2022-12-17	WOS:000684753600001
J	Li, HR; Qi, ZH; Niu, YD; Yang, YF; Li, MJ; Pang, YY; Liu, MM; Cheng, X; Xu, MD; Wang, ZL				Li, Haoran; Qi, Zihao; Niu, Yongdong; Yang, Yufei; Li, Mengjiao; Pang, Yangyang; Liu, Mingming; Cheng, Xi; Xu, Midie; Wang, Ziliang			FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer	ONCOGENE			English	Article							FRUCTOSE-1,6-BISPHOSPHATASE; EXPRESSION; MYC; GLYCOLYSIS; METABOLISM; GROWTH; CELLS; BIOMARKERS; RESISTANCE; PATH	Fructose-1,6-bisphosphatase (FBP1) is a rate-limiting enzyme in gluconeogenesis and an important tumor suppressor in human malignancies. Here, we aimed to investigate the expression profile of FBP1 in ovarian cancer, the molecular mechanisms that regulate FBP1 expression and to examine how the FBP1 regulatory axis contributes to tumorigenesis and progression in ovarian cancer. We showed that FBP1 expression was significantly decreased in ovarian cancer tissues compared with normal ovarian tissues, and low-FBP1 expression predicted poor prognosis in patients with ovarian cancer. The enhanced expression of FBP1 in ovarian cancer cell lines suppressed proliferation and 2-D/3-D invasion, reduced aerobic glycolysis, and sensitized cancer cells to cisplatin-induced apoptosis. Moreover, DNA methylation and C-MYC binding at the promoter inhibited FBP1 expression. Furthermore, through physical interactions with signal transducer and activator of transcription 3 (STAT3), FBP1 suppressed nuclear translocation of STAT3 and exerted its non-metabolic enzymatic activity to induce the dysfunction of STAT3. Thus, our study suggests that FBP1 may be a valuable prognostic predictor for ovarian cancer. C-MYC-dependent downregulation of FBP1 acted as a tumor suppressor via modulating STAT3, and the C-MYC/FBP1/STAT3 axis could be a therapeutic target.	[Li, Haoran; Yang, Yufei; Li, Mengjiao; Cheng, Xi; Wang, Ziliang] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai, Peoples R China; [Li, Haoran; Yang, Yufei; Li, Mengjiao; Cheng, Xi; Wang, Ziliang] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai, Peoples R China; [Li, Haoran; Yang, Yufei; Cheng, Xi; Xu, Midie; Wang, Ziliang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Qi, Zihao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Gen Surg, Sch Med, Shanghai, Peoples R China; [Niu, Yongdong] Shantou Univ Med Coll, Dept Pharmacol, Shantou, Peoples R China; [Yang, Yufei; Wang, Ziliang] Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Clin Med Transformat Ctr, Shanghai, Peoples R China; [Yang, Yufei; Wang, Ziliang] Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Off Acad Res, Shanghai, Peoples R China; [Pang, Yangyang] Fudan Univ, Shanghai Xuhui Cent Hosp, Zhongshan Xuhui Hosp, Shanghai, Peoples R China; [Liu, Mingming] Anhui Med Univ, Sch Pharm, Hefei, Peoples R China; [Xu, Midie] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Xu, Midie] Fudan Univ, Biobank, Shanghai Canc Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong University; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Fudan University; Anhui Medical University; Fudan University; Fudan University	Cheng, X; Wang, ZL (corresponding author), Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai, Peoples R China.; Cheng, X; Wang, ZL (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai, Peoples R China.; Cheng, X; Xu, MD; Wang, ZL (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Wang, ZL (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Clin Med Transformat Ctr, Shanghai, Peoples R China.; Wang, ZL (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai Hosp Tradit Chinese Med, Off Acad Res, Shanghai, Peoples R China.; Xu, MD (corresponding author), Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China.; Xu, MD (corresponding author), Fudan Univ, Biobank, Shanghai Canc Ctr, Shanghai, Peoples R China.	cheng_xi1@hotmail.com; xumd27202003@sina.com; huf_zlwang@126.com	xu, midie/AFS-3427-2022	xu, midie/0000-0003-1775-6608; Niu, Yongdong/0000-0002-5392-3736	National Natural Science Foundation of China [81502235, 81602078]; National Human Genetic Resources Sharing Service Platform [2005DKA21300]; Traditional Chinese Medicine Research Fund of Shanghai Municipal Commission of Health and Family Planning [WS-ZY1201]; Guangdong Provincial Science and technology Program [2014A020212285]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Human Genetic Resources Sharing Service Platform; Traditional Chinese Medicine Research Fund of Shanghai Municipal Commission of Health and Family Planning; Guangdong Provincial Science and technology Program	This work was supported by National Natural Science Foundation of China (81502235 and 81602078), by National Human Genetic Resources Sharing Service Platform (2005DKA21300), by Traditional Chinese Medicine Research Fund of Shanghai Municipal Commission of Health and Family Planning (WS-ZY1201), and by Guangdong Provincial Science and technology Program (2014A020212285).	Ai ZH, 2016, CANCER LETT, V373, P36, DOI 10.1016/j.canlet.2016.01.009; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bigl M, 2008, BIOCHEM BIOPH RES CO, V377, P720, DOI 10.1016/j.bbrc.2008.10.045; Bott AJ, 2015, CELL METAB, V22, P1068, DOI 10.1016/j.cmet.2015.09.025; Chen MQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025564; Chen SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174136; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; de Castro DG, 2013, CLIN PHARMACOL THER, V93, P252, DOI 10.1038/clpt.2012.237; DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b; Delgado M Dolores, 2010, Genes Cancer, V1, P605, DOI 10.1177/1947601910377495; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Garrido P, 2015, J CELL PHYSIOL, V230, P191, DOI 10.1002/jcp.24698; Guo WH, 2011, J CANCER RES CLIN, V137, P65, DOI 10.1007/s00432-010-0860-5; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hijaz M, 2016, GYNECOL ONCOL, V142, P323, DOI 10.1016/j.ygyno.2016.06.005; Hsieh AL, 2015, SEMIN CELL DEV BIOL, V43, P11, DOI 10.1016/j.semcdb.2015.08.003; Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842; Jin X, 2017, CANCER RES, V77, P4328, DOI 10.1158/0008-5472.CAN-16-3143; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li KC, 2016, BIOMED PHARMACOTHER, V84, P1144, DOI 10.1016/j.biopha.2016.10.050; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Liu YF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317708779; Loar P, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.10.883; Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x; Qiu J, 2021, MOL CELL BIOCHEM, V476, P1, DOI 10.1007/s11010-020-03814-7; Sheng HY, 2015, CANCER INVEST, V33, P197, DOI 10.3109/07357907.2015.1020385; Shi L, 2017, NEOPLASMA, V64, P535, DOI 10.4149/neo_2017_407; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soh MA, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-41; Wang B, 2020, THERANOSTICS, V10, P1033, DOI 10.7150/thno.38137; Wang B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0888-y; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Zhang J, 2016, MOL CELL BIOCHEM, V411, P331, DOI 10.1007/s11010-015-2595-8; Zhang YP, 2019, CELL CYCLE, V18, P2432, DOI 10.1080/15384101.2019.1648956; Zheng Y, 2018, AM J TRANSL RES, V10, P3086	38	7	7	4	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5938	5949		10.1038/s41388-021-01957-5	http://dx.doi.org/10.1038/s41388-021-01957-5		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363022	hybrid, Green Published			2022-12-17	WOS:000682519100002
J	Palma, FR; Ratti, BA; Paviani, V; Coelho, DR; Miguel, R; Danes, JM; Zaichik, SV; de Abreu, AL; Silva, SO; Chen, YL; Silverstein, RL; Karan, U; Jones, DP; Bonini, MG				Palma, Flavio R.; Ratti, Bianca A.; Paviani, Veronica; Coelho, Diego R.; Miguel, Rodrigo; Danes, Jeanne M.; Zaichik, Sofia, V; de Abreu, Andre L.; Silva, Sueli O.; Chen, Yiliang; Silverstein, Roy L.; Karan, Uppal; Jones, Dean P.; Bonini, Marcelo G.			AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; PATHWAY	Epidemiologic studies in diabetic patients as well as research in model organisms have indicated the potential of metformin as a drug candidate for the treatment of various types of cancer, including breast cancer. To date most of the anti-cancer properties of metformin have, in large part, been attributed either to the inhibition of mitochondrial NADH oxidase complex (Complex I in the electron transport chain) or the activation of AMP-activated kinase (AMPK). However, it is becoming increasingly clear that AMPK activation may be critical to alleviate metabolic and energetic stresses associated with tumor progression suggesting that it may, in fact, attenuate the toxicity of metformin instead of promoting it. Here, we demonstrate that AMPK opposes the detrimental effects of mitochondrial complex I inhibition by enhancing glycolysis at the expense of, and in a manner dependent on, pyruvate availability. We also found that metformin forces cells to rewire their metabolic grid in a manner that depends on AMPK, with AMPK-competent cells upregulating glycolysis and AMPK-deficient cell resorting to ketogenesis. In fact, while the killing effects of metformin were largely rescued by pyruvate in AMPKcompetent cells, AMPK-deficient cells required instead acetoacetate, a product of fatty acid catabolism indicating a switch from sugar to fatty acid metabolism as a central resource for ATP production in these cells. In summary, our results indicate that AMPK activation is not responsible for metformin anticancer activity and may instead alleviate energetic stress by activating glycolysis.	[Palma, Flavio R.; Paviani, Veronica; Coelho, Diego R.; Miguel, Rodrigo; Danes, Jeanne M.; Bonini, Marcelo G.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Palma, Flavio R.; Paviani, Veronica; Coelho, Diego R.; Danes, Jeanne M.; Chen, Yiliang; Silverstein, Roy L.; Bonini, Marcelo G.] Med Coll Wisconsin, Dept Med & Biophys, Milwaukee, WI 53226 USA; [Ratti, Bianca A.; de Abreu, Andre L.; Silva, Sueli O.] Univ Estadual Maringa, Ave Colombo 5790, BR-87020900 Maringa, PR, Brazil; [Karan, Uppal; Jones, Dean P.] Emory Univ, Sch Med, Dept Med, 615 Michael St NE, Atlanta, GA 30322 USA; [Zaichik, Sofia, V; de Abreu, Andre L.] Univ Illinois, Dept Med, 909 S Wolcott Ave,COMRB 1131, Chicago, IL 60612 USA; [Chen, Yiliang; Silverstein, Roy L.] Versiti, Blood Res Inst, Milwaukee, WI 53226 USA	Northwestern University; Feinberg School of Medicine; Medical College of Wisconsin; Universidade Estadual de Maringa; Emory University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Versiti Blood Center of Wisconsin	Bonini, MG (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA.; Bonini, MG (corresponding author), Med Coll Wisconsin, Dept Med & Biophys, Milwaukee, WI 53226 USA.	marcelo.bonini@northwestern.edu	; Silva, Sueli/P-2164-2017	Chen, Yiliang/0000-0001-9786-8305; Silva, Sueli/0000-0001-9303-0804; Palma, Flavio/0000-0003-4350-2708; Paviani Sampaio, Veronica/0000-0003-0718-2436	U.S. National Institutes of Health, NIAID [R01AI131267]; NIEHS [R01028149]; NCI [R01CA216882]; DOD/ARO [72983]; American Heart Association Scientist Development Grant [17SDG33661117]	U.S. National Institutes of Health, NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD/ARO(United States Department of Defense); American Heart Association Scientist Development Grant(American Heart Association)	The authors acknowledge the technical assistance of Mr. Matheus Pedrosa for his assistance with figure designs, Dr. Juliana C. P. Calado and Metabolomics core from the Robert Lurie Comprehensive Cancer Center for metabolomics analysis. The authors are grateful for funding from the U.S. National Institutes of Health, NIAID R01AI131267 (to MGB); NIEHS R01028149 (to MGB); NCI R01CA216882 (to MGB) and DOD/ARO grant number 72983 (to MGB); and American Heart Association Scientist Development Grant #17SDG33661117 (to YC).	Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Bo S, 2012, J ENDOCRINOL INVEST, V35, P231, DOI 10.1007/BF03345423; Cazzaniga M, 2009, CANCER EPIDEM BIOMAR, V18, P701, DOI 10.1158/1055-9965.EPI-08-0871; Cheong JH, 2011, MOL CANCER THER, V10, P2350, DOI 10.1158/1535-7163.MCT-11-0497; DJAVADIOHANIANCE L, 1975, J BIOL CHEM, V250, P9397; Eichner LJ, 2019, CELL METAB, V29, P285, DOI 10.1016/j.cmet.2018.10.005; Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59; Ferreira GD, 2014, EUR J OBSTET GYN R B, V175, P157, DOI 10.1016/j.ejogrb.2014.01.009; Ferretti AC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39556-w; Flory J, 2019, JAMA-J AM MED ASSOC, V321, P1926, DOI 10.1001/jama.2019.3805; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; GUTMAN M, 1970, P NATL ACAD SCI USA, V65, P763, DOI 10.1073/pnas.65.3.763; Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013; Hart PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7053; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Libby G, 2009, DIABETES CARE, V32, P1620, DOI 10.2337/dc08-2175; Menendez JA, 2012, CELL CYCLE, V11, P2782, DOI 10.4161/cc.20948; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Spinelli JB, 2017, SCIENCE, V358, P941, DOI 10.1126/science.aam9305; Tennakoon JB, 2014, ONCOGENE, V33, P5251, DOI 10.1038/onc.2013.463; Xu J, 2012, CRIT REV FOOD SCI, V52, P373, DOI 10.1080/10408398.2010.500245; Zhao HX, 2019, NAT CELL BIOL, V21, P476, DOI 10.1038/s41556-019-0296-3; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	25	7	7	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5455	5467		10.1038/s41388-021-01943-x	http://dx.doi.org/10.1038/s41388-021-01943-x		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34290400	Green Accepted			2022-12-17	WOS:000677857200004
J	Wei, Y; Huang, CX; Xiao, X; Chen, DP; Shan, H; He, HH; Kuang, DM				Wei, Yuan; Huang, Chun-Xiang; Xiao, Xiao; Chen, Dong-Ping; Shan, Hong; He, Huanhuan; Kuang, Dong-Ming			B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments	ONCOGENE			English	Review							TERTIARY LYMPHOID STRUCTURES; HEPATOCELLULAR-CARCINOMA; IL-10 PRODUCTION; BAFF-RECEPTOR; PLASMA-CELLS; T-CELLS; IMMUNITY; IMMUNOTHERAPY; COMPLEMENT; SUBSET	B cells constitute a major component of tumor-infiltrating leukocytes. However, the influence of these cells on malignancy is currently under debate, reflecting the heterogeneity of B cell subsets in tumors. With recent advances, it becomes apparent that this debate includes not only the evaluation of B cells themselves, but also the underlying immune microenvironment network, which scripts the highly heterogeneous B cell populations in tumors and directs the roles of those sub-populations in disease progression and clinical treatment. In this review, we summarize recent findings on the heterogeneous subset composition of B cells in both human and mouse tumor models and their different impacts on disease progression. We further describe the multidimensional interplays between B cells and other immune cells in the tumor microenvironment, which account for the regulation of B cell differentiation and function in situ. We also assess the potential influences of distinct sub-tumor locations on B cell function in primary tumors during development and those under immunotherapy treatment. Illuminating the heterogeneous nature of B cell subset composition, generation, localization, and related immune network in tumor is of immense significance for comprehensively understanding B cell response in tumor and designing more efficacious cancer immunotherapies.	[Wei, Yuan; Shan, Hong; He, Huanhuan; Kuang, Dong-Ming] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China; [Wei, Yuan; Huang, Chun-Xiang; Chen, Dong-Ping; Kuang, Dong-Ming] Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Biocontrol, Guangzhou, Peoples R China; [Xiao, Xiao] QIMR Berghofer Med Res Inst, Canc Program, Herston, Qld, Australia	Sun Yat Sen University; Sun Yat Sen University; QIMR Berghofer Medical Research Institute	Shan, H; He, HH; Kuang, DM (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China.; Kuang, DM (corresponding author), Sun Yat Sen Univ, Sch Life Sci, MOE Key Lab Gene Funct & Regulat, State Key Lab Biocontrol, Guangzhou, Peoples R China.	shanhong@mail.sysu.edu.cn; hehh23@mail.sysu.edu.cn; kdming@mail.sysu.edu.cn		Wei, Yuan/0000-0001-5694-8835; Xiao, Christos/0000-0003-0402-4221; He, Huanhuan/0000-0002-5903-0840; Kuang, Dong-Ming/0000-0003-3570-9717; shan, hong/0000-0001-6640-1390	National Natural Science Foundation of China [82025016, 31830025, 81901585]; Natural Science Foundation of Guangdong Province, China [2018B030308010, 2019A1515011770, 2020A1515010895]; China Postdoctoral Science Foundation [2020T130738, 2019M653191, 2019M653169, BX20180398]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We sincerely apologize to those colleagues whose important work is not included in this paper. The presentation of a complete and extensive review is extremely challenging owing to the plethora of literature related to the topic described in this review. We apologize in advance for any inadvertent omission. This work was supported by project grants from the National Natural Science Foundation of China (82025016, 31830025, and 81901585); the Natural Science Foundation of Guangdong Province, China (2018B030308010, 2019A1515011770, and 2020A1515010895); and the China Postdoctoral Science Foundation (2020T130738, 2019M653191, 2019M653169, and BX20180398).	Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; Avelos AM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00092; Bagheri Y, 2019, EUR CYTOKINE NETW, V30, P107, DOI 10.1684/ecn.2019.0434; Blair PA, 2010, IMMUNITY, V32, P129, DOI 10.1016/j.immuni.2009.11.009; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; Bruno TC, 2017, CANCER IMMUNOL RES, V5, P898, DOI 10.1158/2326-6066.CIR-17-0075; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen MM, 2016, CANCER DISCOV, V6, P1182, DOI 10.1158/2159-8290.CD-16-0329; Cornillet M, 2019, GASTROENTEROLOGY, V157, P1067, DOI 10.1053/j.gastro.2019.06.023; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; Drago JZ, 2021, NAT REV CLIN ONCOL, V18, P327, DOI 10.1038/s41571-021-00470-8; Elsner RA, 2020, IMMUNITY, V53, P1136, DOI 10.1016/j.immuni.2020.11.006; Fillatreau S, 2021, NAT REV RHEUMATOL, V17, P98, DOI 10.1038/s41584-020-00544-4; Fridman WH, 2020, GASTROENTEROLOGY, V158, P303, DOI 10.1053/j.gastro.2019.09.045; Ganti SN, 2015, SCI REP-UK, V5, DOI 10.1038/srep12255; Garaud S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129641; Garaud S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02660; Germain C, 2014, AM J RESP CRIT CARE, V189, P832, DOI 10.1164/rccm.201309-1611OC; Glass DR, 2020, IMMUNITY, V53, P217, DOI 10.1016/j.immuni.2020.06.013; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Gunderson AJ, 2016, CANCER DISCOV, V6, P270, DOI 10.1158/2159-8290.CD-15-0827; Han TS, 2019, GASTROENTEROLOGY, V156, P1140, DOI 10.1053/j.gastro.2018.11.059; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Hernandez-Ruiz M, 2017, J INTERF CYTOK RES, V37, P62, DOI 10.1089/jir.2016.0076; Hollern DP, 2019, CELL, V179, P1191, DOI 10.1016/j.cell.2019.10.028; Hong S, 2018, IMMUNITY, V49, P695, DOI 10.1016/j.immuni.2018.08.012; Hu XH, 2019, NAT GENET, V51, P560, DOI 10.1038/s41588-018-0339-x; Hua C, 2016, J AUTOIMMUN, V73, P64, DOI 10.1016/j.jaut.2016.06.002; Hua ZL, 2020, IMMUNOL REV, V296, P24, DOI 10.1111/imr.12859; Huang Q, 2019, CELL MOL IMMUNOL, V16, P87, DOI 10.1038/s41423-018-0014-2; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Iwata Y, 2011, BLOOD, V117, P530, DOI 10.1182/blood-2010-07-294249; Jaya FNM, 2019, J TRANSL AUTOIMMUN, V2, DOI 10.1016/j.jtauto.2019.100011; Ji L, 2020, CANCER RES, V80, P2004, DOI 10.1158/0008-5472.CAN-19-3074; Karagiannis P, 2013, CANCER RES, V73, DOI [10.1172/JCI65579, 10.1158/1538-7445.TUMIMM2012-B65]; Kuang DM, 2008, J IMMUNOL, V181, P3089, DOI 10.4049/jimmunol.181.5.3089; Kuang DM, 2007, BLOOD, V110, P587, DOI 10.1182/blood-2007-01-068031; Kuang DM, 2014, J CLIN INVEST, V124, P4657, DOI 10.1172/JCI74381; Kuang DM, 2011, J HEPATOL, V54, P948, DOI 10.1016/j.jhep.2010.08.041; Kuang DM, 2010, HEPATOLOGY, V51, P154, DOI 10.1002/hep.23291; Kurtenkov O, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9579828; Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338; Lechner A, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1535293; Lighaam LC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01913; Liu JL, 2021, CELL MOL GASTROENTER, V12, P251, DOI 10.1016/j.jcmgh.2021.02.008; Liu RX, 2015, HEPATOLOGY, V62, P1779, DOI 10.1002/hep.28020; Liu Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8509805; Lu YW, 2020, CELL, V180, P1081, DOI 10.1016/j.cell.2020.02.015; Ma KY, 2020, CELL MOL IMMUNOL, V17, P421, DOI 10.1038/s41423-019-0308-z; Mauri C, 2021, IMMUNOL REV, V299, P5, DOI 10.1111/imr.12964; Medler TR, 2018, CANCER CELL, V34, P561, DOI 10.1016/j.ccell.2018.09.003; Michaud HA, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955684; Molina-Sanchez P, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.015; Morcrette G, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1583547; Moriyama M, 2017, CURR TOP MICROBIOL, V401, P75, DOI 10.1007/82_2016_40; Muntasell A, 2017, CURR OPIN IMMUNOL, V45, P73, DOI 10.1016/j.coi.2017.01.003; Nielsen JS, 2012, CLIN CANCER RES, V18, P3281, DOI 10.1158/1078-0432.CCR-12-0234; Obeng, NATURE; Obieglo K, 2019, EUR J IMMUNOL, V49, P1226, DOI 10.1002/eji.201847858; Oh JE, 2019, NATURE, V571, P122, DOI 10.1038/s41586-019-1285-1; Okada Y, 2018, J AUTOIMMUN, V88, P103, DOI 10.1016/j.jaut.2017.10.011; Ouyang FZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13453; Ozga AJ, 2021, IMMUNITY, V54, P859, DOI 10.1016/j.immuni.2021.01.012; Paijens ST, 2021, CELL MOL IMMUNOL, V18, P842, DOI 10.1038/s41423-020-00565-9; Patidar A, 2018, CYTOKINE, V104, P114, DOI 10.1016/j.cyto.2017.10.004; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Qian L, 2017, MOL MED REP, V16, P5693, DOI 10.3892/mmr.2017.7269; Ren ZH, 2016, CANCER DISCOV, V6, P477, DOI 10.1158/2159-8290.CD-16-0307; Rosser EC, 2014, NAT MED, V20, P1334, DOI 10.1038/nm.3680; Roumenina LT, 2019, NAT REV CANCER, V19, P698, DOI 10.1038/s41568-019-0210-0; Saulep-Easton D, 2016, LEUKEMIA, V30, P163, DOI 10.1038/leu.2015.174; Schioppa T, 2011, P NATL ACAD SCI USA, V108, P10662, DOI 10.1073/pnas.1100994108; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Shang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.582657; Sharonov GV, 2020, NAT REV IMMUNOL, V20, P294, DOI 10.1038/s41577-019-0257-x; Shen T, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00501-x; Smulski CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02285; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Su SC, 2018, CELL, V175, P442, DOI 10.1016/j.cell.2018.09.007; Takahashi R, 2021, GUT, V70, P330, DOI 10.1136/gutjnl-2019-319912; Tezuka H, 2011, IMMUNITY, V34, P247, DOI 10.1016/j.immuni.2011.02.002; van de Veen W, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3559; Verma R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00979; Wang RX, 2014, NAT MED, V20, P633, DOI 10.1038/nm.3554; Wang SS, 2019, CELL MOL IMMUNOL, V16, P6, DOI 10.1038/s41423-018-0027-x; Wei Y, 2019, J CLIN INVEST, V129, P3347, DOI 10.1172/JCI127726; Wei Y, 2019, GASTROENTEROLOGY, V156, P1890, DOI 10.1053/j.gastro.2019.01.250; Wu Y, 2013, HEPATOLOGY, V57, P1107, DOI 10.1002/hep.26192; Xiao X, 2016, CANCER DISCOV, V6, P546, DOI 10.1158/2159-8290.CD-15-1408; Xu W, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00504; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yang CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064159; Yang ZN, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abb0737; Yazdi MT, 2015, CANCER IMMUNOL IMMUN, V64, P1109, DOI 10.1007/s00262-015-1716-2; Zeng QH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb6296; Zhang CY, 2016, IMMUNITY, V44, P913, DOI 10.1016/j.immuni.2016.04.003; Zhang Z, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1571388	100	7	7	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4737	4745		10.1038/s41388-021-01918-y	http://dx.doi.org/10.1038/s41388-021-01918-y		JUN 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34188249				2022-12-17	WOS:000668080200001
J	Wang, JY; Xiu, J; Baca, Y; Battaglin, F; Arai, H; Kawanishi, N; Soni, S; Zhang, W; Millstein, J; Salhia, B; Goldberg, RM; Philip, PA; Seeber, A; Hwang, JJ; Shields, AF; Marshall, JL; Astsaturov, I; Lockhart, AC; Gatalica, Z; Korn, WM; Lenz, HJ				Wang, Jingyuan; Xiu, Joanne; Baca, Yasmine; Battaglin, Francesca; Arai, Hiroyuki; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Millstein, Joshua; Salhia, Bodour; Goldberg, Richard M.; Philip, Philip A.; Seeber, Andreas; Hwang, Jimmy J.; Shields, Anthony F.; Marshall, John L.; Astsaturov, Igor; Craig Lockhart, A.; Gatalica, Zoran; Michael Korn, W.; Lenz, Heinz-Josef			Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer	ONCOGENE			English	Article							ADENOCARCINOMA; LANDSCAPE; BURDEN	Frequent mutations of genes in the histone-lysine N-methyltransferase 2 (KMT2) family members were identified in gastric cancers (GCs). Understanding how gene mutations of KMT2 family affect cancer progression and tumor immune microenvironment may provide new treatment strategies. A total of 1245 GCs were analyzed using next-generation sequencing, whole transcriptome sequencing, immunohistochemistry (Caris Life Sciences, Phoenix, AZ). The overall mutation rate of genes in the KMT2 family was 10.6%. Compared to KMT2-wild-type GCs, genes involved in epigenetic modification, receptor tyrosine kinases/MAPK/PI3K, and DNA damage repair (DDR) pathways had higher mutation rates in KMT2-mutant GCs (p < 0.05). Significantly higher rates of high tumor mutational burden, microsatellite instability-high/mismatch-repair deficiency (dMMR), and PD-L1 positivity were observed in KMT2-mutant GCs (p < 0.01), compared to KMT2-wild-type GCs. The association between PD-L1 positivity and KMT2 mutations remained significant in the proficient-MMR and microsatellite stable subgroup. Based on transcriptome data from the TCGA, cell cycle, metabolism, and interferon-alpha/beta response pathways were significantly upregulated in KMT2-mutant GCs than in KMT2-wild-type GCs. Patients with KMT2 mutation treated with immune checkpoint inhibitors had longer median overall survival compared to KMT2-wild-type patients with metastatic solid tumors (35 vs. 16 months, HR = 0.73, 95% CI: 0.62-0.87, p = 0.0003). In conclusion, this is the largest study to investigate the distinct molecular features between KMT2-mutant and KMT2-wild-type GCs to date. Our data indicate that GC patients with KMT2 mutations may benefit from ICIs and drugs targeting DDR, MAPK/PI3K, metabolism, and cell cycle pathways.	[Wang, Jingyuan] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China; [Wang, Jingyuan; Battaglin, Francesca; Arai, Hiroyuki; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Lenz, Heinz-Josef] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90007 USA; [Xiu, Joanne; Baca, Yasmine; Gatalica, Zoran; Michael Korn, W.] Caris Life Sci, Phoenix, AZ USA; [Millstein, Joshua] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90007 USA; [Salhia, Bodour] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Translat Genom, Los Angeles, CA 90007 USA; [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA; [Philip, Philip A.; Shields, Anthony F.] Wayne State Univ, Dept Oncol, Karmanos Canc Inst, Detroit, MI USA; [Seeber, Andreas] Innsbruck Med Univ, Dept Hematol & Oncol, Innsbruck, Austria; [Hwang, Jimmy J.] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA; [Marshall, John L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC 20007 USA; [Astsaturov, Igor] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Craig Lockhart, A.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA	Peking University; University of Southern California; University of Southern California; University of Southern California; West Virginia University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Medical University of Innsbruck; Carolinas HealthCare System; Georgetown University; Fox Chase Cancer Center; University of Miami	Lenz, HJ (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90007 USA.	Lenz@usc.edu	Battaglin, Francesca/C-2746-2017	Battaglin, Francesca/0000-0002-9869-0163; Arai, Hiroyuki/0000-0002-1886-7070	National Cancer Institute [P30CA 014089]; Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; V Foundation for Cancer Research; Eddie Money Research Fund	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gloria Borges WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip Wilson Research Fund; San Pedro Peninsula Cancer Guild; V Foundation for Cancer Research; Eddie Money Research Fund	This work was supported by the National Cancer Institute [P30CA 014089 to H-JL], Gloria Borges WunderGlo Foundation, Dhont Family Foundation, Victoria and Philip Wilson Research Fund, San Pedro Peninsula Cancer Guild, the V Foundation for Cancer Research, Eddie Money Research Fund.	Alam H, 2020, CANCER CELL, V37, P599, DOI 10.1016/j.ccell.2020.03.005; Bang YJ, 2010, LANCET, V376, P1302; Bang YJ, 2017, LANCET ONCOL, V18, P1637, DOI 10.1016/S1470-2045(17)30682-4; BECHT E, 2016, GENOME BIOL, V17; Chen H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01113; Chen KX, 2015, P NATL ACAD SCI USA, V112, P1107, DOI 10.1073/pnas.1422640112; Cho SJ, 2018, CLIN CANCER RES, V24, P6556, DOI 10.1158/1078-0432.CCR-17-1679; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Fagan RJ, 2019, CANCER LETT, V458, P56, DOI 10.1016/j.canlet.2019.05.024; Feinberg AP, 2016, NAT REV GENET, V17, P284, DOI 10.1038/nrg.2016.13; Ge S, 2017, AM J CANCER RES, V7, P1540; Italiano A, 2018, LANCET ONCOL, V19, P649, DOI 10.1016/S1470-2045(18)30145-1; Je EM, 2013, NEOPLASMA, V60, P188, DOI 10.4149/neo_2013_025; Jia QZ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127901; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kantidakis T, 2016, GENE DEV, V30, P408, DOI 10.1101/gad.275453.115; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lake J, 2018, PEDIATR BLOOD CANCER, V65; Li XC, 2018, JAMA ONCOL, V4, P1691, DOI 10.1001/jamaoncol.2018.2805; Lv SD, 2019, EPIGENETICS-US, DOI 10.1080/15592294.2019.1634985; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Mardis ER, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0684-0; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mitani S, 2020, CANCERS, V12, DOI 10.3390/cancers12020400; Okamura R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000438; Park Y, 2019, CLIN CANCER RES, V25, P5584, DOI 10.1158/1078-0432.CCR-18-4222; Rampias T, 2019, EMBO REP, V20, DOI 10.15252/embr.201846821; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Salem ME, 2018, ONCOLOGIST, V23, P1319, DOI 10.1634/theoncologist.2018-0143; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Tokunaga R, 2019, CLIN CANCER RES, V25, P3096, DOI 10.1158/1078-0432.CCR-18-3388; Wang F, 2019, ANN ONCOL, V30, P1479, DOI 10.1093/annonc/mdz197; Wang GC, 2020, CANCER DISCOV, V10, P1912, DOI 10.1158/2159-8290.CD-19-1448; Wang K, 2014, NAT GENET, V46, P573, DOI 10.1038/ng.2983; Wang L, 2018, NAT MED, V24, P758, DOI 10.1038/s41591-018-0034-6; Yang L, 2018, ONCOL REP, V40, P479, DOI 10.3892/or.2018.6445; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246	38	7	7	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4894	4905		10.1038/s41388-021-01840-3	http://dx.doi.org/10.1038/s41388-021-01840-3		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163031				2022-12-17	WOS:000664853000004
J	Li, XY; Wu, ZM; He, J; Jin, YT; Chu, CY; Cao, Y; Gu, F; Wang, HY; Hou, CJ; Liu, XP; Zou, Q				Li, Xiaoyan; Wu, Zhengming; He, Jing; Jin, Yiting; Chu, Chengyu; Cao, Yun; Gu, Fei; Wang, Hongying; Hou, Chenjian; Liu, Xiuping; Zou, Qiang			OGT regulated O-GlcNAcylation promotes papillary thyroid cancer malignancy via activating YAP	ONCOGENE			English	Article							HIPPO PATHWAY; GLCNAC; TRANSFERASE; PHOSPHORYLATION; PROLIFERATION; MECHANISMS; NUCLEAR	The incidence of thyroid cancer is growing rapidly during the past decades worldwide. Although most thyroid tumors are curable, some patients diagnosed with distant metastases are associated with poor prognosis. The molecular mechanisms underlying these cases are still largely unknown. Here we found that the upregulated O-Linked N-Acetylglucosamine Transferase (OGT) expression and O-GlcNAcylation (O-GlcNAc) modification in papillary thyroid cancer (PTC) were essential in tumor growth and metastasis. Mass spectrometry analysis showed that YAP was the effector protein modified by OGT. In details, YAP Ser109 O-GlcNAcylation promoted the malignant phenotypes in PTC cells by inducing YAP Ser127 dephosphorylation and activation. Our work clearly showed the critical role of OGT and YAP played in PTC tumors and made it possible for us to seek the clinical potential of manipulating OGT/YAP activity in PTC targeted therapies. These findings also confirmed OGT worked in collaboration with classical Hippo pathway kinases as an upstream regulator of YAP in PTC tumors.	[Li, Xiaoyan; He, Jing; Jin, Yiting; Chu, Chengyu; Cao, Yun; Gu, Fei; Wang, Hongying; Zou, Qiang] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China; [Wu, Zhengming] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Wu, Zhengming] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA; [Hou, Chenjian; Liu, Xiuping] Fudan Univ, Sch Basic Med Sci, Dept Pathol, Shanghai, Peoples R China; [Liu, Xiuping] Fudan Univ, Shanghai Peoples Hosp 5, Dept Pathol, Shanghai, Peoples R China	Fudan University; University of California System; University of California San Diego; University of California System; University of California San Diego; Fudan University; Fudan University	Zou, Q (corresponding author), Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China.; Liu, XP (corresponding author), Fudan Univ, Sch Basic Med Sci, Dept Pathol, Shanghai, Peoples R China.; Liu, XP (corresponding author), Fudan Univ, Shanghai Peoples Hosp 5, Dept Pathol, Shanghai, Peoples R China.	xpliu1228@fudan.edu.cn; zouqiang_hs@163.com		Li, Xiaoyan/0000-0002-1243-3845	National Nature Science Foundation of China and Science and Technology Commission of Shanghai Municipality [81602326];  [15411952503]	National Nature Science Foundation of China and Science and Technology Commission of Shanghai Municipality; 	This work was supported by grant no. 81602326 from the National Nature Science Foundation of China and Science and Technology Commission of Shanghai Municipality (No. 15411952503).	Akella NM, 2020, MOL CANCER RES, V18, P585, DOI 10.1158/1541-7786.MCR-19-0732; Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042; Cao BJ, 2019, J CELL MOL MED, V23, P2384, DOI 10.1111/jcmm.14043; Carling T, 2014, ANNU REV MED, V65, P125, DOI 10.1146/annurev-med-061512-105739; Chen R, 2019, NAT CELL BIOL, V21, P1565, DOI 10.1038/s41556-019-0426-y; Cheng Y, 2016, ONCOL LETT, V12, P572, DOI 10.3892/ol.2016.4647; Coca-Pelaz A, 2020, ADV THER, V37, P3112, DOI 10.1007/s12325-020-01391-1; Di Domenico F, 2019, EXPERT REV NEUROTHER, V19, P1, DOI 10.1080/14737175.2019.1540932; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Duan FF, 2018, J HEPATOL, V68, P1191, DOI 10.1016/j.jhep.2018.02.003; Fardini Y, 2013, FRONT ENDOCRINOL, V4, DOI 10.3389/fendo.2013.00099; Ferrer CM, 2017, ONCOGENE, V36, P559, DOI 10.1038/onc.2016.228; Ferrer CM, 2016, J MOL BIOL, V428, P3282, DOI 10.1016/j.jmb.2016.05.028; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI [10.1038/nchembio.520, 10.1038/NCHEMBIO.520]; Gonzalez-Gonzalez Rogelio, 2011, ISRN Oncol, V2011, P915925, DOI 10.5402/2011/915925; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Itkonen HM, 2020, MOL CANCER RES, V18, P1512, DOI 10.1158/1541-7786.MCR-20-0339; Itkonen HM, 2019, THERANOSTICS, V9, P2183, DOI 10.7150/thno.30834; Jiang MZ, 2019, ONCOGENE, V38, P301, DOI 10.1038/s41388-018-0435-5; Jin L, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00208-x; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kim SH, 2017, BIOCHEM BIOPH RES CO, V483, P793, DOI 10.1016/j.bbrc.2016.10.156; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lin Yi-Cheng, 2018, Oncotarget, V9, P31032, DOI 10.18632/oncotarget.25772; Liu ZM, 2019, APPL IMMUNOHISTO M M, V27, P59, DOI 10.1097/PAI.0000000000000544; Liu ZM, 2017, AM J TRANSL RES, V9, P3212; Lu H, 2020, GLYCOBIOLOGY; Ma ZY, 2013, AMINO ACIDS, V45, P719, DOI 10.1007/s00726-013-1543-8; Makwana V, 2019, BBA-GEN SUBJECTS, V1863, P1302, DOI 10.1016/j.bbagen.2019.04.002; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Moon S, 2017, EMBO REP, V18, P61, DOI 10.15252/embr.201642683; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Nagashima S, 2017, CURR DRUG TARGETS, V18, P447, DOI 10.2174/1389450117666160112115641; Ortiz-Meoz RF, 2015, ACS CHEM BIOL, V10, P1392, DOI 10.1021/acschembio.5b00004; Peng CM, 2017, MOL CELL, V68, P591, DOI 10.1016/j.molcel.2017.10.010; Pepe F, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.35; Pobbati AV, 2015, STRUCTURE, V23, P2076, DOI 10.1016/j.str.2015.09.009; Saiselet Manuel, 2012, Front Endocrinol (Lausanne), V3, P133, DOI 10.3389/fendo.2012.00133; Seo HG, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02999-5; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Singh JP, 2015, CANCER LETT, V356, P244, DOI 10.1016/j.canlet.2014.04.014; Wang LS, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5033-y; Wu ZM, 2021, TRENDS BIOCHEM SCI, V46, P51, DOI 10.1016/j.tibs.2020.08.008; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xu WQ, 2017, J HEPATOL, V67, P310, DOI 10.1016/j.jhep.2017.03.017; Zeidan Q, 2010, J CELL SCI, V123, P13, DOI 10.1242/jcs.053678; Zhang P, 2015, ONCOTARGETS THER, V8, P3305, DOI 10.2147/OTT.S82845; Zhang X, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15280; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zheng W, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1110-9; Zhu GZ, 2016, GLYCOBIOLOGY, V26, P820, DOI 10.1093/glycob/cww025	53	7	7	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4859	4871		10.1038/s41388-021-01901-7	http://dx.doi.org/10.1038/s41388-021-01901-7		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34155345				2022-12-17	WOS:000664006700001
J	Boone, MA; Taslim, C; Crow, JC; Selich-Anderson, J; Byrum, AK; Showpnil, IA; Sunkel, BD; Wang, M; Stanton, BZ; Theisen, ER; Lessnick, SL				Boone, Megann A.; Taslim, Cenny; Crow, Jesse C.; Selich-Anderson, Julia; Byrum, Andrea K.; Showpnil, Iftekhar A.; Sunkel, Benjamin D.; Wang, Meng; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.			The FLI portion of EWS/FLI contributes a transcriptional regulatory function that is distinct and separable from its DNA-binding function in Ewing sarcoma	ONCOGENE			English	Article							FUSION PROTEIN; DOMAIN; TRANSLOCATION; EWS; TRANSFORMATION; PARTNERSHIPS; EXPRESSION; GENERATION; LANDSCAPE; CHROMATIN	Ewing sarcoma is an aggressive bone cancer of children and young adults defined by the presence of a chromosomal translocation: t(11;22)(q24;q12). The encoded protein, EWS/FLI, fuses the amino-terminal domain of EWS to the carboxyl-terminus of FLI. The EWS portion is an intrinsically disordered transcriptional regulatory domain, while the FLI portion contains an ETS DNA-binding domain and two flanking regions of unknown function. Early studies using non-Ewing sarcoma models provided conflicting information on the roles of each domain of FLI in EWS/FLI oncogenic function. We therefore sought to define the specific contributions of each FLI domain to EWS/FLI activity in a well-validated Ewing sarcoma model and, in doing so, to better understand Ewing sarcoma development mediated by the fusion protein. We analyzed a series of engineered EWS/FLI mutants with alterations in the FLI portion using a variety of assays. Fluorescence anisotropy, CUT&RUN, and ATAC-sequencing experiments revealed that the isolated ETS domain is sufficient to maintain the normal DNA-binding and chromatin accessibility function of EWS/FLI. In contrast, RNA-sequencing and soft agar colony formation assays revealed that the ETS domain alone was insufficient for transcriptional regulatory and oncogenic transformation functions of the fusion protein. We found that an additional alpha-helix immediately downstream of the ETS domain is required for full transcriptional regulation and EWS/FLI-mediated oncogenesis. These data demonstrate a previously unknown role for FLI in transcriptional regulation that is distinct from its DNA-binding activity. This activity is critical for the cancer-causing function of EWS/FLI and may lead to novel therapeutic approaches.	[Boone, Megann A.; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Ohio State Univ, Biomed Sci Grad Program, Columbus, OH 43210 USA; [Boone, Megann A.; Taslim, Cenny; Crow, Jesse C.; Selich-Anderson, Julia; Byrum, Andrea K.; Showpnil, Iftekhar A.; Sunkel, Benjamin D.; Wang, Meng; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Childhood Canc & Blood Dis, Columbus, OH 43210 USA; [Showpnil, Iftekhar A.; Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; [Stanton, Benjamin Z.; Theisen, Emily R.; Lessnick, Stephen L.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lessnick, SL (corresponding author), Ohio State Univ, Biomed Sci Grad Program, Columbus, OH 43210 USA.; Lessnick, SL (corresponding author), Nationwide Childrens Hosp, Abigail Wexner Res Inst, Ctr Childhood Canc & Blood Dis, Columbus, OH 43210 USA.; Lessnick, SL (corresponding author), Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA.; Lessnick, SL (corresponding author), Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.	stephen.lessnick@nationwidechildrens.org		Sunkel, Benjamin/0000-0003-1376-9567; Theisen, Emily/0000-0003-2923-1198; Stanton, Benjamin/0000-0002-2613-2955; Boone, Megann/0000-0002-7806-8027	National Institute of Health [T32 GM068412, U54 CA231641]	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Research reported in this publication was supported by the National Institute of Health award T32 GM068412 to MAB, and U54 CA231641 to SLL. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. SLL declares a competing interest as a member of the advisory board for Salarius Pharmaceuticals. SLL is also a listed inventor on United States Patent No. US 7,939,253 B2, "Methods and compositions for the diagnosis and treatment of Ewing's sarcoma," and United States Patent No. US 8,557,532, "Diagnosis and treatment of drug-resistant Ewing's sarcoma." This does not alter our adherence to Oncogene policies on sharing data and materials.	Arvand A, 2001, CANCER RES, V61, P5311; AURIAS A, 1983, CR ACAD SCI III-VIE, V296, P1105; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Boulay G, 2017, CELL, V171, P163, DOI 10.1016/j.cell.2017.07.036; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Erkizan HV, 2010, CLIN CANCER RES, V16, P4077, DOI 10.1158/1078-0432.CCR-09-2261; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal Kunal, 2010, Genes Cancer, V1, P177; Gu ZG, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4625-x; Hodges HC, 2018, NAT STRUCT MOL BIOL, V25, P61, DOI 10.1038/s41594-017-0007-3; Hou CX, 2015, BIOCHEMISTRY-US, V54, P7365, DOI 10.1021/acs.biochem.5b01121; Johnson KM, 2017, P NATL ACAD SCI USA, V114, P9870, DOI 10.1073/pnas.1701872114; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kovar Heinrich, 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/837474; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; Longhi A, 2012, CANCER-AM CANCER SOC, V118, P5050, DOI 10.1002/cncr.27493; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maag Jesper L V, 2018, F1000Res, V7, P1576, DOI 10.12688/f1000research.16409.2; MAO XH, 1994, J BIOL CHEM, V269, P18216; Martinez-Ramirez A, 2003, CANCER GENET CYTOGEN, V141, P138, DOI 10.1016/S0165-4608(02)00670-2; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mendiola M, 2006, INT J CANCER, V118, P1381, DOI 10.1002/ijc.21578; Pishas KI, 2018, MOL CANCER THER, V17, P1902, DOI 10.1158/1535-7163.MCT-18-0373; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Regan MC, 2013, P NATL ACAD SCI USA, V110, P13374, DOI 10.1073/pnas.1301726110; Riggi N, 2014, CANCER CELL, V26, P668, DOI 10.1016/j.ccell.2014.10.004; Sankar S, 2013, ONCOGENE, V32, P5089, DOI 10.1038/onc.2012.525; Sankar S, 2014, CLIN CANCER RES, V20, P4584, DOI 10.1158/1078-0432.CCR-14-0072; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; Sizemore GM, 2017, NAT REV CANCER, V17, P337, DOI 10.1038/nrc.2017.20; Skene PJ, 2017, ELIFE, V6, DOI 10.7554/eLife.21856; Spahn L, 2003, ONCOGENE, V22, P6819, DOI 10.1038/sj.onc.1206810; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Theisen Emily R, 2019, Genes Cancer, V10, P21, DOI 10.18632/genesandcancer.188; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Welford SM, 2001, J BIOL CHEM, V276, P41977, DOI 10.1074/jbc.M106757200; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	48	7	7	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4759	4769		10.1038/s41388-021-01876-5	http://dx.doi.org/10.1038/s41388-021-01876-5		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34145397	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000663295300003
J	McNamara, KM; Gobert, AP; Wilson, KT				McNamara, Kara M.; Gobert, Alain P.; Wilson, Keith T.			The role of polyamines in gastric cancer	ONCOGENE			English	Review							INITIATION-FACTOR 5A; ORNITHINE-DECARBOXYLASE ACTIVITY; HELICOBACTER-PYLORI; HYPUSINE MODIFICATION; MACROPHAGE APOPTOSIS; ALPHA-DIFLUOROMETHYLORNITHINE; DEOXYHYPUSINE HYDROXYLASE; SPERMINE OXIDASE; IMMUNE-RESPONSE; CELL VIABILITY	Advancements in our understanding of polyamine molecular and cellular functions have led to increased interest in targeting polyamine metabolism for anticancer therapeutic benefits. The polyamines putrescine, spermidine, and spermine are polycationic alkylamines commonly found in all living cells and are essential for cellular growth and survival. This review summarizes the existing research on polyamine metabolism and function, specifically the role of polyamines in gastric immune cell and epithelial cell function. Polyamines have been implicated in a multitude of cancers, but in this review, we focus on the role of polyamine dysregulation in the context of Helicobacter pylori-induced gastritis and subsequent progression to gastric cancer. Due to the emerging implication of polyamines in cancer development, there is an increasing number of promising clinical trials using agents to target the polyamine metabolic pathway for potential chemoprevention and anticancer therapy.	[McNamara, Kara M.; Gobert, Alain P.; Wilson, Keith T.] Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA; [McNamara, Kara M.; Wilson, Keith T.] Program Canc Biol, Nashville, TN 37232 USA; [Gobert, Alain P.; Wilson, Keith T.] Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA; [Wilson, Keith T.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA; [Wilson, Keith T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wilson, KT (corresponding author), Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA.; Wilson, KT (corresponding author), Program Canc Biol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Ctr Mucosal Inflammat & Canc, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37232 USA.; Wilson, KT (corresponding author), Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.	keith.wilson@vumc.org		Wilson, Keith/0000-0003-4421-1830	NIH [R01CA190612, P01CA116087, P01CA028842, R21AI142042, T32CA009592]; Veterans Affairs Merit Review grants [I01BX001453, I01CX002171]; Department of Defense [W81XWH-18-1-0301]; Crohn's & Colitis Foundation Senior Research Award [703003]; Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Digestive Disease Research Center (NIH) [P30DK058404]; Thomas F. Frist Sr. Endowment	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Review grants(US Department of Veterans Affairs); Department of Defense(United States Department of Defense); Crohn's & Colitis Foundation Senior Research Award; Vanderbilt Center for Mucosal Inflammation and Cancer; Vanderbilt Digestive Disease Research Center (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Thomas F. Frist Sr. Endowment	This work was funded by NIH grants R01CA190612 (K.T.W.), P01CA116087 (K.T.W.), P01CA028842 (K.T.W.), and R21AI142042 (K.T.W.); Veterans Affairs Merit Review grants I01BX001453 and I01CX002171 (K.T.W.); Department of Defense grant W81XWH-18-1-0301 (K.T.W.); Crohn's & Colitis Foundation Senior Research Award 703003 (K.T.W.); the Thomas F. Frist Sr. Endowment (K.T.W.); and the Vanderbilt Center for Mucosal Inflammation and Cancer (K.T.W.). K.T.W. also receives support from the Vanderbilt Digestive Disease Research Center (NIH grant P30DK058404). K.M.M. was supported by NIH grant T32CA009592.	ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; Aksu M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11952; Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101; Asim M, 2010, J BIOL CHEM, V285, P20343, DOI 10.1074/jbc.M110.116988; Barry DP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017510; Blaser MJ, 1997, J CLIN INVEST, V100, P759, DOI 10.1172/JCI119588; Bussiere FI, 2005, J BIOL CHEM, V280, P2409, DOI 10.1074/jbc.C400498200; Cano VSP, 2008, FEBS J, V275, P44, DOI 10.1111/j.1742-4658.2007.06172.x; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2014, AMINO ACIDS, V46, P531, DOI 10.1007/s00726-013-1531-z; Chaturvedi R, 2010, GASTROENTEROLOGY, V139, P1686, DOI 10.1053/j.gastro.2010.06.060; Chen KY, 1997, BIOL SIGNAL, V6, P105; Cheng Y, 2005, J BIOL CHEM, V280, P22492, DOI 10.1074/jbc.C500122200; Coni S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03174-6; Constanza Camargo M., 2007, Acta Gastroenterologica Latinoamericana, V37, P238; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Correa P, 2010, AM J GASTROENTEROL, V105, P493, DOI 10.1038/ajg.2009.728; Devens BH, 2000, PROSTATE CANCER P D, V3, P275, DOI 10.1038/sj.pcan.4500420; Ehrnstrom RA, 2006, SCAND J GASTROENTERO, V41, P12, DOI 10.1080/00365520510024106; Elitsur Y, 1999, LIFE SCI, V65, P1373, DOI 10.1016/S0024-3205(99)00376-8; Etemadi A, 2020, LANCET GASTROENTEROL, V5, P42, DOI 10.1016/S2468-1253(19)30328-0; Gamble LD, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau1099; Ge S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03121-2; Gobert AP, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108510; Gobert AP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01242; Gobert AP, 2017, CURR TOP MICROBIOL, V400, P27, DOI 10.1007/978-3-319-50520-6_2; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Gutierrez E, 2013, MOL CELL, V51, P35, DOI 10.1016/j.molcel.2013.04.021; Hardbower DM, 2017, P NATL ACAD SCI USA, V114, pE751, DOI 10.1073/pnas.1614958114; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Hardbower DM, 2014, J LEUKOCYTE BIOL, V96, P201, DOI 10.1189/jlb.4BT0214-099R; Hirasawa R, 1999, AM J GASTROENTEROL, V94, P2398; Hooi JKY, 2017, GASTROENTEROLOGY, V153, P420, DOI 10.1053/j.gastro.2017.04.022; HORN Y, 1987, EUR J CANCER CLIN ON, V23, P1103, DOI 10.1016/0277-5379(87)90141-6; Iishi H, 1997, INT J CANCER, V73, P113; Jenkins ZA, 2001, GENOMICS, V71, P101, DOI 10.1006/geno.2000.6418; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Konturek PC, 2003, DIGEST DIS SCI, V48, P36, DOI 10.1023/A:1021774029089; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kountouras J, 2005, HEPATO-GASTROENTEROL, V52, P1305; Kramer DL, 2008, J BIOL CHEM, V283, P4241, DOI 10.1074/jbc.M706806200; Lewis ND, 2011, J IMMUNOL, V186, P3632, DOI 10.4049/jimmunol.1003431; Li DD, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0184-7; Linsalata M, 1998, ITAL J GASTROENTEROL, V30, P484; LoGiudice Nicole, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6010012; LUNDELL L, 1986, SCAND J GASTROENTERO, V21, P829, DOI 10.3109/00365528609011126; Ma JL, 2012, J NATL CANCER I, V104, P488, DOI 10.1093/jnci/djs003; Maier B, 2010, J CLIN INVEST, V120, P2156, DOI 10.1172/JCI38924; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13; MATSUI I, 1981, J BIOL CHEM, V256, P2454; Mera R, 2005, GUT, V54, P1536, DOI 10.1136/gut.2005.072009; Mera RM, 2018, GUT, V67, P1239, DOI 10.1136/gutjnl-2016-311685; Meyskens FL, 2008, CANCER PREV RES, V1, P32, DOI 10.1158/1940-6207.CAPR-08-0042; Miao XP, 2007, WORLD J GASTROENTERO, V13, P2867, DOI 10.3748/wjg.v13.i20.2867; Michael AJ, 2016, J BIOL CHEM, V291, P14896, DOI 10.1074/jbc.R116.734780; Millward MJ, 2005, INVEST NEW DRUG, V23, P253, DOI 10.1007/s10637-005-6734-z; Milovic V, 2003, BIOCHEM SOC T, V31, P381, DOI 10.1042/BST0310381; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Munder M, 2009, BRIT J PHARMACOL, V158, P638, DOI 10.1111/j.1476-5381.2009.00291.x; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; Murray-Stewart T, 2016, ONCOGENE, V35, P5480, DOI 10.1038/onc.2016.91; Nakanishi S, 2016, AMINO ACIDS, V48, P2353, DOI 10.1007/s00726-016-2275-3; NASS MMK, 1984, CANCER RES, V44, P2677; Nishimura K, 2012, AMINO ACIDS, V42, P703, DOI 10.1007/s00726-011-0986-z; Okugawa Y, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1740-z; Oliveira C, 2015, LANCET ONCOL, V16, pE60, DOI 10.1016/S1470-2045(14)71016-2; Pallmann N, 2015, J BIOL CHEM, V290, P18343, DOI 10.1074/jbc.M115.664490; Park JH, 2006, P NATL ACAD SCI USA, V103, P51, DOI 10.1073/pnas.0509348102; Park MH, 1997, BIOL SIGNAL, V6, P115; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; Park MH, 2018, J BIOL CHEM, V293, P18710, DOI 10.1074/jbc.TM118.003341; PATCHETT SE, 1995, GUT, V37, P13, DOI 10.1136/gut.37.1.13; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; Pegg AE, 2006, J BIOL CHEM, V281, P14529, DOI 10.1074/jbc.R500031200; Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230; Pelechano V, 2017, NUCLEIC ACIDS RES, V45, P7326, DOI 10.1093/nar/gkx479; Piazuelo MB, 2021, GASTROENTEROLOGY, V160, P1106, DOI 10.1053/j.gastro.2020.11.017; Pless M, 2004, CLIN CANCER RES, V10, P1299, DOI 10.1158/1078-0432.CCR-0977-03; PRAKASH NJ, 1978, CANCER RES, V38, P3059; Qiu SQ, 2017, CANCER SCI, V108, P163, DOI 10.1111/cas.13122; Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001; Romero-Gallo J, 2008, LAB INVEST, V88, P328, DOI 10.1038/labinvest.3700719; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SAYDJARI R, 1991, CANCER INVEST, V9, P415, DOI 10.3109/07357909109084639; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Schuller AP, 2017, MOL CELL, V66, P194, DOI 10.1016/j.molcel.2017.03.003; Sholler GLS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32659-w; Sierra JC, 2020, ONCOGENE, V39, P4465, DOI 10.1038/s41388-020-1304-6; Sierra JC, 2019, P NATL ACAD SCI USA, V116, P5077, DOI 10.1073/pnas.1814497116; Sievert H, 2014, DIS MODEL MECH, V7, P963, DOI 10.1242/dmm.014449; Takashima T, 2002, ALIMENT PHARM THERAP, V16, P167, DOI 10.1046/j.1365-2036.16.s2.20.x; TATSUTA M, 1995, CARCINOGENESIS, V16, P2107, DOI 10.1093/carcin/16.9.2107; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vakal S, 2020, MOLECULES, V25, DOI 10.3390/molecules25061293; van Zuylen L, 2004, CLIN CANCER RES, V10, P1949, DOI 10.1158/1078-0432.CCR-02-0995; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; WANG JY, 1990, AM J PHYSIOL, V259, pG584; Wang X, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.114637; Wang YL, 2003, BIOCHEM BIOPH RES CO, V304, P605, DOI 10.1016/S0006-291X(03)00636-3; Wei G, 2007, MOL CARCINOGEN, V46, P611, DOI 10.1002/mc.20350; Wilson KT, 2007, GASTROENTEROLOGY, V133, P288, DOI 10.1053/j.gastro.2007.05.008; Wroblewski LE, 2010, CLIN MICROBIOL REV, V23, P713, DOI 10.1128/CMR.00011-10; Xu AG, 2004, BIOCHEM J, V384, P585, DOI 10.1042/BJ20041232; Xu AG, 2001, J BIOL CHEM, V276, P2555, DOI 10.1074/jbc.M008982200; Xu CX, 2011, MOL BIOL REP, V38, P949, DOI 10.1007/s11033-010-0188-x; Xu F, 2020, CANCER MANAG RES, V12, P1789, DOI 10.2147/CMAR.S225229; Xu HX, 2004, CANCER RES, V64, P8521, DOI 10.1158/0008-5472.CAN-04-3511; Xu X, 2012, EXP BIOL MED, V237, P435, DOI 10.1258/ebm.2011.011199; You WC, 2006, JNCI-J NATL CANCER I, V98, P974, DOI 10.1093/jnci/djj264	113	7	7	3	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4399	4412		10.1038/s41388-021-01862-x	http://dx.doi.org/10.1038/s41388-021-01862-x		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108618	Green Accepted			2022-12-17	WOS:000659470200003
J	Xi, SY; Cai, HP; Lu, JB; Zhang, Y; Yu, YJ; Chen, FR; Huang, QT; Wang, F; Chen, ZP				Xi, Shaoyan; Cai, Haiping; Lu, Jiabin; Zhang, Yu; Yu, Yanjiao; Chen, Furong; Huang, Qitao; Wang, Fang; Chen, Zhongping			The pseudogene PRELID1P6 promotes glioma progression via the hnHNPH1-Akt/mTOR axis	ONCOGENE			English	Article							NONCODING RNA; PROTEINS; CANCER; RECOGNITION; DYSFUNCTION; EXPRESSION; CARCINOMA; APOPTOSIS; UBIQUITIN; PATHWAYS	Research over the past decade has suggested important roles for pseudogenes in glioma. This study aimed to show that pseudogene PRELI domain-containing 1 pseudogene 6 (PRELID1P6) promotes glioma progression. Aberrant expression of genes was screened using The Cancer Genome Atlas database. We found that mRNA level of PRELID1P6 was highly upregulated in glioma and was associated with a shorter survival time. Functional studies showed that the knockdown of PRELID1P6 decreased cell proliferation, sphere formation, and clone formation ability and blocked the cell cycle transition at G0/G1, while overexpression of PRELID1P6 had the opposite effects. Mechanistically, knockdown of PRELID1P6 changed the cellular localization of heterogeneous nuclear ribonucleoprotein H1 (hnRNPH1) from nucleus to cytoplasm, which promoted ubiquitin-mediated degradation of hnRNPH1. RNA-sequence and gene set enrichment analysis suggested that knockdown of PRELID1P6 regulates the apoptosis signaling pathway. Western blotting showed that PRELID1P6 increased TRF2 expression by hnRNPH1-mediated alternative splicing effect and activated the Akt/mTOR pathway. Furthermore, Akt inhibitor MK2206 treatment reversed the oncogenic function of PRELID1P6. PRELID1P6 was also found to be negatively regulated by miR-1825. Our result showed that PRELID1P6 promotes glioma progression through the hnHNPH1-Akt/mTOR pathway. These findings shed new light on the important role of PRELID1P6 as a novel oncogene for glioma.	[Xi, Shaoyan; Lu, Jiabin; Zhang, Yu; Huang, Qitao] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Pathol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Cai, Haiping; Yu, Yanjiao; Chen, Furong; Chen, Zhongping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Neurosurg Neurooncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China; [Wang, Fang] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, Canc Ctr, Guangzhou, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Chen, ZP (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Neurosurg Neurooncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.; Wang, F (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, Canc Ctr, Guangzhou, Peoples R China.	wangfang@sysucc.org.cn; chenzhp@sysucc.org.cn	wang, fang/GYD-4295-2022	chen, zhongping/0000-0002-6226-5771	National Natural Science Foundation of China (NSFC) [81902536]; Medical Scientific Research Foundation of Guangdong Province of China [20181030153136778]; Fundamental Research Funds for the Central Universities [20ykpy173, 17ykpy84]; National Basic Research Program of China (973) [2015CB755505]; NSFC [81872059]; National High Technology Research and Development Program of China (863) [2012AA02A508]; Guangzhou Science, Technology and Innovation Project [201508020125]; Science and Technology Planning Project [2016A020213004]; Natural Science Foundation of Guangdong Province [S2013040012894]; Guangdong Natural Science Foundation [2017A030310192]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Medical Scientific Research Foundation of Guangdong Province of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Basic Research Program of China (973)(National Basic Research Program of China); NSFC(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program of China (863)(National High Technology Research and Development Program of China); Guangzhou Science, Technology and Innovation Project; Science and Technology Planning Project; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	The study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center with a no. of GZR2019-053. The authors thank Qi Zhao for the work of bioinformatics. This study was supported by grants from National Natural Science Foundation of China (NSFC; 81902536) and Medical Scientific Research Foundation of Guangdong Province of China (20181030153136778) and Fundamental Research Funds for the Central Universities (20ykpy173) to SX; National Basic Research Program of China (973; 2015CB755505), NSFC (81872059), the National High Technology Research and Development Program of China (863; 2012AA02A508), Guangzhou Science, Technology and Innovation Project (201508020125), Science and Technology Planning Project (2016A020213004) and Natural Science Foundation of Guangdong Province (S2013040012894) to ZC; and Guangdong Natural Science Foundation (2017A030310192) and the Fundamental Research Funds for the Central Universities (17ykpy84) for FW.	Aboudehen K, 2020, BBA-GENE REGUL MECH, V1863, DOI 10.1016/j.bbagrm.2019.194449; Barth RF, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0280-5; Bracken CP, 2016, NAT REV GENET, V17, P719, DOI 10.1038/nrg.2016.134; Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023; Chen X, 2012, TRENDS BIOCHEM SCI, V37, P457, DOI 10.1016/j.tibs.2012.08.005; Chen X, 2020, THERANOSTICS, V10, P1479, DOI 10.7150/thno.40659; da Silva MR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/150514; Deng JM, 2016, MOL NEUROBIOL, V53, P1132, DOI 10.1007/s12035-014-9080-3; Edwards LA, 2005, ONCOGENE, V24, P3596, DOI 10.1038/sj.onc.1208427; Gautrey H, 2015, RNA BIOL, V12, P1139, DOI 10.1080/15476286.2015.1076610; Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5; Grammatikakis I, 2016, CELL CYCLE, V15, P3026, DOI 10.1080/15384101.2016.1222339; Grammatikakis I, 2016, CELL REP, V15, P926, DOI 10.1016/j.celrep.2016.03.080; Grice GL, 2016, CELL MOL LIFE SCI, V73, P3497, DOI 10.1007/s00018-016-2255-5; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Hu XL, 2018, CANCERS, V10, DOI 10.3390/cancers10080256; JACQ C, 1977, CELL, V12, P109, DOI 10.1016/0092-8674(77)90189-1; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Kedzierska H, 2017, CANCER LETT, V396, P53, DOI 10.1016/j.canlet.2017.03.013; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]; Lian YF, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0333-9; Lu XJ, 2015, J MED GENET, V52, P17, DOI 10.1136/jmedgenet-2014-102785; Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802; Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rynkeviciene R, 2019, CANCERS, V11, DOI 10.3390/cancers11010017; Sarkar S, 2013, BIOCHEM SOC T, V41, P1103, DOI 10.1042/BST20130134; Shan K, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.145; Shan YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0759-7; Shen D, 2015, ONCOL REP, V34, P2715, DOI 10.3892/or.2015.4232; Sizoo EM, 2010, NEURO-ONCOLOGY, V12, P1162, DOI 10.1093/neuonc/nop045; Wang F, 2018, ORL J OTO-RHINO-LARY, V80, P227, DOI 10.1159/000489461; Wang L, 2013, CARCINOGENESIS, V34, P1773, DOI 10.1093/carcin/bgt139; Werner C, 2008, J AM COLL CARDIOL, V52, P470, DOI 10.1016/j.jacc.2008.04.034; Xing WL, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705339; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Xu WL, 2017, ONCOTARGET, V8, P51758, DOI 10.18632/oncotarget.17401; Yang N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.358; Zhang YQ, 2018, MOL MED REP, V18, P4239, DOI 10.3892/mmr.2018.9491	43	7	7	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4453	4467		10.1038/s41388-021-01854-x	http://dx.doi.org/10.1038/s41388-021-01854-x		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108621	hybrid, Green Published			2022-12-17	WOS:000659470200005
J	Barnoud, T; Indeglia, A; Murphy, ME				Barnoud, Thibaut; Indeglia, Alexandra; Murphy, Maureen E.			Shifting the paradigms for tumor suppression: lessons from the p53 field	ONCOGENE			English	Review							CELL-CYCLE ARREST; EARLY EMBRYONIC LETHALITY; MUTANT P53; TRANSCRIPTIONAL ACTIVATION; SPLICING REGULATOR; DNA-DAMAGE; WILD-TYPE; CANCER; MUTATIONS; APOPTOSIS	The TP53 gene continues to hold distinction as the most frequently mutated gene in cancer. Since its discovery in 1979, hundreds of research groups have devoted their efforts toward understanding why this gene is so frequently selected against by tumors, with the hopes of harnessing this information toward the improved therapy of cancer. The result is that this protein has been meticulously analyzed in tumor and normal cells, resulting in over 100,000 publications, with an average of 5000 papers published on p53 every year for the past decade. The journey toward understanding p53 function has been anything but straightforward; in fact, the field is notable for the numerous times that established paradigms not only have been shifted, but in fact have been shattered or reversed. In this review, we will discuss the manuscripts, or series of manuscripts, that have most radically changed our thinking about how this tumor suppressor functions, and we will delve into the emerging challenges for the future in this important area of research. It is hoped that this review will serve as a useful historical reference for those interested in p53, and a useful lesson on the need to be flexible in the face of established paradigms.	[Barnoud, Thibaut; Indeglia, Alexandra; Murphy, Maureen E.] Wistar Inst Anat & Biol, Program Mol & Cellular Oncogenesis, 3601 Spruce St, Philadelphia, PA 19104 USA; [Indeglia, Alexandra] Univ Penn, Dept Biochem & Mol Biophys, Perelman Sch Med, Philadelphia, PA USA	The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine	Murphy, ME (corresponding author), Wistar Inst Anat & Biol, Program Mol & Cellular Oncogenesis, 3601 Spruce St, Philadelphia, PA 19104 USA.	mmurphy@wistar.org		Murphy, Maureen/0000-0001-7644-7296; Barnoud, Thibaut/0000-0001-5588-6281	National Institutes of Health [R01 CA201430, CA102184, K99 CA241367]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (R01 CA201430 and CA102184 to MEM, and K99 CA241367 to TB). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors would like to apologize for all the investigators whose references could not be included in this article due to space constraints. The authors would also like to thank Keerthana Gnanapradeepan, Jessica C. Leung, and Joshua L. D. Parris in the Murphy lab for assistance and thoughtful discussions. Figures were created with BioRender.com under a paid subscription to AI.	Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Barnoud T, 2020, CANCER RES, V80, P5270, DOI 10.1158/0008-5472.CAN-20-0397; Barnoud Thibaut, 2019, Oncotarget, V10, P1217, DOI 10.18632/oncotarget.26660; Berger SL, 2010, CELL, V142, P17, DOI 10.1016/j.cell.2010.06.026; Bieging-Rolett KT, 2020, MOL CELL, V80, P452, DOI 10.1016/j.molcel.2020.10.022; Biton J, 2018, CLIN CANCER RES, V24, P5710, DOI 10.1158/1078-0432.CCR-18-0163; Blagih J, 2020, J CELL SCI, V133, DOI 10.1242/jcs.237453; Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028; Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105; Boettcher S, 2019, SCIENCE, V365, P599, DOI 10.1126/science.aax3649; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2004, CELL CYCLE, V3, P429; Chu B, 2019, NAT CELL BIOL, V21, P579, DOI 10.1038/s41556-019-0305-6; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Friedler A, 2002, P NATL ACAD SCI USA, V99, P937, DOI 10.1073/pnas.241629998; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gnanapradeepan K, 2020, ELIFE, V9, DOI 10.7554/eLife.55994; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jiang DD, 2011, P NATL ACAD SCI USA, V108, P17123, DOI 10.1073/pnas.1111245108; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103; Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498; Kadosh E, 2020, NATURE, V586, P133, DOI 10.1038/s41586-020-2541-0; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kang R, 2019, FREE RADICAL BIO MED, V133, P162, DOI 10.1016/j.freeradbiomed.2018.05.074; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Leu JIJ, 2019, P NATL ACAD SCI USA, V116, P8390, DOI 10.1073/pnas.1821277116; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; LUNA RMD, 1995, NATURE, V378, P203; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mello SS, 2017, CANCER CELL, V32, P460, DOI 10.1016/j.ccell.2017.09.007; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Murphy ME, 2004, CELL CYCLE, V3, P836; Muys BR, 2021, GENE DEV, V35, P102, DOI 10.1101/gad.342634.120; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Fernandez-Fernandez MR, 2011, PROTEIN ENG DES SEL, V24, P41, DOI 10.1093/protein/gzq074; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schulz-Heddergott R, 2018, CANCER CELL, V34, P298, DOI 10.1016/j.ccell.2018.07.004; Schulz-Heddergott R, 2018, CANCERS, V10, DOI 10.3390/cancers10060188; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Singh KS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14151-9; Smith KR, 2012, P ROY SOC B-BIOL SCI, V279, P1389, DOI 10.1098/rspb.2011.1697; Speidel D, 2010, TRENDS CELL BIOL, V20, P14, DOI 10.1016/j.tcb.2009.10.002; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Tarangelo A, 2018, CELL REP, V22, P569, DOI 10.1016/j.celrep.2017.12.077; Valente LJ, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201908212; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Vicens A, 2018, GENES-BASEL, V9, DOI 10.3390/genes9120582; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Vousden KH, 2009, BIOCHEM SOC T, V37, P511, DOI 10.1042/BST0370511; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang PY, 2013, NEW ENGL J MED, V368, P1027, DOI 10.1056/NEJMoa1214091; Wang SJ, 2016, CELL REP, V17, P366, DOI 10.1016/j.celrep.2016.09.022; White E, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026120; Williams AB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026070; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yang X, 2003, CELL DEATH DIFFER, V10, P400, DOI 10.1038/cj.cdd.4401182; Yu X, 2018, CLIN CANCER RES, V24, P4505, DOI 10.1158/1078-0432.CCR-18-0822	95	7	7	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4281	4290		10.1038/s41388-021-01852-z	http://dx.doi.org/10.1038/s41388-021-01852-z		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103683	Green Accepted			2022-12-17	WOS:000659032900006
J	Liao, YN; Liu, Y; Shao, ZL; Xia, XH; Deng, YF; Cai, JY; Yao, LY; He, JC; Yu, CF; Hu, TM; Sun, WS; Liu, F; Tang, DL; Liu, JB; Huang, HBA				Liao, Yuning; Liu, Yuan; Shao, Zhenlong; Xia, Xiaohong; Deng, Yuanfei; Cai, Jianyu; Yao, Leyi; He, Jinchan; Yu, Cuifu; Hu, Tumei; Sun, Wenshuang; Liu, Fang; Tang, Daolin; Liu, Jinbao; Huang, Hongbiao			A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance	ONCOGENE			English	Article							SIX1; PROLIFERATION; HOMEOPROTEIN; INHIBITOR; APOPTOSIS; AR-V7	Prostate cancer (PC) is the second most common cancer with limited treatment option in males. Although the reactivation of embryonic signals in adult cells is one of the characteristics of cancer, the underlying protein degradation mechanism remains elusive. Here, we show that the molecular chaperone GRP75 is a key player in PC cells by maintaining the protein stability of SIX1, a transcription factor for embryonic development. Mechanistically, GRP75 provides a platform to recruit the deubiquitinating enzyme USP1 to inhibit K48-linked polyubiquitination of SIX1. Structurally, the C-terminus of GRP75 (433-679 aa) contains a peptide binding domain, which is required for the formation of GRP75-USP1-SIX1 protein complex. Functionally, pharmacological or genetic inhibition of the GRP75-USP1-SIX1 protein complex suppresses tumor growth and overcomes the castration resistance of PC cells in vitro and in xenograft mouse models. Clinically, the protein expression of SIX1 in PC tumor tissues is positively correlated with the expression of GRP75 and USP1. These new findings not only enhance our understanding of the protein degradation mechanism, but also may provide a potential way to enhance the anti-cancer activity of androgen suppression therapy.	[Liao, Yuning; Liu, Yuan; Shao, Zhenlong; Xia, Xiaohong; Liu, Jinbao; Huang, Hongbiao] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China; [Liao, Yuning; Liu, Yuan; Shao, Zhenlong; Xia, Xiaohong; Cai, Jianyu; Yao, Leyi; He, Jinchan; Yu, Cuifu; Hu, Tumei; Sun, Wenshuang; Liu, Jinbao; Huang, Hongbiao] Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou, Guangdong, Peoples R China; [Deng, Yuanfei; Liu, Fang] First Peoples Hosp Foshan, Dept Pathol, Foshan, Guangdong, Peoples R China; [Tang, Daolin] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX USA	Guangzhou Medical University; Guangzhou Medical University; University of Texas System; University of Texas Southwestern Medical Center Dallas	Liu, JB; Huang, HBA (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Guangdong, Peoples R China.; Liu, JB; Huang, HBA (corresponding author), Guangzhou Med Univ, Sch Basic Med Sci, Guangzhou Municipal & Guangdong Prov Key Lab Prot, Guangzhou, Guangdong, Peoples R China.	jliu@gzhmu.edu.cn; hhb800616@126.com	Tang, Daolin/ABD-5062-2021; Tang, Daolin/B-2905-2010	Tang, Daolin/0000-0002-1903-6180; Liao, Yuning/0000-0003-0343-1933; shao, zhenlong/0000-0001-8039-8706	National Natural Science Foundation of China [82072810, 82002481, 81972399]; Science and Technology Program of Guangzhou [202002030107]; projects from Foundation for Higher Education of Guangdong [2019KQNCX113]; Special fund of Foshan Summit plan [2019D001]; Foshan Science technology and Medical foundation [1920001000958]; Guangzhou key medical discipline construction project fund	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangzhou; projects from Foundation for Higher Education of Guangdong; Special fund of Foshan Summit plan; Foshan Science technology and Medical foundation; Guangzhou key medical discipline construction project fund	This work was supported by National Natural Science Foundation of China (82072810, 82002481, 81972399), the Science and Technology Program of Guangzhou (202002030107), projects from Foundation for Higher Education of Guangdong (2019KQNCX113), Special fund of Foshan Summit plan (2019D001), Grant from Foshan Science technology and Medical foundation (1920001000958) and Guangzhou key medical discipline construction project fund.	Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Burress H, 2019, J BIOL CHEM, V294, P12122, DOI 10.1074/jbc.RA119.008568; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Christensen KL, 2007, ONCOGENE, V26, P3406, DOI 10.1038/sj.onc.1210122; Culig Z, 2014, CANCER METAST REV, V33, P413, DOI 10.1007/s10555-013-9474-0; Fizazi K, 2020, LANCET ONCOL; Fushimi C, 2018, ANN ONCOL, V29, P979, DOI 10.1093/annonc/mdx771; He L, 2018, CELL RES, V28, P934, DOI 10.1038/s41422-018-0079-6; Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701; Li L, 2018, CANCER CELL, V33, P368, DOI 10.1016/j.ccell.2018.01.010; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Li ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059203; Liang Q, 2014, NAT CHEM BIOL, V10, P298, DOI [10.1038/NCHEMBIO.1455, 10.1038/nchembio.1455]; Liao YN, 2020, THERANOSTICS, V10, P3366, DOI 10.7150/thno.41849; Liao YN, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-019-0092-z; Liao YN, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1165-4; Liao YN, 2018, ONCOGENE, V37, P1896, DOI 10.1038/s41388-017-0069-z; Liao YN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.477; Lim KS, 2018, MOL CELL, V72, P925, DOI 10.1016/j.molcel.2018.10.045; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; Ryu SW, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000606; Saad F, 2020, EUR UROL; Starenki D, 2015, ONCOGENE, V34, P4624, DOI 10.1038/onc.2014.392; Tian SR, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01508-0; Tucci M, 2019, CANCER TREAT REV, V74, P35, DOI 10.1016/j.ctrv.2019.01.002; Wen SM, 2020, ONCOGENE, V39, P6556, DOI 10.1038/s41388-020-01456-z; Wu KM, 2013, CANCER RES, V73, P4488, DOI 10.1158/0008-5472.CAN-12-4078; Wu PK, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay1478; Wu PK, 2020, ONCOGENE, V39, P4257, DOI 10.1038/s41388-020-1285-5; Wu PK, 2013, MOL CELL BIOL, V33, P4051, DOI 10.1128/MCB.00021-13; Xia XH, 2019, CANCER LETT, V465, P118, DOI 10.1016/j.canlet.2019.09.003; Yi X, 2008, MOL CELL PROTEOMICS, V7, P315, DOI 10.1074/mcp.M700116-MCP200; Zeng J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0215-z; Zhu ZL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1054-7	38	7	7	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4291	4306		10.1038/s41388-021-01851-0	http://dx.doi.org/10.1038/s41388-021-01851-0		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34079090				2022-12-17	WOS:000657217400007
J	Xu, LL; Liu, WZ; Li, TT; Hu, YY; Wang, Y; Huang, LJ; Wang, Y; Shao, SJ; Liu, XF; Zhan, QM				Xu, Lele; Liu, Wenzhong; Li, Tongtong; Hu, Yuying; Wang, Yu; Huang, Lijie; Wang, Yan; Shao, Shujuan; Liu, Xuefeng; Zhan, Qimin			Long non-coding RNA SMASR inhibits the EMT by negatively regulating TGF-beta/Smad signaling pathway in lung cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LNCRNA; METASTASIS; EXPRESSION; PROMOTES; REPRESSION; INTERACTS; TARGET; CELLS; MYC	TGF-beta/Smad signaling pathway plays an important role in EMT during cancer progression. Long non-coding RNAs (lncRNAs) are involved in various behaviors of cancer cells, including EMT. Here, we report a novel lncRNA adjacent to Smad3, named Smad3-associated long non-coding RNA (SMASR). SMASR is downregulated by TGF-beta via Smad2/3 in lung cancer cells. Knockdown of SMASR induces EMT and increases the migration and invasion of lung cancer cells. Moreover, knockdown of SMASR promotes the phosphorylation of Smad2/3. Mechanistically, SMASR interacts with Smad2/3 and inhibits the expression of TGFBR1, the TGF-beta type I receptor responsible for phosphorylation of Smad2/3, thus leading to inactivation of TGF-beta/Smad signaling pathway. Clinically, SMASR is downregulated in lung cancer tissues. Collectively, our findings prove a critical role of SMASR in EMT of lung cancer by forming a negative feedback loop with TGF-beta/Smad signaling pathway.	[Xu, Lele; Liu, Wenzhong; Li, Tongtong; Wang, Yu; Huang, Lijie; Liu, Xuefeng; Zhan, Qimin] Dalian Med Univ, Inst Canc Stern Cell, Dalian, Peoples R China; [Hu, Yuying; Wang, Yan; Zhan, Qimin] Peking Univ Canc Hosp & Inst, Lab Mol Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China; [Shao, Shujuan] Dalian Med Univ, Liaoning Key Lab Prote, Dalian, Peoples R China	Dalian Medical University; Dalian Medical University	Liu, XF; Zhan, QM (corresponding author), Dalian Med Univ, Inst Canc Stern Cell, Dalian, Peoples R China.; Zhan, QM (corresponding author), Peking Univ Canc Hosp & Inst, Lab Mol Oncol, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China.	ixuee@sina.com; zhanqimin@bjmu.edu.cn	Xu, Le/HDN-9623-2022		National Basic Research Program of China (973 Program) [2015CB553906]; National Natural Science Foundation of China [81988101, 81830086]; third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes (Beijing Medical Research Institute) [2019-1]; Beijing Municipal Commission of Health and Family Planning Project [PXM2018_026279_000005]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes (Beijing Medical Research Institute); Beijing Municipal Commission of Health and Family Planning Project	This work was supported by the National Basic Research Program of China (973 Program) (2015CB553906), the National Natural Science Foundation of China (81988101 and 81830086), the third round of public welfare development and reform pilot projects of Beijing Municipal Medical Research Institutes (Beijing Medical Research Institute, 2019-1), and the Beijing Municipal Commission of Health and Family Planning Project (PXM2018_026279_000005). The results shown here are part based upon data generated by the TCGA Research Network:.	Acha-Sagredo A, 2020, BRIT J CANCER, V122, P1050, DOI 10.1038/s41416-020-0742-9; Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767; Hu WL, 2018, NAT CELL BIOL, V20, P492, DOI 10.1038/s41556-018-0066-7; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; MIAO H, 2019, JAMA NEUROL, V15; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mondal T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8743; Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373; Postepska-Igielska A, 2015, MOL CELL, V60, P626, DOI 10.1016/j.molcel.2015.10.001; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rodriguez-Mateo C, 2017, CELL DEATH DIFFER, V24, P785, DOI 10.1038/cdd.2017.9; Rossi M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09754-1; Sakai S, 2019, CANCER RES, V79, P2821, DOI 10.1158/0008-5472.CAN-18-3210; Sang LJ, 2018, MOL CELL, V72, P71, DOI 10.1016/j.molcel.2018.08.014; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Schmitt AM, 2016, NAT GENET, V48, P1370, DOI 10.1038/ng.3673; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Singh M, 2018, PHARMACOL THERAPEUT, V182, P80, DOI 10.1016/j.pharmthera.2017.08.009; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trimarchi T, 2014, CELL, V158, P593, DOI 10.1016/j.cell.2014.05.049; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang LJ, 2015, CELL RES, V25, P335, DOI 10.1038/cr.2015.21; Wang P, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat2039; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wang YQ, 2019, CANCER RES, V79, P3542, DOI 10.1158/0008-5472.CAN-18-2900; Wang ZH, 2018, CANCER CELL, V33, P706, DOI 10.1016/j.ccell.2018.03.006; Wu N, 2021, CELL DEATH DIFFER, V28, P219, DOI 10.1038/s41418-020-0596-y; Xia M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15818; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5, 10.1038/s41467-017-00321-0]; Zheng C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2085-0	54	7	7	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3578	3592		10.1038/s41388-021-01760-2	http://dx.doi.org/10.1038/s41388-021-01760-2		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33931741				2022-12-17	WOS:000645887000002
J	Chen, K; Hou, YF; Liao, R; Li, YZ; Yang, HJ; Gong, J				Chen, Kai; Hou, Yifu; Liao, Rui; Li, Youzan; Yang, Hongji; Gong, Jun			LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1	ONCOGENE			English	Article							LONG NONCODING RNA; CELL-PROLIFERATION; UP-REGULATION; CANCER; PROGRESSION; APOPTOSIS; GROWTH; CERNA; METHYLATION; METASTASIS	Emerging evidence suggests that long noncoding RNAs (lncRNAs) function as competitive endogenous RNA (ceRNA) targeting proteins and genes; however, the role of lncRNAs in hepatocellular carcinoma (HCC) is not well understood. We investigated the mechanism by which lncRNA SNHG6 promotes the development of HCC. RT-qPCR revealed upregulated lncRNA SNHG6 in the HCC setting. Elevated SNHG6 expression was indicative of poor prognosis in patients with HCC. SNHG6 overexpression resulted in increased cyclin D1, cyclin E1, and E2F1 expression both in vitro and in vivo. SNHG6 also promoted HCC cell proliferation by enhancing G1-S phase transition in vitro. Dual luciferase reporter assays, RIP, and RNA pull-down assays demonstrated SNHG6 competitively bound to miR-204-5p and inhibited its expression preventing miR-204-5p from targeting E2F1. Overexpression of miR-204-5p abolished the effect of SNHG6. Our data suggest that SNHG6 functions as a ceRNA that targets miR-204-5p resulting in an increased E2F1 expression and enhanced G1-S phase transition, thereby promoting the tumorigenesis of HCC.	[Chen, Kai; Hou, Yifu; Yang, Hongji] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Organ Transplant Ctr, Chengdu, Peoples R China; [Chen, Kai; Hou, Yifu; Yang, Hongji; Gong, Jun] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China; [Chen, Kai; Hou, Yifu; Yang, Hongji] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 3, Chengdu, Peoples R China; [Liao, Rui; Li, Youzan] Southwest Med Univ, Sch Clin Med, Dept Hepatobiliary, Luzhou, Peoples R China; [Gong, Jun] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 2, Chengdu, Peoples R China	Sichuan Provincial People's Hospital; Chinese Academy of Sciences; Sichuan Provincial People's Hospital; Southwest Medical University; Sichuan Provincial People's Hospital	Yang, HJ (corresponding author), Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Organ Transplant Ctr, Chengdu, Peoples R China.; Yang, HJ; Gong, J (corresponding author), Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China.; Yang, HJ (corresponding author), Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 3, Chengdu, Peoples R China.; Gong, J (corresponding author), Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Ward Hepatobiliary Pancreat Surg 2, Chengdu, Peoples R China.	yanghongji99@163.com; 756772096@qq.com	Hou, Yifu/GYQ-7105-2022					Ali Syeda Z, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051723; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Birgani MT, 2018, PATHOL ONCOL RES, V24, P329, DOI 10.1007/s12253-017-0241-3; Boon RA, 2016, J AM COLL CARDIOL, V67, P1214, DOI 10.1016/j.jacc.2015.12.051; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cao C, 2017, ONCOGENE, V36, P1112, DOI 10.1038/onc.2016.278; Chang L, 2016, CANCER LETT, V383, P183, DOI 10.1016/j.canlet.2016.09.034; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chen L, 2013, J BIOL CHEM, V288, P14510, DOI 10.1074/jbc.M113.458737; Chen QC, 2018, J CELL PHYSIOL, V233, P1213, DOI 10.1002/jcp.25988; Chu Y, 2018, FEBS OPEN BIO, V8, P189, DOI 10.1002/2211-5463.12363; Duan SH, 2018, ONCOL RES, V26, P713, DOI 10.3727/096504017X15016337254641; Duan YJ, 2016, ONCOTARGET, V7, P45863, DOI 10.18632/oncotarget.10244; Duan YX, 2020, ONCOTARGETS THER, V13, P2701, DOI 10.2147/OTT.S237069; Farra R, 2015, BIOCHIMIE, V112, P85, DOI 10.1016/j.biochi.2015.02.015; Farra R, 2011, DIGEST LIVER DIS, V43, P1006, DOI 10.1016/j.dld.2011.07.007; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Ge YX, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005726; Greten TF, 2019, GASTROENTEROLOGY, V156, P510, DOI 10.1053/j.gastro.2018.09.051; Grieco FA, 2019, J MOL ENDOCRINOL, V63, P139, DOI 10.1530/JME-19-0066; Gu Y, 2018, ONCOL REP, V40, P1863, DOI 10.3892/or.2018.6621; He Y, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117656; HU F, 2018, CLIN INFECT DIS, V17; Huang JX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20384; Huang Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01188-4; Ikeda K, 2006, J IMMUNOL METHODS, V317, P38, DOI 10.1016/j.jim.2006.09.010; Ingham M, 2017, J CLIN ONCOL, V35, P2949, DOI 10.1200/JCO.2016.69.0032; Jiang GB, 2017, BIOMED PHARMACOTHER, V90, P806, DOI 10.1016/j.biopha.2017.03.081; Jin Y, 2019, HEPATOL INT, V13, P180, DOI 10.1007/s12072-018-9920-8; Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7; Kumari A, 2015, CELL DEATH DIFFER, V22, P311, DOI 10.1038/cdd.2014.146; Li HM, 2020, ONCOTARGETS THER, V13, P757, DOI 10.2147/OTT.S224550; Li Y, 2018, LIFE SCI, V208, P295, DOI 10.1016/j.lfs.2018.07.032; Liu JY, 2019, PEERJ, V7, DOI 10.7717/peerj.7310; Long JY, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0817-y; Lu M, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110566; Ma L, 2017, ONCOL REP, V38, P2951, DOI 10.3892/or.2017.5971; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Parasramka MA, 2016, PHARMACOL THERAPEUT, V161, P67, DOI 10.1016/j.pharmthera.2016.03.004; Pecoraro A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51723-7; Putzer BM, 2013, TRENDS MOL MED, V19, P89, DOI 10.1016/j.molmed.2012.10.009; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tsang FHC, 2015, LIVER INT, V35, P1597, DOI 10.1111/liv.12746; Wong CM, 2018, NAT REV GASTRO HEPAT, V15, P137, DOI 10.1038/nrgastro.2017.169; Wu G, 2019, CELL CYCLE, V18, P1849, DOI 10.1080/15384101.2019.1629772; Wu XJ, 2015, FEBS LETT, V589, P645, DOI 10.1016/j.febslet.2015.01.030; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yuan SX, 2016, CANCER LETT, V379, P239, DOI 10.1016/j.canlet.2015.08.008; Zhang J, 2020, J CANCER, V11, P3199, DOI 10.7150/jca.33273; Zhang P, 2020, CANCER BIOMARK, V28, P381, DOI 10.3233/CBM-191064; Zhang Y, 2020, MOL NEUROBIOL, V57, P2377, DOI 10.1007/s12035-020-01887-5; Zhao HW, 2016, ONCOL RES, V23, P237, DOI 10.3727/096504016X14562725373671; Zhao LJ, 2019, AGING-US, V11, P7098, DOI 10.18632/aging.102240; Zheng SS, 2013, MOL CELL, V52, P37, DOI 10.1016/j.molcel.2013.08.039	57	7	7	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2021	40	18					3217	3230		10.1038/s41388-021-01671-2	http://dx.doi.org/10.1038/s41388-021-01671-2		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE1MB	33824472				2022-12-17	WOS:000637478800001
J	Puhr, M; Eigentler, A; Handle, F; Hackl, H; Ploner, C; Heidegger, I; Schaefer, G; Brandt, MP; Hoefer, J; Van der Pluijm, G; Klocker, H				Puhr, Martin; Eigentler, Andrea; Handle, Florian; Hackl, Hubert; Ploner, Christian; Heidegger, Isabel; Schaefer, Georg; Brandt, Maximilian P.; Hoefer, Julia; Van der Pluijm, Gabri; Klocker, Helmut			Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer	ONCOGENE			English	Article								Despite increasing options for treatment of castration-resistant prostate cancer, development of drug resistance is inevitable. The glucocorticoid receptor (GR) is a prime suspect for acquired therapy resistance, as prostate cancer (PCa) cells are able to increase GR signaling during anti-androgen therapy and thereby circumvent androgen receptor (AR)-blockade and cell death. As standard AR-directed therapies fail to block the GR and GR inhibitors might result in intolerable side effects, the identification of GR signature genes, which are better suited for a targeted approach, is of clinical importance. Therefore, the specific epithelial and stromal GR signature was determined in cancer-associated fibroblasts as well as in abiraterone and enzalutamide-resistant cells after glucocorticoid (GC) treatment. Microarray and ChIP analysis identified MAO-A as a directly up-regulated mutual epithelial and stromal GR target, which is induced after GC treatment and during PCa progression. Elevated MAO-A levels were confirmed in in vitro cell models, in primary tissue cultures after GC treatment, and in patients after neoadjuvant chemotherapy with GCs. MAO-A expression correlates with GR/AR activity as well as with a reduced progression-free survival. Pharmacological MAO-A inhibition combined with 2(nd) generation AR signaling inhibitors or chemotherapeutics results in impaired growth of androgen-dependent, androgen-independent, and long-term anti-androgen-treated cells. In summary, these findings demonstrate that targeting MAO-A represents an innovative therapeutic strategy to synergistically block GR and AR dependent PCa cell growth and thereby overcome therapy resistance.	[Puhr, Martin; Eigentler, Andrea; Handle, Florian; Heidegger, Isabel; Hoefer, Julia; Klocker, Helmut] Med Univ Innsbruck, Dept Urol, Innsbruck, Austria; [Hackl, Hubert] Med Univ Innsbruck, Bioctr, Inst Bioinformat, Innsbruck, Austria; [Ploner, Christian] Med Univ Innsbruck, Dept Plast Reconstruct & Aesthet Surg Innsbruck, Innsbruck, Austria; [Schaefer, Georg] Med Univ Innsbruck, Dept Pathol, Innsbruck, Austria; [Brandt, Maximilian P.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Urol, Mainz, Germany; [Van der Pluijm, Gabri] Leiden Univ, Med Ctr, Dept Urol, Leiden, Netherlands	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Johannes Gutenberg University of Mainz; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Puhr, M (corresponding author), Med Univ Innsbruck, Dept Urol, Innsbruck, Austria.	martin.puhr@i-med.ac.at	Hackl, Hubert/B-3168-2018	Hackl, Hubert/0000-0003-4055-3841; Ploner, Christian/0000-0002-0313-2960; Handle, Florian/0000-0002-7558-5635; van der Pluijm, Gabri/0000-0002-1351-1884	Anniversary Fund of the Oesterreichische Nationalbank (OeNB) [18280]	Anniversary Fund of the Oesterreichische Nationalbank (OeNB)	This study was supported by the Anniversary Fund of the Oesterreichische Nationalbank (OeNB), grant number 18280 to MP.	Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; Courcot E, 2012, DRUG METAB DISPOS, V40, P1953, DOI 10.1124/dmd.112.046896; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Finberg JPM, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00340; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Gaur S, 2019, PROSTATE, V79, P667, DOI 10.1002/pros.23774; Geney R, 2002, CLIN CHEM LAB MED, V40, P918, DOI 10.1515/CCLM.2002.161; Gordon RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104271; Grupp K, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-145; Handle F, 2018, MOL CANCER THER, V17, P2722, DOI 10.1158/1535-7163.MCT-18-0508; Heidenreich A, 2014, EUR J CANCER, V50, P1090, DOI 10.1016/j.ejca.2014.01.006; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hunter P, 2010, EMBO REP, V11, P667, DOI 10.1038/embor.2010.122; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Kalsbeek AMF, 2016, AGING-US, V8, P2702, DOI 10.18632/aging.101044; Kluetz PG, 2013, CLIN CANCER RES, V19, P6650, DOI 10.1158/1078-0432.CCR-13-2134; Kroon J, 2016, ENDOCR-RELAT CANCER, V23, P35, DOI 10.1530/ERC-15-0343; Lempiainen JK, 2017, MOL CELL PROTEOMICS, V16, P1462, DOI 10.1074/mcp.M117.067488; Leon-Mateos L, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072066; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liao CP, 2018, ONCOGENE, V37, P5175, DOI 10.1038/s41388-018-0325-x; Long QX, 2020, NAT MED, V26, P845, DOI [10.1038/s41591-020-0897-1, DOI 10.1038/S41591-020-0897-1]; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Meyer JH, 2006, ARCH GEN PSYCHIAT, V63, P1209, DOI 10.1001/archpsyc.63.11.1209; Ndibe C, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-014-0320-6; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Puhr M, 2018, CLIN CANCER RES, V24, P927, DOI 10.1158/1078-0432.CCR-17-0989; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Schopf B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15237-5; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Small EJ, 2015, CLIN CANCER RES, V21, P3862, DOI 10.1158/1078-0432.CCR-15-0079; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Vanaja DK, 2003, CANCER RES, V63, P3877; Wang KL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15396-5; Welsh JB, 2001, CANCER RES, V61, P5974; Wu JB, 2017, CANCER CELL, V31, P368, DOI 10.1016/j.ccell.2017.02.003; Wu JB, 2014, J CLIN INVEST, V124, P2891, DOI 10.1172/JCI70982; Yin LJ, 2018, STEM CELLS, V36, P1249, DOI 10.1002/stem.2831	42	7	7	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3087	3100		10.1038/s41388-021-01754-0	http://dx.doi.org/10.1038/s41388-021-01754-0		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33795839	Green Published, hybrid			2022-12-17	WOS:000635873300001
J	Tsuji, T; Maeda, Y; Kita, K; Murakami, K; Saya, H; Takemura, H; Inaki, N; Oshima, M; Oshima, H				Tsuji, Toshikatsu; Maeda, Yusuke; Kita, Kenji; Murakami, Kazuhiro; Saya, Hideyuki; Takemura, Hirofumi; Inaki, Noriyuki; Oshima, Masanobu; Oshima, Hiroko			FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; PROSTAGLANDIN E-2; ACTIVATION; RESISTANCE; AKT; METASTASIS; SURVIVAL; PATHWAY; WNT	FOXO3 is a member of the FOXO transcription factors thought to play a tumor-suppressor role in gastrointestinal cancer, while tumor-promoting function of FOXO3 has also been reported. These results suggest a context-dependent function of FOXO3 in tumor development. However, the relationship between the FOXO3 expression pattern and its role in tumorigenesis has not been elucidated. We examined the FOXO3 expression in 65 human primary gastric cancer and patient-derived xenograft tissues by immunohistochemistry and identified three subtypes according to subcellular localization: FOXO3-nuclear accumulated (FOXO3-Nuc), FOXO3-nuclear/cytoplasmic or cytoplasmic distributed (FOXO3-Cyt), and FOXO3-negative. In the FOXO3-Cyt gastric cancer cells, the expression of the constitutive active mutant FOXO3 (Act-ER FOXO3) induced the nuclear accumulation of FOXO3 and significantly suppressed colony formation and proliferation. The inhibition of the PI3K-AKT pathway by inhibitor treatment also suppressed the proliferation of FOXO3-Cyt gastric cancer cells, which was associated with the nuclear accumulation of endogenous FOXO3. Furthermore, the expression of Act-ER FOXO3 by an endogenous promoter significantly suppressed gastric tumorigenesis in Gan mice, a model of gastric cancer. Finally, treatment of FOXO3-Cyt human gastric cancer-derived organoids with an AKT inhibitor significantly suppressed the survival and proliferation. These results indicate that FOXO3 is a latent tumor suppressor for FOXO3-Cyt-type gastric cancer cells and that activation of the PI3K-AKT pathway protects this type of gastric cancer cell from FOXO3-mediated growth suppression via constitutive nuclear export. Thus, the inhibition of the PI3K-AKT pathway and nuclear translocation of endogenous FOXO3 may have therapeutic applications in the treatment of FOXO3-positive and cytoplasmic-type gastric cancer.	[Tsuji, Toshikatsu; Maeda, Yusuke; Oshima, Masanobu; Oshima, Hiroko] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa, Japan; [Tsuji, Toshikatsu; Takemura, Hirofumi] Kanazawa Univ, Dept Thorac Cardiovasc & Gen Surg, Kanazawa, Ishikawa, Japan; [Tsuji, Toshikatsu] Ishikawa Prefectural Cent Hosp, Dept Surg Gastroenterol, Kanazawa, Ishikawa, Japan; [Maeda, Yusuke; Saya, Hideyuki] Keio Univ, Sch Med, Div Gene Regulat, Inst Adv Med Res IAMR, Tokyo, Japan; [Kita, Kenji] Kanazawa Univ, Canc Res Inst, Cent Res Resource Branch, Kanazawa, Ishikawa, Japan; [Murakami, Kazuhiro] Kanazawa Univ, Canc Res Inst, Div Stem Cell Biol, Kanazawa, Ishikawa, Japan; [Inaki, Noriyuki] Kanazawa Univ, Dept Surg Gastroenterol, Kanazawa, Ishikawa, Japan; [Oshima, Masanobu; Oshima, Hiroko] Kanazawa Univ, WPI Nanolife Sci Inst NanoLSI, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University; Ishikawa Prefectural Central Hospital; Keio University; Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University	Oshima, H (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa, Japan.; Oshima, H (corresponding author), Kanazawa Univ, WPI Nanolife Sci Inst NanoLSI, Kanazawa, Ishikawa, Japan.	hoshima@staff.kanazawa-u.ac.jp	Inaki, Noriyuki/B-4361-2018; Oshima, Masanobu/F-9958-2014; Kita, Kenji/D-8437-2015	Inaki, Noriyuki/0000-0002-4241-5015; Murakami, Kazuhiro/0000-0003-1759-9542; Oshima, Masanobu/0000-0002-3304-0004; Saya, Hideyuki/0000-0001-6610-1902; Kita, Kenji/0000-0002-4622-6633	Ministry of Education, Culture, Sports, Science and Technology of Japan [18H04030, 19H03498]; AMED from the Japan Agency for Medical Research and Development, Japan [20ck0106541h0001]; Takeda Science Foundation	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); AMED from the Japan Agency for Medical Research and Development, Japan; Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank, Manami Watanabe, Ayako Tsuda, and Yoshie Jomen for their technical assistance. This work was supported by Grants-in-Aid for Scientific Research (A) (18H04030) and (B) (19H03498) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; AMED (20ck0106541h0001) from the Japan Agency for Medical Research and Development, Japan; Takeda Science Foundation.	Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bullock MD, 2013, BRIT J CANCER, V109, P387, DOI 10.1038/bjc.2013.355; de Brachene AC, 2016, CELL MOL LIFE SCI, V73, P1159, DOI 10.1007/s00018-015-2112-y; Echizen K, 2019, ONCOGENE, V38, P4250, DOI 10.1038/s41388-019-0702-0; Echizen K, 2016, CANCER SCI, V107, P391, DOI 10.1111/cas.12901; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Hofmann C, 2007, GASTROENTEROLOGY, V132, P587, DOI 10.1053/j.gastro.2006.11.017; Hornsveld M, 2018, SEMIN CANCER BIOL, V50, P90, DOI 10.1016/j.semcancer.2017.11.017; Hornsveld M, 2016, CELL DEATH DIFFER, V23, P1483, DOI 10.1038/cdd.2016.33; Hornsveld M, 2018, CANCER RES, V78, P2356, DOI 10.1158/0008-5472.CAN-17-2511; Jiramongkol Y, 2020, CANCER METAST REV, V39, P681, DOI 10.1007/s10555-020-09883-w; Li L, 2019, J CLIN INVEST, V129, P2374, DOI 10.1172/JCI122256; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; LIU Y, 2018, MOL CANCER, V17; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, CANCER SCI, V102, P713, DOI 10.1111/j.1349-7006.2011.01847.x; Oshima H, 2011, GASTROENTEROLOGY, V140, P596, DOI 10.1053/j.gastro.2010.11.007; Oshima H, 2009, CANCER SCI, V100, P1779, DOI 10.1111/j.1349-7006.2009.01258.x; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Penrose HM, 2019, CELL MOL GASTROENTER, V7, P391, DOI 10.1016/j.jcmgh.2018.10.003; Putker M, 2015, ANTIOXID REDOX SIGN, V22, P15, DOI 10.1089/ars.2014.6056; Storz P, 2009, MOL CELL BIOL, V29, P4906, DOI 10.1128/MCB.00077-09; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Tan SH, 2020, NATURE, V578, P437, DOI 10.1038/s41586-020-1973-x; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Yang XJ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0061801, 10.1371/journal.pone.0062181]; Yeo H, 2013, EMBO J, V32, P2589, DOI 10.1038/emboj.2013.186; Yu S, 2015, INT J CLIN EXP PATHO, V8, P2963	41	7	7	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3072	3086		10.1038/s41388-021-01757-x	http://dx.doi.org/10.1038/s41388-021-01757-x		APR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33795838	hybrid, Green Published			2022-12-17	WOS:000635873300002
J	Wang, XS; Feng, M; Xiao, TF; Guo, BS; Liu, DY; Liu, CL; Pei, JP; Liu, QF; Xiao, Y; Rosin-Arbesfeld, R; Shi, Y; Zhou, Y; Yang, MX; Feng, YX; Jiang, YZ; Shao, ZM; Yu, K; Zhu, D				Wang, Xiaoshuang; Feng, Mei; Xiao, Tengfei; Guo, Baosen; Liu, Danyang; Liu, Chenglong; Pei, Jinpeng; Liu, Qiaofeng; Xiao, Yi; Rosin-Arbesfeld, Rina; Shi, Ying; Zhou, Yang; Yang, Mengxuan; Feng, Yu-Xiong; Jiang, Yizhou; Shao, Zhimin; Yu, Ker; Zhu, Di			BCL9/BCL9L promotes tumorigenicity through immune-dependent and independent mechanisms in triple negative breast cancer	ONCOGENE			English	Article								Treatment of patients with triple-negative breast cancer (TNBC) has been challenging due to a lack of well-defined molecular targets. The Wnt/beta-catenin pathway is known to be activated in many TNBC patients and BCL9 and BCL9L are important transcriptional co-activators of beta-catenin, but whether inhibition of BCL9/BCL9L can suppress TNBC growth and the underlying mechanism are not fully understood. Here we demonstrate that the expression of BCL9 and BCL9L is directly correlated with malignancy in TNBC patient tumors and that BCL9 and BCL9L promote tumor cell growth, cell migration and metastasis in TNBC models. Mechanistically, we found that BCL9/BCL9L promotes tumorigenicity through both the Wnt and TGF-beta pathways. Besides, BCL9/BCL9L expression inversely correlates with CD8(+) T cell infiltration in TNBC and BCL9/BCL9L inhibits the infiltration of CD8(+) T cells in the tumor microenvironment. hsBCL9(CT)-24, an inhibitor of BCL9/beta-catenin peptides, promotes intratumoral infiltration of cytotoxic T cells, reducing regulatory T cells (Treg) and increasing dendritic cells (DCs). Inhibition of BCL9/BCL9L and TGF-beta suppresses activity of Treg. TGF-beta signaling increases tumor infiltration of cytotoxic CD8(+) T cells. In accordance, genetic or pharmacological inhibition of BCL9/BCL9L synergizes with PD-1/L1 antibodies to inhibit tumor growth. In summary, these results suggest that targeting BCL9/BCL9L has a direct anti-tumor effect and also unleashes an anti-cancer immune response through inhibition of both Wnt and TGF-beta signaling, suggesting a viable therapeutic approach for TNBC treatment.	[Wang, Xiaoshuang; Feng, Mei; Liu, Chenglong; Pei, Jinpeng; Liu, Qiaofeng; Shi, Ying; Zhou, Yang; Yu, Ker; Zhu, Di] Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai, Peoples R China; [Xiao, Tengfei] XBH Biotech, Shanghai, Peoples R China; [Guo, Baosen] Shenzhen Digital Life Inst, Shenzhen, Guangdong, Peoples R China; [Liu, Danyang] Fudan Univ, Obstet & Gynecol Hosp, Shanghai, Peoples R China; [Xiao, Yi; Jiang, Yizhou; Shao, Zhimin] Fudan Univ, Dept Surg Breast Canc, Shanghai Canc Ctr, Shanghai, Peoples R China; [Rosin-Arbesfeld, Rina] Tel Aviv Univ, Dept Microbiol & Immunol, Sackler Fac Med, Tel Aviv, Israel; [Yang, Mengxuan; Feng, Yu-Xiong] Zhejiang Univ, Sch Med, Inst Translat Med, Affiliated Hosp 1, Hangzhou, Peoples R China; [Zhu, Di] Fudan Univ, Fudan Affiliated Zhongshan Hosp, Minhang Branch, Shanghai, Peoples R China; [Zhu, Di] Fudan Univ, Key Lab Smart Drug Delivery, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Tel Aviv University; Sackler Faculty of Medicine; Zhejiang University; Fudan University; Fudan University	Yu, K; Zhu, D (corresponding author), Fudan Univ, Sch Pharm, Dept Pharmacol, Shanghai, Peoples R China.; Zhu, D (corresponding author), Fudan Univ, Fudan Affiliated Zhongshan Hosp, Minhang Branch, Shanghai, Peoples R China.; Zhu, D (corresponding author), Fudan Univ, Key Lab Smart Drug Delivery, Shanghai, Peoples R China.	keryu@fudan.edu.cn; zhudi@fudan.edu.cn		Wang, Xiaoshaung/0000-0002-0725-9440; Liu, Chenglong/0000-0002-1657-6683	projects on the National Natural Science Foundation of China [81373442]; National Science and Technology Major Project of China [2018ZX09711002-008]; National Basic Research Program (973 Program) of China [2013CB932500]; Science and Technology Commission of Shanghai [18ZR1403900, 18JC1413800]; National Natural Science Foundation of China [81872895]; project on joint translational research in the School of Pharmacy and Minhang Hospital [RO-MY201712]	projects on the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China; National Basic Research Program (973 Program) of China(National Basic Research Program of China); Science and Technology Commission of Shanghai(Science & Technology Commission of Shanghai Municipality (STCSM)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); project on joint translational research in the School of Pharmacy and Minhang Hospital	The current study was supported by projects on the National Natural Science Foundation of China (81373442) (KY), National Science and Technology Major Project of China (2018ZX09711002-008) (KY), the National Basic Research Program (973 Program) of China (2013CB932500) (KY), the Science and Technology Commission of Shanghai (18ZR1403900, 18JC1413800) (DZ), the National Natural Science Foundation of China (81872895) (DZ), and the project on joint translational research in the School of Pharmacy and Minhang Hospital (RO-MY201712) (DZ).	Adachi S, 2004, CANCER RES, V64, P8496, DOI 10.1158/0008-5472.CAN-04-2254; Ahmadzadeh M, 2005, J IMMUNOL, V174, P5215, DOI 10.4049/jimmunol.174.9.5215; [Anonymous], 2019, CANCER DISCOV, V9; Augustin I, 2016, STEM CELL RES, V17, P607, DOI 10.1016/j.scr.2016.10.010; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Bilir B, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-280; Bishai WR, 2019, P AACR SPEC C TUM IM; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; de la Roche M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-199; Elsarraj HS, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0630-z; Feng M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau5240; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fu CM, 2015, P NATL ACAD SCI USA, V112, P2823, DOI 10.1073/pnas.1414167112; Galluzzi L, 2019, TRENDS CELL BIOL, V29, P44, DOI 10.1016/j.tcb.2018.08.005; Gattinoni L, 2010, CLIN CANCER RES, V16, P4695, DOI 10.1158/1078-0432.CCR-10-0356; Gay DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08586-3; Golovina TN, 2010, CANCER J, V16, P342, DOI 10.1097/PPO.0b013e3181eb336d; Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908; He Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1002-1; Hong Y, 2015, CANCER RES, V75, P656, DOI 10.1158/0008-5472.CAN-14-2377; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; King TD, 2012, J CELL BIOCHEM, V113, P13, DOI 10.1002/jcb.23350; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mani M, 2009, CANCER RES, V69, P7577, DOI 10.1158/0008-5472.CAN-09-0773; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Ovcaricek T, 2011, RADIOL ONCOL, V45, P46, DOI 10.2478/v10019-010-0054-4; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pohl SG, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.14; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Salgado R, 2015, JAMA ONCOL, V1, P448, DOI 10.1001/jamaoncol.2015.0830; Savas P, 2018, NAT MED, V24, P986, DOI 10.1038/s41591-018-0078-7; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Spranger S, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0089-6; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; van Loosdregt J, 2013, IMMUNITY, V39, P298, DOI 10.1016/j.immuni.2013.07.019; Wend P, 2013, EMBO MOL MED, V5, P264, DOI 10.1002/emmm.201201320; Xu YH, 2015, ONCOL REP, V34, P747, DOI 10.3892/or.2015.4056; Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002; Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601; Zatula N, 2014, ONCOTARGET, V5, P6770, DOI 10.18632/oncotarget.2252	50	7	7	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2982	2997		10.1038/s41388-021-01756-y	http://dx.doi.org/10.1038/s41388-021-01756-y		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33767438				2022-12-17	WOS:000632824700002
J	Cheng, C; Pei, XF; Li, SW; Yang, J; Li, CX; Tang, JJ; Hu, KS; Huang, GF; Min, WP; Sang, Y				Cheng, Chun; Pei, Xiaofeng; Li, Si-Wei; Yang, Jun; Li, Chenxi; Tang, Jianjun; Hu, Kaishun; Huang, Guofu; Min, Wei-Ping; Sang, Yi			CRISPR/Cas9 library screening uncovered methylated PKP2 as a critical driver of lung cancer radioresistance by stabilizing beta-catenin	ONCOGENE			English	Article								Radiation resistance is a major cause of lung cancer treatment failure. Armadillo (ARM) superfamily proteins participate in various fundamental cellular processes; however, whether ARM proteins regulate radiation resistance is not fully understood. Here, we used an unbiased CRISPR/Cas9 library screen and identified plakophilin 2 (PKP2), a member of the ARM superfamily of proteins, as a critical driver of radiation resistance in lung cancer. The PKP2 level was significantly higher after radiotherapy than before radiotherapy, and high PKP2 expression after radiotherapy predicted poor overall survival (OS) and postprogression survival (PPS). Mechanistically, mass spectrometry analysis identified that PKP2 was methylated at the arginine site and interacted with protein arginine methyltransferase 1 (PRMT1). Methylation of PKP2 by PRMT1 stabilized beta-catenin by recruiting USP7, further inducing LIG4, a key DNA ligase in nonhomologous end-joining (NHEJ) repair. Concomitantly, PKP2-induced radioresistance depended on facilitating LIG4-mediated NHEJ repair in lung cancer. More strikingly, after exposure to irradiation, treatment with the PRMT1 inhibitor C-7280948 abolished PKP2-induced radioresistance, and C-7280948 is a potential radiosensitizer in lung cancer. In summary, our results demonstrate that targeting the PRMT1/PKP2/beta-catenin/LIG4 pathway is an effective approach to overcome radiation resistance in lung cancer.	[Cheng, Chun; Yang, Jun; Li, Chenxi; Huang, Guofu; Sang, Yi] Nanchang Univ, Affiliated Hosp 3, Dept Ctr Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Nanchang, Jiangxi, Peoples R China; [Pei, Xiaofeng] Sun Yat Sen Univ, Canc Ctr, Affiliated Hosp 5, Dept Thorac Oncol, Zhuhai, Guangdong, Peoples R China; [Li, Si-Wei] Huazhong Univ Sci & Technol, Dept Oncol, Tongji Huangzhou Hosp, Wuhan, Hubei, Peoples R China; [Tang, Jianjun] Nanchang Univ, Dept Resp, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China; [Hu, Kaishun] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Med Res Ctr, Sun Yat Sen Mem Hosp, Guangzhou, Guangdong, Peoples R China; [Min, Wei-Ping] Univ Western Ontario, Dept Surg Pathol & Oncol, London, ON, Canada	Nanchang University; Sun Yat Sen University; Huazhong University of Science & Technology; Nanchang University; Sun Yat Sen University; Western University (University of Western Ontario)	Sang, Y (corresponding author), Nanchang Univ, Affiliated Hosp 3, Dept Ctr Lab, Jiangxi Key Lab Canc Metastasis & Precis Treatmen, Nanchang, Jiangxi, Peoples R China.	ndsfy001889@ncu.edu.cn		Sang, Yi/0000-0001-6534-0741; Hu, Kaishun/0000-0003-2157-6239	special fund for Jiangxi Key Laboratory [20171BCD40026]; Jiangxi Provincial Natural Science Foundation of China [20192BAB215039]; Natural Science Foundation of China [81772821]	special fund for Jiangxi Key Laboratory; Jiangxi Provincial Natural Science Foundation of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the special fund for Jiangxi Key Laboratory (20171BCD40026 to YS), the Jiangxi Provincial Natural Science Foundation of China (20192BAB215039 to YS) and the Natural Science Foundation of China (81772821 to KH).	Adams MM, 2005, CELL CYCLE, V4, P1854, DOI 10.4161/cc.4.12.2282; Arimoto K, 2014, MOL CELL BIOL, V34, P3843, DOI 10.1128/MCB.00758-14; Biau J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01009; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Boisvert FM, 2005, CELL CYCLE, V4, P1834, DOI 10.4161/cc.4.12.2250; Chang JY, 2013, CANCER-AM CANCER SOC, V119, P3402, DOI 10.1002/cncr.28217; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; Coates JC, 2003, TRENDS CELL BIOL, V13, P463, DOI 10.1016/S0962-8924(03)00167-3; Coon D, 2008, CLIN LUNG CANCER, V9, P217, DOI 10.3816/CLC.2008.n.032; Demirag GG, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-1; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dubash AD, 2016, J CELL BIOL, V212, P425, DOI 10.1083/jcb.201507018; Fischer-Keso R, 2014, MOL CELL BIOL, V34, P4244, DOI 10.1128/MCB.00766-14; Gul IS, 2017, CELL MOL LIFE SCI, V74, P525, DOI 10.1007/s00018-016-2319-6; Hao XL, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152438; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hsu JHR, 2017, CANCER RES, V77, P4613, DOI 10.1158/0008-5472.CAN-17-0216; Jeong YK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030871; Jun S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10994; Kanamoto T, 2002, EMBO J, V21, P1219, DOI 10.1093/emboj/21.5.1219; Kim BH, 2020, CLIN CANCER RES, V26, P265, DOI 10.1158/1078-0432.CCR-19-0610; Kim MR, 2015, MOL CANCER RES, V13, P319, DOI 10.1158/1541-7786.MCR-14-0098-T; Laird JH, 2018, CLIN CANCER RES, V24, P5143, DOI 10.1158/1078-0432.CCR-18-0401; Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4; Li D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05286-2; Martin-Padron J, 2020, ONCOGENE, V39, P5479, DOI 10.1038/s41388-019-1129-3; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; Montenegro MF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.85; Montenegro MF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70289-3; Nanavaty P, 2014, CANCER CONTROL, V21, P9, DOI 10.1177/107327481402100102; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Niell N, 2018, INT J CANCER, V142, P792, DOI 10.1002/ijc.31104; Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072; Rubin SM, 2019, NATURE, V569, P343, DOI 10.1038/d41586-019-01319-y; SEOL JH, 2018, MUTAT RES-FUND MOL M, V809, P81, DOI DOI 10.1016/J.MRFMMM.2017.07.002; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Su DX, 2018, J CLIN INVEST, V128, P4280, DOI 10.1172/JCI120518; Suchankova J, 2014, EUR J HISTOCHEM, V58, P1, DOI 10.4081/ejh.2014.2389; Takahashi H, 2012, UROLOGY, V79, DOI 10.1016/j.urology.2011.08.049; Tewari R, 2010, TRENDS CELL BIOL, V20, P470, DOI 10.1016/j.tcb.2010.05.003; Vadnais C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03817-5; Vartak SV, 2018, FEBS J, V285, P3959, DOI 10.1111/febs.14661; Wang Y, 2016, FEBS LETT, V590, P4586, DOI 10.1002/1873-3468.12485; Williams GJ, 2014, DNA REPAIR, V17, P110, DOI 10.1016/j.dnarep.2014.02.009; Wu CYJ, 2020, NEURO-ONCOLOGY, V22, P253, DOI 10.1093/neuonc/noz189; Wu CT, 2015, J MOL MED, V93, P73, DOI 10.1007/s00109-014-1206-6; Yang JH, 2014, NUCLEIC ACIDS RES, V42, P9908, DOI 10.1093/nar/gku705; Zhan TZ, 2019, SEMIN CANCER BIOL, V55, P106, DOI 10.1016/j.semcancer.2018.04.001; Zhang BL, 2019, ACTA BIOCH BIOPH SIN, V51, P375, DOI 10.1093/abbs/gmz015; Zhang DP, 2017, NEUROPATHOLOGY, V37, P207, DOI 10.1111/neup.12363; Zhou WQ, 2019, ONCOTARGETS THER, V12, P8275, DOI 10.2147/OTT.S220536	52	7	7	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2842	2857		10.1038/s41388-021-01692-x	http://dx.doi.org/10.1038/s41388-021-01692-x		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742119				2022-12-17	WOS:000630675000003
J	Esquer, H; Zhou, Q; Nemkov, T; Abraham, AD; Rinaldetti, S; Chen, YC; Zhang, XH; Orman, MV; D'Alessandro, A; Ferrer, M; Messersmith, WA; LaBarbera, DV				Esquer, Hector; Zhou, Qiong; Nemkov, Travis; Abraham, Adedoyin D.; Rinaldetti, Sebastien; Chen, Yu-Chi; Zhang, Xiaohu; Orman, Michael, V; D'Alessandro, Angelo; Ferrer, Marc; Messersmith, Wells A.; LaBarbera, Daniel, V			Isolating and targeting the real-time plasticity and malignant properties of epithelial-mesenchymal transition in cancer	ONCOGENE			English	Article								Epithelial-mesenchymal transition (EMT) is a driving force in promoting malignant cancer, including initiation, growth, and metastasis. EMT is a dynamic process that can undergo a mesenchymal-epithelial transition (MET) and partial transitions between both phenotypes, termed epithelial-mesenchymal plasticity (EMP). In cancer, the acquisition of EMP results in a spectrum of phenotypes, promoting tumor cell heterogeneity and resistance to standard of care therapy. Here we describe a real-time fluorescent dual-reporter for vimentin and E-cadherin, biomarkers of the mesenchymal and epithelial cell phenotypes, respectively. Stable dual-reporter cell lines generated from colorectal (SW620), lung (A549), and breast (MDA-MB-231) cancer demonstrate a spectrum of EMT cell phenotypes. We used the dual-reporter to isolate the quasi epithelial, epithelial/mesenchymal, and mesenchymal phenotypes. Although EMT is a dynamic process, these isolated quasi-EMTphenotypes remain stable to spontaneous EMP in the absence of stimuli and during prolonged cell culture. However, the quasi-EMT phenotypes can readily be induced to undergo EMT or MET with growth factors or small molecules. Moreover, isolated EMT phenotypes display different tumorigenic properties and are morphologically and metabolically distinct. 3D high-content screening of similar to 23,000 compounds using dual-reporter mesenchymal SW620 tumor organoids identified small molecule probes that modulate EMT, and a subset of probes that effectively induced MET. The tools, probes, and models described herein provide a coherent mechanistic understanding of mesenchymal cell plasticity. Future applications utilizing this technology and probes are expected to advance our understanding of EMT and studies aimed at therapeutic strategies targeting EMT.	[Esquer, Hector; Zhou, Qiong; Abraham, Adedoyin D.; Rinaldetti, Sebastien; Orman, Michael, V; LaBarbera, Daniel, V] Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus CU AMC, Aurora, CO 80045 USA; [Nemkov, Travis; D'Alessandro, Angelo] Univ Colorado, Dept Biochem & Mol Genet, Anschutz Med Campus, Aurora, CO USA; [Chen, Yu-Chi; Zhang, Xiaohu; Ferrer, Marc] NIH, Early Translat Branch, Natl Ctr Adv Translat Sci NCATS, Rockville, MD USA; [D'Alessandro, Angelo; Messersmith, Wells A.; LaBarbera, Daniel, V] Univ Colorado Canc Ctr UCCC, Aurora, CO 80045 USA; [D'Alessandro, Angelo; Messersmith, Wells A.; LaBarbera, Daniel, V] Univ Colorado, Anschutz Med Campus, Aurora, CO 80045 USA; [Messersmith, Wells A.] Univ Colorado, Div Med Oncol, Sch Med, Anschutz Med Campus, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	LaBarbera, DV (corresponding author), Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus CU AMC, Aurora, CO 80045 USA.; LaBarbera, DV (corresponding author), Univ Colorado Canc Ctr UCCC, Aurora, CO 80045 USA.; LaBarbera, DV (corresponding author), Univ Colorado, Anschutz Med Campus, Aurora, CO 80045 USA.	daniel.labarbera@cuanschutz.edu	D'Alessandro, Angelo/AAA-4695-2019	D'Alessandro, Angelo/0000-0002-2258-6490; Esquer, Hector/0000-0002-1911-1523; Rinaldetti, Sebastien/0000-0003-1053-3831	Department of Defense Peer Reviewed Cancer Research Program [W81XWH-18-1-0142]; NIH NCI [1R01CA251361-01]; The ALSAM Foundation Therapeutic Innovation Grant; NIH Training Grant [5T32HL7171-42]; Cancer Foundation of Luxembourg; UCCC NIH NCI designated cancer center [P30CA046934]	Department of Defense Peer Reviewed Cancer Research Program(United States Department of Defense); NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); The ALSAM Foundation Therapeutic Innovation Grant; NIH Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Foundation of Luxembourg; UCCC NIH NCI designated cancer center	This research was supported in part by grants awarded to DVL from the Department of Defense Peer Reviewed Cancer Research Program (W81XWH-18-1-0142), the NIH NCI (1R01CA251361-01), and The ALSAM Foundation Therapeutic Innovation Grant. TN was supported by a NIH Training Grant (5T32HL7171-42). SR was supported by the Cancer Foundation of Luxembourg. We thank the Eli Lilly and Company Open Innovation Drug Discovery Program, particularly Evan Castetter and Maria Jose Lorite, for providing the BIC library. We also thank CU AMC shared resource laboratories, including the Drug Discovery and Development Shared Resource (HTS/HCS Discovery Arm), MS Metabolomics, Flow Cytometry, and NMR. These shared resources are supported in part by the UCCC NIH NCI designated cancer center (P30CA046934). We are grateful to Claudia Esquer for graphic design input of Fig. 6.	Abraham AD, 2019, J MED CHEM, V62, P10182, DOI 10.1021/acs.jmedchem.9b01065; Ackland ML, 2003, LAB INVEST, V83, P435, DOI 10.1097/01.LAB.0000059927.97515.FD; Bai FW, 2012, J BIOL CHEM, V287, P30653, DOI 10.1074/jbc.M112.385583; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108; Bierie B, 2017, P NATL ACAD SCI USA, V114, pE2337, DOI 10.1073/pnas.1618298114; Bighetti-Trevisan RL, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9618065; Buchser W., 2004, ASSAY GUIDANCE MANUA; Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7; Choi BJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15139-5; Clasquin Michelle F, 2012, Curr Protoc Bioinformatics, VChapter 14, DOI 10.1002/0471250953.bi1411s37; Cojoc M, 2015, CANCER RES, V75, P1482, DOI 10.1158/0008-5472.CAN-14-1924; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Esquer H, 2020, SLAS DISCOV, V25, P734, DOI 10.1177/2472555220926921; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Hale JS, 2014, STEM CELLS, V32, P1746, DOI 10.1002/stem.1716; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jacobsen A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24982-z; Jia DY, 2019, P NATL ACAD SCI USA, V116, P3909, DOI 10.1073/pnas.1816391116; Kashiwagi S, 2010, BRIT J CANCER, V103, P249, DOI 10.1038/sj.bjc.6605735; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Lee Sang-Kyu, 2018, Advances in Biological Regulation, V68, P46, DOI 10.1016/j.jbior.2018.01.001; Leggett SE, 2016, INTEGR BIOL-UK, V8, P1133, DOI 10.1039/c6ib00139d; Li HX, 2019, NAT MED, V25, P850, DOI 10.1038/s41591-019-0404-8; Li Q, 2011, J BIOMOL SCREEN, V16, P141, DOI 10.1177/1087057110392995; Longo N, 2016, BBA-MOL CELL RES, V1863, P2422, DOI 10.1016/j.bbamcr.2016.01.023; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; McDonald PC, 2015, PRINCIPLES OF STEM CELL BIOLOGY AND CANCER: FUTURE APPLICATIONS AND THERAPEUTICS, P103; Moore SF, 2013, J BIOL CHEM, V288, P3918, DOI 10.1074/jbc.M112.429936; Nemkov T, 2019, METHODS MOL BIOL, V1978, P13, DOI 10.1007/978-1-4939-9236-2_2; Nemkov T, 2017, RAPID COMMUN MASS SP, V31, P663, DOI 10.1002/rcm.7834; Raimundo N, 2011, TRENDS MOL MED, V17, P641, DOI 10.1016/j.molmed.2011.06.001; Richardson F, 2012, ANTICANCER RES, V32, P537; Rodriguez-Pinilla SM, 2007, J CLIN PATHOL, V60, P1006, DOI 10.1136/jcp.2006.042143; San-Millan I, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01536; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sciacovelli M, 2017, FEBS J, V284, P3132, DOI 10.1111/febs.14090; Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Toiyama Y, 2013, CARCINOGENESIS, V34, P2548, DOI 10.1093/carcin/bgt282; Vlachostergios PJ, 2015, CANCER BIOMARK, V15, P725, DOI 10.3233/CBM-150514; Voon DC, 2017, MOL ONCOL, V11, P878, DOI 10.1002/1878-0261.12082; Walenta S, 2003, J CANCER RES CLIN, V129, P321, DOI 10.1007/s00432-003-0450-x; Wang CH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1265-2; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Ye ZH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163162; Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107; Ying M, 2016, ONCOGENE, V35, P4358, DOI [10.1038/onc.2015.503, 10.1038/onc.2016.29]; Yun JA, 2014, ONCOLOGY-BASEL, V86, P318, DOI 10.1159/000360794; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang FX, 2018, PROG NEUROBIOL, V171, P72, DOI 10.1016/j.pneurobio.2018.09.006; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang XJ, 2013, INT J BIOL SCI, V9, P1108, DOI 10.7150/ijbs.7232	59	7	7	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2884	2897		10.1038/s41388-021-01728-2	http://dx.doi.org/10.1038/s41388-021-01728-2		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742123	Green Accepted			2022-12-17	WOS:000630675000001
J	Jing, CY; Fu, YP; Zhou, C; Zhang, MX; Yi, Y; Huang, JL; Gan, W; Zhang, J; Zheng, SS; Zhang, BH; Qiu, SJ				Jing, Chu-Yu; Fu, Yi-Peng; Zhou, Cheng; Zhang, Mei-Xia; Yi, Yong; Huang, Jin-Long; Gan, Wei; Zhang, Juan; Zheng, Su-Su; Zhang, Bo-Heng; Qiu, Shuang-Jian			Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis	ONCOGENE			English	Article								Intrahepatic cholangiocarcinoma (ICC) is a highly fatal malignancy characterized by a vast amount of intra-tumoral fibroblasts. These fibroblasts are potentially implicated in maintaining the high aggressiveness of ICC, whereas its pro-cancer mechanisms remain scarcely reported. Here, by establishing co-culture models of ICC cells and hepatic stellate cells (HSCs), we identified that HSCs triggered the expression of nuclear receptor family 4 subgroup A member 2 (NR4A2), a transcription factor previously reported as a molecular switch between inflammation and cancer, in ICC cells. Functionally, NR4A2 promotes tumor proliferation, metastatic potentiality and represents an independent prognostic indicator for overall survival in ICC patients. Mechanistically, NR4A2 upregulates osteopontin (OPN) expression through transcriptional activation and thereby augments the activity of Wnt/beta-catenin signaling. Intriguingly, in the context of co-culture, vascular endothelial growth factor (VEGF), a previously proved NR4A2 stimulus, not only enhances NR4A2 expression, but also can be blunted by the interference of the NR4A2-OPN axis. Altogether, this study suggests the NR4A2/OPN/Wnt signaling axis to be a pivotal executor of HSC-instigated cancer-promoting roles in ICC, and the NR4A2/OPN/VEGF positive feedback loop may help to reinforce the effect.	[Jing, Chu-Yu; Zhou, Cheng; Yi, Yong; Huang, Jin-Long; Gan, Wei; Zhang, Juan; Zheng, Su-Su; Zhang, Bo-Heng; Qiu, Shuang-Jian] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Jing, Chu-Yu; Zhou, Cheng; Yi, Yong; Huang, Jin-Long; Gan, Wei; Zhang, Juan; Zheng, Su-Su; Zhang, Bo-Heng; Qiu, Shuang-Jian] Fudan Univ, Shanghai Med Sch, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Fu, Yi-Peng] Fudan Univ, Dept Breast Surg, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200090, Peoples R China; [Zhou, Cheng; Yi, Yong; Huang, Jin-Long; Gan, Wei; Qiu, Shuang-Jian] Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Zhang, Mei-Xia] Nanchang Univ, Dept Gastroenterol, Affiliated Hosp 1, 17 Yongwaizheng St, Nanchang 330006, Jiangxi, Peoples R China; [Zhang, Bo-Heng] Fudan Univ, Ctr Evidence Based Med, Shanghai Med Sch, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University; Nanchang University; Fudan University	Zhang, BH; Qiu, SJ (corresponding author), Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Key Lab Carcinogenesis & Canc Invas,Chinese Minis, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Zhang, BH; Qiu, SJ (corresponding author), Fudan Univ, Shanghai Med Sch, Key Lab Carcinogenesis & Canc Invas, Chinese Minist Educ, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Fu, YP (corresponding author), Fudan Univ, Dept Breast Surg, Obstet & Gynecol Hosp, 419 Fangxie Rd, Shanghai 200090, Peoples R China.; Qiu, SJ (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Liver Surg & Transplantat, 180 Fenglin Rd, Shanghai 200032, Peoples R China.; Zhang, BH (corresponding author), Fudan Univ, Ctr Evidence Based Med, Shanghai Med Sch, 138 Yixueyuan Rd, Shanghai 200032, Peoples R China.	fyp0076@163.com; zhang.boheng@zs-hospital.sh.cn; qiu.shuangjian@zs-hospital.sh.cn		Jing, Chuyu/0000-0001-8057-4677; Fu, Yi-Peng/0000-0002-4229-6714	National Natural Science Foundation of China [81772510, 81902419, 81902993, 82072677, 82072672]; National Key Research and Development Program of China [2017YFC0908101, 2017YFC0908102]; Research Programs of Science and Technology Commission Foundation of Shanghai [18XD1401100]; Medical and Health Key Programs of Science and Technology Plan of Xiamen [3502Z20191105]; Research and Development Program of Zhongshan Hospital, Fudan University [2020ZSFZ13, 2019ZSFZ13, 2018ZSFZ055, ZSLC62, 2019-275, 2020-312, 2021-353]; 2020 Youth Talent Program of Obstetrics & Gynecology Hospital of Fudan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Research Programs of Science and Technology Commission Foundation of Shanghai; Medical and Health Key Programs of Science and Technology Plan of Xiamen; Research and Development Program of Zhongshan Hospital, Fudan University; 2020 Youth Talent Program of Obstetrics & Gynecology Hospital of Fudan University	This project is supported by the National Natural Science Foundation of China (NO.81772510; NO.81902419; NO.81902993; NO. 82072677, NO. 82072672); National Key Research and Development Program of China (NO.2017YFC0908101 and NO.2017YFC0908102); Research Programs of Science and Technology Commission Foundation of Shanghai (NO.18XD1401100); Medical and Health Key Programs of Science and Technology Plan of Xiamen (NO.3502Z20191105); 2020 Youth Talent Program of Obstetrics & Gynecology Hospital of Fudan University obtained by Dr. YiPeng Fu and Research and Development Program of Zhongshan Hospital, Fudan University (NO. 2020ZSFZ13, NO. 2019ZSFZ13, NO. 2018ZSFZ055, NO. ZSLC62, NO. ZHZS17, NO. 2019-275, NO. 2020-312, NO. 2021-353).	Ahmed M, 2016, CANCER CELL, V30, P432, DOI 10.1016/j.ccell.2016.08.002; Akeson A, 2010, MICROVASC RES, V80, P65, DOI 10.1016/j.mvr.2010.02.001; [Anonymous], CANCER DISCOV, V7; Bertuccio P, 2019, J HEPATOL, V71, P104, DOI 10.1016/j.jhep.2019.03.013; Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021; Cadamuro M, 2013, HEPATOLOGY, V58, P1042, DOI 10.1002/hep.26384; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cheng JT, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.7; Coulouarn C, 2014, J HEPATOL, V60, P1306, DOI 10.1016/j.jhep.2014.02.003; Crean D, 2015, J IMMUNOL, V195, P1436, DOI 10.4049/jimmunol.1402039; Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001; Dai J, 2009, ONCOGENE, V28, P3412, DOI 10.1038/onc.2009.189; Fingas CD, 2011, HEPATOLOGY, V54, P2076, DOI 10.1002/hep.24588; Gentilini A, 2012, J HEPATOL, V57, P813, DOI 10.1016/j.jhep.2012.06.012; Goradel NH, 2019, J CELL PHYSIOL, V234, P5683, DOI 10.1002/jcp.27411; Han YF, 2012, WORLD J GASTROENTERO, V18, P6865, DOI 10.3748/wjg.v18.i47.6865; Han YF, 2013, EUR J CANCER, V49, P3420, DOI 10.1016/j.ejca.2013.06.001; Han YF, 2013, CANCER-AM CANCER SOC, V119, P3436, DOI 10.1002/cncr.28228; Ji JL, 2015, HEPATOLOGY, V62, P481, DOI 10.1002/hep.27822; Jing CY, 2018, ONCOLOGIST, V23, P1482, DOI 10.1634/theoncologist.2017-0439; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karki K, 2020, J NEURO-ONCOL, V146, P25, DOI 10.1007/s11060-019-03349-y; Kothari AN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5040039; Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003-0247; Li L, 2017, HEPATOLOGY, V65, P501, DOI 10.1002/hep.28735; Li P, 2015, CELL RES, V25, P588, DOI 10.1038/cr.2015.51; McEvoy C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00007; Mohan HM, 2012, CLIN CANCER RES, V18, P3223, DOI 10.1158/1078-0432.CCR-11-2953; Okabe H, 2009, ANN SURG ONCOL, V16, P2555, DOI 10.1245/s10434-009-0568-4; Paule B, 2007, ONCOLOGY-BASEL, V72, P105, DOI 10.1159/000111117; Primrose JN, 2019, LANCET ONCOL, V20, P663, DOI 10.1016/S1470-2045(18)30915-X; Raja R, 2014, ONCOGENE, V33, P2053, DOI 10.1038/onc.2013.171; Ramchandani D, 2015, BBA-REV CANCER, V1855, P202, DOI 10.1016/j.bbcan.2015.02.003; Saha SK, 2016, ONCOLOGIST, V21, P594, DOI 10.1634/theoncologist.2015-0446; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Sekiya T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1272; Shigeishi H, 2011, CANCER LETT, V307, P227, DOI 10.1016/j.canlet.2011.04.008; Sirica AE, 2019, HEPATOLOGY, V69, P1803, DOI 10.1002/hep.30289; Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209; Sulpice L, 2013, HEPATOLOGY, V58, P1992, DOI 10.1002/hep.26577; Urtasun R, 2012, HEPATOLOGY, V55, P594, DOI 10.1002/hep.24701; Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410; Wu LM, 2018, BRIT J HAEMATOL, V183, P445, DOI 10.1111/bjh.15548; Zagani R, 2009, GASTROENTEROLOGY, V137, P1358, DOI 10.1053/j.gastro.2009.06.039; Zhao DZ, 2011, INT J CANCER, V128, P2602, DOI 10.1002/ijc.25600; Zheng Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0226-x; Zhu Y, 2019, GUT, V68, P1653, DOI 10.1136/gutjnl-2019-318419	48	7	7	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2910	2922		10.1038/s41388-021-01705-9	http://dx.doi.org/10.1038/s41388-021-01705-9		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742120				2022-12-17	WOS:000630675000006
J	Berdiel-Acer, M; Maia, A; Hristova, Z; Borgoni, S; Vetter, M; Burmester, S; Becki, C; Michels, B; Abnaof, K; Binenbaum, I; Bethmann, D; Chatziioannou, A; Hasmann, M; Thomssen, C; Espinet, E; Wiemann, S				Berdiel-Acer, Mireia; Maia, Ana; Hristova, Zhivka; Borgoni, Simone; Vetter, Martina; Burmester, Sara; Becki, Corinna; Michels, Birgitta; Abnaof, Khalid; Binenbaum, Ilona; Bethmann, Daniel; Chatziioannou, Aristotelis; Hasmann, Max; Thomssen, Christoph; Espinet, Elisa; Wiemann, Stefan			Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts	ONCOGENE			English	Article							INTRACELLULAR DOMAIN; ERBB RECEPTORS; GENE ONTOLOGY; EXPRESSION; HER3; SUBTYPES; ANTIBODY; HETEROGENEITY; METASTASIS; DISCOVERY	HER3 is highly expressed in luminal breast cancer subtypes. Its activation by NRG1 promotes activation of AKT and ERK1/2, contributing to tumour progression and therapy resistance. HER3-targeting agents that block this activation, are currently under phase 1/2 clinical studies, and although they have shown favorable tolerability, their activity as a single agent has proven to be limited. Here we show that phosphorylation and activation of HER3 in luminal breast cancer cells occurs in a paracrine manner and is mediated by NRG1 expressed by cancer-associated fibroblasts (CAFs). Moreover, we uncover a HER3-independent NRG1 signaling in CAFs that results in the induction of a strong migratory and pro-fibrotic phenotype, describing a subtype of CAFs with elevated expression of NRG1 and an associated transcriptomic profile that determines their functional properties. Finally, we identified Hyaluronan Synthase 2 (HAS2), a targetable molecule strongly correlated with NRG1, as an attractive player supporting NRG1 signaling in CAFs.	[Berdiel-Acer, Mireia; Maia, Ana; Hristova, Zhivka; Borgoni, Simone; Burmester, Sara; Becki, Corinna; Michels, Birgitta; Abnaof, Khalid; Wiemann, Stefan] German Canc Res Ctr, Div Mol Genome Anal, Heidelberg, Germany; [Maia, Ana; Hristova, Zhivka; Borgoni, Simone] Ruprecht Karls Univ Heidelberg, Fac Biosci, Heidelberg, Germany; [Vetter, Martina; Thomssen, Christoph] Martin Luther Univ Halle Wittenberg, Dept Gynecol, Halle, Germany; [Binenbaum, Ilona] German Canc Res Ctr, Div Med Informat Translat Oncol, Heidelberg, Germany; [Binenbaum, Ilona] Univ Patras, Dept Biol, Patras, Greece; [Binenbaum, Ilona; Chatziioannou, Aristotelis] Natl Hellen Res Fdn, Inst Chem Biol, Athens, Greece; [Bethmann, Daniel] Martin Luther Univ Halle Wittenberg, Inst Pathol, Halle, Germany; [Chatziioannou, Aristotelis] E NIOS Pc, Kallithea Athens, Greece; [Hasmann, Max] Roche Diagnostics, Penzberg, Germany; [Espinet, Elisa] German Canc Res Ctr, Div Stem Cells & Canc, Heidelberg, Germany; [Espinet, Elisa] Heidelberg Inst Stem Cell Technol & Expt Med HI S, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Martin Luther University Halle Wittenberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Patras; National Hellenic Research Foundation; Martin Luther University Halle Wittenberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Berdiel-Acer, M; Wiemann, S (corresponding author), German Canc Res Ctr, Div Mol Genome Anal, Heidelberg, Germany.	mireia.berdiel@gmail.com; s.wiemann@dkfz-heidelberg.de	Wiemann, Stefan/E-4424-2013; Thomssen, Christoph/ABC-3102-2021	Wiemann, Stefan/0000-0003-4683-3174; Maia, Ana/0000-0003-1261-7211; Berdiel-Acer, Mireia/0000-0002-9777-9457; Hristova, Zhivka/0000-0003-2609-3623; Espinet, Elisa/0000-0002-0690-9878; Michels, Birgitta E./0000-0001-9948-4567	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Berdiel-Acer M, 2014, MOL ONCOL, V8, P1290, DOI 10.1016/j.molonc.2014.04.006; Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8; Cejalvo JM, 2017, CANCER RES, V77, P2213, DOI 10.1158/0008-5472.CAN-16-2717; Chua YL, 2009, ONCOGENE, V28, P4041, DOI 10.1038/onc.2009.259; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Cortez E, 2014, SEMIN CANCER BIOL, V25, P3, DOI 10.1016/j.semcancer.2013.12.010; Costea DE, 2013, CANCER RES, V73, P3888, DOI 10.1158/0008-5472.CAN-12-4150; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2; Fujiwara S, 2014, BREAST CANCER-TOKYO, V21, P472, DOI 10.1007/s12282-012-0415-5; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jacob W, 2018, CANCER TREAT REV, V68, P111, DOI 10.1016/j.ctrv.2018.06.011; Karachaliou N, 2017, BIODRUGS, V31, P63, DOI 10.1007/s40259-016-0205-2; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kim J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-383; Kim YH, 2019, CANCER SCI, V110, P2226, DOI 10.1111/cas.14070; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kolb A, 2007, INT J CANCER, V120, P514, DOI 10.1002/ijc.22360; Koutsandreas Theodoros, 2016, International Journal of Monitoring and Surveillance Technologies Research, V4, P30, DOI 10.4018/IJMSTR.2016040103; Kudo D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030600; Ledonne A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010275; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lisanti MP, 2014, CELL CYCLE, V13, P580, DOI 10.4161/cc.27379; Liu HY, 2017, DEV CELL, V41, P392, DOI 10.1016/j.devcel.2017.04.024; Liu XL, 2019, BIOL PROCED ONLINE, V21, DOI 10.1186/s12575-019-0093-1; Loeb JA, 1998, MOL CELL NEUROSCI, V11, P77, DOI 10.1006/mcne.1998.0676; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Mei L, 2008, NAT REV NEUROSCI, V9, P437, DOI 10.1038/nrn2392; Mei L, 2014, NEURON, V83, P27, DOI 10.1016/j.neuron.2014.06.007; Meulendijks D, 2017, CLIN CANCER RES, V23, P5406, DOI 10.1158/1078-0432.CCR-17-0812; Meulendijks D, 2016, CLIN CANCER RES, V22, P877, DOI 10.1158/1078-0432.CCR-15-1683; Mirschberger C, 2013, CANCER RES, V73, P5183, DOI 10.1158/0008-5472.CAN-13-0099; Mishra R, 2018, ONCOL REV, V12, P45, DOI 10.4081/oncol.2018.355; Montero JC, 2008, CLIN CANCER RES, V14, P3237, DOI 10.1158/1078-0432.CCR-07-5133; Morrison MM, 2013, J CLIN INVEST, V123, P4329, DOI 10.1172/JCI66764; Morsing M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0769-2; Ocana A, 2016, ONCOTARGET, V7, P45042, DOI 10.18632/oncotarget.8648; Ogier C, 2018, CANCER LETT, V432, P227, DOI 10.1016/j.canlet.2018.06.023; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Orimo A, 2007, CANCER BIOL THER, V6, P618, DOI 10.4161/cbt.6.4.4255; Parra LM, 2015, MOL CELL BIOL, V35, P3381, DOI 10.1128/MCB.00500-15; Patel AK, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0087-x; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Qian GQ, 2015, CANCER-AM CANCER SOC, V121, P3600, DOI 10.1002/cncr.29549; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Saadi A, 2010, P NATL ACAD SCI USA, V107, P2177, DOI 10.1073/pnas.0909797107; Sadlonova A, 2009, CANCER MICROENVIRON, V2, P9, DOI 10.1007/s12307-008-0017-0; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sahin O, 2007, P NATL ACAD SCI USA, V104, P6579, DOI 10.1073/pnas.0606827104; Schneeweiss A, 2018, INVEST NEW DRUG, V36, P848, DOI 10.1007/s10637-018-0562-4; Shee K, 2018, J EXP MED, V215, P895, DOI 10.1084/jem.20171818; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; Sonntag J, 2014, EXPERT REV PROTEOMIC, V11, P757, DOI 10.1586/14789450.2014.971113; Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Vargas AC, 2012, BREAST CANCER RES TR, V135, P153, DOI 10.1007/s10549-012-2123-4; Walker RA, 2001, BREAST CANCER RES, V3, P143, DOI 10.1186/bcr287; Weinstein IB, 1997, CLIN CANCER RES, V3, P2696; Wernig G, 2017, P NATL ACAD SCI USA, V114, P4757, DOI 10.1073/pnas.1621375114; Willem M, 2016, BRAIN RES BULL, V126, P178, DOI 10.1016/j.brainresbull.2016.07.003; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoshida E, 2018, ANTICANCER RES, V38, P5799, DOI 10.21873/anticanres.12919; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yun S, 2018, GASTRIC CANCER, V21, P225, DOI 10.1007/s10120-017-0732-7; Zhang K, 2012, ONCOGENE, V31, P4609, DOI 10.1038/onc.2011.606; Zhang ZW, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0458-0	76	7	7	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2651	2666		10.1038/s41388-021-01719-3	http://dx.doi.org/10.1038/s41388-021-01719-3		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33692466	hybrid, Green Submitted, Green Published			2022-12-17	WOS:000627285600003
J	Ma, HH; Zhang, FQ; Zhou, L; Cao, TY; Sun, DC; Wen, SX; Zhu, JP; Xiong, ZQY; Tsau, MT; Cheng, ML; Hung, LM; Zhou, YM; Li, QX				Ma, Huanhuan; Zhang, Fengqiong; Zhou, Lin; Cao, Tingyan; Sun, Dachao; Wen, Shixiong; Zhu, Jinpei; Xiong, Zhaoqianyu; Tsau, Ming-Tong; Cheng, Mei-Ling; Hung, Li-Man; Zhou, Yanming; Li, Qinxi			c-Src facilitates tumorigenesis by phosphorylating and activating G6PD	ONCOGENE			English	Article								Glucose-6-phosphate dehydrogenase (G6PD) is the first and rate-limiting enzyme in pentose phosphate pathway (PPP), excessive activation of which has been considered to be involved in tumorigenesis. Here, we show that tyrosine kinase c-Src interacts with and phosphorylates G6PD at Tyr 112. This phosphorylation enhances catalytic activity of G6PD by dramatically decreasing its K-m value and increasing its K-cat value for substrate glucose-6-phosphate. Activated G6PD therefore augments the PPP flux for NADPH and ribose-5-phosphate production which is required for detoxification of intracellular reactive oxygen species (ROS) and biosynthesis of cancer cells, and eventually contributes to tumorigenesis. Consistently, c-Src activation is closely correlated with tyrosine phosphorylation and activity of G6PD in clinical colorectal cancer samples. We thus uncover another aspect of c-Src in promoting cell proliferation and tumorigenesis, deepening our understanding of c-Src as a proto-oncogene.	[Ma, Huanhuan; Zhang, Fengqiong; Zhou, Lin; Cao, Tingyan; Sun, Dachao; Wen, Shixiong; Zhu, Jinpei; Xiong, Zhaoqianyu; Li, Qinxi] Xiamen Univ, State Key Lab Cellular Stress Biol, Innovat Ctr Cell Signaling Network, Sch Life Sci, Xiamen, Fujian, Peoples R China; [Tsau, Ming-Tong; Cheng, Mei-Ling] Chang Gung Univ, Hlth Aging Res Ctr, Metabol Core Lab, Taoyuan, Taiwan; [Cheng, Mei-Ling] Chang Gung Mem Hosp, Clin Metabol Core Lab, Taoyuan, Taiwan; [Cheng, Mei-Ling; Hung, Li-Man] Chang Gung Univ, Dept & Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan; [Hung, Li-Man] Chang Gung Univ, Ctr Hlth & Aging Res, Taoyuan, Taiwan; [Hung, Li-Man] Chang Gung Mem Hosp, Kidney Res Ctr, Taoyuan, Taiwan; [Zhou, Yanming] Xiamen Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreatovasc Surg, Xiamen, Fujian, Peoples R China	Xiamen University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Xiamen University	Li, QX (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Innovat Ctr Cell Signaling Network, Sch Life Sci, Xiamen, Fujian, Peoples R China.	liqinxi@xmu.edu.cn	Ma, Huan-Huan/G-8768-2017	Ma, Huan-Huan/0000-0001-8029-6814	National Natural Science Foundation of China, China [U1705287, 91857102]; Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University [SKLCSB2020KF002, SKLCSB2019KF005]	National Natural Science Foundation of China, China(National Natural Science Foundation of China (NSFC)); Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University	This work was supported by the National Natural Science Foundation of China, China (U1705287 and 91857102) and the Open Research Fund of State Key Laboratory of Cellular Stress Biology, Xiamen University (SKLCSB2020KF002 and SKLCSB2019KF005).	Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cho ES, 2018, BIOMOL THER, V26, P29, DOI 10.4062/biomolther.2017.179; COCCO P, 1987, J EPIDEMIOL COMMUN H, V41, P89, DOI 10.1136/jech.41.2.89; Fang ZS, 2016, BBA-MOL CELL RES, V1863, P2245, DOI 10.1016/j.bbamcr.2016.05.016; FORTELEONI G, 1988, TUMORI, V74, P665, DOI 10.1177/030089168807400608; Fury MG, 2011, ANTICANCER RES, V31, P249; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Gupte RS, 2009, FREE RADICAL BIO MED, V47, P219, DOI 10.1016/j.freeradbiomed.2009.01.028; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Jiang P, 2014, PROTEIN CELL, V5, P592, DOI 10.1007/s13238-014-0082-8; Ju HQ, 2017, ONCOGENE, V36, P6282, DOI 10.1038/onc.2017.227; Li TY, 2016, MOL CELL, V62, P359, DOI 10.1016/j.molcel.2016.04.009; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lin RT, 2015, NAT CELL BIOL, V17, P1484, DOI 10.1038/ncb3255; Liu XG, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0496-x; Ma HH, 2020, CELL REP, V30, P4235, DOI 10.1016/j.celrep.2020.03.005; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Musumeci F, 2012, FUTURE MED CHEM, V4, P799, DOI [10.4155/fmc.12.29, 10.4155/FMC.12.29]; Pan JS, 2009, WORLD J GASTROENTERO, V15, P1702, DOI 10.3748/wjg.15.1702; Pan S, 2009, ARTERIOSCL THROM VAS, V29, P895, DOI 10.1161/ATVBAHA.109.184812; Rajeshkumar NV, 2009, CLIN CANCER RES, V15, P4138, DOI 10.1158/1078-0432.CCR-08-3021; Rao XJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9468; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Stincone A, 2015, BIOL REV, V90, P927, DOI 10.1111/brv.12140; Tang HY, 2015, ANTIOXID REDOX SIGN, V22, P744, DOI 10.1089/ars.2014.6142; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tsouko E, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.18; Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Zhang CH, 2014, ANTI-CANCER AGENT ME, V14, P280, DOI 10.2174/18715206113136660337; Zhang J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13732	35	7	8	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2567	2580		10.1038/s41388-021-01673-0	http://dx.doi.org/10.1038/s41388-021-01673-0		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686238				2022-12-17	WOS:000626396000005
J	Ma, RR; Zhang, H; Chen, HF; Zhang, GH; Tian, YR; Gao, P				Ma, Ran-Ran; Zhang, Hui; Chen, Hong-Fang; Zhang, Guo-Hao; Tian, Ya-Ru; Gao, Peng			MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer	ONCOGENE			English	Article								Gastric cancer (GC) is one of the most common malignant neoplasms. Invasion and metastasis are the main causes of GC-related deaths. Recently, kinesins were discovered to be involved in tumor development. The aim of this study was to elucidate the roles of kinesin superfamily protein 26A (KIF26A) in GC and its underlying molecular mechanism in regulating tumor invasion and metastasis. Using real-time quantitative polymerase chain reaction (qPCR) and immunohistochemistry (IHC), we showed that KIF26A expression was lower in GC tissues without lymph node metastasis (LNM) than in nontumorous gastric mucosa, and even lower in GC tissues with LNM than in GC tissues without LNM. Functional experiments showed that KIF26A inhibited migration and invasion of GC cells. We further identified focal-adhesion kinase (FAK), phosphatidylinositol 3-kinase regulatory subunit alpha (PI3KR1), VAV3, Rac1 and p21-activated kinase 2, and beta-PAK (PAK3) as downstream effectors of KIF26A in the focal-adhesion pathway, and we found that KIF26A could regulate FAK mRNA expression through inhibiting c-MYC by MAPK pathway. c-MYC could bind to the promoter of FAK and activate FAK transcription. Moreover, we found that KIF26A-mediated inactivation of the focal-adhesion pathway could reduce the occurrence of the epithelial-to-mesenchymal transition (EMT) by increasing expression of E-cadherin and reducing that of Snail. Luciferase assays and Western blotting revealed that miR-19a and miR-96 negatively regulate KIF26A. Finally, we found that decreased expression of KIF26A has been positively correlated with histological differentiation, Lauren classification, LNM, distal metastasis, and clinical stage, as well as poor survival in patients with GC. These data indicate that KIF26A could inhibit GC migration and invasion by regulating the focal-adhesion pathway and repressing the occurrence of EMT.	[Ma, Ran-Ran; Zhang, Hui; Chen, Hong-Fang; Zhang, Guo-Hao; Tian, Ya-Ru; Gao, Peng] Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China; [Ma, Ran-Ran; Zhang, Hui; Chen, Hong-Fang; Zhang, Guo-Hao; Tian, Ya-Ru; Gao, Peng] Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China; [Ma, Ran-Ran; Zhang, Hui; Gao, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Peoples R China; [Chen, Hong-Fang] Yidu Cent Hosp Weifang, Dept Pathol, Weifang, Peoples R China	Shandong University; Shandong University; Shandong University	Gao, P (corresponding author), Shandong Univ, Sch Basic Med Sci, Minist Educ, Key Lab Expt Teratol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Dept Pathol, Jinan, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81872362, 82072665]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	This study was supported by the National Natural Science Foundation of China (Grant No. 81872362 and 82072665) and the Taishan Scholars Program of Shandong Province (Grant No. ts201511096).	Akhshi TK, 2014, CYTOSKELETON, V71, P1, DOI 10.1002/cm.21150; Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Bachmann A, 2015, BIOCHEM SOC T, V43, P79, DOI 10.1042/BST20140280; Baquero P, 2016, MOL CARCINOGEN, V55, P1639, DOI 10.1002/mc.22415; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Castillo A, 2007, CANCER RES, V67, P10138, DOI 10.1158/0008-5472.CAN-07-0326; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chandrasekaran G, 2015, BRIT J CANCER, V113, P693, DOI 10.1038/bjc.2015.264; Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743; Corson TW, 2006, INT J CANCER, V119, P1088, DOI 10.1002/ijc.21954; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hippo Y, 2002, CANCER RES, V62, P233; Ho JN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108248; Hung PF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061664; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Li PF, 2014, WORLD J GASTROENTERO, V20, P5411, DOI 10.3748/wjg.v20.i18.5411; Lin YW, 2014, CURR PHARM DESIGN, V20, P1698, DOI 10.2174/13816128113199990512; Liu XR, 2013, CANCER SCI, V104, P651, DOI 10.1111/cas.12138; Magnelli L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082893; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Muroyama A, 2017, DEVELOPMENT, V144, P3012, DOI 10.1242/dev.153171; Niwa S, 2015, ANAT SCI INT, V90, P1, DOI 10.1007/s12565-014-0259-5; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Pharoah PDP, 2001, GASTROENTEROLOGY, V121, P1348, DOI 10.1053/gast.2001.29611; Qin S, 2013, ASIAN PAC J CANCER P, V14, P835, DOI 10.7314/APJCP.2013.14.2.835; Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Serrels A, 2011, CELL ADHES MIGR, V5, P360, DOI 10.4161/cam.5.4.17290; Stangel D, 2015, J SURG RES, V197, P91, DOI 10.1016/j.jss.2015.03.070; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Volkov V A, 2013, Ross Fiziol Zh Im I M Sechenova, V99, P153; Wang L, 2018, CELL REP, V24, P2894, DOI 10.1016/j.celrep.2018.05.075; Wang Q, 2013, CANCER EPIDEMIOL, V37, P79, DOI 10.1016/j.canep.2012.08.011; Wang TH, 2016, MOL CARCINOGEN, V55, P366, DOI 10.1002/mc.22286; Wu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.110; Yang L, 2006, WORLD J GASTROENTERO, V12, P17, DOI 10.3748/wjg.v12.i1.17; Yang T, 2013, CANCER SCI, V104, P552, DOI 10.1111/cas.12128; Yu Y, 2010, CANCER-AM CANCER SOC, V116, P5150, DOI 10.1002/cncr.25461; Zhang H, 2017, ONCOGENE, V36, P5609, DOI 10.1038/onc.2017.163; Zhang JF, 2014, ONCOL REP, V31, P1357, DOI 10.3892/or.2013.2934; Zhou RY, 2009, CELL, V139, P802, DOI 10.1016/j.cell.2009.10.023; Zhu HB, 2013, BIOCHEM BIOPH RES CO, V438, P97, DOI 10.1016/j.bbrc.2013.07.032; Zou JX, 2014, MOL CANCER RES, V12, P539, DOI 10.1158/1541-7786.MCR-13-0459	48	7	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2524	2538		10.1038/s41388-020-01610-7	http://dx.doi.org/10.1038/s41388-020-01610-7		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33674746				2022-12-17	WOS:000625607100001
J	Gollavilli, PN; Parma, B; Siddiqui, A; Yang, H; Ramesh, V; Napoli, F; Schwab, A; Natesan, R; Mielenz, D; Asangani, IA; Brabletz, T; Pilarsky, C; Ceppi, P				Gollavilli, Paradesi Naidu; Parma, Beatrice; Siddiqui, Aarif; Yang, Hai; Ramesh, Vignesh; Napoli, Francesca; Schwab, Annemarie; Natesan, Ramakrishnan; Mielenz, Dirk; Asangani, Irfan Ahmed; Brabletz, Thomas; Pilarsky, Christian; Ceppi, Paolo			The role of miR-200b/c in balancing EMT and proliferation revealed by an activity reporter	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; CELL-PROLIFERATION; TARGETING EMT; FEEDBACK LOOP; CANCER; MICRORNAS; METASTASIS; ZEB1; PLASTICITY	Since their discovery, microRNAs (miRNAs) have been widely studied in almost every aspect of biology and medicine, leading to the identification of important gene regulation circuits and cellular mechanisms. However, investigations are generally focused on the analysis of their downstream targets and biological functions in overexpression and knockdown approaches, while miRNAs endogenous levels and activity remain poorly understood. Here, we used the cellular plasticity-regulating process of epithelial-to-mesenchymal transition (EMT) as a model to show the efficacy of a fluorescent sensor to separate cells with distinct EMT signatures, based on miR-200b/c activity. The system was further combined with a CRISPR-Cas9 screening platform to unbiasedly identify miR-200b/c upstream regulating genes. The sensor allows to infer miRNAs fundamental biological properties, as profiling of sorted cells indicated miR-200b/c as a molecular switch between EMT differentiation and proliferation, and suggested a role for metabolic enzymes in miR-200/EMT regulation. Analysis of miRNAs endogenous levels and activity for in vitro and in vivo applications could lead to a better understanding of their biological role in physiology and disease.	[Gollavilli, Paradesi Naidu; Parma, Beatrice; Siddiqui, Aarif; Ramesh, Vignesh; Napoli, Francesca; Schwab, Annemarie; Ceppi, Paolo] Friedrich Alexander Univ Erlangen Nuremberg FAU, Interdisciplinary Ctr Clin Res IZKF, Erlangen, Germany; [Siddiqui, Aarif; Ceppi, Paolo] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark; [Yang, Hai; Pilarsky, Christian] Friedrich Alexander Univ Erlangen Nuremberg FAU, Dept Surg, Odense, Denmark; [Yang, Hai; Pilarsky, Christian] Univ Hosp Erlangen, Erlangen, Germany; [Natesan, Ramakrishnan; Asangani, Irfan Ahmed] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA USA; [Mielenz, Dirk] Friedrich Alexander Univ Erlangen Nuremberg, Dept Mol Immunol, Erlangen, Germany; [Brabletz, Thomas] Friedrich Alexander Univ Erlangen Nuremberg, Dept Expt Med 1, Erlangen, Germany; [Napoli, Francesca] Univ Turin, Dept Oncol, San Luigi Hosp, Turin, Italy	University of Erlangen Nuremberg; University of Southern Denmark; University of Erlangen Nuremberg; University of Pennsylvania; Pennsylvania Medicine; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Turin	Ceppi, P (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg FAU, Interdisciplinary Ctr Clin Res IZKF, Erlangen, Germany.; Ceppi, P (corresponding author), Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark.	pceppi@bmb.sdu.dk	Ceppi, Paolo/GPS-8668-2022; Natesan, Ramakrishnan/AAM-6473-2021	Natesan, Ramakrishnan/0000-0002-7888-9255; Schwab, Annemarie/0000-0002-6351-5920; Siddiqui, Mohammad Aarif/0000-0003-4308-3398; Ceppi, Paolo/0000-0002-3632-8476; Gollavilli, Paradesi Naidu/0000-0003-0956-1296	Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuremberg; German Research Foundation [DFG-CE-281/5-1]; IASLC Young Investigator Award; EU [861196]; Projekt DEAL	Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuremberg; German Research Foundation(German Research Foundation (DFG)); IASLC Young Investigator Award; EU(European Commission); Projekt DEAL	This work was supported by the Interdisciplinary Center for Clinical Research of the University of Erlangen-Nuremberg (PC) and the German Research Foundation grant DFG-CE-281/5-1 (PC). PC was also supported by IASLC Young Investigator Award. CP and HY were supported by the EU (MSCA grant no.: 861196). Open Access funding enabled and organized by Projekt DEAL.	Amendola M, 2005, NAT BIOTECHNOL, V23, P108, DOI 10.1038/nbt1049; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Behan FM, 2019, NATURE, V568, P511, DOI 10.1038/s41586-019-1103-9; Bosson AD, 2014, MOL CELL, V56, P347, DOI 10.1016/j.molcel.2014.09.018; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Brustikova K, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00045; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Carter JV, 2019, ONCOL LETT, V18, P3994, DOI 10.3892/ol.2019.10753; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Ceppi P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6238; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Ebert MS, 2010, CURR BIOL, V20, pR858, DOI 10.1016/j.cub.2010.08.052; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Hugo HJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3580; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; Lima RT, 2011, EUR J CANCER, V47, P163, DOI 10.1016/j.ejca.2010.11.005; Mandal M, 2016, INTEGR BIOL-UK, V8, P167, DOI 10.1039/c5ib00219b; Moustakas A, 2012, SEMIN CANCER BIOL, V22, P446, DOI 10.1016/j.semcancer.2012.04.002; Mukherji S, 2011, NAT GENET, V43, P854, DOI 10.1038/ng.905; Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/NMETH.2078, 10.1038/nmeth.2078]; Nagaraj AB, 2019, STEM CELL REP, V12, P122, DOI 10.1016/j.stemcr.2018.12.002; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Olivieri F, 2013, AGEING RES REV, V12, P1056, DOI 10.1016/j.arr.2013.05.001; Pan Y, 2015, RNA BIOL, V12, P276, DOI 10.1080/15476286.2015.1017208; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Ramesh V, 2020, TRENDS CANCER, V6, P942, DOI 10.1016/j.trecan.2020.06.005; Rubio CA, 2007, J GASTROEN HEPATOL, V22, P1877, DOI 10.1111/j.1440-1746.2007.04839.x; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Savagner P, 2010, ANN ONCOL, V21, P89, DOI 10.1093/annonc/mdq292; Schwab A, 2018, CANCER RES, V78, P1604, DOI 10.1158/0008-5472.CAN-17-2834; Shi Guiling, 2018, Oncotarget, V9, P6771, DOI 10.18632/oncotarget.23645; Siddiqui A, 2017, J PATHOL, V242, P221, DOI 10.1002/path.4897; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thomson DW, 2011, NUCLEIC ACIDS RES, V39, P6845, DOI 10.1093/nar/gkr330; Tian WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029551; Nguyen-Vu T, 2016, ONCOTARGET, V7, P42159, DOI 10.18632/oncotarget.9895; Trumbach D, 2015, CELL TISSUE RES, V359, P161, DOI 10.1007/s00441-014-1911-z; Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056664; Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9; Zhang XH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.37	60	7	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2309	2322		10.1038/s41388-021-01708-6	http://dx.doi.org/10.1038/s41388-021-01708-6		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33654197	Green Published, hybrid			2022-12-17	WOS:000624398900002
J	Bie, QL; Song, H; Chen, XK; Yang, X; Shi, S; Zhang, LH; Zhao, R; Wei, L; Zhang, BG; Xiong, HB; Zhang, B				Bie, Qingli; Song, Hui; Chen, Xinke; Yang, Xiao; Shi, Shuo; Zhang, Lihua; Zhao, Rou; Wei, Li; Zhang, Baogui; Xiong, Huabao; Zhang, Bin			IL-17B/IL-17RB signaling cascade contributes to self-renewal and tumorigenesis of cancer stem cells by regulating Beclin-1 ubiquitination	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; DRUG-RESISTANCE; AUTOPHAGY; PATHWAY; IL-17B; METASTASIS; INTERLEUKIN-17B; TRANSPLANTATION; MIGRATION	Cancer stem cells (CSCs) are characterized by robust self-renewal and tumorigenesis and are responsible for metastasis, drug resistance, and angiogenesis. However, the molecular mechanisms for the regulation of CSC homeostasis are incompletely understood. This study demonstrated that the interleukin-17 (IL-17)B/IL-17RB signaling cascade promotes the self-renewal and tumorigenesis of CSCs by inducing Beclin-1 ubiquitination. We found that IL-17RB expression was significantly upregulated in spheroid cells and Lgr5-positive cells from the same tumor tissues of patients with gastric cancer (GC), which was closely correlated with the degree of cancer cell differentiation. Recombinant IL-17B (rIL-17B) promoted the sphereformation ability of CSCs in vitro and enhanced tumor growth and metastasis in vivo. Interestingly, IL-17B induced autophagosome formation and cleavage-mediated transformation of LC3 in CSCs and 293T cells. Furthermore, inhibition of autophagy activation by ATG7 knockdown reversed rIL-17B-induced self-renewal of GC cells. In addition, we showed that IL-17B also promoted K63-mediated ubiquitination of Beclin-1 by mediating the binding of tumor necrosis factor receptorassociated factor 6 to Beclin-1. Silencing IL-17RB expression abrogated the effects of IL-17B on Beclin-1 ubiquitination and autophagy activation in GC cells. Finally, we showed that IL-17B level in the serum of GC patients was positively correlated with IL-17RB expression in GC tissues, and IL-17B could induce IL-17RB expression in GC cells. Overall, the results elucidate the novel functions of IL-17B for CSCs and suggest that the intervention of the IL-17B/IL-17RB signaling pathway may provide new therapeutic targets for the treatment of cancer.	[Bie, Qingli; Song, Hui; Chen, Xinke; Yang, Xiao; Shi, Shuo; Zhang, Lihua; Zhao, Rou; Wei, Li; Zhang, Bin] Jining Med Univ, Dept Lab Med, Affiliated Hosp Jining Med Univ, Jining, Shandong, Peoples R China; [Bie, Qingli; Zhang, Bin] Jining Med Univ, Inst Forens Med & Lab Med, Jining, Shandong, Peoples R China; [Zhang, Baogui] Jining Med Univ, Dept Gen Surg, Affiliated Hosp, Jining, Shandong, Peoples R China; [Xiong, Huabao] Jining Med Univ, Inst Immunol & Mol Med, Jining, Shandong, Peoples R China	Jining Medical University; Jining Medical University; Jining Medical University; Jining Medical University	Zhang, B (corresponding author), Jining Med Univ, Dept Lab Med, Affiliated Hosp Jining Med Univ, Jining, Shandong, Peoples R China.; Zhang, B (corresponding author), Jining Med Univ, Inst Forens Med & Lab Med, Jining, Shandong, Peoples R China.; Xiong, HB (corresponding author), Jining Med Univ, Inst Immunol & Mol Med, Jining, Shandong, Peoples R China.	xionghb1@yahoo.com; zhb861109@163.com	Zhang, Bin/HCP-1386-2022; B, Zhang/R-4316-2019	B, Zhang/0000-0002-2879-379X	National Natural Science Foundation of China [81702439, 81802446, 81602160]; Tai Shan Young Scholar Foundation of Shandong Province [tsqn201909192]; Shandong Provincial Natural Science Foundation [ZR2019BH050, ZR2020YQ59]; Ph.D. Research Foundation of the Affiliated Hospital of Jining Medical University [2018-BS-001, 2018-BS-013]; Project of Health and Family Planning Commision of Shandong province [2017WS513]; Jining Medical University Teacher Research Support Fund [JYFC2018FKJ035]; Project of Health and Family Planning Commission of Shandong Province [2017WS513]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tai Shan Young Scholar Foundation of Shandong Province; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); Ph.D. Research Foundation of the Affiliated Hospital of Jining Medical University; Project of Health and Family Planning Commision of Shandong province; Jining Medical University Teacher Research Support Fund; Project of Health and Family Planning Commission of Shandong Province	This study was supported by grants from the National Natural Science Foundation of China (Nos. 81702439, 81802446, 81602160), Tai Shan Young Scholar Foundation of Shandong Province (No. tsqn201909192), Shandong Provincial Natural Science Foundation (No. ZR2019BH050, ZR2020YQ59), Ph.D. Research Foundation of the Affiliated Hospital of Jining Medical University (No. 2018-BS-001, 2018-BS-013), the Project of Health and Family Planning Commision of Shandong province (No. 2017WS513), Jining Medical University Teacher Research Support Fund (No. JYFC2018FKJ035) and the Project of Health and Family Planning Commission of Shandong Province (No. 2017WS513).	Ahmad Rizwan, 2016, Biochem Pharmacol (Los Angel), V5, DOI 10.4172/2167-0501.1000202; Bie QL, 2017, MOL IMMUNOL, V90, P50, DOI 10.1016/j.molimm.2017.07.004; Bie QL, 2017, ONCOTARGET, V8, P18914, DOI 10.18632/oncotarget.14835; Bie QL, 2016, SCI REP-UK, V6, DOI 10.1038/srep25447; Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016; Chu BX, 2020, J CELL MOL MED, V24, P14366, DOI 10.1111/jcmm.16055; Corro C, 2018, J PATHOL CLIN RES, V4, P3, DOI 10.1002/cjp2.91; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Guo HZ, 2019, FASEB J, V33, P9565, DOI 10.1096/fj.201900099R; Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019; Huang CK, 2014, ONCOGENE, V33, P2968, DOI 10.1038/onc.2013.268; Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643; Huang SC, 2017, EMBO MOL MED, V9, P1660, DOI 10.15252/emmm.201606914; Ichinohe N, 2017, STEM CELLS, V35, P920, DOI 10.1002/stem.2548; Jiang YX, 2017, ONCOGENE, V36, P1256, DOI 10.1038/onc.2016.291; Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laprevotte E, 2017, ONCOTARGET, V8, P113360, DOI 10.18632/oncotarget.23008; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Li LQ, 2018, EUR REV MED PHARMACO, V22, P3402, DOI 10.26355/eurrev_201806_15162; Li L, 2019, CANCER LETT, V452, P191, DOI 10.1016/j.canlet.2019.03.027; Li XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15909; Luo YL, 2016, CANCER LETT, V375, P390, DOI 10.1016/j.canlet.2016.03.012; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487; Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333; Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Palmieri M, 2017, CELL CYCLE, V16, P1237, DOI 10.1080/15384101.2017.1337968; Qiang L, 2017, AUTOPHAGY, V13, P2086, DOI 10.1080/15548627.2017.1380757; Ramirez-Carrozzi V, 2019, J IMMUNOL, V202, P1935, DOI 10.4049/jimmunol.1800696; Ren L, 2017, MOL IMMUNOL, V90, P126, DOI 10.1016/j.molimm.2017.06.034; Saad MA, 2019, LIFE SCI, V218, P284, DOI 10.1016/j.lfs.2019.01.002; Sharif T, 2017, AUTOPHAGY, V13, P264, DOI 10.1080/15548627.2016.1260808; Shi CS, 2010, AUTOPHAGY, V6, P986, DOI 10.4161/auto.6.7.13288; Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Teng YS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1312-z; Vlashi E, 2015, SEMIN CANCER BIOL, V31, P28, DOI 10.1016/j.semcancer.2014.07.001; Whelan KA, 2017, ONCOGENE, V36, P4843, DOI 10.1038/onc.2017.102; Wu HH, 2015, J EXP MED, V212, P333, DOI 10.1084/jem.20141702; Xia P, 2015, AM J CANCER RES, V5, P1602; Xiang T, 2015, ONCOGENE, V34, P165, DOI 10.1038/onc.2013.537; Yamaguchi Y, 2007, J IMMUNOL, V179, P7128, DOI 10.4049/jimmunol.179.10.7128; Yang DP, 2019, IMMUNITY, V50, P692, DOI 10.1016/j.immuni.2019.02.001; Yang SW, 2016, ONCOTARGET, V7, P39279, DOI 10.18632/oncotarget.9827; Yang YF, 2018, CANCER LETT, V422, P44, DOI 10.1016/j.canlet.2018.02.037; You ZB, 2005, BIOCHEM BIOPH RES CO, V326, P624, DOI 10.1016/j.bbrc.2004.11.087; Zhang B, 2018, STEM CELLS, V36, P990, DOI 10.1002/stem.2821	53	7	7	5	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2200	2216		10.1038/s41388-021-01699-4	http://dx.doi.org/10.1038/s41388-021-01699-4		MAR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649532	Green Published, hybrid			2022-12-17	WOS:000623739900005
J	Xing, YF; Chen, L; Gu, HF; Yang, CL; Zhao, J; Chen, ZH; Xiong, M; Kazobinka, G; Liu, YQ; Hou, T				Xing, Yifei; Chen, Liang; Gu, Haifeng; Yang, Chenlu; Zhao, Jun; Chen, Zhaohui; Xiong, Ming; Kazobinka, Gallina; Liu, Yaqiong; Hou, Teng			Downregulation of NUDT21 contributes to cervical cancer progression through alternative polyadenylation	ONCOGENE			English	Article								Nudix Hydrolase 21 (NUDT21), an alternative polyadenylation (APA)-regulatory protein, exhibits tumor-suppressive effects. However, its role in cervical cancer (CxCa) remains unknown. In the present study, we found that NUDT21 expression was reduced in CxCa tissues and cells, and NUDT21 levels were highly associated with the clinical prognosis of patients with CxCa. Knockdown of NUDT21 promoted CxCa cell proliferation, migration, and invasion in vitro, as well as tumorigenesis and lung metastasis in vivo. Overexpression of NUDT21 produces the opposite effects. Moreover, we performed polyadenylation site sequencing (PAS-Seq) and identified 457 transcripts with lengthened 3 ' untranslated regions (3 ' UTRs) upon NUDT21 overexpression. In particular, NUDT21 modulated the expression of several genes involved in fatty acid metabolism and the Wnt and NF-kappa B signaling pathways in CxCa development. Taken together, our study demonstrated that the APA regulatory effect of NUDT21 is an important mechanism for CxCa suppression.	[Xing, Yifei; Chen, Liang; Zhao, Jun; Chen, Zhaohui; Xiong, Ming; Kazobinka, Gallina; Hou, Teng] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Urol, Wuhan 430022, Peoples R China; [Gu, Haifeng; Hou, Teng] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Yang, Chenlu] Women & Children Hosp Guangdong Prov, Dept Gynecol & Obstet, Guangzhou 510080, Guangdong, Peoples R China; [Kazobinka, Gallina] La Nouvelle Polyclin Cent Bujumbura, Urol Unit, Bujumbura 378, Burundi; [Liu, Yaqiong] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Gynecol & Obstet, Guangzhou 510000, Guangdong, Peoples R China	Huazhong University of Science & Technology; State Key Lab Oncology South China; Sun Yat Sen University; Guangzhou Medical University	Hou, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Urol, Wuhan 430022, Peoples R China.; Hou, T (corresponding author), Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.; Liu, YQ (corresponding author), Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Dept Gynecol & Obstet, Guangzhou 510000, Guangdong, Peoples R China.	lyqgynecol@126.com; h1aiyan@hust.edu.cn		Hou, Teng/0000-0002-2267-0078	National Natural Science Foundation of China [81772714, 81402303]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The study was supported by the National Natural Science Foundation of China (Grant no. 81772714; 81402303).	Abadi MHJN, 2019, CANCER LETT, V459, P112, DOI 10.1016/j.canlet.2019.114430; Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010; Brumbaugh J, 2018, CELL, V172, P106, DOI 10.1016/j.cell.2017.11.023; Chu Y, 2019, ONCOGENE, V38, P4154, DOI 10.1038/s41388-019-0714-9; Creemers EE, 2016, CIRC RES, V118, P433, DOI 10.1161/CIRCRESAHA.115.307082; Elit LM, 2014, EXPERT REV ANTICANC, V14, P319, DOI 10.1586/14737140.2014.866041; Erson-Bensan AE, 2016, J MOL ENDOCRINOL, V57, pF29, DOI 10.1530/JME-16-0070; Friedlander M, 2002, ONCOLOGIST, V7, P342; Gruber AJ, 2019, NAT REV GENET, V20, P599, DOI 10.1038/s41576-019-0145-z; Husseinzadeh N, 2014, GYNECOL ONCOL, V135, P359, DOI 10.1016/j.ygyno.2014.08.013; Jin JB, 2018, MOL CELL ENDOCRINOL, V461, P155, DOI 10.1016/j.mce.2017.09.005; Katoh M, 2007, INT J MOL MED, V19, P699; Lareau LF, 2004, CURR OPIN STRUC BIOL, V14, P273, DOI 10.1016/j.sbi.2004.05.002; Li SS, 2019, LAB INVEST, V99, P1321, DOI 10.1038/s41374-019-0252-7; Li XJ, 2020, ONCOGENE, V39, P891, DOI 10.1038/s41388-019-1030-0; Lou JC, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00420; Ma LY, 2014, P NATL ACAD SCI USA, V111, P9, DOI 10.1073/pnas.1321025111; Martinez FJ, 2016, NEURON, V92, P780, DOI 10.1016/j.neuron.2016.09.050; Martinez-Reyes I, 2018, GENE DEV, V32, P463, DOI 10.1101/gad.315168.118; Masamha CP, 2018, CARCINOGENESIS, V39, P2, DOI 10.1093/carcin/bgx096; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Morale MG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21416-8; Naga CHP, 2018, CURR OPIN ONCOL, V30, P323, DOI 10.1097/CCO.0000000000000471; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Pu Y, 2014, HUM IMMUNOL, V75, P740, DOI 10.1016/j.humimm.2014.05.004; Shang CL, 2018, CANCER RES, V78, P877, DOI 10.1158/0008-5472.CAN-17-2356; Singh AK, 2019, FASEB J, V33, P2526, DOI 10.1096/fj.201801513R; Song ZW, 2016, MED SCI MONITOR, V22, P4475, DOI 10.12659/MSM.898569; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Wang W, 2019, INT J CANCER, V144, P1345, DOI 10.1002/ijc.31757; Weng TT, 2019, J CLIN INVEST, V129, P1984, DOI 10.1172/JCI122106; Wu XH, 2011, P NATL ACAD SCI USA, V108, P12533, DOI 10.1073/pnas.1019732108; Yang Q, 2010, P NATL ACAD SCI USA, V107, P10062, DOI 10.1073/pnas.1000848107; Zhang L, 2018, CANCER MANAG RES, V10, P4311, DOI 10.2147/CMAR.S173496	34	7	8	3	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2051	2064		10.1038/s41388-021-01693-w	http://dx.doi.org/10.1038/s41388-021-01693-w		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33619322				2022-12-17	WOS:000620414400001
J	Xiang, X; Langlois, S; St-Pierre, ME; Blinder, A; Charron, P; Graber, TE; Fowler, SL; Baird, SD; Bennett, SAL; Alain, T; Cowan, KN				Xiang, Xiao; Langlois, Stephanie; St-Pierre, Marie-Eve; Blinder, Anna; Charron, Philippe; Graber, Tyson E.; Fowler, Stephanie L.; Baird, Stephen D.; Bennett, Steffany A. L.; Alain, Tommy; Cowan, Kyle N.			Identification of pannexin 1-regulated genes, interactome, and pathways in rhabdomyosarcoma and its tumor inhibitory interaction with AHNAK	ONCOGENE			English	Article								Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children, is an aggressive cancer with a poor prognosis. Despite current management, the 5-year survival rate for patients with metastatic RMS is similar to 30%; underscoring the need to develop better treatment strategies. We have recently reported that pannexin 1 (PANX1) levels are downregulated in RMS and that restoring its expression inhibits RMS progression. Here, we have surveyed and characterized the molecular changes induced by PANX1 re-expression in RMS. We cataloged transcriptomic changes in this context by RNA sequencing. At the protein level, we unveiled PANX1 interactors using BioID, complemented by co-immunoprecipitation coupled to high-performance liquid chromatography/electrospray ionization tandem mass spectrometry performed in PANX1-enriched fractions. Using these data, we generated searchable public databases for the PANX1 interactome and changes to the RMS transcriptome occurring when PANX1 expression is restored. STRING network analyses revealed a PANX1 interactome involving plasma membrane and cytoskeleton-associated proteins including the previously undescribed interactor AHNAK. Indeed, AHNAK knockdown abrogated the PANX1-mediated reduction in RMS cell viability and migration. Using these unbiased approaches, we bring insight to the mechanisms by which PANX1 inhibits RMS progression, identifying the cell migration protein AHNAK as a key modifier of PANX1-mediated changes in RMS malignant properties.	[Xiang, Xiao; Langlois, Stephanie; St-Pierre, Marie-Eve; Blinder, Anna; Charron, Philippe; Graber, Tyson E.; Baird, Stephen D.; Alain, Tommy; Cowan, Kyle N.] Childrens Hosp Eastern Ontario, Res Inst, Mol Biomed Program, Ottawa, ON, Canada; [Xiang, Xiao; Blinder, Anna; Cowan, Kyle N.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Langlois, Stephanie; Cowan, Kyle N.] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Surg, Ottawa, ON, Canada; [Fowler, Stephanie L.; Bennett, Steffany A. L.; Alain, Tommy] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Fowler, Stephanie L.; Bennett, Steffany A. L.] Univ Ottawa, Neural Regenerat Lab, Ottawa, ON, Canada; [Fowler, Stephanie L.; Bennett, Steffany A. L.] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON, Canada; [Fowler, Stephanie L.] UCL, UK Dementia Res Inst, London, England	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Ottawa; University of London; University College London	Cowan, KN (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Mol Biomed Program, Ottawa, ON, Canada.; Cowan, KN (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.; Cowan, KN (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Surg, Ottawa, ON, Canada.	kcowan@cheo.on.ca		Fowler, Stephanie/0000-0001-6693-9959; Xiang, Xiao/0000-0002-3969-1668	Cancer Research Society (CRS) [19080, 21453]; Ontario Graduate Scholarship (OGS); Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST)	Cancer Research Society (CRS); Ontario Graduate Scholarship (OGS)(Ontario Graduate Scholarship); Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST)	This study was supported by the Cancer Research Society (CRS, Operating Grants 19080 and 21453, KNC), Ontario Graduate Scholarship (OGS, XX), and Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST, XX).	Bargiotas P, 2011, P NATL ACAD SCI USA, V108, P20772, DOI 10.1073/pnas.1018262108; Benaud C, 2004, J CELL BIOL, V164, P133, DOI 10.1083/jcb.200307098; Bennett, 2016, METHOD MOL BIOL, P9; Bhalla-Gehi R, 2010, J BIOL CHEM, V285, P9147, DOI 10.1074/jbc.M109.082008; Boassa D, 2007, J BIOL CHEM, V282, P31733, DOI 10.1074/jbc.M702422200; Boyce AKJ, 2018, BBA-BIOMEMBRANES, V1860, P72, DOI 10.1016/j.bbamem.2017.03.004; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chen B, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0522-4; Chen C., 2019, FRONT ONCOL, V9, P1; Chiu YH, 2018, J GEN PHYSIOL, V150, P19, DOI 10.1085/jgp.201711888; Cowan KN, 2012, CELL COMMUN ADHES, V19, P45, DOI 10.3109/15419061.2012.712575; Cui H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005084; Dobson Christine C., 2016, Critical Reviews in Oncogenesis, V21, P221, DOI 10.1615/CritRevOncog.2016016996; Dossi E, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar3796; Fowler SL, 2013, J PROTEOME RES, V12, P2597, DOI 10.1021/pr301166p; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Freeman TJ, 2019, CANCERS, V11, DOI 10.3390/cancers11010102; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gentil EJ, 2005, J CELL PHYSIOL, V203, P362, DOI 10.1002/jcp.20232; Good ME, 2018, CIRC RES, V122, P606, DOI 10.1161/CIRCRESAHA.117.312380; HASHIMOTO T, 1993, J CELL SCI, V105, P275; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang YC, 2007, FASEB J, V21, P732, DOI 10.1096/fj.06-6628com; Keller C, 2013, FEBS J, V280, P4323, DOI 10.1111/febs.12421; Komuro A, 2004, P NATL ACAD SCI USA, V101, P4053, DOI 10.1073/pnas.0308619101; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lai CPK, 2007, CANCER RES, V67, P1545, DOI 10.1158/0008-5472.CAN-06-1396; Langlois Stephanie, 2017, Adv Exp Med Biol, V925, P57, DOI 10.1007/5584_2016_53; Langlois S, 2014, J BIOL CHEM, V289, P30717, DOI 10.1074/jbc.M114.572131; Lee IH, 2014, ONCOGENE, V33, P4675, DOI 10.1038/onc.2014.69; Lee IH, 2008, J BIOL CHEM, V283, P6312, DOI 10.1074/jbc.M706878200; Liu HF, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109090; Locovei S, 2006, FEBS LETT, V580, P239, DOI 10.1016/j.febslet.2005.12.004; Ma HL, 2012, MOL IMAGING, V11, P487, DOI 10.2310/7290.2012.00012; Ma WH, 2009, J PHARMACOL EXP THER, V328, P409, DOI 10.1124/jpet.108.146365; Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118; Mauro A, 2002, J CELL SCI, V115, P3587, DOI 10.1242/jcs.00037; Minde DP, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0758-y; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; Parham DM, 2013, ADV ANAT PATHOL, V20, P387, DOI 10.1097/PAP.0b013e3182a92d0d; Peng R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1113-3; Penuela S, 2007, J CELL SCI, V120, P3772, DOI 10.1242/jcs.009514; Penuela S, 2012, J BIOL CHEM, V287, P29184, DOI 10.1074/jbc.M112.377176; Pham TL, 2018, J CELL PHYSIOL, V233, P7057, DOI 10.1002/jcp.26629; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Puri PL, 2000, GENE DEV, V14, P574; Richter K, 2014, FASEB J, V28, P45, DOI 10.1096/fj.13-229252; Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098; Salim C, 2009, GLIA, V57, P535, DOI 10.1002/glia.20782; Seminario-Vidal L, 2011, J BIOL CHEM, V286, P26277, DOI 10.1074/jbc.M111.260562; Shankar J, 2010, CANCER RES, V70, P3780, DOI 10.1158/0008-5472.CAN-09-4439; Sheppard HM, 2016, MELANOMA RES, V26, P108, DOI 10.1097/CMR.0000000000000228; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; Silva TA, 2016, ONCOTARGET, V7, P49998, DOI 10.18632/oncotarget.10307; Sudo H, 2014, INT J ONCOL, V44, P530, DOI 10.3892/ijo.2013.2183; Vidal M, 2011, CELL, V144, P986, DOI 10.1016/j.cell.2011.02.016; Wicki-Stordeur LE, 2014, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00287; Wicki-Stordeur LE, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-62; Wicki-Stordeur LE, 2013, CELL COMMUN ADHES, V20, P73, DOI 10.3109/15419061.2013.791681; Xiang X, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0100-4; Xu XX, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00124; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang YL, 2017, CANCER BIOL MED, V14, P90, DOI 10.20892/j.issn.2095-3941.2016.0086; Zhang ZW, 2019, J CANCER, V10, P3860, DOI 10.7150/jca.31291	66	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1868	1883		10.1038/s41388-020-01623-2	http://dx.doi.org/10.1038/s41388-020-01623-2		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564071	Green Published, hybrid			2022-12-17	WOS:000616489100005
J	Campion, NJ; Ally, M; Jank, BJ; Ahmed, J; Alusi, G				Campion, Nicholas J.; Ally, Munira; Jank, Bernhard J.; Ahmed, Jahangir; Alusi, Ghassan			The molecular march of primary and recurrent nasopharyngeal carcinoma	ONCOGENE			English	Review							EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEINS; GROWTH-FACTOR RECEPTOR; REGULATORY T-CELLS; NUCLEAR ANTIGEN 1; ANTITUMOR-ACTIVITY; FUSION GENE; CYCLIN D1; PROGRESSION; RNA	Nasopharyngeal carcinoma (NPC) results from the aberrant and uncontrolled growth of the nasopharyngeal epithelium. It is highly associated with the Epstein-Barr virus, especially in regions where it is endemic. In the last decade, significant advances in genetic sequencing techniques have allowed the discovery of many new abnormal molecular processes that undoubtedly contribute to the establishment, growth and spread of this deadly disease. In this review, we consider NPC as EBV induced. We summarise the recent discoveries and how they add to our understanding of the pathophysiology of NPC in the context of genomics first in primary and then in recurrent disease. Overall, we find key early events lead to p16 inactivation and cyclin D1 expression, allowing latent viral infection. Host and viral factors work together to affect a variety of molecular pathways, the most fundamental being activation of NF-kappa B. Nonetheless, much still yearns to be discovered, especially in recurrent NPC.	[Campion, Nicholas J.; Ally, Munira; Ahmed, Jahangir; Alusi, Ghassan] Royal London Hosp, Barts Hlth NHS Trust, Dept Otorhinolaryngol & Head & Neck Surg, Whitechapel Rd, London E1 1BB, England; [Campion, Nicholas J.; Jank, Bernhard J.] Med Univ Vienna, Vienna Gen Hosp, Dept Otorhinolaryngol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria	Barts Health NHS Trust; Royal London Hospital; Medical University of Vienna	Campion, NJ (corresponding author), Royal London Hosp, Barts Hlth NHS Trust, Dept Otorhinolaryngol & Head & Neck Surg, Whitechapel Rd, London E1 1BB, England.; Campion, NJ (corresponding author), Med Univ Vienna, Vienna Gen Hosp, Dept Otorhinolaryngol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	nicholas.campion@meduniwien.ac.at		Campion, Nicholas James/0000-0003-3345-9486				Ahmed W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099163; Alajez NM, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.64; Almobarak AA, 2019, CUREUS, V11, DOI 10.7759/cureus.4210; Barth S, 2008, NUCLEIC ACIDS RES, V36, P666, DOI 10.1093/nar/gkm1080; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruce JP, 2015, J CLIN ONCOL, V33, P3346, DOI 10.1200/JCO.2015.60.7846; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; Chan ASC, 2002, INT J CANCER, V102, P300, DOI 10.1002/ijc.10689; Chen CL, 2001, HUM PATHOL, V32, P1240, DOI 10.1053/hupa.2001.28950; Chen C, 2013, CANCER CHEMOTH PHARM, V72, P315, DOI 10.1007/s00280-013-2196-8; Chen G, 2018, EUR REV MED PHARMACO, V22, P450, DOI 10.26355/eurrev_201801_14194; Chen L, 2017, ONCOTARGETS THER, V10, P2769, DOI 10.2147/OTT.S126907; Chen TC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10386-y; Chen YP, 2020, CELL RES, V30, P1024, DOI 10.1038/s41422-020-0374-x; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Cheng SY, 2019, BBA-MOL BASIS DIS, V1865, P1201, DOI 10.1016/j.bbadis.2019.01.015; Chin YM, 2015, INT J CANCER, V136, P678, DOI 10.1002/ijc.29035; Chow YP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42980; Chung AK, 2019, CANCER MED-US, V8, P5116, DOI 10.1002/cam4.2429; Dai W, 2016, CHIN CLIN ONCOL, V5, DOI 10.21037/cco.2016.03.06; Dai W, 2016, P NATL ACAD SCI USA, V113, P3317, DOI 10.1073/pnas.1523436113; Dai W, 2015, CANCER MED-US, V4, P1079, DOI 10.1002/cam4.451; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Duan YM, 2015, CANCER LETT, V361, P67, DOI 10.1016/j.canlet.2015.02.037; Fogg M, 2013, VIROLOGY, V441, P107, DOI 10.1016/j.virol.2013.03.016; GAO W, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/404567; GOSSELIN J, 1991, EUR J IMMUNOL, V21, P203, DOI 10.1002/eji.1830210130; Hsu C, 2017, J CLIN ONCOL, V35, P4050, DOI 10.1200/JCO.2017.73.3675; Hua WF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.252; HUANG DP, 1994, CANCER RES, V54, P4003; Huang Zhen-xiao, 2010, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V45, P47; Huang ZX, 2014, INDIAN J OTOLARYNGOL, V66, pS120, DOI 10.1007/s12070-011-0359-7; Hui ABY, 2005, CANCER RES, V65, P8125, DOI 10.1158/0008-5472.CAN-05-0648; Hui EP, 2013, CANCER RES, V73, P1676, DOI 10.1158/0008-5472.CAN-12-2448; Iizasa H, 2010, J BIOL CHEM, V285, P33358, DOI 10.1074/jbc.M110.138362; Jiang N, 2014, ONCOL REP, V32, P1661, DOI 10.3892/or.2014.3376; Jin SZ, 2020, CELL RES, V30, P950, DOI 10.1038/s41422-020-00402-8; KHAN G, 1992, J CLIN PATHOL, V45, P616, DOI 10.1136/jcp.45.7.616; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; Kung CP, 2011, J VIROL, V85, P4399, DOI 10.1128/JVI.01703-10; Lau KM, 2007, BRIT J CANCER, V96, P617, DOI 10.1038/sj.bjc.6603580; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Li J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001122; Li J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/23723556.2014.976507; Li LQ, 2002, BLOOD, V99, P3725, DOI 10.1182/blood.V99.10.3725; Li YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14121; Li Z, 2015, ONCOTARGET, V6, P24291, DOI 10.18632/oncotarget.4552; Liao CL, 2020, CANCER SCI, V111, P857, DOI 10.1111/cas.14305; Lin DC, 2014, NAT GENET, V46, P866, DOI 10.1038/ng.3006; Longan L, 2000, J GEN VIROL, V81, P2245, DOI 10.1099/0022-1317-81-9-2245; Lung RWM, 2018, J PATHOL, V244, P394, DOI 10.1002/path.5018; Lyu XM, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007484; Ma BBY, 2015, INVEST NEW DRUG, V33, P985, DOI 10.1007/s10637-015-0264-0; Ma BBY, 2018, J CLIN ONCOL, V36, P1412, DOI 10.1200/JCO.2017.77.0388; Ma WS, 2017, ANTI-CANCER DRUG, V28, P230, DOI 10.1097/CAD.0000000000000448; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Moody CA, 2003, J VIROL, V77, P8555, DOI 10.1128/JVI.77.15.8555-8561.2003; Nie GH, 2017, ONCOL LETT, V13, P4487, DOI 10.3892/ol.2017.6021; Nie Y, 2013, CANCER SCI, V104, P458, DOI 10.1111/cas.12092; Odumade OA, 2011, CLIN MICROBIOL REV, V24, P193, DOI 10.1128/CMR.00044-10; Ohtani N, 2003, J CELL BIOL, V162, P173, DOI 10.1083/jcb.200302085; Pan Y, 2017, ONCOGENE, V36, P1069, DOI 10.1038/onc.2016.271; Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294; Peng L, 2019, BRIT J RADIOL, V92, DOI 10.1259/bjr.20181031; Peng L, 2018, J CANCER, V9, P4510, DOI 10.7150/jca.27611; Randall RE, 2008, J GEN VIROL, V89, P1, DOI 10.1099/vir.0.83391-0; Ren SL, 2016, ONCOL REP, V36, P1861, DOI 10.3892/or.2016.4981; Roberge CJ, 1997, VIROLOGY, V238, P344, DOI 10.1006/viro.1997.8852; Rovedo M, 2007, J VIROL, V81, P84, DOI 10.1128/JVI.01302-06; Saridakis V, 2005, MOL CELL, V18, P25, DOI 10.1016/j.molcel.2005.02.029; Shah KM, 2009, ONCOGENE, V28, P3903, DOI 10.1038/onc.2009.249; Shen Y, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.20; Song YL, 2016, ONCOTARGET, V7, P36783, DOI 10.18632/oncotarget.9170; Sousa H, 2016, IMMUNOBIOLOGY, V221, P145, DOI 10.1016/j.imbio.2015.09.015; Stelow EB, 2017, HEAD NECK PATHOL, V11, P16, DOI 10.1007/s12105-017-0787-0; Tang M, 2010, GENES IMMUN, V11, P334, DOI 10.1038/gene.2009.109; Tempera I, 2016, J VIROL, V90, P345, DOI 10.1128/JVI.02318-15; Tsang CM, 2020, SEMIN CANCER BIOL, V61, P84, DOI 10.1016/j.semcancer.2019.09.006; Tsang CM, 2015, VIROL SIN, V30, P107, DOI 10.1007/s12250-015-3592-5; Tsang CM, 2012, P NATL ACAD SCI USA, V109, pE3473, DOI 10.1073/pnas.1202637109; Tsang NM, 2003, CANCER, V98, P2385, DOI 10.1002/cncr.11820; Tudor CS, 2012, BRIT J CANCER, V106, P1980, DOI 10.1038/bjc.2012.197; Vockerodt M, 2001, VIROLOGY, V280, P183, DOI 10.1006/viro.2000.0768; Wang C, 2017, ONCOL REP, V37, P2109, DOI 10.3892/or.2017.5489; Wang HY, 2019, CANCER MED-US, V8, P2705, DOI 10.1002/cam4.2146; Wang J, 2019, J ONCOL, V2019, DOI 10.1155/2019/1654724; Wang LW, 2017, J VIROL, V91, DOI 10.1128/JVI.01718-16; Wang LJ, 2014, CANCER LETT, V344, P188, DOI 10.1016/j.canlet.2013.10.023; Wang SM, 2014, MOL CANCER THER, V13, P3163, DOI 10.1158/1535-7163.MCT-14-0317; Wang YH, 2017, EUR J CANCER PREV, V26, P144, DOI 10.1097/CEJ.0000000000000221; Wood VHJ, 2007, ONCOGENE, V26, P4135, DOI 10.1038/sj.onc.1210496; Wu ZH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020682; Xu T, 2015, ONCOL REP, V33, P1418, DOI 10.3892/or.2015.3739; Xu T, 2013, CURR ONCOL, V20, pE406, DOI 10.3747/co.20.1456; Xu YJ, 2019, CANCER LETT, V447, P33, DOI 10.1016/j.canlet.2019.01.022; Yang CF, 2016, ONCOGENE, V35, P3419, DOI 10.1038/onc.2015.402; Ye DM, 2020, J CANCER, V11, P1257, DOI 10.7150/jca.37415; You R, 2019, CANCER RES, V79, P5930, DOI 10.1158/0008-5472.CAN-18-3845; Yuan L, 2014, CANCER BIOL THER, V15, P1613, DOI 10.4161/15384047.2014.961874; Yuan YL, 2008, ANN OTO RHINOL LARYN, V117, P192, DOI 10.1177/000348940811700306; Zhan YT, 2020, J CANCER, V11, P4193, DOI 10.7150/jca.39354; Zhang J, 2019, ONCOGENE, V38, P4669, DOI 10.1038/s41388-019-0749-y; Zhang J, 2017, J VIROL, V91, DOI 10.1128/JVI.02168-16; Zhang L, 2017, MOL CANCER RES, V15, P1722, DOI 10.1158/1541-7786.MCR-17-0134; Zhang W., 2015, BIOMED RES INT, V2015, P618924, DOI DOI 10.1155/2015/618924; Zhao R, 2016, EBIOMEDICINE, V8, P30, DOI 10.1016/j.ebiom.2016.04.017; Zheng H, 2016, P NATL ACAD SCI USA, V113, P11283, DOI 10.1073/pnas.1607606113; Zheng X, 2018, J VIROL, V92, DOI 10.1128/JVI.01022-18; Zhong Q, 2018, CLIN CANCER RES, V24, P659, DOI 10.1158/1078-0432.CCR-17-0352; Zhou XH, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190415; Zhou YJ, 2017, ONCOTARGET, V8, P51210, DOI 10.18632/oncotarget.17214; Zhou YJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep43627	112	7	7	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1757	1774		10.1038/s41388-020-01631-2	http://dx.doi.org/10.1038/s41388-020-01631-2		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33479496				2022-12-17	WOS:000609352300001
J	Zhang, X; Liu, Y; Dai, L; Shi, G; Deng, J; Luo, Q; Xie, Q; Cheng, L; Li, CL; Lin, Y; Wang, QN; Fan, P; Zhang, HT; Su, XL; Zhang, S; Yang, Y; Hu, X; Gong, QY; Yu, DC; Zheng, L; Deng, HX				Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Luo, Qiang; Xie, Qian; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Fan, Ping; Zhang, Hantao; Su, Xiaolan; Zhang, Shuang; Yang, Yang; Hu, Xun; Gong, Qiyong; Yu, Dechao; Zheng, Lei; Deng, Hongxin			BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells	ONCOGENE			English	Article							STEM-CELLS; EXTRACELLULAR VESICLES; CANCER; INFLAMMATION; METASTASIS; ACTIVATION; AP-1	The basic leucine zipper ATF-like transcription factor 2 (BATF2) has been implicated in inflammatory responses and anti-tumour effects. Little, however, is known regarding its extracellular role in maintaining a non-supportive cancer microenvironment. Here, we show that BATF2 inhibits glioma growth and myeloid-derived suppressor cells (MDSCs) recruitment. Interestingly, extracellular vesicles (EVs) from BATF2-overexpressing glioma cell lines (BATF2-EVs) inhibited MDSCs chemotaxis in vitro. Moreover, BATF2 inhibited intracellular SDF-1 alpha and contributes to decreased SDF-1 alpha in EVs. In addition, BATF2 downregulation-induced MDSCs recruitment were reversed by blocking SDF-1 alpha/CXCR4 signalling upon AMD3100 treatment. Specifically, detection of EVs in 24 pairs of gliomas and healthy donors at different stages revealed that the abundance of BATF2-positive EVs in plasma (BATF2(+) plEVs) can distinguish stage III-IV glioma from stage I-II glioma and healthy donors. Taken together, our study identified novel regulatory functions of BATF2 in regulating MDSCs recruitment, providing a prognostic value in terms of the number of BATF2(+) plEVs in glioma stage.	[Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Zhang, Hantao; Su, Xiaolan; Yang, Yang; Yu, Dechao; Deng, Hongxin] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Xin; Liu, Yi; Dai, Lei; Shi, Gang; Deng, Jie; Cheng, Lin; Li, Chunlei; Lin, Yi; Wang, Qingnan; Zhang, Hantao; Su, Xiaolan; Yang, Yang; Yu, Dechao; Deng, Hongxin] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Xin; Zheng, Lei] Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou 510515, Guangdong, Peoples R China; [Luo, Qiang; Gong, Qiyong] Sichuan Univ, West China Hosp, Huaxi MR Res Ctr, Dept Radiol, Chengdu 610041, Sichuan, Peoples R China; [Xie, Qian] Sichuan Univ, Gen Practice Dept, West China Hosp, Chengdu 610041, Sichuan, Peoples R China; [Fan, Ping; Hu, Xun] Sichuan Univ, West China Hosp, Huaxi Biobank, Chengdu 610041, Sichuan, Peoples R China; [Zhang, Shuang] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Southern Medical University - China; Sichuan University; Sichuan University; Sichuan University; Sichuan University	Deng, HX (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Deng, HX (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Zheng, L (corresponding author), Southern Med Univ, Nanfang Hosp, Lab Med Ctr, Guangzhou 510515, Guangdong, Peoples R China.	nfyyzhenglei@smu.edu.cn; denghongx@scu.edu.cn	Gong, Qiyong/W-3052-2019	Gong, Qiyong/0000-0002-5912-4871; Deng, Hongxin/0000-0001-5094-1376; Liu, Yi/0000-0003-3108-7981	National Natural Science Foundation of China [81772939, 81902147]; National Key R&D Program of China [2017YFA0105702]; 1.3.5 project for disciplines of excellence in West China Hospital, Sichuan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; 1.3.5 project for disciplines of excellence in West China Hospital, Sichuan University	Our study was supported by the National Natural Science Foundation of China Program grant (no. 81772939), National Natural Science Foundation of China Program grant (no. 81902147), the National Key R&D Program of China grant (no. 2017YFA0105702) and 1.3.5 project for disciplines of excellence in West China Hospital, Sichuan University.	Alexander BM, 2018, CLIN CANCER RES, V24, P737, DOI 10.1158/1078-0432.CCR-17-0764; Andrade AF, 2017, INVEST NEW DRUG, V35, P26, DOI 10.1007/s10637-016-0401-4; Boussiotis VA, 2018, ONCOGENE, V37, P1121, DOI 10.1038/s41388-017-0024-z; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Dai L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11996; Dash R, 2010, ONCOGENE, V29, P4412, DOI 10.1038/onc.2010.194; Dash R, 2014, CANCER RES, V74, P563, DOI 10.1158/0008-5472.CAN-13-1062; Devignes CS, 2018, P NATL ACAD SCI USA, V115, pE992, DOI 10.1073/pnas.1718009115; Dorayappan KDP, 2018, ONCOGENE, V37, P3806, DOI 10.1038/s41388-018-0189-0; Dubinski D, 2016, NEURO-ONCOLOGY, V18, P807, DOI 10.1093/neuonc/nov280; Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636; Genschmer KR, 2019, CELL, V176, P113, DOI 10.1016/j.cell.2018.12.002; Guo F, 2016, ONCOGENE, V35, P816, DOI 10.1038/onc.2015.139; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Hu Y, 2019, J CLIN INVEST, V129, P3072, DOI 10.1172/JCI124979; Huang Q, 2011, TUMOR BIOL, V32, P1191, DOI 10.1007/s13277-011-0222-1; Huse JT, 2014, CLIN CANCER RES, V20, P5601, DOI 10.1158/1078-0432.CCR-14-0831; Janssens R, 2018, CELL MOL IMMUNOL, V15, P299, DOI 10.1038/cmi.2017.107; Jin X, 2012, BRAIN, V135, P1055, DOI 10.1093/brain/aws028; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kabe Y, 2018, CLIN CHEM, V64, P1463, DOI 10.1373/clinchem.2018.291963; Kalinichenko SV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039505; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3; Khalife J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129348; Kucharzewska P, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20304; Lee SY, 2016, GENES DIS, V3, P198, DOI 10.1016/j.gendis.2016.04.007; Li WH, 2014, APMIS, V122, P1080, DOI 10.1111/apm.12261; Liao YX, 2013, INT J MOL MED, V32, P1239, DOI 10.3892/ijmm.2013.1521; Liu ZB, 2015, CLIN CANCER RES, V21, P1752, DOI 10.1158/1078-0432.CCR-14-1564; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Morad G, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1627164; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Ricklefs F, 2016, CANCER RES, V76, P2876, DOI 10.1158/0008-5472.CAN-15-3432; Santiago-Dieppa DR, 2014, EXPERT REV MOL DIAGN, V14, P819, DOI 10.1586/14737159.2014.943193; Schmid RS, 2016, NEURO-ONCOLOGY, V18, P962, DOI 10.1093/neuonc/nov321; Shao HL, 2018, CHEM REV, V118, P1917, DOI 10.1021/acs.chemrev.7b00534; Shao HL, 2012, NAT MED, V18, P1835, DOI 10.1038/nm.2994; Solito S, 2011, BLOOD, V118, P2254, DOI 10.1182/blood-2010-12-325753; Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x; Tan JN, 2017, J IMMUNOL, V198, P2269, DOI 10.4049/jimmunol.1600610; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Tian Y, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1697028; Wang XX, 2018, CELL STEM CELL, V22, P514, DOI 10.1016/j.stem.2018.03.011; Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17	50	7	7	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1516	1530		10.1038/s41388-020-01627-y	http://dx.doi.org/10.1038/s41388-020-01627-y		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452462	Green Published, hybrid			2022-12-17	WOS:000607998600012
J	Tiede, S; Kalathur, RKR; Luond, F; von Allmen, L; Szczerba, BM; Hess, M; Vlajnic, T; Muller, B; Murillo, JC; Aceto, N; Christofori, G				Tiede, Stefanie; Kalathur, Ravi Kiran Reddy; Luond, Fabiana; von Allmen, Luca; Szczerba, Barbara Maria; Hess, Mathias; Vlajnic, Tatjana; Mueller, Benjamin; Canales Murillo, James; Aceto, Nicola; Christofori, Gerhard			Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression	ONCOGENE			English	Article							BREAST-CANCER; MUTATIONAL EVOLUTION; MOLECULAR PORTRAITS; MELANOMA-CELLS; KI67; EXPRESSION; SUBPOPULATION; STRATEGIES; DYNAMICS; MODEL	Despite major progress in breast cancer research, the functional contribution of distinct cancer cell clones to malignant tumor progression and metastasis remains largely elusive. We have assessed clonal heterogeneity within individual primary tumors and metastases and also during the distinct stages of malignant tumor progression using clonal tracking of cancer cells in the MMTV-PyMT mouse model of metastatic breast cancer. Comparative gene expression analysis of clonal subpopulations reveals a substantial level of heterogeneity across and also within the various stages of breast carcinogenesis. The intra-stage heterogeneity is primarily manifested by differences in cell proliferation, also found within invasive carcinomas of luminal A-, luminal B-, and HER2-enriched human breast cancer. Surprisingly, in the mouse model of clonal tracing of cancer cells, chemotherapy mainly targets the slow-proliferative clonal populations and fails to efficiently repress the fast-proliferative populations. These insights may have considerable impact on therapy selection and response in breast cancer patients.	[Tiede, Stefanie; Kalathur, Ravi Kiran Reddy; Luond, Fabiana; von Allmen, Luca; Szczerba, Barbara Maria; Hess, Mathias; Mueller, Benjamin; Canales Murillo, James; Aceto, Nicola; Christofori, Gerhard] Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland; [Kalathur, Ravi Kiran Reddy] Swiss Inst Bioinformat, CH-4053 Basel, Switzerland; [Vlajnic, Tatjana] Univ Hosp Basel, Inst Pathol, CH-4031 Basel, Switzerland	University of Basel; Swiss Institute of Bioinformatics; University of Basel	Tiede, S; Christofori, G (corresponding author), Univ Basel, Dept Biomed, CH-4058 Basel, Switzerland.	stefanie.tiede@unibas.ch; Gerhard.christofori@unibas.ch			SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation; Swiss Cancer League; Krebsliga Beider Basel	SystemsX.ch MTD project MetastasiX; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Krebsliga Beider Basel	This work was supported by the SystemsX.ch MTD project MetastasiX, the Swiss National Science Foundation, the Swiss Cancer League, and the Krebsliga Beider Basel.	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Cai Y, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3563-3; Casasent AK, 2018, CELL, V172, P205, DOI 10.1016/j.cell.2017.12.007; Chen J, 2017, NAT PROTOC, V12, P566, DOI 10.1038/nprot.2017.003; Chen K, 2015, MOL MED, V21, P792, DOI 10.2119/molmed.2015.00126; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cserni G, 2014, BREAST, V23, P259, DOI 10.1016/j.breast.2014.02.003; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Denkert C, 2015, BREAST, V24, pS67, DOI 10.1016/j.breast.2015.07.017; Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Livet J, 2007, NATURE, V450, P56, DOI 10.1038/nature06293; Macaulay IC, 2016, NAT PROTOC, V11, P36, DOI 10.1038/nprot.2016.138; Macaulay IC, 2015, NAT METHODS, V12, P519, DOI 10.1038/nmeth.3370; Maddipati R, 2015, CANCER DISCOV, V5, P1086, DOI 10.1158/2159-8290.CD-15-0120; Martinez RJ, 2015, J IMMUNOL METHODS, V424, P28, DOI 10.1016/j.jim.2015.04.018; Nguyen LV, 2015, NATURE, V528, P267, DOI 10.1038/nature15742; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Perego M, 2018, ONCOGENE, V37, P302, DOI 10.1038/onc.2017.341; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/NMETH.2639, 10.1038/nmeth.2639]; Reeves MQ, 2018, NAT CELL BIOL, V20, DOI 10.1038/s41556-018-0109-0; Rios AC, 2019, CANCER CELL, V35, P618, DOI 10.1016/j.ccell.2019.02.010; Rodriguez-Enriquez S, 2006, TOXICOL APPL PHARM, V215, P208, DOI 10.1016/j.taap.2006.02.005; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Szczerba BM, 2019, NATURE, V566, P553, DOI 10.1038/s41586-019-0915-y; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Tang YNJ, 2019, CELL REP, V28, P2837, DOI 10.1016/j.celrep.2019.08.029; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang Y, 2014, NATURE, V512, P155, DOI 10.1038/nature13600; Wu FH, 2017, ONCOTARGET, V8, P78466, DOI 10.18632/oncotarget.19638; Yao CH, 2019, ELIFE, V8, DOI 10.7554/eLife.41351; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Yerushalmi R, 2010, LANCET ONCOL, V11, P174, DOI 10.1016/S1470-2045(09)70262-1; Zomer A, 2013, STEM CELLS, V31, P602, DOI 10.1002/stem.1296	48	7	7	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					12	27		10.1038/s41388-020-01508-4	http://dx.doi.org/10.1038/s41388-020-01508-4		OCT 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33046799				2022-12-17	WOS:000578784100003
J	Chu, YJ; Chen, YP; Guo, HD; Li, MK; Wang, BC; Shi, DY; Cheng, XL; Guan, JX; Wang, XM; Xue, CH; Cheng, T; Shi, J; Yuan, WP				Chu, Yajing; Chen, Yangpeng; Guo, Huidong; Li, Mengke; Wang, Bichen; Shi, Deyang; Cheng, Xuelian; Guan, Jinxia; Wang, Xiaomin; Xue, Chenghai; Cheng, Tao; Shi, Jun; Yuan, Weiping			SUV39H1 regulates the progression ofMLL-AF9-induced acute myeloid leukemia	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE SUV39H1; STEM-CELL; NONSPECIFIC INHIBITOR; H3K79 METHYLATION; GENE-EXPRESSION; TARGET; CANCER; IDENTIFICATION; CHAETOCIN; PROTEINS	Epigenetic regulations play crucial roles in leukemogenesis and leukemia progression. SUV39H1 is the dominant H3K9 methyltransferase in the hematopoietic system, and its expression declines with aging. However, the role of SUV39H1 via its-mediated repressive modification H3K9me3 in leukemogenesis/leukemia progression remains to be explored. We found thatSUV39H1was down-regulated in a variety of leukemias, includingMLL-r AML, as compared with normal individuals. Decreased levels ofSuv39h1expression and genomic H3K9me3 occupancy were observed in LSCs fromMLL-r-induced AML mouse models in comparison with that of hematopoietic stem/progenitor cells.Suv39h1overexpression increased leukemia latency and decreased the frequency of LSCs inMLL-rAML mouse models, whileSuv39h1knockdown accelerated disease progression with increased number of LSCs. IncreasedSuv39h1expression led to the inactivation ofHoxb13andSix1, as well as reversion of Hoxa9/Meis1 downstream target genes, which in turn decelerated leukemia progression. Interestingly,Hoxb13expression is up-regulated inMLL-AF9-induced AML cells, while knockdown ofHoxb13inMLL-AF9leukemic cells significantly prolonged the survival of leukemic mice with reduced LSC frequencies. Our data revealed that SUV39H1 functions as a tumor suppressor inMLL-AF9-induced AML progression. These findings provide the direct link of SUV39H1 to AML development and progression.	[Chu, Yajing; Chen, Yangpeng; Guo, Huidong; Li, Mengke; Wang, Bichen; Shi, Deyang; Cheng, Xuelian; Wang, Xiaomin; Cheng, Tao; Shi, Jun; Yuan, Weiping] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Hematol Dis, Inst Hematol, Tianjin 300020, Peoples R China; [Chu, Yajing; Chen, Yangpeng; Guo, Huidong; Li, Mengke; Wang, Bichen; Shi, Deyang; Cheng, Xuelian; Wang, Xiaomin; Cheng, Tao; Shi, Jun; Yuan, Weiping] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China; [Guan, Jinxia; Xue, Chenghai] My Hlth Gene Technol Co Ltd, Serv Ctr Tianjin Chentang Sci & Technol Commercia, Tianjin 300220, Peoples R China; [Guo, Huidong] Peking Univ, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol, Natl Clin Res Ctr Hematol Dis,Peoples Hosp, Beijing 100044, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College; Peking University	Chu, YJ; Shi, J; Yuan, WP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Hematol Dis, Inst Hematol, Tianjin 300020, Peoples R China.; Chu, YJ; Shi, J; Yuan, WP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin 300020, Peoples R China.	chuyajing@ihcams.ac.cn; shijun@ihcams.ac.cn; wpyuan@ihcams.ac.cn	Chu, Yajing/HDN-8398-2022	Guo, Huidong/0000-0003-3851-3656; Mengke, Li/0000-0001-7748-5307; Cheng, Tao/0000-0002-5925-2769	Ministry of Science and Technology of China [2017YFA0103402, 2018YFA0107801]; CAMS Innovation Fund for Medical Sciences [2016-I2M-1-017, 2017-I2M-3-015, 2017-I2M-3-018]; National Natural Science Foundation of China [81600136, 81670120, 81629001, 81770105]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); CAMS Innovation Fund for Medical Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Drs Peng Wu and Xiaowei Xie for their assistance with the bioinformatics analysis of RNA-seq. We would also like to thank the experimental pathology cell bank facility for the storage of human patient samples of SKLEH from IHBD. This work was partially supported by the funds from the Ministry of Science and Technology of China (2017YFA0103402 and 2018YFA0107801), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-017, 2017-I2M-3-015 and 2017-I2M-3-018), National Natural Science Foundation of China (81600136, 81670120, 81629001, and 81770105).	Alharbi RA, 2013, LEUKEMIA, V27, P1000, DOI 10.1038/leu.2012.356; Bagger FO, 2016, NUCLEIC ACIDS RES, V44, pD917, DOI 10.1093/nar/gkv1101; Balgobind BV, 2009, HAEMATOL-HEMATOL J, V94, P1033, DOI 10.3324/haematol.2008.004564; Beebe-Dimmer JL, 2015, CANCER EPIDEM BIOMAR, V24, P1366, DOI 10.1158/1055-9965.EPI-15-0247; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006; Caslini C, 2007, CANCER RES, V67, P7275, DOI 10.1158/0008-5472.CAN-06-2369; Chaib H, 2012, LEUKEMIA, V26, P662, DOI 10.1038/leu.2011.271; Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832; Cheng H, 2015, BLOOD, V126, P1302, DOI 10.1182/blood-2015-01-623645; Cherblanc FL, 2013, J MED CHEM, V56, P8616, DOI 10.1021/jm401063r; Cherblanc FL, 2013, NAT CHEM BIOL, V9, P136, DOI 10.1038/nchembio.1187; Chu YJ, 2019, CANCER SCI, V110, P2200, DOI 10.1111/cas.14033; Djeghloul D, 2016, STEM CELL REP, V6, P970, DOI 10.1016/j.stemcr.2016.05.007; Fong CY, 2014, HAEMATOLOGICA, V99, P1772, DOI 10.3324/haematol.2013.092007; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fritsch L, 2010, MOL CELL, V37, P46, DOI 10.1016/j.molcel.2009.12.017; Goyama S, 2010, LEUKEMIA, V24, P81, DOI 10.1038/leu.2009.202; Greiner D, 2005, NAT CHEM BIOL, V1, P143, DOI 10.1038/nchembio721; Greiner D, 2013, NAT CHEM BIOL, V9, P137, DOI 10.1038/nchembio.1188; Guo HD, 2017, INT J CANCER, V141, P324, DOI 10.1002/ijc.30739; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hess JL, 2006, BLOOD, V108, P297, DOI 10.1182/blood-2005-12-5014; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jo SY, 2011, BLOOD, V117, P4759, DOI 10.1182/blood-2010-12-327668; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Lai YS, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.37; Li L, 2018, CANCER CELL, V33, P368, DOI 10.1016/j.ccell.2018.01.010; Li YY, 2014, CELL, V159, P558, DOI 10.1016/j.cell.2014.09.049; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Monaghan L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00705; Muller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Petti E, 2015, CELL CYCLE, V14, P1438, DOI 10.1080/15384101.2015.1021517; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reimann M, 2010, CANCER CELL, V17, P262, DOI 10.1016/j.ccr.2009.12.043; Ropa J, 2020, HAEMATOLOGICA, V105, P2273, DOI 10.3324/haematol.2019.223883; Ropa James, 2018, Oncotarget, V9, P22123, DOI 10.18632/oncotarget.25204; Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun DQ, 2014, CELL STEM CELL, V14, P673, DOI 10.1016/j.stem.2014.03.002; Tsai CT, 2017, ONCOGENE, V36, P1753, DOI 10.1038/onc.2016.315; Wang QF, 2011, BLOOD, V117, P6895, DOI 10.1182/blood-2010-12-324699; Williams TM, 2005, DEV BIOL, V277, P457, DOI 10.1016/j.ydbio.2004.10.004; Wong SHK, 2015, CANCER CELL, V28, P198, DOI 10.1016/j.ccell.2015.06.003; Yang YJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.98; Yang YJ, 2010, NUCLEIC ACIDS RES, V38, P382, DOI 10.1093/nar/gkp991; Yokoyama A, 2008, CANCER CELL, V14, P36, DOI 10.1016/j.ccr.2008.05.003; Zeisig Bernd B, 2012, Cancer Cell, V22, P698, DOI 10.1016/j.ccr.2012.10.017; Zheng Y, 2016, LEUKEMIA, V30, P2373, DOI 10.1038/leu.2016.112; Zhu XF, 2014, NAT GENET, V46, P287, DOI 10.1038/ng.2894	59	7	10	7	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 10	2020	39	50					7239	7252		10.1038/s41388-020-01495-6	http://dx.doi.org/10.1038/s41388-020-01495-6		OCT 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PD4HE	33037410	hybrid, Green Published			2022-12-17	WOS:000578440800001
J	Ranzuglia, V; Lorenzon, I; Pellarin, I; Sonego, M; Dall'Acqua, A; D'Andrea, S; Lovisa, S; Segatto, I; Coan, M; Polesel, J; Serraino, D; Sabatelli, P; Spessotto, P; Belletti, B; Baldassarre, G; Schiappacassi, M				Ranzuglia, Valentina; Lorenzon, Ilaria; Pellarin, Ilenia; Sonego, Maura; Dall'Acqua, Alessandra; D'Andrea, Sara; Lovisa, Sara; Segatto, Ilenia; Coan, Michela; Polesel, Jerry; Serraino, Diego; Sabatelli, Patrizia; Spessotto, Paola; Belletti, Barbara; Baldassarre, Gustavo; Schiappacassi, Monica			Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells	ONCOGENE			English	Article							OVARIAN-CANCER; CISPLATIN RESISTANCE; DUAL ROLE; PROTEIN; TARGET; ACTIVATION; ATPASE; AKT; MECHANISMS; INHIBITION	For many tumor types chemotherapy still represents the therapy of choice and many standard treatments are based on the use of platinum (PT) drugs. However, de novo or acquired resistance to platinum is frequent and leads to disease progression. In Epithelial Ovarian Cancer (EOC) patients, PT-resistant recurrences are very common and improving the response to treatment still represents an unmet clinical need. To identify new modulators of PT-sensitivity, we performed a loss-of-function screening targeting 680 genes potentially involved in the response of EOC cells to platinum. We found that SGK2 (Serum-and Glucocorticoid-inducible kinase 2) plays a key role in PT-response. We show here that EOC cells relay on the induction of autophagy to escape PT-induced death and that SGK2 inhibition increases PT sensitivity inducing a block in the autophagy cascade due to the impairment of lysosomal acidification. Mechanistically we demonstrate that SGK2 controls autophagy in a kinase-dependent manner by binding and inhibiting the V-ATPase proton pump. Accordingly, SGK2 phosphorylates the subunit V1H (ATP6V1H) of V-ATPase and silencing or chemical inhibition of SGK2, affects the normal autophagic flux and sensitizes EOC cells to platinum. Hence, we identified a new pathway that links autophagy to the survival of cancer cells under platinum treatment in which the druggable kinase SGK2 plays a central role. Our data suggest that blocking autophagy via SGK2 inhibition could represent a novel therapeutic strategy to improve patients' response to platinum.	[Ranzuglia, Valentina; Lorenzon, Ilaria; Pellarin, Ilenia; Sonego, Maura; Dall'Acqua, Alessandra; D'Andrea, Sara; Lovisa, Sara; Segatto, Ilenia; Coan, Michela; Spessotto, Paola; Belletti, Barbara; Baldassarre, Gustavo; Schiappacassi, Monica] IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, Italy; [Polesel, Jerry; Serraino, Diego] IRCCS, Ctr Riferimento Oncol Aviano CRO, Epidemiol, I-33081 Aviano, Italy; [Sabatelli, Patrizia] CNR, Inst Mol Genet, Bologna, Italy; [Sabatelli, Patrizia] Rizzoli Orthoped Inst, Bologna, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Istituto Ortopedico Rizzoli	Baldassarre, G; Schiappacassi, M (corresponding author), IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, Italy.	gbaldassarre@cro.it; mschiappacassi@cro.it	Schiappacassi, Monica/AAX-5505-2020; Lorenzon, Ilaria/AAY-6372-2020; Serraino, Diego/J-3915-2018; Pellarin, Ilenia/AAY-2238-2020; Lovisa, Sara/AAB-1141-2020; Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Spessotto, Paola/K-5005-2012; Segatto, Ilenia/AAX-5513-2020; Dall'Acqua, Alessandra/ABF-8020-2020; Sonego, Maura/AAX-5529-2020	Schiappacassi, Monica/0000-0003-4804-4291; Lorenzon, Ilaria/0000-0001-6336-4678; Serraino, Diego/0000-0003-0565-8920; Pellarin, Ilenia/0000-0002-1041-1722; Lovisa, Sara/0000-0001-7776-2896; Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Spessotto, Paola/0000-0002-3033-404X; Segatto, Ilenia/0000-0001-5282-1028; Dall'Acqua, Alessandra/0000-0003-2297-1361; Sonego, Maura/0000-0002-9505-9771	Ministero della Salute [RF-2010-2309704, RF-2016-02361040, RF-2016-02361041]; Regione Friuli Venezia Giulia (Tichep Grant); 5x1000 CRO; AIRC biannual Fellowship [18171]	Ministero della Salute(Ministry of Health, Italy); Regione Friuli Venezia Giulia (Tichep Grant); 5x1000 CRO; AIRC biannual Fellowship	We thank Dr William Hahn and David Root for SGK2 vector (through Addgene), Dr Tamotsu Yoshimori for ptfLC3 vectors (through Addgene), Dr Roberta Maestro for pLPC vector and Laura Cesaratto and Sara Benevol for technical support. We are grateful to all members of our lab for helpful and stimulating discussions. This work was supported by grants from Ministero della Salute (RF-2010-2309704 and RF-2016-02361040), Regione Friuli Venezia Giulia (Tichep Grant) and 5x1000 CRO to GB; grants from 5x1000 CRO Intramural Young Investigator and from Ministero della Salute (RF-2016-02361041) to MSo. IS was supported by an AIRC biannual Fellowship (# 18171). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010; Bago R, 2016, EMBO J, V35, P2263, DOI 10.15252/embj.201670010; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Berton S, 2014, CELL CYCLE, V13, P3100, DOI 10.4161/15384101.2014.949512; Biazik J, 2015, METHODS, V75, P44, DOI 10.1016/j.ymeth.2014.11.013; Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178; Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Cotter K, 2015, TRENDS BIOCHEM SCI, V40, P611, DOI 10.1016/j.tibs.2015.08.005; Dall'Acqua A, 2017, EMBO MOL MED, V9, P1415, DOI 10.15252/emmm.201607012; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gatti L, 2015, DRUG RESIST UPDATE, V20, P1, DOI 10.1016/j.drup.2015.04.001; He PJ, 2011, MOL BIOL CELL, V22, P3812, DOI 10.1091/mbc.E11-04-0328; Henke G, 2002, KIDNEY BLOOD PRESS R, V25, P370, DOI 10.1159/000068699; Holmes D, 2015, NATURE, V527, P219; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Imai H, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0929-3; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kang X, 2015, CANCER BIOL MED, V12, P362, DOI 10.7497/j.issn.2095-3941.2015.0063; Katayama H, 2008, CELL STRUCT FUNCT, V33, P1, DOI 10.1247/csf.07011; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2011, AUTOPHAGY, V7, P1, DOI 10.4161/auto.7.1.14130; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kulshrestha A, 2016, MOL ONCOL, V10, P789, DOI 10.1016/j.molonc.2016.01.003; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3; Lo Russo G, 2017, CURR DRUG TARGETS, V18, P341, DOI 10.2174/1389450117666160502152331; Loos B, 2014, AUTOPHAGY, V10, P2087, DOI 10.4161/15548627.2014.973338; Lu ZN, 2017, CANCER CHEMOTH PHARM, V80, P925, DOI 10.1007/s00280-017-3426-2; Machiels JPH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-473; Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015; Massarelli E, 2015, ANN ONCOL, V26, P1476, DOI 10.1093/annonc/mdv194; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; O'Keeffe BA, 2013, BIOCHIMIE, V95, P1258, DOI 10.1016/j.biochi.2013.01.019; Pao AC, 2007, AM J PHYSIOL-RENAL, V292, pF1741, DOI 10.1152/ajprenal.00027.2007; Pao AC, 2012, CURR OPIN NEPHROL HY, V21, P534, DOI 10.1097/MNH.0b013e32835571be; Pao AC, 2010, AM J PHYSIOL-RENAL, V299, pF1496, DOI 10.1152/ajprenal.00075.2010; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pellarin I, 2020, ONCOGENE, V39, P4390, DOI 10.1038/s41388-020-1292-6; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Rybstein MD, 2018, NAT CELL BIOL, V20, P243, DOI 10.1038/s41556-018-0042-2; Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047; Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6; Sonego M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3235; Sonego M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07005-1; Sonego M, 2013, EMBO MOL MED, V5, P707, DOI 10.1002/emmm.201201504; Song T, 2017, CANCER RES TREAT, V49, P595, DOI 10.4143/crt.2016.034; Thome MP, 2016, J CELL SCI, V129, P4622, DOI 10.1242/jcs.195057; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019	69	7	7	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6370	6386		10.1038/s41388-020-01433-6	http://dx.doi.org/10.1038/s41388-020-01433-6		AUG 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32848212	Green Published, hybrid			2022-12-17	WOS:000563171700001
J	Wu, DH; Wang, Y; Yang, GC; Zhang, SG; Liu, Y; Zhou, S; Guo, HR; Liang, SH; Cui, YF; Zhang, B; Ma, K; Zhang, CY; Liu, YF; Sun, LM; Wang, JB; Liu, LX				Wu, Dehai; Wang, Yan; Yang, Guangchao; Zhang, Shugeng; Liu, Yao; Zhou, Shuo; Guo, Hongrui; Liang, Shuhang; Cui, Yifeng; Zhang, Bo; Ma, Kun; Zhang, Congyi; Liu, Yufeng; Sun, Linmao; Wang, Jiabei; Liu, Lianxin			A novel mitochondrial amidoxime reducing component 2 is a favorable indicator of cancer and suppresses the progression of hepatocellular carcinoma by regulating the expression of p27	ONCOGENE			English	Article							CYTOCHROME B(5); PATHWAY; P27(KIP1); REDUCTASE	Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer-related mortality in the United States. Exploring the mechanism of HCC and identifying ideal targets is critical. In the present study, we demonstrated metabolism dysfunction might be a key diver for the development of HCC. The mitochondrial amidoxime reducing component 2 (MARC2) as a newly discovered molybdenum enzyme was downregulated in human HCC tissues and HCC cells. Downregulated MARC2 was significantly associated with clinicopathological characteristics of HCC, such as tumor size, AFP levels, and tumor grade and was an independent risk factor of poor prognosis. Both in vitro and in vivo studies suggested that MARC2 suppressed the progression of HCC by regulating the protein expression level of p27. The Hippo signaling pathway and RNF123 were required for this process. Moreover, MARC2 regulated expression of HNF4A via the Hippo signaling pathway. HNF4A was recruited to the promoter of MARC2 forming a feedback loop. MARC2 levels were downregulated by methylation. We demonstrated the prognostic value of MARC2 in HCC and determined the mechanism by which MARC2 suppressed the progression of HCC in this study. These findings may lead to new therapeutic targets for HCC.	[Wu, Dehai; Yang, Guangchao; Zhang, Shugeng; Zhou, Shuo; Guo, Hongrui; Liang, Shuhang; Cui, Yifeng; Zhang, Bo; Ma, Kun; Zhang, Congyi; Liu, Yufeng; Sun, Linmao; Liu, Lianxin] Harbin Med Univ, Affiliated Hosp 1, Minist Educ, Dept Hepat Surg,Key Lab Hepatosplen Surg, Harbin 150001, Heilongjiang, Peoples R China; [Wang, Yan] Harbin Med Univ, Canc Hosp, Dept Colorectal Surg, Harbin 150001, Heilongjiang, Peoples R China; [Liu, Yao; Wang, Jiabei] Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Key Lab Hepatopancreatobiliary Surg, Div Life Sci & Med,Dept Hepatobiliary Surg, Hefei 230001, Anhui, Peoples R China	Harbin Medical University; Harbin Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Liu, LX (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Minist Educ, Dept Hepat Surg,Key Lab Hepatosplen Surg, Harbin 150001, Heilongjiang, Peoples R China.; Wang, JB (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Anhui Prov Key Lab Hepatopancreatobiliary Surg, Div Life Sci & Med,Dept Hepatobiliary Surg, Hefei 230001, Anhui, Peoples R China.	jbwang16@ustc.edu.cn; liulx@ems.hrbmu.edu.cn						Dobashi Y, 2017, HUM PATHOL, V66, P67, DOI 10.1016/j.humpath.2017.05.022; Fitamant J, 2015, CELL REP, V10, P1692, DOI 10.1016/j.celrep.2015.02.027; Ganem NJ, 2014, CELL, V158, P833, DOI 10.1016/j.cell.2014.06.029; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hnit SST, 2015, INT J BIOCHEM CELL B, V68, P9, DOI 10.1016/j.biocel.2015.08.005; Jang W, 2017, EMBO J, V36, P2510, DOI 10.15252/embj.201696089; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Khanna R, 2018, FEBS J, V285, P2243, DOI 10.1111/febs.14477; Kotthaus J, 2011, BIOCHEM J, V433, P383, DOI 10.1042/BJ20100960; Li Z, 2019, J CELL BIOCHEM, V120, P6046, DOI 10.1002/jcb.27891; Liu Y, 2019, CLIN CANCER RES, V25, P5407, DOI 10.1158/1078-0432.CCR-18-4113; Massarweh NN, 2017, CANCER CONTROL, V24, DOI 10.1177/1073274817729245; Mikula M, 2011, FUNCT INTEGR GENOMIC, V11, P215, DOI 10.1007/s10142-010-0200-5; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Neve EPA, 2012, J BIOL CHEM, V287, P6307, DOI 10.1074/jbc.M111.328237; Plitzko B, 2013, J BIOL CHEM, V288, P20228, DOI 10.1074/jbc.M113.474916; Rixen S, 2019, J BIOL CHEM, V294, P17593, DOI 10.1074/jbc.RA119.007606; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sparacino-Watkins CE, 2014, J BIOL CHEM, V289, P10345, DOI 10.1074/jbc.M114.555177; Wahl B, 2010, J BIOL CHEM, V285, P37847, DOI 10.1074/jbc.M110.169532; Wang XD, 2020, ACAD RADIOL, V27, P1720, DOI 10.1016/j.acra.2018.04.021; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112	23	7	7	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6099	6112		10.1038/s41388-020-01417-6	http://dx.doi.org/10.1038/s41388-020-01417-6		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32811980	Green Published, hybrid			2022-12-17	WOS:000561911600001
J	Wang, YC; Liu, YN; Deng, WF; Fu, FX; Yan, SS; Yang, HW; Liu, RM; Geng, J; Xu, J; Wu, YH; Ma, JF; Zhou, JP; Liu, N; Jin, Y; Xia, RF; Elias, N; Lee, RJ; Feldman, AS; Blute, ML; Colvin, RB; Wu, CL; Miao, Y				Wang, Yuchen; Liu, Yanna; Deng, Wenfeng; Fu, Fangxiang; Yan, Susha; Yang, Hongwei; Liu, Rumin; Geng, Jian; Xu, Jian; Wu, Yihan; Ma, Junfeng; Zhou, Jiapeng; Liu, Na; Jin, Yu; Xia, Renfei; Elias, Nahel; Lee, Richard J.; Feldman, Adam S.; Blute, Michael L.; Colvin, Robert B.; Wu, Chin-Lee; Miao, Yun			Viral integration in BK polyomavirus-associated urothelial carcinoma in renal transplant recipients: multistage carcinogenesis revealed by next-generation virome capture sequencing	ONCOGENE			English	Article							CANCER; VIRUS; GENOME; END	BK polyomavirus (BKPyV)-associated cancer after transplantation has gained increasing attention. However, the role of BKPyV integration on oncogenesis is still unclear. In this study, next-generation virome capture sequencing of primary and metastatic tumors were performed in three patients with BKPyV-associated urothelial carcinoma after renal transplantation. As a result, a total of 332 viral integration sites were identified in the six tumors. Integration of BKPyV in both primary and metastatic tumors followed the mechanism of microhomology-mediated end joining mostly, since microhomologies between human and BKPyV genomes were significantly enriched in flanking regions of 84% of the integration sites. Viral DNA breakpoints were nonrandom and tended to assemble in large T gene, small T gene and viral protein 2 gene. There were three, one and one consensus integration sites between the primary and metastatic tumors, which affectedLINC01924,eIF3c, andNEIL2genes in the three cases respectively. Thus, we concluded that integration of BKPyV was a continuous process occurring in both primary and metastatic tumors, generating heterogenous tumor cell populations. Through this ongoing process, certain cell populations might have gained growth advantage or metastatic potential, as a result of viral integration either affecting the cellular genes where the viral DNA integrated to or altering the expression or function of the viral genes.	[Wang, Yuchen; Liu, Yanna; Deng, Wenfeng; Fu, Fangxiang; Yan, Susha; Yang, Hongwei; Liu, Rumin; Xu, Jian; Wu, Yihan; Jin, Yu; Xia, Renfei; Miao, Yun] Southern Med Univ, Nanfang Hosp, Dept Organ Transplantat, Guangzhou, Peoples R China; [Geng, Jian] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Ma, Junfeng; Zhou, Jiapeng; Liu, Na] Mygenostics Co, Beijing, Peoples R China; [Elias, Nahel] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA; [Lee, Richard J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA; [Feldman, Adam S.; Blute, Michael L.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA; [Colvin, Robert B.; Wu, Chin-Lee] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA	Southern Medical University - China; Southern Medical University - China; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Miao, Y (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Organ Transplantat, Guangzhou, Peoples R China.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02115 USA.; Wu, CL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.	cwu2@mgh.harvard.edu; miaoyunecho@126.com		Elias, Nahel/0000-0001-6466-7347	Natural Science Foundation of Guangdong Province [2020A1515010674]; National Natural Science Foundation of China [81500573]; Science and Technology Planning Project of Guangzhou [201803010109]; President Funding of Nanfang Hospital [2018B009, 2018C003]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Planning Project of Guangzhou; President Funding of Nanfang Hospital	The work was funded by Natural Science Foundation of Guangdong Province [grant number 2020A1515010674], National Natural Science Foundation of China [grant number 81500573], Science and Technology Planning Project of Guangzhou [grant number 201803010109] and President Funding of Nanfang Hospital [grant number 2018B009, 2018C003]. And we thanked Dr. Min-Hua Luo (Wuhan Institute of Virology, Wuhan, China) for her assisstant in the study design and critical revision of the manuscript.	Anzivino E, 2016, CANCER GENOM PROTEOM, V13, P499, DOI 10.21873/cgp.20013; Borchert S, 2014, J VIROL, V88, P3144, DOI 10.1128/JVI.02916-13; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; CICALA C, 1993, AM J PATHOL, V142, P1524; Delbue Serena, 2014, Oncoscience, V1, P296; Egli A, 2009, J INFECT DIS, V199, P837, DOI 10.1086/597126; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Fu FX, 2018, CLIN SCI, V132, P1753, DOI 10.1042/CS20180443; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Houben R, 2013, J INVEST DERMATOL, V133, P2453, DOI 10.1038/jid.2013.169; Hu JX, 2019, CANCER INVEST, V37, P199, DOI 10.1080/07357907.2019.1618322; Javorka P, 2019, PLANT DIRECT, V3, DOI 10.1002/pld3.146; Jin Y, 2019, AM J TRANSPLANT, V19, P1158; Kenan DJ, 2017, AM J TRANSPLANT, V17, P1674, DOI 10.1111/ajt.14191; Kenan DJ, 2015, J PATHOL, V237, P379, DOI 10.1002/path.4584; Knowles WA, 2003, J MED VIROL, V71, P115, DOI 10.1002/jmv.10450; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; LI J, 1993, J MED VIROL, V41, P11, DOI 10.1002/jmv.1890410104; Masutani M, 2007, EMBO J, V26, P3373, DOI 10.1038/sj.emboj.7601765; Merid SK, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-308; Moens U, 2005, VIROLOGY, V331, P209, DOI 10.1016/j.virol.2004.10.021; Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226; Muller DC, 2018, J PATHOL, V244, P265, DOI 10.1002/path.5012; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Schwarz A, 2012, TRANSPLANTATION, V94, P396, DOI 10.1097/TP.0b013e31825a505d; Starrett GJ, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00727-4; Starrett GJ, 2019, CURR OPIN VIROL, V39, P8, DOI 10.1016/j.coviro.2019.06.009; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Wei H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038533; Zeitouni B, 2010, BIOINFORMATICS, V26, P1895, DOI 10.1093/bioinformatics/btq293; Zhao LH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12992	31	7	8	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5734	5742		10.1038/s41388-020-01398-6	http://dx.doi.org/10.1038/s41388-020-01398-6		JUL 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32724161				2022-12-17	WOS:000553333400003
J	Burgess, M; Chen, UCE; Mapp, S; Blumenthal, A; Mollee, P; Gill, D; Saunders, NA				Burgess, M.; Chen, U. C. E.; Mapp, S.; Blumenthal, A.; Mollee, P.; Gill, D.; Saunders, N. A.			HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; SKIN-CANCER; CELLS; INHIBITION; PHAGOCYTOSIS; SELECTIVITY; SURVIVAL	Resistance, to therapeutic antibodies used to treat chronic lymphocytic leukemia (CLL) patients is common. Monocyte-derived macrophages (MDMs) are a major effector of antitumour responses to therapeutic antibodies and we have previously reported that resistance to therapeutic antibodies, by MDMs, increases as CLL disease progresses. In this study, we examine the effect of a Class IIa-selective HDAC inhibitor (TMP195) on the phagocytic response to opsonised tumor cells or non-opsonised targets by MDMs derived from CLL patients. We report that TMP195 enhances phagocytic responses to antibody-opsonised CLL cells andE. coliwithin 30 min of treatment. The enhanced response is phenocopied by knockdown of the Class IIa HDAC, HDAC7, or by low concentrations of the pan-HDAC inhibitor, vorinostat. HDAC7 knockdown and inhibition induces hyperacetylation and hyperphosphorylation of Bruton's tyrosine kinase (BTK). Moreover, BTK inhibitors abrogated the enhanced response to HDAC7 inhibition. Our data show that HDAC7 is an actionable driver of resistance to therapeutic antibodies by MDMs derived from CLL patients.	[Burgess, M.; Chen, U. C. E.; Saunders, N. A.] Univ Queensland, Woolloongabba, Qld, Australia; [Burgess, M.; Mapp, S.; Mollee, P.; Gill, D.] Princess Alexandra Hosp, Dept Haematol, Canc Serv Unit, Woolloongabba, Qld, Australia; [Mapp, S.] Univ Queensland, Translat Res Inst, Sch Med, Woolloongabba, Qld, Australia; [Blumenthal, A.] Univ Queensland, Translat Res Inst, Diamantina Inst, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland; University of Queensland	Saunders, NA (corresponding author), Univ Queensland, Woolloongabba, Qld, Australia.	nsaunders@uq.edu.au	saunders, nicholas/E-1544-2014	saunders, nicholas/0000-0002-2478-3420; Chen, Yu Chen Enya/0000-0003-4223-5054	Queensland Health, Princess Alexandra Hospital	Queensland Health, Princess Alexandra Hospital	The authors acknowledge the generosity of the patients who donated their time and blood for this study. This work was supported by a generous donation from Jeff and Fran Maclean and a research support package to DG from Queensland Health, Princess Alexandra Hospital.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0; Bobrowicz M, 2017, BLOOD, V130, P1628, DOI [10.1182/blood-2016-08736066, 10.1182/blood-2016-08-736066]; Boissard F, 2015, LEUKEMIA LYMPHOMA, V56, P1570, DOI 10.3109/10428194.2014.991731; Bosch F, 2019, NAT REV CLIN ONCOL, V16, P684, DOI 10.1038/s41571-019-0239-8; Burgess M, 2017, ONCOGENE, V36, P2366, DOI 10.1038/onc.2016.387; Burgess M, 2013, CLIN CANCER RES, V19, P5675, DOI 10.1158/1078-0432.CCR-13-1037; Burgess M, 2012, LEUKEMIA LYMPHOMA, V53, P1988, DOI 10.3109/10428194.2012.672735; Chen YCE, 2017, BBA-REV CANCER, V1868, P176, DOI 10.1016/j.bbcan.2017.03.006; Chen YCE, 2020, LEUKEMIA, V34, P451, DOI 10.1038/s41375-019-0556-z; Church AK, 2016, CLIN EXP IMMUNOL, V183, P90, DOI 10.1111/cei.12697; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Gul N, 2014, J CLIN INVEST, V124, P812, DOI 10.1172/JCI66776; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Jung JW, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1479627; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Kimbrough D, 2018, J MOL CELL CARDIOL, V119, P51, DOI 10.1016/j.yjmcc.2018.04.011; Lindelof B, 2000, BRIT J DERMATOL, V143, P513, DOI 10.1111/j.1365-2133.2000.03703.x; Liu ZJ, 2010, J IMMUNOL, V184, P244, DOI 10.4049/jimmunol.0902324; Lobera M, 2013, NAT CHEM BIOL, V9, P319, DOI [10.1038/nchembio.1223, 10.1038/NCHEMBIO.1223]; Marek L, 2013, J MED CHEM, V56, P427, DOI 10.1021/jm301254q; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Qi XB, 2018, J CELL BIOCHEM, V119, P3081, DOI 10.1002/jcb.26446; Ramsay HM, 2002, BRIT J DERMATOL, V147, P950, DOI 10.1046/j.1365-2133.2002.04976.x; Ribes S, 2010, INFECT IMMUN, V78, P865, DOI 10.1128/IAI.01110-09; Rogers KA, 2019, LEUKEMIA, V33, P2527, DOI 10.1038/s41375-019-0481-1; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Salvagno C, 2019, NAT CELL BIOL, V21, P511, DOI 10.1038/s41556-019-0298-1; Uribe-Querol E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01368; Van Damme M, 2014, EPIGENETICS-US, V9, P1374, DOI 10.4161/15592294.2014.969628; VanDerMeid KR, 2018, CANCER IMMUNOL RES, V6, P1150, DOI 10.1158/2326-6066.CIR-18-0319; Varughese T, 2018, CLIN INFECT DIS, V67, P687, DOI 10.1093/cid/ciy175; Veillette A, 2018, TRENDS IMMUNOL, V39, P173, DOI 10.1016/j.it.2017.12.005; Weiskopf K, 2017, EUR J CANCER, V76, P100, DOI 10.1016/j.ejca.2017.02.013	37	7	7	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5756	5767		10.1038/s41388-020-01394-w	http://dx.doi.org/10.1038/s41388-020-01394-w		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32709923				2022-12-17	WOS:000552155200001
J	Lee, N; Spears, ME; Carlisle, AE; Kim, D				Lee, Namgyu; Spears, Meghan E.; Carlisle, Anne E.; Kim, Dohoon			Endogenous toxic metabolites and implications in cancer therapy	ONCOGENE			English	Review							MITOCHONDRIAL RESPIRATORY-CHAIN; S-ADENOSYLHOMOCYSTEINE; HEREDITARY TYROSINEMIA; MOLECULAR-MECHANISMS; SALVAGE PATHWAY; QUINOLINIC ACID; DNA-SYNTHESIS; T-CELLS; DEHYDROEPIANDROSTERONE; GANGLIOSIDE	It is well recognized that many metabolic enzymes play essential roles in cancer cells in producing building blocks such as nucleotides, which are required in greater amounts due to their increased proliferation. On the other hand, the significance of enzymes in preventing the accumulation of their substrates is less recognized. Here, we outline the evidence and underlying mechanisms for how many metabolites normally produced in cells are highly toxic, such as metabolites containing reactive groups (e.g., methylglyoxal, 4-hydroxynonenal, and glutaconyl-CoA), or metabolites that act as competitive analogs against other metabolites (e.g., deoxyuridine triphosphate and l-2-hydroxyglutarate). Thus, if a metabolic pathway contains a toxic intermediate, then we may be able to induce accumulation and poison a cancer cell by targeting the downstream enzyme. Furthermore, this poisoning may be cancer cell selective if this pathway is overactive in a cancer cell relative to a nontransformed cell. We describe this concept as illustrated in selenocysteine metabolism and other pathways and discuss future directions in exploiting toxic metabolites to kill cancer cells.	[Lee, Namgyu; Spears, Meghan E.; Carlisle, Anne E.; Kim, Dohoon] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Kim, D (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01605 USA.	Dohoon.Kim@umassmed.edu		Lee, Namgyu/0000-0002-2980-2758; Spears, Meghan/0000-0001-6427-0614	Suh Kyungbae Foundation (SUHF) Young Investigator Award	Suh Kyungbae Foundation (SUHF) Young Investigator Award	We sincerely apologize for not being able to add numerous important studies in our review due to space limitations. We thank Christopher Cervantes and David Sabatini for helpful discussions. All authors are supported by the Suh Kyungbae Foundation (SUHF) Young Investigator Award.	Anso E, 2017, NAT CELL BIOL, V19, P614, DOI 10.1038/ncb3529; Banerjee BD, 1997, HUM EXP TOXICOL, V16, P276, DOI 10.1177/096032719701600508; Baumann T, 2020, NAT IMMUNOL, V21, P555, DOI 10.1038/s41590-020-0666-9; Blackburn PR, 2017, APPL CLIN GENET, V10, P57, DOI 10.2147/TACG.S125962; Blau N, 2010, LANCET, V376, P1417, DOI 10.1016/S0140-6736(10)60961-0; Bleich S, 2004, PROG NEURO-PSYCHOPH, V28, P453, DOI 10.1016/j.pnpbp.2003.11.019; Braidy N, 2009, NEUROTOX RES, V16, P77, DOI 10.1007/s12640-009-9051-z; Breiden B, 2018, METHODS MOL BIOL, V1804, P97, DOI 10.1007/978-1-4939-8552-4_5; Brown AJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08866-y; BROWN GK, 1982, PEDIATRICS, V70, P532; BRUNTON VG, 1990, BIOCHEM PHARMACOL, V40, P1893, DOI 10.1016/0006-2952(90)90371-Q; Burgos-Barragan G, 2017, NATURE, V548, P549, DOI 10.1038/nature23481; Cantor JR, 2017, CELL, V169, P258, DOI 10.1016/j.cell.2017.03.023; Carlisle AE, 2020, NAT METAB, V2, P603, DOI 10.1038/s42255-020-0224-7; Cesaratto L, 2007, J MOL MED, V85, P1099, DOI 10.1007/s00109-007-0204-3; Cheng ML, 2011, BIOCHEM PHARMACOL, V82, P1549, DOI 10.1016/j.bcp.2011.07.104; Choi HJ, 2006, GLYCOBIOLOGY, V16, P573, DOI 10.1093/glycob/cwj105; Choudhury S, 2015, MED HYPOTHESES, V85, P64, DOI 10.1016/j.mehy.2015.03.027; Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138; Copley SD, 2017, CURR OPIN STRUC BIOL, V47, P167, DOI 10.1016/j.sbi.2017.11.001; Csaky Z, 2020, YEAST, V37, P45, DOI 10.1002/yea.3454; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; CURTIN NJ, 1991, CANCER RES, V51, P2346; Dean Erin, 2016, Nurs Stand, V30, P15, DOI 10.7748/ns.30.44.15.s17; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Del Rio D, 2005, NUTR METAB CARDIOVAS, V15, P316, DOI 10.1016/j.numecd.2005.05.003; DEWEY DL, 1979, CANCER LETT, V6, P247, DOI 10.1016/S0304-3835(79)80041-5; DYKENS JA, 1987, BIOCHEM PHARMACOL, V36, P211, DOI 10.1016/0006-2952(87)90691-5; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Fauman EB, 2011, CURR OPIN CHEM BIOL, V15, P463, DOI 10.1016/j.cbpa.2011.05.020; Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI [10.2217/fon.10.11, 10.2217/FON.10.11]; Fujisawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034437; Fujiwara R, 2018, HEPATOLOGY, V67, P1609, DOI 10.1002/hep.29599; Galmarini CM, 2002, LANCET ONCOL, V3, P415, DOI 10.1016/S1470-2045(02)00788-X; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gil-ad I, 2001, ISRAEL MED ASSOC J, V3, P639; Guillemin GJ, 2012, FEBS J, V279, P1356, DOI 10.1111/j.1742-4658.2012.08485.x; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hiramatsu R, 2008, J CELL BIOCHEM, V103, P42, DOI 10.1002/jcb.21384; HUBER M, 1995, CANCER RES, V55, P934; Hunt RJ, 2019, J CELL BIOL, V218, P4007, DOI 10.1083/jcb.201904148; Hyman SE, 2005, CURR BIOL, V15, pR154, DOI 10.1016/j.cub.2005.02.037; INGRAHAM HA, 1982, MOL PHARMACOL, V21, P211; Intlekofer AM, 2015, CELL METAB, V22, P304, DOI 10.1016/j.cmet.2015.06.023; IWATA K, 1984, TOXICOL LETT, V22, P75, DOI 10.1016/0378-4274(84)90048-1; Jeffryes J, 2019, METHODS MOL BIOL, V1927, P11, DOI 10.1007/978-1-4939-9142-6_2; Jeitner TM, 1996, CANCER LETT, V103, P85, DOI 10.1016/0304-3835(96)04200-0; Jeitner TM, 2001, TOXICOL SCI, V63, P57, DOI 10.1093/toxsci/63.1.57; Jiang SH, 2020, ONCOGENE, V39, P503, DOI 10.1038/s41388-019-1006-0; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; KALAPOS MP, 1994, TOXICOL LETT, V73, P3, DOI 10.1016/0378-4274(94)90184-8; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kang Y, 2006, GLYCOBIOLOGY, V16, P375, DOI 10.1093/glycob/cwj087; Kennedy BP, 2004, J NEURAL TRANSM, V111, P547, DOI 10.1007/s00702-003-0096-5; Kennedy EM, 2011, J BIOL CHEM, V286, P25047, DOI 10.1074/jbc.M111.234047; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951; Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006; Kolker S, 2004, ANN NEUROL, V55, P7, DOI 10.1002/ana.10784; Kranendijk M, 2012, J INHERIT METAB DIS, V35, P571, DOI 10.1007/s10545-012-9462-5; KREDICH NM, 1977, CELL, V12, P931, DOI 10.1016/0092-8674(77)90157-X; KREDICH NM, 1979, P NATL ACAD SCI USA, V76, P2450, DOI 10.1073/pnas.76.5.2450; Kubo S, 1998, P NATL ACAD SCI USA, V95, P9552, DOI 10.1073/pnas.95.16.9552; Latini A, 2002, BRAIN RES, V956, P367, DOI 10.1016/S0006-8993(02)03573-4; LEE SE, 2013, OXID MED CELL LONGEV, V2013, DOI DOI 10.1155/2013/629028; Lehnert W, 2005, MED HYPOTHESES, V65, P330, DOI 10.1016/j.mehy.2005.02.021; Li L, 2017, J BIOL CHEM, V292, P4755, DOI 10.1074/jbc.M116.764787; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; LoPachin RM, 2014, CHEM RES TOXICOL, V27, P1081, DOI 10.1021/tx5001046; Lopez-Marure R, 2011, EUR J PHARMACOL, V660, P268, DOI 10.1016/j.ejphar.2011.03.040; Luengo A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13419-4; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Mahoney CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07959-4; Malina HZ, 1999, BIOCHEM BIOPH RES CO, V265, P600, DOI 10.1006/bbrc.1999.1716; Malina HZ, 2001, BMC PHYSL, V1, P34606; Malisan F, 2002, BBA-MOL CELL BIOL L, V1585, P179, DOI 10.1016/S1388-1981(02)00339-6; Mayeur C, 2005, BBA-MOL CELL RES, V1745, P111, DOI 10.1016/j.bbamcr.2004.12.004; Mexas LM, 2011, NEUROTOXICOLOGY, V32, P471, DOI 10.1016/j.neuro.2011.03.013; Moghe A, 2015, TOXICOL SCI, V143, P242, DOI 10.1093/toxsci/kfu233; NaveenKumar SK, 2015, SCI REP-UK, V5, DOI 10.1038/srep15045; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Pegg AE, 2013, CHEM RES TOXICOL, V26, P1782, DOI 10.1021/tx400316s; Perla-Kajan J, 2007, AMINO ACIDS, V32, P561, DOI 10.1007/s00726-006-0432-9; Peyroche G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036343; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; QUASH G, 1995, BIOCHEM J, V305, P1017, DOI 10.1042/bj3051017; Rao MS, 1997, CELL PROLIFERAT, V30, P1; Rawat V, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1801243; Regier DS, 2016, PEDIATR ENDOCR REV P, V13, P663; Richon VM, 2011, CHEM BIOL DRUG DES, V78, P199, DOI 10.1111/j.1747-0285.2011.01135.x; Robinson AD, 2020, CANCER LETT, V470, P134, DOI 10.1016/j.canlet.2019.11.013; RUSSO P, 1990, AM J HUM GENET, V47, P317; Ryu HM, 2016, J CELL MOL MED, V20, P2160, DOI 10.1111/jcmm.12916; Rzem R, 2004, P NATL ACAD SCI USA, V101, P16849, DOI 10.1073/pnas.0404840101; Rzem R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119540; Safiulina D, 2006, TOXICOL SCI, V93, P348, DOI 10.1093/toxsci/kfl064; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sarniak A, 2016, POSTEP HIG MED DOSW, V70, P1150, DOI 10.5604/17322693.1224259; Schalkwijk CG, 2020, PHYSIOL REV, V100, P407, DOI 10.1152/physrev.00001.2019; SCHECTER A, 1980, CHEST, V77, P554, DOI 10.1378/chest.77.4.554; Shoeb M, 2014, CURR MED CHEM, V21, P230; Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037; Sorice M, 2012, ANTI-CANCER AGENT ME, V12, P376, DOI 10.2174/187152012800228670; Stewart BJ, 2007, CHEM RES TOXICOL, V20, P1111, DOI 10.1021/tx700106v; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Tang BQ, 2006, BIOCHEM PHARMACOL, V72, P806, DOI 10.1016/j.bcp.2006.06.018; Taniguchi K, 1996, HEPATOLOGY, V24, P1395, DOI 10.1053/jhep.1996.v24.pm0008938168; Tulpule K, 2013, J NEUROCHEM, V127, P7, DOI 10.1111/jnc.12356; Ueda N, 2015, INT J MOL SCI, V16, P5076, DOI 10.3390/ijms16035076; Valachovic M, 2016, BIOCHEM BIOPH RES CO, V469, P1123, DOI 10.1016/j.bbrc.2015.12.050; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Wexler P, 2001, TOXICOLOGY, V157, P3, DOI 10.1016/S0300-483X(00)00337-1; Wolf C, 2007, MOL PHARMACOL, V71, P276, DOI 10.1124/mol.106.028449; Xu D, 2016, MOL BIOSYST, V12, P3067, DOI 10.1039/c6mb00231e; Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev-bioeng-071516-044546; Ye D, 2018, TRENDS CANCER, V4, P151, DOI 10.1016/j.trecan.2017.12.005; Yoshinaga A, 2016, EUR J PHARMACOL, V782, P21, DOI 10.1016/j.ejphar.2016.04.035; Zhang DS, 2014, CANCER LETT, V355, P176, DOI 10.1016/j.canlet.2014.09.003; Zhao Hui-Ying, 2018, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V26, P1022, DOI 10.7534/j.issn.1009-2137.2018.04.013	122	7	9	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5709	5720		10.1038/s41388-020-01395-9	http://dx.doi.org/10.1038/s41388-020-01395-9		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32709924	hybrid, Green Published			2022-12-17	WOS:000552155200002
J	Zhou, Y; Liu, F; Xu, QY; Yang, BK; Li, X; Jiang, SH; Hu, LP; Zhang, XL; Zhu, LL; Li, Q; Zhu, XL; Shao, HF; Dai, M; Shen, YF; Ni, B; Wang, S; Zhang, ZG; Teng, YC				Zhou, Yang; Liu, Fei; Xu, Qinyang; Yang, Bikang; Li, Xiao; Jiang, Shuheng; Hu, Lipeng; Zhang, Xueli; Zhu, Lili; Li, Qing; Zhu, Xiaolu; Shao, Hongfang; Dai, Miao; Shen, Yifei; Ni, Bo; Wang, Shuai; Zhang, Zhigang; Teng, Yincheng			Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer	ONCOGENE			English	Article							STRAND BREAK REPAIR; CONCURRENT CHEMOTHERAPY; RADIATION-THERAPY; TUMOR-SUPPRESSOR; BINDING-PROTEINS; PELVIC RADIATION; XPO1 INHIBITION; C/EBP-DELTA; CISPLATIN; CARCINOMA	Cervical cancer (CC) remains highest in the mortality of female reproductive system cancers, while cisplatin (CDDP) resistance is the one of main reasons for the lethality. Preceding evidence has supported that karyopherins are associated with chemoresistance. In this study, we simultaneously compared CDDP-incomplete responders with CDDP-complete responders of CC patients and CDDP-insensitive CC cell lines with CDDP-sensitive group. We finally identified that DNA-PKcs (PRKDC) was related to CDDP sensitivity after overlapping in CC sample tissues and CC cell lines. Further functional assay revealed that targeting PRKDC by shRNA and NU7026 (specific PRKDC inhibitor) could enhance CDDP sensitivity in vitro and in vivo, which was mediated by impairing DNA damage repair pathway in CC. Mechanistically, we found that PRKDC was transcriptionally upregulated by CCAAT/enhancer-binding protein delta (CEBPD), while intriguingly, CDDP treatment strengthened the transcriptional activity of CEBPD to PRKDC. We further disclosed that Importin 4 (IPO4) augmented the nuclear translocation of CEBPD through nuclear localization signals (NLS) to activate PRKDC-mediated DNA damage repair in response to CDDP. Moreover, we demonstrated that IPO4 and CEBPD knockdown improved CDDP-induced cytotoxicity in vitro and in vivo. Together, we shed the novel insight into the role of IPO4 in chemosensitivity and provide a clinical translational potential to enhance CC chemosensitivity since the IPO4-CEBPD-PRKDC axis is actionable via NU7026 (PRKDC inhibitor) or targeting IPO4 in combination with CDDP.	[Zhou, Yang; Liu, Fei; Xu, Qinyang; Yang, Bikang; Li, Xiao; Zhu, Xiaolu; Teng, Yincheng] Shanghai Jiao Tong Univ, Dept Gynecol & Obstet, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China; [Zhou, Yang; Teng, Yincheng] Jiangsu Univ, Shanghai Peoples Hosp 8, Dept Gynecol & Obstet, Shanghai 200233, Peoples R China; [Liu, Fei] Shanghai Henlius Biotech Inc, Global Clin Med Affairs GCMA, 7-F,Innov Tower,Zone A,1801 HongMei Rd, Shanghai 200233, Peoples R China; [Jiang, Shuheng; Hu, Lipeng; Zhang, Xueli; Zhu, Lili; Li, Qing; Zhang, Zhigang] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Shanghai, Peoples R China; [Shao, Hongfang] Shanghai Jiao Tong Univ, Ctr Reprod Med, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China; [Dai, Miao] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Dept Gynecol Oncol,Hunan Canc Hosp, Changsha, Peoples R China; [Shen, Yifei] Shanghai Tongji Univ, Shanghai East Hosp, Sch Med, Dept Orthoped, Shanghai 200120, Peoples R China; [Ni, Bo] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Gastrointestinal Surg, Shanghai 200217, Peoples R China; [Wang, Shuai] Jacobi Med Ctr, New York, NY 10461 USA	Shanghai Jiao Tong University; Jiangsu University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Central South University; Tongji University; Shanghai Jiao Tong University; Jacobi Medical Center	Teng, YC (corresponding author), Shanghai Jiao Tong Univ, Dept Gynecol & Obstet, Affiliated Peoples Hosp 6, 600 Yishan Rd, Shanghai 200233, Peoples R China.; Teng, YC (corresponding author), Jiangsu Univ, Shanghai Peoples Hosp 8, Dept Gynecol & Obstet, Shanghai 200233, Peoples R China.; Zhang, ZG (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Shanghai, Peoples R China.	zzhang@shsci.org; ycteng@sjtu.edu.cn		Zhang, Zhi-gang/0000-0001-8965-223X	National Natural Science Foundation of China [81672565, 81702556]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81672565 of YT and 81702556 of XZ).	Ahmad S, 2010, CHEM BIODIVERS, V7, P543, DOI 10.1002/cbdv.200800340; Angus L, 2014, CARCINOGENESIS, V35, P1121, DOI 10.1093/carcin/bgt491; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balamurugan K, 2010, EMBO J, V29, P4106, DOI 10.1038/emboj.2010.280; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Carden S, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5044-8; Casagrande N, 2013, GYNECOL ONCOL, V131, P744, DOI 10.1016/j.ygyno.2013.08.041; Conforti F, 2017, CANCER RES, V77, P5614, DOI 10.1158/0008-5472.CAN-17-1323; Conforti F, 2015, CLIN CANCER RES, V21, P4508, DOI 10.1158/1078-0432.CCR-15-0408; Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996; Friedrich B, 2006, MOL CELL BIOL, V26, P8697, DOI 10.1128/MCB.00708-06; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gao JK, 2014, ONCOTARGET, V5, P3444, DOI 10.18632/oncotarget.1813; Hazawa M, 2019, ONCOGENE, DOI [10.1038/s41388-41019-137-41383, DOI 10.1038/S41388-41019-137-41383]; Hour TC, 2010, BIOCHEM PHARMACOL, V80, P325, DOI 10.1016/j.bcp.2010.04.007; Hu H, 2017, BIOCHEM BIOPH RES CO, V483, P725, DOI 10.1016/j.bbrc.2016.12.074; Hu LP, 2019, CLIN CANCER RES, V25, P1318, DOI 10.1158/1078-0432.CCR-18-2297; Jette N, 2015, PROG BIOPHYS MOL BIO, V117, P194, DOI 10.1016/j.pbiomolbio.2014.12.003; Jiang SH, 2017, GASTROENTEROLOGY, V153, P277, DOI 10.1053/j.gastro.2017.03.008; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Koh WJ, 2019, J NATL COMPR CANC NE, V17, P64, DOI 10.6004/jnccn.2019.0001; Kosyna FK, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110221; Kuo DYS, 2010, GYNECOL ONCOL, V116, P442, DOI 10.1016/j.ygyno.2009.10.082; Kuusisto HV, 2015, BBA-MOL CELL RES, V1853, P1870, DOI 10.1016/j.bbamcr.2015.05.002; Lin KC, 2018, THERANOSTICS, V8, P2477, DOI 10.7150/thno.24173; Liu F, 2018, ONCOGENE, V37, P2394, DOI 10.1038/s41388-017-0119-6; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mahipal A, 2016, PHARMACOL THERAPEUT, V164, P135, DOI 10.1016/j.pharmthera.2016.03.020; Martelli L, 2006, BIOCHEM PHARMACOL, V72, P693, DOI 10.1016/j.bcp.2006.06.008; Moore DH, 2004, J CLIN ONCOL, V22, P3113, DOI 10.1200/JCO.2004.04.170; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Mukherjee B, 2009, CANCER RES, V69, P4252, DOI 10.1158/0008-5472.CAN-08-4853; Pectasides D, 2008, CANCER TREAT REV, V34, P603, DOI 10.1016/j.ctrv.2008.05.006; Peters WA, 2000, J CLIN ONCOL, V18, P1606, DOI 10.1200/JCO.2000.18.8.1606; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Ranganathan P, 2016, CLIN CANCER RES, V22, P6142, DOI 10.1158/1078-0432.CCR-15-2885; Saenz-Ponces N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aar7223; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen YF, 2019, EBIOMEDICINE, V40, P210, DOI 10.1016/j.ebiom.2018.12.038; Shintani S, 2003, CANCER SCI, V94, P894, DOI 10.1111/j.1349-7006.2003.tb01372.x; Stronach EA, 2011, NEOPLASIA, V13, P1069, DOI 10.1593/neo.111032; Sun G, 2017, ONCOL REP, V37, P3536, DOI 10.3892/or.2017.5634; Takeiri M, 2012, ORG BIOMOL CHEM, V10, P3053, DOI 10.1039/c2ob07104e; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Tran EJ, 2014, BBA-MOL CELL RES, V1843, P2784, DOI 10.1016/j.bbamcr.2014.08.003; Verrico A, 2020, ONCOGENE, V39, P454, DOI 10.1038/s41388-019-0989-x; Wang J, 2010, P NATL ACAD SCI USA, V107, P16131, DOI 10.1073/pnas.1002603107; Wang WJ, 2017, CLIN CANCER RES, V23, P503, DOI 10.1158/1078-0432.CCR-15-1169; Wen SY, 2015, ONCOGENE, V34, P717, DOI 10.1038/onc.2014.9; Whitney CW, 1999, J CLIN ONCOL, V17, P1339, DOI 10.1200/JCO.1999.17.5.1339; Wrobel K, 2016, MOL ENDOCRINOL, V30, P1029, DOI 10.1210/me.2016-1101; Wu SR, 2011, J BIOL CHEM, V286, P28662, DOI 10.1074/jbc.M111.270710; Xiang SS, 2019, ONCOGENE, V38, P1269, DOI 10.1038/s41388-018-0494-7; Xu X, 2019, J CELL BIOCHEM, V120, P12638, DOI 10.1002/jcb.28530; Zhang WJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1290-0; Zheng M, 2010, OBSTET GYNECOL, V116, P884, DOI 10.1097/AOG.0b013e3181f104ce	57	7	7	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5633	5648		10.1038/s41388-020-1384-3	http://dx.doi.org/10.1038/s41388-020-1384-3		JUL 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32661323	Green Published, hybrid			2022-12-17	WOS:000548100200001
J	Hruschka, N; Kalisz, M; Subijana, M; Grana-Castro, O; Del Cano-Ochoa, F; Brunet, LP; Chernukhin, I; Sagrera, A; De Reynies, A; Kloesch, B; Chin, SF; Burgues, O; Andreu, D; Bermejo, B; Cejalvo, JM; Sutton, J; Caldas, C; Ramon-Maiques, S; Carroll, JS; Prat, A; Real, FX; Martinelli, P				Hruschka, Natascha; Kalisz, Mark; Subijana, Maria; Grana-Castro, Osvaldo; Del Cano-Ochoa, Francisco; Brunet, Laia Pare; Chernukhin, Igor; Sagrera, Ana; De Reynies, Aurelien; Kloesch, Bernhard; Chin, Suet-Feung; Burgues, Octavio; Andreu, David; Bermejo, Begona; Cejalvo, Juan Miguel; Sutton, Joe; Caldas, Carlos; Ramon-Maiques, Santiago; Carroll, Jason S.; Prat, Aleix; Real, Francisco X.; Martinelli, Paola			The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver	ONCOGENE			English	Article							EXPRESSION; DIFFERENTIATION; BINDING	As the catalog of oncogenic driver mutations is expanding, it becomes clear that alterations in a given gene might have different functions and should not be lumped into one class. The transcription factorGATA3is a paradigm of this. We investigated the functions of the most commonGATA3mutation (X308_Splice) and five additional mutations, which converge into a neoprotein that we called "neoGATA3," associated with excellent prognosis in patients. Analysis of available molecular data from >3000 breast cancer patients revealed a dysregulation of the ER-dependent transcriptional response in tumors carrying neoGATA3-generating mutations. Mechanistic studies in vitro showed that neoGATA3 interferes with the transcriptional programs controlled by estrogen and progesterone receptors, without fully abrogating them. ChIP-Seq analysis indicated that ER binding is reduced in neoGATA3-expressing cells, especially at distal regions, suggesting that neoGATA3 interferes with the fine tuning of ER-dependent gene expression. This has opposite outputs in distinct hormonal context, having pro- or anti-proliferative effects, depending on the estrogen/progesterone ratio. Our data call for functional analyses of putative cancer drivers to guide clinical application.	[Hruschka, Natascha; Subijana, Maria; Kloesch, Bernhard; Martinelli, Paola] Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Vienna, Austria; [Kalisz, Mark; Sagrera, Ana; Real, Francisco X.; Martinelli, Paola] CIBERONC, Epithelial Carcinogenesis Grp, Spanish Natl Canc Res Ctr CNIO, Madrid, Spain; [Grana-Castro, Osvaldo] Spanish Natl Canc Res Ctr CNIO, Bioinformat Unit, Madrid, Spain; [Del Cano-Ochoa, Francisco; Ramon-Maiques, Santiago] CSIC UAM, Dept Genome Dynam & Funct, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Brunet, Laia Pare; Prat, Aleix] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain; [Brunet, Laia Pare; Prat, Aleix] IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain; [Chernukhin, Igor; Sutton, Joe; Carroll, Jason S.] Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England; [De Reynies, Aurelien] Ligue Natl Canc, Programme Cartes Identite Tumeurs, F-75013 Paris, France; [Chin, Suet-Feung; Caldas, Carlos] Univ Cambridge, Canc Res UK Cambridge Inst, Dept Oncol, Cambridge, England; [Burgues, Octavio; Bermejo, Begona; Cejalvo, Juan Miguel] INCLIVA Biomed Res Inst, Valencia, Spain; [Burgues, Octavio] Hosp Clin Univ CIBERONC, Pathol Dept, Valencia, Spain; [Andreu, David] Univ Pompeu Fabra, Lab Prote & Prot Chem, Barcelona, Spain; [Bermejo, Begona; Cejalvo, Juan Miguel] Hosp Clin Univ CIBERONC, Oncol & Hematol Dept, Valencia, Spain; [Real, Francisco X.] Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Barcelona, Spain; [Martinelli, Paola] Boehringer Ingelheim RCV, Canc Cell Signaling Dept, Vienna, Austria	Medical University of Vienna; Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Pompeu Fabra University; Pompeu Fabra University; Boehringer Ingelheim	Martinelli, P (corresponding author), Med Univ Vienna, Comprehens Canc Ctr, Inst Canc Res, Vienna, Austria.; Martinelli, P (corresponding author), CIBERONC, Epithelial Carcinogenesis Grp, Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.; Martinelli, P (corresponding author), Boehringer Ingelheim RCV, Canc Cell Signaling Dept, Vienna, Austria.	paola.martinelli@boehringer-ingelheim.com	Arribas, Francisco X Real/H-5275-2015; Burgues, Octavio/ABC-8699-2021; Caldas, Carlos/U-7250-2019; Ramon-Maiques, Santiago/R-2533-2019	Arribas, Francisco X Real/0000-0001-9501-498X; Caldas, Carlos/0000-0003-3547-1489; Kalisz, Mark/0000-0002-8770-2798; Grana-Castro, Osvaldo/0000-0003-1615-4242; Ramon-Maiques, Santiago/0000-0001-9674-8088; del Cano-Ochoa, Francisco/0000-0003-3093-3103; Carroll, Jason/0000-0003-3643-0080; Burgues, Octavio/0000-0002-2471-5516	Institute of Cancer Research of the Medical University Vienna; Austrian Science Grant (FWF) [P27361-B23]; Ministerio de Economia y Competitividad (Madrid, Spain) [SAF2011-29530, SAF2015-70553-R]; ERDF-EU; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer; Ministerio de Ciencia, Innovacion y Universidades [SEV-2015-0510]; Cancer Research UK; Spanish Ministry of Science, Innovation and Universities (AEI/FEDER, UE) [BFU2016-80570-R]	Institute of Cancer Research of the Medical University Vienna; Austrian Science Grant (FWF)(Austrian Science Fund (FWF)); Ministerio de Economia y Competitividad (Madrid, Spain); ERDF-EU; Fundacion Cientifica de la Asociacion Espanola Contra el Cancer; Ministerio de Ciencia, Innovacion y Universidades; Cancer Research UK(Cancer Research UK); Spanish Ministry of Science, Innovation and Universities (AEI/FEDER, UE)	Work in the lab of PM was supported by the Institute of Cancer Research of the Medical University Vienna and by the grant P27361-B23 from the Austrian Science Grant (FWF), FXR was supported by SAF2011-29530 and SAF2015-70553-R grants from Ministerio de Economia y Competitividad (Madrid, Spain) (co-funded by the ERDF-EU), Fundacion Cientifica de la Asociacion Espanola Contra el Cancer. CNIO is supported by Ministerio de Ciencia, Innovacion y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510. Work in the lab of JSC and CC was supported by Cancer Research UK. Work in the lab of SRM was supported by the Spanish Ministry of Science, Innovation and Universities (BFU2016-80570-R; AEI/FEDER, UE).	Adomas AB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-278; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Chin L, 2011, GENE DEV, V25, P534, DOI 10.1101/gad.2017311; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Gustin JP, 2017, ONCOTARGET, V8, P103415, DOI 10.18632/oncotarget.21910; Izzo F, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0491-x; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Mair B, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006279; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Prat A, 2012, ANN ONCOL, V23, P2866, DOI 10.1093/annonc/mds080; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Singhal H, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501924; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Takaku M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03478-4; Takaku M, 2015, GENE EXPRESSION, V16, P163, DOI 10.3727/105221615X14399878166113; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	31	7	7	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5455	5467		10.1038/s41388-020-1376-3	http://dx.doi.org/10.1038/s41388-020-1376-3		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32587399	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000543299500002
J	Chai, TF; Manu, KA; Casey, PJ; Wang, M				Chai, Tin Fan; Manu, Kanjoormana Aryan; Casey, Patrick J.; Wang, Mei			Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; STEM-CELLS; K-RAS; HIPPO PATHWAY; CARBOXYL METHYLTRANSFERASE; CONDITIONAL EXPRESSION; TUMOR-GROWTH; YAP; PROMOTES; RESISTANCE	Cancer stem cells possess the capacity for self-renewal and resistance to chemotherapy. It is therefore crucial to understand the molecular regulators of stemness in the quest to develop effective cancer therapies. TAZ is a transcription activator that promotes stem cell functions in post-development mammalian cells; suppression of TAZ activity reduces or eliminates cancer stemness in select cancers. Isoprenylcysteine carboxylmethyltransferase (ICMT) is the unique enzyme of the last step of posttranslational prenylation processing pathway that modifies several oncogenic proteins, including RAS. We found that suppression of ICMT results in reduced self-renewal/stemness in KRAS-driven pancreatic and breast cancer cells. Silencing of ICMT led to significant reduction of TAZ protein levels and loss of self-renewal ability, which could be reversed by overexpressing mutant KRAS, demonstrating the functional impact of ICMT modification on the ability of KRAS to control TAZ stability and function. Contrary to expectation, YAP protein levels appear to be much less susceptible than TAZ to the regulation by ICMT and KRAS, and YAP is less consequential in regulating stemness characteristics in these cells. Further, we found that the ICMT-dependent KRAS regulation of TAZ was mediated through RAF, but not PI3K, signaling. Functionally, we demonstrate that a signaling cascade from ICMT modification of KRAS to TAZ protein stability supports cancer cell self-renewal abilities in both in vitro and in vivo settings. In addition, studies using the proof-of-concept small molecule inhibitors of ICMT confirmed its role in regulating TAZ and self-renewal, demonstrating the potential utility of targeting ICMT to control aggressive KRAS-driven cancers.	[Chai, Tin Fan; Manu, Kanjoormana Aryan; Casey, Patrick J.; Wang, Mei] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Chai, Tin Fan; Wang, Mei] Natl Univ Singapore, Dept Biochem, Singapore 117596, Singapore; [Casey, Patrick J.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	National University of Singapore; National University of Singapore; Duke University	Wang, M (corresponding author), Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore.; Wang, M (corresponding author), Natl Univ Singapore, Dept Biochem, Singapore 117596, Singapore.	mei.wang@duke-nus.edu.sg		Casey, Patrick/0000-0002-7366-9309; Kanjoormana Aryan, Manu/0000-0002-4437-6486; Wang, Mei/0000-0001-6887-6840	Ministry of Education [MOE2017-T2-1-039]; National Medical Research Council [NMRC/CIRG/1486/2018]	Ministry of Education; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The work is supported by Ministry of Education (MOE2017-T2-1-039) and National Medical Research Council (NMRC/CIRG/1486/2018) Singapore.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Awasthi N, 2013, CARCINOGENESIS, V34, P2361, DOI 10.1093/carcin/bgt227; Bahmad HF, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00347; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Bender RHF, 2015, STEM CELLS, V33, P1998, DOI 10.1002/stem.1990; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boggiano JC, 2011, DEV CELL, V21, P888, DOI 10.1016/j.devcel.2011.08.028; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Caruso C, 2019, CANCER DISCOV, V9, P988, DOI 10.1158/2159-8290.CD-NB2019-073; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cushman I, 2009, J BIOL CHEM, V284, P27964, DOI 10.1074/jbc.M109.025296; Do MT, 2017, ONCOGENE, V36, P5757, DOI 10.1038/onc.2017.183; Garcia-Rendueles MER, 2015, CANCER DISCOV, V5, P1178, DOI 10.1158/2159-8290.CD-15-0330; Gierut JJ, 2015, STEM CELL RES, V15, P165, DOI 10.1016/j.scr.2015.06.003; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Hong X, 2014, EMBO J, V33, P2447, DOI 10.15252/embj.201489385; Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kutner RH, 2009, NAT PROTOC, V4, P495, DOI 10.1038/nprot.2009.22; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lau HY, 2017, ONCOGENE, V36, P3934, DOI 10.1038/onc.2016.508; Lau HY, 2014, CANCER BIOL THER, V15, P1280, DOI 10.4161/cbt.29692; Lau HK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06477-7; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Manu KA, 2017, MOL CANCER THER, V16, P914, DOI 10.1158/1535-7163.MCT-16-0703; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Pichot CS, 2009, BRIT J CANCER, V101, P38, DOI 10.1038/sj.bjc.6605101; Plouffe SW, 2018, J BIOL CHEM, V293, P11230, DOI 10.1074/jbc.RA118.002715; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Poon CLC, 2011, DEV CELL, V21, P896, DOI 10.1016/j.devcel.2011.09.012; Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Shaheen S, 2016, STEM CELL REV REP, V12, P492, DOI 10.1007/s12015-016-9664-6; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Teh JT, 2015, ONCOGENE, V34, P3296, DOI 10.1038/onc.2014.260; Teh JT, 2019, MOL CANCER THER, V18, P693, DOI 10.1158/1535-7163.MCT-18-0766; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Van den Broeck A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-354; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Wang M, 2010, ONCOGENE, V29, P4959, DOI 10.1038/onc.2010.247; Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200; Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Yuan YL, 2016, MOL MED REP, V13, P237, DOI 10.3892/mmr.2015.4550; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zanconato F, 2016, EMBO J, V35, P459, DOI 10.15252/embj.201593584; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhao X, 2017, CANCER LETT, V402, P61, DOI 10.1016/j.canlet.2017.05.015; Zhao YL, 2018, MOL CANCER RES, V16, P1046, DOI 10.1158/1541-7786.MCR-17-0593; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606; Zhu WL, 2011, J BIOL CHEM, V286, P35291, DOI 10.1074/jbc.M111.280990	78	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5373	5389		10.1038/s41388-020-1364-7	http://dx.doi.org/10.1038/s41388-020-1364-7		JUN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32561852	hybrid, Green Published			2022-12-17	WOS:000541308400004
J	Haider, N; Dutt, P; van de Kooij, B; Ho, JS; Palomero, L; Pujana, MA; Yaffe, M; Stambolic, V				Haider, Nasir; Dutt, Previn; van de Kooij, Bert; Ho, Jason; Palomero, Luis; Pujana, Miquel Angel; Yaffe, Michael; Stambolic, Vuk			NEK10tyrosine phosphorylates p53 and controls its transcriptional activity	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE ARREST; REPLICATION; STRESS; MULTIPLE; ACETYLATION; SENSITIVITY; EXPRESSION; MORTALITY; PATTERNS	In response to genotoxic stress, multiple kinase signaling cascades are activated, many of them directed towards the tumor suppressor p53, which coordinates the DNA damage response (DDR). Defects in DDR pathways lead to an accumulation of mutations that can promote tumorigenesis. Emerging evidence implicates multiple members of the NimA-related kinase (NEK) family (NEK1,NEK10, andNEK11) in the DDR. Here, we describe a function forNEK10in the regulation of p53 transcriptional activity through tyrosine phosphorylation.NEK10loss increases cellular proliferation by modulating the p53-dependent transcriptional output.NEK10directly phosphorylates p53 on Y327, revealingNEK10'sunexpected substrate specificity. A p53 mutant at this site (Y327F) acts as a hypomorph, causing an attenuated p53-mediated transcriptional response. Consistently,NEK10-deficient cells display heightened sensitivity to DNA-damaging agents. Further, a combinatorial score ofNEK10andTP53-target gene expression is an independent predictor of a favorable outcome in breast cancers.	[Haider, Nasir; Stambolic, Vuk] Univ Toronto, Dept Med Biophys, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada; [Haider, Nasir; Dutt, Previn; Ho, Jason; Stambolic, Vuk] Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada; [van de Kooij, Bert; Yaffe, Michael] MIT, David H Koch Inst Integrat Canc Res, Ctr Precis Canc Med, Cambridge, MA 02142 USA; [Palomero, Luis; Pujana, Miquel Angel] Bellvitge Inst Biomed Res IDIBELL, Catalan Inst Oncol, ProCURE, Gran Via 199, Barcelona 08908, Spain; [Yaffe, Michael] MIT, Dept Biol & Biol Engn, Cambridge, MA 02142 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Massachusetts Institute of Technology (MIT); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Massachusetts Institute of Technology (MIT)	Stambolic, V (corresponding author), Univ Toronto, Dept Med Biophys, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada.; Stambolic, V (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Princess Margaret Canc Res Tower, Toronto, ON M5G 1L7, Canada.	vuks@uhnresearch.ca	Pujana, Miquel Angel/N-3127-2014; Pujana, Miguel Angel/ABF-9055-2021; Palomero, Luis/K-1058-2017	Pujana, Miquel Angel/0000-0003-3222-4044; Pujana, Miguel Angel/0000-0003-3222-4044; Stambolic, Vuk/0000-0001-8853-3239; Palomero, Luis/0000-0002-9144-1017; Yaffe, Michael/0000-0002-9547-3251	Princess Margaret Hospital Foundation; CIHR strategic training fellowship of the EIRR 21st Program	Princess Margaret Hospital Foundation; CIHR strategic training fellowship of the EIRR 21st Program(Canadian Institutes of Health Research (CIHR))	We thank Ryan Dowling and members of the Stambolic group (Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada) for their helpful discussion and advice. We thank Anne van Vlimmeren for technical assistance. This work was supported by the Princess Margaret Hospital Foundation and by the CIHR strategic training fellowship of the EIRR 21st Program (Awarded to NH). The results published here are in whole or part based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.	Abeyta A, 2017, CELL CYCLE, V16, P335, DOI 10.1080/15384101.2016.1259038; Ahmed S, 2009, NAT GENET, V41, P585, DOI 10.1038/ng.354; Bai Y, 2012, CANCER RES, V72, P2501, DOI 10.1158/0008-5472.CAN-11-3015; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Burstein MD, 2015, CLIN CANCER RES, V21, P1688, DOI 10.1158/1078-0432.CCR-14-0432; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chen YM, 2008, CELL CYCLE, V7, P3194, DOI 10.4161/cc.7.20.6815; Chen YM, 2011, CELL CYCLE, V10, P655, DOI 10.4161/cc.10.4.14814; Choi HJC, 2013, MOL CELL, V51, P423, DOI 10.1016/j.molcel.2013.08.006; Chong LT, 2006, J MOL BIOL, V357, P1039, DOI 10.1016/j.jmb.2005.12.083; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fletcher L, 2004, RADIAT RES, V162, P128, DOI 10.1667/RR3211; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; GAO J, 2013, SCI SIGNAL, V6, ppp11; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Giono LE, 2006, J CELL PHYSIOL, V209, P13, DOI 10.1002/jcp.20689; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Huang YF, 2014, ONCOTARGET, V5, P5808, DOI 10.18632/oncotarget.2199; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; Jee HJ, 2010, CELL CYCLE, V9, P4703, DOI 10.4161/cc.9.23.14059; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kawaguchi T, 2005, ONCOGENE, V24, P6976, DOI 10.1038/sj.onc.1208839; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Kumari R, 2014, MOL CELL ONCOL, V1; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee MY, 2008, CELL CYCLE, V7, P2705, DOI 10.4161/cc.7.17.6551; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Malkin D., 2011, GENES CANC, V2, P475, DOI DOI 10.1177/1947601911413466; McGale P, 2014, LANCET, V383, P2127, DOI 10.1016/S0140-6736(14)60488-8; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730; Mi J, 2007, CANCER RES, V67, P1082, DOI 10.1158/0008-5472.CAN-06-3071; Moniz L, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-18; Moniz LS, 2011, MOL CELL BIOL, V31, P30, DOI 10.1128/MCB.00648-10; Moniz LS, 2010, CHARACTERIZATION NIM; Noguchi K, 2002, J BIOL CHEM, V277, P39655, DOI 10.1074/jbc.M204599200; Pappas K, 2017, MOL CANCER RES, V15, P1051, DOI 10.1158/1541-7786.MCR-17-0089; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Sabir SR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140975; Salem H, 2010, ONCOGENE, V29, P4046, DOI 10.1038/onc.2010.162; Salic A, 2008, P NATL ACAD SCI USA, V105, P2415, DOI 10.1073/pnas.0712168105; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Smith SC, 2014, NUCLEIC ACIDS RES, V42, P11517, DOI 10.1093/nar/gku840; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tsai CF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7622; Tutt A, 2018, NAT MED, V24, P628, DOI 10.1038/s41591-018-0009-7; van de Kooij B, 2019, ELIFE, V8, DOI 10.7554/eLife.44635; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang SL, 2006, CANCER RES, V66, P6982, DOI 10.1158/0008-5472.CAN-06-0511; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Yakovlev VA, 2010, BIOCHEMISTRY-US, V49, P5331, DOI 10.1021/bi100564w	70	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 23	2020	39	30					5252	5266		10.1038/s41388-020-1361-x	http://dx.doi.org/10.1038/s41388-020-1361-x		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MO5BV	32561851	Green Submitted			2022-12-17	WOS:000541308400003
J	Liu, Y; Zhang, YY; Wang, SQ; Li, M; Long, YH; Li, YF; Liu, YK; Li, YH; Wang, YQ; Mi, JS; Yu, CH; Li, DY; Zhang, JH; Zhang, XJ				Liu, Yan; Zhang, Yuan-Yue; Wang, Shu-Qing; Li, Min; Long, Yue-Hong; Li, Yu-Feng; Liu, Yan-Kun; Li, Yu-Hui; Wang, Ya-Qi; Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Jing-Hua; Zhang, Xiao-Jun			WSTF acetylation by MOF promotes WSTF activities and oncogenic functions	ONCOGENE			English	Article							SYNDROME TRANSCRIPTION FACTOR; HISTONE H3; CANCER CELLS; TARGETS; PROTEIN; COMPLEXES	Williams syndrome transcription factor (WSTF) is a transcription factor and tyrosine kinase. WSTF overexpression promotes migration and proliferation of various cancers, and Ser158 (WSTFS158) phosphorylation plays an important role in this process. However, the role of the other posttranslational modifications of WSTF is unknown. Here, we report that lysine (K) 426 on WSTF is acetylated by MOF and deacetylated by SIRT1. Mechanistically, male-specific lethal (MSL) 1v1 interaction with WSTF facilitates its interaction with MOF for WSTF acetylation, which in turn promotes WSTF(S158)phosphorylation. The kinase and transcriptional regulatory activity of WSTF were enhanced by acetylation. WSTF(K426ac)levels positively and significantly correlated with tumor size, histological grade, and age. Moreover, we demonstrated that acetylated WSTF promotes cancer cell proliferation, migration, invasion, and tumor formation. In conclusion, we identified the enzymes regulating WSTF K426 acetylation, and demonstrated an acetylation-dependent mechanism that modulates the activities of WSTF and contributes to tumorigenesis. Our findings provide new clues to study WSTF-mediated normal development and disease.	[Liu, Yan; Zhang, Yuan-Yue; Long, Yue-Hong] North China Univ Sci & Technol, Coll Life Sci, Tangshan, Peoples R China; [Liu, Yan; Zhang, Yuan-Yue; Li, Yu-Feng; Liu, Yan-Kun; Wang, Ya-Qi; Zhang, Jing-Hua] North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Canc Inst, Tangshan, Peoples R China; [Zhang, Yuan-Yue] North China Univ Sci & Technol, Grad Sch, Tangshan, Peoples R China; [Wang, Shu-Qing] Hosp North China Univ Sci & Technol, Tangshan, Peoples R China; [Li, Min] North China Univ Sci & Technol, Affiliated Hosp, Orthopaed Surg, Tangshan, Peoples R China; [Li, Yu-Hui] North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Neurosurg, Tangshan, Peoples R China; [Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Xiao-Jun] Zunhua Peoples Hosp, Zunhua, Peoples R China	North China University of Science & Technology; North China University of Science & Technology; North China University of Science & Technology; North China University of Science & Technology; North China University of Science & Technology	Li, YF; Zhang, JH (corresponding author), North China Univ Sci & Technol, Affiliated Tangshan Peoples Hosp, Canc Inst, Tangshan, Peoples R China.; Zhang, XJ (corresponding author), Zunhua Peoples Hosp, Zunhua, Peoples R China.	yfli_renmin@qq.com; jhzhang_te@163.com; tech_ol@foxmail.com	zhang, jin/GXV-9154-2022		National Natural Science Foundation of China [81772834]; Natural Science Foundation of Hebei Province [H2019105034]; Science Fund for Distinguished Young Scholars of North China University of Science and Technology [JQ201704]; Doctoral Research Project of North China University of Science and Technology; Program for Innovation Research Team (in Science and Technology) of Tangshan [17130205D]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hebei Province(Natural Science Foundation of Hebei Province); Science Fund for Distinguished Young Scholars of North China University of Science and Technology; Doctoral Research Project of North China University of Science and Technology; Program for Innovation Research Team (in Science and Technology) of Tangshan	This work was supported by the National Natural Science Foundation of China (grant number 81772834); Natural Science Foundation of Hebei Province (grant number H2019105034); Science Fund for Distinguished Young Scholars of North China University of Science and Technology (JQ201704); Doctoral Research Project of North China University of Science and Technology; the Program for Innovation Research Team (in Science and Technology) of Tangshan (17130205D).	Barnett C, 2011, BIOCHEM CELL BIOL, V89, P12, DOI 10.1139/O10-114; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6; Kahali B, 2014, ONCOGENE, V33, P653, DOI 10.1038/onc.2012.613; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031; Liu Y, 2019, ONCOGENE, V38, P980, DOI 10.1038/s41388-018-0466-y; Liu Y, 2016, ONCOTARGET, V7, P53153, DOI 10.18632/oncotarget.10625; Liu Y, 2014, FEBS J, V281, P3315, DOI 10.1111/febs.12863; Liu Y, 2013, FEBS LETT, V587, P847, DOI 10.1016/j.febslet.2013.02.023; Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847; Lundqvist J, 2018, J STEROID BIOCHEM, V177, P171, DOI 10.1016/j.jsbmb.2017.06.003; Meng J, 2016, CELL SIGNAL, V28, P1673, DOI 10.1016/j.cellsig.2016.07.008; Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283; Su JM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010099; Wan JH, 2016, NUCLEIC ACIDS RES, V44, P10662, DOI 10.1093/nar/gkw808; Wang YQ, 2016, INT J CLIN EXP PATHO, V9, P1668; Xiao A, 2009, NATURE, V457, P57, DOI 10.1038/nature07668; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252	21	7	7	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5056	5067		10.1038/s41388-020-1350-0	http://dx.doi.org/10.1038/s41388-020-1350-0		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32518374				2022-12-17	WOS:000539201700001
J	Gou, Q; Jiang, YD; Zhang, RY; Xu, Y; Xu, HH; Zhang, WB; Shi, JJ; Hou, YZ				Gou, Qian; Jiang, Yidan; Zhang, Runyun; Xu, Ying; Xu, Huihui; Zhang, Wenbo; Shi, Juanjuan; Hou, Yongzhong			PPAR delta is a regulator of autophagy by its phosphorylation	ONCOGENE			English	Article							CELL-DEATH; LIGAND ACTIVATION; TUMOR PROGRESSION; CANCER CELLS; LUNG-CANCER; EGFR; APOPTOSIS; GAMMA; INHIBITION; GROWTH	In response to nutrient deficiency, autophagy degrades cytoplasmic materials and organelles in lysosomes, which is nutrient recycling, whereas activation of EGFR mediates autophagy suppression in response to growth factors. It is unclear whether PPAR delta could be the regulator of autophagy in response to active EGFR. Here we found that EGFR induced PPAR delta phosphorylation at tyrosine-108 leading to increased binding of LC3 to PPAR delta by its LIR (LC3 interacting region) motif, consequently, inhibited autophagic flux. Conversely, EGFR inhibitor treatment reversed this event. Furthermore, EGFR-mediated PPAR delta phosphorylation at tyrosine-108 led to autophagy inhibition and tumor growth. These findings suggest that PPAR delta serves as a regulator of autophagy by its phosphorylation.	[Gou, Qian; Jiang, Yidan; Zhang, Runyun; Xu, Ying; Xu, Huihui; Zhang, Wenbo; Shi, Juanjuan; Hou, Yongzhong] Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China	Jiangsu University	Hou, YZ (corresponding author), Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China.	houyz@ujs.edu.cn		Hou, Yongzhong/0000-0003-2019-8686	National Natural Science Foundation of China [81672711, 81972618]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX18_2218]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postgraduate Research & Practice Innovation Program of Jiangsu Province	This work was supported by the National Natural Science Foundation of China (81672711, 81972618); Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX18_2218).	Abu el Maaty MA, 2017, MOL CARCINOGEN, V56, P2486, DOI 10.1002/mc.22696; Ba MC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711952; Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910; Bhatelia K, 2017, CELL SIGNAL, V35, P73, DOI 10.1016/j.cellsig.2017.03.024; Birgisdottir AB, 2013, J CELL SCI, V126, P3237, DOI 10.1242/jcs.126128; Burton LJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164115; Capizzi M, 2017, AUTOPHAGY, V13, P554, DOI 10.1080/15548627.2016.1269989; Chang CH, 2017, INT J ONCOL, V50, P873, DOI 10.3892/ijo.2017.3866; Chang CT, 2017, ARCH TOXICOL, V91, P3341, DOI 10.1007/s00204-017-1967-0; Chang SH, 2017, J DERMATOL SCI, V87, P138, DOI 10.1016/j.jdermsci.2017.04.011; Chung SJ, 2017, AUTOPHAGY, V13, P1386, DOI 10.1080/15548627.2017.1332565; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Foreman JE, 2011, MOL CARCINOGEN, V50, P884, DOI 10.1002/mc.20757; Fung C, 2012, CANCER BIOL THER, V13, P1417, DOI 10.4161/cbt.22002; Gao JM, 2015, ONCOTARGET, V6, P44635, DOI 10.18632/oncotarget.5988; Gou Q, 2017, ONCOTARGET, V8, P60704, DOI 10.18632/oncotarget.19610; Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691; Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hollingshead HE, 2008, CARCINOGENESIS, V29, P169, DOI 10.1093/carcin/bgm209; Hotchkiss RS, 2009, NEW ENGL J MED, V361, P1570, DOI 10.1056/NEJMra0901217; Hou Y, 2014, ONCOGENE, V33, P5619, DOI 10.1038/onc.2013.504; Hou YZ, 2007, J BIOL CHEM, V282, P9279, DOI 10.1074/jbc.M608523200; Hou YZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2270; Hou YZ, 2010, J BIOL CHEM, V285, P35497, DOI 10.1074/jbc.M109.066035; Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509; Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024; Khozoie C, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-665; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366; Lian JQ, 2010, AUTOPHAGY, V6, P1201, DOI [10.4161/auto.6.8.13549, 10.1038/cdd.2010.74]; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749; Nazim UM, 2017, ONCOTARGET, V8, P26819, DOI 10.18632/oncotarget.15819; Oh S, 2011, CELL DEATH DIFFER, V18, P452, DOI 10.1038/cdd.2010.116; Park MA, 2008, AUTOPHAGY, V4, P513, DOI 10.4161/auto.5725; Peng Y, 2017, ONCOTARGET, V8, P52960, DOI 10.18632/oncotarget.17674; Peters Jeffrey M, 2011, Drug Discov Today Dis Mech, V8, pe85; Rautou PE, 2010, J HEPATOL, V53, P1123, DOI 10.1016/j.jhep.2010.07.006; Rodolfo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167672; Venkatachalam G, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S3-S5; Wang DZ, 2014, P NATL ACAD SCI USA, V111, P7084, DOI 10.1073/pnas.1324233111; Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015; Xu Y, 2016, CARCINOGENESIS, V37, P215, DOI 10.1093/carcin/bgv252; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; You ML, 2018, J ONCOL, V2018, DOI 10.1155/2018/6458537; You ML, 2017, J CELL BIOCHEM, V118, P1556, DOI 10.1002/jcb.25817; You ML, 2015, CURR PHARM DESIGN, V21, P2956, DOI 10.2174/1381612821666150514104035; Yu JJ, 2020, CANCER LETT, V474, P23, DOI 10.1016/j.canlet.2020.01.004; Yuan SP, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/3801976; Zhang WB, 2017, CARCINOGENESIS, V38, P748, DOI 10.1093/carcin/bgx035; Zhang Z, 2013, ONKOLOGIE, V36, P598, DOI 10.1159/000355328; Zhou DY, 2019, EUR J PHARMACOL, V842, P248, DOI 10.1016/j.ejphar.2018.10.050; Zhu B, 2014, ONCOGENE, V33, P5348, DOI 10.1038/onc.2013.477; Zuo XS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju052	58	7	7	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4844	4853		10.1038/s41388-020-1329-x	http://dx.doi.org/10.1038/s41388-020-1329-x		MAY 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32439863				2022-12-17	WOS:000534735300001
J	Yoneda, A; Minomi, K; Tamura, Y				Yoneda, Akihiro; Minomi, Kenjiro; Tamura, Yasuaki			HSP47 promotes metastasis of breast cancer by interacting with myosin IIA via the unfolded protein response transducer IRE1 alpha	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; CHAPERONE HSP47; ENDOPLASMIC-RETICULUM; IV COLLAGEN; EXPRESSION; INHIBITORS; INDUCTION; PROGNOSIS; PODOSOMES; APOPTOSIS	Breast cancer (BC) is an aggressive cancer that is a leading cause of cancer-associated death in women worldwide. Although increased expression of heat shock protein 47 (HSP47), a collagen-specific chaperone, is associated with the high malignancy of BC, its role in BC remains largely unclear. Here we show that a small population of high-invasive BC cells expresses HSP47 and that HSP47-positive high-invasive BC cells have a high metastatic potential that is completely abolished by disruption of HSP47. HSP47 interacts with non-muscle myosin IIA (NMIIA) via the unfolded protein response transducer IRE1 alpha, resulting in enhancement of the metastatic potential of high-invasive BC cells by augmenting the contractile force of actin filaments. Ablation of NMIIA abrogates the metastatic potential of HSP47-positive high-invasive BC cells. We further show that forced expression of NMIIA confers a high metastatic potential on low-invasive BC cells in which HSP47 but not NMIIA is expressed. Overall, our study indicates that HSP47 acts as a stimulator for metastasis of BC cells and suggest that HSP47 may be a candidate for a therapeutic target against BC.	[Yoneda, Akihiro; Minomi, Kenjiro; Tamura, Yasuaki] Hokkaido Univ, Ctr Food & Med Innovat, Inst Promot Business Reg Collaborat, Dept Mol Therapeut, Sapporo, Hokkaido 0010021, Japan; [Minomi, Kenjiro] Nitto Denko Corp, Nucle Acid Med Business Div, Res & Dev Dept, Sapporo, Hokkaido 0010021, Japan	Hokkaido University; Nitto Denko Corporation	Yoneda, A (corresponding author), Hokkaido Univ, Ctr Food & Med Innovat, Inst Promot Business Reg Collaborat, Dept Mol Therapeut, Sapporo, Hokkaido 0010021, Japan.	ayoneda@fmi.hokuida.ac.jp						Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Bachmeier BE, 2001, ANTICANCER RES, V21, P3821; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Conti MA, 2008, J CELL SCI, V121, P11, DOI 10.1242/jcs.007112; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Derycke L, 2011, INT J DEV BIOL, V55, P835, DOI 10.1387/ijdb.113336ld; Duarte BD, 2018, J CANCER RES CLIN, V144, P2319, DOI 10.1007/s00432-018-2739-9; Even-Ram S, 2007, NAT CELL BIOL, V9, P299, DOI 10.1038/ncb1540; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He Y, 2012, DEV CELL, V23, P1141, DOI 10.1016/j.devcel.2012.11.006; Honzawa Y, 2014, GUT, V63, P1902, DOI 10.1136/gutjnl-2013-305632; Ishida Y, 2006, MOL BIOL CELL, V17, P2346, DOI 10.1091/mbc.E05-11-1065; Ishiwata-Kimata Y, 2013, CELL STRUCT FUNCT, V38, P135, DOI 10.1247/csf.12033; Ito S, 2019, J BIOL CHEM, V294, P2133, DOI 10.1074/jbc.TM118.002812; Ito S, 2017, SEMIN CELL DEV BIOL, V62, P142, DOI 10.1016/j.semcdb.2016.11.005; Kawasaki K, 2015, J BIOL CHEM, V290, P3639, DOI 10.1074/jbc.M114.592139; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kohrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188; Kumar A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10740-0; Kumar A, 2015, PEERJ, V3, DOI 10.7717/peerj.1026; Li XX, 2017, ONCOGENE, V36, P6738, DOI 10.1038/onc.2017.284; Liu RG, 2017, INT J CLIN EXP PATHO, V10, P5498; Logue SE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05763-8; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Marutani T, 2004, J CELL SCI, V117, P5913, DOI 10.1242/jcs.01514; Matsuoka Y, 2004, MOL BIOL CELL, V15, P4467, DOI 10.1091/mbc.E04-01-0050; Mori K, 2017, INT J CANCER, V140, P1425, DOI 10.1002/ijc.30557; Newell-Litwa KA, 2015, DIS MODEL MECH, V8, P1495, DOI 10.1242/dmm.022103; Parveen A, 2019, GENOMICS, VS0888-7543, P30671; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Poschmann G, 2009, MOL CELL PROTEOMICS, V8, P1105, DOI 10.1074/mcp.M800422-MCP200; Ren FH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135544; Santagata S, 2012, ACS CHEM BIOL, V7, P339, DOI 10.1021/cb200353m; Sasaki H, 2002, J IMMUNOL, V168, P5178, DOI 10.4049/jimmunol.168.10.5178; Sepulveda D, 2018, MOL CELL, V69, P238, DOI 10.1016/j.molcel.2017.12.028; Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087; Vizoso FJ, 2007, BRIT J CANCER, V96, P903, DOI 10.1038/sj.bjc.6603666; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Xiong GF, 2020, P NATL ACAD SCI USA, V117, P3748, DOI 10.1073/pnas.1911951117; Yeo SK, 2017, TRENDS CANCER, V3, P753, DOI 10.1016/j.trecan.2017.09.001; Zhang X, 2010, INT J ONCOL, V36, P405, DOI 10.3892/ijo_00000513; Zhao D, 2014, J NEURO-ONCOL, V118, P39, DOI 10.1007/s11060-014-1412-7; Zhou PT, 2019, ONCOGENE, V38, P5500, DOI 10.1038/s41388-019-0806-6; Zhu JQ, 2015, CANCER RES, V75, P1580, DOI 10.1158/0008-5472.CAN-14-1027	47	7	7	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4519	4537		10.1038/s41388-020-1311-7	http://dx.doi.org/10.1038/s41388-020-1311-7		MAY 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32366908				2022-12-17	WOS:000530271400002
J	Boedicker, C; Hussong, M; Grimm, C; Dolgikh, N; Meister, MT; Enssle, JC; Wanior, M; Knapp, S; Schweiger, MR; Fulda, S				Boedicker, Cathinka; Hussong, Michelle; Grimm, Christina; Dolgikh, Nadezda; Meister, Michael T.; Enssle, Julius C.; Wanior, Marek; Knapp, Stefan; Schweiger, Michal R.; Fulda, Simone			Co-inhibition of BET proteins and PI3K alpha triggers mitochondrial apoptosis in rhabdomyosarcoma cells	ONCOGENE			English	Article							HEMATOLOGICAL MALIGNANCIES; BROMODOMAIN INHIBITORS; SYNTHETIC LETHALITY; GENE-EXPRESSION; IDENTIFICATION; HEDGEHOG; PATHWAY; RESISTANCE; KINASE; ACTIVATION	Remodeling transcription by targeting bromodomain and extraterminal (BET) proteins has emerged as promising anticancer strategy. Here, we identify a novel synergistic interaction of the BET inhibitor JQ1 with the PI3K alpha-specific inhibitor BYL719 to trigger mitochondrial apoptosis and to suppress tumor growth in models of rhabdomyosarcoma (RMS). RNA-Seq revealed that JQ1/BYL719 co-treatment shifts the overall balance of BCL-2 family gene expression towards apoptosis and upregulates expression of BMF, BCL2L11 (BIM), and PMAIP1 (NOXA) while downregulating BCL2L1 (BCL-x(L)). These changes were confirmed by qRT-PCR and western blot analysis. Ingenuity pathway analysis (IPA) of RNA-Seq data followed by validation qRT-PCR and western blot identified MYC and FOXO3a as potential transcription factors (TFs) upstream of the observed gene expression pattern. Immunoprecipitation (IP) studies showed that JQ1/BYL719-stimulated increase in BIM expression enhances the neutralization of antiapoptotic BCL-2, BCL-x(L), and MCL-1. This promotes the activation of BAK and BAX and caspase-dependent apoptosis, as (1) individual silencing of BMF, BIM, NOXA, BAK, or BAX, (2) overexpression of BCL-2 or MCL-1 or (3) the caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethylketone (zVAD.fmk) all rescue JQ1/BYL719-induced cell death. In conclusion, co-inhibition of BET proteins and PI3K alpha cooperatively induces mitochondrial apoptosis by proapoptotic re-balancing of BCL-2 family proteins. This discovery opens exciting perspectives for therapeutic exploitation of BET inhibitors in RMS.	[Boedicker, Cathinka; Dolgikh, Nadezda; Meister, Michael T.; Enssle, Julius C.; Fulda, Simone] Goethe Univ, Inst Expt Canc Res Pediat, Frankfurt, Germany; [Boedicker, Cathinka; Meister, Michael T.; Knapp, Stefan; Fulda, Simone] German Canc Consortium DKTK, Partner Site, Frankfurt, Germany; [Boedicker, Cathinka; Meister, Michael T.; Fulda, Simone] German Canc Res Ctr, Heidelberg, Germany; [Hussong, Michelle; Grimm, Christina; Schweiger, Michal R.] Univ Hosp Cologne, Lab Epigen & Tumor genet, Cologne, Germany; [Hussong, Michelle; Schweiger, Michal R.] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany; [Meister, Michael T.] Univ Hosp Frankfurt, Dept Pediat Hematol & Oncol, Frankfurt, Germany; [Wanior, Marek; Knapp, Stefan] Inst Pharmaceut Chem, Frankfurt, Germany; [Wanior, Marek; Knapp, Stefan] BMLS SGC, Frankfurt, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne; University of Cologne; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Fulda, S (corresponding author), Goethe Univ, Inst Expt Canc Res Pediat, Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Consortium DKTK, Partner Site, Frankfurt, Germany.; Fulda, S (corresponding author), German Canc Res Ctr, Heidelberg, Germany.	simone.fulda@kgu.de	Grimm, Christina/Z-6172-2019; Knapp, Stefan/AAG-2347-2019; Meister, Michael Torsten/AAV-2291-2021; Dolgikh, Nadezda/AAE-2893-2022	Grimm, Christina/0000-0002-4676-8870; Knapp, Stefan/0000-0001-5995-6494; Dolgikh, Nadezda/0000-0001-6186-007X; Meister, Michael Torsten/0000-0001-8311-721X; Fulda, Simone/0000-0002-0459-6417				Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Bid HK, 2016, MOL CANCER THER, V15, P1018, DOI 10.1158/1535-7163.MCT-15-0567; Chou T.C., 1991, SYNERGISM ANTAGONISM, P61; Ciceri P, 2014, NAT CHEM BIOL, V10, P305, DOI 10.1038/nchembio.1471; Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007; Czymai T, 2010, J BIOL CHEM, V285, P10163, DOI 10.1074/jbc.M109.056663; Da Costa D, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.24; Dagher R, 1999, Oncologist, V4, P34; Dantonello TM, 2013, PEDIATR BLOOD CANCER, V60, P224, DOI 10.1002/pbc.24174; Dittmann A, 2014, ACS CHEM BIOL, V9, P495, DOI 10.1021/cb400789e; Eijkelenboom A, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.74; Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286; Fiskus W, 2014, MOL CANCER THER, V13, P2315, DOI 10.1158/1535-7163.MCT-14-0258; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Graab U, 2015, ONCOTARGET, V6, P8722, DOI 10.18632/oncotarget.2726; Gryder BE, 2017, CANCER DISCOV, V7, P884, DOI 10.1158/2159-8290.CD-16-1297; Haydn T, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.239; Hayes-Jordan A, 2009, CURR OPIN PEDIATR, V21, P373, DOI 10.1097/MOP.0b013e32832b4171; Heinicke U, 2015, ONCOTARGET, V6, P37836, DOI 10.18632/oncotarget.6097; Heinicke U, 2014, CANCER LETT, V351, P50, DOI 10.1016/j.canlet.2014.04.021; Hensel T, 2016, ONCOTARGET, V7, P1451, DOI 10.18632/oncotarget.6385; Hornsveld M, 2016, CELL DEATH DIFFER, V23, P1483, DOI 10.1038/cdd.2016.33; Hugle M, 2015, CELL DEATH DIFFER, V22, P1946, DOI 10.1038/cdd.2015.59; Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162; Kuang WH, 2018, KAOHSIUNG J MED SCI, V34, P370, DOI 10.1016/j.kjms.2018.02.004; Lee DH, 2015, INT J CANCER, V136, P2055, DOI 10.1002/ijc.29269; Li GQ, 2016, ONCOTARGET, V7, P2462, DOI 10.18632/oncotarget.6275; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Ma YF, 2017, CLIN CANCER RES, V23, P2027, DOI 10.1158/1078-0432.CCR-16-0453; Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618; Packer LM, 2017, MOL CANCER THER, V16, P637, DOI 10.1158/1535-7163.MCT-16-0415; Satheesha S, 2016, ONCOGENE, V35, P2020, DOI 10.1038/onc.2015.267; Schaffer M, 2018, LEUKEMIA LYMPHOMA, V59, P931, DOI 10.1080/10428194.2017.1349899; Seal J, 2012, BIOORG MED CHEM LETT, V22, P2968, DOI 10.1016/j.bmcl.2012.02.041; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Tinsley S, 2015, BRIT J HAEMATOL, V170, P275, DOI 10.1111/bjh.13283; Toren P, 2015, EUR UROL, V67, P986, DOI 10.1016/j.eururo.2014.08.006; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zuber V, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3620-y	45	7	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3837	3852		10.1038/s41388-020-1229-0	http://dx.doi.org/10.1038/s41388-020-1229-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32161312				2022-12-17	WOS:000530841700004
J	Yang, XT; Hu, F; Liu, JA; Yu, S; Cheung, MPL; Liu, XL; Ng, IOL; Guan, XY; Wong, KKW; Sharma, R; Lung, HL; Jiao, YF; Lee, LTO; Cheung, M				Yang, Xintao; Hu, Feng; Liu, Jessica Aijia; Yu, Shan; Cheung, May Pui Lai; Liu, Xuelai; Ng, Irene Oi-Lin; Guan, Xin-Yuan; Wong, Kelvin K. W.; Sharma, Rakesh; Lung, Hong Lok; Jiao, Yufei; Lee, Leo Tsz On; Cheung, Martin			Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR PROTEIN; NEURAL CREST; TRANSCRIPTIONAL CONTROL; METASTASIS SUPPRESSOR; CELL INVASION; CANCER; PROMOTES; LIVER; GENE; PROLIFERATION	A Rho GTPase-activating protein (RhoGAP), deleted in liver cancer 1 (DLC1), is known to function as a tumor suppressor in various cancer types; however, whether DLC1 is a tumor-suppressor gene or an oncogene in melanoma remains to be clarified. Here we revealed that high DLC1 expression was detected in most of the melanoma tissues where it was localized in both the nuclei and the cytoplasm. Functional studies unveiled that DLC1 was both required and sufficient for melanoma growth and metastasis. These tumorigenic events were mediated by nuclear-localized DLC1 in a RhoGAP-independent manner. Mechanistically, mass spectrometry analysis identified a DLC1-associated protein, FOXK1 transcription factor, which mediated oncogenic events in melanoma by translocating and retaining DLC1 into the nucleus. RNA-sequencing profiling studies further revealed MMP9 as a direct target of FOXK1 through DLC1-regulated promoter occupancy for cooperative activation of MMP9 expression to promote melanoma invasion and metastasis. Concerted action of DLC1-FOXK1 in MMP9 gene regulation was further supported by their highly correlated expression in melanoma patients' samples and cell lines. Together, our results not only unravel a mechanism by which nuclear DLC1 functions as an oncogene in melanoma but also suggest an unexpected role of RhoGAP protein in transcriptional regulation.	[Yang, Xintao; Hu, Feng; Cheung, May Pui Lai; Cheung, Martin] Univ Hong Kong, Shenzhen Inst Res & Innovat HKU SIRI, Shenzhen, Peoples R China; [Yang, Xintao; Hu, Feng; Cheung, May Pui Lai; Cheung, Martin] Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Liu, Jessica Aijia] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anaesthesiol, Hong Kong, Peoples R China; [Yu, Shan; Lee, Leo Tsz On] Univ Macau, Canc Ctr, Fac Hlth Sci, Taipa, Macau, Peoples R China; [Liu, Xuelai] Hebei Med Univ, Dept Pediat Surg, Hosp 2, Shijiazhuang, Hebei, Peoples R China; [Ng, Irene Oi-Lin] Univ Hong Kong, Li Ka Shing Fac Med, State Key Lab Liver Res, Hong Kong, Peoples R China; [Ng, Irene Oi-Lin] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Peoples R China; [Guan, Xin-Yuan] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China; [Wong, Kelvin K. W.; Sharma, Rakesh] Univ Hong Kong, Li Ka Shing Fac Med, Ctr PanorOm Sci, Prote & Metab Core Facil, Hong Kong, Peoples R China; [Lung, Hong Lok] Hong Kong Baptist Univ, Dept Biol, Fac Sci, Hong Kong, Peoples R China; [Jiao, Yufei] Harbin Med Univ, Dept Pathol, Affiliated Hosp 2, Harbin, Peoples R China; [Lee, Leo Tsz On] Univ Macau, Ctr Reprod Dev & Aging, Fac Hlth Sci, Taipa, Macau, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Macau; Hebei Medical University; University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Hong Kong Baptist University; Harbin Medical University; University of Macau	Cheung, M (corresponding author), Univ Hong Kong, Shenzhen Inst Res & Innovat HKU SIRI, Shenzhen, Peoples R China.; Cheung, M (corresponding author), Univ Hong Kong, Sch Biomed Sci, Li Ka Shing Fac Med, Hong Kong, Peoples R China.	mcheung9@hku.hk	Lee, Leo T.O./AAB-1581-2021; Cheung, Martin Chi Hang/C-4235-2009	Sharma, Rakesh/0000-0002-5306-3457; Yang, Xintao/0000-0003-0364-9377; Ng, Irene Oi-lin/0000-0001-7532-2029; Liu, Jessica Aijia/0000-0002-9307-2235; Cheung, Martin Chi Hang/0000-0002-3471-8534; Hu, Feng/0000-0001-9605-7594	Research Grants Council of Hong Kong [GRF_17110715, GRF_17123016, GRF_17114817]; University Grants Council of Hong Kong [GRF_17110715, GRF_17123016, GRF_17114817]; National Natural Science Foundation of China [81972588]; University of Hong Kong [201409176166, 201611159243]; Government Matching Grant Scheme (6th Phase)	Research Grants Council of Hong Kong(Hong Kong Research Grants Council); University Grants Council of Hong Kong; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University of Hong Kong(University of Hong Kong); Government Matching Grant Scheme (6th Phase)	This work was supported by grants from the Research Grants Council and University Grants Council of Hong Kong (GRF_17110715, GRF_17123016, GRF_17114817), National Natural Science Foundation of China (81972588) as well as Small Project Fund (201409176166), Seed Fund for Basic Research (201611159243) from the University of Hong Kong, and Government Matching Grant Scheme (6th Phase).	Bailey CM, 2012, PIGM CELL MELANOMA R, V25, P573, DOI 10.1111/j.1755-148X.2012.01025.x; Barras D, 2014, CANCER METAST REV, V33, P87, DOI 10.1007/s10555-013-9458-0; Chan LK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025547; Cheung M, 2005, DEV CELL, V8, P179, DOI 10.1016/j.devcel.2004.12.010; Cronin JC, 2013, CANCER RES, V73, P5709, DOI 10.1158/0008-5472.CAN-12-4620; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Graf SA, 2014, J INVEST DERMATOL, V134, P2212, DOI 10.1038/jid.2014.128; Harris ML, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003644; Hill VK, 2013, ANNU REV GENOM HUM G, V14, P257, DOI 10.1146/annurev-genom-091212-153429; Huang XT, 2018, CELL PHYSIOL BIOCHEM, V47, P590, DOI 10.1159/000490015; Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD1284, DOI 10.1093/nar/gkx1188; Kim T, 2009, CANCER METAST REV, V28, P77, DOI 10.1007/s10555-008-9167-2; Kulesa PM, 2013, CELLS TISSUES ORGANS, V198, P12, DOI 10.1159/000348418; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Liao YC, 2008, INT J BIOCHEM CELL B, V40, P843, DOI 10.1016/j.biocel.2007.04.008; Liu JA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01107-0; Liu JA, 2016, DEV BIOL, V419, P199, DOI 10.1016/j.ydbio.2016.09.006; Low JSW, 2011, ONCOGENE, V30, P1923, DOI 10.1038/onc.2010.576; Monsonego-Ornan E, 2012, DEV BIOL, V364, P162, DOI 10.1016/j.ydbio.2012.01.028; Park H, 2015, P NATL ACAD SCI USA, V112, P12492, DOI 10.1073/pnas.1507491112; Peng Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.225; Pohl BS, 2004, DEV GENES EVOL, V214, P200, DOI 10.1007/s00427-004-0391-7; Popescu NC, 2014, MOL DIAGN THER, V18, P293, DOI 10.1007/s40291-014-0086-3; Potterf SB, 2001, DEV BIOL, V237, P245, DOI 10.1006/dbio.2001.0372; Scholz RP, 2009, J CELL SCI, V122, P92, DOI 10.1242/jcs.036251; Shakhova O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004877; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shi H, 2014, MELANOMA RES, V24, P99, DOI 10.1097/CMR.0000000000000043; Sjoestroem C, 2014, MODERN PATHOL, V27, P1203, DOI 10.1038/modpathol.2013.223; Tang ZY, 2013, CELL BIOL INT, V37, P849, DOI 10.1002/cbin.10107; Torres-Collado AX, 2018, CANCERS, V10, DOI 10.3390/cancers10060157; Tripathi BK, 2017, J CELL BIOL, V216, P4255, DOI 10.1083/jcb.201703105; Tripathi V, 2014, ONCOGENE, V33, P724, DOI 10.1038/onc.2013.7; Tripathi V, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-27; Wang DR, 2016, ONCOTARGET, V7, P45144, DOI 10.18632/oncotarget.9266; Wang WQ, 2015, DEV CELL, V32, P707, DOI 10.1016/j.devcel.2015.01.031; Wang YF, 2014, J CLIN INVEST, V124, P1646, DOI 10.1172/JCI71812; Wong CM, 2003, CANCER RES, V63, P7646; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Wu M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.68; Xu HT, 2018, EXP THER MED, V15, P3108, DOI 10.3892/etm.2018.5732; Yang XT, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0998-6; Yuan BZ, 2007, EXP CELL RES, V313, P3868, DOI 10.1016/j.yexcr.2007.08.009	46	7	8	3	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4061	4076		10.1038/s41388-020-1274-8	http://dx.doi.org/10.1038/s41388-020-1274-8		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32214200	Green Published, hybrid			2022-12-17	WOS:000521526300001
J	Williams, M; Liu, XH; Zhang, YQ; Reske, J; Bahal, D; Gohl, TG; Hollern, D; Ensink, E; Kiupel, M; Luo, RC; Das, R; Xiao, H				Williams, Mark; Liu, Xinhui; Zhang, Yueqi; Reske, Jake; Bahal, Devika; Gohl, Trevor G.; Hollern, Daniel; Ensink, Elliot; Kiupel, Matti; Luo, Rongcheng; Das, Rupali; Xiao, Hua			NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21(WAF1/CIP1) overexpression, which is reversed by metformin	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; NONALCOHOLIC STEATOHEPATITIS; DIABETIC-PATIENTS; GENE-EXPRESSION; T-CELLS; CANCER; TUMORIGENESIS; IL-6; P21; INFLAMMATION	Prevention and treatment options for hepatocellular carcinoma (HCC) are presently limited, underscoring the necessity for further elucidating molecular mechanisms underlying HCC development and identifying new prevention and therapeutic targets. Here, we demonstrate a unique protumorigenic niche in the livers of Ncoa5(+/)(-) mouse model of HCC, which is characterized by altered expression of a subset of genes including p21(WAF1/CIP1) and proinflammatory cytokine genes, increased putative hepatic progenitors, and expansions of activated and tissue-resident memory (TRM) CD8+ T lymphocytes, myeloid-derived suppressor cells (MDSCs), and alternatively activated M2 macrophages. Importantly, prophylactic metformin treatment reversed these characteristics including aberrant p21(WAF1/CIP1) expression and subsequently reduced HCC incidence in Ncoa5(+/-) male mice. Heterozygous deletion of the p21(WAF1/CIP1) gene alleviated the key features associated with the protumorigenic niche in the livers of Ncoa5(+/-) male mice. Moreover, transcriptomic analysis reveals that preneoplastic livers of Ncoa5(+/-) mice are similar to the livers of nonalcoholic steatohepatitis patients as well as the adjacent noncancerous liver tissues of a subset of HCC patients with a relatively poor prognosis. Together, our results suggest that p21(WAF1/CIP1) overexpression is essential in the development of protumorigenic microenvironment induced by NCOA5 deficiency and metformin prevents HCC development via alleviating p21(WAF1/CIP1) overexpression and protumorigenic microenvironment.	[Williams, Mark; Liu, Xinhui; Zhang, Yueqi; Reske, Jake; Gohl, Trevor G.; Ensink, Elliot; Das, Rupali; Xiao, Hua] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Williams, Mark; Zhang, Yueqi] Michigan State Univ, Cellular & Mol Biol Program, E Lansing, MI 48824 USA; [Liu, Xinhui; Luo, Rongcheng] Southern Med Univ, Canc Ctr, Guangzhou 510315, Guangdong, Peoples R China; [Liu, Xinhui] Southern Med Univ, Integrated Hosp Tradit Chinese Med, Guangzhou 510315, Guangdong, Peoples R China; [Bahal, Devika] Michigan State Univ, Comparat Med & Integrat Biol Program, E Lansing, MI 48824 USA; [Hollern, Daniel] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Kiupel, Matti] Michigan State Univ, Dept Pathobiol & Diagnost Invest, Lansing, MI 48910 USA; [Gohl, Trevor G.] Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Southern Medical University - China; Southern Medical University - China; Michigan State University; University of North Carolina; University of North Carolina Chapel Hill; Michigan State University; Michigan State University; Michigan State University College of Osteopathic Medicine	Xiao, H (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.	xiaoh@msu.edu		Bahal, Devika/0000-0002-4423-6387	National Cancer Institute [R01 CA188305, R21 CA185021]; NIH-NCI K22 award [5K22CA18814802]; NIH F32 student training fellowship [5 T32 GM 92715-3]; Integrated Hospital of Traditional Chinese Medicine, Southern Medical University	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH-NCI K22 award; NIH F32 student training fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Integrated Hospital of Traditional Chinese Medicine, Southern Medical University	This work was supported by the grants (R01 CA188305 and R21 CA185021) of National Cancer Institute to HX and a NIH-NCI K22 award (5K22CA18814802) to RD. MW was supported by a NIH F32 student training fellowship (5 T32 GM 92715-3). XL was partially supported by a fellowship from Integrated Hospital of Traditional Chinese Medicine, Southern Medical University. The authors thank J. Rennhack and E. Andrechek for sharing expertise in RNA-seq data analysis; E. Andrechek for manuscript comments; and members of the HX lab for helpful discussions. The results reported here are partially based on data generated by the TCGA Research Network: http://cancergenome.nih.gov, which we also gratefully acknowledge.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940-6207.CAPR-11-0536; Arendt BM, 2015, HEPATOLOGY, V61, P1565, DOI 10.1002/hep.27695; Bhalla K, 2012, CANCER PREV RES, V5, P544, DOI 10.1158/1940-6207.CAPR-11-0228; Cmielova J, 2011, J CELL BIOCHEM, V112, P3502, DOI 10.1002/jcb.23296; DePeralta DK, 2016, CANCER-AM CANCER SOC, V122, P1216, DOI 10.1002/cncr.29912; Dhar D, 2014, CELL METAB, V19, P6, DOI 10.1016/j.cmet.2013.12.010; Donadon V, 2010, LIVER INT, V30, P750, DOI 10.1111/j.1478-3231.2010.02223.x; Ehedego H, 2015, CANCER RES, V75, P1144, DOI 10.1158/0008-5472.CAN-14-1356; Eikawa S, 2015, P NATL ACAD SCI USA, V112, P1809, DOI 10.1073/pnas.1417636112; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finkin S, 2015, NAT IMMUNOL, V16, P1235, DOI 10.1038/ni.3290; Fujita K, 2016, WORLD J GASTROENTERO, V22, P6100, DOI 10.3748/wjg.v22.i27.6100; Gao SL, 2013, CANCER CELL, V24, P725, DOI 10.1016/j.ccr.2013.11.005; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gentles AJ, 2010, JAMA-J AM MED ASSOC, V304, P2706, DOI 10.1001/jama.2010.1862; Gerbes A, 2018, GUT, V67, P594, DOI 10.1136/gutjnl-2017-315068corr1; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; He GB, 2013, CELL, V155, P384, DOI 10.1016/j.cell.2013.09.031; Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110; Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014; Lee S, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0136385, 10.1371/journal.pone.0128448]; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu XH, 2017, CANCER LETT, V391, P152, DOI 10.1016/j.canlet.2017.01.028; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Luo XL, 2016, CELL REP, V17, P2979, DOI 10.1016/j.celrep.2016.11.048; Marhenke S, 2014, GUT, V63, P1501, DOI 10.1136/gutjnl-2013-304829; Molnar Z, 2014, INT J CHRONIC DIS, V2014, P327640; Nakagawa H, 2012, WORLD J GASTROENTERO, V18, P4071, DOI 10.3748/wjg.v18.i31.4071; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Nicolae CM, 2018, ONCOGENE, V37, P3647, DOI 10.1038/s41388-018-0219-y; Noren Hooten N, 2016, AGING CELL, V15, P572, DOI 10.1111/acel.12469; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Pauken KE, 2016, SCIENCE, V354, P1160, DOI 10.1126/science.aaf2807; Nguyen P, 2018, CELL REP, V24, P1597, DOI 10.1016/j.celrep.2018.07.014; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Rohr-Udilova N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24437-5; Schulte L, 2019, LIVER INT, V39, P714, DOI 10.1111/liv.14048; Shalapour S, 2017, NATURE, V551, P340, DOI 10.1038/nature24302; Sia D, 2017, GASTROENTEROLOGY, V153, P812, DOI 10.1053/j.gastro.2017.06.007; Tajima K, 2013, AM J PHYSIOL-ENDOC M, V305, pE987, DOI 10.1152/ajpendo.00133.2013; Tan XL, 2015, PANCREAS, V44, P636, DOI 10.1097/MPA.0000000000000308; Tomita K, 2012, J HEPATOL, V57, P837, DOI 10.1016/j.jhep.2012.05.013; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Verdura S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1633235; Villanueva A, 2015, HEPATOLOGY, V61, P1945, DOI 10.1002/hep.27732; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yano M, 2013, LIVER INT, V33, P1218, DOI 10.1111/liv.12176; Yu LX, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0048-z; Zheng CH, 2017, CELL, V169, P1342, DOI 10.1016/j.cell.2017.05.035	52	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3821	3836		10.1038/s41388-020-1256-x	http://dx.doi.org/10.1038/s41388-020-1256-x		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203160	Green Accepted			2022-12-17	WOS:000520614000002
J	He, YF; Mi, JQ; Olson, A; Aldahl, J; Hooker, E; Yu, EJ; Le, V; Lee, DH; Kim, WK; Robins, DM; Geradts, J; Sun, ZJ				He, Yongfeng; Mi, Jiaqi; Olson, Adam; Aldahl, Joseph; Hooker, Erika; Yu, Eun-Jeong; Le, Vien; Lee, Dong-Hoon; Kim, Won Kyung; Robins, Diane M.; Geradts, Joseph; Sun, Zijie			Androgen receptor with short polyglutamine tract preferably enhances Wnt/beta-catenin-mediated prostatic tumorigenesis	ONCOGENE			English	Article							BETA-CATENIN; CANCER; GENE; CAG; ACTIVATION; EXPRESSION; TRANSCRIPTION; PROGRESSION; POLYPOSIS; REPEATS	Polyglutamine (polyQ) tract polymorphism within the human androgen receptor (AR) shows population heterogeneity. African American men possess short polyQ tracts significantly more frequently than Caucasian American men. The length of polyQ tracts is inversely correlated with the risk of prostate cancer, age of onset, and aggressiveness at diagnosis. Aberrant activation of Wnt signaling also reveals frequently in advanced prostate cancer, and an enrichment of androgen and Wnt signaling activation has been observed in African American patients. Here, we assessed aberrant expression of AR bearing different polyQ tracts and stabilized beta-catenin in prostate tumorigenesis using newly generated mouse models. We observed an early onset oncogenic transformation, accelerated tumor cell growth, and aggressive tumor phenotypes in the compound mice bearing short polyQ tract AR and stabilized beta-catenin. RNA sequencing analysis showed a robust enrichment of Myc-regulated downstream genes in tumor samples bearing short polyQ AR versus those with longer polyQ tract AR. Upstream regulator analysis further identified Myc as the top candidate of transcriptional regulators in tumor cells from the above mouse samples with short polyQ tract AR and beta-catenin. Chromatin immunoprecipitation analyses revealed increased recruitment of beta-catenin and AR on the c-Myc gene regulatory locus in the tumor tissues expressing stabilized beta-catenin and shorter polyQ tract AR. These data demonstrate a promotional role of aberrant activation of Wnt/beta-catenin in combination with short polyQ AR expression in prostate tumorigenesis and suggest a potential mechanism underlying aggressive prostatic tumor development, which has been frequently observed in African American patients.	[He, Yongfeng; Mi, Jiaqi; Olson, Adam; Aldahl, Joseph; Hooker, Erika; Yu, Eun-Jeong; Le, Vien; Lee, Dong-Hoon; Kim, Won Kyung; Sun, Zijie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA; [Robins, Diane M.] Univ Michigan, Dept Human Genet, Sch Med, Ann Arbor, MI 48109 USA; [Geradts, Joseph] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA; [Geradts, Joseph] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	City of Hope; Beckman Research Institute of City of Hope; University of Michigan System; University of Michigan; City of Hope; Beckman Research Institute of City of Hope; Duke University	Sun, ZJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA.	zjsun@coh.org	He, Yongfeng/AAR-8257-2020; Mi, Jiaqi/GVU-4732-2022; le, vien/GWV-7308-2022	Mi, Jiaqi/0000-0002-6537-7795; Hooker, Erika/0000-0002-4515-4041; Olson, Adam W./0000-0003-3118-0393; Robins, Diane M./0000-0001-6727-6309	Public Health Service [R01CA070297, R01CA166894, R21CA190021, R01DK104941]	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service)	This work was supported by Public Health Service grants R01CA070297, R01CA166894, R21CA190021, and R01DK104941.	Albertelli MA, 2006, MOL ENDOCRINOL, V20, P1248, DOI 10.1210/me.2006-0021; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett CL, 2002, J CLIN ONCOL, V20, P3599, DOI 10.1200/JCO.2002.11.085; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Choong CS, 1998, J MOL ENDOCRINOL, V21, P235, DOI 10.1677/jme.0.0210235; Clark Peter E, 2003, Methods Mol Med, V81, P255; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P211, DOI 10.3322/caac.21555; Dess RT, 2019, JAMA ONCOL, V5, P975, DOI 10.1001/jamaoncol.2019.0826; Drost J, 2016, NAT PROTOC, V11, P347, DOI 10.1038/nprot.2016.006; FLEMING WH, 1986, CANCER RES, V46, P1535; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hsu F, 2006, BIOINFORMATICS, V22, P1036, DOI 10.1093/bioinformatics/btl048; IRVINE RA, 1995, CANCER RES, V55, P1937; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; Jenster G, 1999, SEMIN ONCOL, V26, P407; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kumar R, 2019, CANCER RES, V79, P1353, DOI 10.1158/0008-5472.CAN-18-2383; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Lee J, 2007, NUCLEIC ACIDS RES, V35, P4523, DOI 10.1093/nar/gkm476; Lee SH, 2016, ONCOGENE, V35, P702, DOI 10.1038/onc.2015.117; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; McNamara MA, 2019, PROSTATE, V79, P1106, DOI 10.1002/pros.23822; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Pan HF, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1352-3; Rennoll Sherri, 2015, World J Biol Chem, V6, P290, DOI 10.4331/wjbc.v6.i4.290; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sartor O, 1999, UROLOGY, V53, P378, DOI 10.1016/S0090-4295(98)00481-6; Shukla S, 2013, PROSTATE, V73, P1507, DOI 10.1002/pros.22698; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Spratt DE, 2016, EUR UROL FOCUS, V2, P532, DOI 10.1016/j.euf.2016.03.010; Stanford JL, 1997, CANCER RES, V57, P1194; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang BD, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/763569; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yu ZG, 2006, AM J PATHOL, V168, P195, DOI 10.2353/ajpath.2006.050619; Zhang L, 2012, TRANSGENIC RES, V21, P1117, DOI 10.1007/s11248-012-9598-y; Zheng CG, 2009, CANCER RES, V69, P2324, DOI 10.1158/0008-5472.CAN-08-4113; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	54	7	7	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3276	3291		10.1038/s41388-020-1214-7	http://dx.doi.org/10.1038/s41388-020-1214-7		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32089544	Green Accepted			2022-12-17	WOS:000515215100001
J	Lee, TH; Choi, JY; Park, JM; Kang, TH				Lee, Tae-Hee; Choi, Ji Ye; Park, Jeong-Min; Kang, Tae-Hong			Posttranscriptional control of the replication stress response via TTP-mediated Claspin mRNA stabilization	ONCOGENE			English	Article							DNA-DAMAGE CHECKPOINT; FORK STABILITY; CELL-CYCLE; TNF-ALPHA; TRISTETRAPROLIN; ATR; CHK1; EXPRESSION; DEGRADATION; ACTIVATION	ATR and CHK1 play key roles in the protection and recovery of the stalled replication forks. Claspin, an adaptor for CHK1 activation, is essential for DNA damage signaling and efficient replication fork progression. Here, we show that tristetraprolin (TTP), an mRNA-binding protein, can modulate the replication stress response via stabilization of Claspin mRNA. TTP depletion compromised specifically in the phosphorylation of CHK1, but not p53 or H2AX among other ATR substrates, and produced CHK1-defective replication phenotypes including accumulation of stalled replication forks. Importantly, the expression of siRNA-resistant TTP in TTP-deficient cells restored CHK1 phosphorylation and reduced the number of stalled replication forks as close to the control cells. Besides, we found that TTP was required for efficient replication fork progression even in the absence of exogenous DNA damage in a Claspin-dependent manner. Mechanistically, TTP was able to bind to the 3 '-untranslated region of Claspin mRNA to increase the stability of Claspin mRNA which eventually contributed to the subsequent ATR-CHK1 activation upon DNA damage. Taken together, our results revealed an intimate link between TTP-dependent Claspin mRNA stability and ATR-CHK1-dependent replication fork stability to maintain replication fork integrity and chromosomal stability.	[Lee, Tae-Hee; Choi, Ji Ye; Park, Jeong-Min; Kang, Tae-Hong] Dong A Univ, Dept Biol Sci, Busan 49315, South Korea	Dong A University	Kang, TH (corresponding author), Dong A Univ, Dept Biol Sci, Busan 49315, South Korea.	thkang@dau.ac.kr	Kang, Tae-Hong/Y-8294-2019	Kang, Tae-Hong/0000-0002-6013-900X; Lee, Tae-Hee/0000-0002-6263-6499	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education [NRF-2018R1D1A3B07043817, NRF-2015R1D1A1A01056994]	Basic Science Research Program through the National Research Foundation of Korea - Ministry of Education	We would like to thank Dr Sang-Eun Lee (UT Health San Antonio) for the insightful discussion and comments. We also thank JWP (University of Ulsan) for generous sharing of reagents. This research was supported by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2018R1D1A3B07043817 and NRF-2015R1D1A1A01056994).	Berglund AE, 2016, ONCOTARGET, V7, P83462, DOI 10.18632/oncotarget.13128; Bertoli C, 2016, CELL REP, V15, P1412, DOI 10.1016/j.celrep.2016.04.036; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bianco JN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08886-8; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003; Bye-A-Jee H, 2018, SKELET MUSCLE, V8, DOI 10.1186/s13395-018-0183-9; Carrick DM, 2007, ARCH BIOCHEM BIOPHYS, V462, P278, DOI 10.1016/j.abb.2007.04.011; Choi JY, 2016, ONCOTARGET, V7, P32980, DOI 10.18632/oncotarget.9087; Choi JY, 2015, ONCOTARGET, V6, P22575, DOI 10.18632/oncotarget.4610; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Ciais D, 2013, CELL MOL LIFE SCI, V70, P2031, DOI 10.1007/s00018-012-1150-y; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Freire R, 2006, CELL CYCLE, V5, P2831, DOI 10.4161/cc.5.24.3559; Gao DM, 2009, MOL BIOL CELL, V20, P3305, DOI 10.1091/mbc.E09-01-0092; Izawa N, 2011, CANCER RES, V71, P5621, DOI 10.1158/0008-5472.CAN-11-0385; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Kang TH, 2014, NUCLEIC ACIDS RES, V42, P4427, DOI 10.1093/nar/gku094; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Lee JM, 2016, BMB REP, V49, P566, DOI 10.5483/BMBRep.2016.49.10.097; Lee JY, 2013, NUCLEIC ACIDS RES, V41, P5614, DOI 10.1093/nar/gkt222; Lee TH, 2014, ONCOGENE, V33, P19, DOI 10.1038/onc.2012.539; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lindsey-Boltz LA, 2009, J BIOL CHEM, V284, P33107, DOI 10.1074/jbc.M109.064485; Ma XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179852; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; McGarry E, 2016, CANCER RES, V76, P2384, DOI 10.1158/0008-5472.CAN-15-2890; Oakes V, 2014, CELL CYCLE, V13, P3302, DOI 10.4161/15384101.2014.949111; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Park JM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113384; Park JM, 2015, BIOCHEM BIOPH RES CO, V461, P543, DOI 10.1016/j.bbrc.2015.04.071; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Petermann E, 2008, MOL BIOL CELL, V19, P2373, DOI 10.1091/mbc.E07-10-1035; Pfeiffer JR, 2012, J IMMUNOL, V188, P1828, DOI 10.4049/jimmunol.1102837; Rounbehler RJ, 2012, CELL, V150, P563, DOI 10.1016/j.cell.2012.06.033; Scorah J, 2009, CELL CYCLE, V8, P1036, DOI 10.4161/cc.8.7.8040; Seiler JA, 2007, MOL CELL BIOL, V27, P5806, DOI 10.1128/MCB.02278-06; Sercin O, 2011, CELL CYCLE, V10, P1599, DOI 10.4161/cc.10.10.15562; Shaltiel IA, 2015, J CELL SCI, V128, P607, DOI 10.1242/jcs.163766; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; Vesela E, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7010019; Wei ZR, 2016, ONCOTARGET, V7, P17737, DOI 10.18632/oncotarget.7397; Yang CC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12135; Yazinski SA, 2016, ANNU REV GENET, V50, P155, DOI 10.1146/annurev-genet-121415-121658; Yuan J, 2014, NUCLEIC ACIDS RES, V42, P13110, DOI 10.1093/nar/gku1034; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhu M, 2014, NUCLEIC ACIDS RES, V42, P13074, DOI 10.1093/nar/gku978	50	7	7	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3245	3257		10.1038/s41388-020-1220-9	http://dx.doi.org/10.1038/s41388-020-1220-9		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32086441				2022-12-17	WOS:000514942300001
J	Farhat, D; Ghayad, SE; Icard, P; Le Romancer, M; Hussein, N; Lincet, H				Farhat, Diana; Ghayad, Sandra E.; Icard, Philippe; Le Romancer, Muriel; Hussein, Nader; Lincet, Hubert			Lipoic acid-induced oxidative stress abrogates IGF-1R maturation by inhibiting the CREB/furin axis in breast cancer cell lines	ONCOGENE			English	Article							INDUCED APOPTOSIS; FURIN EXPRESSION; GROWTH; PROLIFERATION; ACTIVATION; TUMORS	The beneficial effects of lipoic acid (LA) in cancer treatment have been well documented in the last decade. Indeed, LA exerts crucial antiproliferative effects by reducing breast cancer cell viability, cell cycle progression and the epithelial-to-mesenchymal transition (EMT). However, the mechanisms of action (MOA) underlying these antiproliferative effects remain to be elucidated. Recently, we demonstrated that LA decreases breast cancer cell proliferation by inhibiting IGF-1R maturation via the downregulation of the proprotein convertase furin. The aim of the present study was to investigate the MOA by which LA inhibits furin expression in estrogen receptor alpha (ER alpha) (+) and (-) breast cancer cell lines. We unveil that LA exerts a pro-oxidant effect on these cell lines, the resulting reactive oxygen species (ROS) generated being responsible for the reduction in the expression of the major (CREB) protein. This transcription factor is overexpressed in many types of cancers and regulates the expression of furin in breast cancer cells independently of ER alpha, as evidenced herein by the inhibition of furin expression following CREB silencing. Consequently, our findings expose for the first time the complete MOA of LA via the CREB/furin axis leading to inhibition of breast cancer cell proliferation.	[Farhat, Diana; Le Romancer, Muriel; Lincet, Hubert] Univ Lyon 1, Lyon, France; [Farhat, Diana; Le Romancer, Muriel; Lincet, Hubert] CRCL, INSERM, U1052, Lyon, France; [Farhat, Diana; Le Romancer, Muriel; Lincet, Hubert] CRCL, CNRS, UMR5286, Lyon, France; [Farhat, Diana; Hussein, Nader] Lebanese Univ, Fac Sci, Canc Biol Stem Cells & Mol Immunol, Hadath Beirut, Lebanon; [Ghayad, Sandra E.] Lebanese Univ, Fac Sci 2, Dept Biol, Fanar, Lebanon; [Icard, Philippe] Normandie Univ, UNICAEN, CHU Caen Normandie, Unite Rech,BioTICLA,INSERM,U119, F-14000 Caen, France; [Icard, Philippe] Hop Cochin, Hop Univ Paris Ctr, Serv Chirurg Thorac, Paris, France; [Lincet, Hubert] Fac Pharm, ISPB, Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Centre de Recherche en cancerologie (CRCL); Lebanese University; Lebanese University; CHU de Caen NORMANDIE; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Caen Normandie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Lincet, H (corresponding author), Univ Lyon 1, Lyon, France.; Lincet, H (corresponding author), CRCL, INSERM, U1052, Lyon, France.; Lincet, H (corresponding author), CRCL, CNRS, UMR5286, Lyon, France.; Lincet, H (corresponding author), Fac Pharm, ISPB, Lyon, France.	hubert.lincet@univ-lyon1.fr		Le Romancer, Muriel/0000-0002-8491-4015	National Council for Scientific Research in Lebanon CNRS-L; Lebanese University; Canceropole Lyon Auvergne Rhone-Alpes (CLARA); CNRS-L	National Council for Scientific Research in Lebanon CNRS-L; Lebanese University; Canceropole Lyon Auvergne Rhone-Alpes (CLARA); CNRS-L	This project has been jointly supported by the National Council for Scientific Research in Lebanon CNRS-L and Lebanese University and Canceropole Lyon Auvergne Rhone-Alpes (CLARA). DF was the recipient of a fellowship from the CNRS-L and Lebanese University.	Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; Cheng M, 2001, J MOL ENDOCRINOL, V26, P95, DOI 10.1677/jme.0.0260095; Choi SY, 2009, ANN NY ACAD SCI, V1171, P149, DOI 10.1111/j.1749-6632.2009.04708.x; Farhat D, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2019.188317; Farhat D, 2020, BRIT J CANCER, V122, P885, DOI 10.1038/s41416-020-0729-6; Fu XH, 2019, MOL MED REP, V19, P3649, DOI 10.3892/mmr.2019.10027; Ireland L, 2018, ONCOGENE, V37, P2022, DOI 10.1038/s41388-017-0115-x; Jaaks P, 2017, INT J CANCER, V141, P654, DOI 10.1002/ijc.30714; Jaaks P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161396; Jeon MJ, 2016, MOL CELL ENDOCRINOL, V419, P113, DOI 10.1016/j.mce.2015.10.005; Kafara P, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0165-z; Kono Y, 2012, EXPERT OPIN THER TAR, V16, pS103, DOI 10.1517/14728222.2011.640320; Lapierre M, 2007, CANCER RES, V67, P9030, DOI 10.1158/0008-5472.CAN-07-0807; Lee HS, 2010, NUTR RES, V30, P403, DOI 10.1016/j.nutres.2010.06.009; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; Moungjaroen J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI 10.1124/jpet.106.110965; Na MH, 2009, NUTR RES PRACT, V3, P265, DOI 10.4162/nrp.2009.3.4.265; Riedemann J, 2006, ENDOCR-RELAT CANCER, V13, pS33, DOI 10.1677/erc.1.01280; Sachdev D, 2004, J BIOL CHEM, V279, P5017, DOI 10.1074/jbc.M305403200; Selvakumar E, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-4; Shi DY, 2008, FEBS LETT, V582, P1667, DOI 10.1016/j.febslet.2008.04.021; Simbula G, 2007, APOPTOSIS, V12, P113, DOI 10.1007/s10495-006-0487-9; Smyth IM, 2019, SEMIN CELL DEV BIOL, V91, P84, DOI 10.1016/j.semcdb.2018.11.003; Steven A, 2016, ONCOTARGET, V7, P35454, DOI 10.18632/oncotarget.7721; Tripathy J, 2018, LIFE SCI, V207, P15, DOI 10.1016/j.lfs.2018.05.039; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; Wang BY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047053; Ward CW, 2001, J CLIN PATHOL-MOL PA, V54, P125; Wenzel U, 2005, APOPTOSIS, V10, P359, DOI 10.1007/s10495-005-0810-x; Yang XK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050479; Zhou Z, 2014, PLACENTA, V35, P907, DOI 10.1016/j.placenta.2014.07.017; ZIEGLER D, 1995, DIABETOLOGIA, V38, P1425, DOI 10.1007/BF00400603	34	7	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	17					3604	3610		10.1038/s41388-020-1211-x	http://dx.doi.org/10.1038/s41388-020-1211-x		FEB 2020	7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LH1YK	32060422				2022-12-17	WOS:000513384600003
J	Lazarian, G; Friedrich, C; Quinquenel, A; Tran, J; Ouriemmi, S; Dondi, E; Martin, A; Mihoub, I; Chiron, D; Bellanger, C; Fleury, C; Gelebart, P; McCormack, E; Ledoux, D; Thieblemont, C; Marzec, J; Gribben, JG; Cymbalista, F; Varin-Blank, N; Gardano, L; Baran-Marszak, F				Lazarian, Gregory; Friedrich, Chloe; Quinquenel, Anne; Tran, Julie; Ouriemmi, Souhail; Dondi, Elisabetta; Martin, Antoine; Mihoub, Imane; Chiron, David; Bellanger, Celine; Fleury, Carole; Gelebart, Pascal; McCormack, Emmet; Ledoux, Dominique; Thieblemont, Catherine; Marzec, Jacek; Gribben, John G.; Cymbalista, Florence; Varin-Blank, Nadine; Gardano, Laura; Baran-Marszak, Fanny			Stabilization of beta-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma	ONCOGENE			English	Article							KAPPA-B; WNT/BETA-CATENIN; SYNTHASE KINASE-3; CYCLIN D1; CONSTITUTIVE ACTIVATION; PATHWAY; WNT; INHIBITION; EXPRESSION; AKT	B-cell receptor (BCR) signaling pathways and interactions with the tumor microenvironment account for mantle cell lymphoma (MCL) cells survival in lymphoid organs. In several MCL cases, the WNT/beta-catenin canonical pathway is activated and beta-catenin accumulates into the nucleus. As both BCR and beta-catenin are important mediators of cell survival and interaction with the microenvironment, we investigated the crosstalk between BCR and WNT/beta-catenin signaling and analyzed their impact on cellular homeostasis as well as their targeting by specific inhibitors. beta-catenin was detected in all leukemic MCL samples and its level of expression rapidly increased upon BCR stimulation. This stabilization was hampered by the BCR-pathway inhibitor Ibrutinib, supporting beta-catenin as an effector of the BCR signaling. In parallel, MCL cells as compared with normal B cells expressed elevated levels of WNT16, a NF-kappa B target gene. Its expression increased further upon BCR stimulation to participate to the stabilization of beta-catenin. Upon BCR stimulation, beta-catenin translocated into the nucleus but did not induce a Wnt-like transcriptional response, i.e., TCF/LEF dependent. beta-catenin rather participated to the regulation of NF-kappa B transcriptional targets, such as IL6, IL8, and IL1. Oligo pull down and chromatin immunoprecipitation experiments demonstrated that beta-catenin is part of a protein complex that binds the NF-kappa B DNA consensus sequence, strengthening the idea of an association between the two proteins. An inhibitor targeting beta-catenin transcriptional interactions hindered both NF-kappa B DNA recruitment and induced primary MCL cells apoptosis. Thus, beta-catenin likely represents another player through which BCR signaling impacts on MCL cell survival.	[Lazarian, Gregory; Friedrich, Chloe; Quinquenel, Anne; Tran, Julie; Ouriemmi, Souhail; Dondi, Elisabetta; Martin, Antoine; Mihoub, Imane; Fleury, Carole; Ledoux, Dominique; Cymbalista, Florence; Varin-Blank, Nadine; Gardano, Laura; Baran-Marszak, Fanny] INSERM, U978, Bobigny, France; [Lazarian, Gregory; Friedrich, Chloe; Quinquenel, Anne; Tran, Julie; Ouriemmi, Souhail; Dondi, Elisabetta; Martin, Antoine; Mihoub, Imane; Fleury, Carole; Ledoux, Dominique; Cymbalista, Florence; Varin-Blank, Nadine; Gardano, Laura; Baran-Marszak, Fanny] Univ Paris 13, Sorbonne Paris Cite, Labex Inflamex, Bobigny, France; [Lazarian, Gregory; Fleury, Carole; Cymbalista, Florence; Baran-Marszak, Fanny] Hop Avicenne, Assistance Publ Hop Paris, Serv Hematol Biol, Bobigny, France; [Martin, Antoine] Hop Avicenne, Assistance Publ Hop Paris, Serv Anatomopathol, Bobigny, France; [Chiron, David; Bellanger, Celine] Univ Nantes, CNRS, U1232 INSERM, Ctr Rech Cancerol & Immunol Nantes Angers,ERL6001, Nantes, France; [Gelebart, Pascal; McCormack, Emmet] Univ Bergen, Dept Clin Sci, Bergen, Norway; [Thieblemont, Catherine] Hop St Louis, Assistance Publ Hop Paris, Hematol, Paris, France; [Marzec, Jacek] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic, Australia; [Gribben, John G.] Queen Mary Univ London, Barts Canc Inst, London, England	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS); Nantes Universite; University of Bergen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; University of Melbourne; University of London; Queen Mary University London	Varin-Blank, N; Baran-Marszak, F (corresponding author), INSERM, U978, Bobigny, France.; Varin-Blank, N; Baran-Marszak, F (corresponding author), Univ Paris 13, Sorbonne Paris Cite, Labex Inflamex, Bobigny, France.; Baran-Marszak, F (corresponding author), Hop Avicenne, Assistance Publ Hop Paris, Serv Hematol Biol, Bobigny, France.	nadine.varin@inserm.fr; fanny.baran-marszak@aphp.fr	Cormack, Emmet Mc/D-2922-2012; Gelebart, Pascal/AAI-1439-2020; Thieblemont, Catherine/AAZ-8423-2020	Cormack, Emmet Mc/0000-0002-7621-4625; Gelebart, Pascal/0000-0003-2434-8987; Thieblemont, Catherine/0000-0002-9941-2448; VARIN-BLANK, Nadine/0000-0003-2769-018X; Dondi, Elisabetta/0000-0003-0975-459X; Lazarian, Gregory/0000-0002-4315-3440; LEDOUX, DOMINIQUE/0000-0002-5886-2266; Marzec, Jacek/0000-0001-6577-8866	APHP; Jansen fellowship; INSERM; Labex INFLAMEX [ANR11 IDEX00502]; University Paris 13	APHP; Jansen fellowship; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Labex INFLAMEX; University Paris 13	CF was the recipient of a "Annee Recherche" support from APHP. AQ was the recipient of a Jansen fellowship. This project was funded by a "Bonus Qualite Recherche" grant from University Paris 13 and benefited from the financial support of INSERM, University Paris 13 and the Labex INFLAMEX, contract ANR11 IDEX00502. We thank Dr C. Leroy for reading the manuscript, Dr L. Guittat for helpful discussion during the experimental work and Dr B. Papp for initiating collaboration with Dr P. Gelebart.	Argatoff LH, 1997, BLOOD, V89, P2067, DOI 10.1182/blood.V89.6.2067; Baran-Marszak F, 2010, HAEMATOL-HEMATOL J, V95, P1865, DOI 10.3324/haematol.2009.019745; Bernard S, 2015, INT J CANCER, V136, P2761, DOI 10.1002/ijc.29326; Bognar MK, 2016, ONCOGENE, V35, P4269, DOI 10.1038/onc.2015.493; BOSCH F, 1994, BLOOD, V84, P2726; Boukhiar MA, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-4; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Christian SL, 2002, J IMMUNOL, V169, P758, DOI 10.4049/jimmunol.169.2.758; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dal Col J, 2008, CELL CYCLE, V7, P2813, DOI 10.4161/cc.7.18.6733; de Rooij MFM, 2015, BLOOD, V125, P2306, DOI 10.1182/blood-2014-12-619163; Gandhirajan RK, 2010, CURR CANCER DRUG TAR, V10, P716; Gelebart P, 2008, BLOOD, V112, P5171, DOI 10.1182/blood-2008-02-139212; Gold MR, 1999, J IMMUNOL, V163, P1894; Gold MR, 2000, IMMUNOL REV, V176, P47; GOODE N, 1992, J BIOL CHEM, V267, P16878; Hadzidimitriou A, 2011, BLOOD, V118, P3088, DOI 10.1182/blood-2011-03-343434; Hallett RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033976; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Khan NI, 2007, BRIT J HAEMATOL, V138, P338, DOI 10.1111/j.1365-2141.2007.06667.x; Kimura Y, 2013, INT J ONCOL, V43, P457, DOI 10.3892/ijo.2013.1982; Koopmans T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01086; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lindvall J, 2002, BIOCHEM BIOPH RES CO, V293, P1319, DOI 10.1016/S0006-291X(02)00382-0; Lovatt M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012794; Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378; Mathur R, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0161-1; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Orchard J, 2003, BLOOD, V101, P4975, DOI 10.1182/blood-2002-06-1864; Perez-Galan P, 2011, BLOOD, V117, P26, DOI 10.1182/blood-2010-04-189977; Raskatov JA, 2012, P NATL ACAD SCI USA, V109, P1023, DOI 10.1073/pnas.1118506109; Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x; Saba NS, 2016, BLOOD, V128, P82, DOI 10.1182/blood-2015-11-681460; Spaargaren M, 2015, ONCOGENE, V34, P2426, DOI 10.1038/onc.2014.181; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Zhang XQ, 2015, AM J CANCER RES, V5, P2344	45	7	8	4	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2934	2947		10.1038/s41388-020-1183-x	http://dx.doi.org/10.1038/s41388-020-1183-x		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32034308				2022-12-17	WOS:000511752600004
J	Ali, S; Zhang, YL; Zhou, M; Li, HZ; Jin, WW; Zheng, L; Yu, XC; Stark, JM; Weitzel, JN; Shen, BH				Ali, Shafat; Zhang, Yilan; Zhou, Mian; Li, Hongzhi; Jin, Weiwei; Zheng, Li; Yu, Xiaochun; Stark, Jeremy M.; Weitzel, Jeffrey N.; Shen, Binghui			Functional deficiency of DNA repair gene EXO5 results in androgen-induced genomic instability and prostate tumorigenesis	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; DELETERIOUS MUTATIONS; SUSCEPTIBILITY LOCI; WIDE ASSOCIATION; END RESECTION; CANCER; MRE11; RISK; IDENTIFICATION	Germline mutations of DNA double-strand break (DSB) response and repair genes that drive tumorigenesis could be a major cause of prostate cancer (PCa) heritability. In this study, we demonstrated the role of novel exonuclease 5 (EXO5) gene in androgen-induced double strand breaks repair via homology-directed repair pathway and prostate tumorigenesis. Using whole-exome sequencing of samples from 20 PCa families, with three or more siblings diagnosed with metastatic PCa, we identified mutations in 31 genes involved in DSB response and repair. Among them, the L151P mutation in the exonuclease 5 (EXO5) gene was present in all affected siblings in three PCa families. We found two other EXO5 SNPs significantly associated with risk of PCa in cases-controls study from databases of genotype and phenotype (dbGaP), which are in linkage disequilibrium (D ' = 1) with Exo5 L151P found in PCa family. The L151 residue is conserved across diverse species and its mutation is deleterious for protein functions, as demonstrated by our bioinformatics analyses. The L151P mutation impairs the DNA repair function of EXO5 due to loss of nuclease activity, as well as failure of nuclear localization. CRISPR elimination of EXO5 in a PCa cell line impaired homology-directed recombination repair (HDR) and caused androgen-induced genomic instability, as indicated by frequent occurrence of the oncogenic fusion transcript TMPRSS2-ERG. Genetic and functional validation of the EXO5 mutations indicated that EXO5 is a risk gene for prostate tumorigenesis, likely due to its functions in HDR.	[Ali, Shafat; Zhang, Yilan; Zhou, Mian; Jin, Weiwei; Zheng, Li; Yu, Xiaochun; Stark, Jeremy M.; Shen, Binghui] City Hope Natl Med Ctr, Dept Canc Genet & Epigenet, Beckman Res Inst, Duarte, CA 91010 USA; [Li, Hongzhi] City Hope Natl Med Ctr, Dept Mol Med, Beckman Res Inst, Duarte, CA USA; [Weitzel, Jeffrey N.] City Hope Natl Med Ctr, Dept Populat Sci, Beckman Res Inst, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Shen, BH (corresponding author), City Hope Natl Med Ctr, Dept Canc Genet & Epigenet, Beckman Res Inst, Duarte, CA 91010 USA.	bshen@coh.org		Shen, Binghui/0000-0002-4408-407X	National Cancer Institute of the National Institutes of Health [P30CA033572]; City of Hope institutional Excellence Award	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); City of Hope institutional Excellence Award	We acknowledge Dr. Theodore Krontiris and Dr. Ching Ouyang in City of Hope for providing the genomic DNA samples of prostate cancer families. We thank Charles Warden and Dr. Xiwei Wu for their help in genomic data deposition. Drs. Keely Walker and Kerin K. Higa for proofreading the manuscript. Research reported in this publication included work performed in the Computational Therapeutics and Integrative Genomics core facilities, which are supported by the National Cancer Institute of the National Institutes of Health under award number P30CA033572. The work was partially supported by City of Hope institutional Excellence Award to B.H.S.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Al Olama AA, 2014, NAT GENET, V46, P1103, DOI 10.1038/ng.3094; Al Olama AA, 2013, HUM MOL GENET, V22, P408, DOI 10.1093/hmg/dds425; Alvarez-Quilon A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4347; Andres-Leon E, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw123; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132; Broderick R, 2016, NAT CELL BIOL, V18, P271, DOI 10.1038/ncb3303; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cejka P, 2015, J BIOL CHEM, V290, P22931, DOI 10.1074/jbc.R115.675942; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CC, 2017, DNA REPAIR, V57, P98, DOI 10.1016/j.dnarep.2017.07.003; Chun S, 2009, GENOME RES, V19, P1553, DOI 10.1101/gr.092619.109; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; Forment JV, 2012, CYTOM PART A, V81A, P922, DOI 10.1002/cyto.a.22155; Garcia V, 2011, NATURE, V479, P241, DOI 10.1038/nature10515; Gudmundsson J, 2012, NAT GENET, V44, P1326, DOI 10.1038/ng.2437; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Howard SM, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004943; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; Leongamornlert D, 2014, BRIT J CANCER, V110, P1663, DOI 10.1038/bjc.2014.30; Liao SR, 2016, NUCLEIC ACIDS RES, V44, P5689, DOI 10.1093/nar/gkw274; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Milanowska K, 2011, NUCLEIC ACIDS RES, V39, pD788, DOI 10.1093/nar/gkq1087; Mimitou EP, 2008, NATURE, V455, P770, DOI 10.1038/nature07312; Mucci LA, 2016, JAMA-J AM MED ASSOC, V315, P68, DOI 10.1001/jama.2015.17703; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; Hoa NN, 2016, MOL CELL, V64, P580, DOI 10.1016/j.molcel.2016.10.011; Nussenzweig A, 2010, CELL, V141, P27, DOI 10.1016/j.cell.2010.03.016; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Reva B, 2011, NUCL ACIDS RES, V39, pe118; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Schumacher FR, 2011, HUM MOL GENET, V20, P3867, DOI 10.1093/hmg/ddr295; Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575; Sishc BJ, 2017, CANCERS, V9, DOI 10.3390/cancers9070081; Sparks JL, 2012, J BIOL CHEM, V287, P42773, DOI 10.1074/jbc.M112.422444; St John Jason, 2012, J Cancer Sci Ther, V4, P94; Stanford JL, 2001, EPIDEMIOL REV, V23, P19, DOI 10.1093/oxfordjournals.epirev.a000789; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wilson S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32611; Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007; Yeager M, 2009, NAT GENET, V41, P1055, DOI 10.1038/ng.444; Zheng SL, 2006, PROSTATE, V66, P1556, DOI 10.1002/pros.20496; Zhu Z, 2008, CELL, V134, P981, DOI 10.1016/j.cell.2008.08.037	57	7	7	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1246	1259		10.1038/s41388-019-1061-6	http://dx.doi.org/10.1038/s41388-019-1061-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31616062	Green Accepted			2022-12-17	WOS:000526714600006
J	Dai, K; Tanaka, M; Kamiyoshi, A; Sakurai, T; Ichikawa-Shindo, Y; Kawate, H; Cui, NQ; Wei, YX; Tanaka, M; Kakihara, S; Matsui, S; Shindo, T				Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Tanaka, Masaaki; Kakihara, Shinji; Matsui, Shuhei; Shindo, Takayuki			Deficiency of the adrenomedullin-RAMP3 system suppresses metastasis through the modification of cancer-associated fibroblasts	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; SQUAMOUS-CELL CARCINOMAS; PANCREATIC-CANCER; POOR-PROGNOSIS; VASCULAR INTEGRITY; BREAST-CANCER; UP-REGULATION; PODOPLANIN; EXPRESSION; INVASION	Tumor metastasis is a primary source of morbidity and mortality in cancer. Adrenomedullin (AM) is a multifunctional peptide regulated by receptor activity-modifying proteins (RAMPs). We previously reported that the AM-RAMP2 system is involved in tumor angiogenesis, but the function of the AM-RAMP3 system remains largely unknown. Here, we investigated the actions of the AM-RAMP2 and 3 systems in the tumor microenvironment and their impact on metastasis. PAN02 pancreatic cancer cells were injected into the spleens of mice, leading to spontaneous liver metastasis. Tumor metastasis was enhanced in vascular endothelial cell-specific RAMP2 knockout mice (DI-E-RAMP2-/-). By contrast, metastasis was suppressed in RAMP3-/- mice, where the number of podoplanin (PDPN)-positive cancer-associated fibroblasts (CAFs) was reduced in the periphery of tumors at metastatic sites. Because PDPN-positive CAFs are a hallmark of tumor malignancy, we assessed the regulation of PDPN and found that Src/Cas/PDPN signaling is mediated by RAMP3. In fact, RAMP3 deficiency CAFs suppressed migration, proliferation, and metastasis in co-cultures with tumor cells in vitro and in vivo. Moreover, the activation of RAMP2 in RAMP3-/- mice suppressed both tumor growth and metastasis. Based on these results, we suggest that the upregulation of PDPN in DI-E-RAMP2-/- mice increases malignancy, while the downregulation of PDPN in RAMP3-/- mice reduces it. Selective activation of RAMP2 and inhibition of RAMP3 would therefore be expected to suppress tumor metastasis. This study provides the first evidence that understanding and targeting to AM-RAMP systems could contribute to the development of novel therapeutics against metastasis.	[Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Tanaka, Masaaki; Kakihara, Shinji; Matsui, Shuhei; Shindo, Takayuki] Shinshu Univ, Interdisciplinary Cluster Cutting Edge Res, Inst Biomed Sci, Dept Life Innovat, Matsumoto, Nagano 3908621, Japan; [Dai, Kun; Tanaka, Megumu; Kamiyoshi, Akiko; Sakurai, Takayuki; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Cui, Nanqi; Wei, Yangxuan; Shindo, Takayuki] Shinshu Univ, Sch Med, Dept Cardiovasc Res, Matsumoto, Nagano 3908621, Japan; [Tanaka, Masaaki; Kakihara, Shinji] Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan; [Matsui, Shuhei] Shinshu Univ, Sch Med, Dept Anesthesiol, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University	Shindo, T (corresponding author), Shinshu Univ, Interdisciplinary Cluster Cutting Edge Res, Inst Biomed Sci, Dept Life Innovat, Matsumoto, Nagano 3908621, Japan.; Shindo, T (corresponding author), Shinshu Univ, Sch Med, Dept Cardiovasc Res, Matsumoto, Nagano 3908621, Japan.	tshindo@shinshu-u.ac.jp	Kakihara, Shinji/AAR-1855-2021	Kakihara, Shinji/0000-0002-8433-8169	Core Research for Evolutionary Science and Technology (CREST) of Japan Science and Technology Agency (JST); Japan Agency for Medical Research and Development (AMED); Bristol-Myers Squibb Company; Japan Foundation for Applied Enzymology; Naito Foundation; Public Foundation of Chubu Science and Technology Center; Yamaguchi Endocrine Research Foundation; Hoyu Science Foundation; Takahashi Industrial and Economic Research Foundation; Akaeda Medical Research Foundation; Shinshu Public Utility Foundation for Promotion of Medial Sciences; Japan Heart Foundation; Otsuka Toshimi Scholarship Foundation	Core Research for Evolutionary Science and Technology (CREST) of Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Bristol-Myers Squibb Company(Bristol-Myers Squibb); Japan Foundation for Applied Enzymology; Naito Foundation(Naito Memorial Foundation); Public Foundation of Chubu Science and Technology Center; Yamaguchi Endocrine Research Foundation; Hoyu Science Foundation; Takahashi Industrial and Economic Research Foundation; Akaeda Medical Research Foundation; Shinshu Public Utility Foundation for Promotion of Medial Sciences; Japan Heart Foundation; Otsuka Toshimi Scholarship Foundation(Otsuka Pharmaceutical)	This study was supported by Grants-in-Aid for Scientific Research (KAKENHI) from the Core Research for Evolutionary Science and Technology (CREST) of Japan Science and Technology Agency (JST) and the Japan Agency for Medical Research and Development (AMED), and research grants from Bristol-Myers Squibb Company, Japan Foundation for Applied Enzymology, the Naito Foundation, the Public Foundation of Chubu Science and Technology Center, Yamaguchi Endocrine Research Foundation, Hoyu Science Foundation, Takahashi Industrial and Economic Research Foundation, Akaeda Medical Research Foundation, Shinshu Public Utility Foundation for Promotion of Medial Sciences, and Japan Heart Foundation. KD received a scholarship from Otsuka Toshimi Scholarship Foundation. The authors are grateful to Prof. Sachie Hiratsuka for valuable comments and tumor cells.	Aoki M, 2011, BRIT J CANCER, V104, P714, DOI 10.1038/sj.bjc.6606075; Berenguer-Daize C, 2013, CLIN CANCER RES, V19, P6138, DOI 10.1158/1078-0432.CCR-13-0691; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Conner MT, 2010, BIOCHEMISTRY-US, V49, P821, DOI 10.1021/bi902068b; Dauer P, 2018, CANCER RES, V78, P1321, DOI 10.1158/0008-5472.CAN-17-2320; Desmouliere A, 2004, INT J DEV BIOL, V48, P509, DOI 10.1387/ijdb.041802ad; Desmouliere A, 2003, LAB INVEST, V83, P1689, DOI 10.1097/01.LAB.0000101911.53973.90; Friedman SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004700; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hikosaka T, 2011, PEPTIDES, V32, P1825, DOI 10.1016/j.peptides.2011.07.012; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hirabayashi K, 2019, AM J PATHOL, V189, P449, DOI 10.1016/j.ajpath.2018.10.021; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hirayama K, 2018, SURG TODAY, V48, P110, DOI 10.1007/s00595-017-1559-x; Iesato Y, 2013, AM J PATHOL, V182, P2380, DOI 10.1016/j.ajpath.2013.02.015; Iimuro S, 2004, CIRC RES, V95, P415, DOI 10.1161/01.RES.0000138018.61065.d1; Inoue H, 2012, J ORAL SCI, V54, P241, DOI 10.2334/josnusd.54.241; Kaafarani I, 2009, FASEB J, V23, P3424, DOI 10.1096/fj.08-127852; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Komohara Y, 2017, J PATHOL, V241, P313, DOI 10.1002/path.4824; Koukourakis MI, 2017, LAB INVEST, V97, P1321, DOI 10.1038/labinvest.2017.79; Koyama T, 2013, CIRCULATION, V127, P842, DOI 10.1161/CIRCULATIONAHA.112.000756; Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019; Liu T, 2018, PEPTIDES, V110, P10, DOI 10.1016/j.peptides.2018.10.006; Martin-Villar E, 2006, J CELL SCI, V119, P4541, DOI 10.1242/jcs.03218; Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Murakami S, 2005, AM J RESP CRIT CARE, V172, P581, DOI 10.1164/rccm.200409-1280OC; Nakashima Y, 2013, CANCER SCI, V104, P1718, DOI 10.1111/cas.12286; Neesse A, 2015, GUT, V64, P1476, DOI 10.1136/gutjnl-2015-309304; Neri S, 2015, INT J CANCER, V137, P784, DOI 10.1002/ijc.29464; Nojiri T, 2015, P NATL ACAD SCI USA, V112, P4086, DOI 10.1073/pnas.1417273112; Nouguerede E, 2013, CANCER MED-US, V2, P196, DOI 10.1002/cam4.51; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Peacock JG, 2007, MOL BIOL CELL, V18, P3860, DOI 10.1091/mbc.E07-01-0075; Prakash J, 2017, ADV DRUG DELIVER REV, V121, P1, DOI 10.1016/j.addr.2017.11.008; Qi LS, 2016, ONCOTARGET, V7, P74015, DOI 10.18632/oncotarget.12187; Ramachandran V, 2007, CANCER RES, V67, P2666, DOI 10.1158/0008-5472.CAN-06-3362; Ramachandran V, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007502; Raof NA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2267-9; Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4; Schacht V, 2005, AM J PATHOL, V166, P913, DOI 10.1016/S0002-9440(10)62311-5; Schoppmann SF, 2012, BREAST CANCER RES TR, V134, P237, DOI 10.1007/s10549-012-1984-x; Sexton PM, 2006, ANN NY ACAD SCI, V1070, P90, DOI 10.1196/annals.1317.076; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; Shindo K, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-168; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; Shindo T, 2019, PEPTIDES, V111, P55, DOI 10.1016/j.peptides.2018.04.004; Siclari VA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0458-y; Singhal PK, 2016, P NATL ACAD SCI USA, V113, P122, DOI 10.1073/pnas.1522401112; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Suchanski J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184970; Tanaka M, 2016, CARDIOVASC RES, V111, P398, DOI 10.1093/cvr/cvw166; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Ugorski M, 2016, AM J CANCER RES, V6, P370; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Yamauchi A, 2014, J MOL CELL CARDIOL, V77, P73, DOI 10.1016/j.yjmcc.2014.09.017; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yazdani S, 2017, ADV DRUG DELIVER REV, V121, P101, DOI 10.1016/j.addr.2017.07.010; Ye L, 2010, CANCER SCI, V101, P2137, DOI 10.1111/j.1349-7006.2010.01648.x; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoshida T, 2015, CLIN CANCER RES, V21, P642, DOI 10.1158/1078-0432.CCR-14-0846; Zhang DX, 2018, CANCER RES, V78, P1700, DOI 10.1158/0008-5472.CAN-17-1366; Zhang XHF, 2013, CELL, V154, P1060, DOI 10.1016/j.cell.2013.07.036; Zou GY, 2018, CANCER SCI, V109, P3416, DOI 10.1111/cas.13780	67	7	7	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1914	1930		10.1038/s41388-019-1112-z	http://dx.doi.org/10.1038/s41388-019-1112-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754214	Green Submitted			2022-12-17	WOS:000516579800007
J	Franke, CM; Gu, VW; Grimm, BG; Cassady, VC; White, JR; Weigel, RJ; Kulak, MV				Franke, Christopher M.; Gu, Vivian W.; Grimm, Benjamin G.; Cassady, Victoria C.; White, Jeffrey R.; Weigel, Ronald J.; Kulak, Mikhail, V			TFAP2C regulates carbonic anhydrase XII in human breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION; ISOZYME-XII; CELL-LINES; CLASSIFICATION; ENHANCER; SUBTYPES; IDENTIFICATION; PROMOTER; TARGET; IX	The expression of carbonic anhydrase XII (CA12) is associated with the expression of estrogen receptor alpha (ER alpha) in breast cancer and is linked to a good prognosis with a lower risk of metastasis. Transcription Factor Activator Protein 2 gamma (TFAP2C, AP-2 gamma) governs luminal breast cancer phenotype through direct and indirect regulation of ER alpha and ER alpha-associated genes, GATA3, FOXA1, EGFR, CDH1, DSP, KRT7, FBP1, MYB, RET, KRT8, MUC1, and ERBB2-genes which are responsible for the luminal signature in breast cancer. Herein, utilizing chromatin immunoprecipitation and direct sequencing (ChIP-seq), we show that CA12 is regulated by AP-2 gamma through binding with its promoter region in luminal breast cancer cell lines and indirectly through a distal estrogen-responsive region in ER alpha-positive cell lines by upregulation of ER alpha. CA12 is transcriptionally silenced in basal breast cancer cell lines through histone deacetylation and CpG methylation of the promoter region and can be re-activated with Trichostatin A (histone deacetylase inhibitor) and/or 5-aza-dC (an inhibitor of DNA methylation). Strong concordance in co-expression of CA12 and ESR1 (R-2 = 0.1128, p = 0486) and TFAP2C (R-2 = 0.1823, p = 0.0105) was found using a panel of primary breast tumor samples (n = 35), supporting a synergetic role of AP-2 gamma and ER alpha in activation of CA12. Our results highlight the essential role of AP-2 gamma in maintaining the luminal breast cancer phenotype and provide evidence that epigenetic mechanisms silence luminal gene expression in the basal phenotype. Additional studies to decipher mechanisms that drive epigenetic silencing of AP-2 gamma target genes are a critical area for further research.	[Franke, Christopher M.; Gu, Vivian W.; Grimm, Benjamin G.; Cassady, Victoria C.; White, Jeffrey R.; Weigel, Ronald J.; Kulak, Mikhail, V] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Weigel, Ronald J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Kulak, MV (corresponding author), Univ Iowa, Dept Surg, Iowa City, IA 52242 USA.	mikhail-kulak@uiowa.edu		Kulak, Mikhail/0000-0002-4307-5868; Weigel, Ronald/0000-0002-9249-0793; Grimm, Benjamin/0000-0002-9604-1266; White, Jeffrey/0000-0003-3146-9605				Barnett DH, 2008, CANCER RES, V68, P3505, DOI 10.1158/0008-5472.CAN-07-6151; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Cyr AR, 2015, ONCOGENE, V34, P436, DOI 10.1038/onc.2013.569; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; De Andrade JP, 2016, MOL CANCER THER, V15, P503, DOI 10.1158/1535-7163.MCT-15-0548-T; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Haapasalo J, 2008, NEURO-ONCOLOGY, V10, P131, DOI 10.1215/15228517-2007-065; Hynninen P, 2006, HISTOPATHOLOGY, V49, P594, DOI 10.1111/j.1365-2559.2006.02523.x; Ilie MI, 2011, INT J CANCER, V128, P1614, DOI 10.1002/ijc.25491; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kivela A, 2000, AM J PATHOL, V156, P577, DOI 10.1016/S0002-9440(10)64762-1; Kivela AJ, 2005, WORLD J GASTROENTERO, V11, P2616, DOI 10.3748/wjg.v11.i17.2616; Kopecka J, 2016, ONCOTARGET, V7, P85861, DOI 10.18632/oncotarget.13040; Kopecka J, 2015, ONCOTARGET, V6, P6776, DOI 10.18632/oncotarget.2882; Kulak MV, 2013, ONCOGENE, V32, P4043, DOI 10.1038/onc.2012.400; Lacroix M, 2004, ONCOL REP, V12, P701; Liu Q, 2018, ONCOGENE, V37, P687, DOI 10.1038/onc.2017.382; Masood S, 2016, WOMENS HEALTH, V12, P103, DOI 10.2217/whe.15.99; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nordfors K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-148; O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533; Palmer MB, 2007, CANCER RES, V67, P6113, DOI 10.1158/0008-5472.CAN-06-4256; Parkkila S, 2000, J HISTOCHEM CYTOCHEM, V48, P1601, DOI 10.1177/002215540004801203; Riaz M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3415; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Spanheimer PM, 2013, ANN SURG ONCOL, V20, P2204, DOI 10.1245/s10434-012-2570-5; Supuran CT, 2008, CURR PHARM DESIGN, V14, P603, DOI 10.2174/138161208783877884; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; U.S. Cancer Statistics Working Group. U.S. Department of Health and Human Services C.f.D.C.a.P.a.N.C.I., US CANC STAT DAT VIS; von Neubeck B, 2018, INT J CANCER, V143, P2065, DOI 10.1002/ijc.31607; Waheed A, 2017, GENE, V623, P33, DOI 10.1016/j.gene.2017.04.027; Watson PH, 2003, BRIT J CANCER, V88, P1065, DOI 10.1038/sj.bjc.6600796; Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343; Wykoff CC, 2001, AM J PATHOL, V158, P1011, DOI 10.1016/S0002-9440(10)64048-5; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753; Yersal O, 2014, WORLD J CLIN ONCOL, V5, P412, DOI 10.5306/wjco.v5.i3.412	42	7	7	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1290	1301		10.1038/s41388-019-1062-5	http://dx.doi.org/10.1038/s41388-019-1062-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636386				2022-12-17	WOS:000526714600009
J	Ito, H; Tsunoda, T; Riku, M; Inaguma, S; Inoko, A; Murakami, H; Ikeda, H; Matsuda, M; Kasai, K				Ito, Hideaki; Tsunoda, Takumi; Riku, Miho; Inaguma, Shingo; Inoko, Akihito; Murakami, Hideki; Ikeda, Hiroshi; Matsuda, Michiyuki; Kasai, Kenji			Indispensable role of STIL in the regulation of cancer cell motility through the lamellipodial accumulation of ARHGEF7-PAK1 complex	ONCOGENE			English	Article							CENTRIOLE DUPLICATION; PAK; MEMBRANE; MIGRATION; CDC42; PROMOTES; RAC1; PLK4; CENTROSOME; ACTIVATION	Cell motility is a tightly regulated phenomenon that supports the accurate formation of organ structure during development and homeostasis, including wound healing and inflammation. Meanwhile, cancer cells exhibit dysregulated motility, which causes spreading and invasion. The Dbl family RhoGEF ARHGEF7/beta-PIX and its binding partner p21-activated kinase PAK1 are overexpressed in a variety of cancers and have been shown to be responsible for cancer cell migration. A key step in motility is the intracellular transport of ARHGEF7-PAK1 complex to the migrating front of cells, where lamellipodia protrusion and cytoskeletal remodeling efficiently occur. However, the molecular mechanisms of the intracellular transport of this complex are not fully understood. Here we revealed that SCL/TAL1-interrupting locus (STIL) is indispensable for the efficient migration of cancer cells. STIL forms a ternary complex with ARHGEF7 and PAK1 and accumulates with those proteins at the lamellipodia protrusion of motile cells. Knockdown of STIL impedes the accumulation of ARHGEF7-PAK1 complex within membrane ruffles and attenuates the phosphorylation of PAK1 substrates and cortical actin remodeling at the migrating front. Intriguingly, ARHGEF7 knockdown also diminishes STIL and PAK1 accumulation in membrane ruffles. Either STIL or ARHGEF7 knockdown impedes cell migration and Rac1 activity at the migrating front of cells. These results indicate that STIL is involved in the ARHGEF7-mediated positive-feedback activation of cytoskeletal remodeling through accumulating the ARHGEF7-PAK1 complex in lamellipodia. We conclude that its involvement is crucial for the polarized formation of Rac1-mediated leading edge, which supports the efficient migration of cancer cells.	[Ito, Hideaki; Tsunoda, Takumi; Riku, Miho; Inaguma, Shingo; Inoko, Akihito; Murakami, Hideki; Ikeda, Hiroshi; Kasai, Kenji] Aichi Med Univ, Dept Pathol, Sch Med, Nagakute, Aichi, Japan; [Matsuda, Michiyuki] Kyoto Univ, Dept Pathol & Biol Dis, Grad Sch Med, Kyoto, Japan	Aichi Medical University; Kyoto University	Kasai, K (corresponding author), Aichi Med Univ, Dept Pathol, Sch Med, Nagakute, Aichi, Japan.	kkasai@aichi-med-u.ac.jp	Riku, Miho/GPP-3435-2022	Riku, Miho/0000-0002-1799-5839; Kasai, Kenji/0000-0001-6566-9483	JSPS KAKENHI [16K19091, 17K08706, 19K06671, 18K07031, 16H06280, 15H05949, 24590456, 19K07449]; Pancreas Research Foundation of Japan	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Pancreas Research Foundation of Japan(Pancreas Research Foundation of Japan)	We thank Norika Yamada, Kazuko Tanimizu, and Minako Suzuki for their excellent technical assistance and Tatsuhito Miyake and Yuji Nakagomi for laser confocal microscope. We also thank Yukiko Kuru (Faculty of Foreign Languages, Aichi Medical University School of Medicine) for English editing. This study was supported in part by JSPS KAKENHI Grant Number 16K19091 (HI), 17K08706 (SI), 19K06671 (AI), 18K07031 (HM), 16H06280 "ABiS" (MM), 15H05949 "Resonance Bio" (MM), 24590456 and 19K07449 (KK); Pancreas Research Foundation of Japan (HI).	APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Arquint C, 2012, J CELL SCI, V125, P1342, DOI 10.1242/jcs.099887; Bryce NS, 2005, CURR BIOL, V15, P1276, DOI 10.1016/j.cub.2005.06.043; Bustelo Xose R, 2012, Small GTPases, V3, P60, DOI 10.4161/sgtp.19111; Byrne KM, 2016, CELL SYST, V2, P38, DOI 10.1016/j.cels.2016.01.003; Castro-Castro A, 2011, EMBO J, V30, P3913, DOI 10.1038/emboj.2011.310; Delattre M, 2004, NAT CELL BIOL, V6, P656, DOI 10.1038/ncb1146; Erez A, 2004, ONCOGENE, V23, P5371, DOI 10.1038/sj.onc.1207685; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Kasai K, 2008, CANCER RES, V68, P7723, DOI 10.1158/0008-5472.CAN-07-6661; Kazazian K, 2017, CANCER RES, V77, P434, DOI 10.1158/0008-5472.CAN-16-2060; Koh CG, 2001, J CELL SCI, V114, P4239; Krause M, 2014, NAT REV MOL CELL BIO, V15, P577, DOI 10.1038/nrm3861; Kumar R, 2017, GENE, V605, P20, DOI 10.1016/j.gene.2016.12.014; Kunida K, 2012, J CELL SCI, V125, P2381, DOI 10.1242/jcs.096859; Kurokawa K, 2004, MOL BIOL CELL, V15, P1003, DOI 10.1091/mbc.E03-08-0609; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Nigg EA, 2018, NAT REV MOL CELL BIO, V19, P297, DOI 10.1038/nrm.2017.127; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; Ohta M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6267; Omelchenko T, 2014, GENE DEV, V28, P2764, DOI 10.1101/gad.251371.114; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Patwardhan D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0101-9; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Rabinowicz N, 2017, ONCOTARGET, V8, P27380, DOI 10.18632/oncotarget.16068; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rosario CO, 2015, ONCOGENE, V34, P3441, DOI 10.1038/onc.2014.275; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; Schnoor M, 2018, TRENDS CELL BIOL, V28, P79, DOI 10.1016/j.tcb.2017.10.009; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stevens NR, 2010, J CELL BIOL, V188, P313, DOI 10.1083/jcb.200910016; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; Vulprecht J, 2012, J CELL SCI, V125, P1353, DOI 10.1242/jcs.104109; Wu XC, 2019, GENE, V686, P220, DOI 10.1016/j.gene.2018.11.048; Yamao M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17527; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	44	7	7	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1931	1943		10.1038/s41388-019-1115-9	http://dx.doi.org/10.1038/s41388-019-1115-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754215				2022-12-17	WOS:000516579800008
J	Broustas, CG; Duval, AJ; Chaudhary, KR; Friedman, RA; Virk, RK; Lieberman, HB				Broustas, Constantinos G.; Duval, Axel J.; Chaudhary, Kunal R.; Friedman, Richard A.; Virk, Renu K.; Lieberman, Howard B.			Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE-5; H2AX PHOSPHORYLATION; ERK ACTIVATION; HISTONE H2AX; EXPRESSION; INHIBITION; CELLS; RADIATION; RADIOSENSITIZATION; MEK5-ALPHA	Radiotherapy is commonly used to treat a variety of solid human tumors, including localized prostate cancer. However, treatment failure often ensues due to tumor intrinsic or acquired radioresistance. Here we find that the MEK5/ERK5 signaling pathway is associated with resistance to genotoxic stress in aggressive prostate cancer cells. MEK5 knockdown by RNA interference sensitizes prostate cancer cells to ionizing radiation (IR) and etoposide treatment, as assessed by clonogenic survival and short-term proliferation assays. Mechanistically, MEK5 downregulation impairs phosphorylation of the catalytic subunit of DNA-PK at serine 2056 in response to IR or etoposide treatment. Although MEK5 knockdown does not influence the initial appearance of radiation- and etoposide-induced gamma H2AX and 53BP1 foci, it markedly delays their resolution, indicating a DNA repair defect. A cell-based assay shows that nonhomologous end joining (NHEJ) is compromised in cells with ablated MEK5 protein expression. Finally, MEK5 silencing combined with focal irradiation causes strong inhibition of tumor growth in mouse xenografts, compared with MEK5 depletion or radiation alone. These findings reveal a convergence between MEK5 signaling and DNA repair by NHEJ in conferring resistance to genotoxic stress in advanced prostate cancer and suggest targeting MEK5 as an effective therapeutic intervention in the management of this disease.	[Broustas, Constantinos G.; Duval, Axel J.; Chaudhary, Kunal R.; Lieberman, Howard B.] Columbia Univ, Ctr Radiol Res, Vagelos Coll Phys & Surg, Irving Med Ctr, New York, NY 10032 USA; [Friedman, Richard A.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Biomed Informat Shared Resource, Irving Med Ctr, New York, NY USA; [Friedman, Richard A.] Columbia Univ, Dept Biomed Informat, Irving Med Ctr, New York, NY USA; [Virk, Renu K.] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY USA; [Lieberman, Howard B.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University	Broustas, CG (corresponding author), Columbia Univ, Ctr Radiol Res, Vagelos Coll Phys & Surg, Irving Med Ctr, New York, NY 10032 USA.	cgb2117@cumc.columbia.edu	Chaudhary, Kunal/AAF-7187-2021	Chaudhary, Kunal/0000-0001-5423-3174; Broustas, Constantinos/0000-0001-7169-807X	Department of Defense Prostate Cancer Research Program [W81XWH-15-1-0296];  [P30CA013696]	Department of Defense Prostate Cancer Research Program(United States Department of Defense); 	This work is supported by the Department of Defense Prostate Cancer Research Program, W81XWH-15-1-0296 (CGB). This study also used the resources of the Herbert Irving Comprehensive Cancer Center Flow Cytometry, Radiation Research, and Confocal and Specialized Microscopy Shared Resources funded in part through Center Grant P30CA013696. We thank Theresa Swayne and Laura Munteanu from the Confocal and Specialized Microscopy Shared Resource of the Irving Cancer Research Center (ICRC) and Drs. Siu-Hong Ho, Wei Wang, and Caisheng Lu from the Flow Cytometry Shared Resource of the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center for their help in performing the immunofluorescence and flow cytometry experiments.	Adachi N, 2003, J BIOL CHEM, V278, P35897, DOI 10.1074/jbc.M306500200; Arnoux V, 2008, MOL BIOL CELL, V19, P4738, DOI 10.1091/mbc.E07-10-1078; Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; Benito-Jardon L, 2019, CANCER RES, V79, P2244, DOI 10.1158/0008-5472.CAN-18-2762; Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0; Bouchaert P, 2012, INT J RADIAT ONCOL, V84, P1179, DOI 10.1016/j.ijrobp.2012.02.014; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Collis SJ, 2003, CANCER RES, V63, P1550; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; Estrada-Bernal A, 2015, CELL CYCLE, V14, P3713, DOI 10.1080/15384101.2015.1104437; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Ghosh AK, 2005, J BIOL CHEM, V280, P14325, DOI 10.1074/jbc.M413313200; Golding SE, 2007, CANCER RES, V67, P1046, DOI 10.1158/0008-5472.CAN-06-2371; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Jiang WW, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0209-3; Kim MR, 2015, MOL CANCER RES, V13, P319, DOI 10.1158/1541-7786.MCR-14-0098-T; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Loveridge CJ, 2017, CANCER RES, V77, P3158, DOI 10.1158/0008-5472.CAN-16-2565; McCracken SRC, 2008, ONCOGENE, V27, P2978, DOI 10.1038/sj.onc.1210963; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Ni XH, 2011, J CLIN INVEST, V121, P2383, DOI 10.1172/JCI45109; Nyati MK, 2006, CANCER RES, V66, P11554, DOI 10.1158/0008-5472.CAN-06-1935; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Palacios DA, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-4; Panier S, 2013, NAT REV MOL CELL BIO, V14, P661, DOI 10.1038/nrm3659; Pavan S, 2018, ONCOGENE, V37, P4197, DOI 10.1038/s41388-018-0270-8; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Ramsay AK, 2011, BRIT J CANCER, V104, P664, DOI 10.1038/sj.bjc.6606062; Schweppe RE, 2006, J BIOL CHEM, V281, P20993, DOI 10.1074/jbc.M604208200; Seyfried J, 2005, MOL CELL BIOL, V25, P9820, DOI 10.1128/MCB.25.22.9820-9828.2005; Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Suzaki Y, 2002, J BIOL CHEM, V277, P9614, DOI 10.1074/jbc.M111790200; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tusa I, 2018, ONCOGENE, V37, DOI 10.1038/s41388-018-0164-9; Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270; Wei FX, 2013, BBA-MOL CELL RES, V1833, P90, DOI 10.1016/j.bbamcr.2012.10.016; Wu CC, 2017, INT J RADIAT ONCOL, V99, P191, DOI 10.1016/j.ijrobp.2017.05.016; Yan Lijun, 2003, BMC Dev Biol, V3, P11, DOI 10.1186/1471-213X-3-11; Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	50	7	7	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2467	2477		10.1038/s41388-020-1163-1	http://dx.doi.org/10.1038/s41388-020-1163-1		JAN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31980741	Green Accepted, Green Submitted			2022-12-17	WOS:000509176900001
J	Chen, D; Ning, Z; Chen, H; Lu, C; Liu, XL; Xia, T; Qi, H; Wang, W; Ling, T; Guo, X; Tekcham, DS; Liu, XM; Liu, J; Wang, AM; Yan, Q; Liu, JW; Tan, G; Piao, HL				Chen, Di; Ning, Zhen; Chen, Huan; Lu, Chang; Liu, Xiaolong; Xia, Tian; Qi, Huan; Wang, Wen; Ling, Ting; Guo, Xin; Tekcham, Dinesh Singh; Liu, Xiumei; Liu, Jing; Wang, Aman; Yan, Qiu; Liu, Ji-Wei; Tan, Guang; Piao, Hai-long			An integrative pan-cancer analysis of biological and clinical impacts underlying ubiquitin-specific-processing proteases	ONCOGENE			English	Article							DEUBIQUITINATING ENZYME; SIGNALING PATHWAY; INHIBITION; KINASE; DEGRADATION; ACTIVATION; HAUSP; TOOL; P53	Ubiquitin-specific-processing proteases (USPs), the largest deubiquitinating enzyme (DUB) subfamily, play critical roles in cancer. However, clinical utility of USPs is hindered by limited knowledge about their varied and substrate-dependent actions. Here, we performed a comprehensive investigation on pan-cancer impacts of USPs by integrating multi-omics data and annotated data resources, especially a deubiquitination network. Meaningful insights into the roles of 54 USPs in 29 types of cancers were generated. Although rare mutations were observed, a majority of USPs exhibited significant expressional alterations, prognostic impacts and strong correlations with cancer hallmark pathways. Notably, from our DUB-substrate interaction prediction model, additional USP-substrate interactions (USIs) were recognized to complement knowledge gap about cancer-relevant USIs. Intriguingly, expression signatures of the USIs revealed clinically meaningful cancer subtypes, where key USPs and substrates cooperatively contributed to significant prognosis differences among subtypes. Overall, this investigation provides a valuable resource to assist mechanism research and clinical utility about USPs.	[Chen, Di; Ning, Zhen; Chen, Huan; Lu, Chang; Liu, Xiaolong; Xia, Tian; Qi, Huan; Wang, Wen; Ling, Ting; Guo, Xin; Tekcham, Dinesh Singh; Liu, Xiumei; Liu, Jing; Piao, Hai-long] Chinese Acad Sci, Dalian Inst Chem Phys, Sci Res Ctr Translat Med, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China; [Ning, Zhen; Lu, Chang; Guo, Xin; Wang, Aman; Yan, Qiu; Liu, Ji-Wei; Tan, Guang] Dalian Med Univ, Affiliated Hosp 2, Dalian 116000, Peoples R China	Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Dalian Medical University	Piao, HL (corresponding author), Chinese Acad Sci, Dalian Inst Chem Phys, Sci Res Ctr Translat Med, CAS Key Lab Separat Sci Analyt Chem, Dalian 116023, Peoples R China.; Liu, JW; Tan, G (corresponding author), Dalian Med Univ, Affiliated Hosp 2, Dalian 116000, Peoples R China.	jiweiliudl@126.com; tanguangdl@126.com; hpiao@dicp.ac.cn		Liu, Xiaolong/0000-0003-4384-0360; Chen, Di/0000-0002-2181-4703	National Natural Science Foundation of China [81672440, 31701156, 81502024, 81572881]; China Postdoctoral Science Foundation [2017M611281]; Innovation program of science and research from the DICP, CAS [DICP TMSR201601, DICP ZZBS201803]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Innovation program of science and research from the DICP, CAS	Dedicated to the 70th anniversary of Dalian Institute of Chemical Physics, CAS. We thank Guowang Xu, Tongming Li, and all members of the Dr. Piao laboratory for helpful discussions and suggestions. This study is supported by the National Natural Science Foundation of China (Grant Nos. 81672440, 31701156, 81502024, and 81572881), Project funded by China Postdoctoral Science Foundation (No. 2017M611281), Innovation program of science and research from the DICP, CAS (DICP TMSR201601, DICP ZZBS201803).	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Barabasi AL, 2009, SCIENCE, V325, P412, DOI 10.1126/science.1173299; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Brown NR, 2007, CELL CYCLE, V6, P1350, DOI 10.4161/cc.6.11.4278; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953; Chen D, 2019, ISCIENCE, V16, P177, DOI 10.1016/j.isci.2019.05.033; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507; Cotto-Rios XM, 2011, CELL CYCLE, V10, P4009, DOI 10.4161/cc.10.23.18501; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Davis MI, 2016, J BIOL CHEM, V291, P24628, DOI 10.1074/jbc.M116.738567; Edwards NJ, 2015, J PROTEOME RES, V14, P2707, DOI 10.1021/pr501254j; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Hanpude P, 2015, IUBMB LIFE, V67, P544, DOI 10.1002/iub.1402; Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302; Landi S, 2003, CANCER RES, V63, P3560; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Li J, 2017, CANCER CELL, V31, P225, DOI 10.1016/j.ccell.2017.01.005; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00299-9; Lu C, 2018, CANCER LETT, V436, P139, DOI 10.1016/j.canlet.2018.07.032; Luise C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015891; Matsumoto M, 1998, ACM T MODEL COMPUT S, V8, P28; Meuwissen MEC, 2016, J EXP MED, V213, P1163, DOI 10.1084/jem.20151529; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Rani J, 2015, J BIOSCIENCES, V40, P671, DOI 10.1007/s12038-015-9552-2; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Srinivas NR, 2017, XENOBIOTICA, V47, P354, DOI 10.1080/00498254.2016.1184356; Sun J, 2018, MOL CELL BIOCHEM, V441, P1, DOI 10.1007/s11010-017-3170-2; Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577; Toloczko A, 2017, CANCER RES, V77, P4921, DOI 10.1158/0008-5472.CAN-16-3413; Torgo L., 2010, DATA MINING R LEARNI; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Weisberg EL, 2017, NAT CHEM BIOL, V13, P1207, DOI [10.1038/NCHEMBIO.2486, 10.1038/nchembio.2486]; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Yang B, 2016, ONCOTARGET, V7, P79501, DOI 10.18632/oncotarget.12819; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yuan T, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01080; Zhang JD, 2009, BIOINFORMATICS, V25, P1470, DOI 10.1093/bioinformatics/btp167; Zhu C, 2018, J BIOL CHEM, V293, P1178, DOI 10.1074/jbc.RA117.000392	57	7	7	1	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					587	602		10.1038/s41388-019-1002-4	http://dx.doi.org/10.1038/s41388-019-1002-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31511647				2022-12-17	WOS:000509718300008
J	Wang, L; Zhao, HY; Li, J; Xu, YQ; Lan, YJ; Yin, WK; Liu, XQ; Yu, L; Lin, SH; Du, MYF; Li, X; Xiao, Y; Zhang, YP				Wang, Li; Zhao, Hongying; Li, Jing; Xu, Yingqi; Lan, Yujia; Yin, Wenkang; Liu, Xiaoqin; Yu, Lei; Lin, Shihua; Du, Michael Yifei; Li, Xia; Xiao, Yun; Zhang, Yunpeng			Identifying functions and prognostic biomarkers of network motifs marked by diverse chromatin states in human cell lines	ONCOGENE			English	Article							FACTOR-BINDING SITES; REGULATORY NETWORK; DNA-DAMAGE; LEUKEMIA; DYNAMICS; GENES; EGR1	Epigenetic modifications play critical roles in modulating gene expression, yet their roles in regulatory networks in human cell lines remain poorly characterized. We integrated multiomics data to construct directed regulatory networks with nodes and edges labeled with chromatin states in human cell lines. We observed extensive association of diverse chromatin states and network motifs. The gene expression analysis showed that diverse chromatin states of coherent type-1 feedforward loop (C1-FFL) and incoherent type-1 feedforward loops (I1-FFL) contributed to the dynamic expression patterns of targets. Notably, diverse chromatin state compositions could help C1- or I1-FFL to control a large number of distinct biological functions in human cell lines, such as four different types of chromatin state compositions cooperating with K562-associated C1-FFLs controlling "regulation of cytokinesis," "G1/S transition of mitotic cell cycle," "DNA recombination," and "telomere maintenance," respectively. Remarkably, we identified six chromatin state-marked C1-FFL instances (HCFC1-NFYA-ABL1, THAP1-USF1-BRCA2, ZNF263-USF1-UBA52, MYC-ATF1-UBA52, ELK1-EGR1-CCT4, and YY1-EGR1-INO80C) could act as prognostic biomarkers of acute myelogenous leukemia though influencing cancer-related biological functions, such as cell proliferation, telomere maintenance, and DNA recombination. Our results will provide novel insight for better understanding of chromatin state-mediated gene regulation and facilitate the identification of novel diagnostic and therapeutic biomarkers of human cancers.	[Wang, Li; Zhao, Hongying; Xu, Yingqi; Lan, Yujia; Yin, Wenkang; Liu, Xiaoqin; Yu, Lei; Lin, Shihua; Li, Xia; Xiao, Yun; Zhang, Yunpeng] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China; [Li, Jing] Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Ultrason Med, Harbin 150040, Peoples R China; [Du, Michael Yifei] Weston High Sch Massachusetts, 444 Wellesley St, Weston, MA 02493 USA	Harbin Medical University; Heilongjiang University of Chinese Medicine	Li, X; Xiao, Y; Zhang, YP (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin 150081, Peoples R China.	lixia@hrbmu.edu.cn; xiaoyun@ems.hrbmu.edu.cn; zyp19871208@126.com	Xiao, Yun/A-8359-2013	Li, Xia/0000-0002-9794-2648; Xu, Yingqi/0000-0001-6879-639X	National Natural Science Foundation of China [31801115, 61803129, 61603116, 61873075]; China Postdoctoral Science Foundation [2018M631943, 2018M641860]; China Postdoctoral Science Special Foundation [2019T120280]; Hei Long Jiang Postdoctoral Foundation [LBH-Z17110, LBH-Z17218]; General Program of Natural Science Foundation of Heilongjiang Province [H2016055]; Fundamental Research Funds for the Provincial Universities [2017JCZX54, 2017JCZX51]; Heilongjiang Provincial Health and Family Planning Commission of Science Foundation [2018476, 2018477]; Heilongjiang Provincial planning office key subjects [GBB1318066]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); China Postdoctoral Science Special Foundation; Hei Long Jiang Postdoctoral Foundation; General Program of Natural Science Foundation of Heilongjiang Province; Fundamental Research Funds for the Provincial Universities; Heilongjiang Provincial Health and Family Planning Commission of Science Foundation; Heilongjiang Provincial planning office key subjects	This work was financially supported by the National Natural Science Foundation of China (31801115, 61803129, 61603116, and 61873075), the China Postdoctoral Science Foundation (2018M631943 and 2018M641860), the China Postdoctoral Science Special Foundation (2019T120280), the Hei Long Jiang Postdoctoral Foundation (LBH-Z17110 and LBH-Z17218), General Program of Natural Science Foundation of Heilongjiang Province (H2016055) and Fundamental Research Funds for the Provincial Universities (2017JCZX54 and 2017JCZX51). Heilongjiang Provincial Health and Family Planning Commission of Science Foundation (2018476 and 2018477). Heilongjiang Provincial planning office key subjects (GBB1318066).	Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; [Anonymous], AM SOC CLIN ONCOL S; Arneson A, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0488-1; Bulut-Karslioglu A, 2012, NAT STRUCT MOL BIOL, V19, P1023, DOI 10.1038/nsmb.2382; Cancer Genome Atlas Research Network. Electronic address: wheeler@bcm.edu, 2017, Cell, V169, P1327, DOI 10.1016/j.cell.2017.05.046; Chepyala SR, 2016, SCI REP-UK, V6, DOI 10.1038/srep23607; Dasgupta Y, 2016, BLOOD, V127, P2131, DOI 10.1182/blood-2015-11-681171; de Hoon MJL, 2010, CURR BIOL, V20, pR735, DOI 10.1016/j.cub.2010.06.031; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Gkountela S, 2014, STEM CELL REV REP, V10, P230, DOI 10.1007/s12015-013-9490-z; Gui R, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00600; Hoffmeyer K, 2012, SCIENCE, V336, P1549, DOI 10.1126/science.1218370; Hong J, 2018, ELIFE, V7, DOI 10.7554/eLife.32323; Hsu YL, 2013, ONCOGENE, V32, P4436, DOI 10.1038/onc.2012.444; Hu JL, 2017, MOLECULES, V22, DOI 10.3390/molecules22122194; Hyka-Nouspikel N, 2012, STEM CELLS, V30, P1901, DOI 10.1002/stem.1177; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759; Kittisopikul M, 2010, P NATL ACAD SCI USA, V107, P13300, DOI 10.1073/pnas.1003975107; Krapf G, 2010, ONCOGENE, V29, P3307, DOI 10.1038/onc.2010.53; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li XT, 2019, IEEE T CYBERNETICS, V49, P1680, DOI 10.1109/TCYB.2018.2817480; Libbrecht MW, 2015, GENOME RES, V25, P544, DOI 10.1101/gr.184341.114; Lu C, 2013, ONCOGENE, V32, P5602, DOI 10.1038/onc.2013.349; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Mahmoudi S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.90; Maifrede S, 2017, MOL CANCER RES, V15, P967, DOI 10.1158/1541-7786.MCR-16-0468; Marco A, 2009, BIOINFORMATICS, V25, P2473, DOI 10.1093/bioinformatics/btp462; Milo R, 2004, SCIENCE, V303, P1538, DOI 10.1126/science.1089167; Ocone A, 2015, BIOINFORMATICS, V31, P89, DOI 10.1093/bioinformatics/btv257; Pan X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0291-9; Plaisier CL, 2016, CELL SYST, V3, P172, DOI 10.1016/j.cels.2016.06.006; Prill RJ, 2005, PLOS BIOL, V3, P1881, DOI 10.1371/journal.pbio.0030343; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; Shizuka D, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0080; Sims D, 2014, NAT REV GENET, V15, P121, DOI 10.1038/nrg3642; Soshnev AA, 2016, MOL CELL, V62, P681, DOI 10.1016/j.molcel.2016.05.004; Steinbrecher D, 2018, LEUKEMIA LYMPHOMA, V59, P1614, DOI 10.1080/10428194.2017.1390236; Stoddart A, 2014, BLOOD, V123, P1069, DOI 10.1182/blood-2013-07-517953; Stuart JR, 2005, ONCOGENE, V24, P8085, DOI 10.1038/sj.onc.1208953; Sun LX, 2015, NUCLEIC ACIDS RES, V43, P6334, DOI 10.1093/nar/gkv598; Taher L, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r117; Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232; Wang L, 2019, INT J CANCER, V144, P1723, DOI 10.1002/ijc.31865; Weirick T, 2016, BRIEF BIOINFORM, V17, P678, DOI 10.1093/bib/bbv067; Wernicke S, 2006, BIOINFORMATICS, V22, P1152, DOI 10.1093/bioinformatics/btl038; Wong JJL, 2014, CANCER SCI, V105, P1457, DOI 10.1111/cas.12532; Wong K. -C., 2016, COMPUTATIONAL BIOL B, DOI 10.1201/b20026; Wu S, 2010, THEOR BIOL MED MODEL, V7, DOI 10.1186/1742-4682-7-18; Yevshin I, 2017, NUCLEIC ACIDS RES, V45, pD61, DOI 10.1093/nar/gkw951; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang S, 2013, FEBS LETT, V587, P645, DOI 10.1016/j.febslet.2013.01.019; Zhao HY, 2016, BBA-GEN SUBJECTS, V1860, P1475, DOI 10.1016/j.bbagen.2016.04.008; Zhao HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11938	57	7	8	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					677	689		10.1038/s41388-019-1005-1	http://dx.doi.org/10.1038/s41388-019-1005-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31537905	Green Published, hybrid			2022-12-17	WOS:000509718300014
J	Berggren, KL; Cruz, SR; Hixon, MD; Cowan, AT; Keysar, SB; Craig, S; James, J; Barry, M; Ozbun, MA; Jimeno, A; McCance, DJ; Beswick, EJ; Gan, GN				Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.; Cowan, Andrew T.; Keysar, Stephen B.; Craig, Stephanie; James, Jacqueline; Barry, Marc; Ozbun, Michelle A.; Jimeno, Antonio; McCance, Dennis J.; Beswick, Ellen J.; Gan, Gregory N.			MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; ENDOTHELIAL-CELLS; NECROSIS-FACTOR; KINASE 2; CANCER; SMOKING; FIBROBLASTS; EXPRESSION; HSP27; IL-6	Radiation therapy (RT) is a cornerstone of treatment in the management of head and neck squamous cell carcinomas (HNSCC), yet treatment failure and disease recurrence are common. The p38/MK2 pathway is activated in response to cellular stressors, including radiation, and promotes tumor inflammation in a variety of cancers. We investigated MK2 pathway activation in HNSCC and the interaction of MK2 and RT in vitro and in vivo. We used a combination of an oropharyngeal SCC tissue microarray, HNSCC cell lines, and patient-derived xenograft (PDX) tumor models to study the effect of RT on MK2 pathway activation and to determine how inhibition of MK2 by pharmacologic (PF-3644022) and genetic (siRNA) methods impacts tumor growth. We show that high phosphorylated MK2 (p-MK2) levels are associated with worsened disease-specific survival in p16-negative HNSCC patients. RT increased p-MK2 in both p16-positive, HPV-positive and p16-negative, HPV-negative HNSCC cell lines. Pharmacologic inhibition or gene silencing of MK2 in vitro abrogated RT-induced increases in p-MK2; inflammatory cytokine expression and expression of the downstream MK2 target, heat shock protein 27 (HSP27); and markers of epithelial-to-mesenchymal transition. Mouse PDX models treated with a combination of RT and MK2 inhibitor experienced decreased tumor growth and increased survival. Our results suggest that MK2 is a potential prognostic biomarker for head and neck cancer and that MK2 pathway activation can mediate radiation resistance in HNSCC.	[Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.] Univ New Mexico, Dept Internal Med, Sect Radiat Oncol, Albuquerque, NM 87131 USA; [Berggren, Kiersten L.; Cruz, Sebastian Restrepo; Hixon, Michael D.] Univ New Mexico, Ctr Comprehens Canc, Canc Therapeut Program, Albuquerque, NM 87131 USA; [Cowan, Andrew T.] Univ New Mexico, Dept Surg, Div Otolaryngol, Albuquerque, NM 87131 USA; [Cowan, Andrew T.; Ozbun, Michelle A.] Univ New Mexico, Ctr Comprehens Canc, Canc Biol & Signaling Program, Albuquerque, NM 87131 USA; [Keysar, Stephen B.; Jimeno, Antonio] Univ Colorado Denver, Dept Med, Div Med Oncol, Aurora, CO USA; [Craig, Stephanie; James, Jacqueline] Queens Univ, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Barry, Marc; McCance, Dennis J.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Ozbun, Michelle A.] Univ New Mexico, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; [Beswick, Ellen J.] Univ Utah, Dept Internal Med, Div Gastroenterol Hepataol & Nutr, Salt Lake City, UT 84112 USA; [Gan, Gregory N.] Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA	University of New Mexico; University of New Mexico; University of New Mexico; University of New Mexico; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Queens University Belfast; University of New Mexico; University of New Mexico; Utah System of Higher Education; University of Utah; University of Kansas; University of Kansas Medical Center	Gan, GN (corresponding author), Univ Kansas, Med Ctr, Dept Radiat Oncol, Kansas City, KS 66103 USA.	greg.gan@gmail.com	Ozbun, Michelle/AAN-2922-2021; Craig, Stephanie/AAX-2060-2020	Ozbun, Michelle/0000-0001-8551-4606; Craig, Stephanie/0000-0002-5476-751X; Gan, Gregory/0000-0001-5090-0064	RSNA Foundation Research Scholar Grant; ACS-IRG [IRG-14-187-19]; University of New Mexico School of Medicine; STI CRC [U19 AI 113187]; NIH P30 Grant NCI [P30CA118100]; Department of Pathology; University of New Mexico Comprehensive Cancer Center [NCI P30CA118100]; NCI [2P30 CA118100]; University of New Mexico Cancer Center Animal Shared Resource - NCI [2P30 CA118100]; NATIONAL CANCER INSTITUTE [R01CA207051, P30CA118100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI113187] Funding Source: NIH RePORTER	RSNA Foundation Research Scholar Grant; ACS-IRG(American Cancer Society); University of New Mexico School of Medicine; STI CRC; NIH P30 Grant NCI; Department of Pathology; University of New Mexico Comprehensive Cancer Center; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of New Mexico Cancer Center Animal Shared Resource - NCI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Work supported in part by RSNA Foundation Research Scholar Grant, ACS-IRG (IRG-14-187-19), Dedicated Health Research Fund from the University of New Mexico School of Medicine (UNM RAC 2018), STI CRC (U19 AI 113187), and the NIH P30 Grant NCI P30CA118100. The research in this paper was supported by the Human Tissue Repository and Tissue Analysis Shared Resource, funded by the Department of Pathology and The University of New Mexico Comprehensive Cancer Center and NCI P30CA118100. Many of the images in this paper were generated in the University of New Mexico Cancer Center Fluorescence Microscopy Shared Resource with current funding from NCI 2P30 CA118100. Initial support with PDX generation was performed with the assistance from the University of New Mexico Cancer Center Animal Shared Resource funded by NCI 2P30 CA118100. We also wish to acknowledge UNM Cancer Center Biostatistics Core Facility for their statistical assistance.	An SS, 2005, AM J PHYSIOL-CELL PH, V289, pC521, DOI 10.1152/ajpcell.00429.2004; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Argiris A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00072; Bae JY, 2014, NEOPLASIA, V16, P928, DOI 10.1016/j.neo.2014.09.003; Cheng JCH, 2014, ANN SURG ONCOL, V21, P2361, DOI 10.1245/s10434-014-3611-z; Duffy SA, 2008, CANCER-AM CANCER SOC, V113, P750, DOI 10.1002/cncr.23615; Gan GN, 2014, CANCER RES, V74, P7024, DOI 10.1158/0008-5472.CAN-14-1346; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Gorska MM, 2007, J EXP MED, V204, P1637, DOI 10.1084/jem.20062621; Gurgis FMS, 2015, ONCOGENE, V34, P2934, DOI 10.1038/onc.2014.225; Guttmann DM, 2013, INT J RADIAT ONCOL, V87, P168, DOI 10.1016/j.ijrobp.2013.05.028; Haigentz M, 2018, ADV THER, V35, P255, DOI 10.1007/s12325-018-0682-4; Jank BJ, 2019, EUR ARCH OTO-RHINO-L, V276, P1487, DOI 10.1007/s00405-019-05381-0; Jomrich G, 2018, J CANCER, V9, P460, DOI 10.7150/jca.22310; Keysar SB, 2013, MOL ONCOL, V7, P776, DOI 10.1016/j.molonc.2013.03.004; Keysar SB, 2013, CANCER RES, V73, P3381, DOI 10.1158/0008-5472.CAN-12-4047; Kim JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22635-9; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kumar B, 2017, ONCOTARGET, V8, P14847, DOI 10.18632/oncotarget.14682; Leon X, 2015, ONCOTARGET, V6, P37407, DOI 10.18632/oncotarget.6054; Liskamp CP, 2016, HEAD NECK-J SCI SPEC, V38, P1780, DOI 10.1002/hed.24516; Liu TG, 2007, AM J RESP CELL MOL, V37, P507, DOI 10.1165/rcmb.2007-0077OC; Mirghani H, 2018, ORAL ONCOL, V82, P131, DOI 10.1016/j.oraloncology.2018.05.007; Morandell S, 2013, CELL REP, V5, P868, DOI 10.1016/j.celrep.2013.10.025; Munshi Anupama, 2013, Genes Cancer, V4, P401, DOI 10.1177/1947601913485414; Muschter D, 2018, CLIN ORAL INVEST, V22, P2251, DOI 10.1007/s00784-017-2323-8; Neininger A, 2002, J BIOL CHEM, V277, P3065, DOI 10.1074/jbc.C100685200; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Pavan S, 2014, INT J CANCER, V134, P1289, DOI 10.1002/ijc.28464; Powrozek T, 2018, J CANCER RES CLIN, V144, P1423, DOI 10.1007/s00432-018-2679-4; Qin X, 2018, THERANOSTICS, V8, P921, DOI 10.7150/thno.22182; Ray AL, 2018, INT J CANCER, V142, P1702, DOI 10.1002/ijc.31191; Ray AL, 2016, INT J CANCER, V138, P770, DOI 10.1002/ijc.29716; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Schernberg A, 2019, HEAD NECK-J SCI SPEC, V41, P1441, DOI 10.1002/hed.25598; Seiwert TY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102112; Sharma RA, 2016, NAT REV CLIN ONCOL, V13, P627, DOI 10.1038/nrclinonc.2016.79; Shen BR, 2017, SCI REP-UK, V7, DOI 10.1038/srep46231; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh MK, 2017, J THERM BIOL, V69, P149, DOI 10.1016/j.jtherbio.2017.06.004; Singh RK, 2017, PHARMACOL REP, V69, P746, DOI 10.1016/j.pharep.2017.03.023; Stein AP, 2015, CANCER MED-US, V4, P699, DOI 10.1002/cam4.387; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; Sumner WA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1268-7; Thuraisingam T, 2010, J INVEST DERMATOL, V130, P278, DOI 10.1038/jid.2009.209; Tribius S, 2012, ORAL ONCOL, V48, P1178, DOI 10.1016/j.oraloncology.2012.05.022; Xu L, 2014, J MOL CELL CARDIOL, V77, P86, DOI 10.1016/j.yjmcc.2014.09.011; Yadav A, 2017, ONCOTARGET, V8, P66912, DOI 10.18632/oncotarget.11464; Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7; Zheng GP, 2018, CLIN CANCER RES, V24, P1163, DOI 10.1158/1078-0432.CCR-17-2619	51	7	7	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7329	7341		10.1038/s41388-019-0945-9	http://dx.doi.org/10.1038/s41388-019-0945-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417185	Green Accepted			2022-12-17	WOS:000499631000004
J	Yuan, YM; Ma, N; Zhang, EB; Chen, TW; Jiang, H; Yin, FF; Wang, JJ; Zhang, FK; Ni, QZ; Wang, X; Bao, Y; Wang, K; Cheng, SQ; Zhang, XL; Wang, XF; Li, JJ; Xie, D				Yuan, Yan-Mei; Ma, Ning; Zhang, Er-Bin; Chen, Tian-Wei; Jiang, Hao; Yin, Fen-Fen; Wang, Jing-Jing; Zhang, Feng-Kun; Ni, Qian-Zhi; Wang, Xiang; Bao, Ying; Wang, Kang; Cheng, Shu-Qun; Zhang, Xue-Li; Wang, Xiao-Fan; Li, Jing-Jing; Xie, Dong			BMP10 suppresses hepatocellular carcinoma progression via PTPRS-STAT3 axis	ONCOGENE			English	Article							GROWTH-FACTOR; TUMOR-SUPPRESSOR; CANCER; EXPRESSION; RECEPTOR; STAT3; CELLS; AGGRESSIVENESS; IDENTIFICATION; PROLIFERATION	Bone morphogenetic protein 10 (BMP10), one member of the BMP family, is involved in various development events. Dysregulation of BMP10 has been observed in several diseases, including hypertensive cardiac hypertrophy, Hirschsprung disease and blood vessel formation. However, its role in liver cancer remains largely unknown. In this study, we reported that BMP10 was significantly downregulated in HCC at both mRNA and protein level. Decreased BMP10 was associated with bigger tumor size, worse TNM stage, earlier recurrence and poorer survival. BMP10 negatively regulated HCC cell proliferation in vitro and in vivo. Mechanism study revealed that BMP10 suppressed tumor cell growth by inhibiting STAT3 signaling. Interestingly, we found that cytoplasmic BMP10 interacted with both receptor protein tyrosine phosphatase sigma (PTPRS) and STAT3, which facilitated dephosphorylation of STAT3 by PTPRS. Altogether, our study has revealed the clinical significance of BMP10 in HCC, and suppression of HCC cell growth by BMP10 via PTPRS-STAT3 axis, providing a potential therapeutic strategy for targeting STAT3 signaling in HCC.	[Yuan, Yan-Mei; Ma, Ning; Zhang, Er-Bin; Chen, Tian-Wei; Jiang, Hao; Yin, Fen-Fen; Wang, Jing-Jing; Zhang, Feng-Kun; Ni, Qian-Zhi; Li, Jing-Jing; Xie, Dong] Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth,CAS Key Lab Nutr Metab, Shanghai 200031, Peoples R China; [Wang, Xiang] Huzhou Univ, First Peoples Hosp Affiliated, Key Lab Translat Med, Huzhou 313000, Peoples R China; [Bao, Ying] Huzhou Univ, First Peoples Hosp Affiliated, Dept Surg, Huzhou 313000, Peoples R China; [Wang, Kang; Cheng, Shu-Qun] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 6, Shanghai 200438, Peoples R China; [Zhang, Xue-Li] Southern Med Univ, Fengxian Hosp, Dept Gen Surg, 6600 Nanfeng Rd, Shanghai 201499, Peoples R China; [Wang, Xiao-Fan] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; [Xie, Dong] ShanghaiTech Univ, Sch Life Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China; [Xie, Dong] China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS; Shanghai Institutes for Biological Sciences, CAS; University of Chinese Academy of Sciences, CAS; Huzhou University; Huzhou University; Naval Medical University; Southern Medical University - China; Duke University; ShanghaiTech University	Li, JJ; Xie, D (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Nutr & Hlth,CAS Key Lab Nutr Metab, Shanghai 200031, Peoples R China.; Xie, D (corresponding author), ShanghaiTech Univ, Sch Life Sci & Technol, 393 Middle Huaxia Rd, Shanghai 201210, Peoples R China.; Xie, D (corresponding author), China Natl Ctr Food Safety Risk Assessment, NHC Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China.	tide7@163.com; dxie@sibs.ac.cn	cheng, sq/GPT-4112-2022	Xie, Dong/0000-0002-1150-8657; Wang, Xiang/0000-0002-0913-0501	National Key R&D Program of China [2018YFC1603002, 2018YFC1604404]; "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12010316]; National Natural Science Foundation of China [31520103907, 81730083, 31771538]; Youth Innovation Promotion Association of Chinese Academy of Sciences; Sanofi-SIBS 2018 Young Faculty Award	National Key R&D Program of China; "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences; Sanofi-SIBS 2018 Young Faculty Award	This work was supported by the National Key R&D Program of China (2018YFC1603002, 2018YFC1604404), the "Personalized Medicines-Molecular Signature-based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences (Grant no. XDA12010316), and National Natural Science Foundation of China (31520103907, 81730083) to Dong Xie; and National Natural Science Foundation of China (31771538), Youth Innovation Promotion Association of Chinese Academy of Sciences fund and Sanofi-SIBS 2018 Young Faculty Award to Jing-Jing Li.	Cai Z, 2018, CANCER RES, V78, P2536, DOI 10.1158/0008-5472.CAN-17-0028; Castonguay R, 2011, J BIOL CHEM, V286, P30034, DOI 10.1074/jbc.M111.260133; Chen YW, 2015, BLOOD, V125, P1589, DOI 10.1182/blood-2014-07-588970; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Deng YZ, 2007, J BIOL CHEM, V282, P36571, DOI 10.1074/jbc.M704141200; Felin JE, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-20; Geiger JL, 2016, ORAL ONCOL, V56, P84, DOI 10.1016/j.oraloncology.2015.11.022; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; Hou JJ, 2013, HEPATOLOGY, V57, P678, DOI 10.1002/hep.25980; Hover LD, 2016, NEURO-ONCOLOGY, V18, P928, DOI 10.1093/neuonc/nov310; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kim BR, 2015, TUMOR BIOL, V36, P9475, DOI 10.1007/s13277-015-3681-y; Langenfeld EM, 2006, ONCOGENE, V25, P685, DOI 10.1038/sj.onc.1209110; Lei HM, 2016, TUMOR BIOL, V37, P3025, DOI 10.1007/s13277-015-4116-5; Levet S, 2015, P NATL ACAD SCI USA, V112, pE3207, DOI 10.1073/pnas.1508386112; Li JJ, 2009, ONCOGENE, V28, P1759, DOI 10.1038/onc.2009.15; Min KW, 2016, ONCOGENE, V35, P377, DOI 10.1038/onc.2015.95; Mitrofan CG, 2017, J BIOL CHEM, V292, P13714, DOI 10.1074/jbc.M117.778506; Nakano N, 2007, AM J PHYSIOL-HEART C, V293, pH3396, DOI 10.1152/ajpheart.00311.2007; Neuhaus H, 1999, MECH DEVELOP, V80, P181, DOI 10.1016/S0925-4773(98)00221-4; Pestana ES, 1999, ONCOGENE, V18, P4069, DOI 10.1038/sj.onc.1202794; Shin DS, 2009, CANCER RES, V69, P193, DOI 10.1158/0008-5472.CAN-08-2575; Su FQ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3134; Sun LJ, 2014, J CELL BIOCHEM, V115, P1868, DOI 10.1002/jcb.24856; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Wu M, 2014, INT J CLIN EXP PATHO, V7, P529; Ye L, 2010, CANCER SCI, V101, P2137, DOI 10.1111/j.1349-7006.2010.01648.x; Ye L, 2009, J UROLOGY, V181, P2749, DOI 10.1016/j.juro.2009.01.098; Zhang N, 2013, ANTICANCER RES, V33, P1917; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104	31	7	8	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7281	7293		10.1038/s41388-019-0943-y	http://dx.doi.org/10.1038/s41388-019-0943-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417183				2022-12-17	WOS:000499631000001
J	Ritchey, L; Ha, T; Otsuka, A; Kabashima, K; Wang, DR; Wang, YY; Lowy, DR; Tosato, G				Ritchey, Lisa; Ha, Taekyu; Otsuka, Atsushi; Kabashima, Kenji; Wang, Dunrui; Wang, Yuyi; Lowy, Douglas R.; Tosato, Giovanna			DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis	ONCOGENE			English	Article							FOCAL ADHESION KINASE; GTPASE-ACTIVATING PROTEIN; ORGAN SIZE CONTROL; HIPPO PATHWAY; TUMOR-SUPPRESSOR; RHO; ANGIOGENESIS; THERAPY; COMPLEX; SRC	Deleted in Liver Cancer 1 (DLC1) is a tumor suppressor gene deleted in many cancers, including angiosarcoma, an aggressive malignancy of endothelial cell derivation. DLC1-deficiency in primary endothelial cells causes the loss of cell contact inhibition of growth through incompletely defined mechanisms. We report that DLC1 is a regulator of YAP, a transcriptional coactivator of proliferation-promoting and tumor-promoting genes; when confluent, active/nuclear YAP was significantly more abundant in DLC1-deficient endothelial cells compared with control cells. We also found that YAP is a required effector of the loss of cell contact inhibition of growth manifested by DLC1-deficient endothelial cells, as the silencing of YAP prevents this loss. Consistently, human angiosarcomas specimens contained a significantly greater proportion of DLC1(-) tumor cells with nuclear YAP compared with the DLC1(+) normal cells in the adjacent tissue. Verteporfin, an inhibitor of YAP, significantly reduced angiosarcoma growth in mice. These results identify YAP as a previously unrecognized effector of DLC1 deficiency-associated loss of cell contact growth inhibition in endothelial cells and a potential therapeutic target in angiosarcoma.	[Ritchey, Lisa; Ha, Taekyu; Wang, Dunrui; Wang, Yuyi; Lowy, Douglas R.; Tosato, Giovanna] NCI, Lab Cellular Oncol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Otsuka, Atsushi; Kabashima, Kenji] Kyoto Univ, Grad Sch Med, Dept Dermatol, Kyoto, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University	Tosato, G (corresponding author), NCI, Lab Cellular Oncol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	tosatog@mail.nih.gov		Otsuka, Atsushi/0000-0001-7365-947X; Tosato, Giovanna/0000-0003-1663-3227	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research; Japan Society for the Promotion of Science KAKENHI [15H05790]; NATIONAL CANCER INSTITUTE [ZIASC010355] Funding Source: NIH RePORTER	Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Michael Kruhlak, Langston Lim, and Andy Tran for helping with confocal imaging and images quantification; Ms. Luowei Li, M. DiPrima, Drs. R. Yarchoan, D. Sanchez-Martin, H. Ohnuki, M. Potente, H. Gerhard and Jing-xin Feng; and members of the Laboratory of Cellular Oncology for contributing in various aspects of this work. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (DSM, XQ, DRL, GT) and by the Japan Society for the Promotion of Science KAKENHI, Grants-in-Aid for Scientific Research 15H05790 (AO, KK).	Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; Behjati S, 2014, NAT GENET, V46, P376, DOI 10.1038/ng.2921; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Braun AC, 2015, CELL SIGNAL, V27, P1643, DOI 10.1016/j.cellsig.2015.04.003; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Choi HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7943; Coxon A, 2010, MOL CANCER THER, V9, P2641, DOI 10.1158/1535-7163.MCT-10-0213; da Costa A, 2017, CLIN EXP DERMATOL, V42, P645, DOI 10.1111/ced.13149; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; EAGLE H, 1967, NATURE, V213, P1102, DOI 10.1038/2131102a0; Edwards DN, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan4667; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Gao YJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5629; Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95; Ishida Y, 2018, CURR OPIN ONCOL, V30, P107, DOI 10.1097/CCO.0000000000000427; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Khan JA, 2018, J CLIN ONCOL, V36, P194, DOI 10.1200/JCO.2017.74.9812; Kim TY, 2007, BIOCHEM BIOPH RES CO, V355, P72, DOI 10.1016/j.bbrc.2007.01.121; Li GR, 2011, P NATL ACAD SCI USA, V108, P17129, DOI 10.1073/pnas.1112122108; Liao YC, 2008, INT J BIOCHEM CELL B, V40, P843, DOI 10.1016/j.biocel.2007.04.008; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Masuzawa M, 1998, J DERMATOL SCI, V16, P91, DOI 10.1016/S0923-1811(97)00032-7; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Murga M, 2004, STEM CELLS, V22, P385, DOI 10.1634/stemcells.22-3-385; Neto F, 2018, ELIFE, V7, DOI 10.7554/eLife.31037; Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005; OBESO J, 1990, LAB INVEST, V63, P259; Pang A, 2016, JAMA ONCOL, V2, P941, DOI 10.1001/jamaoncol.2016.0241; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Qian XL, 2009, CANCER CELL, V16, P246, DOI 10.1016/j.ccr.2009.07.031; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Salvucci O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7576; Sanchez-Martin D, 2018, JNCI-J NATL CANCER I, V110, P390, DOI 10.1093/jnci/djx219; Shih YP, 2010, CANCER RES, V70, P8270, DOI 10.1158/0008-5472.CAN-10-1174; Shimozono N, 2015, CANCER RES, V75, P4458, DOI 10.1158/0008-5472.CAN-15-0418; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Stein C, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005465; STOKER MGP, 1973, NATURE, V246, P200, DOI 10.1038/246200a0; Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; Tripathi BK, 2019, J CELL BIOL, V218, P3060, DOI 10.1083/jcb.201810098; Tsuneki M, 2017, CANCER SCI, V108, P2295, DOI 10.1111/cas.13379; Wu L, 1999, Curr Opin Ophthalmol, V10, P217, DOI 10.1097/00055735-199906000-00011; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418; Zhang H, 2014, J BIOL CHEM, V289, P18681, DOI 10.1074/jbc.M114.554584; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Ziemssen F, 2012, EXPERT OPIN DRUG MET, V8, P1023, DOI 10.1517/17425255.2012.701617	60	7	8	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2019	38	45					7046	7059		10.1038/s41388-019-0944-x	http://dx.doi.org/10.1038/s41388-019-0944-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JL9XI	31409902	Green Accepted			2022-12-17	WOS:000495878400002
J	Hsueh, YS; Chang, HH; Shan, YS; Sun, HS; Fletcher, JA; Li, CF; Chen, LT				Hsueh, Yuan-Shuo; Chang, Hui Hua; Shan, Yan-Shen; Sun, H. Sunny; Fletcher, Jonathan Alfred; Li, Chien-Feng; Chen, Li-Tzong			Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors	ONCOGENE			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; MOLECULAR-BASIS; CELLS; PROLIFERATION; DEGRADATION; EXPRESSION; RECEPTOR; GROWTH; MECHANISMS	Gastrointestinal stromal tumors (GISTs) are frequently driven by auto-activated, mutant KIT and have durable response to KIT tyrosine kinase inhibitor. However, acquired resistance is an increasing clinical issue in GIST patients receiving frontline imatinib therapy. Our previous studies showed the colocalization of KIT with DAPI-stained nuclei in GIST cells without knowing the role of nuclear KIT in GIST tumorigenesis. In this article, we first identified the binding of nuclear KIT to the promoter of NFKB inhibitor beta (NFKBIB) by chromatin immunoprecipitation (ChIP) sequencing and ChIP assays, which was accompanied with enhanced NFKBIB protein expression in GIST cells. Clinically, high NCCN risk GISTs had significantly higher mean expression levels of nuclear phospho-KIT and NFKBIB as compared with those of intermediate or low/very low-risk GISTs. Conversely, downregulation of NFKBIB by siRNA led to RELA nuclear translocation that could bind to the KIT promoter region and subsequently reduced KIT transcription/expression and the viability of GIST cells. These findings were further confirmed by either RELA overexpression or NFKB/RELA inducer, valproic acid, treatment to result in reduced KIT expression and relative cell viability of imatinib-resistant GIST cells. Combining valproic acid with imatinib showed significantly better growth inhibitory effects on imatinib-resistant GIST48 and GIST430 cells in vitro, and in the GIST430 animal xenograft model. Taken together, these results demonstrate the existence of a nuclear KIT-driven NFKBIB-RELA-KIT autoregulatory loop in GIST tumorigenesis, which are potential targets for developing combination therapy to overcome imatinib-resistant of KIT-expressing GISTs.	[Hsueh, Yuan-Shuo; Li, Chien-Feng; Chen, Li-Tzong] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan; [Hsueh, Yuan-Shuo] Natl Cheng Kung Univ, Int Ctr Wound Repair & Regenerat, Tainan, Taiwan; [Chang, Hui Hua; Chen, Li-Tzong] Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan; [Chang, Hui Hua] Natl Cheng Kung Univ, Coll Med, Sch Pharm, Tainan, Taiwan; [Chang, Hui Hua] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pharm, Tainan, Taiwan; [Chang, Hui Hua] Natl Cheng Kung Univ Hosp, Dept Pharm, Dou Liou Branch, Touliu, Yunlin, Taiwan; [Shan, Yan-Shen] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan, Taiwan; [Shan, Yan-Shen] Natl Cheng Kung Univ Hosp, Dept Surg, Tainan, Taiwan; [Sun, H. Sunny] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Sun, H. Sunny] Natl Cheng Kung Univ, Bioinformat Ctr, Tainan, Taiwan; [Fletcher, Jonathan Alfred] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Fletcher, Jonathan Alfred] Harvard Med Sch, Boston, MA 02115 USA; [Li, Chien-Feng] Chi Mei Fdn Med Ctr, Dept Pathol, Tainan, Taiwan; [Li, Chien-Feng] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan; [Chen, Li-Tzong] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan; [Chen, Li-Tzong] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan	National Health Research Institutes - Taiwan; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Chi Mei Hospital; Southern Taiwan University of Science & Technology; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Li, CF; Chen, LT (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan.; Chen, LT (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan, Taiwan.; Li, CF (corresponding author), Chi Mei Fdn Med Ctr, Dept Pathol, Tainan, Taiwan.; Li, CF (corresponding author), Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan, Taiwan.; Chen, LT (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan.; Chen, LT (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan.	angelo.p@yahoo.com.tw; leochen@nhri.org.tw		Sun, Sunny/0000-0002-3661-4448; Li, Chien-Feng/0000-0002-9527-7576; Hsueh, Yuan-Shuo/0000-0002-2584-9380	NHRI [05A1-CAPP19-014, 06A1-CAPP19-014]; Ministry of Science and Technology in Executive Yuan, Taiwan [MOST 104-2321-B-400-019-MY3]	NHRI(National Health Research Institutes - Taiwan); Ministry of Science and Technology in Executive Yuan, Taiwan	We appreciate the funding support provided by NHRI (05A1-CAPP19-014, 06A1-CAPP19-014) and the Ministry of Science and Technology (MOST 104-2321-B-400-019-MY3) in Executive Yuan, Taiwan.	Pavon MA, 2016, HEAD NECK-J SCI SPEC, V38, pE1392, DOI 10.1002/hed.24232; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576; Chen F, 2006, J BIOL CHEM, V281, P37142, DOI 10.1074/jbc.M603631200; Chen PS, 2017, PHARMACOGENOMICS J, V17, P155, DOI 10.1038/tpj.2015.96; Chen YW, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00219; Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1; Dong Y, 2015, CANCER LETT, V361, P137, DOI 10.1016/j.canlet.2015.02.044; Du YP, 2016, TUMOR BIOL, V37, P1261, DOI 10.1007/s13277-015-3921-1; Duensing A, 2004, ONCOGENE, V23, P3999, DOI 10.1038/sj.onc.1207525; Floris G, 2011, MOL CANCER THER, V10, P1897, DOI 10.1158/1535-7163.MCT-11-0148; Foster R, 2004, J MOL GRAPH MODEL, V23, P139, DOI 10.1016/j.jmgm.2004.04.003; Hayashi Y, 2015, GASTROENTEROLOGY, V149, P420, DOI 10.1053/j.gastro.2015.04.006; Hsueh YS, 2014, ONCOTARGET, V5, P11723, DOI 10.18632/oncotarget.2607; Hsueh YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065762; Hsueh YS, 2013, AUTOPHAGY, V9, P220, DOI 10.4161/auto.22802; Isaksson HS, 2014, ONCOTARGET, V5, P4040, DOI 10.18632/oncotarget.1938; Jones J, 2009, J CELL MOL MED, V13, P2342, DOI 10.1111/j.1582-4934.2008.00603.x; Kim J, 2012, P NATL ACAD SCI USA, V109, P6124, DOI 10.1073/pnas.1203203109; Le Gall M, 2015, MOL CANCER THER, V14, P2595, DOI 10.1158/1535-7163.MCT-15-0321; Lee CC, 2010, ONCOGENE, V29, P3110, DOI 10.1038/onc.2010.55; Lerebours F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-41; Liberati S, 2014, CELLS-BASEL, V3, P660, DOI 10.3390/cells3020660; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Ma LJ, 2014, TUMOR BIOL, V35, P1703, DOI 10.1007/s13277-013-1235-8; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Mol CD, 2004, CURR OPIN DRUG DISC, V7, P639; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Nishida T, 2000, HISTOL HISTOPATHOL, V15, P1293, DOI 10.14670/HH-15.1293; Rezaeian AH, 2017, NAT CELL BIOL, V19, P38, DOI 10.1038/ncb3445; Rubin BP, 2007, LANCET, V369, P1731, DOI 10.1016/S0140-6736(07)60780-6; Rusakiewicz S, 2013, CANCER RES, V73, P3499, DOI 10.1158/0008-5472.CAN-13-0371; Sarfstein Rive, 2010, Cancers (Basel), V2, P233, DOI 10.3390/cancers2020233; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sleijfer S, 2007, ONCOLOGIST, V12, P719, DOI 10.1634/theoncologist.12-6-719; Sugito K, 2013, PEDIATR BLOOD CANCER, V60, P383, DOI 10.1002/pbc.24282; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Wang CY, 2016, MOL NEUROBIOL, V53, P6774, DOI 10.1007/s12035-015-9600-9; Warsito D, 2012, EMBO REP, V13, P244, DOI 10.1038/embor.2011.251	46	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6550	6565		10.1038/s41388-019-0900-9	http://dx.doi.org/10.1038/s41388-019-0900-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31363162	Green Published, hybrid			2022-12-17	WOS:000486609000006
J	Tew, BY; Legendre, C; Gooden, GC; Johnson, KN; Martinez, RA; Kiefer, J; Bernstein, M; Glen, J; Butry, L; Hinek, A; Toms, SA; Salhia, B				Tew, Ben Yi; Legendre, Christophe; Gooden, Gerald C.; Johnson, Kyle N.; Martinez, Rae Anne; Kiefer, Jeff; Bernstein, Mark; Glen, Jennifer; Butry, Loren; Hinek, Aleksander; Toms, Steven A.; Salhia, Bodour			Isolation and characterization of patient-derived CNS metastasis-associated stromal cell lines	ONCOGENE			English	Article							MESENCHYMAL STEM-CELLS; BREAST-CANCER; BRAIN METASTASES; EXPRESSION; CARCINOMA; FIBROBLASTS; GENERATION; TUMORS; NICHE	The functional role of human derived stromal cells in the tumor microenviornment of CNS metastases (CM) remain understudied. The purpose of the current study was to isolate and characterize stromal cells of the tumor microenvironment in CM. Four different patient-derived cell lines (PDCs) of stromal and one PDC of tumorigenic origin were generated from breast or lung CM. PDCs were analyzed by DNA/RNA sequencing, DNA methylation profiling, and immunophenotypic assays. The stromal derived PDCs were termed CNS metastasis-associated stromal cells (cMASCs). Functional analysis of cMASCs was tested by co-implanting them with tumorigenic cells in mice. cMASCs displayed normal genotypes compared with tumorigenic cell lines. RNA-seq and DNA methylation analyses demonstrated that cMASCs highly resembled each other, suggesting a common cell of origin. Additionally, cMASCs revealed gene expression signatures associated with cancer associated fibroblasts (CAFs), epithelial to mesenchymal transition, mesenchymal stem cells and expressed high levels of collagen. Functionally, cMASCs restricted tumor growth, and induced desmoplasia in vivo, suggesting that cMASCs may promote a protective host response to impede tumor growth. In summary, we demonstrated the isolation, molecular characterization and functional role of human derived cMASCs, a subpopulation of cells in the microenvironment of CM that have tumor inhibitory functions.	[Tew, Ben Yi; Gooden, Gerald C.; Salhia, Bodour] Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Translat Genom, Los Angeles, CA 90033 USA; [Legendre, Christophe; Gooden, Gerald C.; Johnson, Kyle N.; Martinez, Rae Anne; Kiefer, Jeff; Salhia, Bodour] Translat Genom Res Inst, Phoenix, AZ 85004 USA; [Bernstein, Mark; Glen, Jennifer] Univ Hlth Network, Div Neurosurg, Toronto, ON, Canada; [Hinek, Aleksander] Hosp Sickkids, Peter Gilgan Ctr Res & Learning, Toronto, ON, Canada; [Butry, Loren] Geisinger Hlth Syst, Dept Neurosurg, Danville, PA USA; [Toms, Steven A.] Brown Univ, Lifespan Hlth Syst, Dept Neurosurg, Providence, RI 02912 USA; [Toms, Steven A.] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA	University of Southern California; Translational Genomics Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Geisinger Health System; Brown University; Brown University	Salhia, B (corresponding author), Univ Southern Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Translat Genom, Los Angeles, CA 90033 USA.; Salhia, B (corresponding author), Translat Genom Res Inst, Phoenix, AZ 85004 USA.	salhia@usc.edu	Hinek, Aleksander/V-8790-2019	HINEK, Aleksander/0000-0002-5498-6261; Martinez, Rae Anne M./0000-0003-0262-1049	Avon Foundation; Avon Foundation for Women grant [02-2014-064]; National Center for Research Resources [C06RR030524]	Avon Foundation; Avon Foundation for Women grant; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported in part by a grant from the Avon Foundation (BS). Avon Foundation for Women grant#02-2014-064. Animal studies in this work were performed at the University of Arizona Phoenix Campus Vivarium. The University of Arizona Phoenix Campus Vivarium was supported by Award Number C06RR030524 from the National Center for Research Resources. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The authors would also like to thank the patients who contributed their tumors for our study.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Cheng JC, 2011, CANCER LETT, V304, P107, DOI 10.1016/j.canlet.2011.02.008; Christoforides A, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-302; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cirri P, 2011, AM J CANCER RES, V1, P482; Cook D, 2013, ADV EXP MED BIOL, V786, P213, DOI 10.1007/978-94-007-6621-1_12; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; GOMORI G, 1950, AM J CLIN PATHOL, V20, P661, DOI 10.1093/ajcp/20.7_ts.661; Hasebe T, 2002, MODERN PATHOL, V15, P502, DOI 10.1038/modpathol.3880555; Huijbers IJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009808; Kauppila S, 1998, J PATHOL, V186, P262, DOI 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3; Kim HM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0587-9; Kim J, 2013, THORAC CANCER, V4, P167, DOI 10.1111/j.1759-7714.2012.00164.x; Kim LS, 2004, CLIN EXP METASTAS, V21, P107, DOI 10.1023/B:CLIN.0000024761.00373.55; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Legendre CR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150629; Li AQ, 2010, ONCOL REP, V23, P1247, DOI 10.3892/or_00000757; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lillie RD, 1940, STAIN TECHNOL, V15, P17, DOI 10.3109/10520294009110327; Lojewski X, 2015, STEM CELL TRANSL MED, V4, P1223, DOI 10.5966/sctm.2015-0057; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Maher Elizabeth A, 2009, Cancer Res, V69, P6015, DOI 10.1158/0008-5472.CAN-08-4347; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Miller KD, 2003, ANN ONCOL, V14, P1072, DOI 10.1093/annonc/mdg300; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009; Salgado AJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00249; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Saunders CT, 2012, BIOINFORMATICS, V28, P1811, DOI 10.1093/bioinformatics/bts271; Sekar S, 2015, NEUROBIOL AGING, V36, P583, DOI 10.1016/j.neurobiolaging.2014.09.027; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Tosoni A, 2008, CRIT REV ONCOL HEMAT, V68, P212, DOI 10.1016/j.critrevonc.2008.04.004; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486	42	7	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4002	4014		10.1038/s41388-019-0680-2	http://dx.doi.org/10.1038/s41388-019-0680-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30700832	Green Published, hybrid			2022-12-17	WOS:000468740200003
J	Xie, YQ; Fan, HY; Lu, WF; Yang, Q; Nurkesh, A; Yeleussizov, T; Maipas, A; Lu, J; Manarbek, L; Chen, ZB; Benassi, E				Xie, Yingqiu; Fan, Haiyan; Lu, Wenfu; Yang, Qing; Nurkesh, Ayan; Yeleussizov, Tleubek; Maipas, Aisulu; Lu, Jiang; Manarbek, Limara; Chen, Zhenbang; Benassi, Enrico			Nuclear MET requires ARF and is inhibited by carbon nanodots through binding to phospho-tyrosine in prostate cancer	ONCOGENE			English	Article							KINASE INHIBITORS; TUMOR-SUPPRESSOR; ERK ACTIVATION; C-MET; RECEPTOR; RESISTANCE; DOTS; KEGG; TRANSACTIVATION; NANOPARTICLES	Nuclear receptor tyrosine kinases (nRTKs) are aberrantly upregulated in many types of cancers, but the regulation of nRTK remains unclear. We previously showed androgen deprivation therapy (ADT) induces nMET in castration-resistant prostate cancer (CRPC) specimens. Through gene expression microarray profiles reanalysis, we identified that nMET signaling requires ARF for CRPC growth in Pten/Trp53 conditional knockout mouse model. Accordingly, aberrant MET/nMET elevation correlates with ARF in human prostate cancer (PCa) specimens. Mechanistically, ARF elevates nMET through binding to MET cytoplasmic domain to stabilize MET. Furthermore, carbon nanodots resensitize cancer cells to MET inhibitors through DNA damage response. The inhibition of phosphorylation by carbon nanodots was identified through binding to phosphate group of phospho-tyrosine via computational calculation and experimental assay. Thus, nMET is essential to precision therapy of MET inhibitor. Our findings reveal for the first time that targeting nMET axis by carbon nanodots can be a novel avenue for overcoming drug resistance in cancers especially prostate cancer.	[Xie, Yingqiu; Nurkesh, Ayan; Yeleussizov, Tleubek; Maipas, Aisulu; Manarbek, Limara] Nazarbayev Univ, Dept Biol, Sch Sci & Technol, Astana 010000, Kazakhstan; [Fan, Haiyan; Benassi, Enrico] Nazarbayev Univ, Dept Chem, Sch Sci & Technol, Astana 010000, Kazakhstan; [Lu, Wenfu; Yang, Qing; Chen, Zhenbang] Meharry Med Coll, Dept Biochem Canc Biol Neurosci & Pharmacol, Nashville, TN 37208 USA; [Lu, Jiang] Shenzhen Univ, Luohu Hosp, Dept Urol, Shenzhen 51800, Peoples R China; [Lu, Jiang] Luohu Hosp Grp, Shenzhen Following Precis Med Res Inst, Shenzhen 51800, Peoples R China	Nazarbayev University; Nazarbayev University; Meharry Medical College; Shenzhen University	Xie, YQ (corresponding author), Nazarbayev Univ, Dept Biol, Sch Sci & Technol, Astana 010000, Kazakhstan.; Chen, ZB (corresponding author), Meharry Med Coll, Dept Biochem Canc Biol Neurosci & Pharmacol, Nashville, TN 37208 USA.	xieautumnus@yahoo.com; zchen@mmc.edu	Xie, Yingqiu/C-5346-2011	Manarbek, Limara/0000-0002-6101-5025; Nurkesh, Ayan/0000-0001-6418-8223	NIH [U54 MD007593, G12 MD007586, R24 DA036420, S10RR0254970, CA091408, MD004038, MD007586, CA163069, UL1 RR02497501, UL1 TR000445-06]; NATIONAL CANCER INSTITUTE [U54CA163069] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [R01MD004038, U54MD007586] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We would like to thank Drs. Simon W. Hayward and LaMonica Stewart for cell lines, Lynn M. Matrisian for providing MMP7-Luc plasmid. This work was supported in part by NIH grants MD004038, MD007586, CA091408 and CA163069, UL1 RR02497501 and UL1 TR000445-06. IF and IHC analysis was performed by Meharry Medical College Morphology Core, which is supported in part by NIH grants U54 MD007593, G12 MD007586, R24 DA036420, and S10RR0254970. We would like to thank Dr. Guoliang Li, Zhanna Alexeyeva, Aigerim Kabulova, Zhibek Keneskhanova, Akerke Altaikyzy for the kind help or assistant on research. Quantum mechanical calculations were performed on the clusters of the Siberian Supercomputer Center (http://www2.sscc.ru) of the Institute of Computational Mathematics and Mathematical Geophysics of the Siberian Branch of the Russian Academy of Sciences.	Ahn SY, 2017, ANTICANCER RES, V37, P1127, DOI 10.21873/anticanres.11426; Chen WY, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aam6826; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen ZB, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000053; Ding HM, 2018, NANOSCALE HORIZ, V3, P6, DOI 10.1039/c7nh00138j; Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; Humbey O, 2008, CANCER RES, V68, P9608, DOI 10.1158/0008-5472.CAN-08-2263; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kanehisa M, 2016, NUCLEIC ACIDS RES, V44, pD457, DOI 10.1093/nar/gkv1070; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kaur D, 2011, COMPUT THEOR CHEM, V963, P71, DOI 10.1016/j.comptc.2010.09.011; Khoo CM, 2007, P NATL ACAD SCI USA, V104, P3931, DOI 10.1073/pnas.0700093104; Kim SM, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.48; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Klahn M, 2004, J PHYS CHEM A, V108, P6186, DOI 10.1021/jp048617g; Lachat Y, 2004, ONCOGENE, V23, P6854, DOI 10.1038/sj.onc.1207872; Li CL, 2014, J MATER CHEM B, V2, P4564, DOI 10.1039/c4tb00216d; Likos CN, 2001, PHYS REP, V348, P267, DOI 10.1016/S0370-1573(00)00141-1; Liu ST, 2016, SCI REP-UK, V6, DOI 10.1038/srep37761; Lu WF, 2013, MOL ENDOCRINOL, V27, P635, DOI 10.1210/me.2012-1294; Mizrachi A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14292; Mudryj M, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-5051; Petrushev B, 2016, INT J NANOMED, V11, P641, DOI 10.2147/IJN.S94064; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Pozner-Moulis S, 2006, CANCER RES, V66, P7976, DOI 10.1158/0008-5472.CAN-05-4335; Song A, 2015, CLIN CANCER RES, V21, P2379, DOI 10.1158/1078-0432.CCR-14-1350; Tu WH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-556; Vacha R, 2011, NANO LETT, V11, P5391, DOI 10.1021/nl2030213; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Vivo M, 2017, ONCOGENE, V36, P4913, DOI 10.1038/onc.2017.104; Wanjala J, 2015, MOL CANCER THER, V14, P278, DOI 10.1158/1535-7163.MCT-14-0542-T; Xie Y, 2008, J BIOL CHEM, V283, P3349, DOI 10.1074/jbc.M707773200; Xie YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16441-y; Xie YQ, 2017, CHEMISTRYSELECT, V2, P4079, DOI 10.1002/slct.201700575; Xie YQ, 2016, ONCOTARGET, V7, P47609, DOI 10.18632/oncotarget.10251; Xie YQ, 2016, CURR CANCER DRUG TAR, V16, P572, DOI 10.2174/1568009616666160105105250; Xie YQ, 2014, MOL ONCOL, V8, P1355, DOI 10.1016/j.molonc.2014.05.006; Xie YQ, 2014, MOL ENDOCRINOL, V28, P1629, DOI 10.1210/me.2014-1078; Xie YQ, 2010, MOL PHARMACOL, V78, P310, DOI 10.1124/mol.109.061713; Yu JX, 2009, EMBO J, V28, P21, DOI 10.1038/emboj.2008.238; Yuan YF, 2017, COLLOID SURFACE B, V159, P349, DOI 10.1016/j.colsurfb.2017.07.030; Zhang M, 2017, CANCER BIOL MED, V14, P212, DOI 10.20892/j.issn.2095-3941.2017.0054	50	7	7	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2967	2983		10.1038/s41388-018-0608-2	http://dx.doi.org/10.1038/s41388-018-0608-2			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30568225	Green Accepted, Green Submitted			2022-12-17	WOS:000465167600007
J	Chiang, YJ; Liao, WT; Ho, KC; Wang, SH; Chen, YG; Ho, CL; Huang, SF; Shih, LY; Yang-Yen, HF; Yen, JJY				Chiang, Yun-Jung; Liao, Wei-Ting; Ho, Kun-Chin; Wang, Shih-Hao; Chen, Yu-Guang; Ho, Ching-Liang; Huang, Shiu-Feng; Shih, Lee-Yung; Yang-Yen, Hsin-Fang; Yen, Jeffrey Jong-Young			CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia	ONCOGENE			English	Article							TUBEROUS SCLEROSIS; TSC1-TSC2 COMPLEX; LYSOSOMAL RECRUITMENT; MTOR; TARGET; PTEN; APOPTOSIS; INACTIVATION; INTEGRATION; DOWNSTREAM	High-frequency relapse remains a clinical hurdle for complete remission of T-cell acute lymphoblastic leukemia (T-ALL) patients, with heterogeneous dysregulated signaling profiles-including of Raf-MEK-ERK and Akt-mTORC1-S6K signaling pathways-recently being implicated in disease outcomes. Here we report that GM-CSF/IL-3/IL-5 receptor common beta-chain-associated protein (CBAP) is highly expressed in human T-ALL cell lines and many primary tumor tissues and is required to bolster leukemia cell proliferation in tissue culture and for in vivo leukemogenesis in a xenograft mouse model. Downregulation of CBAP markedly restrains expansion of leukemia cells and alleviates disease aggravation of leukemic mice. Transcriptomic profiling and molecular biological analyses suggest that CBAP acts upstream of Ras and Rac1, and functions as a modulator of both Raf-MEK-ERK and Akt-mTORC1 signaling pathways to control leukemia cell growth. Specifically, CBAP facilitated Akt-dependent TSC2 phosphorylation in cell-based assays and in vitro analysis, decreased lysosomal localization of TSC2, and elevated Rheb-GTP loading and subsequent activation of mTORC1 signaling. Taken together, our findings reveal a novel oncogenic contribution of CBAP in T-ALL leukemic cells, in addition to its original proapoptotic function in cytokine-dependent cell lines and primary hematopoietic cells, by demonstrating its functional role in the regulation of Akt-TSC2-mTORC1 signaling for leukemia cell proliferation. Thus, CBAP represents a novel therapeutic target for many types of cancers and metabolic diseases linked to PI3K-Akt-mTORC1 signaling.	[Chiang, Yun-Jung; Liao, Wei-Ting; Ho, Kun-Chin; Wang, Shih-Hao; Yen, Jeffrey Jong-Young] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chen, Yu-Guang; Ho, Ching-Liang] Natl Def Med Ctr, Div Hematol Oncol, Dept Internal Med, Triserv Gen Hosp, Taipei 11490, Taiwan; [Huang, Shiu-Feng] Natl Hlth Res Inst, Inst Mol & Genom Med, Miaoli 35053, Taiwan; [Shih, Lee-Yung] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Dept Internal Med,Coll Med, Taoyuan 33305, Taiwan; [Yang-Yen, Hsin-Fang] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; Tri-Service General Hospital; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital; Chang Gung University; Academia Sinica - Taiwan	Yen, JJY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.	bmjyen@ibms.sinica.edu.tw	Yen, Jeffrey Jong-Young/Q-5134-2018; Yang-Yen, Hsin-Fang/ABA-5808-2021	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Yang-Yen, Hsin-Fang/0000-0001-9048-4800; Chiang, Yun-Jung/0000-0001-5024-8977	Ministry of Science and Technology, Taiwan [NSC102-2320-B001-007-MY3, MOST105-2320-B-001-012-MY3]; Tri-Service General Hospital [TSGH-106-01-34, MOST103-2811-B-001-090, MOST105-2811-B-001-044]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); Tri-Service General Hospital	We thank Dr. Richard Lin at Stony Brook University Medical Center for his careful reading of the manuscript and his suggestions. We thank the National Center for Genome Medicine, National RNAi Core Facility, and the Molecular and Genetic Imaging Core of the Taiwan Mouse Clinic for their technical support. This work was supported by grants from the Ministry of Science and Technology, Taiwan to JJYY (NSC102-2320-B001-007-MY3 and MOST105-2320-B-001-012-MY3), and was partly supported by Tri-Service General Hospital (TSGH-106-01-34). YJC is supported by postdoctoral fellowships MOST103-2811-B-001-090 and MOST105-2811-B-001-044.	Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Blackburn JS, 2014, CANCER CELL, V25, P366, DOI 10.1016/j.ccr.2014.01.032; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Chiang YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061761; Chiarini F, 2010, CANCER RES, V70, P8097, DOI 10.1158/0008-5472.CAN-10-1814; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Demetriades C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10662; Demetriades C, 2014, CELL, V156, P786, DOI 10.1016/j.cell.2014.01.024; Dennis MD, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005103; Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Gokbuget N, 2012, BLOOD, V120, P2032, DOI 10.1182/blood-2011-12-399287; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Gutierrez A, 2009, BLOOD, V114, P647, DOI 10.1182/blood-2009-02-206722; Ho KC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.474; Hoshii T, 2014, J BIOCHEM, V156, P73, DOI 10.1093/jb/mvu037; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jotta PY, 2010, LEUKEMIA, V24, P239, DOI 10.1038/leu.2009.209; Kao CJ, 2008, ONCOGENE, V27, P1397, DOI 10.1038/sj.onc.1210778; Keeshan K, 2006, CANCER CELL, V10, P401, DOI 10.1016/j.ccr.2006.09.012; Keeshan K, 2010, BLOOD, V116, P4948, DOI 10.1182/blood-2009-10-247361; Kuchta K, 2009, NUCLEIC ACIDS RES, V37, P7701, DOI 10.1093/nar/gkp854; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lin KR, 2007, J BIOL CHEM, V282, P21962, DOI 10.1074/jbc.M701663200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonetti A, 2015, ONCOTARGET, V6, P10399, DOI 10.18632/oncotarget.3295; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049; Nikolaidis N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000204; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Roti G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00170; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616; Silverman LB, 1999, CANCER-AM CANCER SOC, V85, P1395, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1395::AID-CNCR25>3.0.CO;2-2; Stofega Mary, 2006, V332, P269; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Wermuth PJ, 2005, BLOOD, V105, P1222, DOI 10.1182/blood-2004-03-0802; You MJ, 2015, AM J CLIN PATHOL, V144, P411, DOI 10.1309/AJCPMF03LVSBLHPJ; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	44	7	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1432	1447		10.1038/s41388-018-0507-6	http://dx.doi.org/10.1038/s41388-018-0507-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30266989	Green Published, hybrid			2022-12-17	WOS:000459945800005
J	de Boer, HR; Pool, M; Joosten, E; Everts, M; Samplonius, DF; Helfrich, W; Groen, HJM; van Cooten, S; Fusetti, F; Fehrmann, RSN; de Vries, EGE; van Vugt, MATM				de Boer, H. Rudolf; Pool, Martin; Joosten, Esmee; Everts, Marieke; Samplonius, Douwe F.; Helfrich, Wijnand; Groen, Harry J. M.; van Cooten, Suzanne; Fusetti, Fabrizia; Fehrmann, Rudolf S. N.; de Vries, Elisabeth G. E.; van Vugt, Marcel A. T. M.			Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition	ONCOGENE			English	Article							LUNG-CANCER; UP-REGULATION; MET AMPLIFICATION; STAT3 ACTIVATION; DRUG DEVELOPMENT; EXPRESSION; RESISTANCE; FAMILY; GEFITINIB; PROGNOSIS	Tumor responses to cancer therapeutics are generally monitored every 2-3 months based on changes in tumor size. Dynamic biomarkers that reflect effective engagement of targeted therapeutics to the targeted pathway, so-called "effect sensors", would fulfill a need for non-invasive, drug-specific indicators of early treatment effect. Using a proteomics approach to identify effect sensors, we demonstrated MUC1 upregulation in response to epidermal growth factor receptor (EGFR)targeting treatments in breast and lung cancer models. To achieve this, using semi-quantitative mass spectrometry, we found MUC1 to be significantly and durably upregulated in response to erlotinib, an EGFR-targeting treatment. MUC1 upregulation was regulated transcriptionally, involving PI3K-signaling and STAT3. We validated these results in erlotinib-sensitive human breast and non-small lung cancer cell lines. Importantly, erlotinib treatment of mice bearing SUM149 xenografts resulted in increased MUC1 shedding into plasma. Analysis of MUC1 using serial blood sampling may therefore be a new, relatively non-invasive tool to monitor early and drug-specific effects of EGFR-targeting therapeutics.	[de Boer, H. Rudolf; Pool, Martin; Joosten, Esmee; Everts, Marieke; van Cooten, Suzanne; Fehrmann, Rudolf S. N.; de Vries, Elisabeth G. E.; van Vugt, Marcel A. T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Samplonius, Douwe F.; Helfrich, Wijnand] Univ Groningen, Univ Med Ctr Groningen, Dept Surg Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Groen, Harry J. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, Hanzepl 1, NL-9713 GZ Groningen, Netherlands; [Fusetti, Fabrizia] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Biochem, Netherlands Prote Ctr, Groningen, Netherlands; [Fusetti, Fabrizia] Univ Groningen, Zernike Inst Adv Mat, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	m.vugt@umcg.nl	Fehrmann, Rudolf/E-2551-2011; Institute, Zernike/W-7033-2019; Groen, Harry/AAP-2242-2021	Fehrmann, Rudolf/0000-0002-7516-315X; de Vries, Elisabeth/0000-0002-8949-7425; de Boer, Harmen Rudolf/0000-0002-8386-8184; Pool, Martin/0000-0002-4892-3109; Groen, Harry J.M./0000-0002-2978-5265	European Research Council (ERC-Advanced Grant) [ERC-2011-293-445]	European Research Council (ERC-Advanced Grant)(European Research Council (ERC))	We thank members of the Medical Oncology Department and Cancer Research Center Groningen for helpful discussions. This work is financially supported by the European Research Council (ERC-Advanced Grant ERC-2011-293-445 to E.G.E.d.V.). E.G. E.d.V. and M.A.T.M.v.V. conceived the study. H.R.d.B., E.J.,S.v.C., and M.E. designed and performed in vitro experiments. E.J. and F.F. performed MS experiments and analysis. R.S.N.F. and H.R.d.B. performed pathway analysis. M.P., D.F.S., and W.H. designed and manufactured molecular imaging tools. H.R.d.B. and M.P. performed in vivo experiments. H.R.d.B., E.G. E.d.V., and M.A.T.M.v.V. wrote the manuscript and all authors contributed to editing of the manuscript. The mass spectrometry proteomics data have been deposited to the Proteome-Xchange Consortium (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository 51 with the dataset identifier PXD005985.	Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949; Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bearz A, 2007, INT J BIOL MARKER, V22, P307, DOI 10.1177/172460080702200411; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; D'Alessandro R, 2001, BREAST CANCER RES TR, V68, P9, DOI 10.1023/A:1017903724176; de Vries EGE, 2015, J CLIN ONCOL, V33, P2585, DOI 10.1200/JCO.2015.61.6425; de Vries EGE, 2011, CANCER DISCOV, V1, P25, DOI 10.1158/2159-8274.CD-11-0051; Duffy MJ, 2015, ADV CLIN CHEM, V71, P1, DOI [10.1016/bs.acc.2015.05.001, 10.1016/B978-0-12-801401-1.00001-3]; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Fujiwara Y, 2008, LUNG CANCER, V59, P81, DOI 10.1016/j.lungcan.2007.07.018; Gaemers IC, 2001, J BIOL CHEM, V276, P6191, DOI 10.1074/jbc.M009449200; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Ishikawa N, 2008, INT J CANCER, V122, P2612, DOI 10.1002/ijc.23411; Kani K, 2012, MOL CANCER THER, V11, P1071, DOI 10.1158/1535-7163.MCT-11-0852; Kearns NA, 2014, DEVELOPMENT, V141, P219, DOI 10.1242/dev.103341; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee SI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r76; Lopez JS, 2017, NAT REV CLIN ONCOL, V14, P57, DOI 10.1038/nrclinonc.2016.96; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Petrylak DP, 2006, J NATL CANCER I, V98, P516, DOI 10.1093/jnci/djj129; Pool M, 2017, EUR J NUCL MED MOL I, V44, P1328, DOI 10.1007/s00259-017-3672-x; Pool M, 2017, THERANOSTICS, V7, P2111, DOI 10.7150/thno.17934; Pool M, 2016, ONCOTARGET, V7, P68111, DOI 10.18632/oncotarget.11827; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Savage P, 2017, CELL REP, V21, P1140, DOI 10.1016/j.celrep.2017.10.015; Sequist LV, 2013, J CLIN ONCOL, V31; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Starsichova A, 2010, CELL SIGNAL, V22, P1734, DOI 10.1016/j.cellsig.2010.06.014; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Ueno NT, 2011, J CANCER, V2, P324, DOI 10.7150/jca.2.324; Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56; Vizcaino JA, 2013, NUCLEIC ACIDS RES, V41, pD1063, DOI 10.1093/nar/gks1262; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; White DE, 2006, CANCER RES, V66, P11594, DOI 10.1158/0008-5472.CAN-06-4138; Yamasaki F, 2007, MOL CANCER THER, V6, P2168, DOI 10.1158/1535-7163.MCT-06-0514	51	7	7	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1477	1488		10.1038/s41388-018-0522-7	http://dx.doi.org/10.1038/s41388-018-0522-7			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30305724	Green Published			2022-12-17	WOS:000459945800008
J	Kha, ML; Hesse, L; Deisinger, F; Sipos, B; Rocken, C; Arlt, A; Sebens, S; Helm, O; Schafer, H				Kha, My-Lan; Hesse, Lisa; Deisinger, Florian; Sipos, Bence; Roecken, Christoph; Arlt, Alexander; Sebens, Susanne; Helm, Ole; Schaefer, Heiner			The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant Delta Zip2	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; NUCLEAR FACTOR; GENE ATF3; CANCER; APOPTOSIS; PATHWAY; PROLIFERATION; CARCINOMA; ONCOGENE; GROWTH	Pancreatic ductal adenocarcinoma (PDAC) exhibits one of the worst survival rates of all cancers. While death rates show declining trends in the majority of cancers, PDAC registers rising rates. Based on the recently described crosstalk between TGF-beta 1 and Nrf2 in the PDAC development, the involvement of ATF3 and its splice variant Delta Zip2 in TGF-beta 1- and Nrf2-driven pancreatic tumorigenesis was investigated. As demonstrated here, PDAC (Panc1, T3M4) cells or premalignant H6c7 pancreatic ductal epithelial cells differentially express Delta Zip2- and ATF3, relating to stronger Nrf2 activity seen in Panc1 cells and TGF-beta 1 activity in T3M4 or H6c7 cells, respectively. Treatment with the electrophile/oxidative stress inducer tBHQ or the cytostatic drug gemcitabine strongly elevated Delta Zip2 expression in a Nrf2-dependent fashion. The differential expression of ATF3 and Delta Zip2 in response to Nrf2 and TGF-beta 1 relates to differential ATF3-gene promoter usage, giving rise of distinct splice variants. Nrf2-dependent Delta Zip2 expression confers resistance against gemcitabine-induced apoptosis, only partially relating to interference with ATF3 and its proapoptotic activity, e.g., through CHOP-expression. In fact, Delta Zip2 autonomously activates expression of cIAP anti-apoptotic proteins. Moreover, Delta Zip2 favors and ATF3 suppresses growth and clonal expansion of PDAC cells, again partially independent of each other. Using a Panc1 tumor xenograft model in SCID-beige mice, the opposite activities of ATF3 and Delta Zip2 on tumor-growth and chemoresistance were verified in vivo. Immunohistochemical analyses confirmed Delta Zip2 and Nrf2 coexpression in cancerous and PanIN structures of human PDAC and chronic pancreatitis tissues, respectively, which to some extent was reciprocal to ATF3 expression. It is concluded that depending on selective ATF3-gene promoter usage by Nrf2, the Delta Zip2 expression is induced in response to electrophile/oxidative (here through tBHQ) and xenobiotic (here through gemcitabine) stress, providing apoptosis protection and growth advantages to pancreatic ductal epithelial cells. This condition may substantially add to pancreatic carcinogenesis driven by chronic inflammation.	[Kha, My-Lan; Hesse, Lisa; Deisinger, Florian; Schaefer, Heiner] Univ Kiel, Lab Mol Gastroenterol & Tumor Biol, Inst Expt Canc Res, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Kha, My-Lan; Hesse, Lisa; Deisinger, Florian; Sebens, Susanne; Helm, Ole; Schaefer, Heiner] UKSH, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Sipos, Bence] Univ Hosp Tubingen, Dept Pathol & Neuropathol, Liebermeisterstr 8, D-72076 Tubingen, Germany; [Roecken, Christoph] Univ Kiel, Inst Pathol, Campus Kiel,Bldg 14,Arnold Heller Str 3, Kiel, Germany; [Roecken, Christoph] UKSH, Campus Kiel,Bldg 14,Arnold Heller Str 3, Kiel, Germany; [Roecken, Christoph; Sebens, Susanne] UKSH, Biomat Bank, Comprehens Canc Ctr Kiel, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany; [Arlt, Alexander] UKSH, Lab Gastrointestinal Signal Transduct, Dept Internal Med 1, Campus Kiel,Bldg 6,Arnold Heller Str 3, D-24105 Kiel, Germany; [Sebens, Susanne; Helm, Ole] Univ Kiel, Grp Inflammatory Carcinogenesis, Inst Expt Canc Res, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany	University of Kiel; University of Kiel; Schleswig Holstein University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Kiel; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel	Schafer, H (corresponding author), Univ Kiel, Lab Mol Gastroenterol & Tumor Biol, Inst Expt Canc Res, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany.; Schafer, H (corresponding author), UKSH, Campus Kiel,Bldg 17,Arnold Heller Str 3, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Röcken, Christoph/A-9239-2010; Arlt, Alexander/G-7308-2019; Sebens, Susanne/C-1222-2010; Schäfer, Heiner/C-1055-2011	Röcken, Christoph/0000-0002-6989-8002; Arlt, Alexander/0000-0002-6160-1059; 	Medical Faculty of the CAU Kiel; Cluster of Excellence "Inflammation at Interfaces"	Medical Faculty of the CAU Kiel; Cluster of Excellence "Inflammation at Interfaces"	Financial support by the Medical Faculty of the CAU Kiel (to HS and OH) and the Cluster of Excellence "Inflammation at Interfaces" (to HS, AA, and SS) is greatly acknowledged.	Arfmann-Knubel S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132978; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Bachem MG, 2005, GASTROENTEROLOGY, V128, P907, DOI 10.1053/j.gastro.2004.12.036; Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033; Brown SL, 2008, CANCER RES, V68, P364, DOI 10.1158/0008-5472.CAN-07-2170; Buganim Y, 2011, CARCINOGENESIS, V32, P1749, DOI 10.1093/carcin/bgr203; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Disis ML, 2010, J CLIN ONCOL, V28, P4531, DOI 10.1200/JCO.2009.27.2146; Distler M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/474905; Dziunycz PJ, 2014, J INVEST DERMATOL, V134, P1998, DOI 10.1038/jid.2014.77; Erkan M, 2013, PANCREATOLOGY, V13, P106, DOI 10.1016/j.pan.2013.01.008; Esakky P, 2015, J MOL CELL BIOL, V7, P73, DOI 10.1093/jmcb/mju049; Evans A, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00270; Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4; Ganan-Gomez I, 2013, FREE RADICAL BIO MED, V65, P750, DOI 10.1016/j.freeradbiomed.2013.06.041; Geismann C, 2014, ONCOTARGETS THER, V7, P1497, DOI 10.2147/OTT.S36624; Geismann C, 2009, CANCER RES, V69, P4517, DOI 10.1158/0008-5472.CAN-08-3493; Genrich G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2191-7; Hai T, 1999, GENE EXPRESSION, V7, P321; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; Hawkins KE, 2016, CELL REP, V14, P1883, DOI 10.1016/j.celrep.2016.02.003; Hayes AJ, 2015, INT J BIOCHEM CELL B, V65, P288, DOI 10.1016/j.biocel.2015.06.017; Helm O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094357; Hiss DC, 2009, EXPERT OPIN DRUG DIS, V4, P799, DOI 10.1517/17460440903052559; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hua B, 2006, J BIOL CHEM, V281, P1620, DOI 10.1074/jbc.M508471200; Hunt D, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00007; Inman KS, 2014, WORLD J GASTROENTERO, V20, P11160, DOI 10.3748/wjg.v20.i32.11160; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Jiang XJ, 2016, ANTICANCER RES, V36, P509; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kang KW, 2005, ANTIOXID REDOX SIGN, V7, P1664, DOI 10.1089/ars.2005.7.1664; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kim KH, 2010, NUCLEIC ACIDS RES, V38, P48, DOI 10.1093/nar/gkp865; Kimura K, 2006, GENOME RES, V16, P55, DOI 10.1101/gr.4039406; La Rosa S, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00041; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Lohr M, 2001, CANCER RES, V61, P550; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Miyazaki K, 2009, NUCLEIC ACIDS RES, V37, P1438, DOI 10.1093/nar/gkn1082; Muerkoster SS, 2008, INT J CANCER, V123, P1751, DOI 10.1002/ijc.23703; Murakami S, 2015, FREE RADICAL BIO MED, V88, P168, DOI 10.1016/j.freeradbiomed.2015.06.030; Nilsson M, 1997, CELL GROWTH DIFFER, V8, P913; O'Brien A, 2012, ANTICANCER RES, V32, P2679; Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006; Pan YX, 2003, J BIOL CHEM, V278, P38402, DOI 10.1074/jbc.M304574200; Pandol S, 2009, CLIN GASTROENTEROL H, V7, pS44, DOI 10.1016/j.cgh.2009.07.039; Reichert M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9298535; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Sato A, 2014, FEBS J, V281, P1892, DOI 10.1111/febs.12752; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sipos B, 2009, PANCREATOLOGY, V9, P45, DOI 10.1159/000178874; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Thompson MR, 2009, J MOL MED, V87, P1053, DOI 10.1007/s00109-009-0520-x; Wang A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-268; Weng SY, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0442-3; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861; Yin X, 2010, J CELL SCI, V123, P3558, DOI 10.1242/jcs.064915	64	7	7	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2019	38	9					1461	1476		10.1038/s41388-018-0518-3	http://dx.doi.org/10.1038/s41388-018-0518-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN1KL	30302023				2022-12-17	WOS:000459945800007
J	Pai, VC; Hsu, CC; Chan, TS; Liao, WY; Chuu, CP; Chen, WY; Li, CR; Lin, CY; Huang, SP; Chen, LT; Tsai, KK				Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Liao, Wen-Ying; Chuu, Chih-Pin; Chen, Wei-Yu; Li, Chi-Rong; Lin, Ching-Yu; Huang, Shu-Pin; Chen, Li-Tzong; Tsai, Kelvin K.			ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling (vol 38, pg 1340, 2018)	ONCOGENE			English	Correction									[Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei 11031, Taiwan; [Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Wan Fang Hosp, Div Gastroenterol, Dept Internal Med,Lab Adv Mol Therapeut, Taipei 11696, Taiwan; [Pai, Vincent C.; Liao, Wen-Ying; Chen, Li-Tzong; Tsai, Kelvin K.] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan; [Chuu, Chih-Pin; Lin, Ching-Yu] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan 35053, Miaoli County, Taiwan; [Chen, Wei-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 11696, Taiwan; [Li, Chi-Rong] Minist Hlth & Welf, Dept Teaching & Res, Taichung Hosp, Taichung 40343, Taiwan; [Huang, Shu-Pin] Kaohsiung Med Univ, Dept Urol, Chung Ho Mem Hosp, Kaohsiung 80756, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Tsai, KK (corresponding author), Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei 11031, Taiwan.; Tsai, KK (corresponding author), Taipei Med Univ, Wan Fang Hosp, Div Gastroenterol, Dept Internal Med,Lab Adv Mol Therapeut, Taipei 11696, Taiwan.; Tsai, KK (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan.	tsaik@tmu.edu.tw		Li, Chi-Rong/0000-0002-0314-8284; Tsai, Kelvin/0000-0002-1612-2868				Pai VC, 2019, ONCOGENE, V38, P1340, DOI 10.1038/s41388-018-0497-4	1	7	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1354	1354		10.1038/s41388-018-0561-0	http://dx.doi.org/10.1038/s41388-018-0561-0			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30390070	Bronze			2022-12-17	WOS:000459249800015
J	Lin, SC; Chung, CH; Chung, CH; Kuo, MH; Hsieh, CH; Chiu, YF; Shieh, YS; Chou, YT; Wu, CW				Lin, Sheng-Chieh; Chung, Chi-Hsiu; Chung, Chih-Hung; Kuo, Ming-Han; Hsieh, Cheng-Han; Chiu, Yu-Fan; Shieh, Yi-Shing; Chou, Yu-Ting; Wu, Cheng-Wen			OCT4B mediates hypoxia-induced cancer dissemination	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LUNG ADENOCARCINOMA; INDUCIBLE FACTORS; STEM; PROTEIN; CELLS; OCT-4; GENE; SLUG; TRANSACTIVATION	Hypoxia, the reduction of oxygen levels in cells or tissues, elicits a set of genes to adjust physiological and pathological demands during normal development and cancer progression. OCT4, a homeobox transcription factor, is essential for self-renewal of embryonic stem cells, but little is known about the role of OCT4 in non-germ-cell tumorigenesis. Here, we report that hypoxia stimulates a short isoform of OCT4, called OCT4B, via a HIF2 alpha-dependent pathway to induce the epithelial-mesenchymal transition (EMT) and facilitate cancer dissemination. OCT4B overexpression decreased epithelial barrier properties, which led to an increase in cell migration and invasion in lung cancer cells. OCT4B knockdown attenuated HIF2 alpha-induced EMT and inhibited cancer dissemination in cell-line and animal models. We observed that OCT4B bound the SLUG promoter and enhanced its expression, and SLUG silencing inhibited OCT4B-mediated EMT, accompanied with decreased cell migration and invasion. Correlation analysis revealed that OCT4B expression was significantly associated with the SLUG level in lung tumors. These results provide novel insights into OCT4B-mediated oncogenesis in cancer dissemination.	[Lin, Sheng-Chieh; Kuo, Ming-Han; Chiu, Yu-Fan; Chou, Yu-Ting; Wu, Cheng-Wen] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan; [Lin, Sheng-Chieh] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Chung, Chi-Hsiu; Chung, Chih-Hung; Wu, Cheng-Wen] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan; [Hsieh, Cheng-Han; Wu, Cheng-Wen] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan; [Hsieh, Cheng-Han] Taipei Med Univ, Res Ctr Canc Translat Med, Taipei, Taiwan; [Shieh, Yi-Shing] Triserv Gen Hosp, Dept Oral Diag & Pathol, Taipei, Taiwan; [Wu, Cheng-Wen] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan	National Tsing Hua University; China Medical University Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Medical University; Tri-Service General Hospital; Academia Sinica - Taiwan	Chou, YT; Wu, CW (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu, Taiwan.; Wu, CW (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei, Taiwan.; Wu, CW (corresponding author), Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan.; Wu, CW (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.	ytchou@life.nthu.edu.tw; cwwu@ym.edu.tw		Chou, Yu-Ting/0000-0001-9274-8603	National Tsing Hua University; National Yang-Ming University; Institute of Biomedical Science at Academia Sinica; Ministry of Science and Technology [NSC 102-2320-B-007-010, MOST104-2321-B-010-007, MOST 105-2325-B-010-003, MOST 106-2320-B-007-005-MY3]; Ministry of Health and Welfare, Executive Yuan, Taiwan [MOHW105-TDU-B-211-134003]	National Tsing Hua University; National Yang-Ming University; Institute of Biomedical Science at Academia Sinica; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Ministry of Health and Welfare, Executive Yuan, Taiwan	This work was supported by National Tsing Hua University, National Yang-Ming University, Institute of Biomedical Science at Academia Sinica, Ministry of Science and Technology (NSC 102-2320-B-007-010, MOST104-2321-B-010-007, MOST 105-2325-B-010-003, MOST 106-2320-B-007-005-MY3), and Ministry of Health and Welfare (MOHW105-TDU-B-211-134003), Executive Yuan, Taiwan.	Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Bollineni VR, 2012, CANCER TREAT REV, V38, P1027, DOI 10.1016/j.ctrv.2012.04.003; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Chou YT, 2012, CELL DEATH DIFFER, V19, P2015, DOI 10.1038/cdd.2012.91; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; Crino L, 2010, ANN ONCOL, V21, pv103, DOI 10.1093/annonc/mdq207; Gao Y, 2012, STEM CELLS, V30, P665, DOI 10.1002/stem.1034; Gao YA, 2010, J GENET GENOMICS, V37, P461, DOI 10.1016/S1673-8527(09)60065-5; Guo CL, 2012, STEM CELL RES, V9, P69, DOI 10.1016/j.scr.2012.04.004; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Jiang JA, 2011, CANCER BIOL THER, V11, P714, DOI 10.4161/cbt.11.8.15274; Karoubi Golnaz, 2009, Interact Cardiovasc Thorac Surg, V8, P393, DOI 10.1510/icvts.2008.193995; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lee J, 2006, J BIOL CHEM, V281, P33554, DOI 10.1074/jbc.M603937200; Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134; Pani G, 2010, CANCER METAST REV, V29, P351, DOI 10.1007/s10555-010-9225-4; Papamichos SI, 2009, GENE CHROMOSOME CANC, V48, P1112, DOI 10.1002/gcc.20707; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Theodorou E, 2009, GENE DEV, V23, P575, DOI 10.1101/gad.1772509; Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10; Wang X, 2009, STEM CELLS, V27, P1265, DOI 10.1002/stem.58; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje	39	7	8	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1093	1105		10.1038/s41388-018-0487-6	http://dx.doi.org/10.1038/s41388-018-0487-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30209362				2022-12-17	WOS:000458624900012
J	Zhang, MQ; Suarez, E; Vasquez, JL; Nathanson, L; Peterson, LE; Rajapakshe, K; Basil, P; Weigel, NL; Coarfa, C; Agoulnik, IU				Zhang, Manqi; Suarez, Egla; Vasquez, Judy L.; Nathanson, Lubov; Peterson, Leif E.; Rajapakshe, Kimal; Basil, Paul; Weigel, Nancy L.; Coarfa, Cristian; Agoulnik, Irina U.			Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity	ONCOGENE			English	Article							FORKHEAD BOX A1; TUMOR-SUPPRESSOR; SPLICE VARIANT; CANCER DEVELOPMENT; MOUSE PROSTATE; COREPRESSOR 1; PKC-EPSILON; INPP4B; CASTRATION; EXPRESSION	Activation and transcriptional reprogramming of AR in advanced prostate cancer frequently coincides with the loss of two tumor suppressors, INPP4B and PTEN, which are highly expressed in human and mouse prostate epithelium. While regulation of AR signaling by PTEN has been described by multiple groups, it is not known whether the loss of INPP4B affects AR activity. Using prostate cancer cell lines, we showed that INPP4B regulates AR transcriptional activity and the oncogenic signaling pathways Akt and PKC. Analysis of gene expression in prostate cancer patient cohorts showed a positive correlation between INPP4B expression and both AR mRNA levels and AR transcriptional output. Using an Inpp4b(-/-) mouse model, we demonstrated that INPP4B suppresses Akt and PKC signaling pathways and modulates AR transcriptional activity in normal mouse prostate. Remarkably, PTEN protein levels and phosphorylation of S380 were the same in Inpp4b(-/-) and WT males, suggesting that the observed changes were due exclusively to the loss of INPP4B. Our data show that INPP4B modulates AR activity in normal prostate and its loss contributes to the AR-dependent transcriptional profile in prostate cancer.	[Zhang, Manqi] Florida Int Univ, Dept Chem & Biochem, Miami, FL 33199 USA; [Suarez, Egla; Vasquez, Judy L.; Agoulnik, Irina U.] Florida Int Univ, Herbert Wertheim Coll Med, Dept Human & Mol Genet, Miami, FL 33199 USA; [Nathanson, Lubov] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA; [Peterson, Leif E.] Houston Methodist Res Inst, Ctr Biostat, Houston, TX USA; [Rajapakshe, Kimal; Basil, Paul; Weigel, Nancy L.; Coarfa, Cristian; Agoulnik, Irina U.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Agoulnik, Irina U.] Florida Int Univ, Biomol Sci Inst, Sch Integrated Sci & Humanity, Miami, FL 33199 USA	State University System of Florida; Florida International University; State University System of Florida; Florida International University; Nova Southeastern University; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; State University System of Florida; Florida International University	Agoulnik, IU (corresponding author), Florida Int Univ, Herbert Wertheim Coll Med, Dept Human & Mol Genet, Miami, FL 33199 USA.; Agoulnik, IU (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Agoulnik, IU (corresponding author), Florida Int Univ, Biomol Sci Inst, Sch Integrated Sci & Humanity, Miami, FL 33199 USA.	Irina.Agoulnik@fiu.edu	Agoulnik, Irina/AAD-4687-2020; Nathanson, Lubov/ABC-2642-2021	Agoulnik, Irina/0000-0003-4889-0324; Nathanson, Lubov/0000-0003-1038-9083	NCI [P30CA125123, R15 CA17928701A1]; CPRIT grant [RP170005, RP150648]; NATIONAL CANCER INSTITUTE [R15CA179287, P30CA125123] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI grant R15 CA17928701A1 (IUA), NCI grant P30CA125123 (CC), CPRIT grant RP150648 (NLW, CC), and CPRIT grant RP170005 (CC).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Agoulnik IU, 2011, ONCOTARGET, V2, P321; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bin Hafeez B, 2011, CANCER RES, V71, P2318, DOI 10.1158/0008-5472.CAN-10-4170; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chen M, 2014, CLIN CANCER RES, V20, P3057, DOI 10.1158/1078-0432.CCR-12-3680; Chew CL, 2015, CANCER DISCOV, V5, P740, DOI 10.1158/2159-8290.CD-14-1347; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Creba JA, 1983, BIOCHEM J, V212, P15; Darne C, 1998, EUR J BIOCHEM, V256, P9; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Ferron M, 2011, CELL METAB, V14, P466, DOI 10.1016/j.cmet.2011.08.013; Gao N, 2005, DEVELOPMENT, V132, P3431, DOI 10.1242/dev.01917; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Garabedian MJ, 2008, TRENDS BIOCHEM SCI, V33, P301, DOI 10.1016/j.tibs.2008.04.011; Gavrielides MV, 2006, CANCER RES, V66, P11792, DOI 10.1158/0008-5472.CAN-06-1139; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Guedes LB, 2016, CLIN CANCER RES, V22, P4651, DOI 10.1158/1078-0432.CCR-16-0205; Guo ST, 2016, ONCOGENE, V35, P3049, DOI 10.1038/onc.2015.361; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Henttu P, 1998, BIOCHEM BIOPH RES CO, V224, P5; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hodgson MC, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0061-y; Hodgson MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060455; Hodgson MC, 2011, CANCER RES, V71, P572, DOI 10.1158/0008-5472.CAN-10-2314; Hsu IW, 2014, ONCOTARGET, V5, P7917, DOI 10.18632/oncotarget.1421; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; JENSTER G, 1993, BIOCHEM J, V293, P761, DOI 10.1042/bj2930761; Jo YS, 2015, HEPATOLOGY, V62, P1606, DOI 10.1002/hep.27907; Karaca M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126270; Kim JW, 2008, CANCER RES, V68, P6831, DOI 10.1158/0008-5472.CAN-07-6195; Kofuji S, 2015, CANCER DISCOV, V5, P730, DOI 10.1158/2159-8290.CD-14-1329; Kooijman EE, 2009, BIOCHEMISTRY-US, V48, P9360, DOI 10.1021/bi9008616; Krause WC, 2014, INT J BIOCHEM CELL B, V54, P49, DOI 10.1016/j.biocel.2014.06.013; Li Y, 2015, ONCOTARGET, V6, P12; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lokody IB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129470; Lopez SM, 2016, CLIN CANCER RES, V22, P3937, DOI 10.1158/1078-0432.CCR-15-1983; Lopez SM, 2013, BIOCHEM BIOPH RES CO, V440, P277, DOI 10.1016/j.bbrc.2013.09.077; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Mediwala SN, 2013, PROSTATE, V73, P267, DOI 10.1002/pros.22566; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nakazawa M, 2014, HORM CANCER-US, V5, P265, DOI 10.1007/s12672-014-0190-1; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Newton AC, 2004, TRENDS PHARMACOL SCI, V25, P175, DOI 10.1016/j.tips.2004.02.010; Newton AC, 2003, BIOCHEM J, V370, P11; Nishizuka Y, 2001, ALCOHOL CLIN EXP RES, V25, p3S, DOI 10.1111/j.1530-0277.2001.tb02367.x; Patek SC, 2017, ONCOTARGET, V8, P4875, DOI 10.18632/oncotarget.13608; Ponguta LA, 2008, J BIOL CHEM, V283, P20989, DOI 10.1074/jbc.M802392200; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Shafi AA, 2015, ONCOTARGET, V6, P31997, DOI 10.18632/oncotarget.5585; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taneja SS, 2005, J BIOL CHEM, V280, P40916, DOI 10.1074/jbc.M508442200; Tatin F, 2006, J CELL SCI, V119, P769, DOI 10.1242/jcs.02787; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Wu D, 2002, CANCER RES, V62, P7; Wu RC, 2007, CELL, V129, P1125, DOI 10.1016/j.cell.2007.04.039; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yeh S, 2002, PNAS P NATL ACAD SCI, V99, P6; Zhang MQ, 2018, METHODS MOL BIOL, V1786, P219, DOI 10.1007/978-1-4939-7845-8_13	73	7	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1121	1135		10.1038/s41388-018-0498-3	http://dx.doi.org/10.1038/s41388-018-0498-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30228349	Green Accepted			2022-12-17	WOS:000458624900014
J	Hu, YL; Jin, R; Gao, M; Xu, H; Zou, SX; Li, XG; Xing, C; Wang, QY; Wang, HL; Feng, JN; Hu, MR; Song, L				Hu, Yongliang; Jin, Rui; Gao, Ming; Xu, Huan; Zou, Shuxian; Li, Xiaoguang; Xing, Chen; Wang, Qiyu; Wang, Hongli; Feng, Jiannan; Hu, Meiru; Song, Lun			Transcriptional repression of IKK beta by p53 in arsenite-induced GADD45 alpha accumulation and apoptosis	ONCOGENE			English	Article							NF-KAPPA-B; TUMOR-SUPPRESSOR; WILD-TYPE; GENE; ACTIVATION; ALPHA; CELLS; UBIQUITINATION; STABILIZATION; MECHANISMS	Our previous studies revealed that GADD45 alpha is a liable protein, which undergoes MDM2-dependent constitutive ubiquitination and degradation in resting HepG2 hepatoma cells. Arsenite exposure induces ribosomal stress responses mediated by the ribosomal protein S7, which can block MDM2 activity and result in GADD45a accumulation and cell apoptosis. In the present study, we found that one of the catalytic subunits of I.B kinase (IKK), IKK beta, exerted a novel IKK alpha -and NF-kappa B-independent function in stabilizing MDM2 and therefore contributed to ubiquitination-dependent degradation of GADD45 alpha in resting HepG2 cells. Arsenite stimulation induced transactivation of p53, which formed a complex with its downstream target, Ets-1, and then synergistically repressed IKK beta transcription, reduced MDM2 stability, and ultimately removed the inhibitory effect of MDM2 on GADD45 alpha induction. In addition, DAPK1 functioned as an upstream protein kinase triggering p53/Ets-1-dependent IKK beta and MDM2 reduction and GADD45 alpha accumulation, thus promoting apoptosis in HepG2 cells. Subsequent studies further revealed that the activation of the DAPK1/p53/Ets-1/IKK beta/MDM2/GADD45 alpha cascade was a common signaling event in mediating apoptosis of diverse cancer cells induced by arsenite and other tumor therapeutic agents. Therefore, we conclude that data in the current study have revealed a novel role for IKK beta in negatively regulating GADD45 alpha protein stability and the contribution of p53-dependent IKK beta reduction to mediating cancer cell apoptosis.	[Hu, Yongliang; Gao, Ming; Xu, Huan; Zou, Shuxian; Li, Xiaoguang; Xing, Chen; Wang, Qiyu; Wang, Hongli; Feng, Jiannan; Hu, Meiru; Song, Lun] Beijing Inst Brain Sci, Dept Neuroimmunol, 27 Taiping Rd, Beijing 100850, Peoples R China; [Jin, Rui] Beijing Inst Biotechnol, Dept Tumor Biol, 27 Taiping Rd, Beijing 100850, Peoples R China; [Gao, Ming] Chinese Acad Sci, Res Ctr Ecoenvironm Sci, State Key Lab Environm Chem & Ecotoxicol, 18 Shuangqing Rd, Beijing 100085, Peoples R China; [Zou, Shuxian; Song, Lun] Guangxi Med Univ, 22 Shuangyong Rd, Nanning 530021, Peoples R China; [Song, Lun] Anhui Med Univ, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China; [Hu, Yongliang] 309 Hosp PLA, Dept Dermatol, 17 Heishanhu St, Beijing 100091, Peoples R China; [Li, Xiaoguang] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, 270 Dongan Rd, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Research Center for Eco-Environmental Sciences (RCEES); Guangxi Medical University; Anhui Medical University; Fudan University	Song, L (corresponding author), Beijing Inst Brain Sci, Dept Neuroimmunol, 27 Taiping Rd, Beijing 100850, Peoples R China.; Song, L (corresponding author), Guangxi Med Univ, 22 Shuangyong Rd, Nanning 530021, Peoples R China.; Song, L (corresponding author), Anhui Med Univ, 81 Meishan Rd, Hefei 230032, Anhui, Peoples R China.	lunsong0752@163.com	邢, 陈/GWR-2940-2022	邢, 陈/0000-0003-2784-840X	National Natural Science Foundation of China [31570758, 91743115, 31270797]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr. Guojiang Chen to provide the A549 cells. We thank Dr. Ailing Li and Weihua Li to provide the Hep3B cells. This project is supported by the National Natural Science Foundation of China (No. 31570758, 91743115, 31270797) to Dr. Lun Song.	Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Chariot A, 2009, TRENDS CELL BIOL, V19, P404, DOI 10.1016/j.tcb.2009.05.006; Dong W, 2012, NUCLEIC ACIDS RES, V40, P2940, DOI 10.1093/nar/gkr1216; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Gao M, 2013, NUCLEIC ACIDS RES, V41, P5210, DOI 10.1093/nar/gkt223; Gao M, 2010, J CELL BIOCHEM, V109, P1264, DOI 10.1002/jcb.22509; Gao M, 2009, CURR PROTEIN PEPT SC, V10, P388, DOI 10.2174/138920309788922216; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gu LB, 2004, J BIOL CHEM, V279, P52141, DOI 10.1074/jbc.M407915200; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Ho J, 2013, CELL DEATH DIFFER, V10, P403; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang WC, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-3; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Li Y, 2011, MOL CELL BIOCHEM, V358, P61, DOI 10.1007/s11010-011-0921-3; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331; Moskalev AA, 2012, AGEING RES REV, V11, P51, DOI 10.1016/j.arr.2011.09.003; Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev-biophys-083012-130338; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Song L, 2008, EXP CELL RES, V314, P2187, DOI 10.1016/j.yexcr.2008.04.002; Song L, 2007, MOL CELL BIOL, V27, P2713, DOI 10.1128/MCB.00657-06; Song L, 2006, J CELL BIOL, V175, P607, DOI 10.1083/jcb.200602149; Song L, 2010, BBA-MOL CELL RES, V1803, P323, DOI 10.1016/j.bbamcr.2010.01.006; St Clair S, 2004, MOL CELL, V16, P725; Sullivan KD, 2018, CELL DEATH DIFFER, V25, P133, DOI 10.1038/cdd.2017.174; Sullivan KD, 2012, BBA-REV CANCER, V1825, P229, DOI 10.1016/j.bbcan.2012.01.004; Tamura RE, 2012, CURR MOL MED, V12, P634; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Tschaharganeh DF, 2014, CELL, V158, P579, DOI 10.1016/j.cell.2014.05.051; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Xu XD, 2016, AUTOPHAGY, V12, P1832, DOI 10.1080/15548627.2016.1204496; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200	38	7	7	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					731	746		10.1038/s41388-018-0478-7	http://dx.doi.org/10.1038/s41388-018-0478-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177839	hybrid, Green Published			2022-12-17	WOS:000457300300009
J	Hamaidi, M; Coquard, C; Danilin, S; Dormoy, V; Beraud, C; Rothhut, S; Barthelmebs, M; Benkirane-Jessel, N; Lindner, V; Lang, H; Massfelder, T				Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Beraud, Claire; Rothhut, Sylvie; Barthelmebs, Mariette; Benkirane-Jessel, Nadia; Lindner, Veronique; Lang, Herve; Massfelder, Thierry			The Lim1 oncogene as a new therapeutic target for metastatic human renal cell carcinoma	ONCOGENE			English	Article							MOUSE; LHX1; PATHWAY; DIFFERENTIATION; REQUIREMENT; EXPRESSION; GROWTH; LDB1	Metastatic clear cell renal cell carcinoma (CCC) remains incurable despite advances in the development of anti-angiogenic targeted therapies and the emergence of immune checkpoint inhibitors. We have previously shown that the sonic hedgehog-Gli signaling pathway is oncogenic in CCC allowing us to identify the developmental Lim1 transcription factor as a Gli target and as a new oncogene in CCC regulating cell proliferation and apoptosis, and promoting tumor growth. In this previous study, preliminary in vitro results also suggested that Lim1 may be implicated in metastatic spread. Here we investigated the potential pro-metastatic role of Lim1 in advanced CCC (1) in vitro using a panel of CCC cell lines expressing or not the von Hippel-Lindau (VHL) tumor suppressor gene either naturally or by gene transfer and (2) ex vivo in 30 CCC metastatic tissues, including lymph nodes, lung, skin, bone, and adrenal metastases, and (3) in vivo, using a metastatic model by intravenous injection of siRNA-transfected cells into Balb/c nude. Our in vitro results reveal that Lim1 knockdown time-dependently decreased CCC cell motility, migration, invasion, and clonogenicity by up to 50% regardless of their VHL status. Investigating the molecular machinery involved in these processes, we identified a large panel of Lim1 targets known to be involved in cell adhesion (paxillin and fibronectin), epithelial-mesenchymal transition (Twist1/2 and snail), invasion (MMP1/2/3/8/9), and metastatic progression (CXCR4, SDF-1, and ANG-1). Importantly, Lim1 was found constitutively expressed in all metastatic tissues. The H-score in metastatic tissues being significantly superior to the score in the corresponding primary tumor tissues (P value = 0.009). Furthermore, we showed that Lim1 silencing decreases pulmonary metastasis development in terms of number and size in the in vivo metastatic model of human CCC. Taken together, these experiments strengthen the potential therapeutic value of Lim1 targeting as a promising novel approach for treating metastatic human CCC.	[Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Rothhut, Sylvie; Barthelmebs, Mariette; Massfelder, Thierry] INSERM, INSERM UMR S1113, Sect Cell Signalisat & Commun Kidney & Prostate C, F-67085 Strasbourg, France; [Hamaidi, Merle; Coquard, Catherine; Danilin, Sabrina; Dormoy, Valerian; Rothhut, Sylvie; Barthelmebs, Mariette; Benkirane-Jessel, Nadia; Massfelder, Thierry] Univ Strasbourg, Sch Med, FMTS, F-67085 Strasbourg, France; [Beraud, Claire] UROLEAD SAS, Sch Med, F-67085 Strasbourg, France; [Benkirane-Jessel, Nadia] INSERM, UMR S1260, Regenerat Nanomed Lab, F-67085 Strasbourg, France; [Lindner, Veronique] Hop Univ Strasbourg, Dept Pathol, Hop Strasbourg Hautepierre, F-67200 Strasbourg, France; [Lang, Herve] Hop Univ Strasbourg, Dept Urol, Nouvel Hop Civil, F-67200 Strasbourg, France; [Danilin, Sabrina] Firalis, F-68330 Huningue, France; [Dormoy, Valerian] URCA, INSERM UMR S1250, CHU Maison Blanche, 45 Rue Cognacq Jay, F-51092 Reims, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte; CHU Strasbourg; Universite de Franche-Comte; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Reims; Universite de Reims Champagne-Ardenne	Massfelder, T (corresponding author), INSERM, INSERM UMR S1113, Sect Cell Signalisat & Commun Kidney & Prostate C, F-67085 Strasbourg, France.; Massfelder, T (corresponding author), Univ Strasbourg, Sch Med, FMTS, F-67085 Strasbourg, France.	massfeld@unistra.fr	Massfelder, Thierry/I-1260-2016; Benkirane-Jessel, Nadia/H-6438-2016; Dormoy, Valerian/P-5109-2016	Dormoy, Valerian/0000-0003-1725-371X	INSERM; University of Strasbourg; Ligue Contre le Cancer	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University of Strasbourg; Ligue Contre le Cancer(Ligue nationale contre le cancer)	This study was sponsored by INSERM (recipient TM), the University of Strasbourg (recipient TM), and the Ligue Contre le Cancer (recipient TM). The authors thank Martine MUCKENSTURM, Fabienne REYMANN, and Angelique WERCK, from the Department of Pathology, University Hospital, Strasbourg, for their technical assistance in immunohistochemistry.	BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Beksac AT, 2017, UROL ONCOL, pS1078; Beraud C, 2015, INT J CANCER, V137, P1549, DOI 10.1002/ijc.29522; Cheah SS, 2000, GENESIS, V27, P12, DOI 10.1002/1526-968X(200005)27:1<12::AID-GENE30>3.3.CO;2-O; Cirio MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018858; Costello I, 2015, GENE DEV, V29, P2108, DOI 10.1101/gad.268979.115; Delahunt B, 2017, HISTOPATHOLOGY, V71, P5, DOI 10.1111/his.13200; Dormoy V, 2011, ONCOGENE, V30, P1753, DOI 10.1038/onc.2010.557; Dormoy V, 2012, ANTICANCER RES, V32, P3609; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Escudier B, 2014, J CLIN ONCOL, V32, P1412, DOI 10.1200/JCO.2013.50.8267; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao Y, 2017, CANCER RES, V77, P330, DOI 10.1158/0008-5472.CAN-16-0348; Guertl B, 2011, PATHOBIOLOGY, V78, P210, DOI 10.1159/000326769; Huang CC, 2014, DEV BIOL, V389, P124, DOI 10.1016/j.ydbio.2014.01.025; Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2; Jeong DE, 2015, ONCOTARGET, V6, P33046, DOI 10.18632/oncotarget.5422; Kallakury BVS, 2001, CLIN CANCER RES, V7, P3113; Ledig S, 2012, HUM REPROD, V27, P2872, DOI 10.1093/humrep/des206; Li H, 2016, ONCOTARGET, V7, P80415, DOI 10.18632/oncotarget.11246; Li JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0681-0; Lin TC, 2015, J PATHOL, V237, P50, DOI 10.1002/path.4552; Lin YW, 2016, J PINEAL RES, V60, P277, DOI 10.1111/jpi.12308; Liu LQ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711951; Mehta K, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0457-4; Mikami S, 2016, PATHOL INT, V66, P481, DOI 10.1111/pin.12433; Mumert M, 2012, CANCER RES, V72, P4944, DOI 10.1158/0008-5472.CAN-12-1629; Neuberg P, 2018, NANOSCALE, V10, P1587, DOI 10.1039/c7nr09202d; Posadas EM, 2017, NAT REV NEPHROL, V13, P496, DOI 10.1038/nrneph.2017.82; Qu LS, 2016, ONCOL LETT, V11, P624, DOI 10.3892/ol.2015.3958; Ruan HL, 2017, INT J ONCOL, V51, P336, DOI 10.3892/ijo.2017.4010; Sato N, 2003, CANCER RES, V63, P3735; Scelo G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15724; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Sourbier C, 2006, CANCER RES, V66, P5130, DOI 10.1158/0008-5472.CAN-05-1469; Stanton BZ, 2010, MOL BIOSYST, V6, P44, DOI 10.1039/b910196a; Tong Wei-Gang, 2010, Epigenetics, V5, P499; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varis A, 2002, CANCER RES, V62, P2625; Wang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01084-w; Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428; Yang HL, 2017, ONCOL LETT, V13, P4755, DOI 10.3892/ol.2017.6084; Ye L, 2012, HISTOCHEM CELL BIOL, V137, P527, DOI 10.1007/s00418-011-0909-9; Yerokhin VA, 2015, PHYS REV LETT, V115, DOI 10.1103/PhysRevLett.115.233002; Zhao Y, 2007, P NATL ACAD SCI USA, V104, P13182, DOI 10.1073/pnas.0705464104; Zhao ZH, 2017, ONCOL RES, V25, P773, DOI 10.3727/096504016X14774889687280; Zhu JD, 2017, ONCOTARGET, V8, P51559, DOI 10.18632/oncotarget.18086	48	7	7	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					60	72		10.1038/s41388-018-0413-y	http://dx.doi.org/10.1038/s41388-018-0413-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30076415	Green Submitted			2022-12-17	WOS:000454775900005
J	Lin, J; Xia, J; Zhang, T; Zhang, KY; Yang, Q				Lin, Jian; Xia, Jing; Zhang, Tian; Zhang, Keyun; Yang, Qian			Genome-wide profiling of microRNAs reveals novel insights into the interactions between H9N2 avian influenza virus and avian dendritic cells	ONCOGENE			English	Article							LONG NONCODING RNA; NF-KAPPA-B; IMMUNE-RESPONSES; NUCLEAR IMPORT; INNATE IMMUNITY; A(H7N9) VIRUS; BINDING-SITE; INFECTION; HOST; REPLICATION	The antigen-presenting ability of dendritic cells (DCs) plays an important and irreplaceable role in recognising and clearing viruses. Antiviral responses must rapidly defend against infection while minimising inflammatory damage, but the mechanisms that regulate the magnitude of response within an infected cell are not well understood. MicroRNAs (microRNAs), small non-coding RNAs, can regulate mouse or avian DCs to inhibit the infection and replication of avian influenza virus (AIV). Here, we performed a global analysis to understand how avian DCs respond to H9N2 AIV and provide a potential mechanism to explain how avian microRNAs can defend against H9N2 AIV replication. First, we found that both active and inactive H9N2 AIV enhanced the ability of DCs to present antigens and activate T lymphocytes. Next, total microarray analyses suggested that H9N2 AIV stimulation involved protein localisation, nucleotide binding, leucocyte transendothelial migration and MAPK signalling. Moreover, we constructed 551 transcription factor (TF)-miRNA-mRNA loops based on the above analyses. Furthermore, we found that the haemagglutinin (HA) fragment, neither H5N1-HA or H9N2-HA, could not activate DCs, while truncated HA greatly increased the immune function of DCs by activating ERK and STAT3 signalling pathways. Lastly, our results not only suggested that gga-miR1644 targets muscleblind-like protein 2 (MBNL2) to enhance the ability of avian DCs to inhibit virus replication, but also suggested that gga-miR6675 targets the nuclear localisation sequence of polymerase basic protein 1 (PB1) to trigger the silencing of PB1 genes, resulting in the inhibition of H9N2 AIV replication. Altogether, our innovative study will shed new light on the role of avian microRNAs in evoking avian DCs and inhibiting virus replication.	[Lin, Jian; Xia, Jing; Zhang, Tian; Zhang, Keyun] Nanjing Agr Univ, Coll Life Sci, Weigang 1, Nanjing 210095, Jiangsu, Peoples R China; [Lin, Jian; Yang, Qian] Nanjing Agr Univ, Coll Vet Med, Wei Gang 1, Nanjing 210095, Jiangsu, Peoples R China	Nanjing Agricultural University; Nanjing Agricultural University	Yang, Q (corresponding author), Nanjing Agr Univ, Coll Vet Med, Wei Gang 1, Nanjing 210095, Jiangsu, Peoples R China.	zxbyq@njau.edu.cn		Zhang, Keyun/0000-0001-7208-8572; Lin, Jian/0000-0003-0455-9736	National Key Research and Development Program of China [2017YFD500706]; National Natural Science Grant of P. R. China [31702197, 31172302]; National Science Grant of Jiangsu Province [BK20150666]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	National Key Research and Development Program of China; National Natural Science Grant of P. R. China(National Natural Science Foundation of China (NSFC)); National Science Grant of Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Key Research and Development Program of China (2017YFD500706), the National Natural Science Grant of P. R. China (No. 31702197), the National Natural Science Grant of P. R. China (No. 31172302), the National Science Grant of Jiangsu Province (No. BK20150666) and A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Bandyopadhyay S, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-163; Barik S, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-104; Bel M, 2011, VIRUSES-BASEL, V3, P312, DOI 10.3390/v3040312; Boivin S, 2010, J BIOL CHEM, V285, P28411, DOI 10.1074/jbc.R110.117531; Cilloniz C, 2010, J VIROL, V84, P7613, DOI 10.1128/JVI.00553-10; Contreras J, 2012, LEUKEMIA, V26, P404, DOI 10.1038/leu.2011.356; den Brouw MLO, 2009, IMMUNOLOGY, V126, P280, DOI 10.1111/j.1365-2567.2008.02896.x; Dev A, 2011, CURR TOP MICROBIOL, V349, P115, DOI 10.1007/82_2010_102; Droebner K, 2011, ANTIVIR RES, V92, P195, DOI 10.1016/j.antiviral.2011.08.002; Fan NN, 2016, BIOMED PHARMACOTHER, V83, P1464, DOI 10.1016/j.biopha.2016.08.049; Hofer CT, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12679; Hofer U, 2013, NAT REV MICROBIOL, V11, P298, DOI 10.1038/nrmicro3012; Hutchinson EC, 2011, J GEN VIROL, V92, P1859, DOI 10.1099/vir.0.032813-0; Imam H, 2015, SCI REP-UK, V5, DOI 10.1038/srep08639; Ingle H, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab3183; Jiang M, 2014, J VIRAL HEPATITIS, V21, P99, DOI 10.1111/jvh.12126; Jin Y, 2017, J INFECTION, V75, P179, DOI 10.1016/j.jinf.2017.05.006; JONES IM, 1986, EMBO J, V5, P2371, DOI 10.1002/j.1460-2075.1986.tb04506.x; Ke CW, 2017, EMERG INFECT DIS, V23, P1332, DOI 10.3201/eid2308.170600; Khongnomnan K, 2015, EXP BIOL MED, V240, P1630, DOI 10.1177/1535370215589051; Langlois RA, 2012, P NATL ACAD SCI USA, V109, P12117, DOI 10.1073/pnas.1206039109; Le Negrate G, 2012, CELL MICROBIOL, V14, P168, DOI 10.1111/j.1462-5822.2011.01720.x; Li ZH, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00017; Liang JF, 2013, VET IMMUNOL IMMUNOP, V155, P205, DOI 10.1016/j.vetimm.2013.06.014; Lin J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00287; Lin J, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3157-5; Lin J, 2016, ONCOTARGET, V7, P48978, DOI 10.18632/oncotarget.9832; Lin TN, 2017, EMERG INFECT DIS, V23, P1041, DOI 10.3201/eid2306.161902; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loucaides EM, 2009, VIROLOGY, V394, P154, DOI 10.1016/j.virol.2009.08.015; Ma F, 2011, NAT IMMUNOL, V12, P861, DOI 10.1038/ni.2073; Marjuki H, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-134; Metwally A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040766; Moltedo B, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002345; Nakada R, 2017, PROTEIN SCI, V26, P1231, DOI 10.1002/pro.3173; Othumpangat S, 2014, VIROLOGY, V468, P256, DOI 10.1016/j.virol.2014.08.007; Ozawa M, 2007, J VIROL, V81, P30, DOI 10.1128/JVI.01434-06; Perrone LA, 2010, J INFECT DIS, V202, P1161, DOI 10.1086/656365; Pichulik T, 2016, EUR J IMMUNOL, V46, P167, DOI 10.1002/eji.201444970; Pizzolla A, 2017, J LEUKOCYTE BIOL, V101, P851, DOI 10.1189/jlb.4MR0716-290R; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Pu J, 2017, J VIROL, V91, DOI [10.1128/JVI.02055-16, 10.1128/jvi.02055-16]; Pu J, 2015, P NATL ACAD SCI USA, V112, P548, DOI 10.1073/pnas.1422456112; Pumroy RA, 2015, STRUCTURE, V23, P374, DOI 10.1016/j.str.2014.11.015; Ramos I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00361; Rivera A, 2016, VIRAL IMMUNOL, V29, P212, DOI 10.1089/vim.2015.0074; Rosenberger CM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006305; Rosenberger CM, 2012, J IMMUNOL, V189, P5965, DOI 10.4049/jimmunol.1201437; Samir M, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00086; Severin C, 2016, ACTA CRYSTALLOGR D, V72, P245, DOI 10.1107/S2059798316000085; Shen XY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/976575; Sprokholt JK, 2017, J IMMUNOL, V198, P4764, DOI 10.4049/jimmunol.1602121; Tang XY, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.25; Terrier O, 2016, SCI REP-UK, V6, DOI 10.1038/srep29006; Terrier O, 2012, VIROLOGY, V432, P204, DOI 10.1016/j.virol.2012.05.019; Turner JCM, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2016.142; Tzarum N, 2017, J VIROL, V91, DOI 10.1128/JVI.00046-17; Valadkhan S, 2016, VIRUS RES, V212, P127, DOI 10.1016/j.virusres.2015.09.023; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Westenius V, 2014, VIROLOGY, V471, P38, DOI 10.1016/j.virol.2014.10.002; Xiang B, 2017, J INFECTION, V75, P274, DOI 10.1016/j.jinf.2017.05.002; Xu W, 2014, CELL HOST MICROBE, V16, P187, DOI 10.1016/j.chom.2014.07.008; Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060; Yin Y, 2015, MUCOSAL IMMUNOL, V8, P799, DOI 10.1038/mi.2014.110; York A, 2014, J VIROL, V88, P13284, DOI 10.1128/JVI.01813-14; Yuan SF, 2016, ANTIVIR RES, V125, P34, DOI 10.1016/j.antiviral.2015.11.005; Zhang Y, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.38; Zhao Chunling, 2012, BMC Res Notes, V5, P91, DOI 10.1186/1756-0500-5-91; Zhou A, 2014, VIRUS RES, V184, P1, DOI 10.1016/j.virusres.2014.01.019; Zhou Z, 2015, CELL RES, V25, P39, DOI 10.1038/cr.2014.130; Zhu W, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.19.30533	71	7	7	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4562	4580		10.1038/s41388-018-0279-z	http://dx.doi.org/10.1038/s41388-018-0279-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29743596				2022-12-17	WOS:000441736700006
J	O'Bryant, D; Wang, ZX				O'Bryant, Deon; Wang, Zhengxin			The essential role of WD repeat domain 77 in prostate tumor initiation induced by Pten loss	ONCOGENE			English	Article							RECEPTOR COFACTOR P44; TGF-BETA; SUPPRESSOR GENE; CANCER; DELETION; PROLIFERATION; COMPLEX; GROWTH; MOUSE; CELLS	Prostate cancer is the most commonly diagnosed malignancy among men, but few genetic factors that drive prostate cancer initiation have been identified. The WD repeat domain 77 (Wdr77) protein is essential for cellular proliferation when localizes in the cytoplasm of epithelial cells at the early stage of prostate development. In the adult prostate, it is transported into the nucleus and functions as a co-regulator of the androgen receptor to promote cellular differentiation and prostate function. This developmental process is reversed during prostate tumorigenesis, i.e.,Wdr77 is translocated from the nucleus into the cytoplasm to drive proliferation of prostate cancer cells. In this study, we used in vivo genetic studies to further investigate the role of Wdr77 in prostate tumorigenesis. We found that prostate-specific deletion of Wdr77 abolished prostate tumor initiation induced by loss of the tumor suppressor Pten. Mechanistically, Wdr77 ablation inhibited E2F3 activation and enhanced TGF beta signaling, leading to attenuated cellular proliferation induced by loss of Pten. These findings establish a critical role of Wdr77 for prostate tumor initiation.	[O'Bryant, Deon; Wang, Zhengxin] Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Dept Biol Sci, Atlanta, GA 30314 USA	Clark Atlanta University	Wang, ZX (corresponding author), Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Dept Biol Sci, Atlanta, GA 30314 USA.	zwang@cau.edu			NIH NIGMS-RISE [R25GM06414]; NIMHD RCMI [5G12MD007590]; NIMHD [5P20MD002285];  [W81XWH-12-1-0453 PC111461]	NIH NIGMS-RISE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMHD RCMI; NIMHD; 	We thank Ms. Shen Gao for animal work and technique support. DOB is supported by NIH NIGMS-RISE R25GM06414 and ZW is supported by W81XWH-12-1-0453 PC111461, NIMHD RCMI 5G12MD007590, and NIMHD 5P20MD002285. The funding agencies had no role in study design, data collection or analysis, decision to publish or manuscript preparation.	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Bilir B, 2016, CANCER RES, V76, P1112, DOI 10.1158/0008-5472.CAN-15-1868; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Francis JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003180; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Gao S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049173; Gao S, 2010, ENDOCRINOLOGY, V151, P3941, DOI 10.1210/en.2009-1080; Gu Z, 2013, ONCOGENE, V32, P1888, DOI 10.1038/onc.2012.207; Gu ZP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022395; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Hosohata K, 2003, MOL CELL BIOL, V23, P7019, DOI 10.1128/MCB.23.19.7019-7029.2003; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Liu WN, 2016, ASIAN J ANDROL, V18, P533, DOI 10.4103/1008-682X.177120; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024; Peng Y, 2008, P NATL ACAD SCI USA, V105, P5236, DOI 10.1073/pnas.0712262105; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Sheng XM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2632-3; Shtivelman E, 2014, ONCOTARGET, V5, P7217, DOI 10.18632/oncotarget.2406; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sitnicka E, 1996, BLOOD, V88, P82; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tu WH, 2003, NEOPLASIA, V5, P267, DOI 10.1016/S1476-5586(03)80058-1; Wang SI, 1998, CLIN CANCER RES, V4, P811; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Yi PF, 2014, BIOCHEM BIOPH RES CO, V450, P409, DOI 10.1016/j.bbrc.2014.05.125; Yokoyama NN, 2014, AM J CLIN EXP UROL, V2, P27; Zhou LR, 2006, J MOL ENDOCRINOL, V37, P283, DOI 10.1677/jme.1.02062	42	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4151	4163		10.1038/s41388-018-0254-8	http://dx.doi.org/10.1038/s41388-018-0254-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706654				2022-12-17	WOS:000439847000008
J	Lai, SC; Phelps, CA; Short, AM; Dutta, SM; Mu, D				Lai, Shao-Chiang; Phelps, Cody A.; Short, Aleena M.; Dutta, Sucharita M.; Mu, David			Thyroid transcription factor 1 enhances cellular statin sensitivity via perturbing cholesterol metabolism	ONCOGENE			English	Article							HUMAN PROSTATE-CANCER; LUNG ADENOCARCINOMA; MEVALONATE PATHWAY; BINDING PROTEIN; NKX2-1; ABCA1; GENE; EXPRESSION; TTF-1/NKX2-1; PROGRESSION	We have discovered an unexpected connection between a critical lung development and cancer gene termed thyroid transcription factor 1 (TTF-1 also known as NKX2-1) and cholesterol metabolism. Our published work implicates that TTF-1 positively regulates miR-33a which is known to repress ATP-binding cassette transporter 1 (ABCA1) and thus its cholesterol efflux activity. We set out to demonstrate that a higher TTF-1 expression would presumably inhibit cholesterol efflux and consequently raise intracellular cholesterol level. Surprisingly, raising TTF-1 expression actually lowers intracellular cholesterol level, which, we believe, is attributed to a direct transactivation of ABCA1 by TTF-1. Subsequently, we show that lung cancer cells primed with a TTF-1-driven decrease of cholesterol were more vulnerable to simvastatin, a frequently prescribed cholesterol biosynthesis inhibitor. In view of the fact that pathologists routinely interrogate human lung cancers for TTF-1 immunopositivity to guide diagnosis and the prevalent use of statins, TTF-1 should be further investigated as a putative biomarker of lung cancer vulnerability to statins.	[Lai, Shao-Chiang; Phelps, Cody A.; Dutta, Sucharita M.; Mu, David] Eastern Virginia Med Sch, Leroy T Canoles Jr Canc Res Ctr, Norfolk, VA 23501 USA; [Lai, Shao-Chiang; Phelps, Cody A.; Mu, David] Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; [Short, Aleena M.] Eastern Virginia Med Sch, Biotechnol Masters Program, Norfolk, VA 23501 USA; [Lai, Shao-Chiang] bioAffin Technol Inc, San Antonio, TX USA; [Dutta, Sucharita M.] Beth Israel Deaconess Med Sch, Boston, MA USA	Eastern Virginia Medical School; Eastern Virginia Medical School; Eastern Virginia Medical School; Harvard University; Beth Israel Deaconess Medical Center	Mu, D (corresponding author), Eastern Virginia Med Sch, Leroy T Canoles Jr Canc Res Ctr, Norfolk, VA 23501 USA.; Mu, D (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA.	mud@evms.edu	Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182; Qu, Yi/0000-0002-9993-8810	National Cancer Institute of the National Institutes of Health [R21CA198327]; Fraternal Order of Eagles Aerie, Colonial Beach, Virginia [4315]; NATIONAL CANCER INSTITUTE [R21CA198327] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fraternal Order of Eagles Aerie, Colonial Beach, Virginia; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Arjun Poddar and Sohail Khan for assistance with bioinformatics and statistical analyses. This study was supported by the National Cancer Institute of the National Institutes of Health under Award Number R21CA198327. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Mu laboratory also acknowledges funding from the Fraternal Order of Eagles Aerie #4315, Colonial Beach, Virginia.	Allen RM, 2012, EMBO MOL MED, V4, P882, DOI 10.1002/emmm.201201228; Besnard V, 2007, AM J PHYSIOL-LUNG C, V293, pL1395, DOI 10.1152/ajplung.00275.2007; CHEN HW, 1974, NATURE, V251, P419, DOI 10.1038/251419a0; Clendening JW, 2012, ONCOGENE, V31, P4967, DOI 10.1038/onc.2012.6; Costet P, 2000, J BIOL CHEM, V275, P28240; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Fernandez C, 2005, J LIPID RES, V46, P920, DOI 10.1194/jlr.M400407-JLR200; Fernandez-Hernando C, 2011, CURR OPIN LIPIDOL, V22, P86, DOI 10.1097/MOL.0b013e3283428d9d; Flaveny CA, 2015, CANCER CELL, V28, P42, DOI 10.1016/j.ccell.2015.05.007; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Hafiane A, 2017, ATHEROSCLEROSIS, V257, P90, DOI 10.1016/j.atherosclerosis.2017.01.013; Hornstein E, 2006, NAT GENET, V38, pS20, DOI 10.1038/ng1803; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Koldamova RP, 2003, J BIOL CHEM, V278, P13244, DOI 10.1074/jbc.M300044200; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lee BH, 2013, CANCER RES, V73, P1211, DOI 10.1158/0008-5472.CAN-12-3128; Li CMC, 2015, GENE DEV, V29, P1850, DOI 10.1101/gad.267393.115; Li X, 2009, CELL, V137, P273, DOI 10.1016/j.cell.2009.01.058; Lin CY, 2015, NAT REV CANCER, V15, P216, DOI 10.1038/nrc3912; Liu Z, 2017, ONCOGENE, V36, P3740, DOI 10.1038/onc.2016.524; Long J, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01086; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Maeda Y, 2012, J CLIN INVEST, V122, P4388, DOI 10.1172/JCI64048; Mu D, 2013, J BIOL CHEM, V288, P24992, DOI 10.1074/jbc.R113.491647; Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Pandyra A, 2014, CANCER RES, V74, P4772, DOI 10.1158/0008-5472.CAN-14-0130; Peca D, 2015, BIOCHEM SOC T, V43, P913, DOI 10.1042/BST20150100; Phelps CA, 2017, VITAM HORM, V106, P517; Phillips MC, 2014, J BIOL CHEM, V289, P24020, DOI 10.1074/jbc.R114.583658; Qi J, 2012, CELL CYCLE, V11, P177, DOI 10.4161/cc.11.1.18576; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Rice SJ, 2013, J BIOL CHEM, V288, P16348, DOI 10.1074/jbc.M113.474643; Runkle EA, 2012, J BIOL CHEM, V287, P28790, DOI 10.1074/jbc.M112.367987; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Sharpe LJ, 2013, J BIOL CHEM, V288, P18707, DOI 10.1074/jbc.R113.479808; Smith B, 2012, CELL REP, V2, P580, DOI 10.1016/j.celrep.2012.08.011; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Watanabe H, 2013, GENE DEV, V27, P197, DOI 10.1101/gad.203208.112; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Wood LW, 2016, SCI REP-UK, V6, DOI 10.1038/srep19857; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970	55	7	7	5	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2018	37	24					3290	3300		10.1038/s41388-018-0174-7	http://dx.doi.org/10.1038/s41388-018-0174-7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GJ6XB	29551766	Green Accepted			2022-12-17	WOS:000435526600008
J	Monteonofrio, L; Valente, D; Ferrara, M; Camerini, S; Miscione, R; Crescenzi, M; Rinaldo, C; Soddu, S				Monteonofrio, Laura; Valente, Davide; Ferrara, Manuela; Camerini, Serena; Miscione, Roberta; Crescenzi, Marco; Rinaldo, Cinzia; Soddu, Silvia			HIPK2 and extrachromosomal histone H2B are separately recruited by Aurora-B for cytokinesis	ONCOGENE			English	Article							CHROMOSOMAL PASSENGER COMPLEX; INTERACTING PROTEIN KINASE-2; DNA-DAMAGE RESPONSE; COVALENT MODIFICATION; ACTIVATION-LOOP; SPINDLE; CANCER; ABSCISSION; APOPTOSIS; MIDBODY	Cytokinesis, the final phase of cell division, is necessary to form two distinct daughter cells with correct distribution of genomic and cytoplasmic materials. Its failure provokes genetically unstable states, such as tetraploidization and polyploidization, which can contribute to tumorigenesis. Aurora-B kinase controls multiple cytokinetic events, from chromosome condensation to abscission when the midbody is severed. We have previously shown that HIPK2, a kinase involved in DNA damage response and development, localizes at the midbody and contributes to abscission by phosphorylating extrachromosomal histone H2B at Ser14. Of relevance, HIPK2-defective cells do not phosphorylate H2B and do not successfully complete cytokinesis leading to accumulation of binucleated cells, chromosomal instability, and increased tumorigenicity. However, how HIPK2 and H2B are recruited to the midbody during cytokinesis is still unknown. Here, we show that regardless of their direct (H2B) and indirect (HIPK2) binding of chromosomal DNA, both H2B and HIPK2 localize at the midbody independently of nucleic acids. Instead, by using mitotic kinase-specific inhibitors in a spatio-temporal regulated manner, we found that Aurora-B kinase activity is required to recruit both HIPK2 and H2B to the midbody. Molecular characterization showed that Aurora-B directly binds and phosphorylates H2B at Ser32 while indirectly recruits HIPK2 through the central spindle components MgcRacGAP and PRC1. Thus, among different cytokinetic functions, Aurora-B separately recruits HIPK2 and H2B to the midbody and these activities contribute to faithful cytokinesis.	[Monteonofrio, Laura; Valente, Davide; Rinaldo, Cinzia; Soddu, Silvia] Regina Elena Natl Canc Inst IRCCS, Unit Cellular Networks & Mol Therapeut Targets, I-00144 Rome, Italy; [Ferrara, Manuela; Miscione, Roberta; Rinaldo, Cinzia] Sapienza Univ, Natl Res Council CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy; [Camerini, Serena; Crescenzi, Marco] Italian Natl Inst Hlth, Core Facil, I-00161 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Istituto Superiore di Sanita (ISS)	Rinaldo, C; Soddu, S (corresponding author), Regina Elena Natl Canc Inst IRCCS, Unit Cellular Networks & Mol Therapeut Targets, I-00144 Rome, Italy.; Rinaldo, C (corresponding author), Sapienza Univ, Natl Res Council CNR, Inst Mol Biol & Pathol IBPM, I-00185 Rome, Italy.	cinzia.rinaldo@uniroma1.it; silvia.soddu@ifo.gov.it	Monteonofrio, Laura/K-1878-2018; Crescenzi, Marco/J-3603-2018; Camerini, Serena/A-4637-2017; Valente, Davide/ABA-2484-2021; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; Rinaldo, Cinzia/A-4252-2015	Monteonofrio, Laura/0000-0003-3981-942X; Crescenzi, Marco/0000-0003-0156-1494; Camerini, Serena/0000-0001-6131-4335; Valente, Davide/0000-0001-6397-3641; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Rinaldo, Cinzia/0000-0001-6124-762X	Italian Association for Cancer Research [14592, 17739]; Italian Foundation for Cancer Research	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); Italian Foundation for Cancer Research(Fondazione AIRC per la ricerca sul cancro)	We are grateful to all people cited in the text for their gifts of cells and reagents. We thank G. Di Rocco for critical reading of the manuscript and F. Magi and M.P. Gentileschi for technical assistance. This work was supported by grants from Italian Association for Cancer Research to SS (IG #14592), and to CR (IG #17739). LM and DV were recipients of fellowships from Italian Foundation for Cancer Research.	Afonso O, 2017, CHROMOSOMA, V126, P93, DOI 10.1007/s00412-016-0594-5; Agromayor M, 2013, TRENDS CELL BIOL, V23, P433, DOI 10.1016/j.tcb.2013.04.006; Atilla-Gokcumen GE, 2010, ACS CHEM BIOL, V5, P79, DOI 10.1021/cb900256m; Bastos RN, 2013, J CELL BIOL, V202, P605, DOI 10.1083/jcb.201301094; Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blaquiere JA, 2017, CURR TOP DEV BIOL, V123, P73, DOI 10.1016/bs.ctdb.2016.10.002; Borisa AC, 2017, EUR J MED CHEM, V140, P1, DOI 10.1016/j.ejmech.2017.08.045; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Carpinelli P, 2008, EXPERT OPIN THER TAR, V12, P69, DOI 10.1517/14728222.12.1.69; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; D'Avino PP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00221; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Orazi G, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-63; de la Vega L, 2011, BBA-MOL CELL RES, V1813, P283, DOI 10.1016/j.bbamcr.2010.11.022; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; Douglas ME, 2010, SEMIN CELL DEV BIOL, V21, P899, DOI 10.1016/j.semcdb.2010.08.005; Douglas ME, 2010, CURR BIOL, V20, P927, DOI 10.1016/j.cub.2010.03.055; Fededa JP, 2012, NAT CELL BIOL, V14, P440, DOI 10.1038/ncb2482; Feng YY, 2017, ONCOTARGET, V8, P20452, DOI 10.18632/oncotarget.14723; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Gresko E, 2005, BIOCHEM BIOPH RES CO, V329, P1293, DOI 10.1016/j.bbrc.2005.02.113; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hofmann TG, 2013, BIOESSAYS, V35, P55, DOI 10.1002/bies.201200060; Hu CK, 2012, MOL BIOL CELL, V23, P1024, DOI 10.1091/mbc.E11-08-0721; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kobiyama K, 2010, J VIROL, V84, P822, DOI 10.1128/JVI.01339-09; Kollareddy M, 2012, INVEST NEW DRUG, V30, P2411, DOI 10.1007/s10637-012-9798-6; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; KURIYAMA R, 1984, J CELL SCI, V66, P265; Kuwano Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101638; Lau ATY, 2011, J BIOL CHEM, V286, P26628, DOI 10.1074/jbc.M110.215590; Lazzari C, 2011, ONCOGENE, V30, P4802, DOI 10.1038/onc.2011.182; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Li XL, 2007, ONCOGENE, V26, P7231, DOI 10.1038/sj.onc.1210523; Matt S, 2016, CELL MOL LIFE SCI, V73, P2829, DOI 10.1007/s00018-016-2130-4; Mierzwa B, 2014, DEV CELL, V31, P525, DOI 10.1016/j.devcel.2014.11.006; Mollinari C, 2005, MOL BIOL CELL, V16, P1043, DOI 10.1091/mbc.E04-04-0346; Norden C, 2006, CELL, V125, P85, DOI 10.1016/j.cell.2006.01.045; Normand G, 2010, ADV EXP MED BIOL, V676, P27; Pollard TD, 2017, J CELL BIOL, V216, P3007, DOI 10.1083/jcb.201612068; Rinaldo C, 2008, BBA-MOL CELL RES, V1783, P2124, DOI 10.1016/j.bbamcr.2008.06.006; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rinaldo C, 2012, MOL CELL, V47, P87, DOI 10.1016/j.molcel.2012.04.029; Saul VV, 2013, J MOL MED, V91, P1051, DOI 10.1007/s00109-013-1042-0; Saul VV, 2013, J MOL CELL BIOL, V5, P27, DOI 10.1093/jmcb/mjs053; Siepi F, 2013, BBA-MOL CELL RES, V1833, P1443, DOI 10.1016/j.bbamcr.2013.02.018; Storchova Z, 2008, J CELL SCI, V121, P3859, DOI 10.1242/jcs.039537; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Valente D, 2015, ONCOTARGET, V6, P10320, DOI 10.18632/oncotarget.3583; Verdina A, 2017, ONCOTARGET, V8, P16744, DOI 10.18632/oncotarget.14421; Vitale I, 2015, TRENDS CANCER, V1, P124, DOI 10.1016/j.trecan.2015.08.001; Zhao WM, 2005, P NATL ACAD SCI USA, V102, P13158, DOI 10.1073/pnas.0504145102	58	7	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3562	3574		10.1038/s41388-018-0191-6	http://dx.doi.org/10.1038/s41388-018-0191-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563611	hybrid, Green Published			2022-12-17	WOS:000436412500007
J	Fendrich, V; Jendryschek, F; Beeck, S; Albers, M; Lauth, M; Esni, F; Heeger, K; Dengler, J; Slater, EP; Holler, JPN; Baier, A; Bartsch, DK; Waldmann, J				Fendrich, Volker; Jendryschek, Frederike; Beeck, Saskia; Albers, Max; Lauth, Matthias; Esni, Farzad; Heeger, Kristin; Dengler, Janina; Slater, Emily P.; Holler, Julia P. N.; Baier, Aninja; Bartsch, Detlef K.; Waldmann, Jens			Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITIONS; CANCER CELL-LINE; INTRAEPITHELIAL NEOPLASIA; IN-VIVO; METASTASIS; EXPRESSION; MOUSE; CHEMORESISTANCE; GENERATION	Pancreatic cancer (PDAC) is one of the most dismal of human malignancies. Inhibiting or delaying the progression of precursor lesions of PDAC, pancreatic intraepthial neoplasia (PanINs), to invasive cancer, would be a major step. In the present study, we used a transgenic murine model of pancreatic cancer to evaluate the impact of a conditional knockout of the transcription factor Snail1, a major factor in epithelial-to-mesenchymal transition, on acinar-to-ductal formation and on PanIN progression. By interbreeding conditional LsL-Snail(floxf/wt); LsL-Kras(G12D) and Pdx1-Cre strains, we obtained LsL-KrasG12D; Pdx1-Cre(KP) mice, Snail1 heterozygous knockout LsL-KrasG12D; LsL-Snail(flox/-); Pdx1-Cre(KPShet) mice or Snail1 homozygous knockout LsL-Kras(G12D); LsL-Snail(flox/flox); Pdx1-Cre(KPS) mice. Mice were then followed in a longitudinal study for 2, 4, 6, 8, 10, and 12 months. Furthermore, in mice with a genetic or pharmacological inhibition of Snail1, using the Snail1 inhibitor GN25, a model of pancreatic injury by administration of cerulein was introduced to evaluate ADM formation in this setting. A translational approach with a tissue microarray (TMA) of human PanINs and an in vivo nude mouse platform to test GN25 in human pancreatic adenocarcinoma was then adopted. Quantification of PanINs showed delayed initiation and progression of PanIN lesions at all ages in both homozygous and heterozygous Snaildel1; Pdx-1-Cre; LSL-Kras(G12D/+)-Mice. PanINs at TMA revealed snail expression in the majority of cases. GN25 showed growth inhibition in 2/2 human pancreatic adenocarcinomas using a nude mice in vivo platform. Genetic and pharmacologic abrogation of Snail1 signaling in exocrine pancreas impairs development of acinar-to-ductal metaplasia following cerulein-mediated pancreatic injury. The present study suggests a fundamental new approach to delay the progression of PDAC.	[Fendrich, Volker; Jendryschek, Frederike; Beeck, Saskia; Albers, Max; Dengler, Janina; Slater, Emily P.; Baier, Aninja; Bartsch, Detlef K.; Waldmann, Jens] Univ Marburg, Dept Surg, Marburg, Germany; [Lauth, Matthias] IMT, Marburg, Germany; [Esni, Farzad] Univ Pittsburgh, Dept Surg, John G Rangos Res Ctr, Pittsburgh, PA USA; [Heeger, Kristin] Univ Hosp Giessen & Marburg, Dept Internal Med, Div Gastroenterol, Campus Marburg, Marburg, Germany; [Holler, Julia P. N.] Univ Hosp Giessen & Marburg, Dept Surg, Campus Giessen, Giessen, Germany	Philipps University Marburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University Hospital of Giessen & Marburg; University Hospital of Giessen & Marburg	Fendrich, V (corresponding author), Univ Marburg, Dept Surg, Marburg, Germany.	v.fendrich@web.de	Albers, Max/GZA-3575-2022; Esni, Farzad/AAX-1136-2021	Esni, Farzad/0000-0002-0342-6862	Sander Stiftung	Sander Stiftung	Grant support: VF and ML were supported by a Research Grant from the Sander Stiftung	Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Feldmann G, 2007, J HEPATO-BILIARY-PAN, V14, P224, DOI 10.1007/s00534-006-1166-5; Fendrich V, 2008, GASTROENTEROLOGY, V135, P621, DOI 10.1053/j.gastro.2008.04.011; Fendrich V, 2014, NEUROENDOCRINOLOGY, V100, P300, DOI 10.1159/000368610; Fendrich V, 2010, GUT, V59, P630, DOI 10.1136/gut.2009.188961; Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Miyoshi A, 2005, BRIT J CANCER, V92, P252, DOI 10.1038/sj.bjc.6602266; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Murray SA, 2006, GENESIS, V44, P7, DOI 10.1002/gene.20178; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rhim AD, 2013, PANCREATOLOGY, V13, P114, DOI 10.1016/j.pan.2013.01.004; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113; TANIGUCHI S, 1992, CLIN EXP METASTAS, V10, P259; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yin T, 2007, J SURG RES, V141, P196, DOI 10.1016/j.jss.2006.09.027; Zhang S, 2015, PANCREAS, V44, P1121, DOI 10.1097/MPA.0000000000000418; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	29	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1845	1856		10.1038/s41388-017-0100-4	http://dx.doi.org/10.1038/s41388-017-0100-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367759				2022-12-17	WOS:000429303300003
J	Pruitt, HC; Metge, BJ; Weeks, SE; Chen, DQ; Wei, S; Kesterson, RA; Shevde, LA; Samant, RS				Pruitt, Hawley C.; Metge, Brandon J.; Weeks, Shannon E.; Chen, Dongquan; Wei, Shi; Kesterson, Robert A.; Shevde, Lalita A.; Samant, Rajeev S.			Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumors	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; BETA-CATENIN; STEM-CELLS; BREAST-CANCER; PROTEIN NMI; ACTIVATION; TARGET; GLAND; FATE; BETA-CATENIN/LEF-1	The process of organ development requires a delicate balance between cellular plasticity and differentiation. This balance is disrupted in cancer initiation and progression. N-Myc and STAT interactor (NMI: human or Nmi: murine) has emerged as a relevant player in the etiology of breast cancer. However, a fundamental understanding of its relevance to normal mammary biology is lacking. To gain insight into its normal function in mammary gland, we generated a mammary-specific Nmi knockout mouse model. We observed that Nmi protein expression is induced in mammary epithelium at the onset of pregnancy, in luminal cells and persists throughout lactation. Nmi knockout results in a precocious alveolar phenotype. These alveoli exhibit an extensive presence of nuclear beta-catenin and enhanced Wnt/beta-catenin signaling. The Nmi knockout pubertal ductal tree shows enhanced invasion of the mammary fatpad and increased terminal end bud numbers. Tumors from Nmi null mammary epithelium show a significant enrichment of poorly differentiated cells with elevated stem/progenitor markers, active Wnt/beta-catenin signaling, highly invasive morphology as well as, increased number of distant metastases. Our study demonstrates that Nmi has a distinct role in the differentiation process of mammary luminal epithelial cell compartment and developmental aberrations resulting from Nmi absence contribute to metastasis and demonstrates that aberration in normal developmental program can lead to metastatic disease, highlighting the contribution and importance of luminal progenitor cells in driving metastatic disease.	[Pruitt, Hawley C.; Metge, Brandon J.; Weeks, Shannon E.; Wei, Shi; Shevde, Lalita A.; Samant, Rajeev S.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Chen, Dongquan] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Kesterson, Robert A.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA; [Shevde, Lalita A.; Samant, Rajeev S.] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Samant, RS (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.; Samant, RS (corresponding author), Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA.	rsamant@uab.edu		Samant, Rajeev/0000-0001-5681-4976	Cancer Center Core grant [CA013148]; UAB CCTS award [UL1TR001417, BX003374]; NCI/NIH [CA194048, CA169202]; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA169202, R01CA194048, R01CA140472] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008111] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003374] Funding Source: NIH RePORTER	Cancer Center Core grant; UAB CCTS award; NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge Sarah K. Bailey and Ann Hanna for their assistance during experimental procedures. We are grateful to Dr. Jeffrey Rosen and his graduate student Daisy for advice with X-gal staining of mammary tissues. We acknowledge the following grant support: Cancer Center Core grant CA013148, for the Heflin Genomics facility and UAB-Transgenic and knockout facility, to RAK. Support from UAB CCTS award #UL1TR001417 to DC BX003374 (VA) and CA194048 (NCI/NIH) to RSS and CA169202 (NCI/NIH) to LAS. HCP is a HHMI-Med-To-Grad Fellow (UAB).	Alexander C.M., 2012, COLD SPRING HARB PER, P1; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Boras-Granic K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0487-6; Boras-Granic Kata, 2008, Organogenesis, V4, P116; Chakrabarti R, 2012, STEM CELLS, V30, P1496, DOI 10.1002/stem.1112; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107; Devine DJ, 2014, ONCOGENE, V33, P2620, DOI 10.1038/onc.2013.215; Feng X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.200; Gauger KJ, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-25; Gross K, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4010004; Harper KL, 2016, NATURE; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hosseini H., 2016, NATURE; Hou JJ, 2016, CANCER LETT, V376, P22, DOI 10.1016/j.canlet.2016.02.015; Joshi PA, 2012, TRENDS ENDOCRIN MET, V23, P299, DOI 10.1016/j.tem.2012.04.002; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030979; Kouros-Mehr H, 2008, CURR OPIN CELL BIOL, V20, P164, DOI 10.1016/j.ceb.2008.02.003; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Lebrun SJ, 1998, J INTERF CYTOK RES, V18, P767, DOI 10.1089/jir.1998.18.767; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin VTG, 2017, TRENDS CANCER, V3, P126, DOI 10.1016/j.trecan.2016.12.007; Lo PK, 2013, ONCOGENE, V32, P1338, DOI 10.1038/onc.2012.456; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Perotti C, 2009, DIFFERENTIATION, V78, P269, DOI 10.1016/j.diff.2009.05.003; Pruitt HC, 2016, INT J CANCER, V139, P491, DOI 10.1002/ijc.30043; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Tiede B, 2011, CELL RES, V21, P245, DOI 10.1038/cr.2011.11; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhao J, 2017, ONCOTARGET, V8, P12174, DOI 10.18632/oncotarget.14556; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	39	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1610	1623		10.1038/s41388-017-0037-7	http://dx.doi.org/10.1038/s41388-017-0037-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29326438	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000428626700005
J	Comiskey, DF; Jacob, AG; Sanford, BL; Montes, M; Goodwin, AK; Steiner, H; Matsa, E; Tapia-Santos, AS; Bebee, TW; Grieves, J; La Perle, K; Boyaka, P; Chandler, DS				Comiskey, D. F., Jr.; Jacob, A. G.; Sanford, B. L.; Montes, M.; Goodwin, A. K.; Steiner, H.; Matsa, E.; Tapia-Santos, A. S.; Bebee, T. W.; Grieves, J.; La Perle, K.; Boyaka, P.; Chandler, D. S.			A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo	ONCOGENE			English	Article							SPLICED MDM2 TRANSCRIPTS; DNA-DAMAGE RESPONSE; MESSENGER-RNA STABILIZATION; P53 MUTANT MICE; GENOMIC INSTABILITY; PEDIATRIC RHABDOMYOSARCOMA; SIGNALING PATHWAY; ONCOPROTEIN MDM2; TUMOR SPECTRUM; CELL-LINES	Alternative splicing of the oncogene murine double minute 2 (MDM2) is induced in response to genotoxic stress. MDM2-ALT1, the major splice variant generated, is known to activate the p53 pathway and impede full-length MDM2's negative regulation of p53. Despite this perceptible tumor-suppressive role, MDM2-ALT1 is also associated with several cancers. Furthermore, expression of MDM2-ALT1 has been observed in aggressive metastatic disease in pediatric rhabdomyosarcoma (RMS), irrespective of histological subtype. Therefore, we generated a transgenic MDM2-ALT1 mouse model that would allow us to investigate the effects of this splice variant on the progression of tumorigenesis. Here we show that when MDM2-ALT1 is ubiquitously expressed in p53 null mice it leads to increased incidence of spindle cell sarcomas, including RMS. Our data provide evidence that constitutive MDM2-ALT1 expression is itself an oncogenic lesion that aggravates the tumorigenesis induced by p53 loss. On the contrary, when MDM2-ALT1 is expressed solely in B-cells in the presence of homozygous wild-type p53 it leads to significantly increased lymphomagenesis (56%) when compared with control mice (27%). However, this phenotype is observable only at later stages in life (>= 18 months). Moreover, flow cytometric analyses for B-cell markers revealed an MDM2-ALT1-associated decrease in the B-cell population of the spleens of these animals. Our data suggest that the B-cell loss is p53 dependent and is a response mounted to persistent MDM2-ALT1 expression in a wild-type p53 background. Overall, our findings highlight the importance of an MDM2 splice variant as a critical modifier of both p53-dependent and -independent tumorigenesis, underscoring the complexity of MDM2 posttranscriptional regulation in cancer. Furthermore, MDM2-ALT1-expressing p53 null mice represent a novel mouse model of fusion-negative RMS.	[Comiskey, D. F., Jr.; Jacob, A. G.; Montes, M.; Tapia-Santos, A. S.; Bebee, T. W.; Chandler, D. S.] Ohio State Univ, Mol Cellular & Dev Biol Grad Program, Columbus, OH 43210 USA; [Comiskey, D. F., Jr.; Jacob, A. G.; Montes, M.; Tapia-Santos, A. S.; Bebee, T. W.; Chandler, D. S.] Ohio State Univ, Ctr RNA Biol, Columbus, OH 43210 USA; [Comiskey, D. F., Jr.; Jacob, A. G.; Sanford, B. L.; Montes, M.; Goodwin, A. K.; Matsa, E.; Tapia-Santos, A. S.; Bebee, T. W.; Chandler, D. S.] Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc & Blood Dis, 700 Childrens Dr, Columbus, OH 43205 USA; [Steiner, H.; Grieves, J.; La Perle, K.; Boyaka, P.] Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; [Grieves, J.] Takeda Calif Inc, Drug Safety Res & Evaluat 10410 Sci Ctr Dr, San Diego, CA 92121 USA; [Chandler, D. S.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; Takeda Pharmaceutical Company Ltd; Takeda Pharmaceuticals USA Inc. (TPUSA); Takeda California Inc; University System of Ohio; Ohio State University	Chandler, DS (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Childhood Canc & Blood Dis, 700 Childrens Dr, Columbus, OH 43205 USA.	chandler.135@osu.edu	La Perle, Krista Marie DuBray/B-3099-2015	Boyaka, Prosper/0000-0001-6857-9088	NCI Cancer Center Support Grant [P30 CA016058]; Alex's Lemonade Stand; NIH [CA133571]; Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA133571] Funding Source: NIH RePORTER	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Alex's Lemonade Stand; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sarcoma Foundation of America; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Matthew Rouhier for optimizing conditions for cell cycle analysis of B-cells; Juliann Rectenwald and The Ohio State University Comparative Pathology & Mouse Phenotyping Shared Resource, supported in part through NCI Cancer Center Support Grant P30 CA016058; and funding sources Alex's Lemonade Stand, Sarcoma Foundation of America, NIH (CA133571) awarded to DSC and Pelotonia (awarded to DFC and AGJ). We also thank Dr Andras Nagy for kindly providing the plasmid used in generating the mouse models.	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; ALTMANNSBERGER M, 1985, AM J PATHOL, V118, P85; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartel F, 2001, ONCOL RES, V12, P451, DOI 10.3727/096504001108747459; Bartel F, 2001, INT J CANCER, V95, P168, DOI 10.1002/1097-0215(20010520)95:3<168::AID-IJC1029>3.0.CO;2-A; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Brien DO, 2012, HISTOL HISTOPATHOL, V27, P13, DOI 10.14670/HH-27.13; Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Carr MI, 2016, CELL REP, V16, P2618, DOI 10.1016/j.celrep.2016.08.014; Carrillo AM, 2015, ONCOGENE, V34, P846, DOI 10.1038/onc.2014.27; Chamberlain JS, 2007, FASEB J, V21, P2195, DOI 10.1096/fj.06-7353com; Chandler DS, 2006, CANCER RES, V66, P9502, DOI 10.1158/0008-5472.CAN-05-4271; Cheng Q, 2011, MOL CELL BIOL, V31, P4951, DOI 10.1128/MCB.05553-11; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Dang JJ, 2002, CANCER RES, V62, P1222; Davis RJ, 1997, P NATL ACAD SCI USA, V94, P8047, DOI 10.1073/pnas.94.15.8047; de Vree PJP, 2014, NAT BIOTECHNOL, V32, P1019, DOI 10.1038/nbt.2959; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dias CS, 2006, CANCER RES, V66, P9467, DOI 10.1158/0008-5472.CAN-05-3013; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Ellsworth RE, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-297; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Evdokiou A, 2001, INT J ONCOL, V19, P625; FAKHARZADEH SS, 1993, GENOMICS, V15, P283, DOI 10.1006/geno.1993.1058; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fernandez K, 2010, AM J PATHOL, V176, P416, DOI 10.2353/ajpath.2010.090405; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Fridman JS, 2003, CANCER RES, V63, P5703; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Gannon HS, 2012, CANCER CELL, V21, P668, DOI 10.1016/j.ccr.2012.04.011; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gu L, 2012, ONCOGENE, V31, P1342, DOI 10.1038/onc.2011.343; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Hachitanda Y, 1998, MODERN PATHOL, V11, P1222; Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hong SK, 2006, CELL CYCLE, V5, P801, DOI 10.4161/cc.5.8.2638; Hori M, 2000, PATHOL INT, V50, P786, DOI 10.1046/j.1440-1827.2000.01119.x; Hosur V, 2012, CANCER GENET-NY, V205, P232, DOI 10.1016/j.cancergen.2012.03.005; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacob AG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104444; Jacob AG, 2013, NEOPLASIA, V15, P1049, DOI 10.1593/neo.13286; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Jung CH, 2013, CANCER LETT, V335, P270, DOI 10.1016/j.canlet.2013.02.035; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lobe CG, 1999, DEV BIOL, V208, P281, DOI 10.1006/dbio.1999.9209; Lukas J, 2001, CANCER RES, V61, P3212; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; Lynch CJ, 2006, ONCOGENE, V25, P3463, DOI 10.1038/sj.onc.1209387; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; Matsumoto R, 1998, CANCER RES, V58, P609; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; Miron K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8094; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nanni P, 2003, CANCER RES, V63, P2728; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Ognjanovic Simona, 2012, Sarcoma, V2012, P492086, DOI 10.1155/2012/492086; Okoro DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077643; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; RANGDAENG S, 1991, AM J CLIN PATHOL, V96, P32, DOI 10.1093/ajcp/96.1.32; Sanchez-Aguilera A, 2006, ONCOGENE, V25, P2565, DOI 10.1038/sj.onc.1209282; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Singh S, 2013, CELL DEATH DIFFER, V20, P558, DOI 10.1038/cdd.2012.153; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Steinman HA, 2004, J BIOL CHEM, V279, P4877, DOI 10.1074/jbc.M305966200; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Suzuki C, 2007, MOL CANCER THER, V6, P542, DOI 10.1158/1535-7163.MCT-06-0659; Takano Ai, 2011, Kobe J Med Sci, V56, pE220; Takano A, 2010, DEV DYNAM, V239, P1789, DOI 10.1002/dvdy.22287; Tamborini E, 2001, INT J CANCER, V92, P790, DOI 10.1002/ijc.1271; Tang YA, 2012, CLIN CANCER RES, V18, P4325, DOI 10.1158/1078-0432.CCR-11-2617; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Volk EL, 2009, MOL CANCER RES, V7, P863, DOI 10.1158/1541-7786.MCR-08-0418; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Xia SJJ, 2002, CANCER BIOL THER, V1, P97, DOI 10.4161/cbt.51; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Zanola A, 2012, J CELL MOL MED, V16, P1377, DOI 10.1111/j.1582-4934.2011.01518.x; Zheng TS, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3996; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11	101	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					95	106		10.1038/onc.2017.282	http://dx.doi.org/10.1038/onc.2017.282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28892044	Green Accepted			2022-12-17	WOS:000422625000010
J	Plissonnier, ML; Lahlali, T; Raab, M; Michelet, M; Romero-Lopez, C; Rivoire, M; Strebhardt, K; Durantel, D; Levrero, M; Mehlen, P; Zoulim, F; Parent, R				Plissonnier, M-L; Lahlali, T.; Raab, M.; Michelet, M.; Romero-Lopez, C.; Rivoire, M.; Strebhardt, K.; Durantel, D.; Levrero, M.; Mehlen, P.; Zoulim, F.; Parent, R.			Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; DAP-KINASE; ENDOPLASMIC-RETICULUM; TUMOR SUPPRESSORS; GENE-EXPRESSION; AUTOPHAGY; REPLICATION; DEPENDENCE; PARTICLES; APOPTOSIS	Hepatitis C virus (HCV) infection is a leading cause of hepatocellular carcinoma (HCC), mainly through cirrhosis induction, spurring research for a deeper understanding of HCV versus host interactions in cirrhosis. The present study investigated crosstalks between HCV infection and UNC5A, a netrin-1 dependence receptor that is inactivated in cancer. UNC5A and HCV parameters were monitored in patients samples (n = 550) as well as in in vitro. In patients, UNC5A mRNA expression is significantly decreased in clinical HCV(+) specimens irrespective of the viral genotype, but not in (HBV)(+) liver biopsies, as compared to uninfected samples. UNC5A mRNA is downregulated in F2 (3-fold; P = 0.009), in F3 (10-fold, P = 0.0004) and more dramatically so in F4/cirrhosis (44-fold; P < 0.0001) histological stages of HCV(+) hepatic lesions compared to histologically matched HCV(-) tissues. UNC5A transcript was found strongly downregulated in HCC samples (33-fold; P < 0.0001) as compared with non-HCC samples. In vivo, association of UNC5A transcripts with polyribosomes is decreased by 50% in HCV(+) livers. Consistent results were obtained in vitro showing HCV-dependent depletion of UNC5A in HCV-infected hepatocyte-like cells and in primary human hepatocytes. Using luciferase reporter constructs, HCV cumulatively decreased UNC5A transcription from the UNC5 promoter and translation in a UNC5A 5'UTR-dependent manner. Proximity ligation assays, kinase assays, as well as knockdown and forced expression experiments identified UNC5A as capable of impeding autophagy and promoting HCV restriction through specific impact on virion infectivity, in a cell death-independent and DAPK-related manner. In conclusion, while the UNC5A dependence receptor counteracts HCV persistence through regulation of autophagy in a DAPK-dependent manner, it is dramatically decreased in all instances in HCC samples, and specifically by HCV in cirrhosis. Such data argue for the evaluation of the implication of UNC5A in liver carcinogenesis.	[Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Zoulim, F.; Parent, R.] Ctr Rech Cancerol Lyon, Pathogenesis Hepatitis B&C Equipe Labellisee LabE, INSERM U1052, 151 Cours Albert Thomas, F-69424 Lyon, France; [Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Levrero, M.; Mehlen, P.; Zoulim, F.; Parent, R.] Univ Lyon, Lyon, France; [Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Levrero, M.; Mehlen, P.; Zoulim, F.; Parent, R.] Univ Lyon 1, ISPB, Lyon, France; [Plissonnier, M-L; Lahlali, T.; Michelet, M.; Durantel, D.; Levrero, M.; Zoulim, F.; Parent, R.] Ctr Rech Cancerol Lyon, CNRS UMR5286, Lyon, France; [Raab, M.; Strebhardt, K.] Goethe Univ, D-60590 Frankfurt, Germany; [Raab, M.; Strebhardt, K.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Romero-Lopez, C.] Inst Parasitol & Biomed Lopez Neyra, Ave Conocimiento S-N, Armilla, Spain; [Rivoire, M.; Mehlen, P.] Ctr Leon Berard, Lyon, France; [Levrero, M.] Epigenet & Epigenom Hepatocellular Carcinoma, Lyon, France; [Levrero, M.; Zoulim, F.] Hosp Civils Lyon, Serv Hepatogastroenterol, Lyon, France; [Levrero, M.; Mehlen, P.] Ctr Rech Cancerol Lyon, INSERM U1052, Lyon, France; [Mehlen, P.] LabEx DEVweCAN, Apoptosis Canc & Dev Lab Equipe Labellisee La Lig, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); UNICANCER; Centre Leon Berard; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Parent, R (corresponding author), Ctr Rech Cancerol Lyon, Pathogenesis Hepatitis B&C Equipe Labellisee LabE, INSERM U1052, 151 Cours Albert Thomas, F-69424 Lyon, France.	romain.parent@inserm.fr	Zoulim, Fabien/ABD-5594-2021; Romero-López, Cristina/G-8282-2015; Parent, Romain/N-7115-2017; Durantel, David/I-4639-2018; Strebhardt, Klaus/E-8765-2011; Plissonnier, Marie-Laure/Y-9491-2019; Levrero, Massimo/G-5680-2016	Zoulim, Fabien/0000-0002-2245-0083; Romero-López, Cristina/0000-0001-9818-0529; Parent, Romain/0000-0002-3645-7008; Durantel, David/0000-0002-9226-3419; Plissonnier, Marie-Laure/0000-0003-4879-4586; Levrero, Massimo/0000-0002-4978-0875; Strebhardt, Klaus/0000-0003-2173-9763	European Union [248364]; LYric Grant [INCa-DGOS-4664]; French National Agency for AIDS and Viral Hepatitis Research (ANRS) [2011-379]; French Ligue Contre Le Cancer; DevWeCan French Laboratories of Excellence Network (Labex) [ANR-10-LABX-61]	European Union(European Commission); LYric Grant; French National Agency for AIDS and Viral Hepatitis Research (ANRS)(ANRSFrench National Research Agency (ANR)); French Ligue Contre Le Cancer(Ligue nationale contre le cancer); DevWeCan French Laboratories of Excellence Network (Labex)	This study was supported by the European Union (Marie Curie International Reintegration Grant #248364), The LYric Grant (INCa-DGOS-4664), The French National Agency for AIDS and Viral Hepatitis Research (ANRS, Grant #2011-379), The French Ligue Contre Le Cancer and The DevWeCan French Laboratories of Excellence Network (Labex, Grant #ANR-10-LABX-61). We thank T. Wakita (National Institute of Infectious Diseases, Japan), CM Rice (The Rockefeller University, NY, USA) and F Helle (Inserm, France) for Huh7.5 cells and HCV strains.	ANRS Collaborative Study Grp, 2016, J HEPATOL, V65, P734, DOI 10.1016/j.jhep.2016.05.045; Bartoe JL, 2006, J NEUROSCI, V26, P3192, DOI 10.1523/JNEUROSCI.3469-05.2006; Bialik S, 2010, CURR OPIN CELL BIOL, V22, P199, DOI 10.1016/j.ceb.2009.11.004; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Bredesen DE, 2005, CELL DEATH DIFFER, V12, P1031, DOI 10.1038/sj.cdd.4401680; Buehler E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051942; Chang TH, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S2-S4; Conti F, 2016, J HEPATOL, V65, P727, DOI 10.1016/j.jhep.2016.06.015; Dash S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8050150; Delgrange D, 2007, J GEN VIROL, V88, P2495, DOI 10.1099/vir.0.82872-0; Dreux M, 2009, AUTOPHAGY, V5, P1224, DOI 10.4161/auto.5.8.10219; Dreux M, 2009, P NATL ACAD SCI USA, V106, P14046, DOI 10.1073/pnas.0907344106; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guenebeaud C, 2010, MOL CELL, V40, P863, DOI 10.1016/j.molcel.2010.11.021; Helle F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070809; Hibi K, 2012, HEPATO-GASTROENTEROL, V59, P2573, DOI 10.5754/hge10616; Huang H, 2013, AUTOPHAGY, V9, P175, DOI 10.4161/auto.22791; Kohli A, 2014, JAMA-J AM MED ASSOC, V312, P631, DOI 10.1001/jama.2014.7085; Levin-Salomon V, 2014, APOPTOSIS, V19, P346, DOI 10.1007/s10495-013-0918-3; Li MMH, 2015, TRENDS CELL BIOL, V25, P320, DOI 10.1016/j.tcb.2015.02.001; Lindenbach Brett D., 2009, V510, P329, DOI 10.1007/978-1-59745-394-3_24; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Llovet JM, 2016, NAT REV GASTRO HEPAT, V13, P561, DOI 10.1038/nrgastro.2016.140; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Mehlen P, 2011, NAT REV CANCER, V11, P188, DOI 10.1038/nrc3005; Mehlen P, 2010, CURR OPIN ONCOL, V22, P46, DOI 10.1097/CCO.0b013e328333dcd1; Messina JP, 2015, HEPATOLOGY, V61, P77, DOI 10.1002/hep.27259; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Mohl BP, 2016, J GEN VIROL, V97, P680, DOI 10.1099/jgv.0.000387; Paradisi A, 2008, GASTROENTEROLOGY, V135, P1248, DOI 10.1053/j.gastro.2008.06.080; Parent R, 2007, CANCER RES, V67, P4337, DOI 10.1158/0008-5472.CAN-06-3640; Parent R, 2009, HEPATOLOGY, V49, P1798, DOI 10.1002/hep.22852; Parent R, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r19; Picard M, 2009, CELL SIGNAL, V21, P1961, DOI 10.1016/j.cellsig.2009.09.004; Plissonnier ML, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002421; Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75; Romanowski T, 2008, MED SCI MONITOR, V14, pBR147; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; Sainz B, 2006, J VIROL, V80, P10253, DOI 10.1128/JVI.01059-06; Shrivastava S, 2012, J VIROL, V86, P8705, DOI 10.1128/JVI.00616-12; Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014; Stephens SB, 2007, METHOD ENZYMOL, V431, P47, DOI 10.1016/S0076-6879(07)31004-5; Stevens C, 2009, J BIOL CHEM, V284, P334, DOI 10.1074/jbc.M805165200; Stohr S, 2016, GUT, V65, P2017, DOI 10.1136/gutjnl-2014-308971; Tanida I, 2009, AUTOPHAGY, V5, P937, DOI 10.4161/auto.5.7.9243; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100; Thomas DL, 2013, NAT MED, V19, P850, DOI 10.1038/nm.3184; Tian Y, 2015, CELL DEATH DIFFER, V22, P1025, DOI 10.1038/cdd.2014.201; Trinchet JC, 2015, HEPATOLOGY, V62, P737, DOI 10.1002/hep.27743; van der Meer AJ, 2017, J HEPATOL, V66, P485, DOI 10.1016/j.jhep.2016.10.017; Weil D, 2000, RNA, V6, P962, DOI 10.1017/S1355838200000479; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738	55	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 30	2017	36	48					6712	6724		10.1038/onc.2017.271	http://dx.doi.org/10.1038/onc.2017.271			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FO4AJ	28783179				2022-12-17	WOS:000416780800006
J	Garnett, S; Dutchak, KL; McDonough, RV; Dankort, D				Garnett, S.; Dutchak, K. L.; McDonough, R. V.; Dankort, D.			p53 loss does not permit escape from Braf(V600E)-induced senescence in a mouse model of lung cancer	ONCOGENE			English	Article							CELL-CYCLE ARREST; K-RAS ONCOGENE; SOMATIC MUTATIONS; SIGNALING PATHWAY; CDKN2A LOCUS; OPEN-LABEL; PTEN LOSS; IN-VIVO; BRAF; ACTIVATION	Lung cancer arises through the acquisition of a number of genetic lesions, with a preponderance of activating mutations in the canonical mitogen-activated protein kinase (MAPK) cascade (RTK-RAS-RAF-MEK). Braf(V600E) expression induces benign lung adenomas that fail to progress to adenocarcinoma because of oncogene-induced senescence (OIS). BrafV600E expression, coupled with simultaneous p53 ablation, permits bypass of senescence and progression to lung adenocarcinoma. However, spontaneous human tumors sustain mutations in a temporally separated manner. Here, we use a mouse lung cancer model where oncogene activation (Braf(V600E) expression) and tumor suppressor loss (p53 ablation) are independently controlled through the actions of Flp and Cre recombinase, respectively. We show that p53 loss before OIS is permissive for the transition from lung adenoma to adenocarcinoma. In contrast, p53 loss after senescence is established fails to enable escape from senescence and disease progression. This study demonstrates that Braf(V600E) induced senescence is irreversible in vivo and suggests that therapy-induced senescence would halt further tumor progression.	[Garnett, S.; Dutchak, K. L.; McDonough, R. V.; Dankort, D.] McGill Univ, Dept Biol, 1205 Ave Docteur Penfield,Stewart Bldg,N3-17, Montreal, PQ H3A 1B1, Canada; [Dankort, D.] Goodman Canc Res Ctr, Montreal, PQ, Canada	McGill University	Dankort, D (corresponding author), McGill Univ, Dept Biol, 1205 Ave Docteur Penfield,Stewart Bldg,N3-17, Montreal, PQ H3A 1B1, Canada.	david.dankort@mcgill.ca		Dankort, David/0000-0002-5862-6829	Canadian Institutes of Health Research (CIHR) [MOP-97925]; Canadian Cancer Society Research Initiative [704228]; Cancer Research Society [19087]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Initiative; Cancer Research Society	DD would like to thank Martin McMahon for his generosity and guidance, which enabled this work. We thank members of the Dankort lab for discussions, Eve Bigras for administrative assistance, Drs Siegfried Hekimi, Alain Nepveu and Peter M Siegel for critical comments. We thank the lab of Dr Hoang Trang for providing necessary reagents. These studies were supported by grants from the Canadian Institutes of Health Research (CIHR, MOP-97925), Canadian Cancer Society Research Initiative (no. 704228) and Cancer Research Society (no. 19087).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Ameyar-Zazoua M, 2005, ONCOGENE, V24, P2298, DOI 10.1038/sj.onc.1208424; Baek KH, 2013, J CLIN INVEST, V123, P4375, DOI 10.1172/JCI67465; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; BENNETT WP, 1995, CANCER DETECT PREV, V19, P503; Bieging-Rolett KT, 2016, ONCOGENE, V35, P4414, DOI 10.1038/onc.2015.490; Bivona TG, 2016, NAT MED, V22, P472, DOI 10.1038/nm.4091; Chakradeo S, 2016, CURR DRUG TARGETS, V17, P460, DOI 10.2174/1389450116666150825113500; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Cisowski J, 2016, ONCOGENE, V35, P1328, DOI 10.1038/onc.2015.186; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Devarakonda S, 2015, LANCET ONCOL, V16, pE342, DOI 10.1016/S1470-2045(15)00077-7; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Eroglu Z, 2016, THER ADV MED ONCOL, V8, P48, DOI 10.1177/1758834015616934; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Hogan BLM, 2014, CELL STEM CELL, V15, P123, DOI 10.1016/j.stem.2014.07.012; Huillard E, 2012, P NATL ACAD SCI USA, V109, P8710, DOI 10.1073/pnas.1117255109; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kim ES, 2016, ADV EXP MED BIOL, V893, P189, DOI 10.1007/978-3-319-24223-1_10; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Ko A, 2016, BMB REP, V49, P598, DOI 10.5483/BMBRep.2016.49.11.120; Kramer BW, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-24; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Larsson LG, 2011, SEMIN CANCER BIOL, V21, P367, DOI 10.1016/j.semcancer.2011.10.005; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Lemjabbar-Alaoui H, 2015, BBA-REV CANCER, V1856, P189, DOI 10.1016/j.bbcan.2015.08.002; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lipsyc M, 2015, J GASTROINTEST ONCOL, V6, P645, DOI 10.3978/j.issn.2078-6891.2015.045; Mallakin A, 2007, CANCER CELL, V12, P381, DOI 10.1016/j.ccr.2007.08.034; Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Muzumdar MD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12685; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Noguchi M, 2010, CANCER METAST REV, V29, P15, DOI 10.1007/s10555-010-9210-y; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pencik J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8736; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2; Puzanov I, 2010, SEMIN CUTAN MED SURG, V29, P196, DOI 10.1016/j.sder.2010.06.005; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shai A, 2015, CANCER RES, V75, P3167, DOI 10.1158/0008-5472.CAN-14-3701; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tabor V, 2014, CANCER RES, V74, P4222, DOI 10.1158/0008-5472.CAN-13-3234; Trejo CL, 2013, CANCER RES, V73, P6448, DOI 10.1158/0008-5472.CAN-13-0681; Trejo CL, 2012, CANCER RES, V72, P3048, DOI 10.1158/0008-5472.CAN-11-3649; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Turski ML, 2016, MOL CANCER THER, V15, P533, DOI 10.1158/1535-7163.MCT-15-0643; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Volanakis EJ, 2009, BLOOD, V114, P4451, DOI 10.1182/blood-2009-07-233346; Vredeveld LCW, 2012, GENE DEV, V26, P1055, DOI 10.1101/gad.187252.112; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang JQ, 2012, CANCER RES, V72, P4765, DOI 10.1158/0008-5472.CAN-12-0820; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Welsh SJ, 2016, EUR J CANCER, V62, P76, DOI 10.1016/j.ejca.2016.04.005; Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	86	7	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6325	6335		10.1038/onc.2017.235	http://dx.doi.org/10.1038/onc.2017.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28745322				2022-12-17	WOS:000414774800011
J	Zhang, F; Tang, H; Jiang, Y; Mao, Z				Zhang, F.; Tang, H.; Jiang, Y.; Mao, Z.			The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression	ONCOGENE			English	Article							DNA-END RESECTION; DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; CHECKPOINT CONTROL; CANCER; PATHWAY; BRCA1; TUMORIGENESIS; GENES; CELLS	GATA3, a critical transcription factor involved in the development of the mammary gland, also plays important roles in mammary tumorigenesis by regulating transcription in coordination with two essential DNA repair factors, PARP1 and BRCA1. However, whether and how GATA3 participates in the process of DNA repair, which is often associated with tumorigenesis, has not been investigated. Here we demonstrate that GATA3 is required for the repair of DNA double-strand breaks (DSBs) by homologous recominbation (HR). Mechanistic studies indicate that at both the protein and the mRNA level, depleting GATA3 leads to reduced expression of CtIP, an essential HR factor involved in end resection, thereby suppressing the repair of DSBs by HR and sensitizing cells to etoposide induced DNA DSBs. Further studies indicate that upon the occurrence of DNA DSBs GATA3 directly binds to the CtIP promoter at the region of -2119 to -2130 and -2274 to -2285, and promotes the transcription of CtIP. Overexpression of CtIP in GATA3 depleted cells rescues the decline of HR, and cell survival in the presence of etoposide. In addition, through data mining analysis, we observed an extremely strong correlation between the expression levels of GATA3 and CtIP in paratumors, but the correlation turned insignificant in mammary tumors. Using vectors encoding GATA3 with mutations frequently occurring in mammary tumors, we found that several mutations on GATA3 led to a dysregulation of CtIP, and therefore HR repair. In summary, our data delineates the regulatory mechanisms of GATA3 in DNA DSB repair and strongly suggests that it might act as a tumor suppressor by promoting CtIP expression and HR to stabilize genomes.	[Zhang, F.; Tang, H.; Jiang, Y.; Mao, Z.] Tongji Univ, Shanghai Matern & Infant Hosp 1, Shanghai Key Lab Signaling & Dis Res, Clin & Translat Res Ctr,Sch Life Sci & Technol, Shanghai, Peoples R China	Tongji University	Jiang, Y; Mao, Z (corresponding author), Tongji Univ, Sch Life Sci & Technol, 1239 Siping Rd, Shanghai 200092, Peoples R China.	ying_jiang@tongji.edu.cn; zhiyong_mao@tongji.edu.cn		Mao, Zhiyong/0000-0002-5298-1918	Chinese National Program on Key Basic Research Project [2013CB967600, 2015CB964800]; National Science Foundation of China [81502385, 81622019, 31371396, 31570813, 81402543, 81601212]; 1000 Youth Talents Program; Shanghai Municipal Natural Science Foundation [15ZR1442600]; Fundamental Research Funds for the Central Universities	Chinese National Program on Key Basic Research Project; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1000 Youth Talents Program; Shanghai Municipal Natural Science Foundation; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Dr Michael Van Meter for critically reading the manuscript. We thank Yang Yu for helping with the clonogenic assay. We thank Lu Chen for helping create the vector encoding GATA3. We thank TCGA for providing high quality high-throughput data for public analysis. The work was supported by grants from Chinese National Program on Key Basic Research Project (Grant No. 2013CB967600, 2015CB964800), the National Science Foundation of China (Grant No. 81502385, 81622019, 31371396, 31570813, 81402543, 81601212), the 1000 Youth Talents Program, Shanghai Municipal Natural Science Foundation (Grant No. 15ZR1442600), and the Fundamental Research Funds for the Central Universities.	Aqeilan RI, 2007, J CELL PHYSIOL, V212, P307, DOI 10.1002/jcp.21099; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; Chou J, 2010, J CELL PHYSIOL, V222, P42, DOI 10.1002/jcp.21943; Ciocca V, 2009, HUM PATHOL, V40, P489, DOI 10.1016/j.humpath.2008.09.010; Davis AJ, 2014, DNA REPAIR, V17, P21, DOI 10.1016/j.dnarep.2014.02.020; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Guo MZ, 2004, CLIN CANCER RES, V10, P7917, DOI 10.1158/1078-0432.CCR-04-1140; Haveri H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-9; Hsu HM, 2007, CANCER EPIDEM BIOMAR, V16, P2024, DOI 10.1158/1055-9965.EPI-07-0116; Huhn D, 2015, ONCOGENE, V34, P3977, DOI 10.1038/onc.2014.329; Jimeno S, 2015, NUCLEIC ACIDS RES, V43, P987, DOI 10.1093/nar/gku1384; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Li Z, 2016, CELL DEATH DIFFER, V23, P1765, DOI 10.1038/cdd.2016.65; Liu F, 2006, MOL CELL BIOL, V26, P3124, DOI 10.1128/MCB.26.8.3124-3134.2006; Mao ZY, 2007, P NATL ACAD SCI USA, V104, P13068, DOI 10.1073/pnas.0702410104; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Minchenko DO, 2012, AM J MOL BIOL, V2, P21; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NIE ZR, 1995, CANCER RES, V55, P4760; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Pikkarainen S, 2004, CARDIOVASC RES, V63, P196, DOI 10.1016/j.cardiores.2004.03.025; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Shan L, 2014, ONCOGENE, V33, P3205, DOI 10.1038/onc.2013.270; Soria-Bretones I, 2013, CANCER MED-US, V2, P774, DOI 10.1002/cam4.141; Takaku M, 2015, GENE EXPRESSION, V16, P163, DOI 10.3727/105221615X14399878166113; Tkocz D, 2012, ONCOGENE, V31, P3667, DOI 10.1038/onc.2011.531; Wu GK, 2006, CELL CYCLE, V5, P1592, DOI 10.4161/cc.5.15.3127; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006; Zhang L, 2015, CANCER BIOL THER, V16, P1585, DOI 10.1080/15384047.2015.1078021	37	7	7	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5168	5176		10.1038/onc.2017.127	http://dx.doi.org/10.1038/onc.2017.127			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481869				2022-12-17	WOS:000409371100008
J	Antignani, A; Segal, D; Simon, N; Kreitman, RJ; Huang, D; FitzGerald, DJ				Antignani, A.; Segal, D.; Simon, N.; Kreitman, R. J.; Huang, D.; FitzGerald, D. J.			Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins	ONCOGENE			English	Article							HAIRY-CELL LEUKEMIA; PSEUDOMONAS EXOTOXIN; CANCER CELLS; PROTEINS; CYTOSOL; TOXIN; DEATH; GUIDE; BAX	Protein synthesis is crucial for regulating cell homeostasis and, when unrestricted, it can lead to tumorigenesis. Immunotoxins derived from Pseudomonas exotoxin are antibody-toxin fusion proteins that inhibit protein synthesis of mammalian cells via ADP-ribosylation of the eukaryotic elongation factor-2. Here we investigate the role of the Bcl-2 family proteins in the response of cancer cells to immunotoxin challenge. Besides the well-known reduction of the prosurvival Bcl-2 family member, Mcl-1, following inhibition of protein synthesis, we show for the first time that immunotoxins also reduce the levels of selected proapoptotic BH-3-only proteins. Among these, only Bim protein levels correlated with the ability of immunotoxins to induce an apoptotic response. To support our findings, we verified that a Bim knockout completely abolished immunotoxin-mediated apoptosis. Further, mice bearing either wild-type or Bid knockout tumors responded to immunotoxin treatment with a decrease in growth kinetics, whereas mice engrafted with Bim knockout tumors showed no reduction in tumor size or prolongation of survival following immunotoxin treatment. From these results, we conclude that Bim expression is a major susceptibility factor for tumor cell death and, as such, constitutes a potential biomarker that could be evaluated before immunotoxin treatment. In support of this hypothesis, clinically, we analyzed patient cells before immunotoxin treatment and report that samples of hairy cell leukemia with high levels of Bim protein responded with a greater decrease in leukemic cell count compared with those samples expressing a low level of Bim.	[Antignani, A.; Simon, N.; Kreitman, R. J.; FitzGerald, D. J.] NCI, Lab Mol Biol, CCR, NIH, Bldg 37,Room 5124,37 Convent Dr, Bethesda, MD 20892 USA; [Segal, D.; Huang, D.] Walter & Eliza Hall Inst Med Res, Canc & Haematol Div, Melbourne, Vic, Australia; [Segal, D.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Melbourne	Antignani, A; FitzGerald, DJ (corresponding author), NCI, Lab Mol Biol, CCR, NIH, Bldg 37,Room 5124,37 Convent Dr, Bethesda, MD 20892 USA.	antignaa@mail.nih.gov; fitzgerd@helix.nih.gov	Huang, David C. S./C-7586-2013	Huang, David C. S./0000-0002-3101-4873	National Cancer Institute, NIH; Australian National Health and Medical Research Council [1057742, 1016701, 9000220]; Cancer Council Victoria; Leukemia and Lymphoma Society (Specialized Centers of Research) [7001-13]; Australian Cancer Research Foundation; Victorian State Government; NATIONAL CANCER INSTITUTE [ZIABC010301, ZIABC008757] Funding Source: NIH RePORTER	National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Leukemia and Lymphoma Society (Specialized Centers of Research)(Leukemia and Lymphoma Society); Australian Cancer Research Foundation; Victorian State Government; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank R Anderson and W Welch for the gift of reagents and Jianan Gong and Stephen Wilcox for assistance with sequence validation of CRISPR/Cas9 knockout cell lines. We thank E Arons for advice on the RT-PCR. This work was funded by the intramural programs of the National Cancer Institute, NIH and is supported by fellowships, and grants from the Australian National Health and Medical Research Council (research fellowships to DCSH; project grant 1057742 (DCSH); program grant 1016701; and Independent Research Institutes Infrastructure Support Scheme (grant 9000220)), the Cancer Council Victoria (grant-in-aid to DCSH), the Leukemia and Lymphoma Society (Specialized Centers of Research grants 7001-13), the Australian Cancer Research Foundation, a Victorian State Government Operational Infrastructure Support grant.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Alewine C, 2015, ONCOLOGIST, V20, P176, DOI 10.1634/theoncologist.2014-0358; Andersson Y, 2004, INT J CANCER, V112, P475, DOI 10.1002/ijc.20371; Antignani A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161415; Antignani A, 2014, MOL CANCER THER, V13, P1655, DOI 10.1158/1535-7163.MCT-13-0998; Antignani A, 2013, TOXINS, V5, P1486, DOI 10.3390/toxins5081486; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; FitzGerald DJ, 2011, CANCER RES, V71, P6300, DOI 10.1158/0008-5472.CAN-11-1374; Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011; Hollevoet K, 2014, J IMMUNOTHER, V37, P8, DOI 10.1097/CJI.0000000000000010; Kreitman RJ, 2015, BEST PRACT RES CL HA, V28, P236, DOI 10.1016/j.beha.2015.09.003; Kreitman RJ, 2012, J CLIN ONCOL, V30, P1822, DOI 10.1200/JCO.2011.38.1756; Lindqvist LM, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.149; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Salvatore G, 2002, BIOCHEM BIOPH RES CO, V294, P813, DOI 10.1016/S0006-291X(02)00560-0; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Traini R, 2010, MOL CANCER THER, V9, P2007, DOI 10.1158/1535-7163.MCT-10-0257; Wayne AS, 2014, BLOOD, V123, P2470, DOI 10.1182/blood-2014-01-492256; Weldon JE, 2011, FEBS J, V278, P4683, DOI 10.1111/j.1742-4658.2011.08182.x; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289	24	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					4953	4962		10.1038/onc.2017.111	http://dx.doi.org/10.1038/onc.2017.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28436946				2022-12-17	WOS:000408768800001
J	Zhai, W; Sun, Y; Jiang, M; Wang, M; Gasiewicz, TA; Zheng, J; Chang, C				Zhai, W.; Sun, Y.; Jiang, M.; Wang, M.; Gasiewicz, T. A.; Zheng, J.; Chang, C.			Differential regulation of LncRNA-SARCC suppresses VHL-mutant RCC cell proliferation yet promotes VHL-normal RCC cell proliferation via modulating androgen receptor/HIF-2 alpha/C-MYC axis under hypoxia (vol 35, pg 4866, 2016)	ONCOGENE			English	Correction																		Zhai W, 2016, ONCOGENE, V35, P4866, DOI 10.1038/onc.2016.19	1	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4525	4525		10.1038/onc.2016.514	http://dx.doi.org/10.1038/onc.2016.514			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368407	Bronze			2022-12-17	WOS:000406806000014
J	Lin, MC; Lin, JJ; Hsu, CL; Juan, HF; Lou, PJ; Huang, MC				Lin, M-C; Lin, J-J; Hsu, C-L; Juan, H-F; Lou, P-J; Huang, M-C			GATA3 interacts with and stabilizes HIF-1 alpha to enhance cancer cell invasiveness (vol 36, pg 4243, 2017)	ONCOGENE			English	Correction														LOU, PEI-JEN/0000-0002-3383-8593; HUANG, MIN-CHUAN/0000-0002-0704-3447				Lin MC, 2017, ONCOGENE, V36, P4243, DOI 10.1038/onc.2017.8	1	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4380	4380		10.1038/onc.2017.196	http://dx.doi.org/10.1038/onc.2017.196			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28604747	Green Published, hybrid			2022-12-17	WOS:000406360600015
J	Huang, L; Wang, Z; Liu, C; Xu, C; Mbofung, RM; McKenzie, JA; Khong, H; Hwu, P; Peng, W				Huang, L.; Wang, Z.; Liu, C.; Xu, C.; Mbofung, R. M.; McKenzie, J. A.; Khong, H.; Hwu, P.; Peng, W.			CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner	ONCOGENE			English	Article							PLASMACYTOID DENDRITIC CELLS; COMBINING TARGETED THERAPY; METASTATIC MELANOMA; IMMUNE-RESPONSES; VACCINE ADJUVANT; CANCER VACCINES; T-CELLS; TUMOR; ANTIGEN; DNA	Combining immunotherapy with targeted therapy has increasingly become an appealing therapeutic paradigm for cancer treatment due to its great potential for generating durable and synergistic antitumor response. In this study, however, we unexpectedly found that two types of CpG-based tumor peptide vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumors with BRAF mutation rather than showing a synergistic antitumor effect. Our further studies demonstrated that CpG alone was sufficient to dampen BRAF inhibitor-induced antitumor responses, suggesting that the impaired antitumor activity of the BRAF inhibitor observed in mice receiving CpG-based peptide vaccine is mainly dependent upon the use of CpG. Mechanistically, CpG increased the number of circulating B cells, which produced elevated amounts of tumor necrosis factor-alpha (TNF alpha) that contributed to the increased tumor resistance to BRAF inhibitors. More importantly, B-cell depletion or TNF alpha neutralization can restore the antitumor effect of BRAF inhibition in mice receiving CpG treatment, indicating that TNF alpha-secreting B cells play an indispensable role in BRAF inhibitor resistance induced by CpG. Taken together, our results strongly suggest that precautions must be implemented when designing combinatorial approaches for cancer treatment, because distinct regimens, despite their respective therapeutic benefit as monotherapy, may together provide antagonistic clinical outcomes.	[Huang, L.; Wang, Z.; Liu, C.; Xu, C.; Mbofung, R. M.; McKenzie, J. A.; Khong, H.; Hwu, P.; Peng, W.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Peng, W (corresponding author), Univ Texas MD Anderson Canc Ctr, 7455 Fannin St Unit 904, Houston, TX 77054 USA.; Hwu, P (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	phwu@mdanderson.org; wpeng@mdanderson.org	Huang, Lu/I-4148-2018	Khong, Hiep/0000-0003-4888-7862; Mbofung, Rina/0000-0003-3872-3143	National Cancer Institute [R01CA116206, P01CA128913, R01CA187076, P50CA093459, P30CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA116206, R01CA187076, P50CA093459, P01CA128913] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hussein Tawbi for constructive comments on the manuscript. The research was supported in part by the following National Cancer Institute grants: R01CA116206 (to PH), P01CA128913 (to PH), R01CA187076 (to PH and MD), P50CA093459 and P30CA016672 (MDACC Melanoma SPORE and MDACC CCSG for JAM and Flow facility, respectively). By the Cancer Prevention and Research Institute of Texas (CPRIT RP140106 to JAM) and by philanthropic contributions to MDACC Melanoma Moon Shot Program; Melanoma Research Alliance Team Science Award; Dr Miriam and Sheldon G Adelson Medical Research Foundation; Aim at Melanoma Foundation, Miriam and Jim Mulva research funds; Jurgen Sager & Transocean Melanoma Research Fund; El Paso Foundation for Melanoma Research; GillsonLogenbaugh Foundation. We thank Cherie Butts from Biogen for providing antimouse CD20 antibody.	Avalos AM, 2009, J IMMUNOL, V183, P6262, DOI 10.4049/jimmunol.0901941; Bauer S, 2002, CURR TOP MICROBIOL, V270, P145; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Cooper ZA, 2014, CANCER IMMUNOL RES, V2, P643, DOI 10.1158/2326-6066.CIR-13-0215; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davila E, 2003, CANCER RES, V63, P3281; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; Hailemichael Y, 2013, NAT MED, V19, P465, DOI 10.1038/nm.3105; Hanten JA, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-39; Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691; Hu-Lieskovan S, 2014, J CLIN ONCOL, V32, P2248, DOI 10.1200/JCO.2013.52.1377; Jerome V, 2006, J IMMUNOTHER, V29, P294; Kim S, 2008, J IMMUNOTHER, V31, P446, DOI 10.1097/CJI.0b013e31816d1d6a; Kim Teresa, 2014, Cancer Biology Medicine, V11, P237, DOI 10.7497/j.issn.2095-3941.2014.04.002; Koya RC, 2012, CANCER RES, V72, P3928, DOI 10.1158/0008-5472.CAN-11-2837; Liu CW, 2008, J CLIN INVEST, V118, P1165, DOI 10.1172/JCI33583; Liu CW, 2013, CLIN CANCER RES, V19, P393, DOI 10.1158/1078-0432.CCR-12-1626; Lou YY, 2011, J IMMUNOTHER, V34, P279, DOI 10.1097/CJI.0b013e31820d2a05; Mehta NK, 2015, CANCER IMMUNOL RES, V3, P836, DOI 10.1158/2326-6066.CIR-15-0112; Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009; Menon Dinoop R, 2013, Pigment Cell Melanoma Res, V26, P912, DOI 10.1111/pcmr.12139; Pashenkov M, 2006, J CLIN ONCOL, V24, P5716, DOI 10.1200/JCO.2006.07.9129; Peng WY, 2010, CLIN CANCER RES, V16, P5458, DOI 10.1158/1078-0432.CCR-10-0712; Perricone MA, 2004, J IMMUNOTHER, V27, P273, DOI 10.1097/00002371-200407000-00003; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Rothenfusser S, 2002, HUM IMMUNOL, V63, P1111, DOI 10.1016/S0198-8859(02)00749-8; Scheiermann J, 2014, VACCINE, V32, P6377, DOI 10.1016/j.vaccine.2014.06.065; Shirota H, 2015, VACCINES-BASEL, V3, P390, DOI 10.3390/vaccines3020390; Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715; Smith MP, 2014, CANCER DISCOV, V4, P1214, DOI 10.1158/2159-8290.CD-13-1007; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Tadmor T, 2011, CANCER IMMUNOL IMMUN, V60, P609, DOI 10.1007/s00262-011-0972-z; Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008; Weiner GJ, 1997, P NATL ACAD SCI USA, V94, P10833, DOI 10.1073/pnas.94.20.10833	35	7	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 13	2017	36	28					4081	4086		10.1038/onc.2017.35	http://dx.doi.org/10.1038/onc.2017.35			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FA3YD	28263973	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000405379900013
J	Wakim, J; Arman, E; Becker-Herman, S; Kramer, MP; Bakos, E; Shachar, I; Elson, A				Wakim, J.; Arman, E.; Becker-Herman, S.; Kramer, M. P.; Bakos, E.; Shachar, I.; Elson, A.			The PTPROt tyrosine phosphatase functions as an obligate haploinsufficient tumor suppressor in vivo in B-cell chronic lymphocytic leukemia	ONCOGENE			English	Article							RECEPTOR-TYPE-O; HEPATOCELLULAR-CARCINOMA; MOLECULAR-CLONING; MOUSE MODEL; EXPRESSION; CLL; GENE; KINASE; TRANSFORMATION; METHYLATION	The tyrosine phosphatase PTPROt is a suggested tumor suppressor (TS) in B-cell chronic lymphocytic leukemia (CLL), and its expression is reduced in this disease. In order to examine how reduced PTPROt expression affects CLL in vivo we induced CLL in PTPROt-targeted mice. Unexpectedly, loss of both Ptprot alleles delayed disease detection and progression and lengthened survival relative to mice carrying two intact alleles, indicating that PTPROt fulfills a novel tumor-promoting role in CLL. Tumor cells from mice lacking PTPROt exhibited reduced B-cell receptor (BCR)-induced signaling, as well as increased apoptosis and autophagy. Inhibition of BCR/Src signaling in CLL cells induced their apoptosis, indicating that these findings are linked causally. These results suggest a cell-autonomous mechanism for the weakened CLL phenotype of PTPROt-deficient mice and uncover non-redundant roles for PTPROt in support of BCR signaling and survival of CLL cells. In contrast, loss of only one Ptprot allele induced earlier detection and progression of CLL and reduced survival, consistent with a tumor-suppressing role for PTPROt. Tumor cells from mice lacking one or both Ptprot allele exhibited increased interleukin-10 (IL-10) expression and signaling, factors known to support CLL; cells lacking one Ptprot alleles exhibited normal BCR signaling and cell death rates. We conclude that loss of one Ptprot allele promotes CLL, most likely by activating IL-10 signaling. Loss of both Ptprot alleles also reduces BCR signaling and increases cell death rates, offsetting the IL-10 effects and reducing the severity of the disease. PTPROt thus functions as an obligate haploinsufficient TS in CLL, where its expression levels determine its role as a promoter or inhibitor of the tumorigenic process in mice. Partial loss of PTPROt generates the strongest disease phenotype, suggesting that its intermediate expression levels in CLL are selected for.	[Wakim, J.; Arman, E.; Elson, A.] Weizmann Inst Sci, Dept Mol Genet, Rehovot, Israel; [Becker-Herman, S.; Kramer, M. P.; Bakos, E.; Shachar, I.] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Rehovot, Israel.	ari.elson@weizmann.ac.il	Kramer, Matthias/L-1782-2016; Kramer, Matthias P/A-6224-2009	Kramer, Matthias/0000-0002-0289-5261; Elson, Ari/0000-0001-9808-9135	German-Israeli Helmholtz Research School in Cancer Biology; Israel Cancer Research Foundation; Minerva Foundation; Federal German Ministry for Education and Research; Kekst Family Center for Medical Genetics	German-Israeli Helmholtz Research School in Cancer Biology; Israel Cancer Research Foundation; Minerva Foundation; Federal German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); Kekst Family Center for Medical Genetics	We thank Professor Carlo Croce for the E mu-TCL1 mice, Professor Zvulun Elazar for the anti-LC3 antibodies, Dr Rebecca Haffner-Krausz for help in preparing PTPROt-targeted mice, Ms Ofira Higfa and Mr Neriah Sharabi for expert animal care, Dr Ron Rotkopf for help with statistical analyses, Dr Ayala Sharp and Mr Eitan Ariel for help with FACS analyses, and Dr Gil Hornung for assistance with analysis of IL-10 expression. JW is supported in part by a studentship from the German-Israeli Helmholtz Research School in Cancer Biology. This study was supported by project grants from the Israel Cancer Research Foundation, from the Minerva Foundation with funds from the Federal German Ministry for Education and Research, and from the Kekst Family Center for Medical Genetics, to AE. AE is the incumbent of the Marshall and Renette Ezralow Professorial Chair.	Aguiar RCT, 1999, BLOOD, V94, P2403, DOI 10.1182/blood.V94.7.2403.419k39_2403_2413; Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Amoui M, 2004, AM J PHYSIOL-CELL PH, V287, pC874, DOI 10.1152/ajpcell.00294.2003; Amoui M, 2003, J BIOL CHEM, V278, P44273, DOI 10.1074/jbc.M303933200; Asbagh LA, 2014, ONCOTARGET, V5, P10070, DOI 10.18632/oncotarget.2458; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Burger JA, 2013, TRENDS IMMUNOL, V34, P592, DOI 10.1016/j.it.2013.07.002; Chen LF, 2006, BLOOD, V108, P3428, DOI 10.1182/blood-2006-03-013821; Chong SY, 2001, GENES IMMUN, V2, P239, DOI 10.1038/sj.gene.6363773; DiLillo DJ, 2013, LEUKEMIA, V27, P170, DOI 10.1038/leu.2012.165; Fais F, 1998, J CLIN INVEST, V102, P1515, DOI 10.1172/JCI3009; Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200; Fayad L, 2001, BLOOD, V97, P256, DOI 10.1182/blood.V97.1.256; Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388; Gallardo M, 2015, CANCER CELL, V28, P486, DOI 10.1016/j.ccell.2015.09.001; Galletti G, 2016, CELL REP, V14, P1748, DOI 10.1016/j.celrep.2016.01.042; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Hermiston ML, 2009, IMMUNOL REV, V228, P288, DOI 10.1111/j.1600-065X.2008.00752.x; Hou JJ, 2013, HEPATOLOGY, V57, P678, DOI 10.1002/hep.25980; Hsu SH, 2013, J CELL BIOCHEM, V114, P1810, DOI 10.1002/jcb.24525; Iacovelli S, 2015, BLOOD, V125, P1578, DOI 10.1182/blood-2014-07-587790; Jones JA, 2014, BLOOD, V123, P1455, DOI 10.1182/blood-2013-09-453092; Juszczynski P, 2009, BLOOD, V114, P5315, DOI 10.1182/blood-2009-02-204362; Kara IO, 2007, ADV THER, V24, P29, DOI 10.1007/BF02849990; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lau KHW, 2012, AM J PHYSIOL-CELL PH, V302, pC1676, DOI 10.1152/ajpcell.00042.2012; Lau KHW, 2006, J CELL BIOCHEM, V97, P940, DOI 10.1002/jcb.20667; Levy-Apter E, 2014, J BIOL CHEM, V289, P36048, DOI 10.1074/jbc.M114.603548; Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101; Motiwala T, 2015, LEUKEMIA, V29, P1350, DOI 10.1038/leu.2014.341; Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750; Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720; Motiwala T, 2011, BLOOD, V118, P6132, DOI 10.1182/blood-2011-01-323147; Motiwala T, 2010, J CELL BIOCHEM, V110, P846, DOI 10.1002/jcb.22593; Motiwala T, 2009, J BIOL CHEM, V284, P455, DOI 10.1074/jbc.M802840200; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; Saulep-Easton D, 2016, LEUKEMIA, V30, P163, DOI 10.1038/leu.2015.174; Saulep-Easton D, 2014, LEUKEMIA, V28, P2005, DOI 10.1038/leu.2014.105; Sheng MHC, 2009, J BIOL CHEM, V284, P11531, DOI 10.1074/jbc.M808324200; Simonetti G, 2014, BLOOD, V124, P1010, DOI 10.1182/blood-2014-05-577122; Teitell MA, 2005, NAT REV CANCER, V5, P640, DOI 10.1038/nrc1672; Wang ZD, 2000, J IMMUNOL METHODS, V233, P167, DOI 10.1016/S0022-1759(99)00184-2; White HN, 1998, EUR J IMMUNOL, V28, P3268, DOI 10.1002/(SICI)1521-4141(199810)28:10&lt;3268::AID-IMMU3268&gt;3.0.CO;2-F; WIGGINS RC, 1995, GENOMICS, V27, P174, DOI 10.1006/geno.1995.1021; Wu LW, 1996, BIOCHEM J, V316, P515, DOI 10.1042/bj3160515; Yan XJ, 2006, P NATL ACAD SCI USA, V103, P11713, DOI 10.1073/pnas.0604564103; Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12; Zanesi N, 2012, CURR PHARM DESIGN, V18, P3363, DOI 10.2174/138161212801227104	51	7	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3686	3694		10.1038/onc.2016.523	http://dx.doi.org/10.1038/onc.2016.523			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28166196				2022-12-17	WOS:000404349700004
J	Keysselt, K; Kreutzmann, T; Rother, K; Kerner, C; Krohn, K; Przybilla, J; Buske, P; Loffler-Wirth, H; Loeffler, M; Galle, J; Aust, G				Keysselt, K.; Kreutzmann, T.; Rother, K.; Kerner, C.; Krohn, K.; Przybilla, J.; Buske, P.; Loeffler-Wirth, H.; Loeffler, M.; Galle, J.; Aust, G.			Different in vivo and in vitro transformation of intestinal stem cells in mismatch repair deficiency	ONCOGENE			English	Article							COLORECTAL-CANCER; LYNCH SYNDROME; TUMOR-DEVELOPMENT; TUMORIGENESIS; PROLIFERATION; MOUSE; NICHE; MODEL; NOTCH; HOMEOSTASIS	Mutations in mismatch repair (MMR) genes result in microsatellite instability (MSI) and early onset of colorectal cancer. To get mechanistic insights into the time scale, sequence and frequency of intestinal stem cell (ISC) transformation, we quantified MSI and growth characteristics of organoids of Msh2-deficient and control mice from birth until tumor formation and related them to tissue gene expression. Although in Msh2-deficient organoids MSI continuously increased from birth, growth characteristics remained stable at first. Months before tumor onset, normal Msh2-deficient tissue contained tumor precursor cells forming organoids with higher MSI, cystic growth and growth rates resembling temporarily those of tumor organoids. Consistently, Msh2-deficient tissue exhibited a tumor-like gene signature. Normal Msh2-deficient organoids showed increased inheritable transient cyst-like growth, which became independent of R-spondin. ISC transformation proceeded faster in vitro than in vivo independent of the underlying genotype but more under MMR deficiency. Transient cyst-like growth but not MSI was suppressed by aspirin. In summary, as highlighted by organoids, molecular alterations continuously proceeded long before tumor onset in MMR-deficient intestine, thus increasing its susceptibility for ISC transformation.	[Keysselt, K.; Kreutzmann, T.; Rother, K.; Kerner, C.; Aust, G.] Univ Leipzig, Dept Surg, Res Labs, Leipzig, Germany; [Rother, K.; Przybilla, J.; Buske, P.; Loeffler-Wirth, H.; Galle, J.] Univ Leipzig, Interdisciplinary Ctr Bioinformat IZBI, Leipzig, Germany; [Krohn, K.] Univ Leipzig, Core Unit DNA Technol, Interdisciplinary Ctr Clin Res Leipzig IZKF, Leipzig, Germany; [Loeffler, M.] Univ Leipzig, Inst Med Stat Informat & Epidemiol, Leipzig, Germany	Leipzig University; Leipzig University; Leipzig University; Leipzig University	Aust, G (corresponding author), Univ Leipzig, Fac Med, Res Labs, Dept Surg, Liebigstr 19, D-04103 Leipzig, Germany.	gabriela.aust@medizin.uni-leipzig.de	Rother, Karen/GQI-3824-2022; Rother, Karen/GQI-3786-2022	Kreutzmann, Tobias/0000-0002-6070-243X; Loeffler-Wirth, Henry/0000-0001-8239-440X	BMBF grant HNPCC-Sys [031 6065A]; BMBF grant INDRA [031A312]	BMBF grant HNPCC-Sys; BMBF grant INDRA	The study was supported by the BMBF grants HNPCC-Sys (grant number: 031 6065A) and INDRA (grant number: 031A312).	Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bhalla A, 2013, CLIN LAB MED, V33, P835, DOI 10.1016/j.cll.2013.10.001; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Finkbeiner SR, 2015, STEM CELL REP, V4, P1140, DOI 10.1016/j.stemcr.2015.04.010; Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106; Genander M, 2009, CELL, V139, P679, DOI 10.1016/j.cell.2009.08.048; Germann M, 2014, STEM CELL RES, V13, P355, DOI 10.1016/j.scr.2014.08.002; Ghaleb AM, 2011, DEV BIOL, V349, P310, DOI 10.1016/j.ydbio.2010.11.001; Giardiello FM, 2014, GASTROENTEROLOGY, V147, P502, DOI 10.1053/j.gastro.2014.04.001; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Harris AR, 2014, J CELL SCI, V127, P2507, DOI 10.1242/jcs.142349; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; Kloor M, 2012, LANCET ONCOL, V13, P598, DOI 10.1016/S1470-2045(12)70109-2; Kortum B, 2015, GUT, V64, P1905, DOI 10.1136/gutjnl-2014-307663; Kucherlapati MH, 2010, GASTROENTEROLOGY, V138, P993, DOI 10.1053/j.gastro.2009.11.009; Lu YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063056; Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878; Martinez P, 2009, AGING CELL, V8, P2, DOI 10.1111/j.1474-9726.2008.00441.x; Mcilhatton MA, 2011, CANCER PREV RES, V4, P684, DOI 10.1158/1940-6207.CAPR-10-0319; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Przybilla J, 2014, AGING CELL, V13, P320, DOI 10.1111/acel.12177; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006; Schwank G, 2013, CELL STEM CELL, V13, P653, DOI 10.1016/j.stem.2013.11.002; Staffa L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121980; Tao S, 2015, EMBO J, V34, P624, DOI 10.15252/embj.201490700; Tian H, 2015, CELL REP, V11, P33, DOI 10.1016/j.celrep.2015.03.007; Vermeulen L, 2014, NAT REV CANCER, V14, P468, DOI 10.1038/nrc3744; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Woerner SM, 2015, MOL CARCINOGEN, V54, P1376, DOI 10.1002/mc.22213	40	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2750	2761		10.1038/onc.2016.429	http://dx.doi.org/10.1038/onc.2016.429			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27941880	Green Published			2022-12-17	WOS:000401120900012
J	Romero, OA; Verdura, S; Torres-Diz, M; Gomez, A; Moran, S; Condom, E; Esteller, M; Villanueva, A; Sanchez-Cespedes, M				Romero, O. A.; Verdura, S.; Torres-Diz, M.; Gomez, A.; Moran, S.; Condom, E.; Esteller, M.; Villanueva, A.; Sanchez-Cespedes, M.			Sensitization of retinoids and corticoids to epigenetic drugs in MYC-activated lung cancers by antitumor reprogramming	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEXES; C-MYC; SWI/SNF COMPLEX; CELL-LINES; NUCLEOSOME DISRUPTION; ACID RECEPTOR; BRG1 COMPLEX; DIFFERENTIATION; EXPRESSION; GENE	Components of the SWI/SNF chromatin remodeling complex, including BRG1 (also SMARCA4), are inactivated in cancer. Among other functions, SWI/SNF orchestrates the response to retinoid acid (RA) and glucocorticoids (GC) involving downregulation of MYC. The epigenetic drugs SAHA and azacytidine, as well as RA and GC, are currently being used to treat some malignancies but their therapeutic potential in lung cancer is not well established. Here we aimed to determine the possible therapeutic effects of azacytidine and SAHA (A/S) alone or in combination with GC plus RA (GC/RA) in lung cancers with either BRG1 inactivation or MYC amplification. In vitro, responses to GC/RA treatment were more effective in MYC-amplified cells. These effects were mediated by BRG1 and involved a reprogramming towards prodifferentiation gene expression signatures and downregulation of MYC. In MYC-amplified cells, administration of GC/RA enhanced the cell growth inhibitory effects of A/S which, in turn, accentuated the prodifferentiation features promoted by GC/RA. Finally, these treatments improved overall survival of mice orthotopically implanted with MYC-amplified, but not BRG1-mutant, cells and reduced tumor cell viability and proliferation. We propose that the combination of epigenetic treatments with retinoids and corticoids of MYC-driven lung tumors constitute a strategy for therapeutic intervention in this otherwise incurable disease.	[Romero, O. A.; Verdura, S.; Torres-Diz, M.; Sanchez-Cespedes, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Genes & Canc Grp, Barcelona, Spain; [Gomez, A.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Can Epigenet Grp, Barcelona, Spain; [Condom, E.] Bellvitge Hosp, Dept Pathol, Barcelona, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol, Translat Res Lab, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Sanchez-Cespedes, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program, Genes & Canc Grp, Av Gran Via Hosp 199-203, Barcelona 08908, Spain.	mscespedes@idibell.cat	Romero, Octavio A./AAA-8078-2020; verdura, Sara/AAC-3696-2022; Sanchez-Cespedes, Montse/H-8485-2012; Esteller, Manel/L-5956-2014; torres-diz, manuel/ABG-1024-2021; Moran, Sebastian/G-5293-2013	Romero, Octavio A./0000-0003-0229-6530; verdura, Sara/0000-0001-8980-0423; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Esteller, Manel/0000-0003-4490-6093; torres-diz, manuel/0000-0002-5487-8113; condom, enric/0000-0003-0142-3729; Moran, Sebastian/0000-0003-4192-8983	Spanish MINECO [SAF2011-22897]; Institute of Health Carlos III (ISCIII) [PIE13/ 00022]; RTICC [RD12/0036/0045, RD12/0036/0039]; Fundacion Cientifica Asociacion Espanola Contra el Cancer [GCB14-2170]; Spanish MINECO; European Union Seventh Framework Programme (FP7/2007-13) [HEALTH-F2-2010-258677-CURELUNG]	Spanish MINECO(Spanish Government); Institute of Health Carlos III (ISCIII); RTICC(Instituto de Salud Carlos III); Fundacion Cientifica Asociacion Espanola Contra el Cancer; Spanish MINECO(Spanish Government); European Union Seventh Framework Programme (FP7/2007-13)	We thank Patricia Cabral (Genes and Cancer Group) at IDIBELL for technical assistance. This work was supported by the grants from the Spanish MINECO SAF2011-22897, Institute of Health Carlos III (ISCIII)-PIE13/ 00022 ( ONCOPROFILE) and RTICC (RD12/0036/0045 to MS-C and RD12/0036/ 0039 to ME) and a grant from the Fundacion Cientifica Asociacion Espanola Contra el Cancer-GCB14-2170. MT-D is supported by a fellowship from the Spanish MINECO. Funding was also provided by the European Union Seventh Framework Programme (FP7/2007-13), under grant agreement HEALTH-F2-2010-258677-CURELUNG.	Angulo B, 2008, J PATHOL, V214, P347, DOI 10.1002/path.2267; Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007; BOGUE CW, 1994, AM J PHYSIOL, V266, pL448, DOI 10.1152/ajplung.1994.266.4.L448; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Castillo SD, 2012, CANCER RES, V72, P176, DOI 10.1158/0008-5472.CAN-11-3506; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Collins SJ, 2002, LEUKEMIA, V16, P1896, DOI 10.1038/sj.leu.2402718; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; Flajollet S, 2007, MOL CELL ENDOCRINOL, V270, P23, DOI 10.1016/j.mce.2007.02.004; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Hahn CK, 2008, P NATL ACAD SCI USA, V105, P9751, DOI 10.1073/pnas.0710413105; Hopfinger G, 2014, ANN HEMATOL, V93, P459, DOI 10.1007/s00277-014-2009-0; Johnson TA, 2008, MOL BIOL CELL, V19, P3308, DOI 10.1091/mbc.E08-02-0123; Juergens RA, 2011, CANCER DISCOV, V1, P598, DOI 10.1158/2159-8290.CD-11-0214; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Liu SV, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00135; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Malpel S, 2000, DEVELOPMENT, V127, P3057; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Nagl NG, 2006, CANCER RES, V66, P1289, DOI 10.1158/0008-5472.CAN-05-3427; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Romero OA, 2014, ONCOGENE, V33, P2681, DOI 10.1038/onc.2013.227; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Romero OA, 2012, EMBO MOL MED, V4, P603, DOI 10.1002/emmm.201200236; Rutz HP, 2002, LANCET, V360, P1969, DOI 10.1016/S0140-6736(02)11922-2; SAFFIOTTI U, 1967, CANCER-AM CANCER SOC, V20, P857, DOI 10.1002/1097-0142(1967)20:5&lt;857::AID-CNCR2820200545&gt;3.0.CO;2-3; San-Miguel JF, 2014, LANCET ONCOL, V15, P1195, DOI 10.1016/S1470-2045(14)70440-1; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schenk T, 2014, BRIT J CANCER, V111, P2039, DOI 10.1038/bjc.2014.412; Seo S, 2005, DEVELOPMENT, V132, P105, DOI 10.1242/dev.01548; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shi Wei, 2009, Proc Am Thorac Soc, V6, P558, DOI 10.1513/pats.200905-031RM; Siegel D, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-31; Sionov RV, 2008, ADV CANCER RES, V101, P127, DOI 10.1016/S0065-230X(08)00406-5; Sivak LE, 1997, ONCOGENE, V15, P1937, DOI 10.1038/sj.onc.1201363; THULASI R, 1993, J BIOL CHEM, V268, P18306; Vendetti FP, 2013, EXPERT OPIN BIOL TH, V13, P1273, DOI 10.1517/14712598.2013.819337; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068	50	7	7	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1287	1296		10.1038/onc.2016.296	http://dx.doi.org/10.1038/onc.2016.296			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27593925	Green Accepted			2022-12-17	WOS:000395861300012
J	Prazeres, H; Torres, J; Rodrigues, F; Pinto, M; Pastoriza, MC; Gomes, D; Cameselle-Teijeiro, J; Vidal, A; Martins, TC; Sobrinho-Simoes, M; Soares, P				Prazeres, H.; Torres, J.; Rodrigues, F.; Pinto, M.; Pastoriza, M. C.; Gomes, D.; Cameselle-Teijeiro, J.; Vidal, A.; Martins, T. C.; Sobrinho-Simoes, M.; Soares, P.			Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells (vol 30, pg 1302, 2010)	ONCOGENE			English	Correction													Pinto, Marta T/J-2519-2013; Soares, Paula/B-6054-2008; Vidal, Anxo/B-5010-2015	Pinto, Marta T/0000-0002-8521-2904; Soares, Paula/0000-0001-9607-6998; Vidal, Anxo/0000-0002-0866-4202; Sobrinho-Simoes, Manuel/0000-0003-1613-1235	FEDER funds through Programa Operacional Factores de Competitividade-COMPETE [FCOMP-01-0124-FEDER 011267]	FEDER funds through Programa Operacional Factores de Competitividade-COMPETE	This work was also supported by FEDER funds through Programa Operacional Factores de Competitividade-COMPETE (FCOMP-010124-FEDER 011267).	Prazeres H, 2011, ONCOGENE, V30, P1302, DOI 10.1038/onc.2010.512	1	7	7	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					146	146		10.1038/onc.2016.143	http://dx.doi.org/10.1038/onc.2016.143			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27499094	Bronze			2022-12-17	WOS:000394069100013
J	Skalka, N; Caspi, M; Lahav-Ariel, L; Loh, YP; Hirschberg, K; Rosin-Arbesfeld, R				Skalka, N.; Caspi, M.; Lahav-Ariel, L.; Loh, Y. P.; Hirschberg, K.; Rosin-Arbesfeld, R.			Carboxypeptidase E (CPE) inhibits the secretion and activity of Wnt3a	ONCOGENE			English	Article							CELL-PROLIFERATION; ENDOCRINE; AUTOPHAGY; SURVIVAL; STRESS	The Wnt pathway has essential roles in cell proliferation, cell fate determination and tumorigenesis by regulating the expression of a wide range of target genes. As a core signaling cascade, the canonical Wnt pathway is regulated at different levels by numerous proteins. We have previously shown that carboxypeptidase E (CPE) is a novel regulator of the canonical Wnt signaling pathway. Here, we show that CPE and the Wnt3a ligand are co-secreted from cells. We show that although the C'-terminal Lys residue of Wnt3a is critical for its activity and is important for the effect of CPE on the Wnt pathway, CPE does not execute its effect by removing this Wnt3a residue. Interestingly, CPE through its N'-terminal sequence, forms aggregates with Wnt3a and possible endoplasmic reticulum (ER) stress leading to its loss of function. Together, our current results provide a mechanistic insight into the way CPE regulates the canonical Wnt signaling pathway.	[Skalka, N.; Caspi, M.; Lahav-Ariel, L.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel; [Loh, Y. P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Neurobiol, Program Dev Neurosci, NIH, Bethesda, MD USA; [Hirschberg, K.] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Sackler Faculty of Medicine	Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel.	arina@post.tau.ac.il			Rising Tide Foundation for Clinical Cancer Research; Gateway for Cancer Research Foundation; Israel Science Foundation [20120016]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000056] Funding Source: NIH RePORTER	Rising Tide Foundation for Clinical Cancer Research; Gateway for Cancer Research Foundation; Israel Science Foundation(Israel Science Foundation); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported by Rising Tide Foundation for Clinical Cancer Research, by the Gateway for Cancer Research Foundation and by the Israel Science Foundation (Grant no. 20120016).	Bar F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102347; Cawley NX, 2012, ENDOCR REV, V33, P216, DOI 10.1210/er.2011-1039; Chen YX, 2014, NEUROSCI BULL, V30, P282, DOI 10.1007/s12264-013-1408-x; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; Du C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033830; FRICKER LD, 1983, J BIOL CHEM, V258, P950; He P, 2004, HUM PATHOL, V35, P1196, DOI 10.1016/j.humpath.2004.06.014; Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x; Holzer T, 2012, FEBS LETT, V586, P1638, DOI 10.1016/j.febslet.2012.04.035; Kim HJ, 2014, MOL CELLS, V37, P685, DOI 10.14348/molcells.2014.0179; Kunz M, 2004, DEV BIOL, V273, P390, DOI 10.1016/j.ydbio.2004.06.015; Li XH, 2015, INFLAMM RES, V64, P1, DOI 10.1007/s00011-014-0772-y; Liang XH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-412; Liu AA, 2014, TUMOR BIOL, V35, P12459, DOI 10.1007/s13277-014-2564-y; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Moeller C, 2003, DEVELOPMENT, V130, P5103, DOI 10.1242/dev.00686; Murthy SRK, 2013, ENDOCRINOLOGY, V154, P3284, DOI 10.1210/en.2013-1118; Murthy SRK, 2013, CANCER LETT, V341, P204, DOI 10.1016/j.canlet.2013.08.011; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Park JJ, 2008, MOL ENDOCRINOL, V22, P989, DOI 10.1210/me.2007-0473; Polakis P, 2000, GENE DEV, V14, P1837; Qian YM, 1999, J BIOL CHEM, V274, P11582, DOI 10.1074/jbc.274.17.11582; Qin XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112996; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Rhinn M, 2005, DEVELOPMENT, V132, P1261, DOI 10.1242/dev.01685; Selvaraj P, 2015, MOL CELL NEUROSCI, V68, P222, DOI 10.1016/j.mcn.2015.08.005; Sharma K, 2016, BIOCHEM PHARMACOL, V103, P17, DOI 10.1016/j.bcp.2015.12.018; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Skalka N, 2013, ONCOGENE, V32, P2836, DOI 10.1038/onc.2012.308; Thouennon E, 2015, J NEUROCHEM, V134, P463, DOI 10.1111/jnc.13152; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; Wallkamm V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109428; Wang L, 2009, J BONE MINER RES, V24, P265, DOI [10.1359/jbmr.081014, 10.1359/JBMR.081014]; Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864; Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218; Zhou K, 2013, TUMOR BIOL, V34, P3691, DOI 10.1007/s13277-013-0952-3	38	7	7	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6416	6428		10.1038/onc.2016.173	http://dx.doi.org/10.1038/onc.2016.173			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27375026	Bronze			2022-12-17	WOS:000390247600006
J	Yao, R; Oyanagi, J; Natsume, Y; Kusama, D; Kato, Y; Nagayama, S; Noda, T				Yao, R.; Oyanagi, J.; Natsume, Y.; Kusama, D.; Kato, Y.; Nagayama, S.; Noda, T.			Suppression of intestinal tumors by targeting the mitotic spindle of intestinal stem cells	ONCOGENE			English	Article							IN-VIVO; FUNCTION LEADS; CANCER; EXPRESSION; GENE; PROTEIN; TACC3; LRIG1; CRYPT; LGR5	Human colorectal cancer is often initiated by the aberrant activation of Wnt signaling, notably following adenomatous polyposis coli (Apc) inactivation. Recent studies identified adult intestinal stem cells (ISCs) and demonstrated their role as the cells of origin for intestinal tumors. However, the early consequences of aberrant Wnt signaling activation remain to be fully elucidated. Here, using organoid cultures established from conditional knockout mice and in vitro gene ablation, we show that Apc inactivation led to aberrant ISC proliferation and the expansion of the crypt domain. This system was used to evaluate the potential of a cancer-related spindle protein, Tacc3, as a target of cancer therapy, as its disruption led to the suppression of tumor formation in an animal model of intestinal tumors. We found that Tacc3 is required for the proper mitosis of Apc-deficient ISCs, and its disruption significantly attenuated the expansion of the crypt domain. In vivo analysis of corresponding mutant mice demonstrated that Tacc3 disruption led to a significant decrease in tumor number and prolonged survival. These observations demonstrated that Tacc3 is a potential chemotherapeutic target for intestinal tumors by perturbing the aberrant cell proliferation of Apc-deficient ISCs and provides an opportunity for the development of novel cancer prevention and treatment.	[Yao, R.; Oyanagi, J.; Natsume, Y.; Kusama, D.; Kato, Y.; Noda, T.] Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan; [Nagayama, S.] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Koto Ku, Tokyo, Japan; [Noda, T.] Japanese Fdn Canc Res, Inst Canc, Koto Ku, Directors Room, Tokyo, Japan	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research	Yao, R (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	ryao@jfcr.or.jp			Japan Agency for Medical Research and Development, AMED; Ministry of Education, Culture, Sports, Science and Technology of Japan; Vehicle Racing Commemorative Foundation; Grants-in-Aid for Scientific Research [25640094, 16K14620] Funding Source: KAKEN	Japan Agency for Medical Research and Development, AMED(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Vehicle Racing Commemorative Foundation; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Tomoyuki Kitagawa for continuous support and Ms Yuki Ota for technical assistance with the microarray analysis. We also thank Dr Toshiro Sato for valuable advice on the mouse intestine organoid culture. This study is partially supported by the research program for the Project for Development of Innovative Research on Cancer Therapeutics, P-Direct from the Japan Agency for Medical Research and Development, AMED (RY), Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (RY), and The Vehicle Racing Commemorative Foundation (RY).	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Brouhard GJ, 2008, CELL, V132, P79, DOI 10.1016/j.cell.2007.11.043; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; Farin HF, 2012, GASTROENTEROLOGY, V143, P1518, DOI 10.1053/j.gastro.2012.08.031; Fatehullah A, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0014; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Harrison Michael R, 2009, Clin Adv Hematol Oncol, V7, P54; Holik AZ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004453; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kabiri Z, 2014, DEVELOPMENT, V141, P2206, DOI 10.1242/dev.104976; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Phesse TJ, 2008, MOL CELL BIOL, V28, P6094, DOI 10.1128/MCB.00539-08; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Roman AKS, 2014, STEM CELL REP, V2, P127, DOI 10.1016/j.stemcr.2013.12.012; Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Snippert HJ, 2009, GASTROENTEROLOGY, V136, P2187, DOI 10.1053/j.gastro.2009.03.002; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sudakin V, 2007, BIODRUGS, V21, P225, DOI 10.2165/00063030-200721040-00003; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Yao R, 2012, ONCOGENE, V31, P135, DOI 10.1038/onc.2011.235; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x	46	7	8	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6109	6119		10.1038/onc.2016.148	http://dx.doi.org/10.1038/onc.2016.148			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157623				2022-12-17	WOS:000388509800007
J	German, P; Bai, S; Liu, XD; Sun, M; Zhou, L; Kalra, S; Zhang, X; Minelli, R; Scott, KL; Mills, GB; Jonasch, E; Ding, Z				German, P.; Bai, S.; Liu, X-D; Sun, M.; Zhou, L.; Kalra, S.; Zhang, X.; Minelli, R.; Scott, K. L.; Mills, G. B.; Jonasch, E.; Ding, Z.			Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function	ONCOGENE			English	Article							PROTEIN-KINASE CK2; TUMOR-SUPPRESSOR PROTEIN; GENE ALTERATIONS; IN-VIVO; MUTATIONS; PRODUCT; COMPLEX; BINDING; HIF; IDENTIFICATION	Loss of von Hippel Lindau (VHL) protein function is a key driver of VHL diseases, including sporadic and inherited clear cell renal cell carcinoma. Modulation of the proteostasis of VHL, especially missense point-mutated VHL, is a promising approach to augmenting VHL levels and function. VHL proteostasis is regulated by multiple mechanisms including folding, chaperone binding, complex formation and phosphorylation. Nevertheless, many details underlying the regulations of VHL proteostasis are unknown. VHL is expressed as two variants, VHL30 and VHL19. Furthermore, the long-form variant of VHL was often detected as multiple bands by western blotting. However, how these multiple species of VHL are generated and whether the process regulates VHL proteostasis and function are unknown. We hypothesized that the two major species are generated by VHL protein cleavage, and the cleavage regulates VHL proteostasis and subsequent function. We characterized VHL species using genetical and pharmacological approaches and showed that VHL was first cleaved at the N-terminus by chymotrypsin C before being directed for proteasomal degradation. Casein kinase 2-mediated phosphorylation at VHL N-terminus was required for the cleavage. Furthermore, inhibition of cleavage stabilized VHL protein and thereby promoted HIF downregulation. Our study reveals a novel mechanism regulating VHL proteostasis and function, which is significant for identifying new drug targets and developing new therapeutic approaches targeting VHL deficiency in VHL diseases.	[German, P.; Bai, S.; Liu, X-D; Sun, M.; Zhou, L.; Kalra, S.; Zhang, X.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Minelli, R.; Scott, K. L.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Mills, G. B.; Ding, Z.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Jonasch, E (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Unit 1374, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Ding, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Unit 950, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ejonasch@mdanderson.org; zding@mdanderson.org		Liu, xiande/0000-0002-9639-0458	University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; MD Anderson Cancer Center Institutional Research Grant; NIH grant [UO1CA168394, 5 PN2 EY016525-10]; NCI CCSG grant; NATIONAL CANCER INSTITUTE [P30CA016672, U01CA168394] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY016525] Funding Source: NIH RePORTER	University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; MD Anderson Cancer Center Institutional Research Grant; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI CCSG grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank Dr Kimryn Rathmell for providing renal proximal tubule epithelial cells. This work was supported by a grant from The University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program (ZD), an MD Anderson Cancer Center Institutional Research Grant (ZD), the NIH grant UO1CA168394 (KLS and GBM), the NIH grant 5 PN2 EY016525-10 (EJ) and NCI CCSG grant to MD Anderson Cancer Center.	Ampofo E, 2010, INT J BIOCHEM CELL B, V42, P1729, DOI 10.1016/j.biocel.2010.07.008; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Ding ZY, 2014, CANCER RES, V74, P3127, DOI 10.1158/0008-5472.CAN-13-3213; Ding ZY, 2012, J BIOMOL SCREEN, V17, P572, DOI 10.1177/1087057112436557; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; Feldman DE, 2003, MOL CELL, V12, P1213, DOI 10.1016/S1097-2765(03)00423-4; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844; Guerra B, 2015, CANCER LETT, V356, P751, DOI 10.1016/j.canlet.2014.10.026; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Jonasch E, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4797; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lee CM, 2009, ONCOGENE, V28, P1694, DOI 10.1038/onc.2009.12; Lolkema MP, 2005, J BIOL CHEM, V280, P22205, DOI 10.1074/jbc.M503220200; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Montenarh M, 2014, ADV CLIN EXP MED, V23, P153, DOI 10.17219/acem/37040; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Nickerson ML, 2008, CLIN CANCER RES, V14, P4726, DOI 10.1158/1078-0432.CCR-07-4921; Pizzi M, 2015, ONCOTARGET, V6, P6544, DOI 10.18632/oncotarget.3446; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; Rechsteiner MP, 2011, CANCER RES, V71, P5500, DOI 10.1158/0008-5472.CAN-11-0757; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Yang CZ, 2013, CELL REP, V3, P52, DOI 10.1016/j.celrep.2012.12.007	33	7	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					4973	4980		10.1038/onc.2016.40	http://dx.doi.org/10.1038/onc.2016.40			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26973240	Green Accepted			2022-12-17	WOS:000383965300002
J	Fleskens, V; Mokry, M; van der Leun, AM; Huppelschoten, S; Pals, CEM; Peeters, J; Coenen, S; Cardoso, BA; Barata, JT; van Loosdregt, J; Coffer, PJ				Fleskens, V.; Mokry, M.; van der Leun, A. M.; Huppelschoten, S.; Pals, C. E. G. M.; Peeters, J.; Coenen, S.; Cardoso, B. A.; Barata, J. T.; van Loosdregt, J.; Coffer, P. J.			FOXP3 can modulate TAL1 transcriptional activity through interaction with LMO2	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; REGULATORY T-CELLS; GENE-EXPRESSION; TUMOR-SUPPRESSOR; TRANSGENIC MICE; PROTEIN LMO2; CANCER-CELLS; COMPLEX; DIFFERENTIATION; SCL	T-cell acute lymphoblastic leukemia (T-ALL) frequently involves aberrant expression of TAL1 (T-cell acute lymphocytic leukemia 1) and LMO2, oncogenic members of the TAL1 transcriptional complex. Transcriptional activity of the TAL1-complex is thought to have a pivotal role in the transformation of thymocytes and is associated with a differentiation block and self-renewal. The transcription factor Forkhead Box P3 (FOXP3) was recently described to be expressed in a variety of malignancies including T-ALL. Here we show that increased FOXP3 levels negatively correlate with expression of genes regulated by the oncogenic TAL1-complex in human T-ALL patient samples as well as a T-ALL cell line ectopically expressing FOXP3. In these cells, FOXP3 expression results in altered regulation of cell cycle progression and reduced cell viability. Finally, we demonstrate that FOXP3 binds LMO2 in vitro, resulting in decreased interaction between LMO2 and TAL1, providing a molecular mechanism for FOXP3-mediated transcriptional modulation in T-ALL. Collectively, our findings provide initial evidence for a novel role of FOXP3 as a tumor suppressor in T-ALL through modulation of TAL1 transcriptional activity.	[Fleskens, V.; van der Leun, A. M.; Huppelschoten, S.; Pals, C. E. G. M.; Peeters, J.; Coenen, S.; van Loosdregt, J.; Coffer, P. J.] Univ Med Ctr Utrecht, Ctr Mol Med, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands; [Mokry, M.; van Loosdregt, J.; Coffer, P. J.] Wilhelmina Childrens Hosp, Div Pediat, Utrecht, Netherlands; [Cardoso, B. A.; Barata, J. T.] Univ Lisbon, Fac Med, Inst Mol Med, Lisbon, Portugal	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis; Universidade de Lisboa	Coffer, PJ (corresponding author), Univ Med Ctr Utrecht, Ctr Mol Med, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	p.j.coffer@umcutrecht.nl	Barata, João T./D-9181-2015; Mokry, Michal/AAN-3809-2021; Coffer, Paul/AAF-7970-2020	Barata, João T./0000-0002-4826-8976; Mokry, Michal/0000-0002-5298-4852; Cardoso, Bruno/0000-0002-6521-7257; Peeters, Janneke/0000-0002-5777-4352	Dutch Arthritis Foundation (Rheumafonds); Fundacao para a Ciencia e a Tecnologia	Dutch Arthritis Foundation (Rheumafonds); Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission)	We thank S Sakaguchi and T Mutis for providing us with plasmids and T Radstake for providing us with cells. VF and JvL were supported by a grant from the Dutch Arthritis Foundation (Rheumafonds), and BAC was supported by a fellowship from Fundacao para a Ciencia e a Tecnologia. This work was supported by grant from the Dutch Arthritis Foundation (Rheumafonds), and a fellowship from Fundacao para a Ciencia e a Tecnologia.	Aarts-Riemens T, 2008, EUR J IMMUNOL, V38, P1381, DOI 10.1002/eji.200737590; Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304; Atak ZK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003997; Barata JT, 2004, BLOOD, V103, P1891, DOI 10.1182/blood-2002-12-3861; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Cardoso BA, 2011, LEUKEMIA, V25, P1578, DOI 10.1038/leu.2011.140; Chen GY, 2008, J IMMUNOL, V180, P5163, DOI 10.4049/jimmunol.180.8.5163; Condorelli GL, 1996, CANCER RES, V56, P5113; Correia NC, 2013, LEUKEMIA, V27, P1603, DOI 10.1038/leu.2013.63; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; Fleskens V, 2014, INT REV IMMUNOL, V33, P94, DOI 10.3109/08830185.2013.816698; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hansson A, 2003, BIOCHEM BIOPH RES CO, V312, P1073, DOI 10.1016/j.bbrc.2003.11.030; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hinz S, 2007, CANCER RES, V67, P8344, DOI 10.1158/0008-5472.CAN-06-3304; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Josefowicz SZ, 2012, ANNU REV IMMUNOL, V30, P531, DOI 10.1146/annurev.immunol.25.022106.141623; Karanikas V, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-19; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lecuyer E, 2002, BLOOD, V100, P2430, DOI 10.1182/blood-2002-02-0568; Liu RH, 2009, CANCER RES, V69, P2252, DOI 10.1158/0008-5472.CAN-08-3717; Luo XD, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-34; Ma GF, 2013, BIOCHEM BIOPH RES CO, V430, P804, DOI 10.1016/j.bbrc.2012.11.065; Mansour MR, 2013, J EXP MED, V210, P1545, DOI 10.1084/jem.20122516; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Martin F, 2010, ONCOGENE, V29, P4121, DOI 10.1038/onc.2010.174; Matsubara Y, 2005, LEUKEMIA, V19, P482, DOI 10.1038/sj.leu.2403628; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; McMurchy AN, 2013, BLOOD, V121, P1265, DOI 10.1182/blood-2012-05-431023; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Roncador G, 2005, LEUKEMIA, V19, P2247, DOI 10.1038/sj.leu.2403965; Rudra D, 2012, NAT IMMUNOL, V13, P1010, DOI 10.1038/ni.2402; Samon JB, 2008, BLOOD, V112, P1813, DOI 10.1182/blood-2008-03-144980; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Shi XZ, 2010, STEM CELLS, V28, P462, DOI 10.1002/stem.274; Tremblay M, 2003, J BIOL CHEM, V278, P12680, DOI 10.1074/jbc.M209870200; Tremblay M, 2010, GENE DEV, V24, P1093, DOI 10.1101/gad.1897910; Tuovinen H, 2008, IMMUNOL CELL BIOL, V86, P523, DOI 10.1038/icb.2008.36; van Loosdregt J, 2013, IMMUNITY, V39, P259, DOI 10.1016/j.immuni.2013.05.018; van Loosdregt J, 2013, IMMUNITY, V39, P298, DOI 10.1016/j.immuni.2013.07.019; van Loosdregt J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019047; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wang LZ, 2009, CANCER CELL, V16, P336, DOI 10.1016/j.ccr.2009.08.016; Wu YQ, 2006, CELL, V126, P375, DOI 10.1016/j.cell.2006.05.042; Xu ZX, 2003, MOL CELL BIOL, V23, P7585, DOI 10.1128/MCB.23.21.7585-7599.2003; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zuo T, 2007, CELL, V129, P1275, DOI 10.1016/j.cell.2007.04.034	57	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 4	2016	35	31					4141	4148		10.1038/onc.2015.481	http://dx.doi.org/10.1038/onc.2015.481			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DS8GG	26686090				2022-12-17	WOS:000381020900012
J	Kramer, K; Wu, J; Crowe, DL				Kramer, K.; Wu, J.; Crowe, D. L.			Tumor suppressor control of the cancer stem cell niche	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST-CANCER; PPAR-GAMMA; MAMMARY-GLAND; NUCLEAR-ENVELOPE; PROGENITOR CELLS; ANGIOGENESIS; EXPRESSION; VEGF; MOUSE	Mammary stem cells (MSCs) expansion is associated with aggressive human breast cancer. The nuclear receptor peroxisome proliferator activated receptor. (PPAR gamma) is a breast cancer tumor suppressor, but the mechanisms of this suppression are not completely characterized. To determine whether PPAR gamma regulates MSC expansion in mammary cancer, we deleted PPAR gamma expression in the mammary epithelium of an in vivo model of basal breast cancer. Loss of PPAR gamma expression reduced tumor latency, and expanded the CD24+/CD49f(hi) MSC population. PPAR gamma-null mammary tumors exhibited increased angiogenesis, which was detected in human breast cancer. In vivo inhibition of a PPAR gamma-regulated miR-15a/angiopoietin-1 pathway blocked increased angiogenesis and MSC expansion. PPAR gamma bound and activated a canonical response element in the miR-15a gene. PPAR gamma-null tumors were sensitive to the targeted anti-angiogenic drug sunitinib but resistant to cytotoxic chemotherapy. Normalization of tumor vasculature with sunitinib resulted in objective response to cytotoxic chemotherapy. Chemotherapy-treated PPAR gamma-null mammary tumors exhibited luminal phenotype and expansion of unipotent CD61+ luminal progenitor cells. Transplantation of chemotherapy-treated luminal progenitor cells recapitulated the luminal phenotype. These results have important implications for anti-angiogenic therapy in breast cancer patients.	[Kramer, K.; Wu, J.; Crowe, D. L.] Univ Illinois, Ctr Canc, 801 S Paulina St, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Crowe, DL (corresponding author), Univ Illinois, Ctr Canc, 801 S Paulina St, Chicago, IL 60612 USA.	dlcrowe@uic.edu	Wu, Jianchun/AAX-3533-2020	Wu, Jianchun/0000-0002-8473-9368	NIH National Research Service award [DE18381]; Department of Defense Breast Cancer Research Program award [W81XWH-10-1-0081]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [T32DE018381, T32DE007057] Funding Source: NIH RePORTER	NIH National Research Service award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program award; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Ke Ma and Jewell Graves (University of Illinois Research Resources Center) for assistance with microscopy and flow cytometry. KK was supported by NIH National Research Service award DE18381. This study was supported by Department of Defense Breast Cancer Research Program award W81XWH-10-1-0081.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asano A, 2001, MOL CELL ENDOCRINOL, V174, P71, DOI 10.1016/S0303-7207(00)00450-0; Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Caine GJ, 2004, ANN MED, V36, P273, DOI 10.1080/07853890410026098; Chekhonin VP, 2013, CURR CANCER DRUG TAR, V13, P423, DOI 10.2174/15680096113139990074; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Crowe DL, 2004, HISTOL HISTOPATHOL, V19, P505, DOI 10.14670/HH-19.505; Danza K, 2013, EUR J HUM GENET, V21, P824, DOI 10.1038/ejhg.2012.273; Fantozzi A, 2014, CANCER RES, V74, P1566, DOI 10.1158/0008-5472.CAN-13-1641; Fauconnet S, 2002, J BIOL CHEM, V277, P23534, DOI 10.1074/jbc.M200172200; Golembesky AK, 2008, CARCINOGENESIS, V29, P1944, DOI 10.1093/carcin/bgn154; Harfouche R, 2011, J STEROID BIOCHEM, V123, P17, DOI 10.1016/j.jsbmb.2010.09.005; He T, 2014, J PATHOL, V232, P499, DOI 10.1002/path.4324; Heessen S, 2007, EMBO REP, V8, P914, DOI 10.1038/sj.embor.7401075; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Lacroix L, 2005, AM J PATHOL, V167, P223, DOI 10.1016/S0002-9440(10)62967-7; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu Yu-hua, 2011, Zhonghua Zhong Liu Za Zhi, V33, P827; Luo QF, 2013, INT J ONCOL, V43, P1212, DOI 10.3892/ijo.2013.2034; Nielsen R, 2008, GENE DEV, V22, P2953, DOI 10.1101/gad.501108; Nieto Y, 2007, BRIT J CANCER, V97, P391, DOI 10.1038/sj.bjc.6603875; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reddi HV, 2013, CANCER GENE THER, V20, P267, DOI 10.1038/cgt.2013.16; Reiss Y, 2009, J PATHOL, V217, P571, DOI 10.1002/path.2484; Roth C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2766; Saez E, 2004, GENE DEV, V18, P528, DOI 10.1101/gad.1167804; Schmidt SF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-152; Siragam V, 2012, ONCOTARGET, V3, P1370, DOI 10.18632/oncotarget.717; Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065; Steglich B, 2013, NUCLEUS-PHILA, V4, P379, DOI 10.4161/nucl.26394; Tian LF, 2009, CANCER RES, V69, P9236, DOI 10.1158/0008-5472.CAN-09-2067; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Watkins G, 2004, ONCOL REP, V12, P483; Yu J, 2011, J BIOMED RES, V25, P170, DOI 10.1016/S1674-8301(11)60022-5; Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7; Zou C, 2012, CELL CYCLE, V11, P2137, DOI 10.4161/cc.20598	50	7	7	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	32					4165	4178		10.1038/onc.2015.475	http://dx.doi.org/10.1038/onc.2015.475			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3YY	26686086	Green Accepted			2022-12-17	WOS:000382149800002
J	Rampias, T; Favicchio, R; Stebbing, J; Giamas, G				Rampias, T.; Favicchio, R.; Stebbing, J.; Giamas, G.			Targeting tumor-stroma crosstalk: the example of the NT157 inhibitor	ONCOGENE			English	Editorial Material							CANCER; PROGRESSION; INSULIN; STATS; CELLS	Recent clinical research has provided evidence that cancer progression and therapy resistance is driven not only by tumor's genetic profile but also by complex paracrine interactions within the tumor microenvironment (TME). The role of TME in modulating tumor drug sensitivity is increasingly recognized and targeting TME has been the focus of novel therapeutic approaches. Two recent reports show that a new anti-cancer drug, the inhibitor NT157 has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival.	[Rampias, T.; Giamas, G.] Univ Sussex, Dept Biochem & Biomed, Sch Life Sci, Brighton BN1 9QG, E Sussex, England; [Favicchio, R.; Stebbing, J.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Hammersmith Hosp Campus, London, England	University of Sussex; Imperial College London	Rampias, T (corresponding author), Univ Sussex, Dept Biochem & Biomed, Sch Life Sci, Brighton BN1 9QG, E Sussex, England.	rampias@gmail.com	Giamas, Georgios/AAP-3487-2021	Giamas, Georgios/0000-0002-4417-2707; Stebbing, Justin/0000-0002-1117-6947	Department of Health [NIHR-RP-011-053] Funding Source: Medline; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Department of Health; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Castano Z, 2013, CANCER DISCOV, V3, P922, DOI 10.1158/2159-8290.CD-13-0041; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Flashner-Abramson E, 2016, ONCOGENE, V35, P2675, DOI 10.1038/onc.2015.229; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kawada M, 2006, CANCER RES, V66, P4419, DOI 10.1158/0008-5472.CAN-05-4239; Lee C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/502093; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Sanchez-Lopez E, 2016, ONCOGENE, V35, P2634, DOI 10.1038/onc.2015.326; Stebbing J, 2015, MOL CELL PROTEOMICS, V14, P2479, DOI 10.1074/mcp.M115.048090; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	18	7	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2562	2564		10.1038/onc.2015.392	http://dx.doi.org/10.1038/onc.2015.392			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26477311				2022-12-17	WOS:000376165700002
J	Xing, R; Li, L; Chen, L; Gao, Z; Wang, H; Li, W; Cui, J; Tian, G; Liang, Q; Yu, J; Sung, JJ; Luo, G; Gao, H; Xu, X; Yang, H; Wang, J; Zhang, X; Wang, JM; Huang, J; Yu, Y; Wang, J; Lu, Y				Xing, R.; Li, L.; Chen, L.; Gao, Z.; Wang, H.; Li, W.; Cui, J.; Tian, G.; Liang, Q.; Yu, J.; Sung, J. J.; Luo, G.; Gao, H.; Xu, X.; Yang, H.; Wang, J.; Zhang, X.; Wang, J. M.; Huang, J.; Yu, Y.; Wang, J.; Lu, Y.			Copy number variations of HLA-I and activation of NKp30 pathway determine the sensitivity of gastric cancer cells to the cytotoxicity of natural killer cells	ONCOGENE			English	Article							LUNG-CANCER; RECEPTORS NKP30; THERAPY; NKP44; GENE	Nude mice are important in vivo model for characterization of cell malignancy behavior; however, many cancer cells fail to form tumors in it. Understanding this defective mechanism may provide novel insights into tumorigenesis and how tumor cells escape innate immunity. Whole-genome sequencing was conducted on two gastric cancer (GC) cells, BGC823 and AGS, which do and do not form tumors in nude mice, to identify their genomic differences relevant to natural killer (NK) cells. We found that the tumorigenic capacity of human GC cell lines was dependent on the recruitment and activation of NK cells in xenograft tumors. We used whole-genome sequence (WGS) on GC cell lines to identify potential genes controlling susceptibility to NK-mediated killing. The tumorigenic cell line BGC823 expressed high levels of HLA-I because of copy gain and was resistant to NK cell killing. In contrast, another cell line AGS expressing low levels of HLA-I with activated NKp30/MAPK/IL-12 (interleukin-12) or IL-2 (interleukin-2) pathway was susceptible to NK lysis. Treatment of tumor bearing mice with systemic administration of IL-12 in combination with intratumor injection of anti-HLA-I antibody significantly increased NK cell recruitment into xenograft tumors, which became sensitive to NK killing, resulting in reduced tumor progression. In human GC specimens, decreased HLA-I expression and increased NK cells surrounding tumor cells were correlated with decreased metastasis potential and better prognosis of patients. Our results provide a mechanistic basis for GC cells to escape NK lysis and a promising prospect of NK immunotherapy for GC cells.	[Xing, R.; Wang, H.; Li, W.; Cui, J.; Lu, Y.] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Lab Mol Oncol,Minist Educ, Fu Cheng Rd 52, Beijing 100142, Peoples R China; [Li, L.; Chen, L.; Gao, Z.; Tian, G.; Xu, X.; Yang, H.; Wang, J.; Zhang, X.; Wang, J.] Beijing Genom Inst Shenzhen, Shenzhen 518083, Peoples R China; [Liang, Q.; Yu, J.; Sung, J. J.] Chinese Univ Hong Kong, Shenzhen Res Inst, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Liang, Q.; Yu, J.; Sung, J. J.] Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Luo, G.] Case Western Reserve Univ, Sch Med, Dept Genet & Genome Sci, Cleveland, OH USA; [Luo, G.] Beijing Univ Chinese Med, Beijing, Peoples R China; [Gao, H.] Shanghai Engn Ctr Mol Med, Shanghai, Peoples R China; [Wang, J. M.; Huang, J.] NCI, Mol Immunoregulat Lab, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21701 USA; [Yu, Y.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200030, Peoples R China; [Yu, Y.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Surg, Shanghai 200030, Peoples R China	Peking University; Beijing Genomics Institute (BGI); Chinese University of Hong Kong; Chinese University of Hong Kong; Case Western Reserve University; Beijing University of Chinese Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Shanghai Jiao Tong University; Shanghai Jiao Tong University	Lu, Y (corresponding author), Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Lab Mol Oncol,Minist Educ, Fu Cheng Rd 52, Beijing 100142, Peoples R China.; Wang, J (corresponding author), Beijing Genom Inst Shenzhen, Shenzhen 518083, Peoples R China.	wangj@genomics.org.cn; youyonglu@bjmu.edu.cn	Wang, Huanting/G-8399-2011; Yu, Jun/D-8569-2015; Xu, Xun/AAI-6763-2020; Huang, Jiaqiang/C-2375-2011; Sung, Joseph J. Y./R-3203-2018; Liang, Qiaoyi Jessie/G-9612-2019	Wang, Huanting/0000-0002-9887-5555; Yu, Jun/0000-0001-5008-2153; Xu, Xun/0000-0002-5338-5173; Huang, Jiaqiang/0000-0002-6610-8159; Sung, Joseph J. Y./0000-0003-3125-5199; Liang, Qiaoyi Jessie/0000-0001-8496-3442	Ministry of Science and Technology of China (863 program) [2012AA02A203, 2012AA02A504]; Beijing Nova program [XXJH2015037, Z151100000315069]; NATIONAL CANCER INSTITUTE [ZIABC010725, ZIABC010015] Funding Source: NIH RePORTER	Ministry of Science and Technology of China (863 program)(Ministry of Science and Technology, ChinaNational High Technology Research and Development Program of China); Beijing Nova program(Beijing Municipal Science & Technology Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Richard Ascione (Department of Biochemistry and Molecular Biology, Medical School of Georgetown University USA) and Dr Laurie Goodman for critical reviewing and editing of the manuscript. This work was supported by the Ministry of Science and Technology of China (863 program, grants 2012AA02A203, 2012AA02A504) and Beijing Nova program (XXJH2015037, No.Z151100000315069).	Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cheng M, 2013, CELL MOL IMMUNOL, V10, P230, DOI 10.1038/cmi.2013.10; Farhan S, 2012, IMMUNOTHERAPY-UK, V4, P305, DOI [10.2217/IMT.11.174, 10.2217/imt.11.174]; Haraksingh RR, 2013, J MOL BIOL, V425, P3970, DOI 10.1016/j.jmb.2013.07.015; Hecht ML, 2009, J PROTEOME RES, V8, P712, DOI 10.1021/pr800747c; Hsieh CL, 2006, EUR J IMMUNOL, V36, P2170, DOI 10.1002/eji.200635982; Iliopoulou EG, 2010, CANCER IMMUNOL IMMUN, V59, P1781, DOI 10.1007/s00262-010-0904-3; Imai C, 2005, BLOOD, V106, P376, DOI 10.1182/blood-2004-12-4797; Langers I, 2012, BIOL-TARGETS THER, V6, P73, DOI 10.2147/BTT.S23976; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Miller CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016327; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Ni XH, 2013, P NATL ACAD SCI USA, V110, P21083, DOI 10.1073/pnas.1320659110; Ponnampalam AP, 2008, EUR J IMMUNOL, V38, P216, DOI 10.1002/eji.200636429; Santos GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Srivastava BIS, 2006, LEUKEMIA RES, V30, P37, DOI 10.1016/j.leukres.2005.06.020; Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044; Xing R, 2012, GUT, V61, P43, DOI 10.1136/gut.2010.230623	19	7	7	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2584	2591		10.1038/onc.2015.324	http://dx.doi.org/10.1038/onc.2015.324			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364607	Green Accepted			2022-12-17	WOS:000376165700005
J	Nie, J; Liu, L; Xing, G; Zhang, M; Wei, R; Guo, M; Li, X; Xie, P; Li, L; He, F; Han, W; Zhang, L				Nie, J.; Liu, L.; Xing, G.; Zhang, M.; Wei, R.; Guo, M.; Li, X.; Xie, P.; Li, L.; He, F.; Han, W.; Zhang, L.			CKIP-1 acts as a colonic tumor suppressor by repressing oncogenic Smurf1 synthesis and promoting Smurf1 autodegradation (vol 33, pg 3677, 2014)	ONCOGENE			English	Correction														Han, Weidong/0000-0003-3207-3899				Nie J, 2014, ONCOGENE, V33, P3677, DOI 10.1038/onc.2013.340	1	7	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					800	800		10.1038/onc.2015.28	http://dx.doi.org/10.1038/onc.2015.28			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	26865224	Bronze			2022-12-17	WOS:000370331300013
J	Ordonez-Navadijo, A; Fuertes-Yebra, E; Acosta-Iborra, B; Balsa, E; Elorza, A; Aragones, J; Landazuri, MO				Ordonez-Navadijo, A.; Fuertes-Yebra, E.; Acosta-Iborra, B.; Balsa, E.; Elorza, A.; Aragones, J.; Landazuri, M. O.			Mutant versions of von Hippel-Lindau (VHL) can protect HIF1 alpha from SART1-mediated degradation in clear-cell renal cell carcinoma	ONCOGENE			English	Article							HIF-ALPHA; HYPOXIA; HIF-1-ALPHA; EXPRESSION; FACTOR-1-ALPHA; DESTRUCTION; MUTATIONS; PATTERNS; BINDING	Inactivation of the von Hippel-Lindau (VHL) tumor suppressor drives the development of clear-cell renal cell carcinoma (ccRCC) through hypoxia-inducible factors (HIFs). Although ccRCC cells exhibit constitutive normoxic HIF signaling, the potential role of hypoxia in this setting is not fully understood. We show here that the ccRCC cell lines RCC4 and RCC10, which express mutant versions of VHL, have reduced HIF1 alpha expression in hypoxia, whereas HIF2 alpha expression is increased or not affected. Similar findings were observed in normoxia after abrogation of prolyl hydroxylase activity by siRNA or pharmacological inhibition, and by siRNA inhibition of mutant VHL. This reduction of HIF1 alpha protein is due to proteasome-dependent degradation and is mediated by the E3 ubiquitin ligase SART1. HIF1 alpha degradation favors ccRCC proliferation, in line with the previously recognized tumor suppressor capability of HIF1 alpha. Our data indicate that mutant VHL can protect HIF1 alpha from SART1-dependent degradation in normoxic conditions, but this protection is lost in hypoxic settings, favoring hypoxia-dependent ccRCC proliferation. This mechanism of HIF1 alpha degradation might operate in some VHL-related clear-cell renal carcinomas in which the deletion of HIF1 alpha locus does not occur.	[Ordonez-Navadijo, A.; Fuertes-Yebra, E.; Acosta-Iborra, B.; Balsa, E.; Elorza, A.; Aragones, J.; Landazuri, M. O.] Univ Autonoma Madrid, Hosp Univ Princesa, Hosp Univ Santa Cristina, Inst Invest Sanitaria,Unidad Invest, C Maestro Amadeo Vives 2-3,Edificio B,5a Plant, Madrid 28009, Spain; [Landazuri, M. O.] Univ Cent Ecuador, Quito, Ecuador	Autonomous University of Madrid; Universidad Central del Ecuador	Landazuri, MO (corresponding author), Univ Autonoma Madrid, Hosp Univ Princesa, Hosp Univ Santa Cristina, Inst Invest Sanitaria,Unidad Invest, C Maestro Amadeo Vives 2-3,Edificio B,5a Plant, Madrid 28009, Spain.	manuel.ortiz@salud.madrid.org	Elorza, Ainara/I-1642-2015; Acosta-Iborra, M Bárbara/L-5570-2013	Acosta-Iborra, M Bárbara/0000-0002-1517-114X	MINECO [SAF 2010-14851, SAF 2013-48130]; Recava Network [RD12/0042/0065]; Metoxia Project-Health [F2 2009-222741]; Consepoc [S2014/BMD-2542 consepoc-CM]; MICINN [SAF 2011-29716]; Programa Prometeo Government of Ecuador	MINECO(Spanish Government); Recava Network(Instituto de Salud Carlos III); Metoxia Project-Health; Consepoc; MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Programa Prometeo Government of Ecuador	This work was supported by MINECO (SAF 2010-14851), MINECO (SAF 2013-48130), Recava Network (RD12/0042/0065), Programa Prometeo Government of Ecuador and Metoxia Project-Health (F2 2009-222741) to MOL; Consepoc (S2014/BMD-2542 consepoc-CM) and MICINN (SAF 2011-29716) to JA. We thank M. Ohh (Laboratory Medicine & Pathobiology University of Toronto) for providing the RCC10 cell line.	Beroukhim R, 2009, CANCER RES, V69, P4674, DOI 10.1158/0008-5472.CAN-09-0146; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; De Bock K, 2011, CURR OPIN GENET DEV, V21, P73, DOI 10.1016/j.gde.2010.10.008; Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lawrentschuk N, 2011, UROL ONCOL-SEMIN ORI, V29, P411, DOI 10.1016/j.urolonc.2009.03.028; Lidgren A, 2005, CLIN CANCER RES, V11, P1129; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; MAHER ER, 1990, Q J MED, V77, P1151, DOI 10.1093/qjmed/77.2.1151; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metzen E, 2003, J CELL SCI, V116, P1319, DOI 10.1242/jcs.00318; Miller F, 2005, J BIOL CHEM, V280, P7985, DOI 10.1074/jbc.M413160200; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498	31	7	9	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					587	594		10.1038/onc.2015.113	http://dx.doi.org/10.1038/onc.2015.113			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915846				2022-12-17	WOS:000369548800006
J	Kocab, AJ; Veloso, A; Paulsen, MT; Ljungman, M; Duckett, CS				Kocab, A. J.; Veloso, A.; Paulsen, M. T.; Ljungman, M.; Duckett, C. S.			Effects of physiological and synthetic IAP antagonism on c-IAP-dependent signaling	ONCOGENE			English	Article							NF-KAPPA-B; LARGE-CELL LYMPHOMA; TRANSCRIPTION FACTORS; CD30; TNF; DEGRADATION; ACTIVATION; APOPTOSIS; PATHWAYS; COMPLEX	Cellular inhibitor of apoptosis proteins 1 and 2 (c-IAP1/2) have central roles in signal transduction mediated by numerous receptors that participate in inflammatory and immune responses. In certain pathways, such as activation of NF-kappa B, their degradation is a major regulatory event and is physiologically induced by activation of receptors. In addition, a number of synthetic compounds have been developed that also target the c-IAPs and induce their degradation. However, the extent of a synthetic IAP antagonist's ability to mirror the transcriptional program by a physiological signal remains unclear. Here we take a systems approach to compare the transcriptional programs triggered by activation of CD30, a well-characterized receptor previously shown to induce the degradation of the c-IAPs, to SM-164, a synthetic IAP antagonist that specifically triggers c-IAP degradation. Employing a technique that allows the specific analysis of newly transcribed RNA, we have generated comparative transcriptome profiles for CD30 activation and SM-164 treatment. Analysis of these profiles revealed that the genes regulated by each stimulus were not completely shared, indicating novel functions of IAP antagonists and consequences of c-IAP1/2 degradation. The data identified a role for c-IAP1/2 in the regulation of the ribosome and protein synthesis, which was subsequently confirmed by biological assays. These findings expand our knowledge of the roles of c-IAP1/2 in signaling and provide insight into the mechanism of synthetic IAP antagonists, furthering our understanding of their therapeutic potential.	[Kocab, A. J.] Univ Michigan, Grad Program Immunol, Ann Arbor, MI 48109 USA; [Kocab, A. J.; Duckett, C. S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Veloso, A.; Paulsen, M. T.; Ljungman, M.] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Veloso, A.] Univ Michigan, Dept Computat Med & Bioinformat, Bioinformat Program, Ann Arbor, MI 48109 USA; [Ljungman, M.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Duckett, CS (corresponding author), Univ Michigan, Dept Pathol & Internal Med, NCRC Bldg 18,Rm 133,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	colind@med.umich.edu		Kocab, Andrew/0000-0001-6069-2166; Duckett, Colin/0000-0001-9413-2263	NIH [R01CA142809, 1R01HG006786, T32AI007413]; NATIONAL CANCER INSTITUTE [R01CA142809] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG006786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007413] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Drs Shaomeng Wang (University of Michigan, Ann Arbor, MI, USA) for the kind gift of SM-164, Judith Sebolt-Leopold (University of Michigan) for the gift of Trametinib, Niall Kenneth (Newcastle University, Newcastle upon Tyne, UK) for his insightful suggestions, Elizabeth Lawlor (University of Michigan, Ann Arbor, MI, USA) for her critical reading of the manuscript, Thomas Wilson (University of Michigan, Ann Arbor, MI, USA) for use of his data analysis software, the members of the Duckett laboratory for their helpful advice and the personnel at the University of Michigan Molecular and Behavioral Neuroscience Institute computing cluster and the University of Michigan Sequencing Core for their technical assistance. This work was supported in part by NIH R01CA142809 (to CSD), NIH 1R01HG006786 (to ML) and NIH T32AI007413 (to AJK).	Buchan SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045244; Chiarle R, 1999, CLIN IMMUNOL, V90, P157, DOI 10.1006/clim.1998.4636; Csomos RA, 2009, BIOCHEM J, V420, P83, DOI 10.1042/BJ20082140; Darding M, 2012, CELL DEATH DIFFER, V19, P58, DOI 10.1038/cdd.2011.163; Darding M, 2011, CELL DEATH DIFFER, V18, P1376, DOI 10.1038/cdd.2011.10; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Hacker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Kenneth NS, 2014, CELL CYCLE, V13, P1006, DOI 10.4161/cc.27922; Kenneth NS, 2012, CURR OPIN CELL BIOL, V24, P871, DOI 10.1016/j.ceb.2012.11.004; Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008-5472.CAN-08-2655; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Mir SS, 2000, BLOOD, V96, P4307; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Paulsen MT, 2014, METHODS, V67, P45, DOI 10.1016/j.ymeth.2013.08.015; Paulsen MT, 2013, P NATL ACAD SCI USA, V110, P2240, DOI 10.1073/pnas.1219192110; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Silke J, 2011, CURR OPIN IMMUNOL, V23, P620, DOI 10.1016/j.coi.2011.08.002; Smale ST, 2012, IMMUNOL REV, V246, P193, DOI 10.1111/j.1600-065X.2011.01091.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun HY, 2007, J AM CHEM SOC, V129, P15279, DOI 10.1021/ja074725f; TIAN ZG, 1995, CANCER RES, V55, P5335; Vallabhapurapu S, 2008, NAT IMMUNOL, V9, P1364, DOI 10.1038/ni.1678; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Wright CW, 2007, J BIOL CHEM, V282, P10252, DOI 10.1074/jbc.M608817200; Wright CW, 2009, SCIENCE, V323, P251, DOI 10.1126/science.1162818; Zarnegar B, 2008, P NATL ACAD SCI USA, V105, P3503, DOI 10.1073/pnas.0707959105; Zhang JB, 2014, AUTOPHAGY, V10, P901, DOI 10.4161/auto.28267	38	7	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5472	5481		10.1038/onc.2015.3	http://dx.doi.org/10.1038/onc.2015.3			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25659587	Green Accepted			2022-12-17	WOS:000363479700007
J	Wang, WT; Catto, JWF; Meuth, M				Wang, W-T; Catto, J. W. F.; Meuth, M.			Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors	ONCOGENE			English	Article							REPLICATION FORK PROGRESSION; DNA-DAMAGE CHECKPOINT; PHOSPHORYLATION; KINASE; ACTIVATION; APOPTOSIS; RPA; PROMOTES; INACTIVATION; EXPRESSION	While DNA damage response pathways are well characterized in cancer cells, much less is known about their status in normal cells. These pathways protect tumour cells from DNA damage and replication stress and consequently present potential therapeutic targets. Here we characterize the response of human telomerase reverse transcriptase (hTERT)-immortalized normal human urothelial (NHU) and bladder cancer cell lines to agents that disrupt the DNA damage response. Effects of replication and DNA damage response inhibitors on cell cycle progression, checkpoint induction and apoptosis were analysed in hTERT-NHU and bladder cancer cell lines. The primary signalling cascade responding to replication stress in malignant cells (ataxia telangiectasia-mutated (ATM) and Rad3-related-checkpoint kinase 1 (ATR-CHK1)) is not activated in hTERT-NHU cells after treatment with a replication inhibitor and these cells do not depend upon CHK1 for protection from apoptosis during replication stress. Instead, ATM signalling is rapidly activated under these conditions. Intriguingly, an ATM inhibitor suppressed S-phase checkpoint activation after exposure to replication inhibitors and stopped entry of cells into S-phase indicating G1 checkpoint activation. Consistent with this, hTERT-NHU cells treated with the ATM inhibitor showed increased levels of cyclin-dependent kinase inhibitor p19(INK4D), reduced levels of cyclin D1 and CDK4, and reduced phosphorylation of the retinoblastoma protein. In contrast, a bladder cancer cell line cotreated with ATM and replication inhibitors progressed more slowly through S phase and showed a marked increase in apoptosis. Taken together, our findings suggest that ATM and CHK1 signalling cascades have different roles in tumour and normal epithelial cells, confirming these as promising therapeutic targets.	[Wang, W-T; Catto, J. W. F.; Meuth, M.] Univ Sheffield, Sch Med, YCR CRUK Sheffield Canc Res Ctr, Mol Oncol Unit,Dept Oncol, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield	Meuth, M (corresponding author), Univ Sheffield, Sch Med, YCR CRUK Sheffield Canc Res Ctr, Mol Oncol Unit,Dept Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	m.meuth@sheffield.ac.uk		catto, james/0000-0003-2787-8828	Yorkshire Cancer Research [S305PA]; P. A. Banner Trust	Yorkshire Cancer Research; P. A. Banner Trust	This work was supported in part by a programme grant from Yorkshire Cancer Research (S305PA) and the P. A. Banner Trust. We are grateful to Helen Bryant for her comments on the manuscript.	Anantha RW, 2007, J BIOL CHEM, V282, P35910, DOI 10.1074/jbc.M704645200; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bennett CN, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3230; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Blackwood E, 2013, MOL CANCER THER, V12, P1968, DOI 10.1158/1535-7163.MCT-12-1218; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Carrassa L, 2011, CELL CYCLE, V10, P2121, DOI 10.4161/cc.10.13.16398; Ceruti JM, 2005, ONCOGENE, V24, P4065, DOI 10.1038/sj.onc.1208570; Chapman EJ, 2006, ONCOGENE, V25, P5037, DOI 10.1038/sj.onc.1209513; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Clarke CAL, 2005, BIOCHEM J, V388, P705, DOI 10.1042/BJ20041966; Cole KA, 2011, P NATL ACAD SCI USA, V108, P3336, DOI 10.1073/pnas.1012351108; Courcelle J, 2003, SCIENCE, V299, P1064, DOI 10.1126/science.1081328; Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Liu QH, 2000, GENE DEV, V14, P1448; Liu SQ, 2012, NUCLEIC ACIDS RES, V40, P10780, DOI 10.1093/nar/gks849; Lukas C, 2001, CANCER RES, V61, P4990; Meuth M, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-21; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Petermann E, 2006, MOL CELL BIOL, V26, P3319, DOI 10.1128/MCB.26.8.3319-3326.2006; Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Rodriguez R, 2008, CELL DEATH DIFFER, V15, P889, DOI 10.1038/cdd.2008.4; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Smits VAJ, 2006, CURR BIOL, V16, P150, DOI 10.1016/j.cub.2005.11.066; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Stracker TH, 2009, DNA REPAIR, V8, P1047, DOI 10.1016/j.dnarep.2009.04.012; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Tavera-Mendoza L, 2006, EMBO REP, V7, P180, DOI 10.1038/sj.embor.7400594; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vassin VM, 2009, J CELL SCI, V122, P4070, DOI 10.1242/jcs.053702; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Walker M, 2009, ONCOGENE, V28, P2314, DOI 10.1038/onc.2009.102; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Wilsker D, 2008, P NATL ACAD SCI USA, V105, P20752, DOI 10.1073/pnas.0806917106; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhang YW, 2009, MOL CELL, V35, P442, DOI 10.1016/j.molcel.2009.06.030; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zou Y, 2006, J CELL PHYSIOL, V208, P267, DOI 10.1002/jcp.20622	54	7	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2015	34	22					2887	2896		10.1038/onc.2014.221	http://dx.doi.org/10.1038/onc.2014.221			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CJ2OM	25043304	Green Submitted			2022-12-17	WOS:000355324300008
J	Mahajan, P; Leavey, PJ; Galindo, RL				Mahajan, P.; Leavey, P. J.; Galindo, R. L.			PAX genes in childhood oncogenesis: developmental biology gone awry?	ONCOGENE			English	Review							PAIRED BOX GENE; ACUTE LYMPHOBLASTIC-LEUKEMIA; FOLLICULAR THYROID CARCINOMAS; RENAL-CELL CARCINOMA; TRANSCRIPTION FACTOR; SATELLITE CELLS; FUSION GENE; PAX8-PPAR-GAMMA REARRANGEMENT; ALVEOLAR RHABDOMYOSARCOMAS; COOPERATIVE INTERACTIONS	Childhood solid tumors often arise from embryonal-like cells, which are distinct from the epithelial cancers observed in adults, and etiologically can be considered as 'developmental patterning gone awry'. Paired-box (PAX) genes encode a family of evolutionarily conserved transcription factors that are important regulators of cell lineage specification, migration and tissue patterning. PAX loss-of-function mutations are well known to cause potent developmental phenotypes in animal models and underlie genetic disease in humans, whereas dysregulation and/or genetic modification of PAX genes have been shown to function as critical triggers for human tumorigenesis. Consequently, exploring PAX-related pathobiology generates insights into both normal developmental biology and key molecular mechanisms that underlie pediatric cancer, which are the topics of this review.	[Mahajan, P.; Leavey, P. J.; Galindo, R. L.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Galindo, R. L.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Galindo, R. L.] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Galindo, RL (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	rene.galindo@utsouthwestern.edu		Leavey, Patrick/0000-0002-0541-2536	Burroughs Wellcome Fund; Alex's Lemonade Stand Foundation; American Cancer Society; UTSW Department of Pathology	Burroughs Wellcome Fund(Burroughs Wellcome Fund); Alex's Lemonade Stand Foundation; American Cancer Society(American Cancer Society); UTSW Department of Pathology	This work was supported by funding to RLG by the Burroughs Wellcome Fund (Career Award for Medical Scientists), Alex's Lemonade Stand Foundation ("A" Award), American Cancer Society (Research Scholars Grant) and UTSW Department of Pathology (Research Grant). We thank Stephen X. Skapek for helpful suggestions regarding this manuscript.	Ali AN, 2012, CANCER-AM CANCER SOC, V118, P2541, DOI 10.1002/cncr.26554; Apuzzo S, 2007, BIOCHEMISTRY-US, V46, P2984, DOI 10.1021/bi062107q; Avirneni-Vadlamudi U, 2012, J CLIN INVEST, V122, P403, DOI 10.1172/JCI59877; Bai SW, 2011, INVEST OPHTH VIS SCI, V52, P4560, DOI 10.1167/iovs.10-5487; Barr FG, 1999, CANCER RES, V59, P5443; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Bishop JA, 2011, HUM PATHOL, V42, P1873, DOI 10.1016/j.humpath.2011.02.004; BOBER E, 1994, DEVELOPMENT, V120, P603; Bousquet M, 2007, BLOOD, V109, P3417, DOI 10.1182/blood-2006-05-025221; Brun T, 2008, J MOL ENDOCRINOL, V40, P37, DOI 10.1677/JME-07-0134; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Carbe C, 2013, J BIOL CHEM, V288, P12130, DOI 10.1074/jbc.M112.436865; Castro P, 2006, J CLIN ENDOCR METAB, V91, P213, DOI 10.1210/jc.2005-1336; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chen X, 2013, CANCER CELL, V24, P710, DOI 10.1016/j.ccr.2013.11.002; Cheung L, 2003, J CLIN ENDOCR METAB, V88, P354, DOI 10.1210/jc.2002-021020; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Coyaud E, 2010, BLOOD, V115, P3089, DOI 10.1182/blood-2009-07-234229; Czerny T, 1999, MOL CELL, V3, P297, DOI 10.1016/S1097-2765(00)80457-8; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; Denk D, 2012, LEUKEMIA RES, V36, pE178, DOI 10.1016/j.leukres.2012.04.015; Desouki MM, 2010, CLIN MED RES, V8, P84, DOI 10.3121/cmr.2010.891; DIETRICH S, 1995, DEV BIOL, V167, P529, DOI 10.1006/dbio.1995.1047; Discenza MT, 2003, ONCOGENE, V22, P8145, DOI 10.1038/sj.onc.1206997; Dohrmann C, 2000, MECH DEVELOP, V92, P47, DOI 10.1016/S0925-4773(99)00324-X; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Eberhard D, 1999, CANCER RES, V59, p1716S; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; Enomoto K, 2013, ENDOCR J, V60, P629, DOI 10.1507/endocrj.EJ12-0372; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Familiades J, 2009, LEUKEMIA, V23, P1989, DOI 10.1038/leu.2009.135; Fernandez C, 2011, PRINCIPLES PRACTICE, P861; Fonsato V, 2006, AM J PATHOL, V168, P706, DOI 10.2353/ajpath.2006.050776; Frazier-Bowers SA, 2002, CONNECT TISSUE RES, V43, P296, DOI 10.1080/03008200290000961; Galindo RL, 2006, P NATL ACAD SCI USA, V103, P13439, DOI 10.1073/pnas.0605926103; Gehring WJ, 1996, GENES CELLS, V1, P11, DOI 10.1046/j.1365-2443.1996.11011.x; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GNARRA JR, 1995, CANCER RES, V55, P4092; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GURNEY JG, 1999, NIH PUB, P111; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hogan AR, 2009, J SURG RES, V156, P167, DOI 10.1016/j.jss.2009.03.098; Hol FA, 1996, J MED GENET, V33, P655, DOI 10.1136/jmg.33.8.655; Holmes Laurens Jr, 2012, ISRN Oncol, V2012, P906197, DOI 10.5402/2012/906197; Holmes ML, 2008, IMMUNOL CELL BIOL, V86, P47, DOI 10.1038/sj.icb.7100134; Huh WW, 2010, CURR ONCOL REP, V12, P402, DOI 10.1007/s11912-010-0130-3; Hunger SP, 2012, J CLIN ONCOL, V30, P1663, DOI 10.1200/JCO.2011.37.8018; Hurwitz RL, 2011, PRINCIPLES PRACTICE, P809; Iida S, 1996, BLOOD, V88, P1787; Jo W, 2011, TOHOKU J EXP MED, V223, P113, DOI 10.1620/tjem.223.113; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; Jumlongras D, 2004, HUM GENET, V114, P242, DOI 10.1007/s00439-003-1066-6; Jun S, 1996, DEVELOPMENT, V122, P2639; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Kawamata N, 2012, ONCOGENE, V31, P966, DOI 10.1038/onc.2011.291; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; Khan J, 2001, NAT MED, V7, P673, DOI 10.1038/89044; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190; Lacroix L, 2004, EUR J ENDOCRINOL, V151, P367, DOI 10.1530/eje.0.1510367; Lang D, 2007, BIOCHEM PHARMACOL, V73, P1, DOI 10.1016/j.bcp.2006.06.024; Laury AR, 2011, AM J SURG PATHOL, V35, P816, DOI 10.1097/PAS.0b013e318216c112; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Li Caiyun G., 2012, Frontiers in Genetics, V3, P6, DOI 10.3389/fgene.2012.00006; Li L, 2011, INVEST OPHTH VIS SCI, V52, P8393, DOI 10.1167/iovs.11-8139; Mailhos C, 1998, DEVELOPMENT, V125, P937; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Marques AR, 2002, J CLIN ENDOCR METAB, V87, P3947, DOI 10.1210/jc.87.8.3947; Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Naini S, 2008, CANCER RES, V68, P9583, DOI 10.1158/0008-5472.CAN-07-6178; Narlis M, 2007, J AM SOC NEPHROL, V18, P1121, DOI 10.1681/ASN.2006070739; Nebral K, 2009, LEUKEMIA, V23, P134, DOI 10.1038/leu.2008.306; Nebral K, 2007, BRIT J HAEMATOL, V139, P269, DOI 10.1111/j.1365-2141.2007.06731.x; Nikiforova MN, 2002, AM J SURG PATHOL, V26, P1016, DOI 10.1097/00000478-200208000-00006; Nonaka D, 2008, MODERN PATHOL, V21, P192, DOI 10.1038/modpathol.3801002; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Brien P, 2011, CANCER RES, V71, P7345, DOI 10.1158/0008-5472.CAN-11-1874; Ofverholm I, 2013, LEUKEMIA, V27, P1936, DOI 10.1038/leu.2013.92; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Ordonez NG, 2012, ADV ANAT PATHOL, V19, P140, DOI 10.1097/PAP.0b013e318253465d; Oustanina S, 2004, EMBO J, V23, P3430, DOI 10.1038/sj.emboj.7600346; Ozcan A, 2012, ARCH PATHOL LAB MED, V136, P1541, DOI 10.5858/arpa.2012-0072-OA; Ozcan A, 2011, MODERN PATHOL, V24, P751, DOI 10.1038/modpathol.2011.3; Park D, 2006, DEVELOPMENT, V133, P4193, DOI 10.1242/dev.02614; Peters H, 1998, EUR J ORAL SCI, V106, P38, DOI 10.1111/j.1600-0722.1998.tb02151.x; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; PLACHOV D, 1990, DEVELOPMENT, V110, P643; Plengvidhya N, 2007, J CLIN ENDOCR METAB, V92, P2821, DOI 10.1210/jc.2006-1927; POLEEV A, 1992, DEVELOPMENT, V116, P611; Poppe B, 2005, GENE CHROMOSOME CANC, V44, P218, DOI 10.1002/gcc.20214; Powell JG, 2004, ONCOGENE, V23, P3634, DOI 10.1038/sj.onc.1207399; Puglisi F, 2000, ANTICANCER RES, V20, P311; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Ren YX, 2008, CANCER RES, V68, P6587, DOI 10.1158/0008-5472.CAN-08-0859; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; RYAN G, 1995, DEVELOPMENT, V121, P867; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Scouten WT, 2004, THYROID, V14, P1037, DOI 10.1089/thy.2004.14.1037; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Shimajiri Y, 2001, DIABETES, V50, P2864, DOI 10.2337/diabetes.50.12.2864; Silberstein J, 2009, PEDIATR BLOOD CANCER, V52, P237, DOI 10.1002/pbc.21779; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Sosa-Pineda B, 2004, MOL CELLS, V18, P289; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Souabni A, 2007, BLOOD, V109, P281, DOI 10.1182/blood-2006-03-009670; Stockton DW, 2000, NAT GENET, V24, P18, DOI 10.1038/71634; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Strehl S, 2003, LEUKEMIA, V17, P1121, DOI 10.1038/sj.leu.2402923; Su DM, 2001, DEV BIOL, V236, P316, DOI 10.1006/dbio.2001.0342; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; Torres M, 1995, DEVELOPMENT, V121, P4057; von Maltzahn J, 2013, P NATL ACAD SCI USA, V110, P16474, DOI 10.1073/pnas.1307680110; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Walter K, 2010, ONCOGENE, V29, P2927, DOI 10.1038/onc.2010.56; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Wang JW, 2022, FEBS LETT, DOI 10.1016/j.febslet.2013.04.029; Wang J, 2011, ARCH ORAL BIOL, V56, P1027, DOI 10.1016/j.archoralbio.2011.03.023; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Wilm B, 1998, P NATL ACAD SCI USA, V95, P8692, DOI 10.1073/pnas.95.15.8692; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; Winyard PJD, 1996, J CLIN INVEST, V98, P451, DOI 10.1172/JCI118811; Zhai QJ, 2010, APPL IMMUNOHISTO M M, V18, P323, DOI 10.1097/PAI.0b013e3181d712ef	141	7	8	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2681	2689		10.1038/onc.2014.209	http://dx.doi.org/10.1038/onc.2014.209			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043308				2022-12-17	WOS:000354979500001
J	Kanellis, DC; Bursac, S; Tsichlis, PN; Volarevic, S; Eliopoulos, AG				Kanellis, D. C.; Bursac, S.; Tsichlis, P. N.; Volarevic, S.; Eliopoulos, A. G.			Physical and functional interaction of the TPL2 kinase with nucleophosmin	ONCOGENE			English	Article							NF-KAPPA-B; MAP KINASE; UP-REGULATION; ACTIVATE ERK; P53; PHOSPHORYLATION; SUPPRESSOR; INFLAMMATION; PROGRESSION; INDUCTION	Tumor Progression Locus 2 (TPL2) is widely recognized as a cytoplasmic mitogen-activated protein 3 kinase with a prominent role in the regulation of inflammatory and oncogenic signal transduction. Herein we report that TPL2 may also operate in the nucleus as a physical and functional partner of nucleophosmin (NPM/B23), a major nucleolar phosphoprotein with diverse cellular activities linked to malignancy. We demonstrate that TPL2 mediates the phosphorylation of a fraction of NPM at threonine 199, an event required for its proteasomal degradation and maintenance of steady-state NPM levels. Upon exposure to ultraviolet C, Tpl2 is required for the translocation of de-phosphorylated NPM from the nucleolus to the nucleoplasm. NPM is an endogenous inhibitor of HDM2:p53 interaction and knockdown of TPL2 was found to result in reduced binding of NPM to HDM2, with concomitant defects in p53 accumulation following genotoxic or ribosomal stress. These findings expand our understanding of the function of TPL2 as a negative regulator of carcinogenesis by defining a nuclear role for this kinase in the topological sequestration of NPM, linking p53 signaling to the generation of threonine 199-phosphorylated NPM.	[Kanellis, D. C.; Eliopoulos, A. G.] Univ Crete, Sch Med, Div Basic Sci, Mol & Cellular Biol Lab, Iraklion 71003, Greece; [Kanellis, D. C.; Eliopoulos, A. G.] Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol, Canc Biol Lab, Iraklion, Greece; [Bursac, S.; Volarevic, S.] Univ Rijeka, Sch Med, Dept Mol Med & Biotechnol, Rijeka, Croatia; [Tsichlis, P. N.] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA	University of Crete; University of Rijeka; Tufts Medical Center	Eliopoulos, AG (corresponding author), Univ Crete, Sch Med, Div Basic Sci, Mol & Cellular Biol Lab, Iraklion 71003, Greece.	eliopag@imbb.forth.gr	ELIOPOULOS, ARISTIDES/R-9449-2018; Kanellis, Dimitrios/AHB-0318-2022; ELIOPOULOS, ARISTIDES/ABI-6632-2020; Volarevic, Sinisa/O-4349-2018; Bursać, Slađana/Q-7894-2018	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Kanellis, Dimitrios/0000-0001-8690-2010; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Volarevic, Sinisa/0000-0003-4893-389X; Bursać, Slađana/0000-0002-6478-3409	European Commission (EC) research program 'Inflammation AMP; Cancer Research in Europe' (INFLA-CARE) [223151]; EC support program 'Translational Potential' (TransPOT) [285948]; University of Crete Maria Manassaki scholarship; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065298] Funding Source: NIH RePORTER	European Commission (EC) research program 'Inflammation AMP; Cancer Research in Europe' (INFLA-CARE); EC support program 'Translational Potential' (TransPOT); University of Crete Maria Manassaki scholarship; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Moshe Oren and Varda Rotter (Weizmann Institute, Israel), Josef Papamatheakis (FORTH/IMBB, Greece), Angeliki Malliri (Patterson Institute for Cancer Research, UK), Vassilis Gorgoulis (University of Athens Medical School, Greece) and Charalambos Spilianakis (FORTH/IMBB, Greece) for their kind gift of reagents and Marina Ioannou for excellent technical assistance. This work was supported by the European Commission (EC) research program 'Inflammation & Cancer Research in Europe' (INFLA-CARE; EC Contract 223151) to AGE and SV, the EC support program 'Translational Potential' (TransPOT; EC Contract 285948) to AGE and a University of Crete Maria Manassaki scholarship to DK.	Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Brady SN, 2009, ONCOGENE, V28, P3209, DOI 10.1038/onc.2009.178; Bursac S., 2013, BIOCHIM BIOPHYS ACTA, V1842, P817; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Chao A, 2013, J MOL MED, V91, P249, DOI 10.1007/s00109-012-0950-8; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; Choi HS, 2008, FASEB J, V22, P113, DOI 10.1096/fj.07-9078com; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cuomo ME, 2008, NAT CELL BIOL, V10, P723, DOI 10.1038/ncb1735; Das S, 2005, J BIOL CHEM, V280, P23748, DOI 10.1074/jbc.M412837200; DeCicco-Skinner KL, 2011, ONCOGENE, V30, P389, DOI 10.1038/onc.2010.447; Donati G, 2013, CELL REP, V4, P87, DOI 10.1016/j.celrep.2013.05.045; Eliopoulos AG, 2003, EMBO J, V22, P3855, DOI 10.1093/emboj/cdg386; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Endo A, 2009, J CELL SCI, V122, P678, DOI 10.1242/jcs.044461; Erny KM, 1996, ONCOGENE, V13, P2015; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gantke T, 2011, CELL RES, V21, P131, DOI 10.1038/cr.2010.173; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Hatziapostolou M, 2008, CANCER RES, V68, P1851, DOI 10.1158/0008-5472.CAN-07-5793; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Koike A, 2010, CANCER RES, V70, P6746, DOI 10.1158/0008-5472.CAN-10-0382; Koliaraki V, 2012, J CLIN INVEST, V122, P4231, DOI 10.1172/JCI63917; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Lee SB, 2008, P NATL ACAD SCI USA, V105, P16584, DOI 10.1073/pnas.0807668105; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Lin CY, 2010, MOL BIOL CELL, V21, P4409, DOI 10.1091/mbc.E10-03-0239; Lindstrom MS, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/195209; Lopez-Pelaez M, 2012, MOL BIOL CELL, V23, P2982, DOI 10.1091/mbc.E12-02-0135; Louvet E, 2006, MOL BIOL CELL, V17, P2537, DOI 10.1091/mbc.E05-10-0923; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; Moore HM, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009241; Negi SS, 2006, J CELL SCI, V119, P3676, DOI 10.1242/jcs.03090; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Okuwaki M, 2008, J BIOCHEM, V143, P441, DOI 10.1093/jb/mvm222; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; Rousseau S, 2008, J CELL SCI, V121, P149, DOI 10.1242/jcs.018671; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Serebrennikova OB, 2012, P NATL ACAD SCI USA, V109, pE1082, DOI 10.1073/pnas.1115098109; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vougioukalaki M, 2011, CANCER LETT, V304, P80, DOI 10.1016/j.canlet.2011.02.004; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Wu MH, 2002, CARCINOGENESIS, V23, P93, DOI 10.1093/carcin/23.1.93; Wu MH, 2002, J BIOL CHEM, V277, P48234, DOI 10.1074/jbc.M206550200; Zhang MJ, 2012, FEBS J, V279, P2848, DOI 10.1111/j.1742-4658.2012.08663.x; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	60	7	7	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2516	2526		10.1038/onc.2014.183	http://dx.doi.org/10.1038/onc.2014.183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998852				2022-12-17	WOS:000354190400010
J	Feduska, JM; Aller, SG; Garcia, PL; Cramer, SL; Council, LN; van Waardenburg, RCAM; Yoon, KJ				Feduska, J. M.; Aller, S. G.; Garcia, P. L.; Cramer, S. L.; Council, L. N.; van Waardenburg, R. C. A. M.; Yoon, K. J.			ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with alpha-actinin	ONCOGENE			English	Article							INTERCELLULAR-ADHESION MOLECULE-2; CYTOPLASMIC DOMAIN; SUBCELLULAR-LOCALIZATION; LEUKOCYTE ADHESION; STRUCTURAL BASIS; BINDING; CANCER; LIGAND; EXPRESSION; ANCHORAGE	Progressive metastatic disease is a major cause of mortality for patients diagnosed with multiple types of solid tumors. One of the long-term goals of our laboratory is to identify molecular interactions that regulate metastasis, as a basis for developing agents that inhibit this process. Toward this goal, we recently demonstrated that intercellular adhesion molecule-2 (ICAM-2) converted neuroblastoma (NB) cells from a metastatic to a non-metastatic phenotype, a previously unknown function for ICAM-2. Interestingly, ICAM-2 suppressed metastatic but not tumorigenic potential in preclinical models, supporting a novel mechanism of regulating metastasis. We hypothesized that the effects of ICAM-2 on NB cell phenotype depend on the interaction of ICAM-2 with the cytoskeletal linker protein alpha-actinin. The goal of the study presented here was to evaluate the impact of alpha-actinin binding to ICAM-2 on the phenotype of NB tumor cells. We used in silico approaches to examine the likelihood that the cytoplasmic domain of ICAM-2 binds directly to alpha-actinin. We then expressed variants of ICAM-2 with mutated a-actinin-binding domains, and compared the impact of ICAM-2 and each variant on NB cell adhesion, migration, anchorage-independent growth, co-precipitation with alpha-actinin and production of localized and disseminated tumors in vivo. The in vitro and in vivo characteristics of cells expressing ICAM-2 variants with modified alpha-actinin-binding domains differed from cells expressing ICAM-2 wild type (WT) and also from cells that expressed no detectable ICAM-2. Like the WT protein, ICAM-2 variants inhibited cell adhesion, migration and colony growth in vitro. However, unlike the WT protein, ICAM-2 variants did not completely suppress development of disseminated NB tumors in vivo. The data suggest the presence of alpha-actinin-dependent and alpha-actinin-independent mechanisms, and indicate that the interaction of ICAM-2 with alpha-actinin is critical to conferring an ICAM-2-mediated non-metastatic phenotype in NB cells.	[Feduska, J. M.; Aller, S. G.; Garcia, P. L.; van Waardenburg, R. C. A. M.; Yoon, K. J.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; [Cramer, S. L.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; [Council, L. N.] Univ Alabama Birmingham, Dept Pathol, Div Anat Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Yoon, KJ (corresponding author), Univ Alabama Birmingham, Dept Pharmacol & Toxicol, 1670 Univ Blvd, Birmingham, AL 35294 USA.	kyoon@uab.edu		Aller, Stephen/0000-0003-0379-5534	University of Alabama at Birmingham-Comprehensive Cancer Center- YSB-New Faculty Development Award (YSB-NFDA) [P30 CA013148]; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER	University of Alabama at Birmingham-Comprehensive Cancer Center- YSB-New Faculty Development Award (YSB-NFDA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Dr Mary Danks for her support. We thank Dr Phil Potter for allowing us to use the mouse strain developed in his laboratory. We are also grateful to Joanna Remack and Rebecca Bush for outstanding technical assistance. This work was supported by the University of Alabama at Birmingham-Comprehensive Cancer Center- YSB-New Faculty Development Award (YSB-NFDA: P30 CA013148).	[Anonymous], 2010, PYMOL MOL GRAPHICS S; Atkinson RA, 2001, NAT STRUCT BIOL, V8, P853, DOI 10.1038/nsb1001-853; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; Eccles SA, 2005, BIOTECHNOL ANN REV, V11, P391, DOI 10.1016/S1387-2656(05)11013-8; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Feduska JM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-261; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Garcia PL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078183; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Hariharan R, 2008, PROTEINS, V71, P1853, DOI 10.1002/prot.21869; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Heiska L, 1996, J BIOL CHEM, V271, P26214, DOI 10.1074/jbc.271.42.26214; Hiraoka N, 2011, GASTROENTEROLOGY, V140, P310, DOI 10.1053/j.gastro.2010.10.009; Hogg N, 1999, J CLIN INVEST, V103, P97, DOI 10.1172/JCI3312; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Honda K, 2005, GASTROENTEROLOGY, V128, P51, DOI 10.1053/j.gastro.2004.10.004; Huang MT, 2005, BLOOD, V106, P1636, DOI 10.1182/blood-2004-12-4716; Humphries M. J., 2001, CURR PROTOC CELL BIO, V00, DOI DOI 10.1002/0471143030.CB0901500; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kotovuori A, 1999, J IMMUNOL, V162, P6613; Liu J, 2004, J MOL BIOL, V338, P115, DOI 10.1016/j.jmb.2004.02.034; Liu ZY, 2009, J GASTROEN HEPATOL, V24, P900, DOI 10.1111/j.1440-1746.2008.05668.x; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Melero I, 2002, CANCER RES, V62, P3167; Mohamet L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012921; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Morton CL, 2005, CANCER CHEMOTH PHARM, V56, P629, DOI 10.1007/s00280-005-1027-y; Nishiya T, 2004, J BIOL CHEM, V279, P19008, DOI 10.1074/jbc.M311618200; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; Nyman-Huttunen H, 2006, J CELL SCI, V119, P3057, DOI 10.1242/jcs.03045; OTEY CA, 1993, J BIOL CHEM, V268, P21193; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; PASQUALINI R, 1994, J CELL BIOL, V125, P447, DOI 10.1083/jcb.125.2.447; Perez OD, 2002, IMMUNITY, V16, P51, DOI 10.1016/S1074-7613(02)00266-2; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Tovchigrechko A, 2005, PROTEINS, V60, P296, DOI 10.1002/prot.20573; Yang YT, 2004, MOL CELL, V14, P269, DOI 10.1016/S1097-2765(04)00204-7; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yoon KJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003629	46	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1553	1562		10.1038/onc.2014.87	http://dx.doi.org/10.1038/onc.2014.87			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704826	Green Accepted			2022-12-17	WOS:000351416800008
J	Knight, ERW; Patel, EY; Flowers, CA; Crowther, AJ; Ting, JP; Miller, CR; Gershon, TR; Deshmukh, M				Knight, E. R. W.; Patel, E. Y.; Flowers, C. A.; Crowther, A. J.; Ting, J. P.; Miller, C. R.; Gershon, T. R.; Deshmukh, M.			ASC deficiency suppresses proliferation and prevents medulloblastoma incidence	ONCOGENE			English	Article						medulloblastoma; ASC; TMS-1; proliferation; TGF-beta; tumor	SPECK-LIKE PROTEIN; ABERRANT METHYLATION; GENETIC PROFILES; DOWN-REGULATION; MOUSE MODEL; DUAL ROLE; CARD ASC; INFLAMMASOME; GROWTH; CELLS	Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) is silenced by promoter methylation in many types of tumors, yet ASC's role in most cancers remains unknown. Here, we show that ASC is highly expressed in a model of medulloblastoma, the most common malignant pediatric brain cancer; ASC is also expressed in human medulloblastomas. Importantly, while ASC deficiency did not affect normal cerebellar development, ASC knockout mice on the Smoothened (ND2: SmoA1) transgenic model of medulloblastoma exhibited a profound reduction in medulloblastoma incidence and a delayed tumor onset. A similar decrease in tumorigenesis with ASC deficiency was also seen in the hGFAP-Cre: SmoM2 mouse model of medulloblastoma. Interestingly, hyperproliferation of the external granule layer (EGL) was comparable at P20 in both wild-type and ASC-deficient SmoA1 mice. However, while the apoptosis and differentiation markers remained unchanged at this age, proliferation makers were decreased, and the EGL was reduced in thickness and area by P60. This reduction in proliferation with ASC deficiency was also seen in isolated SmoA1 cerebellar granule precursor cells in vitro, indicating that the effect of ASC deletion on proliferation was cell autonomous. Interestingly, ASC-deficient SmoA1 cerebella exhibited disrupted expression of genes in the transforming growth factor-beta pathway and increased level of nuclear Smad3. Taken together, these results demonstrate an unexpected role for ASC in Sonic hedgehog-driven medulloblastoma tumorigenesis, thus identifying ASC as a promising novel target for antitumor therapy.	[Knight, E. R. W.; Ting, J. P.; Gershon, T. R.; Deshmukh, M.] Univ N Carolina, Neurobiol Curriculum, Chapel Hill, NC 27599 USA; [Knight, E. R. W.; Patel, E. Y.; Flowers, C. A.; Crowther, A. J.; Miller, C. R.; Gershon, T. R.; Deshmukh, M.] Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; [Crowther, A. J.; Ting, J. P.; Miller, C. R.; Gershon, T. R.; Deshmukh, M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Ting, J. P.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Miller, C. R.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Miller, C. R.; Gershon, T. R.] Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA; [Deshmukh, M.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Deshmukh, M (corresponding author), Univ N Carolina, Dept Cell Biol & Physiol, 7109E Neurosci Res Bldg,105 Mason Farm Rd, Chapel Hill, NC 27599 USA.	mohanish@med.unc.edu	Miller, Ryan/B-9365-2008; , Pathology Services Core/CEZ-2246-2022; Gershon, Timothy/H-5398-2019	Miller, Ryan/0000-0002-0096-8762; Gershon, Timothy/0000-0001-7034-6400	National Cancer Institute [3P30CA016086]; UNC University Cancer Research Fund; NIH [1K08NS077978]; St Baldrick's Foundation;  [NS042197];  [GM078366]; NATIONAL CANCER INSTITUTE [P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS045892, R01NS042197, K08NS077978] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UNC University Cancer Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); St Baldrick's Foundation; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Drs Vishva Dixit (Genentech), James Olson (Fred Hutchinson Cancer Research Center), Eva Anton (UNC) for generously sharing ASC<SUP>-/-</SUP>, ND2: SmoA1 and hGFAP-cre mice, respectively. We appreciate the technical assistance provided by Vivian Xu, Michael Conlin and Meera Patel in the Deshmukh Lab; Janice Weaver, Lily Wai and Yongjuan Xia in the UNC Histopathology Core; Terese Camp and Ling Li in the UNC Genomics Core; Mark Vincent Olorvida, Stephanie Cohen and Bentley Midkiff in the UNC Translational Pathology Laboratory (TPL); and Joel Parker, George Wu, Chandri Yandava and Chris Fan at UNC for bioinformatics and biostatistics guidance. The UNC TPL is supported in part by grants from the National Cancer Institute (3P30CA016086) and the UNC University Cancer Research Fund. We would like to thank members of the Deshmukh Laboratory for critical review of this manuscript. TRG is supported by NIH Grant 1K08NS077978 and St Baldrick's Foundation. This work was supported by Grants NS042197 and GM078366 to MD.	Alaminos M, 2004, JNCI-J NATL CANCER I, V96, P1208, DOI 10.1093/jnci/djh224; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Aref D, 2013, BRAIN PATHOL, V23, P178, DOI 10.1111/j.1750-3639.2012.00631.x; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Conway KE, 2000, CANCER RES, V60, P6236; Dabiri G, 2008, J INVEST DERMATOL, V128, P280, DOI 10.1038/sj.jid.5700975; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Drexler SK, 2012, P NATL ACAD SCI USA, V109, P18384, DOI 10.1073/pnas.1209171109; Fattet S, 2009, J PATHOL, V218, P86, DOI 10.1002/path.2514; Feierabend D, 2013, J NEUROONCOL, DOI [10.1007/s11060-11013-11286-11060, DOI 10.1007/S11060-11013-11286-11060]; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Guan X, 2003, INT J CANCER, V107, P202, DOI 10.1002/ijc.11376; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hatten ME, 2011, TRENDS NEUROSCI, V34, P134, DOI 10.1016/j.tins.2011.01.002; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; Hong S, 2013, CANCER LETT, V331, P183, DOI 10.1016/j.canlet.2012.12.020; Ippagunta SK, 2010, J BIOL CHEM, V285, P12454, DOI 10.1074/jbc.M109.093252; Jeong JH, 2004, GENE DEV, V18, P937, DOI 10.1101/gad.1190304; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kole AJ, 2011, GENE DEV, V25, P125, DOI 10.1101/gad.1975411; Kolly L, 2009, J IMMUNOL, V183, P4003, DOI 10.4049/jimmunol.0802173; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Liu WM, 2013, J INVEST DERMATOL, V133, P518, DOI 10.1038/jid.2012.317; Machida EO, 2006, CANCER RES, V66, P6210, DOI 10.1158/0008-5472.CAN-05-4447; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Narayan S, 2011, IMMUNOLOGY, V134, P33, DOI 10.1111/j.1365-2567.2011.03462.x; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Ohtsuka T, 2006, ONCOGENE, V25, P1807, DOI 10.1038/sj.onc.1209204; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Parsons MJ, 2006, ONCOGENE, V25, P6948, DOI 10.1038/sj.onc.1209684; Parsons MJ, 2009, CANCER RES, V69, P1706, DOI 10.1158/0008-5472.CAN-08-2351; Polkinghorn WR, 2007, NAT CLIN PRACT ONCOL, V4, P295, DOI 10.1038/ncponc0794; Ramachandran K, 2010, ANTICANCER RES, V30, P3919; Rich JN, 2003, FRONT BIOSCI-LANDMRK, V8, pE245, DOI 10.2741/992; Rios I, 2004, DEVELOPMENT, V131, P3159, DOI 10.1242/dev.01188; Shaw PJ, 2010, J IMMUNOL, V184, P4610, DOI 10.4049/jimmunol.1000217; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; Shibanuma M, 1998, INT J BIOCHEM CELL B, V30, P39, DOI 10.1016/S1357-2725(97)00155-6; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408	46	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					394	402		10.1038/onc.2013.577	http://dx.doi.org/10.1038/onc.2013.577			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469054	Green Accepted, Green Submitted			2022-12-17	WOS:000348145500013
J	Wang, F; Chen, X; Li, C; Sun, Q; Chen, Y; Wang, Y; Peng, H; Liu, Z; Chen, R; Liu, K; Yan, H; Ye, BH; Kwiatkowski, DJ; Zhang, H				Wang, F.; Chen, X.; Li, C.; Sun, Q.; Chen, Y.; Wang, Y.; Peng, H.; Liu, Z.; Chen, R.; Liu, K.; Yan, H.; Ye, B. H.; Kwiatkowski, D. J.; Zhang, H.			Pivotal role of augmented alpha B-crystallin in tumor development induced by deficient TSC1/2 complex	ONCOGENE			English	Article						alpha B-crystallin; mTOR; NF kappa B; TSC; tumor	TUBEROUS SCLEROSIS COMPLEX; SUPPRESSOR GENE-PRODUCT; NF-KAPPA-B; MAMMALIAN TARGET; INDUCED APOPTOSIS; BINDING PARTNER; CELL-ADHESION; UP-REGULATION; CANCER-CELLS; MTOR	Tuberous sclerosis complex 1 (TSC1) and TSC2 are suppressors of mechanistic target of rapamycin (mTOR). mTOR is the major component of two protein complexes: mTOR complex 1 (mTORC1) and mTORC2. Inactive mutation of either TSC1 or TSC2 unleashes mTOR signaling and consequently causes TSC, a benign tumor syndrome affecting multiple organs. We report here that expression of alpha B-crystallin was upregulated in Tsc1-/- or Tsc2-/- mouse embryonic fibroblasts, Eker rat uterine leiomyoma-derived Tsc2-deficient ELT3 cells, mutant Tsc2-associated mouse kidney tumors, and human lung lymphangioleiomyomatosis nodules. alpha B-crystallin was transcriptionally activated by mTOR complex 2 (mTORC2): nuclear factor-kappa B (NF kappa B) signaling cascade. The augmented alpha B-crystallin was critical for the migration, invasion and apoptotic resistance of Tsc2-defective cells. Disruption of alpha B-crystallin suppressed Tsc2-null cell proliferation and tumorigenesis. Therefore, enhanced alpha B-crystallin has an essential role in TSC1/2 complex deficiency-mediated tumorigenesis, and inhibition of alpha B-crystallin may complement the current therapy for TSC.	[Wang, F.; Chen, X.; Li, C.; Wang, Y.; Liu, Z.; Chen, R.; Zhang, H.] Peking Union Med Coll, Grad Sch, Inst Basic Med Sci, State Key Lab Med Mol Biol,Dept Physiol & Pathoph, Beijing 100005, Peoples R China; [Wang, F.; Chen, X.; Li, C.; Wang, Y.; Liu, Z.; Chen, R.; Zhang, H.] Peking Union Med Coll, Grad Sch, Sch Basic Med, Beijing 100005, Peoples R China; [Wang, F.; Chen, X.; Li, C.; Chen, Y.; Wang, Y.; Liu, Z.; Chen, R.; Yan, H.; Zhang, H.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Sun, Q.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China; [Chen, Y.; Yan, H.] Peking Union Med Coll, Cardiovasc Inst, Ctr Coronary Heart Dis, Beijing 100005, Peoples R China; [Chen, Y.; Yan, H.] Peking Union Med Coll, Fu Wai Hosp, Beijing 100005, Peoples R China; [Peng, H.] Scripps Res Inst, Dept Canc Biol, Jupiter, FL USA; [Liu, K.] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450052, Henan, Peoples R China; [Ye, B. H.] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; [Kwiatkowski, D. J.] Brigham & Womens Hosp, Div Translat Med, Boston, MA 02115 USA; [Kwiatkowski, D. J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Scripps Research Institute; Zhengzhou University; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Zhang, H (corresponding author), Peking Union Med Coll, Grad Sch, Inst Basic Med Sci, Dept Physiol & Pathophysiol, Beijing 100005, Peoples R China.	hbzhang@ibms.pumc.edu.cn	Peng, Haiyong/S-8045-2016		National Basic Research Program of China 973 Program [2009CB522203, 2011CB965002]; National Natural Science Foundation of China [81130085, 81101516]	National Basic Research Program of China 973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by National Basic Research Program of China 973 Program Grants 2009CB522203 and 2011CB965002 and National Natural Science Foundation of China Grants 81130085 and 81101516.	AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Bhaskar PT, 2009, MOL CELL BIOL, V29, P5136, DOI 10.1128/MCB.01946-08; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bittmann I, 2003, HUM PATHOL, V34, P95, DOI 10.1053/hupa.2003.50; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; El-Hashemite N, 2003, LANCET, V361, P1348, DOI 10.1016/S0140-6736(03)13044-9; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Goncharova EA, 2011, MOL CELL BIOL, V31, P2484, DOI 10.1128/MCB.01061-10; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; HOWE SR, 1995, AM J PATHOL, V146, P1568; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; IWAKI T, 1991, AM J PATHOL, V139, P1303; Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; KUPSKY WJ, 1993, PEDIATR PATHOL, V13, P869, DOI 10.3109/15513819309048274; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lang SA, 2010, BBA-MOL CELL RES, V1803, P435, DOI 10.1016/j.bbamcr.2010.01.009; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Ma JH, 2011, J GENET GENOMICS, V38, P533, DOI 10.1016/j.jgg.2011.10.002; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935; Ozes ON, 1999, NATURE, V401, P82; Parcellier A, 2005, ANTIOXID REDOX SIGN, V7, P404, DOI 10.1089/ars.2005.7.404; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shi T, 2004, MOL CARCINOGEN, V40, P47, DOI 10.1002/mc.20015; Sitterding SM, 2008, ANN DIAGN PATHOL, V12, P33, DOI 10.1016/j.anndiagpath.2007.02.004; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Tanaka K, 2011, CANCER DISCOV, V1, P524, DOI 10.1158/2159-8290.CD-11-0124; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Young LR, 2008, NEW ENGL J MED, V358, P199, DOI 10.1056/NEJMc0707517; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	49	7	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2014	33	34					4352	4358		10.1038/onc.2013.401	http://dx.doi.org/10.1038/onc.2013.401			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MK	24077282				2022-12-17	WOS:000341156900008
J	Munro, S; Oppermann, U; La Thangue, NB				Munro, S.; Oppermann, U.; La Thangue, N. B.			Pleiotropic effect of somatic mutations in the E2F subunit DP-1 gene in human cancer	ONCOGENE			English	Article						DP-1; E2F; somatic mutation; cancer	TRANSCRIPTION FACTOR DRTF1/E2F; CELL-CYCLE CONTROL; DNA-DAMAGE; RETINOBLASTOMA PROTEIN; NUCLEAR-LOCALIZATION; FAMILY-MEMBERS; RB/E2F PATHWAY; PRB; APOPTOSIS; DISTINCT	Transcription factor E2F-1 and its interaction with pRb provide a key point of control in cell proliferation. E2F-1 participates in both cell cycle progression and apoptosis, and in cells exists with a DP dimerization partner protein, the most prominent being DP-1. By mining the tumor tissue and cancer cell line encyclopedia genomic databases, we identified the first somatic mutations in the DP-1 gene and describe 53 distinct mutation events here. The mutations are mostly missense mutations, but also include nonsense and frame-shift mutations that result in truncated DP-1 derivatives. Mutation occurs throughout the DP-1 gene but generally leaves protein dimerization activity intact. This allows the mutant derivatives to affect the properties of the E2F-1/DP-1 heterodimer through a transdominant mechanism, which changes the DNA binding, transcriptional activation and pRb-binding properties of the heterodimer. In particular, many DP-1 mutants were found to impair E2F-1-dependent apoptosis. Our results establish that somatic mutations in DP-1 uncouple normal control of the E2F pathway, and thus define a new mechanism that could contribute to aberrant proliferation in tumor cells.	[Munro, S.; La Thangue, N. B.] Univ Oxford, Div Med Sci, Dept Oncol, Canc Biol Lab, Oxford OX3 7DQ, England; [Oppermann, U.] Univ Oxford, Nuffield Orthopaed Ctr, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford OX3 7DQ, England	University of Oxford; Nuffield Orthopaedic Centre; University of Oxford	La Thangue, NB (corresponding author), Univ Oxford, Div Med Sci, Dept Oncol, Canc Biol Lab, Old Rd Campus Res Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7DQ, England.	nick.lathangue@oncology.ox.ac.uk			CRUK [C300/A13058]; MRC; LLR; EU; Oxford NIHR BRU; Bayer Healthcare; MRC [G1000807, G0500905] Funding Source: UKRI; Cancer Research UK [13058] Funding Source: researchfish; Medical Research Council [G0500905, G1000807] Funding Source: researchfish	CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); LLR; EU(European Commission); Oxford NIHR BRU; Bayer Healthcare(Bayer AGBayer Healthcare Pharmaceuticals); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from CRUK (programme award C300/A13058), MRC, LLR, EU, Oxford NIHR BRU and Bayer Healthcare. We thank Sarah Atkinson for her help with preparing the manuscript.	Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biswas AK, 2012, CANCER RES, V72, P13, DOI 10.1158/0008-5472.CAN-11-2196; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Botz J, 1996, MOL CELL BIOL, V16, P3401; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeGregori J, 2006, CURR MOL MED, V6, P739; delaLuna S, 1996, J CELL SCI, V109, P2443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Kohn MJ, 2004, MOL CELL BIOL, V24, P7197, DOI 10.1128/MCB.24.16.7197-7205.2004; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Lin WC, 2001, GENE DEV, V15, P1833; Magae J, 1996, J CELL SCI, V109, P1717; Markham D, 2006, EMBO REP, V7, P192, DOI 10.1038/sj.embor.7400591; Milton A, 2006, ONCOGENE, V25, P3212, DOI 10.1038/sj.onc.1209343; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Polager S, 2009, NAT REV CANCER, V9, P738, DOI 10.1038/nrc2718; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr C J, 2000, Harvey Lect, V96, P73; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yu W, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r96; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	42	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3594	3603		10.1038/onc.2013.316	http://dx.doi.org/10.1038/onc.2013.316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23934193				2022-12-17	WOS:000338941100011
J	Busch, SE; Moser, RD; Gurley, KE; Kelly-Spratt, KS; Liggitt, HD; Kemp, CJ				Busch, S. E.; Moser, R. D.; Gurley, K. E.; Kelly-Spratt, K. S.; Liggitt, H. D.; Kemp, C. J.			ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma	ONCOGENE			English	Article						p19(Arf); p14(ARF); ethyl carbamate; metastasis	P53-MEDIATED TUMOR SUPPRESSION; DNA-DAMAGE; MOUSE MODEL; CYCLE ARREST; WILD-TYPE; CANCER; P53; MICE; PATHWAY; LOCUS	Non-small-cell lung carcinoma (NSCLC) is among the deadliest of human cancers. The CDKN2A locus, which houses the INK4a and ARF tumor suppressor genes, is frequently altered in NSCLC. However, the specific role of ARF in pulmonary tumorigenesis remains unclear. KRAS and other oncogenes induce the expression of ARF, thus stabilizing p53 activity and arresting cell proliferation. To address the role of ARF in Kras-driven NSCLC, we compared the susceptibility of NIH/Ola strain wild-type and Arf-knockout mice to urethane-induced lung carcinogenesis. Lung tumor size, malignancy and associated morbidity were significantly increased in Arf(-/-) compared with Arf(+/+) animals at 25 weeks after induction. Pulmonary tumors from Arf-knockout mice exhibited increased cell proliferation and DNA damage compared with wild-type mice. A subgroup of tumors in Arf(-/-) animals presented as dedifferentiated and metastatic, with many characteristics of pulmonary sarcomatoid carcinoma, a neoplasm previously undocumented in mouse models. Our finding of a role for ARF in NSCLC is consistent with the observation that benign adenomas from Arf(+/+) mice robustly expressed ARF, while ARF expression was markedly reduced in malignant adenocarcinomas. ARF expression also frequently colocalized with the expression of p21(CIP1), a transcriptional target of p53, arguing that ARF induces the p53 checkpoint to arrest cell proliferation in vivo. Taken together, these findings demonstrate that induction of ARF is an early response in lung tumorigenesis that mounts a strong barrier against tumor growth and malignant progression.	[Busch, S. E.; Moser, R. D.; Gurley, K. E.; Kelly-Spratt, K. S.; Kemp, C. J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; [Busch, S. E.] Univ Washington, Mol & Cellular Biol Grad Program, Seattle, WA 98195 USA; [Liggitt, H. D.] Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1100 Fairview Ave North,Mail Stop C1-015, Seattle, WA 98109 USA.	cjkemp@fhcrc.org		Busch, Stephanie E/0000-0003-4073-5311	NCI MMHCC [U01 CA141550]; NIEHS [5 R01 ES020116]; PHS NRSA from NIGMS [T32 GM007270]; NATIONAL CANCER INSTITUTE [U01CA141550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCI MMHCC; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS NRSA from NIGMS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Sue Knoblaugh for her assistance in analyzing tumor histopathology, and to numerous colleagues for their helpful commentary. This work was supported by NCI MMHCC U01 CA141550, and by NIEHS 5 R01 ES020116. SEB was supported by PHS NRSA T32 GM007270 from NIGMS.	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Andrique L, 2012, CELL SIGNAL, V24, P1074, DOI 10.1016/j.cellsig.2012.01.002; [Anonymous], 1975, SEER CANC STAT REV 1; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Busch SE, 2012, J PATHOL, V227, P298, DOI 10.1002/path.4024; Cardiff RD, 2005, CLIN CANCER RES, V11, P8534, DOI 10.1158/1078-0432.CCR-05-2250; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; D'Amico M, 2004, CANCER RES, V64, P4122, DOI 10.1158/0008-5472.CAN-03-2519; Dacic S, 2002, AM J SURG PATHOL, V26, P510, DOI 10.1097/00000478-200204000-00015; Debies MT, 2008, J CLIN INVEST, V118, P51, DOI 10.1172/JCI33320; di Tommaso A, 2009, EXP CELL RES, V315, P1326, DOI 10.1016/j.yexcr.2009.01.010; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Gao N, 2001, J CANCER RES CLIN, V127, P359, DOI 10.1007/s004320000184; Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2009, ONCOGENE, V28, P3652, DOI 10.1038/onc.2009.226; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Manenti G, 1997, CANCER RES, V57, P4164; Nicholson SA, 2001, CANCER RES, V61, P5636; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Pelosi G, 2010, INT J SURG PATHOL, V18, P103, DOI 10.1177/1066896908330049; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Pontano LL, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-12; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; ROGERS S, 1951, J EXP MED, V93, P427, DOI 10.1084/jem.93.5.427; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Saporita AJ, 2007, CURR MED CHEM, V14, P1815; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Tam AS, 2003, CARCINOGENESIS, V24, P121, DOI 10.1093/carcin/24.1.121; TANNENBAUM A, 1962, CANCER RES, V22, P1105; Thompson L, 1996, AM J SURG PATHOL, V20, P277, DOI 10.1097/00000478-199603000-00003; Tompkins VS, 2007, J BIOL CHEM, V282, P1322, DOI 10.1074/jbc.M609612200; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang Y, 2006, ONCOGENE, V25, P1277, DOI 10.1038/sj.onc.1209182; Wang Y, 2003, CANCER RES, V63, P4389; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Zeng YX, 2011, CANCER RES, V71, P2781, DOI 10.1158/0008-5472.CAN-10-3483; Zhang W, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-74; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493	60	7	7	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2665	2673		10.1038/onc.2013.208	http://dx.doi.org/10.1038/onc.2013.208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752194	Green Accepted			2022-12-17	WOS:000336502700012
J	Wong, CH; Wu, Z; Yu, Q				Wong, C. H.; Wu, Z.; Yu, Q.			CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis	ONCOGENE			English	Article						E2F1; apoptosis; CTSL2	CELL-DEATH; CANCER; INDUCTION; P53; EXPRESSION; LYSOSOMES; PATHWAYS; THERAPY; GENES; LIFE	Aberrant regulation of the pRB/E2F1 pathway has been invariably linked to inappropriate proliferation and/apoptosis in human cancers. Therefore, understanding the intricacies of the signaling pathway and identification of novel E2F1 targets involved in apoptosis could pave way for new therapeutic manipulation. Here, we identified CTSL2 (cathepsin L2/cathepsin V) as a novel E2F1 target that participates in E2F1-dependent apoptosis. We showed that E2F1 directly binds to CTSL2 promoter and that CTSL2 is regulated by both exogenous and endogenous E2F1. RNAi-mediated depletion of CTSL2 effectively abrogated ectopic E2F1-induced apoptosis, coupled with reduced lysosomal membrane permeabilization (LMP) and mitochondrial membrane depolarization. CTSL2 knockdown also inhibited apoptosis mediated by the endogenous E2F1 activated by DNA damage. Furthermore, we showed that CTSL2 depletion in cancer cells resulted in inhibition of histone deacetylase inhibitor (HDACi)-induced apoptosis, and conversely ectopic overexpression of CTSL2-sensitized cancer cells to HDACi. This study uncovered a novel E2F1 target implicated in LMP and apoptosis activation, as well as in the modulation of HDACi and chemotherapeutic drugs response.	[Wong, C. H.; Yu, Q.] Agcy Sci Technol & Res, Genome Inst Singapore, Canc Biol & Pharmacol, Singapore 138672, Singapore; [Wu, Z.] China Agr Univ, Coll Anim Sci & Technol, State Key Lab Anim Nutr, Beijing 100094, Peoples R China; [Yu, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore; [Yu, Q.] DUKE NUS Grad Med Sch Singapore, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); China Agricultural University; National University of Singapore; National University of Singapore	Yu, Q (corresponding author), Agcy Sci Technol & Res, Genome Inst Singapore, Canc Biol & Pharmacol, 60 Biopolis St,02-01, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg		Yu, Qiang/0000-0003-2132-8278	Agency for Science, Technology and Research for Singapore	Agency for Science, Technology and Research for Singapore	We thank Dr Kristian Helin for the ER-E2F1 plasmids, Dr Joseph Nevins for the adenoviral E2F1, Dr Andrew Turnell for adenoviral E1A and Dr Claudio Brancolini for IMR90-E1A cells. We are grateful to Li Juntao for providing assistance in data analysis. This work was supported by the Agency for Science, Technology and Research for Singapore.	Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Droga-Mazovec G, 2008, J BIOL CHEM, V283, P19140, DOI 10.1074/jbc.M802513200; Dyniacht BD, 2008, CANCER CELL, V13, P1, DOI 10.1016/j.ccr.2007.12.017; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Hallstrom TC, 2008, CANCER CELL, V13, P11, DOI 10.1016/j.ccr.2007.11.031; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ivanova S, 2008, METHOD ENZYMOL, V442, P183, DOI 10.1016/S0076-6879(08)01409-2; Jaattela M, 2004, CELL DEATH DIFFER, V11, P135, DOI 10.1038/sj.cdd.4401333; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kreuzaler PA, 2011, NAT CELL BIOL, V13, P303, DOI 10.1038/ncb2171; Lin WC, 2001, GENE DEV, V15, P1833; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Putzer BM, 2000, GENE THER, V7, P1317, DOI 10.1038/sj.gt.3301235; Santamaria I, 1998, CANCER RES, V58, P1624; Sevenich L, 2010, BIOCHIMIE, V92, P1674, DOI 10.1016/j.biochi.2010.03.014; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Wu ZL, 2009, INT J BIOCHEM CELL B, V41, P2389, DOI 10.1016/j.biocel.2009.06.004; Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046749; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102	32	7	7	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1249	1257		10.1038/onc.2013.72	http://dx.doi.org/10.1038/onc.2013.72			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23542171				2022-12-17	WOS:000332631100005
J	Gravells, P; Hoh, L; Solovieva, S; Patil, A; Dudziec, E; Rennie, IG; Sisley, K; Bryant, HE				Gravells, P.; Hoh, L.; Solovieva, S.; Patil, A.; Dudziec, E.; Rennie, I. G.; Sisley, K.; Bryant, H. E.			Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia	ONCOGENE			English	Article						FANCD2; homologous recombination; non-homologous end-joining; uveal melanoma; sister chromatid exchange; RAD51	SISTER-CHROMATID EXCHANGE; DNA-DAMAGING AGENTS; BREAST-CANCER; HOMOLOGOUS RECOMBINATION; CHROMOSOME-DAMAGE; REPLICATION FORKS; ALKYLATING-AGENTS; GENE CONVERSION; MCL-1 PROMOTER; STRAND BREAKS	Uveal melanoma (UM) is unique among cancers in displaying reduced endogenous levels of sister chromatid exchange (SCE). Here we demonstrate that FANCD2 expression is reduced in UM and that ectopic expression of FANCD2 increased SCE. Similarly, FANCD2-deficient fibroblasts (PD20) derived from Fanconi anaemia patients displayed reduced spontaneous SCE formation relative to their FANCD2-complemented counterparts, suggesting that this observation is not specific to UM. In addition, spontaneous RAD51 foci were reduced in UM and PD20 cells compared with FANCD2-proficient cells. This is consistent with a model where spontaneous SCEs are the end product of endogenous recombination events and implicates FANCD2 in the promotion of recombination-mediated repair of endogenous DNA damage and in SCE formation during normal DNA replication. In both UM and PD20 cells, low SCE was reversed by inhibiting DNA-PKcs (DNA-dependent protein kinase, catalytic subunit). Finally, we demonstrate that both PD20 and UM are sensitive to acetaldehyde, supporting a role for FANCD2 in repair of lesions induced by such endogenous metabolites. Together, these data suggest FANCD2 may promote spontaneous SCE by influencing which double-strand break repair pathway predominates during normal S-phase progression.	[Gravells, P.; Hoh, L.; Solovieva, S.; Patil, A.; Dudziec, E.; Bryant, H. E.] Univ Sheffield, Fac Med Dent & Hlth Sci, Dept Oncol, Inst Canc Studies, Sheffield S10 2RX, Yorks, England; [Hoh, L.; Rennie, I. G.; Sisley, K.] Univ Sheffield, Acad Unit Ophthalmol & Orthopt, Dept Oncol, Fac Med Dent & Hlth Sci,Royal Hallamshire Hosp, Sheffield S10 2RX, Yorks, England	University of Sheffield; University of Sheffield	Bryant, HE (corresponding author), Univ Sheffield, Sch Med, Inst Canc studies, Beech Hill Rd, Sheffield S10 2RX, Yorks, England.	h.bryant@sheffield.ac.uk	bryant, helen/AHB-1139-2022; Sisley, Karen/B-7296-2019	bryant, helen/0000-0003-2720-7020; Sisley, Karen/0000-0002-5565-2618	RCUK fellowship; MRC studentship; Weston Park Hospital Cancer Appeal [CA95]; Sarcoma Trust; Yorkshire Eye Research and Yorkshire Cancer Research [S305PA]	RCUK fellowship(UK Research & Innovation (UKRI)); MRC studentship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Weston Park Hospital Cancer Appeal; Sarcoma Trust; Yorkshire Eye Research and Yorkshire Cancer Research	We thank Professors Toshiyasu Taniguchi and Alan D'Andrea for providing cells, the FANCD2-expressing retroviral vectors and for their technical advice. They also thank Professors Tomas Lindahl and Mark Meuth and Dr Spencer Collis for critical reading of the manuscript and discussion. We are grateful for funding from an RCUK fellowship to HB and MRC studentship to PG and for general funding from Weston Park Hospital Cancer Appeal (CA95), The Sarcoma Trust, Yorkshire Eye Research and Yorkshire Cancer Research (S305PA).	Abraham J, 2011, ALCOHOL CLIN EXP RES, V35, P2113, DOI 10.1111/j.1530-0277.2011.01563.x; Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; Barroso E, 2006, CARCINOGENESIS, V27, P1930, DOI 10.1093/carcin/bgl062; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; Damato B, 2009, INVEST OPHTH VIS SCI, V50, P3048, DOI 10.1167/iovs.08-3165; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Garcia CL, 2009, MUTAT RES-FUND MOL M, V662, P3, DOI 10.1016/j.mrfmmm.2008.11.008; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GEBHART E, 1985, HUM GENET, V69, P309, DOI 10.1007/BF00291647; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Goyanes V., 1994, Cytobios, V77, P67; Gravells P, 2011, BRIT J CANCER, V104, P1098, DOI 10.1038/bjc.2011.56; Harbour JW, 2009, AM J OPHTHALMOL, V148, P823, DOI 10.1016/j.ajo.2009.07.004; HAYASHI K, 1975, HUMANGENETIK, V29, P201, DOI 10.1007/BF00297624; Hoh L, 2011, GENE CHROMOSOME CANC, V50, P34, DOI 10.1002/gcc.20829; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; HOWELL RT, 1991, J MED GENET, V28, P468, DOI 10.1136/jmg.28.7.468; KATO H, 1976, NATURE, V260, P447, DOI 10.1038/260447a0; Kim MK, 2004, CANCER LETT, V210, P85, DOI 10.1016/j.canlet.2004.01.014; Langevin F, 2011, NATURE, V475, P53, DOI 10.1038/nature10192; LATT SA, 1975, P NATL ACAD SCI USA, V72, P4066, DOI 10.1073/pnas.72.10.4066; Lyakhovich A, 2006, CANCER LETT, V232, P99, DOI 10.1016/j.canlet.2005.07.038; Miranda M, 1997, MUTAGENESIS, V12, P233, DOI 10.1093/mutage/12.4.233; NAGASAWA H, 1983, MUTAT RES, V107, P315, DOI 10.1016/0027-5107(83)90173-2; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Neveling K, 2007, CYTOGENET GENOME RES, V118, P166, DOI 10.1159/000108297; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; NOVOTNA B, 1979, HUM GENET, V49, P41; Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277; Pang QS, 2009, MUTAT RES-FUND MOL M, V668, P42, DOI 10.1016/j.mrfmmm.2009.03.013; Patel KA, 2001, BRIT J OPHTHALMOL, V85, P1440, DOI 10.1136/bjo.85.12.1440; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PORFIRIO B, 1983, HUM GENET, V63, P117, DOI 10.1007/BF00291529; Rosado IV, 2011, NAT STRUCT MOL BIOL, V18, P1432, DOI 10.1038/nsmb.2173; Rudland PS, 2010, AM J PATHOL, V176, P2935, DOI 10.2353/ajpath.2010.090779; Saleh-Gohari N, 2005, MOL CELL BIOL, V25, P7158, DOI 10.1128/MCB.25.16.7158-7169.2005; Sisley K, 1997, GENE CHROMOSOME CANC, V19, P22, DOI 10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2; Smiraldo PG, 2005, CANCER RES, V65, P2089, DOI 10.1158/0008-5472.CAN-04-2079; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; SPERLING K, 1975, HUMANGENETIK, V27, P227, DOI 10.1007/BF00278349; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Tian X, 2011, CELL SIGNAL, V23, P193, DOI 10.1016/j.cellsig.2010.09.003; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; van der Groep P, 2008, BREAST CANCER RES TR, V107, P41, DOI 10.1007/s10549-007-9534-7; Wang LC, 2008, DNA REPAIR, V7, P1973, DOI 10.1016/j.dnarep.2008.08.005; Wilson JB, 2001, CARCINOGENESIS, V22, P1939, DOI 10.1093/carcin/22.12.1939; Wojcik A, 2004, CYTOGENET GENOME RES, V104, P304, DOI 10.1159/000077507; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005	58	7	9	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5338	5346		10.1038/onc.2012.627	http://dx.doi.org/10.1038/onc.2012.627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23318456	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000326922400004
J	Doci, CL; Zhou, G; Lingen, MW				Doci, C. L.; Zhou, G.; Lingen, M. W.			The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression	ONCOGENE			English	Article						NOL7; TSP-1; angiogenesis; post-transcriptional	ENDOTHELIAL GROWTH-FACTOR; PROMOTES TRANSCRIPTION TERMINATION; NUCLEAR-RNA SURVEILLANCE; ANTI-ANGIOGENIC ISOFORMS; PRE-MESSENGER-RNA; FACTOR-BETA; CCR4-NOT COMPLEX; 3'-UNTRANSLATED REGION; QUALITY-CONTROL; POLYMERASE-I	Thrombospondin-1 (TSP-1) is an endogenous inhibitor of angiogenesis whose expression suppresses tumor growth in vivo. Like many angiogenesis-related genes, TSP-1 expression is tightly controlled by various mechanisms, but there is little data regarding the contribution of post-transcriptional processing to this regulation. NOL7 is a novel tumor suppressor that induces an antiangiogenic phenotype and suppresses tumor growth, in part through upregulation of TSP-1. Here we demonstrate that NOL7 is an mRNA-binding protein that must localize to the nucleoplasm to exert its antiangiogenic and tumor suppressive effects. There, it associates with the RNA-processing machinery and specifically interacts with TSP-1 mRNA through its 3'UTR. Reintroduction of NOL7 into SiHa cells increases luciferase expression through interaction with the TSP-1 3'UTR at both the mRNA and protein levels. NOL7 also increases endogenous TSP-1 mRNA half-life. Further, NOL7 post-transcriptional stabilization is observed in a subset of angiogenesis-related mRNAs, suggesting that the stabilization of TSP-1 may be part of a larger novel mechanism. These data demonstrate that NOL7 significantly alters TSP-1 expression and may be a master regulator that coordinates the post-transcriptional expression of key signaling factors critical for the regulation of the angiogenic phenotype.	Univ Chicago, Dept Pathol Med & Radiat, Chicago, IL 60637 USA; Univ Chicago, Dept Cellular Oncol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Lingen, MW (corresponding author), Univ Chicago, Dept Pathol Med & Radiat, 5841S Maryland Ave MC6101, Chicago, IL 60637 USA.	mark.lingen@uchospitals.edu	Doci, Colleen L/M-4389-2015		Illinois Department of Public Health Penny Severns Cancer Research Fund	Illinois Department of Public Health Penny Severns Cancer Research Fund	We wish to thank Drs Ira Wool and Yuen-Ling Chan for their assistance in sucrose gradient ultracentrifugation. This work was supported in part by Illinois Department of Public Health Penny Severns Cancer Research Fund (MWL).	Anderson JT, 2009, CRIT REV BIOCHEM MOL, V44, P16, DOI [10.1080/10409230802640218, 10.1080/10409230802640218 ]; Azzouz N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006760; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chung JH, 2011, LUNG CANCER, V73, P176, DOI 10.1016/j.lungcan.2010.11.011; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Collart MA, 2004, PROG NUCLEIC ACID RE, V77, P289, DOI 10.1016/S0079-6603(04)77008-7; de Almeida SF, 2010, NUCLEIC ACIDS RES, V38, P8015, DOI 10.1093/nar/gkq703; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; Dibrov A, 2006, GROWTH FACTORS, V24, P1, DOI 10.1080/08977190500365995; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Doci CL, 2012, INT J GYNECOL PATHOL, V31, P15, DOI 10.1097/PGP.0b013e318220ba16; El Hage A, 2008, GENE DEV, V22, P1069, DOI 10.1101/gad.463708; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Glaunsinger BA, 2010, RNA BIOL, V7, P13, DOI 10.4161/rna.7.1.10255; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hall-Pogar T, 2005, NUCLEIC ACIDS RES, V33, P2565, DOI 10.1093/nar/gki544; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505; HashimotoUoshima M, 1997, J CELL SCI, V110, P2271; Hasina R, 2006, ONCOGENE, V25, P588, DOI 10.1038/sj.onc.1209070; He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964; Janz A, 2000, NUCLEIC ACIDS RES, V28, P2268, DOI 10.1093/nar/28.11.2268; Kang JH, 2006, FEBS LETT, V580, P510, DOI 10.1016/j.febslet.2005.12.065; Kanies CL, 2008, MOL CANCER RES, V6, P1124, DOI 10.1158/1541-7786.MCR-07-2095; Kawauchi J, 2008, GENE DEV, V22, P1082, DOI 10.1101/gad.463408; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Laderoute KR, 2000, CLIN CANCER RES, V6, P2941; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lau NC, 2009, BIOCHEM J, V422, P443, DOI 10.1042/BJ20090500; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1997, BBA-GENE STRUCT EXPR, V1352, P167, DOI 10.1016/S0167-4781(97)00052-3; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lingen MW, 2003, METH MOLEC MED, V78, P337; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Moore MJ, 2002, CELL, V108, P431, DOI 10.1016/S0092-8674(02)00645-1; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Neugebauer KM, 2002, J CELL SCI, V115, P3865, DOI 10.1242/jcs.00073; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Okamoto M, 2002, BBA-GENE STRUCT EXPR, V1574, P24, DOI 10.1016/S0167-4781(01)00345-1; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; Qiu Y, 2009, BIOCHEM SOC T, V37, P1207, DOI 10.1042/BST0371207; Quesada AR, 2007, BIOESSAYS, V29, P1159, DOI 10.1002/bies.20655; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Richard P, 2009, GENE DEV, V23, P1247, DOI 10.1101/gad.1792809; Robinson CJ, 2001, J CELL SCI, V114, P853; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Teixeira A, 2004, NATURE, V432, P526, DOI 10.1038/nature03032; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; Vasudevan S, 2003, CURR OPIN CELL BIOL, V15, P332, DOI 10.1016/S0955-0674(03)00051-6; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; West S, 2004, NATURE, V432, P522, DOI 10.1038/nature03035; Yamazaki Y, 2006, MOL DIVERS, V10, P515, DOI 10.1007/s11030-006-9027-3; Zhou GL, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-74; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	79	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4377	4386		10.1038/onc.2012.464	http://dx.doi.org/10.1038/onc.2012.464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085760	Green Accepted			2022-12-17	WOS:000324404200006
J	Garcia, AG; Nedev, H; Bijian, K; Su, J; Alaoui-Jamali, MA; Saragovi, HU				Garcia, A. Galan; Nedev, H.; Bijian, K.; Su, J.; Alaoui-Jamali, M. A.; Saragovi, H. U.			Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs	ONCOGENE			English	Article						therapeutic window; chemotherapy; herceptin; conjugate; metastasis	MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; DOXORUBICIN; RESISTANCE; HER2; TRASTUZUMAB; EFFICACY; RECEPTOR; THERAPY; MECHANISMS	Anthracyclines and taxanes have remarkable anticancer efficacy, but have poor selectivity and high toxicity. Targeted delivery of chemotherapeutics has emerged as a strategy to achieve higher drug levels at the tumor site, to spare noncancerous tissue and potentially to use lower systemic drug doses, thus preventing side effects. In this study, we targeted the HER2 receptor using the monoclonal antibody (mAb) Herceptin (Trastuzumab) chemically conjugated to Doxorubicin or Taxol. In vitro, drug-Herceptin conjugates exhibited cytotoxicity comparable to equimolar concentrations of free drugs, with the benefit that the cytotoxicity of the conjugates was selective for cells expressing the HER2 target. In vivo, treatment of tumor-bearing mice with Taxol-Herceptin conjugates had a reduction of primary tumors comparable to equivalent doses of free drugs. However, Taxol-Herceptin conjugates significantly reduced metastasis compared with equivalent doses of free drugs. Thus, the data support the concept that conjugates might target metastasis better than primary tumors. This would offer a potential therapeutic approach for management of metastatic breast cancer.	[Garcia, A. Galan; Nedev, H.; Bijian, K.; Su, J.; Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; [Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3T 1E2, Canada; [Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Dept Oncol, Montreal, PQ H3T 1E2, Canada; [Alaoui-Jamali, M. A.; Saragovi, H. U.] McGill Univ, Ctr Canc, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Saragovi, HU (corresponding author), McGill Univ, Jewish Gen Hosp, Lady Davis Inst, 3755 Cote St Catherine E 535, Montreal, PQ H3T 1E2, Canada.	uri.saragovi@mcgill.ca			McGill Center for Experimental Therapeutics in Cancer Fund; Canadian Institutes of Health Research (CIHR); Quebec Breast Cancer Foundation	McGill Center for Experimental Therapeutics in Cancer Fund; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Quebec Breast Cancer Foundation	We are thankful to Amrit Kirpalani for help with in vivo assays. This work was funded by the McGill Center for Experimental Therapeutics in Cancer Fund to Cure Breast Cancer, and by the Canadian Institutes of Health Research (CIHR), and in part by the Quebec Breast Cancer Foundation.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Alley SC, 2010, CURR OPIN CHEM BIOL, V14, P529, DOI 10.1016/j.cbpa.2010.06.170; Anhorn MG, 2008, BIOCONJUGATE CHEM, V19, P2321, DOI 10.1021/bc8002452; Barros FFT, 2010, HISTOPATHOLOGY, V56, P560, DOI 10.1111/j.1365-2559.2010.03494.x; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; da Rocha Adriana B., 2001, Current Opinion in Pharmacology, V1, P364; Danesi R, 2002, CLIN PHARMACOKINET, V41, P431, DOI 10.2165/00003088-200241060-00004; de Azambuja E, 2009, TARGET ONCOL, V4, P77, DOI 10.1007/s11523-009-0112-2; Dean-Colomb W, 2008, EUR J CANCER, V44, P2806, DOI 10.1016/j.ejca.2008.09.013; El Bayoumil T, 2009, CLIN CANCER RES, V15, P1973, DOI 10.1158/1078-0432.CCR-08-2392; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Guillemard V, 2005, DNA CELL BIOL, V24, P350, DOI 10.1089/dna.2005.24.351; Guillemard V, 2004, CURR CANCER DRUG TAR, V4, P313, DOI 10.2174/1568009043332989; Guillemard V, 2004, ONCOGENE, V23, P3613, DOI 10.1038/sj.onc.1207463; Guillemard V, 2001, CANCER RES, V61, P694; Harris M, 2004, LANCET ONCOL, V5, P292, DOI 10.1016/S1470-2045(04)01467-6; KATO H, 1993, J BIOL CHEM, V268, P2655; Kojic LD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003597; Krop IE, 2010, J CLIN ONCOL, V28, P2698, DOI 10.1200/JCO.2009.26.2071; Lyass O, 2000, CANCER, V89, P1037, DOI 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z; MENZIN AW, 1994, GYNECOL ONCOL, V54, P103; Monneret C, 2001, EUR J MED CHEM, V36, P483, DOI 10.1016/S0223-5234(01)01244-2; Nabholtz JM, 2005, EXPERT OPIN PHARMACO, V6, P1073, DOI 10.1517/14656566.6.7.1073; Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509; Omelyanenko V, 1996, J DRUG TARGET, V3, P357, DOI 10.3109/10611869608996827; Paik S, 2000, J NATL CANCER I, V92, P1991, DOI 10.1093/jnci/92.24.1991; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Rayson D, 2008, ANN ONCOL, V19, P1530, DOI 10.1093/annonc/mdn292; Reichert JM, 2008, CURR PHARM BIOTECHNO, V9, P423, DOI 10.2174/138920108786786358; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stan AC, 1999, CANCER RES, V59, P115; Stockmeyer B, 2003, J IMMUNOL, V171, P5124, DOI 10.4049/jimmunol.171.10.5124; Tai WY, 2010, J CONTROL RELEASE, V146, P264, DOI 10.1016/j.jconrel.2010.04.009; TEWEY KM, 1984, J BIOL CHEM, V259, P9182; Tubiana-Hulin M, 2005, CANCER TREAT REV, V31, pS3, DOI 10.1016/S0305-7372(05)80002-7; Windebank AJ, 1999, CURR OPIN NEUROL, V12, P565, DOI 10.1097/00019052-199910000-00010; Xu Y, 2009, BRIT J CANCER, V100, P633, DOI 10.1038/sj.bjc.6604901; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2001, SEMIN ONCOL, V28, P12	46	7	9	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2527	2533		10.1038/onc.2012.283	http://dx.doi.org/10.1038/onc.2012.283			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22797066				2022-12-17	WOS:000319274300004
J	Choi, JD; Ryu, M; Park, MA; Jeong, G; Lee, JS				Choi, J. D.; Ryu, M.; Park, M. Ae; Jeong, G.; Lee, J-S			FIP200 inhibits beta-catenin-mediated transcription by promoting APC-independent beta-catenin ubiquitination	ONCOGENE			English	Article						FIP200; beta-catenin; ubiquitination	BINDING MOTIF; PROTEIN; COMPLEX; RB1CC1; PHOSPHORYLATION; IDENTIFICATION; DEGRADATION; SUPPRESSION; MODULATION; MUTATIONS	Focal adhesion kinase-family-interacting protein of 200 kDa (FIP200) has been shown to regulate multiple cellular functions, including cell adhesion, autophagy, development and proliferation. Furthermore, FIP200 is considered to have tumor-suppressive activity, which may be correlated with its inactivation in human breast cancers, in addition to its role as an important signal transduction node. Herein, we report that FIP200 interacts with the oncoprotein beta-catenin. Moreover, FIP200 promotes destabilization of wild-type beta-catenin, but not a cancer-causing form of beta-catenin, and as a result represses the beta-catenin-mediated transcription. FIP200-induced degradation of beta-catenin is independent of adenomatous polyposis coli (APC) of the well-established beta-catenin destruction complex (glycogen synthase kinase-3b/axin/APC), in a component of beta-catenin E3 ubiquitin ligase, beta-TrCP-dependent manner. Thus, the APC-independent beta-catenin degradation by FIP200 suggests a role for FIP200 in tumor suppression in the presence of APC dysfunction. These findings reveal a new and important function of FIP200 in regulation of the Wnt/beta-catenin pathway.	[Choi, J. D.; Ryu, M.; Park, M. Ae; Lee, J-S] Ajou Univ, Coll Nat Sci, Dept Mol Sci & Technol, Suwon 443749, South Korea; [Choi, J. D.] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea	Ajou University; Seoul National University (SNU)	Lee, JS (corresponding author), Ajou Univ, Coll Nat Sci, Dept Mol Sci & Technol, Wonchun Dong 5, Suwon 443749, South Korea.	jsjlee@ajou.ac.kr			National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [1020210]; National Research Foundation of Korea [313-2008-2-C00626, 2009-0074556, 2010-0018546, 20110030830]	National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (1020210) and the National Research Foundation of Korea (313-2008-2-C00626, 2009-0074556, 2010-0018546 and 20110030830).	Abbi S, 2002, MOL BIOL CELL, V13, P3178, DOI 10.1091/mbc.E02-05-0295; Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bonvini P, 2000, BBA-MOL CELL RES, V1495, P308, DOI 10.1016/S0167-4889(99)00162-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chano T, 2002, GENE, V291, P29, DOI 10.1016/S0378-1119(02)00585-1; Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911; Chano T, 2002, ONCOGENE, V21, P1295, DOI 10.1038/sj.onc.1205178; Chano T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011404; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Gan B, 2008, CELL SIGNAL, V20, P787, DOI 10.1016/j.cellsig.2007.10.021; Gan BY, 2006, J CELL BIOL, V175, P121, DOI 10.1083/jcb.200604129; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Grigoryan T, 2008, GENE DEV, V22, P2308, DOI 10.1101/gad.1686208; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hofmann K, 2009, DNA REPAIR, V8, P544, DOI 10.1016/j.dnarep.2009.01.003; Jang ER, 2011, FEBS LETT, V585, P47, DOI 10.1016/j.febslet.2010.11.034; Koinuma D, 2011, J BIOL CHEM, V286, P32502, DOI 10.1074/jbc.M111.227561; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liang CC, 2010, J BIOL CHEM, V285, P3499, DOI 10.1074/jbc.M109.072389; Liu F, 2010, BLOOD, V116, P4806, DOI 10.1182/blood-2010-06-288589; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martin N, 2008, MOL CELL BIOL, V28, P2771, DOI 10.1128/MCB.01210-07; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Park MA, 2008, NUCLEIC ACIDS RES, V36, P263, DOI 10.1093/nar/gkm969; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Polakis P, 2000, GENE DEV, V14, P1837; Sabbioneda S, 2009, P NATL ACAD SCI USA, V106, pE20, DOI 10.1073/pnas.0812744106; Sukhdeo K, 2012, LEUKEMIA, V26, P1116, DOI 10.1038/leu.2011.303; Ueda H, 2000, J CELL BIOL, V149, P423, DOI 10.1083/jcb.149.2.423; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; Wei HJ, 2009, J BIOL CHEM, V284, P6004, DOI 10.1074/jbc.M806375200; Wood A, 2007, J BIOL CHEM, V282, P20256, DOI 10.1074/jbc.M702366200; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200	43	7	7	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2421	2432		10.1038/onc.2012.262	http://dx.doi.org/10.1038/onc.2012.262			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751121				2022-12-17	WOS:000318694900006
J	Wagner, KU; Booth, BW; Boulanger, CA; Smith, GH				Wagner, K-U; Booth, B. W.; Boulanger, C. A.; Smith, G. H.			Multipotent PI-MECs are the true targets of MMTV-neu tumorigenesis	ONCOGENE			English	Letter							MAMMARY EPITHELIAL-CELLS; STEM		[Wagner, K-U] Univ Nebraska Med Ctr, Omaha, NE 68198 USA; [Booth, B. W.] Clemson Univ, Clemson, NC USA; [Boulanger, C. A.; Smith, G. H.] NCI, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Medical Center; Clemson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wagner, KU (corresponding author), Univ Nebraska Med Ctr, Omaha, NE 68198 USA.	gs4d@nih.gov	Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226	NATIONAL CANCER INSTITUTE [ZIABC010021] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Booth BW, 2011, ONCOGENE, V30, P679, DOI 10.1038/onc.2010.439; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017	6	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1338	1338		10.1038/onc.2012.452	http://dx.doi.org/10.1038/onc.2012.452			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	23045277				2022-12-17	WOS:000316454500014
J	Brennan, DJ; O'Connor, DP; Laursen, H; McGee, SF; McCarthy, S; Zagozdzon, R; Rexhepaj, E; Culhane, AC; Martin, FM; Duffy, MJ; Landberg, G; Ryden, L; Hewitt, SM; Kuhar, MJ; Bernards, R; Millikan, RC; Crown, JP; Jirstrom, K; Gallagher, WM				Brennan, D. J.; O'Connor, D. P.; Laursen, H.; McGee, S. F.; McCarthy, S.; Zagozdzon, R.; Rexhepaj, E.; Culhane, A. C.; Martin, F. M.; Duffy, M. J.; Landberg, G.; Ryden, L.; Hewitt, S. M.; Kuhar, M. J.; Bernards, R.; Millikan, R. C.; Crown, J. P.; Jirstrom, K.; Gallagher, W. M.			The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ER alpha, and is an independent prognostic factor in node-negative breast cancer	ONCOGENE			English	Article						cocaine- and amphetamine-regulated transcript; breast cancer; prognosis; estrogen receptor	NERVE GROWTH-FACTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; CART PEPTIDES; PHOSPHORYLATION; TAMOXIFEN; PROTEIN; TRIAL; SERINE-118; THERAPY	Personalized medicine requires the identification of unambiguous prognostic and predictive biomarkers to inform therapeutic decisions. Within this context, the management of lymph node-negative breast cancer is the subject of much debate with particular emphasis on the requirement for adjuvant chemotherapy. The identification of prognostic and predictive biomarkers in this group of patients is crucial. Here, we demonstrate by tissue microarray and automated image analysis that the cocaine- and amphetamine-regulated transcript (CART) is expressed in primary and metastatic breast cancer and is an independent poor prognostic factor in estrogen receptor (ER)-positive, lymph node-negative tumors in two separate breast cancer cohorts (n = 690; P = 0.002, 0.013). We also show that CART increases the transcriptional activity of ER alpha in a ligand-independent manner via the mitogen-activated protein kinase pathway and that CART stimulates an autocrine/paracrine loop within tumor cells to amplify the CART signal. Additionally, we demonstrate that CART expression in ER-positive breast cancer cell lines protects against tamoxifen-mediated cell death and that high CART expression predicts disease outcome in tamoxifen-treated patients in vivo in three independent breast cancer cohorts. We believe that CART profiling will help facilitate stratification of lymph node-negative breast cancer patients into high- and low-risk categories and allow for the personalization of therapy. Oncogene (2012) 31, 3483-3494; doi:10.1038/onc.2011.519; published online 5 December 2011	[Brennan, D. J.; O'Connor, D. P.; Laursen, H.; McGee, S. F.; McCarthy, S.; Zagozdzon, R.; Rexhepaj, E.; Martin, F. M.; Gallagher, W. M.] Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland; [Culhane, A. C.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biost & Computat Biol, Boston, MA 02115 USA; [Duffy, M. J.] Univ Coll Dublin, UCD Sch Med & Med Sci, UCD Conway Inst, Dublin 2, Ireland; [Duffy, M. J.] St Vincents Univ Hosp, Dept Pathol & Lab Med, Dublin 4, Ireland; [Landberg, G.] Lund Univ, Skane Univ Hosp, Ctr Mol Pathol, Dept Lab Med, Malmo, Sweden; [Hewitt, S. M.] NCI, Tissue Array Res Program, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Kuhar, M. J.] Emory Univ, Yerkes Natl Primate Res Ctr, Div Neurosci, Atlanta, GA 30322 USA; [Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; [Millikan, R. C.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Crown, J. P.] St Vincents Univ Hosp, Dublin 4, Ireland; [Ryden, L.] Lund Univ, Div Surg, Skane Univ Hosp, Dept Clin Sci, Lund, Sweden; [Jirstrom, K.] Lund Univ, Skane Univ Hosp, Div Pathol, Dept Clin Sci, Lund, Sweden	University College Dublin; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health; University College Dublin; University College Dublin; Saint Vincent's University Hospital; Lund University; Skane University Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University; Netherlands Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University College Dublin; Saint Vincent's University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital	Gallagher, WM (corresponding author), Univ Coll Dublin, UCD Conway Inst, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	william.gallagher@ucd.ie	McCarthy, Sarah/HCI-8963-2022; Duffy, Michael/J-5610-2019; Crown, John/AAL-3367-2020; Zagozdzon, Radoslaw/AAC-4298-2019; Culhane, Aedin/AAG-8490-2019; Zagozdzon, Radoslaw/K-2141-2012	Duffy, Michael/0000-0002-9259-6619; Zagozdzon, Radoslaw/0000-0002-7957-2372; Culhane, Aedin/0000-0002-1395-9734; O'Connor, Darran/0000-0002-8835-1547; Hewitt, Stephen/0000-0001-8283-1788; Bernards, Rene/0000-0001-8677-3423; Brennan, Donal/0000-0002-6747-3342; Gallagher, William/0000-0002-4307-5999	Program for Third Level Institutions; Health Research Board of Ireland; Enterprise Ireland; Science Foundation Ireland [08/SRC/B1410]; European Community [224865];  [RR00165]; NATIONAL CANCER INSTITUTE [ZICBC010923, P50CA058223] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010732] Funding Source: NIH RePORTER	Program for Third Level Institutions; Health Research Board of Ireland; Enterprise Ireland; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); European Community(European Commission); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The UCD Conway Institute is funded by the Program for Third Level Institutions, as administered by the Higher Education Authority of Ireland. Funding is acknowledged from the Health Research Board of Ireland, Enterprise Ireland and the Science Foundation Ireland Strategic Research Cluster award to Molecular Therapeutics for Cancer Ireland (08/SRC/B1410). The work of Dr R Zagozdzon has been supported by a Marie Curie International Reintegration Grant no. 224865 within the 7th European Community Framework Program. Dr MJ Kuhar is funded by RR00165.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Adriaenssens E, 2008, CANCER RES, V68, P346, DOI 10.1158/0008-5472.CAN-07-1183; Arora S, 2006, NEUROPEPTIDES, V40, P375, DOI 10.1016/j.npep.2006.07.001; Bech P, 2008, J CLIN ENDOCR METAB, V93, P1246, DOI 10.1210/jc.2007-1946; Borgquist S, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2146; Brennan DJ, 2008, CLIN CANCER RES, V14, P2681, DOI 10.1158/1078-0432.CCR-07-1760; Brennan DJ, 2006, CLIN CANCER RES, V12, P6421, DOI 10.1158/1078-0432.CCR-06-0480; Brennan DJ, 2010, NAT REV CANCER, V10, P605, DOI 10.1038/nrc2902; Cardoso F, 2008, J CLIN ONCOL, V26, P729, DOI 10.1200/JCO.2007.14.3222; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chanrion M, 2008, CLIN CANCER RES, V14, P1744, DOI 10.1158/1078-0432.CCR-07-1833; Cheng JW, 2007, ENDOCRINOLOGY, V148, P4634, DOI 10.1210/en.2007-0148; Clarke M, 1998, LANCET, V351, P1451; Dolle L, 2004, CURR CANCER DRUG TAR, V4, P463, DOI 10.2174/1568009043332853; Dominguez G, 2004, MOL BRAIN RES, V126, P22, DOI 10.1016/j.molbrainres.2004.02.027; Dominguez G, 2006, PEPTIDES, V27, P1913, DOI 10.1016/j.peptides.2006.01.025; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Epping MT, 2007, P NATL ACAD SCI USA, V104, P17777, DOI 10.1073/pnas.0702518104; Goldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Jia J, 2008, NEUROPEPTIDES, V42, P653, DOI 10.1016/j.npep.2008.05.006; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keegan BP, 2006, BREAST CANCER RES TR, V95, P265, DOI 10.1007/s10549-005-9024-8; Koylu EO, 1997, J NEUROENDOCRINOL, V9, P823, DOI 10.1046/j.1365-2826.1997.00651.x; Koylu EO, 2006, PEPTIDES, V27, P1956, DOI 10.1016/j.peptides.2006.03.032; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lakatos A, 2005, NEUROSCI LETT, V384, P198, DOI 10.1016/j.neulet.2005.04.072; Mantzoros CS, 1999, INT J CANCER, V80, P523, DOI 10.1002/(SICI)1097-0215(19990209)80:4<523::AID-IJC7>3.0.CO;2-C; O'Brien SL, 2007, INT J CANCER, V120, P1434, DOI 10.1002/ijc.22413; Rogge G, 2008, NAT REV NEUROSCI, V9, P747, DOI 10.1038/nrn2493; Ruscica M, 2007, PEPTIDES, V28, P426, DOI 10.1016/j.peptides.2006.08.045; Ryden L, 2005, EUR J CANCER, V41, P256, DOI 10.1016/j.ejca.2004.06.030; Ryden L, 2003, BREAST CANCER RES TR, V82, P147, DOI 10.1023/B:BREA.0000004357.92232.cb; Sen A, 2008, MOL ENDOCRINOL, V22, P2655, DOI 10.1210/me.2008-0077; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; TAYLOR AH, 1990, CANCER RES, V50, P7882; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Yamashita H, 2008, ENDOCR-RELAT CANCER, V15, P755, DOI 10.1677/ERC-08-0078; Zoubir M, 2008, ANN ONCOL, V19, P1402, DOI 10.1093/annonc/mdn151; Zujewski JA, 2008, FUTURE ONCOL, V4, P603, DOI 10.2217/14796694.4.5.603; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	43	7	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3483	3494		10.1038/onc.2011.519	http://dx.doi.org/10.1038/onc.2011.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22139072	Green Accepted, Green Submitted			2022-12-17	WOS:000306844100001
J	Chen, X; Zhang, H; Aravindakshan, JP; Gotlieb, WH; Sairam, MR				Chen, X.; Zhang, H.; Aravindakshan, J. P.; Gotlieb, W. H.; Sairam, M. R.			Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization	ONCOGENE			English	Article						ovarian cancer; tumor suppressor; splicing; G2 arrest; apoptosis; drug sensitivity	CARCINOMA CELL-LINE; CANCER CELLS; INDUCE APOPTOSIS; INHIBITS GROWTH; FSH RECEPTOR; FORKO MICE; CIDE-B; EXPRESSION; MODEL; SUPPRESSOR	In studying the age dependence and chronology of ovarian tumors in follicle stimulating hormone receptor knockout mice, we identified a novel ovarian tumor associated gene-12 (OTAG-12), which is progressively downregulated and maps to Chr. 8B3.3. OTAG-12 protein overexpression in mouse ovarian and mammary tumor cells suggested powerful anti-proliferative effects. In human epithelial ovarian cancers (OCs) and OC cell lines, OTAG-12 mRNA expression is downregulated in comparison with normal ovaries. Cloning and identification revealed that human OTAG-12 mapping to gene-rich Chr. 19p13.12 is expressed in three spliced forms: hOTAG-12a, hOTAG-12b and hOTAG-12c, of which b is predominant in the normal ovary. Functionally active hOTAG-12b is a simple protein with no disulfide bonds and a nuclear localization signal is present in all variants. Transfection of OTAG-12 variants in OC and tumorigenic HEK293 cells confirmed nuclear localization. hOTAG-12b overexpression in OC and HEK293 cells effectively suppressed cell growth, anchorage-dependent and independent colony formation followed by apoptosis, whereas hOTAG-12a and hOTAG-12c had no such effects. Deletion mutants identified the critical importance of carboxyl terminus for hOTAG-12b function. Doxycycline-inducible growth inhibition of HEK293 cells by hOTAG-12a was associated with effects on G2 cell cycle arrest and apoptosis induction. hOTAG-12b expression rendered tumorigenic cells more sensitive to four apoptotic stimuli including etoposide-a topoisomerase-II inhibitor. Doxycycline-induced hOTAG-12b expression blocked xenograft tumor growth in nude mice, whereas hOTAG-12a was ineffective. Although p53-pathway-dependent apoptotic agents could upregulate endogenous hOTAG-12b and p53 in UCI-101/107 OC cells, hOTAG-12b could also induce apoptosis in p53-null and platinum-resistant SKOV3 OC cells and Doxycycline-induced hOTAG-12b did not alter p53. Further study showed that hOTAG-12b increases mRNAs of pro-apoptotic genes such as BAD, GADD45 alpha and CIEDB, while inhibiting anti-apoptotic NAIP and Akt1 expression, suggesting that hOTAG-12b-induced apoptosis might be p53-independent. These results indicate that hOTAG-12b is a putative ovarian tumor suppressor gene warranting further studies. Oncogene (2011) 30, 2874-2887; doi:10.1038/onc.2011.11; published online 21 February 2011	[Chen, X.; Zhang, H.; Aravindakshan, J. P.; Sairam, M. R.] Clin Res Inst Montreal, Mol Endocrinol Lab, Montreal, PQ H2W 1R7, Canada; [Gotlieb, W. H.] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada; [Sairam, M. R.] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Sairam, M. R.] McGill Univ, Dept Med, Div Expt Med, Montreal, PQ, Canada; [Sairam, M. R.] McGill Univ, Dept Physiol, Montreal, PQ, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal; McGill University; McGill University	Sairam, MR (corresponding author), Clin Res Inst Montreal, Mol Endocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	sairamm@ircm.qc.ca			NCIC; CIHR	NCIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CIHR(Canadian Institutes of Health Research (CIHR))	We are grateful to Dr P Carpenter (UC Irvine) for providing ovarian cancer cell lines UCI101 and UCI107, Dr Roby KF (Univ Kansas) for ID8 cells, Drs Jolicoeur for HC11-26 cells and Seidah at IRCM for the modified HEK293 cell lines. We appreciate the useful suggestions provided by Drs Zhongjun Dong and Hua Lin during this investigation. We also acknowledge the help of Drs Marie-Claude Beauchamp and Amber Yasmeen in this study. This investigation was supported in part by the NCIC and the CIHR.	Al-Romaih K, 2008, NEOPLASIA, V10, P471, DOI 10.1593/neo.08174; Allen S, 2001, CLIN DIAGN LAB IMMUN, V8, P460, DOI 10.1128/CDLI.8.2.460-464.2001; Aravindakshan J, 2006, BIOCHEM BIOPH RES CO, V351, P507, DOI 10.1016/j.bbrc.2006.10.069; Aravindakshan J, 2010, MOL CELL ENDOCRINOL, V329, P37, DOI 10.1016/j.mce.2010.05.015; Aravindakshan J, 2006, NEOPLASIA, V8, P984, DOI 10.1593/neo.06529; Barnes BJ, 2003, CANCER RES, V63, P6424; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bignone PA, 2007, ONCOGENE, V26, P683, DOI 10.1038/sj.onc.1209827; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; Bruening W, 1999, CANCER RES, V59, P4973; Chen F, 2001, ONCOGENE, V20, P3585, DOI 10.1038/sj.onc.1204442; Chen XL, 2007, NEOPLASIA, V9, P521, DOI 10.1593/neo.07238; Chen XL, 2006, CARCINOGENESIS, V27, P903, DOI 10.1093/carcin/bgi305; Chen ZM, 2000, J BIOL CHEM, V275, P22619, DOI 10.1074/jbc.C000207200; Corney DC, 2008, ADV EXP MED BIOL, V622, P99, DOI 10.1007/978-0-387-68969-2_9; Dai Y, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-392; Danilovich N, 2001, ENDOCRINOLOGY, V142, P3673, DOI 10.1210/en.142.8.3673; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; FUCHTNER C, 1993, GYNECOL ONCOL, V48, P203, DOI 10.1006/gyno.1993.1034; GAMBOA G, 1995, GYNECOL ONCOL, V58, P336, DOI 10.1006/gyno.1995.1239; Grimwood J, 2004, NATURE, V428, P529, DOI 10.1038/nature02399; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jarboe EA, 2008, HISTOPATHOLOGY, V53, P127, DOI 10.1111/j.1365-2559.2007.02938.x; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129; Nowak-Markwitz E, 2004, EUR J GYNAECOL ONCOL, V25, P465; O'Riordan MXD, 2008, DEV CELL, V15, P497, DOI 10.1016/j.devcel.2008.09.012; Pal T, 2005, CANCER-AM CANCER SOC, V104, P2807, DOI 10.1002/cncr.21536; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Schwartz MF, 2003, CELL CYCLE, V2, P384, DOI 10.4161/cc.2.4.457; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Wagner MW, 2008, J BIOL CHEM, V283, P21382, DOI 10.1074/jbc.M709953200; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Wu ZZ, 2005, J LIPID RES, V46, P1396, DOI 10.1194/jlr.M500071-JLR200; Yan XJ, 2006, GYNECOL ONCOL, V102, P348, DOI 10.1016/j.ygyno.2005.12.033; Yin BWT, 2002, INT J CANCER, V98, P737, DOI 10.1002/ijc.10250; Zhu QS, 2008, CANCER RES, V68, P2895, DOI 10.1158/0008-5472.CAN-07-6268	46	7	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	25					2874	2887		10.1038/onc.2011.11	http://dx.doi.org/10.1038/onc.2011.11			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21339736				2022-12-17	WOS:000291977800007
J	Melis, JPM; Hoogervorst, EM; van Oostrom, CTM; Zwart, E; Breit, TM; Pennings, JLA; de Vries, A; van Steeg, H				Melis, J. P. M.; Hoogervorst, E. M.; van Oostrom, C. T. M.; Zwart, E.; Breit, T. M.; Pennings, J. L. A.; de Vries, A.; van Steeg, H.			Genotoxic exposure: novel cause of selection for a functional Delta N-p53 isoform	ONCOGENE			English	Article						DNA damage; gene expression; N-terminal p53 isoform (Delta N-p53, p44, p47); nonsense mutations; mouse urinary bladder tumor	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; MOUSE MODELS; MUTANT P53; EXTRACELLULAR-MATRIX; CANCER; MUTATIONS; MICE; TRANSLATION; INDUCTION	The p53 gene is frequently mutated in cancers and it is vital for cell cycle control, homeostasis and carcinogenesis. We describe a novel p53 mutational spectrum, different to those generally observed in human and murine tumors. Our study shows a high prevalence of nonsense mutations in the p53 N terminus of 2-acetylaminofluorene (2-AAF)-induced urinary bladder tumors. These nonsense mutations forced downstream translation initiation at codon 41 of Trp53, resulting in the aberrant expression of the p53 isoform Delta N-p53 (or p44). We propose a novel mechanism for the origination and the selection for this isoform. We show that chemical exposure can act as a novel cause of selection for this truncated protein. In addition, our data suggest that the occurrence of Delta N-p53 accounts, at least in mice, for a cancer phenotype. We also show that gene expression profiles of embryonic stem (ES) cells carrying the Delta N-p53 isoform in a p53-null background are divergent from p53 knockout ES cells, and therefore postulate that Delta N-p53 itself has functional transcriptional properties. Oncogene (2011) 30, 1764-1772; doi:10.1038/onc.2010.552; published online 13 December 2010	[Melis, J. P. M.; Hoogervorst, E. M.; van Oostrom, C. T. M.; Zwart, E.; Pennings, J. L. A.; de Vries, A.; van Steeg, H.] Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, NL-3720 BA Utrecht, Netherlands; [Breit, T. M.] Univ Amsterdam, Fac Sci, MicroArray Dept, Amsterdam, Netherlands	Netherlands National Institute for Public Health & the Environment; University of Amsterdam	van Steeg, H (corresponding author), Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, POB 1, NL-3720 BA Utrecht, Netherlands.	Harry.van.Steeg@rivm.nl		Pennings, Jeroen L.A./0000-0002-9188-6358	NIH/NIEHS (Comparative Mouse Genomics Centers Consortium) [1UO1 ES11044]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011044] Funding Source: NIH RePORTER	NIH/NIEHS (Comparative Mouse Genomics Centers Consortium)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank the Animal Facilities of the Netherlands Vaccine Institute (NVI) for their skillful (bio)technical support. The work presented here was in part financially supported by NIH/NIEHS (Comparative Mouse Genomics Centers Consortium) Grant 1UO1 ES11044.	Bruins W, 2004, MOL CELL BIOL, V24, P8884, DOI 10.1128/mcb.24.20.8884-8894.2004; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; de Leeuw Wim C, 2008, BMC Res Notes, V1, P66, DOI 10.1186/1756-0500-1-66; de Vries A, 2002, P NATL ACAD SCI USA, V99, P2948, DOI 10.1073/pnas.052713099; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Denys H, 2009, CURR PHARM DESIGN, V15, P1373, DOI 10.2174/138161209787846711; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Grover R, 2009, ONCOGENE, V28, P2766, DOI 10.1038/onc.2009.138; Hailfinger S, 2007, INT J CANCER, V120, P1459, DOI 10.1002/ijc.22519; Heinlein C, 2008, INT J CANCER, V122, P1701, DOI 10.1002/ijc.23317; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hoogervorst EM, 2005, MUTAT RES-FUND MOL M, V574, P3, DOI 10.1016/j.mrfmmm.2005.01.018; Hoogervorst EM, 2005, CANCER RES, V65, P3610, DOI 10.1158/0008-5472.CAN-04-4328; Hoogervorst EM, 2004, CANCER RES, V64, P5118, DOI 10.1158/0008-5472.CAN-04-0350; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Iwakuma T, 2007, ONCOGENE, V26, P2177, DOI 10.1038/sj.onc.1210278; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335; Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Marcel V, 2009, CELL MOL LIFE SCI, V66, P391, DOI 10.1007/s00018-008-8336-3; Matheu A, 2008, CANCER RES, V68, P6031, DOI 10.1158/0008-5472.CAN-07-6851; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Ross JA, 1998, MUTAGENESIS, V13, P173, DOI 10.1093/mutage/13.2.173; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; Wijnhoven SWP, 2005, CANCER RES, V65, P8166, DOI 10.1158/0008-5472.CAN-05-1650; Xu Y, 2008, ONCOGENE, V27, P3501, DOI 10.1038/sj.onc.1211023; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	40	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	15					1764	1772		10.1038/onc.2010.552	http://dx.doi.org/10.1038/onc.2010.552			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	749ZM	21151170				2022-12-17	WOS:000289512200004
J	Zheng, J; Machida, K; Antoku, S; Ng, KY; Claffey, KP; Mayer, BJ				Zheng, J.; Machida, K.; Antoku, S.; Ng, K. Y.; Claffey, K. P.; Mayer, B. J.			Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation	ONCOGENE			English	Article						SH3 domain; SH2/SH3 adaptor; Abl family kinase; SOS1; C3G	PHOSPHOINOSITIDE 3-KINASE/AKT PATHWAY; NUCLEOTIDE-RELEASING FACTOR; FOCAL ADHESION KINASE; ABL TYROSINE KINASE; V-CRK; ADAPTER PROTEIN; MALIGNANT FEATURE; CELL-MIGRATION; POSITIVE CELLS; SH3 DOMAIN	The v-Crk oncogene product consists of two protein interaction modules, a Src homology 2 (SH2) domain and a Src homology 3 (SH3) domain. Overexpression of CrkI, the cellular homolog of v-Crk, transforms mouse fibroblasts, and elevated CrkI expression is observed in several human cancers. The SH2 and SH3 domains of Crk are required for transformation, but the identity of the critical cellular binding partners is not known. A number of candidate Crk SH3-binding proteins have been identified, including the nonreceptor tyrosine kinases c-Abl and Arg, and the guanine nucleotide exchange proteins C3G, SOS1 and DOCK180. The aim of this study is to determine which of these are required for transformation by CrkI. We found that short hairpin RNA-mediated knockdown of C3G or SOS1 suppressed anchorage-independent growth of NIH-3T3 cells over-expressing CrkI, whereas knockdown of SOS1 alone was sufficient to suppress tumor formation by these cells in nude mice. Knockdown of C3G was sufficient to revert morphological changes induced by CrkI expression. By contrast, knockdown of Abl family kinases or their inhibition with imatinib enhanced anchorage-independent growth and tumorigenesis induced by Crk. These results show that SOS1 is essential for CrkI-induced fibroblast transformation, and also reveal a surprising negative role for Abl kinases in Crk transformation. Oncogene (2010) 29, 6378-6389; doi:10.1038/onc.2010.369; published online 23 August 2010	[Zheng, J.; Machida, K.; Antoku, S.; Ng, K. Y.; Mayer, B. J.] Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet & Mol Med, Farmington, CT 06030 USA; [Claffey, K. P.] Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Farmington, CT 06030 USA; [Claffey, K. P.] Univ Connecticut, Ctr Hlth, Dept Cell Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut; University of Connecticut	Mayer, BJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet & Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.	bmayer@neuron.uchc.edu			National Institutes of Health [CA82258, CA064436]; NATIONAL CANCER INSTITUTE [R01CA064436, R01CA082258, R29CA064436] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michiyuki Matsuda (Kyoto University) for providing the shRNAs targeting DOCK180 and the antibody against DOCK180, Dr Peter Davies (Albert Einstein College of Medicine) for Arg antibody and Novartis Pharmaceuticals for imatinib. We thank Kathryn Phoenix and Frank Vumbaca for the technical help. This work was supported by grants CA82258 (to BJM) and CA064436 (to KPC) from the National Institutes of Health.	Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Antoku S, 2009, J CELL SCI, V122, P4228, DOI 10.1242/jcs.054627; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Cipres A, 2007, CELL SIGNAL, V19, P1662, DOI 10.1016/j.cellsig.2007.02.011; Crawford M, 2008, BIOCHEM BIOPH RES CO, V373, P607, DOI 10.1016/j.bbrc.2008.06.090; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2009, NAT MED, V15, P1149, DOI 10.1038/nm1009-1149; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hemmeryckx B, 2001, CANCER RES, V61, P1398; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; Iwahara T, 2004, P NATL ACAD SCI USA, V101, P17693, DOI 10.1073/pnas.0408413102; Iwahara T, 2003, ONCOGENE, V22, P5946, DOI 10.1038/sj.onc.1206633; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Linghu H, 2006, ONCOGENE, V25, P3547, DOI 10.1038/sj.onc.1209398; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller CT, 2003, ONCOGENE, V22, P7950, DOI 10.1038/sj.onc.1206529; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Nievers MG, 1997, J CELL SCI, V110, P389; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Pendergast AM, 2002, ADV CANCER RES, V85, P51, DOI 10.1016/S0065-230X(02)85003-5; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Riggins RB, 2003, MOL CANCER RES, V1, P428; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Sharma A, 2004, PRIN PRACT, P165, DOI 10.1109/ICTTA.2004.1307673; Shishido T, 2001, GENES CELLS, V6, P431, DOI 10.1046/j.1365-2443.2001.00431.x; Stam JC, 2001, J BIOL CHEM, V276, P25176, DOI 10.1074/jbc.M009825200; Takino T, 2003, CANCER RES, V63, P2335; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Ui-Tei K, 2004, NUCLEIC ACIDS RES, V32, P936, DOI 10.1093/nar/gkh247; Wang BL, 1996, ONCOGENE, V13, P1379; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang L, 2007, BIOCHEM BIOPH RES CO, V362, P976, DOI 10.1016/j.bbrc.2007.08.106; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006	55	7	9	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	48					6378	6389		10.1038/onc.2010.369	http://dx.doi.org/10.1038/onc.2010.369			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	688SW	20729917	Green Accepted			2022-12-17	WOS:000284874700008
J	Debnath, J				Debnath, J.			p66(Shc) and Ras: controlling anoikis from the inside-out	ONCOGENE			English	Editorial Material							APOPTOSIS; DEATH; LIFE	Protection from detachment-induced cell death, termed anoikis, facilitates metastasis. Though anoikis is largely attributed to the loss of integrin-related 'outside-in' survival signals, Terada and colleagues demonstrate a novel 'insideout' attachment sensing role for the adapter protein p66(Shc) in promoting anoikis and suppressing metastasis via Ras-dependent control of proliferation and survival. Oncogene (2010) 29, 5556-5558; doi:10.1038/onc.2010.347; published online 16 August 2010	[Debnath, J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Debnath, J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Debnath, J (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW450B Box 0502, San Francisco, CA 94143 USA.	Jayanta.Debnath@ucsf.edu		Debnath, Jayanta/0000-0002-8745-4069	NCI NIH HHS [R01CA126792, CA126792-S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA126792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723; Ma Z, 2010, ONCOGENE, V29, P5559, DOI 10.1038/onc.2010.326; Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097; Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003; Pinton P, 2008, CELL CYCLE, V7, P304, DOI 10.4161/cc.7.3.5360; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537	10	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2010	29	41					5556	5558		10.1038/onc.2010.347	http://dx.doi.org/10.1038/onc.2010.347			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20711240				2022-12-17	WOS:000282946900002
J	Kaulfuss, S; von Hardenberg, S; Schweyer, S; Herr, AM; Laccone, F; Wolf, S; Burfeind, P				Kaulfuss, S.; von Hardenberg, S.; Schweyer, S.; Herr, A. M.; Laccone, F.; Wolf, S.; Burfeind, P.			Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression	ONCOGENE			English	Article						leupaxin; prostate cancer progression; p120CTN-mediated pathways	CELL-ADHESION PROTEINS; BETA-CATENIN; E-CADHERIN; MATRIX METALLOPROTEINASE-7; ANDROGEN RECEPTOR; FOCAL ADHESIONS; DOWN-REGULATION; ALPHA-CATENIN; LIM PROTEIN; CANCER	Recently, we could show that the focal adhesion protein leupaxin (LPXN) is expressed in human prostate carcinomas (PCa) and induces invasiveness of androgen-independent PCa cells. In this study we show that LPXN enhanced the progression of existing PCa in vivo by breeding transgenic mice with prostate-specific LPXN expression and TRAMP mice (transgenic adenocarcinoma of mouse prostate). Double transgenic LPXN/TRAMP mice showed a significant increase in poorly differentiated PCa and distant metastases as compared with control TRAMP mice. Additional studies on primary PCa cells generated from both transgenic backgrounds confirmed the connection regarding LPXN overexpression and increased motility and invasiveness of PCa cells. One mediator of LPXN-induced invasion was found to be the cell-cell adhesion protein p120catenin (p120CTN). Both in vitro and in vivo experiments revealed that p120CTN expression negatively correlates with LPXN expression, followed by a redistribution of beta-catenin. Downregulation of LPXN using small interfering RNAs (siRNAs) resulted in a membranous localization of beta-catenin, whereas strong nuclear accumulation of beta-catenin was observed in p120CTN knockdown cells leading to enhanced transcription of the beta-catenin target gene matrix metalloprotease-7. In conclusion, the present results indicate that LPXN enhances the progression of PCa through downregulation of p120CTN expression and that LPXN could function as a marker for aggressive PCa in the future. Oncogene (2009) 28, 3971-3982; doi:10.1038/onc.2009.254; published online 24 August 2009	[Kaulfuss, S.; von Hardenberg, S.; Herr, A. M.; Wolf, S.; Burfeind, P.] Univ Gottingen, Inst Human Genet, D-37073 Gottingen, Niedersachsen, Germany; [Schweyer, S.] Univ Gottingen, Dept Pathol, D-37073 Gottingen, Niedersachsen, Germany; [Laccone, F.] Med Univ Vienna, Dept Med Genet, Vienna, Austria	University of Gottingen; University of Gottingen; Medical University of Vienna	Kaulfuss, S (corresponding author), Univ Gottingen, Inst Human Genet, Heinrich Duker Weg 12, D-37073 Gottingen, Niedersachsen, Germany.	svoigt1@gwdg.de	Laccone, Franco A/B-3655-2018	Kaulfuss, Silke/0000-0003-2577-9711	Forschungs-forderungsprogramm of the Universitatsmedizin Gottingen; Deutsche Forschungsgemeinschaft [SK KA 2946/1-1]; Deutsche Krebshilfe [108065]; Horst Muggenburg and Gerhard Muggenburg-Stiftung	Forschungs-forderungsprogramm of the Universitatsmedizin Gottingen; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Horst Muggenburg and Gerhard Muggenburg-Stiftung	We thank R Kampe, B Konig and A Klages for their excellent technical assistance. We also thank M Schindler and H Riedesel for their assistance in generation of transgenic LPXN mice. This project was supported in part by the Forschungs-forderungsprogramm of the Universitatsmedizin Gottingen (to SK), by the Deutsche Forschungsgemeinschaft (to SK KA 2946/1-1), the Deutsche Krebshilfe (to PB and SS, no. 108065) and the Horst Muggenburg and Gerhard Muggenburg-Stiftung (to PB and SS).	ANASTASIADIS PZ, 2006, BIOCHIM BIOPHYS ACTA, V1773, P34; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bidard FC, 2008, CANCER METAST REV, V27, P5, DOI 10.1007/s10555-007-9103-x; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Deakin NO, 2009, J CELL SCI, V122, P1654, DOI 10.1242/jcs.049130; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Fuchs SY, 2005, CELL CYCLE, V4, P1522; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Grzmil M, 2003, AM J PATHOL, V163, P543, DOI 10.1016/S0002-9440(10)63682-6; Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016; Ii M, 2006, EXP BIOL MED, V231, P20; Jagadeeswaran R, 2008, CANCER RES, V68, P132, DOI 10.1158/0008-5472.CAN-07-1998; Jaggi M, 2005, UROL ONCOL-SEMIN ORI, V23, P402, DOI 10.1016/j.urolonc.2005.03.024; Jones LE, 2004, CLIN CANCER RES, V10, P2832, DOI 10.1158/1078-0432.CCR-1157-03; Kallakury BVS, 2001, CANCER, V92, P2786, DOI 10.1002/1097-0142(20011201)92:11<2786::AID-CNCR10128>3.0.CO;2-I; Kallakury BVS, 2001, HUM PATHOL, V32, P849, DOI 10.1053/hupa.2001.26463; Kasai M, 2003, CANCER RES, V63, P4927; Kaulfuss S, 2008, MOL ENDOCRINOL, V22, P1606, DOI 10.1210/me.2006-0546; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu SC, 2002, J BIOL CHEM, V277, P20887, DOI 10.1074/jbc.M110928200; MCDONNELL S, 1991, MOL CARCINOGEN, V4, P527, DOI 10.1002/mc.2940040617; Millikan RE, 2008, J CLIN ONCOL, V26, P5936, DOI 10.1200/JCO.2007.15.9830; Nong CZ, 2006, WORLD J GASTROENTERO, V12, P1187, DOI 10.3748/wjg.v12.i8.1187; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sahu SN, 2007, AM J PHYSIOL-CELL PH, V292, pC581, DOI 10.1152/ajpcell.00636.2005; Shibanuma M, 2004, J CELL BIOCHEM, V91, P633, DOI 10.1002/jcb.10754; Shibanuma M, 2003, MOL BIOL CELL, V14, P1158, DOI 10.1091/mbc.02-06-0099; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; van Oort IM, 2007, PROSTATE, V67, P1432, DOI 10.1002/pros.20626; Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200; Wang H, 2008, ONCOGENE, V27, P6791, DOI 10.1038/onc.2008.291; Wegener KL, 2008, MOL MEMBR BIOL, V25, P376, DOI 10.1080/09687680802269886; Whitaker HC, 2008, PROSTATE, V68, P1196, DOI 10.1002/pros.20780; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007	47	7	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					3971	3982		10.1038/onc.2009.254	http://dx.doi.org/10.1038/onc.2009.254			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19701244				2022-12-17	WOS:000272560300003
J	Hirsch, FR				Hirsch, F. R.			The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC INTRODUCTION	ONCOGENE			English	Editorial Material						epidermal growth factor receptor; non-small-cell lung cancer; tyrosine kinase inhibitor	CELL LUNG-CANCER; PREVIOUSLY TREATED PATIENTS; PHASE-II TRIAL; OPEN-LABEL; GEFITINIB; PLUS; CHEMOTHERAPY; MULTICENTER; BEVACIZUMAB; CARBOPLATIN	Lung cancer is the leading cause of cancer deaths worldwide. Non-small-cell lung cancer (NSCLC) is the largest subgroup of the disease and accounts for similar to 80% of lung cancers. Most patients with NSCLC are diagnosed with locally advanced or metastatic disease. The current treatment options for such patients are associated with substantial limitations in efficacy and safety. Targeted therapies have provided some improvement in clinical outcomes. Recent efforts have focused on identifying specific markers that are predictive of response to treatment. A pretreatment detection of such markers could facilitate a more personalized and specific approach to therapy, whereby the most appropriate and efficacious treatment is selected for a specific subset of patients. Such a tailored approach would maximize both the therapeutic index and cost-effectiveness of treatments. In addition, several novel agents are under development, which may have the potential for overcoming acquired resistance to existing treatments. This supplement will review the current and emerging treatments for patients with advanced NSCLC and the molecular predictors of response that may facilitate the future clinical application of personalized medicine. Oncogene (2009) 28, S1-S3; doi:10.1038/onc.2009.195	Univ Colorado, Ctr Canc, Dept Med Oncol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Hirsch, FR (corresponding author), Univ Colorado, Ctr Canc, Dept Med Oncol, MS 8117,POB 6511, Aurora, CO 80045 USA.	fred.hirsch@uchsc.edu						*AM CANC SOC, 2008, NONSM CELL LUNG CANC; *ASTR ZEN PHARM LP, 2008, ASTRAZENECA FIL MARK; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Carney DN, 2002, NEW ENGL J MED, V346, P126, DOI 10.1056/NEJM200201103460211; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; LEE D, 2008, J CLIN ONCOL, V26, pS430; MOK TS, 2009, N ENGL J ME IN PRESS; *NCCN, 2008, CLIN PRACT GUID NONS; Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9; Ries LAG, 2008, SEER CANC STAT REV 1; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Shepherd FA, 2006, J CLIN ONCOL, V24, P1219, DOI 10.1200/JCO.2005.04.4420; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Spigel DR, 2008, CANCER-AM CANCER SOC, V112, P2749, DOI 10.1002/cncr.23490; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; *WHO, 2008, 310 WHO; Wingo PA, 2003, CANCER-AM CANCER SOC, V97, P3133, DOI 10.1002/cncr.11380	19	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2009	28						S1	S3		10.1038/onc.2009.195	http://dx.doi.org/10.1038/onc.2009.195			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680291				2022-12-17	WOS:000269515400001
J	Ragone, G; Bresin, A; Piermarini, F; Lazzeri, C; Picchio, MC; Remotti, D; Kang, SM; Cooper, MD; Croce, CM; Narducci, MG; Russo, G				Ragone, G.; Bresin, A.; Piermarini, F.; Lazzeri, C.; Picchio, M. C.; Remotti, D.; Kang, S-M; Cooper, M. D.; Croce, C. M.; Narducci, M. G.; Russo, G.			The Tcl1 oncogene defines secondary hair germ cells differentiation at catagen-telogen transition and affects stem-cell marker CD34 expression	ONCOGENE			English	Article						Tcl1; hair follicle; bulge cells; secondary hair germ cells; stem-cells; transient-amplifying cells	CHRONIC LYMPHOCYTIC-LEUKEMIA; LABEL-RETAINING CELLS; T-CELL; SELF-RENEWAL; COMPREHENSIVE GUIDE; MOUSE; SKIN; GENE; DISTINCT; CLASSIFICATION	Overexpression of the TCL1 gene family plays a role in the onset of T-cell leukemias in mice and in humans. The Tcl1 gene is tightly regulated during early embryogenesis in which it participates in embryonic stem (ES)-cells proliferation and during lymphoid differentiation. Here, we provide evidences that Tcl1 is also important in mouse hair follicle (HF) and skin homeostasis. We found that Tcl1(-/-) adult mice exhibit hair loss, leading to alopecia with extensive skin lesions. By analysing Tcl1 expression in the wild-type (wt) skin through different stages of hair differentiation, we observe high levels in the secondary hair germ (HG) cells and hair bulges, during early anagen and catagen-telogen transition phases. The loss of Tcl1 does not result in apparent skin morphological defects during embryonic development and at birth, but its absence causes a reduction of proliferation in anagen HFs. Importantly, we show the that absence of Tcl1 induces a significant loss of the stem-cell marker CD34 (but not alpha 6-integrin) expression in the bulge cells, which is necessary to maintain stem-cell characteristics. Therefore, our findings indicate that Tcl1 gene(s) might have important roles in hair formation, by its involvement in cycling and self-renewal of transient amplifying (TA) and stem-cell (SC) populations.	[Ragone, G.; Bresin, A.; Piermarini, F.; Lazzeri, C.; Picchio, M. C.; Narducci, M. G.; Russo, G.] Ist Ricovero & Cura Carattere Sci, Ist Dermopat Immacolata, Mol Oncol Lab, I-167 Rome, Italy; [Remotti, D.] Azienda Osped San Camillo Forlanini, Dept Pathol, Rome, Italy; [Kang, S-M] Emory Univ, Sch Med, Dept Microbiol, Atlanta, GA USA; [Kang, S-M] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA USA; [Cooper, M. D.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Croce, C. M.] Ohio State Univ, Coll Med, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet,Human Canc Gen, Columbus, OH 43210 USA	IRCCS Istituto Dermopatico dell'Immacolata (IDI); Azienda Ospedaliera San Camillo-Forlanini; Emory University; Emory University; Emory University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Russo, G (corresponding author), Ist Ricovero & Cura Carattere Sci, Ist Dermopat Immacolata, Mol Oncol Lab, Via Monti Creta 104, I-167 Rome, Italy.	russo@idi.it	Narducci, Maria Grazia/L-3093-2018; Young, Richard A/F-6495-2012; bresin, antonella/AAG-7189-2020; Russo, Giandomenico/K-9566-2016	Narducci, Maria Grazia/0000-0002-9066-186X; Young, Richard A/0000-0001-8855-8647; Russo, Giandomenico/0000-0002-7718-9687; Narducci, Maria Grazia/0000-0002-8877-4611; BRESIN, antonella/0000-0003-3954-5481	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Bichi R, 2002, P NATL ACAD SCI USA, V99, P6955, DOI 10.1073/pnas.102181599; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Di-Poi N, 2005, MOL CELL BIOL, V25, P1696, DOI 10.1128/MCB.25.5.1696-1712.2005; Ema M, 2008, CELL STEM CELL, V3, P555, DOI 10.1016/j.stem.2008.09.003; French SW, 2007, CANCER LETT, V248, P198, DOI 10.1016/j.canlet.2006.07.006; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Glover CH, 2006, PLOS COMPUT BIOL, V2, P1463, DOI 10.1371/journal.pcbi.0020158; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; Hoyer KK, 2002, P NATL ACAD SCI USA, V99, P14392, DOI 10.1073/pnas.212410199; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ito M, 2004, DIFFERENTIATION, V72, P548, DOI 10.1111/j.1432-0436.2004.07209008.x; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; Kang SM, 2005, BLOOD, V105, P1288, DOI 10.1182/blood-2004-04-1453; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Matoba R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000026; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Murayama K, 2007, ONCOGENE, V26, P4882, DOI 10.1038/sj.onc.1210274; Narducci MG, 1997, CANCER RES, V57, P5452; Narducci MG, 2002, P NATL ACAD SCI USA, V99, P11712, DOI 10.1073/pnas.182412399; Narducci MG, 1997, ONCOGENE, V15, P919, DOI 10.1038/sj.onc.1201246; Narducci MG, 2000, CANCER RES, V60, P2095; Panteleyev AA, 2000, AM J PATHOL, V157, P1071, DOI 10.1016/S0002-9440(10)64621-4; Panteleyev AA, 2001, J CELL SCI, V114, P3419; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; PAUS R, 1994, BRIT J DERMATOL, V131, P177; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Takizawa J, 1998, JPN J CANCER RES, V89, P712, DOI 10.1111/j.1349-7006.1998.tb03275.x; Teitell M, 1999, P NATL ACAD SCI USA, V96, P9809, DOI 10.1073/pnas.96.17.9809; Tiede S, 2007, EUR J CELL BIOL, V86, P355, DOI 10.1016/j.ejcb.2007.03.006; Trempus CS, 2007, CANCER RES, V67, P4173, DOI 10.1158/0008-5472.CAN-06-3128; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Virgilio L, 1998, P NATL ACAD SCI USA, V95, P3885, DOI 10.1073/pnas.95.7.3885; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yu H, 2006, AM J PATHOL, V168, P1879, DOI 10.2353/ajpath.2006.051170; Zanesi N, 2006, CANCER RES, V66, P915, DOI 10.1158/0008-5472.CAN-05-3426	46	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1329	1338		10.1038/onc.2008.489	http://dx.doi.org/10.1038/onc.2008.489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19169282	Green Published			2022-12-17	WOS:000264116000005
J	Banks, L; Humbert, PO				Banks, L.; Humbert, P. O.			On the guardians of polarity and the disorientation of cancer INTRODUCTION	ONCOGENE			English	Editorial Material									[Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [Humbert, P. O.] Peter MacCallum Canc Inst, Div Res, Cell Cycle & Canc Genet Lab, Melbourne, Vic 8006, Australia	International Center for Genetic Engineering & Biotechnology (ICGEB); Peter Maccallum Cancer Center	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org; patrick.humbert@petermac.org	Humbert, Patrick O/L-4264-2016	Humbert, Patrick O/0000-0002-1366-6691					0	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2008	27	55					6876	6877		10.1038/onc.2008.339	http://dx.doi.org/10.1038/onc.2008.339			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029930				2022-12-17	WOS:000261108200001
J	Pandolfi, PP				Pandolfi, P. P.			P-TEN exciting years: from the cytosol to the nucleus and back to keep cancer at bay	ONCOGENE			English	Editorial Material									Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Canc Genet Program, Beth Israel Deaconess Canc Ctr,Dept Med & Pathol, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu							0	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 15	2008	27	41					5386	5386		10.1038/onc.2008.279	http://dx.doi.org/10.1038/onc.2008.279			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349KW	18794874				2022-12-17	WOS:000259280700001
J	Lo, YH; Wu, CC; Shih, HM; Lai, MZ				Lo, Y-H; Wu, C-C; Shih, H-M; Lai, M-Z			Selective activation of NFAT by promyelocytic leukemia protein	ONCOGENE			English	Article						PML; NFAT; CBP; tumor suppressor; transcription activation	ALPHA-INDUCED APOPTOSIS; T-CELLS; NUCLEAR-BODIES; KAPPA-B; DNA-DAMAGE; PML GENE; TRANSCRIPTION; DAXX; COACTIVATOR; EXPRESSION	Promyelocytic leukemia (PML) protein is a tumor suppressor with complicated action mechanisms not yet fully understood. In this study, we found that the nuclear factor of activated T cell ( NFAT) is an unexpected partner of PML: PML specifically enhanced the transcription activation of NFAT. In PML-null mouse embryonic fibroblasts, no transcription activity of NFAT could be detected. There was a selective requirement of PML isoform in NFAT activation: PML-I and PML-VI, but not PML-IV, increased NFAT transactivation. PML specifically promoted the expression of many, but not all, NFAT-targeted genes. We found a specific binding of PML to NFATc. The interaction of PML with NFATc in vivo was further confirmed by chromatin immunoprecipitation and DNA affinity precipitation assay analysis. The unexpected coupling of PML with NFAT reveals a novel mechanism underlying the diverse physiological functions of PML.	[Lo, Y-H; Wu, C-C; Lai, M-Z] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; [Lo, Y-H; Lai, M-Z] Natl Yang Ming Univ, Grad Inst Microbiol & Immunol, Taipei 112, Taiwan; [Shih, H-M] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Lai, M-Z] Natl Taiwan Univ, Sch Med, Grad Inst Immunol, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Taiwan University	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, 128 Acad Rd,Sect 2, Taipei 11529, Taiwan.	mblai@imb.sinica.edu.tw	Shih, Hsiu-Ming/S-7023-2018; Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803				Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bruno S, 2003, BLOOD, V101, P3514, DOI 10.1182/blood-2002-11-3335; Buschbeck M, 2007, ONCOGENE, V26, P3415, DOI 10.1038/sj.onc.1210128; Cairo S, 2005, ONCOGENE, V24, P2195, DOI 10.1038/sj.onc.1208338; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Crowder C, 2005, BLOOD, V105, P1280, DOI 10.1182/blood-2004-04-1614; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; GODDARD AD, 1995, MAMM GENOME, V6, P732, DOI 10.1007/BF00354296; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Ho HY, 1997, EUR J IMMUNOL, V27, P222, DOI 10.1002/eji.1830270133; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Ishov AM, 2004, J CELL SCI, V117, P3807, DOI 10.1242/jcs.01230; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Lin DY, 2004, MOL CELL BIOL, V24, P10529, DOI 10.1128/MCB.24.24.10529-10541.2004; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Moller A, 2003, CANCER RES, V63, P4310; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wu CC, 2003, MOL CELL BIOL, V23, P6442, DOI 10.1128/MCB.23.18.6442-6454.2003; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	40	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3821	3830		10.1038/onc.2008.2	http://dx.doi.org/10.1038/onc.2008.2			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246125				2022-12-17	WOS:000256904700006
J	Chatterjee, A; Chang, X; Nagpal, JK; Chang, S; Upadhyay, S; Califano, J; Trink, B; Sidransky, D				Chatterjee, A.; Chang, X.; Nagpal, J. K.; Chang, S.; Upadhyay, S.; Califano, J.; Trink, B.; Sidransky, D.			Targeting human 8-oxoguanine DNA glycosylase to mitochondria protects cells from 2-methoxyestradiol-induced-mitochondria-dependent apoptosis	ONCOGENE			English	Article						hOGG1; mitochondria; 2-methoxyestradiol; Fas activation	BASE-EXCISION-REPAIR; FAS-MEDIATED APOPTOSIS; HUMAN LEUKEMIA-CELLS; OXIDATIVE STRESS; ESCHERICHIA-COLI; CANCER-CELLS; MAMMALIAN-CELLS; SUPEROXIDE-DISMUTASE; IONIZING-RADIATION; CELLULAR-SURVIVAL	2-Methoxyestradiol (2-ME), an endogenous estrogen metabolite of 17 beta-estradiol, is known to induce mitochondria-mediated apoptosis through several mechanisms. We sought to study the effect of mitochondrialy targeted hOGG1 (MTS-hOGG1) on HeLa cells exposed to 2-ME. MTS-hOGG1-expressing cells exposed to 2-ME showed increased cellular survival and had significantly less G(2)/M cell cycle arrest compared to vector-only-transfected cells. In addition, 2-ME exposure resulted in an increase in mitochondrial membrane potential, increased apoptosis, accompanied by higher activation of caspase-3, -9, cleavage of Bid to tBid and protein poly(ADP-ribose) polymerase (PARP) cleavage in HeLa cells lacking MTS-hOGG1. Fas inhibitors cerulenin or C75 inhibited 2-ME-induced caspase activation, PARP cleavage, apoptosis and reversed mitochondrial membrane hyperpolarization, thereby recapitulating the increased expression of MTS-hOGG1. Hence, MTS-hOGG1 plays an important protective role against 2-ME-mediated mitochondrial damage by blocking apoptosis induced through the Fas pathway.	[Chatterjee, A.; Chang, X.; Nagpal, J. K.; Chang, S.; Upadhyay, S.; Califano, J.; Trink, B.; Sidransky, D.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21231 USA	Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Head & Neck Canc Res Div, 1550 Orleans St,Canc Res Bldg 2, Baltimore, MD 21231 USA.	dsidrans@jhmi.edu			NCI NIH HHS [5-PO1CA 77664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2004, CANCER RES, V64, P6233, DOI 10.1158/0008-5472.CAN-04-0494; ALLEY MC, 1988, CANCER RES, V48, P589; Audebert M, 2002, DNA REPAIR, V1, P497, DOI 10.1016/S1568-7864(02)00034-4; Banki K, 1999, J IMMUNOL, V162, P1466; Blaisdell JO, 2001, P NATL ACAD SCI USA, V98, P7426, DOI 10.1073/pnas.131077798; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; Chatterjee A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-235; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHI NW, 1994, J BIOL CHEM, V269, P29984; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Dhenaut A, 2001, ADV EXP MED BIOL, V500, P613; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; Djavaheri-Mergny M, 2003, ANN NY ACAD SCI, V1010, P159, DOI 10.1196/annals.1299.026; Djavaheri-Mergny M, 2003, ONCOGENE, V22, P2558, DOI 10.1038/sj.onc.1206356; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Druzhyna NM, 2005, J BIOL CHEM, V280, P21673, DOI 10.1074/jbc.m411531200; Druzhyna NM, 2003, GLIA, V42, P370, DOI 10.1002/glia.10230; Dubey RK, 1998, HYPERTENSION, V31, P522, DOI 10.1161/01.HYP.31.1.522; Fanizza C, 2007, TOXICOL IN VITRO, V21, P586, DOI 10.1016/j.tiv.2006.12.002; Fishel ML, 2003, CANCER RES, V63, P608; Gao N, 2005, ONCOGENE, V24, P3797, DOI 10.1038/sj.onc.1208530; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Gui Y, 2006, HYPERTENSION, V47, P271, DOI 10.1161/01.HYP.0000199656.99448.dc; Hagen T, 2004, BIOCHEM BIOPH RES CO, V322, P923, DOI 10.1016/j.bbrc.2004.07.204; Hazra TK, 2001, PROG NUCLEIC ACID RE, V68, P193; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Ide H, 2004, BIOL PHARM BULL, V27, P480, DOI 10.1248/bpb.27.480; Itoh K, 2004, RHEUMATOLOGY, V43, P277, DOI 10.1093/rheumatology/keh039; Kachadourian R, 2001, ARCH BIOCHEM BIOPHYS, V392, P349, DOI 10.1006/abbi.2001.2455; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Lambert C, 2004, INT J CANCER, V108, P493, DOI 10.1002/ijc.11579; Lambert C, 2002, EUR J MED RES, V7, P404; LaVallee TM, 2003, CANCER RES, V63, P468; Li L, 2004, ANTICANCER RES, V24, P3983; Li L, 2004, ANTICANCER RES, V24, P873; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Mambo E, 2005, ONCOGENE, V24, P4496, DOI 10.1038/sj.onc.1208669; Mambo E, 2002, CANCER RES, V62, P1349; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; Mooberry SL, 2003, DRUG RESIST UPDATE, V6, P355, DOI 10.1016/j.drup.2003.10.001; Morgunov I, 1998, J BIOL CHEM, V273, P29540, DOI 10.1074/jbc.273.45.29540; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NABI ZF, 1986, CANCER, V58, P1461, DOI 10.1002/1097-0142(19861001)58:7<1461::AID-CNCR2820580714>3.0.CO;2-D; Pani G, 2000, CANCER RES, V60, P4654; Parlanti E, 2002, ONCOGENE, V21, P5204, DOI 10.1038/sj.onc.1205561; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Rachek LI, 2002, J BIOL CHEM, V277, P44932, DOI 10.1074/jbc.M208770200; Rachek LI, 2006, DIABETES, V55, P1022, DOI 10.2337/diabetes.55.04.06.db05-0865; Rachek LI, 2006, FREE RADICAL BIO MED, V40, P754, DOI 10.1016/j.freeradbiomed.2005.09.028; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rinne ML, 2005, NUCLEIC ACIDS RES, V33, P2859, DOI 10.1093/nar/gki601; Ruchko M, 2005, AM J PHYSIOL-LUNG C, V288, pL530, DOI 10.1152/ajplung.00255.2004; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; SEGALBENDIRDJIAN E, 1988, CANCER RES, V48, P4982; Shimada K, 2004, MOL CARCINOGEN, V39, P1, DOI 10.1002/mc.10158; Shokolenko IN, 2003, DNA REPAIR, V2, P471, DOI 10.1016/S1568-7864(03)00019-3; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381; Srere P A, 1968, Biochem Soc Symp, V27, P11; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yang N, 2004, DNA REPAIR, V3, P1323, DOI 10.1016/j.dnarep.2004.04.014	77	7	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2008	27	26					3710	3720		10.1038/onc.2008.3	http://dx.doi.org/10.1038/onc.2008.3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312HH	18246124				2022-12-17	WOS:000256659300008
J	Saito, Y; Nakagami, H; Kurooka, M; Takami, Y; Kikuchi, Y; Hayashi, H; Nishikawa, T; Tamai, K; Morishita, R; Azuma, N; Sasajima, T; Kaneda, Y				Saito, Y.; Nakagami, H.; Kurooka, M.; Takami, Y.; Kikuchi, Y.; Hayashi, H.; Nishikawa, T.; Tamai, K.; Morishita, R.; Azuma, N.; Sasajima, T.; Kaneda, Y.			Cold shock domain protein A represses angiogenesis and lymphangiogenesis via inhibition of serum response element	ONCOGENE			English	Article						antiangiogenesis; antilymphangiogenesis; gene therapy; endothelial cell serum response element	GROWTH-FACTOR-C; AMELIORATES SECONDARY LYMPHEDEMA; SUPPRESSES TUMOR-GROWTH; GM-CSF PROMOTER; HEMAGGLUTINATING VIRUS; COLORECTAL-CANCER; ENDOTHELIAL-CELLS; NODE METASTASIS; ENVELOPE VECTOR; FACTOR GENE	Dual-targeted therapy for antiangiogenesis and antilymphangiogenesis represents a potentially effective strategy for the treatment of various malignancies. Therefore, the goal of the present study was to identify genes that encode inhibitors of both angiogenesis and lymphangiogenesis. Using a cDNA library obtained from Lewis lung carcinoma (LL/2), a candidate gene was identified by the evaluation of growth inhibition in aortic and lymphatic endothelial cells (EC) as that coding for the mouse cold shock domain protein A (mCSDA). Overexpression of mCSDA significantly repressed cell proliferation and c-fos promoter activity in aortic, venous and lymphatic ECs. CSDA is a DNA-binding protein that binds to the hypoxia response element (HRE). Furthermore, of importance, we revealed that CSDA could directly bind to the serum response element (SRE) sequence, resulting in the inhibition of SRE activity, which may lead to growth inhibition in ECs. In an LL/2-inoculated mouse model, tumor growth was significantly repressed in an mCSDA-injected group. Histopathological analysis revealed that expression of blood and lymphatic EC markers was significantly decreased in mCSDA-injected groups. In conclusion, these data suggest that expression of CSDA can repress angiogenesis and lymphangiogenesis via direct binding to SRE in addition to HRE.	[Saito, Y.; Nakagami, H.; Kurooka, M.; Takami, Y.; Kikuchi, Y.; Hayashi, H.; Nishikawa, T.; Tamai, K.; Kaneda, Y.] Osaka Univ, Grad Sch Med, Div Gen Therapy Sci, Suita, Osaka 5650871, Japan; [Saito, Y.; Azuma, N.] Asahikawa Med Univ, Dept Surg, Hokkaido, Japan; [Morishita, R.] Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, Osaka, Japan	Osaka University; Asahikawa Medical College; Osaka University	Kaneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Div Gen Therapy Sci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneday@gts.med.osaka-u.ac.jp	Nakagami, Hironori/GLU-0570-2022	Nakagami, Hironori/0000-0003-4494-3601				Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; Chilov D, 1997, J BIOL CHEM, V272, P25176, DOI 10.1074/jbc.272.40.25176; Coles LS, 1996, NUCLEIC ACIDS RES, V24, P2311, DOI 10.1093/nar/24.12.2311; Coles LS, 2002, NUCLEIC ACIDS RES, V30, P4845, DOI 10.1093/nar/gkf615; Diamond P, 2001, J BIOL CHEM, V276, P7943, DOI 10.1074/jbc.M009836200; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Kaneda Y, 2002, MOL THER, V6, P219, DOI 10.1006/mthe.2002.0647; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karpanen T, 2001, CANCER RES, V61, P1786; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kobori M, 1998, GENES CELLS, V3, P459, DOI 10.1046/j.1365-2443.1998.00202.x; KUDO S, 1995, EUR J BIOCHEM, V231, P72; LORD BI, 1988, J CELL SCI, P231; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Nakagami H, 2005, ARTERIOSCL THROM VAS, V25, P2542, DOI 10.1161/01.ATV.0000190701.92007.6d; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; Niki T, 2000, CLIN CANCER RES, V6, P2431; Nishikawa T, 2006, HUM GENE THER, V17, P470, DOI 10.1089/hum.2006.17.470; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; Saito Y, 2006, CIRCULATION, V114, P1177, DOI 10.1161/CIRCULATIONAHA.105.602953; Shannon MF, 2001, J LEUKOCYTE BIOL, V69, P21; Shannon MF, 1997, CRIT REV IMMUNOL, V17, P301, DOI 10.1615/CritRevImmunol.v17.i3-4.30; Shimamura M, 2004, GENE THER, V11, P1532, DOI 10.1038/sj.gt.3302323; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Sund M, 2005, P NATL ACAD SCI USA, V102, P2934, DOI 10.1073/pnas.0500180102; Taniyama Y, 2001, GENE THER, V8, P181, DOI 10.1038/sj.gt.3301379; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Watanabe K, 2004, J CLIN INVEST, V114, P898, DOI 10.1172/JC1200421152; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	43	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1821	1833		10.1038/sj.onc.1210824	http://dx.doi.org/10.1038/sj.onc.1210824			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17934523				2022-12-17	WOS:000254150600002
J	Kao, CJ; Chiang, YJ; Chen, PH; Lin, KR; Hwang, PI; Yang-Yen, HF; Yen, JJY				Kao, C-J; Chiang, Y-J; Chen, P-H; Lin, K-R; Hwang, P-I; Yang-Yen, H-F; Yen, J. J-Y			CBAP interacts with the un-liganded common beta-subunit of the GM-CSF/IL-3/IL-5 receptor and induces apoptosis via mitochondrial dysfunction	ONCOGENE			English	Article						apoptosis; cytokine deprivation; mitochondrial dysfunction; cytokine receptor	COLONY-STIMULATING FACTOR; GM-CSF; SIGNAL-TRANSDUCTION; EXPRESSION CLONING; JAK2; CHAIN; ERYTHROPOIETIN; PROLIFERATION; REQUIRES; REGION	The cytoplasmic domain of the common beta-chain (beta c) of the granulocyte-macrophage-colony-stimulating factor (GM-CSF)/interleukin-3 (IL-3)/IL-5 receptor contains a membrane proximal region that is sufficient to mediate ligand-dependent mitogenic activity. Within this region two motifs, designated as box 1 and box 2, are highly conserved among members of the cytokine receptor superfamily. Whereas box 1 is required for the recruitment and phosphorylation of Janus kinase-2, the function of box 2 remains largely unknown. Here, we report the identification of a novel transmembrane protein (common beta-chain associated protein (CBAP)) which directly associated with beta c via the box 2 motif. Interestingly, such an association only occurred in the absence of GM-CSF in vivo. Ectopic overexpression of CBAP triggered apoptosis of factor-dependent cells via mitochondrial dysfunction, which could be inhibited by Bcl-2 overexpression. Reduced expression of endogenous CBAP by small interfering RNA did not interfere GM-CSF-activated signaling molecules, but such treatment significantly inhibited apoptosis induced by GM-CSF deprivation, but not other death stimuli. Domain mapping studies indicated that one apoptogenic domain of CBAP correlated with its ability to interact with beta c. Taken together, these results suggest that CBAP modulates GM-CSF-deprivation-induced apoptosis possibly via a novel mechanism involving interaction with an un-liganded beta c molecule.	[Kao, C-J; Chiang, Y-J; Chen, P-H; Lin, K-R; Yen, J. J-Y] Acad Sinica, Inst Biomed Sci, Agr Biotechnol Res Ctr, Taipei 11529, Taiwan; [Kao, C-J; Yen, J. J-Y] Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 10764, Taiwan; [Hwang, P-I] Acad Sinica, Bioinformat Core Lab, Agr Biotechnol Res Ctr, Taipei 11529, Taiwan; [Yang-Yen, H-F] Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan; National Taiwan University; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Yen, JJY (corresponding author), Acad Sinica, Inst Biomed Sci, Agr Biotechnol Res Ctr, 128 Sec 2,Yen Jiou Yuan Rd, Taipei 11529, Taiwan.	bmjyen@ibms.sinica.edu.tw	Yen, Jeffrey Jong-Young/Q-5134-2018; Chen, Ping-Hung/AAN-6443-2020; Lin, Kuo-Ray/V-6333-2019; Yang-Yen, Hsin-Fang/ABA-5808-2021	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Chen, Ping-Hung/0000-0002-7156-0510; Yang-Yen, Hsin-Fang/0000-0001-9048-4800				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Drachman JG, 2002, J BIOL CHEM, V277, P23544, DOI 10.1074/jbc.M201120200; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; Huang HM, 1999, BLOOD, V93, P2569, DOI 10.1182/blood.V93.8.2569.408k08_2569_2577; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Lee SF, 1999, MOL CELL BIOL, V19, P7399; MIURA O, 1993, BLOOD, V81, P1739; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	15	7	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1397	1403		10.1038/sj.onc.1210778	http://dx.doi.org/10.1038/sj.onc.1210778			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828305				2022-12-17	WOS:000253548200006
J	Foijer, F; Simonis, M; van Vliet, M; Wessels, L; Kerkhoven, R; Sorger, PK; Riele, HT				Foijer, F.; Simonis, M.; van Vliet, M.; Wessels, L.; Kerkhoven, R.; Sorger, P. K.; Riele, H. te			Oncogenic pathways impinging on the G(2)-restriction point	ONCOGENE			English	Article						mitogenic signaling; G2 restriction point; retinoblastoma gene family; expression profiling; c-MYC; RAS	DNA-DAMAGE; MITOGEN REQUIREMENT; RESTRICTION POINT; KINASE-ACTIVITY; G(1) CONTROL; CELL; CYCLE; INHIBITOR; P21; PHOSPHORYLATION	In the absence of mitogenic stimuli, cells normally arrest in G(1/0), because they fail to pass the G(1)-restriction point. However, abrogation of the G(1)-restriction point ( by loss of the retinoblastoma gene family) reveals a second-restriction point that arrests cells in G(2). Serum-starvation-induced G(2) arrest is effectuated through inhibitory interactions of p27(KIP1) and p21(CIP1) with cyclins A and B1 and can be reversed through mitogen re-addition. In this study, we have investigated the pathways that allow cell cycle re-entry from this G(2) arrest. We provide evidence that recovery from G(2) arrest depends on the rat sarcoma viral oncogene ( RAS) and phosphatidylinositol-3 kinase pathways and show that oncogenic hits, such as overexpression of c-MYC or mutational activation of RAS can abrogate the G(2)-restriction point. Together, our results provide new mechanistic insight into multistep carcinogenesis.	[Foijer, F.; van Vliet, M.; Wessels, L.; Riele, H. te] Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; [Foijer, F.; Sorger, P. K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA; [Simonis, M.; Kerkhoven, R.] Netherlands Canc Inst, Cent Microarray Facil, NL-1066 CX Amsterdam, Netherlands; [van Vliet, M.; Wessels, L.] Delft Univ Technol, Fac Elect Engn Math & Comp Sci, Delft, Netherlands	Netherlands Cancer Institute; Harvard University; Harvard Medical School; Netherlands Cancer Institute; Delft University of Technology	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl		Foijer, Floris/0000-0003-0989-3127; Sorger, Peter/0000-0002-3364-1838				Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blagosklonny MV, 2002, CELL CYCLE, V1, P103, DOI 10.4161/cc.1.2.108; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; D'Abaco GM, 2002, J CELL SCI, V115, P4607, DOI 10.1242/jcs.00161; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Foijer F, 2005, CANCER CELL, V8, P455, DOI 10.1016/j.ccr.2005.10.021; Foijer F, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-8; Foijer F, 2006, CELL CYCLE, V5, P831, DOI 10.4161/cc.5.8.2687; Guo QM, 2000, CANCER RES, V60, P5922; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARPER JW, 1993, CELL, V75, P805; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Theodosiou A, 2002, GENOME BIOL, V3; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhu HY, 2005, J BIOL CHEM, V280, P29282, DOI 10.1074/jbc.M407352200	41	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1142	1154		10.1038/sj.onc.1210724	http://dx.doi.org/10.1038/sj.onc.1210724			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700522				2022-12-17	WOS:000253136700014
J	Saenz-Robles, MT; Toma, D; Cantalupo, P; Zhou, J; Gong, H; Edwards, C; Pipas, JM; Xie, W				Saenz-Robles, M. T.; Toma, D.; Cantalupo, P.; Zhou, J.; Gong, H.; Edwards, C.; Pipas, J. M.; Xie, W.			Repression of intestinal drug metabolizing enzymes by the SV40 large T antigen	ONCOGENE			English	Article						cytochrome P450; SV40 T antigen; retinoblastoma	VILLUS-ASSOCIATED ENTEROCYTES; NUCLEAR RECEPTOR; TRANSGENIC MICE; CELL-CYCLE; BILE-ACIDS; EXPRESSION; PROTEIN; CYTOCHROME-P450; TRANSFORMATION; TRANSPORTER	Toxic compounds such as carcinogens are removed from the body by the action of a series of detoxifying enzymes and transporters expressed in the liver and the small intestine. We have found that intestinal epithelial cells expressing the SV40 large T antigen ( TAg) contain significantly lower levels of mRNAs, encoding several drug metabolizing/ detoxifying enzymes and transporters compared to their non- transgenic littermates. In addition, TAg blocks the induction of these mRNAs by xenobiotics. The repression depends on an intact LXCXE motif in TAg, suggesting that inactivation of the retinoblastoma ( Rb) family of tumor suppressors plays a role in the process. These results imply that a functional Rb pathway in the intestine is necessary for the expression of the detoxification system used to clear carcinogens, and suggest that loss of this tumor suppressor might alter susceptibility to chemical injury. In addition, the effect of TAg on the detoxification pathway appears to be tissuespecific, as its ectopic expression in the liver failed to suppress the P450 enzymes. The TAg- mediated suppression of drug metabolizing/ detoxifying enzymes may have broad implications in the metabolism and mechanism of action of both carcinogens and prescription drugs.'	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pipas, JM (corresponding author), Univ Pittsburgh, Dept Biol Sci, 578 Crawford Hall, Pittsburgh, PA 15260 USA.	pipas@pitt.edu; wex6@pitt.edu	Xie, Wen/M-1768-2016		NATIONAL CANCER INSTITUTE [R01CA040586, R37CA040586, R01CA098956, R01CA107011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012479] Funding Source: NIH RePORTER; NCI NIH HHS [CA40586, CA098956, CA107011] Funding Source: Medline; NIEHS NIH HHS [ES012479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Chandrasekaran C, 1996, J BIOL CHEM, V271, P28414, DOI 10.1074/jbc.271.45.28414; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Kim RB, 2003, EUR J CLIN INVEST, V33, P1, DOI 10.1046/j.1365-2362.33.s2.5.x; KIM SH, 1994, P NATL ACAD SCI USA, V91, P6914, DOI 10.1073/pnas.91.15.6914; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kullak-Ublick GA, 2003, J HEPATOL, V39, P628, DOI 10.1016/S0168-8278(03)00397-0; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; McFadyen MCE, 2001, BIOCHEM PHARMACOL, V62, P207, DOI 10.1016/S0006-2952(01)00643-8; Mizuno N, 2003, PHARMACOL REV, V55, P425, DOI 10.1124/pr.55.3.1; Oyama T, 2004, FRONT BIOSCI-LANDMRK, V9, P1967, DOI 10.2741/1378; Puga A, 2002, TOXICOLOGY, V181, P171, DOI 10.1016/S0300-483X(02)00276-7; Renton KW, 2004, CURR DRUG METAB, V5, P235, DOI 10.2174/1389200043335559; Rodriguez-Antona C, 2006, ONCOGENE, V25, P1679, DOI 10.1038/sj.onc.1209377; Rooseboom M, 2004, PHARMACOL REV, V56, P53, DOI 10.1124/pr.56.1.3; Saini SPS, 2005, HEPATOLOGY, V41, P497, DOI 10.1002/hep.20570; Sompayrac L, 1997, VIROLOGY, V233, P130, DOI 10.1006/viro.1997.8610; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Uppal H, 2005, HEPATOLOGY, V41, P168, DOI 10.1002/hep.20512; Williams JA, 2004, DRUG METAB DISPOS, V32, P1201, DOI 10.1124/dmd.104.000794; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2004, DRUG DISCOV TODAY, V9, P442, DOI 10.1016/S1359-6446(04)03061-2	31	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5124	5131		10.1038/sj.onc.1210310	http://dx.doi.org/10.1038/sj.onc.1210310			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17334401				2022-12-17	WOS:000248487400011
J	Takahashi, M; Ozaki, T; Takahashi, A; Miyauchi, M; Ono, S; Takada, N; Koda, T; Todo, S; Kamijo, T; Nakagawara, A				Takahashi, M.; Ozaki, T.; Takahashi, A.; Miyauchi, M.; Ono, S.; Takada, N.; Koda, T.; Todo, S.; Kamijo, T.; Nakagawara, A.			DFF45/ICAD restores cisplatin-induced nuclear fragmentation but not DNA cleavage in DFF45-deficient neuroblastoma cells	ONCOGENE			English	Article						apoptosis; cisplatin; DFF45/ICAD; homozygous deletion; neuroblastoma	CASPASE-ACTIVATED DNASE; TUMOR-SUPPRESSOR GENES; CHROMATIN CONDENSATION; N-MYC; APOPTOSIS; INHIBITOR; DELETION; LINE; IDENTIFICATION; AMPLIFICATION	We have previously defined a homozygously deleted region at chromosome 1p36.2-p36.3 in human neuroblastoma cell lines, NB-1 and NB-C201, and identified six genes including DFF45/ICAD within this region. In this study, we found that NB-C201 cells are much more resistant to various genotoxic stresses such as cisplatin (CDDP) than CHP134 and SH-SY5Y cells that do not have the homozygous deletion. To examine a role(s) of DFF45 in the regulation of apoptosis in response to CDDP, we have established stably DFF45-expressing NB-C 201 cell clones (DFF45-1 and DFF45-3) and a control cell clone (NB-C201-C) using a retrovirus-mediated gene transfer. In contrast to NB-C201-C cells, DFF45-3 cells displayed apoptotic nuclear fragmentation in response to CDDP. Although CDDP-induced proteolytic cleavage of procaspase-3 and DFF45 in DFF45-3 cells, we could not detect a typical apoptotic DNA fragmentation. Additionally, deletion analysis revealed that C-terminal region of DFF45 is required for inducing nuclear fragmentation. Unexpectedly, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that DFF45 has undetectable effect on CDDP sensitivity of NB-C201 cells. Taken together, our present results suggest that DFF45/DFF40 system may be sufficient for CDDP-induced nuclear fragmentation but not DNA cleavage.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Gen Surg, Kita Ku, Sapporo, Hokkaido 060, Japan; Hisamitsu Pharmaceut Co Inc, Ctr Funct Genom, Chuoh Ku, Chiba, Japan; Chiba Canc Ctr, Res Inst, Div Pathol, Chuoh Ku, Chiba, Japan	Chiba Cancer Center; Hokkaido University; Hisamitsu Pharmaceutical Co Ltd; Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						AMLER LC, 1995, ONCOGENE, V10, P1095; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CHENG NC, 1995, ONCOGENE, V10, P291; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gu JJ, 1999, J BIOL CHEM, V274, P20759, DOI 10.1074/jbc.274.30.20759; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Hosoda M, 2005, ONCOGENE, V24, P7156, DOI 10.1038/sj.onc.1208872; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Lu ZG, 2005, P NATL ACAD SCI USA, V102, P2778, DOI 10.1073/pnas.0405374102; MARTINSSON T, 1995, CANCER RES, V55, P5681; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang HW, 2001, NEOPLASIA, V3, P165, DOI 10.1038/sj.neo.7900141; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450	24	7	7	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	38					5669	5673		10.1038/sj.onc.1210352	http://dx.doi.org/10.1038/sj.onc.1210352			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353905				2022-12-17	WOS:000248801900013
J	Gaffre, M; Dupre, A; Valuckaite, R; Suziedelis, K; Jessus, C; Haccard, O				Gaffre, M.; Dupre, A.; Valuckaite, R.; Suziedelis, K.; Jessus, C.; Haccard, O.			Deciphering the H-Ras pathway in Xenopus oocyte	ONCOGENE			English	Article						Ras; Xenopus oocyte; meiotic maturation; Cdc2; MAPK; PI3K	CLASSICAL PROGESTERONE-RECEPTOR; MATURATION-PROMOTING FACTOR; MOS PROTO-ONCOGENE; MEIOTIC MATURATION; CELL-CYCLE; SIGNALING PATHWAY; MAP KINASE; C-MOS; PHOSPHOINOSITIDE 3-KINASE; DISTINCT MECHANISMS	Xenopus oocytes are arrested in prophase of the first meiotic division. In response to progesterone, they re-enter meiosis and arrest again in metaphase of the second meiotic division. This process, called meiotic maturation, is under the control of the Cyclin B-Cdc2 complex, Mphase promoting factor (MPF). Injection of a constitutively active Xenopus H-Ras protein activates MPF, suggesting that Ras proteins could be implicated in the progesterone transduction pathway. The aim of this study was (1) to elucidate the pathway triggered by H-Ras leading to MPF activation in Xenopus oocytes and (2) to investigate whether endogenous H-Ras is involved in the physiological process of meiotic maturation. We generated three constitutively active double mutants, each of them recruiting a single effector in mammalian cells, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K) or RalGDS. Our results show that the activation of a PI3K-related enzyme is crucial for H-Ras-induced MPF activation, whereas the recruitment of either MAPK or RalGDS is not. However, although the H-Ras/PI3K pathway is functional in Xenopus oocytes, it is not the physiological transducer of progesterone responsible for meiotic resumption.	Univ Paris 06, CNRS, UMR 7622, Dev Biol Lab, F-75252 Paris 05, France; Vilnius State Univ, Dept Biochem & Biophys, Vilnius, Lithuania; Inst Oncol, Vilnius, Lithuania	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Vilnius University	Haccard, O (corresponding author), Univ Paris 06, CNRS, UMR 7622, Dev Biol Lab, Boite 24,9 Quai St Bernard, F-75252 Paris 05, France.	olh@ccr.jussieu.fr		Haccard, Olivier/0000-0002-4305-2746				Abrieu A, 1997, EMBO J, V16, P6407, DOI 10.1093/emboj/16.21.6407; Andersen CB, 1998, J BIOL CHEM, V273, P18705, DOI 10.1074/jbc.273.30.18705; ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Castro A, 2001, BIOL CELL, V93, P15, DOI 10.1016/S0248-4900(01)01128-5; De Smedt V, 2002, J BIOL CHEM, V277, P28592, DOI 10.1074/jbc.M202742200; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; Fisher DL, 2000, EMBO J, V19, P1516, DOI 10.1093/emboj/19.7.1516; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Haccard O, 2006, EMBO REP, V7, P321, DOI 10.1038/sj.embor.7400611; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiraoka D, 2004, DEV BIOL, V276, P330, DOI 10.1016/j.ydbio.2004.08.036; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; JESSUS C, 1991, DEVELOPMENT, V111, P813; Karaiskou A, 1999, J CELL SCI, V112, P3747; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lebreton S, 2004, MECH DEVELOP, V121, P1481, DOI 10.1016/j.mod.2004.07.008; LEGUELLEC R, 1991, BIOL CELL, V72, P39, DOI 10.1016/0248-4900(91)90076-Y; Liu XS, 2005, DEV BIOL, V283, P180, DOI 10.1016/j.ydbio.2005.04.011; Liu YS, 2005, CHEM BIOL, V12, P99, DOI 10.1016/j.chembiol.2004.11.009; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Perdiguero E, 2004, CELL CYCLE, V3, P733; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; STACEY DW, 1991, ONCOGENE, V6, P2297; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang J, 2004, J CELL SCI, V117, P5107, DOI 10.1242/jcs.01383; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Zhu Y, 2003, P NATL ACAD SCI USA, V100, P2231, DOI 10.1073/pnas.0336132100	52	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5155	5162		10.1038/sj.onc.1209523	http://dx.doi.org/10.1038/sj.onc.1209523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16607282				2022-12-17	WOS:000240063700008
J	Gu, Y; Siefring, JE; Wang, L; Chae, HD; Bailey, JR; Zheng, Y				Gu, Y.; Siefring, J. E.; Wang, L.; Chae, H-D; Bailey, J. R.; Zheng, Y.			Oncogenic Vav1 induces Rac-dependent apoptosis via inhibition of Bcl-2 family proteins and collaborates with p53 deficiency to promote hematopoietic progenitor cell proliferation	ONCOGENE			English	Article						Vav1 proto-oncogene; Rac GTPase; hematopoietic progenitor cell; proliferation; apoptosis	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE PHOSPHORYLATION; RHO GTPASE; T-CELLS; ACTIVATION; PROTOONCOGENE; EXPRESSION; SURVIVAL; GENE; MEMBER	Vav1 is an hematopoietic-specific Rho guanine nucleotide exchange factor coupling tyrosine kinase receptors and Rac GTPases, and has been implicated in transformation of fibroblasts and pancreas. To determine the biologic effect and oncogenic potential of Vav1 in hematopoietic lineages, we stably express oncogenic mutant of Vav1 in primary bone marrow cells using retrovirus-mediated gene transfer. Contrary to the growth stimulatory effects observed in. broblasts, oncogenic Vav1 inhibits hematopoietic stem cell/progenitor engraftment in vivo and progenitor cell expansion in vitro via inducing apoptosis. The oncogenic Vav1-induced apoptosis is associated with reduced expression of Bcl-2 and Bcl-xL proteins and effectively suppressed by transgenic overexpression of Bcl-2, suggesting Vav1-mediated signaling via Bcl-2 in apoptosis. Also, oncogenic Vav1 stimulates sustained activation of Rac GTPases and the biologic effects of oncogenic Vav1 are Rac-dependent. Further, when expressed in the p53-deficient cells, which express elevated Bcl-2 and Bcl-xL and are resistant to the apoptosis, oncogenic Vav1 enhances both proliferation and self-renewal of hematopoietic progenitor cells. These results demonstrate clear phenotypic differences between wild-type and p53(-/-) hematopoietic cells expressing oncogenic Vav1, and suggest oncogenic potential of Vav1-mediated pathways in primary hematopoietic cell when they collaborate with additional genetic hits that affect the p53 pathway.	Univ Cincinnati, Childrens Hosp, Coll Med, Med Ctr,Res Fdn,Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Gu, Y (corresponding author), Univ Cincinnati, Childrens Hosp, Coll Med, Med Ctr,Res Fdn,Div Expt Hematol, 3333 Burnet Ave,Mail Locat 7013, Cincinnati, OH 45229 USA.	yi.gu@cchmc.org	Chae, Hee-Don/D-2620-2011; Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL CANCER INSTITUTE [K01CA107110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA107110] Funding Source: Medline; NIGMS NIH HHS [R01 GM53943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; ALAI M, 1992, J BIOL CHEM, V267, P18021; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Betz R, 2003, NEUROSCI LETT, V339, P37, DOI 10.1016/S0304-3940(02)01457-X; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Debreceni B, 2004, J BIOL CHEM, V279, P3777, DOI 10.1074/jbc.M308282200; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Filippi MD, 2004, NAT IMMUNOL, V5, P744, DOI 10.1038/ni1081; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Gakidis MAM, 2004, J CELL BIOL, V166, P273, DOI 10.1083/jcb.200404166; Gu Y, 2005, BLOOD, V105, P1467, DOI 10.1182/blood-2004-04-1604; Gu Y, 2003, SCIENCE, V302, P445, DOI 10.1126/science.1088485; Gu Y, 2001, J BIOL CHEM, V276, P15929, DOI 10.1074/jbc.M010445200; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanenberg H, 1997, HUM GENE THER, V8, P2193, DOI 10.1089/hum.1997.8.18-2193; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOLL J, 1991, ONCOGENE, V6, P863; Movilla N, 1999, MOL CELL BIOL, V19, P7870; NAKAHATA T, 1982, J CELL PHYSIOL, V111, P239, DOI 10.1002/jcp.1041110304; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; SHIRSAT NV, 1990, ONCOGENE, V5, P769; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426; Walmsley MJ, 2003, SCIENCE, V302, P459, DOI 10.1126/science.1089709; Wang XW, 1999, ANTICANCER RES, V19, P4759; Williams DA, 2000, BLOOD, V96, P1646; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZMUIDZINAS A, 1995, EMBO J, V14, P1	47	7	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3963	3972		10.1038/sj.onc.1209427	http://dx.doi.org/10.1038/sj.onc.1209427			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474842				2022-12-17	WOS:000238668800010
J	Mangan, JK; Tantravahi, RV; Rane, SG; Reddy, EP				Mangan, JK; Tantravahi, RV; Rane, SG; Reddy, EP			Granulocyte colony-stimulating factor-induced upregulation of Jak3 transcription during granulocytic differentiation is mediated by the cooperative action of Sp1 and Stat3	ONCOGENE			English	Article						granulopoiesis; Jaks; STATs; transcription; cytokines; promoter analysis	MICE LACKING JAK3; PROGENITOR-CELL LINE; MYELOID CELLS; DNA-BINDING; IN-VIVO; PROMOTER; GENE; ACTIVATION; EXPRESSION; PROLIFERATION	We previously demonstrated that Jak3 is a primary response gene for G-CSF and ectopic overexpression of Jak3 can accelerate granulocytic differentiation of normal mouse bone marrow cells induced by G-CSF and GMCSF. To gain insight into the regulation of G-CSF-induced transcription of Jak3, we constructed deletion and linker scanning mutants of the Jak3 promoter sequences and performed luciferase reporter assays in the murine myeloid cell line 32Dcl3, with and without G-CSF stimulation. These experiments showed that mutation of a -67 to -85 element, which contained a putative Sp1 binding site, or mutation of a -44 to -53 GAS element resulted in a marked reduction of Jak3 promoter activity. Electrophoretic mobility shift assays revealed that Sp1 and Stat3 present in nuclear lysates of 32Dcl3 cells stimulated with G-CSF can bind to the -67 to -85 element and -44 to -53 GAS element, respectively. In addition, cotransfection of a constitutively active mutant of Stat3 along with a Jak3 promoter/luciferase reporter resulted in enhanced Jak3 promoter activity. Together, these results demonstrate that activation of Jak3 transcription during G-CSF-induced granulocytic differentiation is mediated by the combined action of Sp1 and Stat3, a mechanism also shown to be important in IL-6-induced monocytic differentiation.	Temple Univ, Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St,AHP Room 154, Philadelphia, PA 19140 USA.	reddy@temple.edu	Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA068239, R24CA088261, R01CA079086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009225] Funding Source: NIH RePORTER; NCI NIH HHS [CA79086, R24 CA88261, CA68239] Funding Source: Medline; NIEHS NIH HHS [ES09225] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aringer M, 2003, J IMMUNOL, V170, P6057, DOI 10.4049/jimmunol.170.12.6057; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Chakraborty A, 1998, LEUKEMIA LYMPHOMA, V30, P433, DOI 10.3109/10428199809057555; CHEN HM, 1993, J BIOL CHEM, V268, P8230; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grossman WJ, 1999, BLOOD, V94, P932, DOI 10.1182/blood.V94.3.932.415k30_932_939; Hauses M, 1998, J BIOL CHEM, V273, P31844, DOI 10.1074/jbc.273.48.31844; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kao WY, 1997, J CELL BIOCHEM, V65, P231, DOI 10.1002/(SICI)1097-4644(199705)65:2<231::AID-JCB8>3.0.CO;2-V; Khanna-Gupta A, 2000, BLOOD, V95, P3734; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Mangan JK, 2004, BLOOD, V103, P4093, DOI 10.1182/blood-2003-06-2165; Martino A, 2001, J IMMUNOL, V166, P1723, DOI 10.4049/jimmunol.166.3.1723; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nuchprayoon I, 1999, J BIOL CHEM, V274, P1085, DOI 10.1074/jbc.274.2.1085; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park SY, 1995, IMMUNITY, V3, P771, DOI 10.1016/1074-7613(95)90066-7; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Rane SG, 2002, BLOOD, V100, P2753, DOI 10.1182/blood.V100.8.2753; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; ROVERA G, 1987, ONCOGENE, V1, P29; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sjin RMTT, 1999, J BIOL CHEM, V274, P28697, DOI 10.1074/jbc.274.40.28697; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Tomita K, 2001, J BIOL CHEM, V276, P25378, DOI 10.1074/jbc.M011363200; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	45	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2489	2499		10.1038/sj.onc.1209280	http://dx.doi.org/10.1038/sj.onc.1209280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16518416				2022-12-17	WOS:000236948000007
J	Carmagnat, M; Drenou, B; Chahal, H; Lord, JM; Charron, D; Estaquier, J; Mooney, NA				Carmagnat, M; Drenou, B; Chahal, H; Lord, JM; Charron, D; Estaquier, J; Mooney, NA			Dissociation of caspase-mediated events and programmed cell death induced via HLA-DR in follicular lymphoma	ONCOGENE			English	Article						MHC class II; apoptosis; signalling	PROTEIN-KINASE-C; LYMPHOCYTIC-LEUKEMIA CELLS; INDUCED APOPTOSIS; PROTEOLYTIC ACTIVATION; MONOCLONAL-ANTIBODIES; CROSS-LINKING; IN-VITRO; B-CELLS; DELTA; TRANSLOCATION	Human leukocyte antigens (HLA) class II antigen-mediated apoptosis has been documented in antigenpresenting cells and B lymphoproliferations. Characteristics of the apoptosis include rapidity and selectivity for mature cells. Follicular lymphomas are particularly refractory to apoptosis. The B-cell lymphoma Ramos shares characteristics of this subgroup and is insensitive to apoptosis via simple HLA-DR engagement. However, oligomerization of HLA-DR antigens induced caspase activation followed byphosphatidylserine externalization, activation of PKC-delta and cleavage of nuclear lamin B. Mitochondrial injury was also detected. However, inhibition of caspase activation simply delayed the apoptotic phenotype but neither protected against cell death nor prevented mitochondrial injury. The data in this report demonstrate that the requirements for the initiating signal ( oligomerization versus engagement) as well as the molecular pathways varies between different B lymphoproliferations despite their common expression of HLADR. Finally, blockade of caspase activation in parallel with HLA-DR mAb stimulation could provide a potent autovaccination stimulus by leading to necrotic death of B-cell lymphomas.	Inst Univ Hematol, Hop St Louis, INSERM U662, F-75010 Paris, France; Hop St Louis, AP HP, Serv Immunol & Histocompatibil, Paris, France; CHU Rennes, Hop Pontchaillou, Lab Hematol, Rennes, France; Univ Birmingham, Sch Med, Dept Immunol, Birmingham, W Midlands, England; Inst Pasteur, Unite Physiopathol Infect Lentivirales, Paris, France; Univ Paris 06, Fac Med, Inst Hematol, Ctr Hayem, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; University of Birmingham; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Mooney, NA (corresponding author), Inst Univ Hematol, Hop St Louis, INSERM U662, F-75010 Paris, France.	nuala.mooney@histo.chu-stlouis.fr	, ESTAQUIER/AAR-7799-2020	, ESTAQUIER/0000-0002-9432-8044; Lord, Janet/0000-0003-1030-6786; Mooney, Nuala/0000-0002-3516-6882	Medical Research Council [G9818340B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; BRICKGHANNAM C, 1991, J BIOL CHEM, V266, P24169; BRICKGHANNAM C, 1994, HUM IMMUNOL, V41, P216, DOI 10.1016/0198-8859(94)90039-6; CHAOUCHI N, 1995, J IMMUNOL, V154, P3096; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Drenou B, 1999, J IMMUNOL, V163, P4115; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Funakoshi S, 1997, BLOOD, V90, P3160, DOI 10.1182/blood.V90.8.3160; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; Inman GJ, 2000, J IMMUNOL, V165, P2500, DOI 10.4049/jimmunol.165.5.2500; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Leveille C, 1999, INT IMMUNOL, V11, P719, DOI 10.1093/intimm/11.5.719; Leverkus M, 2003, INT IMMUNOL, V15, P993, DOI 10.1093/intimm/dxg099; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; McLellan AD, 2000, CELL DEATH DIFFER, V7, P933, DOI 10.1038/sj.cdd.4400734; Mecklenbrauker I, 2002, NATURE, V416, P860, DOI 10.1038/416860a; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Mone AP, 2004, BLOOD, V103, P1846, DOI 10.1182/blood-2003-08-2836; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Rich T, 1997, J IMMUNOL, V159, P3792; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Setterblad N, 2004, J LEUKOCYTE BIOL, V75, P1036, DOI 10.1189/jlb.0703356; Truman JP, 1996, EXP HEMATOL, V24, P1409; Webb PR, 2000, APOPTOSIS, V5, P451, DOI 10.1023/A:1009601220552; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	30	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1914	1921		10.1038/sj.onc.1209222	http://dx.doi.org/10.1038/sj.onc.1209222			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16301998				2022-12-17	WOS:000236224800008
J	Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG				Bajpai, AK; Park, JH; Moon, IJ; Kang, H; Lee, YH; Doh, KO; Suh, SI; Chang, BC; Park, JG			Rapid blockade of telomerase activity and tumor cell growth by the DPL lipofection of ribbon antisense to hTR	ONCOGENE			English	Article						telomerase; hTR; ribbon antisense; DPL transfection	CATALYTIC SUBUNIT; IN-VITRO; MAMMALIAN TELOMERASE; INDUCED APOPTOSIS; RNA COMPONENT; INHIBITION; EXPRESSION; CANCER; OLIGONUCLEOTIDES; GENE	Ribbon antisense (RiAS) to the hTR RNA, a component of the telomerase complex, was employed to inhibit telomerase activity and cancer cell growth. The antisense molecule, hTR-RiAS, combined with enhanced cellular uptake was shown to effectively inhibit telomerase activity and cause rapid cell death in various cancer cell lines. When cancer cells were treated with hTR-RiAS, the level of hTR RNA was reduced by more than 90% accompanied with reduction in telomerase activity. When checked for cancer cell viability, cancer cell lines treated with hTR-RiAS using DNA+Peptide+Lipid complex showed 70-80% growth inhibition in 3 days. The reduced cell viability was due to apoptosis as the percentage of cells exhibiting the sub-G(0) arrest and DNA fragmentation increased after antisense treatment. Further, when subcutaneous tumors of a colon cancer cell line (SW480) were treated intratumorally with hTR-RiAS, tumor growth was markedly suppressed with almost total ablation of hTR RNA in the tumor tissue. Cells in the tumor tissue were also found to undergo apoptosis after hTR-RiAS treatment. These results suggest that hTR-RiAS is an effective anticancer reagent, with a potential for broad efficacy to diverse malignant tumors.	Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, Joongu, Daegu, South Korea; WelGENE Inc 71B4L, Dalseogu 704230, Daegu, South Korea; Keimyung Univ, Sch Med, Chron Dis Res Ctr, Taegu, South Korea; Keimyung Univ, Sch Med, Inst Med Sci, Taegu, South Korea	Keimyung University; Keimyung University; Keimyung University	Park, JG (corresponding author), Keimyung Univ, Sch Med, Dongsan Med Ctr, Dept Med Genet Engn, 194 Dongsadong, Joongu, Daegu, South Korea.	jonggu@kmu.ac.kr						Avilion AA, 1996, CANCER RES, V56, P645; Bisoffi M, 1998, EUR J CANCER, V34, P1242, DOI 10.1016/S0959-8049(98)00049-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; Glukhov AI, 1998, BIOCHEM BIOPH RES CO, V248, P368, DOI 10.1006/bbrc.1998.8801; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Ishikawa T, 1999, CANCER LETT, V141, P187, DOI 10.1016/S0304-3835(99)00103-2; Kanazawa Y, 1996, BIOCHEM BIOPH RES CO, V225, P570, DOI 10.1006/bbrc.1996.1213; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Kondo Y, 2000, ONCOGENE, V19, P2205, DOI 10.1038/sj.onc.1203538; Kosciolek BA, 2003, MOL CANCER THER, V2, P209; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Matsuda M, 1996, MOL BIOL CELL, V7, P1095, DOI 10.1091/mbc.7.7.1095; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Moon IJ, 2000, BIOCHEM J, V346, P295, DOI 10.1042/0264-6021:3460295; Moon IJ, 2000, J BIOL CHEM, V275, P4647, DOI 10.1074/jbc.275.7.4647; Mukai S, 2000, CANCER RES, V60, P4461; Naka K, 1999, BIOCHEM BIOPH RES CO, V255, P753, DOI 10.1006/bbrc.1998.9938; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Urquidi V, 2000, ANNU REV MED, V51, P65, DOI 10.1146/annurev.med.51.1.65; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x	34	7	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6492	6501		10.1038/sj.onc.1208731	http://dx.doi.org/10.1038/sj.onc.1208731			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16170384				2022-12-17	WOS:000232204100003
J	Yanagihara, M; Ishikawa, S; Naito, M; Nakajima, J; Aburatani, H; Hatakeyama, M				Yanagihara, M; Ishikawa, S; Naito, M; Nakajima, J; Aburatani, H; Hatakeyama, M			Paired-like homeoprotein ESXR1 acts as a sequence-specific transcriptional repressor of the human K-ras gene	ONCOGENE			English	Article						ESXR1; homeoprotein; transcriptional repressor; K-ras gene; cancer gene therapy	ACTIVATION; LUNG; ADENOCARCINOMA; ONCOGENES; PROTEINS; CANCER; MOUSE; TUMORIGENESIS; AMPLIFICATION; REGION	Gain-of-function mutation of the K-ras gene is one of the most common genetic changes in human tumors. In tumors carrying K-ras mutation, the presence of oncogenic K-Ras is necessary for maintenance of the transformed phenotype. ESXR1 is a human paired-like homeodomain-containing protein expressed primarily in the testis. In cells, the 65-kDa full-length ESXR1 protein is proteolytically processed into an N-terminal 45-kDa fragment containing the homeodomain, which localizes exclusively within the nucleus, and a C-terminal 20-kDa fragment consisting of a proline-rich repeat region, which is located in the cytoplasm. In this work, we demonstrated that the N-terminal ESXR1 fragment specifically recognizes the TAATNNNATTA P3 consensus sequence for the paired-like homeodomain and functions as a sequence-specific transcriptional repressor. We also showed that the N-terminal ESXR1 fragment binds to the TAATGTTAT TA sequence present within the first intron of the human K-ras gene and inhibits its expression at both mRNA and protein levels. Ectopic expression of the N-terminal ESXR1 fragment in human carcinoma cells that carry mutated K-ras reduces the level of K-Ras and thereby inhibits the tumor cell proliferation. Identification of ESXR1 as a transcriptional repressor of K-ras has an important implication for the development of cancer therapy that inhibits oncogenic K-Ras expression.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Tokyo 1538904, Japan	Hokkaido University; University of Tokyo	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15-Nishi 7, Sapporo, Hokkaido 0600815, Japan.	mhata@igm.hokudai.ac.jp						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Andreyev HJN, 2001, GUT, V48, P230, DOI 10.1136/gut.48.2.230; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; BOS JL, 1989, CANCER RES, V49, P4682; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fohn LE, 2001, GENOMICS, V74, P105, DOI 10.1006/geno.2001.6532; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Galiana C, 1995, MOL CARCINOGEN, V14, P286, DOI 10.1002/mc.2940140409; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; JORDANO J, 1988, ONCOGENE, V2, P359; Knudsen S., 2002, BIOL GUIDE ANAL DNA; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; McIntyre A, 2004, ONCOGENE, V23, P9142, DOI 10.1038/sj.onc.1208115; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Ozawa H, 2004, ONCOGENE, V23, P6590, DOI 10.1038/sj.onc.1207884; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	27	7	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5878	5887		10.1038/sj.onc.1208736	http://dx.doi.org/10.1038/sj.onc.1208736			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15897875				2022-12-17	WOS:000231590400010
J	Chamboredon, S; Castellazzi, M				Chamboredon, S; Castellazzi, M			v-Jun downregulates the alpha 2(I) collagen target gene indirectly through Sp1/3	ONCOGENE			English	Article						v-Jun; Sp1; Sp3; alpha 2 (I) collagen; cell transformation; primary chick embryo fibroblasts	EXTRACELLULAR-MATRIX PROTEIN; CHICK-EMBRYO FIBROBLASTS; C-JUN; TRANSCRIPTION FACTORS; PROMOTER ACTIVITY; BINDING PROTEINS; CELL-LINES; IN-VIVO; EXPRESSION; SPARC	Transformation of chick embryo fibroblasts (CEFs) by the v-Jun oncoprotein correlates with a downregulation of the alpha 2 (I) collagen gene. To investigate whether this gene constitutes a direct target of v-Jun, an analysis of a large proximal fragment of the promoter, extending from position -1080 to +109, was performed. Transient transfections with -1080/+109 and deleted derivatives revealed that a short proximal fragment, -433/-11, is the target for repression by v-Jun. Extensive analysis, conducted in CEFs and in Sp1/3-deficient Drosophila SL2 cells, further showed that (i) high constitutive activity of -433/-11 requires a direct binding of the ubiquitous Sp1 and/or Sp3 transcription factors acting on two distinct motifs, that is, a proximal TCC-rich region and an upstream GC box, and that (ii) repression by v-Jun does not require any direct binding of the oncoprotein to the DNA, but an indirect binding within a v-Jun-Sp1/3-DNA chromatin-associated complex. This situation is reminiscent of a situation previously reported with the tata-less, SPARC ( secreted protein, acidic, and rich in cysteine) target promoter that regulates the expression of another extracellular matrix component in the same model of cell transformation. Taken together, these data reinforce the view that, at least in CEFs, v-Jun downregulates a family of direct target genes by binding to the DNA indirectly through Sp1/3.	Ecole Normale Super, INSERM, U412, Unite Virol Humaine,IFR128 BioSci Lyon Gerland, F-69364 Lyon, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Castellazzi, M (corresponding author), Ecole Normale Super, INSERM, U412, Unite Virol Humaine,IFR128 BioSci Lyon Gerland, 46 Allee Italie, F-69364 Lyon, France.	marc.castellazzi@ens-lyon.fr						Andreu T, 1998, J BIOL CHEM, V273, P13848, DOI 10.1074/jbc.273.22.13848; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2000, MATRIX BIOL, V19, P569, DOI 10.1016/S0945-053X(00)00105-0; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chamboredon S, 2003, ONCOGENE, V22, P4047, DOI 10.1038/sj.onc.1206713; Chlenski A, 2002, CANCER RES, V62, P7357; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Du W, 1999, CANCER RES, V59, P2059; Gao MH, 1996, CANCER RES, V56, P4229; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; JURDIC P, 1995, ONCOGENE, V11, P1699; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; Kilbey A, 1996, ONCOGENE, V12, P2409; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MIKAELIAN I, 1993, J VIROL, V67, P734; Mok SC, 1996, ONCOGENE, V12, P1895; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Pallante KM, 1996, J BIOL CHEM, V271, P25233, DOI 10.1074/jbc.271.41.25233; Perez S, 2001, ONCOGENE, V20, P1135, DOI 10.1038/sj.onc.1204200; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sengupta PK, 2003, CANCER RES, V63, P1789; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Vandel L, 1996, MOL CELL BIOL, V16, P1881; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; VOGELI G, 1981, P NATL ACAD SCI-BIOL, V78, P5334, DOI 10.1073/pnas.78.9.5334; Vogt PK, 1999, CELL GROWTH DIFFER, V10, P777; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898	51	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2547	2557		10.1038/sj.onc.1208489	http://dx.doi.org/10.1038/sj.onc.1208489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735704				2022-12-17	WOS:000228180600012
J	Bower, KE; Fritz, JM; McGuire, KL				Bower, KE; Fritz, JM; McGuire, KL			Transcriptional repression of MMP-1 by p21(SNFT) and reduced in vitro invasiveness of hepatocarcinoma cells	ONCOGENE			English	Article						AP-1; Ets; bZIP; Jun; collagen; matrix metalloproteinase	MATRIX METALLOPROTEINASE-1; GENE-EXPRESSION; COLLAGENASE GENE; POOR-PROGNOSIS; INHIBITORS; CARCINOMA; PROTEIN	p21(SNFT) (21 kDa small nuclear factor isolated from T cells) is a human basic leucine zipper transcription factor that can repress AP-1-mediated transcription. We show here that overexpression of p21(SNFT) in HepG2 cells leads to repression of matrix metalloproteinase-1 by 70-80%. p21(SNFT) interacted with Jun at the matrix metalloproteinase-1 promoter -88 Ets/AP-1 enhancer element, where Jun is known to activate transcription via interaction with Fos and Ets proteins. When p21(SNFT)/Jun dimers bound the element in the presence of Ets, DNA was protected differently than when Fos was paired with Jun. The data suggest a difference in overall conformation between p21(SNFT)-containing and Fos-containing complexes that may be involved in the repression of matrix metalloproteinase-1 by p21(SNFT). Overexpression of p21(SNFT) led to a reduction in invasiveness of HepG2 cells through type I collagen and reconstituted basement membrane, an effect similar to that obtained via direct immunodepletion of matrix metalloproteinase-1. The results indicate that the mechanism of repression of matrix metalloproteinase-1 by p21(SNFT) may be exploited in inhibiting pathological matrix remodeling during cancer progression in vivo.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University	Bower, KE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd BCC239, La Jolla, CA 92037 USA.	kbower@scripps.edu						ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Blanc JF, 2002, INT J ONCOL, V20, P1129; Borden P, 1997, CRIT REV EUKAR GENE, V7, P159, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.90; Bower KE, 2002, J BIOL CHEM, V277, P34967, DOI 10.1074/jbc.M205048200; Buttice G, 1996, ONCOGENE, V13, P2297; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Iacobelli M, 2000, J IMMUNOL, V165, P860, DOI 10.4049/jimmunol.165.2.860; Inoue T, 1999, INT J MOL MED, V4, P73; Ito T, 1999, MODERN PATHOL, V12, P669; Jonat C, 1992, Matrix Suppl, V1, P145; Kim JH, 2001, MOL CELLS, V12, P32; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; McGuire KL, 1997, J IMMUNOL, V159, P1319; Mengshol JA, 2002, ARTHRITIS RHEUM, V46, P13, DOI 10.1002/1529-0131(200201)46:1<13::AID-ART497>3.0.CO;2-S; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Ozaki I, 2002, J HEPATOL, V36, P169, DOI 10.1016/S0168-8278(01)00245-8; Siller-Lopez F, 2000, J HEPATOL, V33, P758, DOI 10.1016/S0168-8278(00)80307-4; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Tini M, 2002, COMP BIOCHEM PHYS A, V131, P569, DOI 10.1016/S1095-6433(01)00508-6; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Westermarck J, 1997, ONCOGENE, V14, P2651, DOI 10.1038/sj.onc.1201111; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781	29	7	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8805	8814		10.1038/sj.onc.1208109	http://dx.doi.org/10.1038/sj.onc.1208109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467742				2022-12-17	WOS:000225165100010
J	Kintscher, J; Yamkamon, V; Braas, D; Klempnauer, KH				Kintscher, J; Yamkamon, V; Braas, D; Klempnauer, KH			Identification of a Myb-responsive enhancer of the chicken C/EBP beta gene	ONCOGENE			English	Article						Myb; C/EBP beta; target gene; chromatin; enhancer	LEUCINE-ZIPPER PROTEINS; RECEPTOR FUSION PROTEIN; I-HYPERSENSITIVE SITES; V-MYB; C-MYB; TRANSCRIPTION FACTOR; MYELOMONOCYTIC CELLS; MYELOID CELLS; MIM-1 GENE; NF-M	The retroviral oncogene v-myb encodes a transcription factor (v-Myb) that disrupts myelomonocytic differentiation and transforms myelomonocytic cells. It is thought that the biological effects of v-Myb are caused by deregulation of specific target genes. The CCAAT box/enhancer binding protein beta (C/EBPbeta), a member of the basic region-leucine zipper (bzip) class of transcription factors, which itself plays an important role during myelomonocytic differentiation, has previously been shown to be regulated by Myb. Here we have addressed the mechanism by which v-Myb affects C/EBPbeta expression. We have employed the mapping of DNase I hypersensitive sites (DHSs) in chromatin as a tool to detect in vivo target sites of v-Myb. Our data identify a DHS downstream of the C/EBPbeta gene that appears to be specific for v-myb-transformed myeloblasts. We have confirmed by chromatin immunoprecipitation that v-Myb is bound to this region in vivo. Furthermore, we have found that ectopic expression of v-Myb in a myelomonocytic cell line is able to induce a DHS downstream of the C/EBPbeta gene, showing for the first time that v-Myb can affect chromatin structure. Reporter gene experiments demonstrate that the downstream DHS acts as a Myb-dependent enhancing element in transiently as well as in stably transfected myelomonocytic cells. Previous work has shown that v-Myb acts on the C/EBPbeta promoter; it now appears that Myb stimulates C/EBPbeta expression by acting on the promoter as well as on an enhancer of the C/EBPbeta gene. Interestingly, the mechanisms by which Myb acts on both elements differ; while Myb activation of the promoter requires the cooperation with C/EBPbeta, activation of the enhancer by Myb is independent of C/EBPbeta. Apart from the identification of a novel Myb-dependent enhancer, our work demonstrates the potential of chromatin structure analysis for the identification of Myb target sites.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1995, DNA CELL BIOL, V14, P529, DOI 10.1089/dna.1995.14.529; Chumakov AM, 1997, MOL CELL BIOL, V17, P1375, DOI 10.1128/MCB.17.3.1375; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kintscher J, 2003, DNA CELL BIOL, V22, P201, DOI 10.1089/104454903321655828; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lin WC, 2002, DNA CELL BIOL, V21, P551, DOI 10.1089/104454902320308924; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Niehof M, 2001, J MOL BIOL, V309, P855, DOI 10.1006/jmbi.2001.4708; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; SCOTT LM, 1992, BLOOD, V80, P1725; Sippel AE, 1996, METHOD ENZYMOL, V274, P233; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; Yamanaka R, 1998, INT J MOL MED, V1, P213; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	58	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5807	5814		10.1038/sj.onc.1207722	http://dx.doi.org/10.1038/sj.onc.1207722			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15195136				2022-12-17	WOS:000222629800010
J	Cervi, D; Truong, AHL; Lee, JS; Sukhai, N; Li, YJ; Koki, A; Ben-David, Y				Cervi, D; Truong, AHL; Lee, JS; Sukhai, N; Li, YJ; Koki, A; Ben-David, Y			Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib	ONCOGENE			English	Article						erythroleukemia; celecoxib; c-Kit phosphorylation; p53 status; resistance	MULV-INDUCED-ERYTHROLEUKEMIAS; CYCLOOXYGENASE-2 EXPRESSION; ERYTHROID PROLIFERATION; TUMOR-GROWTH; CANCER; APOPTOSIS; SULINDAC; GENE; DIFFERENTIATION; CHEMOPREVENTION	It is well established that selective COX-2 inhibitors exhibit potent effects against progression of select solid tumours. However, their effects on liquid tumours have not been fully established. By taking advantage of murine Friend Disease we have shown a strong antileukemic effect of celecoxib by determining novel in vitro targets. Western blot analyses revealed the expression of COX-2 in a panel of Friend Virus-transformed, splenic-derived primary erythroleukemic blasts and established cell lines generated in our laboratory. We have shown that celecoxib at concentrations as low as 20 muM significantly suppresses proliferation of the selected murine erythroleukemia cell line HB60-5. The greatest proliferative inhibition was seen at 40 muM of celecoxib, resulting in apoptosis. Our results also demonstrate that treatment of the established murine erythroleukemia cell line HB60-5 with celecoxib results in suppression of c-Kit and erythropoietin receptor (Epo-R) phosphorylation resulting in apoptosis, likely through decreased levels of survival factors. However, upon overexpression of c-Kit alone in these cells a significant increase in survival and twofold increase in proliferation in the presence of celecoxib were observed (P < 0.05). Finally, since responsiveness of our murine erythroleukemia cell lines to celecoxib is above the reported physiologically achievable levels in vivo, we have provided in vitro evidence to suggest that reduced sensitivity of erythroleukemic cells to lower doses of celecoxib may be a consequence of the loss of wild-type p53. These findings are pivotal in addressing potential discrepancies associated with sensitivity of murine erythroleukemic cells to celecoxib in vitro versus in vivo.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Div Mol & Cellular Biol, Res Bldg,Room S-216,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca						Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; BEN-DAVID Y, 1990, New Biologist, V2, P1015; Berman KS, 2002, CLIN CANCER RES, V8, P354; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Chan G, 1999, CANCER RES, V59, P991; DuBois RN, 1996, GASTROENTEROL CLIN N, V25, P773, DOI 10.1016/S0889-8553(05)70274-0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Harris RE, 2000, CANCER RES, V60, P2101; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; Howard JC, 2001, ONCOGENE, V20, P2291, DOI 10.1038/sj.onc.1204348; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Li YJ, 2001, MOL CELL BIOL, V21, P73, DOI 10.1128/MCB.21.1.73-80.2001; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Mekori YA, 2001, J CLIN IMMUNOL, V21, P171, DOI 10.1023/A:1011083031272; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Nakanishi Y, 2001, EUR J CANCER, V37, P1570, DOI 10.1016/S0959-8049(01)00160-5; Sachinidis A, 1999, BRIT J PHARMACOL, V128, P1761, DOI 10.1038/sj.bjp.0702969; Shamma A, 2000, CLIN CANCER RES, V6, P1229; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 2000, CANCER RES, V60, P6045; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	32	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2305	2314		10.1038/sj.onc.1207400	http://dx.doi.org/10.1038/sj.onc.1207400			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743207				2022-12-17	WOS:000220427700004
J	Adriance, MC; Gendler, SJ				Adriance, MC; Gendler, SJ			Downregulation of Muc1 in MMTV-c-Neu tumors	ONCOGENE			English	Article						transmembrane mucin; erbB receptors; ErbB2; MUC1	HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; EXPRESSION; INDUCTION; MUTATIONS; ONCOGENE; RECEPTOR; DNA; PROTOONCOGENE	MUC1 is a tumor antigen, overexpressed in approximately 90% of human breast cancers. In normal glandular epithelia, MUC1 is expressed at the apical surface; however, in carcinomas an aberrantly glycosylated form of MUC1 is upregulated and expressed around the entire surface of the cell. Previously, we have shown that a lack of Muc1 significantly delays tumor progression and/or onset in MMTV-PyV-mT and MMTV-Wnt-1 transgenic mice. Here we show that, unlike the models mentioned above, a loss of Muc1 in MMTV-c-Neu mice (MMTV-c-Neu/Muc1(-/-)) altered neither mammary tumor onset nor progression. Moreover, characterization of MMTV-cNeu/Muc1(+/+) tumors revealed that Muc1 expression was repressed at the level of transcription. In contrast, normal mammary gland tissue adjacent to tumor tissue expressed Muc1 and pregnant mammary glands from c-Neu transgenic animals expressed high levels of Muc1. We found that transient transfection of activated ErbB2 into human embryonic kidney 293/MUC1 cells resulted in the repression of MUC1 expression. Further, transient transfection of activated ErbB2 resulted in the inhibition of Muc1 transcriptional activation in luciferase reporter assays. These data suggest that the activation of ErbB2, which only occurs in c-Neu tumors, selectively inhibits Muc1 expression.	Mayo Clin Scottsdale, Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Mayo Clin & Mayo Grad Sch Med, Dept Mol Biol & Biochem, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin Scottsdale, Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu			NCI NIH HHS [CA090205, CA064389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA090205, R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akewanlop C, 2001, CANCER RES, V61, P4061; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; Nelson KL, 1996, J BIOL CHEM, V271, P18061, DOI 10.1074/jbc.271.30.18061; PEAT N, 1992, CANCER RES, V52, P1954; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; ROCHLITZ CF, 1989, CANCER RES, V49, P357; Rowse GJ, 1998, CANCER RES, V58, P2675; Rowse GJ, 1998, CANCER RES, V58, P315; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Scibetta AG, 2001, DNA CELL BIOL, V20, P265, DOI 10.1089/104454901750232463; Shiraga T, 2002, MOL MED, V8, P33, DOI 10.1007/BF03402001; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1991, J BIOL CHEM, V266, P15099; Turner BC, 1998, CANCER RES, V58, P5466; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; XING PX, 1989, IMMUNOL CELL BIOL, V67, P183, DOI 10.1038/icb.1989.29; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	32	7	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					697	705		10.1038/sj.onc.1207165	http://dx.doi.org/10.1038/sj.onc.1207165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737104				2022-12-17	WOS:000188304900008
J	Vlaeminck-Guillem, V; Vanacker, JM; Verger, A; Tomavo, N; Stehelin, D; Laudet, V; Duterque-Coquillaud, M				Vlaeminck-Guillem, V; Vanacker, JM; Verger, A; Tomavo, N; Stehelin, D; Laudet, V; Duterque-Coquillaud, M			Mutual repression of transcriptional activation between the ETS-related factor ERG and estrogen receptor	ONCOGENE			English	Article						nuclear receptors; orphan receptors; ETS proteins; transcription factors; repression	CREB-BINDING-PROTEIN; NUCLEAR RECEPTORS; GLUCOCORTICOID-RECEPTOR; ANDROGEN RECEPTOR; STEROID-HORMONE; GENE-EXPRESSION; DNA-BINDING; FUNCTIONAL INTERFERENCE; FAMILY; DOMAIN	Transcription factors are known to interact with each other to modulate their transcriptional activity. In this study, we found that the transcriptional activity of human Erg (one of the Ets family-transcription factors) was repressed by several nuclear receptors, including human estrogen receptor ERalpha, nonsteroid receptors and orphan receptors. Conversely, Erg inhibited ERalpha-dependent transcription. These reciprocal functional interactions extended to other nuclear receptors such as thyroid hormone and retinoic acid receptors, as well as to Fli1, an ERG-related ETS factor. Although similarly inhibited by overexpression of the orphan nuclear receptors ERR1 and RORalpha, ERG activity was unaffected by either REV-ERBalpha1 or COUP-TFII. The antagonism between ERG and ERalpha did not depend on DNA binding inhibition or direct protein-protein interactions. Repression of ERalpha-dependent transcription required the carboxyterminal and aminoterminal transactivation domains of Erg whereas the carboxyterminal AF-2 domain of ERalpha was necessary for repression of Erg activity. Reciprocal inhibition between Erg and ERalpha was not alleviated by overexpressing CBP, SRC-1 or RIP 140, three nuclear coactivator proteins. A negative cross-talk observed between Erg and ERa expands their potential range of regulation and may be relevant in vivo, particularly in endothelial, urogenital and cartilaginous tissues where both factors are expressed.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France; Ecole Normale Super Lyon, CNRS, UMR 5665, Lyon, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Duterque-Coquillaud, M (corresponding author), Inst Biol Lille, CNRS, UMR 8526, BP 447,1 Rue Calmette, F-59021 Lille, France.			verger, alexis/0000-0002-0299-2344; Duterque-Coquillaud, Martine/0000-0003-3943-5629				Aurrekoetxea-Hernandez K, 2000, J VIROL, V74, P4988, DOI 10.1128/JVI.74.11.4988-4998.2000; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chang CY, 1999, MOL CELL BIOL, V19, P8226; COMMITTEE NRN, 1999, CELL, V97, P161; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Glass CK, 2000, GENE DEV, V14, P121; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; INCE BA, 1993, J BIOL CHEM, V268, P14026; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Potthoff SJ, 1996, MOL ENDOCRINOL, V10, P1095, DOI 10.1210/me.10.9.1095; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	57	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8072	8084		10.1038/sj.onc.1207094	http://dx.doi.org/10.1038/sj.onc.1207094			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603248				2022-12-17	WOS:000186403400002
J	Nishizawa, M; Fu, SL; Kataoka, K; Vogt, PK				Nishizawa, M; Fu, SL; Kataoka, K; Vogt, PK			Artificial oncoproteins: modified versions of the yeast bZip protein GCN4 induce cellular transformation	ONCOGENE			English	Article						regulatable transcription; chimeric protein; dimerization	AP-1 TRANSCRIPTION FACTORS; DNA-BINDING DOMAIN; V-JUN; C-JUN; GROWTH-FACTOR; ONCOGENIC TRANSFORMATION; EMBRYO FIBROBLASTS; ESTROGEN-RECEPTOR; DIRECT TARGET; IN-VIVO	We have constructed artificial AP-1 proteins containing elements derived from yeast GCN4 and from the herpes simplex virus activator VP16. These proteins can only homodimerize but do not heterodimerize, and lacking significant homology to Jun outside the DNA-binding domain, they are largely unaffected by proteins that modulate Jun. Constructs in which the transactivation domain of GCN4 is replaced by that of VP16 induce oncogenic transformation in cultures of chicken embryo fibroblasts. The availability of transforming VP16-GCN4 fusion proteins permits an evaluation of downstream target genes, based on the hypothesis that transformation-relevant targets should be common between Jun and the artificial AP-1 proteins. In a pilot study, we examined the expression of several Jun target genes in cells transformed by the VP16-GCN4 fusions and found that some of the Jun targets are not upregulated by the GCN4-derived transforming construct, suggesting that their upregulation in Jun-transformed cells is not essential for cell transformation. We have further constructed a regulatable GCN4-VP16 protein that will permit a kinetic characterization of target gene responses and will facilitate discrimination between direct and indirect targets.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Scripps Research Institute; Tokyo Institute of Technology	Vogt, PK (corresponding author), Natl Yang Ming Univ, Inst Tradit Med, 155 Sec 2,Li Nong St, Taipei 112, Taiwan.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NATIONAL CANCER INSTITUTE [R01CA079616, R35CA042564, R01CA078230] Funding Source: NIH RePORTER; NCI NIH HHS [CA79616, CA78230, CA42564] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1994, ONCOGENE, V9, P791; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Jackson BM, 1996, MOL CELL BIOL, V16, P5557; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; Kataoka K, 2001, J BIOL CHEM, V276, P36849, DOI 10.1074/jbc.M102234200; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	51	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7931	7941		10.1038/sj.onc.1206527	http://dx.doi.org/10.1038/sj.onc.1206527			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970741				2022-12-17	WOS:000185388200008
J	Moghal, N; Sternberg, PW				Moghal, N; Sternberg, PW			Extracellular domain determinants of LET-23 (EGF) receptor tyrosine kinase activity in Caenorhabditis elegans	ONCOGENE			English	Article						LET-23; EGF; ErbB; activation; inhibition; structure	EPIDERMAL-GROWTH-FACTOR; C-ELEGANS; VULVAR DEVELOPMENT; CRYSTAL-STRUCTURE; MAP KINASE; SWISS-MODEL; CELL FATES; GENE; PROTEIN; ENCODES	Negative regulation of ErbB/EGFR signalling pathways is important for normal development and the prevention of cancer. In a genetic screen to uncover mechanisms that negatively regulate ErbB signalling in Caenorhabditis elegans, we isolated a second-site mutation (sy621) that promotes the activity of a gain-of-function allele (sa62gf) of the let-23 (EGF) receptor tyrosine kinase. We show that activation by the sa62 mutation (C359Y) likely results from a break in the conserved disulphide-bonded eighth module at the junction of CR1 and L2. The sy621 mutation causes a G270E change in the third disulphide-bonded module of CR1, and causes no phenotype on its own, but cooperates with the sa62 mutation to. promote receptor activity. Although both sa62 single- and double-mutant receptors can function in the absence of ligand, they can be further activated by ligand. Our results support the current model for ligand-induced dimerization based on the recent crystal structures of HER3 and the EGFR, and provide more evidence for the generation of distinctly activated ErbB family members through mutation.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Moghal, N (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	nmoghal@caltech.edu						Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; Bargmann CI, 1995, METHOD CELL BIOL, V48, P225; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; BRENNER S, 1974, GENETICS, V77, P71; Chang C, 2000, EMBO J, V19, P3283, DOI 10.1093/emboj/19.13.3283; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; FERGUSON EL, 1985, GENETICS, V110, P17; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GRANATO M, 1994, NUCLEIC ACIDS RES, V22, P1762, DOI 10.1093/nar/22.9.1762; Greenwald Iva, 1997, Cold Spring Harbor Monograph Series, V33, P519; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Hopper NA, 2000, MOL CELL, V6, P65, DOI 10.1016/S1097-2765(00)00008-3; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Katz WS, 1996, MOL CELL BIOL, V16, P529; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; LEE JH, 1994, GENE DEV, V8, P60, DOI 10.1101/gad.8.1.60; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Tanner KG, 1999, J BIOL CHEM, V274, P35985, DOI 10.1074/jbc.274.50.35985; Tsuda T, 2000, J BIOL CHEM, V275, P21988, DOI 10.1074/jbc.M003400200; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WU Y, 1994, GENE DEV, V8, P147, DOI 10.1101/gad.8.2.147; Yarden Y, 2001, EUR J CANCER, V37, pS3; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Yu XC, 2002, MOL BIOL CELL, V13, P2547, DOI 10.1091/mbc.01-08-0411	54	7	11	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5471	5480		10.1038/sj.onc.1206648	http://dx.doi.org/10.1038/sj.onc.1206648			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934107				2022-12-17	WOS:000184735000012
J	Stearns, ME; Hu, YJ; Wang, M				Stearns, ME; Hu, YJ; Wang, M			IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation in the IL-10R alpha chain in human primary prostate cancer cell lines	ONCOGENE			English	Article						IL-10; IL-10R; IL-10E1; primary prostate tumor lines; tyrosine phosphorylation; green fluorescent protein tagged IL-10E1; TIMP-1	EPIDERMAL-GROWTH-FACTOR; CYTOKINE RECEPTORS; TRANSCRIPTION FACTOR; TISSUE INHIBITOR; EPITHELIAL-CELLS; INTERLEUKIN-10; ACTIVATION; STAT; BINDING; EXPRESSION	Interleukin 10 (IL-10) stimulates rapid nuclear translocation and binding of a 22 kDa protein, termed interleukin 10 enhancer I (IL-10E1), to a novel enhancer element (i.e. HTE-1) of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene to upregulate TIMP-1 expression. IL10-E1 signaling involves tyrosine phosphorylation of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphorylation of two tyrosine moieties (Y57 and Y62) of a LIM domain of the IL-10E1 protein. In this paper, the studies showed that two tyrosine residues (Tyr(446) and Tyr(496)) located in the cytoplasmic domain of the IL-10R alpha chain were required for receptor function, and for phosphorylation and activation of IL-10E1. Immunoprecipitation studies revealed that 12 amino-acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitate IL-10E1 and blocked figand-dependent IL-10E1 phosphorylation in a cell-free system. In contrast, peptides containing serine substitutions for Tyr(446) and Tyr(496), and tyrosine-phosphorylated peptides containing TNT 2-10 or Tyr(252/259) did not prevent IL-10E1 activation or signaling. To confirm these observations in vivo, fusion protein constructs were made between a modified form of green fluorescent protein or GFP and the intact IL-10E1 protein (IL-10E1-MmGFP) and n-terminal peptides of the IL-10E1 protein (i.e. nt-nls-MmGFP and mutant sequences identified as nt-nls mC61-MmGFP and nt-nis mY57/mY62-MmGFP peptides). Confocal microscopy revealed that IL-10 triggered transport to the nucleus of IL-10E1-MmGFP, nt-nls-MmGFP, and nt-nls mC61-MmGFP by 10-30 min in HPCA-10a (human prostrate cancer cells; derived from Gleason sum 10 tumor tissue) cells. IL-10 failed to induce nuclear translocation of the mY57/mY62-MmGFP peptides with point mutations of the two tyrosine groups. Coinjection of nt-nls-MmGFP with the IL-10R Tyr(446) and Tyr(496) amino-acid residues completely blocked ligand signaling. Coinjection of peptides containing either serine substitutions for Tyr(446) and Tyr(496) or Tyr(230) and Tyr(252/259) failed to block nt-nls-MmGFP signaling. The data demonstrate that IL-10E1 is directly recruited to the ligand-activated IL-10R by binding to specific phosphotyrosine groups which control tyrosine phosphorylation of the LIM domain of the IL-10E1 protein (i.e. Y57/Y62 groups) and IL-10E1 activation.	Drew Univ, Coll Med, Dept Pathol & Lab, Philadelphia, PA 19102 USA		Stearns, ME (corresponding author), Drew Univ, Coll Med, Dept Pathol & Lab, MS 435,15th & Vine Sts, Philadelphia, PA 19102 USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bright RK, 1997, CANCER RES, V57, P995; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P744; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LACRAZ S, 1993, CLIN INVESTIGATOR, V90, P382; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LIU Y, 1994, J IMMUNOL, V152, P1821; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; PEEHL DM, 1994, CELL TISSUE RES, V277, P11, DOI 10.1007/BF00303075; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; RHIM JS, 1994, P NATL ACAD SCI USA, V91, P11874, DOI 10.1073/pnas.91.25.11874; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J., 1989, MOL CLONING, pA1; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEARNS M, 1995, ONCOL RES, V7, P173; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang M, 1996, ONCOL RES, V8, P303; Wang M, 2002, CANCER BIOL THER, V1, P556, DOI 10.4161/cbt.1.5.222; Wang M, 1998, ONCOL RES, V10, P219; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	36	7	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3781	3791		10.1038/sj.onc.1206579	http://dx.doi.org/10.1038/sj.onc.1206579			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802285				2022-12-17	WOS:000183551000012
J	Li, ML; Ren, SX; Tilli, MT; Flaws, JA; Lubet, R; Grubbs, CJ; Furth, PA				Li, ML; Ren, SX; Tilli, MT; Flaws, JA; Lubet, R; Grubbs, CJ; Furth, PA			Chemoprevention of mammary carcinogenesis in a transgenic mouse model by alpha-difluoromethylornithine (DFMO) in the diet is associated with decreased cyclin D1 activity	ONCOGENE			English	Article						DFMO; cell proliferation; apoptosis; cyclin D1; transgenic mouse model; mammary cancer progression	CANCER CELL-LINES; TUMOR PROGRESSION; ORNITHINE DECARBOXYLASE; GROWTH-INHIBITION; MICE; APOPTOSIS; PROLIFERATION; EXPRESSION; INDUCTION; PROTEIN	Mechanisms underlying the chemopreventive effect of difluoromethylornithine (DFMO) on the development of mammary cancer were investigated utilizing the whey acidic protein promoter-T antigen transgenic mouse model of breast cancer progression. Mice were exposed to four different doses of DFMO in the diet (3.5, 4.9, 7.0 and 10 g/kg diet). Tumor latency was increased in a dose-dependent manner. DFMO at the highest dose significantly delayed tumor onset (131 days as compared to 109 days in control unexposed mice, P=0.018). Analyses of preneoplastic mammary tissue collected 1 month after DFMO treatment demonstrated that DFMO (10 g/kg diet) significantly increased the ratio of apoptotic to proliferative indices (P = 0.013) and significantly reduced the percentage of cells demonstrating nuclear localized cyclin D1 (P = 0.013). Nuclear localizations of p27, p21 and Stat5a were not affected. Inhibitory effects of DFMO on cell growth and survival were lost as the cells progressed to cancer. In conclusion, the chemopreventive effects of DFMO on mammary cancer progression were mediated by changes in both apoptosis and cell proliferation in preneoplastic cells. Alterations in cyclin D1 activity in preneoplastic cells could represent an early biomarker of chemopreventive action and are consistent with a mechanistic role for cyclin D1 in progression of mammary cancer.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Univ Maryland, Program Human Genet, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; NCI, Div Canc Prevent, Rockville, MD 20892 USA; Univ Alabama Birmingham, Birmingham, AL 35294 USA	Georgetown University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham	Furth, PA (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg,E518,3970 Reservoir Rd NW, Washington, DC 20057 USA.	paf3@georgetown.edu		Flaws, Jodi/0000-0001-5579-9268	NCI NIH HHS [N01-CN-85076-46] Funding Source: Medline; NICHD NIH HHS [HD 38955] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085076] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Arbeit JM, 1999, CANCER RES, V59, P3610; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Cooper R., 1993, METHODS TOXICOLOGY B, P45; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FOZARD JR, 1980, EUR J PHARMACOL, V65, P379, DOI 10.1016/0014-2999(80)90342-8; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Furth PA, 1998, DEV BIOL STAND, V94, P281; Green JE, 2001, CANCER RES, V61, P7449; Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474; Hursting SD, 2001, J NUTR, V131, p3092S, DOI 10.1093/jn/131.11.3092S; Ioachim EE, 2000, ANTICANCER RES, V20, P4221; Joe AK, 2002, CLIN CANCER RES, V8, P893; Kelloff GJ, 1998, CANCER EPIDEM BIOMAR, V7, P65; KINGSNORTH AN, 1983, CANCER RES, V43, P4035; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 2000, ONCOGENE, V19, P1010, DOI 10.1038/sj.onc.1203271; Masuda M, 2002, JPN J CANCER RES, V93, P329, DOI 10.1111/j.1349-7006.2002.tb02176.x; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; Pidgeon GP, 2002, CANCER RES, V62, P2721; RATKO TA, 1990, ANTICANCER RES, V10, P67; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY PRK, 1981, CONTRACEPTION, V24, P215, DOI 10.1016/0010-7824(81)90094-9; REN S, 2000, CONT TOP LAB ANIMAL, V40, P27; Ren SX, 2002, ONCOGENE, V21, P4335, DOI 10.1038/sj.onc.1205484; Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.2307/3433143; Seufferlein T, 2002, BRIT J CANCER, V86, P1188, DOI 10.1038/sj/bjc/6600186; Soler AP, 1998, CANCER RES, V58, P1654; THOMPSON HJ, 1986, CARCINOGENESIS, V7, P2003, DOI 10.1093/carcin/7.12.2003; TZENG YJ, 1993, ONCOGENE, V8, P1965; Yoshidome K, 2000, CANCER RES, V60, P6901; Zhai SP, 2002, ANN PHARMACOTHER, V36, P905; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006	34	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2568	2572		10.1038/sj.onc.1206314	http://dx.doi.org/10.1038/sj.onc.1206314			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730671				2022-12-17	WOS:000182569000004
J	Comerford, SA; Clouthier, DE; Hinnant, EA; Hammer, RE				Comerford, SA; Clouthier, DE; Hinnant, EA; Hammer, RE			Induction of hepatocyte proliferation and death by modulation of T-Antigen expression	ONCOGENE			English	Article						T-Antigen; apoptosis; Fas; caspase; Akt; hepatocytes	PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; NF-KAPPA-B; ZINC-FINGER PROTEIN; TRANSGENIC MICE; INDUCED APOPTOSIS; CELL-DEATH; CYTOCHROME-C; DIFFERENTIAL REGULATION; DEPENDENT APOPTOSIS; GENE-EXPRESSION	Mice expressing SV40 T-Antigen in liver under control of the phosphoenolpyruvate carboxykinase promoter were generated. By altering the carbohydrate content of the diet, TAg expression, the rate of hepatocyte proliferation and apoptosis, and hence hepatocarcinogenesis, could be regulated. Carbohydrate-mediated suppression of TAg resulted in slow hepatic growth that progressed to focal hepatocellular carcinoma (HCC) after a long latency period. In contrast, induction of TAg by feeding mice a low carbohydrate diet resulted in massive hepatomegaly that progressed rapidly to diffuse multifocal HCC. Hepatic TAg expression could be efficiently repressed by switching mice from the tow to the high-carbohydrate diet, which if instigated prior to the development of HCC, resulted in rapid regression through a p53-independent reduction in hepatocyte proliferation and an increase in hepatocyte apoptosis. Although liver growth was accompanied by compensatory hepatocyte apoptosis, an apoptotic deficit developed following chronic exposure to high levels of TAg. This was associated with Akt phosphorylation and increased expression of the antiapoptotic molecules bfl-1/A1, TIAP, and A20. Mice were resistant to Fas-induced hepatocellular apoptosis due to severely impaired caspase activation and failed activation of the mitochondrial amplification loop. This model will be useful to investigate oncogene-mediated disruption of the cell cycle and apoptosis, and to determine which processes constitute fixed, or reversible aspects of the tumorigenic process.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammer, RE (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Clouthier, David/A-7062-2009	Hammer, Robert E./0000-0001-5487-7551; Comerford, Sarah Ann/0000-0002-7452-7759	NIDDK NIH HHS [DK 53789] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053789] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Arvelo MB, 2002, HEPATOLOGY, V35, P535, DOI 10.1053/jhep.2002.31309; BEALE EG, 1985, J BIOL CHEM, V260, P748; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; Bennoun M, 1998, ONCOGENE, V17, P1253, DOI 10.1038/sj.onc.1202047; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Cole SL, 2002, J VIROL, V76, P8420, DOI 10.1128/JVI.76.16.8420-8432.2002; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; EISENBERGER CL, 1992, MOL CELL BIOL, V12, P1396, DOI 10.1128/MCB.12.3.1396; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Gillet R, 2001, BIOCHEM BIOPH RES CO, V284, P369, DOI 10.1006/bbrc.2001.4988; GIRARD J, 1986, BIOL NEONATE, V50, P237, DOI 10.1159/000242605; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; Kanzler S, 2000, SEMIN CANCER BIOL, V10, P173, DOI 10.1006/scbi.2000.0318; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kohlhoff S, 2000, FREE RADICAL BIO MED, V29, P497, DOI 10.1016/S0891-5849(00)00340-3; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Manickan E, 2001, J BIOL CHEM, V276, P13989, DOI 10.1074/jbc.M009770200; MCGRANE MM, 1990, J BIOL CHEM, V265, P22371; MERLINO G, 1994, CANCER INVEST, V12, P203, DOI 10.3109/07357909409024875; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moens U, 1997, VIRUS GENES, V15, P135, DOI 10.1023/A:1007962908248; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Rodier F, 2000, ONCOGENE, V19, P6261, DOI 10.1038/sj.onc.1204015; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; ROUQUET N, 1995, ONCOGENE, V11, P1061; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; Sartorius U, 2001, CHEMBIOCHEM, V2, P20, DOI 10.1002/1439-7633(20010105)2:1<20::AID-CBIC20>3.3.CO;2-O; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu YJ, 2002, J VIROL, V76, P3731, DOI 10.1128/JVI.76.8.3731-3738.2002; ZIMMER DB, 1990, J HISTOCHEM CYTOCHEM, V38, P171, DOI 10.1177/38.2.1688895; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	74	7	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2515	2530		10.1038/sj.onc.1206259	http://dx.doi.org/10.1038/sj.onc.1206259			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717428				2022-12-17	WOS:000182383500014
J	Petrovas, C; Jeay, S; Lewis, RE; Sonenshein, GE				Petrovas, C; Jeay, S; Lewis, RE; Sonenshein, GE			B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain	ONCOGENE			English	Article						B-myb oncogene; gene repression; cyclin A; type V collagen; smooth muscle cells	SMOOTH-MUSCLE CELLS; GENE-PRODUCT; DNA-BINDING; A-MYB; TRANSCRIPTION; TRANSACTIVATION; EXPRESSION; PROTEIN; PROMOTER; PROLIFERATION	B-Myb is a widely expressed member of the myh oncogene family that has been shown to act as either an activator or repressor of gene transcription in a cell-type-specific fashion. For example, in aortic smooth muscle cells B-Myb represses transcription of the alpha2(V) collagen gene. Recently, phosphorylation of B-Myb by cyclin A was shown to enhance greatly its ability to transactivate. Here, we have tested the effects of cyclin A on the ability of B-Myb to repress. We report that coexpression of cyclin A abolished repression of the alpha2(V) collagen promoter, whereas a dominant-negative cyclin-dependent kinase 2 (cdk2) enhanced repression by ectopic and endogenous B-Myb protein. Mutation of 10 of 22 putative cyclin A sites, which greatly reduces the effects of cyclin A on transactivation by B-Myb, had no effect on the ability of cyclin A to alleviate B-Myb-mediated repression of alpha2(V) collagen promoter activity. Furthermore, the stability of the mutant B-Myb protein was largely unaffected by cyclin A, although ectopic expression of cyclin A enhanced the rate of decay of wild-type B-Myb protein. Thus, the mechanisms of repression and activation appear distinct, for example, mediated by different critical phosphorylation sites or protein-protein interactions. B-Myb mutants with either deletion of aa 374-581 (B-Myb-Mut3) or C-terminal truncation beyond aa 491 (B-Myb-491) positively regulated alpha2(V) collagen promoter activity, and were not affected by cyclin A. Thus, our findings indicate that the ability of B-Myb to function as a repressor of matrix promoter activity is abolished by cyclin A, and maps the sites mediating negative regulation by B-Myb to the region between aa 491 and 582.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	Boston University; University of Nebraska System; University of Nebraska Medical Center	Sonenshein, GE (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.		Lewis, Robert E./H-3404-2019	JEAY, SEBASTIEN/0000-0001-7476-3340	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 P01 HL13262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BELDEKAS JC, 1982, J BIOL CHEM, V257, P2252; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; Bruno MD, 1999, J BIOL CHEM, V274, P27523, DOI 10.1074/jbc.274.39.27523; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; Grassilli E, 1999, CANCER RES, V59, P2451; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; Iwai N, 2001, ONCOGENE, V20, P1425, DOI 10.1038/sj.onc.1204236; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; Kypreos KE, 1999, MATRIX BIOL, V18, P275, DOI 10.1016/S0945-053X(99)00023-2; Kypreos KE, 1998, CELL GROWTH DIFFER, V9, P723; LAM EWF, 1992, ONCOGENE, V7, P1885; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; Marhamati DJ, 1996, J BIOL CHEM, V271, P3359; Masselink H, 2001, CANCER LETT, V171, P87, DOI 10.1016/S0304-3835(01)00631-0; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Muller-Tidow C, 2001, BLOOD, V97, P2091, DOI 10.1182/blood.V97.7.2091; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Penkov D, 2000, J BIOL CHEM, V275, P16681, DOI 10.1074/jbc.M909345199; Piccinini G, 1999, J INVEST DERMATOL, V112, P191, DOI 10.1046/j.1523-1747.1999.00485.x; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1999, J CELL PHYSIOL, V179, P245; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; TASHIRO S, 1995, ONCOGENE, V10, P1699; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	39	7	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					2011	2020		10.1038/sj.onc.1206231	http://dx.doi.org/10.1038/sj.onc.1206231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673206				2022-12-17	WOS:000181967700011
J	Famulski, KS; Al-Hijailan, RS; Dobler, K; Pienkowska, M; Al-Mohanna, F; Paterson, MC				Famulski, KS; Al-Hijailan, RS; Dobler, K; Pienkowska, M; Al-Mohanna, F; Paterson, MC			Aberrant sensing of extracellular Ca2+ by cultured ataxia telangiectasia fibroblasts	ONCOGENE			English	Article						ataxia telangiectasia; extracellular calcium-sensing receptor; intracellular Ca2+ mobilization; mitogen-activated protein kinase; calmodulin-dependent protein kinase II	ACTIVATED PROTEIN-KINASE; DNA-DAMAGE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; ATM; RADIATION; RECEPTOR; CELLS; EXPRESSION; GROWTH	Ataxia telangiectasia (AT) is a human hereditary syndrome whose underlying gene product, ataxia telangiectasia mutated (ATM) protein kinase, is involved in multiple intracellular signaling pathways. We demonstrated previously that AT fibroblasts are defective in intracellular Ca2+ mobilization in response to both stress-inducing and mitogenic stimuli. To extend these findings, normal and AT cells were exposed to serum in the presence of different concentrations of extracellular Ca2+ ([Ca2+](o)), and release of intracellular Ca2+, activation of calmodulin-dependent protein kinase 11 and phosphorylation of kinases ERK1 and 2 were monitored. When maintained in high [Ca2+](o) (0.42 mM), normal fibroblasts responded to serum introduction more rapidly and efficiently than did AT cells. Unexpectedly, decreasing the [Ca2+](o) in the medium had a diametrically opposite effect. Under low [Ca2+](o) (0.0022 mM) conditions, normal cells were slow and inefficient in their responses, whereas AT cells showed a substantial improvement in all three end points. These findings demonstrate that loss of ATM kinase function deregulates the extracellular calcium-sensing receptor (CaR). This malfunction presumably arises from a post-transcriptional event, since CaR mRNA proved to be normal in AT cells. Together, our data suggest that ATM may mediate cell response to mitogenic factors by tightly regulating the set point of the CaR and thereby modulating the crosstalk between this metabotropic receptor and growth factor receptors. Alternatively, the faulty sensing of extracellular calcium in AT cells may be secondary to a state of chronic oxidative stress attributable to ATM deficiency.	King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia; Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore	King Faisal Specialist Hospital & Research Center; National Cancer Centre Singapore (NCCS)	Famulski, KS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, MCB-03,POB 3354, Riyadh 11211, Saudi Arabia.	konrad@kfshrc.edu.sa	Famulski, Konrad/J-8685-2012					Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; Chattopadhyay N, 2000, INT J BIOCHEM CELL B, V32, P789, DOI 10.1016/S1357-2725(00)00031-5; Chiesa N, 2000, NEUROSCIENCE, V96, P575, DOI 10.1016/S0306-4522(99)00581-3; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Enns L, 1999, BRIT J CANCER, V81, P959, DOI 10.1038/sj.bjc.6690793; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Famulski KS, 1999, FEBS LETT, V453, P183, DOI 10.1016/S0014-5793(99)00664-X; Fukao T, 1999, BLOOD, V94, P1998; Gueven N, 2001, J BIOL CHEM, V276, P8884, DOI 10.1074/jbc.M006190200; Hall J, 1999, MOL MED TODAY, V5, P157, DOI 10.1016/S1357-4310(99)01435-5; Heyer BS, 2000, GENE DEV, V14, P2072; HUANG SX, 1995, BIOCHEM J, V310, P881, DOI 10.1042/bj3100881; Kamsler A, 2001, CANCER RES, V61, P1849; Keating KE, 2001, ONCOGENE, V20, P4281, DOI 10.1038/sj.onc.1204527; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; McNeil L, 1998, AM J OBSTET GYNECOL, V178, P305, DOI 10.1016/S0002-9378(98)80017-3; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; MIRZAYANS R, 1995, ONCOGENE, V11, P1597; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; PIENKOWSKA M, 2002, CANC DETECT PREV S1, V26, pS64; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Soares HD, 1998, NEUROSCIENCE, V86, P1045, DOI 10.1016/S0306-4522(98)00117-1; Speer G, 2002, INT J COLORECTAL DIS, V17, P20, DOI 10.1007/s003840100359; Squier TC, 2001, EXP GERONTOL, V36, P1539, DOI 10.1016/S0531-5565(01)00139-5; Taylor AMR, 1998, INT J RADIAT BIOL, V73, P365, DOI 10.1080/095530098142185; Yan J, 2000, INT J RADIAT BIOL, V76, P1025, DOI 10.1080/09553000050111497; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	34	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					471	475		10.1038/sj.onc.1206167	http://dx.doi.org/10.1038/sj.onc.1206167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545170				2022-12-17	WOS:000180379100018
J	Yawata, T; Kamino, H; Kugoh, H; Katoh, M; Nomura, N; Oishi, M; Horikawa, I; Barrett, JC; Oshimura, M				Yawata, T; Kamino, H; Kugoh, H; Katoh, M; Nomura, N; Oishi, M; Horikawa, I; Barrett, JC; Oshimura, M			Identification of a <= 600-kb region on human chromosome 1q42.3 inducing cellular senescence	ONCOGENE			English	Article						cellular senescence; chromosome transfer; chromosome 1; telomerase; mouse melanoma	TELOMERASE REPRESSOR GENE; IMMORTAL CELLS; INDEPENDENT SENESCENCE; SUPPRESSES TELOMERASE; MULTIPLE PATHWAYS; GROWTH ARREST; HETEROZYGOSITY; CARCINOMA; CANCER; ALLELOTYPE	The introduction of a human chromosome 1 via microcell-mediated chromosome transfer (MMCT) induces the cellular senescence in mouse melanoma B16-F10 cells. The senescent cells maintained still the telomerase activity, which is frequently associated with immortal growth of human cells, suggesting that a telomerase-independent mechanism is involved in the senescence observed in this mouse cell line. To map the senescence-inducing gene to a specific chromosomal region, we took two experimental approaches: identification of a minimal region with the senescence-inducing activity via MMCT of a series of subchromosomal transferrable fragments (STFs), each consisting of a different profile of human chromosome 1-derived regions, and identification of a region commonly deleted from the transferred chromosome 1 in the revertant clones that escaped cellular senescence. These approaches identified a 2.7-3.0 Mb of senescence-inducing region shared among the active STFs and a 2.4-3.0 Mb of commonly deleted region in the revertant clones. These two regions overlapped each other to map the responsible gene at the 450 to 600-kb interval between UniSTS93710 and D1S3542 on chromosome 1q42.3. This study provides essential information and materials for cloning and characterization of a novel senescence-inducing gene that functions in a telomerase-independent pathway, which is likely to be conserved between mice and humans.	Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, Yonago, Tottori 6838503, Japan; NCI, Lab Biosyst & Canc, Canc Res Ctr, NIH, Bethesda, MD 20892 USA; Tottori Univ, Dept Human Genome Sci, Div Life Sci, Grad Sch Med, Yonago, Tottori 6838503, Japan; Kazusa DNA Res Inst, Chiba, Japan	Tottori University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tottori University; Kazusa DNA Research Institute	Oshimura, M (corresponding author), Tottori Univ, Fac Med, Sch Life Sci, Dept Mol & Cell Genet, 86 Nishimachi, Yonago, Tottori 6838503, Japan.	oshimura@grape.med.tottori-u.ac.jp		KAMINO, HIROKI/0000-0002-2489-0453	DIVISION OF BASIC SCIENCES - NCI [Z01BC010417] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; BUNN CL, 1980, EXP CELL RES, V127, P385, DOI 10.1016/0014-4827(80)90443-7; Carman TA, 1998, EXP CELL RES, V244, P33, DOI 10.1006/excr.1998.4207; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOWDY SF, 1990, GENE CHROMOSOME CANC, V2, P318, DOI 10.1002/gcc.2870020410; DUNCAN EL, 1993, EXP CELL RES, V205, P337, DOI 10.1006/excr.1993.1095; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Groth A, 2000, J BIOL CHEM, V275, P27473; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Horikawa I, 2000, J ANTI-AGING MED, V3, P373, DOI 10.1089/rej.1.2000.3.373; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kitamura Y, 2000, GENE CHROMOSOME CANC, V27, P244; KOI M, 1986, P NATL ACAD SCI USA, V83, P5992, DOI 10.1073/pnas.83.16.5992; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KUGOH H, 1995, GENOMICS, V27, P207, DOI 10.1006/geno.1995.1028; Kugoh H, 1999, DNA Res, V6, P165, DOI 10.1093/dnares/6.3.165; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LOUPART ML, 1995, GENE CHROMOSOME CANC, V12, P16, DOI 10.1002/gcc.2870120104; Mathon NF, 2001, SCIENCE, V291, P872, DOI 10.1126/science.1056782; Nakabayashi K, 1999, EXP CELL RES, V252, P376, DOI 10.1006/excr.1999.4619; Nishimoto A, 2001, ONCOGENE, V20, P828, DOI 10.1038/sj.onc.1204165; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Polascik TJ, 1996, CANCER RES, V56, P1892; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Russo I, 1998, ONCOGENE, V17, P3417, DOI 10.1038/sj.onc.1202261; SANO T, 1991, CANCER RES, V51, P2926; Sasaki K, 1998, MOL CARCINOGEN, V23, P20; SASAKI M, 1994, CANCER RES, V54, P6090; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Steenbergen RDM, 2001, JNCI-J NATL CANCER I, V93, P865, DOI 10.1093/jnci/93.11.865; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Tanaka H, 1999, MOL CARCINOGEN, V25, P249, DOI 10.1002/(SICI)1098-2744(199908)25:4<249::AID-MC3>3.0.CO;2-Z; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; TSUCHIYA E, 1992, CANCER RES, V52, P2478; Uejima H, 1998, MOL CARCINOGEN, V22, P34, DOI 10.1002/(SICI)1098-2744(199805)22:1<34::AID-MC5>3.0.CO;2-L; Vojta PJ, 1996, GENE CHROMOSOME CANC, V16, P55; YAMADA H, 1990, ONCOGENE, V5, P1141	49	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					281	290		10.1038/sj.onc.1206143	http://dx.doi.org/10.1038/sj.onc.1206143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527897				2022-12-17	WOS:000180322400013
J	Kattmann, D; Klempnauer, KH				Kattmann, D; Klempnauer, KH			Identification and characterization of the Myb-inducible promoter of the chicken adenosine receptor 2B gene	ONCOGENE			English	Article						v-myb oncogene; target gene; A2B adenosine receptor; promoter	V-MYB; C-MYB; MYELOMONOCYTIC CELLS; C/EBP-BETA; TRANSCRIPTION FACTORS; MIM-1 GENE; SYNERGISTIC ACTIVATION; CELLULAR PROGENITOR; TRANS-ACTIVATION; PDCD4 GENE	Numerous studies have shown that the retroviral oncogene v-myb encodes a transcription factor (v-Myb) which interferes with the differentiation program of myelomonocytic cells. It is generally thought that v-Myb deregulates the expression of specific target genes and thereby causes transformation of these cells. By using an estrogen-inducible version of v-Myb we have previously identified the gene for the chicken A2B adenosine receptor (A2B-AR), a member of the seven-pass transmembrane receptor superfamily, as a bona fide target gene for v-Myb. The chicken A2B-AR gene is expressed in v-myb transformed myeloblasts as well as in c-myb expressing erythroblasts, offering the opportunity to study how Myb transcription factors activate a target gene in two different hematopoietic lineages. Here, we report the characterization of the promoter of the A2B-AR gene. We show that the A2B-AR promoter region contains an exceptionally large number of Myb binding sites, many of which contribute to the Myb-inducibility of the promoter. The same sites were required for promoter activity in myelomonocytic and erythroid cells. In contrast to the promoters of other Myb target genes the A2B-AR promoter was not activated synergistically by Myb and other lineage-specific transcription factors that have been identified as Myb cooperation partners before. Taken together, our data suggest that the activation of the A2B-AR promoter by Myb depends on the simultaneous binding of a large number of Myb molecules.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Burk O, 1999, BBA-GENE STRUCT EXPR, V1446, P243, DOI 10.1016/S0167-4781(99)00097-4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHEN LC, 1983, MOL CELL BIOL, V3, P1077, DOI 10.1128/MCB.3.6.1077; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NATSUKA S, 1992, BLOOD, V79, P460; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Reizis B, 2001, J EXP MED, V194, P979, DOI 10.1084/jem.194.7.979; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; SCOTT LM, 1992, BLOOD, V80, P1725; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179; Zhang XH, 1997, J BIOL CHEM, V272, P29272, DOI 10.1074/jbc.272.46.29272	46	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4663	4672		10.1038/sj.onc.1205579	http://dx.doi.org/10.1038/sj.onc.1205579			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096342				2022-12-17	WOS:000176625100007
J	Benezra, R				Benezra, R			Preface: Regulation by Id	ONCOGENE			English	Editorial Material						Id; helix-loop-helix; dominant negative; tumorigenesis; angiogenesis; cell cycle; development			Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.	r-benezra@ski.mskcc.org							0	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8288	8289		10.1038/sj.onc.1205161	http://dx.doi.org/10.1038/sj.onc.1205161			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT					2022-12-17	WOS:000173319500001
J	Miethe, J; Schwartz, C; Wottrich, K; Wenning, D; Klempnauer, KH				Miethe, J; Schwartz, C; Wottrich, K; Wenning, D; Klempnauer, KH			Crosstalk between Myc and activating transcription factor 2 (ATF2): Myc prolongs the half-life and induces phosphorylation of ATF2	ONCOGENE			English	Article						Myc; ATF2; phosphorylation; protein turnover	CYCLIN-A PROMOTER; C-MYC; DNA-BINDING; CELL-CYCLE; V-MYB; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; EXPRESSION; PROTEIN; GENE	Myc is a key regulator of cell growth, differentiation and apoptosis, and affects cell fate decisions by activating as well as by inhibiting the expression of cellular genes. Myc is a member of the basic region-helix-loop-helix-leucine zipper (b-HLH-Zip) class of transcription factors, which heterodimerizes with the Max protein and recognizes a consensus Myc binding motif. Stimulation of gene expression by Myc is thought to be mediated by direct binding of Myc-Max heterodimers to specific target genes. So far, only a few genes have been identified as direct binding targets of Myc, raising the possibility that Myc affects gene expression also by indirect mechanisms. In this work we present evidence that v-Myc encoded by the avian retrovirus MC29 stimulates activating transcription factor 2 (ATF2)-dependent transcription. Analysis of the effect of Myc on ATF2 shows that v-Myc prolongs the half-life of ATF2 and induces the phosphorylation of N-terminal sites of ATF2 (Thr-69 and Thr-71) which have previously been identified as the target sites of stress-activated protein kinases and implicated in the regulation of ATF2 activity. Taken together, our results suggest that v-Myc can affect gene expression indirectly by modulating the activity of ATF2.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de						AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dang CV, 1999, MOL CELL BIOL, V19, P1; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kamano H, 1995, ONCOGENE, V11, P2575; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGTON C, 1995, EMBO J, V14, P1798; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rudolph B, 1996, EMBO J, V15, P3065, DOI 10.1002/j.1460-2075.1996.tb00669.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	58	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2001	20	56					8116	8124		10.1038/sj.onc.1204966	http://dx.doi.org/10.1038/sj.onc.1204966			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781825				2022-12-17	WOS:000172396800009
J	Bost, F; Caron, L; Vial, E; Montreau, N; Marchetti, I; Dejong, V; Defize, L; Castellazzi, M; Binetruy, B				Bost, F; Caron, L; Vial, E; Montreau, N; Marchetti, I; Dejong, V; Defize, L; Castellazzi, M; Binetruy, B			The defective transforming phenotype of c-Jun Ala(63/73) is rescued by mutation of the C-terminal phosphorylation site	ONCOGENE			English	Article						c-Jun transcription factor; phosphorylation sites; rat embryo fibroblasts; CBP interaction; oncogene cooperation	EMBRYO FIBROBLASTS; DNA-BINDING; IN-VITRO; RAS; ACTIVATION; CBP; COOPERATION; REQUIRES; DOMAIN; GROWTH	Cotransfection of primary rat embryo fibroblasts (REF) with c-Jun and activated Ras leads to oncogenic transformation and this process requires the phosphorylation of the N-terminal domain of c-Jun. Ras augments this phosphorylation and, consequently activates the c-Jun transactivation property of TRE (TPA Responsive Element)-dependent promoters. To analyse the role of the c-Jun C-terminal phosphorylation site in oncogenic cooperation we tested the activities of N-terminal c-Jun Ala(63/73) (named Nt), C-terminal c-Jun Ala(234/242/246/252) (named Ct) and (Nt+Ct)-with both mutations-nonphosphorylatable c-Jun mutants. In cooperation with Ras, the Ct mutant and wt c-Jun display similar oncogenic properties whereas the Nt form was defective in transforming REF cells. Unexpectedly, the Nt+Ct mutant exhibited identical oncogenic properties to wt c-Jun, demonstrating that the Ct mutation rescues in cis the Nt mutation. The transcriptional activity and the capacity to bind the c-Jun coactivator CREB Binding Protein (CBP) were enhanced by Ras for the wt and Ct proteins but not for the Nt mutant. Interestingly, the Nt+Ct mutant presents identical transactivation and CBP binding activities to wt c-Jun. Therefore the rescue in cis of the defective Nt mutation by the Ct mutation seems to be due to the recovery of CBP binding. Our results revealed that the process of oncogenic cooperation can occur between Ras and the Nt+Ct non-phosphorylatable c-Jun protein.	Univ Nice Sophia Antipolis, Fac Med, INSERM E99 11, F-06107 Nice, France; ENS Lyon, INSERM U412, F-69364 Lyon, France; Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Binetruy, B (corresponding author), Univ Nice Sophia Antipolis, Fac Med, INSERM E99 11, Av Valombrose, F-06107 Nice, France.		Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/A-6465-2009; Binetruy, Bernard/AFL-7188-2022; BOST, Frederic/AAN-4691-2020; Caron, Leslie/AAE-3511-2022	Binetruy, Bernard/0000-0001-8012-7092; BOST, Frederic/0000-0003-4509-4701; Caron, Leslie/0000-0003-4118-2974				ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; METIVIER C, 1993, ONCOGENE, V8, P2311; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Vandel L, 1996, MOL CELL BIOL, V16, P1881; VANDEL L, 1995, ONCOGENE, V10, P495	17	7	7	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 1	2001	20	50					7425	7429		10.1038/sj.onc.1204924	http://dx.doi.org/10.1038/sj.onc.1204924			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704873				2022-12-17	WOS:000171894200016
J	Crisanti, P; Raguenez, G; Blancher, C; Neron, B; Mamoune, A; Omri, B				Crisanti, P; Raguenez, G; Blancher, C; Neron, B; Mamoune, A; Omri, B			Cloning and characterization of a novel transcription factor involved in cellular proliferation arrest: PATF	ONCOGENE			English	Article						PATF; retina; transcription factor; proliferation arrest	ROUS-SARCOMA VIRUS; GENE-EXPRESSION; E2F FAMILY; RETINA; CELLS; DIFFERENTIATION; RETINOBLASTOMA; MECHANISMS; PROTEINS; GROWTH	Cell cycle withdrawal involves several transcription factors such as E2Fs members that play a key role in cell growth control. Here we describe a novel putative bZIP transcription factor isolated from the retina and involved in neuronal proliferation arrest at the terminal differentiation: PATF (Proliferation Arrest Transcription Factor). We show that PATF associates with E2F4 protein and interacts with the E2F consensus site. PATF expression increases with establishment of quiescent state. Furthermore, the nuclear PATF localization like E2F4, depends on cell growth arrest. The decrease of PATF amount, using a retroviral antisense strategy, results in pursued neuroretina cell mitosis. Our results indicate that PATF could be a new molecular signal implicated in the final neuronal cell cycle withdrawal.	Assoc Claude Bernard, CNRS, INSERM, U450, F-75016 Paris, France; Univ Paris 06, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite	Crisanti, P (corresponding author), Assoc Claude Bernard, CNRS, INSERM, U450, 29 Rue Wilhem, F-75016 Paris, France.							BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRISANTI P, 1985, EMBO J, V4, P1467, DOI 10.1002/j.1460-2075.1985.tb03804.x; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; Dyer MA, 2000, DEVELOPMENT, V127, P3593; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Kastner A, 1998, CELL GROWTH DIFFER, V9, P857; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Levine EM, 2000, DEV BIOL, V219, P299, DOI 10.1006/dbio.2000.9622; Maniatis T., 1989, MOL CLONING LAB MANU; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Omri B, 1998, ONCOGENE, V16, P2351, DOI 10.1038/sj.onc.1201761; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; REID TW, 1974, J NATL CANCER I, V53, P347, DOI 10.1093/jnci/53.2.347; ROUET P, 1992, J BIOL CHEM, V267, P20765; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WANG SZ, 1994, P NATL ACAD SCI USA, V91, P1351, DOI 10.1073/pnas.91.4.1351; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199	29	7	8	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5475	5483		10.1038/sj.onc.1204711	http://dx.doi.org/10.1038/sj.onc.1204711			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571645				2022-12-17	WOS:000170781100008
J	Drynan, LF; Hamilton, TL; Rabbitts, TH				Drynan, LF; Hamilton, TL; Rabbitts, TH			T cell tumorigenesis in Lmo2 transgenic mice is independent of V-D-J recombinase activity	ONCOGENE			English	Article						chromosomal translocation; leukaemia; T cells; T-ALL	LIM-PROTEIN RBTN2; HUMAN CD2 GENE; CHROMOSOMAL TRANSLOCATIONS; RAG-1-DEFICIENT MICE; EXPRESSION; LEUKEMIA; COMPLEX; TAL1; SCL; DIFFERENTIATION	The LMO2 gene is involved in T-cell acute leukaemia (T-ALL) in children with chromosomal translocations t(11;14)(p13;q11) or (7;11)(q35;p13). Transgenic expression of Lmo2 in T cells results in clonal tumours with long latency indicating that mutations in other genes are required for the development of overt tumours, RAG V-D-J recombinase can mediate genetic transposition and thus might create the secondary mutations necessary for T-ALL. Tumour development was compared in Lmo2 transgenic mice in the presence or absence of the Rag1 gene, No difference was observed in the rate of tumour formation nor in tumour histology in Lmo2-transgenic mice with or without Rag1. We conclude that, in this model, RAG recombinase is not a major mediator of mutations needed for T cell tumorigenesis and that antigen binding to alpha-beta or to gamma-delta T cell receptor does not play a role in tumorigenesis, The driving force behind the mutational process involved in this transgenic model remains obscure.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Drynan, Lesley/V-2984-2019; Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Chervinsky DS, 1999, MOL CELL BIOL, V19, P5025; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FISCH P, 1992, ONCOGENE, V7, P2389; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEALE GAM, 1995, BLOOD, V86, P3060; Neale Geoffrey A. M., 1997, Leukemia (Basingstoke), V11, P289; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Rabbitts TH, 1999, CANCER RES, V59, p1794S; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1991, ONCOGENE, V6, P577; SHINKAI Y, 1992, CELL, V68, P885; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; Valge-Archer V, 1998, ONCOGENE, V17, P3199, DOI 10.1038/sj.onc.1202353; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145	31	7	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4412	4415		10.1038/sj.onc.1204538	http://dx.doi.org/10.1038/sj.onc.1204538			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466623				2022-12-17	WOS:000169912600016
J	Munoz, P; Baus, F; Piette, J				Munoz, P; Baus, F; Piette, J			Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193	ONCOGENE			English	Article						cell cycle; DNA topoisomerase II; Ku antigen; DNA replication	DEPENDENT PROTEIN-KINASE; CELL-CYCLE; MAMMALIAN-CELLS; V(D)J RECOMBINATION; M-PHASE; CHROMOSOME STRUCTURE; ENZYME; SEGREGATION; CHECKPOINT; MECHANISM	Ku antigen is necessary for DNA double-strand break (DSB) repair through its ability to bind DNA ends with high affinity and to recruit the catalytic subunit of DNA-PK to the DSBs, Ku-deficient cells are hypersensitive to agents causing DSBs in DNA but also to the DNA topoisomerase II (topo II) inhibitor ICRF-193, which does not induce DSBs, This suggests a new role of Ku antigen, that is independent of DSB repair by DNA-PK. Here we characterize the basis for the hypersensitivity of Ku-deficient cells to ICRF-193, Chromosome condensation and segregation, which are dependent on topo II, but also the catalytic activity of topo II in Late S-G2 were inhibited to a comparable extent when ICRF-193 was applied to Ku-deficient cells or wild-type cells. However, mutant cells arrested in G2 by ICRF-193 treatment were unable to progress into M phase upon drug removal, although drug-trapped topo II complexes were removed from DNA and the two isoforms of topo II recovered their catalytic activity as in wild-type cells, The reversibility of G2 arrest was recovered by complementation of mutant cells with a human Ku86 cDNA, Notably, chromosome condensation was abnormal in Ku-deficient cells after suppression of the G2 arrest by caffeine, even in the absence of ICRF-193, These results reflect the involvement of Ku-antigen in the cellular response to topo II inhibition, more particularly in relieving G2 arrest caused by topo II inhibition in late S/G2 and the subsequent recovery of chromosome condensation.	Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piette, J (corresponding author), Inst Genet Mol Montpellier, CNRS, UMR 5535, IFR 24,1919 Route Mende, F-34293 Montpellier 5, France.							Anderson H, 1996, CELL GROWTH DIFFER, V7, P83; ANDOH T, 1993, BIOTECHNOL APPL BIOC, V18, P165; Andoh T, 1998, BBA-GENE STRUCT EXPR, V1400, P155, DOI 10.1016/S0167-4781(98)00133-X; Andreassen PR, 1997, J CELL BIOL, V136, P29, DOI 10.1083/jcb.136.1.29; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CLARKE DJ, 1993, J CELL SCI, V105, P563; Cooper MP, 2000, GENE DEV, V14, P907; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Duguet M, 1997, J CELL SCI, V110, P1345; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Errami A, 1996, MOL CELL BIOL, V16, P1519; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; GORBSKY GJ, 1994, CANCER RES, V54, P1042; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kimura K, 1996, J BIOL CHEM, V271, P21439, DOI 10.1074/jbc.271.35.21439; KIMURA K, 1994, J BIOL CHEM, V269, P1173; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Patel S, 2000, MOL PHARMACOL, V58, P560, DOI 10.1124/mol.58.3.560; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; TANABE K, 1991, CANCER RES, V51, P4903; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; Wu L, 1999, CURR BIOL, V9, pR518, DOI 10.1016/S0960-9822(99)80325-X; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239	47	7	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					1990	1999		10.1038/sj.onc.1204262	http://dx.doi.org/10.1038/sj.onc.1204262			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360183				2022-12-17	WOS:000168043800007
J	Rubinstein, YR; Driggers, PH; Ogryzko, VV; Thornton, AM; Ozato, K; Pontzer, CH				Rubinstein, YR; Driggers, PH; Ogryzko, VV; Thornton, AM; Ozato, K; Pontzer, CH			An IFN regulatory factor-2 DNA-binding domain dominant negative mutant exhibits altered cell growth and gene expression	ONCOGENE			English	Article						interferon; interferon regulatory factor; cell growth	FACTOR-I IRF-1; TRANSCRIPTION FACTOR; PROTEIN-KINASE; INTERFERON SYSTEM; CYCLIN KINASES; INHIBITOR P21; DIFFERENTIATION; INDUCTION; ARREST; TRANSFORMATION	In order to study interferon regulatory factor (IRF) family mediation of cell growth regulation, we established U937 cell lines stably transfected with a truncated form of IRF-2 lacking the transcriptional repressor domain. The truncated IRF-2 contained the DNA binding domain (DBD) and bound the ISRE, Phenotypically, the IRF-2 DBD transfectants exhibited reduced cell growth, altered morphology and increased cell death, Consistent with alterations in growth characteristics, the IRF-2 DBD transfectants constitutively expressed higher levels of the cyclin dependent kinase inhibitor p21(WAF1/Cip1) than did control clones. The level of p21(WAF1/Cip1) expression was positively correlated with the level of DBD expressed, as well as with the level of growth inhibition in these clones, DBD expression also correlated with expression of other members of the growth regulatory complex, cyclin dependent kinase 2 and cyclin A, but not proliferating cell nuclear antigen. These results imply active repression by IRF-2 to keep p21(WAF1/Cip1) transcriptionally silent.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA	University System of Maryland; University of Maryland College Park; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Pontzer, CH (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.		Ogryzko, Vasily/M-6665-2015	Ogryzko, Vasily/0000-0002-8548-1389				ANTALIS TM, 1991, NUCLEIC ACIDS RES, V19, P4301, DOI 10.1093/nar/19.15.4301; Beretta L, 1996, ONCOGENE, V12, P1593; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARPER JW, 1993, CELL, V75, P805; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAMPHIER M, 1994, IMMUNOLOGIST, V2, P167; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SCHRODER FH, 1989, PROSTATE, P17; STEWART HJ, 1987, J ENDOCRINOL, V115, pR13, DOI 10.1677/joe.0.115R013; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thornton AM, 1996, J IMMUNOL, V157, P5145; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	36	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1411	1418		10.1038/sj.onc.1203435	http://dx.doi.org/10.1038/sj.onc.1203435			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723132				2022-12-17	WOS:000085942700006
J	Luque, I; Zong, WX; Chen, CL; Gelinas, C				Luque, I; Zong, WX; Chen, CL; Gelinas, C			N-terminal determinants of I kappa B alpha necessary for the cytoplasmic regulation of c-Rel	ONCOGENE			English	Article						I kappa B alpha; c-Rel; NF-kappa B	DNA-BINDING; NUCLEAR-LOCALIZATION; MEDIATED INHIBITION; ANKYRIN REPEATS; SEQUENCES; COMPLEX; DOMAIN; PHOSPHORYLATION; TRANSCRIPTION; EXPRESSION	I kappa-B alpha is a dual regulator of Rel/NF-kappa B transcription factors. I kappa B alpha retains inactive NF-kappa B dimers in the cytoplasm, and inhibits their DNA-binding and transcriptional activities in the nucleus. Our previous studies identified discrete functional domains in I kappa B alpha responsible for the cytoplasmic and nuclear regulation of c-Rel, Determinants necessary for regulating c-Rel in the nucleus mapped to the central ankyrin domain of I kappa-B alpha and a fen negatively-charged amino acids that follow in the C-terminal PEST region. In contrast, sequences involved in the cytoplasmic regulation of c-Rel reside in the N-terminal and central ankyrin domains of I kappa B alpha. Here, we present a refined mapping of the N-terminal determinants of I kappa B alpha necessary for the cytoplasmic regulation of c-Rel homodimers, We demonstrate that amino acids 48-58 in p40/I kappa-B alpha are essential to block the nuclear localization of c-Rel dimers, These data define a region of I kappa B alpha that may be required for optimal masking of the c-Rel NLS, or for the nuclear export of c-Rel/I kappa B alpha complexes. These findings highlight a novel function for the N-terminus of I kappa B alpha in the control of the subcellular localization of Rel/NF-kappa B dimers, Given the implication of deregulated NF-kappa B activity in hematopoietic and solid tumors, our findings predict that certain alterations in this domain of I kappa B alpha may have severe biological repercussions.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gelinas, C (corresponding author), CABM, 679 Hoes Lane, Piscataway, NJ 08854 USA.		Luque, Ignacio/D-5060-2009; Luque, Inmaculada/K-9464-2014	Luque, Ignacio/0000-0002-0336-5094; Luque, Inmaculada/0000-0003-1838-2636	NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Luque I, 1998, MOL CELL BIOL, V18, P1213, DOI 10.1128/MCB.18.3.1213; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; RAYETB, 1999, ONCOGENE, V18, P6938; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; SACHDEV S, 1995, ONCOGENE, V11, P811; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Xu X, 1997, ONCOGENE, V14, P1521, DOI 10.1038/sj.onc.1200985; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	41	7	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1239	1244		10.1038/sj.onc.1203400	http://dx.doi.org/10.1038/sj.onc.1203400			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713713				2022-12-17	WOS:000085567800015
J	Evans, JA; Wagner, U; Santos, CM; Hennighausen, L				Evans, JA; Wagner, U; Santos, CM; Hennighausen, L			The interactive web-based histology atlas system	ONCOGENE			English	Article						histology; internet; breast; carcinogenesis; mouse models		Molecular pathways and mechanisms underlying human cancer are frequently investigated in animal models. Studies to identify and dissect molecular pathways include the discovery of genes and their subsequent analysis in transgenic and 'knock-out' mice. A critical aspect in such investigations is the evaluation of organ integrity and histology upon the alteration or inactivation of specific genes. Results from such studies are usually published in scientific journals. However, due to print space and costs the display of large high quality images is limited, Furthermore, the printed media does not permit an easy comparison of histological images published in different journals and different years; The Internet provides a tool for the timely and inexpensive dissemination of scientific data to the research community. However, its potential for the analysis of histological images has not been explored. Here we present a web-based interactive histology atlas (http://histology,nih,gov) that permits the retrieval of annotated, high-resolution histology images via the Internet, This histology atlas also takes advantage of the interactive nature of the Internet to support the communication between different research groups. As an outline forum this atlas provides the framework to evaluate and understand cancer pathology, and to develop a consensus between veterinary and human pathologists.	NIH, Ctr Informat Technol, Div Computat Biosci, Bethesda, MD 20892 USA; NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Evans, JA (corresponding author), NIH, Ctr Informat Technol, Div Computat Biosci, Bldg 12A,Room 1018, Bethesda, MD 20892 USA.			Wagner, Ulrike/0000-0002-3230-5058; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))			0	7	9	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		989	991		10.1038/sj.onc.1203279	http://dx.doi.org/10.1038/sj.onc.1203279			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713681				2022-12-17	WOS:000085796400003
J	Cull, V; Tilbrook, PA; Adenan, AS; Chappell, D; Ingley, E; Sarna, MK; Palmer, TN; Watowich, SS; Klinken, SP				Cull, V; Tilbrook, PA; Adenan, AS; Chappell, D; Ingley, E; Sarna, MK; Palmer, TN; Watowich, SS; Klinken, SP			Dominant action of mutated erythropoietin receptors on differentiation in vitro and erythroleukemia development in vivo	ONCOGENE			English	Article						erythroleukemia; erythropoietin; erythropoietin receptors	J2E ERYTHROID-CELLS; PRIMARY FAMILIAL POLYCYTHEMIA; TYROSINE PHOSPHORYLATION; STAT5 ACTIVATION; EPO RECEPTOR; TERMINAL DIFFERENTIATION; ENDOPLASMIC-RETICULUM; HEMATOPOIETIC-CELLS; KINASE PATHWAY; POINT MUTATION	J2E cells produce rapid, fatal erythroleukemias in vivo but still respond to erythropoietin (epo) in vitro by differentiating, proliferating and remaining viable in the absence of serum. Mutant epo receptors were introduced into these cells to determine whether they could influence the different biological responses to epo in vitro and the development of erythroleukemias. Three mutant receptors were used as cytoplasmic truncation mutants Delta 257 and Delta 321 (above box 1 and below box 2 respectively), and the cytoplasmic point mutant W282R (defective for JAK2 activation). Strikingly, the Delta 321 mutation produced a hyper-sensitive response in vitro to epo-induced differentiation and viability, but not to proliferation. In contrast with the Delta 321 receptor, the Delta 257 and W282R mutants inhibited all biological responses to epo due to impaired JAK2 phosphorylation. Significantly, erythroleukemias took almost twice as long to develop with cells containing the W282R mutation, indicating that JAK2 plays an important role in the emergence of these leukemias. These data demonstrate that mutant epo receptors dominantly altered responses of J2E cells to epo in culture and the development of erythroleukemias.	Univ Western Australia, Lab Canc Med, Dept Biochem, Perth, WA 6000, Australia; Royal Perth Hosp, Perth, WA 6000, Australia; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Texas System; UTMD Anderson Cancer Center	Klinken, SP (corresponding author), Univ Western Australia, Lab Canc Med, Dept Biochem, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Fear, Vanessa/A-6876-2013; Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/GYR-3271-2022; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Fear, Vanessa S/AAF-9805-2020	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Fear, Vanessa S/0000-0001-8363-6685; Watowich, Stephanie/0000-0003-1969-659X				Arcasoy MO, 1999, EXP HEMATOL, V27, P63, DOI 10.1016/S0301-472X(98)00003-4; Arcasoy MO, 1997, BLOOD, V89, P4628, DOI 10.1182/blood.V89.12.4628; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BITTORF T, 1994, CELL SIGNAL, V6, P305, DOI 10.1016/0898-6568(94)90035-3; BUSFIELD SJ, 1992, BLOOD, V80, P412; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P317, DOI 10.3109/08977199308991592; BUSFIELD SJ, 1993, GROWTH FACTORS, V9, P307, DOI 10.3109/08977199308991591; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Chappell D, 1997, CELL DEATH DIFFER, V4, P105, DOI 10.1038/sj.cdd.4400219; CHRETIEN S, 1994, BLOOD, V83, P1813; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; FARR TJ, 1995, LEUKEMIA, V9, P900; Furukawa T, 1997, BRIT J HAEMATOL, V99, P222, DOI 10.1046/j.1365-2141.1997.3583172.x; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HAWLEY RG, 1994, GENE THER, V1, P136; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JOHANNSEN H, 1989, ERYTHROPOIETIN, P80; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1990, LEUKEMIA, V4, P24; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; Kralovics R, 1997, BLOOD, V90, P2057, DOI 10.1182/blood.V90.5.2057; KRANTZ SB, 1991, BLOOD, V77, P419; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LAI CM, 1995, J INTERF CYTOK RES, V15, P669, DOI 10.1089/jir.1995.15.669; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MITIAVILA MT, 1991, J CLIN INVEST, V88, P789, DOI 10.1172/JCI115378; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIURA Y, 1994, J BIOL CHEM, V269, P29962; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; Sharlow ER, 1997, BLOOD, V90, P2175, DOI 10.1182/blood.V90.6.2175.2175_2175_2187; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1996, CELL GROWTH DIFFER, V7, P511; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TORTI M, 1992, J BIOL CHEM, V267, P8293; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Watowich SS, 1999, J BIOL CHEM, V274, P5415, DOI 10.1074/jbc.274.9.5415; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WINKELMANN JC, 1995, BLOOD, V85, P179, DOI 10.1182/blood.V85.1.179.bloodjournal851179; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500	74	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					953	960		10.1038/sj.onc.1203370	http://dx.doi.org/10.1038/sj.onc.1203370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702804				2022-12-17	WOS:000085567700013
J	Schulz, RA; Gajewski, K				Schulz, RA; Gajewski, K			Ventral neuroblasts and the Heartless FGF receptor are required for muscle founder cell specification in Drosophila	ONCOGENE			English	Article						D-mef2; heartless; muscle founder cells; signal transduction; ventral neuroblasts	GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; SINGLE-MINDED GENE; MESODERM; EXPRESSION; MIGRATION; HOMOLOG; EMBRYO; TINMAN; BREATHLESS	Muscle founder cells are uniquely specified cells that fuse with neighboring myoblasts to generate the complex pattern of body wall muscles in the Drosophila embryo. We have investigated the positional specification of founder cells for ventral oblique muscles, marked by the restricted expression of tinman RNA and the activity of a D-mef2 enhancer. The formation of these ventral myoblasts requires the function of the Heartless FGF receptor in the mesoderm and the presence of ventral neuroblasts in the central nervous system. Overproduction of ventral neuroblasts due to the forced expression of the homeodomain protein Vnd leads to increased numbers of founder cells. These results suggest the use of a neuroectoderm-to-mesoderm signaling pathway in the specification of ventral muscle precursors.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Schulz, RA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NHLBI NIH HHS [HL59151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BAKER R, 1995, DEVELOPMENT, V121, P1387; Bate M, 1996, SEMIN CELL DEV BIOL, V7, P103, DOI 10.1006/scdb.1996.0015; Bate Michael, 1993, P1013; BAYLIES MK, 1995, DEVELOPMENT, V121, P3829; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Baylies MK, 1998, CELL, V93, P921, DOI 10.1016/S0092-8674(00)81198-8; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND AH, 1993, DEVELOPMENT, V118, P401; Buff E, 1998, DEVELOPMENT, V125, P2075; Chu H, 1998, GENE DEV, V12, P3613, DOI 10.1101/gad.12.22.3613; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gajewski K, 1997, EMBO J, V16, P515, DOI 10.1093/emboj/16.3.515; Gajewski K, 1998, DEV GENES EVOL, V208, P382, DOI 10.1007/s004270050194; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; Grass S, 1996, DEVELOPMENT, V122, P141; HILLIKER AJ, 1981, DROS INFORM SERV, V56, P65; Ingham P. W., 1997, The molecular biology of insect disease vectors: a methods manual., P268; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; McDonald JA, 1998, GENE DEV, V12, P3603, DOI 10.1101/gad.12.22.3603; Michelson AM, 1998, DEV GENET, V22, P212, DOI 10.1002/(SICI)1520-6408(1998)22:3<212::AID-DVG4>3.0.CO;2-9; NAMBU JR, 1990, CELL, V63, P63, DOI 10.1016/0092-8674(90)90288-P; Nguyen HT, 1998, DEV BIOL, V204, P550, DOI 10.1006/dbio.1998.9081; Ranganayakulu G, 1996, DEV BIOL, V176, P143, DOI 10.1006/dbio.1996.9987; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; RUSHTON E, 1995, DEVELOPMENT, V121, P1979; Shishido E, 1997, DEVELOPMENT, V124, P2119; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; VOLK T, 1994, DEVELOPMENT, V120, P59; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354	34	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6818	6823		10.1038/sj.onc.1203081	http://dx.doi.org/10.1038/sj.onc.1203081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597291				2022-12-17	WOS:000083792000025
J	Sakaguchi, K; Lorenzi, MV; Matsushita, H; Miki, T				Sakaguchi, K; Lorenzi, MV; Matsushita, H; Miki, T			Identification of a novel activated form of the keratinocyte growth factor receptor by expression cloning from parathyroid adenoma tissue	ONCOGENE			English	Article						fibroblast growth factor receptor 2; alternative splicing; receptor tyrosine kinase; morphological transformation	GTP-BINDING PROTEINS; CDNA CLONING; MOLECULAR-CLONING; POINT MUTATION; K-SAM; GENE; ONCOGENE; MITOGENESIS; REGULATORS; CANCER	Parathyroid adenomas are benign tumors in the parathyroid glands, whose pathogenesis is largely unknown, We utilized an expression cDNA cloning strategy to identify oncogenes activated in parathyroid adenomas, An expression cDNA library was prepared directly from a clinical sample of parathyroid adenoma tissue, transfected into NIH3T3 cells, and foci of morphologically transformed cells were isolated, Following plasmid rescue, we identified cDNAs for the keratinocyte growth factor receptor at a high frequency, Interestingly, approximately half of the clones encoded a variant receptor containing an altered C-terminus, Analysis of the transforming activity of the variant receptor revealed that the altered C-terminus upregulated the transforming activity in a ligand-independent manner, The higher transforming activity was not accompanied by increase of dimerization or overall autophosphorylation of the receptor. However, tyrosine phosphorylation of downstream receptor substrates, including Shc isoforms and possibly FRS2, are increased in the transfectants expressing the parathyroid tumor-derived receptor. Genomic analysis showed that a previously unidentified exon was used to form the novel isoform, This alternative splicing appears to occur preferentially in parathyroid adenomas.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; NIDR, Glycobiol Program, Bethesda, MD 20892 USA; Toranomon Gen Hosp, Dept Pathol, Minato Ku, Tokyo 105, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Toranomon Hospital	Miki, T (corresponding author), NCI, Cellular & Mol Biol Lab, Bldg 37 Room 1E24,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.							ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Bilezikian John P., 1993, P155; CHAN AML, 1994, ONCOGENE, V9, P1057; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; ITOH H, 1994, CANCER RES, V54, P3237; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; Lorenzi MV, 1997, ONCOGENE, V15, P817, DOI 10.1038/sj.onc.1201242; LORENZI MV, 1999, IN PRESS ONCOGENE; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1995, METHOD ENZYMOL, V254, P196; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MIKI T, 1993, METHODS MOL GENETICS, V1, P3; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; TAKAGI Y, 1994, J BIOL CHEM, V269, P23743	20	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5497	5505		10.1038/sj.onc.1202947	http://dx.doi.org/10.1038/sj.onc.1202947			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523826				2022-12-17	WOS:000082894700002
J	Hodzic, D; Frey, B; Marechal, D; Scarcez, T; Grooteclaes, M; Winkler, R				Hodzic, D; Frey, B; Marechal, D; Scarcez, T; Grooteclaes, M; Winkler, R			Cloning of breakpoints in and downstream the IGF2 gene that are associated with overexpression of IGF2 transcripts in colorectal tumours	ONCOGENE			English	Article						IGF2; overexpression; gene rearrangement; imprinting; colon cancer	GROWTH-FACTOR-II; BECKWITH-WIEDEMANN-SYNDROME; WILMS-TUMOR; HUMAN CANCER; INSULIN; HETEROZYGOSITY; CHROMOSOME-11; HYPOGLYCEMIA; EXPRESSION; REGION	The human IGF2 gene belongs to a group of imprinted genes clustered on the short arm of chromosome 11, band p15.5. It contains 9 exons and spans over 30 kb, IGF2 mRNA overexpression has been reported in human tumours and in some inherited growth disorders. It was recently demonstrated that IGF2 mRNA overexpression contributes to tumour progression and that loss of parental imprinting as well as altered transcription factors are contributing to this overexpression. We have reported structural alterations in the 3 ' region of the IGF2 gene in two colorectal tumours that overexpressed the IGF2 transcript by 200- and 800-fold. We cloned by the, vectorette-PCR strategy, genomic DNA fragments containing the breakpoints from these tumours, The sequencing of these fragments positioned the breakpoint 2 kb downstream the IGF2 gene in one tumour, and in exon 9 in the second. Both breakpoints occurred in regions containing repetitive elements: a TGGA repeat we have identified downstream the gene, and the (CA)n repetition in exon 9, We hypothesize that a negative regulatory element, located downstream the IGF2 gene, has been deleted following these structural alterations and leads to IGF2 gene overexpression.	Univ Liege, Dept Pathol, Mol Oncol Lab, B-4000 Liege, Belgium; Roche Mol Biochem, Munich, Germany; Eurogentec, B-4102 Seraing, Belgium	University of Liege	Winkler, R (corresponding author), Univ Liege, Dept Pathol, Mol Oncol Lab, Tour Pathol B23, B-4000 Liege, Belgium.							Arnold C, 1991, PCR Methods Appl, V1, P39; Baffa R, 1996, CANCER RES, V56, P268; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEMOOR CH, 1994, EUR J BIOCHEM, V222, P1017; ELLSWORTH DL, 1994, MOL BIOL EVOL, V11, P875; FIDLER AE, 1992, LANCET, V339, P243, DOI 10.1016/0140-6736(92)90042-2; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GICQUEL C, 1995, EUR J ENDOCRINOL, V133, P133, DOI 10.1530/eje.0.1330133; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; IRMINGER JC, 1989, EUR J PEDIATR, V148, P620, DOI 10.1007/BF00441514; Ishida S, 1995, INTERNAL MED, V34, P1201, DOI 10.2169/internalmedicine.34.1201; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Karnik P, 1998, ONCOGENE, V17, P237, DOI 10.1038/sj.onc.1201959; LAMBERT S, 1990, INT J CANCER, V46, P405, DOI 10.1002/ijc.2910460313; Mannens M., 1994, European Journal of Human Genetics, V2, P3; MINNITI CP, 1994, CURRENT DIRECTIONS G, P327; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; SCHNEID H, 1992, GROWTH REGULAT, V2, P45; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; SUSSENBACH JS, 1994, CURRENT DIRECTIONS I, P63; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; WINQVIST R, 1995, CANCER RES, V55, P2660	28	7	8	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 19	1999	18	33					4710	4717		10.1038/sj.onc.1202877	http://dx.doi.org/10.1038/sj.onc.1202877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467418				2022-12-17	WOS:000082154400008
J	Rouer, E; Brule, F; Benarous, R				Rouer, E; Brule, F; Benarous, R			A single base mutation in the 5 ' splice site of intron 7 of the lck gene is responsible for the deletion of exon 7 in lck mRNA of the JCaM1 cell line	ONCOGENE			English	Article						lck gene; alternative splicing; point mutation	TYROSINE KINASE; MESSENGER-RNA; HEMATOPOIETIC MALIGNANCIES; ANTIGEN RECEPTOR; TRANSCRIPTS; EXPRESSION; ACTIVATION; ICK; PHOSPHORYLATION; PROTEINS	The failure of signal transduction in the JCaM1 cell line was associated with the presence of an abnormal lck mRNA deleted of the exon 7 encoding for an inactive p56(lck) kinase. Our study of the Cck mRNA from various T cell lines and from peripheral blood lymphocytes of healthy donors has revealed the presence of both complete and exon 7-deleted lck transcripts. Thus the exon 7-deleted lck transcript initially described in the JCaM1 mutant cell line, arises from an alternative splicing event occurring in each cells expressing the lck gene. Genomic DNA sequencing of the lck exons 6-8 portion from both the mutant JCaM1 and its parental Jurkat cell lines revealed as the only difference, the presence of a A to G mutation within the 5' splice site of intron 7 in the JCaM1 cell line DNA. To demonstrate the role of this point mutation in the lck pre-mRNA maturation, COS cells were transfected by lck minigenes from the Jurkat and JCaM1 cell lines. In COS cells transfected with minigene from the Jurkat cell line both lck transcripts (with and without exon 7) were observed whereas only the exon 7-spliced lck transcript was observed in COS cells transfected with minigene from the JCaM1 cell line. Thus the mutation is per se responsible for the deletion of exon 7 and the absence of complete lck mRNA in the JCaM1 cell line. Presence of a restriction site (HphI) in the 5' splice site of lck intron 7 from Jurkat DNA allowed to confirm the presence of the mutation on both alleles in the JCaM1 cell line.	CHU Cochin Port Royal, ICGM, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Rouer, E (corresponding author), CHU Cochin Port Royal, ICGM, 24 Rue Faubourg St Jacques,CJF97-03 Interact Mol, F-75014 Paris, France.							Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; COOKE M P, 1989, New Biologist, V1, P66; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HSI ED, 1989, J BIOL CHEM, V264, P10836; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; JUCKER M, 1991, LEUKEMIA, V5, P528; KRAWCZAK M, 1992, HUM GENET, V90, P41; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROUER E, 1992, ONCOGENE, V7, P2535; ROUER E, 1994, CELL GROWTH DIFFER, V5, P659; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; ROUER E, 1993, LEUKEMIA, V7, P246; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDOL M, 1993, ONCOGENE, V8, P823; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	30	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4262	4268		10.1038/sj.onc.1202720	http://dx.doi.org/10.1038/sj.onc.1202720			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435639				2022-12-17	WOS:000081542400010
J	Li, KY; Shao, RP; Hung, MC				Li, KY; Shao, RP; Hung, MC			Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway	ONCOGENE			English	Article						tyrosine kinase receptor; neu; Shc; transformation; MAPK	EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; HUMAN-BREAST-CANCER; GUANINE-NUCLEOTIDE EXCHANGE; CYCLE-DEPENDENT REGULATION; RECEPTOR TYROSINE KINASES; EGF RECEPTOR; POINT MUTATION; OVARIAN-CANCER; PROGNOSTIC-SIGNIFICANCE	Shc proteins are implicated in coupling receptor tyrosine kinase to the mitogen-activated protein kinase (MAPK) pathway by recruiting Grb2/SOS to the plasma membrane. To better understand the role of Shc in the oncogenesis by point-mutation activated neu (p185*), we transfected a Shc mutant (Shc Delta CH1), which lacks the Grb2 binding site Y317 by deletion of collagen-homology domain 1, into p185*-transformed NIH3T3 cells. The cellular transformation phenotypes mere found to be largely suppressed by expression of Shc Delta CH1. Although Shc Delta CH1 still retained another Grb2 binding site (Y239/240), we did not detect its physical association with Grb2. We also found that Shc Delta CH1 could associate with p185*; however, this association did not interfere,vith the endogenous Shc-p185* interaction or the Shc-Grb2 interaction. In addition, p185*-mediated MAPK and Elk activation likewise were not inhibited by Shc Delta CH1 expression. Taken together, these data demonstrate that Shc Delta CH1 suppresses the transformation induced by activated neu through a MAPK-independent pathway, indicating that Shc may be involved in other signal pathway(s) critical for cellular transformation in addition to the MAPK pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Sect Mol Cell Biol, Box 79,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA77858, R01-CA58880] Funding Source: Medline; PHS HHS [16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077858, R01CA058880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BAAK JPA, 1991, LAB INVEST, V64, P215; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERCHUCK A, 1990, CANCER RES, V50, P4087; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; Kiyokawa N, 1997, ONCOGENE, V15, P2633, DOI 10.1038/sj.onc.1201442; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCCANN AH, 1991, CANCER RES, V51, P3296; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REARDON DB, 1994, ONCOL REP, V1, P37; RICCI A, 1995, ONCOGENE, V11, P1519; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TOIKKANEN S, 1992, J CLIN ONCOL, V10, P1044, DOI 10.1200/JCO.1992.10.7.1044; TYSON FL, 1991, AM J OBSTET GYNECOL, V165, P640, DOI 10.1016/0002-9378(91)90300-G; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINER DB, 1990, CANCER RES, V50, P421; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Xia WY, 1997, CLIN CANCER RES, V3, P3; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559; XIE YM, 1995, ONCOGENE, V10, P2409; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1991, ONCOGENE, V6, P1991	68	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2617	2626		10.1038/sj.onc.1202605	http://dx.doi.org/10.1038/sj.onc.1202605			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353605				2022-12-17	WOS:000079907100009
J	Guo, XYD; Balague, C; Wang, T; Randhawa, G; Yuan, ZM; Bachier, C; Greenberger, J; Arlinghaus, R; Kufe, D; Deisseroth, AB				Guo, XYD; Balague, C; Wang, T; Randhawa, G; Yuan, ZM; Bachier, C; Greenberger, J; Arlinghaus, R; Kufe, D; Deisseroth, AB			The presence of the Rb c-box peptide in the cytoplasm inhibits p210(bcr-abl) transforming function	ONCOGENE			English	Article						CML; kinases; oncogenes; leukemia; suppressor genes	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL; HEMATOPOIETIC-CELLS; GENE-PRODUCT; ACTIVATION; ONCOGENE; BCR/ABL; DNA; BINDING	In order to test if the carboxyl terminal polypeptide of the Retinoblastoma (Rb) tumor suppressor protein, could be used to suppress the growth factor-independent growth phenotype of p210(bcr-abl) positive myeloid cells, we introduced a truncated form of the 3' end of the Rb cDNA encoding its last 173 amino acid residues (Rb C-box) which localize into the cytoplasm where the p210(bcr-abl) transforming protein is found, into myeloid cells (32D) which depends on the p210(bcr-abl) protein for IL3 growth factor-independent growth (32D-p210). The expression of the plasmid vectors carrying the Rb C-box cDNAs was shown to inhibit the abl tyrosine specific protein kinase activity of the p210(bcr-abl) oncoprotein and to suppress the IL3-independent growth phenotype of the 32D-p210 cells, The Rb C-box polypeptides did not suppress the growth of the untransfected 32D parental cell line in methylcellulose in the presence of IL3-conditioned medium, These results suggest that the cytoplasmic localization of the p210(bcr-abl) allows it to escape the effect of intranuclear proteins such as Rb which negatively regulate the p145(c-abl) kinase.	Yale Univ, Sch Med, Yale Canc Ctr, Dept Internal Med,Med Oncol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, Gene Therapy Program, New Haven, CT 06520 USA; Baxter Hlth Care Corp, Round Lake, IL USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Yale University; Yale University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute	Deisseroth, AB (corresponding author), Yale Univ, Sch Med, Yale Canc Ctr, Dept Internal Med,Med Oncol Sect, WWW221,333 Cedar St, New Haven, CT 06520 USA.				NCI NIH HHS [P01 CA55164, P01 CA49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055164, P01CA049639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Henderson YC, 1997, CLIN CANCER RES, V3, P145; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588; ZHANG W, 1994, ONCOGENE, V9, P2513	24	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1589	1595		10.1038/sj.onc.1202479	http://dx.doi.org/10.1038/sj.onc.1202479			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102629				2022-12-17	WOS:000078770700009
J	Prasad, MVVSV; Dhanasekaran, N				Prasad, MVVSV; Dhanasekaran, N			GTPase deficient mutant of G alpha(13) regulates the expression of Egr-1 through the small GTPase Rho	ONCOGENE			English	Article						G protein; G alpha(13); Rho; Egr-1; transcription factors; SRE; signal transduction; oncogene	TRANSCRIPTION FACTOR EGR-1; C-FOS; CELLS; DIFFERENTIATION; ACTIVATION; GROWTH; TRANSFORMATION; ELEMENTS; IDENTIFICATION; REPRESSION	The alpha-subunit of the heterotrimeric G protein G13 regulate cell growth, differentiation and apoptosis in different cell types. Expression of the constitutively activated mutant of G alpha(13) (G alpha(13)QL) increases the expression of Egr-1, an immediate-early response gene that is identified to be involved in cell growth, differentiation, and apoptosis. Here we report that G alpha(13)QL activates the promoter of Egr-1 through specific sequence which includes the characteristic CArG boxes. We also demonstrate that the G alpha(13)QL activation of Egr-1 promoter is mediated by the Ras-like small GTPase Rho.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA.				NIGMS NIH HHS [GM 49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG H, 1993, FEBS LETT, V3, P319; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; MICEL JB, 1994, J CLIN INVEST, V94, P277; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Nair P, 1997, J BIOL CHEM, V272, P20131, DOI 10.1074/jbc.272.32.20131; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RIM M, 1992, ONCOGENE, V7, P2065; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; Watanabe S, 1997, BLOOD, V89, P1197, DOI 10.1182/blood.V89.4.1197; Wolf G, 1996, HYPERTENSION, V27, P897, DOI 10.1161/01.HYP.27.4.897; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	28	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	1999	18	8					1639	1642		10.1038/sj.onc.1202461	http://dx.doi.org/10.1038/sj.onc.1202461			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102635				2022-12-17	WOS:000078770700015
J	Scheele, JS; Pilz, RB; von Lintig, FC; Boss, GR				Scheele, JS; Pilz, RB; von Lintig, FC; Boss, GR			Deficient post-translational processing of Rap 1A in variant HL-60 cells	ONCOGENE			English	Article						Rap 1A; HL-60 cells; post-translational processing	DEPENDENT PROTEIN-KINASE; GTP-BINDING PROTEINS; PROMYELOCYTIC LEUKEMIA-CELLS; INDUCED DIFFERENTIATION; HUMAN-PLATELETS; GRANULOCYTIC DIFFERENTIATION; PHOSPHORYLATION SITE; CARBOXYL METHYLATION; SIGNAL TRANSDUCTION; KINETIC MECHANISM	Variant HL-60 cells resistant to differentiation induced by nitroprusside and cGMP analogs have normal guanylate cyclase and cGMP-dependent protein kinase (G-kinase) activity (J, Biol. Chem. 269, 32155-32161, 1994). We found decreased phosphorylation of a low molecular weight protein (pp23) in the variant cells and by co-migration on two-dimensional polyacrylamide gels, phosphopeptide mapping, immunoprecipitation and immunoblotting, we showed that pp23 was one of three post-translationally modified forms of Rap 1A expressed in HL-60 cells. Using an in vitro transcription/ translation system, rye studied each of the posttranslational processing steps of Rap 1A and we showed that pp23 represented fully processed Rap 1A. By immunoprecipitation, immunoblotting and S-35-methionine/cysteine incorporation, we showed that the variant cells were deficient in pp23, and thus in fully processed Rap 1A, but that these cells did express normal amounts of completely unprocessed Rap 1A and geranylgeranylated Rap 1A; the lack of Rap 1A processing beyond geranylgeranylation in the variant cells was not secondary to a change in Rap 1A's amino acid sequence, The variant cells had normal carboxyl methyltransferase activity suggesting they are deficient in proteolytic cleavage of Rap 1A, The deficient post-translational processing of Rap 1A had no effect on Rap 1A's subcellular distribution and we found no evidence for altered post-translational processing of H-Ras.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem & Chem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Boss, GR (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49360] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, ONCOGENE, V7, P323; ALTSCHULER D, 1993, J BIOL CHEM, V268, P7527; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BOKOCH GM, 1991, SCIENCE, V254, P1794, DOI 10.1126/science.1763330; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOSS GR, 1989, P NATL ACAD SCI USA, V86, P7174, DOI 10.1073/pnas.86.18.7174; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; CORBIN JD, 1990, ADV SEC MESS PHOSPH, V24, P411; EKLUND EA, 1991, J BIOL CHEM, V266, P13964; FISCHER TH, 1991, FEBS LETT, V283, P173, DOI 10.1016/0014-5793(91)80581-M; GALLAGHER R, 1979, BLOOD, V54, P713; GLASS DB, 1980, ANNU REV PHARMACOL, V20, P363, DOI 10.1146/annurev.pa.20.040180.002051; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HANCOCK JF, 1995, METHOD ENZYMOL, V255, P60; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLINZ FJ, 1992, EUR J BIOCHEM, V207, P207, DOI 10.1111/j.1432-1033.1992.tb17039.x; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; MA YT, 1993, FEBS LETT, V332, P105, DOI 10.1016/0014-5793(93)80493-E; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1994, J BIOL CHEM, V269, P32155; PILZ RB, 1990, J BIOL CHEM, V265, P8880; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROVERA G, 1979, SCIENCE, V204, P868, DOI 10.1126/science.286421; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHEELE JS, 1998, IN PRESS MOL CELL BI; SHI YQ, 1992, J BIOL CHEM, V267, P9547; STUDZINSKI GP, 1987, LAB INVEST, V56, P499; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOLKER C, 1990, Methods (Orlando), V1, P283, DOI 10.1016/S1046-2023(05)80329-9; VOLKER C, 1991, J BIOL CHEM, V266, P21515; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZHANG FL, 1994, J BIOL CHEM, V269, P23465	57	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2211	2223		10.1038/sj.onc.1202137	http://dx.doi.org/10.1038/sj.onc.1202137			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811452				2022-12-17	WOS:000076698200007
J	Yonetani, N; Akasaka, T; Akasaka, H; Ohno, H; Okuma, M; Miura, I; Takahashi, N; Miyanishi, S; Okumura, A; Muramatsu, M; Fukuhara, S				Yonetani, N; Akasaka, T; Akasaka, H; Ohno, H; Okuma, M; Miura, I; Takahashi, N; Miyanishi, S; Okumura, A; Muramatsu, M; Fukuhara, S			Molecular features of a new human lymphoma cell line carrying both BCL2 and BCL6 gene rearrangements	ONCOGENE			English	Article						non-Hodgkin's lymphoma; BCL2 gene; t(2 ; 18)(p11 ; q21); BCL6 gene; t(3;16)(q27;p11.2)	HUMAN FOLLICULAR LYMPHOMA; NON-HODGKINS-LYMPHOMAS; FINGER ENCODING GENE; CHROMOSOMAL TRANSLOCATIONS; 3Q27 TRANSLOCATION; LAZ3 GENE; REGION; EXPRESSION; NEOPLASMS; PROTEIN	Chromosomal translocations and/or their molecular equivalents involving the BCL6 gene on 3q27 band have been suggested to be involved in the development of non-Hodgkin's lymphoma of B-cell type (B-NHL), The rearrangement of BCL6 sometimes coexists with other translocations specific to B-NHL, Here, we report a novel B-cell lymphoma cell line, YM, established from a patient with diffuse large cell lymphoma, The YM cells expressed B-cell-associated antigens in addition to mu delta/kappa monoclonal immunoglobulin, Southern blot analysis of DNA from YM cells demonstrated rearrangement of the BCL2 gene within the 5' flanking region (5'-BCL2), Polymerase chain reaction (PCR) using primer pairs for the BCL2 exons 1 and 2, and for the constant region of the immunoglobulin re light chain gene (IG kappa) revealed PCR products encompassing the 5'-BCL2/IG kappa fusion, indicating that the YM cells had a t(2;18)(p11;q21) translocation, The BCL6 gene was rearranged at a point within the first intron, and cloning of the rearranged BCL6 revealed unidentified sequences juxtaposed to the 5' side of the gene, The isolated clones were mapped to 16p11.2 by high resolution fluorescence in situ chromosomal hybridization. Thus, the YM cells carried a 3q27 translocation involving 16p11.2 as a partner, Chromosome painting of metaphase spreads confirmed that the YM cells had both t(2;18) and t(3;16), Northern blot analysis using a fragment immediately adjacent to the breakpoint on 16p11.2 revealed transcriptional activity within this locus, The YM cells expressed abundant transcripts with aberrant sizes from BCL2 and BCL6, indicating deregulated overexpression of the two genes resulting from the t(2;18) and t(3;16). The YM cell line will therefore be useful to study whether BCL2 and BCL6 genes collaborate in the pathogenesis of B-NHL.	Kyoto Univ, Fac Med, Dept Internal Med, Div 1, Kyoto 6068507, Japan; Akita Univ, Sch Med, Dept Internal Med 3, Akita 0108543, Japan; Kansai Med Univ, Dept Internal Med 1, Moriguchi, Osaka 5708506, Japan; Tenri Med Res Inst, Tenri, Nara 6328552, Japan	Kyoto University; Akita University; Kansai Medical University	Ohno, H (corresponding author), Kyoto Univ, Fac Med, Dept Internal Med, Div 1, Kyoto 6068507, Japan.							ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1990, ONCOGENE, V5, P1653; Akasaka T, 1998, GENE CHROMOSOME CANC, V21, P17, DOI 10.1002/(SICI)1098-2264(199801)21:1<17::AID-GCC4>3.0.CO;2-B; Akasaka T, 1996, BLOOD, V88, P985; Akasaka T, 1997, CANCER RES, V57, P7; AMAKAWA R, 1991, BLOOD, V77, P1970; BASTARD C, 1994, BLOOD, V83, P2423; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CLEARY ML, 1986, J EXP MED, V164, P315, DOI 10.1084/jem.164.1.315; DALLERY E, 1995, ONCOGENE, V10, P2171; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; HIETER PA, 1982, J BIOL CHEM, V257, P1516; HORSMAN DE, 1995, BRIT J HAEMATOL, V89, P569, DOI 10.1111/j.1365-2141.1995.tb08365.x; KAWAMATA N, 1994, LEUKEMIA, V8, P1327; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KLUIN PM, 1994, NEW ENGL J MED, V331, P116, DOI 10.1056/NEJM199407143310210; KORSMEYER SJ, 1992, BLOOD, V80, P879; MARIN MC, 1995, EXP CELL RES, V217, P240, DOI 10.1006/excr.1995.1083; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIKI T, 1994, BLOOD, V83, P217; MIKI T, 1994, BLOOD, V83, P26; Muramatsu M, 1996, BRIT J HAEMATOL, V93, P911, DOI 10.1046/j.1365-2141.1996.d01-1728.x; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SEITE P, 1993, LEUKEMIA, V7, P410; SEITE P, 1993, ONCOGENE, V8, P3073; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TAKAHASHI E, 1992, GENOMICS, V13, P1047, DOI 10.1016/0888-7543(92)90018-N; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; WYATT RT, 1992, J EXP MED, V175, P1575, DOI 10.1084/jem.175.6.1575; Yabumoto K, 1996, LEUKEMIA, V10, P970; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; YE BHH, 1993, CANCER RES, V53, P2732	41	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					971	979		10.1038/sj.onc.1202027	http://dx.doi.org/10.1038/sj.onc.1202027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747876				2022-12-17	WOS:000075560900005
J	Espanel, X; Le Cam, L; North, S; Sardet, C; Brun, G; Gillet, G				Espanel, X; Le Cam, L; North, S; Sardet, C; Brun, G; Gillet, G			Regulation of E2F-1 gene expression in avian cells	ONCOGENE			English	Article						E2F; retina; differentiation; transcription; genomic footprinting	UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; S-PHASE; DIFFERENTIATION; PROLIFERATION; DEGRADATION; APOPTOSIS; INDUCTION; ELEMENTS; PROMOTER	E2F-1 is the prototype of a family of transcription factors playing a central role in the control of cell proliferation and apoptosis, E2F DNA binding activity is down-regulated during cellular differentiation, which is correlated with cell division arrest. We report here that the expression of E2F-1 itself is down-regulated in the developing quail neural retina between embryonic days E8-E10, This event occurs just after the massive arrest of the quail neuroretina cell division (E7-E8), To gain further insight into the regulatory mechanisms monitoring E2F-1 expression in differentiating neurons, we have cloned the quail E2F-1 promoter. In vivo DNA footprintings of this promoter have shown that a number of potential SP-1 and C/EBP response elements are constitutively occupied in the entire quail neuroretina of E5 and E14, whereas the two consensus palindromic E2F binding sites are only protected at E5, This suggests that these E2F elements participate in down-regulation of E2F-1 gene expression during avian neuroretina development. CAT reporter assays have shown that E2F-1 in association with its partner DP-1 transactivates its own promoter, whereas p105(Rb) inhibits the E2F-1 promoter. Both E2F-1/DP-1 and pl05(Rb) require the presence of the E2F binding sites to mediate their effects. However, experiments performed with deletion mutants of the promoter strongly suggest that other regions located upstream of the E2F binding sites also mediate part of the E2F-1 transactivating effect on its own promoter. Altogether, these results suggest that the down-regulation of E2F-1 gene expression in differentiating neurons could be due, in part, to the E2F/Rb complexes binding to the E2F-1 promoter.	Inst Biol & Chim Prot, UPR 412 CNRS, F-69367 Lyon 07, France; Ecole Normale Super Lyon, UMR 49 CNRS, Lab Biol Mol & Cellulaire, F-69364 Lyon 07, France; CNRS, UMR 9942, Ctr Mol Genet, F-34033 Montpellier 01, France	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS)	Gillet, G (corresponding author), Inst Biol & Chim Prot, UPR 412 CNRS, 7 Passage Vercors, F-69367 Lyon 07, France.		Le Cam, Laurent/O-1408-2016; gillet, germain/A-9095-2013	GILLET, Germain/0000-0002-1514-327X; LE CAM, Laurent/0000-0003-0325-878X				ALTSHULER DM, 1991, P RET RES F, V3, P37; ANTIN PB, 1991, DEV BIOL, V143, P111, DOI 10.1016/0012-1606(91)90058-B; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Espanel X, 1997, INT J DEV BIOL, V41, P469; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GILLET G, 1993, ONCOGENE, V8, P565; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUGUES SH, 1987, J VIROL, V61, P3004; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kaisse Ellen M., 1985, PHONOLOGY YB, V2, P1, DOI DOI 10.1017/S0952675700000361; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; Lin SY, 1996, MOL CELL BIOL, V16, P1668; METIVIER C, 1993, ONCOGENE, V8, P2311; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; Neuman E, 1996, GENE, V173, P163, DOI 10.1016/0378-1119(96)00184-9; North S, 1996, CELL GROWTH DIFFER, V7, P339; PASTEAU S, 1995, ONCOGENE, V11, P1475; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SARDET C, 1997, E2FS RETINOBLASTOMA; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	36	7	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	1998	17	5					585	594		10.1038/sj.onc.1201962	http://dx.doi.org/10.1038/sj.onc.1201962			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704924				2022-12-17	WOS:000075195300006
J	Tang, XX; Pleasure, DE; Brodeur, GM; Ikegaki, N				Tang, XX; Pleasure, DE; Brodeur, GM; Ikegaki, N			A variant transcript encoding an isoform of the human protein tyrosine kinase EPHB2 is generated by alternative splicing and alternative use of polyadenylation signals	ONCOGENE			English	Article						ephrin; functional diversity; neurodevelopment	RECEPTOR; FAMILY; EXPRESSION; LIGAND; GENE; SEQUENCES; REGION; MOUSE; FORMS; EHK-1	We previously isolated and characterized cDNA clones of DRT (EPHB2), encoding a receptor protein-tyrosine kinase of the EPH family, Northern blot analysis showed that EPHB2 transcripts are expressed in three sizes of approximately 4, 5, and 11 kb, suggesting that these transcripts are generated by alternative splicing and/or alternative use of polyadenylation sites. To explore this possibility, we isolated additional EPHB2 cDNA clones, including clone 5K-1, by re-screening the human fetal brain cDNA library. Nucleotide sequence analysis of clone 5K-1 revealed that it represents a variant transcript of EPHB2 (EPHB2v), Relative to the EPHB2 cDNA sequence previously reported, clone 5K-1 has two coding region deletions of 3 and 93 nucleotides. Nucleotide sequence analyses of EPHB2 genomic DNA fragments corresponding to these deletions suggest that the EPHB2v transcript is generated by alternative splicing. The 3' end of clone 5K-1 contains a polyadenosine stretch preceded by a potential polyadenylation signal, which is not used to generate the EPHB2 transcript, Taken together, these data indicate that EPHB2v is generated by both alternative splicing and alternative use of polyadenylation sites. The EPHB2v protein lacks one arginine residue that resides immediately following the EPHB2 transmembrane domain, In contrast, as a result of the frame shift caused by the 93 nucleotide deletion, the C-terminus of the EPHB2v protein is longer by 70 amino acids than that of EPHB2. We also show that the human neuroblastoma cell line SY5Y and NTera-2N neurons express high levels of EPHB2 and lower levels of EPHB2v, These structural variations found between the EPHB2 and EPHB2v proteins may reflect functional heterogeneity of EPHB2.	Childrens Hosp, Div Neurol Res, Philadelphia, PA 19104 USA; Childrens Hosp, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania	Ikegaki, N (corresponding author), Childrens Hosp, Div Neurol Res, Philadelphia, PA 19104 USA.				NCI NIH HHS [F32 CA75748] Funding Source: Medline; NINDS NIH HHS [NS08075, NS25044] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA075748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS008075, P50NS008075, R01NS025044] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Connor RJ, 1995, ONCOGENE, V11, P2429; Flanagan JG, 1997, CELL, V90, P403; IKEGAKI N, 1995, HUM MOL GENET, V4, P2033, DOI 10.1093/hmg/4.11.2033; Magal E, 1996, J NEUROSCI RES, V43, P735, DOI 10.1002/(SICI)1097-4547(19960315)43:6<735::AID-JNR10>3.0.CO;2-X; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PROUDFOOT N, 1982, NATURE, V298, P516, DOI 10.1038/298516a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SAJJADI FG, 1991, NEW BIOL, V3, P769; TAHIRA T, 1990, ONCOGENE, V5, P97; TAYLOR V, 1994, NEUROSCIENCE, V63, P163, DOI 10.1016/0306-4522(94)90014-0; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xing YD, 1996, BIOTECHNIQUES, V21, P186	17	7	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					521	526		10.1038/sj.onc.1201960	http://dx.doi.org/10.1038/sj.onc.1201960			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696046				2022-12-17	WOS:000075043000015
J	Sato, S; Tunashima, K; Mafune, Y; Ohtsuka, H; Koide, N; Endo, Y; Saito, Y; Asakura, H; Kominami, R				Sato, S; Tunashima, K; Mafune, Y; Ohtsuka, H; Koide, N; Endo, Y; Saito, Y; Asakura, H; Kominami, R			Allele-specific inactivation of the alpha 4 integrin gene expression in fibrosarcoma cell lines and relevance for spontaneous metastasis	ONCOGENE			English	Article						allele-specific inactivation; alpha 4 integrin; metastasis	TUMOR-SUPPRESSOR GENE; E-CADHERIN; DNA METHYLATION; CPG METHYLATION; HUMAN CANCERS; HUMAN COLON; CARCINOMAS; MOUSE; ADHESION; RECEPTORS	Deregulated expression of genes is found in cancer cells, which may affect malignant properties, but it is unclear whether such modulation occurs allele-specifically. This study shows that the gene coding alpha 4 integrin, a cell adhesion molecule, underwent allelic inactivation in a series of heterozygous murine fibrosarcoma cell lines (MST lines) with different metastatic potentials. P4 cells expressed the alpha 4 integrin gene from one allele at a level comparable to that of the primary MST1 tumor, whereas the descendent lines of P4 exhibited decreased expression of both alleles, No allelic loss of DNA was observed in these cells, Other four clones derived from P4 and five clones from a different tumor also showed such two-step inactivation, Intriguingly, the loss of expression was correlated with the acquisition of spontaneous, but not artificial, metastatic ability, This is consistent with the previous result of inverse relation between the expression of alpha 4/beta 1 integrin and the invasive potential of B14 melanoma cells. Analysis of DNA methylation and chromatin state of the alpha 4 integrin gene failed to provide a clue to difference between the two alleles in the cell lines, These results suggest that the allelic inactivation is a process giving loss of function to one allele, although the mechanism is unclear.	Niigata Univ, Sch Med, Dept Biochem 1, Niigata 951, Japan; Niigata Univ, Sch Med, Dept Internal Med 3, Niigata 951, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Sch Med, Dept Biochem 1, Asahimachi 1-757, Niigata 951, Japan.							ADAMS RLP, 1982, CRC CR REV BIOCH MOL, V13, P349, DOI 10.3109/10409238209108714; Akama TO, 1997, CANCER RES, V57, P3294; ANTEQUERA F, 1993, DNA METHYLATION MOL, P169; BONHOMME F, 1989, GENETIC VARIANTS STR, P649; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; Cost GJ, 1997, CANCER RES, V57, P926; DAMJANOVICH L, 1992, AM J RESP CELL MOL, V6, P197, DOI 10.1165/ajrcmb/6.2.197; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Gao AC, 1997, CANCER RES, V57, P846; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAN KA, 1992, CANCER RES, V52, P749; HERMAN JG, 1995, CANCER RES, V55, P4525; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNUDSON AG, 1985, CANCER RES, V45, P1437; KORETZ K, 1991, AM J PATHOL, V138, P741; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MAFUNE Y, 1994, ONCOGENE, V9, P2191; MAKOS M, 1993, CANCER RES, V53, P2715; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORTON RA, 1993, CANCER RES, V53, P3585; NEUHAUS H, 1991, J CELL BIOL, V115, P1149, DOI 10.1083/jcb.115.4.1149; NIGAM AK, 1993, BRIT J CANCER, V68, P507, DOI 10.1038/bjc.1993.377; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OHTSUKA H, 1994, JPN J CANCER RES, V85, P1015, DOI 10.1111/j.1349-7006.1994.tb02899.x; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAAVONEN T, 1994, INT J CANCER, V58, P298, DOI 10.1002/ijc.2910580225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PIGNATELLI M, 1990, BRIT J CANCER, V61, P636, DOI 10.1038/bjc.1990.141; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RODRIGUEZALFAGEME C, 1992, P NATL ACAD SCI USA, V89, P1482, DOI 10.1073/pnas.89.4.1482; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI T, 1991, AM J HUM GENET, V48, P880; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; Suda T, 1994, DNA Res, V1, P169, DOI 10.1093/dnares/1.4.169; SUZUKI S, 1993, JPN J CANCER RES, V84, P168, DOI 10.1111/j.1349-7006.1993.tb02851.x; TAKADA T, 1992, JPN J CANCER RES, V83, P165, DOI 10.1111/j.1349-7006.1992.tb00082.x; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	52	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					105	113		10.1038/sj.onc.1201913	http://dx.doi.org/10.1038/sj.onc.1201913			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671319				2022-12-17	WOS:000074677800012
J	Mizutani, S; Koide, H; Kaziro, Y				Mizutani, S; Koide, H; Kaziro, Y			Isolation of a new protein factor required for activation of Raf-1 by Ha-Ras: partial purification from rat brain cytosols	ONCOGENE			English	Article						Ras; Raf; reconstitution; cell-free system	SIGNAL-TRANSDUCTION PATHWAY; KINASE KINASE KINASE; KSR-1 GENE ENCODES; PLASMA-MEMBRANE; IN-VITRO; TYROSINE PHOSPHORYLATION; C-ELEGANS; B-RAF; CASCADE; 14-3-3-PROTEINS	Ras-mediated signaling pathways play a critical role in cellular proliferation and differentiation. Although it has been demonstrated that Ras interacts with Raf-1 to stimulate the serine/threonine kinase activity of Raf-1, the precise mechanism by which Ras activates Raf-1 remains obscure. To address this question, we developed a cell-free system in which the activated form of H-Ras can induce Raf-1 activation. Using this system, we found the presence of a new protein factor, in cytosolic fractions of both human embryonic kidney 293 cells and rat brain tissues, that is required for Ras-dependent activation of Raf-1. The factor was purified from rat brain cytosols through successive column chromatographies on DEAE Sephacel, SP Sepharose and Sephacryl S-300, The approximate molecular weight of the activator was estimated as 400000 by gel filtration. Its activity was sensitive to heat and trypsin treatments. The purified activator did not contain Src, 14-3-3, protein kinase C, JAK2 or Ksr-1, as judged by immunoblotting, Further characterization of the activator is underway.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 227, Japan	Tokyo Institute of Technology	Kaziro, Y (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 227, Japan.		Koide, Hiroshi/E-9000-2011	Koide, Hiroshi/0000-0001-5916-3179				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOTOH Y, 1994, ONCOGENE, V9, P1891; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; Kuroda S, 1996, J BIOL CHEM, V271, P14680, DOI 10.1074/jbc.271.25.14680; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; Miyake M, 1996, FEBS LETT, V378, P15, DOI 10.1016/0014-5793(95)01416-0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2781	2786		10.1038/sj.onc.1201806	http://dx.doi.org/10.1038/sj.onc.1201806			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652745				2022-12-17	WOS:000073812200010
J	Laursen, NB; Kessler, R; Frohli, E; Klemenz, R				Laursen, NB; Kessler, R; Frohli, E; Klemenz, R			Effects of ras transformation on the induction of the IL-1 receptor related T1 gene in response to mitogens, anisomycin, IL-1 and TNF alpha	ONCOGENE			English	Article						anisomycin; IL-1R family; IL-1; TNF alpha; MAP kinases; SB203580; signal transduction pathway; ras oncogene	ACTIVATED PROTEIN-KINASE; MURINE ST2 GENE; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; SIGNAL-TRANSDUCTION PATHWAYS; TUMOR-NECROSIS-FACTOR; NIH 3T3 FIBROBLASTS; HEAT-SHOCK PROTEINS; MAP KINASE; INTERLEUKIN-1 RECEPTOR; C-JUN	The T1 gene gives rise to two transcripts encoding a 62 kDa membrane-bound and a 37 kDa secreted protein with similarity to the type I IL-1 receptor. It is weakly expressed in proliferating but not in resting fibroblasts and is strongly induced during the entry of quiescent cells into the cell cycle. Here we show that the T1 gene is also transcriptionally activated in response to the treatment of fibroblasts with cycloheximide and anisomycin. These protein synthesis inhibitors are known to stimulate the JNK and p38/RK signal transduction pathways. We provide evidence that anisomycin triggers T1 gene induction through the stimulation of the p38/RK MAP kinase. This observation is in line with our finding that physiological activators of the p38/RK pathway, the proinflammatory cytokines IL-1 and TNF alpha, stimulate T1 gene expression efficiently. Growth factor mediated T1 gene induction is a delayed early event, requiring ongoing protein synthesis. In contrast, anisomycin induces T1 gene expression at concentrations which block translation completely. Thus, transcriptional induction of the T1 gene via the p38/RK pathway is an immediate early event not requiring de novo protein synthesis. The T1 gene is strongly induced by various mitogens in quiescent NIH3T3 fibroblasts but not in ras transformed NIH3T3 cells. In contrast, all of the three tested agent which activate the p38/RK pathway, IL-1, TNF alpha, and anisomycin led to strong T1 gene expression in normal and ras transformed NIH3T3 cells alike. Thus, the T1 gene can be induced through the activation of at least two MAP kinase pathways: signaling through the ERK pathway can occur in normal but not in ras transformed NIH3T3 cells, whereas the signaling through the p38/RK pathway is not affected by ras transformation.	Univ Zurich Hosp, Dept Pathol, Div Canc Res, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital	Klemenz, R (corresponding author), Univ Zurich Hosp, Dept Pathol, Div Canc Res, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.							ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P240; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DANESCU J, 1995, FEBS LETT, V367, P89, DOI 10.1016/0014-5793(95)00542-H; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gachter T, 1996, J BIOL CHEM, V271, P124; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; KLEMENZ R, 1993, J CELL BIOL, V120, P639, DOI 10.1083/jcb.120.3.639; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1991, GENES INDUCED SERUM, P257; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Parnet P, 1996, J BIOL CHEM, V271, P3967; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; REIKERSTORFER A, 1995, J BIOL CHEM, V270, P17645, DOI 10.1074/jbc.270.30.17645; ROSSLER U, 1993, ONCOGENE, V8, P609; ROSSLER U, 1995, DEV BIOL, V168, P86, DOI 10.1006/dbio.1995.1063; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS JA, 1995, P NATL ACAD SCI USA, V92, P1714, DOI 10.1073/pnas.92.5.1714; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; TOMINAGA S, 1992, BIOCHIM BIOPHYS ACTA, V1171, P215, DOI 10.1016/0167-4781(92)90125-J; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TRUB T, 1994, P NATL ACAD SCI USA, V91, P3896, DOI 10.1073/pnas.91.9.3896; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	69	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					575	586		10.1038/sj.onc.1201522	http://dx.doi.org/10.1038/sj.onc.1201522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482103	Bronze			2022-12-17	WOS:000071816600002
J	Keynan, S; Asipu, A; Hooper, NM; Turner, AJ; Blair, GE				Keynan, S; Asipu, A; Hooper, NM; Turner, AJ; Blair, GE			Stable and temperature-sensitive transformation of baby rat kidney cells by SV40 suppresses expression of membrane dipeptidase	ONCOGENE			English	Article						SV40; adenoviruses; cell transformation; tumour cells; peptidases	PHOSPHATIDYLINOSITOL-ANCHORED ECTOENZYME; HUMAN RENAL DIPEPTIDASE; MOLECULAR-CLONING; MICROSOMAL DIPEPTIDASE; WILMS-TUMOR; GENE DPEP1; DNA; PURIFICATION; BINDING; 16Q24.3	Membrane dipeptidase (MDP) is a zinc metalloenzyme located in the lungs and on the brush border membranes of the kidney and intestine, The gene for MDP (also termed DPEP1) is both frequently lost in Wilm's tumours and is located on human chromosome 16q24.3, a region of the genome known to contain a tumour suppressor gene(s), We now report on the regulation of MDP gene expression in normal and transformed cells, MDP enzyme activity and mRNA was detected in primary baby rat kidney (BRK) cells maintained in culture for up to 4 weeks. In contrast all stable transformed cell lines that were tested, derived either by transformation with the DNA tumour viruses SV40 or adenovirus, or in human tumour cell lines, contained very low levels of or no detectable MDP mRNA or enzyme activity, In BRK cells transformed by the temperature-sensitive tsA58 mutant of SV40 T antigen, MDP activity was not detectable, in cell lines grown at the permissive temperature (33 degrees C) but after 5-14 days of incubation at the non-permissive temperature (39.5 degrees C), MDP protein and enzyme activity could be readily detected. Taken together, these results indicate that MDP expression is characteristic of differentiated kidney epithelial cells and is down-regulated in proliferating, transformed cells.	UNIV LEEDS,DEPT BIOCHEM & MOL BIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND	University of Leeds			Blair, George Eric/A-5906-2008	Blair, George Eric/0000-0003-0440-1795; Hooper, Nigel/0000-0002-5811-3484	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1132, P311, DOI 10.1016/0167-4781(92)90167-X; ADACHI H, 1990, J BIOL CHEM, V265, P3992; AN SZ, 1994, BBA-MOL BASIS DIS, V1226, P337, DOI 10.1016/0925-4439(94)90046-9; AUSTRUY E, 1993, CANCER RES, V53, P2888; AUSTRUY E, 1993, GENOMICS, V15, P684, DOI 10.1006/geno.1993.1126; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; Fukuda S, 1996, HUM MUTAT, V7, P123, DOI 10.1002/(SICI)1098-1004(1996)7:2<123::AID-HUMU6>3.3.CO;2-V; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUENAL I, 1995, FEBS LETT, V374, P384, DOI 10.1016/0014-5793(95)01157-A; HABIB GB, 1996, J BIOL CHEM, V217, P16273; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGARASHI P, 1991, BIOCHEM J, V280, P71, DOI 10.1042/bj2800071; KAHAN FM, 1983, J ANTIMICROB CHEMOTH, V12, P1; KEYNAN S, 1994, FEBS LETT, V349, P50, DOI 10.1016/0014-5793(94)00637-7; Keynan S, 1996, ZINC METALLOPROTEASE, P285; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLEWOOD GM, 1989, BIOCHEM J, V257, P361, DOI 10.1042/bj2570361; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MAW MA, 1992, CANCER RES, V52, P3094; NAKAGAWA H, 1992, CYTOGENET CELL GENET, V59, P258, DOI 10.1159/000133263; NANUS DM, 1993, RENAL CELL CARCINOMA, P53; RACHED E, 1990, BIOCHEM J, V271, P755, DOI 10.1042/bj2710755; Sambrook J, 1989, MOL CLONING LAB MANU; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1163, P234, DOI 10.1016/0167-4838(93)90157-M; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P181, DOI 10.1016/0167-4781(93)90289-P; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; van der Eb A J, 1980, Methods Enzymol, V65, P826; VERITY AN, 1993, J NEUROCHEM, V60, P577, DOI 10.1111/j.1471-4159.1993.tb03188.x; ZAJDEL MEB, 1988, ONCOGENE, V2, P579	32	7	7	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1241	1245		10.1038/sj.onc.1201297	http://dx.doi.org/10.1038/sj.onc.1201297			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294618				2022-12-17	WOS:A1997XU99100014
J	Whitaker, LL; Hansen, MF				Whitaker, LL; Hansen, MF			Induction of apoptosis in Mv1Lu cells by expression of competitive RB1 mutants	ONCOGENE			English	Article						dominant-negative; growth suppression domain; tumor suppressor	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN LYMPHOID NEOPLASMS; LARGE T-ANTIGEN; SUSCEPTIBILITY GENE; HUMAN CANCER; FUNCTIONAL INTERACTIONS; PROTEIN; BINDING; MUTATIONS	The Retinoblastoma tumor suppressor gene (RB1) plays a role in a variety of human cancers, Experimental analyses have indicated that the protein product of the RB1 gene (pRb) plays a role in cell cycle regulation. pRb function is dependent on its ability to bind to cellular factors, which is facilitated by multiple protein binding domains within pRb. Mutations within these domains which eliminate the ability of pRb to bind its targets result in loss of function. Although loss of pRb function may lead to uncontrolled cellular proliferation, tumorigenesis is not the only response to pRb inactivation. Examination of various tissues from RB1-nullizygous mouse embryos showed problems in differentiation and induction of apoptosis, suggesting that the ultimate response to the loss of pRb is influenced by cellular context. It has previously been demonstrated in RB1-negative Saos-2 cells that co-expression of the C-terminal domain of pRb with wildtype pRb resulted in escape from G1 arrest and continued cell cycling. In this paper we demonstrate that in RB1-positive Mv1Lu cells, expression of the A/B pocket region or the N-terminus (when combined with a nuclear localization signal), but not the C-terminal domain, is able to competitively disrupt the function of the endogenous pRb, and that the result of this disruption is apoptosis.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009299, R01CA050331] Funding Source: NIH RePORTER; NCI NIH HHS [CA09299, CA50331] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHUJA HG, 1991, BLOOD, V78, P3259; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ANTELMAN D, 1995, ONCOGENE, V10, P697; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANERJEE A, 1992, CANCER RES, V52, P6297; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN YC, 1990, BLOOD, V76, P2060; CHITTENDEN T, 1991, COLD SPRING HARB SYM, V56, P187; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FATTAEY AR, 1993, ONCOGENE, V8, P3149; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fung Y K, 1992, Cancer Treat Res, V61, P59; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GALLIE BL, 1994, NEW ENGL J MED, V330, P786, DOI 10.1056/NEJM199403173301112; GINSBERG AM, 1992, LEUKEMIA LYMPHOMA, V7, P359, DOI 10.3109/10428199209049791; GINSBERG AM, 1991, BLOOD, V77, P833; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; ISHIKAWA J, 1991, CANCER RES, V51, P5736; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KATO J, 1993, GENE DEV, V7, P331; KATO MV, 1994, HUM MUTAT, V3, P44, DOI 10.1002/humu.1380030108; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KLOSS K, 1991, AM J MED GENET, V39, P196, DOI 10.1002/ajmg.1320390215; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MELING GI, 1991, BRIT J CANCER, V64, P475, DOI 10.1038/bjc.1991.334; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NAKAMURA T, 1991, JPN J CLIN ONCOL, V21, P325; NEVINS JR, 1991, COLD SH Q B, V56, P157; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; REISSMANN PT, 1989, ONCOGENE, V4, P839; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TANG A, 1989, ONCOGENE, V4, P401; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UZVOLGYI E, 1991, CELL GROWTH DIFFER, V2, P297; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEIDE R, 1991, BRIT J HAEMATOL, V78, P500, DOI 10.1111/j.1365-2141.1991.tb04479.x; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1992, Semin Immunol, V4, P389; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XU HJ, 1991, CANCER RES, V51, P4481; Yamaguchi T, 1996, ANTICANCER RES, V16, P2009; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	79	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1069	1077		10.1038/sj.onc.1201277	http://dx.doi.org/10.1038/sj.onc.1201277			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285561				2022-12-17	WOS:A1997XT16100008
J	Pasteau, S; Loiseau, L; Brun, G				Pasteau, S; Loiseau, L; Brun, G			Proliferation of chicken neuroretina cells induced by v-src, in vitro, depends on activation of the E2F transcription factor	ONCOGENE			English	Article						neuroretina cells; mitogenesis; v-src; E2F activity; dominant-negative mutants	ROUS-SARCOMA VIRUS; GREEN FLUORESCENT PROTEIN; RETINA-SPECIFIC GENE; S-PHASE ENTRY; GLUCOCORTICOID RECEPTOR; RETINOBLASTOMA PROTEIN; DEVELOPMENTAL CONTROL; EMBRYONIC RETINA; CYCLE CONTROL; C-JUN	Quiescent chicken or quail retina neuroblasts (NR) can be induced to proliferate actively, in culture, by the v-src oncoprotein. The chE2F-1 transcription factor, a physiological partner of the retinoblastoma gene product, is highly expressed in vivo, in dividing chicken neuroretina cells (CNR), It is sharply down-regulated as cells enter the post-mitotic differentiation stage, thus suggesting that E2F activity is a prerequisite for NR cell proliferation. In the present paper, transient expression assays of different forms of chE2F-1 mere used to investigate the function of E2F for switching CNR cells from a quiescent to a proliferative state in vitro. Attempts to substitute the effects of v-src by an ectopic expression of E2F-1 were unsuccessful. However, in the same conditions, E2F-1 supports full growth of CEF in serum-depleted medium, Deletion mutants of E2F-1, with potential dominant-negative properties, mere transfected in RSV infected CNR cells. One of these truncated mutants induces a G1 phase block in RSV-transformed CNR cells indicating that, although E2F-1 overexpression cannot overcome the cell proliferation block of postmitotic CNR cells E2F-1, activity is an important component of the growth signal pathway delivered by v-src in these nervous cells.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,CNRS,UMR 49,F-69364 LYON 07,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)								ADLER R, 1989, SCIENCE, V243, P391, DOI 10.1126/science.2911751; ALTSHULER D, 1993, DEVELOPMENT, V119, P1317; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BENDROR I, 1993, P NATL ACAD SCI USA, V90, P1117, DOI 10.1073/pnas.90.3.1117; BERKOFLINT Y, 1994, EMBO J, V13, P646, DOI 10.1002/j.1460-2075.1994.tb06303.x; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COLL J, 1988, J VIROL, V62, P2808, DOI 10.1128/JVI.62.8.2808-2816.1988; CRISANTI P, 1995, METHOD ENZYMOL, V254, P77; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOZIER C, 1988, BIOCHIMIE, V70, P885, DOI 10.1016/0300-9084(88)90229-5; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESPANEL X, 1997, IN PRESS INT J DEV B; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Gan L, 1996, P NATL ACAD SCI USA, V93, P3920, DOI 10.1073/pnas.93.9.3920; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOROVITS R, 1994, P NATL ACAD SCI USA, V91, P4786, DOI 10.1073/pnas.91.11.4786; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JAMAL HH, 1994, ONCOGENE, V9, P417; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI X, 1994, J BIOL CHEM, V269, P6263; LILLIEN L, 1992, DEVELOPMENT, V115, P253; LOISEAU L, 1997, IN PRESS GENE EXPRES; MARTIN P, 1992, ONCOGENE, V7, P1721; MICHEL D, 1989, ONCOGENE RES, V4, P127; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NEVINS JR, 1992, SCIENCE, V258, P424; North S, 1996, CELL GROWTH DIFFER, V7, P339; PASTEAU S, 1995, ONCOGENE, V11, P1475; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIERANI A, 1995, MOL CELL BIOL, V15, P642; PINES J, 1995, TRENDS GENET, V11, P326, DOI 10.1016/S0168-9525(00)89092-7; PLAZA S, 1995, ONCOGENE, V10, P329; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROPP JD, 1995, CYTOMETRY, V21, P309, DOI 10.1002/cyto.990210402; SAMARUT J, 1995, METHOD ENZYMOL, V254, P206; Sambrook J, 1989, MOL CLONING LAB MANU; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEFTON BM, 1980, J VIROL, V33, P220, DOI 10.1128/JVI.33.1.220-229.1980; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TCHENG M, 1994, EXP CELL RES, V212, P30, DOI 10.1006/excr.1994.1114; VARDIMON L, 1991, MOL CELL BIOL, V11, P5275, DOI 10.1128/MCB.11.10.5275; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; Yang Xiao-He, 1995, Gene Expression, V4, P195; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; YOON HY, 1994, ONCOGENE, V9, P801; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; Zhou H, 1996, J NEUROSCI, V16, P2261, DOI 10.1523/jneurosci.16-07-02261.1996; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	72	7	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 3	1997	15	1					17	28		10.1038/sj.onc.1201177	http://dx.doi.org/10.1038/sj.onc.1201177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233774				2022-12-17	WOS:A1997XH58600003
J	Yatsula, BA; Plachy, J; Mikhailik, A; DavidPfeuty, T; Lecoq, O; Yatsula, V; Geryk, J; Svoboda, J; Calothy, G; Dezelee, P				Yatsula, BA; Plachy, J; Mikhailik, A; DavidPfeuty, T; Lecoq, O; Yatsula, V; Geryk, J; Svoboda, J; Calothy, G; Dezelee, P			Phenotypic changes induced by wild type and variant c-src genes carrying C-terminal sequence alterations	ONCOGENE			English	Article						c-src; avian sarcoma virus; oncogene activation; neuroretina	ROUS-SARCOMA VIRUS; NEURORETINAL CELL-PROLIFERATION; NIH 3T3 CELLS; TRANSFORMATION DEFECTIVE MUTANT; TYROSINE KINASE-ACTIVITY; V-SRC; TRANSFECTED DNA; GROWTH-FACTOR; PP60C-SRC; ACTIVATION	We previously reported the isolation of PR2257, a novel avian sarcoma retrovirus which transduced the c-src protooncogene. The v-src gene of PR2257 differs from the c-src gene by a sequence change after amino acid 525, resulting in the replacement of tyrosine 527 by a valine, and an extension of the open reading frame into the non coding region of c-src. We investigated the respective roles of Tyr527 mutation and of the C-terminal extension in activating the oncogenic properties of c-src. Therefore we overexpressed the wild type c-src gene and c-src variants, carrying either a substitution of tyrosine 527 or an extension of the C-terminus or both modifications in combination, in chicken embryo fibroblasts and post mitotic neuroretina (NR) cells, using replication defective retroviruses. We also used in vivo inoculation of plasmid DNA to assess the tumorigenicity of the various c-src genes, We report that, in contrast to previous results, overexpression of c-src is sufficient to induce NR cell division, While mutation of tyrosine 527 alone significantly activates c-src transforming and tumorigenic properties, its combination with the C-terminal extension of PR2257 confers to this gene full oncogenic properties and increased metastatic potential as compared to the v-src of Rous sarcoma virus strains.	INST CURIE,UMR 146 CNRS,F-91405 ORSAY,FRANCE; ACAD SCI CZECH REPUBL,INST MOL GENET,CR-16637 PRAGUE 6,CZECH REPUBLIC	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences			Josef, Geryk/I-8729-2014; Plachy, Jiri/G-4381-2014; Geryk, Josef/G-3548-2014	Josef, Geryk/0000-0002-3992-2980; 				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; CALOTHY G, 1978, VIROLOGY, V89, P75, DOI 10.1016/0042-6822(78)90041-7; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COSSET FL, 1990, J VIROL, V64, P1070, DOI 10.1128/JVI.64.3.1070-1078.1990; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEZELEE P, 1992, VIROLOGY, V189, P556, DOI 10.1016/0042-6822(92)90579-E; FELDER MP, 1991, J VIROL, V65, P3633, DOI 10.1128/JVI.65.7.3633-3640.1991; GERYK J, 1989, J VIROL, V63, P481, DOI 10.1128/JVI.63.2.481-492.1989; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IBA H, 1985, MOL CELL BIOL, V5, P2856, DOI 10.1128/MCB.5.10.2856; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEBKOWSKI JS, 1984, MOL CELL BIOL, V4, P1951, DOI 10.1128/MCB.4.10.1951; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIN PH, 1995, ONCOGENE, V10, P401; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PLACHY J, 1994, IMMUNOGENETICS, V40, P257, DOI 10.1007/BF00189970; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REDDY S, 1988, MOL CELL BIOL, V8, P704, DOI 10.1128/MCB.8.2.704; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SVOBODA J, 1992, IMMUNOGENETICS, V35, P309, DOI 10.1007/BF00189893; SVOBODA J, 1984, FOLIA BIOL-PRAGUE, V31, P135; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; WAKE CT, 1984, MOL CELL BIOL, V4, P387, DOI 10.1128/MCB.4.3.387; YATSULA BA, 1994, BBA-GENE STRUCT EXPR, V1218, P473, DOI 10.1016/0167-4781(94)90210-0; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298	45	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2717	2725						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000146				2022-12-17	WOS:A1996VZ65400022
J	Vaillancourt, RR; Gardner, AM; Kazlauskas, A; Johnson, GL				Vaillancourt, RR; Gardner, AM; Kazlauskas, A; Johnson, GL			The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells	ONCOGENE			English	Article						PDGF receptor; HepG2 cells; MAP kinase; Raf-1	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; BINDING-SITE; PHOSPHATIDYLINOSITOL-3 KINASE; AUTOPHOSPHORYLATION SITES; INSULIN-RECEPTORS; CDNA CLONING	The PDGF beta-receptor in which the active-site lysine in the kinase domain has been mutated to arginine (K634R) lacks intrinsic kinase activity, When expressed in HepG2 cells, the kinase-inactive PDGF beta-receptor was tyrosine phosphorylated in response to PDGF-BB. Previously, HepG2 cells were thought to be devoid of PDGF alpha-receptor primarily due to lack of specific antibody which precluded detection of the PDGF alpha-receptor. In fact, these cells express low levels of PDGF alpha-receptor. In HepG2 cells that express the kinase-inactive PDGF beta-receptor, PDGF-BB activates the PDGF alpha-receptors to trans phosphorylate the kinase-inactive PDGF beta-receptor in an intermolecular fashion. As a result, stimulation of HepG2 cells that express the kinase-inactive receptor leads to activation of serine-threonine kinases of the MAP kinase cascade which include RAF-1, MEK-1 and p42 MAP kinase. In contrast, the kinase-inactive receptor does not activate any signaling pathways when it is expressed in PC12 cells which do not express the endogenous PDGF alpha-receptor. Thus, the kinase-inactive K634R PDGF beta-receptor is able to enhance PDGF-BB signaling in HepG2 cells that express the PDGF alpha-receptor.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Vaillancourt, RR (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.			Gardner, Anne/0000-0001-7095-772X	NCI NIH HHS [CA58187] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1993, ONCOGENE, V9, P517; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS CM, 1992, SCIENCE, V25; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; RUSSELL M, 1995, BIOCHEMISTRY-US, V34, P6611, DOI 10.1021/bi00020a005; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SELVA E, 1993, J BIOL CHEM, V268, P2250; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	73	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					151	159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700541				2022-12-17	WOS:A1996UX31900017
J	Brockmann, D; Schafer, D; Kirch, HC; Esche, H				Brockmann, D; Schafer, D; Kirch, HC; Esche, H			Repression of c-Jun-induced mouse major histocompatibility class I promoter (H-2K(b)) activity by the Adenovirus type 12-unique 52R E1A protein	ONCOGENE			English	Article						adenovirus type 12; E1A; MHC class I; oncogenicity; transformation	NF-KAPPA-B; TRANSFORMED RAT-CELLS; EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GEL-ELECTROPHORESIS; NEGATIVE REGULATION; RESPONSE ELEMENT; FACTOR BINDING; AP-1 ACTIVITY	Down-regulation of major histocompatibility (MHC) class I gene expression by protein products of the early region 1A (E1A), which might allow transformed cells to escape the host immune system, is discussed as one cause for the oncogenicity of Adenovirus (Ad) subtype 12-transformed cells, The MHC class I promoter is activated through several cellular transcription factors among them AP-1, whose target sequences are located in the enhancers A and B, and NF kappa B, In this report we present evidence that the Ad12-unique 52R E1A protein inhibits c-Jun-induced activation of MHC class I gene expression, Repression occurs through both AP-1 recognition sequences with the AP-1 binding site of Enhancer A, which can be bound by c-Jun dimers irt vitro, being the main target for c-Jun activation as well as 52R-mediated down-regulation, Furthermore our data revealed that both promoter elements of Enhancer A, the AP-1 and NF kappa B binding sites, are necessary for full promoter activity, As NF kappa B is down-regulated by the 266R protein of Ad12 E1A our results suggest a model in which two Ad12 E1A proteins co-operate in the repression of MHC class I gene expression.			Brockmann, D (corresponding author), UNIV ESSEN GESAMTHSCH, SCH MED, INST MOL BIOL CANC RES, HUFELANDSTR 55, D-45122 ESSEN, GERMANY.							ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMANN D, 1994, VIROLOGY, V198, P717, DOI 10.1006/viro.1994.1085; BROCKMANN D, 1995, J BIOL CHEM, V270, P10754, DOI 10.1074/jbc.270.18.10754; BROCKMANN D, 1995, MOL REPERTOIRE ADENO, V3, P81; BYRD PJ, 1988, ONCOGENE, V2, P477; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; FLINT SJ, 1981, STRUCTURE GENOMIC OR, P383; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JOCHEMSEN H, 1982, VIROLOGY, V122, P15, DOI 10.1016/0042-6822(82)90373-7; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LEE KAW, 1987, P NATL ACAD SCI USA, V84, P8355, DOI 10.1073/pnas.84.23.8355; LIU XH, 1994, ONCOGENE, V9, P2183; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, MOL CLONING; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIROKI K, 1977, VIROLOGY, V82, P462, DOI 10.1016/0042-6822(77)90019-8; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TANG XR, 1995, J BIOL CHEM, V270, P2327, DOI 10.1074/jbc.270.51.30428; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDEREB AJ, 1979, COLD SPRING HARB SYM, V44, P383, DOI 10.1101/SQB.1980.044.01.043; WHITE E, 1995, MOL REPERTOIRE ADENO, V3, P33; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; WILLIAMS J, 1995, MOL REPERTOIRE ADENO, V3, P149; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	66	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1715	1725						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622892				2022-12-17	WOS:A1996UG45800014
J	Zhang, GQ; Humphries, EH				Zhang, GQ; Humphries, EH			v-rel and c-rel induce a membrane protein, p75, on avian hematopoietic cells	ONCOGENE			English	Article						rel oncogene; p75; ectopic expression	NF-KAPPA-B; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATOR; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; LYMPHOID-CELLS; LINES; IDENTIFICATION; REPRESSION	v-rel-induced neoplasias are thought to be caused by the aberrant expression of cellular genes. Using a monoclonal antibody we detected a 75 kDa-protein (p75) on vrel-transformed chicken hematopoietic cells. This protein is normally expressed only on a certain type of non-T, non-B cells in the chicken caecal tonsils. Overexpression of v-rel in two B-cell lines and in splenic cells induced the expression of p75. In contrast, overexpression of c-rel in these cells resulted in variable expression of p75. These data indicated that p75 is ectopically expressed on v-rel-transformed hematopoietic cells and that it responds differently to v-rel and c-rel induction.	W VIRGINIA UNIV,HLTH SCI CTR,MARY BABB RANDOLPH CANC CTR,MORGANTOWN,WV 26506; W VIRGINIA UNIV,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,MORGANTOWN,WV 26506	West Virginia University; West Virginia University					NATIONAL CANCER INSTITUTE [R01CA041450] Funding Source: NIH RePORTER; NCI NIH HHS [CA41450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA Y, 1974, BIKEN J, V17, P105; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CH, 1988, EUR J IMMUNOL, V18, P539, DOI 10.1002/eji.1830180408; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HUFFNAGLE GB, 1989, HYBRIDOMA, V8, P589, DOI 10.1089/hyb.1989.8.589; HUMPHRIES EH, 1992, CURRENT TOPIC MICROB, V18, P475; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAZERIAN K, 1982, J GEN VIROL, V58, P351, DOI 10.1099/0022-1317-58-2-351; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; OKAZAKI W, 1980, AVIAN PATHOL, V9, P311, DOI 10.1080/03079458008418416; OLSON LD, 1967, AM J VET RES, V28, P1501; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	34	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1153	1157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649808				2022-12-17	WOS:A1996UA88400025
J	ENGELKE, U; SMARDA, J; LIPSICK, JS				ENGELKE, U; SMARDA, J; LIPSICK, JS			BYPASS OF TPA-INDUCED DIFFERENTIATION AND CELL-CYCLE ARREST BY THE C-MYB DNA-BINDING DOMAIN	ONCOGENE			English	Article						MYB; CELL CYCLE; TPA	TRANSFORMATION; TRUNCATION; GENE; ACTIVATION; EXPRESSION; ONCOGENE; PROTEIN	Monoblasts transformed by v-Myb can be induced to differentiate into macrophages by treatment with phorbol ester (TPA). This differentiation occurs during both the G(1) and the G(2) phases of the cell cycle and is accompanied by cell cycle arrest. The introduction of a protein consisting of the three repeats (3R) of the c-Myb DNA-binding domain permits the by-pass of this phorbol ester-induced differentiation and cell cycle arrest. In particular, monoblasts which express the 3R protein progress through both the G(1)/S and G(2)/M transitions in the presence of phorbol ester. However, the 3R protein contains no detectable transcriptional activation domain. These results demonstrate that the c-Myb DNA-binding domain can regulate the cell cycle without functioning as a direct transcriptional activator.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305; MASARYK UNIV,FAC SCI,DEPT MOLEC BIOL & GENET,CS-61137 BRNO,CZECH REPUBLIC	Stanford University; Masaryk University Brno					FOGARTY INTERNATIONAL CENTER [R03TW000291] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043592] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00291] Funding Source: Medline; NCI NIH HHS [R01 CA43592] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; GARCIA A, 1991, ONCOGENE, V6, P265; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SMARDA J, 1993, GENE, V137, P145; SMARDA J, 1994, ONCOGENE, V9, P237; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587	21	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					735	741						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651737				2022-12-17	WOS:A1995RQ46900015
J	CARRERA, AC; BORLADO, LR; GONZALEZGARCIA, A; ROBERTS, TM; MARTINEZA, C				CARRERA, AC; BORLADO, LR; GONZALEZGARCIA, A; ROBERTS, TM; MARTINEZA, C			ROLE OF THE AUTOPHOSPHORYLATION SITE ON THE BIOLOGICAL FUNCTION OF PP56(LCK)	ONCOGENE			English	Article						AUTOPHOSPHORYLATION; KINASES; FUNCTION	CELL ANTIGEN RECEPTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE P56LCK; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; THYMOCYTE DEVELOPMENT; SIGNAL TRANSDUCTION; NUCLEAR FACTOR; EXPRESSION; GENE	Src-family tyrosine kinases act as signaling molecules in a aide array of cellular activation processes. The existence of the various src-family members reflects the requirement for different cell-surface receptors to transmit cell-type specific intracellular signals. The structural basis for the functional specificity of src-kinases is being actively investigated. In the present report we have analysed the contribution of the area surrounding the autophosphorylation site (located at subdomain VII of the catalytic domain) in determining src-kinases activity and functional specificity. To this end we analysed the kinase activities of the lymphoid src-kinase pp56(lck) and a mutant of pp56(lck) in which this region has been exchanged for the corresponding area of the serine/threonine kinase c-Raf. Our studies indicate that the change at subdomain VII affected the ability of pp56(lck) to phosphorylate physiological substrates. Furthermore, when analysed in T cells, the mutant at subdomain VII failed to induce interleukin-2 production, a specific biological function of pp56(lck). Thus, the area surrounding the autophosphorylation site of pp56(lck) plays a critical role in mediating its specific biological function.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MOLEC & CELLULAR BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	CARRERA, AC (corresponding author), UNIV AUTONOMA MADRID, CSIC, CTR NACL BIOTECNOL, CAMPUS CANTOBLANCO, E-28049 MADRID, SPAIN.		Gonzalez-Garcia, Ana/D-9736-2014	Gonzalez-Garcia, Ana/0000-0002-6669-1735; Carrera, Ana/0000-0002-3999-5434	NCI NIH HHS [CA 43803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; BEVERLEY PCL, 1981, EUR J IMMUNOL, V11, P329, DOI 10.1002/eji.1830110412; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WOODROW MA, 1993, J IMMUNOL, V150, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	7	7	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2379	2386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784086				2022-12-17	WOS:A1995RE54300013
J	BORYCKI, AG; FOUCRIER, J; SAFFAR, L; LEIBOVITCH, SA				BORYCKI, AG; FOUCRIER, J; SAFFAR, L; LEIBOVITCH, SA			REPRESSION OF THE CSF-1 RECEPTOR (C-FMS PROTOONCOGENE PRODUCT) BY ANTISENSE TRANSFECTION INDUCES G1-GROWTH ARREST IN L6-ALPHA-1 RAT MYOBLASTS	ONCOGENE			English	Article						D-TYPE CYCLINS; C-FMS; MYOGENESIS	CYCLIN MESSENGER-RNA; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; DNA-REPLICATION; GROWTH-FACTOR; G1 PHASE; S-PHASE	Colony Stimulating Factor (CSF-1) and the CSF-1 receptor (the c-fms product) are expressed during the proliferation of L6 alpha 1 rat myogenic cell line and both are down regulated during the formation of myotubes. In this study, we demonstrated that the expression of c-fms antisense RNA in stably transfected myoblasts repressed the CSF-1 receptor (c-fms protein) and induced a G1-growth arrest. Expression of the cyclin genes, that control passage through the G1 phase and in particular the cyclins identified as genes induced late in G1 by CSF-1 in mouse macrophages was studied in comparative Northern blot analyses of RNAs of subpopulations prepared by centrifugal elutriation of L6 alpha 1 myoblasts and induced Antifms D5 cells expressing c-fms antisense RNA. Repression of the CSF-1 receptor (c-fms product) did not affect cyclins A, B and G expression during the cell cycle. However, D-type cyclins and, at a lesser extend, cyclin E expression were dramatically altered specifically during the late G1 and early S phases, in Antifms D5 cells. These results suggest a role for the CSF-1/c-fms autocrine loop in the control of the proliferation of L6 alpha 1 rat myogenic cell line at the G1/S boundary via the D-type and E cyclins expression.	INST GUSTAVE ROUSSY, EXPTL CANCEROL LAB, CNRS, UA1158, URA126, F-94800 VILLEJUIF, FRANCE; UNIV PARIS 13, BIOL DEV & DIFFERENCIAT LAB, F-93012 BOBIGNY, FRANCE; UNIV PARIS 13, BIOL CELLULAIRE LAB, UFR BIOMED, F-93012 BOBIGNY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Universite Paris 13; Universite Paris 13								AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BORYCKI, 1995, IN PRESS EYPT CELL R; BORYCKI AG, 1993, BIOCHIM BIOPHYS ACTA, V1174, P143, DOI 10.1016/0167-4781(93)90108-P; Borycki AG, 1992, GROWTH FACTORS, V6, P209, DOI 10.3109/08977199209021534; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUILLIER M, 1991, NUCLEIC ACIDS RES, V19, P1339, DOI 10.1093/nar/19.6.1339; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HILLION J, 1984, CANCER RES, V44, P2959; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LU XP, 1992, J BIOL CHEM, V267, P2841; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSENTHAL ET, 1980, CELL, V20, P487, DOI 10.1016/0092-8674(80)90635-2; RUTSGI AK, 1991, NATURE, V352, P541; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; SURMACZ E, 1992, CANCER RES, V52, P4522; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAMURA K, 1993, ONCOGENE, V8, P2113; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YEN A, 1993, J CELL PHYSIOL, V157, P379, DOI 10.1002/jcp.1041570222; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	67	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	1995	10	9					1799	1811						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753556				2022-12-17	WOS:A1995QX46900013
J	VANAMSTERDAM, JR; WANG, Y; SULLIVAN, RC; ZARBL, H				VANAMSTERDAM, JR; WANG, Y; SULLIVAN, RC; ZARBL, H			ELEVATED EXPRESSION OF THE JUNB PROTOONCOGENE IS ESSENTIAL FOR V-FOS INDUCED TRANSFORMATION OF RAT-1 CELLS	ONCOGENE			English	Article							OSTEO-SARCOMA VIRUS; C-JUN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NEGATIVE REGULATOR; MOLECULAR-CLONING; MOUSE FIBROBLASTS; LEUCINE ZIPPER; GENE; AP-1	We previously described the isolation of non-tumorigenic revertants from mutagenized populations of v-fos-transformed Rat-1 cells (Zarbl et al., 1987). In the present study we examined the possibility that the revertant phenotype resulted from mutations that altered the expression or activities of the c-jun or junB protooncogenes. The results demonstrated that levels of the c-jun mRNA and protein were unchanged in the revertants when compared to the transformed parental cells, and ectopic overexpression of c-jun failed to retransform the revertants. Although one mutant allele was detected in revertant EMS-1-19, overexpression of this mutant allele failed to inhibit v-fos induced cell transformation. Together these results indicated that the revertant phenotype did not result from altered expression or mutations in the c-jun gene. In contrast to the results obtained with c-jun, the levels of junB mRNA and protein were found to be reduced two- or threefold in revertant EMS-1-19. Ectopic overexpression of junB induced transformation of revertant EMS-1-19, but failed to transform Rat-1 cells. Moreover, about 10% of v-fos transformed cells transfected with vectors that express antisense junB mRNA acquired a non-transformed phenotype. Together these results indicate that expression of junB above a threshold level is essential for v-fos-induced transformation of Rat-1 fibroblasts.	MIT, WHITAKER COLL HLTH SCI & TECHNOL, DIV TOXICOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)					NATIONAL CANCER INSTITUTE [R01CA047571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007020] Funding Source: NIH RePORTER; NCI NIH HHS [CA47571] Funding Source: Medline; NIEHS NIH HHS [2-T32-ES07020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOYLAN MO, 1991, J CELL BIOCHEM, V46, P199, DOI 10.1002/jcb.240460303; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KHO CJ, 1992, P NATL ACAD SCI USA, V89, P2200, DOI 10.1073/pnas.89.6.2200; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OKUNO H, 1991, ONCOGENE, V6, P1491; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	43	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2969	2976						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084600				2022-12-17	WOS:A1994PG82200023
J	MAFUNE, Y; ASAKURA, H; KOMINAMI, R				MAFUNE, Y; ASAKURA, H; KOMINAMI, R			ALLELIC LOSSES AND METASTATIC ABILITY OF MOUSE-TUMOR CELL CLONES DERIVED FROM A HETEROZYGOUS MOUSE	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; DNA POLYMORPHISMS; SUPPRESSOR GENES; PROSTATIC-CANCER; ALLELOTYPE; MUTATIONS; CARCINOMA; GENOME; P53; MAP	Some chromosomal or subchromosomal deletions observed in a variety of cancer cells may be related with metastatic properties of the tumor cells. Thus, relationship between allelic losses and metastatic ability is here investigated of ten in vitro clones obtained from 505 cells that are derived from a fibrosarcoma induced in a F-1 mouse between C3H and C57BL strains. Allelic loss was examined using 61 microsatellite markers spanning all autosomes and deletions of various loci were observed in all of the clones. One clone showed a metastatic ability higher than the parental 505 cells and the other clones. This particular clone specifically lost a chromosome 16 derived from C57BL, suggesting an association of this chromosome deletion with the metastatic ability. Consistently, examination of metastatic nodules derived from 505 cells and one in vitro clone showed that the cells with deletion of the C57BL chromosome increased in number during metastasis. These results suggest that mouse chromosome 16 may harbor a gene(s) involved in metastasis.	NIIGATA UNIV,SCH MED,DEPT BIOCHEM 1,NIIGATA 951,JAPAN; NIIGATA UNIV,SCH MED,DEPT INTERNAL MED 3,NIIGATA 951,JAPAN	Niigata University; Niigata University								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BACKER JM, 1993, ONCOGENE, V8, P497; BRATHWAITE O, 1992, CANCER RES, V52, P3791; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; DIETRICH W, 1992, GENETICS, V131, P423; EMANUEL BS, 1991, CYTOGENET CELL GENET, V58, P827, DOI 10.1159/000133182; ENOKI Y, 1990, JPN J CANCER RES, V81, P141, DOI 10.1111/j.1349-7006.1990.tb02540.x; FUJIMORI M, 1991, CANCER RES, V51, P89; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAYASHI H, 1993, JPN J CANCER RES, V84, P1292; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; Hirohashi S, 1991, Princess Takamatsu Symp, V22, P87; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; ICHIKAWA T, 1992, P NATL ACAD SCI USA, V89, P1607, DOI 10.1073/pnas.89.5.1607; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KODAMA Y, 1982, J NATL CANCER I, V69, P595; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LIOTTA LA, 1986, CANCER RES, V46, P1; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MIYAKI M, 1990, CANCER RES, V50, P7166; MOHLER JL, 1988, CANCER RES, V48, P4312; MORITA R, 1991, CANCER RES, V51, P820; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OSHIMURA M, 1986, ENVIRON MUTAGEN, V8, P129, DOI 10.1002/em.2860080112; RAMSHAW IA, 1983, INT J CANCER, V32, P471, DOI 10.1002/ijc.2910320414; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; TAKADA T, 1992, JPN J CANCER RES, V83, P165, DOI 10.1111/j.1349-7006.1992.tb00082.x; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WANG LM, 1993, CANCER RES, V53, P717; WEBER JL, 1989, AM J HUM GENET, V44, P388; YAMAGUCHI T, 1992, CANCER RES, V52, P2419	40	7	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2191	2196						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036005				2022-12-17	WOS:A1994NX62900010
J	BURGAYA, F; GARCIAFERNANDEZ, J; RIUTORT, M; BAGUNA, J; SALO, E				BURGAYA, F; GARCIAFERNANDEZ, J; RIUTORT, M; BAGUNA, J; SALO, E			STRUCTURE AND EXPRESSION OF SPK-1, AN SRC-RELATED GENE-PRODUCT FOUND IN THE PLANARIAN DUGESIA-(G)-TIGRINA	ONCOGENE			English	Note							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; PATTERN-FORMATION; SEQUENCE-ANALYSIS; FAMILY; DOMAIN; REGENERATION; NEOBLASTS; PHYLOGENY; RNAS	A cDNA clone encoding a 497 amino acid protein 75% similar to most Src proteins has been isolated from the planarian Dugesia (Girardia) tigrina (Platyhelminthes; Turbellaria) by PCR followed by screening procedures. This gene product has been designated Spk-1 as it is the first Src-related kinase isolated in a planarian. The predicted amino acid sequence of Spk-1 suggest that it is anchored to the plasma membrane and that it interacts with other phosphotyrosine proteins. Spk-1 is expressed in both intact and regenerating organisms as an mRNA transcript of about 1.9 kb. Planarians, which conserve most features of the common ancestor to protostomian and deuterostomian phyla, are the most primitive triploblastic organisms from which a protein tyrosine kinase gene product has been isolated. The presence of this gene product in such a primitive organism, and its presumed role, are discussed.	UNIV BARCELONA,FAC BIOL,DEPT GENET,DIAGONAL 645,E-08028 BARCELONA,SPAIN	University of Barcelona			Salo, Emili/M-3928-2014; Garcia-Fernandez, Jordi/B-3839-2013; Riutort, Marta/B-6441-2009	Salo, Emili/0000-0001-5460-9223; Garcia-Fernandez, Jordi/0000-0001-5677-5970; Riutort, Marta/0000-0002-2134-7674				BAGUNA J, 1981, NATURE, V290, P14, DOI 10.1038/290014b0; BAGUNA J, 1989, DEVELOPMENT, V107, P77; BAGUNA J, 1990, EXPT EMBRYOLOGY AQUA, P129; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BERGSTROM L, 1987, MOL PHARMACOL, V32, P764; BOLEN JB, 1993, ONCOGENE, V8, P2025; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOSCH TCG, 1989, MOL CELL BIOL, V9, P4141, DOI 10.1128/MCB.9.10.4141; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GALLIOT B, 1993, TRENDS GENET, V9, P3, DOI 10.1016/0168-9525(93)90051-I; GARCIAFERNANDEZ J, 1993, DEVELOPMENT, V118, P241; GARCIAFERNANDEZ J, 1991, P NATL ACAD SCI USA, V88, P7338, DOI 10.1073/pnas.88.16.7338; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Karlstedt K.A., 1990, Acta Academiae Aboensis Ser B Mathematica et Physica Matematik Naturvetenskaper Teknik, V50, P59; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OTTILIE S, 1992, ONCOGENE, V7, P1625; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, NATURE, V356, P285, DOI 10.1038/356285a0; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RIDLEY AJ, 1992, NATURE, V355, P497, DOI 10.1038/355497a0; RIUTORT M, 1992, CAN J ZOOL, V70, P1425, DOI 10.1139/z92-199; SALO E, 1984, J EMBRYOL EXP MORPH, V83, P63; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; Willmer P, 1990, INVERTEBRATE RELATIO	36	7	10	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1267	1272						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	7510865				2022-12-17	WOS:A1994NC04800033
J	HAINZL, T; BOEHM, T				HAINZL, T; BOEHM, T			A VERSATILE EXPRESSION VECTOR FOR THE IN-VITRO STUDY OF PROTEIN-PROTEIN INTERACTIONS - CHARACTERIZATION OF E47 MUTANT PROTEINS	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; HELIX ZIPPER PROTEIN; DNA-BINDING; ESCHERICHIA-COLI; ENHANCER-BINDING; TRANSLOCATION; CLONING; MYC; PURIFICATION; DIMERIZATION	Several mutants of the E47 protein, a member of the family of basic/helix-loop-helix (b-HLH) transcriptional regulators, were examined for their ability to homo- and heterodimerize with the protein product of the T-cell oncogene tal-1/SCL. For this purpose, a novel bacterial expression system was developed in which proteins are expressed as fusions appended to glutathione-S-transferase via a thrombin cleavage site and either one or four protein kinase recognition sites embedded in a glycine-rich domain. Since the interaction domain can be purified away from the glutathione-S-transferase moiety and the radioactive label is located in a flexible N-terminal tag, protein folding should occur normally. Our studies with E47 proteins prepared in this system indicate that the ratio between E47 homodimers and E47/tal-1 heterodimers can dramatically shift upon subtle mutations in the loop region and the second helix of the E47 protein. This unexpected result suggests a novel mechanism to alter the equilibrium between different transactivating protein complexes of the b-HLH class.	UNIV FREIBURG, DEPT MED 1, MOLEC MED GRP, D-79106 FREIBURG, GERMANY	University of Freiburg								BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GREEN AR, 1992, ONCOGENE, V7, P653; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEHLS M, 1993, TRENDS GENET, V9, P336, DOI 10.1016/0168-9525(93)90024-C; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RABBITTS TH, 1994, IN PRESS NATURE; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SACCHETTA P, 1993, EUR J BIOCHEM, V215, P741, DOI 10.1111/j.1432-1033.1993.tb18087.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUJN XH, 1991, MOL CELL BIOL, V11, P5603; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	30	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1994	9	3					885	891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108132				2022-12-17	WOS:A1994MW55100025
J	SCHULZ, RA; HOGUE, DA; THE, SM				SCHULZ, RA; HOGUE, DA; THE, SM			CHARACTERIZATION OF LETHAL ALLELES OF D-ELG, AN ETS PROTOONCOGENE RELATED GENE WITH MULTIPLE FUNCTIONS IN DROSOPHILA DEVELOPMENT	ONCOGENE			English	Article							POSTERIOR DETERMINANT; FAMILY; LOCALIZATION; POLARITY; DOMAIN; MELANOGASTER; SEQUENCE; PRODUCT; EMBRYO; OSKAR	We have used genetic complementation rescue to identify two lethal alleles of D-elg, an ets proto-oncogene related gene of Drosophila. Animals that are hemizygous or trans-heterozygous for the alleles die as pharate adults, demonstrating normal gene function is required to complete Drosophila development. Females trans-heterozygous for the 1(3)902 lethal allele and the previously characterized tne female sterile allele produce embryos with abdominal segmentation defects. This finding implicates a role for the D-elg gene in anterior-posterior patterning. The cloning and sequencing of the lethal alleles identified molecular mutations that may result in ELG protein truncation, altered ELG protein interactions, or defective D-elg mRNA splicing.			SCHULZ, RA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; Ashburner M, 1989, DROSOPHILA LAB HDB, P139; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; GALEWSKY S, 1990, GENE, V96, P227, DOI 10.1016/0378-1119(90)90257-R; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LINDSLEY DL, 1992, GENOME DROSOPHILA MA; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; SCHULZ RA, 1993, IN PRESS P NATL ACAD; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; STJOHNSTON D, 1992, CELL, V68, P201; THE SM, 1992, ONCOGENE, V7, P2471; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; Wieschaus E., 1986, P199	28	7	7	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3369	3374						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247539				2022-12-17	WOS:A1993MG78200021
J	GARRIDO, C; PLAZA, S; GOSPODAROWICZ, D; SAULE, S				GARRIDO, C; PLAZA, S; GOSPODAROWICZ, D; SAULE, S			FOS EXPRESSION INDUCES GROWTH ARREST IN TUMORIGENIC NEURORETINA CELLS	ONCOGENE			English	Article							PROTO-ONCOGENE; C-MYC; V-FOS; GENE; JUN; TRANSFORMATION; PROTEINS; P135GAG-MYB-ETS; STIMULATION; INDUCTION	E26-infected chicken neuroretina (CNR) cells expressing P135gag-myb-ets are non-transformed and growth can be stimulated by basic fibroblast growth factor (bFGF). In contrast, MHE226-infected CNR cells, which express p61/63myc in addition to the P135gag-myb-ets of E26, are transformed, tumorigenic cells and are growth inhibited by bFGF. We looked for differences in both cells types which could help to understand the molecular basis of the bFGF response. We found marked differences in c-fos expression. In MHE226-CNR cells c-fos mRNA was induced by 12-0-tetradecanoyl phorbol 13-acetate (TPA) and bFGF, both inhibitors of MHE226-infected cell growth. In contrast, serum, a strong growth inducer, did not stimulate c-fos expression. In E26-infected cells all of these factors induced cell growth and c-fos expression. MHE226-CNR cells superinfected with v-fos(FBJ)-expressing retrovirus were inhibited in their growth and unresponsive to bFGF. Introduction of V-fos(FBJ) in E26 CNR cells transformed them but they remained sensitive to bFGF. These results suggest that fos is involved in the induced growth arrest of MHE226-CNR cells.	UNIV CALIF SAN FRANCISCO,MED CTR,CANC RES INST,M-1282,SAN FRANCISCO,CA 94143; INST PASTEUR,CNRS,EP 56,F-59019 LILLE,FRANCE	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			plaza, serge/F-5290-2015; Garrido, Carolina/GWM-5557-2022					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRICK KK, 1990, MOL CELL BIOL, V10, P184, DOI 10.1128/MCB.10.1.184; FUJIWARA KT, 1987, J VIROL, V61, P4012, DOI 10.1128/JVI.61.12.4012-4018.1987; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IBA H, 1988, ONCOGENE RES, V2, P121; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; OKUNO H, 1991, ONCOGENE, V6, P1491; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROBINSON CJ, 1991, TRENDS PHARMACOL SCI, V12, P123, DOI 10.1016/0165-6147(91)90525-W; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9	28	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2713	2719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397368				2022-12-17	WOS:A1993LX34300012
J	HEVEZI, P; ALIN, K; GOFF, SP				HEVEZI, P; ALIN, K; GOFF, SP			TRANSFORMING ACTIVITY AND TISSUE TROPISM OF HYBRID RETROVIRAL GENOMES CONTAINING PORTIONS OF THE V-ABL AND V-SRC ONCOGENES	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; ROUS-SARCOMA VIRUS; AMINO-TERMINAL DOMAIN; CELL TRANSFORMATION; HOMOLOGY REGION-2; TYROSINE KINASE; LYMPHOID-CELLS; INVITRO TRANSFORMATION; SIGNAL TRANSDUCTION; SH3 DOMAINS	The v-abl and v-src oncogenes encode activated cytoplasmic tyrosine kinases with considerable sequence similarity. The v-abl oncogene of the Abelson murine leukemia virus exhibits a narrow tissue tropism for transformation, almost exclusively forming pre-B-cell tumors, while the v-src oncogene can induce a variety of sarcomas and other tumors. To localize the determinants of the narrow tropism of the v-abl gene, we generated a series of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes in a Moloney murine leukemia virus backbone. Each virus was tested for transforming activity in NIH3T3 cells; for transforming activity on bone marrow cultures; and for pathogenicity in newborn mice. Many of the hybrid oncogenes carried by these viruses exhibited transforming activity, and demonstrate that the SH2 domain of each oncogene can be utilized by the kinase domain of the other oncogene for that activity. The results further suggest that a portion of the C-terminal region of v-abl is necessary for the pre-B-cell specificity of the oncogene.	COLUMBIA UNIV,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University								ABELSON HT, 1970, CANCER RES, V30, P2213; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ANDERSON SM, 1983, J VIROL, V46, P594, DOI 10.1128/JVI.46.2.594-605.1983; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHESTERMAN FC, 1966, CANCER RES, V26, P1759; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; FEUERMAN MH, 1985, J VIROL, V54, P804, DOI 10.1128/JVI.54.3.804-816.1985; FEUERMAN MH, 1988, MOL CARCINOGEN, V1, P57, DOI 10.1002/mc.2940010112; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; HEVEZI P, 1991, J VIROL, V65, P5333, DOI 10.1128/JVI.65.10.5333-5341.1991; HEVEZI P, 1992, ONCOGENE, V7, P2323; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARDON G, 1983, CELL, V32, P871, DOI 10.1016/0092-8674(83)90072-7; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MOLONEY JOHN B., 1966, NAT CANCER INST MONOGR, V22, P139; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; PARMAR K, 1991, J VIROL, V65, P6478, DOI 10.1128/JVI.65.12.6478-6485.1991; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P80; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Pawson T., 1992, CURR OPIN STRUC BIOL, V2, P432; PIERCE JH, 1984, P NATL ACAD SCI-BIOL, V81, P2374, DOI 10.1073/pnas.81.8.2374; Potts W M, 1988, Oncogene Res, V3, P343; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; PRIVALSKY ML, 1987, J VIROL, V61, P1938, DOI 10.1128/JVI.61.6.1938-1948.1987; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; RAYMOND VW, 1987, VIROLOGY, V160, P400, DOI 10.1016/0042-6822(87)90011-0; REESJONES RW, 1988, J VIROL, V62, P978, DOI 10.1128/JVI.62.3.978-986.1988; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1980, VIRAL ONCOLOGY, P187; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WANG LH, 1988, VIRUS RES, V9, P159; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	57	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2413	2423						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361756				2022-12-17	WOS:A1993LT36800012
J	MARSHALL, H; POPOWICZ, P; ENGEL, G; MARTENS, I; LINDER, S				MARSHALL, H; POPOWICZ, P; ENGEL, G; MARTENS, I; LINDER, S			LACK OF C-JUN EXPRESSION IN A TRANSFORMED-CELL LINE ISOLATED BY GLUCOCORTICOID PROMOTION OF RAS-TRANSFECTED RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Article							GROWTH ARREST; DNA-BINDING; ONCOGENE; DOMAIN; COOPERATION; ACTIVATION; REQUIRES; PROTEINS; RECEPTOR; HORMONE	Rat embryo fibroblasts (REFs) are inefficiently transformed by the T24-ras oncogene. A contributing factor to cellular resistance to transformation is the limited tolerance to p21-ras oncoprotein expression. Here we present data suggesting that long-term glucocorticoid treatment of ras oncogene-transfected REFs results in increased tolerance to p21-ras oncoproteins, leading to expression of the transformed phenotype. Stably transformed cell lines that expressed high levels of H-ras and could be maintained in the absence of hormone were isolated. In three out of four tines studied, the AP-1-dependent collagenase gene was expressed at a low level. In one of these lines, low collagenase expression was paralleled by lack of c-jun mRNA. Immunochemical analysis revealed that progression to hormone independence was not paralleled by mutations in the p53 gene. We propose that a decreased expression of AP-1-driven genes may result in increased tolerance to p21-ras oncoprotein.	KAROLINSKA INST & HOSP, RADIUMHEMMET, DEPT ONCOL, DIV EXPTL ONCOL, S-10401 STOCKHOLM, SWEDEN	Karolinska Institutet; Karolinska University Hospital								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; CUZIN F, 1984, CANCER CELL, V2, P109; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOTTO GP, 1985, NATURE, V318, P472; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURTH ME, 1987, ONCOGENE, V1, P47; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, ONCOGENE, V6, P669; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LINDER S, 1990, VIROLOGY, V179, P78, DOI 10.1016/0042-6822(90)90276-W; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARSHALL H, 1991, EXP CELL RES, V194, P35, DOI 10.1016/0014-4827(91)90126-F; MARTENS I, 1988, P NATL ACAD SCI USA, V85, P5571, DOI 10.1073/pnas.85.15.5571; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; QUINN CO, 1990, J BIOL CHEM, V265, P22342; REIHSAUS E, 1990, ONCOGENE, V5, P137; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RUBIN E, 1992, CANCER RES, V52, P878; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; WEINBERG RA, 1989, CANCER RES, V49, P3713; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YAMASHITA T, 1988, INT J CANCER, V42, P930, DOI 10.1002/ijc.2910420624; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	53	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1993	8	5					1303	1309						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479751				2022-12-17	WOS:A1993KY32800023
J	BASTYR, EJ; LU, J; STOWE, R; GREEN, A; VINIK, AI				BASTYR, EJ; LU, J; STOWE, R; GREEN, A; VINIK, AI			LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEINS ARE ALTERED IN PLATELET HYPERAGGREGATION IN IDDM	ONCOGENE			English	Note							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; KINASE-C; PHOSPHOLIPASE-C; GENE-PRODUCT; ACTIVATION; PHOSPHORYLATION; PURIFICATION; THROMBIN; MEMBRANES; CYTOSOL	We examined the hypothesis that hyperaggregating platelets from patients with insulin dependent diabetes mellitus (IDDM) have an alteration in location and function of the guanine nucleotide (GTP)-binding proteins. Platelets from 10 IDDM and 12 age-matched healthy control subjects were collected and washed. Thrombin-induced platelet aggregation (0.025 and 0.05 units for 60 seconds) was increased in IDDM (8.3 +/- 1.8% vs 22.3 +/- 4.4%, P < .05 and 49.9 +/- 7.3% vs 70.9 +/- 7.0%, P < .05). Four small molecular weight GTP-binding proteins were identified by binding of [P-32]-GTP on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the cytosol and membranes of these platelets. Each showed specificity for binding [P-32]-GTP by competitive inhibition with unlabeled GTP. The total of the 27/28 kDa proteins was decreased in the membrane fraction (414 +/- 30 vs 252 +/- 40 dpm mug-1 protein x min, P < .05) and increased in the cytosolic fraction (62 +/- 8 vs 129 +/- 21 dpm unit-1 LDH x min, P < .05) in IDDM. The 21 kDa protein (60.3 +/- 3.5 vs 45.4 +/- 2.9 dpm mug-1 protein x min, P < .05) was decreased in platelet membrane in persons with IDDM. In conclusion, increased platelet aggregation in IDDM is accompanied by an altered cellular distribution of a 27/28 kDa GTP-binding protein. These data suggest that the low molecular weight GTP-binding proteins of the 27/28 kDa range may play an important regulatory role in the hyperaggregatory platelets in diabetes.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL,GALVESTON,TX 77550; EASTERN VIRGINIA MED SCH,DIABET RES INST,DEPT INTERNAL MED,NORFOLK,VA 23501	University of Texas System; University of Texas Medical Branch Galveston; Eastern Virginia Medical School	BASTYR, EJ (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,DIV ENDOCRINOL,3152 MED RES BLDG,GALVESTON,TX 77555, USA.		Bastyr, Edward/AFP-2625-2022					BALDASSARE JJ, 1986, BIOCHEM BIOPH RES CO, V137, P801, DOI 10.1016/0006-291X(86)91150-2; BALDASSARE JJ, 1989, BIOCHEMISTRY-US, V28, P56, DOI 10.1021/bi00427a009; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BASTYR EJ, 1989, DIABETES, V38, P1097, DOI 10.2337/diabetes.38.9.1097; BASTYR EJ, 1992, THROMB RES, V65, P241, DOI 10.1016/0049-3848(92)90244-5; BASTYR EJ, 1987, DIABETES S1, V236, pA208; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; COLWELL JA, 1976, DIABETES, V25, P826; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P840; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KLAFF LJ, 1981, AM J MED, V70, P627, DOI 10.1016/0002-9343(81)90585-4; Kobbah M, 1985, Acta Paediatr Scand Suppl, V320, P50; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; LEE TS, 1989, P NATL ACAD SCI USA, V86, P5141, DOI 10.1073/pnas.86.13.5141; MACINTYRE DE, 1985, FEBS LETT, V180, P160, DOI 10.1016/0014-5793(85)81063-2; NAGATA K, 1989, J BIOL CHEM, V264, P17000; OHMORI T, 1989, J BIOL CHEM, V264, P1877; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RESNICK RJ, 1988, P NATL ACAD SCI USA, V85, P2474, DOI 10.1073/pnas.85.8.2474; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SIESS W, 1990, BIOCHEM J, V271, P815, DOI 10.1042/bj2710815; STASIA MJ, 1989, BIOCHEMISTRY-US, V28, P9659, DOI 10.1021/bi00451a018; WATSON SP, 1985, P NATL ACAD SCI USA, V82, P2623, DOI 10.1073/pnas.82.9.2623; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P759; ZAVOICO GB, 1985, P NATL ACAD SCI USA, V82, P3859, DOI 10.1073/pnas.82.11.3859; 1979, DIABETES, V28, P1039	31	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					515	518						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426753				2022-12-17	WOS:A1993KN00600033
J	GIBSON, AW; YE, R; JOHNSTON, RN; BROWDER, LW				GIBSON, AW; YE, R; JOHNSTON, RN; BROWDER, LW			A POSSIBLE ROLE FOR C-MYC ONCOPROTEINS IN POSTTRANSCRIPTIONAL REGULATION OF RIBOSOMAL-RNA	ONCOGENE			English	Note							MESSENGER-RNA; XENOPUS-LAEVIS; PROTO-ONCOGENE; DNA-SYNTHESIS; 2-NITRO-5-THIOCYANOBENZOIC ACID; CELL-DIVISION; GROWTH-FACTOR; EXPRESSION; BINDING; GENE	Overexpression of members of the myc family of oncogenes contributes to the development of many vertebrate malignancies. Although several functions for myc gene products have been proposed, the targets for Myc activity during oncogenesis or normal development remain to be identified. Oocytes of Xenopus laevis, which are non-dividing cells that accumulate abundant c-Myc protein, provide an unusual opportunity to examine c-Myc function. We have investigated whether the accumulation of massive amounts of ribosomal RNA (rRNA) by Xenopus laevis oocytes may be related to their elevated expression of myc proto-oncogenes. Our data show that anti-Myc antibodies and some (but not all) c-Myc peptides from conserved regions of the c-Myc protein enhance the turnover of rRNA synthesized in homogenates of oocyte nuclei. These results suggest that one or more members of the Myc protein family may be involved in post-transcriptional regulation of rRNA metabolism. The regulation by c-Myc of rRNA could account, in part, for the generalized stimulation of cells during tumorigenesis.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary	GIBSON, AW (corresponding author), UNIV CALGARY,SO ALBERTA CANC RES CTR,DEPT MED BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA.		Johnston, Randal/B-9247-2009					ABELSON HT, 1979, BIOCHIM BIOPHYS ACTA, V561, P269, DOI 10.1016/0005-2787(79)90136-9; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Cole MD, 1990, CURR OPIN CELL BIOL, V2, P502, DOI 10.1016/0955-0674(90)90134-Z; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COOPER HL, 1970, NATURE, V227, P1105, DOI 10.1038/2271105a0; COOPER HL, 1971, J BIOL CHEM, V246, P5059; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GIBSON AW, 1992, IN PRESS BIOCH CELL; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GRAMMAGE MD, 1991, CLIN SCI, V80, P405; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HANN SR, 1988, CELL, V52, P15; HILL JM, 1975, J CELL BIOL, V64, P260, DOI 10.1083/jcb.64.1.260; HIPSKIND RA, 1980, J BIOL CHEM, V255, P7896; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JOHNSON LF, 1976, J CELL BIOL, V71, P933, DOI 10.1083/jcb.71.3.933; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; LIAO TH, 1979, J BIOL CHEM, V254, P9602; LUSCHER B, 1989, EMBO J, V8, P111; NATH P, 1987, EXP CELL RES, V169, P215, DOI 10.1016/0014-4827(87)90239-4; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SPECTOR DL, 1987, ONCOGENE, V1, P5; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VIZE PD, 1990, DEVELOPMENT, V110, P885; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	38	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2363	2367						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437160				2022-12-17	WOS:A1992JW66500033
J	HEVEZI, P; ALIN, K; REESJONES, R; GOFF, SP				HEVEZI, P; ALIN, K; REESJONES, R; GOFF, SP			BONE MARROW-TRANSFORMING ACTIVITY OF LINKER INSERTION MUTANTS OF ABELSON MURINE LEUKEMIA-VIRUS	ONCOGENE			English	Note							SRC HOMOLOGY REGION-2; PROTEIN-TYROSINE KINASE; LYMPHOID-CELLS; SIGNAL TRANSDUCTION; CHAIN GENES; C-SRC; V-ABL; SEQUENCES; DOMAINS; SEGMENT	Two sets of mutants of the Abelson murine leukemia virus, generated by linker insertion mutagenesis of a cloned proviral DNA, were tested for their ability to transform bone marrow cultures in vitro. All the viruses retained an intact tyrosine kinase domain and were competent for transformation of NIH3T3 fibroblasts in culture. One series contained 12-bp linker insertions in the regions flanking the kinase domain, and the other contained frameshift mutations that truncated the gene product downstream of the kinase domain. The majority of the 12-bp insertion mutants retained full bone marrow-transforming activity; only one insertion in the SH2 domain showed reduced activity. This mutant suggests that some aspect of the SH2 domain may be more important in transformation of lymphocytes than fibroblasts. In contrast to the first set of mutants, the bone marrow-transforming activity of the majority of the truncation mutants was significantly reduced or completely lost. We conclude that there is a broad requirement for an intact C-terminal domain of the v-abl protein for the transformation of pre-B cells, but that no single part of this domain is critical.	COLUMBIA UNIV, DEPT MICROBIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Columbia University; Columbia University								ABELSON HT, 1970, CANCER RES, V30, P2208; ABELSON HT, 1970, CANCER RES, V30, P2213; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BALTIMORE D, 1979, IMMUNOL REV, V48, P3, DOI 10.1111/j.1600-065X.1979.tb00296.x; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; ENGELMAN A, 1990, J VIROL, V64, P4242, DOI 10.1128/JVI.64.9.4242-4251.1990; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOFF SP, 1982, ADV VIRAL ONCOL, P127; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MATHEYPREVOT B, 1988, MOL CELL BIOL, V8, P234, DOI 10.1128/MCB.8.1.234; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; PARMAR K, 1991, IN PRESS J VIROL, V65; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; PRATT DM, 1977, CELL, V12, P683, DOI 10.1016/0092-8674(77)90268-9; PRYWES R, 1985, J VIROL, V54, P123, DOI 10.1128/JVI.54.1.123-132.1985; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REESJONES RW, 1989, MOL CELL BIOL, V9, P278, DOI 10.1128/MCB.9.1.278; REESJONES RW, 1988, J VIROL, V62, P978, DOI 10.1128/JVI.62.3.978-986.1988; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; RISSER R, 1989, CURR TOP MICROBIOL, V147, P129; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG N, 1980, VIRAL ONCOLOGY, P187; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; SIDEN E, 1981, P NATL ACAD SCI-BIOL, V78, P1823, DOI 10.1073/pnas.78.3.1823; SIDEN EJ, 1979, CELL, V16, P389, DOI 10.1016/0092-8674(79)90014-X; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WITTE ON, 1980, P NATL ACAD SCI-BIOL, V77, P4993, DOI 10.1073/pnas.77.8.4993; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WITTE ON, 1983, CURR TOP MICROBIOL, V103, P127; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	48	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2323	2328						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437154				2022-12-17	WOS:A1992JW66500026
J	BLACKMORE, PF; OAKES, SG; SOMERS, KD				BLACKMORE, PF; OAKES, SG; SOMERS, KD			ALTERED H1 HISTAMINE-RECEPTOR SIGNALING IN BALB/3T3 CELLS TRANSFORMED BY V-K-RAS AND V-H-RAS ONCOGENES	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; TUMOR; PROTEIN; ACTIVATE; H-1	Transformation of Balb/3T3 cells with the v-K-ras oncogene resulted in the expression of functional Ca2+-mobilizing receptors for histamine, whereas v-H-ras-transformed Balb/3T3 cells failed to show a similar response to histamine. Stimulation of histamine receptors in v-K-ras-transformed cells produced a dose-dependent increase in intracellular free calcium ([Ca2+]i), which was inhibited by the H-1 histamine antagonist pyrilamine but unaffected by the H-1 histamine receptor antagonist cimetidine. Histamine-mediated elevation of [Ca2+]i was partially inhibited by the removal of extracellular Ca2+, which indicates that the H-1 histamine receptors mobilize intracellular Ca2+ and also promote Ca2+ influx. H-1 histamine receptors were identified in both v-K-ras- and v-H-ras-transformed Balb/3T3 cells, but not in untransformed cells, using the specific H-1 antagonist [H-3]-pyrilamine. Transformation of Balb/3T3 cells with the viral ras oncogene results in a complex regulation of H-1 histamine receptors. K-ras and H-ras transformation results in the expression of H-1 histamine receptors; however, H-1 receptor expression and Ca2+ mobilization are uncoupled in v-H-ras-transformed cells.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501	Eastern Virginia Medical School	BLACKMORE, PF (corresponding author), EASTERN VIRGINIA MED SCH,DEPT PHARMACOL,POB 1980,NORFOLK,VA 23501, USA.							BATHOLEYNS J, 1984, CANCER RES, V44, P639; BATHOLEYNS J, 1985, TRENDS PHARMACOL SCI, V6, P123; BURTIN C, 1982, BRIT J CANCER, V45, P54, DOI 10.1038/bjc.1982.7; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; FISCHER SM, 1990, CARCINOGENESIS, V11, P991, DOI 10.1093/carcin/11.6.991; GALLOPIN L, 1984, AGENTS ACTIONS, V14, P494; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HILL SJ, 1990, PHARMACOL REV, V42, P45; MARSHALL CJ, 1988, J CELL SCI S, V10, P157; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MITSUHASHI M, 1989, MOL PHARMACOL, V35, P751; MITSUHASHI M, 1989, J CELL BIOCHEM, V40, P183, DOI 10.1002/jcb.240400207; MITSUHASHI M, 1988, J CELL PHYSIOL, V134, P367, DOI 10.1002/jcp.1041340307; MITSUHASHI M, 1989, MOL PHARMACOL, V35, P311; SOMERS KD, 1980, CELL BIOL INT REP, V4, P487, DOI 10.1016/0309-1651(80)90036-3; SOMERS KD, 1980, CANCER RES, V40, P4410; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TILLY BC, 1990, J CELL BIOL, V110, P1211, DOI 10.1083/jcb.110.4.1211; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x	26	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					2053	2057						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408146				2022-12-17	WOS:A1992JP42400020
J	KUSSICK, SJ; COOPER, JA				KUSSICK, SJ; COOPER, JA			PHOSPHORYLATION AND REGULATORY EFFECTS OF THE CARBOXY TERMINUS OF A DROSOPHILA-SRC HOMOLOG	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; C-SRC; TRANSFORMING PROTEIN; CELL-TRANSFORMATION; NUCLEOTIDE-SEQUENCE; RETROVIRUS VECTORS; GENE-PRODUCT; PP60C-SRC; ACTIVATION	The kinase activities of the vertebrate src family members are repressed by phosphorylation of a tyrosine residue in the carboxy-terminal `tail' of these molecules. To explore whether the tail of an invertebrate src homolog might also serve a regulatory function, we examined the ability of the carboxy terminus of a Drosophila src homolog (p62D), which contains a tyrosine homologous to those in the vertebrate src family members, to regulate the following molecules in mammalian fibroblasts: (1) a chimeric protein, p60CD, containing the amino terminus and catalytic domains of chicken p60c-src joined to the C-terminus of p62D; and (2) full-length p62D itself. By a variety of criteria p60CD appears to be a partially, rather than fully, repressed form of p60c-src. Phosphopeptide mapping indicates that partial repression correlates with partial phosphorylation of the tyrosine in the p62D tail of the chimera. Phosphorylation of the tail may also regulate full-length p62D. Expression of p62D in fibroblasts does not affect cell morphology or the overall abundance of tyrosine-phosphorylated proteins. The molecule is phosphorylated at its C-terminal tyrosine (Tyr-547), but not at its in vitro autophosphorylation sites, suggesting that it is catalytically repressed in fibroblasts. Expression of a truncated p62D mutant lacking Tyr-547 is associated with a clear alteration in cellular morphology and a two- to threefold increase in cellular phosphotyrosine levels. These results suggest that phosphorylation of the C-terminal tyrosine of the tail of an invertebrate src-like kinase can repress the activity of adjacent catalytic domains.	UNIV WASHINGTON,SCH MED,FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	KUSSICK, SJ (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PATHOL,1124 COLUMBIA ST,SEATTLE,WA 98195, USA.				NCI NIH HHS [CA-41072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KUSICK SJ, 1991, NATO ASI SERIES H, V56, P295; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MACAULEY A, 1990, New Biologist, V2, P828; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	38	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1992	7	8					1577	1586						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630818				2022-12-17	WOS:A1992JE81300014
J	ALBAGLI, O; FLOURENS, A; CREPIEUX, P; BEGUE, A; STEHELIN, D; LEPRINCE, D				ALBAGLI, O; FLOURENS, A; CREPIEUX, P; BEGUE, A; STEHELIN, D; LEPRINCE, D			PHYLOGENY OF THE P68C-ETS-1 AMINO-TERMINAL TRANSACTIVATING DOMAIN REVEALS SOME HIGHLY CONSERVED STRUCTURAL FEATURES	ONCOGENE			English	Note								The chicken c-ets-1 locus gives rise to two distinct transcription factors differing only in their structurally and functionally unrelated N-termini. One of these transcription factors, p54c-ets-1, contains a specific, short (27 amino acids), hydrophilic N-terminus encoded by a single exon, I54, that is widely conserved among vertebrates. The other one, p68c-ets-1, the cellular counterpart of the viral ets oncogene product, differs in the replacement of the I54 by two exons, termed alpha and beta encoding a larger (71 amino acids), hydrophobic N-terminus which, in contrast to I54, exhibits properties of a transactivating domain. To date the alpha and beta exons have only been found in chicken. Here, we demonstrate the existence of the alpha and beta-exons in other avian species (quail and duck) and the existence of the alpha exon in reptiles (turtle). However, none of them could be detected in mammals. Our results strongly suggest that, in contrast to the phylogenetically well-conserved I54 exon, the alpha-exon is restricted to reptilian species (birds and 'true' reptiles), whereas the beta-exon is detectable so far only in birds. Comparison of their amino acid sequences reveals that the alpha-exon and to a much greater extent the beta-exon have diverged faster than the I54 exon. In addition, we show that the N- and C-terminal thirds of the alpha-exon and the highly hydrophobic nature of the alpha-beta-encoded sequence are heavily conserved features and thus likely to be required for function as a transactivating domain in p68c-ets-1 and possibly in the viral P135gag-myb-ets transforming protein.	INST PASTEUR, CNRS, URA 1160, 1 RUE CALMETTE, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Crepieux, Pascale/X-3217-2019	Leprince, Dominique/0000-0002-1999-0775				BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CHEN JH, 1990, ONCOGENE RES, V5, P277; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRASER N, 1991, NATURE, V349, P278, DOI 10.1038/349278a0; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; RAULF F, 1989, J NEUROSCI RES, V24, P81, DOI 10.1002/jnr.490240112; REISZ RR, 1991, NATURE, V349, P324, DOI 10.1038/349324a0; SCHNEIKERT J, 1992, IN PRESS ONCOGENE; SEEGER MA, 1990, EMBO J, V9, P2977, DOI 10.1002/j.1460-2075.1990.tb07490.x; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049	27	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1435	1439						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620554				2022-12-17	WOS:A1992HZ97100024
J	MULLER, O; FRECH, M; GIDEON, P; WITTINGHOFER, A; SCHWARZ, M				MULLER, O; FRECH, M; GIDEON, P; WITTINGHOFER, A; SCHWARZ, M			DIFFERENCES IN GTPASE-ACTIVATING PROTEIN-ACTIVITY BETWEEN LIVER-TUMORS AND NORMAL LIVER-TISSUE IN MICE	ONCOGENE			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; RAS-P21 GTPASE; B6C3F1 MOUSE; RAS P21; GAP; PURIFICATION; IDENTIFICATION; INHIBITION; BINDING; PRODUCT	The intrinsic GTPase activity of the cellular protein p21ras is strongly increased by two cytosolic proteins, the GTPase-activating protein (GAP) produced by the neurofibromatosis type 1 gene (NF1-GAP) and a GAP of 120 kDa molecular mass (p120-GAP). The GAP-mediated stimulation of p21ras GTPase activity was measured in cytosol obtained from carcinogen-induced liver tumors and normal liver tissues of mice of two strains, namely C3H/He and C57BL/6J. For this purpose, cytosolic extracts were incubated with recombinant human p21ras complexed to [gamma-P-32]GTP and the time-dependent decrease in p21ras bound radioactivity was measured. Liver cytosolic extracts mediated an increase in the GTPase activity of wild-type p21ras. There were great differences between tumor and normal tissues in the maximal velocity (V(max)) and in the apparent Michaelis constant (K(M)) of the p21ras GTPase reaction. Both V(max), and apparent K(M) were decreased in the liver tumors. Cytosolic extracts isolated from liver tumors that harbored point mutations in codon 61 of the c-H-ras gene did not differ in their activity from extracts obtained from non-mutated liver tumors. Since both GAP proteins are important cellular regulators of the ras signaling pathway and probably also effectors of p21ras, the observed differences in GAP activity may be of relevance for the tumorigenic process in mouse liver.	GERMAN CANC RES CTR,PROJECT GRP TUMOR PROMOT LIVER,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; MAX PLANCK INST MED RES,W-6900 HEIDELBERG 1,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; DOWNWARD J, 1988, COLD SPRING HARB SYM, V53, P883, DOI 10.1101/SQB.1988.053.01.101; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, G PROTEINS MEDIATORS, P173; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HATA Y, 1990, J BIOL CHEM, V265, P7104; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; LIU XQ, 1991, MOL CELL BIOL, V11, P2511, DOI 10.1128/MCB.11.5.2511; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; SERTH J, 1991, EMBO J, V10, P1325, DOI 10.1002/j.1460-2075.1991.tb07651.x; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; WOLFMAN A, 1990, FEBS LETT, V259, P245; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	29	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1407	1412						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620552				2022-12-17	WOS:A1992HZ97100020
J	ERWIN, JL; ANDERSON, SM				ERWIN, JL; ANDERSON, SM			ANALYSIS OF PHOSPHOTYROSINE-CONTAINING PROTEINS PRESENT IN V-SRC-INFECTED MYELOID PROGENITOR CELLS	ONCOGENE			English	Note							AVIAN-SARCOMA VIRUS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3; LINE; KINASES; GAP; RECEPTORS; GENE	We examined the phosphotyrosine-containing proteins in v-src-infected myeloid cells. Proteins with relative molecular weights (M(r)) of 180 000, 175 000, 135 000, 125 000, 120 000, 90 000, 75 000, and 60 000 were present in v-src-infected but not in uninfected 32D c13 cells. Stimulation of 32D c13 cells with interleukin 3 (IL-3) resulted in the tyrosine phosphorylation of a protein of 150 000 (M(r)), which was not phosphorylated in v-src-infected 32D ct3 cells. A panel of monoclonal antibodies directed against phosphotyrosine-containing proteins in v-src-transformed chicken embryo fibroblasts (3C4, 2A7, 2B12 and 4F11, directed against p210, p125, p120 and p85 respectively) was used to characterize these substrates. We did not observe tyrosine phosphorylation of proteins recognized by these four monoclonal antibodies in either IL-3-stimulated or v-src-infected 32D c13 cells. However, we did detect tyrosine phosphorylation of proteins recognized by these monoclonal antibodies in v-src-transformed NIH3T3 cells. Tyrosine phosphorylation of GTPase-activating protein (GAP)-and the GAP-associated proteins p62 and p190 was observed in v-src-infected 32D c13 cells. Stimulation of 32D c13 celts with IL-3 does not induce phosphorylation of GAP or the GAP-associated proteins p62 or p190. These results suggest that substrates for v-src vary between different cell types.	SUNY STONY BROOK,DEPT PATHOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA45241] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA045241, R01CA045241] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1990, BLOOD, V76, P706; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KRUGER A, 1991, ONCOGENE, V6, P245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; METCALF D, 1985, BLOOD, V65, P357; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; ROTTAPEL R, 1991, MOL CELL BIOL, V11, P3043, DOI 10.1128/MCB.11.6.3043; ROVERA G, 1987, ONCOGENE, V1, P29; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	28	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1101	1107						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1375716				2022-12-17	WOS:A1992HU64200007
J	MISAWA, Y; SHIBUYA, M				MISAWA, Y; SHIBUYA, M			AMPLIFICATION AND REARRANGEMENT OF MELF/MOUSE CD43 (LEUKOSIALIN) GENE ENCODING A HIGHLY GLYCOSYLATED MEMBRANE-PROTEIN GP120 IN FRIEND-ERYTHROLEUKEMIA CELLS	ONCOGENE			English	Article							LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; WISKOTT-ALDRICH SYNDROME; MURINE LEUKEMIA-VIRUS; ELECTROPHORETIC TRANSFER; TRANSCRIPTION FACTOR; POLYACRYLAMIDE GELS; PUTATIVE ONCOGENE; RIBONUCLEIC-ACID; DIFFERENTIATION; SIALOPHORIN	Using a differential hybridization method, we isolated a cDNA (melF) overexpressed in a murine Friend erythroleukemia cell line, F5-5. Southern blotting and sequence analysis revealed that the melF cDNA encodes a membrane protein of 395 amino acids that is the counterpart to human CD43 (leukosialin) surface antigen of lymphocytes in mice. The melF/mouse CD43 (mCD43) gene was found to be amplified eight- to 10-fold not only in F5-5 cells, but also in their sib cell lines, including the earliest clone established. This indicates that the amplification of melF/mCD43 gene occurred at an early stage of malignant transformation of the F5-5 family. Furthermore, the same gene was rearranged in another Friend erythroleukemia cell line TSA8. In both cell lines, F5-5 and TSA8, the levels of melF/mCD43 mRNA were 30- to 50-fold higher than that in uninfected spleen cells. Among normal tissues examined, the expression of melF/mCD43 gene was restricted to hematopoietic tissues. These results suggest that melF/mCD43 gene has an important role in progression of leukemic cells in the erythroid lineage and also has a physiological function in normal hematopoiesis.	UNIV TOKYO,INST MED SCI,DEPT GENET,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								AXELSSON B, 1988, J IMMUNOL, V141, P2912; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BOYD AW, 1981, J IMMUNOL, V126, P2466; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; DUBE SK, 1975, P NATL ACAD SCI USA, V72, P183; FEINBERG A, 1982, ANAL BIOCHEM, V132, P6; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HINIKOFF S, 1984, GENE, V28, P351; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; IKAWA Y, 1966, GANN, V57, P641; IKAWA Y, 1976, GANN, V67, P767; IKAWA Y, 1975, BIBL HAEMATOL, V43, P37; KILEEN N, 1987, EMBO J, V6, P4029; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; Maniatis T., 1982, MOL CLONING; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MISAWA Y, 1990, BIOCHEM BIOPH RES CO, V170, P39, DOI 10.1016/0006-291X(90)91237-M; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OLIFF A, 1980, J VIROL, V35, P924, DOI 10.1128/JVI.35.3.924-936.1980; OSTERTAG W, 1973, NATURE-NEW BIOL, V243, P203, DOI 10.1038/newbio243203a0; OSTERTAG W, 1987, ADV CANCER RES, V48, P193, DOI 10.1016/S0065-230X(08)60693-4; PARK SH, 1990, PCR PROTOCOLS GUIDE, P407; PARKMAN R, 1981, LANCET, V2, P1387; RALPH P, 1973, J NATL CANCER I, V51, P883, DOI 10.1093/jnci/51.3.883; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1986, J BIOL CHEM, V261, P7526; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SASAKI H, 1987, JPN J CANCER RES, V78, P776; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WONG RCK, 1990, J IMMUNOL, V144, P1455; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	47	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					919	926						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1533277				2022-12-17	WOS:A1992HP64200011
J	AVIVI, A				AVIVI, A			CORRECTION	ONCOGENE			English	Correction, Addition																		AVIVI A, 1991, ONCOGENE, V6, P1089	1	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					823	823						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682					2022-12-17	WOS:A1992HQ68200031
J	OSIPOVICH, OA; MISUNO, NI; KOLESNIKOVA, TS; SUDARIKOV, AB; VOITENOK, NN				OSIPOVICH, OA; MISUNO, NI; KOLESNIKOVA, TS; SUDARIKOV, AB; VOITENOK, NN			THE DIFFERENCE IN P53 ANTIONCOGENE TRANSCRIPTION IN HUMAN MONOCYTES AND LYMPHOCYTES	ONCOGENE			English	Article							MESSENGER-RNA; CELL-LINES; GENE; ERYTHROLEUKEMIA; EXPRESSION; INDUCTION; ANTIGEN	The p53 gene is associated with malignant transformation as well as 'antioncogene' activity. In this report expression of p53 in resting and activated human blood monocytes and lymphocytes was studied. It is shown that human monocytes freshly isolated by continuous Percoll-gradient centrifugation contain detectable levels of p53 mRNA. Stimulation of monocytes by the potent activation inducer Staphylococcus aureus Cowan I (SAC) for 3-5 h caused the disappearance of p53 mRNA. In contrast, induction of a high level of tumor necrosis factor alpha mRNA was detected. The addition of cycloheximide did not increase the p53 mRNA content in stimulated monocytes, and decreased the mRNA level in resting cells. p53 mRNA was absent in freshly isolated lymphocytes and in resting cells cultured for 20 h. Activation of lymphocytes by phytohemagglutinin caused accumulation of p53 mRNA. We suggest that p53 gene regulation and functions might be different in human monocytes and lymphocytes.	MOSCOW EXPT HEMATOL & BIOTECHNOL INST,NOVOZYKOVSKY LANE 4,MOSCOW 125167,USSR; BYELORUSSIAN INST HEMATOL & BLOOD TRANSFUS,MINSK,BELORUSSIA,USSR				Sudarikov, Andrey/E-7528-2013	Sudarikov, Andrey/0000-0001-9463-9187				BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRAWFORD LV, 1981, P NATL ACAD SCI USA, V78, P1695; GMELIGMEYLING F, 1980, J IMMUNOL METHODS, V33, P1, DOI 10.1016/0022-1759(80)90077-0; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LING NR, 1968, LYMPHOCYTE STIMULATI, pCH4; LUBBERT M, 1989, ONCOGENE, V4, P643; Maniatis T., 1982, MOL CLONING; MISUNO N I, 1990, Cytokine, V2, P464, DOI 10.1016/1043-4666(90)90056-Y; MUNROE DG, 1988, ONCOGENE, V2, P621; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TURPIN JA, 1991, NAT IMMUN CELL GROW, V10, P19; VANFURTH R, 1979, BLOOD, V54, P485; VOITENOK NN, 1989, IMMUNOL LETT, V20, P77, DOI 10.1016/0165-2478(89)90072-2	22	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					549	552						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549368				2022-12-17	WOS:A1992HK00500022
J	SONOBE, MH; BRAVO, R; ARMELIN, MS				SONOBE, MH; BRAVO, R; ARMELIN, MS			IMBALANCED EXPRESSION OF CELLULAR NUCLEAR ONCOGENES CAUSED BY V-SIS PDGF-2	ONCOGENE			English	Article							SIMIAN SARCOMA-VIRUS; TRANSFORMING GENE-PRODUCT; FACTOR-LIKE PROTEIN; C-FOS GENE; GROWTH-FACTOR; 3T3 CELLS; LEUCINE ZIPPER; MESSENGER-RNA; DNA-SYNTHESIS; ONC GENE	Two murine cell lines that overexpress v-sis/PDGF-2 were used to study the mechanism of cell transformation by SSV (simian sarcoma virus). In contrast to the parental cells that are phenotypically normal and serum-dependent for growth, v-sis-overexpressing cells grow in PDGF-free plasma medium, are unable to enter the G0 state and are highly tumorigenic. Analysis of the expression of some growth factor-induced early response genes in v-sis-overexpressing cells revealed: (a) high and constitutive c-myc mRNA levels in SSV-NRK cells; (b) unaltered levels of fra-1, fos B, jun B and krox 20 transcripts; (c) high and constitutive FOS staining due to c-FOS and FOS-related protein(s); (d) constitutive c-JUN and higher JUN D expression. These results are compatible with a model in which endogenous production of v-sis/PDGF-2 leads to deregulated expression of key cellular transregulators that, in turn, alter the cells' transcriptional program leading to the transformed state and malignancy.	UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, CP 20780, BR-01498 SAO PAULO, BRAZIL; SQUIBB INST MED RES, PRINCETON, NJ 08543 USA	Universidade de Sao Paulo			Sonobe, Martha/I-2877-2015					AARONSON SA, 1975, J VIROL, V16, P1117, DOI 10.1128/JVI.16.5.1117-1123.1975; Abate C, 1990, Semin Cancer Biol, V1, P19; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANTONIADES HN, 1987, ONCOGENES GENES GROW, P1; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CROCE CM, 1985, BLOOD, V65, P1; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1984, CELL, V36, P259; DALLAFAVERA R, 1982, NATURE, V299, P61; DEUEL TF, 1983, SCIENCE, V221, P1348, DOI 10.1126/science.6310754; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DICORLETO PE, 1983, P NATL ACAD SCI-BIOL, V80, P1919, DOI 10.1073/pnas.80.7.1919; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GAZIT A, 1984, CELL, V39, P89, DOI 10.1016/0092-8674(84)90194-6; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; JOHNSSON A, 1985, NATURE, V317, P438, DOI 10.1038/317438a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEAL F, 1985, SCIENCE, V230, P327, DOI 10.1126/science.2996133; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OWEN AJ, 1984, SCIENCE, V225, P54, DOI 10.1126/science.6328659; PANTAZIS P, 1986, P NATL ACAD SCI USA, V83, P5526, DOI 10.1073/pnas.83.15.5526; PECH M, 1989, P NATL ACAD SCI USA, V86, P2693, DOI 10.1073/pnas.86.8.2693; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMEH LE, 1991, IN PRESS ONCOGENE; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; ROBBINS KC, 1982, SCIENCE, V218, P1131, DOI 10.1126/science.6293053; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHATZL HM, 1989, ONCOGENE, V4, P1095; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; THEILEN GH, 1971, JNCI-J NATL CANCER I, V47, P881; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VOGT PK, 1988, ONCOGENE, V3, P3; VOGT PK, 1990, CANCER BIOL, V1, P27; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	71	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1531	1537						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923519				2022-12-17	WOS:A1991GX27400006
J	BAMEZAI, A; ROCK, KL				BAMEZAI, A; ROCK, KL			EFFECT OF RAS-ACTIVATION ON THE EXPRESSION OF GLYCOSYL-PHOSPHATIDYLINOSITOL-ANCHORED PROTEINS ON THE PLASMA-MEMBRANE	ONCOGENE			English	Article							T-CELL ACTIVATION; EPIDERMAL GROWTH-FACTOR; KINASE-C; MONOCLONAL-ANTIBODY; TRANSFORMED-CELLS; DOWN-REGULATION; INSULIN ACTION; LYMPHOCYTES-T; LY-6 LOCUS; STIMULATION	NIH3T3 cells were transfected with a vector containing c-H-ras under the transcriptional control of the mouse metallothionein-I promoter. When c-H-ras expression was induced with heavy metal ions there was a marked reduction in the expression of two glycosyl-phosphatidylinositol (GPI) anchored proteins, TAP/Ly-6A.2 and Thy-1, on the plasma membrane of the transformed cells. In contrast the cell-surface expression of other non-GPI-anchored proteins was unaltered. The major loss of Thy-1 induced by ras activation occurred from the pool of molecules expressed on the cell surface. The Thy-1 molecules that were preferentially lost from the surface of the ras-transformed cells could not be recovered from the extracellular fluid by immunoprecipitation. In contrast, the rate of internalization of Thy-1 was increased approximately 69% subsequent to ras activation. The possible significance of these findings to the function of c-H-ras is discussed.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV LYMPHOCYTE BIOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	BAMEZAI, A (corresponding author), HARVARD UNIV, SCH MED, DEPT PATHOL, 44 BINNEY ST, BOSTON, MA 02115 USA.			Bamezai, Anil/0000-0002-2447-7706	NIGMS NIH HHS [5 RO1 GM 38535] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMEZAI A, 1988, J IMMUNOL, V141, P1423; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; CHIARUGI VP, 1989, FEBS LETT, V252, P129, DOI 10.1016/0014-5793(89)80904-4; DAVIGNON D, 1981, P NATL ACAD SCI-BIOL, V78, P4535, DOI 10.1073/pnas.78.7.4535; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ESPINAL J, 1987, NATURE, V328, P574, DOI 10.1038/328574a0; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HSIAO WLW, 1990, ONCOGENE, V5, P417; IVANYI D, 1986, INT J CANCER, V38, P575, DOI 10.1002/ijc.2910380418; KAMATA T, 1987, ONCOGENE, V1, P37; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MALEK TR, 1986, J EXP MED, V164, P709, DOI 10.1084/jem.164.3.709; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROCK KL, 1982, J IMMUNOL, V129, P1360; ROCK KL, 1986, J EXP MED, V163, P315, DOI 10.1084/jem.163.2.315; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; SALTIEL AR, 1986, P NATL ACAD SCI USA, V83, P5793, DOI 10.1073/pnas.83.16.5793; SANDRIGOLDIN RM, 1981, MOL CELL BIOL, V1, P743, DOI 10.1128/MCB.1.8.743; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; STALLCUP KC, 1981, J IMMUNOL, V127, P923; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUSSMAN JJ, 1988, J IMMUNOL, V140, P2520; TRIMBLE WS, 1986, NATURE, V321, P782, DOI 10.1038/321782a0; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WEYMAN CM, 1988, CANCER RES, V48, P6535; WILKISON WO, 1989, ONCOGENE, V4, P625; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7; YEH ETH, 1987, J IMMUNOL, V138, P91	46	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1445	1451						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679532				2022-12-17	WOS:A1991GX27200022
J	EAGER, KB				EAGER, KB			MOLECULAR CHARACTERIZATION OF HUMAN TRK PROTOONCOGENE PRODUCT MONOCLONAL-ANTIBODIES	ONCOGENE			English	Article							POINT MUTATION; BIOCHEMICAL-CHARACTERIZATION; KINASE DOMAIN; ACTIVATION; SEQUENCES; RECOMBINATION; DELETION; PROTOONCOGENE; FUSION	Monoclonal antibodies specific for the human trk proto-oncogene product, a tyrosine kinase receptor, have been produced from mice in which tumors were generated by injection of stably transfected NIH3T3 cells expressing the human trk proto-oncogene product. The panel of eleven antibodies are reactive in ELISA, immunostaining and immunoprecipitation. These antibodies bind to the extracellular domain of the human trk proto-oncogene product and demonstrate no cross-reactivity to the trk oncogene or murine trkB gene products. The antibodies are equally effective in recognizing human proto-trk when expressed by transfected human or mouse cell lines. These antibodies either bind to the carbohydrate moieties or are dependent upon the conformational structure created by the extensive glycosylations. The localization and nature of the epitopes recognized by these monoclonal antibodies were defined by immunoprecipitation analyses using several different trk oncoproteins. Potential applications of these antibodies are discussed.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb	EAGER, KB (corresponding author), AMER CYANAMID CO,POB 400,PRINCETON,NJ 08543, USA.							BARBACID M, 1980, J VIROL, V33, P196, DOI 10.1128/JVI.33.1.196-207.1980; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BONGARZONE I, 1989, ONCOGENE, V4, P1457; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Kennett R H, 1978, Curr Top Microbiol Immunol, V81, P77; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1980, MONOCLONAL ANTIBODIE, P395; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	24	7	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					819	824						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052359				2022-12-17	WOS:A1991GT82500018
J	TSAI, LH; NANU, L; SMITH, RG; OZANNE, B				TSAI, LH; NANU, L; SMITH, RG; OZANNE, B			OVEREXPRESSION OF C-FOS IN A HUMAN PRE-B-CELL ACUTE LYMPHOCYTIC-LEUKEMIA DERIVED CELL-LINE, SMS-SB	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; OSTEO-SARCOMA VIRUS; PROTO-ONCOGENE FOS; MESSENGER-RNA; MOLECULAR-CLONING; GENE-EXPRESSION; BINDING-SITES; V-FOS; TRANSCRIPTION; DNA	The c-fos proto-oncogene is found to be overexpressed at least 30-fold in SMS-SB, a pre-B leukemic cell line compared to other cell types. No gross alteration of the c-fos gene structure in SMS-SB cells can be detected by karyotypic or Southern analyses. C-fos in SMS-SB cells can still be induced by serum, TPA and the calcium inophore, A23187, and superinduced by the combination of serum and cyloheximide. The elevated levels of c-fos transcripts are not due merely to an increased life span of mRNA, as the half-life of steady state c-fos mRNA in SMS-SB cells is about 40 min. Nuclear run-on transcription assays demonstrate that the transcription rate of c-fos in SMS-SB cells is up-regulated about 30-fold as compared to another pre-B leukemic cell line, NALM-6. In order to determine whether this is a cis- or transacting effect, we sequenced the 550 base pairs upstream of the SMS-SB c-fos coding region and found no mutations upstream of the mRNA CAP site. However, two point mutations at positions + 23 and + 98, respectively, were found in the 5' noncoding region of the first exon. Consistant with the overexpression of c-fos mRNA, the 55 kD c-fos protein is present in SMS-SB cells through detection by immunoprecipitation, but could not be detected in NALM-6 cells. SMS-SB cells however, do not appear to contain more abundant AP-1 DNA binding activity than NALM-6 cells.	BEATSON INST CANC RES,CANC RES CAMPAIGN LABS,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND; SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	Beatson Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas								ANGEL P, 1985, CANCER CELL, V3, P315; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BONNIEU A, 1989, ONCOGENE, V4, P881; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KLEMSZ MJ, 1989, J IMMUNOL, V143, P1032; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LEPRINCE D, 1983, EMBO J, V2, P1073, DOI 10.1002/j.1460-2075.1983.tb01548.x; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NISHIKURA K, 1987, MOL CELL BIOL, V7, P629; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PINTO A, 1987, BLOOD, V70, P1450; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMITH RG, 1984, CANCER, V54, P471, DOI 10.1002/1097-0142(19840801)54:3<471::AID-CNCR2820540315>3.0.CO;2-4; SMITH RG, 1981, J IMMUNOL, V126, P596; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WELHAM MJ, 1990, ONCOGENE, V5, P161; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YUAN D, 1984, J EXP MED, V160, P564, DOI 10.1084/jem.160.2.564; ZACK J, 1987, LEUKEMIA, V1, P737	54	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					81	88						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1704120				2022-12-17	WOS:A1991EY03900011
J	SCHAEFERREGO, KE; LEIBOWITZ, D; MEARS, JG				SCHAEFERREGO, KE; LEIBOWITZ, D; MEARS, JG			CHROMATIN ALTERATIONS SURROUNDING THE BCR/ABL FUSION GENE IN K562 CELLS	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR COMPREHENS CANC,NEW YORK,NY 10032; DEPT MED,INDIANAPOLIS,IN; DEPT MED GENET,INDIANAPOLIS,IN; WALTHER ONCOL CTR,INDIANAPOLIS,IN	Columbia University; Columbia University; Walther Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA037193, R01CA044028] Funding Source: NIH RePORTER; NCI NIH HHS [CA44028, CA37193] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLLINS SJ, 1984, SCIENCE, V225, P72, DOI 10.1126/science.6587568; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIMERY IW, 1983, EXP HEMATOL, V11, P601; GALE RP, 1984, P NATL ACAD SCI-BIOL, V81, P5648, DOI 10.1073/pnas.81.18.5648; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LACHMAN HM, 1983, NUCLEIC ACIDS RES, V17, P6065; LEIBOWITZ D, 1985, BLOOD, V65, P526; LEIBOWITZ D, 1985, BLOOD, V66, P243; MANIATIS T, 1973, P NATL ACAD SCI USA, V72, P184; POPENOE DW, 1986, BLOOD, V68, P1123; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SCHTIVELMAN E, 1985, NATURE, V315, P550; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3	17	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1669	1673						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267134				2022-12-17	WOS:A1990EL40100009
J	DAHLLOF, B				DAHLLOF, B			DOWN-REGULATION OF MHC CLASS-I ANTIGENS IS NOT A GENERAL MECHANISM FOR THE INCREASED TUMORIGENICITY CAUSED BY C-MYC AMPLIFICATION	ONCOGENE			English	Note											DAHLLOF, B (corresponding author), LUDWIG INST CANC RES,BOX 60202,S-10401 STOCKHOLM,SWEDEN.							BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DAHLLOF B, 1984, EXP CELL RES, V152, P415, DOI 10.1016/0014-4827(84)90642-6; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; MARTINSSON T, 1988, ONCOGENE, V3, P437; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	12	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1990	5	3					433	435						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	2156210				2022-12-17	WOS:A1990CW41500024
J	APPLEBY, MW; GREENFIELD, IM; CROOK, T; PARKINSON, EK; STANLEY, MA				APPLEBY, MW; GREENFIELD, IM; CROOK, T; PARKINSON, EK; STANLEY, MA			INVIVO AND INVITRO EFFECTS OF V-FOS AND EJ-HA-RAS ONCOGENE EXPRESSION IN MURINE EPIDERMAL-KERATINOCYTES	ONCOGENE			English	Article									UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,CAMBRIDGE CB2 1QP,ENGLAND; BEATSON INST CANC RES,GLASGOW G61 1BD,SCOTLAND	University of Cambridge; Beatson Institute								ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BRAVO R, 1982, J MOL BIOL, V154, P121, DOI 10.1016/0022-2836(82)90421-1; BREITKREUTZ D, 1984, DIFFERENTIATION, V26, P154, DOI 10.1111/j.1432-0436.1984.tb01389.x; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BUICK RN, 1984, CANCER RES, V44, P4909; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; CURRAN T, 1986, P NATL ACAD SCI USA, V83, P8521, DOI 10.1073/pnas.83.22.8521; CURRAN T, 1988, ONCOGENE HDB; DORAN TI, 1980, CELL, V22, P17, DOI 10.1016/0092-8674(80)90150-6; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GREEN H, 1977, CELL, V11, P405, DOI 10.1016/0092-8674(77)90058-7; GREENHALGH DA, 1988, MOL CARCINOGEN, V1, P134, DOI 10.1002/mc.2940010209; HAMMOND EJ, 1987, TRANSPLANTATION, V44, P106, DOI 10.1097/00007890-198707000-00022; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; JANOSSY G, 1987, LYMPHOCYTES PRACTICA, P67; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; MACKENZIE IC, 1983, J INVEST DERMATOL, V81, pS189, DOI 10.1111/1523-1747.ep12541093; Maniatis T., 1982, MOL CLONING; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NELSON KG, 1982, CANCER RES, V42, P4176; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKINSON EK, 1987, CARCINOGENESIS, V8, P907, DOI 10.1093/carcin/8.7.907; PERA MF, 1984, CARCINOGENESIS, V5, P671, DOI 10.1093/carcin/5.5.671; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; ROOP DR, 1983, P NATL ACAD SCI-BIOL, V80, P716, DOI 10.1073/pnas.80.3.716; ROSEJOHN S, 1982, CELL, V29, P161; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STANLEY MA, 1979, INT J CANCER, V24, P407, DOI 10.1002/ijc.2910240406; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUN TT, 1977, NATURE, V269, P489, DOI 10.1038/269489a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; YUSPA SH, 1981, J INVEST DERMATOL, V76, P144, DOI 10.1111/1523-1747.ep12525490	43	7	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1323	1330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682460				2022-12-17	WOS:A1989AX65900008
J	SHORE, SK; REDDY, EP				SHORE, SK; REDDY, EP			TRANSFORMATION OF NIH3T3 CELLS BY A-MULV PROVIRAL DNA - EFFECT OF PLASMID LINEARIZATION AND CARRIER DNA ON TRANSFORMATION EFFICIENCY	ONCOGENE			English	Note											SHORE, SK (corresponding author), WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA047937] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47937-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KRUMPKONVALINKOVA V, 1981, VIROLOGY, V109, P215, DOI 10.1016/0042-6822(81)90491-8; REDDY EP, 1988, ONCOGENE HDB, P3; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	10	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1989	4	11					1411	1413						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2554240				2022-12-17	WOS:A1989AX65900020
J	SIMPSON, SC; BOLEN, JB; VEILLETTE, A				SIMPSON, SC; BOLEN, JB; VEILLETTE, A			CD4 AND P56LCK CAN STABLY ASSOCIATE WHEN CO-EXPRESSED IN NIH3T3 CELLS	ONCOGENE			English	Note									MCGILL UNIV,MCGILL CANC CTR,ROOM 701,MCINTYRE BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; NCI,TUMOR VIRUS BIOL LAB,BETHESDA,MD 20892	McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANDERSON P, 1988, J IMMUNOL, V140, P1732; BALLHAUSEN WG, 1988, J EXP MED, V167, P1493, DOI 10.1084/jem.167.4.1493; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RIVAS A, 1988, J IMMUNOL, V140, P2912; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SLECKMAN BP, 1988, J IMMUNOL, V141, P49; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; VEILLETTE A, IN PRESS ONCOGENES; WILDE DB, 1983, J IMMUNOL, V131, P2178	20	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1989	4	9					1141	1143						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AM531	2789360				2022-12-17	WOS:A1989AM53100014
J	FISCHER, S; WENDLING, F; BOULET, I; COCAULT, L; SOULA, M; FAGARD, R; TAMBOURIN, P				FISCHER, S; WENDLING, F; BOULET, I; COCAULT, L; SOULA, M; FAGARD, R; TAMBOURIN, P			ELEVATED LEVEL OF P60C-SRC IN VIRUS-TRANSFORMED MURINE MEGAKARYOCYTIC CELL-LINES	ONCOGENE			English	Article									HOP COCHIN,INSERM,UNITE 152,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	FISCHER, S (corresponding author), CHU COCHIN,INSERM,UNITE 15,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE.			PETIT, Laurence/0000-0002-2475-9367				BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; COOPER JA, 1984, J BIOL CHEM, V259, P7835; FERREL JE, 1988, MOL CELL BIOL, V8, P3609; FISCHER S, 1987, BIOCHEM BIOPH RES CO, V143, P819, DOI 10.1016/0006-291X(87)90322-6; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GACON G, 1982, EMBO J, V1, P1579, DOI 10.1002/j.1460-2075.1982.tb01358.x; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LONG MW, 1981, BLOOD, V58, P1032; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; Maniatis T., 1982, MOL CLONING; MATHEYPREVOT B, 1985, EMBO J, V4, P1769, DOI 10.1002/j.1460-2075.1985.tb03849.x; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PENCIOLELLI JF, 1987, J VIROL, V61, P579, DOI 10.1128/JVI.61.2.579-583.1987; RENDU F, 1989, IN PRESS BLOOD; STENBERG PE, 1986, BLOOD, V68, P696; TAKATA K, 1988, BLOOD, V71, P818; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X	25	7	7	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					901	905						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2474138				2022-12-17	WOS:A1989AE58400013
J	MOREAU, J; LEGUELLEC, R; LEIBOVICI, M; COUTURIER, A; PHILIPPE, M; MECHALI, M				MOREAU, J; LEGUELLEC, R; LEIBOVICI, M; COUTURIER, A; PHILIPPE, M; MECHALI, M			DETECTION OF PROTO-ONCOGENES IN THE GENOME OF THE AMPHIBIAN XENOPUS-LAEVIS	ONCOGENE			English	Article									UNIV RENNES 1, BIOL & GENET DEV LAB, CNRS, UA 256, F-35042 RENNES, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes 1	MOREAU, J (corresponding author), INST JACQUES MONOD, EQUIPE EMBRYOL MOLEC, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.							ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENDER W, 1987, CELL, V50, P519, DOI 10.1016/0092-8674(87)90023-7; BERGMANN DG, 1981, J VIROL, V40, P450, DOI 10.1128/JVI.40.2.450-455.1981; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BROACH J, 1985, DNA-J MOLEC CELL BIO, V4, P64; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; Davidson E. H, 1987, GENE ACTIVITY EARLY; DAWID IB, 1965, J MOL BIOL, V12, P581, DOI 10.1016/S0022-2836(65)80313-8; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; DHAR R, 1984, NUCLEIC ACIDS RES, V12, P3611, DOI 10.1093/nar/12.8.3611; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCHINI G, 1981, NATURE, V290, P154, DOI 10.1038/290154a0; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOODMAN M, 1975, NATURE, V253, P603, DOI 10.1038/253603a0; Gudernatsch JF, 1912, ARCH ENTWICKLUNG ORG, V35, P457, DOI 10.1007/BF02277051; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; Maniatis T., 1982, MOL CLONING; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MOREAU J, 1981, P NATL ACAD SCI-BIOL, V78, P1341, DOI 10.1073/pnas.78.3.1341; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NECKAMEYER WS, 1984, J VIROL, V50, P914, DOI 10.1128/JVI.50.3.914-921.1984; NEUMANSILBERBERG FS, 1984, CELL, V37, P1027; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAPAS TS, 1984, CANCER CELL, V2, P153; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; REDDY EP, 1980, P NATL ACAD SCI-BIOL, V77, P5234, DOI 10.1073/pnas.77.9.5234; REYMOND CD, 1984, CELL, V39, P141, DOI 10.1016/0092-8674(84)90199-5; ROBBINS KC, 1981, P NATL ACAD SCI-BIOL, V78, P2918, DOI 10.1073/pnas.78.5.2918; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; Smith T.F., 1981, ADV APPL MATH, V2, P482, DOI DOI 10.1016/0196-8858(81)90046-4; SOUSSI T, 1987, ONCOGENE, V1, P71; SPECTOR DH, 1978, P NATL ACAD SCI USA, V75, P4102, DOI 10.1073/pnas.75.9.4102; STEELE RE, 1985, NUCLEIC ACIDS RES, V13, P1747, DOI 10.1093/nar/13.5.1747; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X	68	7	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1989	4	4					443	449						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2654808				2022-12-17	WOS:A1989U567700008
J	BALLMERHOFER, K; ZIEGLER, A; BURGER, MM				BALLMERHOFER, K; ZIEGLER, A; BURGER, MM			ASSOCIATION OF POLYOMA-VIRUS MIDDLE T-ANTIGEN AND PP60SRC WITH CYTOSKELETAL ELEMENTS	ONCOGENE			English	Article											BALLMERHOFER, K (corresponding author), FRIEDRICH MIESCHER INST,POB 2543,CH-4002 BASEL,SWITZERLAND.			Ballmer-Hofer, Kurt/0000-0002-3800-9129; Ziegler, Annemarie/0000-0003-0018-7031				ABERCROMBIE M, 1975, EXP CELL RES, V92, P57, DOI 10.1016/0014-4827(75)90636-9; ASH JF, 1976, P NATL ACAD SCI USA, V73, P3603, DOI 10.1073/pnas.73.10.3603; BALLMERHOFER K, 1985, EMBO J, V4, P2321, DOI 10.1002/j.1460-2075.1985.tb03933.x; BENDIG MM, 1980, J VIROL, V33, P1215, DOI 10.1128/JVI.33.3.1215-1220.1980; BENZEEV A, 1985, BIOCHIM BIOPHYS ACTA, V780, P197; Bishop J, 1982, MOL BIOL TUMOR VIRUS, P999; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BROWN DJ, 1984, J BIOL CHEM, V259, P9580; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; COLLETT MS, 1984, MOL CELL BIOL, V4, P1213, DOI 10.1128/MCB.4.7.1213; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; GEIGER B, 1981, COLD SPRING HARBOR S, V2, P671; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; ITO S, 1983, J BIOL CHEM, V258, P4626; KORNBLUTH S, 1986, MOL CELL BIOL, V6, P1545, DOI 10.1128/MCB.6.5.1545; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; NIGG EA, 1982, P NATL ACAD SCI-BIOL, V79, P5322, DOI 10.1073/pnas.79.17.5322; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; POLLACK R, 1975, P NATL ACAD SCI USA, V72, P994, DOI 10.1073/pnas.72.3.994; Rohrschneider L, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P953; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SCHAFFHAUSEN B, 1981, J VIROL, V40, P184, DOI 10.1128/JVI.40.1.184-196.1981; SCHAFFHAUSEN B, 1981, COLD SPRING HARBOR C, V8, P1281; SCHLEGEL R, 1978, CELL, V14, P587, DOI 10.1016/0092-8674(78)90244-1; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SHRIVER K, 1981, J CELL BIOL, V89, P525, DOI 10.1083/jcb.89.3.525; SHRIVER K, 1981, COLD SPRING HARBOR C, V8, P1247; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WITTELSBERGER SC, 1981, CELL, V24, P859, DOI 10.1016/0092-8674(81)90111-2; YONEMOTO W, 1987, MOL CELL BIOL, V7, P905, DOI 10.1128/MCB.7.2.905	37	7	7	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					365	371						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	2856248				2022-12-17	WOS:A1988Q773900003
J	MANNE, V				MANNE, V			IDENTIFICATION OF POLYPHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C AND ITS RESOLUTION FROM PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE-C FROM HUMAN-PLATELET EXTRACT	ONCOGENE			English	Article											MANNE, V (corresponding author), WISTAR INST ANAT & BIOL,36TH & SPRUCE ST,PHILADELPHIA,PA 19104, USA.		manne, veeraswamy/B-1954-2010	manne, veeraswamy/0000-0002-1179-5529	NCI NIH HHS [CA 21124-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan D, 1974, Biochem J, V142, P599; BALDASSARE JJ, 1986, J BIOL CHEM, V261, P1942; BANNO Y, 1986, BIOCHEM BIOPH RES CO, V140, P728, DOI 10.1016/0006-291X(86)90792-8; BANNO Y, 1986, BIOCHEM BIOPH RES CO, V136, P713, DOI 10.1016/0006-291X(86)90498-5; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; CHIARUGI V, 1985, BIOCHEM BIOPH RES CO, V132, P900, DOI 10.1016/0006-291X(85)91892-3; COCKCROFT S, 1984, BIOCHEM J, V221, P477, DOI 10.1042/bj2210477; DAWSON RMC, 1959, BIOCHIM BIOPHYS ACTA, V33, P68, DOI 10.1016/0006-3002(59)90499-8; DECKMYN H, 1986, J BIOL CHEM, V261, P6553; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; DOWNES CP, 1985, MOL MECHANISMS TRANS, P3; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GONZALES RA, 1985, BIOCHEM J, V232, P799, DOI 10.1042/bj2320799; GRAFF G, 1984, ARCH BIOCHEM BIOPHYS, V228, P299, DOI 10.1016/0003-9861(84)90071-7; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HAKATA H, 1982, J BIOCHEM-TOKYO, V92, P929, DOI 10.1093/oxfordjournals.jbchem.a134008; HASLAM RJ, 1984, FEBS LETT, V174, P90, DOI 10.1016/0014-5793(84)81084-4; HIRASAWA K, 1982, BIOCHEM J, V205, P437, DOI 10.1042/bj2050437; HOFMANN SL, 1982, J BIOL CHEM, V257, P6461; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; HOLUB BJ, 1984, CAN J BIOCHEM CELL B, V62, P115, DOI 10.1139/o84-017; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IRVINE RF, 1979, EUR J BIOCHEM, V99, P525, DOI 10.1111/j.1432-1033.1979.tb13284.x; IRVINE RF, 1984, BIOCHEM J, V218, P177, DOI 10.1042/bj2180177; JACKOWSKI S, 1986, J BIOL CHEM, V261, P4978; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; JUNGALWALA FB, 1971, BIOCHEM J, V123, P19, DOI 10.1042/bj1230019; KAMATA T, 1987, ONCOGENE, V1, P37; LAPETINA EG, 1981, NATURE, V292, P367, DOI 10.1038/292367a0; LAPETINA EG, 1973, BIOCHEM J, V131, P433, DOI 10.1042/bj1310433; LENSTRA R, 1984, BIOCHIM BIOPHYS ACTA, V792, P199, DOI 10.1016/0005-2760(84)90223-6; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MANNE V, 1987, BIOCHEM J, V243, P763, DOI 10.1042/bj2430763; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MITCHELL RH, 1984, NATURE, V306, P770; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OBERDISSE E, 1987, BIOCHEM BIOPH RES CO, V144, P1188, DOI 10.1016/0006-291X(87)91437-9; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PRIESS J, 1986, J BIOL CHEM, V261, P8597; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RITTENHOUSE SE, 1979, METHODS ENZYMOL, V86, P3; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHUKLA SD, 1982, LIFE SCI, V30, P1323, DOI 10.1016/0024-3205(82)90016-9; SIESS W, 1983, BIOCHIM BIOPHYS ACTA, V752, P329, DOI 10.1016/0005-2760(83)90131-5; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAKENAWA T, 1981, J BIOL CHEM, V256, P6769; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILSON DB, 1985, J BIOL CHEM, V260, P1046; WILSON DB, 1984, J BIOL CHEM, V259, P1718	65	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					49	54						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	2830583				2022-12-17	WOS:A1987L481300007
J	Kudaravalli, S; den Hollander, P; Mani, SA				Kudaravalli, Sriya; den Hollander, Petra; Mani, Sendurai A.			Role of p38 MAP kinase in cancer stem cells and metastasis	ONCOGENE			English	Review							ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; ALDEHYDE DEHYDROGENASE 1; BREAST-CANCER; DRUG-RESISTANCE; TUMOR-GROWTH; INHIBITION; PLAYS; BONE; EXPRESSION	Therapeutic resistance and metastatic progression are responsible for the majority of cancer mortalities. In particular, the development of resistance is a significant barrier to the efficacy of cancer treatments such as chemotherapy, radiotherapy, targeted therapies, and immunotherapies. Cancer stem cells (CSCs) underlie treatment resistance and metastasis. p38 mitogen-activated protein kinase (p38 MAPK) is downstream of several CSC-specific signaling pathways, and it plays an important role in CSC development and maintenance and contributes to metastasis and chemoresistance. Therefore, the development of therapeutic approaches targeting p38 can sensitize tumors to chemotherapy and prevent metastatic progression.	[Kudaravalli, Sriya; den Hollander, Petra; Mani, Sendurai A.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Kudaravalli, Sriya] Rice Univ, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Rice University	Mani, SA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.	smani@mdanderson.org	Mani, Sendurai/A-7244-2009	Mani, Sendurai/0000-0002-5918-4276	CPRIT [RP160710/RP170172]; NIH/NCI [R01CA200970/2R01CA155243]; NSF [PHY-1935762]; Bowes Foundation; MD Anderson Cancer Center Support Grant [CA016672]	CPRIT; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF(National Science Foundation (NSF)); Bowes Foundation; MD Anderson Cancer Center Support Grant	This research was awarded to SAM and supported by CPRIT (RP160710/RP170172), NIH/NCI (R01CA200970/2R01CA155243), the NSF (PHY-1935762), the Bowes Foundation and in part by the MD Anderson Cancer Center Support Grant CA016672 (MRP to SAM).	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Afify SM, 2019, CANCERS, V11, DOI 10.3390/cancers11030345; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Antoon JW, 2013, INT J ONCOL, V42, P1139, DOI 10.3892/ijo.2013.1814; Bakewell SJ, 2003, P NATL ACAD SCI USA, V100, P14205, DOI 10.1073/pnas.2234372100; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Barriere G, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-114; Boothello RS, 2019, MOL CANCER THER, V18, P51, DOI 10.1158/1535-7163.MCT-18-0104; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Canovas B, 2018, CANCER CELL, V33, P1094, DOI 10.1016/j.ccell.2018.04.010; Cao WH, 2005, J BIOL CHEM, V280, P42731, DOI 10.1074/jbc.M506223200; Cervenka I, 2011, MOL CELL BIOL, V31, P179, DOI 10.1128/MCB.00550-10; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen W, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1740936; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076; De Chiara G, 2006, J BIOL CHEM, V281, P21353, DOI 10.1074/jbc.M511052200; Barrantes IDB, 2011, P NATL ACAD SCI USA, V108, P12764, DOI 10.1073/pnas.1015013108; Demuth T, 2007, MOL CANCER THER, V6, P1212, DOI 10.1158/1535-7163.MCT-06-0711; Deng KY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0126-x; Desgrosellier JS, 2014, DEV CELL, V30, P295, DOI 10.1016/j.devcel.2014.06.005; Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965; El Amrani M, 2019, MOL CARCINOGEN, V58, P1985, DOI 10.1002/mc.23090; Escos A, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00031; Fang Y, 2017, ONCOTARGET, V8, P26702, DOI 10.18632/oncotarget.15804; Felding-Habermann B, 2001, HAEMOSTASIS, V31, P55; Grun D, 2018, ONCOGENE, V37, P4711, DOI 10.1038/s41388-018-0290-4; Gui Ting, 2012, J Signal Transduct, V2012, P289243, DOI 10.1155/2012/289243; Guo XL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-375; Gyorffy B, 2021, COMPUT STRUCT BIOTEC, V19, P4101, DOI 10.1016/j.csbj.2021.07.014; Haq R, 2002, CANCER RES, V62, P5076; Hara J, 2014, ONCOL REP, V31, P589, DOI 10.3892/or.2013.2876; Hayakawa M, 2017, J BIOL CHEM, V292, P1762, DOI 10.1074/jbc.M116.764548; He D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054181; He YL, 2018, J CELL BIOL, V217, P315, DOI 10.1083/jcb.201701049; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P302, DOI 10.1073/pnas.1016917108; Hirose Y, 2003, MOL CELL BIOL, V23, P8306, DOI 10.1128/MCB.23.22.8306-8315.2003; Hollander PD., 2019, CANCER RES, V79, P4669; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; IKAWA M, 1983, J BIOL CHEM, V258, P6282; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kalli M, 2022, MOL CANCER RES, V20, P485, DOI 10.1158/1541-7786.MCR-21-0266; Kasimir-Bauer S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3099; Keely SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC339, DOI 10.1152/ajpcell.00144.2002; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738; Kucuksayan H., 2017, TUMOR BIOL, V39, DOI DOI 10.1177/1010428317706212; Kumar D, 2016, J INVEST DERMATOL, V136, P2462, DOI 10.1016/j.jid.2016.07.024; Kurosu T, 2005, APOPTOSIS, V10, P1111, DOI 10.1007/s10495-005-3372-z; Lathia J, 2020, ONCOLOGIST, V25, P123, DOI 10.1634/theoncologist.2019-0517; Li F, 2007, CELL RES, V17, P3, DOI 10.1038/sj.cr.7310118; Lin SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049605; Lin Y, 2016, ORAL ONCOL, V60, P81, DOI 10.1016/j.oraloncology.2016.06.010; Llopis A, 2012, CELL CYCLE, V11, P3627, DOI 10.4161/cc.21917; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Loret N, 2019, CANCERS, V11, DOI 10.3390/cancers11060838; Lu HQ, 2018, CANCER RES, V78, P4191, DOI 10.1158/0008-5472.CAN-18-0270; Mak VCY, 2021, NEOPLASIA, V23, P718, DOI 10.1016/j.neo.2021.05.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041; Marengo B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.118; Martinez-Limon A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061913; Mathews LA, 2011, CANCER METAST REV, V30, P185, DOI 10.1007/s10555-011-9277-0; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Munne PM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27220-9; Osz A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96340-5; Paillas S, 2011, CANCER RES, V71, P1041, DOI 10.1158/0008-5472.CAN-10-2726; Paranjape AN, 2016, ONCOGENE, V35, P5963, DOI 10.1038/onc.2015.498; Patel NJ, 2016, ONCOTARGET, V7, P84608, DOI 10.18632/oncotarget.12358; Pereira L, 2013, EMBO MOL MED, V5, P1759, DOI 10.1002/emmm.201302732; Pokhrel RH, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01420-9; Pradella D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0579-2; Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574; Qi XT, 2019, ACTA PHARMACOL SIN, V40, P546, DOI 10.1038/s41401-018-0050-6; Qi XM, 2015, STEM CELLS, V33, P2738, DOI 10.1002/stem.2068; Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456; Raimondi C, 2011, BREAST CANCER RES TR, V130, P449, DOI 10.1007/s10549-011-1373-x; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roy S, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0062-6; Roy S, 2018, J ORAL PATHOL MED, V47, P492, DOI 10.1111/jop.12707; Saha RN, 2007, J IMMUNOL, V179, P7101, DOI 10.4049/jimmunol.179.10.7101; Sahu V, 2019, CANCER RES TREAT, V51, P313, DOI 10.4143/crt.2018.105; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43; Singh SK, 2003, CANCER RES, V63, P5821; Soeda A, 2017, ONCOTARGET, V8, P33316, DOI 10.18632/oncotarget.16741; Su XM, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145296; Takayama S, 2005, ANTICANCER RES, V25, P79; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Tan W, 2014, MOL MED REP, V10, P3275, DOI 10.3892/mmr.2014.2598; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tang J, 2018, CANCER MED-US, V7, P3965, DOI 10.1002/cam4.1640; Thomas ML., 2014, CHEMOTHERAPY, V3, P10; Uddin S, 2004, P NATL ACAD SCI USA, V101, P147, DOI 10.1073/pnas.0307075101; Vergote I, 2020, GYNECOL ONCOL, V156, P23, DOI 10.1016/j.ygyno.2019.11.006; Warr N, 2012, DEV CELL, V23, P1020, DOI 10.1016/j.devcel.2012.09.016; Werden SJ, 2016, ONCOGENE, V35, P5977, DOI 10.1038/onc.2016.203; Xiang T, 2015, ONCOGENE, V34, P165, DOI 10.1038/onc.2013.537; Xie CF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1052-z; Xie Y, 2014, MOL MED REP, V10, P2346, DOI 10.3892/mmr.2014.2490; Xiong Y, 2007, J BIOL CHEM, V282, P4975, DOI 10.1074/jbc.M606742200; Xu M, 2018, BBA-MOL BASIS DIS, V1864, P3605, DOI 10.1016/j.bbadis.2018.08.024; Xu M, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0532-4; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang SY, 2011, INT J ONCOL, V38, P1695, DOI 10.3892/ijo.2011.982; Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058915; Yu ZR, 2012, INT J BIOCHEM CELL B, V44, P2144, DOI 10.1016/j.biocel.2012.08.022; Yu-Lee LY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54566-4; Yuan B, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242809; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257	122	6	6	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2022	41	23					3177	3185		10.1038/s41388-022-02329-3	http://dx.doi.org/10.1038/s41388-022-02329-3		APR 2022	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1V0EG	35501462	hybrid, Green Published			2022-12-17	WOS:000789736600002
J	Xia, ZC; Kon, N; Gu, AP; Tavana, O; Gu, W				Xia, Zhangchuan; Kon, Ning; Gu, Alyssa P.; Tavana, Omid; Gu, Wei			Deciphering the acetylation code of p53 in transcription regulation and tumor suppression	ONCOGENE			English	Review							CREB-BINDING PROTEIN; CELL-CYCLE ARREST; DNA-BINDING; P300/CBP-ASSOCIATED FACTOR; TRANSACTIVATION DOMAIN; FUNCTIONAL-ANALYSIS; COMPLEX-FORMATION; TERNARY COMPLEX; GENE-EXPRESSION; EMERGING ROLES	Although it is well-established that p53-mediated tumor suppression mainly acts through its ability in transcriptional regulation, the molecular mechanisms of this regulation are not completely understood. Among a number of regulatory modes, acetylation of p53 attracts great interests. p53 was one of the first non-histone proteins found to be functionally regulated by acetylation and deacetylation, and subsequent work has established that reversible acetylation is a general mechanism for regulation of non-histone proteins. Unlike other types of posttranslational modifications occurred during stress responses, the role of p53 acetylation has been recently validated in vivo by using the knock-in mice with both acetylation-defective and acetylation-mimicking p53 mutants. Here, we review the role of acetylation in p53-mediated activities, with a focus on which specific acetylation sites are critical for p53-dependent transcription regulation during tumor suppression and how acetylation of p53 recruits specific "readers" to execute its promoter-specific regulation of different targets. We also discuss the role of p53 acetylation in differentially regulating its classic activities in cell cycle arrest, senescence and apoptosis as well as newly identified unconventional functions such as cell metabolism and ferroptosis.	[Xia, Zhangchuan; Kon, Ning; Gu, Alyssa P.; Tavana, Omid; Gu, Wei] Columbia Univ, Vagelos Coll Phys & Surg, Inst Canc Genet, 1130 Nicholas Ave, New York, NY 10032 USA; [Xia, Zhangchuan; Kon, Ning; Gu, Alyssa P.; Tavana, Omid; Gu, Wei] Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, 1130 Nicholas Ave, New York, NY 10032 USA; [Gu, Wei] Columbia Univ, Vagelos Coll Phys & Surg, Dept Pathol & Cell Biol, 1130 Nicholas Ave, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, Inst Canc Genet, 1130 Nicholas Ave, New York, NY 10032 USA.; Gu, W (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, 1130 Nicholas Ave, New York, NY 10032 USA.; Gu, W (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, Dept Pathol & Cell Biol, 1130 Nicholas Ave, New York, NY 10032 USA.	wg8@cumc.columbia.edu	Xia, Zhangchuan/AAO-3890-2020	Xia, Zhangchuan/0000-0002-1176-0027; Gu, Wei/0000-0002-1480-2368	National Cancer Institute of the National Institutes of Health [R35CA253059, RO1CA258390, R01CA254970]	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute of the National Institutes of Health under Award R35CA253059, RO1CA258390 and R01CA254970 to WG. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abida WM, 2007, J BIOL CHEM, V282, P1797, DOI 10.1074/jbc.M609001200; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Amodio N, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0606-4; Assi M, 2017, AM J PHYSIOL-REG I, V313, pR646, DOI 10.1152/ajpregu.00247.2017; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Badgley MA, 2020, SCIENCE, V368, P85, DOI 10.1126/science.aaw9872; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Barnoud T, 2021, ONCOGENE, V40, P4281, DOI 10.1038/s41388-021-01852-z; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Boutelle AM, 2021, TRENDS CELL BIOL, V31, P298, DOI 10.1016/j.tcb.2020.12.011; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Buschmann T, 2000, CANCER RES, V60, P896; Cai WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13608-1; Campaner S, 2011, MOL CELL, V43, P681, DOI 10.1016/j.molcel.2011.08.007; Carter S, 2007, NAT CELL BIOL, V9, P428, DOI 10.1038/ncb1562; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Chaudhary R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1410; Chehab NH, 2000, GENE DEV, V14, P278; Chen Ruibing, 2021, Nucleic Acids Res, V49, P4199, DOI 10.1093/nar/gkab222; Cheung EC, 2020, CANCER CELL, V37, P168, DOI 10.1016/j.ccell.2019.12.012; Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001; Cheung EC, 2012, P NATL ACAD SCI USA, V109, P20491, DOI 10.1073/pnas.1206530109; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chu B, 2019, NAT CELL BIOL, V21, P579, DOI 10.1038/s41556-019-0305-6; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]; Feng LJ, 2005, MOL CELL BIOL, V25, P5389, DOI 10.1128/MCB.25.13.5389-5395.2005; Ferreon JC, 2009, P NATL ACAD SCI USA, V106, P6591, DOI 10.1073/pnas.0811023106; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Gao MH, 2015, MOL CELL, V59, P298, DOI 10.1016/j.molcel.2015.06.011; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamard PJ, 2013, GENE DEV, V27, P1868, DOI 10.1101/gad.224386.113; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jenkins LMM, 2009, BIOCHEMISTRY-US, V48, P1244, DOI 10.1021/bi801716h; Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115; Jiang L, 2015, CELL CYCLE, V14, P2881, DOI 10.1080/15384101.2015.1068479; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Jiang LR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2445-9; Jiang MC, 2019, AM J CANCER RES, V9, P1354; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Joubel A, 2009, MOL CELL PROTEOMICS, V8, P1167, DOI 10.1074/mcp.M800487-MCP200; Juillard F, 2020, P NATL ACAD SCI USA, V117, P22443, DOI 10.1073/pnas.2004809117; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238]; Kaiser AM, 2018, CELL DEATH DIFFER, V25, P93, DOI 10.1038/cdd.2017.171; Kar S, 2002, J BIOL CHEM, V277, P15579, DOI 10.1074/jbc.M106915200; Knights CD, 2006, J CELL BIOL, V173, P533, DOI 10.1083/jcb.200512059; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kon Ning, 2021, Oncoscience, V8, P58, DOI 10.18632/oncoscience.534; Kon N, 2021, GENE DEV, V35, DOI 10.1101/gad.348236.121; Kon N, 2021, CANCER RES, V81, P935, DOI 10.1158/0008-5472.CAN-20-1804; Kon Ning, 2018, Oncotarget, V9, P7282, DOI 10.18632/oncotarget.23837; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lee CW, 2010, P NATL ACAD SCI USA, V107, P19290, DOI 10.1073/pnas.1013078107; Lehnertz B, 2011, MOL CELL, V43, P673, DOI 10.1016/j.molcel.2011.08.006; Leu JIJ, 2019, P NATL ACAD SCI USA, V116, P8390, DOI 10.1073/pnas.1821277116; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Li AG, 2007, MOL CELL, V28, P408, DOI 10.1016/j.molcel.2007.09.006; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li TY, 2016, ONCOTARGET, V7, P11838, DOI 10.18632/oncotarget.7864; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Li XZ, 2009, MOL CELL, V36, P290, DOI 10.1016/j.molcel.2009.07.031; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin T, 2019, INT J BIOL SCI, V15, P1287, DOI 10.7150/ijbs.33218; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y., 2022, CELL DEATH DIFFER; Liu Yanqing, 2022, Semin Cancer Biol, V85, P4, DOI 10.1016/j.semcancer.2021.03.010; Liu YQ, 2019, J MOL CELL BIOL, V11, P564, DOI 10.1093/jmcb/mjz060; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Ma XY, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1881-x; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Mello SS, 2018, CURR OPIN CELL BIOL, V51, P65, DOI 10.1016/j.ceb.2017.11.005; Naidu SR, 2012, CELL CYCLE, V11, P2717, DOI 10.4161/cc.21091; Narita T, 2019, NAT REV MOL CELL BIO, V20, P156, DOI 10.1038/s41580-018-0081-3; Nitsch S, 2021, EMBO REP, V22, DOI 10.15252/embr.202152774; Ou Y, 2016, P NATL ACAD SCI USA, V113, pE6806, DOI 10.1073/pnas.1607152113; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Puca R, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-85; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Rokudai S, 2013, P NATL ACAD SCI USA, V110, P3895, DOI 10.1073/pnas.1300490110; Rokudai S, 2009, J BIOL CHEM, V284, P237, DOI 10.1074/jbc.M805101200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Scolnick DM, 1997, CANCER RES, V57, P3693; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Simeonova I, 2013, CELL REP, V3, P2046, DOI 10.1016/j.celrep.2013.05.028; Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017; Statello L, 2021, NAT REV MOL CELL BIO, V22, P159, DOI 10.1038/s41580-021-00330-4; STERNER R, 1979, J BIOL CHEM, V254, P1577; Stockwell BR, 2020, TRENDS CELL BIOL, V30, P478, DOI 10.1016/j.tcb.2020.02.009; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Teufel DP, 2009, ONCOGENE, V28, P2112, DOI 10.1038/onc.2009.71; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verdin E, 2015, NAT REV MOL CELL BIO, V16, P258, DOI 10.1038/nrm3931; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang DL, 2017, NUCLEUS-PHILA, V8, P360, DOI 10.1080/19491034.2017.1313939; Wang DL, 2016, NATURE, V538, P118, DOI 10.1038/nature19759; Wang SJ, 2016, CELL REP, V17, P366, DOI 10.1016/j.celrep.2016.09.022; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; Wen J, 2021, J MOL CELL BIOL, V13, P774, DOI 10.1093/jmcb/mjab047; Wu SY, 2009, EMBO J, V28, P1246, DOI 10.1038/emboj.2009.83; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang X, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abi6684; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang A, 2014, J MOL CELL BIOL, V6, P181, DOI 10.1093/jmcb/mju013; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117	131	6	6	11	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2022	41	22					3039	3050		10.1038/s41388-022-02331-9	http://dx.doi.org/10.1038/s41388-022-02331-9		APR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	1U7PG	35487975	Green Accepted			2022-12-17	WOS:000788990000002
J	Ciraku, L; Bacigalupa, ZA; Ju, J; Moeller, RA; Minh, GL; Lee, RH; Smith, MD; Ferrer, CM; Trefely, S; Izzo, LT; Doan, MT; Gocal, WA; D'Agostino, L; Shi, WY; Jackson, JG; Katsetos, CD; Wellen, KE; Snyder, NW; Reginato, MJ				Ciraku, Lorela; Bacigalupa, Zachary A.; Ju, Jing; Moeller, Rebecca A.; Giang Le Minh; Lee, Rusia H.; Smith, Michael D.; Ferrer, Christina M.; Trefely, Sophie; Izzo, Luke T.; Doan, Mary T.; Gocal, Wiktoria A.; D'Agostino, Luca; Shi, Wenyin; Jackson, Joshua G.; Katsetos, Christos D.; Wellen, Kathryn E.; Snyder, Nathaniel W.; Reginato, Mauricio J.			O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5-dependent ACSS2 phosphorylation	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE-5; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; CYTOSOLIC PROTEINS; EXPRESSION; INHIBITOR; CDK5; DINACICLIB; SURVIVAL; NUCLEAR	Glioblastomas (GBMs) preferentially generate acetyl-CoA from acetate as a fuel source to promote tumor growth. O-GlcNAcylation has been shown to be elevated by increasing O-GlcNAc transferase (OGT) in many cancers and reduced O-GlcNAcylation can block cancer growth. Here, we identify a novel mechanism whereby OGT regulates acetate-dependent acetyl-CoA and lipid production by regulating phosphorylation of acetyl-CoA synthetase 2 (ACSS2) by cyclin-dependent kinase 5 (CDK5). OGT is required and sufficient for GBM cell growth and regulates acetate conversion to acetyl-CoA and lipids. Elevating O-GlcNAcylation in GBM cells increases phosphorylation of ACSS2 on Ser-267 in a CDK5-dependent manner. Importantly, we show that ACSS2 Ser-267 phosphorylation regulates its stability by reducing polyubiquitination and degradation. ACSS2 Ser-267 is critical for OGT-mediated GBM growth as overexpression of ACSS2 Ser-267 phospho-mimetic rescues growth in vitro and in vivo. Importantly, we show that pharmacologically targeting OGT and CDK5 reduces GBM growth ex vivo. Thus, the OGT/CDK5/ACSS2 pathway may be a way to target altered metabolic dependencies in brain tumors.	[Ciraku, Lorela; Bacigalupa, Zachary A.; Ju, Jing; Moeller, Rebecca A.; Giang Le Minh; Lee, Rusia H.; Smith, Michael D.; Ferrer, Christina M.; Gocal, Wiktoria A.; Reginato, Mauricio J.] Drexel Univ, Dept Biochem & Mol Biol, Coll Med, Philadelphia, PA 19102 USA; [Trefely, Sophie; Doan, Mary T.; Snyder, Nathaniel W.] Temple Univ, Ctr Metab Dis Res, Dept Microbiol & Immunol, Lewis Katz Sch Med, Philadelphia, PA 19140 USA; [Izzo, Luke T.; Wellen, Kathryn E.] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Izzo, Luke T.; Wellen, Kathryn E.] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [D'Agostino, Luca; Katsetos, Christos D.] Drexel Univ, Dept Pathol & Lab Med, Coll Med, Philadelphia, PA 19102 USA; [Shi, Wenyin] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA; [Jackson, Joshua G.] Drexel Univ, Dept Pharmacol & Physiol, Coll Med, Philadelphia, PA 19102 USA; [Reginato, Mauricio J.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Translat Cellular Oncol Program, Philadelphia, PA 19107 USA	Drexel University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Drexel University; Jefferson University; Drexel University; Jefferson University	Reginato, MJ (corresponding author), Drexel Univ, Dept Biochem & Mol Biol, Coll Med, Philadelphia, PA 19102 USA.; Reginato, MJ (corresponding author), Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Translat Cellular Oncol Program, Philadelphia, PA 19107 USA.	mjr53@drexel.edu		, Jing/0000-0002-1901-6980; Gocal, Wiktoria/0000-0001-8894-8047; Doan, Mary/0000-0001-6295-4895; Izzo, Luke/0000-0002-6217-9240	PA CURE grant [UO1CA244303]; Drexel University Dean's Fellowship award;  [R01CA228339];  [2-T32-CA-115299-14]	PA CURE grant; Drexel University Dean's Fellowship award; ; 	This work was supported by PA CURE grant (to MJR, NWS and JGJ), UO1CA244303 (to MJR), Drexel University Dean's Fellowship award (to ZAB and LC). KEW acknowledges R01CA228339. LTI is supported by 2-T32-CA-115299-14. The authors thank Chaitali Bhadiadra for technical assistance, Dr. Valerie Sodi and Dr. Edward Hartsough for helpful discussions. In memoriam Christos D. Katsetos.	Antoniou X, 2011, BRAIN RES, V1381, P1, DOI 10.1016/j.brainres.2010.10.071; Bond MR, 2015, J CELL BIOL, V208, P869, DOI 10.1083/jcb.201501101; Bulusu V, 2017, CELL REP, V18, P647, DOI 10.1016/j.celrep.2016.12.055; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Catania A, 2001, NEURO-ONCOLOGY, V3, P89, DOI 10.1093/neuonc/3.2.89; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen XX, 2015, ONCOTARGET, V6, P14926, DOI 10.18632/oncotarget.3717; Ciraku L, J VIS EXP, V2021, P175; Comerford SA, 2014, CELL, V159, P1591, DOI 10.1016/j.cell.2014.11.020; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Feldmann G, 2011, CANCER BIOL THER, V12, P598, DOI 10.4161/cbt.12.7.16475; Ferraro GB, 2021, NAT CANCER, V2, P414, DOI 10.1038/s43018-021-00183-y; Ferrer CM, 2016, J MOL BIOL, V428, P3282, DOI 10.1016/j.jmb.2016.05.028; Ferrer CM, 2014, MOL CELL, V54, P820, DOI 10.1016/j.molcel.2014.04.026; Fu AKY, 2004, P NATL ACAD SCI USA, V101, P6728, DOI 10.1073/pnas.0307606100; Futatsugi A, 2012, CELL CYCLE, V11, P1603, DOI 10.4161/cc.20009; Gao Y, 2001, J BIOL CHEM, V276, P9838, DOI 10.1074/jbc.M010420200; Gloster TM, 2011, NAT CHEM BIOL, V7, P174, DOI [10.1038/nchembio.520, 10.1038/NCHEMBIO.520]; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Hothi P, 2012, ONCOTARGET, V3, P1124; Jackson JG, 2014, J NEUROSCI, V34, P1613, DOI 10.1523/JNEUROSCI.3510-13.2014; Jin X, 2020, NATURE, V588, P331, DOI 10.1038/s41586-020-2969-2; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; Kumar SK, 2015, BLOOD, V125, P443, DOI 10.1182/blood-2014-05-573741; Lenjisa JL, 2017, FUTURE MED CHEM, V9, P1939, DOI 10.4155/fmc-2017-0097; Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439; Li XJ, 2017, MOL CELL, V66, P684, DOI 10.1016/j.molcel.2017.04.026; Lin H, 2007, J BIOL CHEM, V282, P2776, DOI 10.1074/jbc.M607234200; Lindqvist J, 2015, MOL BIOL CELL, V26, P1971, DOI 10.1091/mbc.E14-12-1634; Liu R, 2008, P NATL ACAD SCI USA, V105, P7570, DOI 10.1073/pnas.0712306105; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Magistretti PJ, 2015, NEURON, V86, P883, DOI 10.1016/j.neuron.2015.03.035; Mashimo T, 2014, CELL, V159, P1603, DOI 10.1016/j.cell.2014.11.025; Ning XJ, 2017, CELL MOL NEUROBIOL, V37, P527, DOI 10.1007/s10571-016-0391-y; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535-7163.MCT-10-0324; Piedrahita D, 2010, J NEUROSCI, V30, P13966, DOI 10.1523/JNEUROSCI.3637-10.2010; Pozo K, 2016, TRENDS CANCER, V2, P606, DOI 10.1016/j.trecan.2016.09.001; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Schug ZT, 2016, NAT REV CANCER, V16, P708, DOI 10.1038/nrc.2016.87; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Sharma S, 2020, P NATL ACAD SCI USA, V117, P8001, DOI 10.1073/pnas.1912617117; Sodi VL, 2018, ONCOGENE, V37, P924, DOI 10.1038/onc.2017.395; Sodi VL, 2015, MOL CANCER RES, V13, P923, DOI 10.1158/1541-7786.MCR-14-0536; Thompson JW, 2018, METHOD ENZYMOL, V598, P101, DOI 10.1016/bs.mie.2017.06.009; Trefely S, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1360-7; Ubeda M, 2004, ENDOCRINOLOGY, V145, P3023, DOI 10.1210/en.2003-1522; Yoshii Y, 2009, CANCER SCI, V100, P821, DOI 10.1111/j.1349-7006.2009.01099.x; Yushan R., 2015, WORLD J SURG ONCOL, V13; Zachara NE, 2004, TRENDS CELL BIOL, V14, P218, DOI 10.1016/j.tcb.2004.03.005; Zhao S, 2016, CELL REP, V17, P1037, DOI 10.1016/j.celrep.2016.09.069	53	6	6	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2022	41	14					2122	2136		10.1038/s41388-022-02237-6	http://dx.doi.org/10.1038/s41388-022-02237-6		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0F2FY	35190642	Green Submitted, Green Accepted			2022-12-17	WOS:000758961200001
J	Guo, XY; Liu, TT; Zhu, WJ; Liu, HT; Zhang, GH; Song, L; Zhao, RN; Chen, X; Gao, P				Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Song, Lin; Zhao, Rui-Nan; Chen, Xu; Gao, Peng			CircKDM4B suppresses breast cancer progression via the miR-675/NEDD4L axis	ONCOGENE			English	Article							CIRCULAR RNAS; ANGIOGENESIS; PROMOTES; INVASION; VEGFA; PROLIFERATION; CELLS	Increasing studies have indicated that circular RNAs (circRNAs) play pivotal roles in various cancers. Here, we aimed to explore the roles of circRNAs in breast cancer. We identified a novel circRNA circKDM4B (hsa_circ_0002926) by whole-transcriptome sequencing and validated this by Real-time quantitative polymerase chain reaction (RT-qPCR) and Sanger sequencing. It was significantly decreased in breast cancer tissues compared with adjacent non-tumor tissues. Furthermore, circKDM4B, which is mainly localized in the cytoplasm, was more resistant to actinomycin D or ribonuclease R than its linear transcript KDM4B. In addition, the overexpression of circKDM4B inhibited cell migration and invasion in vitro, while knockdown of circKDM4B induced the opposite effects. In vivo, circKDM4B suppressed tumor growth and metastasis. Additionally, circKDM4B inhibited migration and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro and angiogenesis in vivo. Mechanically, circKDM4B sponged miR-675 to upregulate the expression of NEDD4-like E3 ubiquitin protein ligase (NEDD4L), which catalyzes ubiquitination of PI3KCA, thereby inhibiting PI3K/AKT and VEGFA secretion. Collectively, these findings uncovered the tumor-suppressor role of circKDM4B in breast cancer, especially in angiogenesis and tumor metastasis, indicating that circKDM4B could be a potential therapeutic target for breast cancer progression.	[Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Zhao, Rui-Nan; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Peoples R China; [Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Zhao, Rui-Nan; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China; [Guo, Xiang-Yu; Liu, Tian-Tian; Zhu, Wen-Jie; Liu, Hai-Ting; Zhang, Guo-Hao; Song, Lin; Zhao, Rui-Nan; Chen, Xu; Gao, Peng] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pathol, Jinan, Peoples R China; [Song, Lin] Shandong First Med Univ, Dept Pathol, Shandong Prov Hosp, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences	Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Pathol, Jinan, Peoples R China.; Gao, P (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Pathol, Jinan, Peoples R China.	gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81872362, 82072665]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	This study was supported by the National Natural Science Foundation of China (Grant nos. 81872362 and 82072665), the Taishan Scholars Program of Shandong Province (Grant no. ts201511096).	Barbagallo D, 2019, CANCERS, V11, DOI 10.3390/cancers11020194; Chen B, 2018, THERANOSTICS, V8, P4003, DOI 10.7150/thno.24106; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Cheng J, 2019, CLIN CANCER RES, V25, P3732, DOI 10.1158/1078-0432.CCR-18-3001; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Goel P, 2015, GENE, V557, P1, DOI 10.1016/j.gene.2014.11.051; Guarnieri AL, 2018, ONCOGENE, V37, P3879, DOI 10.1038/s41388-018-0239-7; Guo JP, 2021, ADV SCI, V8, DOI 10.1002/advs.202004303; Gyparaki MT, 2014, CANCER LETT, V354, P1, DOI 10.1016/j.canlet.2014.07.036; Hanniford D, 2020, CANCER CELL, V37, P55, DOI 10.1016/j.ccell.2019.12.007; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; He QR, 2018, MOL THER-NUCL ACIDS, V10, P331, DOI 10.1016/j.omtn.2017.12.014; Karedath T, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5723-0; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Li QD, 2019, CELL METAB, V30, P157, DOI 10.1016/j.cmet.2019.05.009; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Liang YR, 2019, ONCOGENE, V38, P6850, DOI 10.1038/s41388-019-0926-z; Liu G, 2016, ONCOL RES, V23, P99, DOI 10.3727/096504015X14496932933575; Lu J, 2020, CANCER LETT, V471, P38, DOI 10.1016/j.canlet.2019.11.038; Luo Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01203-8; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Morland C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15557; Protopsaltis NJ, 2019, ANGIOGENESIS, V22, P311, DOI 10.1007/s10456-018-9658-x; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Suhasini AN, 2016, LEUKEMIA, V30, P617, DOI 10.1038/leu.2015.302; Szabo L, 2016, NAT REV GENET, V17, P679, DOI 10.1038/nrg.2016.114; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9; Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7; Wang ZX, 2016, J BIOL CHEM, V291, P17467, DOI 10.1074/jbc.M116.726083; Xiao MS, 2020, TRENDS CELL BIOL, V30, P226, DOI 10.1016/j.tcb.2019.12.004; Xu JZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1382-y; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zhang HY, 2019, ONCOGENE, V38, P2844, DOI 10.1038/s41388-018-0619-z; Zheng J, 2019, ONCOGENE, V38, P7073, DOI 10.1038/s41388-019-0934-z; Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027; Zhuang M, 2014, BIOCHEM BIOPH RES CO, V448, P315, DOI 10.1016/j.bbrc.2013.12.126	41	6	6	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2022	41	13					1895	1906		10.1038/s41388-022-02232-x	http://dx.doi.org/10.1038/s41388-022-02232-x		FEB 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J9BT	35145234				2022-12-17	WOS:000754011900001
J	Lv, DM; Ding, SR; Zhong, L; Tu, J; Li, HB; Yao, H; Zou, YT; Zeng, ZL; Liao, Y; Wan, XS; Wen, LL; Xie, XB				Lv, Dongming; Ding, Shirong; Zhong, Li; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Wan, Xuesi; Wen, Lili; Xie, Xianbiao			M(6)A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes Wnt signaling to facilitate osteosarcoma progression	ONCOGENE			English	Article							GENE; SUPPRESSES; PROTEIN	Despite advances in clinical diagnosis and treatment, the prognosis of patients with osteosarcoma (OS) remains poor, and the treatment efficacy has plateaued. Therefore, it is important to identify new therapeutic targets for OS. N-6-methyladenosine (m(6)A) modification has been reported to participate in tumor malignancy. In this study, functional screening showed that the m(6)A demethylase FTO could be a candidate therapeutic target for OS. Upregulated FTO in OS could predict a poorer prognosis. FTO promoted the growth and metastasis of OS in vitro and in vivo. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) were performed to identify DACT1 as a potential target of FTO. In vitro assays demonstrated that FTO could reduce the mRNA stability of DACT1 via m(6)A demethylation, which decreased DACT1 expression and further activated the Wnt signaling pathway. The oncogenic effect of FTO on OS was dependent on DACT1. In addition, the m(6)A reader IGF2BP1 was validated to participate in the regulation of DACT1. Entacapone, a conventional drug for Parkinson's disease, was confirmed to suppress OS via m(6)A-mediated regulation through the FTO/DACT1 axis. Our findings demonstrate that FTO may be a novel therapeutic target and that entacapone has preclinical value to be repurposed for OS.	[Lv, Dongming; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Xie, Xianbiao] Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Lv, Dongming; Tu, Jian; Li, Hongbo; Yao, Hao; Zou, Yutong; Zeng, Ziliang; Liao, Yan; Xie, Xianbiao] Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Peoples R China; [Ding, Shirong] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou, Peoples R China; [Zhong, Li] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Peoples R China; [Zhong, Li] Sun Yat Sen Univ, Affiliated Hosp 7, Sci Res Ctr, Shenzhen, Peoples R China; [Wan, Xuesi] Sun Yat Sen Univ, Dept Endocrinol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Wan, Xuesi] Sun Yat Sen Univ, Diabet Ctr, Affiliated Hosp 1, Guangzhou, Peoples R China; [Wen, Lili] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Xie, XB (corresponding author), Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Xie, XB (corresponding author), Guangdong Prov Key Lab Orthoped & Traumatol, Guangzhou, Peoples R China.; Wen, LL (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Anesthesiol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.	wenll@sysucc.org.cn; xiexbiao@mail.sysu.edu.cn		DONGMING, LV/0000-0001-9642-0410; Zeng, Ziliang/0000-0002-0095-8396	National Natural Science Foundation of China [81972510, 81772864, 81572638]; Natural Science Foundation of Guangdong Province [2016A030313239]; Medical Scientific Research Foundation of Guangdong Province [A2020483]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Medical Scientific Research Foundation of Guangdong Province	This study was supported by National Natural Science Foundation of China (Grants 81972510, 81772864 and 81572638), Natural Science Foundation of Guangdong Province (No.2016A030313239), and Medical Scientific Research Foundation of Guangdong Province (A2020483).	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P1; Barbieri I, 2020, NAT REV CANCER, V20, P303, DOI 10.1038/s41568-020-0253-2; Berulava T, 2020, EUR J HEART FAIL, V22, P54, DOI 10.1002/ejhf.1672; Cacabelos R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030551; Chen CYA, 2008, METHOD ENZYMOL, V448, P335, DOI 10.1016/S0076-6879(08)02617-7; Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013; Chen SJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02847-6; Chen XX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01220-7; Chen YB, 2021, AUTOPHAGY, V17, P457, DOI 10.1080/15548627.2020.1720431; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Eaton BR, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28352; Esposito M, 2021, NAT CELL BIOL, V23, P257, DOI 10.1038/s41556-021-00641-w; Fischer J, 2009, NATURE, V458, P894, DOI 10.1038/nature07848; Fisher DA, 2006, DEV DYNAM, V235, P2620, DOI 10.1002/dvdy.20917; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Gao X, 2008, J BIOL CHEM, V283, P35679, DOI 10.1074/jbc.M804088200; Gilbert WV, 2016, SCIENCE, V352, P1408, DOI 10.1126/science.aad8711; Gordin A, 2004, J NEURAL TRANSM, V111, P1343, DOI 10.1007/s00702-004-0190-3; Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Li HY, 2020, THERANOSTICS, V10, P9477, DOI 10.7150/thno.45763; Li JH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00769; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liao D, 2015, CLIN CANCER RES, V21, P5349, DOI 10.1158/1078-0432.CCR-15-0198; Lin ZY, 2020, EMBO J, V39, DOI 10.15252/embj.2019103181; Liu H, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02422-5; Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006; Lv DM, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-01745-4; Matsuoka K, 2020, CELL RES, V30, P885, DOI 10.1038/s41422-020-0370-1; Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4; Okerlund ND, 2010, J NEUROSCI, V30, P4362, DOI 10.1523/JNEUROSCI.0354-10.2010; Peng SM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7116; Simpson E, 2018, JAAPA-J AM ACAD PHYS, V31, P15, DOI 10.1097/01.JAA.0000541477.24116.8d; Stojic L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14978-7; Su R, 2020, CANCER CELL, V38, P79, DOI 10.1016/j.ccell.2020.04.017; Sun T, 2020, ONCOGENE, V39, P5358, DOI 10.1038/s41388-020-1338-9; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang XR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15304-x; Wang YJ, 2019, EPIGENOMICS-UK, V11, P1693, DOI 10.2217/epi-2019-0262; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xiao YR, 2020, P NATL ACAD SCI USA, V117, P21441, DOI 10.1073/pnas.2000516117; Yang CF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21196985; Yang JH, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0238-3; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399; Zhang CZ, 2020, ONCOGENE, V39, P4507, DOI 10.1038/s41388-020-1303-7; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132; Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00414-1; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhou B, 2021, HEPATOLOGY, V73, P91, DOI 10.1002/hep.31220; Zhou L, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109964; Zhou ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01216-3; Zhu ST, 2020, MOL THER-NUCL ACIDS, V22, P957, DOI 10.1016/j.omtn.2020.10.010; Zhuang CS, 2019, J CELL MOL MED, V23, P2163, DOI 10.1111/jcmm.14128	58	6	6	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1727	1741		10.1038/s41388-022-02214-z	http://dx.doi.org/10.1038/s41388-022-02214-z		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35121825				2022-12-17	WOS:000751251500003
J	Howley, BV; Mohanty, B; Dalton, A; Grelet, S; Karam, J; Dincman, T; Howe, PH				Howley, Breege, V; Mohanty, Bidyut; Dalton, Annamarie; Grelet, Simon; Karam, Joseph; Dincman, Toros; Howe, Philip H.			The ubiquitin E3 ligase ARIH1 regulates hnRNP E1 protein stability, EMT and breast cancer progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MESSENGER-RNA; TGF-BETA; PCBP 1; TRANSLATION; METASTASIS; EXPRESSION; PARKIN; SWITCH; HHARI	The epithelial to mesenchymal transition (EMT), a process that is aberrantly activated in cancer and facilitates metastasis to distant organs, requires coordinated transcriptional and post-transcriptional control of gene expression. The tumor-suppressive RNA binding protein, hnRNP-E1, regulates splicing and translation of EMT-associated transcripts and it is thought that it plays a major role in the control of epithelial cell plasticity during cancer progression. We have utilized yeast 2 hybrid screening to identify novel hnRNP-E1 interactors that play a role in regulating hnRNP-E1; this approach led to the identification of the E3 ubiquitin ligase ARIH1. Here, we demonstrate that hnRNP-E1 protein stability is increased upon ARIH1 silencing, whereas, overexpression of ARIH1 leads to a reduction in hnRNP-E1. Reduced ubiquitination of hnRNP-E1 detected in ARIH1 knockdown (KD) cells compared to control suggests a role for ARIH1 in hnRNP-E1 degradation. The identification of hnRNP-E1 as a candidate substrate of ARIH1 led to the characterization of a novel function for this ubiquitin ligase in EMT induction and cancer progression. We demonstrate a delayed induction of EMT and reduced invasion in mammary epithelial cells silenced for ARIH1. Conversely, ARIH1 overexpression promoted EMT induction and invasion. ARIH1 silencing in breast cancer cells significantly attenuated cancer cell stemness in vitro and tumor formation in vivo. Finally, we utilized miniTurboID proximity labeling to identify novel ARIH1 interactors that may contribute to ARIH1's function in EMT induction and cancer progression.	[Howley, Breege, V; Mohanty, Bidyut; Dalton, Annamarie; Grelet, Simon; Karam, Joseph; Howe, Philip H.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Grelet, Simon] Univ S Alabama, Mitchell Canc Inst, Dept Biochem & Mol Biol, Mobile, AL USA; [Dincman, Toros] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA; [Howe, Philip H.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; University of South Alabama; Medical University of South Carolina; Medical University of South Carolina	Howe, PH (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.; Howe, PH (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.	howep@musc.edu		Karam, Joseph/0000-0002-4536-7362; Howe, Philip/0000-0002-1358-1313	National Cancer Institute [CA154663]; DOD BCRP [BC170301, W81XWH-18-1-0003]; NIH [5KL2TR001452]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD BCRP(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by CA154663 from the National Cancer Institute to PHH, DOD BCRP BC170301 under Award No. W81XWH-18-1-0003 to ACD, and NIH 5KL2TR001452 to TD. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense. This study used the services of the Cell & Molecular Imaging Shared Resource of MUSC, the Biorepository & Tissue Analysis Shared Resource, and the Gene Targeting and Knockout Shared Resource at MUSC. We would like to thank members of the Howe lab and Dr. Shaun Olsen for providing helpful feedback during the preparation of this manuscript.	Abudayyeh OO, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5573; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Calderwood DA, 2003, NAT CELL BIOL, V5, P694, DOI 10.1038/ncb0803-694; Cao L, 2017, CANCER LETT, V403, P246, DOI 10.1016/j.canlet.2017.06.021; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen Q, 2021, CELL MOL LIFE SCI, V78, P949, DOI 10.1007/s00018-020-03544-5; Elmehdawi F, 2013, EXP CELL RES, V319, P161, DOI 10.1016/j.yexcr.2012.10.002; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Harvey SE, 2018, RNA, V24, P1326, DOI 10.1261/rna.066712.118; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Howley BV, 2016, ONCOGENE, V35, P1725, DOI 10.1038/onc.2015.238; Howley BV, 2019, CYTOKINE, V118, P19, DOI 10.1016/j.cyto.2017.12.032; Howley BV, 2018, ONCOGENE, V37, P1308, DOI 10.1038/s41388-017-0023-0; Huang LX, 2017, CANCER SCI, V108, P1985, DOI 10.1111/cas.13338; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; James P, 1996, GENETICS, V144, P1425; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kelsall IR, 2013, EMBO J, V32, P2848, DOI 10.1038/emboj.2013.209; Ko TY, 2019, FASEB J, V33, P7143, DOI 10.1096/fj.201801534RR; Lee IH, 2014, ONCOGENE, V33, P4675, DOI 10.1038/onc.2014.69; LeFave CV, 2011, EMBO J, V30, P4084, DOI 10.1038/emboj.2011.259; Li F, 2019, EBIOMEDICINE, V45, P208, DOI 10.1016/j.ebiom.2019.06.017; Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Meng Q, 2007, P NATL ACAD SCI USA, V104, P5866, DOI 10.1073/pnas.0701065104; Okumura F, 2007, GENE DEV, V21, P255, DOI 10.1101/gad.1521607; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Schnoor M, 2018, TRENDS CELL BIOL, V28, P79, DOI 10.1016/j.tcb.2017.10.009; Scott DC, 2016, CELL, V166, P1198, DOI 10.1016/j.cell.2016.07.027; Shinriki S, 2018, J PATHOL, V244, P367, DOI 10.1002/path.5019; Sohn M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32796-2; Tan KL, 2018, DEV CELL, V45, P226, DOI 10.1016/j.devcel.2018.03.020; Tripathi V, 2016, MOL CELL, V64, P549, DOI 10.1016/j.molcel.2016.09.013; Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087; von Stechow L, 2015, MOL CELL BIOL, V35, P1254, DOI 10.1128/MCB.01152-14; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; Woosley AN, 2019, ONCOGENE, V38, P3794, DOI 10.1038/s41388-019-0703-z; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; Zhang MP, 2017, AM J TRANSL RES, V9, P708; Zhang MP, 2016, AM J TRANSL RES, V8, P3567; Zhang ZZ, 2015, MOL CANCER THER, V14, P1162, DOI 10.1158/1535-7163.MCT-14-0695; Zihni C, 2016, NAT REV MOL CELL BIO, V17, P564, DOI 10.1038/nrm.2016.80	49	6	6	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2022	41	12					1679	1690		10.1038/s41388-022-02199-9	http://dx.doi.org/10.1038/s41388-022-02199-9		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV6UV	35102251	hybrid, Green Published			2022-12-17	WOS:000750409400003
J	Xu, QC; Tien, YC; Shi, YH; Chen, S; Zhu, YQ; Huang, XT; Huang, CS; Zhao, W; Yin, XY				Xu, Qiong-Cong; Tien, Yi-Chih; Shi, Yin-Hao; Chen, Siyun; Zhu, Ying-Qin; Huang, Xi-Tai; Huang, Chen-Song; Zhao, Wei; Yin, Xiao-Yu			METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m(6)A-YTHDF2-dependent manner	ONCOGENE			English	Article							CANCER; RNA	N6-methyladenosine (m(6)A) RNA methylation has recently been found involving in regulatory mechanism of the tumor progression. Our aim was to explore the biological function and clinical significance of the m(6)A methyltransferase METTL3 in intrahepatic cholangiocarcinoma (ICC). In this study, we revealed that METTL3 was upregulated and predicted poor prognosis of patients with ICC. Multivariate regression analysis demonstrated that METTL3 expression was an independent predictor for overall survival in patients with ICC. Moreover, METTL3 knockdown inhibited ICC progression, while METTL3 overexpression showed the opposite effect. METTL3 inhibitor STM2457 also showed anti-tumor effect in ICC. Mechanistically, METTL3 transcription was driven by H3K4me3 activation. Upregulation of METTL3 mediated m(6)A modification of IFIT2 mRNA and accelerated IFIT2 mRNA decay in a YTHDF2-dependent manner, which promoted the development of ICC and lead to poorer prognosis. In summary, our findings revealed that H3K4me3 activation-driven METTL3 transcription promotes ICC progression by YTHDF2-mediated IFIT2 mRNA degradation, suggesting that METTL3 may serve as a potential target for human ICC therapy.	[Xu, Qiong-Cong; Tien, Yi-Chih; Shi, Yin-Hao; Zhu, Ying-Qin; Huang, Xi-Tai; Huang, Chen-Song; Yin, Xiao-Yu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, Guangzhou 510080, Peoples R China; [Chen, Siyun; Zhao, Wei] Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou 510080, Peoples R China; [Zhao, Wei] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Yin, XY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pancreatobiliary Surg, Guangzhou 510080, Peoples R China.; Zhao, W (corresponding author), Sun Yat Sen Univ, Minist Educ, Key Lab Stem Cells & Tissue Engn, Guangzhou 510080, Peoples R China.; Zhao, W (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangzhou 510080, Peoples R China.	zhaowei23@mail.sysu.edu.cn; yinxy@mail.sysu.edu.cn			National Natural Science Foundation of China [81772522, 82002501, 82072644, 81972651, 31771630]; Guangdong Basic and Applied Basic Research Foundation [2021A1515010123, 2019A1515010096, 2019A1515010686]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Basic and Applied Basic Research Foundation	The authors greatly acknowledge the financial support from National Natural Science Foundation of China (81772522, 82002501, 82072644, 81972651, and 31771630), the Guangdong Basic and Applied Basic Research Foundation (2021A1515010123, 2019A1515010096 and 2019A1515010686).	Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Chen MN, 2018, HEPATOLOGY, V67, P2254, DOI 10.1002/hep.29683; Cheng MS, 2019, ONCOGENE, V38, P3667, DOI 10.1038/s41388-019-0683-z; Deng XL, 2018, CELL RES, V28, P507, DOI 10.1038/s41422-018-0034-6; He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9; Huang CS, 2018, CANCER LETT, V421, P63, DOI 10.1016/j.canlet.2018.02.020; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Jusakul A, 2017, CANCER DISCOV, V7, P1116, DOI 10.1158/2159-8290.CD-17-0368; Koh SY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030624; Lai KC, 2013, ONCOGENE, V32, P3686, DOI 10.1038/onc.2012.384; Lai KC, 2016, CANCER LETT, V370, P207, DOI 10.1016/j.canlet.2015.10.016; Li JF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01267-6; Mavros MN, 2014, JAMA SURG, V149, P565, DOI 10.1001/jamasurg.2013.5137; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Moore MJ, 2014, NAT PROTOC, V9, P263, DOI 10.1038/nprot.2014.012; Nepal C, 2018, HEPATOLOGY, V68, P949, DOI 10.1002/hep.29764; Pidugu VK, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00148; Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0; Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157; Shen H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0107-3; Shroff RT, 2019, JAMA ONCOL, V5, P824, DOI 10.1001/jamaoncol.2019.0270; Su WY, 2019, ONCOTARGETS THER, V12, P8139, DOI 10.2147/OTT.S220698; Valle Juan, 2010, N Engl J Med, V362, P1273, DOI 10.1056/NEJMoa0908721; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang HS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1108-x; Wang Q, 2020, GUT, V69, P1193, DOI 10.1136/gutjnl-2019-319639; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wardell CP, 2018, J HEPATOL, V68, P959, DOI 10.1016/j.jhep.2018.01.009; Yang C, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03143-z; Yankova E, 2021, NATURE, V593, P597, DOI 10.1038/s41586-021-03536-w; Zeng CW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00951-w	31	6	6	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1622	1633		10.1038/s41388-022-02185-1	http://dx.doi.org/10.1038/s41388-022-02185-1		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35094011	Green Published, hybrid			2022-12-17	WOS:000750486500004
J	Fu, LC; Fan, J; Maity, S; McFadden, G; Shi, YX; Kong, W				Fu, Lingchen; Fan, Jia; Maity, Sudipa; McFadden, Grant; Shi, Yixin; Kong, Wei			PD-L1 interacts with Frizzled 6 to activate beta-catenin and form a positive feedback loop to promote cancer stem cell expansion	ONCOGENE			English	Article							COLON-CANCER; WNT/BETA-CATENIN; EXPRESSION; DIFFERENTIATION; MICE; APC; IDENTIFICATION; PROGENITORS; PROGRESSION; CLONING	Cancer stem cells (CSCs) drive tumor initiation, progression, metastasis, and drug resistance. We report here that programmed cell death ligand 1 (PD-L1) is constitutively expressed in cancer cells to maintain and expand CSC through a novel mechanism in addition to promoting cancer cell immune evasion. We discovered that PD-L1 interacts with receptor Frizzled 6 to activate beta-catenin signaling and increase beta-catenin-targeted gene expression, such as a putative stem cell marker leucine-rich-repeat-containing G-protein-coupled receptor 5. Blockage of PD-L1 function, using a specific small hairpin RNA or a specific antibody, inhibits disease progression by reducing the CSC population in both colorectal and breast tumors. Moreover, beta-catenin conversely regulates PD-L1 expression through a beta-catenin complex binding site in the PD-L1 promoter. Our discoveries reveal that besides assistant tumor cell immune escaping, PD-L1 and beta-catenin signaling form a positive feedback loop to promote cancer progression through CSC maintenance and expansion.	[Fu, Lingchen; McFadden, Grant; Shi, Yixin; Kong, Wei] Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virotherap, Tempe, AZ 85281 USA; [Fan, Jia; Maity, Sudipa] Tulane Univ, Sch Med, Ctr Cellular & Mol Diagnost, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Fan, Jia; Maity, Sudipa] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [McFadden, Grant; Shi, Yixin] Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA	Arizona State University; Arizona State University-Tempe; Tulane University; Tulane University; Arizona State University; Arizona State University-Tempe	Shi, YX; Kong, W (corresponding author), Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virotherap, Tempe, AZ 85281 USA.; Shi, YX (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85281 USA.	yixin.shi@asu.edu; wei.kong@asu.edu			National Institutes of Health/National Cancer Institute [CA249517]; Arizona State University [5300]; National Institutes of Health National/Institute of Dental and Craniofacial [DE024607]	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Arizona State University; National Institutes of Health National/Institute of Dental and Craniofacial	This work was supported by grants National Institutes of Health/National Cancer Institute (CA249517 to WK); Arizona State University (Startup fund 5300 to WK); National Institutes of Health National/Institute of Dental and Craniofacial (DE024607 to YS and WK).	Adams S, 2010, BREAST CANCER RES TR, V124, P723, DOI 10.1007/s10549-010-1181-8; American Cancer Society, 2021, KEY STAT CHILDH CANC; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173; Birnbaum DJ, 2016, ONCOTARGET, V7, P71198, DOI 10.18632/oncotarget.11685; Cantilena S, 2011, ONCOTARGET, V2, P976, DOI 10.18632/oncotarget.410; Castagnoli L, 2019, ONCOGENE, V38, P4047, DOI 10.1038/s41388-019-0700-2; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Corda G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.69; Corda G, 2017, J PATHOL, V241, P350, DOI 10.1002/path.4841; Cortez MA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv303; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dong PX, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00386; Du LY, 2020, J EXP MED, V217, DOI 10.1084/jem.20191115; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Finkbeiner SR, 2013, DIGEST DIS SCI, V58, P1176, DOI 10.1007/s10620-013-2620-2; FZD6, 2021, HUM PROT ATL; Garcia MI, 2009, DEV BIOL, V331, P58, DOI 10.1016/j.ydbio.2009.04.020; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; HASHIMOTO Y, 1993, AM J HEMATOL, V43, P319, DOI 10.1002/ajh.2830430420; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735; Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212; Kawai T, 2016, SCI REP-UK, V6, DOI 10.1038/srep30489; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee Y, 2016, CLIN CANCER RES, V22, P3571, DOI 10.1158/1078-0432.CCR-15-2665; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Lin YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116711; Litviakov Nikolai, 2020, Oncotarget, V11, P1988, DOI 10.18632/oncotarget.27608; Liu Z, 2014, NEOPLASMA, V61, P177, DOI 10.4149/neo_2014_016; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Mansour FA, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1729299; Pearce DJ, 2005, STEM CELLS, V23, P752, DOI 10.1634/stemcells.2004-0292; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shenoy AK, 2012, CANCER RES, V72, P5091, DOI 10.1158/0008-5472.CAN-12-1806; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Singh SK, 2003, CANCER RES, V63, P5821; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tokuhara M, 1998, BIOCHEM BIOPH RES CO, V243, P622, DOI 10.1006/bbrc.1998.8143; Tong GL, 2019, CANCER MED-US, V8, P7044, DOI 10.1002/cam4.2542; Van Raay TJ, 2005, NEURON, V46, P23, DOI 10.1016/j.neuron.2005.02.023; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Wei F, 2019, CANCER LETT, V450, P1, DOI 10.1016/j.canlet.2019.02.022; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yang L, 2015, STEM CELLS, V33, P2913, DOI 10.1002/stem.2083; Yanheng W., 2017, CLIN EXP PHARM PHYSL, V44, P3; Yu WD, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2701-z; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zheng AY, 2019, ONCOL REP, V41, P2833, DOI 10.3892/or.2019.7053	53	6	6	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1100	1113		10.1038/s41388-021-02144-2	http://dx.doi.org/10.1038/s41388-021-02144-2		JAN 2022	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35034965				2022-12-17	WOS:000743007800001
J	Fjaestad, KY; Romer, AMA; Goitea, V; Johansen, AZ; Thorseth, ML; Carretta, M; Engelholm, LH; Grontved, L; Junker, N; Madsen, DH				Fjaestad, Klaire Yixin; Romer, Anne Mette Askehoj; Goitea, Victor; Johansen, Astrid Zedlitz; Thorseth, Marie-Louise; Carretta, Marco; Engelholm, Lars Henning; Grontved, Lars; Junker, Niels; Madsen, Daniel Hargbol			Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment	ONCOGENE			English	Article							NERVOUS-SYSTEM; OPEN-LABEL; PROPRANOLOL; CELLS; PEMBROLIZUMAB; COMBINATION; MANAGEMENT; SUPPRESSES; PHENOTYPE; MORTALITY	The development of immune checkpoint inhibitors (ICI) marks an important breakthrough of cancer therapies in the past years. However, only a limited fraction of patients benefit from such treatments, prompting the search for immune modulating agents that can improve the therapeutic efficacy. The nonselective beta blocker, propranolol, which for decades has been prescribed for the treatment of cardiovascular conditions, has recently been used successfully to treat metastatic angiosarcoma. These results have led to an orphan drug designation by the European Medicines Agency for the treatment of soft tissue sarcomas. The anti-tumor effects of propranolol are suggested to involve the reduction of cancer cell proliferation as well as angiogenesis. Here, we show that oral administration of propranolol delays tumor progression of MCA205 fibrosarcoma model and MC38 colon cancer model and increases the survival rate of tumor bearing mice. Propranolol works by reducing tumor angiogenesis and facilitating an anti-tumoral microenvironment with increased T cell infiltration and reduced infiltration of myeloid-derived suppressor cells (MDSCs). Using T cell deficient mice, we demonstrate that the full anti-tumor effect of propranolol requires the presence of T cells. Flow cytometry-based analysis and RNA sequencing of FACS-sorted cells show that propranolol treatment leads to an upregulation of PD-L1 on tumor associated macrophages (TAMs) and changes in their chemokine expression profile. Lastly, we observe that the co-administration of propranolol significantly enhances the efficacy of anti-CTLA4 therapy. Our results identify propranolol as an immune modulating agent, which can improve immune checkpoint inhibitor therapies in soft tissue sarcoma patients and potentially in other cancers.	[Fjaestad, Klaire Yixin; Romer, Anne Mette Askehoj; Johansen, Astrid Zedlitz; Thorseth, Marie-Louise; Carretta, Marco; Madsen, Daniel Hargbol] Copenhagen Univ Hosp Herlev & Gentofte, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark; [Fjaestad, Klaire Yixin; Thorseth, Marie-Louise; Madsen, Daniel Hargbol] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark; [Romer, Anne Mette Askehoj] Roskilde Univ, Dept Sci & Environm, Roskilde, Denmark; [Goitea, Victor; Grontved, Lars] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark; [Engelholm, Lars Henning] Univ Copenhagen, Biotech Res & Innovat Ctr, Finsen Lab, Copenhagen, Denmark; [Junker, Niels] Copenhagen Univ Hosp Herlev & Gentofte, Dept Oncol, Herlev, Denmark	University of Copenhagen; Roskilde University; University of Southern Denmark; University of Copenhagen	Madsen, DH (corresponding author), Copenhagen Univ Hosp Herlev & Gentofte, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark.; Madsen, DH (corresponding author), Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark.	daniel.hargboel.madsen@regionh.dk	Johansen, Astrid/CAF-7679-2022	Fjaestad, Klaire Yixin/0000-0002-0141-6898; Thorseth, Marie-Louise/0000-0001-7978-5549; CARRETTA, MARCO/0000-0002-8135-7188; Goitea, Victor/0000-0002-1564-4111; Engelholm, Lars/0000-0002-6616-1232; Grontved, Lars/0000-0002-6735-8483; Madsen, Daniel Hargboel/0000-0002-3183-6201; Askehoj Romer, Anne Mette/0000-0002-5408-7020	Lundbeck Foundation [R307-2018-3326]; Danish Cancer Society [R231-A14035, R231-A13832]; Independent Research Fund Denmark; department of Oncology, Herlev Hospital	Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); Independent Research Fund Denmark; department of Oncology, Herlev Hospital	This work was supported by the Lundbeck Foundation (R307-2018-3326) (to DHM), Danish Cancer Society (R231-A14035 and R231-A13832 (to DHM and LHE)), the Independent Research Fund Denmark (to LG), and department of Oncology, Herlev Hospital.	Agac D, 2018, BRAIN BEHAV IMMUN, V74, P176, DOI 10.1016/j.bbi.2018.09.004; Amaya Clarissa N, 2018, Oncoscience, V5, P109, DOI 10.18632/oncoscience.413; Awad RM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01977; Baghba R, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0530-4; Bai RL, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00209-0; Banavali S, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.499; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Barnes TA, 2017, BRIT J CANCER, V117, P451, DOI 10.1038/bjc.2017.220; Barron TI, 2011, J CLIN ONCOL, V29, P2635, DOI 10.1200/JCO.2010.33.5422; Barton AL, 2015, J PEDIATR-US, V166, P115, DOI 10.1016/j.jpeds.2014.08.067; Brohee L, 2015, ONCOTARGET, V6, P11264, DOI 10.18632/oncotarget.3595; Bucsek MJ, 2017, CANCER RES, V77, P5639, DOI 10.1158/0008-5472.CAN-17-0546; Casali PG, 2014, ANN ONCOL, V25, P102, DOI 10.1093/annonc/mdu254; Chandran S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00787; Cole SW, 2015, NAT REV CANCER, V15, P563, DOI 10.1038/nrc3978; D'Angelo SP, 2018, LANCET ONCOL, V19, P416, DOI 10.1016/S1470-2045(18)30006-8; Daher C, 2019, CANCER IMMUNOL RES, V7, P1849, DOI 10.1158/2326-6066.CIR-18-0833; Eng JWL, 2014, CANCER IMMUNOL IMMUN, V63, P1115, DOI 10.1007/s00262-014-1617-9; Enot DP, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1462431; Fares Charlene M, 2019, Am Soc Clin Oncol Educ Book, V39, P147, DOI 10.1200/EDBK_240837; Field CS, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1376154; Gandhi S, 2021, CLIN CANCER RES, V27, P87, DOI 10.1158/1078-0432.CCR-20-2381; Hoang NT, 2018, CANCER MANAG RES, V10, P1089, DOI 10.2147/CMAR.S159641; Hou AH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00783; Idos GE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60255-4; Jin MZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00280-x; Jurberg AD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01440; Kamiya A, 2019, NAT NEUROSCI, V22, P1289, DOI 10.1038/s41593-019-0430-3; Kokolus KM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1405205; Liu YT, 2020, CLIN CANCER RES, V26, P970, DOI [10.1158/1078-0432.CCR-19-1040z, 10.1158/1078-0432.CCR-19-1040]; Magnon C, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.975643; Makale MT, 2017, BIOCYBERN BIOMED ENG, V37, P443, DOI 10.1016/j.bbe.2017.05.001; Mohammadpour H, 2019, J CLIN INVEST, V129, P5537, DOI 10.1172/JCI129502; Mravec B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217958; Nagaraja AS, 2013, J CLIN INVEST, V123, P558, DOI 10.1172/JCI67887; Neophytou CM, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00899; Pantziarka Pan, 2018, Ecancermedicalscience, V12, ped82, DOI 10.3332/ecancer.2018.ed82; Pantziarka P, 2016, ECANCERMEDICALSCIENC, V10, DOI 10.3332/ecancer.2016.680; Pasquier E, 2016, EBIOMEDICINE, V6, P87, DOI 10.1016/j.ebiom.2016.02.026; Pedersen L, 2016, CELL METAB, V23, P554, DOI 10.1016/j.cmet.2016.01.011; Peranzoni E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01590; Qiao GX, 2019, CANCER IMMUNOL IMMUN, V68, P11, DOI 10.1007/s00262-018-2243-8; Rains Steven L, 2017, Oncoscience, V4, P95, DOI 10.18632/oncoscience.357; Srinivasan AV, 2019, ANN INDIAN ACAD NEUR, V22, P21, DOI 10.4103/aian.AIAN_201_18; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; Wagner Michael J, 2018, J Exp Pharmacol, V10, P51, DOI 10.2147/JEP.S146211; Wesolowski R, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-10; Wieduwild E, 2020, J EXP MED, V217, DOI 10.1084/jem.20190554; Wood Laura S, 2020, JCO Oncol Pract, V16, p15s, DOI 10.1200/JOP.19.00647; Zhong SL, 2016, EUR J CANCER PREV, V25, P440, DOI 10.1097/CEJ.0000000000000192; Zhou L, 2016, J IMMUNOL, V196, P3460, DOI 10.4049/jimmunol.1501677	52	6	6	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1364	1375		10.1038/s41388-021-02170-0	http://dx.doi.org/10.1038/s41388-021-02170-0		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	35017664	Green Published, hybrid			2022-12-17	WOS:000741240600002
J	He, ZS; Khatib, AM; Creemers, JWM				He, Zongsheng; Khatib, Abdel-Majid; Creemers, John W. M.			The proprotein convertase furin in cancer: more than an oncogene	ONCOGENE			English	Review							TUMOR-NECROSIS-FACTOR; TRANS-GOLGI NETWORK; ENDOPROTEOLYTIC CLEAVAGE; SELECTIVE-INHIBITION; PROCESSING ENZYME; IMMUNE EVASION; FACTOR-ALPHA; E-CADHERIN; IN-VITRO; T-CELLS	Furin is the first discovered proprotein convertase member and is present in almost all mammalian cells. Therefore, by regulating the maturation of a wide range of proproteins, Furin expression and/or activity is involved in various physiological and pathophysiological processes ranging from embryonic development to carcinogenesis. Since many of these protein precursors are involved in initiating and maintaining the hallmarks of cancer, Furin has been proposed as a potential target for treating several human cancers. In contrast, other studies have revealed that some types of cancer do not benefit from Furin inhibition. Therefore, understanding the heterogeneous functions of Furin in cancer will provide important insights into the design of effective strategies targeting Furin in cancer treatment. Here, we present recent advances in understanding how Furin expression and activity are regulated in cancer cells and their influences on the activity of Furin substrates in carcinogenesis. Furthermore, we discuss how Furin represses tumorigenic properties of several cancer cells and why Furin inhibition leads to aggressive phenotypes in other tumors. Finally, we summarize the clinical applications of Furin inhibition in treating human cancers.	[He, Zongsheng] Army Med Univ, Daping Hosp, Dept Gastroenterol, Chongqing, Peoples R China; [He, Zongsheng; Creemers, John W. M.] Katholieke Univ Leuven, Lab Biochem Neuroendocrinol, Dept Human Genet, Leuven, Belgium; [Khatib, Abdel-Majid] INSERM, LAMC, UMR 1029, Allee Geoffroy St Hilaire, Pessac, France; [Khatib, Abdel-Majid] Inst Bergoinie, Bordeaux, France	Army Medical University; KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm)	Creemers, JWM (corresponding author), Katholieke Univ Leuven, Lab Biochem Neuroendocrinol, Dept Human Genet, Leuven, Belgium.; Khatib, AM (corresponding author), INSERM, LAMC, UMR 1029, Allee Geoffroy St Hilaire, Pessac, France.; Khatib, AM (corresponding author), Inst Bergoinie, Bordeaux, France.	majid.khatib@inserm.fr; john.creemers@kuleuven.be		Creemers, John/0000-0003-2518-9295; He, Zongsheng/0000-0003-2499-8402	FWO Vlaanderen [G.0738.15]	FWO Vlaanderen(FWO)	We would like to thank Sandra McElroy for proofreading manuscript. We acknowledge grant support from FWO Vlaanderen (Grant no. G.0738.15) to JC.	Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077; Al Rifai O, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.690681; Bassi DE, 2017, MOL CARCINOGEN, V56, P1182, DOI 10.1002/mc.22550; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Baumgart A, 2015, ONCOGENE, V34, P578, DOI 10.1038/onc.2013.592; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Bertrand F, 2015, CANCER RES, V75, P2619, DOI 10.1158/0008-5472.CAN-14-2524; Bilbao D, 2014, EMBO MOL MED, V6, P1423, DOI 10.15252/emmm.201303376; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blanchette F, 2001, J CELL PHYSIOL, V188, P264, DOI 10.1002/jcp.1116; Bommireddy R, 2007, TRENDS MOL MED, V13, P492, DOI 10.1016/j.molmed.2007.08.005; Brouwers B, 2021, DIABETES, V70, P492, DOI 10.2337/db20-0474; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Casazza A, 2012, EMBO MOL MED, V4, P234, DOI 10.1002/emmm.201100205; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang LY, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1040215; Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309; Coppola I, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126344; Cordova ZM, 2016, ONCOTARGET, V7, P54392, DOI 10.18632/oncotarget.11106; Couture F, 2015, EXPERT OPIN THER PAT, V25, P379, DOI 10.1517/13543776.2014.1000303; Creemers JWM, 2008, FRONT BIOSCI-LANDMRK, V13, P4960, DOI 10.2741/3055; D'Anjou F, 2011, TRANSL ONCOL, V4, P157, DOI 10.1593/tlo.10295; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Declercq J, 2017, EUR J CELL BIOL, V96, P432, DOI 10.1016/j.ejcb.2017.03.010; Declercq J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321276; Declercq J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/148651; DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6; Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1; Doci CL, 2015, CANCER RES, V75, P2937, DOI 10.1158/0008-5472.CAN-14-3121; Duguay SJ, 1998, J BIOL CHEM, V273, P18443, DOI 10.1074/jbc.273.29.18443; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; Duval S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02893-0; Essalmani R, 2011, J BIOL CHEM, V286, P4257, DOI 10.1074/jbc.M110.192104; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; Fu J, 2015, MOL CARCINOGEN, V54, P698, DOI 10.1002/mc.22131; Garancher A, 2020, NAT NEUROSCI, V23, P842, DOI 10.1038/s41593-020-0628-4; Ghisoli M, 2017, J PEDIAT HEMATOL ONC, V39, pE183, DOI 10.1097/MPH.0000000000000822; Ghisoli M, 2016, MOL THER, V24, P1478, DOI 10.1038/mt.2016.86; Ghisoli M, 2015, MOL THER, V23, P1103, DOI 10.1038/mt.2015.43; Ginefra P, 2018, CELL REP, V22, P2176, DOI 10.1016/j.celrep.2018.02.005; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartley G, 2017, CANCER IMMUNOL IMMUN, V66, P523, DOI 10.1007/s00262-017-1955-5; Hasegawa-Minato J, 2018, ONCOTARGET, V9, P3483, DOI 10.18632/oncotarget.23322; He ZS, 2020, CANCERS, V12, DOI 10.3390/cancers12092686; He ZS, 2020, CANCER LETT, V484, P40, DOI 10.1016/j.canlet.2020.05.001; He ZS, 2020, ONCOGENE, V39, P3571, DOI 10.1038/s41388-020-1238-z; Huang YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040738; Huo X, 2021, ONCOTARGETS THER, V14, P809, DOI 10.2147/OTT.S276553; Jaaks P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161396; Jin WJ, 2005, J BIOL CHEM, V280, P36551, DOI 10.1074/jbc.M502264200; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kara I, 2015, J BIOL CHEM, V290, P2812, DOI 10.1074/jbc.M114.592543; Kearney CJ, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar3451; Khatib AM, 2016, ONCOTARGET, V7, P12102, DOI 10.18632/oncotarget.7728; Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 1999, CANCER RES, V59, P1356; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Klein-Szanto AJ, 2017, BIOCHEM PHARMACOL, V140, P8, DOI 10.1016/j.bcp.2017.04.027; Kusmartsev S, 2006, CANCER IMMUNOL IMMUN, V55, P237, DOI 10.1007/s00262-005-0048-z; Lapierre M, 2007, CANCER RES, V67, P9030, DOI 10.1158/0008-5472.CAN-07-0807; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lehmann M, 1996, BIOCHEM J, V317, P803, DOI 10.1042/bj3170803; Lei RX, 2009, HEPATOLOGY, V50, P763, DOI 10.1002/hep.23062; Levesque C, 2012, J MED CHEM, V55, P10501, DOI 10.1021/jm3011178; Liefers-Visser JAL, 2017, CANCER TREAT REV, V60, P90, DOI 10.1016/j.ctrv.2017.08.012; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Louagie E, 2008, P NATL ACAD SCI USA, V105, P12319, DOI 10.1073/pnas.0800340105; Lowell S, 2000, CURR BIOL, V10, P491, DOI 10.1016/S0960-9822(00)00451-6; Ma J, 2017, EUR J CELL BIOL, V96, P457, DOI 10.1016/j.ejcb.2017.06.001; Maret D, 2012, NEOPLASIA, V14, P880, DOI 10.1593/neo.121250; Maret D, 2010, NEOPLASIA, V12, P1066, DOI 10.1593/neo.10954; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; McColl BK, 2007, FASEB J, V21, P1088, DOI 10.1096/fj.06-7060com; McMahon S, 2006, J BIOL CHEM, V281, P24171, DOI 10.1074/jbc.M604507200; Mesnard D, 2011, GENE DEV, V25, P1871, DOI 10.1101/gad.16738711; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Mumblat Y, 2015, CANCER RES, V75, P2177, DOI 10.1158/0008-5472.CAN-14-2464; Nemunaitis J, 2014, ONCOLOGY-BASEL, V87, P21, DOI 10.1159/000360993; Oh J, 2016, GYNECOL ONCOL, V143, P504, DOI 10.1016/j.ygyno.2016.09.018; Paleyanda RK, 1997, J BIOL CHEM, V272, P15270, DOI 10.1074/jbc.272.24.15270; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Parker MW, 2010, BIOCHEMISTRY-US, V49, P4068, DOI 10.1021/bi100327r; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Pesu M, 2008, NATURE, V455, P246, DOI 10.1038/nature07210; Plaimauer B, 2001, BIOCHEM J, V354, P689, DOI 10.1042/0264-6021:3540689; Posthaus H, 1998, FEBS LETT, V438, P306, DOI 10.1016/S0014-5793(98)01330-1; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Ramirez C, 2019, NATURE, V576, P477, DOI 10.1038/s41586-019-1831-x; Rocconi RP, 2020, J CLIN ONCOL, V38; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Rose M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.667850; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Sarkar FH, 2007, MINI-REV MED CHEM, V7, P599; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Scamuffa N, 2008, J CLIN INVEST, V118, P352, DOI 10.1172/JCI32040; Scamuffa N, 2014, CARCINOGENESIS, V35, P528, DOI 10.1093/carcin/bgt345; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Senzer N, 2012, MOL THER, V20, P679, DOI 10.1038/mt.2011.269; Shakya M, 2021, ENDOCR REV, V42, P259, DOI 10.1210/endrev/bnaa033; Shiryaev SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054290; Siegfried G, 2005, ONCOGENE, V24, P6925, DOI 10.1038/sj.onc.1208838; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Siegfried G, 2003, CANCER RES, V63, P1458; Siegfried G, 2020, CANCER LETT, V473, P50, DOI 10.1016/j.canlet.2019.12.027; Soulet F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.129070; Srour N, 2003, FEBS LETT, V554, P275, DOI 10.1016/S0014-5793(03)01159-1; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Susan-Resiga D, 2011, J BIOL CHEM, V286, P22785, DOI 10.1074/jbc.M111.233577; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tian S, 2011, INT J MOL SCI, V12, P1060, DOI 10.3390/ijms12021060; Tome M, 2019, CANCER RES, V79, P5008, DOI 10.1158/0008-5472.CAN-19-0086; Turpeinen H, 2011, ATHEROSCLEROSIS, V219, P799, DOI 10.1016/j.atherosclerosis.2011.08.011; Ueda J, 2003, ONCOGENE, V22, P8716, DOI 10.1038/sj.onc.1206962; Uhlen M, 2019, SCIENCE, V366, P1471, DOI 10.1126/science.aax9198; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vahatupa M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1245266; van der Veeken J, 2016, CELL, V166, P977, DOI 10.1016/j.cell.2016.07.006; VANDEVEN WJM, 1991, ENZYME, V45, P257, DOI 10.1159/000468900; Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Yakala GK, 2019, ARTERIOSCL THROM VAS, V39, P387, DOI 10.1161/ATVBAHA.118.311903; Yu WN, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00989; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang YZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0796-y; Zhang YL, 2017, INT J ONCOL, V50, P1352, DOI 10.3892/ijo.2017.3896; Zhao XD, 2017, CANCER RES, V77, P817, DOI 10.1158/0008-5472.CAN-16-2379; Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou BL, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.648402; Zhu JJ, 2012, BIOCHEM J, V448, P73, DOI 10.1042/BJ20120537	144	6	6	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2022	41	9					1252	1262		10.1038/s41388-021-02175-9	http://dx.doi.org/10.1038/s41388-021-02175-9		JAN 2022	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZI1MQ	34997216				2022-12-17	WOS:000740148500002
J	Qu, JW; Hou, YF; Chen, QX; Chen, J; Li, Y; Zhang, EF; Gu, HY; Xu, RY; Liu, Y; Cao, W; Zhang, JN; Cao, LQ; He, JS; Cai, Z				Qu, Jianwei; Hou, Yifan; Chen, Qingxiao; Chen, Jing; Li, Yi; Zhang, Enfan; Gu, Huiyao; Xu, Ruyi; Liu, Yang; Cao, Wen; Zhang, Jinna; Cao, Liqin; He, Jingsong; Cai, Zhen			RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-kappa B and MAPK signaling pathways	ONCOGENE			English	Article							LARGE-CELL LYMPHOMA; GENE-EXPRESSION; MOLECULAR CLASSIFICATION; NUCLEAR-RNA; STEM-CELLS; LEUKEMIA; N6-METHYLADENOSINE; HYPERDIPLOIDY; METHYLATION; PROGRESSION	N-6-methyladenosine (m(6)A), an internal modification in mRNA, plays a critical role in regulating gene expression. Dysregulation of m(6)A modifiers promotes oncogenesis through enzymatic functions that disrupt the balance between the deposition and removal of m(6)A modification on critical transcripts. However, the roles of mRNA m(6)A in multiple myeloma (MM) are poorly understood. The present study showed that RNA demethylase ALKBH5 was overexpressed in MM and associated with a poor prognosis in MM patients. Knocking down ALKBH5 induced apoptosis and inhibited the growth of MM cells in vitro. Xenograft models and gene set enrichment analysis with patient transcriptome datasets also supported the oncogenic role of ALKBH5 in MM. Mechanistic studies showed that ALKBH5 exerted tumorigenic effects in myeloma in an m(6)A-dependent manner, and TNF receptor-associated factor 1 (TRAF1) was a critical target of ALKBH5. Specifically, ALKBH5 regulated TRAF1 expression via decreasing m(6)A abundance in the 3'-untranslated region (3'-UTR) of TRAF1 transcripts and enhancing TRAF1 mRNA stability. As a result, ALKBH5 promoted MM cell growth and survival through TRAF1-mediated activation of NF-kappa B and MAPK signaling pathways. Collectively, our data demonstrated that ALKBH5 played a critical role in MM tumorigenesis and suggested that ALKBH5 could be a novel therapeutic target in MM.	[Qu, Jianwei; Hou, Yifan; Chen, Qingxiao; Chen, Jing; Li, Yi; Zhang, Enfan; Gu, Huiyao; Xu, Ruyi; Liu, Yang; Cao, Wen; Zhang, Jinna; Cao, Liqin; He, Jingsong; Cai, Zhen] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China; [Cai, Zhen] Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University	Cai, Z (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr, Hangzhou, Zhejiang, Peoples R China.; Cai, Z (corresponding author), Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China.	caiz@zju.edu.cn			National Natural Science Foundation of China [81800201, 81800202, 81872322]; Zhejiang Key Research and Development Project [2020C03014]; National Major Scientific and Technological Special Project for Significant New Drug Development [2018ZX09733-003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Key Research and Development Project; National Major Scientific and Technological Special Project for Significant New Drug Development	We thank the members of our laboratory for helpful discussions and assistance. This study was supported by grants from the National Natural Science Foundation of China (81800201, 81800202, and 81872322), the Zhejiang Key Research and Development Project (2020C03014), and the National Major Scientific and Technological Special Project for Significant New Drug Development (2018ZX09733-003).	Abate F, 2015, LEUKEMIA, V29, P1390, DOI 10.1038/leu.2014.347; Aik W, 2014, NUCLEIC ACIDS RES, V42, P4741, DOI 10.1093/nar/gku085; Alzrigat M, 2018, SEMIN CANCER BIOL, V51, P101, DOI 10.1016/j.semcancer.2017.09.007; Avet-Loiseau H, 2007, BLOOD, V109, P3489, DOI 10.1182/blood-2006-08-040410; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood-2009-12-261032; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chen Y, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01207-4; Chng W, 2006, LEUKEMIA, V20, P807, DOI 10.1038/sj.leu.2404172; Chretien ML, 2015, BLOOD, V126, P2713, DOI 10.1182/blood-2015-06-650242; Dixit D, 2021, CANCER DISCOV, V11, P480, DOI 10.1158/2159-8290.CD-20-0331; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626; Durkop H, 2003, J PATHOL, V200, P229, DOI 10.1002/path.1351; Edilova MI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02969; Feldman AL, 2013, GENE CHROMOSOME CANC, V52, P1097, DOI 10.1002/gcc.22104; Hao LL, 2021, AGING-US, V13, P4045, DOI 10.18632/aging.202371; Heuck CJ, 2014, LEUKEMIA, V28, P2410, DOI 10.1038/leu.2014.232; Hideshima T, 2021, CANCERS, V13, DOI 10.3390/cancers13020216; Huang HL, 2020, CANCER CELL, V37, P270, DOI 10.1016/j.ccell.2020.02.004; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jiang FJ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01066-6; Kumar SK, 2018, NAT REV CLIN ONCOL, V15, P409, DOI 10.1038/s41571-018-0018-y; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Li J, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01259-6; Li Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03763-z; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Mao SW, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04192-8; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Mitchell JS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12050; Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood-2006-09-044974; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Pawlyn C, 2015, BLOOD, V125, P831, DOI 10.1182/blood-2014-07-584268; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Pinto V, 2020, CANCERS, V12, DOI 10.3390/cancers12020407; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; Ren ZH, 2019, BLOOD, V134, P1176, DOI 10.1182/blood.2019000578; Shen C, 2020, CELL STEM CELL, V27, P64, DOI 10.1016/j.stem.2020.04.009; Shen XD, 2021, FRONT GENET, V11, DOI 10.3389/fgene.2020.592042; Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood-2002-10-3161; Thalhammer A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016210; Todoerti K, 2013, CLIN CANCER RES, V19, P3247, DOI 10.1158/1078-0432.CCR-12-3461; van de Donk NWCJ, 2021, LANCET, V397, P410, DOI 10.1016/S0140-6736(21)00135-5; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JZ, 2020, CELL STEM CELL, V27, P81, DOI 10.1016/j.stem.2020.04.001; Wang JY, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01807-0; Wang QS, 2018, CANCER RES, V78, P3982, DOI 10.1158/0008-5472.CAN-18-0429; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Weinhold N, 2016, BLOOD, V128, P1735, DOI 10.1182/blood-2016-06-723007; Wen XX, 2018, CLIN RESPIR J, V12, P2197, DOI 10.1111/crj.12789; Wu TF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695930; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Yang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00980-5; Zaccara S, 2019, NAT REV MOL CELL BIO, V20, P608, DOI 10.1038/s41580-019-0168-5; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zapata Juan M, 2002, Sci STKE, V2002, ppe27; Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood-2006-07-037077; Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015; Zhong L, 2019, CANCER LETT, V442, P252, DOI 10.1016/j.canlet.2018.11.006; Zhu SN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02111	68	6	6	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					400	413		10.1038/s41388-021-02095-8	http://dx.doi.org/10.1038/s41388-021-02095-8		NOV 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34759347	hybrid, Green Published			2022-12-17	WOS:000716867900004
J	Huang, HW; Chen, CY; Huang, YH; Yeh, CT; Wang, CS; Chang, CC; Lin, KH				Huang, Hsiang-Wei; Chen, Ching-Ying; Huang, Ya-Hui; Yeh, Chau-Ting; Wang, Chia-Siu; Chang, Cheng-Chih; Lin, Kwang-Huei			CMAHP promotes metastasis by reducing ubiquitination of Snail and inducing angiogenesis via GM-CSF overexpression in gastric cancer	ONCOGENE			English	Article							NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA METASTASIS; ACETYLNEURAMINIC ACID HYDROXYLASE; CELL-MIGRATION; GLYCOLYLNEURAMINIC ACID; GROWTH-FACTOR; HISTONE H1; INFLAMMATION; PATHWAY; PROGRESSION	Pseudogenes are generally considered "junk" DNA or "genomic fossils" generated during the evolution process that lack biological activity. However, accumulating reports indicate that pseudogenes have biological functions critical for cancer development. Experiments from the current study showed marked overexpression of the cytidine monophospho-N-acetylneuraminic acid hydroxylase pseudogene (CMAHP) in gastric cancer, which was associated with poor overall survival. However, the mechanisms underlying the activity of CMAHP in tumor development are largely unknown. Gene Set Enrichment Analysis (GSEA) revealed that CMAHP-correlated genes are significantly involved in epithelial-mesenchymal transition (EMT) and angiogenesis. Functional studies further confirmed that CMAHP mediates metastasis and angiogenesis in vitro and in vivo. Furthermore, CMAHP promoted cancer cell migration, invasion, and metastasis through Snail overexpression, which decreased ubiquitination mediated by NF-kappa B signaling. Angiogenesis is known to be induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulation. CMAHP increased GM-CSF transactivation via promoting direct binding of c-Jun to the -1981/-1975 region of the GM-CSF promoter. Notably, CMAHP interacts with Histone H1.4 promoting histone acetylation to enhance c-Jun and RelA (p65) expression. Our collective findings provide novel evidence that CMAHP contributes to tumor progression and modulates metastasis and angiogenesis in gastric cancer.	[Huang, Hsiang-Wei; Chen, Ching-Ying; Lin, Kwang-Huei] Chang Gung Univ, Coll Med, Dept Biochem, Taoyuan, Taiwan; [Huang, Hsiang-Wei; Chen, Ching-Ying; Lin, Kwang-Huei] Chang Gung Univ, Coll Med, Dept Biomed Sci, Taoyuan, Taiwan; [Huang, Ya-Hui; Yeh, Chau-Ting; Lin, Kwang-Huei] Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan; [Wang, Chia-Siu; Chang, Cheng-Chih] Chang Gung Mem Hosp Chia Yi, Dept Gen Surg, Chiayi, Taiwan; [Lin, Kwang-Huei] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan	Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Coll Med, Dept Biochem, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ, Coll Med, Dept Biomed Sci, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan.	khlin@mail.cgu.edu.tw		Huang, Hsiang-Wei/0000-0001-5590-7695; Lin, Kwang-Huei/0000-0002-5649-2222	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CMRPD1H0631, CMRPD1H0632, CMRPD1H0633, CMRPG6K0031, CMRPG6K0032, CMRPG6K0033]; Ministry of Science and Technology of the Republic of China [MOST 106-2314-B182A-130-to CSW]; Chang Gung Memorial Hospital, Taoyuan, Taiwan	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital)	This research was funded by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CMRPD1H0631, CMRPD1H0632, CMRPD1H0633 to KHL; CMRPG6K0031, CMRPG6K0032, CMRPG6K0033 to CCC, and CSW) and from the Ministry of Science and Technology of the Republic of China (MOST 106-2314-B182A-130-to CSW). And The APC was funded by Chang Gung Memorial Hospital, Taoyuan, Taiwan.	Bardor M, 2005, J BIOL CHEM, V280, P4228, DOI 10.1074/jbc.M412040200; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Becher B, 2016, IMMUNITY, V45, P963, DOI 10.1016/j.immuni.2016.10.026; Bull C, 2018, CANCER RES, V78, P3574, DOI 10.1158/0008-5472.CAN-17-3376; Cao F, 2020, GENOMICS, V112, P694, DOI 10.1016/j.ygeno.2019.05.002; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CY, 2019, THERANOSTICS, V9, P2361, DOI 10.7150/thno.29628; Chen ZH, 2014, CELL REP, V8, P2003, DOI 10.1016/j.celrep.2014.08.008; Chou HH, 2002, P NATL ACAD SCI USA, V99, P11736, DOI 10.1073/pnas.182257399; Feng HT, 2017, CELL ADHES MIGR, V11, P464, DOI 10.1080/19336918.2016.1259058; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hao FJ, 2020, J CELL MOL MED, V24, P11779, DOI 10.1111/jcmm.15790; He WJ, 2020, ONCOTARGETS THER, V13, P11059, DOI 10.2147/OTT.S235643; Hedlund M, 2008, P NATL ACAD SCI USA, V105, P18936, DOI 10.1073/pnas.0803943105; Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3; Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383; Hergeth SP, 2015, EMBO REP, V16, P1439, DOI 10.15252/embr.201540749; Hirayama M, 2016, INT IMMUNOL, V28, P319, DOI 10.1093/intimm/dxw027; Hsieh HL, 2019, WORLD J GASTRO ONCOL, V11, P686, DOI 10.4251/wjgo.v11.i9.686; Hu XL, 2018, CANCERS, V10, DOI 10.3390/cancers10080256; Huang HW, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010067; Jaatinen T, 2006, STEM CELLS, V24, P631, DOI 10.1634/stemcells.2005-0185; Jin L, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101036; Joo YY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45537-w; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kang CL, 2019, THERANOSTICS, V9, P4421, DOI 10.7150/thno.32854; Khanna S, 2018, CLIN CANCER RES, V24, P2859, DOI 10.1158/1078-0432.CCR-17-3757; Lin YH, 2021, ONCOGENE, V40, P4675, DOI 10.1038/s41388-021-01905-3; Lin YH, 2018, HEPATOLOGY, V67, P188, DOI 10.1002/hep.29462; Lotfi N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01265; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Newton R, 2010, BIOCHEM J, V427, P113, DOI 10.1042/BJ20091038; Nystedt J, 2010, STEM CELLS, V28, P258, DOI 10.1002/stem.250; Samraj AN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00033; Skrzypek K, 2020, CANCERS, V12, DOI 10.3390/cancers12010209; Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5; Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9; Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Takahashi T, 2014, J VIROL, V88, P8445, DOI 10.1128/JVI.00716-14; Tang DF, 2017, MED SCI MONIT BASIC, V23, P141, DOI 10.12659/MSMBR.903910; Tawara Ken, 2011, Cancer Manag Res, V3, P177, DOI 10.2147/CMR.S18101; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Wang H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19540-z; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; Wang Y, 2014, CANCER RES, V74, P716, DOI 10.1158/0008-5472.CAN-13-1459; Wu Y, 2010, BRIT J CANCER, V102, P639, DOI 10.1038/sj.bjc.6605530; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yu B, 2016, NUCLEUS-PHILA, V7, P155, DOI 10.1080/19491034.2016.1179408; Yusufova N, 2021, NATURE, V589, P299, DOI 10.1038/s41586-020-3017-y; Zhang XY, 2017, ONCOL LETT, V13, P543, DOI 10.3892/ol.2016.5506; Zhang YM, 2020, CELL CYCLE, V19, P142, DOI 10.1080/15384101.2019.1699753; Zhang YH, 2019, CELL DEATH DIFFER, V26, P565, DOI 10.1038/s41418-018-0147-y; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003; Zheng LF, 2015, BREAST CANCER RES TR, V150, P105, DOI 10.1007/s10549-015-3298-2	56	6	6	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					159	172		10.1038/s41388-021-02087-8	http://dx.doi.org/10.1038/s41388-021-02087-8		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34716430				2022-12-17	WOS:000712720900002
J	Chen, J; Hou, SF; Tang, FJ; Liu, DS; Chen, ZZ; Zhang, HL; Wang, SH				Chen, Jia; Hou, Shu-Fen; Tang, Feng-Jie; Liu, Dai-Song; Chen, Zi-Zi; Zhang, Hong-Lian; Wang, Shao-Hua			HOTAIR/Sp1/miR-199a critically regulates cancer stemness and malignant progression of cutaneous squamous cell carcinoma	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; DNA METHYLATION; EXPRESSION; HOTAIR; CD44; IDENTIFICATION; PROLIFERATION; SP1	The long non-coding RNA (lncRNA), HOX antisense intergenic RNA (HOTAIR) is a well-characterized oncogene in multiple human cancers, but not in cutaneous squamous cell carcinoma (CSCC). In this study, we focused on investigating the potential role of HOTAIR in stemness of CSCC. By measuring its expression using RT-qPCR in CSCC vs. normal tissues, as well as in CSCC cell lines A431 or SCC13, A431- or SCC13-derived CSCC stem cells (CSCSCs), and normal skin fibroblasts (HSFs), we detected higher expression of HOTAIR in CSCC than in normal tissues, in recurrent than in non-recurrent CSCC tissues, in CSCCs and CSCSCs than in HSFs, and particularly, in CSCSCs than in CSCCs. Kaplan-Meier analysis suggested that higher expression of HOTAIR was positively correlated with worse overall survival of CSCC patients. Functional assays on colony formation, EdU incorporation, sphere formation, western blot on stem-cell biomarkers, and in vivo models showed that HOTAIR was essential in maintaining multiple stem cell phenotypes of CSCSCs in vitro and in vivo xenograft growth as well as metastasis. Mechanistically, HOTAIR directly interacted with and up-regulated Sp1. Sp1 then induced DNMT1-mediated promoter methylation and direct transcriptional repression of miR-199a-5p. Targeting Sp1 or DNMT1 further boosted the in vivo anti-tumor and anti-metastasis activities of targeting HOTAIR. In conclusion, HOTAIR, by up-regulating Sp1 and targeting miR-199a, promotes stemness and progression of CSCC. Targeting HOTAIR, Sp1 or the underlying mechanisms may thus benefit CSCC treatment.	[Chen, Jia; Hou, Shu-Fen; Tang, Feng-Jie; Liu, Dai-Song; Chen, Zi-Zi; Zhang, Hong-Lian; Wang, Shao-Hua] Cent South Univ, Dept Plast Surg, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China	Central South University	Wang, SH (corresponding author), Cent South Univ, Dept Plast Surg, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.	shaahww789@163.com			"perfect medical run-up" talent engineering project of The Third Xiangya Hospital of Central South University [JY201719]	"perfect medical run-up" talent engineering project of The Third Xiangya Hospital of Central South University	We would like to give our sincere gratitude to the reviewers for their constructive comments. This work was supported by the "perfect medical run-up" talent engineering project of The Third Xiangya Hospital of Central South University (Project Number: JY201719).	Alves CP, 2013, STEM CELLS, V31, P2827, DOI 10.1002/stem.1547; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bhat Shakil Ahmad, 2016, Noncoding RNA Res, V1, P43, DOI 10.1016/j.ncrna.2016.11.002; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Borena BM, 2014, CELL PHYSIOL BIOCHEM, V34, P1291, DOI 10.1159/000366338; Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998; Burton KA, 2016, AM J CLIN DERMATOL, V17, P491, DOI 10.1007/s40257-016-0207-3; Chen BF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06413; Chen BF, 2014, EPIGENETICS-US, V9, P119, DOI 10.4161/epi.25799; Deng J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170860; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Dou J, 2016, AM J TRANSL RES, V8, P98; Gao SM, 2018, EXP HEMATOL, V67, P32, DOI 10.1016/j.exphem.2018.08.005; He J, 2019, TOXICOL APPL PHARM, V378, DOI 10.1016/j.taap.2019.114606; Hervouet E, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0450-y; Jian Z, 2017, J INVEST DERMATOL, V137, P31, DOI 10.1016/j.jid.2016.07.033; Jin YL, 2020, EUR J PHARMACOL, V878, DOI 10.1016/j.ejphar.2020.173105; Kim BK, 2015, J DERMATOL SCI, V79, P137, DOI 10.1016/j.jdermsci.2015.05.005; Kishikawa S, 2002, EUR J BIOCHEM, V269, P2961, DOI 10.1046/j.1432-1033.2002.02972.x; Koh SP, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02257; Kokko LL, 2011, ORAL ONCOL, V47, P510, DOI 10.1016/j.oraloncology.2011.03.026; Li JP, 2016, TUMOR BIOL, V37, P13287, DOI 10.1007/s13277-016-5244-2; Li XG, 2017, J CANCER RES CLIN, V143, P2189, DOI 10.1007/s00432-017-2478-3; Li Y, 2019, J ONCOL, V2019, DOI 10.1155/2019/5613417; Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161; Liu JM, 2013, INT J ONCOL, V42, P453, DOI 10.3892/ijo.2012.1720; Liu Y, 2020, REPROD SCI, V27, P110, DOI 10.1007/s43032-019-00016-5; Lu MY, 2017, ONCOTARGET, V8, P98542, DOI 10.18632/oncotarget.21614; Lu RH, 2020, CELL CYCLE, V19, P1, DOI 10.1080/15384101.2019.1689482; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Najafi M, 2019, J CELL PHYSIOL, V234, P8381, DOI 10.1002/jcp.27740; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Olivero Carlotta, 2019, Methods Mol Biol, V1879, P415, DOI 10.1007/7651_2018_134; PRIETO VG, 1995, AM J DERMATOPATH, V17, P447, DOI 10.1097/00000372-199510000-00003; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Sand M, 2016, EPIGENOMICS-UK, V8, P501, DOI 10.2217/epi-2015-0012; Senbanjo LT, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00018; Shen J, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/230642; Song Y, 2019, INT J ONCOL, V54, P77, DOI 10.3892/ijo.2018.4625; Tang Q, 2018, CELL PHYSIOL BIOCHEM, V47, P893, DOI 10.1159/000490131; Wang SH, 2014, INT J CLIN EXP PATHO, V7, P7131; Wang SH, 2016, ONCOL LETT, V12, P97, DOI 10.3892/ol.2016.4602; Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003; Wang YJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00158; Wu JJ, 2019, J ETHNOPHARMACOL, V237, P128, DOI 10.1016/j.jep.2019.03.027; Yu GJ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0992-x; Zhang CY, 2019, ARTIF CELL NANOMED B, V47, P4110, DOI 10.1080/21691401.2019.1683566	47	6	6	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					99	111		10.1038/s41388-021-02014-x	http://dx.doi.org/10.1038/s41388-021-02014-x		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34697449				2022-12-17	WOS:000710873200001
J	Amin, P; Awal, S; Vigneron, S; Roque, S; Mechali, F; Labbe, JC; Lorca, T; Castro, A				Amin, Priya; Awal, Sushil; Vigneron, Suzanne; Roque, Sylvain; Mechali, Francisca; Labbe, Jean Claude; Lorca, Thierry; Castro, Anna			PP2A-B55: substrates and regulators in the control of cellular functions	ONCOGENE			English	Review							PROTEIN PHOSPHATASE 2A; GREATWALL KINASE; TUMOR-SUPPRESSOR; SUBUNIT INTERACTION; MITOTIC EXIT; T-ANTIGEN; PHOSPHORYLATION; DEPHOSPHORYLATION; CANCER; B55-ALPHA	PP2A is a major serine/threonine phosphatase class involved in the regulation of cell signaling through the removal of protein phosphorylation. This class of phosphatases is comprised of different heterotrimeric complexes displaying distinct substrate specificities. The present review will focus on one specific heterocomplex, the phosphatase PP2A-B55. Herein, we will report the direct substrates of this phosphatase identified to date, and its impact on different cell signaling cascades. We will additionally describe its negative regulation by its inhibitors Arpp19 and ENSA and their upstream kinase Greatwall. Finally, we will describe the essential molecular features defining PP2A-B55 substrate specificity that confer the correct temporal pattern of substrate dephosphorylation. The main objective of this review is to provide the reader with a unique source compiling all the knowledge of this particular holoenzyme that has evolved as a key enzyme for cell homeostasis and cancer development.	[Amin, Priya; Awal, Sushil; Vigneron, Suzanne; Roque, Sylvain; Mechali, Francisca; Labbe, Jean Claude; Lorca, Thierry; Castro, Anna] Univ Montpellier, Ctr Rech Biol Cellulaire Montpellier CRBM, CNRS UMR 5237, 1919 Route Mende, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lorca, T; Castro, A (corresponding author), Univ Montpellier, Ctr Rech Biol Cellulaire Montpellier CRBM, CNRS UMR 5237, 1919 Route Mende, F-34293 Montpellier 5, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	CASTRO, ANNA/F-4350-2010	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924	Agence National de la Recherche [ANR-18CE13-0013, ANR-18-CE13-0018-01]; La Ligue Nationale Contre le Cancer; Fondation ARC [PJA 20181207931]; LABEX EpiGenMed [ANR-10-LABEX-12-01]	Agence National de la Recherche(French National Research Agency (ANR)); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Fondation ARC; LABEX EpiGenMed	This work was supported by the Agence National de la Recherche (KiPARPP, ANR-18CE13-0013 and REPLIGREAT, ANR-18-CE13-0018-01), La Ligue Nationale Contre le Cancer (Equipe Labellisee, EL2019 CASTRO), the Fondation ARC (PJA 20181207931), and the LABEX EpiGenMed (ANR-10-LABEX-12-01). PA is a Fondation pour la Recherche Medicale (FRM) fellow. SA and SR are LABEX EpiGenMed fellows.	Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Alvarez-Fernandez M, 2011, J BIOL CHEM, V286, P33029, DOI 10.1074/jbc.M111.253724; Andrade EC, 2017, J NEUROSCI, V37, P2709, DOI 10.1523/JNEUROSCI.4559-15.2017; Batut J, 2008, DEVELOPMENT, V135, P2927, DOI 10.1242/dev.020842; Bollen M, 2010, TRENDS BIOCHEM SCI, V35, P450, DOI 10.1016/j.tibs.2010.03.002; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Charrasse S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00339-4; Chen S, 2008, J BIOL CHEM, V283, P10513, DOI 10.1074/jbc.M709852200; Cheng Y, 2011, CANCER GENET-NY, V204, P375, DOI 10.1016/j.cancergen.2011.05.002; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Cundell MJ, 2016, J CELL BIOL, V214, P539, DOI 10.1083/jcb.201606033; Cundell MJ, 2013, MOL CELL, V52, P393, DOI 10.1016/j.molcel.2013.09.005; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Di Conza G, 2017, CELL REP, V18, P1699, DOI 10.1016/j.celrep.2017.01.051; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Diril MK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006310; Dupre A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4318; Eichhorn PJA, 2007, PLOS GENET, V3, P2381, DOI 10.1371/journal.pgen.0030218; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989; Fritz A, 2006, J BIOL CHEM, V281, P6236, DOI 10.1074/jbc.M509249200; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; Fujiwara N, 2016, J BIOL CHEM, V291, P10858, DOI 10.1074/jbc.M115.704908; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Godfrey M, 2017, MOL CELL, V65, P393, DOI 10.1016/j.molcel.2016.12.018; Gong YP, 2018, AM J CANCER RES, V8, P1030; Hached K, 2019, J CELL BIOL, V218, P541, DOI 10.1083/jcb.201708105; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Hegarat N, 2020, EMBO J, V39, DOI 10.15252/embj.2020104419; Heim A, 2015, EMBO REP, V16, P1501, DOI 10.15252/embr.201540876; Hein AL, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0172-9; Hein JB, 2017, NAT CELL BIOL, V19, P1433, DOI 10.1038/ncb3634; Heroes E, 2013, FEBS J, V280, P584, DOI 10.1111/j.1742-4658.2012.08547.x; Hertz EPT, 2016, MOL CELL, V63, P686, DOI 10.1016/j.molcel.2016.06.024; Hoermann B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17334-x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hutter LH, 2017, CELL CYCLE, V16, P1885, DOI 10.1080/15384101.2017.1371885; Jayadeva G, 2010, J BIOL CHEM, V285, P29863, DOI 10.1074/jbc.M110.162354; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kabashima T, 2003, P NATL ACAD SCI USA, V100, P5107, DOI 10.1073/pnas.0730817100; Kalev P, 2012, CANCER RES, V72, P6414, DOI 10.1158/0008-5472.CAN-12-1667; Kamada Y, 2012, INT J HEMATOL, V96, P492, DOI 10.1007/s12185-012-1171-1; Kamenz J, 2021, CURR BIOL, V31, P794, DOI 10.1016/j.cub.2020.11.058; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Kruse T, 2020, EMBO J, V39, DOI 10.15252/embj.2019103695; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; Kurimchak A, 2013, MOL CELL BIOL, V33, P3330, DOI 10.1128/MCB.00082-13; Labbe JC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23657-0; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Lipina C, 2016, TRENDS ENDOCRIN MET, V27, P868, DOI 10.1016/j.tem.2016.08.005; Longin S, 2007, J BIOL CHEM, V282, P26971, DOI 10.1074/jbc.M704059200; Lu MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep08735; Ma S, 2016, J CELL SCI, V129, P1329, DOI 10.1242/jcs.178855; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Margolis SS, 2006, CELL, V127, P759, DOI 10.1016/j.cell.2006.10.035; Mazhar S, 2019, BBA-MOL CELL RES, V1866, P51, DOI 10.1016/j.bbamcr.2018.08.020; McCloy RA, 2015, MOL CELL PROTEOMICS, V14, P2194, DOI 10.1074/mcp.M114.046938; Mehsen H, 2018, J CELL BIOL, V217, P4106, DOI 10.1083/jcb.201804018; Merrill RA, 2013, FEBS J, V280, P662, DOI 10.1111/j.1742-4658.2012.08631.x; Mochida S, 2016, CURR BIOL, V26, P3361, DOI 10.1016/j.cub.2016.10.022; Mochida S, 2014, FEBS J, V281, P1159, DOI 10.1111/febs.12685; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Mochida S, 2009, EMBO J, V28, P2777, DOI 10.1038/emboj.2009.238; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; Mosca L, 2013, AM J HEMATOL, V88, P16, DOI 10.1002/ajh.23339; Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466; Murphy AK, 2014, J CELL BIOL, V206, P493, DOI 10.1083/jcb.201404111; Nasa I, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aba7823; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Paroni G, 2008, MOL BIOL CELL, V19, P655, DOI 10.1091/mbc.E07-06-0623; Pomerening JR, 2003, NAT CELL BIOL, V5, P346, DOI 10.1038/ncb954; Porter IM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3677; Rata S, 2018, CURR BIOL, V28, P3824, DOI 10.1016/j.cub.2018.09.059; Reid MA, 2013, MOL CELL, V50, P200, DOI 10.1016/j.molcel.2013.02.008; Reilly PT, 2014, BIOESSAYS, V36, P1062, DOI 10.1002/bies.201400058; Ren DP, 2017, J BIOL CHEM, V292, P10026, DOI 10.1074/jbc.M117.778233; Ricotta D, 2008, J BIOL CHEM, V283, P5510, DOI 10.1074/jbc.M707166200; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruvolo PP, 2011, LEUKEMIA, V25, P1711, DOI 10.1038/leu.2011.146; Ruvolo PP, 2016, BBA CLIN, V6, P87, DOI 10.1016/j.bbacli.2016.08.002; Ruvolo PP, 2014, BBA-MOL CELL RES, V1843, P1969, DOI 10.1016/j.bbamcr.2014.05.006; Sha W, 2003, P NATL ACAD SCI USA, V100, P975, DOI 10.1073/pnas.0235349100; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Skoczylas C, 2004, CELL CYCLE, V3, P606; Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021; Tan YM, 2014, CANCER RES, V74, P2006, DOI 10.1158/0008-5472.CAN-13-1263; Tavernier N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21922-w; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Vigneron S, 2018, DEV CELL, V45, P637, DOI 10.1016/j.devcel.2018.05.005; Vigneron S, 2009, EMBO J, V28, P2786, DOI 10.1038/emboj.2009.228; Voets E, 2010, CELL CYCLE, V9, P3591, DOI 10.4161/cc.9.17.12832; Wang FF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21040-6; Wang J, 2017, EMBO REP, V18, P437, DOI 10.15252/embr.201642788; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Wang XR, 2016, STRUCTURE, V24, P2174, DOI 10.1016/j.str.2016.09.010; Wei YJ, 2015, ELIFE, V4, DOI 10.7554/eLife.05289; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Williams BC, 2014, ELIFE, V3, DOI 10.7554/eLife.01695; Wirth M, 2013, SEMIN CANCER BIOL, V23, P301, DOI 10.1016/j.semcancer.2013.05.007; Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048; Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840; Wu CG, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.27; Xie FF, 2020, CANCER BIOTHER RADIO, V35, P129, DOI 10.1089/cbr.2019.2960; Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Ye HF, 2020, CANCER MANAG RES, V12, P419, DOI 10.2147/CMAR.S228429; Yeong FM, 2003, CURR BIOL, V13, P2058, DOI 10.1016/j.cub.2003.10.032; Yu JT, 2004, J CELL BIOL, V164, P487, DOI 10.1083/JCB.200310059; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	117	6	6	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					1	14		10.1038/s41388-021-02068-x	http://dx.doi.org/10.1038/s41388-021-02068-x		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34686773				2022-12-17	WOS:000710056600001
J	Yu, SY; Zang, WC; Qiu, YC; Liao, LM; Zheng, XF				Yu, Shuyu; Zang, Weicheng; Qiu, Yuchong; Liao, Liming; Zheng, Xiaofeng			Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis	ONCOGENE			English	Article							KINASE; GROWTH; DEGRADATION; SUPPRESS; PATHWAY; PARKIN; SWITCH	Aberrant regulation of ubiquitination often leads to metabolic reprogramming in tumor cells. However, the underlying mechanisms are not fully understood. Here we demonstrate that OTUB2, an OTU deubiquitinase, is upregulated in colorectal cancer (CRC) and exacerbates the progression of CRC through modulating the aerobic glycolysis. Mechanistically, OTUB2 directly interacts with pyruvate kinase M2 (PKM2) and inhibits its ubiquitination by blocking the interaction between PKM2 and its ubiquitin E3 ligase Parkin, thereby enhancing PKM2 activity and promoting glycolysis. In response to glucose starvation stress, the effect of OTUB2 on PKM2 is enhanced, which confers metabolic advantage to CRC cells. Moreover, OTUB2 depletion reduces glucose consumption, lactate production, and cellular ATP production. OTUB2-knockout CRC cells exhibit attenuated proliferation and migration, as well as an elevated level of apoptosis and increased sensitivity to chemotherapy drugs. Furthermore, in vivo assays show that knockout of OTUB2 inhibits tumor growth in mice. Taken together, these findings reveal the critical role of OTUB2 in the regulation of glycolysis and illustrate the molecular mechanism underlying its role as a negative regulator of PKM2 ubiquitination in CRC, establishing a bridge between OTUB2-regulated PKM2 ubiquitination and altered metabolic patterns in CRC and suggesting that OTUB2 is a promising target for CRC treatment.	[Yu, Shuyu; Zang, Weicheng; Qiu, Yuchong; Liao, Liming; Zheng, Xiaofeng] Peking Univ, Sch Life Sci, State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China; [Yu, Shuyu; Zang, Weicheng; Qiu, Yuchong; Liao, Liming; Zheng, Xiaofeng] Peking Univ, Sch Life Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China	Peking University; Peking University	Zheng, XF (corresponding author), Peking Univ, Sch Life Sci, State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China.; Zheng, XF (corresponding author), Peking Univ, Sch Life Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China.	xiaofengz@pku.edu.cn			National Natural Science Foundation of China [81730080, 82130081]; Beijing Natural Science Foundation [5212008]; National Key Research and Development Program of China [2016YFC1302401]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); National Key Research and Development Program of China	This work was supported by the National Natural Science Foundation of China (grant nos. 81730080 and 82130081), Beijing Natural Science Foundation (5212008), and the National Key Research and Development Program of China (grant no. 2016YFC1302401). We sincerely thank Prof. Lingqiang Zhang for providing human deubiquitinase OTU subfamily plasmids, Prof. Wensheng Wei for providing the CRISPR/Cas9 related plasmids, Prof. Jianguo Ji for providing HT-29 cell line, Prof. Dajun Deng for providing CCD-18Co cell line, Prof. Binghui Li for providing FHC cell line, and Prof. Zhijie Chang for providing NCM460 and DLD-1 cell lines. We thank the National Center for Protein Sciences at Peking University, particularly Guilan Li, Jia Luo, Yinghua Guo, Liying Du and Hongxia Lv for technical help. We also appreciate the assistance of Dong Liu, Xiaochen Li and Liqin Fu from the Core Facilities of Life Sciences at Peking University for their assistance with the protein MS analysis work and microscopic imaging.	Beck A, 2013, DIABETOLOGIA, V56, P1317, DOI 10.1007/s00125-013-2889-x; Bhardwaj A, 2016, P NATL ACAD SCI USA, V113, pE538, DOI 10.1073/pnas.1520045113; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai JL, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01324; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Choi HS, 2020, CANCERS, V12, DOI 10.3390/cancers12061548; Clague MJ, 2019, NAT REV MOL CELL BIO, V20, P338, DOI 10.1038/s41580-019-0099-1; Dang CV, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.297pe75; Das Gupta K, 2020, CELL REP, V30, P2712, DOI 10.1016/j.celrep.2020.02.007; Dayton TL, 2016, EMBO REP, V17, P1721, DOI 10.15252/embr.201643300; Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0; Diefenbacher ME, 2014, J CLIN INVEST, V124, P3407, DOI 10.1172/JCI73733; Feng YL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2278-6; FITZMAURICE C, 2018, J CLIN ONCOL, V36; Gu ZL, 2020, KAOHSIUNG J MED SCI, V36, P399, DOI 10.1002/kjm2.12187; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; HAN C, 2016, NAT COMMUN, V7; Harper JW, 2018, NAT REV MOL CELL BIO, V19, P93, DOI 10.1038/nrm.2017.129; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hou PP, 2020, MOL CELL, V78, P1192, DOI 10.1016/j.molcel.2020.05.004; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; Jin X, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.21; Johmura Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep31194; Kato K, 2014, MOL CELL, V53, P617, DOI 10.1016/j.molcel.2014.01.030; Kim SR, 2015, INT J ONCOL, V46, P2116, DOI 10.3892/ijo.2015.2901; Kwasna D, 2018, MOL CELL, V70, P150, DOI 10.1016/j.molcel.2018.02.023; Lee HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10374-y; Lee SB, 2019, NAT CELL BIOL, V21, P940, DOI 10.1038/s41556-019-0356-8; Li J, 2019, THERANOSTICS, V9, P179, DOI 10.7150/thno.29545; Li S, 2010, J BIOL CHEM, V285, P4291, DOI 10.1074/jbc.M109.074971; Li XY, 2018, BIOCHEM BIOPH RES CO, V505, P113, DOI 10.1016/j.bbrc.2018.09.071; Liang J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12431; Lim KS, 2018, MOL CELL, V72, P925, DOI 10.1016/j.molcel.2018.10.045; Liu FB, 2017, NAT CELL BIOL, V19, P1358, DOI 10.1038/ncb3630; Liu J, 2020, J CLIN INVEST, V130, P3253, DOI 10.1172/JCI132876; Liu K, 2016, J BIOL CHEM, V291, P10307, DOI 10.1074/jbc.M115.703066; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Ma YF, 2019, CANCER MANAG RES, V11, P13, DOI 10.2147/CMAR.S184781; Macintyre AN, 2011, MOL CELL, V42, P713, DOI 10.1016/j.molcel.2011.06.003; Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072; Ordureau A, 2020, MOL CELL, V77, P1124, DOI 10.1016/j.molcel.2019.11.013; Park SH, 2016, CANCER RES, V76, P3802, DOI 10.1158/0008-5472.CAN-15-2498; Qi HL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1271-9; Shang Y, 2017, ONCOGENE, V36, P4191, DOI 10.1038/onc.2017.31; Singh JP, 2020, ONCOGENE, V39, P560, DOI 10.1038/s41388-019-0975-3; Sobol A, 2017, MOL CANCER RES, V15, P117, DOI 10.1158/1541-7786.MCR-16-0281-T; Spoden GA, 2009, J CELL BIOCHEM, V107, P293, DOI 10.1002/jcb.22125; Viana R, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0053-6; Wang B, 2017, NATURE, V545, P365, DOI 10.1038/nature22344; Wang Y, 2017, P NATL ACAD SCI USA, V114, P13732, DOI 10.1073/pnas.1704145115; Xing C, 2016, CANCER RES, V76, P83, DOI 10.1158/0008-5472.CAN-14-3595; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yoshino S, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.19; Yuan L, 2015, NAT CELL BIOL, V17, P1169, DOI 10.1038/ncb3218; Yuan P, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8450606; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030	60	6	7	8	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					46	56		10.1038/s41388-021-02071-2	http://dx.doi.org/10.1038/s41388-021-02071-2		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34671086				2022-12-17	WOS:000709271000001
J	Mirzakhani, K; Kallenbach, J; Rasa, SMM; Ribaudo, F; Ungelenk, M; Ehsani, M; Gong, WR; Gassler, N; Leeder, M; Grimm, MO; Neri, F; Baniahmad, A				Mirzakhani, Kimia; Kallenbach, Julia; Rasa, Seyed Mohammad Mahdi; Ribaudo, Federico; Ungelenk, Martin; Ehsani, Marzieh; Gong, Wenrong; Gassler, Nikolaus; Leeder, Mirjam; Grimm, Marc-Oliver; Neri, Francesco; Baniahmad, Aria			The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; THERAPY BAT; RECEPTOR; RATIONALE; TESTOSTERONE; ACTIVATION; APOPTOSIS; PATHWAY; KINASE	The bipolar androgen therapy (BAT) to treat prostate cancer (PCa) includes cycles of supraphysiological androgen levels (SAL) under androgen-deprivation therapy (ADT). We showed previously that SAL induces cellular senescence in androgen-sensitive PCa cells and in ex vivo-treated patient PCa tumor samples. Here, we analyzed the underlying molecular pathway and reveal that SAL induces cellular senescence in both, castration-sensitive (CSPC) LNCaP and castration-resistant PCa (CRPC) C4-2 cells through the cell cycle inhibitor p15(INK4b) and increased phosphorylation of AKT. Treatment with the AKT inhibitor (AKTi) potently inhibited SAL-induced expression of p15(INK4b) and cellular senescence in both cell lines. Proximity-ligation assays (PLA) combined with high-resolution laser-scanning microscopy indicate that SAL promotes interaction of endogenous androgen receptor (AR) with AKT in the cytoplasm as well as in the nucleus detectable after three days. Transcriptome sequencing (RNA-seq) comparing the SAL-induced transcriptomes of LNCaP with C4-2 cells as well as with AKTi-treated cell transcriptomes revealed landscapes for cell senescence. Interestingly, one of the identified genes is the lncRNASAT1. SAL treatment of native patient tumor samples ex vivo upregulates lncRNASAT1. In PCa tumor tissues, lncRNASAT1 is downregulated compared with nontumor tissues of the same patients. Knockdown indicates that the lncRNASAT1 is crucial for SAL-induced cancer-cell senescence as an upstream factor for pAKT and for p15(INK4b). Further, knockdown of lncRNASAT1 enhances cell proliferation by SAL, suggesting that lncRNASAT1 serves as a tumor suppressor at SAL. Interestingly, immunoprecipitation of AR detected lncRNASAT1 as an AR-interacting partner that regulates AR target-gene expression. Similarly, RNA-ChIP experiments revealed the interaction of AR with lncRNASAT1 on chromatin. Thus, we identified a novel AR-lncRNASAT1-AKT-p15(INK4b) signaling axis to mediate SAL-induced cellular senescence.	[Mirzakhani, Kimia; Kallenbach, Julia; Ribaudo, Federico; Ungelenk, Martin; Ehsani, Marzieh; Leeder, Mirjam; Baniahmad, Aria] Jena Univ Hosp, Inst Human Genet, Jena, Germany; [Rasa, Seyed Mohammad Mahdi; Neri, Francesco] Leibniz Inst Aging, Jena, Germany; [Gong, Wenrong] Hubei Univ Arts & Sci, Med Coll, Xiangyang, Peoples R China; [Gassler, Nikolaus] Jena Univ Hosp, Inst Forens Med, Sect Pathol, Jena, Germany; [Grimm, Marc-Oliver] Jena Univ Hosp, Dept Adult & Pediat Urol, Jena, Germany; [Gong, Wenrong] SCW Medicath LTD, Shenzhen, Peoples R China	Friedrich Schiller University of Jena; Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Hubei University of Arts & Science; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Baniahmad, A (corresponding author), Jena Univ Hosp, Inst Human Genet, Jena, Germany.	aria.baniahmad@med.uni-jena.de	Neri, Francesco/A-3321-2014	Neri, Francesco/0000-0003-3903-1974	German Academic Exchange Service (DAAD); German Cancer Aid	German Academic Exchange Service (DAAD)(Deutscher Akademischer Austausch Dienst (DAAD)); German Cancer Aid(Deutsche Krebshilfe)	This work was supported by the German Academic Exchange Service (DAAD) to K.M. and M.E. and the German Cancer Aid to A.B.	Calabrese EJ, 2001, CRIT REV TOXICOL, V31, P517, DOI 10.1080/20014091111794; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chuu CP, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-63; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Coa LL, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181312; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Deng Q, 2017, CELL PHYSIOL BIOCHEM, V43, P223, DOI 10.1159/000480343; Denmeade SR, 2010, PROSTATE, V70, P1600, DOI 10.1002/pros.21196; Denmeade SR, 2018, CLIN ADV HEMATOL ONC, V16, P408; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Esmaeili M, 2016, J MOL MED, V94, P1167, DOI 10.1007/s00109-016-1440-1; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Handa RJ, 2008, HORM BEHAV, V53, P741, DOI 10.1016/j.yhbeh.2007.09.012; Hessenkemper W, 2014, MOL ENDOCRINOL, V28, P1831, DOI 10.1210/me.2014-1170; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Isaacs JT, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.10.32; Isaacs JT, 2017, CELL CYCLE, V16, P1639, DOI 10.1080/15384101.2017.1360645; Isaacs JT, 2012, PROSTATE, V72, P1491, DOI 10.1002/pros.22504; Kikani CK, 2005, J CELL BIOCHEM, V96, P1157, DOI 10.1002/jcb.20651; Lasher RA, 2012, J TISSUE ENG, V3, DOI 10.1177/2041731412455354; Leibowitz RL, 2010, BJU INT, V105, P1397, DOI 10.1111/j.1464-410X.2009.08980.x; Leung JK, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00002; Liao RS, 2013, TRANSL ANDROL UROL, V2, P187, DOI 10.3978/j.issn.2223-4683.2013.09.07; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Martelli AM, 2012, BBA-MOL CELL RES, V1823, P2168, DOI 10.1016/j.bbamcr.2012.08.017; Mearini L, 2013, WORLD J UROL, V31, P247, DOI 10.1007/s00345-011-0793-x; Mirochnik Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031052; Moehren U, 2008, FASEB J, V22, P1258, DOI 10.1096/fj.07-9360com; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Prehn RT, 1999, CANCER RES, V59, P4161; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Roediger J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-214; Rosner M, 2012, METHODS MOL BIOL, V821, P105, DOI 10.1007/978-1-61779-430-8_8; Schweizer MT, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010563; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Stattin P, 2004, INT J CANCER, V108, P418, DOI 10.1002/ijc.11572; Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3; Umekita Y, 1996, P NATL ACAD SCI USA, V93, P11802, DOI 10.1073/pnas.93.21.11802; Wang Y, 2007, CURR CANCER DRUG TAR, V7, P591, DOI 10.2174/156800907781662248; Xu YH, 2019, CANCER LETT, V464, P37, DOI 10.1016/j.canlet.2019.08.010; Yang Q, 2019, GENE, V716, DOI 10.1016/j.gene.2019.144010	44	6	6	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					943	959		10.1038/s41388-021-02060-5	http://dx.doi.org/10.1038/s41388-021-02060-5		OCT 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34667276	hybrid, Green Published			2022-12-17	WOS:000708806900004
J	Yu, L; Cao, C; Li, X; Zhang, ML; Gu, QS; Gao, H; Balic, JJ; Xu, DG; Zhang, L; Ying, L; Xu, DK; Yang, YQ; Wu, D; He, BK; Jenkins, BJ; Liu, YD; Li, JK				Yu, Liang; Cao, Can; Li, Xu; Zhang, Mili; Gu, Qisheng; Gao, Hugh; Balic, Jesse J.; Xu, Duogang; Zhang, Lei; Ying, Le; Xu, Dakang; Yang, Yuqin; Wu, Di; He, Baokun; Jenkins, Brendan J.; Liu, Youdong; Li, Jikun			Complete loss of miR-200 family induces EMT associated cellular senescence in gastric cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; TARGETING ZEB1; TUMORIGENESIS; EXPRESSION; INHIBITORS	The EMT (epithelial-to-mesenchymal-transition) subtype of gastric cancer (GC) is associated with poor treatment responses and unfavorable clinical outcomes. Despite the broad physiological roles of the micro-RNA (miR)-200 family, they largely serve to maintain the overall epithelial phenotype. However, during late-stage gastric tumorigenesis, members of the miR-200 family are markedly suppressed, resulting in the transition to the mesenchymal state and the acquisition of invasive properties. As such, the miR-200 family represents a robust molecular marker of EMT, and subsequently, disease severity and prognosis. Most reports have studied the effect of single miR-200 family member knockdown. Here, we employ a multiplex CRISPR/Cas9 system to generate a complete miR-200 family knockout (FKO) to investigate their collective and summative role in regulating key cellular processes during GC pathogenesis. Genetic deletion of all miR-200s in the human GC cell lines induced potent morphological alterations, G1/S cell cycle arrest, increased senescence-associated beta-galactosidase (SA-beta-Gal) activity, and aberrant metabolism, collectively resembling the senescent phenotype. Coupling RNA-seq data with publicly available datasets, we revealed a clear separation of senescent and non-senescent states amongst FKO cells and control cells, respectively. Further analysis identified key senescence-associated secretory phenotype (SASP) components in FKO cells and a positive feedback loop for maintenance of the senescent state controlled by activation of TGF-beta and TNF-alpha pathways. Finally, we showed that miR-200 FKO associated senescence in cancer epithelial cells significantly recruited stromal cells in the tumor microenvironment. Our work has identified a new role of miR-200 family members which function as an integrated unit serving to link senescence with EMT, two major conserved biological processes.	[Yu, Liang; Cao, Can; Li, Xu; Zhang, Mili; Xu, Duogang; Liu, Youdong; Li, Jikun] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200080, Peoples R China; [Gu, Qisheng] Chinese Acad Sci, Inst Pasteur Shanghai, Shanghai 200031, Peoples R China; [Gao, Hugh] Univ Melbourne, Dept Clin Pathol, Melbourne, Vic 3133, Australia; [Gao, Hugh] Monash Hlth, Dept Upper Gastrointestinal & Hepatobiliary Surg, Clayton, Vic 3168, Australia; [Balic, Jesse J.; Ying, Le; Jenkins, Brendan J.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia; [Balic, Jesse J.; Ying, Le; Jenkins, Brendan J.] Monash Univ, Fac Med Nursing & Hlth Sci, Dept Mol Translat Sci, Clayton, Vic 3800, Australia; [Zhang, Lei; He, Baokun] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Key Lab Pancreat Dis, Sch Med, Shanghai 201620, Peoples R China; [Xu, Dakang] Shanghai Jiao Tong Univ, Ruijin Hosp, Fac Med Lab Sci, Sch Med, Shanghai, Peoples R China; [Yang, Yuqin] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Lab Anim Ctr, Sch Med, Shanghai 201620, Peoples R China; [Wu, Di] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Biostat, Chapel Hill, NC USA	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Le Reseau International des Instituts Pasteur (RIIP); University of Melbourne; Hudson Institute of Medical Research; Monash University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of North Carolina; University of North Carolina Chapel Hill	Liu, YD; Li, JK (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200080, Peoples R China.	liuyddoc@163.com; jkli65975@163.com		liu, youdong/0000-0001-7788-1916; cao, can/0000-0001-7011-9435	National Natural Science Foundation of China (NSFC) [81673034, 82072643]; Shanghai Natural Science Foundation [19ZR1441000, 21ZR1452100]; National Health and Medical Research Council (NHMRC) of Australia [APP1139371, APP1154279]; Australian Postgraduate Award from the Australian Government	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award from the Australian Government(Australian Research CouncilAustralian Government)	This work was supported by grants from the National Natural Science Foundation of China (NSFC) (81673034 and 82072643) as well as the Shanghai Natural Science Foundation (19ZR1441000 and 21ZR1452100). This work was also funded by the National Health and Medical Research Council (NHMRC) of Australia (B.J. Jenkins; APP1139371 and APP1154279). J.J. Balic was supported by an Australian Postgraduate Award from the Australian Government.	Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599; Battram AM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124346; Breen DM, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.10.023; Casella G, 2019, NUCLEIC ACIDS RES, V47, P11476, DOI 10.1093/nar/gkz879; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; de Barrios O, 2017, GUT, V66, P666, DOI 10.1136/gutjnl-2015-310838; Enache OM, 2020, NAT GENET, V52, P662, DOI 10.1038/s41588-020-0623-4; Furuya S, 2017, FEBS OPEN BIO, V7, P1586, DOI 10.1002/2211-5463.12300; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Jiang YN, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00081; Kabadi AM, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku749; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192; Mateescu B, 2011, NAT MED, V17, P1627, DOI 10.1038/nm.2512; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Pu MF, 2019, CELL MOL LIFE SCI, V76, P441, DOI 10.1007/s00018-018-2940-7; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; Seok H, 2016, MOL CELLS, V39, P375, DOI 10.14348/molcells.2016.0013; Song FJ, 2014, CLIN CANCER RES, V20, P878, DOI 10.1158/1078-0432.CCR-13-1844; Stavast CJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111465; Stramucci L, 2018, CANCERS, V10, DOI 10.3390/cancers10050131; Tang HL, 2013, CLIN CANCER RES, V19, P5602, DOI 10.1158/1078-0432.CCR-13-1326; Yu L, 2018, CLIN CANCER RES, V24, P1459, DOI 10.1158/1078-0432.CCR-17-2485; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zhao T, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00303-7	36	6	6	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					26	36		10.1038/s41388-021-02067-y	http://dx.doi.org/10.1038/s41388-021-02067-y		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34667277	Green Published, hybrid			2022-12-17	WOS:000708806900003
J	Gorka, J; Marona, P; Kwapisz, O; Waligorska, A; Pospiech, E; Dobrucki, JW; Rys, J; Jura, J; Miekus, K				Gorka, Judyta; Marona, Paulina; Kwapisz, Oliwia; Waligorska, Agnieszka; Pospiech, Ewelina; Dobrucki, Jurek W.; Rys, Janusz; Jura, Jolanta; Miekus, Katarzyna			MCPIP1 inhibits Wnt/beta-catenin signaling pathway activity and modulates epithelial-mesenchymal transition during clear cell renal cell carcinoma progression by targeting miRNAs	ONCOGENE			English	Article							BETA-CATENIN; DECREASED EXPRESSION; E-CADHERIN; KAPPA-B; PROMOTES; PROTEIN; DEGRADATION; MICRORNA; PHOSPHORYLATION; INFLAMMATION	Epithelial-mesenchymal transition (EMT) refers to the acquisition of mesenchymal properties in cells participating in tumor progression. One hallmark of EMT is the increased level of active beta-catenin, which can trigger the transcription of Wnt-specific genes responsible for the control of cell fate. We investigated how Monocyte Chemotactic Protein-1-Induced Protein-1 (MCPIP1), a negative regulator of inflammatory processes, affects EMT in a clear cell renal cell carcinoma (ccRCC) cell line, patient tumor tissues and a xenotransplant model. We showed that MCPIP1 degrades miRNAs via its RNase activity and thus protects the mRNA transcripts of negative regulators of the Wnt/beta-catenin pathway from degradation, which in turn prevents EMT. Mechanistically, the loss of MCPIP1 RNase activity led to the upregulation of miRNA-519a-3p, miRNA-519b-3p, and miRNA-520c-3p, which inhibited the expression of Wnt pathway inhibitors (SFRP4, KREMEN1, CXXC4, CSNK1A1 and ZNFR3). Thus, the level of active nuclear beta-catenin was increased, leading to increased levels of EMT inducers (SNAI1, SNAI2, ZEB1 and TWIST) and, consequently, decreased expression of E-cadherin, increased expression of mesenchymal markers, and acquisition of the mesenchymal phenotype. This study revealed that MCPIP1 may act as a tumor suppressor that prevents EMT by stabilizing Wnt inhibitors and decreasing the levels of active beta-catenin and EMT inducers.	[Gorka, Judyta; Marona, Paulina; Kwapisz, Oliwia; Jura, Jolanta; Miekus, Katarzyna] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Gen Biochem, Gronostajowa 7, PL-30387 Krakow, Poland; [Waligorska, Agnieszka; Dobrucki, Jurek W.] Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Cell Biophys, Gronostajowa 7, PL-30387 Krakow, Poland; [Pospiech, Ewelina] Jagiellonian Univ, Malopolska Ctr Biotechnol, Human Genome Variat Res Grp, Gronostajowa 7A, PL-30387 Krakow, Poland; [Rys, Janusz] Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Dept Tumor Pathol, Cracow Branch, Garncarska 11, PL-31115 Krakow, Poland	Jagiellonian University; Jagiellonian University; Jagiellonian University; Maria Sklodowska-Curie National Research Institute of Oncology	Miekus, K (corresponding author), Jagiellonian Univ, Fac Biochem Biophys & Biotechnol, Dept Gen Biochem, Gronostajowa 7, PL-30387 Krakow, Poland.	katarzyna.miekus@uj.edu.pl	Górka, Judyta/GLU-4157-2022	Górka, Judyta/0000-0002-1298-329X; Miekus, Katarzyna/0000-0002-2716-203X	National Science Centre [2015/19/B/NZ5/01405, 2017/26/E/NZ5/00691]; KNOW [BMN 1/2017, BMN 1/2018]	National Science Centre(National Science Centre, Poland); KNOW	This work was supported in part by research grants from the National Science Centre nos. 2015/19/B/NZ5/01405 and 2017/26/E/NZ5/00691 (to KM) and KNOW BMN 1/2017 and BMN 1/2018 (to JG).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boratyn E, 2016, J CELL BIOCHEM, V117, P694, DOI 10.1002/jcb.25354; CHEN F, 2021, CELL DEATH DIS, V12; Choi H, 2010, CANCER RES, V70, P10101, DOI 10.1158/0008-5472.CAN-10-0505; Dahl E, 2007, ONCOGENE, V26, P5680, DOI 10.1038/sj.onc.1210345; Dobosz E, 2016, J INNATE IMMUN, V8, P564, DOI 10.1159/000448038; Elyada E, 2011, NATURE, V470, P409, DOI 10.1038/nature09673; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Gorka J, 2020, EUR J PHARMACOL, V888, DOI 10.1016/j.ejphar.2020.173591; Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hsu RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047649; Iwasaki H, 2011, NAT IMMUNOL, V12, P1167, DOI 10.1038/ni.2137; Kojima T, 2009, ONCOGENE, V28, P297, DOI 10.1038/onc.2008.391; Kruck S, 2013, INT J MOL SCI, V14, P10944, DOI 10.3390/ijms140610944; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Li M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032152; Ligeza J, 2017, ANGIOGENESIS, V20, P325, DOI 10.1007/s10456-017-9540-2; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lu WB, 2016, CANCER RES, V76, P1429, DOI 10.1158/0008-5472.CAN-15-1115; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Marona P, 2017, CANCER RES, V77, P4905, DOI 10.1158/0008-5472.CAN-16-3190; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Mino T, 2015, CELL, V161, P1058, DOI 10.1016/j.cell.2015.04.029; Mizgalska D, 2009, FEBS J, V276, P7386, DOI 10.1111/j.1742-4658.2009.07452.x; Mlcochova H, 2016, SCI REP-UK, V6, DOI 10.1038/srep31852; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orsulic S, 1999, J CELL SCI, V112, P1237; Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pW169, DOI 10.1093/nar/gkt393; Reczko M, 2012, BIOINFORMATICS, V28, P771, DOI 10.1093/bioinformatics/bts043; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Shang S, 2017, ONCOTARGET, V8, P33972, DOI 10.18632/oncotarget.15687; Simon-Friedt BR, 2015, BIOL TRACE ELEM RES, V166, P66, DOI 10.1007/s12011-015-0339-y; Skalniak A, 2014, ONCOL REP, V31, P2385, DOI 10.3892/or.2014.3076; Skalniak L, 2013, FEBS J, V280, P2665, DOI 10.1111/febs.12264; Skalniak L, 2009, FEBS J, V276, P5892, DOI 10.1111/j.1742-4658.2009.07273.x; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Uehata T, 2013, BBA-GENE REGUL MECH, V1829, P708, DOI 10.1016/j.bbagrm.2013.03.001; Urakami S, 2006, CLIN CANCER RES, V12, P2109, DOI 10.1158/1078-0432.CCR-05-2468; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vlad-Fiegen A, 2012, FEBS OPEN BIO, V2, P26, DOI 10.1016/j.fob.2012.02.004; Xu JW, 2012, NUCLEIC ACIDS RES, V40, P6957, DOI 10.1093/nar/gks359; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027	53	6	6	3	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6720	6735		10.1038/s41388-021-02062-3	http://dx.doi.org/10.1038/s41388-021-02062-3		OCT 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34657130	Green Published, hybrid			2022-12-17	WOS:000707687400002
J	Gao, SS; Soares, F; Wang, SY; Wong, CC; Chen, HR; Yang, ZJ; Liu, WX; Go, MYY; Ahmed, M; Zeng, Y; O'Brien, CA; Sung, JJY; He, HH; Yu, J				Gao, Shanshan; Soares, Fraser; Wang, Shiyan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Ahmed, Musaddeque; Zeng, Yong; O'Brien, Catherine Adell; Sung, Joseph J. Y.; He, Housheng Hansen; Yu, Jun			CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer	ONCOGENE			English	Article							COLORECTAL-CANCER; TGF-BETA; INITIATING CELLS; SELF-RENEWAL; ENDOCRINE THERAPY; ZOLEDRONIC ACID; BREAST; ID1; IDENTIFICATION; INHIBITORS	Cancer stem cells (CSCs) are responsible for tumor progression, recurrence, and drug resistance. To identify genetic vulnerabilities of colon cancer, we performed targeted CRISPR dropout screens comprising 657 Drugbank targets and 317 epigenetic regulators on two patient-derived colon CSC-enriched spheroids. Next-generation sequencing of pooled genomic DNAs isolated from surviving cells yielded therapeutic candidates. We unraveled 44 essential genes for colon CSC-enriched spheroids propagation, including key cholesterol biosynthetic genes (HMGCR, FDPS, and GGPS1). Cholesterol biosynthesis was induced in colon cancer tissues, especially CSC-enriched spheroids. The genetic and pharmacological inhibition of HMGCR/FDPS impaired self-renewal capacity and tumorigenic potential of the spheroid models in vitro and in vivo. Mechanistically, HMGCR or FDPS depletion impaired cancer stemness characteristics by activating TGF-beta signaling, which in turn downregulated expression of inhibitors of differentiation (ID) proteins, key regulators of cancer stemness. Cholesterol and geranylgeranyl diphosphate (GGPP) rescued the growth inhibitory and signaling effect of HMGCR/FDPS blockade, implying a direct role of these metabolites in modulating stemness. Finally, cholesterol biosynthesis inhibitors and 5-FU demonstrated antitumor synergy in colon CSC-enriched spheroids, tumor organoids, and xenografts. Taken together, our study unravels novel genetic vulnerabilities of colon CSC-enriched spheroids and suggests cholesterol biosynthesis as a potential target in conjunction with traditional chemotherapy for colon cancer treatment.	[Gao, Shanshan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Gao, Shanshan; Wong, Chi Chun; Chen, Huarong; Yang, Zhenjie; Liu, Weixin; Go, Minnie Y. Y.; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Gao, Shanshan; Soares, Fraser; Wang, Shiyan; Ahmed, Musaddeque; Zeng, Yong; O'Brien, Catherine Adell; He, Housheng Hansen] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario, ON, Canada; [He, Housheng Hansen] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.; He, HH (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Ontario, ON, Canada.; He, HH (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.	hansenhe@uhnresearch.ca; junyu@cuhk.edu.hk	chen, huarong/ABH-8561-2020; Chen, Huarong/ABZ-5810-2022	chen, huarong/0000-0003-2192-1864; Zeng, Yong/0000-0001-5719-1272; Soares, Fraser/0000-0002-3977-7939; Wong, Chi Chun/0000-0003-1362-3541	National Natural Science Foundation of China (NSFC) [81972576]; RGC-CRF Hong Kong [C4039-19G, C7065-18G]; RGC-GRF Hong Kong [14110819, 14163817, 14108718, 24100520]; HMRF Hong Kong [06170686]; Princess Margaret Cancer Foundation [886012001223]; NSERC discovery Grants [498706]; CIHR operating Grants [142246, 152863, 152864, 159567]; Terry Fox New Frontiers Program Project Grant [1090 P3]; TFRI New Investigator Awards; CIHR New Investigator Awards; OMIR Early Researcher Award; Vice-Chancellor's Discretionary Fund CUHK	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); RGC-CRF Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; Princess Margaret Cancer Foundation(University of Toronto); NSERC discovery Grants(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR operating Grants(Canadian Institutes of Health Research (CIHR)); Terry Fox New Frontiers Program Project Grant; TFRI New Investigator Awards; CIHR New Investigator Awards(Canadian Institutes of Health Research (CIHR)); OMIR Early Researcher Award; Vice-Chancellor's Discretionary Fund CUHK	This project was supported by National Natural Science Foundation of China (NSFC; 81972576), RGC-CRF Hong Kong (C4039-19G, C7065-18G), RGC-GRF Hong Kong (14110819, 14163817, 14108718, 24100520), HMRF Hong Kong (06170686), the Princess Margaret Cancer Foundation (886012001223 to HHH), NSERC discovery Grants (498706 to HHH), CIHR operating Grants (142246, 152863, 152864, and 159567 to HHH), Terry Fox New Frontiers Program Project Grant (1090 P3 to HHH). HHH was supported by TFRI New Investigator Awards and CIHR New Investigator Awards. HHH holds an OMIR Early Researcher Award, Vice-Chancellor's Discretionary Fund CUHK.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Carpentino JE, 2009, CANCER RES, V69, P8208, DOI 10.1158/0008-5472.CAN-09-1132; Chen CL, 2008, J CELL PHYSIOL, V215, P223, DOI 10.1002/jcp.21303; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031864; Cheung KS, 2019, GUT, V68, P1979, DOI 10.1136/gutjnl-2018-317714; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Ehmsen S, 2019, CELL REP, V27, P3927, DOI 10.1016/j.celrep.2019.05.104; Gabitova-Cornell L, 2020, CANCER CELL, V38, P567, DOI 10.1016/j.ccell.2020.08.015; Ginestier C, 2012, STEM CELLS, V30, P1327, DOI 10.1002/stem.1122; Gnant M, 2015, ANN ONCOL, V26, P313, DOI 10.1093/annonc/mdu544; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Griffith M, 2013, NAT METHODS, V10, P1209, DOI [10.1038/NMETH.2689, 10.1038/nmeth.2689]; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Haynes J, 2018, CLIN CANCER RES, V24, P2116, DOI 10.1158/1078-0432.CCR-17-1715; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Katsuno Y, 2012, J PATHOL, V228, P391, DOI 10.1002/path.4020; Kloudova A, 2017, TRENDS ENDOCRIN MET, V28, P485, DOI 10.1016/j.tem.2017.03.002; Kodach LL, 2007, GASTROENTEROLOGY, V133, P1272, DOI 10.1053/j.gastro.2007.08.021; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Kurata M, 2018, J HUM GENET, V63, P179, DOI 10.1038/s10038-017-0376-9; Lasorella A, 2014, NAT REV CANCER, V14, P77, DOI 10.1038/nrc3638; Li HY, 2003, BLOOD, V101, P3628, DOI 10.1182/blood-2002-07-2283; Liang YY, 2009, CELL RES, V19, P140, DOI 10.1038/cr.2008.321; Liu CG, 2013, CANCER LETT, V339, P60, DOI 10.1016/j.canlet.2013.07.022; MacLeod G, 2019, CELL REP, V27, P971, DOI 10.1016/j.celrep.2019.03.047; Meng DL, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.152595; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Park HJ, 1999, P NATL ACAD SCI USA, V96, P11525, DOI 10.1073/pnas.96.20.11525; Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez-Vita J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003959; Shen Y, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw023; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Teng CF, 2018, CELL TRANSPLANT, V27, P1313, DOI 10.1177/0963689718779777; Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Voorneveld PW, 2017, GASTROENTEROLOGY, V153, P470, DOI 10.1053/j.gastro.2017.05.011; Wang B, 2018, CELL STEM CELL, V22, P206, DOI 10.1016/j.stem.2017.12.017; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang XX, 2017, CANCER RES, V77, P4947, DOI 10.1158/0008-5472.CAN-17-0114; Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098; Xia Y, 2018, CELL, V175, P1059, DOI 10.1016/j.cell.2018.08.070; Zhao ZQ, 2019, ONCOGENE, V38, P2076, DOI 10.1038/s41388-018-0570-z	52	6	6	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6601	6613		10.1038/s41388-021-01882-7	http://dx.doi.org/10.1038/s41388-021-01882-7		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34621019	Green Published, hybrid			2022-12-17	WOS:000705775200001
J	Wang, SY; Wong, CC; Zhang, YQ; Huang, JZ; Li, CG; Zhai, JN; Wang, GP; Wei, H; Zhang, XJ; He, HH; Yu, J				Wang, Shiyan; Wong, Chi Chun; Zhang, Yanquan; Huang, Junzhe; Li, Chuangen; Zhai, Jianning; Wang, Guoping; Wei, Hong; Zhang, Xueji; He, Housheng Hansen; Yu, Jun			ZNF545 loss promotes ribosome biogenesis and protein translation to initiate colorectal tumorigenesis in mice	ONCOGENE			English	Article							RNA-POLYMERASE-I; NUCLEOLAR TRANSCRIPTION; BINDING	Ribosome biogenesis plays a pivotal role in tumorigenesis by supporting robust protein translation. We investigate the functional and molecular mechanism of Zinc finger protein 545 (ZNF545), a transcriptional repressor for ribosomal RNA (rRNA), in colorectal cancer (CRC). ZNF545 was silenced in CRC compared to adjacent normal tissues (P < 0.0001), implying a tumor-suppressive role. Colon-specific Znf545 knockout in mice accelerated CRC in Apc(Min/+) and azoxymethane/dextran sulfate sodium-induced CRC. Mechanistically, we demonstrated that ZNF545 uses its two zinc finger clusters to bind to minimal rDNA promoter, where it assembled transcriptional repressor complex by interacting with KAP1. Znf545 deletion in mouse embryonic fibroblasts not only increased rRNA transcription rate and the nucleolar size and number but also altered the nucleolar composition and architecture with an increased number of fibrillar centers surrounded by net-like dense fibrillar components. Consequently, Znf545 deletion promoted the gene expression of translation machinery, protein translation, and cell growth. Consistent with its tumor-suppressive role, ZNF545 overexpression in CRC cells induced growth arrest and apoptosis. Finally, administration of rRNA synthesis inhibitor, CX-5461, inhibited CRC development in Znf545(Delta/Delta)Apc(Min/+) mice. In conclusion, ZNF545 suppresses CRC through repressing rRNA transcription and protein translation. Targeting rRNA biosynthesis in ZNF545-silenced tumors is a potential therapeutic strategy for CRC.	[Wang, Shiyan; Wong, Chi Chun; Zhang, Yanquan; Huang, Junzhe; Li, Chuangen; Zhai, Jianning; Wang, Guoping; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China; [Wang, Shiyan; Wong, Chi Chun; Zhang, Yanquan; Huang, Junzhe; Li, Chuangen; Zhai, Jianning; Wang, Guoping; Yu, Jun] Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China; [Wei, Hong] Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Guangzhou, Peoples R China; [Zhang, Xueji] Shenzhen Univ, Hlth Sci Ctr, Sch Biomed Engn, Shenzhen, Peoples R China; [He, Housheng Hansen] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Dept Med Biophys, Toronto, ON, Canada	Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Shenzhen University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, CUHK Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	zhai, jianning/GSD-4306-2022; zhang, xueji/ABE-6497-2020	zhai, jianning/0000-0002-8780-492X; zhang, xueji/0000-0002-0035-3821; he, housheng hansen/0000-0003-2898-3363; Wong, Chi Chun/0000-0003-1362-3541	National Key R&D Program of China [2020YFA0509200/2020YFA0509203]; RGC-CRF Hong Kong [C4039-19G, C7065-18GF]; RGC-GRF Hong Kong [14163817, 14110819]; Vice-Chancellor's Discretionary Fund CUHK	National Key R&D Program of China; RGC-CRF Hong Kong; RGC-GRF Hong Kong(Hong Kong Research Grants Council); Vice-Chancellor's Discretionary Fund CUHK	This study was supported by National Key R&D Program of China (No. 2020YFA0509200/2020YFA0509203); RGC-CRF Hong Kong (C4039-19G, C7065-18GF); RGC-GRF Hong Kong (14163817, 14110819); Vice-Chancellor's Discretionary Fund CUHK.	Bruno PM, 2020, P NATL ACAD SCI USA, V117, P4053, DOI 10.1073/pnas.1921649117; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Cheng YD, 2012, MOL CANCER RES, V10, P925, DOI 10.1158/1541-7786.MCR-11-0594; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Goodfellow SJ., 2013, SUBCELL BIOCH, V61, P211, DOI DOI 10.1007/978-94-007-4525-4_10); Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227; Helleboid PY, 2019, EMBO J, V38, DOI 10.15252/embj.2018101220; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; Khot A, 2019, CANCER DISCOV, V9, P1036, DOI 10.1158/2159-8290.CD-18-1455; Klug A, 2010, Q REV BIOPHYS, V43, P1, DOI 10.1017/S0033583510000089; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004; Popp MW, 2016, CELL, V165, P1319, DOI 10.1016/j.cell.2016.05.053; Quin JE, 2014, BBA-MOL BASIS DIS, V1842, P802, DOI 10.1016/j.bbadis.2013.12.009; Sanij E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16393-4; Scott MS, 2010, NUCLEIC ACIDS RES, V38, P7388, DOI 10.1093/nar/gkq653; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; SMALE ST, 1985, MOL CELL BIOL, V5, P352, DOI 10.1128/MCB.5.2.352; Srivastava R, 2016, MICROBIOL MOL BIOL R, V80, P545, DOI 10.1128/MMBR.00005-16; Torrano V, 2006, J CELL SCI, V119, P1746, DOI 10.1242/jcs.02890; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Wang SY, 2020, CLIN CANCER RES, V26, P746, DOI 10.1158/1078-0432.CCR-19-1611; Wang SY, 2019, CANCER RES, V79, P4086, DOI 10.1158/0008-5472.CAN-18-3614; Wang SY, 2013, GUT, V62, P833, DOI 10.1136/gutjnl-2011-301776; Weeks SE, 2019, CELL MOL LIFE SCI, V76, P4511, DOI 10.1007/s00018-019-03231-0; Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432; Yang P, 2017, TRENDS GENET, V33, P871, DOI 10.1016/j.tig.2017.08.006; Zeng W, 2010, EPIGENETICS-US, V5, P287, DOI 10.4161/epi.5.4.11683	38	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6590	6600		10.1038/s41388-021-01938-8	http://dx.doi.org/10.1038/s41388-021-01938-8		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34615997	Green Published, hybrid			2022-12-17	WOS:000705759400002
J	Liu, ZD; Sang, XL; Wang, M; Liu, YC; Liu, J; Wang, XF; Liu, PX; Cheng, HL				Liu, Zundong; Sang, Xiaolin; Wang, Min; Liu, Yichao; Liu, Jiao; Wang, Xuefei; Liu, Pixu; Cheng, Hailing			Melatonin potentiates the cytotoxic effect of Neratinib in HER2(+) breast cancer through promoting endocytosis and lysosomal degradation of HER2	ONCOGENE			English	Article							IRREVERSIBLE INHIBITOR; HSP90; GROWTH; ERBB2; IDENTIFICATION; CHEMOTHERAPY; TRAFFICKING; COMBINATION; ACTIVATION; RESISTANCE	Complete blockade of the HER2 protein itself and HER signaling network is critical to achieving effective HER2-targeted therapies. Despite the success of HER2-targeted therapies, the diseases will relapse in a significant fraction of patients with HER2(+) breast cancers. How to improve the therapeutic efficacy of existing HER2-targeted agents remains an unmet clinical need. Here, we uncover a role of Melatonin in diminishing HER2-mediated signaling by destruction of HER2 protein. Mechanistically, Melatonin treatment attenuated the protective effect of the HSP90 chaperone complex on its client protein HER2, triggering ubiquitylation and subsequent endocytic lysosomal degradation of HER2. The inhibitory effect of Melatonin on HER2 signaling substantially enhanced the cytotoxic effects of the pan-HER inhibitor Neratinib in HER2(+) breast cancer cells. Lastly, we demonstrate that dual inhibition of HER2 by combined use of Melatonin and Neratinib effectively blocked the growth of HER2(+) breast tumor xenografts in vivo. Our findings shed light on the potential use of Melatonin in a novel dual HER2 blockade strategy for HER2(+) breast cancer treatment.	[Liu, Zundong; Sang, Xiaolin; Wang, Min; Liu, Yichao; Liu, Jiao; Wang, Xuefei; Cheng, Hailing] Dalian Med Univ, Inst Canc, Hosp 2, Dalian, Liaoning, Peoples R China; [Liu, Pixu] Dalian Med Univ, Inst Canc Stem Cell, Hosp 2, Dalian, Liaoning, Peoples R China	Dalian Medical University; Dalian Medical University	Cheng, HL (corresponding author), Dalian Med Univ, Inst Canc, Hosp 2, Dalian, Liaoning, Peoples R China.; Liu, PX (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Hosp 2, Dalian, Liaoning, Peoples R China.	pixu_liu@163.com; hailingcheng_dmu@163.com		Sang, Xiaolin/0000-0001-8154-2853	Dalian Key Laboratory of Molecular Targeted Cancer Therapy; Molecular Biology Laboratory of National Administration of Traditional Chinese Medicine (Class III); National Natural Science Foundation of China [81672575, 81874111, 81972482]; Liaoning Provincial Key Research and Development Program [2020JH2/10300049]; Liaoning Revitalization Talents Program [XLYC2002043]; Dalian Leading Talents Fund [203598]; Liaoning Provincial Climbing Scholars Supporting Program of China; Scientific Research Fund of Liaoning Provincial Department of Education [LZ2020006, LZ2020069]; Science and Technology Innovation Fund of Dalian Department of Science and Technology [2020JJ27SN079, 2021JJ12SN39]	Dalian Key Laboratory of Molecular Targeted Cancer Therapy; Molecular Biology Laboratory of National Administration of Traditional Chinese Medicine (Class III); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning Provincial Key Research and Development Program; Liaoning Revitalization Talents Program; Dalian Leading Talents Fund; Liaoning Provincial Climbing Scholars Supporting Program of China; Scientific Research Fund of Liaoning Provincial Department of Education; Science and Technology Innovation Fund of Dalian Department of Science and Technology	We acknowledge the support of the Dalian Key Laboratory of Molecular Targeted Cancer Therapy and the Molecular Biology Laboratory of National Administration of Traditional Chinese Medicine (Class III). This work was supported by the National Natural Science Foundation of China (Nos. 81672575 and 81874111 to HC; No. 81972482 to PL), the Liaoning Provincial Key Research and Development Program (No. 2020JH2/10300049 to PL), Liaoning Revitalization Talents Program (XLYC2002043 to PL), Dalian Leading Talents Fund (203598 to PL), the Liaoning Provincial Climbing Scholars Supporting Program of China (HC and PL), the Scientific Research Fund of Liaoning Provincial Department of Education (LZ2020006 to PL; LZ2020069 to XS), and Science and Technology Innovation Fund of Dalian Department of Science and Technology (2020JJ27SN079 to HC, 2021JJ12SN39 to PL.).	Andersen LPH, 2016, CLIN DRUG INVEST, V36, P169, DOI 10.1007/s40261-015-0368-5; Anisimov VN, 2010, CELL CYCLE, V9, P188, DOI 10.4161/cc.9.1.10407; Anisimov VN, 2003, INT J CANCER, V103, P300, DOI 10.1002/ijc.10827; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008-5472.CAN-14-3763; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Breslin S, 2017, BRIT J CANCER, V116, P620, DOI 10.1038/bjc.2016.445; Burstein HJ, 2010, J CLIN ONCOL, V28, P1301, DOI 10.1200/JCO.2009.25.8707; Chung SS, 2014, INT J ONCOL, V44, P403, DOI 10.3892/ijo.2013.2195; Clague MJ, 2012, DEV CELL, V23, P457, DOI 10.1016/j.devcel.2012.08.011; Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012; Chuffa LGD, 2017, CARCINOGENESIS, V38, P945, DOI 10.1093/carcin/bgx054; Deeks ED, 2017, DRUGS, V77, P1695, DOI 10.1007/s40265-017-0811-4; Ding JL, 2019, CANCER LETT, V440, P54, DOI 10.1016/j.canlet.2018.09.030; Dodda BR, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00525; Galano A, 2018, MOLECULES, V23, DOI 10.3390/molecules23030530; Gingras I, 2017, NAT REV CLIN ONCOL, V14, P669, DOI 10.1038/nrclinonc.2017.96; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Goutsouliak K, 2020, NAT REV CLIN ONCOL, V17, P233, DOI 10.1038/s41571-019-0299-9; Hallett ST, 2017, CELL REP, V21, P1386, DOI 10.1016/j.celrep.2017.10.042; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hendriks BS, 2003, CANCER RES, V63, P1130; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Karakas B, 2018, BBA-MOL CELL RES, V1865, P1073, DOI 10.1016/j.bbamcr.2018.05.002; Kong XY, 2020, TRENDS ENDOCRIN MET, V31, P859, DOI 10.1016/j.tem.2020.08.001; Li BT, 2020, CANCER DISCOV, V10, P674, DOI 10.1158/2159-8290.CD-20-0215; Li Y, 2017, ONCOTARGET, V8, P39896, DOI 10.18632/oncotarget.16379; Lissoni P, 1999, EUR J CANCER, V35, P1688, DOI 10.1016/S0959-8049(99)00159-8; Malow BA, 2021, J AM ACAD CHILD PSY, V60, P252, DOI 10.1016/j.jaac.2019.12.007; Mao LL, 2016, MOL CANCER RES, V14, P1159, DOI 10.1158/1541-7786.MCR-16-0158; Mao LL, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2794; Marx C, 2010, CANCER RES, V70, P3709, DOI 10.1158/0008-5472.CAN-09-3768; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3; Pariente R, 2016, J PINEAL RES, V60, P55, DOI 10.1111/jpi.12288; Pedersen NM, 2008, MOL CANCER RES, V6, P491, DOI 10.1158/1541-7786.MCR-07-0191; Powers MV, 2008, CANCER CELL, V14, P250, DOI 10.1016/j.ccr.2008.08.002; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Ren YL, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00426-y; Sang XL, 2021, CANCER LETT, V518, P82, DOI 10.1016/j.canlet.2021.06.011; Shevtsov M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215284; Sletten TL, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002587; Sookprasert A, 2014, ANTICANCER RES, V34, P7327; Strous GJ, 1999, J CELL SCI, V112, P1417; Talib WH, 2018, MOLECULES, V23, DOI 10.3390/molecules23030518; Huynh TK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194812; Tikhomirov O, 2003, CANCER RES, V63, P39; Wang JN, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0069-2; Wang M, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101225; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Wissner A, 2003, J MED CHEM, V46, P49, DOI 10.1021/jm020241c; Wissner A, 2008, ARCH PHARM, V341, P465, DOI 10.1002/ardp.200800009; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Xu WP, 2005, NAT STRUCT MOL BIOL, V12, P120, DOI 10.1038/nsmb885; Yi JY, 2019, EBIOMEDICINE, V43, P225, DOI 10.1016/j.ebiom.2019.03.027; Zhang J, 2020, AGING-US, V12, P5423, DOI 10.18632/aging.102968; Zhang JR, 2020, CELL DEATH DIFFER, V27, P2710, DOI 10.1038/s41418-020-0538-8; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang YQ, 2016, CANCER LETT, V382, P176, DOI 10.1016/j.canlet.2016.08.026	61	6	6	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6273	6283		10.1038/s41388-021-02015-w	http://dx.doi.org/10.1038/s41388-021-02015-w		SEP 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34556812	Green Published, hybrid			2022-12-17	WOS:000698556400002
J	Li, BW; Xia, YW; Lv, JL; Wang, WZ; Xuan, Z; Chen, C; Jiang, TL; Fang, L; Wang, LJ; Li, Z; He, ZY; Li, QY; Xie, L; Qiu, SK; Zhang, L; Zhang, DC; Xu, H; Xu, ZK				Li, Bowen; Xia, Yiwen; Lv, Jialun; Wang, Weizhi; Xuan, Zhe; Chen, Cen; Jiang, Tianlu; Fang, Lang; Wang, Linjun; Li, Zheng; He, Zhongyuan; Li, Qingya; Xie, Li; Qiu, Shengkui; Zhang, Lu; Zhang, Diancai; Xu, Hao; Xu, Zekuan			miR-151a-3p-rich small extracellular vesicles derived from gastric cancer accelerate liver metastasis via initiating a hepatic stemness-enhancing niche	ONCOGENE			English	Article							PREMETASTATIC NICHE; PROSTATE-CANCER; KUPFFER CELLS; MICROENVIRONMENT; EXOSOMES; BONE; TRANSLATION; ACTIVATION; INHIBITOR; PHENOTYPE	Liver metastasis (LM) severely affects gastric cancer (GC) patients' prognosis. Small extracellular vesicles (sEVs) play key roles in intercellular communication. Specific sEV-miRNAs from several types of cancer were found to induce a premetastatic niche in target organs before tumor cell arrive. However, whether the primary GC affects hepatic microenvironment or the role of sEV-miRNAs in GC-LM is yet unclear. We report that GC-derived sEVs are primarily absorbed by Kupffer cells (KCs). sEV-miR-151a-3p is highly expressed in GC-LM patients' plasma and presents poor prognosis. Treating mice with sEVs-enriched in miR-151a-3p promotes GC-LM, whereas has no influence on the proliferation of GC cells in situ. Mechanistically, sEV-miR-151a-3p inhibits SP3 in KCs. Simultaneously, sEV-miR-151a-3p targets YTHDF3 to decrease the transcriptional inhibitory activity of SP3 by reducing SUMO1 translation in a N6-methyladenosine-dependent manner. These factors contribute to TGF-beta 1 transactivation in KCs, subsequently activating the SMAD2/3 pathway and enhancing the stem cell-like properties of incoming GC cells. Furthermore, sEV-miR-151a-3p induces miR-151a-3p transcription in KCs to form a positive feedback loop. In summary, our results reveal a previously unidentified regulatory axis initiated by sEV-miR-151a-3p that establishes a hepatic stemness-permissive niche to support GC-LM. sEV-miR-151a-3p could be a promising diagnostic biomarker and preventive treatment candidate for GC-LM.	[Li, Bowen; Xia, Yiwen; Lv, Jialun; Wang, Weizhi; Xuan, Zhe; Jiang, Tianlu; Fang, Lang; Wang, Linjun; Li, Zheng; He, Zhongyuan; Li, Qingya; Xie, Li; Qiu, Shengkui; Zhang, Lu; Zhang, Diancai; Xu, Hao; Xu, Zekuan] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Cen] Southern Med Univ, Sch Clin Med 1, Jinling Hosp, Dept Resp & Crit Care Med, Nanjing 210002, Jiangsu, Peoples R China; [Qiu, Shengkui] Nantong Univ, Affiliated Hosp 2, Dept Gen Surg, Nantong 226001, Jiangsu, Peoples R China; [Xu, Zekuan] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China	Nanjing Medical University; Southern Medical University - China; Nantong University; Nanjing Medical University	Xu, ZK (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China.; Xu, ZK (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.	xuzekuan@njmu.edu.cn	wang, lili/HDL-7210-2022; wang, lin/GSE-3040-2022	xu, zekuan/0000-0001-5179-4128	National Natural Science Foundation of China [81871946, 82002558, 82072708]; Special Foundation for National Science and Technology Basic Research Program of China [2019FY101104]; Primary Research & Development Plan of Jiangsu Province [BE2016786]; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; Jiangsu Key Medical Discipline (General Surgery) [ZDXKA2016005]; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Special Foundation for National Science and Technology Basic Research Program of China; Primary Research & Development Plan of Jiangsu Province; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Key Medical Discipline (General Surgery); Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	This work was partially supported by the National Natural Science Foundation of China (81871946, 82002558, 82072708); Special Foundation for National Science and Technology Basic Research Program of China (2019FY101104); the Primary Research & Development Plan of Jiangsu Province (BE2016786); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801); Jiangsu Key Medical Discipline (General Surgery) (ZDXKA2016005); Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University. We would like to express our gratitude to Dr Xiaofei Zhi and Dr Zheng Chen for their valuable advice on our study. We also thank Prof. Xinyu Xu for her help on FACS experiments.	Badiola I, 2012, GUT, V61, P1465, DOI 10.1136/gutjnl-2011-300810; Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460; Celia-Terrassa T, 2017, NAT CELL BIOL, V19, P711, DOI 10.1038/ncb3533; Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Chen J, 2013, EJSO-EUR J SURG ONC, V39, P701, DOI 10.1016/j.ejso.2013.03.023; Chen L, 2012, BIOMATERIALS, V33, P1437, DOI 10.1016/j.biomaterials.2011.10.056; Colletti M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1774144; Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Dou CW, 2018, GASTROENTEROLOGY, V154, P2209, DOI 10.1053/j.gastro.2018.02.015; Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Gonzalez-Ramos M, 2013, INT J BIOCHEM CELL B, V45, P232, DOI 10.1016/j.biocel.2012.10.001; Grillet F, 2017, GUT, V66, P1802, DOI 10.1136/gutjnl-2016-311447; Grunwald B, 2016, GASTROENTEROLOGY, V151, P1011, DOI 10.1053/j.gastro.2016.07.043; Hashimoto K, 2018, P NATL ACAD SCI USA, V115, P2204, DOI 10.1073/pnas.1717363115; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Hsu KW, 2016, ONCOTARGET, V7, P38036, DOI 10.18632/oncotarget.9342; Huang XY, 2015, EUR UROL, V67, P33, DOI 10.1016/j.eururo.2014.07.035; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; KAN ZX, 1995, HEPATOLOGY, V21, P487, DOI 10.1002/hep.1840210233; Kasar S, 2014, ONCOGENE, V33, P3307, DOI 10.1038/onc.2013.291; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Lee D, 2015, HEPATOLOGY, V61, P1978, DOI 10.1002/hep.27721; Leek RD, 1999, BRIT J CANCER, V79, P991, DOI 10.1038/sj.bjc.6690158; Li A, 2017, CELL RES, V27, P444, DOI 10.1038/cr.2017.10; Li X, 2020, AGING-US, V12, P14157, DOI 10.18632/aging.103423; Lima CR, 2017, MOL CELL ENDOCRINOL, V456, P62, DOI 10.1016/j.mce.2017.03.015; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Little AC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00456; Liu BH, 2019, BRIEF FUNCT GENOMICS, V18, P255, DOI 10.1093/bfgp/elz002; Liu C, 2017, ACS NANO, V11, P6968, DOI 10.1021/acsnano.7b02277; Liu HB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191357; Liu TR, 2018, CANCER RES, V78, P6632, DOI 10.1158/0008-5472.CAN-18-0650; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Luo Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01353; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Ma G, 2019, CANCER BIOMARK, V26, P491, DOI 10.3233/CBM-190256; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Matsumura H, 2014, INT J ONCOL, V45, P2303, DOI 10.3892/ijo.2014.2662; O'Dea KP, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1706708; PAGET S, 1989, CANCER METAST REV, V8, P98; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Qiu XL, 2019, THERANOSTICS, V9, P2618, DOI 10.7150/thno.32363; Rosonina E, 2017, TRANSCR-AUSTIN, V8, P220, DOI 10.1080/21541264.2017.1311829; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Stielow B, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001203; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Wang YG, 2019, HEPATOLOGY, V70, P1409, DOI 10.1002/hep.30668; Wen SW, 2013, CANCER BIOL THER, V14, P606, DOI 10.4161/cbt.24593; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Yeh TC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168171; Yue CC, 2020, J BIOMED NANOTECHNOL, V16, P876, DOI 10.1166/jbn.2020.2941; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhang XP, 2019, ONCOGENE, V38, P699, DOI 10.1038/s41388-018-0447-1; Zhang Y, 2019, P NATL ACAD SCI USA, V116, P976, DOI 10.1073/pnas.1812536116; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhang ZR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1139-6	64	6	6	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6180	6194		10.1038/s41388-021-02011-0	http://dx.doi.org/10.1038/s41388-021-02011-0		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34535770				2022-12-17	WOS:000696766300002
J	Guo, W; Zhang, CY; Feng, PP; Li, MY; Wang, X; Xia, Y; Chen, DW; Li, JX				Guo, Wei; Zhang, Cuiyu; Feng, Panpan; Li, Mingying; Wang, Xia; Xia, Yuan; Chen, Dawei; Li, Jingxin			M6A methylation of DEGS2, a key ceramide-synthesizing enzyme, is involved in colorectal cancer progression through ceramide synthesis	ONCOGENE			English	Article							STEM-LIKE CELLS; DIHYDROCERAMIDE DESATURASE; EXPRESSION; N-6-METHYLADENOSINE; SUPPRESSOR; TUMORS	N6-methyladenosine (m6A) is the most prevalent RNA epigenetic regulator in cancer. However, the understanding of m6A modification on lipid metabolism regulation in colorectal cancer (CRC) is very limited. Here, we observed that human CRCs exhibited increased m6A mRNA methylation mediated by dysregulation of m6A erasers and readers. By performing methylated RNA-immunoprecipitation sequencing (MeRIP-seq) and transcriptomic sequencing (RNA-seq), we identified DEGS2 as a downstream target of m6A dysregulation. Overexpression or knockdown of DEGS2 confirmed the role of DEGS2 in proliferation, invasion and metastasis of CRC both in vitro and in vivo. Mechanistic studies identified the specific m6A modification site within DEGS2 mRNA, and mutation of this target site was found to drastically enhance the proliferative and invasive ability of CRC cells in vitro and promote tumorigenicity in vivo. Lipidome analysis showed that lipid metabolism was dysregulated in CRC. Moreover, ceramide synthesis was suppressed due to DEGS2 upregulation mediated by m6A modification in CRC tissues. Our findings highlight that the function of DEGS2 m6A methylation in CRC and extend the understanding of the importance of RNA epigenetics in cancer biology.	[Guo, Wei] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Colorectal Surg, Jinan, Shandong, Peoples R China; [Zhang, Cuiyu; Wang, Xia; Li, Jingxin] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Physiol, Jinan, Shandong, Peoples R China; [Feng, Panpan; Li, Mingying; Xia, Yuan] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Hematol, Jinan, Shandong, Peoples R China; [Chen, Dawei] Univ Liege, CHU, Interdisciplinary Cluster Appl Genoprote GIGA Ste, Fac Med,Lab Med Chem, Liege, Belgium	Shandong University; Shandong University; Shandong University; University of Liege	Li, JX (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Dept Physiol, Jinan, Shandong, Peoples R China.	ljingxin@sdu.edu.cn	Li, Jing/GYU-5036-2022	Guo, Wei/0000-0001-8405-832X; Chen, Dawei/0000-0002-2541-4512; wang, xia/0000-0002-4294-8022	National Natural Science Foundation of China [82000779, 31971061]; Taishan Pandeng Scholar Program of Shandong Province [tspd20210321]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Pandeng Scholar Program of Shandong Province	This work was supported in part by the National Natural Science Foundation of China (82000779, 31971061); and Taishan Pandeng Scholar Program of Shandong Province (tspd20210321).	Antony J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf8175; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Casasampere M, 2016, CHEM PHYS LIPIDS, V197, P33, DOI 10.1016/j.chemphyslip.2015.07.025; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013; Dang W, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00417; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Engel M, 2018, GENES BRAIN BEHAV, V17, DOI 10.1111/gbb.12428; Fabrias G, 2012, PROG LIPID RES, V51, P82, DOI 10.1016/j.plipres.2011.12.002; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao X, 2010, ONCOGENE, V29, P4555, DOI 10.1038/onc.2010.213; Garborg K, 2013, ANN ONCOL, V24, P1963, DOI 10.1093/annonc/mdt157; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hua WF, 2018, GYNECOL ONCOL, V151, P356, DOI 10.1016/j.ygyno.2018.09.015; Lan Q, 2019, CANCER RES, V79, P1285, DOI 10.1158/0008-5472.CAN-18-2965; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liu J, 2018, NAT CELL BIOL, V20, P1074, DOI 10.1038/s41556-018-0174-4; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Mathiyalagan P, 2019, CIRCULATION, V139, P518, DOI 10.1161/CIRCULATIONAHA.118.033794; Meyer KD, 2017, ANNU REV CELL DEV BI, V33, P319, DOI 10.1146/annurev-cellbio-100616-060758; Meyer KD, 2014, NAT REV MOL CELL BIO, V15, P313, DOI 10.1038/nrm3785; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362; Selzner M, 2001, CANCER RES, V61, P1233; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220; Tong JY, 2018, FRONT MED-PRC, V12, P481, DOI 10.1007/s11684-018-0654-8; Tuncel G, 2019, MED ONCOL, V36, DOI 10.1007/s12032-019-1260-6; Visvanathan A, 2018, ONCOGENE, V37, P522, DOI 10.1038/onc.2017.351; Xu JH, 2020, ONCOL REP, V44, P973, DOI 10.3892/or.2020.7665; Yang X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1146-4; Yang Y, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0740-0; Yang Y, 2019, J CLIN ENDOCR METAB, V104, P665, DOI 10.1210/jc.2018-00619; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhao BXS, 2017, NAT REV MOL CELL BIO, V18, P31, DOI 10.1038/nrm.2016.132	42	6	6	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2021	40	40					5913	5924		10.1038/s41388-021-01987-z	http://dx.doi.org/10.1038/s41388-021-01987-z		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD5KT	34363020	hybrid, Green Published			2022-12-17	WOS:000682519100001
J	Kobelt, D; Perez-Hernandez, D; Fleuter, C; Dahlmann, M; Zincke, F; Smith, J; Migotti, R; Popp, O; Burock, S; Walther, W; Dittmar, G; Mertins, P; Stein, U				Kobelt, Dennis; Perez-Hernandez, Daniel; Fleuter, Claudia; Dahlmann, Mathias; Zincke, Fabian; Smith, Janice; Migotti, Rebekka; Popp, Oliver; Burock, Susen; Walther, Wolfgang; Dittmar, Gunnar; Mertins, Philipp; Stein, Ulrike			The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis	ONCOGENE			English	Article							ERK1/2 MAP KINASES; AZD6244 ARRY-142886; CELL-SURVIVAL; IN-VIVO; PROGRESSION; MELANOMA; OVEREXPRESSION; SPECIFICITY; ACTIVATION; RESISTANCE	Cancer metastasis causes >90% of cancer deaths and remains a major treatment challenge. Here we deciphered the impact of tyrosine phosphorylation of MACC1, a causative driver for cancer metastasis, for cancer cell signaling and novel interventions to restrict cancer metastasis. We identified MACC1 as new MEK1 substrate. MEK1 directly phosphorylates MACC1, leading to accelerated and increased ERK1 activation. Mutating in silico predicted hierarchical MACC1 tyrosine phosphorylation sites abrogates MACC1-induced migration, invasion, and MET expression, a transcriptional MACC1 target. Targeting MEK1 by RNAi or clinically applicable MEK1 inhibitors AZD6244 and GSK1120212 reduces MACC1 tyrosine phosphorylation and restricts MACC1-induced metastasis formation in mice. Although MEK1 levels, contrary to MACC1, are not of prognostic relevance for CRC patients, MEK1 expression was found indispensable for MACC1-induced metastasis. This study identifies MACC1 as new MEK1 substrate for tyrosine phosphorylation decisively impacting cell motility, tumor growth, and metastasis. Thus, MAP kinase signaling is not linear leading to ERK activation, but branches at the level of MEK1. This fundamental finding opens new therapeutic options for targeting the MEK1/MACC1 axis as novel vulnerability in patients at high risk for metastasis. This might be extended from CRC to further solid tumor entities.	[Kobelt, Dennis; Fleuter, Claudia; Dahlmann, Mathias; Zincke, Fabian; Smith, Janice; Walther, Wolfgang; Stein, Ulrike] Charite Univ Med Berlin, Expt & Clin Res Ctr, Translat Oncol Solid Tumors, Berlin, Germany; [Kobelt, Dennis; Fleuter, Claudia; Dahlmann, Mathias; Zincke, Fabian; Smith, Janice; Walther, Wolfgang; Stein, Ulrike] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany; [Kobelt, Dennis; Dahlmann, Mathias; Zincke, Fabian; Stein, Ulrike] German Canc Consortium DKTK, Heidelberg, Germany; [Perez-Hernandez, Daniel; Migotti, Rebekka; Popp, Oliver; Dittmar, Gunnar; Mertins, Philipp] Helmholtz Assoc, Mass Spectrometry Core Unit, Max Delbruck Ctr Mol Med, Berlin, Germany; [Popp, Oliver; Mertins, Philipp] Berlin Inst Hlth BIH, Berlin, Germany; [Burock, Susen] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany; [Perez-Hernandez, Daniel; Dittmar, Gunnar] Luxembourg Inst Hlth, Proteome & Genome Res Lab, Strassen, Luxembourg	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Luxembourg Institute of Health	Stein, U (corresponding author), Charite Univ Med Berlin, Expt & Clin Res Ctr, Translat Oncol Solid Tumors, Berlin, Germany.; Stein, U (corresponding author), Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany.; Stein, U (corresponding author), German Canc Consortium DKTK, Heidelberg, Germany.	ustein@mdc-berlin.de	; Dittmar, Gunnar/B-6383-2016	Dahlmann, Mathias/0000-0002-0036-5283; Dittmar, Gunnar/0000-0003-3647-8623; Stein, Ulrike/0000-0001-7006-282X; Burock, Susen/0000-0002-0964-4174; Perez Hernandez, Daniel/0000-0003-0266-9050	German Cancer Consortium (DKTK); Preclinical Comprehensive Cancer Center (PCCC); Projekt DEAL	German Cancer Consortium (DKTK); Preclinical Comprehensive Cancer Center (PCCC); Projekt DEAL	This work was supported by grants from the German Cancer Consortium (DKTK; to US) and from the Preclinical Comprehensive Cancer Center (PCCC; to US). Open Access funding enabled and organized by Projekt DEAL.	Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-27; Ashktorab H, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0971-0; Becker M, 2002, BRIT J CANCER, V87, P1328, DOI 10.1038/sj.bjc.6600573; Budczies J, 2020, SEMIN CANCER BIOL, V60, P365, DOI 10.1016/j.semcancer.2019.08.010; Burock S, 2015, WORLD J GASTROENTERO, V21, P333, DOI 10.3748/wjg.v21.i1.333; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Duan GY, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004049; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Flanigan SA, 2013, CLIN CANCER RES, V19, P6219, DOI 10.1158/1078-0432.CCR-13-0145; Germann UA, 2017, MOL CANCER THER, V16, P2351, DOI 10.1158/1535-7163.MCT-17-0456; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Grimaldi AM, 2017, AM J CLIN DERMATOL, V18, P745, DOI 10.1007/s40257-017-0292-y; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Hagemann C, 2013, NEURO-ONCOLOGY, V15, P1696, DOI 10.1093/neuonc/not136; Huang LL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00977-0; Huang PH, 2010, MOL BIOSYST, V6, P1227, DOI 10.1039/c001196g; Hunter T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020644; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Ilm K, 2016, ONCOTARGET, V7, P53443, DOI 10.18632/oncotarget.10803; Ilm K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0316-2; Juneja M, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000784; Juneja M, 2013, MOL ONCOL, V7, P929, DOI 10.1016/j.molonc.2013.05.003; Kaneko T, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-32; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Koelzer VH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1150-z; Kyriakakis E, 2017, CELL SIGNAL, V35, P163, DOI 10.1016/j.cellsig.2017.04.004; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7; Lederer A, 2015, HEPATOLOGY, V62, P841, DOI 10.1002/hep.27885; Lemos C, 2016, CLIN CANCER RES, V22, P2812, DOI 10.1158/1078-0432.CCR-15-1425; Link T, 2019, MOL ONCOL, V13, P1268, DOI 10.1002/1878-0261.12484; Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4; Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438; Martin-Liberal J, 2014, EXPERT OPIN DRUG SAF, V13, P483, DOI 10.1517/14740338.2014.892578; Mudduluru G, 2017, MECH MOL CARCINOGENE, V1, P11; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nitsche U, 2012, ANN SURG, V256, P763, DOI 10.1097/SLA.0b013e318272de87; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Pichorner A, 2012, CLIN EXP METASTAS, V29, P573, DOI 10.1007/s10585-012-9472-6; Radhakrishnan H, 2018, CANCER METAST REV, V37, P805, DOI 10.1007/s10555-018-9771-8; Raghu VK, 2018, BIOCHEM BIOPH RES CO, V495, P659, DOI 10.1016/j.bbrc.2017.11.065; Rappsilber J, 2007, NAT PROTOC, V2, P1896, DOI 10.1038/nprot.2007.261; Rohr UP, 2017, ANN ONCOL, V28, P1869, DOI 10.1093/annonc/mdx207; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Roskoski R, 2012, BIOCHEM BIOPH RES CO, V417, P5, DOI 10.1016/j.bbrc.2011.11.145; Rozevsky Y, 2020, ACS NANO, V14, P13964, DOI 10.1021/acsnano.0c06375; Schmid F, 2016, ONCOGENE, V35, P5942, DOI 10.1038/onc.2015.451; Schmid F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-49; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stein Ulrike, 2007, V176, P61; Stein U, 2013, EXPERT OPIN THER TAR, V17, P1039, DOI 10.1517/14728222.2013.815727; Stein U, 2010, J MOL MED, V88, P11, DOI 10.1007/s00109-009-0537-1; Stein U, 2009, CELL CYCLE, V8, P2467, DOI 10.4161/cc.8.15.9018; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Sun DW, 2015, INT J CLIN EXP MED, V8, P4769; Tang ZJ, 2015, CELL, V160, P729, DOI 10.1016/j.cell.2015.01.028; Wang G, 2015, TUMOR BIOL, V36, P1055, DOI 10.1007/s13277-014-2736-9; Wright CJM, 2013, DRUGS, V73, P1245, DOI 10.1007/s40265-013-0096-1; Wu ZZ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/252043; Xue Z, 2018, CELL RES, V28, P719, DOI 10.1038/s41422-018-0044-4; Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015; Yang BC, 2017, CANCER LETT, V388, P167, DOI 10.1016/j.canlet.2016.11.037; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Zeiser R, 2014, RECENT RESULTS CANC, V201, P241, DOI 10.1007/978-3-642-54490-3_15; Zhao Y, 2016, ONCOTARGET, V7, P62966, DOI 10.18632/oncotarget.11287	75	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5286	5301		10.1038/s41388-021-01917-z	http://dx.doi.org/10.1038/s41388-021-01917-z		JUL 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34247190	hybrid, Green Published			2022-12-17	WOS:000671644900001
J	Hamalian, S; Guth, R; Runa, F; Sanchez, F; Vickers, E; Agajanian, M; Molnar, J; Nguyen, T; Gamez, J; Humphries, JD; Nayak, A; Humphries, MJ; Tchou, J; Zervantonakis, IK; Kelber, JA				Hamalian, Sarkis; Guth, Robert; Runa, Farhana; Sanchez, Francesca; Vickers, Eric; Agajanian, Megan; Molnar, Justin; Nguyen, Tuan; Gamez, Joshua; Humphries, Jonathan D.; Nayak, Anupma; Humphries, Martin J.; Tchou, Julia; Zervantonakis, Ioannis K.; Kelber, Jonathan A.			A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers	ONCOGENE			English	Article							THERAPY; HETEROGENEITY; GROWTH	Intercellular mechanisms by which the stromal microenvironment contributes to solid tumor progression and targeted therapy resistance remain poorly understood, presenting significant clinical hurdles. PEAK1 (Pseudopodium-Enriched Atypical Kinase One) is an actin cytoskeleton- and focal adhesion-associated pseudokinase that promotes cell state plasticity and cancer metastasis by mediating growth factor-integrin signaling crosstalk. Here, we determined that stromal PEAK1 expression predicts poor outcomes in HER2-positive breast cancers high in SNAI2 expression and enriched for MSC content. Specifically, we identified that the fibroblastic stroma in HER2-positive breast cancer patient tissue stains positive for both nuclear SNAI2 and cytoplasmic PEAK1. Furthermore, mesenchymal stem cells (MSCs) and cancer-associated fibroblasts (CAFs) express high PEAK1 protein levels and potentiate tumorigenesis, lapatinib resistance and metastasis of HER2-positive breast cancer cells in a PEAK1-dependent manner. Analysis of PEAK1-dependent secreted factors from MSCs revealed INHBA/activin-A as a necessary factor in the conditioned media of PEAK1-expressing MSCs that promotes lapatinib resistance. Single-cell CycIF analysis of MSC-breast cancer cell co-cultures identified enrichment of p-Akt(high)/p-gH2AX(low), MCL1(high)/p-gH2AX(low) and GRP78(high)/VIMhigh breast cancer cell subpopulations by the presence of PEAK1-expressing MSCs and lapatinib treatment. Bioinformatic analyses on a PEAK1-centric stroma-tumor cell gene set and follow-up immunostaining of co-cultures predict targeting antiapoptotic and stress pathways as a means to improve targeted therapy responses and patient outcomes in HER2-positive breast cancer and other stroma-rich malignancies. These data provide the first evidence that PEAK1 promotes tumorigenic phenotypes through a previously unrecognized SNAI2-PEAK1-INHBA stromal cell axis.	[Hamalian, Sarkis; Guth, Robert; Runa, Farhana; Sanchez, Francesca; Vickers, Eric; Agajanian, Megan; Molnar, Justin; Nguyen, Tuan; Gamez, Joshua; Kelber, Jonathan A.] Calif State Univ Northridge, Dept Biol, Northridge, CA 91330 USA; [Humphries, Jonathan D.; Humphries, Martin J.] Univ Manchester, Fac Biol Med & Hlth, Wellcome Ctr Cell Matrix Res, Manchester, Lancs, England; [Nayak, Anupma] Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA; [Nayak, Anupma] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Tchou, Julia] Univ Penn, Perelman Sch Med, Abramson Canc Ctr,Rena Rowan Breast Ctr, Div Endocrine & Oncol Surg,Dept Surg, Philadelphia, PA 19104 USA; [Zervantonakis, Ioannis K.] Univ Pittsburgh, Dept Bioengn, Ctr Bioengn, Pittsburgh, PA 15213 USA; [Humphries, Jonathan D.] Manchester Metropolitan Univ, Dept Life Sci, Manchester, Lancs, England	California State University System; California State University Northridge; University of Manchester; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Manchester Metropolitan University	Kelber, JA (corresponding author), Calif State Univ Northridge, Dept Biol, Northridge, CA 91330 USA.	jonathan.kelber@csun.edu	Humphries, Jonathan D./AAE-7760-2022	Humphries, Jonathan D./0000-0002-8953-7079; Agajanian, Megan/0000-0002-1296-5665	California State University Northridge College of Science and Mathematics; Wellcome Centre for Cell-Matrix Research at the University of Manchester; Ludwig Center at Harvard Medical School; Sidney Stern Memorial Trust; Sutter family; Aylozyan Family Foundation; NIH NCI [R00CA222554]; DOD [W81XWH-14-1-0222]; Cancer Research UK [C13329/A21671]; NCI Cancer Center Support Grant [2P30CA016520]; Linda and Paul Richardson Breast Cancer Research Funds; NSF [DUE1842386]; NIH NIGMS [SC1GM121182]; ASCB MAC Visiting Professorship; US-UK Fulbright-CRUK Scholar Award	California State University Northridge College of Science and Mathematics; Wellcome Centre for Cell-Matrix Research at the University of Manchester; Ludwig Center at Harvard Medical School; Sidney Stern Memorial Trust; Sutter family; Aylozyan Family Foundation; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Cancer Research UK(Cancer Research UK); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Linda and Paul Richardson Breast Cancer Research Funds; NSF(National Science Foundation (NSF)); NIH NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); ASCB MAC Visiting Professorship; US-UK Fulbright-CRUK Scholar Award	We thank Dr. Joan Brugge for sponsorship of Dr. Jonathan Kelber's ASCB-MAC Visiting Professorship and helpful discussions during the experiment design and manuscript writing/revising phases. We thank Dr. Lesley Ellies for providing Py230 cells. We thank members of the Developmental Oncogene Laboratory at California State University Northridge for valuable feedback during manuscript preparation. This work was supported by California State University Northridge College of Science and Mathematics; Wellcome Centre for Cell-Matrix Research at the University of Manchester; Ludwig Center at Harvard Medical School; Sidney Stern Memorial Trust; Sutter family; Aylozyan Family Foundation; NIH NCI grant R00CA222554 (to I.K.Z.); DOD grant W81XWH-14-1-0222 (to I.K.Z.); Cancer Research UK programme grant C13329/A21671 (to M.J.H.); NCI Cancer Center Support Grant 2P30CA016520 (to J.T.); Linda and Paul Richardson Breast Cancer Research Funds (to J.T.); NSF Grant DUE1842386 (to C.S./A.A. for support of T.N.); NIH NIGMS grant SC1GM121182 (to J.A.K.); ASCB MAC Visiting Professorship (to J.A.K.); and US-UK Fulbright-CRUK Scholar Award (to J.A.K.).	Agajanian M, 2015, BIOCHEM BIOPH RES CO, V465, P606, DOI 10.1016/j.bbrc.2015.08.071; Agajanian M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135748; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Bartoschek M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07582-3; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bashari MH, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0686-4; Chastney MR, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202003038; Ding CB, 2019, CANCER LETT, V442, P383, DOI 10.1016/j.canlet.2018.11.014; Ding CB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0817-1; Do MT, 2017, ONCOGENE, V36, P5757, DOI 10.1038/onc.2017.183; El-Haibi CP, 2012, P NATL ACAD SCI USA, V109, P17460, DOI 10.1073/pnas.1206653109; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465; Gori S, 2012, ANN ONCOL, V23, P1436, DOI 10.1093/annonc/mdr474; Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011; Guth R, 2019, BIOCHEM BIOPH RES CO, V519, P838, DOI 10.1016/j.bbrc.2019.09.075; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Horton ER, 2015, NAT CELL BIOL, V17, P1577, DOI 10.1038/ncb3257; Huang LL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0320-8; Kabraji S, 2018, CLIN CANCER RES, V24, P1795, DOI 10.1158/1078-0432.CCR-17-3351; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kelber JA, 2012, CANCER RES, V72, P2554, DOI 10.1158/0008-5472.CAN-11-3552; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Lin JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9390; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; Marusyk A, 2016, CANCER RES, V76, P6495, DOI 10.1158/0008-5472.CAN-16-1457; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Pawlikowska P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73632-w; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Qu YD, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0992-4; Runa F, 2017, Curr Mol Biol Rep, V3, P218, DOI 10.1007/s40610-017-0073-7; Seachrist DD, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0857-y; Smith JC, 2008, PHILOS T R SOC B, V363, P1387, DOI 10.1098/rstb.2007.2256; Stoletov K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04743-2; Tchou J, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-39; Wang HW, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0024-3; Wang YC, 2010, P NATL ACAD SCI USA, V107, P10920, DOI 10.1073/pnas.0914776107; Yang ZY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0732-6; Yeh HW, 2019, CANCER RES, V79, P3797, DOI 10.1158/0008-5472.CAN-18-2019; Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015; Zervantonakis IK, 2020, P NATL ACAD SCI USA, V117, P16500, DOI 10.1073/pnas.2000648117; Zheng Y, 2013, NATURE, V499, P166, DOI 10.1038/nature12308; Zijlstra A, 2002, CANCER RES, V62, P7083; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031; Zoeller JJ, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0020-z	46	6	6	2	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5224	5235		10.1038/s41388-021-01906-2	http://dx.doi.org/10.1038/s41388-021-01906-2		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34239043	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000670851600002
J	Karunanithi, S; Liu, RF; Hou, YC; Gonzalez, G; Oldford, N; Roe, AJ; Idipilly, N; Gupta, K; Amara, CS; Putluri, S; Lee, GK; Valentin-Goyco, J; Stetson, L; Moreton, SA; Putluri, V; Kavuri, SM; Saunthararajah, Y; de Lima, M; Tochtrop, GP; Putluri, N; Wald, DN				Karunanithi, Sheelarani; Liu, Ruifu; Hou, Yongchun; Gonzalez, Giancarlo; Oldford, Natasha; Roe, Anne Jessica; Idipilly, Nethrie; Gupta, Kalpana; Amara, Chandra Sekhar; Putluri, Satwikreddy; Lee, Grace Kyueun; Valentin-Goyco, Juan; Stetson, Lindsay; Moreton, Stephen A.; Putluri, Vasanta; Kavuri, Shyam M.; Saunthararajah, Yogen; de Lima, Marcos; Tochtrop, Gregory P.; Putluri, Nagireddy; Wald, David N.			Thioredoxin reductase is a major regulator of metabolism in leukemia cells	ONCOGENE			English	Article							OXIDATIVE STRESS; INHIBITION; APOPTOSIS; SYSTEM	Despite the fact that AML is the most common acute leukemia in adults, patient outcomes are poor necessitating the development of novel therapies. We identified that inhibition of Thioredoxin Reductase (TrxR) is a promising strategy for AML and report a highly potent and specific inhibitor of TrxR, S-250. Both pharmacologic and genetic inhibition of TrxR impairs the growth of human AML in mouse models. We found that TrxR inhibition leads to a rapid and marked impairment of metabolism in leukemic cells subsequently leading to cell death. TrxR was found to be a major and direct regulator of metabolism in AML cells through impacts on both glycolysis and the TCA cycle. Studies revealed that TrxR directly regulates GAPDH leading to a disruption of glycolysis and an increase in flux through the pentose phosphate pathway (PPP). The combined inhibition of TrxR and the PPP led to enhanced leukemia growth inhibition. Overall, TrxR abrogation, particularly with S-250, was identified as a promising strategy to disrupt AML metabolism.	[Karunanithi, Sheelarani; Liu, Ruifu; Gonzalez, Giancarlo; Oldford, Natasha; Roe, Anne Jessica; Idipilly, Nethrie; Gupta, Kalpana; Lee, Grace Kyueun; Valentin-Goyco, Juan; Stetson, Lindsay; Wald, David N.] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA; [Karunanithi, Sheelarani; Hou, Yongchun; Roe, Anne Jessica; Idipilly, Nethrie; Moreton, Stephen A.; Wald, David N.] CuronBiotech Inc, Cleveland, OH 44106 USA; [Amara, Chandra Sekhar; Putluri, Satwikreddy; Putluri, Nagireddy] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Putluri, Vasanta; Putluri, Nagireddy] Baylor Coll Med, Alkek Ctr Mol Discovery, Dan L Duncan Canc Ctr, Adv Technol Core, Houston, TX 77030 USA; [Kavuri, Shyam M.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Kavuri, Shyam M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Saunthararajah, Yogen] Cleveland Clin Fdn, Dept Translat Hematol & Oncol Res, 9500 Euclid Ave, Cleveland, OH 44195 USA; [de Lima, Marcos] Univ Hosp Cleveland, Dept Med, Med Ctr, 2074 Abington Rd, Cleveland, OH 44106 USA; [Tochtrop, Gregory P.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; [Wald, David N.] Louis Stokes Cleveland VA Med Ctr, Dept Pathol, Cleveland, OH 44106 USA	Case Western Reserve University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Wald, DN (corresponding author), Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA.; Wald, DN (corresponding author), CuronBiotech Inc, Cleveland, OH 44106 USA.; Wald, DN (corresponding author), Louis Stokes Cleveland VA Med Ctr, Dept Pathol, Cleveland, OH 44106 USA.	dnw@case.edu			Case Comprehensive Cancer Center [P30CA043703]; NIH [U24DK097153, R43CA22870]; VA medical center grant [I01BX004995]; American Cancer Society (ACS) [127430-RSG-15-105-01-CNE]; NIH/NCI [R01CA216426, R01CA220297];  [W81XWH-18-10035];  [W81XWH-18-1-0084]	Case Comprehensive Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA medical center grant; American Cancer Society (ACS)(American Cancer Society); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	analysis of the mass spectrometry data. This research was supported by the Hematopoietic Biorepository and Cellular Therapy, Athymic Animal and Preclinical Therapeutics, Proteomics and Cytometry and Imaging Microscopy Shared Resources of the Case Comprehensive Cancer Center (P30CA043703). The research was also supported by the NIH grant R43CA22870 (D.N.W. and Y.H.) and VA medical center grant I01BX004995. Targeted metabolomics performed at the University of Michigan metabolomics core was supported by the NIH grant U24DK097153. This research was supported by American Cancer Society (ACS) Award 127430-RSG-15-105-01-CNE (N.P.), NIH/NCI R01CA220297 (N.P), and NIH/NCI R01CA216426 (N.P.). W81XWH-18-10035 and W81XWH-18-1-0084 to S.M.K.	American Cancer Society, 2018, CANC FACTS FIG, DOI [10.1182/blood-2015-12-687814, DOI 10.1182/BLOOD-2015-12-687814]; Arner ESJ, 2009, BBA-GEN SUBJECTS, V1790, P495, DOI 10.1016/j.bbagen.2009.01.014; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arnold JM., 2019, ONCOGENE, P3138; BEUTLER JA, 1985, BRAIN RES, V330, P135, DOI 10.1016/0006-8993(85)90014-9; Cassidy PB, 2015, PIGM CELL MELANOMA R, V28, P685, DOI 10.1111/pcmr.12398; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chapuis N, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00405; Chaturvedi A, 2013, BLOOD, V122, P2877, DOI 10.1182/blood-2013-03-491571; Daloso DM, 2015, P NATL ACAD SCI USA, V112, pE1392, DOI 10.1073/pnas.1424840112; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dong NZ, 1999, ACTA PHARMACOL SIN, V20, P267; Fritz-Wolf K, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1382; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gupta K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021203; Hou W, 2016, EUR J MED CHEM, V122, P149, DOI 10.1016/j.ejmech.2016.06.021; Kaplan A, 2015, ACS MED CHEM LETT, V6, P966, DOI 10.1021/acsmedchemlett.5b00014; Leonoudakis D, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8302636; Levis M, 2013, BLOOD, V122, P2770, DOI 10.1182/blood-2013-09-522441; Li L, 2015, REDOX BIOL, V4, P127, DOI 10.1016/j.redox.2014.12.001; Lincoln DT, 2003, ANTICANCER RES, V23, P2425; Liu XD, 2011, CHEM RES TOXICOL, V24, P726, DOI 10.1021/tx2000152; Lomenick Brett, 2011, Curr Protoc Chem Biol, V3, P163; Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Peng XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep28080; Pfleger J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.202; Pollyea DA, 2018, NAT MED, V24, P1859, DOI 10.1038/s41591-018-0233-1; Radenkovic F, 2017, BIOCHEM PHARMACOL, V146, P42, DOI 10.1016/j.bcp.2017.09.009; Rana S, 2010, FASEB J, V24, P2126, DOI 10.1096/fj.09-148999; Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Schmidtmann E, 2014, MOL PLANT, V7, P156, DOI 10.1093/mp/sst144; Shipman M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041278; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Sriskanthadevan S, 2015, BLOOD, V125, P2120, DOI 10.1182/blood-2014-08-594408; Stafford WC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaf7444; Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937; Urig S, 2006, SEMIN CANCER BIOL, V16, P452, DOI 10.1016/j.semcancer.2006.09.004; Vantaku V, 2019, CLIN CANCER RES, V25, P3689, DOI 10.1158/1078-0432.CCR-18-1515; Yu R, 1997, J BIOL CHEM, V272, P28962, DOI 10.1074/jbc.272.46.28962; Zhang BX, 2017, EXPERT OPIN THER PAT, V27, P547, DOI 10.1080/13543776.2017.1272576; Zhang JM, 2019, MED RES REV, V39, P5, DOI 10.1002/med.21507; Zhang JM, 2017, TRENDS PHARMACOL SCI, V38, P794, DOI 10.1016/j.tips.2017.06.001; Zhang JM, 2017, BBA-MOL BASIS DIS, V1863, P129, DOI 10.1016/j.bbadis.2016.10.019	46	6	6	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5236	5246		10.1038/s41388-021-01924-0	http://dx.doi.org/10.1038/s41388-021-01924-0		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34239044	Green Accepted			2022-12-17	WOS:000670851600001
J	Kaida, A; Yamamoto, S; Parrales, A; Young, ED; Ranjan, A; Alalem, MA; Morita, K; Oikawa, Y; Harada, H; Ikeda, T; Thomas, SM; Diaz, FJ; Iwakuma, T				Kaida, Atsushi; Yamamoto, Satomi; Parrales, Alejandro; Young, Eric D.; Ranjan, Atul; Alalem, Mohamed A.; Morita, Kei-ichi; Oikawa, Yu; Harada, Hiroyuki; Ikeda, Tohru; Thomas, Sufi M.; Diaz, Francisco J.; Iwakuma, Tomoo			DNAJA1 promotes cancer metastasis through interaction with mutant p53	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; TP53 MUTATIONS; HEAD; IDENTIFICATION; ARCHITECTURE; PROGRESSION; CHAPERONES; DISEASE	Accumulation of mutant p53 (mutp53) is crucial for its oncogenic gain of function activity. DNAJA1, a member of J-domain containing proteins or heat shock protein 40, is shown to prevent unfolded mutp53 from proteasomal degradation. However, the biological function of DNAJA1 remains largely unknown. Here we show that DNAJA1 promotes tumor metastasis by accumulating unfolded mutp53. Levels of DNAJA1 in head and neck squamous cell carcinoma (HNSCC) tissues were higher than those in normal tissues. Knockdown of DNAJA1 in HNSCC cell lines carrying unfolded mutp53 significantly decreased the levels of mutp53, filopodia/lamellipodia formation, migratory potential, and active forms of CDC42/RAC1, which were not observed in HNSCC cells with DNA contact mutp53, wild-type p53, or p53 null. Such mutp53-dependent functions of DNAJA1 were supported by the observation that DNAJA1 selectively bound to unfolded mutp53. Moreover, DNAJA1 knockdown in HNSCC cells carrying unfolded mutp53 inhibited primary tumor growth and metastases to the lymph nodes and lungs. Our study suggests that DNAJA1 promotes HNSCC metastasis mainly in a manner dependent on mutp53 status, suggesting DNAJA1 as a potential therapeutic target for HNSCC harboring unfolded mutp53.	[Kaida, Atsushi; Yamamoto, Satomi; Parrales, Alejandro; Young, Eric D.; Ranjan, Atul; Iwakuma, Tomoo] Univ Kansas, Med Ctr, Dept Canc Biol, Lawrence, KS 66045 USA; [Kaida, Atsushi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Radiat Oncol, Tokyo, Japan; [Parrales, Alejandro; Ranjan, Atul; Alalem, Mohamed A.; Iwakuma, Tomoo] Childrens Mercy Res Inst, Dept Pediat, Kansas City, MO 64108 USA; [Morita, Kei-ichi] Grad Sch Med & Dent Sci, Dept Maxillofacial Surg, Tokyo, Japan; [Morita, Kei-ichi] Bioresource Res Ctr, Tokyo, Japan; [Oikawa, Yu; Harada, Hiroyuki] Grad Sch Med & Dent Sci, Dept Oral & Maxillofacial Surg, Tokyo, Japan; [Ikeda, Tohru] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Pathol, Tokyo, Japan; [Thomas, Sufi M.] Dept Otolaryngol Head & Neck Surg, Kansas City, KS USA; [Diaz, Francisco J.] Univ Kansas, Med Ctr, Dept Biostat & Data Sci, Kansas City, KS USA	University of Kansas; University of Kansas Medical Center; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); University of Kansas; University of Kansas Medical Center	Iwakuma, T (corresponding author), Univ Kansas, Med Ctr, Dept Canc Biol, Lawrence, KS 66045 USA.; Iwakuma, T (corresponding author), Childrens Mercy Res Inst, Dept Pediat, Kansas City, MO 64108 USA.	tiwakuma@cmh.edu	Thomas, Sufi Mary/AFR-1642-2022	Thomas, Sufi Mary/0000-0001-5370-0842; Young, Eric/0000-0002-0014-1482	NIH [R01 CA174735, R01 CA214916, P30 CA168524]; Braden's Hope For Childhood Cancer; Masonic Cancer Alliance	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Braden's Hope For Childhood Cancer; Masonic Cancer Alliance	We thank Elizabeth Thoenen for technical assistance, helpful discussion, and editing of the manuscript, as well as Dr. Kei Sakamoto for tumor specimen collection. This study is supported by NIH R01 CA174735 (TI), R01 CA214916 (TI), Braden's Hope For Childhood Cancer (TI), Masonic Cancer Alliance (TI), and NIH P30 CA168524 (RAJ).	Ahn BY, 2010, ONCOGENE, V29, P1155, DOI 10.1038/onc.2009.413; Chen CY, 2013, CANCER RES, V73, P4009, DOI 10.1158/0008-5472.CAN-12-4066; Chen CY, 2009, J PATHOL, V219, P347, DOI 10.1002/path.2604; Chen JS, 2001, BLOOD, V97, P2115, DOI 10.1182/blood.V97.7.2115; Chen KY, 2021, CANCERS, V13, DOI 10.3390/cancers13010138; Cyr Douglas M, 2015, Subcell Biochem, V78, P91, DOI 10.1007/978-3-319-11731-7_4; Ergulen E, 2016, BIOCHEM J, V473, P3889, DOI 10.1042/BCJ20160440; Escoll M, 2017, ONCOGENE, V36, P3515, DOI 10.1038/onc.2016.518; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317; He HL, 2015, EXP MOL PATHOL, V98, P338, DOI 10.1016/j.yexmp.2015.03.029; Iyer SV, 2016, ONCOTARGET, V7, P5401, DOI 10.18632/oncotarget.6634; Kampinga HH, 2010, NAT REV MOL CELL BIO, V11, P579, DOI 10.1038/nrm2941; Large AT, 2009, BIOCHEM SOC T, V37, P46, DOI 10.1042/BST0370046; Liu TT, 2012, ONCOL LETT, V4, P1274, DOI 10.3892/ol.2012.903; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Nishizawa S, 2012, CANCER RES, V72, P2844, DOI 10.1158/0008-5472.CAN-11-3062; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Parrales A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194224; Parrales A, 2018, CELL DEATH DIFFER, V25, P460, DOI 10.1038/s41418-017-0026-y; Parrales A, 2016, NAT CELL BIOL, V18, P1233, DOI 10.1038/ncb3427; Parrales A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00288; Peltonen JK, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-36; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Sakabe M, 2017, P NATL ACAD SCI USA, V114, P10918, DOI 10.1073/pnas.1704030114; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tracz-Gaszewska Z, 2017, ONCOTARGET, V8, P82123, DOI 10.18632/oncotarget.18899; Uno Y, 2019, ANN SURG ONCOL, V26, P836, DOI 10.1245/s10434-018-07149-y; VOJTESEK B, 1995, ONCOGENE, V10, P389; Walerych D, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00289; Xu DD, 2019, MOL CARCINOGEN, V58, P2052, DOI 10.1002/mc.23097; Yang SS, 2020, ONCOGENE, V39, P249, DOI 10.1038/s41388-019-0978-0; Yang T, 2014, BIOCHEM BIOPH RES CO, V455, P298, DOI 10.1016/j.bbrc.2014.11.011; Yue XT, 2017, GENE DEV, V31, P1641, DOI 10.1101/gad.301564.117; Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592	40	6	6	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2021	40	31					5013	5025		10.1038/s41388-021-01921-3	http://dx.doi.org/10.1038/s41388-021-01921-3		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV5MG	34183772	Green Accepted			2022-12-17	WOS:000667587200003
J	Liang, SK; Hsu, CC; Song, HL; Huang, YC; Kuo, CW; Yao, X; Li, CC; Yang, HC; Hung, YL; Chao, SY; Wu, SC; Tsai, FR; Chen, JK; Liao, WN; Cheng, SC; Tsou, TC; Wang, IC				Liang, Sheng-Kai; Hsu, Chia-Chan; Song, Hsiang-Lin; Huang, Yu-Chi; Kuo, Chun-Wei; Yao, Xiang; Li, Chien-Cheng; Yang, Hui-Chen; Hung, Yu-Ling; Chao, Sheng-Yang; Wu, Shun-Chi; Tsai, Feng-Ren; Chen, Jen-Kun; Liao, Wei-Neng; Cheng, Shin-Chin; Tsou, Tsui-Chun; Wang, I-Ching			FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis	ONCOGENE			English	Article							M1 TRANSCRIPTION FACTOR; PROGRESSION; EXPRESSION; BORTEZOMIB; INITIATION; INDUCTION; LANDSCAPE; SURVIVAL; TARGET; GENES	Small cell lung cancer (SCLC) continues to cause poor clinical outcomes due to limited advances in sustained treatments for rapid cancer cell proliferation and progression. The transcriptional factor Forkhead Box M1 (FOXM1) regulates cell proliferation, tumor initiation, and progression in multiple cancer types. However, its biological function and clinical significance in SCLC remain unestablished. Analysis of the Cancer Cell Line Encyclopedia and SCLC datasets in the present study disclosed significant upregulation of FOXM1 mRNA in SCLC cell lines and tissues. Gene set enrichment analysis (GSEA) revealed that FOXM1 is positively correlated with pathways regulating cell proliferation and DNA damage repair, as evident from sensitization of FOXM1-depleted SCLC cells to chemotherapy. Furthermore, Foxm1 knockout inhibited SCLC formation in the Rb1(fl/fl)Trp53(fl/fl)Myc(LSL/LSL) (RPM) mouse model associated with increased levels of neuroendocrine markers, Ascl1 and Cgrp, and decrease in Yap1. Consistently, FOXM1 depletion in NCI-H1688 SCLC cells reduced migration and enhanced apoptosis and sensitivity to cisplatin and etoposide. SCLC with high FOXM1 expression (N = 30, 57.7%) was significantly correlated with advanced clinical stage, extrathoracic metastases, and decrease in overall survival (OS), compared with the low-FOXM1 group (7.90 vs. 12.46 months). Moreover, the high-FOXM1 group showed shorter progression-free survival after standard chemotherapy, compared with the low-FOXM1 group (3.90 vs. 8.69 months). Our collective findings support the utility of FOXM1 as a prognostic biomarker and potential molecular target for SCLC.	[Liang, Sheng-Kai; Yang, Hui-Chen] Natl Taiwan Univ Hosp, Dept Internal Med, Hsinchu Branch, Hsinchu 300, Taiwan; [Liang, Sheng-Kai; Hsu, Chia-Chan; Huang, Yu-Chi; Yao, Xiang; Li, Chien-Cheng; Hung, Yu-Ling; Chao, Sheng-Yang; Wang, I-Ching] Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 300, Taiwan; [Song, Hsiang-Lin; Kuo, Chun-Wei] Natl Taiwan Univ Hosp, Dept Pathol, Hsinchu Branch, Hsinchu, Taiwan; [Huang, Yu-Chi; Hung, Yu-Ling; Wang, I-Ching] Natl Tsing Hua Univ, Train Res Ctr, Hsinchu 300, Taiwan; [Wu, Shun-Chi; Tsai, Feng-Ren] Natl Tsing Hua Univ, Dept Engn & Syst Sci, Hsinchu 300, Taiwan; [Chen, Jen-Kun; Liao, Wei-Neng] Natl Hlth Res Inst, Inst Biomed Engn & Nanomed, Miaoli 350, Taiwan; [Cheng, Shin-Chin] Xiamen Univ, Sch Life Sci, Xiamen 361102, Fujian, Peoples R China; [Tsou, Tsui-Chun] Natl Hlth Res Inst, Natl Inst Environm Hlth Sci, Miaoli 350, Taiwan; [Wang, I-Ching] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; National Taiwan University; National Taiwan University Hospital; National Tsing Hua University; National Tsing Hua University; National Health Research Institutes - Taiwan; Xiamen University; National Health Research Institutes - Taiwan; National Tsing Hua University	Wang, IC (corresponding author), Natl Tsing Hua Univ, Inst Biotechnol, Hsinchu 300, Taiwan.; Wang, IC (corresponding author), Natl Tsing Hua Univ, Train Res Ctr, Hsinchu 300, Taiwan.; Wang, IC (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan.	icwang@life.nthu.edu.tw	; CHENG, SHIH-CHIN/H-4567-2015	LIANG, SHENG-KAI/0000-0003-3486-2293; CHENG, SHIH-CHIN/0000-0003-1251-8774; Wang, I-Ching/0000-0003-4398-2975; Liao, WEI NENG/0000-0002-1857-741X; SONG, HSIANG-LIN/0000-0002-8720-6436	NHRI Laboratory Animal Center [LA-109-PP-01]; National Taiwan University Hospital Hsinchu Branch research grant [NTUH-HC 108-s267]; Ministry of Science and Technology of Taiwan grant [MOST105-2628-B-007-003-MY3, MOST109-2314-B-007-005-MY3]; National Tsing Hua University [108Q2502E1, 109Q2714E1, 110Q2501E1]; Brain Research Center under the Higher Education Sprout Project; Ministry of Education in Taiwan; Ministry of Science and Technology in Taiwan	NHRI Laboratory Animal Center; National Taiwan University Hospital Hsinchu Branch research grant; Ministry of Science and Technology of Taiwan grant; National Tsing Hua University; Brain Research Center under the Higher Education Sprout Project; Ministry of Education in Taiwan(Ministry of Education, Taiwan); Ministry of Science and Technology in Taiwan(Ministry of Science and Technology, Taiwan)	We thank all study participants and staff at NTUH-HC for their contribution to this project, Feng-Yuan Tsai (NHRI), and NHRI Laboratory Animal Center (LA-109-PP-01), and I-BEN Service (TSSI-BN-31) for technical assistance, Stephen Elledge (Harvard Medical School) for kindly providing the pInducer10-mir-RUP-PheS plasmid, Pradip Raychaudhuri (UIC) and Vladimir Kalinichenko (CCHMC) for kindly providing the Foxm1fl/ fl mice. This work was supported by the National Taiwan University Hospital Hsinchu Branch research grant NTUH-HC 108-s267 (S-K L), the Ministry of Science and Technology of Taiwan grant MOST105-2628-B-007-003-MY3 and MOST109-2314-B-007-005-MY3 (I-C W), National Tsing Hua University grant 108Q2502E1, 109Q2714E1, 110Q2501E1 (I-C W), and by the Brain Research Center under the Higher Education Sprout Project, co-funded by the Ministry of Education and the Ministry of Science and Technology in Taiwan.	Alexandrov LB, 2016, SCIENCE, V354, P618, DOI 10.1126/science.aag0299; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; BHAT UG, 2009, PLOS ONE, V4; Borromeo MD, 2016, CELL REP, V16, P1259, DOI 10.1016/j.celrep.2016.06.081; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Dammert MA., 2019, NAT COMMUN, V10; Davies AM, 2007, CLIN CANCER RES, V13, p4647S, DOI 10.1158/1078-0432.CCR-07-0334; de Moraes GN, 2015, CELL SIGNAL, V27, P2496, DOI 10.1016/j.cellsig.2015.09.013; Fang PP, 2018, MOL CANCER RES, V16, P961, DOI 10.1158/1541-7786.MCR-17-0607; Gardner EE, 2017, CANCER CELL, V31, P286, DOI 10.1016/j.ccell.2017.01.006; Gartel AL, 2010, EXPERT OPIN INV DRUG, V19, P235, DOI 10.1517/13543780903563364; Gemenetzidis E, 2010, CANCER RES, V70, P9515, DOI 10.1158/0008-5472.CAN-10-2173; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1; Jiang LY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005895; Kalemkerian GP, 2013, J NATL COMPR CANC NE, V11, P78, DOI 10.6004/jnccn.2013.0011; Karachaliou N, 2013, TRANSL LUNG CANCER R, V2, P172, DOI 10.3978/j.issn.2218-6751.2013.01.01; KARIM S, 2012, ONCOL REV, V6; Keenan AB, 2019, NUCLEIC ACIDS RES, V47, pW212, DOI 10.1093/nar/gkz446; Kim SH, 2015, STEM CELL REP, V4, P226, DOI 10.1016/j.stemcr.2014.12.006; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; McColl K, 2017, ONCOTARGET, V8, P73745, DOI 10.18632/oncotarget.20572; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Nicholson AG, 2016, J THORAC ONCOL, V11, P300, DOI 10.1016/j.jtho.2015.10.008; Okada K, 2013, ANN SURG ONCOL, V20, P1035, DOI 10.1245/s10434-012-2680-0; Pal S, 2018, CANCER RES, V78, P4007, DOI 10.1158/0008-5472.CAN-17-3691; PAN C, 2016, BMC CANCER, V16; Pandit B, 2009, CELL CYCLE, V8, P3425, DOI 10.4161/cc.8.20.9628; Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911; Semenova EA, 2015, GENE DEV, V29, P1447, DOI 10.1101/gad.263145.115; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; Taromi S, 2017, ONCOTARGET, V8, P97061, DOI 10.18632/oncotarget.21221; Ustiyan V, 2012, DEV BIOL, V370, P198, DOI 10.1016/j.ydbio.2012.07.028; vanDiest PJ, 1997, J CLIN PATHOL, V50, P801, DOI 10.1136/jcp.50.10.801; Varemo L, 2013, NUCLEIC ACIDS RES, V41, P4378, DOI 10.1093/nar/gkt111; Wang IC, 2008, ONCOGENE, V27, P4137, DOI 10.1038/onc.2008.60; Wang IC, 2014, ONCOGENE, V33, P5391, DOI 10.1038/onc.2013.475; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang ZB, 2011, CANCER RES, V71, P4292, DOI 10.1158/0008-5472.CAN-10-4087; Wierstra I, 2006, FEBS J, V273, P4645, DOI 10.1111/j.1742-4658.2006.05468.x	57	6	6	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4847	4858		10.1038/s41388-021-01895-2	http://dx.doi.org/10.1038/s41388-021-01895-2		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34155349				2022-12-17	WOS:000664006700004
J	Xu, F; Jiang, LY; Zhao, QW; Zhang, ZBA; Liu, YX; Yang, SS; Yu, MD; Chen, HP; Zhang, JY; Zhang, JT				Xu, Fang; Jiang, Liya; Zhao, Qianwei; Zhang, Zhibiao; Liu, Yixian; Yang, Shuangshuang; Yu, Mengdan; Chen, Huiping; Zhang, Jianying; Zhang, Jintao			Whole-transcriptome and proteome analyses identify key differentially expressed mRNAs, miRNAs, lncRNAs and circRNAs associated with HCC	ONCOGENE			English	Article							LONG NONCODING RNAS; LIVER-CANCER CELL; HEPATOCELLULAR-CARCINOMA; BIG DATA; ROLES; RISK	Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer and one of the leading causes of cancer-related death worldwide. To gain more insights into the transcriptomic landscape and molecular mechanism of HCC, we performed TMT-labelled tandem mass spectrometry (n = 4) and whole-transcriptome sequencing (n = 3) based on HCC tumour (T) and adjacent normal (N) tissues from seven HCC patients. To comprehensively evaluate the gene-regulatory circuits in HCC, differential expression and enrichment analyses were performed on the differentially expressed proteins (DEPs), genes (DEGs), miRNAs (555), lncRNAs (29) and circRNAs (895). A total of 977 proteins and 243 genes were found to be differentially expressed in HCC tumours compared with adjacent normal tissues. HCC data from The Cancer Genome Atlas were used to validate the results. Combined with the results above, 56 DEP-DEGs with common changes in relative quantity were identified. Functional pathway analysis showed that the DEP-DEGs were mainly enriched in the spliceosome and various metabolic processes. Bioinformatics analysis showed that hsa-miR-1266-5p, hsa-miR-128-1-5p, hsa-miR-139-5p, hsa-miR-34b-3p and hsa-miR-570-3p were involved in the regulation of the hub genes mentioned above. The crucial coexpression (lncRNA-mRNA, circRNA-mRNA) and competing endogenous RNA interaction axes showed the possible functions of the lncRNAs and circRNAs. We explored potential cancer biomarkers by combining proteomic and transcriptomic studies. Our study provides a valuable resource for understanding regulatory mechanisms at the RNA level and may ultimately further assist in the development of diagnostic and/or therapeutic targets for HCC.	[Xu, Fang; Jiang, Liya; Zhao, Qianwei; Liu, Yixian; Yang, Shuangshuang; Chen, Huiping; Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, Henan Inst Med & Pharmaceut Sci, Zhengzhou, Peoples R China; [Xu, Fang; Jiang, Liya; Zhao, Qianwei; Liu, Yixian; Yang, Shuangshuang; Chen, Huiping; Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, BGI Coll, Zhengzhou, Peoples R China; [Jiang, Liya; Zhang, Zhibiao] Zhengzhou Univ, Sch Life Sci, Zhengzhou, Peoples R China; [Yu, Mengdan] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou, Peoples R China; [Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, Henan Key Lab Tumor Epidemiol, Zhengzhou, Peoples R China; [Zhang, Jianying; Zhang, Jintao] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University; Zhengzhou University	Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, Henan Inst Med & Pharmaceut Sci, Zhengzhou, Peoples R China.; Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, BGI Coll, Zhengzhou, Peoples R China.; Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, Henan Key Lab Tumor Epidemiol, Zhengzhou, Peoples R China.; Zhang, JY; Zhang, JT (corresponding author), Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Peoples R China.	jianyingzhang@hotmail.com; zhangjt_66@126.com		Xu, Fang/0000-0002-5722-0798	Natural Science Foundation of Henan Province [182300410361]; Major Project of Science and Technology in Henan Province [161100311400]; National Science and Technology Major Project of China [2018ZX10302205]; Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences [2020BP0107, 2020BP0111]; Zhengzhou Major Project for Collaborative Innovation [18XTZX12007]; Key Scientific and Technological Project of Henan Province [212102310124]	Natural Science Foundation of Henan Province; Major Project of Science and Technology in Henan Province; National Science and Technology Major Project of China; Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences; Zhengzhou Major Project for Collaborative Innovation; Key Scientific and Technological Project of Henan Province	We gratefully acknowledge Henan Key Laboratory of Pharmacology for Liver Diseases for providing experimental platform support. We thank Dr. Jianxiang Shi for assistance in bioinformatic analysis. This work was supported by grants from Natural Science Foundation of Henan Province (No. 182300410361); the Major Project of Science and Technology in Henan Province (No. 161100311400); the National Science and Technology Major Project of China (No. 2018ZX10302205); Project of Basic Research Fund of Henan Institute of Medical and Pharmacological Sciences (No. 2020BP0107; No. 2020BP0111); Zhengzhou Major Project for Collaborative Innovation (18XTZX12007) and The Key Scientific and Technological Project of Henan Province (No. 212102310124).	Alqahtani A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090526; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen B, 2016, CLIN PHARMACOL THER, V99, P285, DOI 10.1002/cpt.318; Chen SZ, 2019, CANCER LETT, V460, P1, DOI 10.1016/j.canlet.2019.114428; Chen TC, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008346; Chen XJ, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010066; Dhanasekaran R, 2019, GASTROENTEROLOGY, V156, P492, DOI 10.1053/j.gastro.2018.11.001; DiStefano JK, 2019, CANCERS, V11, DOI 10.3390/cancers11040486; Dragomir MP, 2020, GUT, V69, P748, DOI 10.1136/gutjnl-2019-318279; Du ZH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72510-9; El Khodiry A, 2018, WORLD J GASTROENTERO, V24, P549, DOI 10.3748/wjg.v24.i5.549; Fu J, 2018, CANCER LETT, V412, P283, DOI 10.1016/j.canlet.2017.10.008; Fujiwara N, 2018, J HEPATOL, V68, P526, DOI 10.1016/j.jhep.2017.09.016; He J, 2019, CANCER LETT, V450, P98, DOI 10.1016/j.canlet.2019.02.033; Henley SJ, 2020, CANCER-AM CANCER SOC, V126, P2225, DOI 10.1002/cncr.32802; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01188-4; Jiang Y, 2019, NATURE, V567, P257, DOI 10.1038/s41586-019-0987-8; Kim YA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082883; Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978-1-60761-987-1_18; Kong S, 2020, CANCER LETT, V483, P59, DOI 10.1016/j.canlet.2020.04.006; Lanzafame M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030682; Li L, 2016, CANCER LETT, V379, P191, DOI 10.1016/j.canlet.2015.07.018; Lim LJ, 2019, CANCER RES, V79, P5131, DOI 10.1158/0008-5472.CAN-19-0255; Lin YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123742; Liu YX, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12378; Llovet JM, 2018, NAT REV CLIN ONCOL, V15, P599, DOI 10.1038/s41571-018-0073-4; Mahipal A, 2019, MOL TRANSL MED, P225, DOI 10.1007/978-3-030-21540-8_11; Mahpour A, 2021, JHEP REP, V3, DOI 10.1016/j.jhepr.2020.100177; Nekvindova J, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113912; Niu ZS, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i29.4240; Sasaki R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061406; Shi J, 2019, J CANCER, V10, P4892, DOI 10.7150/jca.32768; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Tseng CS, 2005, AM J GASTROENTEROL, V100, P1758, DOI 10.1111/j.1572-0241.2005.41857.x; Umeda S, 2019, EXPERT REV MOL DIAGN, V19, P725, DOI 10.1080/14737159.2019.1638254; Wei L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1086-z; Wooden B, 2017, GASTROENTEROLOGY, V152, P53, DOI 10.1053/j.gastro.2016.09.065; Xu G, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01581-5; Yan TM, 2015, PHARM RES-DORDR, V32, P1141, DOI 10.1007/s11095-014-1525-x; Ye X, 2019, HEPATOLOGY, V69, P2489, DOI 10.1002/hep.30519; Yin YT, 2019, J CANCER, V10, P5015, DOI 10.7150/jca.30828; Yousry A, 2019, SEMIN LIVER DIS, V39, P463, DOI 10.1055/s-0039-1688442; Zhang H, 2020, INT J ONCOL, V56, P18, DOI 10.3892/ijo.2019.4909; Zhao QW, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.572663; Zhao YB, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108487	47	6	5	6	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2021	40	29					4820	4831		10.1038/s41388-021-01908-0	http://dx.doi.org/10.1038/s41388-021-01908-0		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR9TO	34155346				2022-12-17	WOS:000664006700003
J	Garcia-Navas, R; Liceras-Boillos, P; Gomez, C; Baltanas, FC; Calzada, N; Nuevo-Tapioles, C; Cuezva, JM; Santos, E				Garcia-Navas, Rosula; Liceras-Boillos, Pilar; Gomez, Carmela; Baltanas, Fernando C.; Calzada, Nuria; Nuevo-Tapioles, Cristina; Cuezva, Jose M.; Santos, Eugenio			Critical requirement of SOS1 RAS-GEF function for mitochondrial dynamics, metabolism, and redox homeostasis	ONCOGENE			English	Article							OXIDATIVE STRESS; CELL-PROLIFERATION; ACTIVATION; FISSION; SUPEROXIDE; INDUCTION; PATHWAYS; CANCER; FUSION; MASS	SOS1 ablation causes specific defective phenotypes in MEFs including increased levels of intracellular ROS. We showed that the mitochondria-targeted antioxidant MitoTEMPO restores normal endogenous ROS levels, suggesting predominant involvement of mitochondria in generation of this defective SOS1-dependent phenotype. The absence of SOS1 caused specific alterations of mitochondrial shape, mass, and dynamics accompanied by higher percentage of dysfunctional mitochondria and lower rates of electron transport in comparison to WT or SOS2-KO counterparts. SOS1-deficient MEFs also exhibited specific alterations of respiratory complexes and their assembly into mitochondrial supercomplexes and consistently reduced rates of respiration, glycolysis, and ATP production, together with distinctive patterns of substrate preference for oxidative energy metabolism and dependence on glucose for survival. RASless cells showed defective respiratory/metabolic phenotypes reminiscent of those of SOS1-deficient MEFs, suggesting that the mitochondrial defects of these cells are mechanistically linked to the absence of SOS1-GEF activity on cellular RAS targets. Our observations provide a direct mechanistic link between SOS1 and control of cellular oxidative stress and suggest that SOS1-mediated RAS activation is required for correct mitochondrial dynamics and function.	[Garcia-Navas, Rosula; Liceras-Boillos, Pilar; Gomez, Carmela; Baltanas, Fernando C.; Calzada, Nuria; Santos, Eugenio] Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Salamanca, Spain; [Garcia-Navas, Rosula; Liceras-Boillos, Pilar; Gomez, Carmela; Baltanas, Fernando C.; Calzada, Nuria; Santos, Eugenio] Ctr Invest Biomed Red Canc Canc CIBERONC, Madrid, Spain; [Nuevo-Tapioles, Cristina; Cuezva, Jose M.] Univ Autonoma Madrid, Dept Biol Mol, Ctr Biol Mol Severo Ochoa3, CSIC, Madrid, Spain; [Nuevo-Tapioles, Cristina; Cuezva, Jose M.] Ctr Invest Biomed Red Canc Enfermedades Raras CIB, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Santos, E (corresponding author), Univ Salamanca, Ctr Invest Canc, Inst Biol Mol & Celular Canc, CSIC, Salamanca, Spain.; Santos, E (corresponding author), Ctr Invest Biomed Red Canc Canc CIBERONC, Madrid, Spain.	esantos@usal.es	Baltanas, Fernando C./D-4756-2018; Nuevo-Tapioles, Cristina/AAT-5772-2021; Nuevo-Tapioles, Cristina/F-5970-2016; Baltanas, Fernando C./AAU-7451-2021	Baltanas, Fernando C./0000-0001-8110-0991; Nuevo-Tapioles, Cristina/0000-0001-5809-2030; Baltanas, Fernando C./0000-0001-8110-0991; Cuezva Marcos, Jose Manuel/0000-0003-1118-248X; Santos, Eugenio/0000-0003-3565-0321	ISCIII-MCUI [FIS PI19/00934, CIBERONC-CB16/12/00352]; Junta de Castilla y Leon [SA264P18-UIC 076]; Ramon Areces Foundation [CIVP19A5942]; FEDER funds	ISCIII-MCUI; Junta de Castilla y Leon(Junta de Castilla y Leon); Ramon Areces Foundation; FEDER funds(European Commission)	This work was supported by grants from ISCIII-MCUI (FIS PI19/00934 and CIBERONC-CB16/12/00352), Junta de Castilla y Leon (SA264P18-UIC 076), and Ramon Areces Foundation (CIVP19A5942). The research was co-financed by FEDER funds.	Amendola CR, 2019, NATURE, V576, P482, DOI 10.1038/s41586-019-1832-9; Amer YO, 2018, BBA-BIOENERGETICS, V1859, P868, DOI 10.1016/j.bbabio.2018.04.005; Enriquez JA, 2016, ANNU REV PHYSIOL, V78, P533, DOI 10.1146/annurev-physiol-021115-105031; Apostolova N, 2010, BRIT J PHARMACOL, V160, P2069, DOI 10.1111/j.1476-5381.2010.00866.x; Azrak SS, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-731; Babu D, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00031; Baker N, 2019, MITOCHONDRION, V49, P259, DOI 10.1016/j.mito.2019.06.003; Baltanas FC, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188445; Baltanas FC, 2013, MOL CELL BIOL, V33, P4562, DOI 10.1128/MCB.01026-13; Bandaru P, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a031534; Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Bartolini D, 2015, FREE RADICAL BIO MED, V88, P466, DOI 10.1016/j.freeradbiomed.2015.06.039; Brand MD, 2004, FREE RADICAL BIO MED, V37, P755, DOI 10.1016/j.freeradbiomed.2004.05.034; Buday L, 2008, BBA-REV CANCER, V1786, P178, DOI 10.1016/j.bbcan.2008.05.001; Byun JK, 2019, EMBO REP, V20, DOI 10.15252/embr.201847451; Caruana NJ, 2020, BIOCHEM SOC T, V48, P621, DOI 10.1042/BST20190930; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Cuezva JM, 2002, CANCER RES, V62, P6674; Demine S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080795; Ding S, 2020, BIOGENESIS NDUFS3 LE, DOI 10.22.350587; Dong J, 2008, ANTIOXID REDOX SIGN, V10, P2023, DOI 10.1089/ars.2007.2019; Drose S, 2012, ADV EXP MED BIOL, V748, P145, DOI 10.1007/978-1-4614-3573-0_6; Drosten M, 2014, P NATL ACAD SCI USA, V111, P15155, DOI 10.1073/pnas.1417549111; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Dudkina NV, 2010, BBA-BIOENERGETICS, V1797, P664, DOI 10.1016/j.bbabio.2009.12.013; Esteban LM, 2000, MOL CELL BIOL, V20, P6410, DOI 10.1128/MCB.20.17.6410-6413.2000; Gerboth S, 2018, LEUKEMIA, V32, P820, DOI 10.1038/leu.2017.267; Guo RY, 2018, BIOMED J, V41, P9, DOI 10.1016/j.bj.2017.12.001; Hong YA, 2018, ANTIOXID REDOX SIGN, V28, P1543, DOI 10.1089/ars.2017.7207; Iershov A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09598-9; Jha Pooja, 2016, Curr Protoc Mouse Biol, V6, P1, DOI 10.1002/9780470942390.mo150182; Kim H, 1999, J AM CHEM SOC, V121, P4902, DOI 10.1021/ja990190h; Koeberle SC, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101388; Kortum RL, 2011, P NATL ACAD SCI USA, V108, P12407, DOI 10.1073/pnas.1104295108; Kunkel GH, 2016, HEART FAIL REV, V21, P499, DOI 10.1007/s10741-016-9561-8; Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1159/000064724; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lee YK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15061; Liang HL, 2010, FREE RADICAL BIO MED, V49, P1550, DOI 10.1016/j.freeradbiomed.2010.08.018; Liceras-Boillos P, 2016, ONCOGENE, V35, P6389, DOI 10.1038/onc.2016.169; Liceras-Boillos P, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00049-18; Liesa M, 2013, CELL METAB, V17, P491, DOI 10.1016/j.cmet.2013.03.002; Markevich NI, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.557721; Martinez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3; Maus M, 2017, CELL METAB, V25, P698, DOI 10.1016/j.cmet.2016.12.021; Mishra P, 2014, CELL METAB, V19, P630, DOI 10.1016/j.cmet.2014.03.011; Monteiro LD, 2020, METHODSX, V7, DOI 10.1016/j.mex.2020.100938; Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031; Nazarewicz RR, 2013, ANTIOXID REDOX SIGN, V19, P344, DOI 10.1089/ars.2013.5185; Ong SB, 2015, EUR J PHARMACOL, V763, P104, DOI 10.1016/j.ejphar.2015.04.056; Peng JY, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002212; Pernas L, 2016, ANNU REV PHYSIOL, V78, P505, DOI 10.1146/annurev-physiol-021115-105011; Pierre S, 2011, BIOCHEM PHARMACOL, V82, P1049, DOI 10.1016/j.bcp.2011.07.072; Qian XL, 2000, EMBO J, V19, P642, DOI 10.1093/emboj/19.4.642; Raghunath A, 2018, REDOX BIOL, V17, P297, DOI 10.1016/j.redox.2018.05.002; Ren Y, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2019.101154; Sanchez-Caballero L, 2016, BBA-BIOENERGETICS, V1857, P980, DOI 10.1016/j.bbabio.2016.03.031; Scarpulla RC, 2012, TRENDS ENDOCRIN MET, V23, P459, DOI 10.1016/j.tem.2012.06.006; Schrepfer E, 2016, MOL CELL, V61, P683, DOI 10.1016/j.molcel.2016.02.022; Semenza GL, 2017, EMBO J, V36, P252, DOI 10.15252/embj.201695204; Seo BJ, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101599; Serasinghe MN, 2017, HANDB EXP PHARMACOL, V240, P159, DOI 10.1007/164_2016_38; Seyfried TN, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101761; Son MJ, 2015, CELL DEATH DIFFER, V22, P1957, DOI 10.1038/cdd.2015.43; Suire S, 2019, J LEUKOCYTE BIOL, V106, P815, DOI 10.1002/JLB.2HI0918-359RR; Tan ZQ, 2016, MOL CANCER THER, V15, P774, DOI 10.1158/1535-7163.MCT-15-0621; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Toma-Fukai S, 2019, MOLECULES, V24, DOI 10.3390/molecules24183308; Valvona CJ, 2016, BRAIN PATHOL, V26, P3, DOI 10.1111/bpa.12299; Villena JA, 2015, FEBS J, V282, P647, DOI 10.1111/febs.13175; Vogel RO, 2007, J BIOL CHEM, V282, P7582, DOI 10.1074/jbc.M609410200; Wang DW, 2020, J CANCER, V11, P5042, DOI 10.7150/jca.45553; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Wong GS, 2018, NAT MED, V24, P968, DOI 10.1038/s41591-018-0022-x; You XN, 2018, BLOOD, V132, P2575, DOI 10.1182/blood-2018-09-874107; Young TW, 2004, CANCER RES, V64, P4577, DOI 10.1158/0008-5472.CAN-04-0222; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; Zanotti F, 2009, BIOCHEM BIOPH RES CO, V384, P43, DOI 10.1016/j.bbrc.2009.04.046; Zarich N, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-018-0111-1; Zhang Z, 2020, BRIT J CANCER, V122, P209, DOI 10.1038/s41416-019-0658-4	80	6	6	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4538	4551		10.1038/s41388-021-01886-3	http://dx.doi.org/10.1038/s41388-021-01886-3		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34120142	hybrid, Green Published			2022-12-17	WOS:000660811300001
J	Truong, TH; Benner, EA; Hagen, KM; Temiz, NA; Kerkvliet, CP; Wang, Y; Cortes-Sanchez, E; Yang, CH; Pengo, T; Guillen, KP; Welm, BE; Telang, S; Lange, CA; Ostrander, JH; Trousdell, MC; Camila				Truong, Thu H.; Benner, Elizabeth A.; Hagen, Kyla M.; Temiz, Nuri A.; Kerkvliet, Carlos Perez; Wang, Ying; Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Pengo, Thomas; Guillen, Katrin P.; Welm, Bryan E.; Telang, Sucheta; Lange, Carol A.; Ostrander, Julie H.; Trousdell, Marygrace C.; Camila			PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer	ONCOGENE			English	Article							STEM-CELL MARKERS; COACTIVATOR; RECEPTOR; PELP1; AIB1; INHIBITOR; PATHWAY; PFK-158; GROWTH; SRC-3	Recurrence of metastatic breast cancer stemming from acquired endocrine and chemotherapy resistance remains a health burden for women with luminal (ER+) breast cancer. Disseminated ER+ tumor cells can remain viable but quiescent for years to decades. Contributing factors to metastatic spread include the maintenance and expansion of breast cancer stem cells (CSCs). Breast CSCs frequently exist as a minority population in therapy resistant tumors. In this study, we show that cytoplasmic complexes composed of steroid receptor (SR) co-activators, PELP1 and SRC-3, modulate breast CSC expansion through upregulation of the HIF-activated metabolic target genes PFKFB3 and PFKFB4. Seahorse metabolic assays demonstrated that cytoplasmic PELP1 influences cellular metabolism by increasing both glycolysis and mitochondrial respiration. PELP1 interacts with PFKFB3 and PFKFB4 proteins, and inhibition of PFKFB3 and PFKFB4 kinase activity blocks PELP1-induced tumorspheres and protein-protein interactions with SRC-3. PFKFB4 knockdown inhibited in vivo emergence of circulating tumor cell (CTC) populations in mammary intraductal (MIND) models. Application of PFKFB inhibitors in combination with ER targeted therapies blocked tumorsphere formation in multiple models of advanced breast cancer including tamoxifen (TamR) and paclitaxel (TaxR) resistant models, murine tumor cells, and ER+ patient-derived organoids (PDxO). Together, our data suggest that PELP1, SRC-3, and PFKFBs cooperate to drive ER+ tumor cell populations that include CSCs and CTCs. Identifying non-ER pharmacological targets offers a useful approach to blocking metastatic escape from standard of care ER/estrogen (E2)-targeted strategies to overcome endocrine and chemotherapy resistance.	[Truong, Thu H.; Benner, Elizabeth A.; Hagen, Kyla M.; Temiz, Nuri A.; Kerkvliet, Carlos Perez; Wang, Ying; Lange, Carol A.; Ostrander, Julie H.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA; [Temiz, Nuri A.] Univ Minnesota, Inst Hlth Informat, Minneapolis, MN USA; [Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Guillen, Katrin P.; Welm, Bryan E.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT USA; [Cortes-Sanchez, Emilio; Yang, Chieh-Hsiang; Guillen, Katrin P.; Welm, Bryan E.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Trousdell, Marygrace C.; Camila] Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA; [Pengo, Thomas] Univ Minnesota, Informat Inst, Minneapolis, MN USA; [Welm, Bryan E.] Univ Utah, Dept Surg, Salt Lake City, UT USA; [Telang, Sucheta] Univ Louisville, Dept Med, James Graham Brown Canc Ctr, Div Med Oncol & Hematol, Louisville, KY 40292 USA; [Lange, Carol A.; Ostrander, Julie H.] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA; [Lange, Carol A.] Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Cold Spring Harbor Laboratory; University of Minnesota System; University of Minnesota Twin Cities; Utah System of Higher Education; University of Utah; University of Louisville; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Lange, CA; Ostrander, JH (corresponding author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.; Lange, CA; Ostrander, JH (corresponding author), Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA.; Lange, CA (corresponding author), Univ Minnesota, Dept Pharmacol, 3-249 Millard Hall, Minneapolis, MN 55455 USA.	lange047@umn.edu; hans1354@umn.edu	; Pengo, Thomas/D-5867-2013	Truong, Thu/0000-0003-2394-551X; Wang, Ying/0000-0001-9052-0023; Perez, Ph.D., Carlos/0000-0003-2530-840X; Pengo, Thomas/0000-0002-9632-918X; Trousdell, Marygrace/0000-0002-4824-7040	NIH [R01 CA236948, R01 CA229697, F32 CA210340, T32 HL007741, U54 CA224076, R01 CA248158-01, R01 AG069727-01]; ACS Institutional Research Grant [124166-IRG-58-001-52-IRG5]; University of Minnesota Masonic Cancer Center; Tickle Family Land Grant Endowed Chair in Breast Cancer Research; National Center for Advancing Translational Sciences of the NIH [UL1TR000114]; Department of Defense [W81XWH-14-1-0417]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS Institutional Research Grant; University of Minnesota Masonic Cancer Center; Tickle Family Land Grant Endowed Chair in Breast Cancer Research; National Center for Advancing Translational Sciences of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Department of Defense(United States Department of Defense)	This work was supported by NIH grants R01 CA236948 (JHO, CAL), R01 CA229697 (CAL), F32 CA210340 (THT), T32 HL007741 (THT), U54 CA224076 (BEW), R01 CA248158-01 (CODS), and R01 AG069727-01 (CODS). ACS Institutional Research Grant #124166-IRG-58-001-52-IRG5 (JHO), University of Minnesota Masonic Cancer Center (CAL, JHO), the Tickle Family Land Grant Endowed Chair in Breast Cancer Research (CAL), National Center for Advancing Translational Sciences of the NIH Award UL1TR000114 (JHO), and Department of Defense W81XWH-14-1-0417 (BEW). We thank Bruce Lindgren for biostatistics support, and the Masonic Cancer Center Biostatistics and Bioinformatics, Analytical Biochemistry, University Imaging Core (UIC), and Flow Cytometry cores. We also thank Zohar Sachs and Michael Franklin for critical reading of this manuscript.	Anderson TMR, 2018, MOL CANCER RES, V16, P1761, DOI 10.1158/1541-7786.MCR-18-0410; Anderson TMR, 2016, CANCER RES, V76, P1653, DOI 10.1158/0008-5472.CAN-15-2510; Banerjee Arindam, 2018, Oncotarget, V9, P23274, DOI 10.18632/oncotarget.25299; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bosco DB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128511; Burandt E, 2013, BREAST CANCER RES TR, V137, P745, DOI 10.1007/s10549-013-2406-4; Chesney J, 2014, ONCOTARGET, V5, P6670, DOI 10.18632/oncotarget.2213; Chu Z., 2021, BREAST CANC PATIENT, DOI [10.1101/2021.02.28.433268, DOI 10.1101/2021]; Dasgupta S, 2018, NATURE, V556, P249, DOI 10.1038/s41586-018-0018-1; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dwyer AR, 2021, BRIT J CANCER, V124, P217, DOI 10.1038/s41416-020-01094-y; Gao RF, 2018, THERANOSTICS, V8, P6248, DOI 10.7150/thno.28721; Giordano A, 2012, MOL CANCER THER, V11, P2526, DOI 10.1158/1535-7163.MCT-12-0460; Girard BJ, 2017, J BIOL CHEM, V292, P339, DOI 10.1074/jbc.M116.739847; Girard BJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121206; Girard BJ, 2014, MOL CELL ENDOCRINOL, V382, P642, DOI 10.1016/j.mce.2013.07.031; Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9; Imamura Y, 2015, ONCOL REP, V33, P1837, DOI 10.3892/or.2015.3767; Kilgour E, 2020, CANCER CELL, V37, P485, DOI 10.1016/j.ccell.2020.03.012; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Kumar R, 2009, CLIN CANCER RES, V15, P4123, DOI 10.1158/1078-0432.CCR-08-2347; Liu Y, 2014, BRIT J CANCER, V110, P2063, DOI 10.1038/bjc.2014.105; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868; Moore N, 2011, J ONCOL, V2011, DOI 10.1155/2011/396076; Nair BC, 2010, CANCER RES, V70, P7166, DOI 10.1158/0008-5472.CAN-10-0628; O'Neill S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39789-9; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Raj GV, 2017, ELIFE, V6, DOI 10.7554/eLife.26857; Ravindranathan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2912; Redman R, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-CT206; Rohira AD, 2017, CANCER RES, V77, P4293, DOI 10.1158/0008-5472.CAN-16-2982; Sflomos G, 2016, CANCER CELL, V29, P407, DOI 10.1016/j.ccell.2016.02.002; Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; Tasdemir N, 2018, CANCER RES, V78, P6209, DOI 10.1158/0008-5472.CAN-18-1416; Telang S, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.PANCA16-B90; Torres-Arzayus MI, 2006, CANCER RES, V66, P11381, DOI 10.1158/0008-5472.CAN-06-2316; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Truong TH, 2018, MOL CANCER RES, V16, P707, DOI 10.1158/1541-7786.MCR-17-0598; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Vlashi E, 2014, BREAST CANCER RES TR, V146, P525, DOI 10.1007/s10549-014-3051-2; Wang XQ, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-77; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yang YZ, 2018, HORM CANCER-US, V9, P371, DOI 10.1007/s12672-018-0343-8; Yao L, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0882-2	50	6	6	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4384	4397		10.1038/s41388-021-01871-w	http://dx.doi.org/10.1038/s41388-021-01871-w		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103681	Green Accepted			2022-12-17	WOS:000659032900004
J	Wang, XY; Dong, JN; Li, XJ; Cheng, ZN; Zhu, QB				Wang, Xueying; Dong, Jiani; Li, Xiaojing; Cheng, Zeneng; Zhu, Qubo			CPSF4 regulates circRNA formation and microRNA mediated gene silencing in hepatocellular carcinoma	ONCOGENE			English	Article							CIRCULAR RNAS; POLYADENYLATION; IDENTIFICATION; CLEAVAGE; GROWTH	CircRNAs play essential roles in various physiological processes and involves in many diseases, in particular cancer. Global downregulation of circRNA expression has been observed in hepatocellular carcinoma (HCC) in many studies. Previous studies revealed that the pre-mRNA 3 ' end processing complex participates in circRNA cyclization and plays an important role in HCC tumorigenesis. Therefore, we explored the role of CPSF4, for 3 ' end formation and cleavage, in circRNA formation. Clinical research has shown that CPSF4 expression is upregulated in HCC and that high expression of CPSF4 is associated with poor prognosis in HCC patients. Mechanistic studies have demonstrated that CPSF4 reduces the levels of circRNAs, which possess a polyadenylation signal sequence and this decrease in circRNAs reduces the accumulation of miRNA and disrupts the miRNA-mediated gene silencing in HCC. Experiments in cell culture and xenograft mouse models showed that CPSF4 promotes the proliferation of HCC cells and enhances tumorigenicity. Moreover, CPSF4 antagonizes the tumor suppressor effect of its downstream circRNA in HCC. In summary, CPSF4 acts as an oncogene in HCC through circRNA inhibition and disruption of miRNA-mediated gene silencing.	[Wang, Xueying; Dong, Jiani; Cheng, Zeneng; Zhu, Qubo] Cent South Univ, Xiangya Sch Pharmaceut Sci, Changsha 2, Peoples R China; [Li, Xiaojing] Shanghai Gen Hosp, Shanghai, Peoples R China		Zhu, QB (corresponding author), Cent South Univ, Xiangya Sch Pharmaceut Sci, Changsha 2, Peoples R China.	qubozhu@csu.edu.cn	Zhu, Qubo/ACT-7180-2022		National Natural Science Foundation of China [C0709-31201056]; Hunan Provincial Natural Science Foundation of China [2018JJ2493]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hunan Provincial Natural Science Foundation of China(Natural Science Foundation of Hunan Province)	This work was supported by the National Natural Science Foundation of China (C0709-31201056) and the Hunan Provincial Natural Science Foundation of China (2018JJ2493).	Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Bezzi M, 2017, CELL RES, V27, P1401, DOI 10.1038/cr.2017.136; Chan SL, 2014, GENE DEV, V28, P2370, DOI 10.1101/gad.250993.114; Chang CC, 2016, BIOSENS BIOELECTRON, V78, P200, DOI 10.1016/j.bios.2015.11.051; Chen Q, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152872; Clerici M, 2017, ELIFE, V6, DOI 10.7554/eLife.33111; Ding JY, 2019, BIOL CHEM, V400, P247, DOI 10.1515/hsz-2018-0232; Ebermann Constanze, 2020, F1000Res, V9, DOI 10.12688/f1000research.25060.1; Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881; Greene J, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00038; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Li XJ, 2020, ONCOGENE, V39, P891, DOI 10.1038/s41388-019-1030-0; Liang DM, 2017, MOL CELL, V68, P940, DOI 10.1016/j.molcel.2017.10.034; Lin XM, 2018, MED SCI MONIT BASIC, V24, P70, DOI 10.12659/MSMBR.909737; Liu SY, 2019, BMC CANCER, V19, P1; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Meng XW, 2017, BIOINFORMATICS, V33, P3314, DOI 10.1093/bioinformatics/btx446; Misra A, 2016, RNA BIOL, V13, P259, DOI 10.1080/15476286.2015.1112490; Misra A, 2015, MOL CELL, V58, P819, DOI 10.1016/j.molcel.2015.03.016; Noble CG, 2007, NUCLEIC ACIDS RES, V35, P87, DOI 10.1093/nar/gkl1010; Qiu LP, 2019, LIFE SCI, V231, DOI 10.1016/j.lfs.2019.116660; Qu SB, 2017, RNA BIOL, V14, P992, DOI 10.1080/15476286.2016.1220473; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Song CL, 2019, J CELL PHYSIOL, V234, P2460, DOI 10.1002/jcp.26764; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Tan S, 2018, ONCOGENE, V37, P4887, DOI 10.1038/s41388-018-0280-6; Trifonov A, 2016, J PHYS CHEM C, V120, P15743, DOI 10.1021/acs.jpcc.5b11308; Wang ZL, 2013, GLAND SURG, V2, P25, DOI 10.3978/j.issn.2227-684X.2013.02.07; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Wu BW, 2020, J CANCER, V11, P5727, DOI 10.7150/jca.46554; Wu JR, 2019, BIOCHEM CELL BIOL, V97, P722, DOI 10.1139/bcb-2019-0008; Xu S, 2018, PEERJ, V6, DOI 10.7717/peerj.5503; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yang Q, 2019, BBA-MOL CELL RES, V1866, P1533, DOI 10.1016/j.bbamcr.2019.07.001; Yi CH, 2016, CANCER LETT, V381, P1, DOI 10.1016/j.canlet.2016.07.016; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zhang H, 2015, CANCER LETT, V367, P49, DOI 10.1016/j.canlet.2015.07.010; Zhang XW, 2018, ONCOTARGETS THER, V11, P2853, DOI 10.2147/OTT.S158008; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8	44	6	6	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4338	4351		10.1038/s41388-021-01867-6	http://dx.doi.org/10.1038/s41388-021-01867-6		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103682				2022-12-17	WOS:000659032900002
J	Qiao, YN; Jin, T; Guan, SD; Cheng, SJ; Wen, SY; Zeng, H; Zhao, MJ; Yang, LP; Wan, XY; Qiu, YX; Li, Q; Liu, MR; Hou, YX				Qiao, Yina; Jin, Ting; Guan, Shengdong; Cheng, Shaojie; Wen, Siyang; Zeng, Huan; Zhao, Maojia; Yang, Liping; Wan, Xueying; Qiu, Yuxiang; Li, Qiao; Liu, Manran; Hou, Yixuan			Long non-coding RNA Lnc-408 promotes invasion and metastasis of breast cancer cell by regulating LIMK1	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LNCRNA HOTAIR; MIGRATION; MOTILITY; GROWTH; DIFFERENTIATION; PROGRESSION; STATISTICS; ACTIVATION; APOPTOSIS	Invasion and metastasis are the leading causes of death in patients with breast cancer (BC), and epithelial-mesenchymal transformation (EMT) plays an essential role in this process. Here, we found that Lnc-408, a novel long noncoding RNA (lncRNA), is significantly upregulated in BC cells undergoing EMT and in BC tumor with lymphatic metastases compared with those without lymphatic metastases. Lnc-408 can enhance BC invasion and metastasis by regulating the expression of LIMK1. Mechanistically, Lnc-408 serves as a sponge for miR-654-5p to relieve the suppression of miR-654-5p on its target LIMK1. Knockdown or knockout of Lnc-408 in invasive BC cells clearly decreased LIMK1 levels, and ectopic Lnc-408 in MCF-7 cells increased LIMK1 expression to promote cell invasion. Lnc-408-mediated enhancement of LIMK1 plays a key role in cytoskeletal stability and promotes invadopodium formation in BC cells via p-cofilin/F-actin. In addition, the increased LIMK1 also facilitates the expression of MMP2, ITGB1, and COL1A1 by phosphorylating CREB. In conclusion, our findings reveal that Lnc-408 promotes BC invasion and metastasis via the Lnc-408/miR-654-5p/LIMK1 axis, highlighting a novel promising target for the diagnosis and treatment of BC.	[Qiao, Yina; Jin, Ting; Guan, Shengdong; Cheng, Shaojie; Wen, Siyang; Zeng, Huan; Zhao, Maojia; Yang, Liping; Wan, Xueying; Qiu, Yuxiang; Li, Qiao; Liu, Manran] Chongqing Med Univ, Chinese Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China; [Hou, Yixuan] Chongqing Med Univ, Expt Teaching & Lab Management Ctr, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Hou, YX (corresponding author), Chongqing Med Univ, Expt Teaching & Lab Management Ctr, Chongqing, Peoples R China.	yixuan_hou@cqmu.edu.cn		Qiao, Yina/0000-0001-5351-0870	National Natural Science Foundation of China (NSFC) [81874199, 31671481, 81773078, 81560430]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported in part by the National Natural Science Foundation of China (NSFC 81773078, NSFC 81560430) for YH. And also supported by the National Natural Science Foundation of China (NSFC 81874199, and NSFC 31671481) for ML.	Aggelou H, 2018, VIRCHOWS ARCH, V472, P727, DOI 10.1007/s00428-018-2298-0; Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Chen PX, 2014, ONCOL REP, V32, P2070, DOI 10.3892/or.2014.3461; Chi YJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091015; Collette J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112319; Dong LF, 2019, J CELL BIOCHEM, V120, P4851, DOI 10.1002/jcb.27435; Fan CN, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1640-2; Grayson M, 2012, NATURE, V485, pS49, DOI 10.1038/485S49a; Hu P, 2014, CELL SIGNAL, V26, P83, DOI 10.1016/j.cellsig.2013.10.001; Huang FD, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4914707; Huang QY, 2019, CANCERS, V11, DOI 10.3390/cancers11111802; Huang Y, 2018, J CELL MOL MED, V22, P5768, DOI 10.1111/jcmm.13866; Jang I, 2012, KOREAN J PHYSIOL PHA, V16, P159, DOI 10.4196/kjpp.2012.16.3.159; Kang CG, 2015, BIOORG MED CHEM LETT, V25, P1956, DOI 10.1016/j.bmcl.2015.03.024; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030; Li DF, 2018, MOL CELL BIOCHEM, V444, P169, DOI 10.1007/s11010-017-3241-4; Li M, 2017, MOL ONCOL, V11, P1698, DOI 10.1002/1878-0261.12133; Li Z, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21933; Li ZW, 2017, ONCOTARGET, V8, P67329, DOI 10.18632/oncotarget.18622; Liang YR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01206-5; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Lu H, 2018, INT J ONCOL, V53, P2695, DOI 10.3892/ijo.2018.4592; Lu RZ, 2018, CANCER BIOMARK, V22, P249, DOI 10.3233/CBM-170874; Majem B, 2019, ONCOGENE, V38, P6035, DOI 10.1038/s41388-019-0860-0; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Mitra A, 2015, ONCOTARGET, V6, P10697, DOI 10.18632/oncotarget.4037; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Perkel JM, 2013, BIOTECHNIQUES, V54, P119, DOI 10.2144/000113997; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Tan YY, 2016, AM J CANCER RES, V6, P522; Tapia T, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-6; Todorovski Z, 2015, MOL CELL BIOL, V35, P1316, DOI 10.1128/MCB.01263-14; Wang LY, 2013, MOL ONCOL, V7, P1116, DOI 10.1016/j.molonc.2013.08.007; Wu YA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00407; Xu XZ, 2020, EUR REV MED PHARMACO, V24, P3517, DOI 10.26355/eurrev_202004_20811; Yang EJ, 2004, J BIOL CHEM, V279, P8903, DOI 10.1074/jbc.M311913200; Yang JJ, 2016, INT J BIOCHEM CELL B, V71, P62, DOI 10.1016/j.biocel.2015.12.004; Yin JL, 2020, FASEB J, V34, P4557, DOI 10.1096/fj.201901384RR; Yu TH, 2014, J STEROID BIOCHEM, V143, P392, DOI 10.1016/j.jsbmb.2014.05.003; Yu Y, 2017, BIOMED PHARMACOTHER, V90, P555, DOI 10.1016/j.biopha.2017.03.054; Zhao WY, 2018, CANCER MED-US, V7, P842, DOI 10.1002/cam4.1353; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219	46	6	7	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4198	4213		10.1038/s41388-021-01845-y	http://dx.doi.org/10.1038/s41388-021-01845-y		JUN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079084	hybrid, Green Published			2022-12-17	WOS:000657217400002
J	Wang, Y; Yu, HT; Xie, XZ; Deng, T; Ye, LY; Wu, LJ; Ding, XW; Yang, Z; Zhu, QD; Li, JJ; Zheng, YH; Yu, ZP; Chen, G				Wang, Yi; Yu, Haitao; Xie, Xiaozai; Deng, Tuo; Ye, Longyun; Wu, Lijun; Ding, Xiwei; Yang, Zhen; Zhu, Qiandong; Li, Junjian; Zheng, Yihu; Yu, Zhengping; Chen, Gang			Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway	ONCOGENE			English	Article							GROWTH-FACTOR; INTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; PROGNOSTIC-FACTORS; PHASE-II; VEGF; GEMCITABINE; EXPRESSION; RECEPTOR; ENDOTHELIUM	Cholangiocarcinoma (CCA) is aggressive and has poor clinical outcomes because of typically delayed diagnosis and a lack of effective non-surgical therapeutic options. Recent studies have shown that plasmalemma vesicle-associated protein (PLVAP) is related to angiogenesis in various tumors, and in vivo PLVAP targeting therapy has been proven effective against hepatocellular carcinoma and pancreatic cancer. The goal of this study was to determine the potential therapeutic utility of targeting PLVAP and thus angiogenesis in CCA and explore the underlying molecular mechanisms. We found that the PLVAP expression levels were significantly higher in CCA tissues when compared with matched adjacent non-tumor tissues obtained from a total of 90 CCA patients; higher expression levels of PLVAP were associated with shorter overall survival of patients. In addition, overexpression of PLVAP was associated with higher micro-vessel density in CCA tissues. In a PLVAP overexpressing CCA patient-derived xenograft model, a novel humanized anti-PLVAP antibody in combination with Gemcitabine plus Cisplatin was significantly inhibited tumor growth. Molecular analysis of CCA cells co-cultured with human umbilical vascular endothelial cells or human hepatic sinusoidal endothelial cells showed that Dickkopf-related protein 1 (DKK1) secreted by CCA cells activated the PI3K/Akt pathway after binding to its receptor, cytoskeleton-associated protein 4 (CKAP4), resulting in the upregulation of PLVAP. Thus, CCA cells increased the angiogenic potency of endothelial cells in a paracrine fashion. Consistently, patients bearing CKAP4 and PLVAP overexpressing tumors had a poor prognosis. In conclusion, the DKK1/CKAP4/PI3K/PLVAP pathway increases angiogenesis in CCA and is therefore a potential anti-angiogenic target.	[Wang, Yi] Wenzhou Med Univ, Sch Publ Hlth & Management, Div Prevent Med, Wenzhou, Peoples R China; [Yu, Haitao; Xie, Xiaozai; Deng, Tuo; Ye, Longyun; Wu, Lijun; Zhu, Qiandong; Li, Junjian; Zheng, Yihu; Yu, Zhengping; Chen, Gang] Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Wenzhou, Peoples R China; [Yu, Haitao; Xie, Xiaozai; Deng, Tuo; Ye, Longyun; Wu, Lijun; Zhu, Qiandong; Li, Junjian; Zheng, Yihu; Yu, Zhengping; Chen, Gang] Wenzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Wenzhou, Peoples R China; [Ding, Xiwei] Nanjing Univ, Dept Gastroenterol, Affiliated Hosp, Med Sch,Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China; [Yang, Zhen] Shandong Univ, Dept Infect Dis, Shandong Prov Hosp, Jinan, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Nanjing University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Wang, Y (corresponding author), Wenzhou Med Univ, Sch Publ Hlth & Management, Div Prevent Med, Wenzhou, Peoples R China.; Chen, G (corresponding author), Wenzhou Med Univ, Key Lab Diag & Treatment Severe Hepatopancreat Di, Affiliated Hosp 1, Wenzhou, Peoples R China.; Chen, G (corresponding author), Wenzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Wenzhou, Peoples R China.	wang.yi@wmu.edu.cn; chen.gang@wmu.edu.cn	Chen, Gang/ABG-9894-2021	Wang, Yi/0000-0002-0558-7491	National Natural Science Foundation of China [81201953, 81772628, 82072685, 81703310]; Project of National Health Council [WKJ-ZJ-1706]; Project of Zhejiang Province [WKJ-ZJ-1706]; Natural Science Foundation of Zhejiang Province [LY17H160047]; Public Projects of Zhejiang Province [2016C37127, 2018C37114]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of National Health Council; Project of Zhejiang Province; Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Public Projects of Zhejiang Province	We thank Jungang Zhao, Yifan Tong, Ziyan Chen, and Mingxun Wang for discussing the paper. We also appreciate Sina Zhang for her help with statistical analysis and bioinformatics analysis. We are deeply thankful to Prof Lewis R.Roberts (Mayo Clinic, USA) for valuable advice and discussions on the paper. This work was supported by the National Natural Science Foundation of China (Grant No. 81201953, 81772628, 82072685 to GC and 81703310 to YW); the Joint Projects of National Health Council and Zhejiang Province (No.WKJ-ZJ-1706 to GC); the Natural Science Foundation of Zhejiang Province (No.LY17H160047 to GC); the Public Projects of Zhejiang Province (No.2016C37127 to ZPY and 2018C37114 to YW).	Aparicio S, 2015, NAT REV CANCER, V15, P311, DOI 10.1038/nrc3944; Banales JM, 2016, NAT REV GASTRO HEPAT, V13, P261, DOI 10.1038/nrgastro.2016.51; Bengala C, 2010, BRIT J CANCER, V102, P68, DOI 10.1038/sj.bjc.6605458; Brechon M, 2018, INVEST NEW DRUG, V36, P156, DOI 10.1007/s10637-017-0492-6; Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727; Cavalloni G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2136-1; Deharvengt SJ, 2012, J CELL MOL MED, V16, P2690, DOI 10.1111/j.1582-4934.2012.01587.x; El-Khoueiry AB, 2014, BRIT J CANCER, V110, P882, DOI 10.1038/bjc.2013.801; El-Khoueiry AB, 2012, INVEST NEW DRUG, V30, P1646, DOI 10.1007/s10637-011-9719-0; Hall C, 2017, CANCER LETT, V386, P179, DOI 10.1016/j.canlet.2016.11.025; Ioannidou S, 2006, P NATL ACAD SCI USA, V103, P16770, DOI 10.1073/pnas.0603501103; Kennedy L, 2018, HEPATOLOGY, V68, P1042, DOI 10.1002/hep.29898; Kim JH, 2008, CANCER-AM CANCER SOC, V113, P1614, DOI 10.1002/cncr.23787; Kimura H, 2019, CLIN CANCER RES, V25, P1936, DOI 10.1158/1078-0432.CCR-18-2124; Kimura H, 2016, J CLIN INVEST, V126, P2689, DOI 10.1172/JCI84658; Klein D, 2008, HEPATOLOGY, V47, P1018, DOI 10.1002/hep.22084; Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992; Matsuyama M, 2015, INVEST NEW DRUG, V33, P490, DOI 10.1007/s10637-014-0197-z; Mittal K, 2014, SEMIN ONCOL, V41, P235, DOI 10.1053/j.seminoncol.2014.02.007; Mobius C, 2007, EJSO-EUR J SURG ONC, V33, P1025, DOI 10.1016/j.ejso.2007.02.020; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Paes KT, 2011, INVEST OPHTH VIS SCI, V52, P6452, DOI 10.1167/iovs.10-7146; Peng H, 2016, ONCOTARGET, V7, P17220, DOI 10.18632/oncotarget.7948; Phoenix TN, 2016, CANCER CELL, V29, P508, DOI 10.1016/j.ccell.2016.03.002; Rantakari P, 2016, NATURE, V538, P392, DOI 10.1038/nature19814; Rantakari P, 2015, NAT IMMUNOL, V16, P386, DOI 10.1038/ni.3101; Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Shi RY, 2013, CANCER-AM CANCER SOC, V119, P993, DOI 10.1002/cncr.27788; Shi XD, 2016, ONCOTARGET, V7, P70378, DOI 10.18632/oncotarget.11859; Shinno N, 2018, ONCOGENE, V37, P3471, DOI 10.1038/s41388-018-0179-2; Shirabe K, 2004, AM J SURG, V187, P538, DOI 10.1016/j.amjsurg.2003.12.044; Shirota T, 2015, MOL CANCER THER, V14, P1985, DOI 10.1158/1535-7163.MCT-15-0069; Shroff RT, 2017, BRIT J CANCER, V116, P1402, DOI 10.1038/bjc.2017.119; Stan RV, 2012, DEV CELL, V23, P1203, DOI 10.1016/j.devcel.2012.11.003; Strickland LA, 2005, J PATHOL, V206, P466, DOI 10.1002/path.1805; Tichauer KM, 2014, MOL IMAGING BIOL, V16, P372, DOI 10.1007/s11307-013-0692-1; Valle Juan, 2010, N Engl J Med, V362, P1273, DOI 10.1056/NEJMoa0908721; Wang YY, 2009, CLIN CANCER RES, V15, P5784, DOI 10.1158/1078-0432.CCR-09-0814; Wang Y, 2016, CANCER LETT, V380, P163, DOI 10.1016/j.canlet.2016.05.017; Wang YH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-815; Xu YF, 2019, ONCOGENE, V38, P868, DOI 10.1038/s41388-018-0485-8; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129; Zhang JQ, 2013, AM J PATHOL, V182, P1629, DOI 10.1016/j.ajpath.2013.01.045	44	6	6	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4324	4337		10.1038/s41388-021-01844-z	http://dx.doi.org/10.1038/s41388-021-01844-z		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34079085				2022-12-17	WOS:000657217400001
J	Fernandes, M; Jamme, P; Cortot, AB; Kherrouche, Z; Tulasne, D				Fernandes, Marie; Jamme, Philippe; Cortot, Alexis B.; Kherrouche, Zoulika; Tulasne, David			When the MET receptor kicks in to resist targeted therapies	ONCOGENE			English	Review							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; C-MET; DRIVEN RESISTANCE; TRASTUZUMAB RESISTANCE; GEFITINIB RESISTANCE; ACTIVATING MUTATIONS; MOLECULAR-MECHANISMS	Although targeted therapies have increased the life expectancy of patients with druggable molecular alterations directly involved in tumor development, the efficacy of these therapies is limited by acquired resistances leading to treatment failure. Most targeted therapies, including ones exploiting therapeutic antibodies and kinase inhibitors, are directed against receptor tyrosine kinases (RTKs) or major signaling hubs. Resistances to these therapies arise when inhibition of these targets is bypassed through activation of alternative signaling pathways. In recent years, activation of the receptor tyrosine kinase MET has been shown to promote resistance to various targeted therapies. This casts MET as important actor in resistance. In this review, we describe how the MET receptor triggers resistance to targeted therapies against RTKs such as EGFR, VEGFR, and HER2 and against signaling hubs such as BRAF. We also describe how MET can be its own resistance factor, as illustrated by on-target resistance of lung tumors harboring activating mutations causing MET exon 14 skipping. Interestingly, investigation of all these situations reveals functional physiological relationships between MET and the target of the therapy to which the cancer becomes resistant, suggesting that resistance stems from preexisting mechanisms. Identification of MET as a resistance factor opens the way to co-treatment strategies that are being tested in current clinical trials.	[Fernandes, Marie; Jamme, Philippe; Cortot, Alexis B.; Kherrouche, Zoulika; Tulasne, David] Univ Lille, CHU Lille, Inst Pasteur Lille, CNRS,UMR9020,Inserm,U1277,CANTHER,Canc Heterogene, Lille, France; [Cortot, Alexis B.] Univ Lille, CHU, Thorac Oncol Dept, Lille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille	Tulasne, D (corresponding author), Univ Lille, CHU Lille, Inst Pasteur Lille, CNRS,UMR9020,Inserm,U1277,CANTHER,Canc Heterogene, Lille, France.	david.tulasne@ibl.cnrs.fr	KHERROUCHE, Zoulika/HHN-0213-2022; Tulasne, David/AAR-5287-2020	Tulasne, David/0000-0002-6764-7242	CNRS; Institut Pasteur de Lille; INSERM; Canceropole Nord-Ouest; Ligue Contre le Cancer, Comites Nord et Aisne; Agence nationale de la recherche; Institut National du Cancer	CNRS(Centre National de la Recherche Scientifique (CNRS)); Institut Pasteur de Lille; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Canceropole Nord-Ouest; Ligue Contre le Cancer, Comites Nord et Aisne; Agence nationale de la recherche(French National Research Agency (ANR)); Institut National du Cancer(Institut National du Cancer (INCA) France)	This work was supported by the CNRS, the Institut Pasteur de Lille, and INSERM, and by grants from the "Canceropole Nord-Ouest", the "Ligue Contre le Cancer, Comites Nord et Aisne", the "Agence nationale de la recherche" and the "Institut National du Cancer".	Agarwal S, 2009, BRIT J CANCER, V100, P941, DOI 10.1038/sj.bjc.6604937; Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Awad MM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9069; Bahcall M, 2016, CANCER DISCOV, V6, P1334, DOI 10.1158/2159-8290.CD-16-0686; Baldacci S, 2018, LUNG CANCER, V125, P57, DOI 10.1016/j.lungcan.2018.09.008; Baldacci S, 2017, ONCOTARGET, V8, P105103, DOI 10.18632/oncotarget.21707; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000643; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Bruix J, 2012, J HEPATOL, V57, P821, DOI 10.1016/j.jhep.2012.06.014; Byeon HK, 2016, MOL CARCINOGEN, V55, P1678, DOI 10.1002/mc.22418; Calvi C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003228; Camidge DR, 2019, J CLIN ONCOL, V37, P855, DOI 10.1200/JCO.19.00033; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cascone T, 2017, CLIN CANCER RES, V23, P5489, DOI 10.1158/1078-0432.CCR-16-3216; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chia SK, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0836-3; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Choueiri TK, 2016, LANCET ONCOL, V17, P917, DOI 10.1016/S1470-2045(16)30107-3; Ciamporcero E, 2015, MOL CANCER THER, V14, P101, DOI 10.1158/1535-7163.MCT-14-0094; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cortot AB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw262; Cortot AB, 2014, EUR RESPIR REV, V23, P356, DOI 10.1183/09059180.00004614; Daudigeos-Dubus E, 2017, INT J ONCOL, V50, P203, DOI 10.3892/ijo.2016.3792; Descarpentries C, 2018, J THORAC ONCOL, V13, P1873, DOI 10.1016/j.jtho.2018.08.2023; Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993; Dong HJ, 2016, LUNG CANCER, V102, P118, DOI 10.1016/j.lungcan.2016.11.006; Drilon A, 2020, NAT MED, V26, P47, DOI 10.1038/s41591-019-0716-8; Duplaquet L, 2020, ELIFE, V9, DOI 10.7554/eLife.50041; Duplaquet L, 2018, ONCOGENE, V37, P3200, DOI 10.1038/s41388-018-0185-4; Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Engstrom LD, 2017, CLIN CANCER RES, V23, P6661, DOI 10.1158/1078-0432.CCR-17-1192; Escudier B, 2018, J CLIN ONCOL, V36, P765, DOI 10.1200/JCO.2017.74.7352; Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200; Flaifel A, 2019, CLIN CANCER RES, V25, P6080, DOI 10.1158/1078-0432.CCR-19-1135; Fujino T, 2019, J THORAC ONCOL, V14, P1753, DOI 10.1016/j.jtho.2019.06.023; Giovannetti E, 2018, CANCER DRUG RESIST, V1, P82, DOI 10.20517/cdr.2018.05; Griffioen AW, 2012, CLIN CANCER RES, V18, P3961, DOI 10.1158/1078-0432.CCR-12-0002; Guo R, 2019, J CLIN ONCOL, V37; Hashigasako A, 2004, J BIOL CHEM, V279, P26445, DOI 10.1074/jbc.M314254200; HASSAN M, 2019, SCI REP-UK, V9; Haura EB, 2019, J CLIN ONCOL, V37; Heist RS, 2016, J THORAC ONCOL, V11, P1242, DOI 10.1016/j.jtho.2016.06.013; Huang PH, 2007, P NATL ACAD SCI USA, V104, P12867, DOI 10.1073/pnas.0705158104; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Ishikawa D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062104; Jamme P, 2020, J THORAC ONCOL, V15, P741, DOI 10.1016/j.jtho.2020.01.027; Janne PA, 2016, J THORAC ONCOL, V11, P737, DOI 10.1016/j.jtho.2016.01.022; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jin W, 2019, J THORAC ONCOL, V14, pE137, DOI 10.1016/j.jtho.2019.04.021; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Kasahara K, 2010, CLIN CANCER RES, V16, P4616, DOI 10.1158/1078-0432.CCR-10-0383; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Knauf JA, 2018, J CLIN INVEST, V128, P4086, DOI 10.1172/JCI120966; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lai GG, 2019, J CLIN ONCOL, V37, P876, DOI 10.1200/JCO.18.00177; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Le XN, 2018, CLIN CANCER RES, V24, P6195, DOI 10.1158/1078-0432.CCR-18-1542; Lefebvre J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.377; Leighl NB, 2017, ONCOTARGET, V8, P69651, DOI 10.18632/oncotarget.18753; Leone JP, 2020, BREAST CANCER RES TR, V179, P113, DOI 10.1007/s10549-019-05445-z; Li A, 2017, CLIN CANCER RES, V23, P4929, DOI 10.1158/1078-0432.CCR-16-3273; Loibl S, 2016, ANN ONCOL, V27, P1519, DOI 10.1093/annonc/mdw197; LONGATI P, 1994, ONCOGENE, V9, P49; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Michaelso MD, 2019, ONCOLOGIST, V24, P1151, DOI 10.1634/theoncologist.2018-0749; Minuti G, 2012, BRIT J CANCER, V107, P793, DOI 10.1038/bjc.2012.335; Moores SL, 2016, CANCER RES, V76, P3942, DOI 10.1158/0008-5472.CAN-15-2833; Mueller KL, 2008, CANCER RES, V68, P3314, DOI 10.1158/0008-5472.CAN-08-0132; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nakajima M, 1999, CANCER, V85, P1894; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Obaid NM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030585; Ou SHI, 2017, J THORAC ONCOL, V12, P145, DOI 10.1016/j.jtho.2016.09.131; Oxnard GR, 2018, JAMA ONCOL, V4, P1527, DOI 10.1001/jamaoncol.2018.2969; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407; Patnaik A, 2018, CANCER CHEMOTH PHARM, V82, P407, DOI 10.1007/s00280-018-3623-7; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Ramalingam SS, 2018, ANN ONCOL, V29; Recondo G, 2020, CLIN CANCER RES, V26, P2615, DOI 10.1158/1078-0432.CCR-19-3608; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Rotow JK, 2020, CLIN CANCER RES, V26, P439, DOI 10.1158/1078-0432.CCR-19-1667; Sanchez-Vega F, 2019, CANCER DISCOV, V9, P199, DOI 10.1158/2159-8290.CD-18-0598; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Scagliotti G, 2015, J CLIN ONCOL, V33, P2667, DOI 10.1200/JCO.2014.60.7317; Schiering N, 2003, P NATL ACAD SCI USA, V100, P12654, DOI 10.1073/pnas.1734128100; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schoenfeld AJ, 2020, CLIN CANCER RES, V26, P2654, DOI [10.1158/10780432.CCR-19-3563, 10.1158/1078-0432.CCR-19-3563]; Sehnal D., 2018, WORKSH MOL GRAPH VIS, DOI [/10.5555/3293503.3293509, DOI 10.5555/3293503.3293509, 10.2312/molva.20181103]; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Sequist LV, 2020, LANCET ONCOL, V21, P373, DOI 10.1016/S1470-2045(19)30785-5; Sequist LV, 2011, J CLIN ONCOL, V29, P3307, DOI 10.1200/JCO.2010.34.0570; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Shitara K, 2020, JPN J CLIN ONCOL, V50, P859, DOI 10.1093/jjco/hyaa042; Spigel DR, 2017, J CLIN ONCOL, V35, P412, DOI 10.1200/JCO.2016.69.2160; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Suzawa K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.19.00011; Suzawa K, 2019, CLIN CANCER RES, V25, P1248, DOI 10.1158/1078-0432.CCR-18-1640; Takahashi N, 2016, ONCOTARGET, V7, P4925, DOI 10.18632/oncotarget.6753; Takeuchi S, 2012, AM J PATHOL, V181, P1034, DOI 10.1016/j.ajpath.2012.05.023; Tan EH, 2018, CLIN PHARM DRUG DEV, V7, P532, DOI 10.1002/cpdd.427; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Van Cutsem E, 2014, CLIN CANCER RES, V20, P4240, DOI 10.1158/1078-0432.CCR-13-2752; Vernieri C, 2019, CRIT REV ONCOL HEMAT, V139, P53, DOI 10.1016/j.critrevonc.2019.05.001; Virzi AR, 2018, P NATL ACAD SCI USA, V115, P10058, DOI 10.1073/pnas.1721147115; Wagner JP, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003994; Wakelee H, 2017, CLIN LUNG CANCER, V18, P50, DOI 10.1016/j.cllc.2016.09.013; Werbin JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12257-y; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787; Wu YL, 2020, LANCET RESP MED, V8, P1132, DOI 10.1016/S2213-2600(20)30154-5; Wu YL, 2018, J CLIN ONCOL, V36, P3101, DOI 10.1200/JCO.2018.77.7326; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yamada T, 2012, J THORAC ONCOL, V7, P272, DOI 10.1097/JTO.0b013e3182398e69; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yano S, 2011, J THORAC ONCOL, V6, P2011, DOI 10.1097/JTO.0b013e31823ab0dd; Yoshioka T, 2019, CANCER SCI, V110, P2549, DOI 10.1111/cas.14089; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0750-2; Zhang Y, 2017, LUNG CANCER, V113, P69, DOI 10.1016/j.lungcan.2017.09.006; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	141	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4061	4078		10.1038/s41388-021-01835-0	http://dx.doi.org/10.1038/s41388-021-01835-0		MAY 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34031544				2022-12-17	WOS:000653694600001
J	Naso, FD; Boi, D; Ascanelli, C; Pamfil, G; Lindon, C; Paiardini, A; Guarguaglini, G				Naso, Francesco Davide; Boi, Dalila; Ascanelli, Camilla; Pamfil, Georgiana; Lindon, Catherine; Paiardini, Alessandro; Guarguaglini, Giulia			Nuclear localisation of Aurora-A: its regulation and significance for Aurora-A functions in cancer	ONCOGENE			English	Review							SMALL-MOLECULE INHIBITORS; RNA-POLYMERASE-II; N-MYC; BREAST-CANCER; C-MYC; KINASE INHIBITOR; ONCOGENE; IDENTIFICATION; DEGRADATION; EXPRESSION	The Aurora-A kinase regulates cell division, by controlling centrosome biology and spindle assembly. Cancer cells often display elevated levels of the kinase, due to amplification of the gene locus, increased transcription or post-translational modifications. Several inhibitors of Aurora-A activity have been developed as anti-cancer agents and are under evaluation in clinical trials. Although the well-known mitotic roles of Aurora-A point at chromosomal instability, a hallmark of cancer, as a major link between Aurora-A overexpression and disease, recent evidence highlights the existence of non-mitotic functions of potential relevance. Here we focus on a nuclear-localised fraction of Aurora-A with oncogenic roles. Interestingly, this pool would identify not only non-mitotic, but also kinase-independent functions of the kinase. We review existing data in the literature and databases, examining potential links between Aurora-A stabilisation and localisation, and discuss them in the perspective of a more effective targeting of Aurora-A in cancer therapy.	[Naso, Francesco Davide; Pamfil, Georgiana; Guarguaglini, Giulia] Sapienza Univ Rome, Inst Mol Biol & Pathol, Natl Res Council Italy, Rome, Italy; [Boi, Dalila; Paiardini, Alessandro] Sapienza Univ Rome, Dept Biochem Sci, Rome, Italy; [Ascanelli, Camilla; Lindon, Catherine] Univ Cambridge, Dept Pharmacol, Cambridge, England	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; University of Cambridge	Guarguaglini, G (corresponding author), Sapienza Univ Rome, Inst Mol Biol & Pathol, Natl Res Council Italy, Rome, Italy.; Paiardini, A (corresponding author), Sapienza Univ Rome, Dept Biochem Sci, Rome, Italy.; Lindon, C (corresponding author), Univ Cambridge, Dept Pharmacol, Cambridge, England.	acl34@cam.ac.uk; alessandro.paiardini@uniroma1.it; giulia.guarguaglini@uniroma1.it		Ascanelli, Camilla/0000-0002-6266-2822; Paiardini, Alessandro/0000-0001-9078-7545; Lindon, Catherine/0000-0003-3554-2574	Royal Society International Exchanges grant [IES\R3\170195]; BBSRC [BB/R004137/1]; AstraZeneca Ph.D. studentship; Associazione Italiana Ricerca sul Cancro (AIRC MFAG) [20447]	Royal Society International Exchanges grant; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); AstraZeneca Ph.D. studentship(AstraZeneca); Associazione Italiana Ricerca sul Cancro (AIRC MFAG)(Fondazione AIRC per la ricerca sul cancro)	We thank people from the Guarguaglini, Paiardini and Lindon labs for insightful discussions. This work was made possible by a Royal Society International Exchanges grant (IES\R3\170195) to CL and GG. Work in CL's lab is funded by BBSRC (BB/R004137/1) and CA is a recipient of an AstraZeneca Ph.D. studentship. AP is funded by Associazione Italiana Ricerca sul Cancro (AIRC MFAG id. 20447).	Adhikari B, 2020, NAT CHEM BIOL, V16, P1179, DOI 10.1038/s41589-020-00652-y; Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Almeida EG, 2020, NUCLEIC ACIDS RES, V48, P7844, DOI 10.1093/nar/gkaa570; Amin M, 2016, INVEST NEW DRUG, V34, P84, DOI 10.1007/s10637-015-0306-7; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017; Puig-Butille JA, 2017, J INVEST DERMATOL, V137, P1297, DOI 10.1016/j.jid.2017.01.021; Aradottir M, 2015, J PATHOL CLIN RES, V1, P33, DOI 10.1002/cjp2.6; Asteriti IA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00283; Asteriti IA, 2017, ONCOTARGET, V8, P32117, DOI 10.18632/oncotarget.16738; Asteriti IA, 2014, ONCOTARGET, V5, P6229, DOI 10.18632/oncotarget.2190; Asteriti IA, 2010, BBA-REV CANCER, V1806, P230, DOI 10.1016/j.bbcan.2010.08.001; Bamborough P, 2008, J MED CHEM, V51, P7898, DOI 10.1021/jm8011036; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278; Bertolin G, 2020, CELL MOL LIFE SCI, V77, P1031, DOI 10.1007/s00018-019-03310-2; Bertolin G, 2018, ELIFE, V7, DOI 10.7554/eLife.38111; Bibby RA, 2009, J BIOL CHEM, V284, P33177, DOI 10.1074/jbc.M109.032722; Bondeson DP, 2018, CELL CHEM BIOL, V25, P78, DOI 10.1016/j.chembiol.2017.09.010; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Buchel G, 2017, CELL REP, V21, P3483, DOI 10.1016/j.celrep.2017.11.090; Burgess SG, 2018, EMBO J, V37, DOI 10.15252/embj.201797902; Burgess SG, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160089; Byrum AK, 2019, J CELL BIOL, V218, P422, DOI 10.1083/jcb.201803003; D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628; Dai Q, 2004, CANCER EPIDEM BIOMAR, V13, P2065; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dauch D, 2016, NAT MED, V22, P744, DOI 10.1038/nm.4107; de Groot CO, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00285; den Hollander J, 2010, BLOOD, V116, P1498, DOI 10.1182/blood-2009-11-251074; Ding X, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00045; Donovan KA, 2020, CELL, V183, P1714, DOI 10.1016/j.cell.2020.10.038; dos Santos EO, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0494-6; Du J, 2019, MOL CANCER THER, V18, P2207, DOI 10.1158/1535-7163.MCT-18-0529; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Garcia-Escudero R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-193; Garrido G, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00088; Gomes SM, 2020, CELL ONCOL, V43, P445, DOI 10.1007/s13402-020-00498-5; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Gustafson WC, 2014, CANCER CELL, V26, P414, DOI 10.1016/j.ccr.2014.07.015; Hasanov E, 2017, ONCOGENE, V36, P3450, DOI 10.1038/onc.2016.495; Hegde AM., 2015, INVESTIGATING INTERA, P625; Ho JSL, 2005, MOL CELL BIOL, V25, P7423, DOI 10.1128/MCB.25.17.7423-7431.2005; Hsueh KW, 2011, FEBS LETT, V585, P2671, DOI 10.1016/j.febslet.2011.07.031; Inamdar KV, 2008, MODERN PATHOL, V21, P1428, DOI 10.1038/modpathol.2008.173; Janecek M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28528; Joukov V, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar4195; Kitajima S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000944; Kongsema M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.57; Konstantinidou M, 2019, EXPERT OPIN DRUG DIS, V14, P1255, DOI 10.1080/17460441.2019.1659242; Kwon YW, 2012, MOL CANCER RES, V10, P834, DOI 10.1158/1541-7786.MCR-12-0025; Lake EW, 2018, P NATL ACAD SCI USA, V115, pE11894, DOI 10.1073/pnas.1811158115; Lassus H, 2011, GYNECOL ONCOL, V120, P11, DOI 10.1016/j.ygyno.2010.09.003; Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964; Levens David, 2010, Genes Cancer, V1, P547; Liao GB, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0266-6; Lin XR, 2020, AM J CANCER RES, V10, P2705; Liu X, 2016, ONCOTARGET, V7, P33152, DOI 10.18632/oncotarget.8888; Magnaghi-Jaulin L, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010028; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Meyer HJ, 2014, CELL, V157, P910, DOI 10.1016/j.cell.2014.03.037; Mikhaylova O, 2008, MOL CELL BIOL, V28, P2701, DOI 10.1128/MCB.01231-07; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Piskacek S, 2007, GENOMICS, V89, P756, DOI 10.1016/j.ygeno.2007.02.003; Rannou Y, 2008, CELL CYCLE, V7, P3012, DOI 10.4161/cc.7.19.6718; Richards MW, 2016, P NATL ACAD SCI USA, V113, P13726, DOI 10.1073/pnas.1610626113; Roeschert I, 2021, NAT CANCER, V2, P312, DOI 10.1038/s43018-020-00171-8; Santoro A, 2019, CELL REP, V26, P624, DOI 10.1016/j.celrep.2018.12.071; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 2004, CANCER LETT, V204, P179, DOI 10.1016/S0304-3835(03)00454-3; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sillars-Hardebol AH, 2010, TUMOR BIOL, V31, P89, DOI 10.1007/s13277-009-0012-1; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Sun HZ, 2014, BBA-MOL CELL RES, V1843, P934, DOI 10.1016/j.bbamcr.2014.01.019; Takahashi Y, 2015, ANN ONCOL, V26, P935, DOI 10.1093/annonc/mdv034; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tatsuka M, 2009, MOL CARCINOGEN, V48, P810, DOI 10.1002/mc.20525; Tayyar Y, 2017, CRIT REV ONCOL HEMAT, V119, P59, DOI 10.1016/j.critrevonc.2017.09.006; Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Wang R, 2020, BIORXIV, V2; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Wierstra I, 2007, BIOL CHEM, V388, P1257, DOI 10.1515/BC.2007.159; Willems E, 2018, CELL DIV, V13, DOI 10.1186/s13008-018-0040-6; Yan M, 2016, MED RES REV, V36, P1036, DOI 10.1002/med.21399; Yan VC, 2020, TRENDS CANCER, V6, P924, DOI 10.1016/j.trecan.2020.05.010; Yang G, 2013, INT J CANCER, V133, P275, DOI 10.1002/ijc.28032; Yang N, 2017, ONCOGENE, V36, P3428, DOI 10.1038/onc.2016.490; Yang N, 2019, J CELL MOL MED, V23, P6442, DOI 10.1111/jcmm.14538; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358; Yoshida GJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0835-y; Zheng FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10180; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	99	6	6	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3917	3928		10.1038/s41388-021-01766-w	http://dx.doi.org/10.1038/s41388-021-01766-w		MAY 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33981003	Green Published, hybrid			2022-12-17	WOS:000650165600001
J	Xu, QP; Zhang, JW; Telfer, BA; Zhang, H; Ali, N; Chen, FH; Risa, B; Pearson, AJ; Zhang, W; Finegan, KG; Ucar, A; Giurisato, E; Tournier, C				Xu, Qiuping; Zhang, Jingwei; Telfer, Brian A.; Zhang, Hao; Ali, Nisha; Chen, Fuhui; Risa, Blanca; Pearson, Adam J.; Zhang, Wei; Finegan, Katherine G.; Ucar, Ahmet; Giurisato, Emanuele; Tournier, Cathy			The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion	ONCOGENE			English	Article							FAK; ACTIVATION; TRANSITION; MIGRATION; PATHWAYS; ROLES; SRC	There is overwhelming clinical evidence that the extracellular-regulated protein kinase 5 (ERK5) is significantly dysregulated in human breast cancer. However, there is no definite understanding of the requirement of ERK5 in tumor growth and metastasis due to very limited characterization of the pathway in disease models. In this study, we report that a high level of ERK5 is a predictive marker of metastatic breast cancer. Mechanistically, our in vitro data revealed that ERK5 was critical for maintaining the invasive capability of triple-negative breast cancer (TNBC) cells through focal adhesion protein kinase (FAK) activation. Specifically, we found that phosphorylation of FAK at Tyr397 was controlled by a kinase-independent function of ERK5. Accordingly, silencing ERK5 in mammary tumor grafts impaired FAK phosphorylation at Tyr397 and suppressed TNBC cell metastasis to the lung without preventing tumor growth. Collectively, these results establish a functional relationship between ERK5 and FAK signaling in promoting malignancy. Thus, targeting the oncogenic ERK5-FAK axis represents a promising therapeutic strategy for breast cancer exhibiting aggressive clinical behavior.	[Xu, Qiuping; Zhang, Jingwei; Chen, Fuhui; Risa, Blanca; Pearson, Adam J.; Zhang, Wei; Ucar, Ahmet; Giurisato, Emanuele; Tournier, Cathy] Univ Manchester, Div Canc Sci, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Telfer, Brian A.; Finegan, Katherine G.] Univ Manchester, Div Pharm & Optometry, Sch Hlth Sci, Fac Biol Med & Hlth, Manchester, Lancs, England; [Zhang, Hao] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Guangzhou, Peoples R China; [Ali, Nisha] Manchester Univ NHS FT, Wythenshawe Hosp, Manchester, Lancs, England; [Giurisato, Emanuele] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy	University of Manchester; University of Manchester; Sun Yat Sen University; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of Siena	Tournier, C (corresponding author), Univ Manchester, Div Canc Sci, Sch Med Sci, Fac Biol Med & Hlth, Manchester, Lancs, England.	cathy.tournier@manchester.ac.uk	GIURISATO, EMANUELE/AAO-2352-2020	GIURISATO, EMANUELE/0000-0003-0598-6449; Tournier, Cathy/0000-0002-4618-2570; Zhang, Wei/0000-0002-3826-7128; Finegan, Katie/0000-0003-2885-0122; Telfer, Brian/0000-0003-1857-5120; Ucar, Ahmet/0000-0002-6551-3486; Pearson, Adam/0000-0002-6719-9750	Worldwide Cancer Research; Medical Research Council	Worldwide Cancer Research; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a grant from Worldwide Cancer Research to CT and a Confidence in Concept scheme award from the Medical Research Council to KGF. We thank Peter March and Roger Meadow (Bioimaging), Mike Jackson (Flow Cytometry), George Taylor (Mass Spectrometry), Duncan Forster (Wolfson Molecular Imaging Center), and Peter Walker (Histology) from core research facilities (University of Manchester) for very helpful advice, and the staff at the University of Manchester Biological Safety Unit for looking after the mice. We would also like to thank Andrew Gilmore and Stuart Cain from the University of Manchester for providing essential reagents for the execution of the work.	Al-Ejeh F, 2014, ONCOTARGET, V5, P3145, DOI 10.18632/oncotarget.1865; Ali M, 2019, BIOCHEM BIOPH RES CO, V513, P179, DOI 10.1016/j.bbrc.2019.03.145; Antoon JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069291; Barros JC, 2005, J CELL SCI, V118, P1663, DOI 10.1242/jcs.02308; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Brami-Cherrier K, 2014, EMBO J, V33, P356, DOI 10.1002/embj.201386399; Montero JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005565; Castro NE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2622; Chen RQ, 2012, CANCER RES, V72, P1579, DOI 10.1158/0008-5472.CAN-11-2055; Cronan MR, 2012, ONCOGENE, V31, P3889, DOI 10.1038/onc.2011.544; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Goel RK, 2015, BBA-REV CANCER, V1856, P39, DOI 10.1016/j.bbcan.2015.05.001; Javaid S, 2015, MOL CANCER RES, V13, P934, DOI 10.1158/1541-7786.MCR-14-0604; Ortiz-Ruiz MJ, 2014, ONCOTARGET, V5, P11308, DOI 10.18632/oncotarget.2324; Jiang WW, 2020, PROTEIN CELL, V11, P825, DOI 10.1007/s13238-020-00701-1; Jiang XH, 2007, CELL SIGNAL, V19, P1000, DOI 10.1016/j.cellsig.2006.11.004; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Liu F, 2017, ONCOL REP, V37, P83, DOI 10.3892/or.2016.5256; Locatelli A, 2011, J BIOL CHEM, V286, P21062, DOI 10.1074/jbc.M110.211409; Madak-Erdogan Z, 2014, MOL CANCER RES, V12, P714, DOI 10.1158/1541-7786.MCR-13-0588; Miranda Mariska, 2015, Oncoscience, V2, P99; Narod SA, 2015, J Cancer Policy, V5, P8, DOI 10.1016/j.jcpo.2015.03.002; Nithianandarajah-Jones GN, 2012, CELL SIGNAL, V24, P2187, DOI 10.1016/j.cellsig.2012.07.007; Pavan S, 2018, ONCOGENE, V37, P4197, DOI 10.1038/s41388-018-0270-8; Pearson AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030929; Perez-Madrigal D, 2012, CELL SIGNAL, V24, P2360, DOI 10.1016/j.cellsig.2012.08.001; Sawhney RS, 2009, J CELL PHYSIOL, V219, P152, DOI 10.1002/jcp.21662; Schramp M, 2008, J CELL BIOL, V181, P1195, DOI 10.1083/jcb.200801078; Sledge GW, 2014, J CLIN ONCOL, V32, P1979, DOI 10.1200/JCO.2014.55.4139; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Tanjoni I, 2010, CANCER BIOL THER, V9, P764, DOI 10.4161/cbt.9.10.11434; Hoang VT, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01164; Villa-Moruzzi E, 2007, BIOCHEM J, V408, P7, DOI 10.1042/BJ20070058; Vuong D, 2014, VIRCHOWS ARCH, V465, P1, DOI 10.1007/s00428-014-1593-7; Wang JH, 2018, ACS CHEM BIOL, V13, P2438, DOI 10.1021/acschembio.7b00638; Williams CAC, 2016, CELL REP, V16, P1820, DOI 10.1016/j.celrep.2016.07.033; Wu JC, 2015, SCI REP-UK, V5, DOI 10.1038/srep18476; Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210; Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478; Zuo YF, 2015, J CELL BIOCHEM, V116, P124, DOI 10.1002/jcb.24950	41	6	6	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3929	3941		10.1038/s41388-021-01798-2	http://dx.doi.org/10.1038/s41388-021-01798-2		MAY 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33981002	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000650166200002
J	Liu, JY; Huang, Z; Chen, HN; Qin, SY; Chen, Y; Jiang, JW; Zhang, Z; Luo, MC; Ye, Q; Xie, N; Zhou, ZG; Wei, YQ; Xie, K; Huang, CH				Liu, Jiayang; Huang, Zhao; Chen, Hai-Ning; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Ye, Qin; Xie, Na; Zhou, Zong-Guang; Wei, Yuquan; Xie, Ke; Huang, Canhua			ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-beta axis in colorectal cancer	ONCOGENE			English	Article							DIFFERENTIATION	Poorly differentiated colorectal cancer (CRC) is characterized by aggressive invasion and stromal fibroblast activation, which results in rapid progression and poor therapeutic consequences. However, the regulatory mechanism involved remains unclear. Here, we showed that ZNF37A, a member of KRAB-ZFP family, was upregulated in poorly differentiated CRCs and associated with tumor metastasis. ZNF37A enhanced the metastatic potential of multiple CRC cell lines and promoted distant metastasis in an orthotopic CRC model. Further investigation attributed the ZNF37A-exacerbated metastasis to increased extracellular TGF-beta and the consequent activation of cancer-associated fibroblasts (CAFs) in tumor microenvironment (TME). Mechanistically, ZNF37A formed a complex with KAP1 and bound to the promoter of THSD4, a TME modulator, to suppress its transcription, which is required for ZNF37A-mediated TGF-beta activation and CRC metastasis. Collectively, our study indicates that ZNF37A promotes TGF-beta signaling in CRC cells and activates CAFs by transcriptionally repressing THSD4 to drive CRC metastasis, implicating ZNF37A as a potential biomarker for CRC differentiation and progression.	[Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] West China Hosp, Ctr Canc, Chengdu, Peoples R China; [Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China; [Liu, Jiayang; Huang, Zhao; Qin, Siyuan; Chen, Yan; Jiang, Jingwen; Zhang, Zhe; Luo, Maochao; Wei, Yuquan; Huang, Canhua] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China; [Chen, Hai-Ning; Zhou, Zong-Guang] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Gastrointestinal Surg, Chengdu, Peoples R China; [Chen, Hai-Ning; Zhou, Zong-Guang] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China; [Ye, Qin; Xie, Ke] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Sichuan, Peoples R China; [Ye, Qin; Xie, Ke] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu, Sichuan, Peoples R China; [Xie, Na] Sichuan Univ, West China Hosp, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China; [Xie, Na] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Xie, Na] Sichuan Univ, West China Hosp, Ctr Canc, Chengdu, Peoples R China; [Xie, Na] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China; [Huang, Canhua] Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Sichuan University; Sichuan University; Sichuan University; Chengdu University of Traditional Chinese Medicine	Huang, CH (corresponding author), West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.; Huang, CH (corresponding author), West China Hosp, Ctr Canc, Chengdu, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China.; Huang, CH (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China.; Xie, K (corresponding author), Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Oncol, Chengdu, Sichuan, Peoples R China.; Xie, K (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu, Sichuan, Peoples R China.; Huang, CH (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu, Sichuan, Peoples R China.	mei97@sina.com; hcanhua@hotmail.com	Jiang, Jing wen/AAP-5996-2021; Chen, Hai-Ning/AAR-8059-2021	Chen, Hai-Ning/0000-0003-0104-8498; Huang, Zhao/0000-0001-9994-2070; , Zongguang/0000-0002-7616-1199	Guangdong Basic and Applied Basic Research Foundation [2019B030302012]; National Key RAMP;D Program of China [2020YFA0509400, 2020YFC2002700]; Chinese NSFC [81821002, 81672867, 81790251, 81702378]; China Postdoctoral Science Foundation [2019T120845, 2018M643496]	Guangdong Basic and Applied Basic Research Foundation; National Key RAMP;D Program of China; Chinese NSFC(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from Guangdong Basic and Applied Basic Research Foundation (2019B030302012), National Key R&D Program of China (2020YFA0509400, 2020YFC2002700), the Chinese NSFC (nos 81821002, 81672867, 81790251, 81702378) and China Postdoctoral Science Foundation (2019T120845, 2018M643496).	Adamski V, 2020, ONCOGENE, V39, P4421, DOI 10.1038/s41388-020-1302-8; Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827; Alexandre C., 2015, NAT GENET, V47; Alonso-Alconada L, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-223; Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238; Arendt D, 2016, NAT REV GENET, V17, P744, DOI 10.1038/nrg.2016.127; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Berg KCG, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0691-y; Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06654-8; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; Derwinger K, 2010, ACTA ONCOL, V49, P57, DOI 10.3109/02841860903334411; Ecco G, 2017, DEVELOPMENT, V144, P2719, DOI 10.1242/dev.132605; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Gauthier M, 2013, HUM MOL GENET, V22, P5188, DOI 10.1093/hmg/ddt373; Gremel G, 2015, J GASTROENTEROL, V50, P46, DOI 10.1007/s00535-014-0958-7; Guo Z, 2017, NUCLEIC ACIDS RES, V46, P1266; Iwafuchi-Doi M, 2014, GENE DEV, V28, P2679, DOI 10.1101/gad.253443.114; Jung B, 2017, GASTROENTEROLOGY, V152, P36, DOI 10.1053/j.gastro.2016.10.015; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Koliaraki V, 2017, GASTROENTEROLOGY, V152, P964, DOI 10.1053/j.gastro.2016.11.049; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Liu R, 2013, CANCER RES, V73, P5926, DOI 10.1158/0008-5472.CAN-12-4718; McCarthy N, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3272; Nathan RW., 2015, NAT REV IMMUNOL, V15; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171; Robertson IB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021907; Saito M, 2011, J BIOL CHEM, V286, P38602, DOI 10.1074/jbc.M111.243451; Schmitges FW, 2016, GENOME RES, V26, P1742, DOI 10.1101/gr.209643.116; Tada Y, 2015, ONCOGENE, V34, P752, DOI 10.1038/onc.2013.599; Takahashi K, 2016, NAT REV MOL CELL BIO, V17, P183, DOI 10.1038/nrm.2016.8; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Tauriello DVF, 2016, TRENDS CANCER, V2, P495, DOI 10.1016/j.trecan.2016.08.001; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tsutsui K, 2010, J BIOL CHEM, V285, P4870, DOI 10.1074/jbc.M109.076919; Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1; Wu D, 2016, HEPATOLOGY, V64, P1148, DOI 10.1002/hep.28708; Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	45	6	6	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3394	3407		10.1038/s41388-021-01713-9	http://dx.doi.org/10.1038/s41388-021-01713-9		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33875786				2022-12-17	WOS:000641218600005
J	Azizi, N; Toma, J; Martin, M; Khalid, MF; Mousavi, F; Win, PW; Borrello, MT; Steele, N; Shi, JQ; di Magliano, MP; Pin, CL				Azizi, Nawab; Toma, Jelena; Martin, Mickenzie; Khalid, Muhammad Faran; Mousavi, Fatemeh; Win, Phyo Wei; Borrello, Maria Teresa; Steele, Nina; Shi, Jiaqi; di Magliano, Marina Pasca; Pin, Christopher L.			Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer	ONCOGENE			English	Article								The unfolded protein response (UPR) is activated in pancreatic pathologies and suggested as a target for therapeutic intervention. In this study, we examined activating transcription factor 3 (ATF3), a mediator of the UPR that promotes acinar-to-ductal metaplasia (ADM) in response to pancreatic injury. Since ADM is an initial step in the progression to pancreatic ductal adenocarcinoma (PDAC), we hypothesized that ATF3 is required for initiation and progression of PDAC. We generated mice carrying a germline mutation of Atf3 (Atf3(-/-)) combined with acinar-specific induction of oncogenic KRAS (Ptf1a(creERT/+)Kras(G12D/+)). Atf3(-/-) mice with (termed APK) and without KRAS(G12D) were exposed to cerulein-induced pancreatitis. In response to recurrent pancreatitis, Atf3(-/-) mice showed decreased ADM and enhanced regeneration based on morphological and biochemical analysis. Similarly, an absence of ATF3 reduced spontaneous pancreatic intraepithelial neoplasia (PanIN) formation and PDAC in Ptf1a(creERT/+)Kras(G12D/+) mice. In response to injury, KRAS(G12D) bypassed the requirement for ATF3 with a dramatic loss in acinar tissue and PanIN formation observed regardless of ATF3 status. Compared to Ptf1a(creERT/+)Kras(G12D/+) mice, APK mice exhibited a significant decrease in pancreatic and total body weight, did not progress through to PDAC, and showed altered pancreatic fibrosis and immune cell infiltration. These findings suggest a complex, multifaceted role for ATF3 in pancreatic cancer pathology.	[Azizi, Nawab; Toma, Jelena; Martin, Mickenzie; Khalid, Muhammad Faran; Mousavi, Fatemeh; Win, Phyo Wei; Pin, Christopher L.] Childrens Hlth Res Inst, London, ON, Canada; [Azizi, Nawab; Toma, Jelena; Martin, Mickenzie; Mousavi, Fatemeh; Pin, Christopher L.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada; [Toma, Jelena; Pin, Christopher L.] Univ Western Ontario, Dept Oncol, London, ON, Canada; [Martin, Mickenzie] Univ Western Ontario, Dept Biol, London, ON, Canada; [Khalid, Muhammad Faran; Win, Phyo Wei; Pin, Christopher L.] Univ Western Ontario, Dept Paediat, London, ON, Canada; [Borrello, Maria Teresa] Aix Marseille Univ, Ctr Canc Res Marseille, INSERM, CNRS,UMR 7258,U1068, Marseille, France; [Borrello, Maria Teresa] Inst Paoli Calmettes, Marseille, France; [Steele, Nina; Shi, Jiaqi] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [di Magliano, Marina Pasca] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Pin, CL (corresponding author), Childrens Hlth Res Inst, London, ON, Canada.; Pin, CL (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, London, ON, Canada.; Pin, CL (corresponding author), Univ Western Ontario, Dept Oncol, London, ON, Canada.; Pin, CL (corresponding author), Univ Western Ontario, Dept Paediat, London, ON, Canada.	cpin@uwo.ca		Shi, Jiaqi/0000-0003-4893-1587; Azizi, Nawab/0000-0003-1474-6543	Canadian Institutes of Health Research (MOP) [PJT166029]; Cancer Research Society of Canada; Rob Lutterman Foundation for Pancreatic Cancer Research; University of Western Ontario; Ontario Graduate Scholarships; Cancer Research and Technology Training (CaRTT) program; NSERC summer studentship; National Cancer Institute of the National Institutes of Health [K08CA234222]; London Regional Cancer Centre Catalyst Grant	Canadian Institutes of Health Research (MOP)(Canadian Institutes of Health Research (CIHR)); Cancer Research Society of Canada; Rob Lutterman Foundation for Pancreatic Cancer Research; University of Western Ontario; Ontario Graduate Scholarships(Ontario Graduate Scholarship); Cancer Research and Technology Training (CaRTT) program; NSERC summer studentship(Natural Sciences and Engineering Research Council of Canada (NSERC)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); London Regional Cancer Centre Catalyst Grant	The authors wish to acknowledge the ongoing support of several national research funding agencies for this work including the Canadian Institutes of Health Research (MOP#PJT166029), the Cancer Research Society of Canada, and the Rob Lutterman Foundation for Pancreatic Cancer Research. This work would not be possible without specific support from a London Regional Cancer Centre Catalyst Grant, co-supported by Keith Sammit and an internal bridge grant from the University of Western Ontario. NA and JT were funded by studentships from the Ontario Graduate Scholarships and Cancer Research and Technology Training (CaRTT) program. MFK was supported by an NSERC summer studentship. JS was supported by National Cancer Institute of the National Institutes of Health under award number K08CA234222.	B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bandyopadhyay S, 2006, CANCER RES, V66, P11983, DOI 10.1158/0008-5472.CAN-06-0943; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Boespflug ND, 2014, BLOOD, V123, P2084, DOI 10.1182/blood-2013-06-510909; Carriere C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027725; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chien WW, 2014, ONCOTARGET, V5, P4881, DOI 10.18632/oncotarget.2051; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Dawn B, 2004, CARDIOVASC RES, V64, P61, DOI 10.1016/j.cardiores.2004.05.011; Delous M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002754; Fazio EN, 2017, MOL BIOL CELL, V28, P2347, DOI 10.1091/mbc.E17-04-0254; Garcia-Carbonero N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092468; Gardian K, 2012, J CANCER, V3, P285, DOI 10.7150/jca.4537; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Hackl C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-668; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Helm O, 2014, INT J CANCER, V135, P843, DOI 10.1002/ijc.28736; Hess DA, 2011, GASTROENTEROLOGY, V141, P1463, DOI 10.1053/j.gastro.2011.06.045; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Iida K, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-38; Iwawaki T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013052; Je YJ, 2014, BIOCHEM BIOPH RES CO, V444, P81, DOI 10.1016/j.bbrc.2014.01.010; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Johnson CL, 2004, MECH DEVELOP, V121, P261, DOI 10.1016/j.mod.2004.01.003; Kadowaki H, 2013, GENES-BASEL, V4, P306, DOI 10.3390/genes4030306; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kim DE, 2017, J EXP MED, V214, P2349, DOI 10.1084/jem.20170724; Kim KJ, 2015, BIOMOL THER, V23, P134, DOI 10.4062/biomolther.2014.107; Kopp JL, 2011, DEVELOPMENT, V138, P653, DOI 10.1242/dev.056499; Kowalik AS, 2007, AM J PHYSIOL-GASTR L, V292, pG1123, DOI 10.1152/ajpgi.00512.2006; Kubisch CH, 2007, AM J PHYSIOL-GASTR L, V292, pG1804, DOI 10.1152/ajpgi.00078.2007; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Mallano T, 2016, ANN RHEUM DIS, V75, P586, DOI 10.1136/annrheumdis-2014-206214; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Pin CL, 2000, ANAT REC, V259, P157, DOI 10.1002/(SICI)1097-0185(20000601)259:2<157::AID-AR6>3.0.CO;2-0; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Pinho AV, 2011, GUT, V60, P958, DOI 10.1136/gut.2010.225920; Prevot PP, 2012, GUT, V61, P1723, DOI 10.1136/gutjnl-2011-300266; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roy N, 2016, GENE DEV, V30, P2669, DOI 10.1101/gad.291021.116; Shi G, 2013, ONCOGENE, V32, P1950, DOI 10.1038/onc.2012.210; Song HM, 2016, BIOMOL THER, V24, P140, DOI 10.4062/biomolther.2015.109; Song XX, 2012, THORAC CANCER, V3, P217, DOI 10.1111/j.1759-7714.2011.00110.x; Steele NG, 2021, CLIN CANCER RES, V27, P2023, DOI 10.1158/1078-0432.CCR-20-3715; Thakur PC, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1562-z; Tsuda M, 2018, J CLIN INVEST, V128, P3475, DOI 10.1172/JCI94287; Wang A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-268; Wu XW, 2010, NATURE, V465, P368, DOI 10.1038/nature08996; Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068; Yan F, 2017, ONCOTARGET, V8, P47020, DOI 10.18632/oncotarget.16638; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4; Young CC, 2019, CELL MOL GASTROENTER, V7, P93, DOI 10.1016/j.jcmgh.2018.09.004	55	6	6	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3118	3135		10.1038/s41388-021-01771-z	http://dx.doi.org/10.1038/s41388-021-01771-z		APR 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33864001	Green Submitted, Green Accepted			2022-12-17	WOS:000640748600003
J	Xiao, Q; Gan, YQ; Li, YM; Fan, LL; Liu, JQ; Lu, PY; Liu, JX; Chen, AA; Shu, G; Yin, G				Xiao, Qing; Gan, Yaqi; Li, Yimin; Fan, Lili; Liu, Jiaqi; Lu, Pengyan; Liu, Jiaxin; Chen, Aoao; Shu, Guang; Yin, Gang			MEF2A transcriptionally upregulates the expression of ZEB2 and CTNNB1 in colorectal cancer to promote tumor progression	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; GROWTH-FACTOR; METASTASIS; DEGRADATION; DOWNSTREAM; ACTIVATION; TRANSITION; REPRESSOR; P38	Colorectal cancer (CRC) is one of the leading cancers worldwide, accounting for high morbidity and mortality. The mechanisms governing tumor growth and metastasis in CRC require detailed investigation. The results of the present study indicated that the transcription factor (TF) myocyte enhancer factor 2A (MEF2A) plays a dual role in promoting proliferation and metastasis of CRC by inducing the epithelial-mesenchymal transition (EMT) and activation of WNT/beta-catenin signaling. Aberrant expression of MEF2A in CRC clinical specimens was significantly associated with poor prognosis and metastasis. Functionally, MEF2A directly binds to the promoter region to initiate the transcription of ZEB2 and CTNNB1. Simultaneous activation of the expression of EMT-related TFs and Wnt/beta-catenin signaling by MEF2A overexpression induced the EMT and increased the frequency of tumor formation and metastasis. The present study identified a new critical oncogene involved in the growth and metastasis of CRC, providing a potential novel therapeutic target for CRC intervention.	[Xiao, Qing; Gan, Yaqi; Li, Yimin; Fan, Lili; Liu, Jiaqi; Lu, Pengyan; Liu, Jiaxin; Yin, Gang] Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China; [Chen, Aoao] Cent South Univ, Sch Basic Med Sci, Dept Immunol, Changsha, Peoples R China; [Shu, Guang] Cent South Univ, Sch Basic Med Sci, Dept Histol & Embryol, Changsha, Peoples R China; [Yin, Gang] Cent South Univ, Sch Basic Med Sci, China Africa Res Ctr Infect Dis, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University	Yin, G (corresponding author), Cent South Univ, Sch Basic Med Sci, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China.; Yin, G (corresponding author), Cent South Univ, Sch Basic Med Sci, China Africa Res Ctr Infect Dis, Changsha, Peoples R China.	gangyin@csu.edu.cn		Gan, Yaqi/0000-0001-8097-4603; Liu, Jiaxin/0000-0002-8903-114X; Yin, Gang/0000-0003-3753-0753	National Key RAMP;D Program of China, Stem Cell and Translational Research [2016YFA0102000]; National Natural Science Foundation of China [81572900]; Student Innovation Project of Central South University [1053320183731]	National Key RAMP;D Program of China, Stem Cell and Translational Research; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Student Innovation Project of Central South University	This work was supported by the National Key R&D Program of China, Stem Cell and Translational Research (no. 2016YFA0102000); National Natural Science Foundation of China (no. 81572900); and Student Innovation Project of Central South University (no. 1053320183731).	[Anonymous], 2016, MOL CELL BIOL, V36, P330; Bai XL, 2015, ONCOGENE, V34, P4089, DOI 10.1038/onc.2014.337; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Brown FC, 2018, CANCER DISCOV, V8, P478, DOI 10.1158/2159-8290.CD-17-1271; Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942; Chen HH, 2015, CIRC RES, V117, P671, DOI 10.1161/CIRCRESAHA.114.305777; Chen SX, 2012, CELL, V151, P41, DOI 10.1016/j.cell.2012.08.028; Clark RI, 2013, CELL, V155, P435, DOI 10.1016/j.cell.2013.09.007; Deczkowska A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00769-0; Di Giorgio E, 2018, BBA-REV CANCER, V1870, P261, DOI 10.1016/j.bbcan.2018.05.007; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Gjyshi A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26670-4; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; He Y, 2017, ONCOGENE, V36, P3490, DOI 10.1038/onc.2016.492; Herglotz J, 2016, BLOOD, V127, P572, DOI 10.1182/blood-2015-04-643270; Hua F, 2019, GASTROENTEROLOGY, V156, P708, DOI 10.1053/j.gastro.2018.10.031; Ishikawa F, 2010, ONCOGENE, V29, P909, DOI 10.1038/onc.2009.387; Kim JM, 2017, INTEGR CANCER THER, V16, P360, DOI 10.1177/1534735416670987; Li L, 2018, PHYSIOL GENOMICS, V50, P10, DOI 10.1152/physiolgenomics.00076.2017; Liu JJ, 2015, CELL PHYSIOL BIOCHEM, V36, P155, DOI 10.1159/000374060; Ma LN, 2014, CANCER RES, V74, P1452, DOI 10.1158/0008-5472.CAN-13-2171; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Mehta PB, 2001, ONCOGENE, V20, P5359, DOI 10.1038/sj.onc.1204688; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Ryan RJH, 2015, CANCER DISCOV, V5, P1058, DOI 10.1158/2159-8290.CD-15-0370; Shalizi A, 2006, SCIENCE, V311, P1012, DOI 10.1126/science.1122513; She H, 2012, J NEUROCHEM, V122, P1203, DOI 10.1111/j.1471-4159.2012.07860.x; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Snyder CM, 2013, DEVELOPMENT, V140, P31, DOI 10.1242/dev.081851; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Sreekumar R, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3115; Su L, 2016, CANCER RES, V76, P5054, DOI 10.1158/0008-5472.CAN-16-0246; Tang XL, 2005, J NEUROSCI, V25, P4823, DOI 10.1523/JNEUROSCI.1331-05.2005; Tung B, 2017, P NATL ACAD SCI USA, V114, pE707, DOI 10.1073/pnas.1610383114; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang FF, 2017, CANCER LETT, V388, P85, DOI 10.1016/j.canlet.2016.11.031; Xiang JY, 2020, GASTROENTEROLOGY, V158, P664, DOI 10.1053/j.gastro.2019.10.025; Xiang JY, 2017, CANCER LETT, V400, P117, DOI 10.1016/j.canlet.2017.04.037; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Zhang L, 2014, AUTOPHAGY, V10, P1015, DOI 10.4161/auto.28477; Zhang M, 2015, HYPERTENSION, V65, P335, DOI 10.1161/HYPERTENSIONAHA.114.04467	43	6	6	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3364	3377		10.1038/s41388-021-01774-w	http://dx.doi.org/10.1038/s41388-021-01774-w		APR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33863999	Green Published, hybrid			2022-12-17	WOS:000640748600001
J	Pan, ZH; Liu, CQ; Zhi, YF; Xie, ZY; Wu, L; Jiang, MH; Zhang, YJ; Zhou, R; Zhao, L				Pan, Zhihua; Liu, Chaoqun; Zhi, Yunfei; Xie, Zhiyue; Wu, Ling; Jiang, Muhong; Zhang, Yujie; Zhou, Rui; Zhao, Liang			LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation	ONCOGENE			English	Article							FACTOR RECEPTOR INHIBITION; KINASE 1; ACTIN DYNAMICS; GROWTH; CETUXIMAB; COFILIN; PHOSPHORYLATION; SENSITIVITY; THREONINE; SERINE	LIM kinase 1 (LIMK1) is a serine/threonine and tyrosine kinase that is predominantly located in the cytoplasm. In our study, nuclear translocation of LIMK1 in clinical hepatocellular carcinoma (HCC) samples was demonstrated for the first time, especially in samples from those with intravascular tumour thrombus. LIMK1 was overexpressed in HCC tissues, and nuclear LIMK1 expression was associated with poor prognosis in HCC patients. Although the effects of cytoplasmic LIMK1 on cofilin phosphorylation and actin filament dynamics have been well studied, the function of nuclear LIMK1 is still unclear. Gain- and loss-of-function experiments were performed both in vitro and in vivo and demonstrated a correlation between nuclear LIMK1 and the enhanced aggressive phenotype of HCC. EGF could drive the nuclear translocation of LIMK1 by activating the interaction of p-ERK and LIMK1 and facilitating their roles in nuclear shuttling. Moreover, nuclear LIMK1 could directly bind to the promoter region of c-Myc and stimulate c-Myc transcription. Although the EGFR monoclonal antibody cetuximab has a poor therapeutic effect on advanced HCC patients, in vivo animal study showed that cetuximab achieved a significant inhibitory effect on the progression of nuclear LIMK1-overexpressing HCC cells. In addition, recent data have demonstrated the potential of cetuximab in combination therapy for HCC patients with LIMK1 nuclear translocation.	[Pan, Zhihua; Liu, Chaoqun; Zhi, Yunfei; Xie, Zhiyue; Wu, Ling; Jiang, Muhong; Zhang, Yujie; Zhou, Rui; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Pan, Zhihua; Liu, Chaoqun; Zhi, Yunfei; Xie, Zhiyue; Wu, Ling; Jiang, Muhong; Zhang, Yujie; Zhou, Rui; Zhao, Liang] Southern Med Univ, Dept Pathol, Guangdong Prov Key Lab Mol Tumor Pathol, Sch Basic Med Sci, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China	Zhou, R; Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China.; Zhou, R; Zhao, L (corresponding author), Southern Med Univ, Dept Pathol, Guangdong Prov Key Lab Mol Tumor Pathol, Sch Basic Med Sci, Guangzhou, Peoples R China.	yaruisunny@sina.com; liangsmu@foxmail.com	Zhi, Yunfei/GQI-2937-2022	Zhi, Yunfei/0000-0002-0084-6810	National Natural Science Foundation of China [81773082, 81872423, 81972813, 81702903]; Guangdong Natural Science Foundation [2017A030310038, 2018B030311036, 2019A1515010974]; Fork Ying Tung Education Foundation [161035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fork Ying Tung Education Foundation	This work was supported by the National Natural Science Foundation of China (Nos. 81773082, 81872423, 81972813, 81702903), Guangdong Natural Science Foundation (2017A030310038, 2018B030311036, 2019A1515010974) and Fork Ying Tung Education Foundation (161035).	Abu Dayyeh BK, 2011, GASTROENTEROLOGY, V141, P141, DOI 10.1053/j.gastro.2011.03.045; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Asnacios A, 2008, CANCER-AM CANCER SOC, V112, P2733, DOI 10.1002/cncr.23489; Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650; Bonomi PD, 2018, ANN ONCOL, V29, P1701, DOI 10.1093/annonc/mdy196; Buonaguro L, 2013, J HEPATOL, V59, P897, DOI 10.1016/j.jhep.2013.05.031; Caruso S., 2020, HEPATOLOGY, V35, P331; Chen W, 2012, LIVER INT, V32, P70, DOI 10.1111/j.1478-3231.2011.02631.x; Craig AJ, 2020, NAT REV GASTRO HEPAT, V17, P139, DOI 10.1038/s41575-019-0229-4; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Ding XF, 2019, GASTROENTEROLOGY, V157, P1630, DOI 10.1053/j.gastro.2019.09.005; Fuchs BC, 2008, CANCER RES, V68, P2391, DOI 10.1158/0008-5472.CAN-07-2460; Fuchs BC, 2014, HEPATOLOGY, V59, P1577, DOI 10.1002/hep.26898; Gao QZ, 2020, ONCOGENE, V39, P3926, DOI 10.1038/s41388-020-1266-8; Ge LS, 2004, J HEPATOL, V41, P823, DOI 10.1016/j.jhep.2004.07.021; Gebbia V, 2007, ANN ONCOL, V18, P5, DOI 10.1093/annonc/mdm215; Goldberg Richard M, 2005, Nat Rev Drug Discov, VSuppl, pS10; Hamill S, 2016, MOL CELL, V62, P397, DOI 10.1016/j.molcel.2016.04.001; Hirsch FR, 2013, J THORAC ONCOL, V8, P373, DOI 10.1097/JTO.0b013e31827ed0ff; Huang JB, 2020, J CELL MOL MED, V24, P4698, DOI 10.1111/jcmm.15138; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kim E, 2018, HEPATOLOGY, V67, P2287, DOI 10.1002/hep.29738; Kremer D, 2009, P NATL ACAD SCI USA, V106, P9087, DOI 10.1073/pnas.0900204106; LAGOUTTE E, 2016, INT J BIOCHEM CELL B, V6; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Li WY, 2019, LIVER INT, V39, P147, DOI 10.1111/liv.13957; Liao Q, 2017, BRIT J CANCER, V117, P563, DOI 10.1038/bjc.2017.193; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 2018, NAT REV CLIN ONCOL, V15, P599, DOI 10.1038/s41571-018-0073-4; Maiello E, 2007, Ann Oncol, V18 Suppl 6, pvi8, DOI 10.1093/annonc/mdm216; Maik-Rachline G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051194; McConnell BV, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-75; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; NUNOUE K, 1995, ONCOGENE, V11, P701; Ohashi K, 2000, BIOCHEM BIOPH RES CO, V276, P1178, DOI 10.1006/bbrc.2000.3599; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; Perugorria MJ, 2019, NAT REV GASTRO HEPAT, V16, P121, DOI 10.1038/s41575-018-0075-9; Po'uha ST, 2010, ONCOGENE, V29, P597, DOI 10.1038/onc.2009.367; PROSCHEL C, 1995, ONCOGENE, V11, P1271; Schofield AV, 2013, BIOCHEM BIOPH RES CO, V436, P571, DOI 10.1016/j.bbrc.2013.05.076; Schofield AV., 2014, ADV BIOSCI BIOTECHNO, V05, P353, DOI [10.4236/abb.2014.54043, DOI 10.4236/ABB.2014.54043]; Sheng H, 2020, EUR REV MED PHARMACO, V24, P2625, DOI 10.26355/eurrev_202003_20531; Simhadri PK, 2017, ANN NEUROL, V82, P429, DOI 10.1002/ana.25028; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Stanyon CA, 1999, INT J BIOCHEM CELL B, V31, P389, DOI 10.1016/S1357-2725(98)00116-2; Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Yang N, 1999, BIOCHEM J, V338, P793, DOI 10.1042/0264-6021:3380793; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053; Yao Z, 2001, ONCOGENE, V20, P7588, DOI 10.1038/sj.onc.1204963; Zhao CC, 2020, CANCER LETT, V493, P120, DOI 10.1016/j.canlet.2020.08.006; Zhu AX, 2007, CANCER-AM CANCER SOC, V110, P581, DOI 10.1002/cncr.22829	52	6	6	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2581	2595		10.1038/s41388-021-01736-2	http://dx.doi.org/10.1038/s41388-021-01736-2		MAR 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686242				2022-12-17	WOS:000626396000006
J	Ali, R; Alblihy, A; Miligy, IM; Alabdullah, ML; Alsaleem, M; Toss, MS; Algethami, M; Abdel-Fatah, T; Moseley, P; Chan, S; Mongan, NP; Narayan, S; Rakha, EA; Madhusudan, S				Ali, Reem; Alblihy, Adel; Miligy, Islam M.; Alabdullah, Muslim L.; Alsaleem, Mansour; Toss, Michael S.; Algethami, Mashael; Abdel-Fatah, Tarek; Moseley, Paul; Chan, Stephen; Mongan, Nigel P.; Narayan, Satya; Rakha, Emad A.; Madhusudan, Srinivasan			Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers	ONCOGENE			English	Article							BASE EXCISION-REPAIR; POLY(ADP-RIBOSE) PAR POLYMER; GLYCOHYDROLASE PARG; CELLS; MECHANISMS; NAD(+); REPLICATION; DEFICIENT; PATHWAYS; DAMAGE	Targeting PARP1 [Poly(ADP-Ribose) Polymerase 1] for synthetic lethality is a new strategy for BRCA germ-line mutated or platinum sensitive ovarian cancers. However, not all patients respond due to intrinsic or acquired resistance to PARP1 inhibitor. Development of alternative synthetic lethality approaches is a high priority. DNA polymerase beta (Pol beta), a critical player in base excision repair (BER), interacts with PARP1 during DNA repair. Here we show that pol beta deficiency is a predictor of platinum sensitivity in human ovarian tumours. Pol beta depletion not only increased platinum sensitivity but also reduced invasion, migration and impaired EMT (epithelial to mesenchymal transition) of ovarian cancer cells. Pol beta small molecular inhibitors (Pamoic acid and NSC666719) were selectively toxic to BRCA2 deficient cells and associated with double-strand breaks (DSB) accumulation, cell cycle arrest and increased apoptosis. Interestingly, PARG [Poly(ADP-Ribose) Glycohydrolase] inhibitor (PDD00017273) [but not PARP1 inhibitor (Olaparib)] was synthetically lethal in pol beta deficient cells. Selective toxicity to PDD00017273 was associated with poly (ADP-ribose) accumulation, reduced nicotinamide adenine dinucleotide (NAD(+)) level, DSB accumulation, cell cycle arrest and increased apoptosis. In human tumours, pol beta-PARG co-expression adversely impacted survival in patients. Our data provide evidence that pol beta targeting is a novel strategy and warrants further pharmaceutical development in epithelial ovarian cancers.	[Ali, Reem; Alblihy, Adel; Alabdullah, Muslim L.; Algethami, Mashael; Madhusudan, Srinivasan] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Translat Oncol, Nottingham, England; [Alblihy, Adel] King Fahad Secur Coll KFSC, Med Ctr, Riyadh, Saudi Arabia; [Miligy, Islam M.; Alabdullah, Muslim L.; Alsaleem, Mansour; Toss, Michael S.; Rakha, Emad A.] Univ Nottingham, Acad Pathol, Div Canc & Stem Cells, Sch Med, Nottingham, England; [Miligy, Islam M.] Menoufia Univ, Dept Pathol, Fac Med, Menoufia, Egypt; [Abdel-Fatah, Tarek; Moseley, Paul; Chan, Stephen; Madhusudan, Srinivasan] Nottingham Univ Hosp, Dept Oncol, Nottingham, England; [Mongan, Nigel P.] Univ Nottingham, Ctr Canc Sci, Fac Med & Hlth Sci, Sutton Bonington Campus, Loughborough, Leics, England; [Mongan, Nigel P.] Weill Cornell Med, Dept Pharmacol, New York, NY USA; [Narayan, Satya] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL USA	University of Nottingham; University of Nottingham; Egyptian Knowledge Bank (EKB); Menofia University; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; Cornell University; State University System of Florida; University of Florida	Madhusudan, S (corresponding author), Univ Nottingham, Sch Med, Div Canc & Stem Cells, Translat Oncol, Nottingham, England.; Madhusudan, S (corresponding author), Nottingham Univ Hosp, Dept Oncol, Nottingham, England.	srinivasan.madhusudan@nottingham.ac.uk		Madhusudan, Srinivasan/0000-0002-5354-5480; Mongan, Nigel/0000-0001-5438-1126	Naaz-Coker Ovarian Cancer Fellowship, University of Nottingham, UK	Naaz-Coker Ovarian Cancer Fellowship, University of Nottingham, UK	Research in Madhusudan lab is supported by Naaz-Coker Ovarian Cancer Fellowship, University of Nottingham, UK.	Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103; Beaufort CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103988; Blaschuk OW, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0039; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Croteau DL, 2017, CELL CYCLE, V16, P491, DOI 10.1080/15384101.2017.1285631; D'Andrea AD, 2018, DNA REPAIR, V71, P172, DOI 10.1016/j.dnarep.2018.08.021; DELFINI C, 1985, P NATL ACAD SCI USA, V82, P2220, DOI 10.1073/pnas.82.8.2220; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; Dianov GL, 2013, NUCLEIC ACIDS RES, V41, P3483, DOI 10.1093/nar/gkt076; Dong ZM, 2006, DIS ESOPHAGUS, V19, P172, DOI 10.1111/j.1442-2050.2006.00560.x; Farina AR, 2014, CANCERS, V6, P240, DOI 10.3390/cancers6010240; Fathers C, 2012, CELL CYCLE, V11, P990, DOI 10.4161/cc.11.5.19482; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Fouquerel E, 2014, DNA REPAIR, V23, P27, DOI 10.1016/j.dnarep.2014.09.004; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gogola E, 2018, CANCER CELL, V33, P1078, DOI 10.1016/j.ccell.2018.05.008; Gravells P, 2017, DNA REPAIR, V52, P81, DOI 10.1016/j.dnarep.2017.02.010; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hazan C, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-22; Iwatsuki M, 2009, J SURG ONCOL, V100, P261, DOI 10.1002/jso.21275; Jaiswal AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123808; Jaiswal AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016691; Jaiswal AS, 2009, MOL CANCER RES, V7, P1973, DOI 10.1158/1541-7786.MCR-09-0309; Khanra K, 2012, CANCER BIOMARK, V11, P155, DOI 10.3233/CBM-2012-00275; Koh DW, 2005, CELL CYCLE, V4, P397, DOI 10.4161/cc.4.3.1559; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Lombard DB, 2009, AGING-US, V1, P12, DOI 10.18632/aging.100014; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Loret N, 2019, CANCERS, V11, DOI 10.3390/cancers11060838; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Min W, 2009, FRONT BIOSCI-LANDMRK, V14, P1619, DOI 10.2741/3329; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Moore K, 2018, NEW ENGL J MED, V379, P2495, DOI 10.1056/NEJMoa1810858; Moustakas A, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070063; Oughtred R, 2019, NUCLEIC ACIDS RES, V47, pD529, DOI 10.1093/nar/gky1079; Parlanti E, 2007, NUCLEIC ACIDS RES, V35, P1569, DOI 10.1093/nar/gkl1159; Pascal JM, 2015, DNA REPAIR, V32, P10, DOI 10.1016/j.dnarep.2015.04.008; Pillay N, 2019, CANCER CELL, V35, P519, DOI 10.1016/j.ccell.2019.02.004; Pu H, 2014, CARCINOGENESIS, V35, P2592, DOI 10.1093/carcin/bgu183; Raudenska M., 2019, SCI REP-UK, V9, DOI [10.1038/s41598-018-38199-7, DOI 10.1038/S41598-018-38199-7]; Raudenska M, 2019, METALLOMICS, V11, P1182, DOI 10.1039/c9mt00049f; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sobol RW, 2001, PROG NUCLEIC ACID RE, V68, P57; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Starcevic D, 2004, CELL CYCLE, V3, P998; Sweasy JB, 2003, PROG NUCLEIC ACID RE, V73, P137, DOI 10.1016/S0079-6603(03)01005-5; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/s1470-2045(16)30559-9, 10.1016/S1470-2045(16)30559-9]; Weyemi U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10711; Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010; Yang J, 2010, ONCOGENE, V29, P463, DOI 10.1038/onc.2009.327; Ying WH, 2005, J NEUROSCI RES, V79, P216, DOI 10.1002/jnr.20289; Yu SW, 2006, P NATL ACAD SCI USA, V103, P18314, DOI 10.1073/pnas.0606528103	55	6	6	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2496	2508		10.1038/s41388-021-01710-y	http://dx.doi.org/10.1038/s41388-021-01710-y		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33674744	hybrid, Green Published			2022-12-17	WOS:000625607100004
J	Cui, KS; Yao, SR; Zhang, H; Zhou, MY; Liu, BX; Cao, YL; Fei, BJ; Huang, SL; Huang, ZH				Cui, Kaisa; Yao, Surui; Zhang, Han; Zhou, Mingyue; Liu, Bingxin; Cao, Yulin; Fei, Bojian; Huang, Shenglin; Huang, Zhaohui			Identification of an immune overdrive high-risk subpopulation with aberrant expression of FOXP3 and CTLA4 in colorectal cancer	ONCOGENE			English	Article								Colorectal cancer (CRC) is characterized by a heterogeneous tumor microenvironment (TME) that regulates cancer progression and therapeutic response. Overexpression of FOXP3 and CTLA4 is associated with immunosuppressive TME and poor prognosis in many cancer types. However, opposite results were reported in CRC. Thus, we performed comprehensive analyses to evaluate the exact prognostic value of FOXP3 and CTLA4 in CRC. Here, the expression levels of FOXP3 and CTLA4 were used to construct a subtyping system based on >1200 CRC patients from multiple independent public datasets. We revealed that, in CRC patients with relatively high expression of FOXP3, there exist two different subpopulations with opposite survival patterns according to CLTA4 expression. We further established a method for evaluating all cohorts and identified a novel FOXP3(High)CTLA4(High*) CRC risk subpopulation that accounts for 5-10% of CRC patients. Moreover, different methods of functional enrichment and immune evaluation were used to analyze the TME characteristics of different FOXP3/CTLA4 subtypes. The FOXP3(High)CTLA4(High*) CRC risk subpopulation was characterized by an immune overdrive TME phenotype, including high immune cell infiltration, low tumor purity, high immune checkpoint levels, and TGF-beta activation. Finally, the constructed FOXP3/CTLA4 subtyping system was further validated by quantitative RT-PCR, immunochemistry staining, and multicolor immunofluorescence in an independent CRC cohort we collected. This high-risk subpopulation was also observed in kidney cancers and low-grade glioma patients by a Pan-cancer analysis. Together, our study revealed that the established FOXP3/CTLA4 molecular subtyping system could be used to select treatment and management strategies for CRC and other cancers.	[Cui, Kaisa; Yao, Surui; Zhang, Han; Zhou, Mingyue; Liu, Bingxin; Cao, Yulin; Fei, Bojian; Huang, Zhaohui] Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi, Jiangsu, Peoples R China; [Cui, Kaisa; Zhang, Han; Zhou, Mingyue; Liu, Bingxin; Cao, Yulin; Huang, Zhaohui] Jiangnan Univ, Wuxi Sch Med, Lab Canc Epigenet, Wuxi, Jiangsu, Peoples R China; [Huang, Shenglin] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China; [Huang, Shenglin] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China	Jiangnan University; Jiangnan University; Fudan University; Fudan University	Huang, ZH (corresponding author), Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, Wuxi, Jiangsu, Peoples R China.; Huang, ZH (corresponding author), Jiangnan Univ, Wuxi Sch Med, Lab Canc Epigenet, Wuxi, Jiangsu, Peoples R China.	zhaohuihuang@jiangnan.edu.cn	Huang, Zhaohui/S-9410-2019; Cui, Kaisa/AAM-6601-2020	Huang, Zhaohui/0000-0002-0117-9976; Cui, Kaisa/0000-0001-7255-2689; Fei, Bojian/0000-0002-3672-0216; Liu, Bingxin/0000-0002-6744-4912	National Natural Science Foundation of China [82002550, 81672328, 81972220]; Jiangsu Key Research and Development Plan [BE2019632]; Medical Key Professionals Program of Jiangsu Province [AF052141]; National First-class Discipline Program of Food Science and Technology [JUFSTR20180101]; Wuxi Medical Innovation Team [CXTP003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Key Research and Development Plan; Medical Key Professionals Program of Jiangsu Province; National First-class Discipline Program of Food Science and Technology; Wuxi Medical Innovation Team	We thank the TCGA, GEO, and CPTAC project. We thank the Affiliated Hospital of Jiangnan University for providing the CRC samples. This work was supported by grants from the National Natural Science Foundation of China (82002550, 81672328, and 81972220), Jiangsu Key Research and Development Plan (BE2019632), Medical Key Professionals Program of Jiangsu Province (AF052141), National First-class Discipline Program of Food Science and Technology (JUFSTR20180101), and Wuxi Medical Innovation Team (CXTP003).	Andrews LP, 2019, NAT IMMUNOL, V20, P1425, DOI 10.1038/s41590-019-0512-0; Bai XG, 2019, ONCOTARGETS THER, V12, P9527, DOI 10.2147/OTT.S224013; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chew A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022047; Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003; Cui KS, 2020, ONCOGENE, V39, P786, DOI 10.1038/s41388-019-1026-9; Deng L, 2015, J THORAC ONCOL, V10, P1020, DOI 10.1097/JTO.0000000000000550; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; Fakih M, 2019, J CLIN INVEST, V129, P4464, DOI 10.1172/JCI127046; Fiegle E, 2019, NEOPLASIA, V21, P932, DOI 10.1016/j.neo.2019.07.006; Freeman ZT, 2020, J CLIN INVEST, V130, P1405, DOI 10.1172/JCI128672; Ganapathi SK, 2014, BRIT J CANCER, V111, P1581, DOI 10.1038/bjc.2014.477; Gemignani, 2020, SEMIN CANCER BIOL; Giraldo NA, 2019, BRIT J CANCER, V120, P45, DOI 10.1038/s41416-018-0327-z; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Heinzerling L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0152-y; Herrmann A, 2017, CANCER RES, V77, P5118, DOI 10.1158/0008-5472.CAN-16-0342; Iglesia MD, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw144; Lal A, 2013, BREAST CANCER RES TR, V139, P381, DOI 10.1007/s10549-013-2556-4; Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Lu LG, 2017, BREAST CANCER RES TR, V164, P689, DOI 10.1007/s10549-017-4281-x; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Petitprez F, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00783-w; Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171; Punt S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0350-0; Raffin C, 2020, NAT REV IMMUNOL, V20, P158, DOI 10.1038/s41577-019-0232-6; Ramos-Casals M, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0160-6; Riera-Domingo C, 2020, PHYSIOL REV, V100, P1, DOI 10.1152/physrev.00018.2019; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Shi JY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3633-6; Stack EC, 2014, METHODS, V70, P46, DOI 10.1016/j.ymeth.2014.08.016; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun XW, 2017, INT J IMMUNOPATH PH, V30, P201, DOI 10.1177/0394632017710415; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Toor SM, 2020, SEMIN CANCER BIOL, V65, P1, DOI 10.1016/j.semcancer.2019.06.021; Wei YF, 2018, LUNG CANCER, V125, P35, DOI 10.1016/j.lungcan.2018.09.002; Weller P, 2014, EUR J CANCER, V50, P1291, DOI 10.1016/j.ejca.2014.02.016; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Wu CC, 2019, SCI CHINA LIFE SCI, V62, P640, DOI 10.1007/s11427-018-9461-5; Wu F, 2020, MOL ONCOL, V14, P2081, DOI 10.1002/1878-0261.12707; Xiang Z, 2019, IMMUNOPHARM IMMUNOT, V41, P386, DOI 10.1080/08923973.2018.1533968; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1; Yin Y, 2017, CLIN CANCER RES, V23, P7375, DOI 10.1158/1078-0432.CCR-17-1283; Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu HM, 2015, CANCER IMMUNOL IMMUN, V64, P853, DOI 10.1007/s00262-015-1696-2; Zaravinos A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1372-z	58	6	6	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2130	2145		10.1038/s41388-021-01677-w	http://dx.doi.org/10.1038/s41388-021-01677-w		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627780				2022-12-17	WOS:000621289100007
J	Ke, XY; Chen, Y; Tham, VYY; Lin, RYT; Dakle, P; Nacro, K; Puhaindran, ME; Houghton, P; Pang, A; Lee, VK; Ding, LW; Gery, S; Hill, J; Chen, LL; Xu, L; Koeffler, HP				Ke, Xin-Yu; Chen, Ye; Tham, Valarie Yu-Yan; Lin, Ruby Yu-Tong; Dakle, Pushkar; Nacro, Kassoum; Puhaindran, Mark Edward; Houghton, Peter; Pang, Angela; Lee, Victor Kwanmin; Ding, Ling-Wen; Gery, Sigal; Hill, Jeffrey; Chen, Leilei; Xu, Liang; Koeffler, H. Phillip			MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma	ONCOGENE			English	Article								Soft tissue sarcoma (STS) is a heterogeneous disease that arises from connective tissues. Clinical outcome of patients with advanced tumors especially de-differentiated liposarcoma and uterine leiomyosarcoma remains unsatisfactory, despite intensive treatment regimens including maximal surgical resection, radiation, and chemotherapy. MAP kinase-interacting serine/threonine-protein kinase 1 and 2 (MNK1/2) have been shown to contribute to oncogenic translation via phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). However, little is known about the role of MNK1/2 and their downstream targets in STS. In this study, we show that depletion of either MNK1 or MNK2 suppresses cell viability, anchorage-independent growth, and tumorigenicity of STS cells. We also identify a compelling antiproliferative efficacy of a novel, selective MNK inhibitor ETC-168. Cellular responsiveness of STS cells to ETC-168 correlates positively with that of phosphorylated ribosomal protein S6 (RPS6). Mirroring MNK1/2 silencing, ETC-168 treatment strongly blocks eIF4E phosphorylation and represses expression of sarcoma-driving onco-proteins including E2F1, FOXM1, and WEE1. Moreover, combination of ETC-168 and MCL1 inhibitor S63845 exerts a synergistic antiproliferative activity against STS cells. In summary, our study reveals crucial roles of MNK1/2 and their downstream targets in STS tumorigenesis. Our data encourage further clinical translation of MNK inhibitors for STS treatment.	[Ke, Xin-Yu; Chen, Ye; Tham, Valarie Yu-Yan; Lin, Ruby Yu-Tong; Dakle, Pushkar; Chen, Leilei; Xu, Liang; Koeffler, H. Phillip] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore; [Ke, Xin-Yu; Chen, Leilei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore; [Nacro, Kassoum] Agcy Sci Technol & Res, Expt Drug Dev Ctr, Singapore, Singapore; [Puhaindran, Mark Edward; Pang, Angela; Koeffler, H. Phillip] Natl Univ, Natl Univ Hosp, Canc Inst, Singapore, Singapore; [Puhaindran, Mark Edward] Natl Univ Singapore Hosp, Div Musculoskeletal Oncol, Univ Orthopaed Hand & Reconstruct Microsurg Clust, Singapore, Singapore; [Puhaindran, Mark Edward] Natl Univ Singapore Hosp, Dept Hand & Reconstruct Microsurg, Singapore, Singapore; [Houghton, Peter] UT Hlth San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX USA; [Lee, Victor Kwanmin] Natl Univ Singapore Hosp, Dept Pathol, Singapore, Singapore; [Ding, Ling-Wen] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pathol, Singapore, Singapore; [Gery, Sigal; Koeffler, H. Phillip] Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; [Hill, Jeffrey] Univ Sussex, Sch Life Sci, Sussex Drug Discovery Ctr, Brighton, E Sussex, England	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Experimental Drug Development Centre (EDDC); National University of Singapore; National University of Singapore; National University of Singapore; University of Texas System; University of Texas Health San Antonio; National University of Singapore; National University of Singapore; Cedars Sinai Medical Center; University of Sussex	Chen, Y; Xu, L (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.	zjuchenye@gmail.com; xuliang.zju@gmail.com	Xu, Liang/I-9877-2014; Ding, Ling-Wen/H-6916-2019	Xu, Liang/0000-0002-2700-4840; Ding, Ling-Wen/0000-0003-0022-1551; Lin, Ruby/0000-0003-3229-4659; Lee, Victor Kwan Min/0000-0001-7803-0005	Biomedical Sciences Institutes; Joint Council Office (JCO), Agency for Science, Technology and Research, Singapore [11 03 FG 07 05]; National Institutes of Health [R01-CA200992-04]; Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award [NMRC/STaR/0021/2014]; Singapore Ministry of Education [MOE2017-T21-033]; RNA Biology Center at the Cancer Science Institute of Singapore of NUS as part of Singapore Ministry of Education's AcRF [MOE2014-T3-1-006]; NMRC Centre Grant Programme [NMRC/CG/012/2013, CGAug16M005, NMRC/CG/M005/2017_NCIS]; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiatives; NUS Center for Cancer Research (N2CR), Cancer Programme under Translational Research Programmes; Yong Loo Lin School of Medicine, NUS [NUHSRO/2020/122/MSC/07/Cancer]; NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; NMRC Open Fund Young Individual Research Grants [MOH-OFYIRG19Nov-0016, MOH-OFYIRG18May-0001]; Walk Foundation	Biomedical Sciences Institutes; Joint Council Office (JCO), Agency for Science, Technology and Research, Singapore; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award(Ministry of Health-SingaporeNational Medical Research Council, Singapore); Singapore Ministry of Education(Ministry of Education, Singapore); RNA Biology Center at the Cancer Science Institute of Singapore of NUS as part of Singapore Ministry of Education's AcRF; NMRC Centre Grant Programme(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiatives(Ministry of Education, Singapore); NUS Center for Cancer Research (N2CR), Cancer Programme under Translational Research Programmes; Yong Loo Lin School of Medicine, NUS; NCIS Centre Grant; NCIS Yong Siew Yoon Research grant; NMRC Open Fund Young Individual Research Grants; Walk Foundation	We thank Drs Pierre Aman, Christopher DM Fletcher, Florence Pedeutour, Eugenio Erba, Jun Nishio, Peter Moller, Dominique Broccoli, Raphael Pollock, Peter Houghton, Stefan Frohling, Karen Sisley, Abdulazeez Salawu, Matthew Ho, Omid Khorram, Rebecca Lock, and Alex Matter for generous sharing of cell lines and reagents. We also thank kind helps from Dr Motomi Osato, Dr Yangyang Song, Mr. Haoqing Shen, and Dr Jian Han in experiments and discussion. The discovery of ETC-168 (also known as AUM168 in AUM Biosciences) was financially supported by Biomedical Sciences Institutes and Joint Council Office (JCO Project 11 03 FG 07 05), Agency for Science, Technology and Research, Singapore. This work is funded by the National Institutes of Health (R01-CA200992-04 to HPK), Singapore Ministry of Health's National Medical Research Council (NMRC) under its Singapore Translational Research (STaR) Investigator Award to HPK. (NMRC/STaR/0021/2014), the Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2017-T21-033), the RNA Biology Center at the Cancer Science Institute of Singapore of NUS as part of funding under the Singapore Ministry of Education's AcRF Tier 3 grants (MOE2014-T3-1-006), the NMRC Centre Grant Programme awarded to National University Cancer Institute of Singapore (NMRC/CG/012/2013, CGAug16M005 and NMRC/CG/M005/2017_NCIS) and the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiatives. It is additionally supported by NUS Center for Cancer Research (N2CR), Cancer Programme under Translational Research Programmes, Yong Loo Lin School of Medicine, NUS (NUHSRO/2020/122/MSC/07/Cancer), a Seed Funding Program within the NCIS Centre Grant, a NCIS Yong Siew Yoon Research grant through donations from the Yong Loo Lin Trust, and philanthropic donations from the Wendy Walk Foundation, Ms. Tricia West and Ms. Linda Abrams. YC and LX are supported by the NMRC Open Fund Young Individual Research Grants (MOH-OFYIRG19Nov-0016 and MOH-OFYIRG18May-0001).	AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Bhat M, 2015, NAT REV DRUG DISCOV, V14, P261, DOI 10.1038/nrd4505; Brown MC, 2017, CELL REP, V18, P1444, DOI 10.1016/j.celrep.2017.01.023; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09257-z; Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Diab S, 2014, CHEM BIOL, V21, P441, DOI 10.1016/j.chembiol.2014.01.011; Dreas A, 2017, CURR MED CHEM, V24, P3025, DOI 10.2174/0929867324666170203123427; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Fletcher CDM, 2013, WHO CLASSIFICATION T; George S, 2018, J CLIN ONCOL, V36, P144, DOI 10.1200/JCO.2017.75.9845; Grzmil M, 2014, J CLIN INVEST, V124, P742, DOI 10.1172/JCI70198; Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112; Guo QY, 2019, CANCER RES, V79, P1646, DOI 10.1158/0008-5472.CAN-18-1602; Guo ZH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10397-9; Hay N, 2010, P NATL ACAD SCI USA, V107, P13975, DOI 10.1073/pnas.1008908107; Hazawa M, 2020, ONCOGENE, V39, P2212, DOI 10.1038/s41388-019-1137-3; Hazawa M, 2018, EMBO REP, V19, P73, DOI 10.15252/embr.201744523; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Hou S, 2017, CLIN TRANSL ONCOL, V19, P1107, DOI 10.1007/s12094-017-1646-x; Hu SI, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002466; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Lim S, 2013, P NATL ACAD SCI USA, V110, pE2298, DOI 10.1073/pnas.1301838110; Lock R, 2016, J CLIN INVEST, V126, P2181, DOI 10.1172/JCI85183; Lopez G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188859; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Matheson CJ, 2016, TRENDS PHARMACOL SCI, V37, P872, DOI 10.1016/j.tips.2016.06.006; Nishio J, 2003, INT J ONCOL, V22, P535; Pang A, 2016, JAMA ONCOL, V2, P941, DOI 10.1001/jamaoncol.2016.0241; Persson F, 2008, CANCER LETT, V260, P37, DOI 10.1016/j.canlet.2007.10.032; Salawu A, 2016, BRIT J CANCER, V115, P1058, DOI 10.1038/bjc.2016.259; Santag S, 2017, CANCER LETT, V390, P21, DOI 10.1016/j.canlet.2016.12.029; Sekiyama N, 2015, P NATL ACAD SCI USA, V112, pE4036, DOI 10.1073/pnas.1512118112; Sharma B, 2012, J BIOL CHEM, V287, P42352, DOI 10.1074/jbc.M112.400721; Snyder EL, 2009, J PATHOL, V218, P292, DOI 10.1002/path.2564; Thelin-Jarnum S, 1999, INT J CANCER, V83, P30, DOI 10.1002/(SICI)1097-0215(19990924)83:1<30::AID-IJC6>3.0.CO;2-4; Uboldi S, 2012, INT J CANCER, V131, P59, DOI 10.1002/ijc.26340; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Vitale G, 2012, BIOTECHNOL ADV, V30, P169, DOI 10.1016/j.biotechadv.2011.08.001; Wabitsch M, 2000, INT J CANCER, V88, P889, DOI 10.1002/1097-0215(20001215)88:6<889::AID-IJC8>3.0.CO;2-N; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webster KR, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.1554.1554; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wilson C, 2014, CANCER RES, V74, P5878, DOI 10.1158/0008-5472.CAN-14-1009; Xu L, 2018, P NATL ACAD SCI USA, V115, pE5086, DOI 10.1073/pnas.1712363115; Xu YC, 2019, NAT MED, V25, P301, DOI 10.1038/s41591-018-0321-2; Yang H, 2018, J MED CHEM, V61, P4348, DOI 10.1021/acs.jmedchem.7b01714; Yang W, 2020, ONCOGENE, V39, P3650, DOI 10.1038/s41388-020-1240-5; Yao S, 2018, SEMIN CANCER BIOL, V50, P77, DOI 10.1016/j.semcancer.2017.11.018; Zhan Y, 2017, J CLIN INVEST, V127, P4179, DOI 10.1172/JCI91258	56	6	6	6	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1851	1867		10.1038/s41388-021-01661-4	http://dx.doi.org/10.1038/s41388-021-01661-4		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564073	hybrid, Green Published			2022-12-17	WOS:000616489100006
J	Jung, H; Lee, KS; Choi, JK				Jung, Hyunchul; Lee, Kang Seon; Choi, Jung Kyoon			Comprehensive characterisation of intronic mis-splicing mutations in human cancers	ONCOGENE			English	Article							MESSENGER-RNA DECAY; ANTISENSE OLIGONUCLEOTIDES; SPLICING FACTORS; GENOME; IDENTIFICATION; NONSENSE; ANNOTATION; SUPPRESSOR; MECHANISM; VARIANTS	Previous studies studying mis-splicing mutations were based on exome data and thus our current knowledge is largely limited to exons and the canonical splice sites. To comprehensively characterise intronic mis-splicing mutations, we analysed 1134 pan-cancer whole genomes and transcriptomes together with 3022 normal control samples. The ratio-based splicing analysis resulted in 678 somatic intronic mutations, with 46% residing in deep introns. Among the 309 deep intronic single nucleotide variants, 245 altered core splicing codes, with 38% activating cryptic splice sites, 12% activating cryptic polypyrimidine tracts, and 36% and 12% disrupting authentic polypyrimidine tracts and branchpoints, respectively. All the intronic cryptic splice sites were created at pre-existing GT/AG dinucleotides or by GC-to-GT conversion. Notably, 85 deep intronic mutations indicated gain of splicing enhancers or loss of splicing silencers. We found that 64 tumour suppressors were affected by intronic mutations and blood cancers showed higher proportion of deep intronic mutations. In particular, a telomere maintenance gene, POT1, was recurrently mis-spliced by deep intronic mutations in blood cancers. We validated a pseudoexon activation involving a splicing silencer in POT1 by CRISPR/Cas9. Our results shed light on previously unappreciated mechanisms by which noncoding mutations acting on splicing codes in deep introns contribute to tumourigenesis.	[Jung, Hyunchul; Lee, Kang Seon; Choi, Jung Kyoon] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 34141, South Korea; [Jung, Hyunchul] Wellcome Sanger Inst, Canc Ageing & Somat Mutat Programme, Cambridge, England; [Choi, Jung Kyoon] Penta Medix Co Ltd, Seongnam Si 13449, Gyeongi Do, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Wellcome Trust Sanger Institute	Jung, H; Choi, JK (corresponding author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon 34141, South Korea.; Jung, H (corresponding author), Wellcome Sanger Inst, Canc Ageing & Somat Mutat Programme, Cambridge, England.; Choi, JK (corresponding author), Penta Medix Co Ltd, Seongnam Si 13449, Gyeongi Do, South Korea.	hj6@sanger.ac.uk; jungkyoon@kaist.ac.kr			Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT) [2017M3A9A7050612]; National Research Foundation of Korea - Korean Government [NRF-2020R1A6A3A03039805]	Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIT)(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea); National Research Foundation of Korea - Korean Government(National Research Foundation of KoreaKorean Government)	This research was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2017M3A9A7050612). HJ was supported by a grant from the National Research Foundation of Korea funded by the Korean Government (NRF-2020R1A6A3A03039805).	Alexander RP, 2010, NAT REV GENET, V11, P559, DOI 10.1038/nrg2814; Alsamman K, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171672; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Brogna S, 2009, NAT STRUCT MOL BIOL, V16, P107, DOI 10.1038/nsmb.1550; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cornish AJ, 2019, BLOOD ADV, V3, P21, DOI 10.1182/bloodadvances.2018026419; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; de Miranda NFCC, 2014, BLOOD, V124, P2544, DOI 10.1182/blood-2013-12-546309; De Paoli L, 2013, LEUKEMIA LYMPHOMA, V54, P1087, DOI 10.3109/10428194.2012.723706; Diederichs S, 2016, EMBO MOL MED, V8, P442, DOI 10.15252/emmm.201506055; Dong XS, 2020, ONCOGENE, V39, P2231, DOI 10.1038/s41388-019-1138-2; Dvinge H, 2016, NAT REV CANCER, V16, P413, DOI 10.1038/nrc.2016.51; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; Erkelenz S, 2013, RNA, V19, P96, DOI 10.1261/rna.037044.112; Fairbrother WG, 2004, NUCLEIC ACIDS RES, V32, pW187, DOI 10.1093/nar/gkh393; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fu XD, 2014, NAT REV GENET, V15, P689, DOI 10.1038/nrg3778; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Havens MA, 2016, NUCLEIC ACIDS RES, V44, P6549, DOI 10.1093/nar/gkw533; Jaganathan K, 2019, CELL, V176, P535, DOI 10.1016/j.cell.2018.12.015; Jayasinghe RG, 2018, CELL REP, V23, P270, DOI 10.1016/j.celrep.2018.03.052; Jung- H, 2015, NAT GENET, V47, P1242, DOI 10.1038/ng.3414; Kahles A, 2018, CANCER CELL, V34, P211, DOI 10.1016/j.ccell.2018.07.001; Ke SD, 2011, GENOME RES, V21, P1360, DOI 10.1101/gr.119628.110; Khurana E, 2016, NAT REV GENET, V17, P93, DOI 10.1038/nrg.2015.17; Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260; Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525; Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824; Lewandowska MA, 2013, INT J CLIN EXP PATHO, V6, P2675; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Lindeboom RGH, 2016, NAT GENET, V48, P1112, DOI 10.1038/ng.3664; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Lopez-Bigas N, 2005, FEBS LETT, V579, P1900, DOI 10.1016/j.febslet.2005.02.047; Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26; Mercer TR, 2015, GENOME RES, V25, P290, DOI 10.1101/gr.182899.114; Morin RD, 2016, CLIN CANCER RES, V22, P2290, DOI 10.1158/1078-0432.CCR-15-2123; Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533; Parker JDK, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a000679; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pinzaru AM, 2016, CELL REP, V15, P2170, DOI 10.1016/j.celrep.2016.05.008; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Rinaldi C, 2018, NAT REV NEUROL, V14, P9, DOI 10.1038/nrneurol.2017.148; Scotti MM, 2016, NAT REV GENET, V17, P19, DOI 10.1038/nrg.2015.3; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Shiraishi Y, 2018, GENOME RES, V28, P1111, DOI 10.1101/gr.231951.117; Sibley CR, 2016, NAT REV GENET, V17, P407, DOI 10.1038/nrg.2016.46; Sickmier EA, 2006, MOL CELL, V23, P49, DOI 10.1016/j.molcel.2006.05.025; Signal B, 2018, BIOINFORMATICS, V34, P920, DOI 10.1093/bioinformatics/btx688; Soemedi R, 2017, NAT GENET, V49, P848, DOI 10.1038/ng.3837; Sterne-Weiler T, 2011, GENOME RES, V21, P1563, DOI 10.1101/gr.118638.110; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Taggart AJ, 2017, GENOME RES, V27, P639, DOI 10.1101/gr.202820.115; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vaz-Drago R, 2017, HUM GENET, V136, P1093, DOI 10.1007/s00439-017-1809-4; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vorechovsky I, 2006, NUCLEIC ACIDS RES, V34, P4630, DOI 10.1093/nar/gkl535; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041; Wang Y, 2012, NAT STRUCT MOL BIOL, V19, P1044, DOI 10.1038/nsmb.2377; Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010; Yeo G, 2004, J COMPUT BIOL, V11, P377, DOI 10.1089/1066527041410418	64	6	6	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1347	1361		10.1038/s41388-020-01614-3	http://dx.doi.org/10.1038/s41388-020-01614-3		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420369	hybrid, Green Published			2022-12-17	WOS:000607346000005
J	Lu, YW; Li, XD; Liu, HL; Xue, J; Zeng, Z; Dong, XR; Zhang, T; Wu, G; Yang, KY; Xu, SB				Lu, Yanwei; Li, Xudong; Liu, Hongli; Xue, Jun; Zeng, Zhen; Dong, Xiaorong; Zhang, Tao; Wu, Gang; Yang, Kunyu; Xu, Shuangbing			beta-Trcp and CK1 delta-mediated degradation of LZTS2 activates PI3K/AKT signaling to drive tumorigenesis and metastasis in hepatocellular carcinoma	ONCOGENE			English	Article							ZIPPER TUMOR-SUPPRESSOR; UBIQUITIN LIGASE; MEDIATED DEGRADATION; RADIORESISTANCE; PROLIFERATION; PROTEINS; CATENIN; FAMILY; EXPORT	Distant metastasis is the leading cause of treatment failure in patients with hepatocellular carcinoma (HCC). However, the underlying mechanisms have not been fully elucidated. Here, we report that Leucine zipper tumor suppressor 2 (LZTS2) is downregulated and correlated with poor prognosis in HCC. Furthermore, we provide evidence that LZTS2 associates with p85 to inhibit the activation of PI3K/AKT signaling and impairs HCC tumorigenesis and metastasis in vitro and in vivo. Moreover, we identify LZTS2 as a bona fide substrate of the E3 ligase beta-Trcp and protein kinase CK1 delta, which are responsible for the ubiquitination and degradation of LZTS2. Importantly, we show that the beta-Trcp and CK1 delta-mediated degradation of LZTS2 promotes HCC progression and metastasis by activating PI3K/AKT signaling. Collectively, our study not only illustrates the roles of LZTS2 in regulating HCC tumorigenesis and metastasis but also reveals a novel posttranslational modification of LZTS2 by beta-Trcp and CK1 delta, indicating that the beta-Trcp/CK1 delta/LZTS2/PI3K axis may be a novel oncogenic driver involved in HCC progression and metastasis.	[Lu, Yanwei; Li, Xudong; Liu, Hongli; Xue, Jun; Zeng, Zhen; Dong, Xiaorong; Zhang, Tao; Wu, Gang; Yang, Kunyu; Xu, Shuangbing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology	Wu, G; Yang, KY; Xu, SB (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430022, Peoples R China.	xhzlwg@163.com; yangky71@aliyun.com; xsb723@hust.edu.cn		Xu, Shuangbing/0000-0002-9166-7788	Hubei Provincial Natural Science Fund for Distinguished Young Scholars [2019CFA063]; National Natural Science Foundation of China [81874041]; Wuhan Science and Technology Bureau [2019020701011437]	Hubei Provincial Natural Science Fund for Distinguished Young Scholars; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wuhan Science and Technology Bureau	This work was supported by the Hubei Provincial Natural Science Fund for Distinguished Young Scholars (2019CFA063 to SX), the National Natural Science Foundation of China (81874041 to SX), and the grants from the Wuhan Science and Technology Bureau (2019020701011437 to SX).	Asrani SK, 2019, J HEPATOL, V70, P151, DOI 10.1016/j.jhep.2018.09.014; Buetow L, 2016, NAT REV MOL CELL BIO, V17, P626, DOI 10.1038/nrm.2016.91; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P6707, DOI 10.1038/sj.onc.1204866; Cui QZ, 2013, J HISTOCHEM CYTOCHEM, V61, P659, DOI 10.1369/0022155413495875; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Huang LY., 2018, NAT COMMUN, V9; Huang YM, 2018, THERANOSTICS, V8, P1286, DOI 10.7150/thno.22552; Johnson DT, 2013, J BIOL CHEM, V288, P3727, DOI 10.1074/jbc.M112.417568; Kim JM, 2011, MOL CELL BIOCHEM, V346, P125, DOI 10.1007/s11010-010-0599-y; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Li YY, 2011, J BIOL CHEM, V286, P45116, DOI 10.1074/jbc.M111.267328; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Lu YW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.434; Ma J, 2018, CELL DEATH DIFFER, V25, P1473, DOI 10.1038/s41418-017-0055-6; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Peng Y, 2011, J BIOL CHEM, V286, P40331, DOI 10.1074/jbc.M111.302059; Rosenberg LH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac8773; Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105; Shaik S, 2012, J EXP MED, V209, P1289, DOI 10.1084/jem.20112446; Shen ZS, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1349-y; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Thyssen G, 2006, MOL CELL BIOL, V26, P8857, DOI 10.1128/MCB.01031-06; Wang Q, 2017, ONCOGENE, V36, P5321, DOI 10.1038/onc.2017.161; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wen W, 2012, HEPATOLOGY, V55, P1787, DOI 10.1002/hep.25596; Xie J, 2018, THERANOSTICS, V8, P650, DOI 10.7150/thno.21963; Xu SB, 2018, CANCER LETT, V420, P38, DOI 10.1016/j.canlet.2018.01.067; Xu SB, 2014, MOL CELL PROTEOMICS, V13, P2986, DOI 10.1074/mcp.M113.036699; Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358; Zhang DM, 2014, J MOL NEUROSCI, V53, P637, DOI 10.1007/s12031-014-0230-x; Zheng NN, 2016, BBA-REV CANCER, V1866, P12, DOI 10.1016/j.bbcan.2016.05.001; Zheng NN, 2016, INT J BIOCHEM CELL B, V73, P99, DOI 10.1016/j.biocel.2016.02.005	37	6	6	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1269	1283		10.1038/s41388-020-01596-2	http://dx.doi.org/10.1038/s41388-020-01596-2		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420362	hybrid, Green Published			2022-12-17	WOS:000607346000010
J	Qasim, SL; Sierra, L; Shuck, R; Kurenbekova, L; Patel, TD; Rajapakshe, K; Wulff, J; Nakahata, K; Kim, HR; Landesman, Y; Unger, TJ; Coarfa, C; Yustein, JT				Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Rajapakshe, Kimal; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Landesman, Yosef; Unger, T. J.; Coarfa, Cristian; Yustein, Jason T.			p21-activated kinases as viable therapeutic targets for the treatment of high-risk Ewing sarcoma	ONCOGENE			English	Article							BETA-CATENIN; CELL-LINES; PAK4; TRANSLOCATION; TUMORS; CYTOTOXICITY; CONSISTENCY; CHROMOSOME; ACTIVATION; GROWTH	Ewing sarcoma (ES) is the second most common bone tumor in children and young adults. Unfortunately, there have been minimal recent advancements in improving patient outcomes, especially in metastatic and recurrent diseases. In this study, we investigated the biological role of p21-activated kinases (PAKs) in ES, and the ability to therapeutically target them in high-risk disease. Via informatics analysis, we established the inverse association of PAK1 and PAK4 expression with clinical stage and outcome in ES patients. Through expression knockdown and small-molecule inhibition of PAKs, utilizing FRAX-597, KPT-9274, and PF-3758309 in multiple ES cell lines and patient-derived xenograft models, we further explored the role of PAKs in ES tumor growth and metastatic capabilities. In vitro studies in several ES cell lines indicated that diminishing PAK1 and PAK4 expression reduces tumor cell viability, migratory, and invasive properties. In vivo studies using PAK4 inhibitors, KPT-9274 and PF-3758309 demonstrated significant inhibition of primary and metastatic tumor formation, while transcriptomic analysis of PAK4-inhibitor-treated tumors identified concomitant suppression of Notch, beta-catenin, and hypoxia-mediated signatures. In addition, the analysis showed enrichment of anti-tumor immune regulatory mechanisms, including interferon (IFN)-gamma and IFN-alpha responses. Altogether, our molecular and pre-clinical studies are the first to establish a critical role for PAKs in ES development and progression, and consequently as viable therapeutic targets for the treatment of high-risk ES in the near future.	[Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Yustein, Jason T.] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Yustein, Jason T.] Baylor Coll Med, Texas Childrens Hematol Ctr, Houston, TX 77030 USA; [Qasim, Shawki L.; Sierra, Laura; Shuck, Ryan; Kurenbekova, Lyazat; Patel, Tajhal D.; Wulff, Jade; Nakahata, Kengo; Kim, Ha Ram; Yustein, Jason T.] Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA; [Rajapakshe, Kimal; Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Rajapakshe, Kimal; Coarfa, Cristian; Yustein, Jason T.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA; [Landesman, Yosef; Unger, T. J.] Karyopharm Therapeut Inc, Newton, MA 02459 USA; [Yustein, Jason T.] Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; Texas Children's Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Texas Childrens Hematol Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Faris D Virani Ewing Sarcoma Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA.; Yustein, JT (corresponding author), Baylor Coll Med, Canc & Cell Biol Program, Houston, TX 77030 USA.	yustein@bcm.edu			Cancer Prevention and Research Institute of Texas (CPRIT) post-doctoral training grant [RP160283]; Faris D. Virani Ewing sarcoma Center; Cytometry and Cell Sorting Core at Baylor College of Medicine; CPRIT Core Facility Support Award [CPRIT-RP180672]; NIH [CA125123, RR024574]	Cancer Prevention and Research Institute of Texas (CPRIT) post-doctoral training grant; Faris D. Virani Ewing sarcoma Center; Cytometry and Cell Sorting Core at Baylor College of Medicine; CPRIT Core Facility Support Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by Cancer Prevention and Research Institute of Texas (CPRIT) post-doctoral training grant RP160283 (S.Q.) and The Faris D. Virani Ewing sarcoma Center. This project was supported by the Cytometry and Cell Sorting Core at Baylor College of Medicine with funding from the CPRIT Core Facility Support Award (CPRIT-RP180672) and the NIH (CA125123 and RR024574).	Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Aboukameel A, 2017, MOL CANCER THER, V16, P76, DOI 10.1158/1535-7163.MCT-16-0205; Abu Aboud O, 2016, MOL CANCER THER, V15, P2119, DOI 10.1158/1535-7163.MCT-16-0197; [Anonymous], 2018, CELLTITER GLO LUMINE; Arias-Romero LE, 2010, ONCOGENE, V29, P5839, DOI 10.1038/onc.2010.318; Batra S, 2004, CANCER RES, V64, P5415, DOI 10.1158/0008-5472.CAN-04-0377; BLOOM ET, 1972, CANCER RES, V32, P960; Callow MG, 2002, J BIOL CHEM, V277, P550, DOI 10.1074/jbc.M105732200; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; Co LLC S-A, 96992 CELL COUNT KIT; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Hawkins AG, 2018, MOL CELL PROTEOMICS, V17, P901, DOI 10.1074/mcp.RA118.000596; He H, 2013, P21 ACTIVATED KINASE; Heske CM, 2017, CLIN CANCER RES, V23, P7301, DOI 10.1158/1078-0432.CCR-17-1121; Jin-Xing Y, 2018, EXPRESSION PAK4 BREA; JOUNG M, 2012, EPJ WEB C, V32; Li Y, 2012, BBA-MOL CELL RES, V1823, P465, DOI 10.1016/j.bbamcr.2011.11.013; Liu YY, 2008, MOL CANCER RES, V6, P1215, DOI 10.1158/1541-7786.MCR-08-0087; Lu W, 2013, ONCOL REP, V29, P1547, DOI 10.3892/or.2013.2237; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Mileshkin LR, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e13607; Mutz CN, 2017, ONCOTARGET, V8, P24679, DOI 10.18632/oncotarget.14976; Naing A, 2017, ANN ONCOL, P28; Pedersen EA, 2016, CANCER RES, V76, P5040, DOI 10.1158/0008-5472.CAN-15-3422; Pietsch T, 2018, MHH ES 1 NEW EWING S; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Radu M, PAK SIGNALING DEV PR; Rane C, 2017, SCI REP-UK, V7, DOI 10.1038/srep42555; Rane CK, 2019, SEMIN CANCER BIOL, V54, P40, DOI 10.1016/j.semcancer.2018.01.006; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; Ries LAG, 1975, NIH PUB; Ryu BJ, 2014, MOL CELL BIOCHEM, V389, P69, DOI 10.1007/s11010-013-1928-8; Salamon J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095822; Satterfield L, 2017, INT J CANCER, V141, P2062, DOI 10.1002/ijc.30909; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Siu MK, 2018, P21 ACTIVATED KINASE; Stiller CA, 2006, EUR J CANCER, V42, P2006, DOI 10.1016/j.ejca.2006.06.002; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Technologies L, 2018, LIP RNAIMAX REAG PRO; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Volchenboum SL, 2015, J PATHOL CLIN RES, V1, P83, DOI 10.1002/cjp2.9; WHANGPENG J, 1986, CANCER GENET CYTOGEN, V21, P185, DOI 10.1016/0165-4608(86)90001-4; Yeo D, 2018, ROLE P21 ACTIVATED K; Yeo D, 2018, FRAX597 PAK1 INHIBIT; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	47	6	6	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1176	1190		10.1038/s41388-020-01600-9	http://dx.doi.org/10.1038/s41388-020-01600-9		JAN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33414491				2022-12-17	WOS:000605931900001
J	Lu, J; Bang, H; Kim, SM; Cho, SJ; Ashktorab, H; Smoot, DT; Zheng, CH; Ryeom, SW; Yoon, SS; Yoon, C; Lee, JH				Lu, Jun; Bang, Heejin; Kim, Su Mi; Cho, Soo-Jeong; Ashktorab, Hassan; Smoot, Duane T.; Zheng, Chao-hui; Ryeom, Sandra W.; Yoon, Sam S.; Yoon, Changhwan; Lee, Jun Ho			Lymphatic metastasis-related TBL1XR1 enhances stemness and metastasis in gastric cancer stem-like cells by activating ERK1/2-SOX2 signaling	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; DRUG-RESISTANCE; DOWN-REGULATION; BREAST-CANCER; PROMOTES LYMPHANGIOGENESIS; CHEMOTHERAPY RESISTANCE; LUNG; EXPRESSION; CHEMORESISTANCE; PATHWAY	The poor prognosis of gastric cancer (GC) results largely from metastasis and chemotherapy resistance. Toward novel therapeutic strategies that target or evade these phenomena, we evaluated the function of the transcriptional regulator transducin (beta)-like 1 X-linked receptor 1 (TBL1XR1) in GC cells, including stem-like cells. In this study, the correlation of expression of TBL1XR1 and clinical features and GC patients' outcomes was evaluated. Knockdown or exogenous expression of TBL1XR1 was combined with in vitro (2D and 3D cultures) and in vivo (mouse lung and lymphatic metastasis models) assays to evaluate the function of TBL1XR1. TBL1XR1's downstream signaling was delineated by phospho-kinase array and knockdown of candidate mediators. Analysis of clinical data showed that TBL1XR1 overexpression was correlated with worse prognosis. Functional assays showed that TBL1XR1 promoted stemness, epithelial-mesenchymal transition (EMT), and lung and lymphatic metastasis in GC cells. TBL1XR1 activated ERK1/2-Sox2 signaling and was dependent on signaling via PI3K/AKT, in GC stem-like cells distinguished by CD44 expression. Moreover, inhibition of these signaling proteins reversed chemoresistance in in vitro and in vivo models. Taken together, our results indicate that TBL1XR1 promotes stemness and metastasis in GC, making it a potential prognostic indicator. The PI3K/AKT-TBL1XR1-ERK1/2-Sox2 axis may represent a target for the treatment of GC.	[Lu, Jun; Yoon, Sam S.; Yoon, Changhwan] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA; [Lu, Jun; Zheng, Chao-hui] Fujian Med Univ, Union Hosp, Dept Gastr Surg, Fuzhou, Fujian, Peoples R China; [Bang, Heejin] Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Pathol, Seoul, South Korea; [Kim, Su Mi; Lee, Jun Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea; [Kim, Su Mi] CHA Univ, Sch Med, CHA Bundang Med Ctr, Dept Surg, Seongnam, Gyeonggi Do, South Korea; [Cho, Soo-Jeong] Seoul Natl Univ Hosp, Liver Res Inst, Dept Internal Med, Seoul, South Korea; [Ashktorab, Hassan; Smoot, Duane T.] Howard Univ, Dept Med, Washington, DC 20059 USA; [Ryeom, Sandra W.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	Memorial Sloan Kettering Cancer Center; Fujian Medical University; Hallym University; Sungkyunkwan University (SKKU); Samsung Medical Center; Pochon Cha University; Seoul National University (SNU); Seoul National University Hospital; Howard University; University of Pennsylvania	Yoon, C (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.; Lee, JH (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul, South Korea.	yoonc1@mskcc.org; gsjunholee@gmail.com	Yoon, Changhwan/AAK-7842-2021; Zheng, Chao-hui/HGE-3348-2022; Lu, Jun/AAP-1222-2021	Yoon, Changhwan/0000-0002-8420-9818; Zheng, Chao-hui/0000-0001-8680-3127; CHO, SOO-JEONG/0000-0001-7144-0589	NIH/NCI [1R01 CA158301-01]; Cancer Center Support Grant [P30 CA008748]; Natural Science Foundation of Fujian Province [2019J01155]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support Grant; Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province)	This research was supported by NIH/NCI through 1R01 CA158301-01 (SSY), Cancer Center Support Grant P30 CA008748 (MSKCC), and Natural Science Foundation of Fujian Province (2019J01155). Authors thank Jessica Moore, MS, senior editor and grant writer at MSK, for help in editing and revising the manuscript.	An YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2308-4; Banerjee A, 2017, NEURO-ONCOLOGY, V19, P1135, DOI 10.1093/neuonc/now282; Bekaii-Saab T, 2017, CANCER-AM CANCER SOC, V123, P1303, DOI 10.1002/cncr.30538; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen SP, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-195; Cho SJ, 2018, CLIN CANCER RES, V24, P6556, DOI 10.1158/1078-0432.CCR-17-1679; Cho SJ, 2015, INT J CANCER, V136, P810, DOI 10.1002/ijc.29056; Choi HK, 2011, MOL CELL, V43, P203, DOI 10.1016/j.molcel.2011.05.027; Dawood S, 2014, ONCOLOGY-NY, V28, P1101; Dong H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1776-x; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Etoh T, 2001, CANCER RES, V61, P2145; Farley J, 2013, LANCET ONCOL, V14, P134, DOI 10.1016/S1470-2045(12)70572-7; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Garcia-Mayea Y, 2020, SEMIN CANCER BIOL, V60, P166, DOI 10.1016/j.semcancer.2019.07.022; Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z; Hao SN, 2014, TUMOR BIOL, V35, P5675, DOI 10.1007/s13277-014-1751-1; Herrera B, 2009, CANCER RES, V69, P9254, DOI 10.1158/0008-5472.CAN-09-2912; Hu J, 2010, INT J CANCER, V127, P2455, DOI 10.1002/ijc.25253; Huang WF, 2014, INT J MOL SCI, V15, P3432, DOI 10.3390/ijms15033432; Ji RB, 2015, CELL CYCLE, V14, P2473, DOI 10.1080/15384101.2015.1005530; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Khromova N, 2012, ONCOGENE, V31, P1389, DOI 10.1038/onc.2011.330; Khurana SS, 2013, J BIOL CHEM, V288, P16085, DOI 10.1074/jbc.M112.445551; Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009; Li XH, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0465-z; Liu LP, 2015, GUT, V64, P26, DOI 10.1136/gutjnl-2013-306388; Liu SQ, 2006, DIGEST LIVER DIS, V38, P310, DOI 10.1016/j.dld.2006.01.012; Lu J, 2019, GASTRIC CANCER, V22, P536, DOI 10.1007/s10120-018-0892-0; Martelli AM, 2011, CURR MED CHEM, V18, P2715; Martins-Neves SR, 2018, PHARMACOL RES, V137, P193, DOI 10.1016/j.phrs.2018.10.011; Mashino K, 2002, CANCER RES, V62, P2937; Masters JRW, 2000, BRIT J CANCER, V82, P1495; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646; Nguyen PH, 2017, CLIN CANCER RES, V23, P1586, DOI 10.1158/1078-0432.CCR-15-2157; Ruan XH, 2019, MOL THER-ONCOLYTICS, V14, P94, DOI 10.1016/j.omto.2019.04.002; Salaroglio IC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102505; Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111; Sciacovelli M, 2017, FEBS J, V284, P3132, DOI 10.1111/febs.14090; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Skog M, 2011, BRIT J CANCER, V105, P1346, DOI 10.1038/bjc.2011.297; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Till JE, 2017, CANCER RES, V77, P5349, DOI 10.1158/0008-5472.CAN-17-0061; Turk CM, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-17; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Wang J, 2014, BRIT J CANCER, V111, P112, DOI 10.1038/bjc.2014.278; Wang YK, 2010, CARCINOGENESIS, V31, P1376, DOI 10.1093/carcin/bgq120; Wildi S, 2001, GUT, V49, P409, DOI 10.1136/gut.49.3.409; Wu G, 2014, INT J CLIN EXP PATHO, V7, P1449; Xi XH, 2019, EUR J PHARMACOL, V844, P259, DOI 10.1016/j.ejphar.2018.12.013; Xia P, 2015, AM J CANCER RES, V5, P1602; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Yoon C, 2019, MOL CANCER RES, V17, P1945, DOI 10.1158/1541-7786.MCR-19-0077; Yoon C, 2016, CLIN CANCER RES, V22, P971, DOI 10.1158/1078-0432.CCR-15-1356; Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011; Yoon SS, 1999, CANCER RES, V59, P6251; Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057; Zhang HZ, 2019, INT J BIOL MACROMOL, V128, P574, DOI 10.1016/j.ijbiomac.2019.01.195; Zhang JX, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0586-y; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9; Zhao YY, 2015, MOL MED REP, V12, P7335, DOI 10.3892/mmr.2015.4367; Zhou L, 2018, CANCER SCI, V109, P1044, DOI 10.1111/cas.13538; Zhou Q, 2017, ONCOGENE, V36, P1873, DOI 10.1038/onc.2016.352	65	6	6	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					922	936		10.1038/s41388-020-01571-x	http://dx.doi.org/10.1038/s41388-020-01571-x		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33288885				2022-12-17	WOS:000599011200003
J	Yao, LF; Xuan, Y; Zhang, HY; Yang, B; Ma, XL; Wang, TZ; Meng, TY; Sun, WS; Wei, HB; Ma, XQ; Moses, R; Xiao, JR; Zhang, P; Ge, C; Li, JJ; Li, L; Li, XT; Li, JB; Zhang, BH				Yao, Liangfang; Xuan, Yang; Zhang, Haiyang; Yang, Bo; Ma, Xinglong; Wang, Tianzhen; Meng, Tianyuan; Sun, Wenshe; Wei, Haibin; Ma, Xueqing; Moses, Robb; Xiao, Jianru; Zhang, Pei; Ge, Chao; Li, Jinjun; Li, Lei; Li, Xiaotao; Li, Jinbao; Zhang, Bianhong			Reciprocal REG gamma-mTORC1 regulation promotes glycolytic metabolism in hepatocellular carcinoma	ONCOGENE			English	Article							PROTEASOME ACTIVATOR; PI3K/AKT/MTOR PATHWAY; MTOR PATHWAY; CELL-GROWTH; CANCER; INHIBITION; PHOSPHATASES; INVOLVEMENT; RESISTANCE; HYPOXIA	Despite significant progression in the study of hepatocellular carcinoma (HCC), the role of the proteasome in regulating cross talk between mTOR signaling and glycolysis in liver cancer progression is not fully understood. Here, we demonstrate that deficiency of REG gamma, a proteasome activator, in mice significantly attenuates DEN-induced liver tumor formation. Ablation of REG gamma increases the stability of PP2Ac (protein phosphatase 2 catalytic subunit) in vitro and in vivo, which dephosphorylates PRAS40 (AKT1 substrate 1) and stabilizes the interaction between PRAS40 and Raptor to inactive mTORC1-mediated hyper-glycolytic metabolism. In the DEN-induced animal model and clinical hepato-carcinoma samples, high levels of REG gamma in HCC tumor regions contribute to reduced expression of PP2Ac, leading to accumulation of phosphorylated PRAS40 and mTORC1-mediated activation of HIF1 alpha. Interestingly, mTORC1 enhances REG gamma activity in HCC, forming a positive feedback regulatory loop. In conclusion, our study identifies REG gamma-PP2Ac-PRAS40 axis as a new layer in regulating mTORC1 activity and downstream glycolytic alterations during HCC development, highlighting the REG gamma-proteasome as a potential target for personalized HCC therapy.	[Yao, Liangfang; Xuan, Yang; Zhang, Haiyang; Yang, Bo; Ma, Xinglong; Wang, Tianzhen; Meng, Tianyuan; Sun, Wenshe; Wei, Haibin; Ma, Xueqing; Li, Lei; Li, Xiaotao; Zhang, Bianhong] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China; [Yao, Liangfang; Li, Jinbao] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Anesthesiol, Shanghai 201620, Peoples R China; [Moses, Robb; Li, Xiaotao] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA; [Xiao, Jianru] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, 415 Fengyang Rd, Shanghai 200003, Peoples R China; [Zhang, Pei] Second Chengdu Municipal Hosp, Dept Pathol, Chengdu 610017, Peoples R China; [Ge, Chao; Li, Jinjun] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Renji Hosp,Sch Med, Shanghai 200032, Peoples R China	East China Normal University; Shanghai Jiao Tong University; Baylor College of Medicine; Naval Medical University; Shanghai Jiao Tong University	Li, XT; Zhang, BH (corresponding author), East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.; Li, JB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Anesthesiol, Shanghai 201620, Peoples R China.; Li, XT (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza, Houston, TX 77030 USA.	xiaotaol@bcm.edu; lijingbaoshanghai@163.com; bhzhang@bio.ecnu.edu.cn	Xiao, Jian/GYU-4351-2022	wenshe, sun/0000-0003-3290-0671	National Natural Science Foundation of China [31730017, 31670882, 81672883]; Science and Technology Commission of Shanghai Municipality [19JC1411900, 16ZR1410000, 16QA1401500]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by the National Natural Science Foundation of China (31730017, 31670882, 81672883), the Science and Technology Commission of Shanghai Municipality (19JC1411900, 16ZR1410000, 16QA1401500). We thank Dr. Wei Liu from Zhejiang University for providing TSC2<SUP>-/-</SUP> cell line. We also thank the ECNU Multifunctional Platform for Innovation (011) for keeping and raising mice.	Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003; Alfarouk Khalid O, 2011, Cancers (Basel), V3, P408, DOI 10.3390/cancers3010408; Alqahtani A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090526; Bhat M, 2013, HEPATOLOGY, V58, P810, DOI 10.1002/hep.26323; Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Chong ZZ, 2016, DRUG DISCOV TODAY, V21, P1222, DOI 10.1016/j.drudis.2016.04.005; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dhanasekaran R, 2016, J HEPATOL, V64, P736, DOI 10.1016/j.jhep.2015.09.008; Ding M, 2016, NAT CELL BIOL, V18, P319, DOI 10.1038/ncb3311; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI 10.1016/j.ejca.2011.12.021; Gao X, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17667-7; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gill KS, 2016, BBA-REV CANCER, V1866, P87, DOI 10.1016/j.bbcan.2016.06.005; Guo JF, 2017, CANCER LETT, V386, P161, DOI 10.1016/j.canlet.2016.08.018; Han XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100380; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-75; Hindupur SK, 2018, NATURE, V555, P678, DOI 10.1038/nature26140; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Karim S, 2012, WORLD J GASTROENTERO, V18, P6771, DOI 10.3748/wjg.v18.i46.6771; Khemlina G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0712-x; Kunter I, 2014, ONCOL REP, V31, P573, DOI 10.3892/or.2013.2932; Laursen Lucas, 2014, Nature, V516, pS2, DOI 10.1038/516S2a; Li S, 2015, CELL DEATH DIFFER, V22, P1000, DOI 10.1038/cdd.2014.188; Li XT, 2007, MOL CELL, V26, P831, DOI 10.1016/j.molcel.2007.05.028; Li XT, 2006, CELL, V124, P381, DOI 10.1016/j.cell.2005.11.037; Lin D, 2015, WORLD J GASTROENTERO, V21, P12171, DOI 10.3748/wjg.v21.i42.12171; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Mendez-Blanco C, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0159-1; Mi WT, 2015, ONCOTARGET, V6, P13962, DOI 10.18632/oncotarget.3920; Miyamoto H, 2007, J VIROL, V81, P1727, DOI 10.1128/JVI.01683-06; Moncsek A, 2015, APOPTOSIS, V20, P1211, DOI 10.1007/s10495-015-1149-6; Moriishi K, 2007, P NATL ACAD SCI USA, V104, P1661, DOI 10.1073/pnas.0607312104; Munoz-Sanchez J, 2019, J APPL TOXICOL, V39, P556, DOI 10.1002/jat.3749; Obre E, 2015, INT J BIOCHEM CELL B, V59, P167, DOI 10.1016/j.biocel.2014.12.008; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sun WJ, 2009, CELL SIGNAL, V21, P95, DOI 10.1016/j.cellsig.2008.09.012; Wang QW, 2018, CLIN CANCER RES, V24, P2015, DOI 10.1158/1078-0432.CCR-17-2986; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xiong S, 2014, BRIT J CANCER, V110, P353, DOI 10.1038/bjc.2013.728; Yao LF, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.05.010; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Zannini L, 2008, CELL CYCLE, V7, P504, DOI 10.4161/cc.7.4.5355; Zhu AX, 2014, JAMA-J AM MED ASSOC, V312, P57, DOI 10.1001/jama.2014.7189	48	6	6	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					677	692		10.1038/s41388-020-01558-8	http://dx.doi.org/10.1038/s41388-020-01558-8		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33230243				2022-12-17	WOS:000591975500001
J	Kajino-Sakamoto, R; Fujishita, T; Taketo, MM; Aoki, M				Kajino-Sakamoto, Rie; Fujishita, Teruaki; Taketo, Makoto Mark; Aoki, Masahiro			Synthetic lethality between MyD88 loss and mutations in Wnt/beta-catenin pathway in intestinal tumor epithelial cells	ONCOGENE			English	Article							TUMORIGENESIS; MICE; APC; ACTIVATION; IMMUNITY	Although the Wnt/beta-catenin pathway plays a central role in the carcinogenesis and maintenance of colorectal cancer (CRC), attempts to target the pathway itself have not been very successful. MyD88, an adaptor protein of the TLR/IL-1 beta signaling, has been implicated in the integrity of the intestines as well as in their tumorigenesis. In this study, we aimed to clarify the mechanisms by which epithelial MyD88 contributes to intestinal tumor formation and to address whether MyD88 can be a therapeutic target of CRC. Conditional knockout of MyD88 in intestinal epithelial cells (IECs) reduced tumor formation in Apc(+/Delta 716) mice, accompanied by decreased proliferation and enhanced apoptosis of tumor epithelial cells. Mechanistically, the MyD88 loss caused inactivation of the JNK-mTORC1, NF-kappa B, and Wnt/beta-catenin pathways in tumor cells. Induction of MyD88 knockout in the intestinal tumor-derived organoids, but not in the normal IEC-derived organoids, induced apoptosis and reduced their growth. Treatment with the MyD88 inhibitor ST2825 also suppressed the growth of the intestinal tumor-derived organoids. Knockdown of MYD88 in human CRC cell lines with mutations in APC or CTNNB1 induced apoptosis and reduced their proliferation as well. These results indicate that MyD88 loss is synthetic lethal with mutational activation of the Wnt/beta-catenin signaling in intestinal tumor epithelial cells. Inhibition of MyD88 signaling can thus be a novel therapeutic strategy for familial adenomatous polyposis (FAP) as well as for colorectal cancer harboring mutations in the Wnt/beta-catenin signaling.	[Kajino-Sakamoto, Rie; Fujishita, Teruaki; Aoki, Masahiro] Aichi Canc Ctr Res Inst, Div Pathophysiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan; [Taketo, Makoto Mark] Kyoto Univ, Grad Sch Med, Div Expt Therapeut, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan; [Aoki, Masahiro] Nagoya Univ, Dept Canc Physiol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4648550, Japan	Aichi Cancer Center; Kyoto University; Nagoya University	Aoki, M (corresponding author), Aichi Canc Ctr Res Inst, Div Pathophysiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.; Aoki, M (corresponding author), Nagoya Univ, Dept Canc Physiol, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4648550, Japan.	msaoki@aichi-cc.jp	Aoki, Masahiro/A-5149-2016	Aoki, Masahiro/0000-0003-4316-9490; Fujishita, Teruaki/0000-0002-4397-2438	JSPS [JP18K07254, JP26111001]	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by JSPS Grant-in-Aid for Scientific Research (JP18K07254) to RKS and JSPS Grant-in-Aid for Scientific Research on Innovative Areas (JP26111001) to MA.	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Colomer C, 2018, BRIT J CANCER, V118, P839, DOI 10.1038/bjc.2017.459; Dhar R, 2009, BIOCHEMISTRY-US, V48, P1474, DOI 10.1021/bi801840s; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fujishita T, 2017, ONCOGENE, V36, P6480, DOI 10.1038/onc.2017.242; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Fujishita T, 2015, CANCER SCI, V106, P692, DOI 10.1111/cas.12670; Fujishita T, 2011, GASTROENTEROLOGY, V140, P1556, DOI 10.1053/j.gastro.2011.02.007; Fujishita T, 2009, CELL CYCLE, V8, P3684, DOI 10.4161/cc.8.22.9946; Holtorf A, 2018, ONCOIMMUNOLOGY, V7, P1, DOI [10.1080/2162402X.2018.1477461, DOI 10.1080/2162402X.2018.1477461]; Hou B, 2008, IMMUNITY, V29, P272, DOI 10.1016/j.immuni.2008.05.016; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Miyoshi H, 2013, NAT PROTOC, V8, P2471, DOI 10.1038/nprot.2013.153; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Rohwer N, 2019, ONCOGENE, V38, P5670, DOI 10.1038/s41388-019-0816-4; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Scheeren FA, 2014, NAT CELL BIOL, V16, P1238, DOI 10.1038/ncb3058; Scholer-Dahirel A, 2011, P NATL ACAD SCI USA, V108, P17135, DOI 10.1073/pnas.1104182108; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Vadde R, 2017, CRIT REV ONCOL HEMAT, V113, P22, DOI 10.1016/j.critrevonc.2017.02.025; Wang EL, 2010, BRIT J CANCER, V102, P908, DOI 10.1038/sj.bjc.6605558; Weber ANR, 2018, CANCER IMMUNOL IMMUN, V67, P1797, DOI 10.1007/s00262-018-2242-9; Xue X, 2014, AM J PHYSIOL-GASTR L, V307, pG187, DOI 10.1152/ajpgi.00112.2014; Zundel W, 2000, GENE DEV, V14, P391	39	6	6	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					408	420		10.1038/s41388-020-01541-3	http://dx.doi.org/10.1038/s41388-020-01541-3		NOV 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33177648				2022-12-17	WOS:000588591400001
J	Yoshida, A; Choi, J; Jin, HR; Li, Y; Bajpai, S; Qie, S; Diehl, JA				Yoshida, Akihiro; Choi, Jaewoo; Jin, Hong Ri; Li, Yan; Bajpai, Sagar; Qie, Shuo; Diehl, J. Alan			Fbxl8 suppresses lymphoma growth and hematopoietic transformation through degradation of cyclin D3	ONCOGENE			English	Article							D1; PHOSPHORYLATION; OVEREXPRESSION; EXPRESSION; TARGETS; PHASE; UBIQUITINATION; ACCUMULATION; PROTEOLYSIS; PROGRESSION	Overexpression of D-type cyclins in human cancer frequently occurs as a result of protein stabilization, emphasizing the importance of identification of the machinery that regulates their ubiqutin-dependent degradation. Cyclin D3 is overexpressed in similar to 50% of Burkitt's lymphoma correlating with a mutation of Thr-283. However, the E3 ligase that regulates phosphorylated cyclin D3 and whether a stabilized, phosphorylation deficient mutant of cyclin D3, has oncogenic activity are undefined. We describe the identification of SCF-Fbxl8 as the E3 ligase for Thr-283 phosphorylated cyclin D3. SCF-Fbxl8 poly-ubiquitylates p-Thr-283 cyclin D3 targeting it to the proteasome. Functional investigation demonstrates that Fbxl8 antagonizes cell cycle progression, hematopoietic cell proliferation, and oncogene-induced transformation through degradation of cyclin D3, which is abolished by expression of cyclin D3T283A, a non-phosphorylatable mutant. Clinically, the expression of cyclin D3 is inversely correlated with the expression of Fbxl8 in lymphomas from human patients implicating Fbxl8 functions as a tumor suppressor. Highlights Fbxl8 suppresses cell division, cell proliferation, and tumorigenesis through phosphorylation-dependent degradation of cyclin D3. Fbxl8 suppresses oncogene-induced transformation of hematopoietic cells and lymphoma cell proliferation through cyclin D3 degradation.	[Yoshida, Akihiro; Bajpai, Sagar; Qie, Shuo; Diehl, J. Alan] Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Biochem, Cleveland, OH 44106 USA; [Yoshida, Akihiro; Jin, Hong Ri; Li, Yan; Bajpai, Sagar] Med Univ South Carolina, Hollings Canc Ctr, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Yoshida, Akihiro; Qie, Shuo; Diehl, J. Alan] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Choi, Jaewoo] Univ Penn, Abramson Canc Ctr, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA	Case Western Reserve University; Medical University of South Carolina; Case Western Reserve University; University of Pennsylvania; Pennsylvania Medicine	Diehl, JA (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Biochem, Cleveland, OH 44106 USA.; Diehl, JA (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.	jad283@case.edu	Qie, Shuo/O-4382-2015	Qie, Shuo/0000-0002-3481-3582; , J. Alan/0000-0001-9854-5049	National Institutes of Health [R01CA093237, P01CA098101]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Louis M. Staudt for providing Gumbus cell line. This work was supported by grants from National Institutes of Health: R01CA093237, P01CA098101 (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bu YW, 2018, NAT CELL BIOL, V20, P104, DOI 10.1038/s41556-017-0006-y; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; Chen BB, 2012, ONCOGENE, V31, P2566, DOI 10.1038/onc.2011.432; Chen BB, 2012, BLOOD, V119, P3132, DOI 10.1182/blood-2011-06-358911; de Leeuw R, 2018, CLIN CANCER RES, V24, P4201, DOI 10.1158/1078-0432.CCR-18-0410; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dong H, 2020, CANCER MED-US, V9, P1790, DOI 10.1002/cam4.2829; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Li Y, 2015, CANCER DISCOV, V5, P288, DOI 10.1158/2159-8290.CD-14-0625; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Nagasawa S, 2001, J SURG ONCOL, V78, P208, DOI 10.1002/jso.1152; Ott MM, 1997, BLOOD, V90, P3154, DOI 10.1182/blood.V90.8.3154; Qie S, 2016, J MOL MED, V94, P1313, DOI 10.1007/s00109-016-1475-3; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Russell A, 1999, ONCOGENE, V18, P1983, DOI 10.1038/sj.onc.1202511; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Vaites LP, 2011, MOL CELL BIOL, V31, P4513, DOI 10.1128/MCB.05733-11; Yoshida A, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax6352; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931	31	6	6	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					292	306		10.1038/s41388-020-01532-4	http://dx.doi.org/10.1038/s41388-020-01532-4		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122824	hybrid, Green Published			2022-12-17	WOS:000582827800001
J	Zarei, M; Giannikou, K; Du, H; Liu, HJ; Duarte, M; Johnson, S; Nassar, AH; Widlund, HR; Henske, EP; Long, HW; Kwiatkowski, DJ				Zarei, Mahsa; Giannikou, Krinio; Du, Heng; Liu, Heng-Jia; Duarte, Melissa; Johnson, Sneha; Nassar, Amin H.; Widlund, Hans R.; Henske, Elizabeth P.; Long, Henry W.; Kwiatkowski, David J.			MITF is a driver oncogene and potential therapeutic target in kidney angiomyolipoma tumors through transcriptional regulation of CYR61	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; CELL-GROWTH; MICROPHTHALMIA; GENE; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; TUMORIGENESIS; ACTIVATION; EXPRESSION	Tuberous sclerosis complex (TSC) is an autosomal dominant tumor suppressor syndrome, characterized by tumor development in multiple organs, including renal angiomyolipoma. Biallelic loss of TSC1 or TSC2 is a known genetic driver of angiomyolipoma development, however, whether an altered transcriptional repertoire contributes to TSC-associated tumorigenesis is unknown. RNA-seq analyses showed that MITF A isoform (MITF-A) was consistently highly expressed in angiomyolipoma, immunohistochemistry showed microphthalmia-associated transcription factor nuclear localization, and Chromatin immuno-Precipitation Sequencing analysis showed that the MITF-A transcriptional start site was highly enriched with H3K27ac marks. Using the angiomyolipoma cell line 621-101, MITF knockout (MITF.KO) and MITF-A overexpressing (MITF.OE) cell lines were generated. MITF.KO cells showed markedly reduced growth and invasion in vitro, and were unable to form xenografted tumors. In contrast, MITF.OE cells grew faster in vitro and as xenografted tumors compared to control cells. RNA-Seq analysis showed that both ID2 and Cysteine-rich angiogenic inducer 61 (CYR61) expression levels were increased in the MITF.OE cells and reduced in the MITF.KO cells, and luciferase assays showed this was due to transcriptional effects. Importantly, CYR61 overexpression rescued MITF.KO cell growth in vitro and tumor growth in vivo. These findings suggest that MITF-A is a transcriptional oncogenic driver of angiomyolipoma tumor development, acting through regulation of CYR61.	[Zarei, Mahsa; Giannikou, Krinio; Du, Heng; Nassar, Amin H.; Kwiatkowski, David J.] Brigham & Womens Hosp, Dept Med, Canc Genet Lab, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Zarei, Mahsa; Giannikou, Krinio; Du, Heng; Liu, Heng-Jia; Duarte, Melissa; Nassar, Amin H.; Widlund, Hans R.; Henske, Elizabeth P.; Long, Henry W.; Kwiatkowski, David J.] Harvard Med Sch, Boston, MA 02115 USA; [Zarei, Mahsa; Johnson, Sneha] Texas A&M Univ, Dept Vet Physiol & Pharmacol, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Giannikou, Krinio; Duarte, Melissa; Long, Henry W.] Dana Farber Canc Inst, Dept Med Oncol, Ctr Funct Canc Epigenet, Boston, MA 02115 USA; [Liu, Heng-Jia; Henske, Elizabeth P.] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Widlund, Hans R.] Brigham & Womens Hosp, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Texas A&M University System; Texas A&M University College Station; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Dept Med, Canc Genet Lab, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.; Kwiatkowski, DJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu	Giannikou, Krinio/AAC-9214-2022	Du, Heng/0000-0001-9067-0910; Nassar, Amin/0000-0002-8084-9105; Zarei, Mahsa/0000-0002-0554-6163	Engles Fund for TSC and LAM; University of Pennsylvania Orphan Disease Center; LAM Foundation; NIH NCI [1P01CA120964];  [DOD-18-1-0592];  [DOD-17-1-0205]	Engles Fund for TSC and LAM; University of Pennsylvania Orphan Disease Center; LAM Foundation; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	This work was supported by the Engles Fund for TSC and LAM; the University of Pennsylvania Orphan Disease Center in partnership with the LAM Foundation; DOD-18-1-0592 (MZ), DOD-17-1-0205 (KG), and the NIH NCI 1P01CA120964 (DJK).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Badri KR, 2013, AM J RESP CRIT CARE, V187, P663, DOI 10.1164/ajrccm.187.6.663; Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; BONETTI F, 1993, AM J SURG PATHOL, V17, P1092, DOI 10.1097/00000478-199311000-00002; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Dhar A., 2010, Experimental Oncology, V32, P2; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Giannikou K, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006242; Harbst K, 2012, CLIN CANCER RES, V18, P4026, DOI 10.1158/1078-0432.CCR-12-0343; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Henske EP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.35; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Hsiao JJ, 2014, ARCH BIOCHEM BIOPHYS, V563, P28, DOI 10.1016/j.abb.2014.07.019; Huang YT, 2016, ONCOTARGET, V7, P1663, DOI 10.18632/oncotarget.6411; Johansson CH, 2013, MELANOMA RES, V23, P360, DOI 10.1097/CMR.0b013e328362f9cd; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Li CG, 2014, J EXP MED, V211, P15, DOI 10.1084/jem.20131080; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Martin KR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15816; Mayer S, 2017, ONCOL LETT, V14, P2334, DOI 10.3892/ol.2017.6406; McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391; NELLIST M, 1993, CELL, V75, P1305; Tong XJ, 2004, ONCOGENE, V23, P4847, DOI 10.1038/sj.onc.1207628; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Yu J, 2004, AM J PHYSIOL-LUNG C, V286, pL694, DOI 10.1152/ajplung.00204.2003; Zarei M, 2019, J EXP MED, V216, P2635, DOI 10.1084/jem.20190251; Zarei M, 2017, CANCER RES, V77, P4460, DOI 10.1158/0008-5472.CAN-17-0015; Zavala-Pompa A, 2001, AM J SURG PATHOL, V25, P65, DOI 10.1097/00000478-200101000-00007; Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108; Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492	46	6	6	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					112	126		10.1038/s41388-020-01504-8	http://dx.doi.org/10.1038/s41388-020-01504-8		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33082558	Green Accepted			2022-12-17	WOS:000582339900001
J	Horiguchi, H; Kadomatsu, T; Miyata, K; Terada, K; Sato, M; Torigoe, D; Morinaga, J; Moroishi, T; Oike, Y				Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Miyata, Keishi; Terada, Kazutoyo; Sato, Michio; Torigoe, Daisuke; Morinaga, Jun; Moroishi, Toshiro; Oike, Yuichi			Stroma-derived ANGPTL2 establishes an anti-tumor microenvironment during intestinal tumorigenesis	ONCOGENE			English	Article							ANGIOPOIETIN-LIKE PROTEIN-2; CANCER; MACROPHAGES; CELLS; EXPRESSION; ANTIBODY; ROLES; MECHANISMS; INFECTION; SUBSETS	Previous studies show that tumor cell-derived angiopoietin-like protein 2 (ANGPTL2) functions as a tumor promoter in some cancer contexts. However, we recently reported that host ANGPTL2 also shows tumor suppressive activity by enhancing dendritic cell-mediated CD8(+)T cell anti-tumor immune responses in mouse kidney cancer and murine syngeneic models. However, mechanisms underlying ANGPTL2-mediated tumor suppression are complex and not well known. Here, we investigated ANGPTL2 tumor suppressive function in chemically-induced intestinal tumorigenesis. ANGPTL2 deficiency enhanced intestinal tumor growth in an experimental mouse colitis-associated colon cancer (CAC) model.Angptl2-deficient mice also showed a decrease not only in CD8(+)T cell responses but in CD4(+)T cell responses during intestinal tumorigenesis. Furthermore, we show that stroma-derived ANGPTL2 can activate the myeloid immune response. Notably, ANGPTL2 drove generation of immunostimulatory macrophages via the NF-kappa B pathway, accelerating CD4(+)T helper 1 (Th1) cell activation. These findings overall provide novel insight into the complex mechanisms underlying ANGPTL2 anti-tumor function in cancer pathology.	[Horiguchi, Haruki; Kadomatsu, Tsuyoshi; Miyata, Keishi; Terada, Kazutoyo; Sato, Michio; Morinaga, Jun; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan; [Horiguchi, Haruki; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan; [Kadomatsu, Tsuyoshi; Miyata, Keishi; Terada, Kazutoyo; Moroishi, Toshiro; Oike, Yuichi] Kumamoto Univ, Grad Sch Med Sci, Ctr Metab Regulat Hlth Aging CMHA, Kumamoto 8608556, Japan; [Sato, Michio; Torigoe, Daisuke] Kumamoto Univ, Inst Resource Dev & Anal IRDA, Kumamoto 8600811, Japan; [Moroishi, Toshiro] Kumamoto Univ, Dept Cell Signaling & Metab Med, Fac Life Sci, Kumamoto 8608556, Japan; [Moroishi, Toshiro] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi 3320012, Japan	Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto University; Japan Science & Technology Agency (JST)	Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Mol Genet, Kumamoto 8608556, Japan.; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Aging & Geriatr Med, Kumamoto 8608556, Japan.; Kadomatsu, T; Oike, Y (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Ctr Metab Regulat Hlth Aging CMHA, Kumamoto 8608556, Japan.	tkado@gpo.kumamoto-u.ac.jp; oike@gpo.kumamoto-u.ac.jp	Miyata, Keishi/HGF-1876-2022	Miyata, Keishi/0000-0003-0336-1859; Moroishi, Toshiro/0000-0001-6419-3882; SATO, MICHIO/0000-0001-9339-1642	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [18K07236, 18K15246]; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) [13417915]; CREST program of the Japan Agency for Medical Research and Development (AMED) [JP18gm0610007]; Takeda Science Foundation	Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)); CREST program of the Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Kiyoka Tabu, Noriko Shirai, and Sayomi Iwaki for technical assistance. This work was supported by the Scientific Research Fund of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (grant 18K07236 to TK, grant 18K15246 to HH), the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology Agency (JST) (grant 13417915 to YO), the CREST program of the Japan Agency for Medical Research and Development (AMED) (grant JP18gm0610007 to YO), and the Takeda Science Foundation (HH, TK).	Advani R, 2018, NEW ENGL J MED, V379, P1711, DOI 10.1056/NEJMoa1807315; Aoi J, 2011, CANCER RES, V71, P7502, DOI 10.1158/0008-5472.CAN-11-1758; Bain CC, 2013, MUCOSAL IMMUNOL, V6, P498, DOI 10.1038/mi.2012.89; Bain CC, 2014, IMMUNOL REV, V260, P102, DOI 10.1111/imr.12192; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994; De Calisto J, 2012, EUR J IMMUNOL, V42, P3136, DOI 10.1002/eji.201243061; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Endo M, 2012, CANCER RES, V72, P1784, DOI 10.1158/0008-5472.CAN-11-3878; Galdiero MR, 2016, INT J CANCER, V139, P446, DOI 10.1002/ijc.30076; Gnjatic S, 2003, P NATL ACAD SCI USA, V100, P8862, DOI 10.1073/pnas.1133324100; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Ho WL, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0334-6; Horiguchi H, 2019, GENE DEV, V33, P1641, DOI 10.1101/gad.329417.119; Horiguchi H, 2017, EMBO J, V36, P409, DOI 10.15252/embj.201695690; Horiguchi H, 2014, CANCER SCI, V105, P1550, DOI 10.1111/cas.12554; Kadomatsu T, 2014, TRENDS ENDOCRIN MET, V25, P245, DOI 10.1016/j.tem.2014.03.012; Kather JN, 2019, BRIT J CANCER, V120, P871, DOI 10.1038/s41416-019-0441-6; Kennedy R, 2008, IMMUNOL REV, V222, P129, DOI 10.1111/j.1600-065X.2008.00616.x; Khalil H, 2013, JOVE-J VIS EXP, V12, P1; Kikuchi R, 2008, CANCER RES, V68, P5067, DOI 10.1158/0008-5472.CAN-08-0062; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Kubota Y, 2005, GENE EXPR PATTERNS, V5, P679, DOI 10.1016/j.modgep.2005.02.006; Kuchiike D, 2013, ANTICANCER RES, V33, P2881; Kuraishy A, 2011, IMMUNITY, V35, P467, DOI 10.1016/j.immuni.2011.09.006; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Masuda T, 2015, SCI REP-UK, V5, DOI 10.1038/srep09170; Moynihan KD, 2017, CANCER RES, V77, P5215, DOI 10.1158/0008-5472.CAN-17-1340; Na YR, 2019, NAT REV GASTRO HEPAT, V16, P531, DOI 10.1038/s41575-019-0172-4; Netsirisawan P, 2015, CANCER GENOM PROTEOM, V12, P201; Odagiri H, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004612; Oike Y, 2003, P NATL ACAD SCI USA, V100, P9494, DOI 10.1073/pnas.1531901100; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694, DOI 10.1016/0016-5085(90)90290-H; Osumi H, 2020, CANCER SCI, V111, P1241, DOI 10.1111/cas.14337; RUGTVEIT J, 1994, GUT, V35, P669, DOI 10.1136/gut.35.5.669; Rugtveit J, 1997, GASTROENTEROLOGY, V112, P1493, DOI 10.1016/S0016-5085(97)70030-1; Saleh M, 2011, NAT REV IMMUNOL, V11, P9, DOI 10.1038/nri2891; Sheng JP, 2015, IMMUNITY, V43, P382, DOI 10.1016/j.immuni.2015.07.016; Soncin I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02834-8; Tabata M, 2009, CELL METAB, V10, P178, DOI 10.1016/j.cmet.2009.08.003; Tamoutounour S, 2012, EUR J IMMUNOL, V42, P3150, DOI 10.1002/eji.201242847; Tay RE, 2021, CANCER GENE THER, V28, P5, DOI 10.1038/s41417-020-0183-x; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315; Wirtz S, 2017, NAT PROTOC, V12, P1295, DOI 10.1038/nprot.2017.044; Yanagita T, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89140; Yugami M, 2016, J BIOL CHEM, V291, P18843, DOI 10.1074/jbc.M116.720870; Zhang L, 2020, CELL, V181, P442, DOI 10.1016/j.cell.2020.03.048	52	6	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					55	67		10.1038/s41388-020-01505-7	http://dx.doi.org/10.1038/s41388-020-01505-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051596				2022-12-17	WOS:000577556100002
J	Wang, GW; Wang, J; Chang, AT; Cheng, DM; Huang, S; Wu, D; Sirkisoon, S; Yang, S; Lin, HK; Lo, HW; Xiang, R; Sun, PQ				Wang, Guanwen; Wang, Juan; Chang, Antao; Cheng, Dongmei; Huang, Shan; Wu, Dan; Sirkisoon, Sherona; Yang, Shuang; Lin, Hui-Kuan; Lo, Hui-Wen; Xiang, Rong; Sun, Peiqing			Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MAP KINASE; CELL DISSEMINATION; CATENIN COMPLEX; BETA-CATENIN; ACTIVATION; PHOSPHORYLATION; INVASION; TUMORIGENESIS; PROGRESSION	While mechanisms for metastasis were extensively studied in cancer cells from patients with detectable tumors, pathways underlying metastatic dissemination from early lesions before primary tumors appear are poorly understood. Her2 promotes breast cancer early dissemination by suppressing p38, but how Her2 downregulates p38 is unclear. Here, we demonstrate that in early lesion breast cancer models, Her2 inhibits p38 by inducing Skp2 through Akt-mediated phosphorylation, which promotes ubiquitination and proteasomal degradation of Tpl2, a p38 MAP3K. The early disseminating cells are Her2(+)Skp2(high)Tpl2(low)p-p38(low)E-cadherin(low)in the MMTV-Her2 breast cancer model. In human breast carcinoma, high Skp2 and low Tpl2 expression are associated with the Her2(+)status; Tpl2 expression positively correlates with that of activated p38; Skp2 expression negatively correlates with that of Tpl2 and activated p38. Moreover, the Her2-Akt-Skp2-Tpl2-p38 axis plays a key role in the disseminating phenotypes in early lesion breast cancer cells; inhibition of Tpl2 enhances early dissemination in vivo. These findings identify the Her2-Akt-Skp2-Tpl2-p38 cascade as a novel mechanism mediating breast cancer early dissemination and a potential target for novel therapies targeting early metastatic dissemination.	[Wang, Guanwen; Wang, Juan; Chang, Antao; Cheng, Dongmei; Huang, Shan; Wu, Dan; Sirkisoon, Sherona; Lin, Hui-Kuan; Lo, Hui-Wen; Sun, Peiqing] Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China; [Wang, Guanwen; Wang, Juan; Chang, Antao; Huang, Shan; Yang, Shuang; Xiang, Rong] Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA; [Wang, Guanwen; Wang, Juan; Chang, Antao; Huang, Shan; Yang, Shuang; Xiang, Rong] Wake Forest Baptist Med Ctr, Ctr Comprehens Canc, Winston Salem, NC USA	Nankai University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sun, PQ (corresponding author), Nankai Univ, Sch Med, Dept Immunol, Tianjin, Peoples R China.; Xiang, R (corresponding author), Wake Forest Baptist Med Ctr, Dept Canc Biol, Winston Salem, NC 27157 USA.	rxiang@nankai.edu.cn; psun@wakehealth.edu		Lo, Hui-Wen/0000-0002-0681-7914; Lin, Hui-Kuan/0000-0002-3501-2410	NIH/NCI [CA131231, CA172115, P30CA012197]; Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China [81972882, 2018YFE0114300]; Cell Engineering Shared Resource of WFBCCC; Tumor Tissue and Pathology Shared Resource of WFBCCC	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China; Cell Engineering Shared Resource of WFBCCC; Tumor Tissue and Pathology Shared Resource of WFBCCC	We thank Cell Engineering and Tumor Tissue and Pathology Shared Resources of WFBCCC for support. This study was supported by NIH/NCI grants CA131231, CA172115, and P30CA012197 (PS) and Bilateral Inter-Governmental S&T Cooperation Project grants from Ministry of Science and Technology of China (81972882 and 2018YFE0114300) (RX). PS is an Anderson Oncology Research Professor.	ABBRUZZESE JL, 1994, J CLIN ONCOL, V12, P1272, DOI 10.1200/JCO.1994.12.6.1272; Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Anwar T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05078-8; Barrantes ID, 2012, BIOCHEM SOC T, V40, P79, DOI 10.1042/BST20110676; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Candas D, 2014, CANCER RES, V74, P7498, DOI 10.1158/0008-5472.CAN-14-0844; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chan CH, 2010, THESCIENTIFICWORLDJO, V10, P1001, DOI 10.1100/tsw.2010.89; Cho J, 2005, J BIOL CHEM, V280, P20442, DOI 10.1074/jbc.M413554200; Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323; DeCicco-Skinner KL, 2011, ONCOGENE, V30, P389, DOI 10.1038/onc.2010.447; Dodhiawala PB, 2020, J CLIN INVEST, V130, P4771, DOI 10.1172/JCI137660; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gantke T, 2012, IMMUNOL REV, V246, P168, DOI 10.1111/j.1600-065X.2012.01104.x; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Gkirtzimanaki K, 2013, P NATL ACAD SCI USA, V110, pE1470, DOI 10.1073/pnas.1215938110; Gong J, 2019, HEPATOLOGY, V69, P524, DOI 10.1002/hep.29820; Han YC, 2017, ONCOL REP, V38, P3574, DOI 10.3892/or.2017.6017; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Kato H, 2020, ONCOGENE, V39, P3322, DOI 10.1038/s41388-020-1218-3; Kim G, 2015, MOL CARCINOGEN, V54, P440, DOI 10.1002/mc.22112; Kim K, 2014, CARCINOGENESIS, V35, P1352, DOI 10.1093/carcin/bgu044; Krcova Z, 2008, BIOMED PAP, V152, P21, DOI 10.5507/bp.2008.003; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lopez-Lazaro Miguel, 2015, Oncoscience, V2, P467; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Narod SA, 2015, JAMA ONCOL, V1, P888, DOI 10.1001/jamaoncol.2015.2510; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Pattison MJ, 2016, BIOCHEM J, V473, P2845, DOI 10.1042/BCJ20160502; Riethmuller G, 2001, SEMIN CANCER BIOL, V11, P307, DOI 10.1006/scbi.2001.0386; Ruiz-Saenz A, 2018, CANCER RES, V78, P3645, DOI 10.1158/0008-5472.CAN-18-0430; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Senger K, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4273; She QB, 2001, CANCER RES, V61, P1604; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wei W, 2016, CANCER CELL, V29, P563, DOI 10.1016/j.ccell.2016.03.012; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Wen HC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001684; Wisinski KB, 2016, CLIN CANCER RES, V22, P2659, DOI 10.1158/1078-0432.CCR-15-2365; Wu MZ, 2015, CANCER RES, V75, P3912, DOI 10.1158/0008-5472.CAN-14-3208; Xu L, 2006, ONCOGENE, V25, P2987, DOI 10.1038/sj.onc.1209337; Yan MH, 2019, IMMUNOBIOLOGY, V224, P383, DOI 10.1016/j.imbio.2019.02.010; Zheng H, 2013, MOL CELL, V50, P699, DOI 10.1016/j.molcel.2013.04.013	59	6	6	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7034	7050		10.1038/s41388-020-01481-y	http://dx.doi.org/10.1038/s41388-020-01481-y		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989258	Green Accepted			2022-12-17	WOS:000573446900005
J	Bisteau, X; Lee, J; Srinivas, V; Lee, JHS; Niska-Blakie, J; Tan, GF; Yap, SYX; Hom, KW; Wong, CK; Chae, J; Wang, LC; Kim, J; Rancati, G; Sobota, RM; Tan, CSH; Kaldis, P				Bisteau, Xavier; Lee, Joann; Srinivas, Vinayaka; Lee, Joanna H. S.; Niska-Blakie, Joanna; Tan, Gifford; Yap, Shannon Y. X.; Hom, Kevin W.; Wong, Cheng Kit; Chae, Jeongjun; Wang, Loo Chien; Kim, Jinho; Rancati, Giulia; Sobota, Radoslaw M.; Tan, Chris S. H.; Kaldis, Philipp			The Greatwall kinase safeguards the genome integrity by affecting the kinome activity in mitosis	ONCOGENE			English	Article							CELL-CYCLE; PROTEIN-KINASE; MITOTIC EXIT; HOMOLOGOUS RECOMBINATION; NEK2 KINASE; BINDING PROTEIN; HISTONE H2AX; AURORA-A; PHOSPHORYLATION; DEPHOSPHORYLATION	Progression through mitosis is balanced by the timely regulation of phosphorylation and dephosphorylation events ensuring the correct segregation of chromosomes before cytokinesis. This balance is regulated by the opposing actions of CDK1 and PP2A, as well as the Greatwall kinase/MASTL. MASTL is commonly overexpressed in cancer, which makes it a potential therapeutic anticancer target. Loss ofMastlinduces multiple chromosomal errors that lead to the accumulation of micronuclei and multilobulated cells in mitosis. Our analyses revealed that loss ofMastlleads to chromosome breaks and abnormalities impairing correct segregation. Phospho-proteomic data forMastlknockout cells revealed alterations in proteins implicated in multiple processes during mitosis including double-strand DNA damage repair. In silico prediction of the kinases with affected activity unveiled NEK2 to be regulated in the absence ofMastl. We uncovered that, RAD51AP1, involved in regulation of homologous recombination, is phosphorylated by NEK2 and CDK1 but also efficiently dephosphorylated by PP2A/B55. Our results suggest thatMastlKOdisturbs the equilibrium of the mitotic phosphoproteome that leads to the disruption of DNA damage repair and triggers an accumulation of chromosome breaks even in noncancerous cells.	[Bisteau, Xavier; Lee, Joann; Lee, Joanna H. S.; Niska-Blakie, Joanna; Tan, Gifford; Yap, Shannon Y. X.; Hom, Kevin W.; Wang, Loo Chien; Sobota, Radoslaw M.; Tan, Chris S. H.; Kaldis, Philipp] ASTAR, Inst Mol & Cell Biol IMCB, Singapore 138673, Singapore; [Srinivas, Vinayaka] Duke NUS Grad Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Niska-Blakie, Joanna; Tan, Chris S. H.] ASTAR, Bioinformat Inst BII, Singapore 138671, Singapore; [Wong, Cheng Kit; Rancati, Giulia] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Chae, Jeongjun] Sungkyunkwan Univ, SAIHST, Dept Hlth Sci & Technol, Seoul 06351, South Korea; [Wang, Loo Chien; Sobota, Radoslaw M.] ASTAR, IMCB, Funct Prote Lab, Singapore 138673, Singapore; [Kim, Jinho] Samsung Med Ctr, Samsung Genome Inst, Seoul 06351, South Korea; [Kaldis, Philipp] Lund Univ, Clin Res Ctr CRC, Dept Clin Sci, Box 50332, S-20213 Malmo, Sweden; [Bisteau, Xavier] Univ Libre Bruxelles ULB, IRIBHM, Campus Erasme Blg C, Brussels, Belgium; [Lee, Joanna H. S.] Ewha Womans Univ, 52 Ewhayeodae Gil, Seoul, South Korea; [Tan, Chris S. H.] Southern Univ Sci & Technol, Coll Sci, Dept Chem, Shenzhen, Peoples R China	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Sungkyunkwan University (SKKU); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center; Lund University; Universite Libre de Bruxelles; Ewha Womans University; Southern University of Science & Technology	Bisteau, X; Kaldis, P (corresponding author), ASTAR, Inst Mol & Cell Biol IMCB, Singapore 138673, Singapore.; Kaldis, P (corresponding author), Lund Univ, Clin Res Ctr CRC, Dept Clin Sci, Box 50332, S-20213 Malmo, Sweden.; Bisteau, X (corresponding author), Univ Libre Bruxelles ULB, IRIBHM, Campus Erasme Blg C, Brussels, Belgium.	xbisteau@ulb.ac.be; philipp.kaldis@med.lu.se	Kaldis, Philipp/G-2714-2010; Bisteau, Xavier/Q-7239-2018; Bisteau, Xavier/AAH-6744-2021	Kaldis, Philipp/0000-0002-7247-7591; Bisteau, Xavier/0000-0002-8896-5098; Lee, Joanna/0000-0002-1941-935X	Biomedical Research Council (BMRC), Agency for Science, Technology and Research (A*STAR); Bomedial Research Council-Young investigator Grant 2016 [1610151039]; Bomedial Research Council-Young investigator Grant 2015; MSCA-IF-2018 [843107]; Innoviris BB2B-Attract [RBC/BFB1]; Biomedical Research Council-Joint Council Office Grant [1231AFG031]; National Medical Research Council Singapore, NMRC [NMRC/CBRG/0091/2015]; National Research Foundation Singapore [NRF2016-CRP001-103]; Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research [IRC15-0067]; Swedish Research Council, Strategic Research Area EXODIAB [2009-1039]	Biomedical Research Council (BMRC), Agency for Science, Technology and Research (A*STAR)(Agency for Science Technology & Research (A*STAR)); Bomedial Research Council-Young investigator Grant 2016; Bomedial Research Council-Young investigator Grant 2015; MSCA-IF-2018; Innoviris BB2B-Attract(Innoviris); Biomedical Research Council-Joint Council Office Grant; National Medical Research Council Singapore, NMRC(National Medical Research Council, Singapore); National Research Foundation Singapore(National Research Foundation, Singapore); Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council, Strategic Research Area EXODIAB(Swedish Research Council)	This work is supported by the Biomedical Research Council (BMRC), Agency for Science, Technology and Research (A*STAR) to PK and RMS, by the Bomedial Research Council-Young investigator Grant 2016 (1610151039) to XB, and Young investigator Grant 2015 to RMS, by a MSCA-IF-2018 (843107) to XB, by a Innoviris BB2B-Attract (RBC/BFB1) to XB, by the Biomedical Research Council-Joint Council Office Grant (1231AFG031 to Sang Hyun Lee and PK); by the National Medical Research Council Singapore, NMRC (NMRC/CBRG/0091/2015) to PK, and by National Research Foundation Singapore Grant NRF2016-CRP001-103 to PK, the Faculty of Medicine, Lund University to PK, the Swedish Foundation for Strategic Research Dnr IRC15-0067, and Swedish Research Council, Strategic Research Area EXODIAB, Dnr 2009-1039.	Alexander J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001796; Alvarez-Fernandez M, 2018, CELL DEATH DIFFER, V25, P828, DOI 10.1038/s41418-017-0024-0; Alvarez-Fernandez M, 2013, P NATL ACAD SCI USA, V110, P17374, DOI 10.1073/pnas.1310745110; Anania MC, 2015, ONCOTARGET, V6, P34629, DOI 10.18632/oncotarget.5282; Bahe S, 2005, J CELL BIOL, V171, P27, DOI 10.1083/jcb.200504107; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Bisteau X, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003546; Blethrow JD, 2008, P NATL ACAD SCI USA, V105, P1442, DOI 10.1073/pnas.0708966105; Boeing S, 2016, CELL REP, V15, P1597, DOI 10.1016/j.celrep.2016.04.047; Booth DG, 2017, TRENDS CELL BIOL, V27, P906, DOI 10.1016/j.tcb.2017.08.001; Breitwieser FP, 2013, J PROTEOMICS, V90, P77, DOI 10.1016/j.jprot.2013.02.022; Breitwieser FP, 2011, J PROTEOME RES, V10, P2758, DOI 10.1021/pr1012784; Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Byeon IJL, 2005, NAT STRUCT MOL BIOL, V12, P987, DOI 10.1038/nsmb1008; Castilho PV, 2009, MOL BIOL CELL, V20, P4777, DOI 10.1091/mbc.E09-07-0643; Cervenka I, 2016, P NATL ACAD SCI USA, V113, P9304, DOI 10.1073/pnas.1608783113; Cetti E, 2019, CANCER LETT, V442, P362, DOI 10.1016/j.canlet.2018.11.010; Charrasse S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00339-4; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen W, 2005, CANCER RES, V65, P8183, DOI 10.1158/0008-5472.CAN-05-1103; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Choi BK, 2018, P NATL ACAD SCI USA, V115, P10666, DOI 10.1073/pnas.1806643115; Cukras S, 2016, CELL CYCLE, V15, P2636, DOI 10.1080/15384101.2016.1209613; Cundell MJ, 2016, J CELL BIOL, V214, P539, DOI 10.1083/jcb.201606033; Cundell MJ, 2013, MOL CELL, V52, P393, DOI 10.1016/j.molcel.2013.09.005; Cuylen S, 2016, NATURE, V535, P308, DOI 10.1038/nature18610; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Diril MK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006310; Diril MK, 2012, P NATL ACAD SCI USA, V109, P3826, DOI 10.1073/pnas.1115201109; Domingo-Sananes MR, 2011, PHILOS T R SOC B, V366, P3584, DOI 10.1098/rstb.2011.0087; Dray E, 2010, NAT STRUCT MOL BIOL, V17, P1255, DOI 10.1038/nsmb.1916; Duan HQ, 2016, J BIOL CHEM, V291, P21123, DOI 10.1074/jbc.M116.745372; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Gelot C, 2015, GENES-BASEL, V6, P267, DOI 10.3390/genes6020267; Gerard C, 2009, P NATL ACAD SCI USA, V106, P21643, DOI 10.1073/pnas.0903827106; Gharbi-Ayachi A, 2010, SCIENCE, V330, P1673, DOI 10.1126/science.1197048; Godfrey M, 2017, MOL CELL, V65, P393, DOI 10.1016/j.molcel.2016.12.018; Grallert A, 2015, NATURE, V517, P94, DOI 10.1038/nature14019; Gutierrez A, 2014, J CLIN INVEST, V124, P644, DOI 10.1172/JCI65093; Hayashi Y, 2017, BIOCHEM BIOPH RES CO, V493, P1043, DOI 10.1016/j.bbrc.2017.09.092; Hegarat N, 2016, BIOESSAYS, V38, P627, DOI 10.1002/bies.201600057; Hegarat N, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004004; Hein JB, 2017, NAT CELL BIOL, V19, P1433, DOI 10.1038/ncb3634; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Horn H, 2014, NAT METHODS, V11, P603, DOI 10.1038/nmeth.2968; Innocenti P, 2012, J MED CHEM, V55, P3228, DOI 10.1021/jm201683b; Jowsey P, 2007, DNA REPAIR, V6, P1536, DOI 10.1016/j.dnarep.2007.04.011; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Julien E, 2003, EMBO J, V22, P2360, DOI 10.1093/emboj/cdg242; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; Kovalenko OV, 1997, NUCLEIC ACIDS RES, V25, P4946, DOI 10.1093/nar/25.24.4946; Lara-Gonzalez P, 2019, DEV CELL, V51, P313, DOI 10.1016/j.devcel.2019.09.005; Lebraud H, 2014, ORG BIOMOL CHEM, V12, P141, DOI 10.1039/c3ob41806e; Liang FS, 2016, CELL REP, V15, P2118, DOI 10.1016/j.celrep.2016.05.007; Liu XS, 2010, EMBO REP, V11, P626, DOI 10.1038/embor.2010.90; Ma S, 2016, J CELL SCI, V129, P1329, DOI 10.1242/jcs.178855; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mbom BC, 2014, MOL BIOL CELL, V25, P977, DOI 10.1091/mbc.E13-06-0349; McCloy RA, 2015, MOL CELL PROTEOMICS, V14, P2194, DOI 10.1074/mcp.M114.046938; Mi J, 2007, CANCER RES, V67, P1082, DOI 10.1158/0008-5472.CAN-06-3071; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Mochida S, 2010, SCIENCE, V330, P1670, DOI 10.1126/science.1195689; Modesti M, 2007, MOL CELL, V28, P468, DOI 10.1016/j.molcel.2007.08.025; Morozumi Y, 2009, NUCLEIC ACIDS RES, V37, P4296, DOI 10.1093/nar/gkp298; Neviani P, 2013, J CLIN INVEST, V123, P4144, DOI 10.1172/JCI68951; O'Shea JP, 2013, NAT METHODS, V10, P1211, DOI [10.1038/NMETH.2646, 10.1038/nmeth.2646]; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Pachis ST, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180109; Pan WA, 2015, RNA BIOL, V12, P255, DOI 10.1080/15476286.2015.1017221; Park J, 2013, BIOCHEM BIOPH RES CO, V431, P302, DOI 10.1016/j.bbrc.2012.12.106; Parplys AC, 2014, DNA REPAIR, V24, P87, DOI 10.1016/j.dnarep.2014.09.007; Peng AM, 2010, CELL CYCLE, V9, P4364, DOI 10.4161/cc.9.21.13632; Pires E, 2017, DNA REPAIR, V59, P76, DOI 10.1016/j.dnarep.2017.09.008; Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738; Rogers S, 2018, ONCOGENE, V37, P4518, DOI 10.1038/s41388-018-0295-z; Rogers S, 2016, J CELL SCI, V129, P1340, DOI 10.1242/jcs.179754; Sangodkar J, 2017, J CLIN INVEST, V127, P2081, DOI 10.1172/JCI89548; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Shim SY, 2015, J BIOL CHEM, V290, P9122, DOI 10.1074/jbc.M114.591545; Sobecki M, 2016, ELIFE, V5, DOI 10.7554/eLife.13722; Takagi M, 2001, J BIOL CHEM, V276, P25386, DOI 10.1074/jbc.M102227200; Tang X, 2008, MOL CELL BIOL, V28, P2559, DOI 10.1128/MCB.01711-07; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tzelepis K, 2016, CELL REP, V17, P1193, DOI 10.1016/j.celrep.2016.09.079; van de Kooij B, 2019, ELIFE, V8, DOI 10.7554/eLife.44635; Vera J, 2015, ELIFE, V4, DOI 10.7554/eLife.10115; Vigneron S, 2011, MOL CELL BIOL, V31, P2262, DOI 10.1128/MCB.00753-10; Wagner SA, 2016, PROTEOMICS, V16, P402, DOI 10.1002/pmic.201500172; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wei R, 2011, MOL BIOL CELL, V22, P3584, DOI 10.1091/mbc.E11-01-0012; Wiese C, 2007, MOL CELL, V28, P482, DOI 10.1016/j.molcel.2007.08.027; Wiredja DD, 2017, BIOINFORMATICS, V33, P3489, DOI 10.1093/bioinformatics/btx415; Wong J, 2008, MOL BIOL CELL, V19, P2083, DOI 10.1091/mbc.E07-10-1088; Wu JM, 2013, P NATL ACAD SCI USA, V110, pE1779, DOI 10.1073/pnas.1220523110; Wu JQ, 2009, NAT CELL BIOL, V11, P644, DOI 10.1038/ncb1871; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Yu JT, 2004, J CELL BIOL, V164, P487, DOI 10.1083/JCB.200310059	103	6	6	3	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6816	6840		10.1038/s41388-020-01470-1	http://dx.doi.org/10.1038/s41388-020-01470-1		SEP 2020	25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978522	Green Published, hybrid			2022-12-17	WOS:000572714000006
J	Li, LY; Chen, XS; Wang, KS; Guan, YD; Ren, XC; Cao, DS; Sun, XY; Li, AX; Tao, YG; Zhang, Y; Yin, MZ; Wang, XL; Wu, MH; Yang, JM; Cheng, Y				Li, Lan-Ya; Chen, Xi-Sha; Wang, Kuan-Song; Guan, Yi-Di; Ren, Xing-Cong; Cao, Dong-Sheng; Sun, Xin-Yuan; Li, Ao-Xue; Tao, Yong-Guang; Zhang, Yi; Yin, Ming-Zhu; Wang, Xin-Luan; Wu, Ming-Hua; Yang, Jin-Ming; Cheng, Yan			RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPK alpha 2-mediated autophagy	ONCOGENE			English	Article							ER STRESS; SIGNALING PATHWAY; INDUCED APOPTOSIS; CARCINOMA-CELLS; INHIBITION; SURVIVAL; KINASE; PROTEINS; PHOSPHORYLATION; SENSITIVITY	Autophagy can protect stressed cancer cell by degradation of damaged proteins and organelles. However, the regulatory mechanisms behind this cellular process remain incompletely understood. Here, we demonstrate that RSK2 (p90 ribosomal S6 kinase 2) plays a critical role in ER stress-induced autophagy in breast cancer cells. We demonstrated that the promotive effect of RSK2 on autophagy resulted from directly binding of AMPK alpha 2 in nucleus and phosphorylating it at Thr172 residue. IRE1 alpha, an ER membrane-associated protein mediating unfolded protein response (UPR), is required for transducing the signal for activation of ERK1/2-RSK2 under ER stress. Suppression of autophagy by knockdown of RSK2 enhanced the sensitivity of breast cancer cells to ER stress both in vitro and in vivo. Furthermore, we demonstrated that inhibition of RSK2-mediated autophagy rendered breast cancer cells more sensitive to paclitaxel, a chemotherapeutic agent that induces ER stress-mediated cell death. This study identifies RSK2 as a novel controller of autophagy in tumor cells and suggests that targeting RSK2 can be exploited as an approach to reinforce the efficacy of ER stress-inducing agents against cancer.	[Li, Lan-Ya; Chen, Xi-Sha; Guan, Yi-Di; Sun, Xin-Yuan; Cheng, Yan] Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Peoples R China; [Li, Lan-Ya; Cao, Dong-Sheng; Sun, Xin-Yuan; Li, Ao-Xue] Cent South Univ, Xiangya Sch Pharmaceut Sci, Changsha 410008, Peoples R China; [Wang, Kuan-Song] Cent South Univ, Sch Basic Med, Xiangya Hosp, Dept Pathol, Changsha 410078, Peoples R China; [Wang, Kuan-Song] Cent South Univ, Sch Basic Med, Dept Pathol, Changsha 410078, Peoples R China; [Ren, Xing-Cong; Yang, Jin-Ming] Univ Kentucky, Coll Med, Markey Canc Ctr, Dept Pharmacol,Dept Canc Biol & Toxicol, Lexington, KY 40536 USA; [Tao, Yong-Guang; Wu, Ming-Hua] Cent South Univ, Sch Basic Med, Canc Res Inst, Changsha 410078, Peoples R China; [Tao, Yong-Guang; Wu, Ming-Hua] Cent South Univ, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Peoples R China; [Zhang, Yi] Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 410008, Peoples R China; [Yin, Ming-Zhu] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Dept Dermatol,Hunan Key Lab Skin Canc & Psoriasis, Changsha 410008, Hunan, Peoples R China; [Wang, Xin-Luan] Chinese Acad Sci, Shenzhen Inst Adv Technol, Translat Med R&D Ctr, Inst Biomed & Hlth Engn, Shenzhen 518057, Peoples R China	Central South University; Central South University; Central South University; Central South University; University of Kentucky; Central South University; Central South University; Soochow University - China; Central South University; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Cheng, Y (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Peoples R China.	yancheng@csu.edu.cn		tao, yongguang/0000-0003-2354-5321	National Natural Science Foundation of China [81472593, 81972480]; Postgraduate Research and Innovation Project of Central South University [1053320183910]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postgraduate Research and Innovation Project of Central South University	This work was supported by the National Natural Science Foundation of China under Grant Nos. 81472593 and 81972480; the Postgraduate Research and Innovation Project of Central South University under Grant No. 1053320183910.	Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Bhardwaj M, 2020, SEMIN CANCER BIOL, V66, P116, DOI 10.1016/j.semcancer.2019.11.007; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120; Cheng Y, 2013, AUTOPHAGY, V9, P208, DOI 10.4161/auto.22801; Cho YY, 2012, CARCINOGENESIS, V33, P2529, DOI 10.1093/carcin/bgs271; Cho YY, 2009, CANCER RES, V69, P4398, DOI 10.1158/0008-5472.CAN-08-4959; Cho YY, 2005, CANCER RES, V65, P3596, DOI 10.1158/0008-5472.CAN-04-3935; Ciechomska IA, 2013, ONCOGENE, V32, P1518, DOI 10.1038/onc.2012.174; Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004; Dey S, 2013, AUTOPHAGY, V9, P612, DOI 10.4161/auto.23486; Eisinger-Mathason TSK, 2008, MOL CELL, V31, P722, DOI 10.1016/j.molcel.2008.06.025; Fujiki K, 2014, ARCH TOXICOL, V88, P403, DOI 10.1007/s00204-013-1129-y; Gao J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.444; Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032; Gawecka JE, 2012, J BIOL CHEM, V287, P43424, DOI 10.1074/jbc.M112.423046; Goncalves RLS, 2019, CELL METAB, V30, P999, DOI 10.1016/j.cmet.2019.11.008; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781; Hong-Brown LQ, 2017, ALCOHOL CLIN EXP RES, V41, P895, DOI 10.1111/acer.13377; Hospital MA, 2018, LEUKEMIA, V32, P597, DOI 10.1038/leu.2017.284; Houles T, 2018, SEMIN CANCER BIOL, V48, P53, DOI 10.1016/j.semcancer.2017.04.016; Im JY, 2018, ONCOGENE, V37, P1251, DOI 10.1038/s41388-017-0025-y; Janczar S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.346; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Kang SM, 2011, EXPERT OPIN THER TAR, V15, P11, DOI 10.1517/14728222.2010.531013; Lara R, 2013, CANCER RES, V73, P5301, DOI 10.1158/0008-5472.CAN-12-4448; Lei Y, 2015, ONCOGENE, V34, P485, DOI 10.1038/onc.2013.566; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li N, 2013, ONCOGENE, V32, P1933, DOI 10.1038/onc.2012.212; Li X, 2016, AUTOPHAGY, V12, P1521, DOI 10.1080/15548627.2016.1191722; Lim HC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074334; Liu KD, 2011, J BIOL CHEM, V286, P2057, DOI 10.1074/jbc.M110.147306; Liu SL, 2015, INT J ONCOL, V46, P2399, DOI 10.3892/ijo.2015.2937; Lozy F, 2014, AUTOPHAGY, V10, P662, DOI 10.4161/auto.27867; Luan Q, 2015, AUTOPHAGY, V11, P975, DOI 10.1080/15548627.2015.1049800; Maddalena F, 2013, MOL ONCOL, V7, P895, DOI 10.1016/j.molonc.2013.04.009; Nam HY, 2013, AUTOPHAGY, V9, P1631, DOI 10.4161/auto.25879; Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394; Piasecka D, 2016, ONCOTARGET, V7, P86011, DOI 10.18632/oncotarget.13322; Qiang L, 2017, AUTOPHAGY, V13, P2086, DOI 10.1080/15548627.2017.1380757; Rao SV, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3055-5; Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166; Salt IP, 2017, CIRC RES, V120, P1825, DOI 10.1161/CIRCRESAHA.117.309633; Schaffer BE, 2015, CELL METAB, V22, P907, DOI 10.1016/j.cmet.2015.09.009; Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818; Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014; Smith MD, 2018, DEV CELL, V44, P217, DOI 10.1016/j.devcel.2017.11.024; Spaan CN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1729-4; Stratford AL, 2012, STEM CELLS, V30, P1338, DOI 10.1002/stem.1128; Sulzmaier FJ, 2016, ONCOTARGET, V7, P79855, DOI 10.18632/oncotarget.13084; Tameire F, 2019, NAT CELL BIOL, V21, P889, DOI 10.1038/s41556-019-0347-9; van Jaarsveld MTM, 2013, EUR J CANCER, V49, P345, DOI 10.1016/j.ejca.2012.08.024; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang QL, 2017, AUTOPHAGY, V13, P404, DOI 10.1080/15548627.2016.1263776; Wen J, 2015, BREAST CANCER RES TR, V149, P619, DOI 10.1007/s10549-015-3283-9; Xiang XY, 2016, ONCOL REP, V35, P3471, DOI 10.3892/or.2016.4725; Xu L, 2015, CANCER RES TREAT, V47, P313, DOI 10.4143/crt.2013.222; Xu LY, 2012, MOL CANCER THER, V11, P2174, DOI 10.1158/1535-7163.MCT-12-0602; Zaouali MA, 2013, J PINEAL RES, V55, P65, DOI 10.1111/jpi.12051; Zhang DY, 2016, AUTOPHAGY, V12, P1447, DOI 10.1080/15548627.2016.1185576; Zhang SF, 2015, AUTOPHAGY, V11, P225, DOI 10.1080/15548627.2014.998931; Zhao C, 2013, AUTOPHAGY, V9, P196, DOI 10.4161/auto.22805; Zhu YX, 2015, BLOOD, V125, P483, DOI 10.1182/blood-2014-05-577130	66	6	8	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6704	6718		10.1038/s41388-020-01447-0	http://dx.doi.org/10.1038/s41388-020-01447-0		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32958832				2022-12-17	WOS:000571674200001
J	Tabassum, N; Cereser, B; Stebbing, J				Tabassum, Neha; Cereser, Biancastella; Stebbing, Justin			A cell-cycle signature classifier for pan-cancer analysis	ONCOGENE			English	Editorial Material									[Tabassum, Neha; Cereser, Biancastella; Stebbing, Justin] Imperial Coll, Dept Surg & Canc, London, England	Imperial College London	Tabassum, N (corresponding author), Imperial Coll, Dept Surg & Canc, London, England.	n.tabassum16@imperial.ac.uk		Stebbing, Justin/0000-0002-1117-6947; Constantin, Theodora Alexandra/0000-0003-2132-5165; Tabassum, Neha/0000-0002-0812-3692; Cereser, Biancastella/0000-0003-1243-1767	Department of Health [NIHR-RP-011-053] Funding Source: Medline	Department of Health		Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Gospodarowicz M, 2001, CANCER-AM CANCER SOC, V91, P1688, DOI 10.1002/1097-0142(20010415)91:8+<1688::AID-CNCR1184>3.0.CO;2-7; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Lundberg A, 2017, CLIN CANCER RES, V23, P7512, DOI 10.1158/1078-0432.CCR-17-1535; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Mozas P, 2020, BLOOD CANCER J, V10, DOI 10.1038/s41408-020-0299-0; Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005; Tobin NP, 2017, CLIN CANCER RES, V23, P7225, DOI 10.1158/1078-0432.CCR-17-2301	8	6	6	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6041	6042		10.1038/s41388-020-01426-5	http://dx.doi.org/10.1038/s41388-020-01426-5		AUG 2020	2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32820254	Bronze			2022-12-17	WOS:000561253800003
J	Cai, J; Liu, WF; Wong, CW; Zhu, WB; Lin, Y; Hu, J; Xu, WC; Zhang, JF; Sander, M; Wang, Z; Dan, J; Zhang, JY; Liu, Y; Guo, L; Qin, Z; Liu, XC; Liu, Y; Yan, GM; Wu, SH; Liang, JK				Cai, Jing; Liu, Wenfeng; Wong, Chun Wa; Zhu, Wenbo; Lin, Yuan; Hu, Jun; Xu, Wencang; Zhang, Jifu; Sander, Max; Wang, Zhuo; Dan, Jia; Zhang, Jiayu; Liu, Yang; Guo, Li; Qin, Zhen; Liu, Xincheng; Liu, Ying; Yan, Guangmei; Wu, Sihan; Liang, Jiankai			Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer	ONCOGENE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; VIRAL MESSENGER-RNAS; ZAP; TRAIL; INTERFERONS; INHIBITION; RECEPTOR; EXPRESSION; INFECTION; CASPASE-8	Avoiding immune destruction is essential for tumorigenesis. Current research into the interaction between tumor and immunological niches complement tumor pathology beyond cancer genetics. Intrinsic host defense immunity is a specialized innate immunity component to restrict viral infection. However, whether intrinsic immunity participates in tumor pathology is unclear. Previously, we identified a zinc-finger antiviral protein ZAP that is commonly downregulated in a panel of clinical cancer specimens. However, whether ZAP has an impact on tumor development was unknown. Here we report ZAP as a genuine tumor suppressor. Pan-caner analysis with TCGA data from 712 patients and large-scale immunohistochemistry in tissue microarrays from 1552 patients reveal that ZAP is prevalently downregulated, and associated with poor survival in liver, colon, and bladder cancer patients. Ectopic over-expression of ZAP inhibits the malignant phenotypes of colorectal tumor by cell cycle arrest. Using RNA immunoprecipitation and RNA decay assays, we demonstrate that ZAP directly and specifically binds to and degrades the transcript of TRAILR4, which in turn represses TRAILR4 expression and inhibits the aggressiveness of colorectal cancer cells. Furthermore, our CRISPR-engineered mice models show that loss-of-function of ZAP synergizes with APC-deficiency to drive malignant colorectal cancer in vivo. Overall, we identify a previously unknown function of the antiviral factor ZAP in colorectal tumorigenesis, linking intrinsic immunity to tumor pathogenetics.	[Cai, Jing; Liu, Wenfeng; Wong, Chun Wa; Zhu, Wenbo; Lin, Yuan; Hu, Jun; Dan, Jia; Zhang, Jiayu; Liu, Yang; Guo, Li; Qin, Zhen; Liu, Xincheng; Yan, Guangmei; Liang, Jiankai] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou 510080, Peoples R China; [Xu, Wencang; Zhang, Jifu; Sander, Max] Guangzhou Virotech Pharmaceut Co Ltd, Guangzhou 510663, Peoples R China; [Wang, Zhuo] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Peoples R China; [Liu, Ying] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou 510630, Peoples R China; [Wu, Sihan] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Liang, JK (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pharmacol, Guangzhou 510080, Peoples R China.; Wu, SH (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	siw048@ucsd.edu; liangjk5@mail.sysu.edu.cn	Wu, Sihan/AAB-6812-2020	Wu, Sihan/0000-0001-8329-7492; Wong, Chun-wa/0000-0003-3476-9283; Lin, Yuan/0000-0002-7152-0965	National Natural Science Foundation of China [81872887, 81902809, 81872886, 81773751, 81973342, 81973347]; Fundamental Research Funds for the Central Universities [18ykpy37]; National Major Scientific and Technological Special Project for "Significant New Drugs Development" [2018ZXO9733002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Major Scientific and Technological Special Project for "Significant New Drugs Development"	JC: the National Natural Science Foundation of China (No. 81902809) and the Fundamental Research Funds for the Central Universities (No. 18ykpy37). WZ: the National Natural Science Foundation of China (No. 81872886). JH: the National Natural Science Foundation of China (No. 81773751). JL: the National Natural Science Foundation of China (No. 81973342). YL: the National Natural Science Foundation of China (No. 81973347). GY: the National Natural Science Foundation of China (No. `81872887) and the National Major Scientific and Technological Special Project for "Significant New Drugs Development" during the 13th Five-Year Plan Period (No. 2018ZXO9733002).	Bick MJ, 2003, J VIROL, V77, P11555, DOI 10.1128/JVI.77.21.11555-11562.2003; Charron G, 2013, P NATL ACAD SCI USA, V110, P11085, DOI 10.1073/pnas.1302564110; Chen SD, 2012, NAT STRUCT MOL BIOL, V19, P430, DOI 10.1038/nsmb.2243; Chiu HP, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007166; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Feng MY, 2019, NAT REV CANCER, V19, P568, DOI 10.1038/s41568-019-0183-z; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; Guo XM, 2004, J VIROL, V78, P12781, DOI 10.1128/JVI.78.23.12781-12787.2004; Guo XM, 2007, P NATL ACAD SCI USA, V104, P151, DOI 10.1073/pnas.0607063104; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang Z, 2010, PROTEIN CELL, V1, P752, DOI 10.1007/s13238-010-0096-9; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Lee H, 2013, P NATL ACAD SCI USA, V110, P12379, DOI 10.1073/pnas.1310604110; Leung AKL, 2011, MOL CELL, V42, P489, DOI 10.1016/j.molcel.2011.04.015; Li S, 2016, NAT IMMUNOL, V17, P241, DOI 10.1038/ni.3311; Lin Y, 2014, P NATL ACAD SCI USA, V111, pE4504, DOI 10.1073/pnas.1408759111; Liu CH, 2015, P NATL ACAD SCI USA, V112, P14048, DOI 10.1073/pnas.1509745112; MacDonald MR, 2007, J VIROL, V81, P13509, DOI 10.1128/JVI.00402-07; Mao RC, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003494; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muller S, 2007, J VIROL, V81, P2391, DOI 10.1128/JVI.01601-06; Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563; Saito Y, 2016, SCI REP, V6; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Snell LM, 2017, TRENDS IMMUNOL, V38, P542, DOI 10.1016/j.it.2017.05.005; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Textor S, 2011, CANCER RES, V71, P5998, DOI 10.1158/0008-5472.CAN-10-3211; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Todorova T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6362; von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28; Vyas S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3240; Wang XS, 2019, GENOMICS, V111, P1464, DOI 10.1016/j.ygeno.2018.09.020; Xuan YF, 2012, J VIROL, V86, P12431, DOI 10.1128/JVI.01514-12; Yoon KW, 2015, SCIENCE, V349, DOI 10.1126/science.1261669; Zhu YP, 2012, EMBO J, V31, P4236, DOI 10.1038/emboj.2012.271; Zhu YP, 2011, P NATL ACAD SCI USA, V108, P15834, DOI 10.1073/pnas.1101676108; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	45	6	7	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5995	6008		10.1038/s41388-020-01416-7	http://dx.doi.org/10.1038/s41388-020-01416-7		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32770142				2022-12-17	WOS:000557117100001
J	Ouyang, HY; Luong, P; Frodin, M; Hansen, SH				Ouyang, Hanyue; Luong, Phi; Frodin, Morten; Hansen, Steen H.			p190A RhoGAP induces CDH1 expression and cooperates with E-cadherin to activate LATS kinases and suppress tumor cell growth	ONCOGENE			English	Article							GAP-ASSOCIATED PROTEINS; MESENCHYMAL TRANSITION; CONTACT INHIBITION; SIGNALING-PATHWAY; HIPPO PATHWAY; RAS-GAP; GTPASE; P190RHOGAP; YAP; MIGRATION	TheARHGAP35gene encoding p190A RhoGAP (p190A) is significantly altered by both mutation and allelic deletion in human cancer, but the functional implications of such alterations are not known. Here, we demonstrate for the first time that p190A is a tumor suppressor using a xenograft mouse model with carcinoma cells harboring definedARHGAP35alterations. In vitro, restoration of p190A expression in carcinoma cells promotes contact inhibition of proliferation (CIP) through activation of LATS kinases and phosphorylation of the proto-oncogenic transcriptional co-activator YAP. In contrast, p190A forms harboring recurrent cancer mutations exhibit loss of function in modulating the Hippo pathway, inducing CIP, as well as attenuated suppression of tumor growth in mice. We determine that p190A promotes mesenchymal to epithelial transition (MET) and elicits expression of a cassette of epithelial adherens junction-associated genes in a cell density-dependent manner. This cassette includesCDH1encoding E-cadherin, which amplifies p190A-mediated LATS activation and is necessary for CIP. Oppositely, we establish that p190A is obligatory for E-cadherin to activate LATS kinases and induce CIP. Collectively, this work defines a novel mechanism by which p190A and E-cadherin cooperate in modulating Hippo signaling to suppress tumor cell growth.	[Ouyang, Hanyue; Luong, Phi; Hansen, Steen H.] Boston Childrens Hosp, GI Cell Biol Lab, Boston, MA 02115 USA; [Ouyang, Hanyue; Luong, Phi; Hansen, Steen H.] Harvard Med Sch, Boston, MA 02115 USA; [Frodin, Morten] Univ Copenhagen, Biotech Res & Innovat Ctr BRIC, DK-2200 Copenhagen N, Denmark	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Copenhagen	Hansen, SH (corresponding author), Boston Childrens Hosp, GI Cell Biol Lab, Boston, MA 02115 USA.; Hansen, SH (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	steen.hansen@childrens.harvard.edu		Frodin, Morten/0000-0003-3691-9820	Harvard Digestive Diseases Center (HDDC) [NIH P30DK034854]; NIH [R01CA205158]; Roy and Lynne Frank Foundation	Harvard Digestive Diseases Center (HDDC); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roy and Lynne Frank Foundation	We are grateful to Suzanne L. White and Dr. Lay-Hong Ang, BIDMC confocal imaging and IHC core for assistance with histology procedures, and Dr. Olga Olstrup, Center for Genomic Medicine, Rigshospitalet, University of Copenhagen for assistance with CNV analysis, as well as to Dr. Michael Grey, Boston Children's Hospital for helpful suggestions. This work utilized Harvard Digestive Diseases Center (HDDC) core facilities (NIH P30DK034854) and was funded by NIH R01CA205158, as well as an endowment from the Roy and Lynne Frank Foundation (to SHH).	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biname F, 2016, J CELL BIOL, V214, P859, DOI 10.1083/jcb.201601063; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; Bustos RI, 2008, CURR BIOL, V18, P1606, DOI 10.1016/j.cub.2008.09.019; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; CHANG JH, 1993, ONCOGENE, V8, P959; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frank SR, 2017, ONCOGENE, V36, P1816, DOI 10.1038/onc.2016.345; Frank SR, 2018, J CELL BIOL, V217, P3183, DOI 10.1083/jcb.201710058; Hajra KM, 2002, CANCER RES, V62, P1613; Heckman-Stoddard BM, 2011, DEV BIOL, V360, P1, DOI 10.1016/j.ydbio.2011.09.006; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jiang W, 2008, J BIOL CHEM, V283, P20978, DOI 10.1074/jbc.M802588200; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kusama T, 2006, CANCER SCI, V97, P848, DOI 10.1111/j.1349-7006.2006.00242.x; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Levay M, 2009, BIOCHEMISTRY-US, V48, P8615, DOI 10.1021/bi900667y; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Maatta AM, 2008, INT J CANCER, V123, P1704, DOI 10.1002/ijc.23646; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Notsuda H, 2013, INT J ONCOL, V43, P1569, DOI 10.3892/ijo.2013.2096; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Parasuraman P, 2017, J BIOL CHEM, V292, P2679, DOI 10.1074/jbc.M116.769216; Pullikuth AK, 2010, MOL CELL BIOL, V30, P3233, DOI 10.1128/MCB.01178-09; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Shen CH, 2008, CANCER RES, V68, P7779, DOI 10.1158/0008-5472.CAN-08-0997; Smith SA, 2019, J MED CHEM, V62, P1291, DOI 10.1021/acs.jmedchem.8b01402; Sordella R, 2003, CELL, V113, P147, DOI 10.1016/S0092-8674(03)00271-X; Stewart K, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005785; Su L, 2003, J CELL BIOL, V163, P571, DOI 10.1083/jcb.200308007; Sun Q, 2014, CELL RES, V24, P1288, DOI 10.1038/cr.2014.137; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wang DZM, 1997, CANCER RES, V57, P2478; Wei J, 2005, MOL CELL, V17, P23, DOI 10.1016/j.molcel.2004.11.024; Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zebda N, 2013, J BIOL CHEM, V288, P18290, DOI 10.1074/jbc.M112.432757; Zhang ZZ, 2014, ACS MED CHEM LETT, V5, P993, DOI 10.1021/ml500160m; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	69	6	6	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5570	5587		10.1038/s41388-020-1385-2	http://dx.doi.org/10.1038/s41388-020-1385-2		JUL 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32641858	hybrid, Green Published			2022-12-17	WOS:000546526000001
J	El-Khoury, M; Cabagnols, X; Mosca, M; Vertenoeil, G; Marzac, C; Favale, F; Bluteau, O; Lorre, F; Tisserand, A; Moraes, GR; Ugo, V; Ianotto, JC; Rey, J; Solary, E; Roy, L; Rameau, P; Debili, N; Pasquier, F; Casadevall, N; Marty, C; Constantinescu, SN; Raslova, H; Vainchenker, W; Plo, I				El-Khoury, Mira; Cabagnols, Xenia; Mosca, Matthieu; Vertenoeil, Gaelle; Marzac, Christophe; Favale, Fabrizia; Bluteau, Olivier; Lorre, Florence; Tisserand, Amandine; Moraes, Graciela Rabadan; Ugo, Valerie; Ianotto, Jean-Christophe; Rey, Jerome; Solary, Eric; Roy, Lydia; Rameau, Philippe; Debili, Najet; Pasquier, Florence; Casadevall, Nicole; Marty, Caroline; Constantinescu, Stefan N.; Raslova, Hana; Vainchenker, William; Plo, Isabelle			Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms	ONCOGENE			English	Article							ESSENTIAL THROMBOCYTHEMIA; THROMBOPOIETIN RECEPTOR; MUTANT CALRETICULIN; POLYCYTHEMIA-VERA; CALR MUTATIONS; SOMATIC MUTATIONS; JAK2 MUTATION; STEM-CELLS; MPL; MYELOFIBROSIS	Mutations of calreticulin (CALRm) define a subtype of myeloproliferative neoplasms (MPN). We studied the biological and genetic features ofCALR-mutated essential thrombocythemia and myelofibrosis patients. In most cases,CALRmwere found in granulocytes, monocytes, B and NK cells, but also in T cells. However, the type 1CALRmspreads more easily than the type 2CALRmin lymphoid cells. TheCALRmwere also associated with an early clonal dominance at the level of hematopoietic stem and progenitor cells (HSPC) with no significant increase during granulo/monocytic differentiation in most cases. Moreover, we found that half of type 2CALRmpatients harbors some homozygous progenitors. Those patients were associated with a higher clonal dominance during granulo/monocytic differentiation than patients with only heterozygous type 2CALRmprogenitors. When associated mutations were present,CALRmwere the first genetic event suggesting that they are both the initiating and phenotypic event. In blood, type 1CALRmled to a greater increased number of all types of progenitors compared with the type 2CALRm. However, both types ofCALRminduced an increase in megakaryocytic progenitors associated with a ruxolitinib-sensitive independent growth and with a mild constitutive signaling in megakaryocytes. At the transcriptional level, type 1CALRmseems to deregulate more pathways than the type 2CALRmin megakaryocytes. Altogether, our results show thatCALRmmodify both the HSPC and megakaryocyte biology with a stronger effect for type 1 than for type 2CALRm.	[El-Khoury, Mira; Cabagnols, Xenia; Mosca, Matthieu; Bluteau, Olivier; Tisserand, Amandine; Moraes, Graciela Rabadan; Solary, Eric; Debili, Najet; Pasquier, Florence; Casadevall, Nicole; Marty, Caroline; Raslova, Hana; Vainchenker, William; Plo, Isabelle] INSERM, UMR1287, Villejuif, France; [El-Khoury, Mira; Cabagnols, Xenia; Mosca, Matthieu; Bluteau, Olivier; Tisserand, Amandine; Moraes, Graciela Rabadan; Solary, Eric; Rameau, Philippe; Debili, Najet; Pasquier, Florence; Casadevall, Nicole; Marty, Caroline; Raslova, Hana; Vainchenker, William; Plo, Isabelle] Gustave Roussy, Villejuif, France; [El-Khoury, Mira; Cabagnols, Xenia; Tisserand, Amandine; Moraes, Graciela Rabadan] Univ Paris Diderot Paris 7, Gustave Roussy, UMR1287, Villejuif, France; [Mosca, Matthieu; Bluteau, Olivier; Solary, Eric; Debili, Najet; Pasquier, Florence; Marty, Caroline; Raslova, Hana; Vainchenker, William; Plo, Isabelle] Univ Paris XI, UMR1287, Gustave Roussy, Villejuif, France; [Vertenoeil, Gaelle; Constantinescu, Stefan N.] Ludwig Inst Canc Res Brussels, Brussels, Belgium; [Vertenoeil, Gaelle; Constantinescu, Stefan N.] Catholic Univ Louvain, Brussels, Belgium; [Vertenoeil, Gaelle; Constantinescu, Stefan N.] Duve Inst, Brussels, Belgium; [Marzac, Christophe; Solary, Eric; Pasquier, Florence] Gustave Roussy, Dept Hematol, Villejuif, France; [Favale, Fabrizia; Lorre, Florence] Sorbonne Univ, INSERM, Ctr Rech St Antoine, CRSA,UMR S 938, Paris, France; [Ugo, Valerie] CHU Angers, Lab Hematol, Angers, France; [Ianotto, Jean-Christophe] CHRU Brest, Serv Hematol, Brest, France; [Rey, Jerome] Inst Paoli Calmettes, Dept Hematol, Serv Hematol, Marseille, France; [Roy, Lydia] CHU Henri Mondor, Assistance Publ Hop Paris, Serv Hematol, Creteil, France; [Casadevall, Nicole] Hop St Antoine, Assistance Publ Hop Paris, Lab Hematol, Paris, France; [Constantinescu, Stefan N.] WELBIO Walloon Excellence Life Sci & Biotechnol, Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Universite Catholique Louvain; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Brest; Universite de Bretagne Occidentale; UNICANCER; Institut Paoli-Calmette (IPC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; WELBIO	Vainchenker, W; Plo, I (corresponding author), INSERM, UMR1287, Villejuif, France.; Vainchenker, W; Plo, I (corresponding author), Gustave Roussy, Villejuif, France.; Vainchenker, W; Plo, I (corresponding author), Univ Paris XI, UMR1287, Gustave Roussy, Villejuif, France.	william.vainchenker@gustaveroussy.fr; isabelle.plo@gustaveroussy.fr	Plo, Isabelle/C-9056-2017; Plo, Isabelle/AAT-6742-2021; Raslova, Hana/N-3562-2018	Plo, Isabelle/0000-0002-5915-6910; Ugo, Valerie/0000-0002-4678-2138; Ianotto, Jean-Christophe/0000-0001-9074-7287; Bluteau, Olivier/0000-0002-6943-8858; Raslova, Hana/0000-0001-8846-5299; Solary, Eric/0000-0002-8629-1341	Agence Nationale pour la Recherche; Ligue Nationale contre le Cancer; Fondation Laurette Fugain; INCA PLBIO 2016; grant "Taxe d'apprentissage" Gustave Roussy-2016; INSERM; program "Investissements d'avenir"; Salus Sanguinis Action de recherche concertee (ARC) [16/21-073]; WelBio [F 44/8/5-MCF/UIG-10955]; SFH (Societe francaise d'hematologie); university Paris-Diderot (MENRT grant); Gustave Roussy Foundation; SFH; Fonds Nationals de la Recherche Scientifique, Belgium; Fondation contre le cancer; la Ligue Nationale contre le Cancer	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Fondation Laurette Fugain; INCA PLBIO 2016; grant "Taxe d'apprentissage" Gustave Roussy-2016; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); program "Investissements d'avenir"(French National Research Agency (ANR)); Salus Sanguinis Action de recherche concertee (ARC); WelBio(WELBIO); SFH (Societe francaise d'hematologie); university Paris-Diderot (MENRT grant); Gustave Roussy Foundation; SFH; Fonds Nationals de la Recherche Scientifique, Belgium; Fondation contre le cancer; la Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This work was funded by grants from the Agence Nationale pour la Recherche (Thrombocytosis, WV), the Ligue Nationale contre le Cancer (equipe labellelisee HR 2016, 2019), the Fondation Laurette Fugain (WV, IP), INCA PLBIO 2016 (IP), by grant "Taxe d'apprentissage" Gustave Roussy-2016 (LS and MEK) and from the INSERM. Labex GR-Ex (IP, WV) is funded by the program "Investissements d'avenir." Support to SNC was from Fondation contre le cancer, Salus Sanguinis Action de recherche concertee (ARC) 16/21-073 and WelBio F 44/8/5-MCF/UIG-10955. MEK was supported by the SFH (Societe francaise d'hematologie), XC and AT were supported by the university Paris-Diderot (MENRT grant), MM by la Ligue Nationale contre le Cancer, Gustave Roussy Foundation and SFH. GRM was a recipient from allocations doctorales sur domaines cibles (ARDoc, Ile-de-France region). GV was supported by a PhD aspirant fellowship of the Fonds Nationals de la Recherche Scientifique, Belgium. We want to thank the platforms of bioinformatic (Khadija M Diop, Guillaume Meurice and Marc Deloger) and flow cytometry and Edwige Leclercq, Marie-Helene Courtier for CALR sizing analysis.	Allen C, 2014, BLOOD, V124, P2091, DOI 10.1182/blood-2014-06-580183; Anand S, 2011, BLOOD, V118, P177, DOI 10.1182/blood-2010-12-327593; Andrikovics H, 2014, HAEMATOLOGICA, V99, P1184, DOI 10.3324/haematol.2014.107482; Araki M, 2016, BLOOD, V127, P1307, DOI 10.1182/blood-2015-09-671172; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Balligand T, 2020, LEUKEMIA, V34, P510, DOI 10.1038/s41375-019-0538-1; Barosi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035631; Cabagnols X, 2015, LEUKEMIA, V29, P249, DOI 10.1038/leu.2014.270; Cabagnols X, 2016, BLOOD, V127, P333, DOI 10.1182/blood-2015-07-661983; Campbell PJ, 2005, LANCET, V366, P1945, DOI 10.1016/S0140-6736(05)67785-9; Chachoua I, 2016, BLOOD, V127, P1325, DOI 10.1182/blood-2015-11-681932; Chagraoui H, 2002, BLOOD, V100, P3495, DOI 10.1182/blood-2002-04-1133; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Delhommeau F, 2007, BLOOD, V109, P71, DOI 10.1182/blood-2006-03-007146; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; Di Buduo CA, 2020, BLOOD, V135, P133, DOI 10.1182/blood.2019001103; Dupont S, 2007, BLOOD, V110, P1013, DOI 10.1182/blood-2006-10-054940; Eder-Azanza L, 2014, LEUKEMIA, V28, P2106, DOI 10.1038/leu.2014.190; Elf S, 2018, BLOOD, V131, P782, DOI 10.1182/blood-2017-08-800896; Elf S, 2016, CANCER DISCOV, V6, P368, DOI 10.1158/2159-8290.CD-15-1434; Feenstra JDM, 2016, BLOOD, V127, P325, DOI 10.1182/blood-2015-07-661835; Gekas C, 2013, BLOOD, V121, P4463, DOI 10.1182/blood-2012-09-457929; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; James C, 2008, BLOOD, V112, P2429, DOI 10.1182/blood-2008-02-137877; Kent DG, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001576; Kjaer L, 2018, LEUKEMIA LYMPHOMA, V59, P973, DOI 10.1080/10428194.2017.1359743; Kjaer L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165336; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kollmann K, 2017, LEUKEMIA, V31, P934, DOI 10.1038/leu.2016.280; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Lau WWY, 2015, BLOOD, V125, P1679, DOI 10.1182/blood-2014-12-618074; Li J, 2018, BLOOD, V131, P649, DOI 10.1182/blood-2017-09-806356; Lundberg P, 2014, BLOOD, V123, P2220, DOI 10.1182/blood-2013-11-537167; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Mondet J, 2015, HAEMATOLOGICA, V100, DOI 10.3324/haematol.2014.118927; Nam AS, 2019, NATURE, V571, P355, DOI 10.1038/s41586-019-1367-0; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Ortmann CA, 2015, NEW ENGL J MED, V372, P601, DOI 10.1056/NEJMoa1412098; Passamonti F, 2010, LEUKEMIA, V24, P1574, DOI 10.1038/leu.2010.148; Pietra D, 2016, LEUKEMIA, V30, P431, DOI 10.1038/leu.2015.277; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Pronier E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122703; Rodriguez-Meira A, 2019, MOL CELL, V73, P1292, DOI 10.1016/j.molcel.2019.01.009; Rotunno G, 2014, BLOOD, V123, P1552, DOI 10.1182/blood-2013-11-538983; Rumi E, 2014, BLOOD, V123, P1544, DOI 10.1182/blood-2013-11-539098; Rumi E, 2013, BLOOD, V121, P4388, DOI 10.1182/blood-2013-02-486050; Saint-Martin C, 2009, BLOOD, V114, P1628, DOI 10.1182/blood-2009-01-197525; Sanjuan-Pla A, 2013, NATURE, V502, P232, DOI 10.1038/nature12495; Scott LM, 2006, BLOOD, V108, P2435, DOI 10.1182/blood-2006-04-018259; Shide K, 2017, LEUKEMIA, V31, P1136, DOI 10.1038/leu.2016.308; Tefferi A, 2014, LEUKEMIA, V28, P1568, DOI 10.1038/leu.2014.83; Tefferi A, 2014, LEUKEMIA, V28, P1407, DOI 10.1038/leu.2014.35; Tefferi A, 2014, AM J HEMATOL, V89, pE121, DOI 10.1002/ajh.23743; Vainchenker W, 2011, BLOOD, V118, P1723, DOI 10.1182/blood-2011-02-292102	54	6	6	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5323	5337		10.1038/s41388-020-1368-3	http://dx.doi.org/10.1038/s41388-020-1368-3		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32572159	Green Published			2022-12-17	WOS:000542723000001
J	Li, QL; Karim, RM; Cheng, M; Das, M; Chen, LH; Zhang, C; Lawrence, HR; Daughdrill, GW; Schonbrunn, E; Ji, HT; Chen, JD				Li, Qingliang; Karim, Rezaul M.; Cheng, Mo; Das, Mousumi; Chen, Lihong; Zhang, Chen; Lawrence, Harshani R.; Daughdrill, Gary W.; Schonbrunn, Ernst; Ji, Haitao; Chen, Jiandong			Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity	ONCOGENE			English	Article							PARADOXICAL ACTIVATION; PROLIFERATING CELLS; INVOLVEMENT; EXPRESSION; STABILITY; PROMOTES; DAMAGE; ALPHA; RAF	Transcription factors are attractive therapeutic targets that are considered non-druggable because they do not have binding sites for small drug-like ligands. We established a cell-free high-throughput screening assay to search for small molecule inhibitors of DNA binding by transcription factors. A screen was performed using p53 as a target, resulting in the identification of NSC194598 that inhibits p53 sequence-specific DNA binding in vitro (IC50 = 180 nm) and in vivo. NSC194598 selectively inhibited DNA binding by p53 and homologs p63/p73, but did not affect E2F1, TCF1, and c-Myc. Treatment of cells with NSC194598 alone paradoxically led to p53 accumulation and modest increase of transcriptional output owing to disruption of the MDM2-negative feedback loop. When p53 was stabilized and activated by irradiation or chemotherapy drug treatment, NSC194598 inhibited p53 DNA binding and induction of target genes. A single dose of NSC194598 increased the survival of mice after irradiation. The results suggest DNA binding by p53 can be targeted using small molecules to reduce acute toxicity to normal tissues by radiation and chemotherapy.	[Li, Qingliang; Das, Mousumi; Chen, Lihong; Chen, Jiandong] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Karim, Rezaul M.; Cheng, Mo; Lawrence, Harshani R.; Schonbrunn, Ernst; Ji, Haitao] H Lee Moffitt Canc Ctr & Res Inst, Dept Drug Discovery, Tampa, FL USA; [Karim, Rezaul M.] Univ S Florida, Morsani Coll Med, Dept Mol Med, Tampa, FL 33620 USA; [Zhang, Chen] Univ Illinois, High Throughput Screening Facil, Urbana, IL USA; [Daughdrill, Gary W.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Illinois System; University of Illinois Urbana-Champaign; State University System of Florida; University of South Florida	Chen, JD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org	Karim, Rezaul M./H-7930-2016; Ji, Haitao/P-6441-2015	Karim, Rezaul M./0000-0002-0424-127X; Ji, Haitao/0000-0001-5526-4503; Schonbrunn, Ernst/0000-0002-3589-3510	National Institutes of Health [CA141244, CA186917, CA208363, GM115556, R50CA211447]; H. Lee Moffitt Cancer Center & Research Institute [P30-CA076292]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); H. Lee Moffitt Cancer Center & Research Institute	The authors wish to thank the National Cancer Institute Developmental Therapeutics Program for providing key compounds. This work is supported in part by grants from the National Institutes of Health (CA141244, CA186917, CA208363 to J.C. GM115556 to D.G. R50CA211447 to H. R. L.). H. Lee Moffitt Cancer Center & Research Institute is an NCI designated Comprehensive Cancer Center (P30-CA076292).	Berg T, 2011, CURR TOP MICROBIOL, V348, P139, DOI 10.1007/82_2010_90; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Checler F, 2014, PHARMACOL THERAPEUT, V142, P99, DOI 10.1016/j.pharmthera.2013.11.009; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Goh AM, 2015, ONCOTARGET, V6, P17968, DOI 10.18632/oncotarget.4956; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He F, 2019, P NATL ACAD SCI USA, V116, P8859, DOI 10.1073/pnas.1903077116; Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236; Hoggard LR, 2015, J AM CHEM SOC, V137, P12249, DOI 10.1021/jacs.5b04988; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang M, 2006, ONCOGENE, V25, P4056, DOI 10.1038/sj.onc.1209440; Khoo KH, 2009, J MOL BIOL, V393, P161, DOI 10.1016/j.jmb.2009.08.013; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Luker KE, 2004, P NATL ACAD SCI USA, V101, P12288, DOI 10.1073/pnas.0404041101; Mandell JG, 2006, NUCLEIC ACIDS RES, V34, pW516, DOI 10.1093/nar/gkl209; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Pochampally R, 2000, BIOCHEM BIOPH RES CO, V279, P1001, DOI 10.1006/bbrc.2000.4056; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Retzlaff M, 2013, J MOL BIOL, V425, P144, DOI 10.1016/j.jmb.2012.10.015; Ross FA, 2017, CELL CHEM BIOL, V24, P813, DOI 10.1016/j.chembiol.2017.05.021; Segal DJ, 2006, J MOL BIOL, V363, P405, DOI 10.1016/j.jmb.2006.08.016; Shin YJ, 2015, ONCOGENE, V34, P1292, DOI 10.1038/onc.2014.65; Tisato V, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0500-5; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Walton MI, 2005, MOL CANCER THER, V4, P1369, DOI 10.1158/1535-7163.MCT-04-0341; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wassman CD, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2361; Wei QQ, 2007, AM J PHYSIOL-RENAL, V293, pF1282, DOI 10.1152/ajprenal.00230.2007; Westphal CH, 1998, CANCER RES, V58, P5637; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhu JW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58051-1	41	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5187	5200		10.1038/s41388-020-1344-y	http://dx.doi.org/10.1038/s41388-020-1344-y		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32555331	Green Accepted			2022-12-17	WOS:000545371000002
J	Wolf, ER; Mabry, AR; Damania, B; Mayo, LD				Wolf, Eric R.; Mabry, Alexander R.; Damania, Blossom; Mayo, Lindsey D.			Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; WILD-TYPE P53; TUMOR ANGIOGENESIS; HIF-ALPHA; VHL GENE; MDM2; HYPOXIA; EXPRESSION; BINDING; STABILIZATION	Mutations in the tumor suppressorTP53are rare in renal cell carcinomas. p53 is a key factor for inducing antiangiogenic genes and RCC are highly vascularized, which suggests that p53 is inactive in these tumors. One regulator of p53 is the Mdm2 oncogene, which is correlated with high-grade, metastatic tumors. However, the sole activity of Mdm2 is not just to regulate p53, but it can also function independent of p53 to regulate the early stages of metastasis. Here, we report that the oncoprotein Mdm2 can bind directly to the tumor suppressor VHL, and conjugate nedd8 to VHL within a region that is important for the p53-VHL interaction. Nedd8 conjugated VHL is unable to bind to p53 thereby preventing the induction of antiangiogenic factors. These results highlight a previously unknown oncogenic function of Mdm2 during the progression of cancer to promote angiogenesis through the regulation of VHL. Thus, the Mdm2-VHL interaction represents a pathway that impacts tumor angiogenesis.	[Wolf, Eric R.; Mabry, Alexander R.; Mayo, Lindsey D.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Damania, Blossom] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Mayo, Lindsey D.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Indiana University System; Indiana University Bloomington	Mayo, LD (corresponding author), Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.; Mayo, LD (corresponding author), Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.	ldmayo@iu.edu		Mayo, Lindsey/0000-0002-5997-5166; Mabry, Alex/0000-0003-1635-8800	NIH/NCI [CA172256]; Riley Children's Foundation	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Riley Children's Foundation	This research was supported by NIH/NCI CA172256 and the Riley Children's Foundation. We thank Dr. Ohh for the VHL expression plasmid, Dr. Bouck for the Thrombospondin reporter plasmid, and Dr. Ivan for the renal cell carcinoma cell lines to aid in this study.	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Batuello CN, 2015, P NATL ACAD SCI USA, V112, P1749, DOI 10.1073/pnas.1416656112; Bohlman Stephen, 2014, Subcell Biochem, V85, P235, DOI 10.1007/978-94-017-9211-0_13; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Ding XY, 2019, CELL DEATH DIFFER, V26, P1750, DOI 10.1038/s41418-018-0242-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Ganguli G, 2003, MOL CANCER RES, V1, P1027; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Haitel A, 2000, CLIN CANCER RES, V6, P1840; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Hauck PM, 2017, ONCOTARGET, V8, P104455, DOI 10.18632/oncotarget.22320; Hauck PM, 2017, MOL CANCER RES, V15, P1598, DOI 10.1158/1541-7786.MCR-17-0174; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jin YL, 2018, CLIN CANCER RES, V24, P3741, DOI 10.1158/1078-0432.CCR-17-1703; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Joshi S, 2014, J BIOL CHEM, V289, P22785, DOI 10.1074/jbc.M114.587493; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kaelin WG, 2007, ANNU REV PATHOL-MECH, V2, P145, DOI 10.1146/annurev.pathol.2.010506.092049; Kamat CD, 2007, CANCER LETT, V249, P209, DOI 10.1016/j.canlet.2006.08.017; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Miled C, 2005, CANCER RES, V65, P5096, DOI 10.1158/0008-5472.CAN-04-4232; MIYASHITA T, 1995, CELL, V80, P293; Mizuno S, 2011, AM J PHYSIOL-LUNG C, V300, pL753, DOI 10.1152/ajplung.00286.2010; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nieminen AL, 2005, J CELL PHYSIOL, V204, P364, DOI 10.1002/jcp.20406; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Noon AP, 2010, CANCER-AM CANCER SOC, V116, P780, DOI 10.1002/cncr.24841; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pan Y, 2004, ONCOGENE, V23, P4975, DOI 10.1038/sj.onc.1207657; Patterson DM, 2011, ANGIOGENESIS, V14, P255, DOI 10.1007/s10456-011-9210-8; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Russell RC, 2008, EMBO REP, V9, P486, DOI 10.1038/embor.2008.19; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Venkatesan T, 2018, CELLS, V7, P3; Wang XQ, 2001, CANCER RES, V61, P1598; Wolf ER, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao4170; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong J, 2014, ANGIOGENESIS, V17, P37, DOI 10.1007/s10456-013-9376-3; Yao WT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.21; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.3.CO;2-9; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	59	6	6	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5228	5239		10.1038/s41388-020-1359-4	http://dx.doi.org/10.1038/s41388-020-1359-4		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32555333	Green Submitted, Green Accepted			2022-12-17	WOS:000545371000003
J	Pei, GS; Hu, RF; Dai, YL; Zhao, ZM; Jia, PL				Pei, Guangsheng; Hu, Ruifeng; Dai, Yulin; Zhao, Zhongming; Jia, Peilin			Decoding whole-genome mutational signatures in 37 human pan-cancers by denoising sparse autoencoder neural network	ONCOGENE			English	Article							DNA-DAMAGE; SEQUENCE; MECHANISMS; DISEASE; REPAIR; P53	Millions of somatic mutations have recently been discovered in cancer genomes. These mutations in cancer genomes occur due to internal and external mutagenesis forces. Decoding the mutational processes by examining their unique patterns has successfully revealed many known and novel signatures from whole exome data, but many still remain undiscovered. Here, we developed a deep learning approach, DeepMS, to decompose mutational signatures using 52,671,908 somatic mutations from 2780 highly curated cancer genomes with whole genome sequencing (WGS) in 37 cancer types/subtypes. With rigorous model training and comparison, we characterized 54 signatures for single base substitutions (SBSs), 11 for doublet base substitutions (DBSs) and 16 for small insertions and deletions (Indels). Compared to the previous methods, DeepMS could discover 37 SBS, 5 DBS, and 9 Indel new signatures, many of which represent associations with DNA mismatch or base excision repair and cisplatin therapy mechanisms. We further developed a regression-based model to estimate the correlation between signatures and clinical and demographical phenotypes. The first deep learning model DeepMS on WGS somatic mutational profiles enable us identify more comprehensive context-based mutational signatures than traditional NMF approaches. Our work substantially expands the landscape of the naturally occurring mutational signatures in cancer genomes, and provides new insights into cancer biology.	[Pei, Guangsheng; Hu, Ruifeng; Dai, Yulin; Zhao, Zhongming; Jia, Peilin] Univ Texas Hlth Sci Ctr Houston, Ctr Precis Hlth, Sch Biomed Informat, Houston, TX 77030 USA; [Zhao, Zhongming] Univ Texas Hlth Sci Ctr Houston, Human Genet Ctr, Sch Publ Hlth, Houston, TX 77030 USA; [Zhao, Zhongming] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Zhao, Zhongming] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37203 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; UTMD Anderson Cancer Center; Vanderbilt University	Zhao, ZM; Jia, PL (corresponding author), Univ Texas Hlth Sci Ctr Houston, Ctr Precis Hlth, Sch Biomed Informat, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Human Genet Ctr, Sch Publ Hlth, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37203 USA.	zhongming.zhao@uth.tmc.edu; peilin.jia@uth.tmc.edu	Hu, Ruifeng/AAF-8619-2019	Hu, Ruifeng/0000-0001-5549-3082; Pei, Guangsheng/0000-0003-1804-7598; dai, yulin/0000-0003-1874-7893	Cancer Prevention and Research Institute of Texas [CPRIT RP180734]; National Institutes of Health [R01LM012806]	Cancer Prevention and Research Institute of Texas; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Cancer Prevention and Research Institute of Texas (CPRIT RP180734), National Institutes of Health (R01LM012806).	Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Alexandrov LB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9683; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008; Ardin M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1011-z; Bengio, 2011, P 28 INT C MACH LEAR, P833; Bengio Y, 2013, IEEE T PATTERN ANAL, V35, P1798, DOI 10.1109/TPAMI.2013.50; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blokzijl F, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0539-0; Boot A, 2018, GENOME RES, V28, P654, DOI 10.1101/gr.230219.117; Brash DE, 2015, PHOTOCHEM PHOTOBIOL, V91, P15, DOI 10.1111/php.12377; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chuzhanova NA, 2003, HUM MUTAT, V21, P28, DOI 10.1002/humu.10146; Cooper David N, 2010, Hum Genomics, V4, P406; Drost J, 2017, SCIENCE, V358, P234, DOI 10.1126/science.aao3130; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gehring JS, 2015, BIOINFORMATICS, V31, P3673, DOI 10.1093/bioinformatics/btv408; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Haradhvala NJ, 2016, CELL, V164, P538, DOI 10.1016/j.cell.2015.12.050; Hatakeyama K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26967-4; Jia PL, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0489-9; Jia PL, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-11; Kelley DR, 2016, GENOME RES, V26, P990, DOI 10.1101/gr.200535.115; Krawczak M, 1998, AM J HUM GENET, V63, P474, DOI 10.1086/301965; Krizhevsky A., 2012, COMMUN ACM, P1097, DOI DOI 10.1145/3065386; Kucab JE, 2019, CELL, V177, P821, DOI 10.1016/j.cell.2019.03.001; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Ollila J, 1996, FEBS LETT, V396, P119, DOI 10.1016/0014-5793(96)01075-7; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Pena-Diaz J, 2012, MOL CELL, V47, P669, DOI 10.1016/j.molcel.2012.07.006; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Pilati C, 2017, J PATHOL, V242, P10, DOI 10.1002/path.4880; Rosenthal R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0893-4; Thurau C, 2011, KNOWL INF SYST, V29, P457, DOI 10.1007/s10115-010-0352-6; Tomasetti C, 2017, SCIENCE, V355, P1330, DOI 10.1126/science.aaf9011; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Viel A, 2017, EBIOMEDICINE, V20, P39, DOI 10.1016/j.ebiom.2017.04.022; Vincent E, 2008, INT CONF ACOUST SPEE, P109, DOI 10.1109/ICASSP.2008.4517558; Vincent P, 2010, J MACH LEARN RES, V11, P3371; Zhang JJ, 2019, NAT BIOTECHNOL, V37, P367, DOI 10.1038/s41587-019-0055-9	43	6	6	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5031	5041		10.1038/s41388-020-1343-z	http://dx.doi.org/10.1038/s41388-020-1343-z		JUN 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32528130	Green Accepted			2022-12-17	WOS:000539817600003
J	Wohlberedt, K; Klusmann, I; Derevyanko, PK; Henningsen, K; Choo, JAMY; Manzini, V; Magerhans, A; Giansanti, C; Eischen, CM; Jochemsen, AG; Dobbelstein, M				Wohlberedt, Kai; Klusmann, Ina; Derevyanko, Polina K.; Henningsen, Kester; Choo, Josephine Ann Mun Yee; Manzini, Valentina; Magerhans, Anna; Giansanti, Celeste; Eischen, Christine M.; Jochemsen, Aart G.; Dobbelstein, Matthias			Mdm4 supports DNA replication in a p53-independent fashion	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; THERAPEUTIC TARGET; P53; TRANSFORMATION; SUPPRESSION; INSTABILITY; REPRESSOR; PATHWAY; COMPLEX; LEADS	The Mdm4 (alias MdmX) oncoprotein, like its paralogue and interaction partner Mdm2, antagonizes the tumor suppressor p53. p53-independent roles of the Mdm proteins are emerging, and we have reported the ability of Mdm2 to modify chromatin and to support DNA replication by suppressing the formation of R-loops (DNA/RNA-hybrids). We show here that the depletion of Mdm4 in p53-deficient cells compromises DNA replication fork progression as well. Among various deletion mutants, only full-length Mdm4 was able to support DNA replication fork progression. Co-depletion of Mdm4 and Mdm2 further impaired DNA replication, and the overexpression of each partially compensated for the other's loss. Despite impairing replication, Mdm4 depletion only marginally hindered cell proliferation, likely due to compensation through increased firing of replication origins. However, depleting Mdm4 sensitized p53-/- cells to the nucleoside analog gemcitabine, raising the future perspective of using Mdm4 inhibitors as chemosensitizers. Mechanistically, Mdm4 interacts with members of the Polycomb Repressor Complexes and supports the ubiquitination of H2A, thereby preventing the accumulation of DNA/RNA-hybrids. Thus, in analogy to previously reported activities of Mdm2, Mdm4 enables unperturbed DNA replication through the avoidance of R-loops.	[Wohlberedt, Kai; Klusmann, Ina; Derevyanko, Polina K.; Henningsen, Kester; Choo, Josephine Ann Mun Yee; Manzini, Valentina; Magerhans, Anna; Giansanti, Celeste; Dobbelstein, Matthias] Univ Med Ctr Gottingen, Gottingen Ctr Mol Biosci GZMB, Inst Mol Oncol, D-37077 Gottingen, Germany; [Eischen, Christine M.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; [Jochemsen, Aart G.] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands	University of Gottingen; Jefferson University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Dobbelstein, M (corresponding author), Univ Med Ctr Gottingen, Gottingen Ctr Mol Biosci GZMB, Inst Mol Oncol, D-37077 Gottingen, Germany.	mdobbel@uni-goettingen.de		Choo, Josephine Ann Mun Yee/0000-0001-6457-8395; Giansanti, Celeste/0000-0003-3229-8385	Deutsche Krebshilfe; Wilhelm Sander Stiftung; Else Kroner Fresenius Stiftung; Deutsche Jose Carreras Leukamie Stiftung; Deutsche Forschungsgemeinschaft; Boehringer Ingelheim Fonds; German Academic Scholarship Foundation	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm Sander Stiftung; Else Kroner Fresenius Stiftung; Deutsche Jose Carreras Leukamie Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Boehringer Ingelheim Fonds(Boehringer Ingelheim); German Academic Scholarship Foundation	We thank Guillermina Lozano for the MEFs with p53/Mdm4/Mdm2 deletions. pCMV-Flag-Mdm4 was a gift from Zhi-Min Yuan. pCMV-MDM2 was a gift from Bert Vogelstein (Addgene plasmid #16441), pCMV-MDM2(C464A) was provided by Tyler Jacks (Addgene plasmid #12086), pICE-RNaseHI-WT-NLS-mCherry (Addgene plasmid #60365) as well as pICE-RNaseHI-D10R-E48R-NLS-mCherry (Addgene plasmid #60367) were obtained from Patrick Calsou. H2A and EZH2 expression plasmids were from Titia Sixma (Addgene plasmids #63561 and #63564) and Kristian Helin (Addgene plasmid #24230), respectively. pLenti6/V5-DEST-RNF2 was a gift from Lynda Chin (Addgene plasmid #31216). This work was supported by the Deutsche Krebshilfe (to MD and KW), the Wilhelm Sander Stiftung, the Else Kroner Fresenius Stiftung, the Deutsche Jose Carreras Leukamie Stiftung, the Deutsche Forschungsgemeinschaft, the Boehringer Ingelheim Fonds (to IK) and the German Academic Scholarship Foundation (to KW). IK, PD, and VM were members of the IMPRS/MSc/PhD program Molecular Biology and IK, VM, CG and JC also of the Gottingen Graduate School GGNB Gottingen.	Aguilera A, 2012, MOL CELL, V46, P115, DOI 10.1016/j.molcel.2012.04.009; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Blow JJ, 2011, TRENDS BIOCHEM SCI, V36, P405, DOI 10.1016/j.tibs.2011.05.002; BOGUSLAWSKI SJ, 1986, J IMMUNOL METHODS, V89, P123, DOI 10.1016/0022-1759(86)90040-2; Bohlman Stephen, 2014, Subcell Biochem, V85, P235, DOI 10.1007/978-94-017-9211-0_13; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Carillo Alexia M, 2015, ONCOGENE, V34, P846; Carvajal LA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3003; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Dewaele M, 2016, J CLIN INVEST, V126, P68, DOI 10.1172/JCI82534; Dobbelstein M, 2015, NAT REV DRUG DISCOV, V14, P405, DOI 10.1038/nrd4553; El Hage A, 2010, GENE DEV, V24, P1546, DOI 10.1101/gad.573310; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; Fischer M, 2014, CELL CYCLE, V13, P3037, DOI 10.4161/15384101.2014.949083; Gan WJ, 2011, GENE DEV, V25, P2041, DOI 10.1101/gad.17010011; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gazdar AF, 2010, LUNG CANCER, V68, P309, DOI 10.1016/j.lungcan.2009.12.005; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Gradiz R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21648; Han X, 2016, CL LYMPH MYELOM LEUK, V16, pS30, DOI 10.1016/j.clml.2016.03.012; Haupt S, 2019, J MOL CELL BIOL, V11, P231, DOI 10.1093/jmcb/mjz007; Heijkants RC, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0041-y; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Klusmann I, 2018, P NATL ACAD SCI USA, V115, pE11311, DOI 10.1073/pnas.1809592115; Klusmann I, 2016, CELL REP, V17, P1845, DOI 10.1016/j.celrep.2016.10.036; Kuser-Abali G, 2018, P NATL ACAD SCI USA, V115, P3452, DOI 10.1073/pnas.1719532115; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lee J, 2013, MOL BIOL CELL, V24, P1343, DOI 10.1091/mbc.E13-01-0025; Li YB, 2019, J MED CHEM, V62, P448, DOI 10.1021/acs.jmedchem.8b00909; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Marine JC, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026237; Matijasevic Z, 2008, CELL CYCLE, V7, P2967, DOI 10.4161/cc.7.19.6797; Matijasevic Z, 2008, MOL CELL BIOL, V28, P1265, DOI 10.1128/MCB.01108-07; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Miranda PJ, 2017, J PATHOL, V241, P661, DOI 10.1002/path.4877; Momand J, 2011, GENE, V486, P23, DOI 10.1016/j.gene.2011.06.030; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Park DE, 2019, P NATL ACAD SCI USA, V116, P1027, DOI 10.1073/pnas.1818798116; Pellegrino M, 2015, CANCER RES, V75, P4560, DOI 10.1158/0008-5472.CAN-15-0439; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Quinet A, 2017, METHOD ENZYMOL, V591, P55, DOI 10.1016/bs.mie.2017.03.019; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Strachan GD, 2003, J CELL BIOCHEM, V88, P557, DOI 10.1002/jcb.10318; Techer H, 2013, J MOL BIOL, V425, P4845, DOI 10.1016/j.jmb.2013.03.040; Valentin-Vega YA, 2009, DIFFERENTIATION, V77, P442, DOI 10.1016/j.diff.2009.03.001; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Wienken M, 2016, MOL CELL, V61, P68, DOI 10.1016/j.molcel.2015.12.008; Zhang H, 2015, ONCOGENE, V34, P5560, DOI 10.1038/onc.2015.11	51	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4828	4843		10.1038/s41388-020-1325-1	http://dx.doi.org/10.1038/s41388-020-1325-1		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32427989	Green Accepted, Green Published			2022-12-17	WOS:000534491700002
J	Yang, CL; Yong, L; Liang, C; Li, Y; Ma, YL; Wei, F; Jiang, L; Zhou, H; He, GP; Pan, XY; Hai, B; Wu, J; Xu, YL; Liu, ZJ; Liu, XG				Yang, Chenlong; Yong, Lei; Liang, Chen; Li, Yan; Ma, Yunlong; Wei, Feng; Jiang, Liang; Zhou, Hua; He, Guanping; Pan, Xiaoyu; Hai, Bao; Wu, Jian; Xu, Yulun; Liu, Zhongjun; Liu, Xiaoguang			Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target	ONCOGENE			English	Article							PATHWAY; GROWTH; CANCER; EXPRESSION; CARCINOMA; MUTATIONS; BIOLOGY; BCL-2; PTCH; GLI1	Chordoma, a rare neoplasm derived from intraosseous notochordal remnants, is unresponsive to conventional chemotherapy and radiotherapy. Sonic Hedgehog (Shh) is a crucial fetal notochord-secreted morphogen that directs notochordal development. The aim of this study was to determine the functional roles and therapeutic potential of Shh-Gli1 signaling in chordomas. Tissue samples and clinical profiles were collected from 42 patients with chordoma. The chordoma cell lines U-CH1 and MUG-Chor1 were used for functional experiments. Shh-Gli1 signaling pathway genetic alterations were screened, and the functions of the identified novel variants were analyzed using in silico analyses, real-time quantitative PCR, and minigene assays. Ligand-dependent Shh-Gli1 signaling activation was assessed using single- and dual-label immunostaining, western blot analysis, and a Shh-responsive Gli-luciferase reporter assay. The small-molecule inhibitor vismodegib was used to target Shh-Gli1 signaling in vitro and in vivo. Overall, 44 genetic alterations were identified, including four novel variants (c.67_69dupCTG in SMO, c.-6_-4dupGGC and c.3306 + 83_3306 + 84insG in PTCH1, and c.183-67_183-66delinsA in SUFU). Shh, PTCH1, SMO, SUFU, and Gli1 were extensively expressed in chordomas, and higher Gli1 expression correlated with poorer prognosis. A luciferase reporter assay and dual-label immunostaining indicated the occurrence of juxtacrine ligand-dependent Shh-Gli1 signaling activation. Vismodegib significantly inhibited cell proliferation and induced apoptosis and G1/S cell cycle arrest. In vivo investigation demonstrated that vismodegib effectively inhibited chordoma xenograft growth. This current preclinical evidence elucidates the therapeutic potential of Shh-Gli1 signaling pathway targeting for chordoma treatment. Vismodegib may be a promising targeted agent, and further clinical trials are warranted.	[Yang, Chenlong; Yong, Lei; Liang, Chen; Ma, Yunlong; Wei, Feng; Jiang, Liang; Zhou, Hua; He, Guanping; Pan, Xiaoyu; Hai, Bao; Liu, Zhongjun; Liu, Xiaoguang] Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China; [Li, Yan] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Pathol, Beijing, Peoples R China; [Wu, Jian] Capital Med Univ, Sch Clin Med, Beijing, Peoples R China; [Xu, Yulun] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Dept Neurosurg, Beijing, Peoples R China	Peking University; Peking University; Capital Medical University; Capital Medical University	Liu, XG (corresponding author), Peking Univ, Hosp 3, Dept Orthoped, Beijing, Peoples R China.	liuxg.puth@hotmail.com	Pan, Xiaoyu/ABE-1764-2021; Zhou, Hua/HGC-9504-2022	Pan, Xiaoyu/0000-0002-5184-222X; Yang, Jun/0000-0002-7460-2800; Yang, Chenlong/0000-0001-8102-8811; Wu, Jian/0000-0003-3199-0492; Zhou, hua/0000-0002-2718-4108	National Natural Science Foundation of China [81641103, 81901202]; Postdoctoral Science Foundation of China [2018M630047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81641103 to XL; 81901202 to CY) and the Postdoctoral Science Foundation of China (2018M630047 to CY).	Ahmed AT, 2018, SPINE, V43, pE1157, DOI 10.1097/BRS.0000000000002638; Akhavan-Sigari R, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020248; Amini P, 2017, BMC MOL BIOL, V18, DOI 10.1186/s12867-017-0099-7; Armas-Lopez L, 2017, ONCOTARGET, V8, P60684, DOI 10.18632/oncotarget.19527; Bari R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11098; Begnini A, 2010, BRIT J DERMATOL, V163, P364, DOI 10.1111/j.1365-2133.2010.09776.x; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Cates JMM, 2010, HISTOPATHOLOGY, V56, P978, DOI 10.1111/j.1365-2559.2010.03572.x; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177; Choi KS, 2008, DEV DYNAM, V237, P3953, DOI 10.1002/dvdy.21805; Cortes JE, 2019, CANCER TREAT REV, V76, P41, DOI 10.1016/j.ctrv.2019.04.005; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; GOTZ W, 1995, CELL TISSUE RES, V280, P455; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Incardona JP, 2000, CELL MOL LIFE SCI, V57, P1709, DOI 10.1007/PL00000653; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kitamura Y, 2017, BRAIN TUMOR PATHOL, V34, P78, DOI 10.1007/s10014-017-0283-y; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Lee IJ, 2017, WORLD NEUROSURG, V104, P346, DOI 10.1016/j.wneu.2017.04.118; Magic M, 2019, CLIN ORAL INVEST, V23, P2675, DOI 10.1007/s00784-018-2686-5; Otani R, 2018, J NEUROSURG, V128, P1428, DOI 10.3171/2016.12.JNS161444; Raffel C, 1997, CANCER RES, V57, P842; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208; Scheil-Bertram S, 2014, INT J ONCOL, V44, P1041, DOI 10.3892/ijo.2014.2268; Sebaugh JL, 2011, PHARM STAT, V10, P128, DOI 10.1002/pst.426; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; SINICROPE FA, 1995, CANCER RES, V55, P237; Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756; Sun X, 2015, CURR REV MUSCULOSKE, V8, P344, DOI 10.1007/s12178-015-9311-x; Szkandera J, 2014, CLIN CANCER RES, V20, P1687, DOI 10.1158/1078-0432.CCR-13-1517; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Vinall RL, 2007, CLIN CANCER RES, V13, P6204, DOI 10.1158/1078-0432.CCR-07-0600; Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075407; Williams S, 2019, CURR TOP DEV BIOL, V133, P49, DOI 10.1016/bs.ctdb.2018.11.018; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Yakldoui Y, 2014, BBA-REV CANCER, V1846, P655, DOI 10.1016/j.bbcan.2014.07.012; Zhu JJ, 2016, P NATL ACAD SCI USA, V113, P3820, DOI 10.1073/pnas.1601252113	44	6	6	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4711	4727		10.1038/s41388-020-1324-2	http://dx.doi.org/10.1038/s41388-020-1324-2		MAY 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32404987				2022-12-17	WOS:000532807900002
J	Shmulevich, R; Nissim, TBK; Wolf, I; Merenbakh-Lamin, K; Fishman, D; Sekler, I; Rubinek, T				Shmulevich, Riva; Nissim, Tsipi Ben-Kasus; Wolf, Ido; Merenbakh-Lamin, Keren; Fishman, Daniel; Sekler, Israel; Rubinek, Tami			Klotho rewires cellular metabolism of breast cancer cells through alteration of calcium shuttling and mitochondrial activity	ONCOGENE			English	Article							OPERATED CA2+ ENTRY; TUMOR-SUPPRESSOR; PROTEIN-KINASE; TCA CYCLE; GROWTH; AMPK; ACTIVATION; PATHWAY; PROLIFERATION; LIVER	Klotho is a transmembrane protein, which can be shed and act as a circulating hormone and is involved in regulating cellular calcium levels and inhibition of the PI3K/AKT pathway. As a longevity hormone, it protects normal cells from oxidative stress, and as a tumor suppressor it inhibits growth of cancer cells. Mechanisms governing these differential activities have not been addressed. Altered cellular metabolism is a hallmark of cancer and dysregulation of mitochondrial activity is a hallmark of aging. We hypothesized that klotho exerts its differential effects through regulation of these two hallmarks. Treatment with klotho inhibited glycolysis, reduced mitochondrial activity and membrane potential only in cancer cells. Accordingly, global metabolic screen revealed that klotho altered pivotal metabolic pathways, amongst them glycolysis and tricarboxylic acid cycle in breast cancer cells. Alteration of metabolic activity and increased AMP/ATP ratio lead to LKB1-dependent AMPK activation. Indeed, klotho induced AMPK phosphorylation; furthermore, inhibition of LKB1 partially abolished klotho's tumor suppressor activity. By diminishing deltapsi (Delta psi) klotho also inhibited mitochondria Ca2+ shuttling thereby impairing mitochondria communication with SOCE leading to reduced Ca2+ influx by SOCE channels. The reduced SOCE was followed by ER Ca2+ depletion and stress. These data delineate mechanisms mediating the differential effects of klotho toward cancer versus normal cells, and indicate klotho as a potent regulator of metabolic activity.	[Shmulevich, Riva; Wolf, Ido; Merenbakh-Lamin, Keren; Rubinek, Tami] Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel; [Shmulevich, Riva; Wolf, Ido; Rubinek, Tami] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Nissim, Tsipi Ben-Kasus; Fishman, Daniel; Sekler, Israel] Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, Beer Sheva, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University	Rubinek, T (corresponding author), Tel Aviv Sourasky Med Ctr, Inst Oncol, Tel Aviv, Israel.; Rubinek, T (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.; Sekler, I (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Physiol & Cell Biol, Beer Sheva, Israel.	sekler@bgu.ac.il; rubinekt@gmail.com						Abramovitz L, 2011, CLIN CANCER RES, V17, P4254, DOI 10.1158/1078-0432.CCR-10-2749; Brown KA, 2013, MOL CELL ENDOCRINOL, V366, P170, DOI 10.1016/j.mce.2012.06.016; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Cha SK, 2008, P NATL ACAD SCI USA, V105, P9805, DOI 10.1073/pnas.0803223105; Chang Q, 2005, SCIENCE, V310, P490, DOI 10.1126/science.1114245; Chen B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-99; Chen CD, 2007, P NATL ACAD SCI USA, V104, P19796, DOI 10.1073/pnas.0709805104; Corbet C, 2017, BBA-REV CANCER, V1868, P7, DOI 10.1016/j.bbcan.2017.01.002; Cui CC, 2017, ACTA PHARM SIN B, V7, P3, DOI 10.1016/j.apsb.2016.11.001; Delcroix V, 2018, CANCERS, V10, DOI 10.3390/cancers10110439; Demaurex N, 2009, BBA-BIOENERGETICS, V1787, P1383, DOI 10.1016/j.bbabio.2008.12.012; Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037; Fedida-Metula S, 2012, CARCINOGENESIS, V33, P740, DOI 10.1093/carcin/bgs021; Fox Melissa M, 2013, Genes Cancer, V4, P3, DOI 10.1177/1947601913486346; Hadad SM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-307; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2014, PHYSIOLOGY, V29, P99, DOI 10.1152/physiol.00050.2013; Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Kato Y, 2000, BIOCHEM BIOPH RES CO, V267, P597, DOI 10.1006/bbrc.1999.2009; Kim Hak-Su, 2014, Genes Cancer, V5, P175; Krishnan S, 2019, FASEB J, V33; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Kurosu H, 2006, J BIOL CHEM, V281, P6120, DOI 10.1074/jbc.C500457200; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109; Lee Minjong, 2015, World J Biol Chem, V6, P148, DOI 10.4331/wjbc.v6.i3.148; Lewis RS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003970; Ligumsky H, 2015, MOL CANCER RES, V13, P1398, DOI 10.1158/1541-7786.MCR-15-0141; Lim K, 2015, J CLIN ENDOCR METAB, V100, P1308, DOI DOI 10.1210/jc.2015-1800; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Lojkin I, 2015, CANCER LETT, V362, P149, DOI 10.1016/j.canlet.2015.03.035; Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031; Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]; Manjarres IM, 2011, CELL CALCIUM, V49, P153, DOI 10.1016/j.ceca.2011.01.007; Martinez-Reyes I, 2016, MOL CELL, V61, P199, DOI 10.1016/j.molcel.2015.12.002; Mignen O, 2005, J CELL SCI, V118, P5615, DOI 10.1242/jcs.02663; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Nabeshima Y, 2002, AGEING RES REV, V1, P627, DOI 10.1016/S1568-1637(02)00027-2; Palty R, 2012, J BIOL CHEM, V287, P31650, DOI 10.1074/jbc.R112.355867; Palty R, 2010, P NATL ACAD SCI USA, V107, P436, DOI 10.1073/pnas.0908099107; Pesakhov S, 2016, ONCOTARGET, V7, P31847, DOI 10.18632/oncotarget.7240; Putney JW, 2017, BBA-MOL CELL RES, V1864, P900, DOI 10.1016/j.bbamcr.2016.11.028; Raffaello A, 2016, TRENDS BIOCHEM SCI, V41, P1035, DOI 10.1016/j.tibs.2016.09.001; Rios M, 2013, CANCER RES, V73, P2628, DOI 10.1158/0008-5472.CAN-12-0861; Rubinek T, 2016, VITAM HORM, V101, P197, DOI 10.1016/bs.vh.2016.03.001; Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4; Rubinstein TA, 2019, ONCOGENE, V38, P794, DOI 10.1038/s41388-018-0489-4; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Spat A, 2017, ADV EXP MED BIOL, V993, P257, DOI 10.1007/978-3-319-57732-6_14; To MS, 2010, ARCH BIOCHEM BIOPHYS, V495, P152, DOI 10.1016/j.abb.2010.01.004; Urakawa I, 2006, NATURE, V444, P770, DOI 10.1038/nature05315; Vashisht A, 2015, AM J PHYSIOL-CELL PH, V309, pC457, DOI 10.1152/ajpcell.00064.2015; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292; Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8; Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18; Zinger L, 2019, CLIN CANCER RES, V25, P2900, DOI 10.1158/1078-0432.CCR-18-1505; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	61	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4636	4649		10.1038/s41388-020-1313-5	http://dx.doi.org/10.1038/s41388-020-1313-5		MAY 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32398866				2022-12-17	WOS:000532103100001
J	Chen, K; Cai, YX; Cheng, C; Zhang, JQ; Lv, F; Xu, GF; Duan, PW; Wu, YM; Wu, ZX				Chen, Kai; Cai, Yuanxia; Cheng, Cheng; Zhang, Junqi; Lv, Fan; Xu, Guofeng; Duan, Peiwen; Wu, Yeming; Wu, Zhixiang			MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex	ONCOGENE			English	Article							FINGER TRANSCRIPTION FACTORS; HISTONE DEACETYLASE; RETINOIC ACID; NEURONAL DIFFERENTIATION; NERVOUS-SYSTEM; INHIBITION; EXPRESSION; THERAPY; FAMILY; COREST	Impaired neuronal differentiation is a feature of neuroblastoma tumorigenesis, and the differentiation grade of neuroblastoma tumors is associated with patient prognosis. Detailed understanding of the molecular mechanisms underlying neuroblastoma differentiation will facilitate the development of effective treatment strategies. Recent studies have shown that myelin transcription factor 1 (MYT1) promotes vertebrate neurogenesis by regulating gene expression. We performed quantitative analysis of neuroblastoma samples, which revealed that MYT1 was differentially expressed among neuroblastoma patients with different pathological diagnoses. Analysis of clinical data showed that MYT1 overexpression was associated with a significantly shorter 3-year overall survival rate and poor differentiation in neuroblastoma specimens. MYT1 knockdown inhibited proliferation and promoted the expression of multiple differentiation-associated proteins. Integrated omics data indicated that many genes involved in neuro-differentiation were regulated by MYT1. Interestingly, many of these genes are targets of the REST complex; therefore, we further identified the physical interaction of MYT1 with LSD1/CoREST. Depletion of LSD1 or inhibition of LSD1 by ORY-1001 decreased MYT1 expression, providing an alternative approach to target MYT1. Taken together, our results indicate that MYT1 significantly attenuates cell differentiation by interacting with the LSD1/CoREST complex. MYT1 is, therefore, a promising therapeutic target for enhancing the neurite-inducing effect of retinoic acid and for inhibiting the growth of neuroblastoma.	[Chen, Kai; Cai, Yuanxia; Cheng, Cheng; Lv, Fan; Duan, Peiwen; Wu, Yeming; Wu, Zhixiang] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Surg, Shanghai 200092, Peoples R China; [Chen, Kai; Cai, Yuanxia; Cheng, Cheng; Lv, Fan; Duan, Peiwen; Wu, Yeming; Wu, Zhixiang] Shanghai Inst Pediat Res, Div Pediat Oncol, Shanghai 200092, Peoples R China; [Zhang, Junqi; Xu, Guofeng] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Urol,Natl Key Clin Specialty,Shanghai, Shanghai 200092, Peoples R China; [Lv, Fan; Wu, Yeming; Wu, Zhixiang] Soochow Univ, Dept Pediat Surg, Childrens Hosp, Suzhou 215003, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Soochow University - China	Wu, YM; Wu, ZX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Pediat Surg, Shanghai 200092, Peoples R China.; Wu, YM; Wu, ZX (corresponding author), Shanghai Inst Pediat Res, Div Pediat Oncol, Shanghai 200092, Peoples R China.; Wu, YM; Wu, ZX (corresponding author), Soochow Univ, Dept Pediat Surg, Childrens Hosp, Suzhou 215003, Peoples R China.	wuyeming@xinhuamed.com.cn; wuzhixiang@xinhuamed.com.cn		Wu, Zhixiang/0000-0002-3947-2035; Chen, Kai/0000-0002-8845-1820	Natural Science Foundation of China [81672488, 81572918, 81402478]; Suzhou Clinical Medicine Innovation Team Introduction Project [SZYJTD201706]; Shanghai Jiao Tong University School of Medicine Doctoral Innovation Fund [BXJ201826]; Shanghai Rising-Star Program [16QA1402900]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Suzhou Clinical Medicine Innovation Team Introduction Project; Shanghai Jiao Tong University School of Medicine Doctoral Innovation Fund; Shanghai Rising-Star Program	This work is supported by the Natural Science Foundation of China (No. 81572918) and Suzhou Clinical Medicine Innovation Team Introduction Project (SZYJTD201706) to YW, Shanghai Jiao Tong University School of Medicine Doctoral Innovation Fund (No. BXJ201826) to KC, Natural Science Foundation of China (No. 81402478), Shanghai Rising-Star Program (16QA1402900) to ZW, and Natural Science Foundation of China (No. 81672488) to GX. We thank Lisa Kreiner, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of this paper.	Ambros PF, 2009, BRIT J CANCER, V100, P1471, DOI 10.1038/sj.bjc.6605014; ANDERSON DJ, 1986, CELL, V47, P1079, DOI 10.1016/0092-8674(86)90823-8; ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; ARMSTRONG RC, 1995, GLIA, V14, P303, DOI 10.1002/glia.440140407; Ballas N, 2005, CELL, V121, P645, DOI 10.1016/j.cell.2005.03.013; Bellefroid EJ, 1996, CELL, V87, P1191, DOI 10.1016/S0092-8674(00)81815-2; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Chen K, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27229; Chen K, 2016, ONCOTARGET, V7, P75968, DOI 10.18632/oncotarget.12513; Cho HS, 2011, CANCER RES, V71, P655, DOI 10.1158/0008-5472.CAN-10-2446; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Gu YT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0931-z; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hudson LD, 2011, TRANSGENIC RES, V20, P951, DOI 10.1007/s11248-010-9470-x; Jiang YH, 1996, J BIOL CHEM, V271, P10723, DOI 10.1074/jbc.271.18.10723; Lee JY, 2017, ONCOGENE, V36, P5512, DOI 10.1038/onc.2017.158; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li LF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00702-5; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; Mall M, 2017, NATURE, V544, P245, DOI 10.1038/nature21722; Manukyan A, 2018, J CELL BIOCHEM, V119, P4644, DOI 10.1002/jcb.26636; Matsushita F, 2014, DEV DYNAM, V243, P588, DOI 10.1002/dvdy.24091; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Pandey GK, 2014, CANCER CELL, V26, P722, DOI 10.1016/j.ccell.2014.09.014; Qadeer ZA, 2019, CANCER CELL, V36, P512, DOI 10.1016/j.ccell.2019.09.002; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Romm E, 2005, J NEUROCHEM, V93, P1444, DOI 10.1111/j.1471-4159.2005.03131.x; Schor NF, 2013, J CHILD NEUROL, V28, P765, DOI 10.1177/0883073813483173; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; SIDELL N, 1982, J NATL CANCER I, V68, P589; Singh A, 2011, CANCER-AM CANCER SOC, V117, P5189, DOI 10.1002/cncr.26145; Vasconcelos FF, 2016, CELL REP, V17, P469, DOI 10.1016/j.celrep.2016.09.024; Wang S, 2007, MECH DEVELOP, V124, P898, DOI 10.1016/j.mod.2007.08.004; Wang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0581-6; Xu GF, 2013, CELL PHYSIOL BIOCHEM, V31, P854, DOI 10.1159/000350103; Yokoyama A, 2014, J BIOL CHEM, V289, P18152, DOI 10.1074/jbc.M114.566448; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118	41	6	6	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4212	4226		10.1038/s41388-020-1268-6	http://dx.doi.org/10.1038/s41388-020-1268-6		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32251364				2022-12-17	WOS:000523950600001
J	Floren, M; Cruz, SR; Termini, CM; Marjon, KD; Lidke, KA; Gillette, JM				Floren, Muskan; Cruz, Sebastian; Termini, Christina M.; Marjon, Kristopher D.; Lidke, Keith A.; Gillette, Jennifer M.			Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and beta 1 integrin activation	ONCOGENE			English	Article							INTEGRIN PROMOTES CHEMORESISTANCE; P38 MAPK; PROGENITOR CELLS; DUAL INHIBITOR; PHASE-II; SURVIVAL; STEM; CLASSIFICATION; RESISTANCE; PKC	A principal challenge in treating acute myeloid leukemia (AML) is chemotherapy refractory disease. As such, there remains a critical need to identify key regulators of chemotherapy resistance in AML. In this study, we demonstrate that the membrane scaffold, CD82, contributes to the chemoresistant phenotype of AML. Using an RNA-seq approach, we identified the increased expression of the tetraspanin family member, CD82, in response to the chemotherapeutic, daunorubicin. Analysis of the TARGET and BEAT AML databases identifies a correlation between CD82 expression and overall survival of AML patients. Moreover, using a combination of cell lines and patient samples, we find that CD82 overexpression results in significantly reduced cell death in response to chemotherapy. Investigation of the mechanism by which CD82 promotes AML survival in response to chemotherapy identified a crucial role for enhanced protein kinase c alpha (PKC alpha) signaling and downstream activation of the beta 1 integrin. In addition, analysis of beta 1 integrin clustering by super-resolution imaging demonstrates that CD82 expression promotes the formation of dense beta 1 integrin membrane clusters. Lastly, evaluation of survival signaling following daunorubicin treatment identified robust activation of p38 mitogen-activated protein kinase (MAPK) downstream of PKC alpha and beta 1 integrin signaling when CD82 is overexpressed. Together, these data propose a mechanism where CD82 promotes chemoresistance by increasing PKC alpha activation and downstream activation/clustering of beta 1 integrin, leading to AML cell survival via activation of p38 MAPK. These observations suggest that the CD82-PKC alpha signaling axis may be a potential therapeutic target for attenuating chemoresistance signaling in AML.	[Floren, Muskan; Cruz, Sebastian; Termini, Christina M.; Marjon, Kristopher D.; Gillette, Jennifer M.] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA; [Lidke, Keith A.] Univ New Mexico, Dept Phys & Astron, Albuquerque, NM 87131 USA; [Lidke, Keith A.; Gillette, Jennifer M.] Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico	Gillette, JM (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA.; Gillette, JM (corresponding author), Univ New Mexico, Ctr Comprehens Canc, Albuquerque, NM 87131 USA.	jgillette@salud.unm.edu		Termini, Christina/0000-0002-1831-1347	NHLBI investigator grant [F31CA232480, F31HL124977, T32HL007736, RO1HL122483]; American Cancer Society Research Scholar Grant [130675]; UNM Spatiotemporal Modeling Center [P50GM085273]; UNM Comprehensive Cancer Center Support Grant [P30CA118100]	NHLBI investigator grant; American Cancer Society Research Scholar Grant(American Cancer Society); UNM Spatiotemporal Modeling Center; UNM Comprehensive Cancer Center Support Grant	This work was supported by fellowships: F31CA232480 to MF, F31HL124977 to CMT, and T32HL007736 to KDM, and an NHLBI investigator grant (RO1HL122483 to JMG), and an American Cancer Society Research Scholar Grant (130675 to JMG). This work was partially supported by the UNM Spatiotemporal Modeling Center (P50GM085273) and the UNM Comprehensive Cancer Center Support Grant (P30CA118100) through the following shared resources: Analytical and Translational Genomics, Human Tissue Repository, Fluorescence Microscopy, Flow Cytometry and Biostatistics. We also acknowledge Victoria Balise for critical manuscript review and the experimental assistance of Christian Doyle.	American Cancer Society, 2015, CANC FACTS FIG 2015; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Aoudjit Fawzi, 2012, Chemother Res Pract, V2012, P283181, DOI 10.1155/2012/283181; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bachegowda L, 2016, CANCER RES, V76, P4841, DOI 10.1158/0008-5472.CAN-15-3062; Beckwith KA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00091; Berrazouane S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1593-2; Bonardi F, 2013, MOL CELL PROTEOMICS, V12, P626, DOI 10.1074/mcp.M112.021931; Bosman MCJ, 2016, CRIT REV ONCOL HEMAT, V98, P35, DOI 10.1016/j.critrevonc.2015.10.001; Boyer T, 2016, ONCOTARGET, V7, P62377, DOI 10.18632/oncotarget.11481; Brayer KJ, 2016, CANCER DISCOV, V6, P176, DOI 10.1158/2159-8290.CD-15-0859; Brockstein B, 2001, INVEST NEW DRUG, V19, P249, DOI 10.1023/A:1010628903248; Brown RB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176675; Burchert A, 1999, BRIT J HAEMATOL, V107, P494, DOI 10.1046/j.1365-2141.1999.01741.x; Byun JM, 2016, ANN HEMATOL, V95, P1223, DOI 10.1007/s00277-016-2691-1; Cloos J, 2006, LEUKEMIA, V20, P1217, DOI 10.1038/sj.leu.2404246; Cook AM, 2014, BLOOD, V123, P2826, DOI 10.1182/blood-2013-05-505735; Crump M, 2016, J CLIN ONCOL, V34, P2484, DOI 10.1200/JCO.2015.65.7171; Davoudi Z, 2014, ASIAN PAC J CANCER P, V15, P4353, DOI 10.7314/APJCP.2014.15.10.4353; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; El Fakih R, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7010004; Ester M., 1996, KDD-96 Proceedings. Second International Conference on Knowledge Discovery and Data Mining, P226; Frerich Candace A, 2018, Oncotarget, V9, P7341, DOI 10.18632/oncotarget.23641; Garcia-Manero G, 2015, CLIN CANCER RES, V21, P985, DOI 10.1158/1078-0432.CCR-14-1765; Gupta J, 2015, ONCOTARGET, V6, P8539, DOI 10.18632/oncotarget.3816; Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640; Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736; HOCEVAR BA, 1992, J CELL SCI, V101, P671; Huang F, 2011, BIOMED OPT EXPRESS, V2, P1377, DOI 10.1364/BOE.2.001377; Hwang S, 2019, CELL MOL LIFE SCI, V76, P1595, DOI 10.1007/s00018-019-03014-7; Ji HY, 2019, PEDIATR RES, V85, P1024, DOI 10.1038/s41390-019-0370-3; Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116; Kohmo S, 2010, CANCER RES, V70, P8025, DOI 10.1158/0008-5472.CAN-10-0996; Kolanus W, 1997, CURR OPIN CELL BIOL, V9, P725, DOI 10.1016/S0955-0674(97)80127-5; Kurinna S, 2006, LEUKEMIA, V20, P1316, DOI 10.1038/sj.leu.2404248; Kwon HY, 2015, CELL STEM CELL, V17, P152, DOI 10.1016/j.stem.2015.06.006; Marjon KD, 2016, ONCOGENE, V35, P4132, DOI 10.1038/onc.2015.449; McCubrey JA, 2008, LEUKEMIA, V22, P708, DOI 10.1038/leu.2008.27; Miranti CK, 2009, CELL SIGNAL, V21, P196, DOI 10.1016/j.cellsig.2008.08.023; Myklebust JH, 2000, BLOOD, V95, P510, DOI 10.1182/blood.V95.2.510; Naci D, 2014, CELL SIGNAL, V26, P2008, DOI 10.1016/j.cellsig.2014.05.016; Naci D, 2012, J BIOL CHEM, V287, P17065, DOI 10.1074/jbc.M112.349365; Nair MG, 2016, EXP CELL RES, V346, P137, DOI 10.1016/j.yexcr.2016.05.015; Nasir SS, 2017, CL LYMPH MYELOM LEUK, V17, P126, DOI 10.1016/j.clml.2016.09.011; Nishioka C, 2015, LEUKEMIA, V29, P2296, DOI 10.1038/leu.2015.219; Nishioka C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125017; Nishioka C, 2014, INT J CANCER, V134, P55, DOI 10.1002/ijc.28348; Nishioka C, 2013, INT J CANCER, V132, P2006, DOI 10.1002/ijc.27904; Okamoto Y, 2019, BONE MARROW TRANSPL, V54, P1489, DOI 10.1038/s41409-019-0461-0; Ramirez P, 2009, BLOOD, V114, P1340, DOI 10.1182/blood-2008-10-184721; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Ruvolo PP, 2011, J CELL BIOCHEM, V112, P1696, DOI 10.1002/jcb.23090; Saito-Reis CA, 2018, MOL BIOL CELL, V29, P2946, DOI 10.1091/mbc.E18-05-0305; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Sansing HA, 2011, BIOCHEM BIOPH RES CO, V406, P171, DOI 10.1016/j.bbrc.2011.01.109; Scott MJ, 2008, J BIOL CHEM, V283, P29433, DOI 10.1074/jbc.M803905200; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Takami M, 2018, BIOCHEM BIOPH RES CO, V503, P1364, DOI 10.1016/j.bbrc.2018.07.049; Termini CM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29859; TERMINI CM, 2012, MOL BIOL CELL, V23, P1545; Thornton TM, 2009, INT J BIOL SCI, V5, P44, DOI 10.7150/ijbs.5.44; Tonoli H, 2005, TRENDS MOL MED, V11, P563, DOI 10.1016/j.molmed.2005.10.002; Tsai YC, 2011, FEBS LETT, V585, P3166, DOI 10.1016/j.febslet.2011.08.031; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Ullah Mujib, 2019, Oncotarget, V10, P3435, DOI 10.18632/oncotarget.26952; Valley CC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123941; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Varet H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157022; Varterasian ML, 2000, CLIN CANCER RES, V6, P825; Veuger M, 2001, LEUKEMIA, V15, P503; Wakui M, 2008, INT J HEMATOL, V87, P144, DOI 10.1007/s12185-008-0025-3; Walter RB, 2013, BLOOD, V121, P2424, DOI 10.1182/blood-2012-10-462440; Wood CD, 2009, INT J BIOL SCI, V5, P428; Ye MT, 2017, BIOCHEM BIOPH RES CO, V486, P349, DOI 10.1016/j.bbrc.2017.03.044; Zhang J, 2019, ONCOTARGETS THER, V12, P1937, DOI 10.2147/OTT.S191621; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	77	6	7	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3910	3925		10.1038/s41388-020-1261-0	http://dx.doi.org/10.1038/s41388-020-1261-0		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203165	Green Accepted			2022-12-17	WOS:000520614100001
J	Liu, K; Wang, BJ; Han, WW; Chi, CH; Gu, C; Wang, Y; Fu, XH; Huang, W; Liu, ZG; Song, XL				Liu, Kai; Wang, Ben-Jun; Han, WeiWei; Chi, Chun-Hua; Gu, Chao; Wang, Yu; Fu, Xiaohai; Huang, Wei; Liu, Zhiguo; Song, Xilin			CFIm25-regulated lncRNA acv3UTR promotes gastric tumorigenesis via miR-590-5p/YAP1 axis	ONCOGENE			English	Article							COMPETING ENDOGENOUS RNA; MONOCYTE/MACROPHAGE DIFFERENTIATION; POSTTRANSCRIPTIONAL REGULATION; CANCER CELLS; CERNA; EXPRESSION; INVASION; ACTIVIN; PROLIFERATION; PHOSPHORYLATION	Accumulating evidences indicate that 3MODIFIER LETTER PRIMEUTR of the coding gene can act as crucial regulators in gastric cancer (GC). However, the detailed mechanisms and responsive targets are not well established. Here, we found that acvr1b gene 3MODIFIER LETTER PRIMEUTR (acv3UTR) was elevated in GC tissue, the expression of which was significantly correlated with advanced pTNM-stage and poor outcome in clinical patients. Forced expression of acv3UTR promoted GC cells growth in vitro and in vivo. Mechanistically, our results suggested that acv3UTR functioned as an oncogenic competing endogenous RNA via sponging miR-590-5p and enhancing YAP1 level. Tumor suppressor miR-590-5p was a molecular module in acv3UTR regulatory axis, the forced expression of which led to impairing of oncogenic potential of acv3UTR. The positive correlation of acv3UTR and YAP1 expression, and the negative correlation of acv3UTR and miR-590-5p expression, were verified in GC patients. Moreover, CFIm25 was identified as a key regulator contributing to acv3UTR aberrant expression in GC binding to UGUA-264 motif. Overall, our finding defines a mechanism for understanding the potential role of acv3UTR transcription in GC tumorigenesis, and indicates a correlation between 3MODIFIER LETTER PRIMEUTR trans-regulatory effect and GC development.	[Liu, Kai; Song, Xilin] Shandong Canc Hosp & Inst, Dept Gastrointestinal Surg, Jinan, Peoples R China; [Wang, Ben-Jun; Han, WeiWei; Chi, Chun-Hua; Gu, Chao] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Anorectal Surg, Jinan 250014, Shandong, Peoples R China; [Wang, Yu] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Radiol, Jinan 250014, Shandong, Peoples R China; [Fu, Xiaohai] Shouguang Peoples Hosp, Dept Intens Care Unit, Shouguang, Shandong, Peoples R China; [Huang, Wei] Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China; [Liu, Zhiguo] Shandong Canc Hosp & Inst, PET CT Ctr, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University of Traditional Chinese Medicine; Shandong University of Traditional Chinese Medicine; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Song, XL (corresponding author), Shandong Canc Hosp & Inst, Dept Gastrointestinal Surg, Jinan, Peoples R China.	xilin_song1980@163.com			National Natural Science Foundation of China [81773232, 81601554]; Natural Science Foundation of Shandong Province [ZR2013H1109, ZR2013HM43]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shandong Province(Natural Science Foundation of Shandong Province)	This study was supported by the National Natural Science Foundation of China (81773232 and 81601554) and Natural Science Foundation of Shandong Province (ZR2013H1109 and ZR2013HM43).	Abdelmohsen K, 2010, WIRES RNA, V1, P214, DOI 10.1002/wrna.4; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Arun Kanagaraj, 2018, Oncotarget, V9, P18386, DOI 10.18632/oncotarget.24841; Briata P, 2011, FRONT BIOSCI-LANDMRK, V16, P1787, DOI 10.2741/3821; Chen MT, 2015, MOL CELL BIOL, V35, P3212, DOI 10.1128/MCB.00429-15; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Ergun S, 2015, TUMOR BIOL, V36, P3129, DOI 10.1007/s13277-015-3346-x; Ferro A, 2014, EUR J CANCER, V50, P1330, DOI 10.1016/j.ejca.2014.01.029; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gao SM, 2016, J MOL HISTOL, V47, P135, DOI 10.1007/s10735-016-9659-2; Gratacos FM, 2010, WIRES RNA, V1, P457, DOI 10.1002/wrna.26; Hanninen UA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007200; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200; Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249; Hu-Lowe DD, 2011, CANCER RES, V71, P1362, DOI 10.1158/0008-5472.CAN-10-1451; Jiang XF, 2012, MOL CELLS, V33, P545, DOI 10.1007/s10059-012-2267-4; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057; Karreth FA, 2015, CELL, V161, P319, DOI 10.1016/j.cell.2015.02.043; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li FX, 2018, MED SCI MONITOR, V24, P37, DOI 10.12659/MSM.905410; Lin HS, 2014, J LEUKOCYTE BIOL, V96, P1023, DOI 10.1189/jlb.1A0514-240R; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Lu MH, 2016, ONCOGENE, V35, P3524, DOI 10.1038/onc.2015.413; Mahoney S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152010; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mercer TR, 2011, NUCLEIC ACIDS RES, V39, P2393, DOI 10.1093/nar/gkq1158; Mitchell D, 2010, MOL CANCER THER, V9, P379, DOI 10.1158/1535-7163.MCT-09-0650; Mizuno Y, 2009, FEBS LETT, V583, P2263, DOI 10.1016/j.febslet.2009.06.006; Morlando M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020570; Nomura M, 2013, BIOCHEM BIOPH RES CO, V430, P340, DOI 10.1016/j.bbrc.2012.11.011; Ogilvie RL, 2005, J IMMUNOL, V174, P953, DOI 10.4049/jimmunol.174.2.953; Ou CL, 2017, CANCER LETT, V399, P53, DOI 10.1016/j.canlet.2017.04.011; Peleteiro B, 2014, EUR J CANCER PREV, V23, P524, DOI 10.1097/CEJ.0b013e328364f2b6; Qiu WL, 2016, GASTROENTEROLOGY, V150, P218, DOI 10.1053/j.gastro.2015.09.013; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Song M, 2012, ANTICANCER RES, V32, P3827; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; TENDIJKE P, 1993, ONCOGENE, V8, P2879; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Togashi Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-126; Vislovukh Andrii, 2014, World J Biol Chem, V5, P40, DOI 10.4331/wjbc.v5.i1.40; Wan XC, 2018, ONCOTARGET, V9, P4798, DOI 10.18632/oncotarget.23219; Xiao XC, 2012, ONCOL RES, V20, P537, DOI 10.3727/096504013X13775486749335; Xu J, 2015, NUCLEIC ACIDS RES, V43, P8169, DOI 10.1093/nar/gkv853; Xu Y, 2018, CELL PHYSIOL BIOCHEM, V46, P2445, DOI 10.1159/000489651; Yang Q, 2011, STRUCTURE, V19, P368, DOI 10.1016/j.str.2010.12.021; Zanconato F, 2019, NAT REV CANCER, V19, P454, DOI 10.1038/s41568-019-0168-y; Zhang G, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0829-6; Zhang JL, 2019, ONCOGENE, V38, P33, DOI 10.1038/s41388-018-0430-x; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao J, 2015, CELL CYCLE, V14, P3112, DOI 10.1080/15384101.2015.1078034; Zheng LF, 2018, EUR J CELL BIOL, V97, P23, DOI 10.1016/j.ejcb.2017.11.002; Zhu Y, 2018, MOL CELL, V69, P62, DOI 10.1016/j.molcel.2017.11.031	60	6	6	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3075	3088		10.1038/s41388-020-1213-8	http://dx.doi.org/10.1038/s41388-020-1213-8		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066878	hybrid, Green Published			2022-12-17	WOS:000514052700001
J	Kluz, PN; Kolb, R; Xie, Q; Borcherding, N; Liu, Q; Luo, YW; Kim, MC; Wang, LN; Zhang, YN; Li, W; Stipp, C; Gibson-Corley, KN; Zhao, C; Qi, HH; Bellizzi, A; Tao, AW; Sugg, S; Weigel, RJ; Zhou, DH; Shen, X; Zhang, WZ				Kluz, Paige N.; Kolb, Ryan; Xie, Qing; Borcherding, Nicholas; Liu, Qi; Luo, Yuewan; Kim, Myung-Chul; Wang, Linna; Zhang, Yinan; Li, Wei; Stipp, Christopher; Gibson-Corley, Katherine N.; Zhao, Chen; Qi, Hank H.; Bellizzi, Andrew; Tao, Andy W.; Sugg, Sonia; Weigel, Ronald J.; Zhou, Daohong; Shen, Xian; Zhang, Weizhou			Cancer cell-intrinsic function of CD177 in attenuating beta-catenin signaling	ONCOGENE			English	Article							MAMMARY-GLAND HYPERPLASIA; GENE-EXPRESSION; TRANSGENIC MICE; WNT PATHWAY; BREAST; CADHERIN; ACTIVATION; PROMOTES; METASTASIS; SURVIVAL	Aiming to identify immune molecules with a novel function in cancer pathogenesis, we found the cluster of differentiation 177 (CD177), a known neutrophil antigen, to be positively correlated with relapse-free, metastasis-free, or overall survival in breast cancer. In addition, CD177 expression is correlated with good prognosis in several other solid cancers including prostate, cervical, and lung. Focusing on breast cancer, we found that CD177 is expressed in normal breast epithelial cells and is significantly reduced in invasive cancers. Loss of CD177 leads to hyperproliferative mammary epithelium and contributes to breast cancer pathogenesis. Mechanistically, we found that CD177-deficiency is associated with an increase in beta-catenin signaling. Here we identified CD177 as a novel regulator of mammary epithelial proliferation and breast cancer pathogenesis likely via the modulation of Wnt/beta-catenin signaling pathway, a key signaling pathway involved in multiple cancer types.	[Kluz, Paige N.; Xie, Qing; Borcherding, Nicholas; Gibson-Corley, Katherine N.; Zhao, Chen; Bellizzi, Andrew] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; [Kluz, Paige N.; Luo, Yuewan; Kim, Myung-Chul; Li, Wei] Univ Iowa, Coll Med, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA; [Kolb, Ryan; Zhang, Weizhou] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Borcherding, Nicholas] Univ Iowa, Coll Med, Med Sci Training Program, Iowa City, IA 52242 USA; [Liu, Qi; Qi, Hank H.] Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; [Wang, Linna; Tao, Andy W.] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; [Zhang, Yinan] Nankai Univ, Coll Life Sci, Dept Biol, Tianjin 300071, Peoples R China; [Stipp, Christopher] Univ Iowa, Coll Med, Dept Biol, Iowa City, IA 52242 USA; [Stipp, Christopher; Gibson-Corley, Katherine N.; Bellizzi, Andrew; Sugg, Sonia; Weigel, Ronald J.] Univ Iowa, Coll Med, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA; [Sugg, Sonia; Weigel, Ronald J.] Univ Iowa, Coll Med, Dept Surg, Iowa City, IA 52242 USA; [Zhou, Daohong] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA; [Shen, Xian] Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China; [Xie, Qing] Xinxiang Med Univ, Sch Basic Med Sci, Tumor Signaling & Transduct Lab, Xinxiang 453000, Henan, Peoples R China	University of Iowa; University of Iowa; State University System of Florida; University of Florida; University of Iowa; University of Iowa; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Nankai University; University of Iowa; University of Iowa; University of Iowa; State University System of Florida; University of Florida; Wenzhou Medical University; Xinxiang Medical University	Zhang, WZ (corresponding author), Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.; Shen, X (corresponding author), Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China.	13968888872@126.com; zhangw@ufl.edu	Kluz, Paige/AAT-4892-2021	Borcherding, Nicholas/0000-0003-1427-6342; Weigel, Ronald/0000-0002-9249-0793; Luo, Yuewan/0000-0002-8964-5301; Bellizzi, Andrew/0000-0002-8264-6379; Sugg, Sonia/0000-0001-7530-8526	NIH [CA206255, CA200673, CA203834]; V Scholar award; American Cancer Society; Breast Cancer Research Award; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa, University of Iowa [P30CA086862]; National Natural Science Foundation of China [81502313]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Scholar award; American Cancer Society(American Cancer Society); Breast Cancer Research Award; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa, University of Iowa; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	W.Z. was supported by NIH grants CA200673 and CA203834, the V Scholar award, American Cancer Society seed grant, Breast Cancer Research Award and Oberley Award (National Cancer Institute Award P30CA086862) from Holden Comprehensive Cancer Center at the University of Iowa, University of Iowa. N.B. was supported by NIH CA206255. Q.X. was supported by the National Natural Science Foundation of China (No. 81502313). We thank Dr. Foekens for sharing the site-specific metastasis information related to GSE2034. We thank Dr. Shay for sharing the human colon epithelial cells.	Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594; Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89; Borcherding N, 2018, AM J PATHOL, V188, P1910, DOI 10.1016/j.ajpath.2018.05.003; Brisken C, 2000, GENE DEV, V14, P650; Bulut G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027243; Caruccio L, 2006, TRANSFUSION, V46, P441, DOI 10.1111/j.1537-2995.2006.00741.x; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Q, 2014, ONCOTARGET, V5, P9092, DOI 10.18632/oncotarget.2377; Chiurillo MA, 2015, WORLD J EXP MED, V5, P84, DOI [DOI 10.5493/WJEM.V5.I2.84, 10.5493/wjem.v5.i2.84]; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; HEASMAN J, 1994, DEVELOPMENT, V120, P49; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Incassati A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2723; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kissel K, 2001, EUR J IMMUNOL, V31, P1301, DOI 10.1002/1521-4141(200105)31:5<1301::AID-IMMU1301>3.0.CO;2-J; Koesters R, 1999, CANCER RES, V59, P3880; Kuphal F, 2006, EXP CELL RES, V312, P457, DOI 10.1016/j.yexcr.2005.11.007; Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lindvall C, 2006, J BIOL CHEM, V281, P35081, DOI 10.1074/jbc.M607571200; Lindvall C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005813; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Matsuzawa A, 2008, SCIENCE, V321, P663, DOI 10.1126/science.1157340; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Nakashima N, 2012, LUNG CANCER, V76, P228, DOI 10.1016/j.lungcan.2011.10.007; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Orsulic S, 1999, J CELL SCI, V112, P1237; Ozaki S, 2005, ONCOL REP, V14, P1437; Passamonti F, 2004, BRIT J HAEMATOL, V126, P650, DOI 10.1111/j.1365-2141.2004.05098.x; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Temerinac S, 2000, BLOOD, V95, P2569; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Toyoda T, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-122; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Xie Q, 2015, PROTEIN CELL, V6, P117, DOI 10.1007/s13238-014-0109-1; Yokoyama NN, 2014, AM J CLIN EXP UROL, V2, P27; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020; Zhang J, 2010, ONCOGENE, V29, P539, DOI 10.1038/onc.2009.339; Zhang YN, 2014, INT J CLIN EXP PATHO, V7, P3908	63	6	6	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	14					2877	2889		10.1038/s41388-020-1203-x	http://dx.doi.org/10.1038/s41388-020-1203-x		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KZ2VB	32042113	Green Accepted			2022-12-17	WOS:000512528200001
J	Shao, AW; Lang, Y; Wang, MD; Qin, C; Kuang, Y; Mei, YD; Lin, DG; Zhang, S; Tang, J				Shao, Anwen; Lang, Yue; Wang, Mengdong; Qin, Chao; Kuang, Yu; Mei, Yide; Lin, Degui; Zhang, Shuo; Tang, Jun			Bclaf1 is a direct target of HIF-1 and critically regulates the stability of HIF-1 alpha under hypoxia	ONCOGENE			English	Article							INDUCIBLE FACTORS; MESSENGER-RNA; PROTEINS; ALPHA; DEATH; CELLS; DESTABILIZATION; TRANSCRIPTION; DEGRADATION; METABOLISM	Hypoxic stress is intimately connected with tumor progression, with hypoxia-inducible factor-1 alpha (HIF-1 alpha) being a critical regulator in this process. HIF-1 alpha is stabilized in response to hypoxia, which is required for the induction of gene transcriptions important for hypoxic adaptation. Bclaf1 is a multifunctional protein involved in tumorigenesis, however, its role in this process is not well characterized. Here we report Bclaf1 is a direct transcriptional target of HIF-1 and upregulated in multiple cell lines during hypoxia. Importantly, we found Bclaf1 is involved in the stabilization of HIF-1 alpha during long-term hypoxic treatments. Compared with the control cells, the protein level and stability of HIF-1 alpha in Bclaf1 knockdown or knockout cells is greatly compromised after long-term hypoxic treatments, concomitant with the impaired inductions of HIF-1 target gene transcription. Bclaf1 knockout HeLa cells exhibit a reduced tumor growth in mice xenografts, in which the expressions of HIF-1 alpha and its target genes are also decreased. Bclaf1 binds to HIF-1 alpha in the nucleus, and this interaction is required for Bclaf1 to stabilize HIF-1 alpha in hypoxic condition. These results uncover a positive feedback loop, HIF-1-Bclaf1, that sustains HIF-1 activity during long-term hypoxic conditions by binding to and protecting HIF-1 alpha from degradation, and suggest that Bclaf1 may promote tumor progression by enhancing HIF-1 alpha stability.	[Shao, Anwen; Lang, Yue; Wang, Mengdong; Qin, Chao; Kuang, Yu; Tang, Jun] China Agr Univ, Coll Vet Med, Dept Basic Vet Med, Beijing 100193, Peoples R China; [Mei, Yide] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Lin, Degui; Zhang, Shuo] China Agr Univ, Coll Vet Med, Dept Clin Vet Med, Beijing 100193, Peoples R China	China Agricultural University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; China Agricultural University	Tang, J (corresponding author), China Agr Univ, Coll Vet Med, Dept Basic Vet Med, Beijing 100193, Peoples R China.	jtang@cau.edu.cn	Mei, Yide/M-4468-2013		National Natural Science Foundation of China [31671488, 31872834]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (31671488 and 31872834).	Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bracken CP, 2008, CANCER RES, V68, P7621, DOI 10.1158/0008-5472.CAN-08-1217; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cavadas MAS, 2015, SCI REP-UK, V5, DOI 10.1038/srep17851; Chamboredon S, 2011, MOL BIOL CELL, V22, P3366, DOI 10.1091/mbc.E10-07-0617; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10347; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Kong SY, 2011, J BIOL CHEM, V286, P16967, DOI 10.1074/jbc.M111.218206; Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017; Lee SH, 2012, P NATL ACAD SCI USA, V109, P9575, DOI 10.1073/pnas.1207496109; Lee YY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.76; Liu H, 2007, MOL CELL BIOL, V27, P8480, DOI 10.1128/MCB.01126-07; Liu J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01947-w; Luo WB, 2018, CELL MOL LIFE SCI, V75, P1043, DOI 10.1007/s00018-017-2684-9; Luo WB, 2010, J BIOL CHEM, V285, P3651, DOI 10.1074/jbc.M109.068577; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; McPherson JP, 2009, CELL DEATH DIFFER, V16, P331, DOI 10.1038/cdd.2008.167; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; Qin C, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007559; Sarras H, 2010, THESCIENTIFICWORLDJO, V10, P1450, DOI 10.1100/tsw.2010.132; Savage KI, 2014, MOL CELL, V54, P445, DOI 10.1016/j.molcel.2014.03.021; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shao AW, 2016, CELL DEATH DIFFER, V23, P865, DOI 10.1038/cdd.2015.150; Shih JW, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0358-4; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Vohhodina J, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx1046; Wen Y, 2019, ONCOGENE, V38, P1845, DOI 10.1038/s41388-018-0552-1; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Ziegelbauer JM, 2009, NAT GENET, V41, P130, DOI 10.1038/ng.266	41	6	7	3	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2807	2818		10.1038/s41388-020-1185-8	http://dx.doi.org/10.1038/s41388-020-1185-8		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32029898				2022-12-17	WOS:000511540800003
J	Bommi, PV; Chand, V; Mukhopadhyay, NK; Raychaudhuri, P; Bagchi, S				Bommi, Prashant, V; Chand, Vaibhav; Mukhopadhyay, Nishit K.; Raychaudhuri, Pradip; Bagchi, Srilata			NER-factor DDB2 regulates HIF1 alpha and hypoxia-response genes in HNSCC	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; NF-KAPPA-B; LYSYL OXIDASE; NECK-CANCER; HEAD; PROTEIN; EXPRESSION; CARCINOMA; THROMBOSPONDIN-1; METASTASIS	Cancers in the oral/head & neck region (HNSCC) are aggressive due to high incidence of recurrence and distant metastasis. One prominent feature of aggressive HNSCC is the presence of severely hypoxic regions in tumors and activation of hypoxia-inducible factors (HIFs). In this study, we report that the XPE gene product DDB2 (damaged DNA binding protein 2), a nucleotide excision repair protein, is upregulated by hypoxia. Moreover, DDB2 inhibits HIF1 alpha in HNSCC cells. It inhibits HIF1 alpha in both normoxia and hypoxia by reducing mRNA expression. Knockdown of DDB2 enhances the expression of angiogenic markers and promotes tumor growth in a xenograft model. We show that DDB2 binds to an upstream promoter element in the HIF1 Alpha gene and promotes histone H3K9 trimethylation around the binding site by recruiting Suv39h1. Also, we provide evidence that DDB2 has a significant suppressive effect on expression of the endogenous markers of hypoxia that are also prognostic indicators in HNSCC. Together, these results describe a new mechanism of hypoxia regulation that opposes expression of HIF1 Alpha mRNA and the hypoxia-response genes.	[Bommi, Prashant, V; Bagchi, Srilata] Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA; [Chand, Vaibhav; Mukhopadhyay, Nishit K.; Raychaudhuri, Pradip] Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA; [Bommi, Prashant, V] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Biol Sci Res Bldg,6767 Bertner Ave, Houston, TX 77030 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Texas System; UTMD Anderson Cancer Center	Bagchi, S (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.; Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	pradip@uic.edu; sbagchi@uic.edu		Bommi, Prashant/0000-0002-9457-1730	National Cancer Institute (NCI) [R01CA156164]	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the grants from National Cancer Institute (NCI) to SB (R03CA227308) and the multi-PI grant from the National Cancer Institute (NCI) to PR and SB (R01CA156164).	Albinger-Hegyi A, 2010, INT J CANCER, V126, P2653, DOI 10.1002/ijc.24948; Bae SH, 2004, BIOCHEM BIOPH RES CO, V324, P394, DOI 10.1016/j.bbrc.2004.09.068; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bommi Prashant V, 2018, Oncotarget, V9, P34708, DOI 10.18632/oncotarget.26168; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Ennen M, 2013, CANCER RES, V73, P5040, DOI 10.1158/0008-5472.CAN-12-3655; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Firlej V, 2011, CANCER RES, V71, P7649, DOI 10.1158/0008-5472.CAN-11-0833; Gandini NA, 2012, EXP MOL PATHOL, V93, P237, DOI 10.1016/j.yexmp.2012.05.001; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Han CH, 2014, MOL CANCER RES, V12, P784, DOI 10.1158/1541-7786.MCR-13-0638; Hayashido Y, 2003, INT J MOL MED, V12, P447; Horiguchi Hidehisa, 2013, J Med Invest, V60, P91; Hoskin PJ, 2003, BRIT J CANCER, V89, P1290, DOI 10.1038/sj.bjc.6601260; Huang S, 2017, CANCER RES, V77, P6562, DOI 10.1158/0008-5472.CAN-17-1570; Iyer AK, 2013, ADV DRUG DELIVER REV, V65, P1784, DOI 10.1016/j.addr.2013.07.012; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jayachandran A, 2014, ONCOTARGET, V5, P5782, DOI 10.18632/oncotarget.2164; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Koumenis C, 2014, ADV EXP MED BIOL, V772, pV; Le QT, 2009, J CLIN ONCOL, V27, P4281, DOI 10.1200/JCO.2008.20.6003; Li F, 2007, MOL CELL, V26, P63, DOI 10.1016/j.molcel.2007.02.024; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; McDonald PC, 2014, SUBCELL BIOCHEM, V75, P255, DOI 10.1007/978-94-007-7359-2_13; Minig V, 2009, J BIOL CHEM, V284, P14165, DOI 10.1074/jbc.M808208200; Nowrousian MR, 2008, RECOMBINANT HUMAN ER; Overgaard J, 2005, LANCET ONCOL, V6, P757, DOI 10.1016/S1470-2045(05)70292-8; Pal SK, 2016, J ORAL PATHOL MED, V45, P730, DOI 10.1111/jop.12430; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perez-Sayans M, 2013, J ORAL PATHOL MED, V42, P1, DOI 10.1111/j.1600-0714.2012.01144.x; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Roy N, 2013, CANCER RES, V73, P3771, DOI 10.1158/0008-5472.CAN-12-4069; Roy N, 2013, CANCER BIOL THER, V14, P108, DOI 10.4161/cbt.22631; Roy N, 2012, INT J MOL SCI, V13, P11012, DOI 10.3390/ijms130911012; Ryu JH, 2011, J BIOL CHEM, V286, P6963, DOI 10.1074/jbc.M110.188706; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354; Sorensen BS, 2015, RADIOTHER ONCOL, V116, P346, DOI 10.1016/j.radonc.2015.06.028; Stoyanova T, 2012, J BIOL CHEM, V287, P3019, DOI 10.1074/jbc.M111.295816; Stoyanova T, 2009, CELL CYCLE, V8, P4067, DOI 10.4161/cc.8.24.10109; Sui H, 2014, ONCOL RES TREAT, V37, P584, DOI 10.1159/000367802; Toustrup K, 2016, ACTA ONCOL, V55, P1091, DOI 10.3109/0284186X.2016.1167959; Toustrup K, 2011, CANCER RES, V71, P5923, DOI 10.1158/0008-5472.CAN-11-1182; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Vaupel P, 2002, Wien Med Wochenschr, V152, P334; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Waypa GB, 2016, MOL ASPECTS MED, V47-48, P76, DOI 10.1016/j.mam.2016.01.002; Wittschieben BO, 2005, J BIOL CHEM, V280, P39982, DOI 10.1074/jbc.M507854200; Wittschieben BO, 2003, DNA REPAIR, V2, P1065, DOI 10.1016/S1568-7864(03)00113-7; Wykoff CC, 2000, CANCER RES, V60, P7075; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhang S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2408-9; Zhao R, 2015, NUCLEIC ACIDS RES, V43, P7838, DOI 10.1093/nar/gkv667; Zhao R, 2014, MOL CANCER RES, V12, P370, DOI 10.1158/1541-7786.MCR-13-0281	64	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1784	1796		10.1038/s41388-019-1105-y	http://dx.doi.org/10.1038/s41388-019-1105-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740787				2022-12-17	WOS:000514923000012
J	Hu, LY; Sun, Y; Luo, J; He, X; Ye, MH; Li, GH; Zhang, Y; Bai, J; Zhang, DH; Chang, CS				Hu, Linyi; Sun, Yin; Luo, Jie; He, Xiang; Ye, Meihua; Li, Gonghui; Zhang, Yong; Bai, Jian; Zhang, Dahong; Chang, Chawnshang			Targeting TR4 nuclear receptor with antagonist bexarotene increases docetaxel sensitivity to better suppress the metastatic castration-resistant prostate cancer progression	ONCOGENE			English	Article							LINCRNA-P21; MECHANISMS; APOPTOSIS; ROLES; CELLS	Prostate cancer (PCa) is the second leading cause of cancer death in men in America, and there are no curative options for metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (DTX) has been used as a standard chemotherapy for the mCRPC. However, resistance to DTX is a significant clinical problem as half of patients fail to respond to therapy. The TR4 nuclear receptor has been reported to play an important role in PCa progression, however, its linkage to the DTX resistance remains unclear. Here we found that TR4 was upregulated after DTX chemotherapy in the mCRPC cells and patients, and TR4 expression is correlated with DTX sensitivity with a higher level conferring chemo-resistance. Targeting TR4 with an antagonist bexarotene (Bex, a derivative of retinoid) suppressed the TR4 transactivation with increased DTX chemo-sensitivity. Mechanism dissection studies revealed that TR4 might alter the DTX chemo-sensitivity via modulating the TR4/lincRNA-p21/HIF-1 alpha/VEGF-A signaling. Together, these results suggest that targeting this newly identified TR4/lincRNA-p21/HIF-1 alpha/VEGF-A signaling with Bex, an FDA-approved drug, may increase the DTX chemo-sensitivity to better suppress the mCRPC progression.	[Hu, Linyi; He, Xiang; Ye, Meihua; Zhang, Dahong] Zhejiang Prov Peoples Hosp, Dept Urol, Hangzhou 310014, Peoples R China; [Hu, Linyi; Sun, Yin; Luo, Jie; Li, Gonghui; Bai, Jian; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; [Hu, Linyi; Sun, Yin; Luo, Jie; Li, Gonghui; Bai, Jian; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA; [Hu, Linyi; Sun, Yin; Luo, Jie; Li, Gonghui; Bai, Jian; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA; [Zhang, Yong] Hebei Med Univ, Hosp 2, Dept Urol, Shijiazhuang 050000, Hebei, Peoples R China; [Chang, Chawnshang] China Med Univ & Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan	Zhejiang Provincial People's Hospital; University of Rochester; University of Rochester; University of Rochester; Hebei Medical University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Zhang, DH (corresponding author), Zhejiang Prov Peoples Hosp, Dept Urol, Hangzhou 310014, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14642 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA.; Chang, CS (corresponding author), China Med Univ & Hosp, Dept Urol, Sex Hormone Res Ctr, Taichung 404, Taiwan.	zhangdahongzhj@163.co; chang@urmc.rochester.edu	Luo, Jie/AAG-3091-2019	Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477, CA156700]; George Whipple Professorship Endowment; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence [MOHW104-TDU-B-212-113002]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George Whipple Professorship Endowment; Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence	This work was supported by NIH grants (CA155477 and CA156700), George Whipple Professorship Endowment and Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002). We thank Karen Wolf for help preparing the manuscript.	Bos TJ, 2009, CURR GENE THER, V9, P192, DOI 10.2174/156652309788488578; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; Chen B, 2014, CANCER GENE THER, V21, P411, DOI 10.1038/cgt.2014.41; Chen SY, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0959-5; Chen S, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0048747, 10.1371/journal.pone.0046703, 10.1371/journal.pone.0029579, 10.1371/journal.pone.0050850]; Chen YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep27301; Corcoran C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050999; Ding XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0281-1; Ding XF, 2015, INT J CANCER, V136, P955, DOI 10.1002/ijc.29049; Fayda M, 2016, TUMOR BIOL, V37, P3969, DOI 10.1007/s13277-015-4189-1; Fenner Annette, 2015, Nat Rev Urol, V12, P361, DOI 10.1038/nrurol.2015.135; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Isin M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00168; Lee YF, 2004, BIOCHEM BIOPH RES CO, V323, P876, DOI 10.1016/j.bbrc.2004.08.176; Lin SJ, 2012, REPROD BIOL ENDOCRIN, V10, DOI 10.1186/1477-7827-10-43; Liu S, 2014, ENDOCR-RELAT CANCER, V21, pR279, DOI 10.1530/ERC-13-0529; O'Neill AJ, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-126; Obasaju C, 2001, HEMATOL ONCOL CLIN N, V15, P525, DOI 10.1016/S0889-8588(05)70230-6; Pan Y, 2016, CELL PHYSIOL BIOCHEM, V40, P219, DOI 10.1159/000452539; Pileri A, 2013, IMMUNOTHERAPY-UK, V5, P427, DOI [10.2217/IMT.13.15, 10.2217/imt.13.15]; Qiu XF, 2015, ONCOTARGET, V6, P15397, DOI 10.18632/oncotarget.3778; Saad F, 2018, CUAJ-CAN UROL ASSOC, V12, pE415, DOI 10.5489/cuaj.5154; Sakuma T, 2016, NAT PROTOC, V11, P118, DOI 10.1038/nprot.2015.140; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Shen YM, 2017, EXP CELL RES, V358, P188, DOI 10.1016/j.yexcr.2017.06.016; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047; Wang XH, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12395; Wang XH, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12318; Wu GZ, 2014, CIRCULATION, V130, P1452, DOI 10.1161/CIRCULATIONAHA.114.011675; Yang DR, 2013, J BIOL CHEM, V288, P16476, DOI 10.1074/jbc.M112.448142; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027; Yu SC, 2015, PROSTATE, V75, P1632, DOI 10.1002/pros.23044; Zhou XE, 2011, J BIOL CHEM, V286, P2877, DOI 10.1074/jbc.M110.168740	35	6	6	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1891	1903		10.1038/s41388-019-1070-5	http://dx.doi.org/10.1038/s41388-019-1070-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31748715	Green Published, hybrid			2022-12-17	WOS:000516579800005
J	Njeru, SN; Kraus, J; Meena, JK; Lechel, A; Katz, SF; Kumar, M; Knippschild, U; Azoitei, A; Wezel, F; Bolenz, C; Leithauser, F; Gollowitzer, A; Omrani, O; Hoischen, C; Koeberle, A; Kestler, HA; Gunes, C; Rudolph, KL				Njeru, Sospeter N.; Kraus, Johann; Meena, Jitendra K.; Lechel, Andre; Katz, Sarah-Fee; Kumar, Mukesh; Knippschild, Uwe; Azoitei, Anca; Wezel, Felix; Bolenz, Christian; Leithaeuser, Frank; Gollowitzer, Andre; Omrani, Omid; Hoischen, Christian; Koeberle, Andreas; Kestler, Hans A.; Guenes, Cagatay; Rudolph, K. Lenhard			Aneuploidy-inducing gene knockdowns overlap with cancer mutations and identify Orp3 as a B-cell lymphoma suppressor	ONCOGENE			English	Article							FATTY-ACIDS; STEM-CELLS; EXPRESSION; IMMORTALIZATION; PROLIFERATION; TUMORIGENESIS; CONTRIBUTE	Aneuploidy can instigate tumorigenesis. However, mutations in genes that control chromosome segregation are rare in human tumors as these mutations reduce cell fitness. Screening experiments indicate that the knockdown of multiple classes of genes that are not directly involved in chromosome segregation can lead to aneuploidy induction. The possible contribution of these genes to cancer formation remains yet to be defined. Here we identified gene knockdowns that lead to an increase in aneuploidy in checkpoint-deficient human cancer cells. Computational analysis revealed that the identified genes overlap with recurrent mutations in human cancers. The knockdown of the three strongest selected candidate genes (ORP3, GJB3, and RXFP1) enhances the malignant transformation of human fibroblasts in culture. Furthermore, the knockout of Orp3 results in an aberrant expansion of lymphoid progenitor cells and a high penetrance formation of chromosomal instable, pauci-clonal B-cell lymphoma in aging mice. At pre-tumorous stages, lymphoid cells from the animals exhibit deregulated phospholipid metabolism and an aberrant induction of proliferation regulating pathways associating with increased aneuploidy in hematopoietic progenitor cells. Together, these results support the concept that aneuploidy-inducing gene deficiencies contribute to cellular transformation and carcinogenesis involving the deregulation of various molecular processes such as lipid metabolism, proliferation, and cell survival.	[Njeru, Sospeter N.; Meena, Jitendra K.; Omrani, Omid; Hoischen, Christian; Rudolph, K. Lenhard] Fritz Lipmann Inst eV, Leibniz Inst Aging, D-07745 Jena, Germany; [Kraus, Johann; Kestler, Hans A.] Ulm Univ, Inst Med Syst Biol, D-89081 Ulm, Germany; [Lechel, Andre; Katz, Sarah-Fee] Ulm Univ Hosp, Dept Internal Med 1, D-89081 Ulm, Germany; [Kumar, Mukesh; Azoitei, Anca; Wezel, Felix; Bolenz, Christian; Guenes, Cagatay] Ulm Univ Hosp, Dept Urol, D-89081 Ulm, Germany; [Knippschild, Uwe] Ulm Univ Hosp, Dept Gen & Visceral Surg, D-89081 Ulm, Germany; [Leithaeuser, Frank] Ulm Univ, Inst Pathol, D-89075 Ulm, Germany; [Gollowitzer, Andre; Koeberle, Andreas] Friedrich Schiller Univ Jena, Inst Pharm, D-07743 Jena, Germany; [Njeru, Sospeter N.] Paul Ehrlich Inst, Div Immunol, D-63225 Langen, Germany; [Meena, Jitendra K.] Baylor Coll Med, Houston, TX 77030 USA; [Koeberle, Andreas] Univ Innsbruck, Michael Popp Res Inst, Innsbruck, Austria	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI); Ulm University; Ulm University; Ulm University; Ulm University; Ulm University; Friedrich Schiller University of Jena; Paul Ehrlich Institute; Baylor College of Medicine; University of Innsbruck	Rudolph, KL (corresponding author), Fritz Lipmann Inst eV, Leibniz Inst Aging, D-07745 Jena, Germany.; Kestler, HA (corresponding author), Ulm Univ, Inst Med Syst Biol, D-89081 Ulm, Germany.; Gunes, C (corresponding author), Ulm Univ Hosp, Dept Urol, D-89081 Ulm, Germany.	hans.kestler@uni-ulm.de; cagatay.guenes@uniklinik-ulm.de; lenhard.rudolph@leibniz-fli.de	Wezel, Felix/AAO-8761-2021; Gollowitzer, André/AAH-7653-2020; Lechel, André/AAQ-2041-2021; Koeberle, Andreas/ABB-2356-2020; Kestler, Hans A./D-5799-2012; Meena, Jitendra Kumar/C-7444-2016	Lechel, André/0000-0003-0221-6959; Koeberle, Andreas/0000-0001-6269-5088; Kestler, Hans A./0000-0002-4759-5254; Meena, Jitendra Kumar/0000-0003-0199-9357; Gollowitzer, Andre/0000-0003-1524-8298; Njeru, Sospeter/0000-0003-1154-0777	Erich und Gertrud Roggenbuck Stiftung; Deutsche Krebshilfe [10-2086-Gu 2]; European Union (advanced ERC grant) [323136]; German Science Foundation (DFG) [SFB 1074, GRK 2254 HEIST]; Free State of Thuringia [41-5507-2016]; Leibniz ScienceCampus InfectoOptics (SAS-2015-HKI-LWC); Leibniz Graduate School on Ageing and Age-Related Diseases (LGSA), the government of Kenya; Federal Government of Germany through DAAD/NACOSTI scholarship; NRF	Erich und Gertrud Roggenbuck Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); European Union (advanced ERC grant); German Science Foundation (DFG)(German Research Foundation (DFG)); Free State of Thuringia(European Commission); Leibniz ScienceCampus InfectoOptics (SAS-2015-HKI-LWC); Leibniz Graduate School on Ageing and Age-Related Diseases (LGSA), the government of Kenya; Federal Government of Germany through DAAD/NACOSTI scholarship; NRF	This work was supported by the Erich und Gertrud Roggenbuck Stiftung and Deutsche Krebshilfe (C. Gunes, grant 10-2086-Gu 2), the European Union (advanced ERC grant to K. L. Rudolph, grant 323136), and the German Science Foundation (DFG, grants: SFB 1074 Projekt Z1 and GRK 2254 HEIST to H.A. Kestler). A.K. was supported by a Strategy and Innovation Grant from the Free State of Thuringia (41-5507-2016) and the Leibniz ScienceCampus InfectoOptics (SAS-2015-HKI-LWC). The FLI Core Facilities; Flow Cytometry, Histology, S2 laboratory, and Mouse facilities are gratefully acknowledged. We would like to thank the members of the K.L. Rudolph laboratory for helpful support. We thank Lars Zender and Torsten Wustefeld for the cooperation in providing the lentiviral shRNA library targeting human cells and deep sequencing expertize. We also thank Sabrina Eichwald and Michaela Eggel for technical support and Lucien Frappart for his help with the histological evaluation of the xenograft mouse tumors. We acknowledge the Leibniz Graduate School on Ageing and Age-Related Diseases (LGSA), the government of Kenya and the Federal Government of Germany for financing S.N.N. through DAAD/NACOSTI (present NRF) scholarship	Abdelbaset-Ismail A, 2019, STEM CELL REV REP, V15, P139, DOI 10.1007/s12015-018-9853-6; Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Barth TFE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05116-3; Begus-Nahrmann Y, 2009, NAT GENET, V41, P1138, DOI 10.1038/ng.426; Bejarano E, 2014, NAT CELL BIOL, V16, P401, DOI 10.1038/ncb2934; Carneiro MC, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005798; Carricaburu V, 2001, EUR J BIOCHEM, V268, P1238, DOI 10.1046/j.1432-1327.2001.01984.x; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Conery AR, 2010, P NATL ACAD SCI USA, V107, P15455, DOI 10.1073/pnas.1010627107; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Deshpande I, 2019, NATURE, V571, P284, DOI 10.1038/s41586-019-1355-4; Du XM, 2018, SEMIN CELL DEV BIOL, V81, P149, DOI 10.1016/j.semcdb.2017.07.017; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Ema H, 2006, NAT PROTOC, V1, P2979, DOI 10.1038/nprot.2006.447; Fujimura S, 2005, CANCER RES, V65, P5925, DOI 10.1158/0008-5472.CAN-04-3259; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Gunes C, 2018, NAT REV UROL, V15, P386, DOI 10.1038/s41585-018-0001-5; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Harris H, 2008, J CELL SCI, V121, P3, DOI [10.1242/jcs.017483, 10.1242/jcs.025742]; Hell MP, 2014, CANCER RES, V74, P2422, DOI 10.1158/0008-5472.CAN-13-2040; Holubcova Z, 2015, SCIENCE, V348, P1143, DOI 10.1126/science.aaa9529; Kaftanovskaya EM, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.127209; Koeberle A, 2013, P NATL ACAD SCI USA, V110, P2546, DOI 10.1073/pnas.1216182110; Koeberle A, 2010, FASEB J, V24, P4929, DOI 10.1096/fj.10-162818; Lehto M, 2004, CELL TISSUE RES, V315, P39, DOI 10.1007/s00441-003-0817-y; Lehto M, 2008, J CELL SCI, V121, P695, DOI 10.1242/jcs.016964; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; MAGNUSON T, 1985, J EXP ZOOL, V236, P353, DOI 10.1002/jez.1402360313; Martins VC, 2014, NATURE, V509, P465, DOI 10.1038/nature13317; Meena JK, 2015, EMBO J, V34, P1371, DOI 10.15252/embj.201490070; Orr B, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00164; Passerini V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10754; Patel D, 2017, OXID MED CELL LONGEV, V2017, P1, DOI 10.1155/2017/4829180; Petzoldt JL, 1995, UROL RES, V23, P377, DOI 10.1007/BF00698738; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raychaudhuri S, 2010, ANNU REV CELL DEV BI, V26, P157, DOI 10.1146/annurev.cellbio.042308.113334; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; SEGAL DJ, 1974, J CELL PHYSIOL, V83, P85, DOI 10.1002/jcp.1040830112; Shen KC, 2005, CANCER RES, V65, P8747, DOI 10.1158/0008-5472.CAN-05-1471; Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163; Tang YC, 2013, CELL, V152, P394, DOI 10.1016/j.cell.2012.11.043; Thapa N, 2016, TRENDS CANCER, V2, P378, DOI 10.1016/j.trecan.2016.05.009; Wang PY, 2005, SCIENCE, V307, P1472, DOI 10.1126/science.1107710; Weber-Boyvat M, 2015, EXP CELL RES, V331, P278, DOI 10.1016/j.yexcr.2014.10.019; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	49	6	6	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1445	1465		10.1038/s41388-019-1073-2	http://dx.doi.org/10.1038/s41388-019-1073-2			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31659255				2022-12-17	WOS:000513289600005
J	Naert, T; Dimitrakopoulou, D; Tulkens, D; Demuynck, S; Carron, M; Noelanders, R; Eeckhout, L; Van Isterdael, G; Deforce, D; Vanhove, C; Van Dorpe, J; Creytens, D; Vleminckx, K				Naert, Thomas; Dimitrakopoulou, Dionysia; Tulkens, Dieter; Demuynck, Suzan; Carron, Marjolein; Noelanders, Rivka; Eeckhout, Liza; Van Isterdael, Gert; Deforce, Dieter; Vanhove, Christian; Van Dorpe, Jo; Creytens, David; Vleminckx, Kris			RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma in Xenopus tropicalis	ONCOGENE			English	Article							RETINOBLASTOMA PROTEIN; GENOMIC PROFILES; HIGH-GRADE; BETA-CELL; P53; INACTIVATION; TP53; DELETION; MICE; PRB	Alterations of the retinoblastoma and/or the p53 signaling network are associated with specific cancers such as high-grade astrocytoma/glioblastoma, small-cell lung cancer (SCLC), choroid plexus tumors, and small-cell pancreatic neuroendocrine carcinoma (SC-PaNEC). However, the intricate functional redundancy between RB1 and the related pocket proteins RBL1/p107 and RBL2/p130 in suppressing tumorigenesis remains poorly understood. Here we performed lineage-restricted parallel inactivation of rb1 and rbl1 by multiplex CRISPR/Cas9 genome editing in the true diploid Xenopus tropicalis to gain insight into this in vivo redundancy. We show that while rb1 inactivation is sufficient to induce choroid plexus papilloma, combined rb1 and rbl1 inactivation is required and sufficient to drive SC-PaNEC, retinoblastoma and astrocytoma. Further, using a novel Li-Fraumeni syndrome-mimicking tp53 mutant X. tropicalis line, we demonstrate increased malignancy of rb1/rbl1-mutant glioma towards glioblastoma upon concomitant inactivation of tp53. Interestingly, although clinical SC-PaNEC samples are characterized by abnormal p53 expression or localization, in the current experimental models, the tp53 status had little effect on the establishment and growth of SC-PaNEC, but may rather be essential for maintaining chromosomal stability. SCLC was only rarely observed in our experimental setup, indicating requirement of additional or alternative oncogenic insults. In conclusion, we used CRISPR/Cas9 to delineate the tumor suppressor properties of Rbl1, generating new insights in the functional redundancy within the retinoblastoma protein family in suppressing neuroendocrine pancreatic cancer and glioma/glioblastoma.	[Naert, Thomas; Dimitrakopoulou, Dionysia; Tulkens, Dieter; Demuynck, Suzan; Carron, Marjolein; Noelanders, Rivka; Eeckhout, Liza; Vleminckx, Kris] Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium; [Naert, Thomas; Dimitrakopoulou, Dionysia; Tulkens, Dieter; Vanhove, Christian; Van Dorpe, Jo; Creytens, David; Vleminckx, Kris] Canc Res Inst Ghent, Ghent, Belgium; [Carron, Marjolein; Vleminckx, Kris] Univ Ghent, Ctr Med Genet, Ghent, Belgium; [Van Isterdael, Gert] VIB, VIB Ctr Inflammat Res, Ghent, Belgium; [Deforce, Dieter] Univ Ghent, Lab Pharmaceut Biotechnol, Ghent, Belgium; [Vanhove, Christian] Ghent Univ Hosp, Infin Lab, Ghent, Belgium; [Van Dorpe, Jo; Creytens, David] Univ Ghent, Dept Pathol, Ghent, Belgium; [Van Dorpe, Jo; Creytens, David] Ghent Univ Hosp, Ghent, Belgium	Ghent University; Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University; Ghent University Hospital	Vleminckx, K (corresponding author), Univ Ghent, Dept Biomed Mol Biol, Ghent, Belgium.; Vleminckx, K (corresponding author), Canc Res Inst Ghent, Ghent, Belgium.; Vleminckx, K (corresponding author), Univ Ghent, Ctr Med Genet, Ghent, Belgium.	kris.vleminckx@irc.UGent.be	Deforce, Dieter LD/J-4725-2013; Vleminckx, Kris/AAZ-4170-2020	Deforce, Dieter LD/0000-0002-0635-661X; Vanhove, Christian/0000-0002-3988-5980; Tulkens, Dieter/0000-0003-1688-5619	Research Foundation-Flanders (FWO-Vlaanderen) [G0A1515N, G029413N]; Belgian Science Policy (Interuniversity Attraction Poles) [IAP7/07]; Concerted Research Actions from Ghent University [BOF15/GOA/011]; Hercules Foundation, Flanders [AUGE/11/14]; Desmoid Tumor Research Foundation; "Kom op tegen Kanker" (Stand up to Cancer); Flemish cancer society; VLAIO-HERMES; Research Foundation-Flanders (FWO-Vlaanderen); NIH [R24 AI059830]; VIB BioImaging Core	Research Foundation-Flanders (FWO-Vlaanderen)(FWO); Belgian Science Policy (Interuniversity Attraction Poles); Concerted Research Actions from Ghent University; Hercules Foundation, Flanders; Desmoid Tumor Research Foundation; "Kom op tegen Kanker" (Stand up to Cancer); Flemish cancer society; VLAIO-HERMES; Research Foundation-Flanders (FWO-Vlaanderen)(FWO); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VIB BioImaging Core	Research in the authors' laboratory is supported by the Research Foundation-Flanders (FWO-Vlaanderen) (grants G0A1515N and G029413N), by the Belgian Science Policy (Interuniversity Attraction Poles-IAP7/07) and by the Concerted Research Actions from Ghent University (BOF15/GOA/011). Further support was obtained by the Hercules Foundation, Flanders (grant AUGE/11/14) and the Desmoid Tumor Research Foundation. TN is funded by "Kom op tegen Kanker" (Stand up to Cancer), the Flemish cancer society and previously held PhD fellowship with VLAIO-HERMES during the course of this work. DT and MC have a PhD fellowship from the Research Foundation-Flanders (FWO-Vlaanderen). We thank the Xenopus laevis Resource for Immunobiology (Rochester, NY, NIH R24 AI059830) for the kind gift of monoclonal antibody AM20 (10A91, CD8). We are indebted to Tim Deceuninck for animal care, Kelly Lemeire for technical assistance with TUNEL staining. We would like to thank the VIB BioImaging Core, and in particular Chris Guerin, Eef Parthoens, and Anneke Kremer, for access to the instrument park, training, and support.	Abou-El-Ardat K, 2017, NEURO-ONCOLOGY, V19, P546, DOI 10.1093/neuonc/now231; Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4; Basturk O, 2015, AM J SURG PATHOL, V39, P683, DOI 10.1097/PAS.0000000000000408; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Boel A, 2016, SCI REP-UK, V6, DOI 10.1038/srep30330; Bougeard G, 2015, J CLIN ONCOL, V33, P2345, DOI 10.1200/JCO.2014.59.5728; Cai EP, 2014, DIABETOLOGIA, V57, P2555, DOI 10.1007/s00125-014-3381-y; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chow LML, 2011, CANCER CELL, V19, P305, DOI 10.1016/j.ccr.2011.01.039; Chow RD, 2017, NAT NEUROSCI, V20, P1329, DOI 10.1038/nn.4620; Costa C, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00307; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026096; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Glenn ST, 2014, ONCOGENE, V33, P5706, DOI 10.1038/onc.2013.514; Hann CL, 2008, ONCOLOGY-NY, V22, P1486; Harb G, 2009, DIABETES, V58, P1852, DOI 10.2337/db08-0759; Ignatius MS, 2018, ELIFE, V7, DOI 10.7554/eLife.37202; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Konukiewitz B, 2017, MODERN PATHOL, V30, P587, DOI 10.1038/modpathol.2016.217; Liu F, 2014, ONCOGENE, V33, P4813, DOI 10.1038/onc.2013.428; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu XD, 2001, MOL CELL BIOL, V21, P6017, DOI 10.1128/MCB.21.17.6017-6030.2001; Manning AL, 2014, ONCOGENE, V33, P2487, DOI 10.1038/onc.2013.201; Maresch R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10770; Marino S, 2000, GENE DEV, V14, P994; McEvoy J, 2011, CANCER CELL, V20, P260, DOI 10.1016/j.ccr.2011.07.005; Moreno-Mateos MA, 2015, NAT METHODS, V12, P982, DOI [10.1038/NMETH.3543, 10.1038/nmeth.3543]; Naert T, 2019, CRISPR NSID IN VIVO, DOI DOI 10.1101/595769V1; Naert Thomas, 2018, Drug Discov Today Technol, V28, P41, DOI 10.1016/j.ddtec.2018.07.001; Naert T, 2018, METHODS MOL BIOL, V1865, P33, DOI 10.1007/978-1-4939-8784-9_3; Naert T, 2017, GENESIS, V55, DOI 10.1002/dvg.23005; Naert T, 2016, SCI REP-UK, V6, DOI 10.1038/srep35264; Neely HR, 2018, EUR J IMMUNOL, V48, P430, DOI 10.1002/eji.201747260; Pan D, 2017, ONCOTARGET, V8, P4422, DOI 10.18632/oncotarget.12647; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Schmid RS, 2016, NEURO-ONCOLOGY, V18, P962, DOI 10.1093/neuonc/nov321; Shi ZY, 2019, FASEB J, V33, P6962, DOI 10.1096/fj.201802661R; Shim J, 2017, ONCOTARGET, V8, P55280, DOI 10.18632/oncotarget.19424; Solin SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13745; Steed TC, 2016, ONCOTARGET, V7, P24899, DOI 10.18632/oncotarget.8551; Strecker J, 2019, SCIENCE, V365, P48, DOI 10.1126/science.aax9181; Tabori U, 2010, J CLIN ONCOL, V28, P1995, DOI 10.1200/JCO.2009.26.8169; Tong YA, 2015, CANCER CELL, V27, P712, DOI 10.1016/j.ccell.2015.04.005; Vanderluit JL, 2007, J CELL BIOL, V178, P129, DOI 10.1083/jcb.200703176; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; VANZOEST ID, 1989, GEN COMP ENDOCR, V76, P19, DOI 10.1016/0016-6480(89)90028-2; Vasavada RC, 2007, DIABETES, V56, P57, DOI 10.2337/db06-0517; Vitucci M, 2017, NEURO-ONCOLOGY, V19, P1237, DOI 10.1093/neuonc/nox050; Ward JM, 1999, LAB INVEST, V79, P3; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Wojton J, 2013, MOL THER, V21, P1517, DOI 10.1038/mt.2013.114; Xiao A, 2002, CANCER CELL, V1, P157, DOI 10.1016/S1535-6108(02)00029-6; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36	57	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2692	2706		10.1038/s41388-020-1173-z	http://dx.doi.org/10.1038/s41388-020-1173-z		JAN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32001819	Green Submitted			2022-12-17	WOS:000510328400001
J	Lempiainen, JK; Manjur, ABMK; Malinen, M; Ketola, K; Niskanen, EA; Palvimo, JJ				Lempiainen, Joanna K.; Manjur, A. B. M. Kaiser; Malinen, Marjo; Ketola, Kirsi; Niskanen, Einari A.; Palvimo, Jorma J.			BCOR-coupled H2A monoubiquitination represses a subset of androgen receptor target genes regulating prostate cancer proliferation	ONCOGENE			English	Article							LENZ MICROPHTHALMIA SYNDROMES; GROUP PROTEIN EZH2; BCL6 BTB DOMAIN; TRANSCRIPTION FACTORS; HOMEOBOX GENE; HOX GENES; POLYCOMB; COMPLEX; CELLS; EXPRESSION	We have identified BCL6 corepressor (BCOR) as a hormone-dependent interaction partner of androgen receptor (AR), a key transcription factor in the development of normal and cancerous prostate. BCOR is often mutated in cancers and hematological diseases and as a component of a non-canonical polycomb repressive complex 1 (ncPRC1.1) required for arranging many facets of cellular differentiation. However, its role in androgen signaling or prostate cancer cells remains unknown. Here, our genome-wide analyses reveal that BCOR is recruited in an androgen-dependent fashion to majority of AR-binding chromatin sites in castration-resistant prostate cancer (CRPC) cells. Interestingly, depletion of BCOR has a significant effect on the expression of androgen-repressed genes linked to regulation of cell proliferation, differentiation and development. At many of these genes, such as HOX genes, the depletion leads to a decrease in H2A K119 monoubiquitination and an increase in mRNA expression. Consistently, BCOR depletion impairs the proliferation and viability of CRPC cells, inducing their apoptosis. Collectively, our data indicate a key role for the BCOR-ncPRC1.1 complex in the corepression of an important subset of AR target genes and the regulation of prostate cancer cell proliferation.	[Lempiainen, Joanna K.; Manjur, A. B. M. Kaiser; Malinen, Marjo; Ketola, Kirsi; Niskanen, Einari A.; Palvimo, Jorma J.] Univ Eastern Finland, Inst Biomed, Kuopio, Finland; [Malinen, Marjo] Univ Eastern Finland, Dept Environm & Biol Sci, Joensuu, Finland	University of Eastern Finland; University of Eastern Finland	Palvimo, JJ (corresponding author), Univ Eastern Finland, Inst Biomed, Kuopio, Finland.	jorma.palvimo@uef.fi	Ketola, Kirsi/O-1071-2016; Niskanen, Einari/F-2883-2017; Lempiainen, Joanna/M-8833-2017	Ketola, Kirsi/0000-0001-6484-9861; Manjur, Kaiser/0000-0001-8260-1915; Niskanen, Einari/0000-0001-9471-7026; Palvimo, Jorma/0000-0003-2373-0578; Lempiainen, Joanna/0000-0001-6100-5815	Academy of Finland; Cancer Foundation Finland; Sigrid Juselius Foundation; UEF Doctoral Programme in Molecular Medicine; Jalmari and Rauha Ahokas Foundation; Instrumentarium Foundation; Orion Research Foundation; Ida Montini Foundation; Kuopio University Foundation	Academy of Finland(Academy of Finland); Cancer Foundation Finland; Sigrid Juselius Foundation(Sigrid Juselius Foundation); UEF Doctoral Programme in Molecular Medicine; Jalmari and Rauha Ahokas Foundation; Instrumentarium Foundation; Orion Research Foundation; Ida Montini Foundation; Kuopio University Foundation	This work was supported by the Academy of Finland, the Cancer Foundation Finland, the Sigrid Juselius Foundation, the UEF Doctoral Programme in Molecular Medicine, the Jalmari and Rauha Ahokas Foundation, the Instrumentarium Foundation, the Orion Research Foundation, the Ida Montini Foundation and the Kuopio University Foundation.	Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Astolfi A, 2019, EPIGENOMICS-UK, V11, P835, DOI 10.2217/epi-2018-0195; Axlund SD, 2010, MOL CANCER RES, V8, P1643, DOI 10.1158/1541-7786.MCR-10-0111; Banerjee PP, 2018, AM J CLIN EXP UROL, V6, P62; Beguelin W, 2016, CANCER CELL, V30, P197, DOI 10.1016/j.ccell.2016.07.006; Bhatlekar S, 2014, J MOL MED, V92, P811, DOI 10.1007/s00109-014-1181-y; Blackledge NP, 2015, NAT REV MOL CELL BIO, V16, P643, DOI 10.1038/nrm4067; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Cao Q, 2016, LEUKEMIA, V30, P1155, DOI 10.1038/leu.2016.2; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chatr-aryamontri A, 2017, NUCLEIC ACIDS RES, V45, pD369, DOI 10.1093/nar/gkw1102; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Cohen I, 2018, CELL STEM CELL, V22, P726, DOI 10.1016/j.stem.2018.04.005; Connelly ZM, 2018, AM J CLIN EXP UROL, V6, P172; Cooper S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13661; Cooper S, 2014, CELL REP, V7, P1456, DOI 10.1016/j.celrep.2014.04.012; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Dickson BC, 2018, GENE CHROMOSOME CANC, V57, P598, DOI 10.1002/gcc.22649; Dobashi A, 2016, GENE CHROMOSOME CANC, V55, P460, DOI 10.1002/gcc.22348; Foley C, 2016, HORM CANCER-US, V7, P84, DOI 10.1007/s12672-015-0239-9; Fursova NA, 2019, MOL CELL, V74, P1020, DOI 10.1016/j.molcel.2019.03.024; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Ghetu AF, 2008, MOL CELL, V29, P384, DOI 10.1016/j.molcel.2007.12.026; Granadino-Roldan JM, 2014, J MOL GRAPH MODEL, V50, P142, DOI 10.1016/j.jmgm.2014.04.003; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Han SJ, 2016, MOL PHARMACOL, V89, P14, DOI 10.1124/mol.115.100925; Hatzi K, 2013, CELL REP, V4, P578, DOI 10.1016/j.celrep.2013.06.016; Heemers HV, 2010, PROSTATE, V70, P959, DOI 10.1002/pros.21130; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Helsen C, 2014, ENDOCR-RELAT CANCER, V21, pT105, DOI 10.1530/ERC-13-0545; Hilton E, 2009, EUR J HUM GENET, V17, P1325, DOI 10.1038/ejhg.2009.52; Hsiao JJ, 2016, J BIOL CHEM, V291, P18818, DOI 10.1074/jbc.M116.732313; Hsiao JJ, 2015, MOL ENDOCRINOL, V29, P1195, DOI 10.1210/me.2015-1021; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huynh KD, 2000, GENE DEV, V14, P1810; Javed S, 2014, BJU INT, V113, P535, DOI 10.1111/bju.12269; Junco SE, 2013, STRUCTURE, V21, P665, DOI 10.1016/j.str.2013.02.013; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kelly MJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09250-6; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Lempiainen JK, 2017, MOL CELL PROTEOMICS, V16, P1462, DOI 10.1074/mcp.M117.067488; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Linke T, 2011, METHODS MOL BIOL, V776, P225, DOI 10.1007/978-1-61779-243-4_14; Liu QP, 2019, INT J CANCER, V145, P415, DOI 10.1002/ijc.32118; Liu S, 2017, ELIFE, V6, DOI 10.7554/eLife.28482.001; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Malinen M, 2017, NUCLEIC ACIDS RES, V45, P619, DOI 10.1093/nar/gkw855; Manjur ABMK, 2019, J STEROID BIOCHEM, V192, DOI 10.1016/j.jsbmb.2019.105382; Meier K, 2014, EPIGENETICS-US, V9, P1485, DOI 10.4161/15592294.2014.971580; Millard CJ, 2013, J MOL ENDOCRINOL, V51, pT23, DOI 10.1530/JME-13-0227; Miller GJ, 2003, CANCER RES, V63, P5879; Minner S, 2019, PROSTATE, V79, P302, DOI 10.1002/pros.23736; Mostaghel EA, 2014, CLIN CANCER RES, V20, P791, DOI 10.1158/1078-0432.CCR-12-3601; Ng D, 2004, NAT GENET, V36, P411, DOI 10.1038/ng1321; Oliviero G, 2015, SCI REP-UK, V5, DOI 10.1038/srep18388; Panagopoulos I, 2013, GENE CHROMOSOME CANC, V52, P733, DOI 10.1002/gcc.22068; Pretorius E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159867; Reiter F, 2017, CURR OPIN GENET DEV, V43, P73, DOI 10.1016/j.gde.2016.12.007; Ren CY, 2016, ACS MED CHEM LETT, V7, P601, DOI 10.1021/acsmedchemlett.6b00042; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Rytinki MM, 2011, METHODS MOL BIOL, V776, P183, DOI 10.1007/978-1-61779-243-4_12; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schuettengruber B, 2017, CELL, V171, P34, DOI 10.1016/j.cell.2017.08.002; Shah N, 2017, ELIFE, V6, DOI 10.7554/eLife.27861; Skowron KJ, 2019, MOL CELL ENDOCRINOL, V493, DOI 10.1016/j.mce.2019.110471; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Stelloo S, 2018, ONCOGENE, V37, P313, DOI 10.1038/onc.2017.330; Su WJ, 2019, CANCER CELL, V36, P139, DOI 10.1016/j.ccell.2019.06.009; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; Tiberi L, 2014, CANCER CELL, V26, P797, DOI 10.1016/j.ccell.2014.10.021; Tilki D, 2016, EUR UROL FOCUS, V2, P499, DOI 10.1016/j.euf.2016.11.013; Toropainen S, 2016, SCI REP-UK, V6, DOI 10.1038/srep33510; Toropainen S, 2015, NUCLEIC ACIDS RES, V43, P848, DOI 10.1093/nar/gku1375; van den Boom V, 2016, CELL REP, V14, P332, DOI 10.1016/j.celrep.2015.12.034; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang Z, 2018, CELL STEM CELL, V22, P235, DOI 10.1016/j.stem.2017.12.002; Wei M, 2017, ONCOTARGET, V8, P5323, DOI 10.18632/oncotarget.14142; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yamamoto Y, 2014, MOL CANCER RES, V12, P479, DOI 10.1158/1541-7786.MCR-13-0596; Yamamoto Y, 2010, BLOOD, V116, P4274, DOI 10.1182/blood-2010-01-264432; Yao JQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46064-4; Zhang X, 2016, ONCOL REP, V36, P2349, DOI 10.3892/or.2016.5018; Zhu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02863-3	88	6	6	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2391	2407		10.1038/s41388-020-1153-3	http://dx.doi.org/10.1038/s41388-020-1153-3		JAN 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31925334				2022-12-17	WOS:000508151400001
J	Pinto, I; Duque, M; Goncalves, J; Akkapeddi, P; Oliveira, ML; Cabrita, R; Yunes, JA; Durum, SK; Barata, JT; Fragoso, R				Pinto, Ines; Duque, Mafalda; Goncalves, Joana; Akkapeddi, Padma; Oliveira, Mariana L.; Cabrita, Rita; Yunes, J. Andres; Durum, Scott K.; Barata, Joao T.; Fragoso, Rita			NRARP displays either pro- or anti-tumoral roles in T-cell acute lymphoblastic leukemia depending on Notch and Wnt signaling	ONCOGENE			English	Article							ANKYRIN-REPEAT PROTEIN; ENHANCER FACTOR-I; ACTIVATING MUTATIONS; DIFFERENTIATION; NOTCH1/NICD; INHIBITOR; ISOFORM; ENCODES; LEF1	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis in patients with resistant or relapsed disease. Although NOTCH is a known driver in T-ALL, its clinical inhibition has significant limitations. Our previous studies suggested that NRARP, a negative regulator of Notch signaling, could have a suppressive role in T-ALL. Here, we report that NRARP levels are significantly increased in primary T-ALL cells suggesting that NRARP is not sufficient to block NOTCH oncogenic signals. Interestingly, although NRARP overexpression blocks NOTCH1 signaling and delays the proliferation of T-ALL cells that display high levels of Notch1 signaling, it promotes the expansion of T-ALL cells with lower levels of Notch1 activity. We found that NRARP interacts with lymphoid enhancer-binding factor 1 (LEF1) and potentiates Wnt signaling in T-ALL cells with low levels of Notch. Together these results indicate that NRARP plays a dual role in T-ALL pathogenesis, regulating both Notch and Wnt pathways, with opposite functional effects depending on Notch activity. Consistent with this hypothesis, mice transplanted with T-cells co-expressing NOTCH1 and NRARP develop leukemia later than mice transplanted with T-NOTCH1 cells. Importantly, mice transplanted with T-cells overexpressing NRARP alone developed leukemia with similar kinetics to those transplanted with T-NOTCH1 cells. Our findings uncover a role for NRARP in T-ALL pathogenesis and indicate that Notch inhibition may be detrimental for patients with low levels of Notch signaling, which would likely benefit from the use of Wnt signaling inhibitors. Importantly, our findings may extend to other cancers where Notch and Wnt play a role.	[Pinto, Ines; Duque, Mafalda; Goncalves, Joana; Akkapeddi, Padma; Oliveira, Mariana L.; Cabrita, Rita; Barata, Joao T.; Fragoso, Rita] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal; [Yunes, J. Andres] Ctr Infantil Boldrini, Campinas, SP, Brazil; [Yunes, J. Andres] Univ Estadual Campinas, Fac Med Sci, Dept Med Genet, Campinas, SP, Brazil; [Durum, Scott K.] NCI, Canc & Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA	Universidade de Lisboa; Universidade Estadual de Campinas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fragoso, R (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal.	arfragoso@medicina.ulisboa.pt	Pinto, Inês/GVT-4690-2022; Fragoso, Rita/ABH-3528-2020; Gonçalves, Joana/AAL-5516-2020; Fragoso, Rita/O-7164-2019; Akkapeddi, Ph.D., Padma/AAX-9406-2021; Barata, Joao/D-9181-2015	Fragoso, Rita/0000-0002-9206-1964; durum, scott/0000-0003-1307-9582; Yunes, Jose Andres/0000-0002-1316-3525; Barata, Joao/0000-0002-4826-8976; dos Santos Dias Duque, Mafalda/0000-0002-1459-161X; Oliveira, Mariana/0000-0001-8669-7627; Goncalves, Joana/0000-0003-1997-9514	Fundacao para a Ciencia e a Tecnologia (FCT) [IF/00788/2013]; European Research Council [ERC CoG-648455]; Marie Curie Protein Conjugates ITN; FCT [PD/BD/114102/2015]; Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado [UID/BIM/50005/2019]	Fundacao para a Ciencia e a Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); European Research Council(European Research Council (ERC)European Commission); Marie Curie Protein Conjugates ITN; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado	The authors thank the members of the JBarata laboratory for comments and discussions, and Sergio Almeida e Joao Sabino for the valuable help with PLA assays. The authors especially thank the generosity of patients and their families for providing primary samples, and the health care professionals (Service directors, physicians, and nurses) from IPO Lisboa and Centro Infantil Boldrini involved in the collection of those samples. This work was supported by the grant IF/00788/2013 from Fundacao para a Ciencia e a Tecnologia (FCT) awarded to RF and by the consolidator grant ERC CoG-648455 from the European Research Council awarded to JTB. PA is a Marie Curie ITN PhD student, supported by Marie Curie Protein Conjugates ITNand. MLO is a LisbonBioMed student supported by an FCT PhD fellowship (PD/BD/114102/2015). RF and JTB are FCT starting and consolidator investigators, respectively. Publication costs of this work were supported by UID/BIM/50005/2019, project funded by Fundacao para a Ciencia e a Tecnologia (FCT)/Ministerio da Ciencia, Tecnologia e Ensino Superior (MCTES) through Fundos do Orcamento de Estado.	Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252; Arensman MD, 2014, MOL CANCER THER, V13, P2303, DOI 10.1158/1535-7163.MCT-13-1005; Bernasconi-Elias P, 2016, ONCOGENE, V35, P6077, DOI 10.1038/onc.2016.133; Correia NC, 2016, SCI REP-UK, V6, DOI 10.1038/srep31894; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Fragoso R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002855; Fullmer Amber, 2009, Curr Hematol Malig Rep, V4, P148, DOI 10.1007/s11899-009-0021-6; Guo X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125429; Gutierrez A, 2010, BLOOD, V115, P2845, DOI 10.1182/blood-2009-07-234377; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Ishitani T, 2005, NAT CELL BIOL, V7, P1106, DOI 10.1038/ncb1311; Jin YH, 2009, MOL CELLS, V27, P15, DOI 10.1007/s10059-009-0001-7; Jin YH, 2009, BBA-MOL CELL RES, V1793, P290, DOI 10.1016/j.bbamcr.2008.10.002; Kobielak A, 2001, ACTA BIOCHIM POL, V48, P221; Krebs LT, 2001, DEV BIOL, V238, P110, DOI 10.1006/dbio.2001.0408; Kwon C, 2011, NAT CELL BIOL, V13, P1244, DOI 10.1038/ncb2313; Lahaye K, 2002, MECH DEVELOP, V110, P113, DOI 10.1016/S0925-4773(01)00570-6; Lamar E, 2001, GENE DEV, V15, P1885, DOI 10.1101/gad.908101; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Papayannidis C, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.80; Phng LK, 2009, DEV CELL, V16, P70, DOI 10.1016/j.devcel.2008.12.009; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Roti G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00170; Shang S, 2017, ONCOTARGET, V8, P33972, DOI 10.18632/oncotarget.15687; Silva A, 2010, HAEMATOL-HEMATOL J, V95, P674, DOI 10.3324/haematol.2009.011999; Smith Malcolm A, 2009, Curr Hematol Malig Rep, V4, P175, DOI 10.1007/s11899-009-0024-3; Spaulding C, 2007, BLOOD, V110, P2650, DOI 10.1182/blood-2007-04-084202; Squiban B, 2017, LEUKEMIA LYMPHOMA, V58, P2728, DOI 10.1080/10428194.2017.1300896; Van de Walle I, 2009, BLOOD, V113, P2988, DOI 10.1182/blood-2008-06-164871; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Wang WB, 2005, ACTA BIOCH BIOPH SIN, V37, P173, DOI 10.1111/j.1745-7270.2005.00023.x; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yun TJ, 2003, J IMMUNOL, V170, P5834, DOI 10.4049/jimmunol.170.12.5834; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924	35	6	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					975	986		10.1038/s41388-019-1042-9	http://dx.doi.org/10.1038/s41388-019-1042-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31586130	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000511209700002
J	Buffiere, A; Uzan, B; Aucagne, R; Hermetet, F; Mas, M; Nassurdine, S; Aznague, A; Carmignac, V; Tournier, B; Bouchot, O; Ballerini, P; Barata, JT; Bastie, JN; Delva, L; Pflumio, F; Quere, R				Buffiere, Anne; Uzan, Benjamin; Aucagne, Romain; Hermetet, Francois; Mas, Manon; Nassurdine, Sandra; Aznague, Aziza; Carmignac, Virginie; Tournier, Benjamin; Bouchot, Olivier; Ballerini, Paola; Barata, Joao T.; Bastie, Jean-Noel; Delva, Laurent; Pflumio, Francoise; Quere, Ronan			T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7	ONCOGENE			English	Article							OF-FUNCTION MUTATIONS; IL-7; PROGRESSION; ACTIVATION; SURVIVAL; ISLANDS; GROWTH; IL7R	T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy characterized by an accumulation of immature T cells. Although patient outcomes have improved, novel targeted therapies are needed to reduce the intensity of chemotherapy and improve the prognosis of high-risk patients. Interleukin-7 (IL-7) modulates the survival and proliferation of normal and malignant T cells. Targeting the IL-7 signaling pathway is thus a potentially effective therapeutic strategy. To achieve such aim, it is essential to first understand how the IL-7 signaling pathway is activated. Although IL-7 production has been observed from multiple stromal tissues, T-ALL autocrine IL-7 secretion has not yet been described. Interestingly, using T-ALL cell lines, primary and patient-derived xenotransplanted (PDX) T-ALL cells, we demonstrate that T-ALL cells produce IL-7 whereas normal T cells do not. Finally, using knock down of IL7 gene in T-ALL cells, we describe to what extent IL-7 autocrine secretion is involved in the T-ALL cells propagation in bone marrow and how it affects the number of leukemia-initiating cells in PDX mice. Together, these results demonstrate how the autocrine production of the IL-7 cytokine mediated by T-ALL cells can be involved in the oncogenic development of T-ALL and offer novel insights into T-ALL spreading.	[Buffiere, Anne; Aucagne, Romain; Hermetet, Francois; Mas, Manon; Nassurdine, Sandra; Aznague, Aziza; Carmignac, Virginie; Bastie, Jean-Noel; Delva, Laurent; Quere, Ronan] Univ Bourgogne Franche Comte, Inserm, UMR1231, Dijon, France; [Buffiere, Anne; Aucagne, Romain; Hermetet, Francois; Aznague, Aziza; Bastie, Jean-Noel; Delva, Laurent; Quere, Ronan] LipSTIC Lab, Dijon, France; [Uzan, Benjamin; Pflumio, Francoise] Univ Paris 11, Univ Paris 7, CEA, Inserm,UMR967, Fontenay Aux Roses, France; [Uzan, Benjamin; Pflumio, Francoise] CEA, IRCM, LSHL, Fontenay Aux Roses, France; [Tournier, Benjamin] Hop Univ Francois Mitterrand, Serv Genet Canc, Dijon, France; [Bouchot, Olivier] Hop Univ Francois Mitterrand, Chirurg Cardiovasc, Dijon, France; [Ballerini, Paola] Hop Trousseau, AP HP, Lab Hematol, Paris, France; [Barata, Joao T.] Univ Lisbon, Fac Med, Inst Med Mol, Lisbon, Portugal; [Bastie, Jean-Noel] Hop Univ Francois Mitterrand, Serv Hematol Clin, Dijon, France; [Bastie, Jean-Noel] Hop Univ Francois Mitterrand, CRB Ferdinand Cabanne, BB 0033-00044, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU Dijon Bourgogne; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Universidade de Lisboa; CHU Dijon Bourgogne; CHU Dijon Bourgogne	Quere, R (corresponding author), Univ Bourgogne Franche Comte, Inserm, UMR1231, Dijon, France.; Quere, R (corresponding author), LipSTIC Lab, Dijon, France.	ronan.quere@inserm.fr	Hermetet, François/GPF-8614-2022; Quere, Ronan/C-6178-2017	Tournier, Benjamin/0000-0001-6609-8096; DELVA, Laurent/0000-0002-1086-3964; Hermetet, Francois/0000-0001-5549-1992; Pflumio, Francoise/0000-0001-8995-596X; Quere, Ronan/0000-0002-1615-6769; Aucagne, Romain/0000-0002-5644-3287	Association Laurette Fugain; Conference de Coordination Interregionale du Grand Est - Bourgogne Franche-Comte (CCIRGE-BFC) de la Ligue contre le Cancer; National Research Agency under the program "Investissements d'Avenir" [ANR-11-LABX-0021]; (LipSTIC Labex); Conseil Regional de Bourgogne through the plan d'action regional pour l'innovation (PARI); European Union through the PO FEDER-FSE Bourgogne; French Ministere de la Recherche et de l'Enseignement Superieur (MRES); Ligue contre le Cancer; INSERM; Universite Paris Diderot	Association Laurette Fugain; Conference de Coordination Interregionale du Grand Est - Bourgogne Franche-Comte (CCIRGE-BFC) de la Ligue contre le Cancer; National Research Agency under the program "Investissements d'Avenir"(French National Research Agency (ANR)); (LipSTIC Labex); Conseil Regional de Bourgogne through the plan d'action regional pour l'innovation (PARI); European Union through the PO FEDER-FSE Bourgogne; French Ministere de la Recherche et de l'Enseignement Superieur (MRES); Ligue contre le Cancer(Ligue nationale contre le cancer); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris Diderot	The authors express their gratitude to the animal housing facility and cytometry platform staff at the University of Burgundy (Dijon, France), especially Valerie Saint-Giorgio, David Lheraud, Sebastien Lapipe, Anabelle Sequeira, and Serge Monier, for their excellent suggestions and valuable technical support. The authors also thank Julien Guy for providing information on T-ALL immune data that helped in the EGIL characterization, as well as Antonio Vitobello for providing insight about DNA methylation. The authors are also grateful to Suzanne Rankin (CHU Dijon) for editing and proofreading this paper. This study was supported by grants from the Association Laurette Fugain (RQ), the Conference de Coordination Interregionale du Grand Est - Bourgogne Franche-Comte (CCIRGE-BFC) de la Ligue contre le Cancer (RQ), by the National Research Agency under the program "Investissements d'Avenir" (reference ANR-11-LABX-0021, LipSTIC Labex), by the Conseil Regional de Bourgogne through the plan d'action regional pour l'innovation (PARI), and the European Union through the PO FEDER-FSE Bourgogne 2014/2020 programs. AB was supported by fellowships from the French Ministere de la Recherche et de l'Enseignement Superieur (MRES) and the Ligue contre le Cancer. FP and BU have grants from LNCC, INSERM, CEA, and Universite Paris Diderot.	Alves NL, 2009, P NATL ACAD SCI USA, V106, P1512, DOI 10.1073/pnas.0809559106; Barata JT, 2006, EXP HEMATOL, V34, P1133, DOI 10.1016/j.exphem.2006.05.001; Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Black KL, 2018, NUCLEIC ACIDS RES, V46, P11357, DOI 10.1093/nar/gky946; Buffiere A, 2018, LEUKEMIA, V32, P2062, DOI 10.1038/s41375-018-0081-5; Cai YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058647; Cramer SD, 2016, BLOOD, V128, P473, DOI 10.1182/blood-2016-03-679209; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Freyer DR, 2011, BLOOD, V117, P3010, DOI 10.1182/blood-2010-07-294678; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; FUNK PE, 1995, BLOOD, V86, P2661; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972; Jacobs SR, 2010, J IMMUNOL, V184, P3461, DOI 10.4049/jimmunol.0902593; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Karawajew L, 2000, BLOOD, V96, P297, DOI 10.1182/blood.V96.1.297.013k24_297_306; Laouar Y, 2004, BLOOD, V103, P1985, DOI 10.1182/blood-2003-06-2126; Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909; Marks DI, 2009, BLOOD, V114, P5136, DOI 10.1182/blood-2009-08-231217; Oosterwegel MA, 1997, IMMUNITY, V6, P351, DOI 10.1016/S1074-7613(00)80337-4; Oshima S, 2004, MOL CELL BIOL, V24, P6298, DOI 10.1128/MCB.24.14.6298-6310.2004; Poglio S, 2015, LEUKEMIA, V29, P977, DOI 10.1038/leu.2014.317; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Richter-Pechanska P, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809443; Scupoli MT, 2007, HAEMATOLOGICA, V92, P264, DOI 10.3324/haematol.10356; Scupoli MT, 2003, HAEMATOLOGICA, V88, P1229; Shochat C, 2011, J EXP MED, V208, P901, DOI 10.1084/jem.20110580; Silva A, 2011, CANCER RES, V71, P4780, DOI 10.1158/0008-5472.CAN-10-3606; Thomas X, 2004, J CLIN ONCOL, V22, P4075, DOI 10.1200/JCO.2004.10.050; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Zenatti PP, 2011, NAT GENET, V43, P932, DOI 10.1038/ng.924	32	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7357	7365		10.1038/s41388-019-0921-4	http://dx.doi.org/10.1038/s41388-019-0921-4			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417180				2022-12-17	WOS:000499631000006
J	Salama, MF; Liu, ML; Clarke, CJ; Espaillat, MP; Haley, JD; Jin, T; Wang, DF; Obeid, LM; Hannun, YA				Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Haley, John D.; Jin, Ting; Wang, Daifeng; Obeid, Lina M.; Hannun, Yusuf A.			PKC alpha is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation	ONCOGENE			English	Article							PROTEIN-KINASE-C; AKT PHOSPHORYLATION; TUMOR-FORMATION; CANCER; SUPPRESSES; RESISTANCE; EXPRESSION; SEQUESTRATION; ENZASTAURIN; MIGRATION	Mutational activation of the epidermal growth factor receptor (EGFR) is a major player in the pathogenesis of non-small cell lung cancer (NSCLC). NSCLC patients with constitutively active EGFR mutations eventually develop drug resistance against EGFR tyrosine-kinase inhibitors; therefore, better understandings of key components of mutant EGFR (mtEGFR) signaling are required. Here, we initially observed aberrantly high expression of protein kinase C alpha (PKC alpha) in lung adenocarcinomas, especially those with EGFR mutations, and proceeded to examine the role of PKC alpha in the regulation of the signaling pathways downstream of mtEGFR. The results showed that NSCLC cell lines with constitutively active EGFR mutations tend to have very or moderately high PKC alpha levels. Furthermore, PKC alpha was constitutively activated in HCC827 and H4006 cells which have an EGFR deletion mutation in exon 19. Interestingly, mtEGFR was not required for the induction of PKC alpha at protein and message levels suggesting that the increased levels of PKC alpha are due to independent selection. On the other hand, mtEGFR activity was required for robust activation of PKC alpha. Loss of functions studies revealed that the NSCLC cells rely heavily on PKC alpha for the activation of the mTORC1 signaling pathway. Unexpectedly, the results demonstrated that PKC alpha was required for activation of Akt upstream of mTOR but only in cells with the mtEGFR and with the increased expression of PKC alpha. Functionally, inhibition of PKC alpha in HCC827 led to caspase-3-dependent apoptosis and a significant decrease in cell survival in response to cellular stress induced by serum starvation. In summary, the results identified important roles of PKC alpha in regulating mTORC1 activity in lung cancer cells, whereby a primary switching occurs from PKC alpha-independent to PKC alpha-dependent signaling in the presence of EGFR mutations. The results present PKC alpha as a potential synergistic target of personalized treatment for NSCLC with constitutively active mutant forms of EGFR and constitutively active PKC alpha.	[Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Obeid, Lina M.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; [Salama, Mohamed F.; Liu, Mengling; Clarke, Christopher J.; Espaillat, Mel Pilar; Obeid, Lina M.; Hannun, Yusuf A.] Stony Brook Univ Hosp, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA; [Salama, Mohamed F.] Mansoura Univ, Dept Biochem, Fac Vet Med, Mansoura, Egypt; [Liu, Mengling] HD Biosci Inc, Dept Immunooncol, San Diego, CA 92121 USA; [Haley, John D.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA; [Haley, John D.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; [Jin, Ting; Wang, Daifeng] SUNY Stony Brook, Dept Biomed Informat, Stony Brook, NY 11794 USA; [Wang, Daifeng] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA; [Wang, Daifeng] Univ Wisconsin, Waisman Ctr, Madison, WI 53792 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Egyptian Knowledge Bank (EKB); Mansoura University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hannun, YA (corresponding author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), Stony Brook Univ Hosp, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Biochem, Stony Brook, NY 11794 USA.; Hannun, YA (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	yusuf.hannun@stonybrookmedicine.edu	Salama, Mohamed/S-3493-2019; Salama, Mohamed F/C-9010-2017	Salama, Mohamed/0000-0002-0002-9108; Salama, Mohamed F/0000-0002-0002-9108; obeid, lina/0000-0002-0734-0847	NCI [CA97132]; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI grant CA97132.	Abera MB, 2015, MOL PHARMACOL, V87, P832, DOI 10.1124/mol.115.097725; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Antonicelli A, 2013, INT J MED SCI, V10, P320, DOI 10.7150/ijms.4609; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Cheng CY, 2009, J CELL PHYSIOL, V219, P183, DOI 10.1002/jcp.21669; Cooper WA, 2013, J THORAC DIS, V5, pS479, DOI 10.3978/j.issn.2072-1439.2013.08.03; El Osta M, 2014, FASEB J, V28, P495, DOI 10.1096/fj.13-230557; Fan Q. W., 2009, SCI SIGNAL, V2, pra4, DOI DOI 10.1126/SCISIGNAL.2000014; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gallay N, 2009, LEUKEMIA, V23, P1029, DOI 10.1038/leu.2008.395; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gupta AK, 1996, CELL PROLIFERAT, V29, P655, DOI 10.1111/j.1365-2184.1996.tb00979.x; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Idkowiak-Baldys J, 2006, J BIOL CHEM, V281, P22321, DOI 10.1074/jbc.M512540200; Idkowiak-Baldys J, 2009, J BIOL CHEM, V284, P22322, DOI 10.1074/jbc.M109.026765; Jiang XH, 2004, CANCER RES, V64, P5787, DOI 10.1158/0008-5472.CAN-03-1172; Jin G, 2010, LUNG CANCER, V69, P279, DOI 10.1016/j.lungcan.2009.11.012; Kanne JP, 2014, AM J ROENTGENOL, V202, P530, DOI 10.2214/AJR.13.11540; Kim S, 2012, J SURG RES, V176, pE21, DOI 10.1016/j.jss.2011.11.1041; Kong CZ, 2005, UROLOGY, V65, P1228, DOI 10.1016/j.urology.2005.01.007; Lahn Michael, 2004, Clin Lung Cancer, V6, P184, DOI 10.3816/CLC.2004.n.032; LaPorta CAM, 1997, CARCINOGENESIS, V18, P715, DOI 10.1093/carcin/18.4.715; Liu ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080721; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; O'Neill AK, 2011, J BIOL CHEM, V286, P43559, DOI 10.1074/jbc.M111.294603; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Pulkoski-Gross MJ, 2018, J LIPID RES, V59, P462, DOI 10.1194/jlr.M081307; REISSMANN PT, 1993, ONCOGENE, V8, P1913; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shames DS, 2014, J PATHOL, V232, P121, DOI 10.1002/path.4275; Singhal SS, 2005, FEBS LETT, V579, P4635, DOI 10.1016/j.febslet.2005.07.032; Smith SD, 2012, J BIOL CHEM, V287, P29336, DOI 10.1074/jbc.M112.341917; Song XL, 2015, CANCER RES, V75, P1035, DOI 10.1158/0008-5472.CAN-13-1625; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007; Steins M, 2014, RECENT RESULTS CANC, V201, P109, DOI 10.1007/978-3-642-54490-3_6; Tsurutani J, 2006, J CLIN ONCOL, V24, P306, DOI 10.1200/JCO.2005.02.4133; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vansteenkiste J, 2012, ONCOLOGY-BASEL, V82, P25, DOI 10.1159/000335268; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; Wang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073985; Willey CD, 2010, INT J RADIAT ONCOL, V77, P1518, DOI 10.1016/j.ijrobp.2009.06.044	52	6	6	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7311	7328		10.1038/s41388-019-0950-z	http://dx.doi.org/10.1038/s41388-019-0950-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31420605	Green Accepted			2022-12-17	WOS:000499631000003
J	Zhang, YH; Feng, XL; Zhang, J; Chen, MY; Huang, E; Chen, XB				Zhang, Yanhong; Feng, Xiuli; Zhang, Jin; Chen, Minyi; Huang, Eric; Chen, Xinbin			Iron regulatory protein 2 is a suppressor of mutant p53 in tumorigenesis	ONCOGENE			English	Article							FERREDOXIN REDUCTASE; MITOCHONDRIAL FERREDOXIN; BINDING PROTEIN; MOUSE MODELS; CELL-GROWTH; CANCER; GAIN; MUTATION; GENE; FERROPTOSIS	p53 is known to play a role in iron homeostasis and is required for FDXR-mediated iron metabolism via iron regulatory protein 2 (IRP2). Interestingly, p53 is frequently mutated in tumors wherein iron is often accumulated, suggesting that mutant p53 may exert its gain of function by altering iron metabolism. In this study, we found that FDXR deficiency decreased mutant p53 expression along with altered iron metabolism in p53(R270H)(/-) MEFs and cancer cells carrying mutant p53. Consistently, we found that decreased expression of mutant p53 by FDXR deficiency inhibited mutant p53-R270H to induce carcinoma and high grade pleomorphic sarcoma in FDXR+/-; p53(R270H)(/-) mice as compared with p53(R270H)(/-) mice. Moreover, we found that like its effect on wild-type p53, loss of IRP2 increased mutant p53 expression. However, unlike its effect to suppress cell growth in cells carrying wild-type p53, loss of IRP2 promoted cell growth in cancer cells expressing mutant p53. Finally, we found that ectopic expression of IRP2 suppressed cell growth in a mutant p53-dependent manner. Together, our data indicate that mutant p53 gain-of-function can be suppressed by IRP2 and FDXR deficiency, both of which may be explored to target tumors carrying mutant p53.	[Zhang, Yanhong; Feng, Xiuli; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Zhang, Yanhong; Feng, Xiuli; Zhang, Jin; Chen, Xinbin] Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA; [Feng, Xiuli] Nanjing Agr Univ, Coll Vet Med, Nanjing 210095, Jiangsu, Peoples R China; [Chen, Minyi] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Huang, Eric] Univ Washington, Dept Pathol, Seattle, WA 98104 USA	University of California System; University of California Davis; University of California System; University of California Davis; Nanjing Agricultural University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Washington; University of Washington Seattle	Chen, XB (corresponding author), Univ Calif Davis, Sch Med, Comparat Oncol Lab, Davis, CA 95616 USA.; Chen, XB (corresponding author), Univ Calif Davis, Sch Vet Med, Comparat Oncol Lab, Davis, CA 95616 USA.	xbchen@ucdavis.edu		chen, xinbin/0000-0002-4582-6506	National Institutes of Health [CA224433-01]; NATIONAL CANCER INSTITUTE [R01CA224433] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health grants CA224433-01. The authors would like to thank Dr. Elizabeth Leibold and Dr. Kuanyu Li for their generous gifts of IRP2 antibodies.	Bertout JA, 2009, CANCER RES, V69, P3213, DOI 10.1158/0008-5472.CAN-08-4223; Beutler E, 2006, ANNU REV MED, V57, P331, DOI 10.1146/annurev.med.57.121304.131310; BRANDT ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P735, DOI 10.1016/0003-9861(92)90749-M; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Edmondson DA, 2016, RADIAT RES, V186, P235, DOI 10.1667/RR14263.1; Elbendary AA, 1996, CLIN CANCER RES, V2, P1571; Fonseca-Nunes A, 2014, CANCER EPIDEM BIOMAR, V23, P12, DOI 10.1158/1055-9965.EPI-13-0733; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Gunshin H, 2001, FEBS LETT, V509, P309, DOI 10.1016/S0014-5793(01)03189-1; GUO B, 1994, J BIOL CHEM, V269, P24252; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; HANN HWL, 1990, HEPATOLOGY, V11, P566, DOI 10.1002/hep.1840110407; Henderson ER, 1996, J BIOL CHEM, V271, P4900; Hentze MW, 2010, CELL, V142, P24, DOI 10.1016/j.cell.2010.06.028; HENTZE MW, 1989, NUCLEIC ACIDS RES, V17, P6103, DOI 10.1093/nar/17.15.6103; HERSHKO C, 1991, BLOOD, V77, P2049; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; Lacombe J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198851; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Lawen A, 2013, ANTIOXID REDOX SIGN, V18, P2473, DOI 10.1089/ars.2011.4271; Lee MK, 2012, CANCER CELL, V22, P751, DOI 10.1016/j.ccr.2012.10.022; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; O'Brien G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19043-w; Okumura H, 2015, ANTICANCER RES, V35, P6471; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Porter JB, 1996, BLOOD, V88, P705, DOI 10.1182/blood.V88.2.705.bloodjournal882705; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; Rouault TA, 2006, NAT CHEM BIOL, V2, P406, DOI 10.1038/nchembio807; Sauer L, 2010, ONCOGENE, V29, P2628, DOI 10.1038/onc.2010.24; Shaheen NJ, 2003, JNCI-J NATL CANCER I, V95, P154, DOI 10.1093/jnci/95.2.154; Sheftel AD, 2010, P NATL ACAD SCI USA, V107, P11775, DOI 10.1073/pnas.1004250107; Shi YB, 2012, BBA-MOL CELL RES, V1823, P484, DOI 10.1016/j.bbamcr.2011.11.002; Simcox JA, 2013, CELL METAB, V17, P329, DOI 10.1016/j.cmet.2013.02.007; Smith AG, 1995, TOXICOL LETT, V82-3, P945, DOI 10.1016/0378-4274(95)03530-3; Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495; Wang JA, 2011, BIOCHEM J, V434, P365, DOI 10.1042/BJ20101825; Xie YC, 2017, CELL REP, V20, P1692, DOI 10.1016/j.celrep.2017.07.055; Yan WS, 2010, J BIOL CHEM, V285, P14229, DOI 10.1074/jbc.M109.097253; Yang HJ, 2017, P NATL ACAD SCI USA, V114, P11500, DOI 10.1073/pnas.1711814114; Yu JS, 2003, CANCER RES, V63, P6170; Zhang F, 2008, J BIOL CHEM, V283, P33911, DOI 10.1074/jbc.M806432200; Zhang J, 2018, CANCER RES, V78, P1511, DOI 10.1158/0008-5472.CAN-17-2457; Zhang J, 2015, EMBO J, V34, P2953, DOI 10.15252/embj.201591437; Zhang YH, 2017, GENE DEV, V31, P1243, DOI 10.1101/gad.299388.117; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024	54	6	6	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6256	6269		10.1038/s41388-019-0876-5	http://dx.doi.org/10.1038/s41388-019-0876-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31332290	Green Accepted			2022-12-17	WOS:000483919400002
J	Noeparast, A; Giron, P; Noor, A; Shahi, RB; De Brakeleer, S; Eggermont, C; Vandenplas, H; Boeckx, B; Lambrechts, D; De Greve, J; Teugels, E				Noeparast, Amir; Giron, Philippe; Noor, Alfiah; Shahi, Rajendra Bahadur; De Brakeleer, Sylvia; Eggermont, Carolien; Vandenplas, Hugo; Boeckx, Bram; Lambrechts, Diether; De Greve, Jacques; Teugels, Erik			CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition	ONCOGENE			English	Article							DABRAFENIB PLUS TRAMETINIB; C-RAF; COMBINED BRAF; MAPK PATHWAY; B-RAF; KINASE; ACTIVATION; SORAFENIB; KRAS; PHOSPHORYLATION	Two out of 41 non-small cell lung cancer patients enrolled in a clinical study were found with a somatic CRAF mutation in their tumor, namely CRAF(P261A) and CRAF(P207S). To our knowledge, both mutations are novel in lung cancer and CRAF(P261A) has not been previously reported in cancer. Expression of CRAF(P261A) in HEK293T cells and BEAS-2B lung epithelial cells led to increased ERK pathway activation in a dimer-dependent manner, accompanied with loss of CRAF phosphorylation at the negative regulatory S259 residue. Moreover, stable expression of CRAF(P261A) in mouse embryonic fibroblasts and BEAS-2B cells led to anchorage-independent growth. Consistent with a previous report, we could not observe a gain-of-function with CRAF(P207S). Type II but not type I RAF inhibitors suppressed the CRAF(P261A)-induced ERK pathway activity in BEAS-2B cells, and combinatorial treatment with type II RAF inhibitors and a MEK inhibitor led to a stronger ERK pathway inhibition and growth arrest. Our findings suggest that the acquisition of a CRAF(P261A) mutation can provide oncogenic properties to cells, and that such cells are sensitive to combined MEK and type II RAF inhibitors. CRAF mutations should be diagnostically and therapeutically explored in lung and perhaps other cancers.	[Noeparast, Amir; Giron, Philippe; Noor, Alfiah; Shahi, Rajendra Bahadur; De Brakeleer, Sylvia; Eggermont, Carolien; Vandenplas, Hugo; De Greve, Jacques; Teugels, Erik] Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Lab Mol Oncol, Brussels, Belgium; [Noeparast, Amir; Giron, Philippe; Noor, Alfiah; Shahi, Rajendra Bahadur; De Brakeleer, Sylvia; Eggermont, Carolien; Vandenplas, Hugo; De Greve, Jacques; Teugels, Erik] Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Dept Med Oncol, Brussels, Belgium; [Boeckx, Bram; Lambrechts, Diether] VIB, Vesalius Res Ctr, B-3000 Leuven, Belgium; [Boeckx, Bram; Lambrechts, Diether] Katholieke Univ Leuven, Dept Oncol, Lab Translat Genet, B-3000 Louvain, Belgium	University Hospital Brussels; Vrije Universiteit Brussel; University Hospital Brussels; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); KU Leuven	Noeparast, A; De Greve, J; Teugels, E (corresponding author), Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Lab Mol Oncol, Brussels, Belgium.; Noeparast, A; De Greve, J; Teugels, E (corresponding author), Vrije Univ Brussel, UZ Brussel, Oncol Ctr, Dept Med Oncol, Brussels, Belgium.	amir.noeparast@vub.be; jacques.degreve@uzbrussel.be; eteugels@uzbrussel.be	Lambrechts, Diether/AAJ-3167-2020; , Noeparast/AAV-7252-2020; De Greve, Jacques/J-4939-2012	Lambrechts, Diether/0000-0002-3429-302X; , Noeparast/0000-0002-3216-5630; Shahi, Rajendra Bahadur/0000-0002-7751-6852; De Greve, Jacques/0000-0002-2389-0742; Eggermont, Carolien/0000-0001-6411-6422; Teugels, Erik/0000-0002-7828-4555; Giron, Philippe/0000-0002-1331-1890	Cancer Plan 29-39 Belgium; Wetenschappelijk Fonds Willy Gepts of the UZ Brussel; Interdisciplinary Research Program (IRP) Vrije Universiteit Brussel; Vrije Universiteit Brussel; Armand Everaert; Research Foundation-Flanders (FWO); Emmanuel van der Schueren research scholarship by Kom op Tegen Kanker	Cancer Plan 29-39 Belgium; Wetenschappelijk Fonds Willy Gepts of the UZ Brussel; Interdisciplinary Research Program (IRP) Vrije Universiteit Brussel; Vrije Universiteit Brussel; Armand Everaert; Research Foundation-Flanders (FWO)(FWO); Emmanuel van der Schueren research scholarship by Kom op Tegen Kanker	Grant Support The work was funded by the Cancer Plan 29-39 Belgium and by the Wetenschappelijk Fonds Willy Gepts of the UZ Brussel; Noeparast A. was funded by an Interdisciplinary Research Program (IRP) Vrije Universiteit Brussel. Noor A. is the beneficiary of Ph.D. Fellowship from Vrije Universiteit Brussel and was funded by Armand Everaert. Giron P. and Eggermont C. are the beneficiaries of a Ph.D. Fellowship from the Research Foundation-Flanders (FWO) and Emmanuel van der Schueren research scholarship by Kom op Tegen Kanker.	Antony R, 2013, CANCER RES, V73, P4840, DOI 10.1158/0008-5472.CAN-12-4089; Arnault JP, 2012, CLIN CANCER RES, V18, P263, DOI 10.1158/1078-0432.CCR-11-1344; Atefi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27454; Baik CS, 2017, ONCOLOGIST, V22, P786, DOI 10.1634/theoncologist.2016-0458; Chen YC, 2017, SCI REP-UK, V7, DOI 10.1038/srep44123; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dierks C, 2013, BLOOD, V122, P4121; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Emuss V, 2005, CANCER RES, V65, P9719, DOI 10.1158/0008-5472.CAN-05-1683; Fouladi F, 2015, LEUKEMIA LYMPHOMA, V56, P2690, DOI 10.3109/10428194.2014.1003055; Geissmann Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054072; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Holderfield M, 2014, BRIT J CANCER, V111, P640, DOI 10.1038/bjc.2014.139; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Imielinski M, 2014, J CLIN INVEST, V124, P1582, DOI 10.1172/JCI72763; Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535; Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79; King AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062613; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Li L, 2010, J CHROMATOGR B, V878, P3033, DOI 10.1016/j.jchromb.2010.08.049; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MOLNAR E, 2018, ONCOGENE, V18, DOI DOI 10.1186/S12885-018-4455-X; Molzan M, 2012, J MOL BIOL, V423, P486, DOI 10.1016/j.jmb.2012.08.009; Molzan M, 2010, MOL CELL BIOL, V30, P4698, DOI 10.1128/MCB.01636-09; Noeparast Amir, 2018, Oncotarget, V9, P16110, DOI 10.18632/oncotarget.24576; Noeparast A, 2017, ONCOTARGET, V8, P60094, DOI 10.18632/oncotarget.11635; Nussinov Ruth, 2018, Biophys Rev, V10, P1263, DOI 10.1007/s12551-018-0461-0; Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Rosell R, 2017, LANCET ONCOL, V18, P1286, DOI 10.1016/S1470-2045(17)30678-2; Shapira S, 2007, CELL DEATH DIFFER, V14, P895, DOI 10.1038/sj.cdd.4402057; Takezawa K, 2009, CANCER RES, V69, P6515, DOI 10.1158/0008-5472.CAN-09-1076; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vakana E, 2017, ONCOTARGET, V8, P9251, DOI 10.18632/oncotarget.14002; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Whittaker SR, 2015, MOL CANCER THER, V14, P2700, DOI 10.1158/1535-7163.MCT-15-0136-T; Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001; Zang MW, 2008, J BIOL CHEM, V283, P31429, DOI 10.1074/jbc.M802855200; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	55	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5933	5941		10.1038/s41388-019-0866-7	http://dx.doi.org/10.1038/s41388-019-0866-7			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31285551	hybrid, Green Published			2022-12-17	WOS:000482740000002
J	Chen, L; Zhang, S; Wu, J; Cui, J; Zhong, L; Zeng, L; Ge, S				Chen, L.; Zhang, S.; Wu, J.; Cui, J.; Zhong, L.; Zeng, L.; Ge, S.			RETRACTION: circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family (Retraction of Vol 36, Pg 4551, 2017)	ONCOGENE			English	Retraction									[Chen, L.; Zhang, S.; Zhong, L.; Zeng, L.; Ge, S.] Cent South Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China; [Wu, J.] Peoples Hosp New Dist Longhua Shenzhen, Dept Stomatol, Shenzhen, Peoples R China; [Cui, J.] Sichuan Univ, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China	Central South University; Sichuan University	Chen, L (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China.	drlc2011@163.com						Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89	1	6	6	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2019	38	28					5750	5750		10.1038/s41388-019-0828-0	http://dx.doi.org/10.1038/s41388-019-0828-0			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IH9RW	31197212	hybrid, Green Published			2022-12-17	WOS:000474845100021
J	Sun, Y; Ding, YY; Guo, C; Liu, CM; Ma, P; Ma, S; Wang, Z; Liu, J; Qian, T; Ma, LY; Deng, Y; Wu, CY				Sun, Ying; Ding, Yanyan; Guo, Chen; Liu, Chengmin; Ma, Ping; Ma, Shuang; Wang, Zhe; Liu, Jie; Qian, Tao; Ma, Luyao; Deng, Yi; Wu, Chuanyue			alpha-Parvin promotes breast cancer progression and metastasis through interaction with G3BP2 and regulation of TWIST1 signaling	ONCOGENE			English	Article							INTEGRIN-LINKED KINASE; FOCAL ADHESION PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; CH-ILKBP; TUMOR-METASTASIS; CELL-SURVIVAL; MATRIX; PHOSPHORYLATION; ACTOPAXIN; INVASION	Identification of molecular alterations driving breast cancer progression is critical for the development of effective therapy. In this study, we show that the level of alpha-parvin is elevated in triple-negative breast cancer cells. The depletion of alpha-parvin from triple-negative breast cancer cells effectively inhibits breast cancer cell growth, migration, and invasion in vitro, and tumor progression and metastasis in vivo. At the molecular level, we identify Ras-GTPase-activing protein SH3-domain-binding protein 2 (G3BP2) as an alpha-parvin-binding protein. Knockdown of alpha-parvin promotes G3BP2 interaction with TWIST1, increases ubiquitination and proteasome-dependent degradation of TWIST1, and consequently reduces the cellular level of TWIST1 and its downstream signaling. Importantly, the depletion of G3BP2 reverses the reduction in the level and signaling of TWIST1 and the suppression of breast cancer progression induced by the loss of alpha-parvin. Furthermore, the reexpression of an alpha-parvin mutant in which the G3BP2-binding site is ablated, unlike that of wild-type alpha-parvin, in alpha-parvin-deficient breast cancer cells, is unable to restore the level and signaling of TWIST1 and promote breast cancer progression. Finally, we show that protein level of alpha-parvin is highly positively correlated with that of TWIST1 in human triple-negative breast cancer patients. Our studies reveal a novel signaling pathway consisting of alpha-parvin, G3BP2, and TWIST1 that regulates breast cancer progression and metastasis, and suggest that the activation of this signaling pathway is a key factor for driving the progression and poor clinical outcome of human ER-negative breast cancer.	[Sun, Ying; Ding, Yanyan; Guo, Chen; Liu, Chengmin; Ma, Ping; Ma, Shuang; Wang, Zhe; Liu, Jie; Qian, Tao; Ma, Luyao; Deng, Yi] Southern Univ Sci & Technol, Dept Biol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Peoples R China; [Sun, Ying; Ding, Yanyan; Guo, Chen; Liu, Chengmin; Ma, Ping; Ma, Shuang; Wang, Zhe; Liu, Jie; Qian, Tao; Ma, Luyao; Deng, Yi] Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China; [Wu, Chuanyue] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Wu, Chuanyue] Univ Pittsburgh, Canc Inst, Pittsburgh, PA 15260 USA	Southern University of Science & Technology; Southern University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, Y (corresponding author), Southern Univ Sci & Technol, Dept Biol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Peoples R China.; Sun, Y (corresponding author), Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China.; Wu, CY (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA.; Wu, CY (corresponding author), Univ Pittsburgh, Canc Inst, Pittsburgh, PA 15260 USA.	suny@sustc.edu.cn; carywu@pitt.edu	Sun, Ying/F-9124-2019; MA, ShuangYue/GWV-0339-2022; Liu, Chengmin/GRO-0365-2022	Deng, Yi/0000-0003-1378-015X; Liu, Chengmin/0000-0002-0882-582X	Chinese Ministry of Science and Technology [2016YFC1302100]; National Natural Science Foundation of China [81772983, 81430068, 31471311]; Natural Science Foundation of Guangdong Province [2017B030301018]; Shenzhen Innovation Committee of Science and Technology, China [JCYJ20170817104854302, ZDSYS20140509142721429, JCYJ20150831142427959]	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Innovation Committee of Science and Technology, China	We thank Dr. Ruijun Tian of the Department of Chemistry, Southern University of Science and Technology, for help with nano LC-MS/MS analyses, Dr. Z-M Yuan (Harvard School of Public Health) for the Flag-G3BP2a construct, and Drs. Jason D. Weber (Washington University) and Yandong Zhang (Southern University of Science and Technology) for pLVX-AcGFP1-N1 and pLVX-IRES-Hyg vectors. This work was supported by the Chinese Ministry of Science and Technology (2016YFC1302100), the National Natural Science Foundation of China (81772983, 81430068, and 31471311), the Natural Science Foundation of Guangdong Province (2017B030301018), and the Shenzhen Innovation Committee of Science and Technology, China (JCYJ20170817104854302, ZDSYS20140509142721429, and JCYJ20150831142427959).	Ashikari D, 2017, ONCOGENE, V36, P6272, DOI 10.1038/onc.2017.225; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Bikkavilli RK, 2012, J CELL SCI, V125, P2446, DOI 10.1242/jcs.100933; Chen WD, 2016, ANAL CHEM, V88, P4864, DOI 10.1021/acs.analchem.6b00631; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clarke DM, 2004, J CELL BIOL, V166, P901, DOI 10.1083/jcb.200404024; Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025; Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Guo L, 2002, FASEB J, V16, P1298, DOI 10.1096/fj.02-0089fje; Gupta N, 2017, P NATL ACAD SCI USA, V114, P1033, DOI 10.1073/pnas.1525387114; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hu W, 2017, ELIFE, V6, DOI 10.7554/eLife.26057; Huang AH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118530; Irvine K, 2004, INT J DEV BIOL, V48, P1065, DOI 10.1387/ijdb.041893ki; Ito M, 2014, BREAST CANCER RES TR, V144, P59, DOI 10.1007/s10549-014-2859-0; Jin X, 2015, BREAST CANCER-BASIC, V9, P23, DOI 10.4137/BCBCR.S25460; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Koren S, 2015, MOL CELL, V60, P537, DOI 10.1016/j.molcel.2015.10.031; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LaLonde DP, 2005, J BIOL CHEM, V280, P21680, DOI 10.1074/jbc.m500752200; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Li CW, 2016, CANCER RES, V76, P1451, DOI 10.1158/0008-5472.CAN-15-1941; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Matsuki H, 2013, GENES CELLS, V18, P135, DOI 10.1111/gtc.12023; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Moon S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04376; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Olski TM, 2001, J CELL SCI, V114, P525; Pignatelli J, 2012, J BIOL CHEM, V287, P37309, DOI 10.1074/jbc.M112.385229; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; Qin L, 2009, CANCER RES, V69, P3819, DOI 10.1158/0008-5472.CAN-08-4389; Qin Q, 2012, CELL RES, V22, P90, DOI 10.1038/cr.2011.144; Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002; Sepulveda JL, 2006, CELL MOL LIFE SCI, V63, P25, DOI 10.1007/s00018-005-5355-1; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Sun Y, 2017, J AM SOC NEPHROL, V28, P3545, DOI 10.1681/ASN.2016091021; Sun Y, 2012, J CELL SCI, V125, P4507, DOI 10.1242/jcs.105023; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Turashvili G, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00227; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Watson MA, 2007, CLIN CANCER RES, V13, P5001, DOI 10.1158/1078-0432.CCR-07-0024; Wei SC, 2015, NAT CELL BIOL, V17, P678, DOI 10.1038/ncb3157; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Xu Y, 2013, AM J PATHOL, V183, P1281, DOI 10.1016/j.ajpath.2013.06.021; Xu YX, 2017, P NATL ACAD SCI USA, V114, P11494, DOI 10.1073/pnas.1618091114; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang YJ, 2004, J BIOL CHEM, V279, P41695, DOI 10.1074/jbc.M401563200; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166	57	6	6	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4856	4874		10.1038/s41388-019-0762-1	http://dx.doi.org/10.1038/s41388-019-0762-1			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30804457				2022-12-17	WOS:000471160500014
J	Aguilera-Montilla, N; Bailon, E; Uceda-Castro, R; Ugarte-Berzal, E; Santos, A; Gutierrez-Gonzalez, A; Perez-Sanchez, C; Van den Steen, PE; Opdenakker, G; Garcia-Marco, JA; Garcia-Pardo, A				Aguilera-Montilla, Noemi; Bailon, Elvira; Uceda-Castro, Rebeca; Ugarte-Berzal, Estefania; Santos, Andrea; Gutierrez-Gonzalez, Alejandra; Perez-Sanchez, Cristina; Van den Steen, Philippe E.; Opdenakker, Ghislain; Garcia-Marco, Jose A.; Garcia-Pardo, Angeles			MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest	ONCOGENE			English	Article							ALPHA-4-BETA-1 INTEGRIN; GELATINASE-B; MATRIX-METALLOPROTEINASE-9; SP1; PATHOGENESIS; INHIBITION; HEMOPEXIN; INVASION; PATHWAYS; SURVIVAL	We previously showed that MMP-9 contributes to CLL pathology by regulating cell survival and migration and that, when present at high levels, MMP-9 induces cell arrest. To further explore the latter function, we studied whether MMP-9 influences the gene-expression profile in CLL. Microarray analyses rendered 131 differentially expressed genes in MEC-1 cells stably transfected with MMP-9 (MMP-9-cells) versus cells transfected with empty vector (Mock-cells). Ten out of twelve selected genes were also differentially expressed in MEC-1 cells expressing the catalytically inactive MMP-9MutE mutant (MMP-9MutE-cells). Incubation of primary CLL cells with MMP-9 or MMP-9MutE also regulated gene and protein expression, including CD99, CD226, CD52, and CD274. Because CD99 is involved in leukocyte transendothelial migration, we selected CD99 for functional and mechanistic studies. The link between MMP-9 and CD99 was reinforced with MMP-9 gene silencing studies, which resulted in CD99 upregulation. CD99 gene silencing significantly reduced CLL cell adhesion, chemotaxis and transendothelial migration, while CD99 overexpression increased cell migration. Mechanistic analyses indicated that MMP-9 downregulated CD99 via binding to alpha 4 beta 1 integrin and subsequent inactivation of the Sp1 transcription factor. This MMP-9-induced mechanism is active in CLL lymphoid tissues, since CD99 expression and Sp1 phosphorylation was lower in bone marrow-derived CLL cells than in their peripheral blood counterparts. Our study establishes a new gene regulatory function for MMP-9 in CLL. It also identifies CD99 as an MMP-9 target and a novel contributor to CLL cell adhesion, migration and arrest. CD99 thus constitutes a new therapeutic target in CLL, complementary to MMP-9.	[Aguilera-Montilla, Noemi; Bailon, Elvira; Uceda-Castro, Rebeca; Santos, Andrea; Gutierrez-Gonzalez, Alejandra; Perez-Sanchez, Cristina; Garcia-Pardo, Angeles] CSIC, Ctr Invest Biol, Dept Mol Biomed, Madrid, Spain; [Ugarte-Berzal, Estefania; Van den Steen, Philippe E.; Opdenakker, Ghislain] Univ Leuven, KU Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Leuven, Belgium; [Garcia-Marco, Jose A.] Hosp Univ Puerta Hierro, Dept Hematol, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); KU Leuven; Hospital Puerta de Hierro-Majadahonda	Garcia-Pardo, A (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Biomed, Madrid, Spain.	agarciapardo@cib.csic.es	Gutiérrez, Alejandra/ABH-7404-2020; Opdenakker, Ghislain/V-8562-2019; Opdenakker, Ghislain/Q-3130-2017; Van den Steen, Philippe E/K-5132-2012	Gutiérrez, Alejandra/0000-0002-2858-2730; Opdenakker, Ghislain/0000-0003-1714-2294; Opdenakker, Ghislain/0000-0003-1714-2294; Van den Steen, Philippe E/0000-0002-7334-9145	Red Tematica de Investigacion Cooperativa en Cancer Grant from the Ministry of Economy and Competitivity (Spain) [RD12/0036/0061]; Comunidad de Madrid/European Union [S2010/BMD-2314]; Concerted Research Actions (KU Leuven C1 Grant) [C16/17/010]; Research Foundation of Flanders (FWO-Vlaanderen); Ministry of Economy and Competitivity (Spain) [SAF2015-69180R]	Red Tematica de Investigacion Cooperativa en Cancer Grant from the Ministry of Economy and Competitivity (Spain); Comunidad de Madrid/European Union; Concerted Research Actions (KU Leuven C1 Grant); Research Foundation of Flanders (FWO-Vlaanderen)(FWO); Ministry of Economy and Competitivity (Spain)	This work was supported by Grant SAF2015-69180R and Red Tematica de Investigacion Cooperativa en Cancer Grant RD12/0036/0061 from the Ministry of Economy and Competitivity (Spain) (to AGP); S2010/BMD-2314 (to AGP) from the Comunidad de Madrid/European Union; and by the Concerted Research Actions (KU Leuven C1 Grant C16/17/010) and the Research Foundation of Flanders (FWO-Vlaanderen, to EUB, PEVdS, and GO).	Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; Amigo-Jimenez I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099993; Bailon E, 2018, BIOCHEM BIOPH RES CO, V495, P124, DOI 10.1016/j.bbrc.2017.10.129; Bailon E, 2014, J LEUKOCYTE BIOL, V96, P185, DOI 10.1189/jlb.3HI0913-521R; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Brachtl G, 2014, ANN HEMATOL, V93, P361, DOI 10.1007/s00277-013-1967-y; Coustan-Smith E, 2011, BLOOD, V117, P6267, DOI 10.1182/blood-2010-12-324004; Creighton Chad, 2003, In Silico Biology, V3, P301; Dal Bo M, 2016, LEUKEMIA, V30, P2011, DOI 10.1038/leu.2016.88; Davids MS, 2012, OPEN J HEMATOL, V3, pi, DOI DOI 10.13055/OJHMT_3_S1_03; Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388; Ganghammer S, 2016, HAEMATOLOGICA, V101, pE99, DOI 10.3324/haematol.2015.133470; Garc~ia-Pardo A, 2015, METALLOPROTEINASES M, V2015, P19, DOI DOI 10.2147/MNM.S63629; Gonzalo P, 2010, DEV CELL, V18, P77, DOI 10.1016/j.devcel.2009.11.012; Goswami D, 2017, BLOOD, V129, P1811, DOI 10.1182/blood-2016-08-733394; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hallek M, 2017, AM J HEMATOL, V92, P946, DOI 10.1002/ajh.24826; Herishanu Y, 2011, BLOOD, V117, P563, DOI 10.1182/blood-2010-05-284984; Imbert AM, 2006, BLOOD, V108, P2578, DOI 10.1182/blood-2005-12-010827; Kamiguti AS, 2004, BRIT J HAEMATOL, V125, P128, DOI 10.1111/j.1365-2141.2004.04877.x; Lee IS, 2001, BLOOD, V97, P3596, DOI 10.1182/blood.V97.11.3596; Lee JH, 2007, CLIN CANCER RES, V13, P2584, DOI 10.1158/1078-0432.CCR-06-1785; Manara MC, 2018, GENES-BASEL, V9, DOI 10.3390/genes9030159; Marchant DJ, 2014, NAT MED, V20, P497, DOI 10.1038/nm.3508; McClanahan F, 2015, BLOOD, V126, P203, DOI 10.1182/blood-2015-01-622936; Mittal AK, 2014, MOL MED, V20, P290, DOI 10.2119/molmed.2012.00303; Muller WA, 2016, IMMUNOL REV, V273, P61, DOI 10.1111/imr.12443; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Parry HM, 2016, ONCOTARGET, V7, P68513, DOI 10.18632/oncotarget.12097; Pasello M, 2018, J CELL COMMUN SIGNAL, V12, P55, DOI 10.1007/s12079-017-0445-z; Pettitt AR, 2012, J CLIN ONCOL, V30, P1647, DOI 10.1200/JCO.2011.35.9695; Prudova A, 2010, MOL CELL PROTEOMICS, V9, P894, DOI 10.1074/mcp.M000050-MCP201; Redondo-Munoz J, 2008, BLOOD, V112, P169, DOI 10.1182/blood-2007-08-109249; Redondo-Munoz J, 2008, BLOOD, V111, P383, DOI 10.1182/blood-2007-08-107300; Redondo-Munoz J, 2006, BLOOD, V108, P3143, DOI 10.1182/blood-2006-03-007294; Redondo-Munoz J, 2010, CANCER CELL, V17, P160, DOI 10.1016/j.ccr.2009.12.044; Sakamoto T, 2009, GENES CELLS, V14, P617, DOI 10.1111/j.1365-2443.2009.01293.x; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2007, ONCOGENE, V26, P6604, DOI 10.1038/sj.onc.1210481; Seol Ho Jun, 2012, Genes Cancer, V3, P535, DOI 10.1177/1947601912473603; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; ten Hacken E, 2016, BBA-MOL CELL RES, V1863, P401, DOI 10.1016/j.bbamcr.2015.07.009; Van den Steen PE, 2006, J BIOL CHEM, V281, P18626, DOI 10.1074/jbc.M512308200; Vandooren J, 2013, CRIT REV BIOCHEM MOL, V48, P222, DOI 10.3109/10409238.2013.770819; Vestweber D, 2015, NAT REV IMMUNOL, V15, P692, DOI 10.1038/nri3908; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zucchini C, 2014, ONCOGENE, V33, P1912, DOI 10.1038/onc.2013.152	49	6	6	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4605	4619		10.1038/s41388-019-0744-3	http://dx.doi.org/10.1038/s41388-019-0744-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30760844	Green Submitted			2022-12-17	WOS:000470240300012
J	Venkadakrishnan, VB; DePriest, AD; Kumari, S; Senapati, D; Ben-Salem, S; Su, YX; Mudduluru, G; Hu, Q; Cortes, E; Pop, E; Mohler, JL; Azabdaftari, G; Attwood, K; Shah, RB; Jamieson, C; Dehm, SM; Magi-Galluzzi, C; Klein, E; Sharifi, N; Liu, S; Heemers, HV				Venkadakrishnan, Varadha Balaji; DePriest, Adam D.; Kumari, Sangeeta; Senapati, Dhirodatta; Ben-Salem, Salma; Su, Yixue; Mudduluru, Giridhar; Hu, Qiang; Cortes, Eduardo; Pop, Elena; Mohler, James L.; Azabdaftari, Gissou; Attwood, Kristopher; Shah, Rajal B.; Jamieson, Christina; Dehm, Scott M.; Magi-Galluzzi, Cristina; Klein, Eric; Sharifi, Nima; Liu, Song; Heemers, Hannelore V.			Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy	ONCOGENE			English	Article							LESTAURTINIB CEP701; RECEPTOR; INHIBITOR; PHOSPHORYLATION; INDUCTION; RESISTANT; CEP-701; TRIAL; IDENTIFICATION; PROLIFERATION	Sustained reliance on androgen receptor (AR) after failure of AR-targeting androgen deprivation therapy (ADT) prevents effective treatment of castration-recurrent (CR) prostate cancer (CaP). Interfering with the molecular machinery by which AR drives CaP progression may be an alternative therapeutic strategy but its feasibility remains to be tested. Here, we explore targeting the mechanism by which AR, via RhoA, conveys androgen-responsiveness to serum response factor (SRF), which controls aggressive CaP behavior and is maintained in CR-CaP. Following a siRNA screen and candidate gene approach, RNA-Seq studies confirmed that the RhoA effector Protein Kinase N1 (PKN1) transduces androgen-responsiveness to SRF. Androgen treatment induced SRF-PKN1 interaction, and PKN1 knockdown or overexpression severely impaired or stimulated, respectively, androgen regulation of SRF target genes. PKN1 overexpression occurred during clinical CR-CaP progression, and hastened CaP growth and shortened CR-CaP survival in orthotopic CaP xenografts. PKN1's effects on SRF relied on its kinase domain. The multikinase inhibitor lestaurtinib inhibited PKN1 action and preferentially affected androgen regulation of SRF over direct AR target genes. In a CR-CaP patient-derived xenograft, expression of SRF target genes was maintained while AR target gene expression declined and proliferative gene expression increased. PKN1 inhibition decreased viability of CaP cells before and after ADT. In patient-derived CaP explants, lestaurtinib increased AR target gene expression but did not significantly alter SRF target gene or proliferative gene expression. These results provide proof-of-principle for selective forms of ADT that preferentially target different fractions of AR's transcriptional output to inhibit CaP growth.	[Venkadakrishnan, Varadha Balaji; Kumari, Sangeeta; Senapati, Dhirodatta; Ben-Salem, Salma; Su, Yixue; Mudduluru, Giridhar; Sharifi, Nima; Heemers, Hannelore V.] Cleveland Clin, Dept Canc Biol, Cleveland, OH 44106 USA; [Venkadakrishnan, Varadha Balaji] Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; [DePriest, Adam D.] Roswell Pk Comprehens Canc Ctr, Dept Canc Genet, Buffalo, NY USA; [Hu, Qiang; Cortes, Eduardo; Attwood, Kristopher; Liu, Song] Roswell Pk Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Pop, Elena; Mohler, James L.; Azabdaftari, Gissou] Roswell Pk Comprehens Canc Ctr, Dept Urol, Buffalo, NY USA; [Azabdaftari, Gissou] Roswell Pk Comprehens Canc Ctr, Dept Pathol & Lab Med, Buffalo, NY USA; [Shah, Rajal B.; Magi-Galluzzi, Cristina] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA; [Jamieson, Christina] Univ Calif San Diego, Dept Urol, La Jolla, CA 92093 USA; [Dehm, Scott M.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Dehm, Scott M.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; [Dehm, Scott M.] Univ Minnesota, Dept Urol, Minneapolis, MN USA; [Klein, Eric; Sharifi, Nima; Heemers, Hannelore V.] Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA; [Sharifi, Nima; Heemers, Hannelore V.] Cleveland Clin, Dept Hematol Med Oncol, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation; University of California System; University of California San Diego; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Heemers, HV (corresponding author), Cleveland Clin, Dept Canc Biol, Cleveland, OH 44106 USA.; Heemers, HV (corresponding author), Cleveland Clin, Dept Urol, Cleveland, OH 44106 USA.; Heemers, HV (corresponding author), Cleveland Clin, Dept Hematol Med Oncol, Cleveland, OH 44106 USA.	heemerh@ccf.org	Kumari, Sangeeta/AAB-7154-2022; Ben-Salem, Salma/E-1702-2016; Cortes, Eduardo/AAW-8005-2021; Magi-Galluzzi, Cristina/AAW-6484-2020	Ben-Salem, Salma/0000-0001-5023-6781; Klein, Eric A/0000-0002-1783-0698; Kumari, Sangeeta/0000-0002-0692-0452	DOD PCRP award [W81XWH-16-1-0404]; NIH NCI [CA166440, CA174777, CA077739, CA232979, CA016056]; NATIONAL CANCER INSTITUTE [R01CA174777, R01CA166440, P30CA016056, U24CA232979] Funding Source: NIH RePORTER	DOD PCRP award; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by DOD PCRP award W81XWH-16-1-0404 (HVH), NIH NCI grants CA166440 (HVH), CA174777 (SMD), CA077739 (JLM), CA232979 (SL) and CA016056 (JLM and SL).	Attard G, 2018, J CLIN ONCOL, V36, P2639, DOI 10.1200/JCO.2018.77.9827; Centenera MM, 2013, NAT REV UROL, V10, P483, DOI 10.1038/nrurol.2013.126; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Collins C, 2007, CANCER BIOL THER, V6, P1360; Dai C, 2017, COLD SPRING HARB PER, V7; Esnault C, 2014, GENE DEV, V28, P943, DOI 10.1101/gad.239327.114; George DJ, 1999, CANCER RES, V59, P2395; Godebu E, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0275-1; Gualdrini F, 2016, MOL CELL, V64, P1048, DOI 10.1016/j.molcel.2016.10.016; He AB, 2011, P NATL ACAD SCI USA, V108, P5632, DOI 10.1073/pnas.1016959108; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heemers HV, 2007, CANCER RES, V67, P10592, DOI 10.1158/0008-5472.CAN-07-1917; Heemers HV, 2013, CURR DRUG TARGETS, V14, P481; Heemers HV, 2011, CANCER RES, V71, P1978, DOI 10.1158/0008-5472.CAN-10-2512; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hexner EO, 2008, BLOOD, V111, P5663, DOI 10.1182/blood-2007-04-083402; Itkonen HM, 2017, ONCOTARGET, V8, P38264, DOI 10.18632/oncotarget.16123; Iyer R, 2010, CLIN CANCER RES, V16, P1478, DOI 10.1158/1078-0432.CCR-09-1531; Jilg CA, 2014, ONCOTARGET, V5, P12646, DOI 10.18632/oncotarget.2653; Kajimoto K, 2011, AM J PHYSIOL-HEART C, V300, pH191, DOI 10.1152/ajpheart.00232.2010; Karantanos T, 2015, EUR UROL, V67, P470, DOI 10.1016/j.eururo.2014.09.049; Kim JY, 2014, MOL CELL, V54, P613, DOI 10.1016/j.molcel.2014.03.043; Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368; Knapper S, 2006, BLOOD, V108, P3262, DOI 10.1182/blood-2006-04-015560; Kohler J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034973; Kumari S, 2017, ENDOCR-RELAT CANCER, V24, pR275, DOI 10.1530/ERC-17-0121; Labbe DP, 2017, CLIN CANCER RES, V23, P7072, DOI 10.1158/1078-0432.CCR-17-0413; Li JN, 2017, ELIFE, V6, DOI 10.7554/eLife.20183; Li ZF, 2016, NATURE, V533, P547, DOI 10.1038/nature17954; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Liu S, 2017, ELIFE, V6, DOI 10.7554/eLife.28482.001; Luo J, 2018, EUR UROL, V73, P715, DOI 10.1016/j.eururo.2017.11.038; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Marshall JL, 2005, INVEST NEW DRUG, V23, P31, DOI 10.1023/B:DRUG.0000047103.64335.b0; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Mills IG, 2014, NAT REV CANCER, V14, P187, DOI 10.1038/nrc3678; Mitchell SH, 2000, MOL CELL ENDOCRINOL, V168, P89, DOI 10.1016/S0303-7207(00)00319-1; Miyamoto DT, 2018, CANCER DISCOV, V8, P288, DOI 10.1158/2159-8290.CD-16-1406; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Nakagawa T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002318; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; O'Hurley G, 2014, PROSTATE, V74, P306, DOI 10.1002/pros.22752; O'Sullivan AG, 2017, BBA-MOL BASIS DIS, V1863, P838, DOI 10.1016/j.bbadis.2017.01.011; Olmos D, 2012, LANCET ONCOL, V13, P1114, DOI 10.1016/S1470-2045(12)70372-8; Prencipe M, 2015, PROSTATE, V75, P1704, DOI 10.1002/pros.23051; Prencipe M, 2013, PROSTATE, V73, P743, DOI 10.1002/pros.22618; Ravindranathan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2912; Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702; Schlesinger J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001313; Schmidt LJ, 2012, MOL ENDOCRINOL, V26, P716, DOI 10.1210/me.2011-1130; Shabbir M, 2010, EXPERT OPIN INV DRUG, V19, P427, DOI 10.1517/13543781003598862; Shibata H, 1999, MOL BRAIN RES, V74, P126, DOI 10.1016/S0169-328X(99)00273-9; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Sun Q, 2006, GENOME RES, V16, P197, DOI 10.1101/gr.4108706; Takanaga H, 1998, EXP CELL RES, V241, P363, DOI 10.1006/excr.1998.4060; Taniguchi T, 2001, J BIOL CHEM, V276, P10025, DOI 10.1074/jbc.M007427200; Treisman R, 1998, COLD SPRING HARB SYM, V63, P643, DOI 10.1101/sqb.1998.63.643; Viswanathan SR, 2018, CELL, V174, P433, DOI 10.1016/j.cell.2018.05.036; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Weeraratna AT, 2001, CLIN CANCER RES, V7, P2237; Yamoah K, 2015, J CLIN ONCOL, V33, P2789, DOI 10.1200/JCO.2014.59.8912; Yu WD, 2011, CLIN CANCER RES, V17, P4355, DOI 10.1158/1078-0432.CCR-10-2858	63	6	6	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4496	4511		10.1038/s41388-019-0732-7	http://dx.doi.org/10.1038/s41388-019-0732-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30742064	Green Accepted			2022-12-17	WOS:000470240300005
J	Kumar, R; Njauw, CN; Reddy, BY; Ji, ZY; Rajadurai, A; Klebanov, N; Tsao, HS				Kumar, Raj; Njauw, Ching-Ni; Reddy, Bobby Y.; Ji, Zhenyu; Rajadurai, Anpuchchelvi; Klebanov, Nikolai; Tsao, Hensin			Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma	ONCOGENE			English	Article							GENE-EXPRESSION; SINGLE-CELL; B-RAF; SENESCENCE; BRAF; RESISTANCE; PATHWAYS; MITF; INHIBITOR; MUTATIONS	The underlying forces that shape mutational patterns within any type of cancer have been poorly characterized. One of the best preserved exclusionary relationships is that between BRAF(V600E) and NRAS(Q61) in melanomas. To explore possible mechanisms which could explain this phenomenon, we overexpressed NRAS(Q61) in a set of BRAF(V600E) melanoma lines and vice versa. Controlled expression of a second activating oncogene led to growth arrest ("synthetic suppression") in a subset of cells, which was accompanied by cell cycle arrest and senescence in several melanoma cell lines along with apoptosis. Through differential gene expression analysis, we identified SPRY4 as the potential mediator of this synthetic response to dual oncogene suppression. Ectopic introduction of SPRY4 recapitulated the growth arrest phenotype of dual BRAF(V600E)/NRAS(Q61) expression while SPRY4 depletion led to a partial rescue from oncogenic antagonism. This study thus defined SPRY4 as a potential mediator of synthetic suppression, which is likely to contribute to the observed exclusivity between BRAF(V600E) and NRAS(Q61R) mutations in melanoma. Further leverage of the SPRY4 pathway may also hold therapeutic promise for NRAS(Q61) melanomas.	[Kumar, Raj; Njauw, Ching-Ni; Reddy, Bobby Y.; Ji, Zhenyu; Rajadurai, Anpuchchelvi; Klebanov, Nikolai; Tsao, Hensin] Harvard Med Sch, Dept Dermatol, Massachusetts Gen Hosp, Edwards 211 50 Blossom St, Boston, MA 02115 USA; [Kumar, Raj; Njauw, Ching-Ni; Reddy, Bobby Y.; Ji, Zhenyu; Rajadurai, Anpuchchelvi; Klebanov, Nikolai] Harvard Med Sch, Wellman Ctr Photomed, Massachusetts Gen Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Tsao, HS (corresponding author), Harvard Med Sch, Dept Dermatol, Massachusetts Gen Hosp, Edwards 211 50 Blossom St, Boston, MA 02115 USA.	htsao@partners.org			Melanoma Research Alliance; NIH [K24 CA149202]; CDMRP grant: Department of Defense [CA160385]; Massachusetts General Hospital; NATIONAL CANCER INSTITUTE [K24CA149202] Funding Source: NIH RePORTER	Melanoma Research Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CDMRP grant: Department of Defense(United States Department of Defense); Massachusetts General Hospital(General Electric); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Jie Zhao, and technical assistants, Danian Cao, Jermaine Henderson and Neema Kumar for performing FACS, H&E and IHC staining (MGH). Technical Associate, Jennifer Love, for performing mRNA microarray (MIT). We thank the MGH-IACUC for animal care. This research was partially supported by grants from the Melanoma Research Alliance and NIH (K24 CA149202), CDMRP grant: Department of Defense CA160385 and by the generous donors at the Massachusetts General Hospital.	Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Hoek KS, 2008, PIGM CELL MELANOMA R, V21, P665, DOI 10.1111/j.1755-148X.2008.00505.x; Ji ZY, 2015, J INVEST DERMATOL, V135, P1863, DOI 10.1038/jid.2015.105; Kumar R, 2015, J INVEST DERMATOL, V135, P1089, DOI 10.1038/jid.2014.528; Lackner DH, 2014, AGING CELL, V13, P946, DOI 10.1111/acel.12234; Lu C, 2015, J INVEST DERMATOL, V135, P816, DOI 10.1038/jid.2014.425; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47; Opriessnig T, 2003, VET PATHOL, V40, P521, DOI 10.1354/vp.40-5-521; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Petti C, 2006, CANCER RES, V66, P6503, DOI 10.1158/0008-5472.CAN-05-4671; Sasaki A, 2003, CELL CYCLE, V2, P281, DOI 10.4161/cc.2.4.418; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Seo H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17591-9; Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tennis MA, 2010, MOL CANCER RES, V8, P833, DOI 10.1158/1541-7786.MCR-09-0400; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; van Tuyn J, 2017, J INVEST DERMATOL, V137, P2197, DOI 10.1016/j.jid.2017.05.030; Vizioli MG, 2014, ONCOTARGET, V5, P8270, DOI 10.18632/oncotarget.2013; Wagatsuma A, 2005, J EXP BIOL, V208, P2389, DOI 10.1242/jeb.01625; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Xu YX, 2014, TRENDS BIOCHEM SCI, V39, P268, DOI 10.1016/j.tibs.2014.04.004; 2016, ONCOTARGET, V7, P7716, DOI DOI 10.18632/ONCOTARGET.12848	32	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3504	3520		10.1038/s41388-018-0632-2	http://dx.doi.org/10.1038/s41388-018-0632-2			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651601	Green Published, hybrid			2022-12-17	WOS:000466610000013
J	Li, M; Tang, Y; Li, QS; Xiao, M; Yang, YY; Wang, YL				Li, Ming; Tang, Yi; Li, Qingshu; Xiao, Ming; Yang, Yaying; Wang, Yalan			Mono-ADP-ribosylation of H3R117 traps 5mC hydroxylase TET1 to impair demethylation of tumor suppressor gene TFPI2	ONCOGENE			English	Article							COLORECTAL-CANCER; DNA METHYLATION; 5-HYDROXYMETHYLCYTOSINE; EXPRESSION; 5-CARBOXYLCYTOSINE; 5-FORMYLCYTOSINE; HYPERMETHYLATION; 5-METHYLCYTOSINE; TRANSCRIPTION; INHIBITORS	Recently, nuclear poly-ADP-ribosylation had aroused research interest in epigenetics, but little attempt to explore functions of mono-ADP-ribosylation of histone, the major formation of histone ADP-ribosylated modification. We have previously reported a novel mono-ADP-ribosylation of H3R117, which promoted proliferation of LoVo cells. Here we showed that mono-ADP-ribosylated H3R117 of LoVo cells depressed demethylation of tumor suppressor TFPI2 promoter by suppressing TET1 expression and adjusting H3K9me3 enrichment of TFPI2 promoter to attenuate affinity of TET1, besides, since high H3K27me3 level was associated with hypermethylation, mono-ADP-ribosylated-H3R117-depended-H3K27me3 of TFPI2 promoter may contribute to hypermethylation of TFPI2. However, H3R117A mutation increased poly-ADPribosylated modification of TET1 promoter not TFPI2 promoter, which resulted in boosting transcription and expression of TET1 by altering DNA methylated modification, chromatin accessibility, and histone-methylated modification of TET1 promoter, while knockout TET1 of H3R117A LoVo cells directly led to hypermethylation of TFPI2 promoter and depression of TFPI2 secretion as well as enhanced proliferation, suggested that TET1 played a key role in demethylation of TFPI2, production of TFPI2, and cell proliferation. Bioinformatics analyses reveal prevalent hypermethylation of TFPI2 was an early event in tumorigenesis of colorectal caner, and expression of TET1 and TFPI2 was positive correlation in colorectal cancer and normal tissue. These data suggested that mono-ADP-ribosylation of H3R117 upregulated methylation of TFPI2 by impact TET1, since hypermethyaltion of TFPI2 was an early event in tumorigenesis, selectively target mono-ADP-ribosylation of H3R117 deficiency could be a feasible way to block tumorigenesis of colorectal cancer.	[Li, Ming; Tang, Yi; Li, Qingshu; Xiao, Ming; Yang, Yaying; Wang, Yalan] Chongqing Med Univ, Dept Pathol, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China	Chongqing Medical University	Wang, YL (corresponding author), Chongqing Med Univ, Dept Pathol, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China.	wangyalan074@126.com			Science and Technology Plan Projects of Yuzhong District in Chongqing [20170409, 20140106]; Scientific Research Foundation of Chongqing Medical University [201413]	Science and Technology Plan Projects of Yuzhong District in Chongqing; Scientific Research Foundation of Chongqing Medical University	We gratefully acknowledge Professor Wei-Xue Tang (Chongqing, China) for his gift of LoVo cell line. This work was supported by the Science and Technology Plan Projects of Yuzhong District in Chongqing [grant numbers 20170409 and 20140106], and the Scientific Research Foundation of Chongqing Medical University [grant number 201413].	BURZIO LO, 1979, J BIOL CHEM, V254, P3029; Ciccarone F, 2014, ONCOTARGET, V5, P10356, DOI 10.18632/oncotarget.1905; Gao Shenglan, 2017, Cell Cycle, V16, P2249, DOI 10.1080/15384101.2017.1373223; Glockner SC, 2009, CANCER RES, V69, P4691, DOI 10.1158/0008-5472.CAN-08-0142; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hibi K, 2012, ANTICANCER RES, V32, P787; Hibi K, 2011, CANCER LETT, V311, P96, DOI 10.1016/j.canlet.2011.07.006; Hottiger MO, 2015, ANNU REV BIOCHEM, V84, P227, DOI 10.1146/annurev-biochem-060614-034506; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Ichimura N, 2015, CANCER PREV RES, V8, P702, DOI 10.1158/1940-6207.CAPR-14-0306; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Kroeze LI, 2015, BBA-REV CANCER, V1855, P144, DOI 10.1016/j.bbcan.2015.01.001; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Li YF, 2015, EPIGENETICS-US, V10, P229, DOI 10.1080/15592294.2015.1006506; Ling F, 2017, ONCOTARGET, V8, P72773, DOI 10.18632/oncotarget.20347; Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380; Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620; Martinez-Zamudio R, 2012, MOL CELL BIOL, V32, P2490, DOI 10.1128/MCB.06667-11; McInnes T, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3226-4; Neri F, 2015, ONCOGENE, V34, P4168, DOI 10.1038/onc.2014.356; Neri F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r91; Nocchi L, 2011, J BIOL CHEM, V286, P19478, DOI 10.1074/jbc.M110.217331; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Putiri EL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r81; Rasmussen SL, 2016, COLORECTAL DIS, V18, P549, DOI 10.1111/codi.13336; Rawluszko-Wieczorek AA, 2015, J CANCER RES CLIN, V141, P1379, DOI 10.1007/s00432-014-1901-2; Robertson J, 2011, BIOCHEM BIOPH RES CO, V411, P40, DOI 10.1016/j.bbrc.2011.06.077; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thomson JP, 2016, CANCER RES, V76, P3097, DOI 10.1158/0008-5472.CAN-15-1910; Wu H, 2011, GENE DEV, V25, P679, DOI 10.1101/gad.2036011; Xu YF, 2011, MOL CELL, V42, P451, DOI 10.1016/j.molcel.2011.04.005; Yamaguchi H, 2018, ONCOGENE, V37, P208, DOI 10.1038/onc.2017.311; Yuan XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20005; Zampieri M, 2012, BIOCHEM J, V441, P645, DOI 10.1042/BJ20111417; Zampieri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004717; Zhou Z, 2018, J CELL PHYSIOL, V233, P1359, DOI 10.1002/jcp.26012; 1999, BIOL CHEM, V274, P1786	40	6	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3488	3503		10.1038/s41388-018-0671-8	http://dx.doi.org/10.1038/s41388-018-0671-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651599	hybrid, Green Published			2022-12-17	WOS:000466610000012
J	Hong, SY; Xu, JF; Li, Y; Andrade, J; Hoover, P; Kaminski, PJ; Laimins, LA				Hong, Shiyuan; Xu, Junfen; Li, Yan; Andrade, Jorge; Hoover, Paul; Kaminski, Paul J.; Laimins, Laimonis A.			Topoisomerase II beta-binding protein 1 activates expression of E2F1 and p73 in HPV-positive cells for genome amplification upon epithelial differentiation	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; DNA-DAMAGE RESPONSE; LIFE-CYCLE; IN-VIVO; REPLICATION; TOPBP1; E6; P53; STABILITY; CANCER	High-risk human papillomaviruses (HPVs) constitutively activate ataxia telangiectasia mutated (ATM) and ataxia telangiectasia- and Rad3-related (ATR) DNA damage repair pathways for viral genome amplification. HPVs activate these pathways through the immune regulator STAT-5. For the ATR pathway, STAT-5 increases expression of the topoisomerase II beta-binding protein 1 (TopBP1), a scaffold protein that binds ATR and recruits it to sites of DNA damage. TopBP1 also acts as a transcriptional regulator, and we investigated how this activity influenced the HPV life cycle. We determined that TopBP1 levels are increased in cervical intraepithelial neoplasias as well as cervical carcinomas, consistent with studies in HPV-positive cell lines. Suppression of TopBP1 by shRNAs impairs HPV genome amplification and activation of the ATR pathway but does not affect the total levels of ATR and CHK1. In contrast, knockdown reduces the expression of other DNA damage factors such as RAD51 and Mre11 but not BRCA2 or NBS1. Interestingly, TopBP1 positively regulates the expression of E2F1, a TopBP1-binding partner, and p73 in HPV-positive cells in contrast to its effects in other cell types. TopBP1 transcriptional activity is regulated by AKT, and treatment with AKT inhibitors suppresses expression of E2F1 and p73 without interfering with ATR signaling. Importantly, the levels of p73 are elevated in HPV-positive cells and its knockdown impairs HPV genome amplification. This demonstrates that p73, like p63 and p53, is an important regulator of the HPV life cycle that is controlled by the transcriptional activating properties of the multifunctional TopBP1 protein.	[Hong, Shiyuan; Hoover, Paul; Kaminski, Paul J.; Laimins, Laimonis A.] Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; [Xu, Junfen] Zhejiang Univ, Womens Hosp, Sch Med, Dept Gynecol Oncol, Hangzhou 310006, Zhejiang, Peoples R China; [Li, Yan; Andrade, Jorge] Univ Chicago, Ctr Res Informat, Chicago, IL 60637 USA	Northwestern University; Feinberg School of Medicine; Zhejiang University; University of Chicago	Hong, SY; Laimins, LA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	shiyuan-hong@northwestern.edu; l-laimins@northwestern.edu	Fan, Qing/AAI-8294-2021	Andrade, Jorge/0000-0003-3210-2186; Kaminski, Paul/0000-0002-5513-2962	NCI [CA059655, CA142861]; ACS [IRG-15-173-21]; National Natural Scientific Foundation of China [81702552]; NATIONAL CANCER INSTITUTE [R01CA059655, R01CA142861] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); National Natural Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by grants from NCI (CA059655 and CA142861) to L.A.L., ACS grant IRG-15-173-21 to S.H., and National Natural Scientific Foundation of China (No. 81702552) to J.X.	Accardi R, 2006, EMBO REP, V7, P334, DOI 10.1038/sj.embor.7400615; Andrews S., 2010, FASTQC QUALITY CONTR; Chappell WH, 2016, J VIROL, V90, P2639, DOI 10.1128/JVI.02495-15; Concin N, 2004, CANCER RES, V64, P2449, DOI 10.1158/0008-5472.CAN-03-1060; Connell C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032442; Conway MJ, 2009, J DENT RES, V88, P307, DOI 10.1177/0022034509333446; DiMaio D, 2013, VIROLOGY, V445, P99, DOI 10.1016/j.virol.2013.05.006; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Donaldson MM, 2012, J VIROL, V86, P12806, DOI 10.1128/JVI.01002-12; Doorbar J, 2013, VIROLOGY, V445, P80, DOI 10.1016/j.virol.2013.07.008; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Edwards TG, 2013, J VIROL, V87, P3979, DOI 10.1128/JVI.03473-12; Fang YF, 2014, CANCER BIOL THER, V15, P1268, DOI 10.4161/cbt.29691; Fehrmann Frauke, 2005, Methods Mol Biol, V292, P317; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Gunasekharan V, 2012, J VIROL, V86, P5393, DOI 10.1128/JVI.07239-11; Gunasekharan VK, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005747; Habiger C, 2016, J VIROL, V90, P694, DOI 10.1128/JVI.02137-15; Hartley KA, 2002, J VIROL, V76, P5014, DOI 10.1128/JVI.76.10.5014-5023.2002; Hebner CM, 2006, REV MED VIROL, V16, P83, DOI 10.1002/rmv.488; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; Hong SY, 2017, J ZHEJIANG UNIV-SC B, V18, P215, DOI 10.1631/jzus.B1600306; Hong SY, 2015, MBIO, V6, DOI 10.1128/mBio.02006-15; Hong SY, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003295; Hong SY, 2011, J VIROL, V85, P9486, DOI 10.1128/JVI.05007-11; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Kidiyoor GR, 2016, DNA REPAIR, V44, P143, DOI 10.1016/j.dnarep.2016.05.020; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; Liu K, 2006, EMBO J, V25, P4795, DOI 10.1038/sj.emboj.7601355; Liu K, 2013, MOL CELL BIOL, V33, P4685, DOI 10.1128/MCB.00373-13; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Liu K, 2009, MOL CELL BIOL, V29, P2673, DOI 10.1128/MCB.01140-08; Lorenz LD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003717; McBride AA, 2013, VIROLOGY, V445, P57, DOI 10.1016/j.virol.2013.06.006; McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042; Mehta K, 2018, MBIO, V9, DOI 10.1128/mBio.00064-18; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Mighty KK, 2011, J VIROL, V85, P8863, DOI 10.1128/JVI.00750-11; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Moody CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000605; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Niklison-Chirou MV, 2016, MOL NEUROBIOL, V53, P4509, DOI 10.1007/s12035-015-9381-1; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; OFFORD EA, 1990, J VIROL, V64, P4792, DOI 10.1128/JVI.64.10.4792-4798.1990; Pacini L, 2015, J VIROL, V89, P11396, DOI 10.1128/JVI.02151-15; Reiser J, 2011, J VIROL, V85, P11372, DOI 10.1128/JVI.05279-11; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Spurgeon ME, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080219; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stunkel W, 1999, J VIROL, V73, P1918; Thomas JT, 1999, P NATL ACAD SCI USA, V96, P8449, DOI 10.1073/pnas.96.15.8449; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Wallace NA, 2015, ANNU REV VIROL, V2, P403, DOI 10.1146/annurev-virology-100114-055021; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wise-Draper TM, 2008, FRONT BIOSCI-LANDMRK, V13, P1003, DOI 10.2741/2739; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yuan X, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.69; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; J VIROL, V74, P5198	68	6	6	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2019	38	17					3274	3287		10.1038/s41388-018-0633-1	http://dx.doi.org/10.1038/s41388-018-0633-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU8RI	30631149	Green Accepted			2022-12-17	WOS:000465557200012
J	Zhang, R; Hong, JJ; Yang, QY; Ong, CT; Li, BA; Liou, YC				Zhang, Rui; Hong, Jing-Jing; Yang, Qiaoyun; Ong, Chin-Tong; Li, Bo-An; Liou, Yih-Cherng			Poly(ADP-ribosyl)ation of OVOL2 regulates aneuploidy and cell death in cancer cells	ONCOGENE			English	Article							DROSOPHILA-OVO; CYCLIN-E; CHROMOSOMAL INSTABILITY; CENTROSOME; PHOSPHORYLATION; UBIQUITINATION; IDENTIFICATION; POLYMERASE; EXPRESSION; MECHANISM	Poly(ADP-ribosyl)ation (PARylation) is a post-translational modification by which poly ADP-ribose (PAR) polymers are covalently added to proteins through a PAR polymerase (PARP). Here, using proteomic approach, we identify the transcriptional regulator, OVOL2, is a novel substrate of PARP1 and can be PARylated at residues Lysine 145, Lysine 176, and Lysine 212 within its C2H2 zinc finger domains. Overexpression of PARylated OVOL2 alters cell morphology and induces lagging chromosomes and aneuploidy. To define the underlying molecular mechanism by which OVOL2 induces abnormal cell cycle and centrosome amplification, we uncover that the OVOL2 elevates the protein levels of Cyclin E by enhancing its stability. Furthermore, we identify Skp2, the E3 ubiquitin ligase of Cyclin E, as a direct target of PARylated OVOL2. Using ChIP assay, the OVOL2 binding site on the promoter region of Skp2 is mapped. To further explore the physiological effect, we show that PARylated OVOL2 can induce cell death. Furthermore, to investigate PARylated OVOL2 function in vivo, we further develop a null-mice xenograft model and generate MMTV-PyVT transgenic mice and monitor the effect of wild-type OVOL2 and non-PARylated OVOL2-3IQA mutants on tumor progression. Consistently, overexpression of wild-type OVOL2 in both null-mice xenograft and MMTV-PyVT transgenic mice displays significantly reduction of tumor progression, respectively, further indicating that the function of OVOL2 as a tumor suppressor in vivo is highly regulated by PARylation. Taken together, our study sheds new light on PARP1-induced PARylation as a critical event in the OVOL2-mediated regulation of chromosomal integrity and suppression of cancer cells growth.	[Zhang, Rui; Yang, Qiaoyun; Ong, Chin-Tong; Liou, Yih-Cherng] Natl Univ Singapore, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore; [Hong, Jing-Jing; Li, Bo-An] Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China; [Ong, Chin-Tong] Natl Univ Singapore, Temasek Life Sci Lab, Singapore 117604, Singapore; [Liou, Yih-Cherng] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117573, Singapore	National University of Singapore; Xiamen University; National University of Singapore; National University of Singapore	Liou, YC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Fac Sci, Singapore 117543, Singapore.; Li, BA (corresponding author), Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China.; Liou, YC (corresponding author), Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117573, Singapore.	bali@xmu.edu.cn; dbslyc@nus.edu.sg		ZHANG, RUI/0000-0003-2250-8617	Ministry of Education, Singapore [R-154-000-A61-112, A15-114]; National Natural Science Foundation of China [U1705284, 81772958]	Ministry of Education, Singapore(Ministry of Education, Singapore); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank all members in the Y-C Liou laboratory for their support and valuable discussion. We would also like to thank the Center of BioImaging Sciences (CBIS) for their technical support on confocal microscopy, and Flow Cytometry Laboratory in Yong Loo Lin School of Medicine at the National University of Singapore for FACS assay. In addition, the authors thank Protein Proteomic Center (PPC) for the technical support on protein identification. We particularly thank Dr. Boon Chuan Low for kindly providing several reagents and helpful discussions and suggestions. In addition, we thank Dr. Kyunghee Lee for helping imaging and cell cycle assay. This work was supported in part by MOE grants Tier 2, R-154-000-A61-112 and Tier 1, A15-114 from the Ministry of Education, Singapore to Y.-C.L; grants from the National Natural Science Foundation of China (Grant Numbers U1705284, 81772958) to B.-A.L.	Ahel I, 2008, NATURE, V451, P81, DOI 10.1038/nature06420; Altmeyer M, 2009, NUCLEIC ACIDS RES, V37, P3723, DOI 10.1093/nar/gkp229; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; Amiri KI, 2006, ONCOGENE, V25, P7714, DOI 10.1038/sj.onc.1209751; Bakhoum SF, 2014, CURR BIOL, V24, pR148, DOI 10.1016/j.cub.2014.01.019; Caiafa P, 2009, FASEB J, V23, P672, DOI 10.1096/fj.08-123265; CHAMBON P, 1963, BIOCHEM BIOPH RES CO, V11, P39, DOI 10.1016/0006-291X(63)90024-X; Coldwell MJ, 2013, CELL CYCLE, V12, P3615, DOI 10.4161/cc.26588; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Giam M, 2015, CELL DIV, V10, DOI 10.1186/s13008-015-0009-7; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Gonzalez-Sanchez M, 2004, GENETICS, V166, P999, DOI 10.1534/genetics.166.2.999; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; JUAREZSALINAS H, 1982, J BIOL CHEM, V257, P607; Kanai M, 2007, BIOCHEM BIOPH RES CO, V359, P426, DOI 10.1016/j.bbrc.2007.05.108; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Lee B, 2014, DEV CELL, V29, P47, DOI 10.1016/j.devcel.2014.03.005; Lee S, 2000, NUCLEIC ACIDS RES, V28, P826, DOI 10.1093/nar/28.3.826; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Leung AKL, 2014, J CELL BIOL, V205, P613, DOI 10.1083/jcb.201402114; Li B, 2002, GENOMICS, V80, P319, DOI 10.1006/geno.2002.6831; Liu DW, 2015, ONCOTARGET, V6, P38552, DOI 10.18632/oncotarget.6035; Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111; Mackay DR, 2006, DEV BIOL, V291, P38, DOI 10.1016/j.ydbio.2005.12.003; Masutani M, 2003, GENE CHROMOSOME CANC, V38, P339, DOI 10.1002/gcc.10250; MIWA M, 1981, J BIOL CHEM, V256, P2916; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Oei SL, 1998, BIOCHEMISTRY-US, V37, P1465, DOI 10.1021/bi9727390; Ogden A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.164; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ong CT, 2013, CELL, V155, P148, DOI 10.1016/j.cell.2013.08.052; Salisbury JL, 2004, J MAMMARY GLAND BIOL, V9, P275, DOI 10.1023/B:JOMG.0000048774.27697.30; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Teng A, 2007, BBA-MOL BASIS DIS, V1772, P89, DOI 10.1016/j.bbadis.2006.08.012; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Unezaki S, 2007, GENES CELLS, V12, P773, DOI 10.1111/j.1365-2443.2007.01084.x; van Drogen F, 2006, MOL CELL, V23, P37, DOI 10.1016/j.molcel.2006.05.020; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Watanabe K, 2014, DEV CELL, V29, P59, DOI 10.1016/j.devcel.2014.03.006; Wells J, 2009, J BIOL CHEM, V284, P29125, DOI 10.1074/jbc.M109.008847; Ye GD, 2016, GASTROENTEROLOGY, V150, P659, DOI 10.1053/j.gastro.2015.11.041	49	6	7	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2750	2766		10.1038/s41388-018-0615-3	http://dx.doi.org/10.1038/s41388-018-0615-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542118				2022-12-17	WOS:000464121600006
J	Toppaldoddi, KR; Cacemiro, MD; Bluteau, O; Panneau-Schmaltz, B; Pioch, A; Muller, D; Villeval, JL; Raslova, H; Constantinescu, SN; Plo, I; Vainchenker, W; Marty, C				Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Panneau-Schmaltz, Barbara; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Constantinescu, Stefan N.; Plo, Isabelle; Vainchenker, William; Marty, Caroline			Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice	ONCOGENE			English	Article							THROMBOPOIETIN RECEPTOR; ESSENTIAL THROMBOCYTHEMIA; CALR MUTATIONS; MYELOFIBROSIS; ACTIVATION	Frameshift mutations in the calreticulin (CALR) gene are present in 30% of essential thrombocythemia and myelofibrosis patients. The two most frequent mutations are CALR del52 (type 1, approximately 60%) and CALR ins5 (type 2, around 30%), but many other rarer mutations exist accounting each for less than 2% of all CALR mutations. Most of them are structurally classified as type 1-like and type 2-like CALR mutations according to the absence or presence of a residual wild-type calcium-binding motif and the modification of the alpha-helix structure. Yet, several key questions remain unanswered, especially the reason of such low frequencies of these other mutations. In an attempt to investigate specific pathogenic differences between type 1-like and type 2-like CALR mutations and del52 and ins5, we modeled two type 1-like (del34 and del46) and one type 2-like (dell9) mutations in cell lines and in mice. All CALR mutants constitutively activate JAK2 and STAT5/3/1 in a similar way in the presence of the thrombopoietin receptor (MPL) and induced cytokine-independent cell growth but to a lesser extent with rare mutants over time. This correlates with reduced expression levels of rare CALR mutants compared to del52 and ins5. Lethally irradiated mice that were engrafted with bone marrow transduced with the different CALR mutations developed thrombocytosis, but to a much lesser extent with ins5 and the type 2-like CALR mutation. In contrast to type 2-like mice, type 1-like mice developed marked myelofibrosis and splenomegaly 10 months after engraftment. Similar to del52, type 1-like CALR mutations induced an expansion at an early stage of hematopoiesis compared to ins5 and type 2-like mutation. Thus, type 1-like and type 2-like CALR mutants structurally and functionally resemble del52 and ins5 mutants, respectively.	[Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Plo, Isabelle; Vainchenker, William; Marty, Caroline] INSERM, UMR 1170, Gustave Roussy, Villejuif, France; [Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Panneau-Schmaltz, Barbara; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Plo, Isabelle; Vainchenker, William; Marty, Caroline] Univ Paris Saclay, UMR 1170, Gustave Roussy, Villejuif, France; [Toppaldoddi, Katte Rao; Cacemiro, Maira da Costa; Bluteau, Olivier; Panneau-Schmaltz, Barbara; Pioch, Amelie; Muller, Delphine; Villeval, Jean-Luc; Raslova, Hana; Plo, Isabelle; Vainchenker, William; Marty, Caroline] Gustave Roussy, UMR 1170, Villejuif, France; [Cacemiro, Maira da Costa] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Ribeirao Preto, SP, Brazil; [Constantinescu, Stefan N.] Ludwig Inst Canc Res, Brussels, Belgium; [Constantinescu, Stefan N.] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Universidade de Sao Paulo; Ludwig Institute for Cancer Research; Universite Catholique Louvain	Marty, C (corresponding author), INSERM, UMR 1170, Gustave Roussy, Villejuif, France.; Marty, C (corresponding author), Univ Paris Saclay, UMR 1170, Gustave Roussy, Villejuif, France.; Marty, C (corresponding author), Gustave Roussy, UMR 1170, Villejuif, France.	caroline.marty@gustaveroussy.fr	Plo, Isabelle/C-9056-2017; MARTY, Caroline/I-1721-2017; Plo, Isabelle/AAT-6742-2021; Raslova, Hana/N-3562-2018; da Costa Cacemiro, Maira/S-4458-2017	Plo, Isabelle/0000-0002-5915-6910; MARTY, Caroline/0000-0003-4350-2302; Raslova, Hana/0000-0001-8846-5299; da Costa Cacemiro, Maira/0000-0002-4170-2063; Villeval, Jean-Luc/0000-0002-0562-925X; Vainchenker, William/0000-0003-4705-202X	Ligue Nationale Contre le Cancer ("Equipe labellisee 2016"); Institut National du Cancer (PLBIO-2015); MPN Research Foundation; Agence Nationale de la Recherche (ANR-DFG 2014, JAK-POT); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Medecine Moleculaire Personnalisee du Cancer (MMO, ANR); Agence Nationale de la Recherche; Ludwig Institute for Cancer Research; Salus Sanguinis; Fondation contre le Cancer; Action de Recherche Concertee; Belgian Genetic Medical Initiative Interuniversity Attraction Pole, Belspo	Ligue Nationale Contre le Cancer ("Equipe labellisee 2016"); Institut National du Cancer (PLBIO-2015); MPN Research Foundation; Agence Nationale de la Recherche (ANR-DFG 2014, JAK-POT)(French National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut de Medecine Moleculaire Personnalisee du Cancer (MMO, ANR)(French National Research Agency (ANR)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Ludwig Institute for Cancer Research; Salus Sanguinis; Fondation contre le Cancer; Action de Recherche Concertee; Belgian Genetic Medical Initiative Interuniversity Attraction Pole, Belspo	This work was supported by grants from Ligue Nationale Contre le Cancer ("Equipe labellisee 2016", H.R.), Institut National du Cancer (PLBIO-2015, I.P.), MPN Research Foundation (I.P.), Agence Nationale de la Recherche (ANR-DFG 2014, JAK-POT, J.L.V.) and Institut National de la Sante et de la Recherche Medicale (Inserm). B. P-S. was funded by Institut de Medecine Moleculaire Personnalisee du Cancer (MMO, ANR). O.B. was supported by Agence Nationale de la Recherche. Support to S.N.C. was from Ludwig Institute for Cancer Research, Salus Sanguinis, Fondation contre le Cancer, Action de Recherche Concertee and Belgian Genetic Medical Initiative Interuniversity Attraction Pole, Belspo. We thank O. Bawa for histology, the staff of the animal facilities of Gustave Roussy directed by P. Gonin, and P. Rameau and Y. Lecluse at the Imaging and Cytometry Platform.	Araki M, 2016, BLOOD, V127, P1307, DOI 10.1182/blood-2015-09-671172; Balligand T, 2016, LEUKEMIA, V30, P1775, DOI 10.1038/leu.2016.47; Barbui T, 2016, BLOOD REV, V30, P453, DOI 10.1016/j.blre.2016.06.001; Cabagnols X, 2015, LEUKEMIA, V29, P249, DOI 10.1038/leu.2014.270; Chachoua I, 2016, BLOOD, V127, P1325, DOI 10.1182/blood-2015-11-681932; Eder-Azanza L, 2014, LEUKEMIA, V28, P2106, DOI 10.1038/leu.2014.190; Elala YC, 2016, AM J HEMATOL, V91, P503, DOI 10.1002/ajh.24338; Elf S, 2016, CANCER DISCOV, V6, P368, DOI 10.1158/2159-8290.CD-15-1434; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Li J, 2018, BLOOD, V131, P649, DOI 10.1182/blood-2017-09-806356; Marty C, 2016, BLOOD, V127, P1317, DOI 10.1182/blood-2015-11-679571; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Pietra D, 2016, LEUKEMIA, V30, P431, DOI 10.1038/leu.2015.277; Shide K, 2017, LEUKEMIA, V31, P1136, DOI 10.1038/leu.2016.308; Tefferi A, 2014, BLOOD, V124, P2465, DOI 10.1182/blood-2014-07-588426; Tefferi A, 2014, AM J HEMATOL, V89, pE121, DOI 10.1002/ajh.23743; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940	17	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2019	38	10					1651	1660		10.1038/s41388-018-0538-z	http://dx.doi.org/10.1038/s41388-018-0538-z			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HN8DD	30846848				2022-12-17	WOS:000460423800006
J	Best, SA; Harapas, CR; Kersbergen, A; Rathi, V; Asselin-Labat, ML; Sutherland, KD				Best, Sarah A.; Harapas, Cassandra R.; Kersbergen, Ariena; Rathi, Vivek; Asselin-Labat, Marie-Liesse; Sutherland, Kate D.			FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium	ONCOGENE			English	Article							CELL LUNG-CANCER; MEDIATED GENE-TRANSFER; MOUSE MODEL; STEM-CELLS; TUMOR-SUPPRESSOR; OF-ORIGIN; IN-VIVO; ADENOCARCINOMA; IDENTIFICATION; CARCINOMA	Structural rearrangements of the genome can drive lung tumorigenesis through the generation of fusion genes with oncogenic properties. Advanced genomic approaches have identified the presence of a genetic fusion between fibroblast growth factor receptor 3 (FGFR3) and transforming acidic coiled-coil 3 (TACC3) in non-small cell lung cancer (NSCLC), providing a novel target for FGFR inhibition. To interrogate the functional consequences of the FGFR3-TACC3 fusion in the transformation of lung epithelial cells, we generated a novel transgenic mouse model that expresses FGFR3-TACC3 concomitant with loss of the p53 tumor suppressor gene. Intranasal delivery of an Ad5-CMV-Cre virus promoted seromucinous glandular transformation of olfactory cells lining the nasal cavities of FGFR3-TACC3 (LSL-F3T3) mice, which was further accelerated upon loss of p53 (LSL-F3T3/p53). Surprisingly, lung tumors failed to develop in intranasally infected LSL-F3T3 and LSL-F3T3/p53 mice. In line with these observations, we demonstrated that intranasal delivery of Ad5-CMV-Cre induces widespread Cre-mediated recombination in the olfactory epithelium. Intra-tracheal delivery of Ad5-CMV-Cre into the lungs of LSL-F3T3 and LSL-F3T3/p53 mice, however, resulted in the development of lung adenocarcinomas. Taken together, these findings provide in vivo evidence for an oncogenic function of FGFR3-TACC3 in respiratory epithelium.	[Best, Sarah A.; Harapas, Cassandra R.; Kersbergen, Ariena; Asselin-Labat, Marie-Liesse; Sutherland, Kate D.] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia; [Best, Sarah A.; Asselin-Labat, Marie-Liesse; Sutherland, Kate D.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia; [Rathi, Vivek] Univ Melbourne, St Vincents Hosp, Dept Anat Pathol, Fitzroy, Vic 3065, Australia	Walter & Eliza Hall Institute; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Sutherland, KD (corresponding author), Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia.; Sutherland, KD (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia.	sutherland.k@wehi.edu.au	Rathi, Vivek/AAD-5983-2021	Best, Sarah/0000-0002-4232-9432; Sutherland, Kate/0000-0002-7453-3366	Worldwide Cancer Research Project Grant [14-0433]; Victorian Cancer Agency (VCA) Early Career Seed Grant [ECSG16001]; Viertel Foundation Senior Medical Research Fellowship; Peter and Julie Alston Centenary Fellowship	Worldwide Cancer Research Project Grant; Victorian Cancer Agency (VCA) Early Career Seed Grant; Viertel Foundation Senior Medical Research Fellowship; Peter and Julie Alston Centenary Fellowship	We are grateful to C. Alvarado, L. Scott, H. Johnson, K. Birchall, and L. Mackiewicz for animal husbandry, E. Tsui and C. Tsui in the WEHI Histology Facility for expert support and P. Maltezos for preparation of the nasal cavity graphic image. The authors thank T. Wilson, J. Mighall, and J. Pasquet for technical support and W. Alexander for useful discussions and critically reading the manuscript. This work was supported in part by a Worldwide Cancer Research Project Grant [14-0433]. SAB is supported by a Victorian Cancer Agency (VCA) Early Career Seed Grant (ECSG16001); M-LA-L is supported by a Viertel Foundation Senior Medical Research Fellowship; KDS is supported by the Peter and Julie Alston Centenary Fellowship. This work was made possible through Victorian Government Operational Infrastructure Support and Australian Government.	[Anonymous], 2016, CANC FACTS FIG 2016; Arimoto Y, 2002, ACTA OTO-LARYNGOL, V122, P627, DOI 10.1080/000164802320396303; Beard C, 2006, GENESIS, V44, P23, DOI 10.1002/gene.20180; Best SA, 2018, CELL METAB, V27, P935, DOI 10.1016/j.cmet.2018.02.006; Best SA, 2018, METHODS MOL BIOL, V1725, P15, DOI 10.1007/978-1-4939-7568-6_2; Best SA, 2017, J INVEST DERMATOL, V137, P506, DOI 10.1016/j.jid.2016.09.027; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Capelletti M, 2014, CLIN CANCER RES, V20, P6551, DOI 10.1158/1078-0432.CCR-14-1337; Carneiro BA, 2015, GYNECOL ONCOL REP, V13, P53, DOI 10.1016/j.gore.2015.06.005; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen Z, 2010, CANCER RES, V70, P9827, DOI 10.1158/0008-5472.CAN-10-1671; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Daly C, 2017, ONCOGENE, V36, P471, DOI 10.1038/onc.2016.216; Damjanovic Daniela, 2008, Genet Vaccines Ther, V6, P5, DOI 10.1186/1479-0556-6-5; Doi K, 2005, ANN OTO RHINOL LARYN, V114, P629, DOI 10.1177/000348940511400808; Duggan CD, 2007, NAT NEUROSCI, V10, P673, DOI 10.1038/nn0607-673; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao QS, 2018, CELL REP, V23, P227, DOI 10.1016/j.celrep.2018.03.050; George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hatch TF, 1964, PULM DEP RET INH AER; Huijbers IJ, 2014, EMBO MOL MED, V6, P212, DOI 10.1002/emmm.201303297; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Johnson VJ, 2007, J IMMUNOL, V179, P1864, DOI 10.4049/jimmunol.179.3.1864; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Jordan EJ, 2017, CANCER DISCOV, V7, P596, DOI 10.1158/2159-8290.CD-16-1337; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kwon MC, 2013, MOL ONCOL, V7, P165, DOI 10.1016/j.molonc.2013.02.010; Leong HS, 2013, CANCER RES, V73, P1591, DOI 10.1158/0008-5472.CAN-12-3019; Leung CT, 2007, NAT NEUROSCI, V10, P720, DOI 10.1038/nn1882; Majewski IJ, 2013, J PATHOL, V230, P270, DOI 10.1002/path.4209; Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Nelson KN, 2016, MOL CANCER RES, V14, P458, DOI 10.1158/1541-7786.MCR-15-0497; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834; Snyder EL, 2013, MOL CELL, V50, P185, DOI 10.1016/j.molcel.2013.02.018; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2008, P NATL ACAD SCI USA, V105, P19893, DOI 10.1073/pnas.0805381105; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019; Sutherland KD, 2010, MOL ONCOL, V4, P397, DOI 10.1016/j.molonc.2010.05.002; Weeden CE, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000731; Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486; Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Yin YJ, 2013, CANCER RES, V73, P5730, DOI 10.1158/0008-5472.CAN-13-0495; Yuan L, 2014, CANCER BIOL THER, V15, P1613, DOI 10.4161/15384047.2014.961874; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhao HQ, 1996, J NEUROBIOL, V30, P521, DOI 10.1002/(SICI)1097-4695(199608)30:4<521::AID-NEU7>3.0.CO;2-5	58	6	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2018	37	46					6096	6104		10.1038/s41388-018-0399-5	http://dx.doi.org/10.1038/s41388-018-0399-5			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HA3SQ	29991799	Green Accepted			2022-12-17	WOS:000450175900007
J	Kong, FY; Deng, X; Kong, XY; Du, YQ; Li, L; Zhu, HY; Wang, YX; Xie, DC; Guha, S; Li, ZS; Guan, M; Xie, KP				Kong, Fanyang; Deng, Xuan; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Xie, Dacheng; Guha, Shivani; Li, Zhaoshen; Guan, Ming; Xie, Keping			ZFPM2-AS1, a novel IncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF (vol 37 pg 5982, 2018)	ONCOGENE			English	Correction									[Kong, Fanyang; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Li, Zhaoshen] Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Kong, Fanyang; Kong, Xiangyu; Xie, Dacheng; Guha, Shivani; Xie, Keping] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Deng, Xuan; Guan, Ming] Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai, Peoples R China	Naval Medical University; University of Texas System; UTMD Anderson Cancer Center; Fudan University	Li, ZS (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.; Guan, M (corresponding author), Fudan Univ, Shanghai Med Coll, Huashan Hosp, Dept Lab Med, Shanghai, Peoples R China.	zhaoshenli5610@hotmail.com; guanminghsyy@hotmail.com; kepxie@mdanderson.org						Kong FY, 2018, ONCOGENE, V37, P5982, DOI 10.1038/s41388-018-0387-9	1	6	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					6010	6010		10.1038/s41388-018-0412-z	http://dx.doi.org/10.1038/s41388-018-0412-z			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	30108331	Bronze			2022-12-17	WOS:000449562500008
J	Chow, M; Gao, LN; MacManiman, JD; Bicocca, VT; Chang, BH; Alumkal, JJ; Tyner, JW				Chow, Marilynn; Gao, Lina; MacManiman, Jason D.; Bicocca, Vincent T.; Chang, Bill H.; Alumkal, Joshi J.; Tyner, Jeffrey W.			Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RECEPTOR TYROSINE KINASE; CHRONIC LYMPHOCYTIC-LEUKEMIA; HEMI-METHYLATED DNA; CELL RECEPTOR; ANTIGEN ROR1; SRA DOMAIN; CANCER; EXPRESSION; NAPHTHAZARIN	Expression of the transmembrane pseudokinase ROR1 is required for survival of t(1;19)-pre-B-cell acute lymphoblastic leukemia (t(1;19) pre-B-ALL), chronic lymphocytic leukemia, and many solid tumors. However, targeting ROR1 with small-molecules has been challenging due to the absence of ROR1 kinase activity. To identify genes that regulate ROR1 expression and may, therefore, serve as surrogate drug targets, we employed an siRNA screening approach and determined that the epigenetic regulator and E3 ubiquitin ligase, UHRF1, is required for t(1;19) pre-B-ALL cell viability in a ROR1-dependent manner. Upon UHRF1 silencing, ROR1 protein is reduced without altering ROR1 mRNA, and ectopically expressed UHRF1 is sufficient to increase ROR1 levels. Additionally, proteasome inhibition rescues loss of ROR1 protein after UHRF1 silencing, suggesting a role for the proteasome in the UHRF1-ROR1 axis. Finally, we show that ROR1-positive cells are twice as sensitive to the UHRF1-targeting drug, naphthazarin, and undergo increased apoptosis compared to ROR1-negative cells. Naphthazarin elicits reduced expression of UHRF1 and ROR1, and combination of naphthazarin with inhibitors of pre-B cell receptor signaling results in further reduction of cell survival compared with either inhibitor alone. Therefore, our work reveals a mechanism by which UHRF1 stabilizes ROR1, suggesting a potential targeting strategy to inhibit ROR1 in t(1;19) pre-B-ALL and other malignancies.	[Chow, Marilynn; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Gao, Lina; MacManiman, Jason D.; Bicocca, Vincent T.; Chang, Bill H.; Alumkal, Joshi J.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Gao, Lina; Alumkal, Joshi J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; [MacManiman, Jason D.; Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Chang, Bill H.] Oregon Hlth & Sci Univ, Div Pediat Hematol & Oncol, Doernbecher Childrens Hosp, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.; Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.; Tyner, JW (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA.	tynerj@ohsu.edu		Chow-Castro, Marilynn/0000-0001-8819-4441; Bicocca, Vincent/0000-0002-5702-4586	Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) [TL1TR000129]; Hyundai Hope on Wheels; Leukemia and Lymphoma Society; V Foundation for Cancer Research; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute [5R00CA151457-04, 1R01CA183947-01]; NATIONAL CANCER INSTITUTE [R00CA151457, K99CA151457] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR000129] Funding Source: NIH RePORTER	Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Hyundai Hope on Wheels; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); V Foundation for Cancer Research; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	The pCS2-6XMYC vector was a generous gift from Dr. Monika Davare. The authors would like to thank David K. Edwards V, Samantha L. Savage, Anna M. Reister Schultz, Dr. Haijiao Zhang, and Janet Pittsenbarger for their technical expertise and Dr. Kevin M. Watanabe-Smith for editing the manuscript. MC was supported in part by the Oregon Clinical and Translational Research Institute (OCTRI) (TL1TR000129) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). BHC is supported by the Hyundai Hope on Wheels. JWT is supported by The Leukemia and Lymphoma Society, the V Foundation for Cancer Research, Gabrielle's Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01).	Abu-Alainin W, 2016, J PATHOL, V238, P423, DOI 10.1002/path.4665; Acharya BR, 2011, APOPTOSIS, V16, P924, DOI 10.1007/s10495-011-0613-1; Alhosin M, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0453-5; Alhosin M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08996; Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Balakrishnan A, 2017, CLIN CANCER RES, V23, P3061, DOI 10.1158/1078-0432.CCR-16-2083; Baskar S, 2008, CLIN CANCER RES, V14, P396, DOI 10.1158/1078-0432.CCR-07-1823; Baskar S, 2012, MABS-AUSTIN, V4, P349, DOI 10.4161/mabs.19870; Bicocca VT, 2012, CANCER CELL, V22, P656, DOI 10.1016/j.ccr.2012.08.027; Borcherding N, 2014, PROTEIN CELL, V5, P496, DOI 10.1007/s13238-014-0059-7; Fernandez NB, 2016, MOL CARCINOGEN, V55, P1772, DOI 10.1002/mc.22426; Broome HE, 2011, LEUKEMIA RES, V35, P1390, DOI 10.1016/j.leukres.2011.06.021; Chen DF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162638; Choi MY, 2015, CL LYMPH MYELOM LEUK, V15, pS167, DOI 10.1016/j.clml.2015.02.010; DaneshManesh AH, 2008, INT J CANCER, V123, P1190, DOI 10.1002/ijc.23587; Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Foa R, 2003, BRIT J HAEMATOL, V120, P484, DOI 10.1046/j.1365-2141.2003.04113.x; Fukuda T, 2008, P NATL ACAD SCI USA, V105, P3047, DOI 10.1073/pnas.0712148105; Gentile A, 2011, CANCER RES, V71, P3132, DOI 10.1158/0008-5472.CAN-10-2662; Hudecek M, 2010, BLOOD, V116, P4532, DOI 10.1182/blood-2010-05-283309; Hunger SP, 1996, BLOOD, V87, P1211, DOI 10.1182/blood.V87.4.1211.bloodjournal8741211; Jia YH, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.7; Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07; Kaucka M, 2011, ACTA PHYSIOL, V203, P351, DOI 10.1111/j.1748-1716.2011.02306.x; Kim JA, 2012, INT J ONCOL, V40, P157, DOI 10.3892/ijo.2011.1195; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Kim MY, 2015, INT J ONCOL, V46, P1659, DOI 10.3892/ijo.2015.2857; Kueh AJ, 2011, MOL CELL BIOL, V31, P845, DOI 10.1128/MCB.00159-10; Li P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011859; Loh ML, 2012, CLIN CANCER RES, V18, P2754, DOI 10.1158/1078-0432.CCR-11-1936; Ma J, 2015, BIOCHEM BIOPH RES CO, V464, P147, DOI 10.1016/j.bbrc.2015.06.104; Mani R, 2015, LEUKEMIA, V29, P346, DOI 10.1038/leu.2014.199; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Moorman AV, 2010, BLOOD, V115, P206, DOI 10.1182/blood-2009-07-232124; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003; Myrianthopoulos V, 2016, EUR J MED CHEM, V114, P390, DOI 10.1016/j.ejmech.2016.02.043; Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244; Nygren MK, 2009, EXP HEMATOL, V37, P225, DOI 10.1016/j.exphem.2008.10.007; Qu XY, 2015, EPIGENETICS-US, V10, P526, DOI 10.1080/15592294.2015.1048060; Rajakumara E, 2011, MOL CELL, V43, P275, DOI 10.1016/j.molcel.2011.07.006; Rau R, 2009, HEMATOL ONCOL, V27, P171, DOI 10.1002/hon.904; Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152; Sanchez-Aguilera A, 2010, LEUKEMIA, V24, P97, DOI 10.1038/leu.2009.217; Sanda T, 2013, CANCER DISCOV, V3, P564, DOI 10.1158/2159-8290.CD-12-0504; Shabani M, 2008, LEUKEMIA LYMPHOMA, V49, P1360, DOI 10.1080/10428190802124000; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Tasian SK, 2017, BRIT J HAEMATOL, V176, P867, DOI 10.1111/bjh.14474; Troeger A, 2012, BLOOD, V119, P4708, DOI 10.1182/blood-2011-12-395939; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1; Widhopf GF, 2014, P NATL ACAD SCI USA, V111, P793, DOI 10.1073/pnas.1308374111; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Zhang SP, 2012, AM J PATHOL, V181, P1903, DOI 10.1016/j.ajpath.2012.08.024; Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]	60	6	6	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5221	5232		10.1038/s41388-018-0299-8	http://dx.doi.org/10.1038/s41388-018-0299-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849118	Green Accepted			2022-12-17	WOS:000445093100006
J	Basu, SK; Gonit, M; Salotti, J; Chen, JJ; Bhat, A; Gorospe, M; Viollet, B; Claffey, KP; Johnson, PF				Basu, Sandip K.; Gonit, Mesfin; Salotti, Jacqueline; Chen, Jiji; Bhat, Atharva; Gorospe, Myriam; Viollet, Benoit; Claffey, Kevin P.; Johnson, Peter F.			A RAS-CaMKK beta-AMPK alpha 2 pathway promotes senescence by licensing post-translational activation of C/EBP beta through a novel 3'UTR mechanism	ONCOGENE			English	Article							PROTEIN-KINASE; SECRETORY PHENOTYPE; UPSTREAM KINASE; CELL-GROWTH; AMPK; PHOSPHORYLATION; PROGRESSION; FIBROBLASTS; METABOLISM; INITIATION	Oncogene-induced senescence (OIS) is an intrinsic tumor suppression mechanism that requires the p53 and RB pathways and post-translational activation of C/EBP beta through the RAS-ERK cascade. We previously reported that in transformed/proliferating cells, C/EBP beta activation is inhibited by G/U-rich elements (GREs) in its 3'UTR. This mechanism, termed "3' UTR regulation of protein activity" (UPA), maintains C/EBP beta in a low-activity state in tumor cells and thus facilitates senescence bypass. Here we show that C/EBP beta UPA is overridden by AMPK signaling. AMPK activators decrease cytoplasmic levels of the GRE binding protein HuR, which is a key UPA component. Reduced cytoplasmic HuR disrupts 3'-UTR-mediated trafficking of Cebpb transcripts to the peripheral cytoplasm-a fundamental feature of UPA-thereby stimulating C/EBP beta activation and growth arrest. In primary cells, oncogenic RAS triggers a Ca++-CaMKK beta-AMPK alpha 2-HuR pathway, independent of AMPK alpha 1, that is essential for C/EBP beta activation and OIS. This axis is disrupted in cancer cells through down-regulation of AMPK alpha 2 and CaMKK beta. Thus, CaMKK beta-AMPK alpha 2 signaling constitutes a key tumor suppressor pathway that activates a novel UPA-cancelling mechanism to unmask the cytostatic and pro-senescence functions of C/EBP beta.	[Basu, Sandip K.; Gonit, Mesfin; Salotti, Jacqueline; Johnson, Peter F.] NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA; [Chen, Jiji; Bhat, Atharva] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA; [Gorospe, Myriam] NIA, Lab Genet, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Viollet, Benoit] Inst Cochin, INSERM, U1016, F-75014 Paris, France; [Viollet, Benoit] CNRS, UMR8104, F-75014 Paris, France; [Viollet, Benoit] Univ Paris 05, Sorbonne Paris Cite, F-75014 Paris, France; [Claffey, Kevin P.] Univ Connecticut, Hlth Ctr, Dept Cell Biol, Farmington, CT USA; [Gonit, Mesfin] Lentigen Tech Inc, Gaithersburg, MD USA; [Chen, Jiji] NIH, Adv Imaging & Microscopy Resource, Bldg 10, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Connecticut; National Institutes of Health (NIH) - USA	Johnson, PF (corresponding author), NCI, Mouse Canc Genet Program, Ctr Canc Res, Frederick, MD 21701 USA.	johnsope@mail.nih.gov	Viollet, Benoit/N-2397-2019; Gorospe, Myriam/Y-3613-2019; Salotti, Jacqueline/M-4515-2019; Viollet, Benoit/O-6927-2017	Viollet, Benoit/0000-0002-0121-0224; Salotti, Jacqueline/0000-0001-6009-6751; Viollet, Benoit/0000-0002-0121-0224	NIH, National Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000393, ZIAAG000511] Funding Source: NIH RePORTER	NIH, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank R. Jones for the CA-AMPK vector, N. Bardeesy for Lkb1<SUP>-/-</SUP> MEFs, T. Brown for a pan-AMPK alpha knockdown vector, K. Saylor and N. Martin for animal husbandry and genotyping, and A. Kane (Scientific Publications, Graphics & Media, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research) for preparation of figures. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.	Anderson KA, 2008, CELL METAB, V7, P377, DOI 10.1016/j.cmet.2008.02.011; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Basu SK, 2018, CANCER RES, V78, P891, DOI 10.1158/0008-5472.CAN-17-2353; Basu SK, 2011, EMBO J, V30, P3714, DOI 10.1038/emboj.2011.250; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Doller A, 2008, CELL SIGNAL, V20, P2165, DOI 10.1016/j.cellsig.2008.05.007; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Fox Melissa M, 2013, Genes Cancer, V4, P3, DOI 10.1177/1947601913486346; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Huggins CJ, 2013, MOL CELL BIOL, V33, P3242, DOI 10.1128/MCB.01674-12; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jeon Sang-Min, 2012, Cell Logist, V2, P197; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim HH, 2008, CELL CYCLE, V7, P3124, DOI 10.4161/cc.7.20.6884; Kim HH, 2008, GENE DEV, V22, P1804, DOI 10.1101/gad.1645808; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Lee S, 2010, MOL CELL BIOL, V30, P2621, DOI 10.1128/MCB.00782-09; Lopez de Silanes Isabel, 2005, RNA Biol, V2, P11; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nandy K, 2016, IEEE J-STSP, V10, P140, DOI 10.1109/JSTSP.2015.2505148; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Ovesny M, 2014, BIOINFORMATICS, V30, P2389, DOI 10.1093/bioinformatics/btu202; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Phoenix Kathryn N, 2012, Genes Cancer, V3, P51, DOI 10.1177/1947601912452883; Rios M, 2013, CANCER RES, V73, P2628, DOI 10.1158/0008-5472.CAN-12-0861; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rook MS, 2000, J NEUROSCI, V20, P6385, DOI 10.1523/JNEUROSCI.20-17-06385.2000; Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0; Salotti J, 2015, MOL CELL BIOL, V35, P866, DOI 10.1128/MCB.01489-14; Scheffler JM, 2014, METHOD ENZYMOL, V535, P93, DOI 10.1016/B978-0-12-397925-4.00006-7; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Sebastian T, 2009, CANCER RES, V69, P2588, DOI 10.1158/0008-5472.CAN-08-2312; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shen CH, 2013, MOL CELL, V52, P161, DOI 10.1016/j.molcel.2013.08.044; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Tangeman Larissa, 2012, J RNAi Gene Silencing, V8, P470; Vila IK, 2017, CANCER CELL, V31, P208, DOI 10.1016/j.ccell.2017.01.003; Wang SB, 2012, J BIOL CHEM, V287, P8001, DOI 10.1074/jbc.M111.315812; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wang WG, 2003, J BIOL CHEM, V278, P27016, DOI 10.1074/jbc.M300318200; Whelan DR, 2015, SCI REP-UK, V5, DOI 10.1038/srep07924; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yoo PS, 2009, ANN SURG ONCOL, V16, P200, DOI 10.1245/s10434-008-0209-3	62	6	6	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3528	3548		10.1038/s41388-018-0190-7	http://dx.doi.org/10.1038/s41388-018-0190-7			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563610	Green Accepted			2022-12-17	WOS:000436412500005
J	Park, J; Kim, J; Park, B; Yang, KM; Sun, EJ; Tognon, CE; Sorensen, PH; Kim, SJ				Park, Jinah; Kim, Junil; Park, Bora; Yang, Kyung-Min; Sun, Eun Jin; Tognon, Cristina E.; Sorensen, Poul H.; Kim, Seong-Jin			Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; PHOSPHORYLATION-ACETYLATION SWITCH; GENE FUSION; RNA-SEQ; CONGENITAL FIBROSARCOMA; MYELOGENOUS LEUKEMIA; REGULATORY NETWORK; BREAST-CANCER; TRANSFORMATION; TRANSCRIPTION	Chromosomal rearrangements that facilitate tumor formation and progression through activation of oncogenic tyrosine kinases are frequently observed in cancer. The ETV6-NTRK3 (EN) fusion has been implicated in various cancers, including infantile fibrosarcoma, secretory breast carcinoma, and acute myeloblastic leukemia, and has exhibited in vivo and in vitro transforming ability. In the present study, we analyzed transcriptome alterations using DNA microarray and RNA-Seq in EN-transduced NIH3T3 fibroblasts to identify the mechanisms that are involved in EN-mediated tumorigenesis. Through functional profile assessment of EN-regulated transcriptome alterations, we found that upregulated genes by EN were mainly associated with cell motion, membrane invagination, and cell proliferation, while downregulated genes were involved in cell adhesion, which correlated with the transforming potential and increased proliferation in EN-transduced cells. KEGG pathway analysis identified the JAK-STAT signaling pathway with the highest statistical significance. Moreover, Ingenuity Pathway Analysis and gene regulatory network analysis identified the STAT1 transcription factor and its target genes as top EN-regulated molecules. We further demonstrated that EN enhanced STAT1 phosphorylation but attenuated STAT1 acetylation, eventually inhibiting the interaction between the NF-kappa B p65 subunit and acetylated STAT1. Consequently, nuclear translocation of NF-kappa B p65 and subsequent NF-kappa B activity were increased by EN. Notably, inhibition of STAT1 phosphorylation attenuated tumorigenic ability of EN in vitro and in vivo. Taken together, here we report, for the first time, STAT1 as a significant EN-regulated transcription factor and a crucial mediator of EN-induced tumorigenesis.	[Park, Jinah; Park, Bora; Yang, Kyung-Min; Sun, Eun Jin; Kim, Seong-Jin] Seoul Natl Univ, Precis Med Res Ctr, Adv Inst Convergence Technol, Suwon 16229, Gyeonggi Do, South Korea; [Kim, Junil] Inst Diabet Obes & Metab, Philadelphia, PA 19104 USA; [Kim, Junil] Univ Penn, Dept Genet, Perelman Sch Med, Philadelphia, PA 19104 USA; [Tognon, Cristina E.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA; [Sorensen, Poul H.] British Columbia Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Kim, Seong-Jin] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Suwon 16229, Gyeonggi Do, South Korea	Seoul National University (SNU); University of Pennsylvania; Pennsylvania Medicine; Oregon Health & Science University; British Columbia Cancer Agency; Seoul National University (SNU)	Kim, SJ (corresponding author), Seoul Natl Univ, Precis Med Res Ctr, Adv Inst Convergence Technol, Suwon 16229, Gyeonggi Do, South Korea.; Kim, SJ (corresponding author), Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Suwon 16229, Gyeonggi Do, South Korea.	jasonsjkim@snu.ac.kr		kim, junil/0000-0002-1202-1808	National Research Foundation grant of Korea [NRF-2014M3A9B5073918]; National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea - Korean government [1520120]; British Columbia Cancer Foundation	National Research Foundation grant of Korea(National Research Foundation of Korea); National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea - Korean government; British Columbia Cancer Foundation	This work was supported by a National Research Foundation grant of Korea (NRF-2014M3A9B5073918), a National R&D Program for Cancer Control, Ministry for Health and Welfare, Republic of Korea (1520120) funded by the Korean government, and the British Columbia Cancer Foundation through generous donations from Team Finn and the Ride to Conquer Cancer (to PHS).	Adamaki M, 2015, LEUKEMIA RES, V39, P1285, DOI 10.1016/j.leukres.2015.09.004; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bishop JA, 2017, AM J SURG PATHOL, V41, P62, DOI 10.1097/PAS.0000000000000734; Blake Judith A, 2008, Curr Protoc Bioinformatics, VChapter 7, DOI 10.1002/0471250953.bi0702s23; Brenca M, 2016, J PATHOL, V238, P543, DOI 10.1002/path.4677; Cetinbas N, 2013, J BIOL CHEM, V288, P27940, DOI 10.1074/jbc.M113.475301; Chen JK, 2013, NAT GENET, V45, P34, DOI 10.1038/ng.2491; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fazekas D, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-7; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gridelli C, 2014, CANCER TREAT REV, V40, P300, DOI 10.1016/j.ctrv.2013.07.002; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Hix LM, 2013, J BIOL CHEM, V288, P11676, DOI 10.1074/jbc.M112.441402; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kim J, 2012, NUCLEIC ACIDS RES, V40, P8849, DOI 10.1093/nar/gks664; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Kramer OH, 2010, MOL CELL ENDOCRINOL, V315, P40, DOI 10.1016/j.mce.2009.10.007; Kramer OH, 2009, GENE DEV, V23, P223, DOI 10.1101/gad.479209; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Lannon CL, 2005, SEMIN CANCER BIOL, V15, P215, DOI 10.1016/j.semcancer.2005.01.003; Li B, 2010, BIOINFORMATICS, V26, P493, DOI 10.1093/bioinformatics/btp692; Li Z, 2007, CANCER CELL, V12, P542, DOI 10.1016/j.ccr.2007.11.012; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Malone JH, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-34; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; Shaw AT, 2013, NAT REV CANCER, V13, P772, DOI 10.1038/nrc3612; Skalova A, 2010, AM J SURG PATHOL, V34, P599, DOI 10.1097/PAS.0b013e3181d9efcc; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Tognon C, 2001, CANCER RES, V61, P8909; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Tognon CE, 2011, CANCER RES, V71, P1060, DOI 10.1158/0008-5472.CAN-10-3096; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tymoszuk P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-257; Vlahopoulos SA, 2015, CYTOKINE GROWTH F R, V26, P389, DOI 10.1016/j.cytogfr.2015.06.001; Wada R, 2016, PATHOL INT, V66, P431, DOI 10.1111/pin.12431; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105; Zaidi MR, 2011, CLIN CANCER RES, V17, P6118, DOI 10.1158/1078-0432.CCR-11-0482	46	6	6	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	17					2270	2284		10.1038/s41388-017-0102-2	http://dx.doi.org/10.1038/s41388-017-0102-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE3FW	29391602				2022-12-17	WOS:000431100200005
J	Yoo, JY; Yang, WS; Lee, JH; Kim, BG; Broaddus, RR; Lim, JM; Kim, TH; Jeong, JW				Yoo, J-Y; Yang, W. S.; Lee, J. H.; Kim, B. G.; Broaddus, R. R.; Lim, J. M.; Kim, T. H.; Jeong, J-W			MIG-6 negatively regulates STAT3 phosphorylation in uterine epithelial cells	ONCOGENE			English	Article							PROGESTERONE-RECEPTOR; ENDOMETRIAL CANCER; CONSERVATIVE TREATMENT; SIGNAL TRANSDUCER; ACTIVATION; EXPRESSION; PROLIFERATION; HYPERPLASIA; LACTOFERRIN; INHIBITOR	Endometrial cancer is the most common malignancy of the female genital tract. Progesterone (P4) has been used for several decades in endometrial cancer treatment, especially in women who wish to retain fertility. However, it is unpredictable which patients will respond to P4 treatment and which may have a P4-resistant cancer. Therefore, identifying the mechanism of P4 resistance is essential to improve the therapies for endometrial cancer. Mitogen-inducible gene 6 (Mig-6) is a critical mediator of progesterone receptor (PGR) action in the uterus. In order to study the function of Mig-6 in P4 resistance, we generated a mouse model in which we specifically ablated Mig-6 in uterine epithelial cells using Sprr2f-cre mice (Sprr2f(cre+) Mig-6(f/f)). Female mutant mice develop endometrial hyperplasia due to aberrant phosphorylation of signal transducers and activators of transcription 3 (STAT3) and proliferation of the endometrial epithelial cells. The results from our immunoprecipitation and cell culture experiments showed that MIG-6 inhibited phosphorylation of STAT3 via protein interactions. Our previous study showed P4 resistance in mice with Mig-6 ablation in Pgr-positive cells (Pgr(cre/+) Mig-6(f/f)). However, Sprr2f(cre+) Mig-6(f/f) mice were P4-responsive. P4 treatment significantly decreased STAT3 phosphorylation and epithelial proliferation in the uterus of mutant mice. We showed that Mig-6 has an important function of tumor suppressor via inhibition of STAT3 phosphorylation in uterine epithelial cells, and the antitumor effects of P4 are mediated by the endometrial stroma. These data help to develop a new signaling pathway in the regulation of steroid hormones in the uterus, and to overcome P4 resistance in human reproductive diseases, such as endometrial cancer.	[Yoo, J-Y; Yang, W. S.; Lee, J. H.; Kim, B. G.; Kim, T. H.; Jeong, J-W] Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA; [Yoo, J-Y] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea; [Yang, W. S.; Lim, J. M.] Seoul Natl Univ, Dept Agr Biotechnol, Seoul, South Korea; [Broaddus, R. R.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Lim, J. M.] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul, South Korea; [Jeong, J-W] Spectrum Hlth Syst, Dept Womens Hlth, Grand Rapids, MI USA	Michigan State University; Michigan State University College of Human Medicine; Yonsei University; Yonsei University Health System; Seoul National University (SNU); University of Texas System; UTMD Anderson Cancer Center; Seoul National University (SNU)	Kim, TH; Jeong, JW (corresponding author), Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	TaeHoon.Kim@hc.msu.edu; JaeWook.Jeong@hc.msu.edu		Yoo, Jung-Yoon/0000-0001-9366-3863	America Cancer Society [RSG-12-084-01-TBG]; National Institutes of Health (NIH) [HD084478]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology [NRF-2016R1D1A1B03934346]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD084478] Funding Source: NIH RePORTER	America Cancer Society; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology(National Research Foundation of Korea); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We would like to thank Dr Diego H Castrillon (University of Texas Southwestern Medical Center, Dallas, TX, USA) for Sprr2f-cre mice. We would also like to thank Hanna E Teasley and Paige Wells for manuscript preparation. This work was supported by America Cancer Society, RSG-12-084-01-TBG and National Institutes of Health (NIH, HD084478) to JWJ and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (NRF-2016R1D1A1B03934346) to JYY.	Ambros RA, 2000, INT J GYNECOL PATHOL, V19, P206, DOI 10.1097/00004347-200007000-00002; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Bovicelli A, 2013, J CELL PHYSIOL, V228, P1154, DOI 10.1002/jcp.24292; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen CL, 2007, BRIT J CANCER, V96, P591, DOI 10.1038/sj.bjc.6603597; Cheng JG, 2001, P NATL ACAD SCI USA, V98, P8680, DOI 10.1073/pnas.151180898; Contreras CM, 2010, DIS MODEL MECH, V3, P181, DOI 10.1242/dmm.004440; Critchley HOD, 2009, REPROD SCI, V16, P191, DOI 10.1177/1933719108331121; Daikoku T, 2014, ENDOCRINOLOGY, V155, P2718, DOI 10.1210/en.2014-1265; Decruze SB, 2007, INT J GYNECOL CANCER, V17, P964, DOI 10.1111/j.1525-1438.2007.00897.x; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; Duncan CG, 2010, ONCOTARGET, V1, P265, DOI 10.18632/oncotarget.137; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; Franco HL, 2012, FASEB J, V26, P1218, DOI 10.1096/fj.11-193334; Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945; Graham JD, 1997, ENDOCR REV, V18, P502, DOI 10.1210/er.18.4.502; Hahn HS, 2009, INT J GYNECOL CANCER, V19, P1068, DOI 10.1111/IGC.0b013e3181aae1fb; HUETHUDSON YM, 1989, ENDOCRINOLOGY, V125, P1683, DOI 10.1210/endo-125-3-1683; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jeong JW, 2009, P NATL ACAD SCI USA, V106, P8677, DOI 10.1073/pnas.0903632106; Kaunitz AM, 1998, INT J FERTIL WOMEN M, V43, P73; Kim BG, 2015, HUM REPROD, V30, P1069, DOI 10.1093/humrep/dev050; Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043; Kim TH, 2010, ONCOGENE, V29, P3770, DOI 10.1038/onc.2010.126; Kim TH, 2013, CANCER RES, V73, P5090, DOI 10.1158/0008-5472.CAN-13-0241; Kurita T, 2000, BIOL REPROD, V62, P831, DOI 10.1095/biolreprod62.4.831; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Lee JH, 2013, FASEB J, V27, P2553, DOI 10.1096/fj.12-225664; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lin CI, 2011, J CLIN ENDOCR METAB, V96, pE554, DOI 10.1210/jc.2010-1800; Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; Pirone DM, 2001, TRENDS GENET, V17, P370, DOI 10.1016/S0168-9525(01)02311-3; Reschke M, 2010, HEPATOLOGY, V51, P1383, DOI 10.1002/hep.23428; Rubel CA, 2010, SEMIN REPROD MED, V28, P27, DOI 10.1055/s-0029-1242990; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; van Laar T, 2001, MOL CARCINOGEN, V31, P63, DOI 10.1002/mc.1040; Wang XC, 2012, INT J ONCOL, V41, P1181, DOI 10.3892/ijo.2012.1568; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Xiong AL, 2014, CANCERS, V6, P926, DOI 10.3390/cancers6020926; Yang S, 2011, TRENDS ENDOCRIN MET, V22, P145, DOI 10.1016/j.tem.2011.01.005; Ying HQ, 2010, P NATL ACAD SCI USA, V107, P6912, DOI 10.1073/pnas.0914930107; Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790; Zhang YW, 2007, CELL CYCLE, V6, P507, DOI 10.4161/cc.6.5.3928	48	6	7	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					255	262		10.1038/onc.2017.335	http://dx.doi.org/10.1038/onc.2017.335			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925396	Green Accepted, Green Submitted			2022-12-17	WOS:000422631700011
J	Huskova, H; Ardin, M; Weninger, A; Vargova, K; Barrin, S; Villar, S; Olivier, M; Stopka, T; Herceg, Z; Hollstein, M; Zavadil, J; Korenjak, M				Huskova, H.; Ardin, M.; Weninger, A.; Vargova, K.; Barrin, S.; Villar, S.; Olivier, M.; Stopka, T.; Herceg, Z.; Hollstein, M.; Zavadil, J.; Korenjak, M.			Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing	ONCOGENE			English	Article							TUMOR P53 MUTATIONS; SWI/SNF COMPLEXES; SOMATIC MUTATIONS; ARISTOLOCHIC ACID; PATHWAYS; PATTERNS; GENES; CELLS; IMMORTALIZATION; INVESTIGATE	The information on candidate cancer driver alterations available from public databases is often descriptive and of limited mechanistic insight, which poses difficulties for reliable distinction between true driver and passenger events. To address this challenge, we performed in-depth analysis of whole-exome sequencing data from cell lines generated by a barrier bypass-clonal expansion (BBCE) protocol. The employed strategy is based on carcinogen-driven immortalization of primary mouse embryonic fibroblasts and recapitulates early steps of cell transformation. Among the mutated genes were almost 200 COSMIC Cancer Gene Census genes, many of which were recurrently affected in the set of 25 immortalized cell lines. The alterations affected pathways regulating DNA damage response and repair, transcription and chromatin structure, cell cycle and cell death, as well as developmental pathways. The functional impact of the mutations was strongly supported by the manifestation of several known cancer hotspot mutations among the identified alterations. We identified a new set of genes encoding subunits of the BAF chromatin remodeling complex that exhibited Ras-mediated dependence on PRC2 histone methyltransferase activity, a finding that is similar to what has been observed for other BAF subunits in cancer cells. Among the affected BAF complex subunits, we determined Smarcd2 and Smarcc1 as putative driver candidates not yet fully identified by large-scale cancer genome sequencing projects. In addition, Ep400 displayed characteristics of a driver gene in that it showed a mutually exclusive mutation pattern when compared with mutations in the Trrap subunit of the TIP60 complex, both in the cell line panel and in a human tumor data set. We propose that the information generated by deep sequencing of the BBCE cell lines coupled with phenotypic analysis of the mutant cells can yield mechanistic insights into driver events relevant to human cancer development.	[Huskova, H.; Ardin, M.; Villar, S.; Olivier, M.; Hollstein, M.; Zavadil, J.; Korenjak, M.] Int Agcy Res Canc, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69008 Lyon, France; [Huskova, H.; Stopka, T.] Charles Univ Prague, Fac Med 1, Biocev, Prague, Czech Republic; [Weninger, A.; Hollstein, M.] Deutsch Krebsforschungszentrum, Heidelberg, Germany; [Vargova, K.] Charles Univ Prague, Fac Med 1, Pathol Physiol, Prague, Czech Republic; [Barrin, S.] Inst Cochin, Inserm U1016, Dynam T Cell Interact Team, Paris, France; [Herceg, Z.] Int Agcy Res Canc, Epigenet Grp, Lyon, France; [Hollstein, M.] Univ Leeds, LIGHT Labs, Fac Med & Hlth, Leeds, W Yorkshire, England	World Health Organization; International Agency for Research on Cancer (IARC); Charles University Prague; Helmholtz Association; German Cancer Research Center (DKFZ); Charles University Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; World Health Organization; International Agency for Research on Cancer (IARC); University of Leeds	Zavadil, J; Korenjak, M (corresponding author), Int Agcy Res Canc, Mol Mech & Biomarkers Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.; Hollstein, M (corresponding author), Univ Leeds, LIGHT Labs, Fac Med & Hlth, Leeds, W Yorkshire, England.	M.Hollstein@leeds.ac.uk; zavadilj@iarc.fr; korenjakm@iarc.fr	Savvulidi Vargova, Karina/ABE-7513-2021; Stopka, Tomáš/D-5864-2017; Zavadil, Jiri/ABG-1780-2020	Savvulidi Vargova, Karina/0000-0002-4969-4133; Stopka, Tomáš/0000-0001-7236-6894; Zavadil, Jiri/0000-0003-0640-5562; Huskova, Hana/0000-0003-3088-4081	INCa-INSERM Plan Cancer [2015 ENV201507]; Ministry of Education, Youth and sports of the Czech Republic [LQ1604]; European Regional Development Fund [CZ.1.05/1.1.00/02.0109]; Czech Science Foundation GACR [GACR 16-27790A]; Ministry of Health/Grant Agency for Health Research of the Czech Republic [AZV 16-27790A]; Charles University in Prague [LH15170, UNCE 204021]; First Faculty of Medicine, Charles University in Prague, Czech Republic; NIH/NCI [P30 CA016087-33]; NATIONAL CANCER INSTITUTE [P30CA016087] Funding Source: NIH RePORTER	INCa-INSERM Plan Cancer; Ministry of Education, Youth and sports of the Czech Republic(Ministry of Education, Youth & Sports - Czech Republic); European Regional Development Fund(European Commission); Czech Science Foundation GACR(Grant Agency of the Czech Republic); Ministry of Health/Grant Agency for Health Research of the Czech Republic; Charles University in Prague; First Faculty of Medicine, Charles University in Prague, Czech Republic; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the group of Hiroyuki Marusawa, Kyoto University, Japan, for providing cells from Hupki-activation-induced cytidine deaminase transgenic mice, Adriana Heguy (NYU Genome Technology Center) for next-generation sequencing support, Christine Carreira (IARC) for antibodies, the Centre Leon Berard in Lyon, France, for providing computational capacity, and Leigh Ellis, Roswell Park Cancer Institute for technical advice. This work was supported by INCa-INSERM Plan Cancer 2015 ENV201507 Grant to JZ; Ministry of Education, Youth and sports of the Czech Republic (LQ1604), European Regional Development Fund (CZ.1.05/1.1.00/02.0109), Czech Science Foundation GACR (GACR 16-27790A) and Ministry of Health/Grant Agency for Health Research of the Czech Republic (AZV 16-27790A) to TS; and Charles University in Prague institutional financing ([LH15170, UNCE 204021) and the Mobility fund, First Faculty of Medicine, Charles University in Prague, Czech Republic to KV. NYU Technology Center is funded in part by grant NIH/NCI P30 CA016087-33.	Alexandrov LB, 2014, CURR OPIN GENET DEV, V24, P52, DOI 10.1016/j.gde.2013.11.014; Blokzijl F, 2016, NATURE, V538, P260, DOI 10.1038/nature19768; Celis JE, 2006, CELL BIOL LAB HDB, P4; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Feldmeyer N, 2006, MUTAT RES-GEN TOX EN, V608, P163, DOI 10.1016/j.mrgentox.2006.02.017; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gonzalez-Perez A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r106; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Hahn WC, 2002, NEW ENGL J MED, V347, P1593, DOI 10.1056/NEJMra021902; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Helleday T, 2014, NAT REV GENET, V15, P585, DOI 10.1038/nrg3729; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Hollstein M, 2017, ONCOGENE, V36, P158, DOI 10.1038/onc.2016.192; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kim JE, 2017, ONCOGENE, V36, P219, DOI 10.1038/onc.2016.193; Kim KH, 2015, NAT MED, V21, P1491, DOI 10.1038/nm.3968; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Leiserson MDM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003054; Liu Zhipei, 2007, Genet Eng (N Y), V28, P45, DOI 10.1007/978-0-387-34504-8_3; Liu ZP, 2005, CANCER RES, V65, P2583, DOI 10.1158/0008-5472.CAN-04-3675; Liu ZP, 2004, P NATL ACAD SCI USA, V101, P2963, DOI 10.1073/pnas.0308607101; Miller CA, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-34; Nedelko T, 2009, INT J CANCER, V124, P987, DOI 10.1002/ijc.24006; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; Olivier M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04482; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Poon SL, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006086; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68; Reinbold M, 2008, ONCOGENE, V27, P2788, DOI 10.1038/sj.onc.1210932; Severson PL, 2014, MUTAT RES-GEN TOX EN, V775, P48, DOI 10.1016/j.mrgentox.2014.10.011; Shain AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055119; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tamborero D, 2013, BIOINFORMATICS, V29, P2238, DOI 10.1093/bioinformatics/btt395; Vandin F, 2012, GENOME RES, V22, P375, DOI 10.1101/gr.120477.111; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; vom Brocke J, 2006, CARCINOGENESIS, V27, P2141, DOI 10.1093/carcin/bg1101; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Yeang CH, 2008, FASEB J, V22, P2605, DOI 10.1096/fj.08-108985; Youn A, 2011, BIOINFORMATICS, V27, P175, DOI 10.1093/bioinformatics/btq630; Zhao JF, 2012, BIOINFORMATICS, V28, P2940, DOI 10.1093/bioinformatics/bts564	51	6	6	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6041	6048		10.1038/onc.2017.215	http://dx.doi.org/10.1038/onc.2017.215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28692054	Green Published, hybrid			2022-12-17	WOS:000413841400012
J	Song, ZB; Wu, P; Ni, JS; Liu, T; Fan, C; Bao, YL; Wu, Y; Sun, LG; Yu, CL; Huang, YX; Li, YX				Song, Z-B; Wu, P.; Ni, J-S; Liu, T.; Fan, C.; Bao, Y-L; Wu, Y.; Sun, L-G; Yu, C-L; Huang, Y-X; Li, Y-X			Testes-specific protease 50 promotes cell proliferation via inhibiting activin signaling	ONCOGENE			English	Article							NF-KAPPA-B; HUMAN BREAST-CANCER; GROWTH-FACTOR; TGF-BETA; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; CYCLE ARREST; TSP50; ACTIVATION; APOPTOSIS	Testes-specific protease 50 (TSP50), a novelly identified oncogene, has the capacity to induce cell proliferation, cell invasion and tumor growth. Further studies indicated that CAGA-luc (an activin-responsive reporter construct) reporter activity could be significantly suppressed by TSP50 overexpression, implying that the activin signaling may participate in TSP50-mediated cell proliferation. Here, we reported that TSP50 had an inhibitory effect on activin signaling. Mechanistic studies revealed that TSP50 could interact with ActRIIA, inhibit activin type. receptor (ActRIB) phosphorylation, repress Smad2/3 nuclear accumulation and finally promote cell proliferation by reducing the expression of activin signal target gene p27. Additionally, we found that ActRIB activation could reverse TSP50-mediated cell proliferation and tumor growth. Furthermore, analysis of human breast cancer specimens by immunohistochemistry indicated that TSP50 expression was negatively related to p-Smad2/3 and p27 protein levels. Most importantly, breast cancer diagnosis-related indicators such as tumor size, tumor grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) levels, were correlated well with TSP50/p-Samd2/3 and TSP50/p27 expression status. Thus, our studies revealed a novel regulatory mechanism underlying TSP50-induced cell proliferation and provided a new favorable intervention target for the treatment of breast cancer.	[Song, Z-B; Wu, P.; Fan, C.; Bao, Y-L; Sun, L-G; Yu, C-L] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, 5268 Renmin St, Changchun 130024, Jilin, Peoples R China; [Song, Z-B; Wu, Y.; Sun, L-G; Yu, C-L; Huang, Y-X; Li, Y-X] Northeast Normal Univ, Inst Genet & Cytol, Changchun, Jilin, Peoples R China; [Ni, J-S; Liu, T.] Jilin Univ, Dept Pathol, Hosp 1, Changchun, Jilin, Peoples R China	Northeast Normal University - China; Northeast Normal University - China; Jilin University	Bao, YL; Li, YX (corresponding author), Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, 5268 Renmin St, Changchun 130024, Jilin, Peoples R China.	baoyl800@nenu.edu.cn; liyx486@nenu.edu.cn			National Natural Science Foundation of China [81272242, 81502284]; National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University [130014561, 130028683]; Jilin outstanding young talent Foundation [20170520031JH]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University; Jilin outstanding young talent Foundation	This research was supported by grants from the National Natural Science Foundation of China (Grant no. 81272242 and 81502284), the Open Project of the National Engineering Laboratory for Druggable Gene and Protein Screening, Northeast Normal University (No. 130014561 and 130028683) and Jilin outstanding young talent Foundation (Grant no. 20170520031JH).	Alexander JM, 1996, J CLIN ENDOCR METAB, V81, P783, DOI 10.1210/jc.81.2.783; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Burdette JE, 2005, CANCER RES, V65, P7968, DOI 10.1158/0008-5472.CAN-04-3553; Burdette JE, 2007, ENDOCR-RELAT CANCER, V14, P679, DOI 10.1677/ERC-07-0054; Chen XS, 2010, TUMORI J, V96, P103, DOI 10.1177/030089161009600117; Chen YG, 2006, EXP BIOL MED, V231, P534; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Dai Jian-Yi, 2003, Ai Zheng, V22, P1093; Danila DC, 2002, J CLIN ENDOCR METAB, V87, P4741, DOI 10.1210/jc.2002-020527; Deli A, 2008, WORLD J GASTROENTERO, V14, P1699, DOI 10.3748/wjg.14.1699; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fang Z, 2012, J BIOL CHEM, V287, P2090, DOI 10.1074/jbc.M111.323303; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Galizia G, 2004, DIS COLON RECTUM, V47, P1904, DOI 10.1007/s10350-004-0695-8; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Huang HJ, 2005, J CLIN PATHOL, V58, P611, DOI 10.1136/jcp.2004.022772; Kaneda H, 2011, BRIT J CANCER, V105, P1210, DOI 10.1038/bjc.2011.348; Landis MD, 2005, ONCOGENE, V24, P5173, DOI 10.1038/sj.onc.1208712; Li YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035030; Liu F, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/498246; Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; Monteleone G, 2004, J BIOL CHEM, V279, P3925, DOI 10.1074/jbc.M303654200; Mylonas I, 2005, ONCOL REP, V13, P81; Panopoulou E, 2005, CANCER RES, V65, P1877, DOI 10.1158/0008-5472.CAN-04-2828; Reis FM, 2004, MOL CELL ENDOCRINOL, V225, P77, DOI 10.1016/j.mce.2004.02.016; Shan JD, 2002, CANCER RES, V62, P290; Shav-Tal Y, 2002, STEM CELLS, V20, P493, DOI 10.1634/stemcells.20-6-493; Shi Y, 2011, J BIOMOL SCREEN, V16, P525, DOI 10.1177/1087057111398486; Song ZB, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.61; Song ZB, 2014, CELL SIGNAL, V26, P2266, DOI 10.1016/j.cellsig.2014.07.012; Song ZB, 2011, BIOCHEM J, V436, P457, DOI 10.1042/BJ20101780; Sozzani S, 2011, BLOOD, V117, P5013, DOI 10.1182/blood-2011-03-342691; Tsuchida K, 2004, MOL CELL ENDOCRINOL, V220, P59, DOI 10.1016/j.mce.2004.03.009; Tsuchida Kunihiro, 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P157, DOI 10.2174/1568008043339901; Wang X, 2011, MED ONCOL, V28, P1225, DOI 10.1007/s12032-010-9552-x; Wiercinska E, 2011, BREAST CANCER RES TR, V128, P657, DOI 10.1007/s10549-010-1147-x; Xu HP, 2007, CANCER RES, V67, P1239, DOI 10.1158/0008-5472.CAN-06-3688; Ying SY, 1997, P SOC EXP BIOL MED, V214, P114; Yuan J, 2015, CELL BIOCHEM BIOPHYS, V71, P891, DOI 10.1007/s12013-014-0279-8; Yuan LM, 1999, CANCER RES, V59, P3215; Zhang Y, 2010, CHEM-BIOL INTERACT, V185, P174, DOI 10.1016/j.cbi.2010.03.035	47	6	6	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					5948	5957		10.1038/onc.2017.198	http://dx.doi.org/10.1038/onc.2017.198			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28650473				2022-12-17	WOS:000413841400004
J	Yurugi, H; Marini, F; Weber, C; David, K; Zhao, Q; Binder, H; Desaubry, L; Rajalingam, K				Yurugi, H.; Marini, F.; Weber, C.; David, K.; Zhao, Q.; Binder, H.; Desaubry, L.; Rajalingam, K.			Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours (vol 36, pg 4778, 2017)	ONCOGENE			English	Correction													Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970				Yurugi H, 2017, ONCOGENE, V36, P4778, DOI 10.1038/onc.2017.93	1	6	7	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5914	5914		10.1038/onc.2017.307	http://dx.doi.org/10.1038/onc.2017.307			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28846116	Bronze			2022-12-17	WOS:000413292900013
J	Fan, LC; Shiau, CW; Tai, WT; Hung, MH; Chu, PY; Hsieh, FS; Lin, H; Yu, HC; Chen, KF				Fan, L-C; Shiau, C-W; Tai, W-T; Hung, M-H; Chu, P-Y; Hsieh, F-S; Lin, H.; Yu, H-C; Chen, K-F			SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma (vol 36, pg 5768, 2017)	ONCOGENE			English	Correction																		Fan LC, 2017, ONCOGENE, V36, P5768, DOI 10.1038/onc.2017.251	1	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5768	5769		10.1038/onc.2017.251	http://dx.doi.org/10.1038/onc.2017.251			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28714962	Bronze			2022-12-17	WOS:000412843900010
J	Agaesse, G; Barbollat-Boutrand, L; Sulpice, E; Bhajun, R; El Kharbili, M; Berthier-Vergnes, O; Degoul, F; de la Fouchardiere, A; Berger, E; Voeltzel, T; Lamartine, J; Gidrol, X; Masse, I				Agaesse, G.; Barbollat-Boutrand, L.; Sulpice, E.; Bhajun, R.; El Kharbili, M.; Berthier-Vergnes, O.; Degoul, F.; de la Fouchardiere, A.; Berger, E.; Voeltzel, T.; Lamartine, J.; Gidrol, X.; Masse, I.			A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion (vol 36, pg 446, 2017)	ONCOGENE			English	Correction														Sulpice, Eric/0000-0001-7695-0561; Gidrol, Xavier/0000-0002-4233-3749; Lamartine, Jerome/0000-0003-2322-1618				Agaesse G, 2017, ONCOGENE, V36, P446, DOI 10.1038/onc.2016.219	1	6	6	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5084	5084		10.1038/onc.2017.195	http://dx.doi.org/10.1038/onc.2017.195			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28628117	Bronze			2022-12-17	WOS:000408768800014
J	Sakurai, T; Isogaya, K; Sakai, S; Morikawa, M; Morishita, Y; Ehata, S; Miyazono, K; Koinuma, D				Sakurai, T.; Isogaya, K.; Sakai, S.; Morikawa, M.; Morishita, Y.; Ehata, S.; Miyazono, K.; Koinuma, D.			RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma (vol 35, pg 5000, 2016)	ONCOGENE			English	Correction														Ehata, Shogo/0000-0002-6740-9391				Sakurai T, 2016, ONCOGENE, V35, P5000, DOI 10.1038/onc.2016.35	1	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5083	5083		10.1038/onc.2017.191	http://dx.doi.org/10.1038/onc.2017.191			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28604754	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000408768800013
J	Frieling, JS; Shay, G; Izumi, V; Aherne, ST; Saul, RG; Budzevich, M; Koomen, J; Lynch, CC				Frieling, J. S.; Shay, G.; Izumi, V.; Aherne, S. T.; Saul, R. G.; Budzevich, M.; Koomen, J.; Lynch, C. C.			Matrix metalloproteinase processing of PTHrP yields a selective regulator of osteogenesis, PTHrP(1-17)	ONCOGENE			English	Article							HORMONE-RELATED PROTEIN; STABLE-ISOTOPE STANDARDS; OSTEOBLAST-DERIVED PTHRP; PARATHYROID-HORMONE; PROSTATE-CANCER; BONE METASTASIS; PTH/PTHRP-RECEPTOR; ANTIPEPTIDE ANTIBODIES; SIGNALING PATHWAYS; MASS-SPECTROMETRY	Parathyroid hormone-related protein (PTHrP) is a critical regulator of bone resorption and augments osteolysis in skeletal malignancies. Here we report that the mature PTHrP(1-36) hormone is processed by matrix metalloproteinases to yield a stable product, PTHrP(1-17). PTHrP(1-17) retains the ability to signal through PTH1R to induce calcium flux and ERK phosphorylation but not cyclic AMP production or CREB phosphorylation. Notably, PTHrP(1-17) promotes osteoblast migration and mineralization in vitro, and systemic administration of PTHrP(1-17) augments ectopic bone formation in vivo. Further, in contrast to PTHrP(1-36), PTHrP(1-17) does not affect osteoclast formation/function in vitro or in vivo. Finally, immunoprecipitation-mass spectrometry analyses using PTHrP(1-17)-specific antibodies establish that PTHrP(1-17) is indeed generated by cancer cells. Thus, matrix metalloproteinase-directed processing of PTHrP disables the osteolytic functions of the mature hormone to promote osteogenesis, indicating important roles for this circuit in bone remodelling in normal and disease contexts.	[Frieling, J. S.; Shay, G.; Aherne, S. T.; Lynch, C. C.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, SRB-3,12902,Magnolia Dr, Tampa, FL USA; [Izumi, V.; Koomen, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL USA; [Saul, R. G.] Leidos Biomed Res, Antibody Characterizat Lab, Frederick, MD USA; [Budzevich, M.] H Lee Moffitt Canc Ctr & Res Inst, Canc Imaging & Metab, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); H Lee Moffitt Cancer Center & Research Institute	Lynch, CC (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, SRB-3,12902,Magnolia Dr, Tampa, FL USA.	conor.lynch@moffitt.org		Shay, Gemma/0000-0001-6126-7049; Frieling, Jeremy/0000-0002-2181-1836	State of Florida Bankhead Coley Program [5BC-O1]; Miles for Moffitt Foundation Award; Moffitt Cancer Center Grant [P30-CA076292];  [R01-CA143094]	State of Florida Bankhead Coley Program; Miles for Moffitt Foundation Award; Moffitt Cancer Center Grant; 	This work was supported by R01-CA143094 (CCL), the State of Florida Bankhead Coley Program grant 5BC-O1 (CCL) and by a Miles for Moffitt Foundation Award. This work was also supported in part by the Core Facilities of the Moffitt Cancer Center Grant P30-CA076292. The authors thank Joe Johnson (Moffitt Analytical Microscopy), Robert Sprung (Moffitt Proteomics) and Gordon Whiteley (SAIC-Frederick, NCI-Frederick) for their helpful suggestions and expertise, and Drs John Cleveland and Srikumar Chellappan for critical review of this study.	Amizuka N, 2000, HISTOL HISTOPATHOL, V15, P957, DOI 10.14670/HH-15.957; Anderson NL, 2004, J PROTEOME RES, V3, P235, DOI 10.1021/pr034086h; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; Bilezikian JP, 2015, PARATHYROIDBASIC C, P946; Bonfil RD, 2006, INT J CANCER, V118, P2721, DOI 10.1002/ijc.21645; Cook LM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29384; Cramer SD, 1996, J UROLOGY, V156, P526, DOI 10.1016/S0022-5347(01)65919-6; Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44; Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752; Cuthbertson RM, 1999, BBA-PROTEIN STRUCT M, V1432, P64, DOI 10.1016/S0167-4838(99)00078-3; Datta NS, 2007, J BONE MINER RES, V22, P951, DOI 10.1359/JBMR.070328; Esbrit P, 2013, BIOCHEM PHARMACOL, V85, P1417, DOI 10.1016/j.bcp.2013.03.002; Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114; Fukushima H, 2005, J DENT RES, V84, P329, DOI 10.1177/154405910508400407; Gallien S, 2012, MOL CELL PROTEOMICS, V11, P1709, DOI 10.1074/mcp.O112.019802; Garcia-Martin A, 2014, MOL ENDOCRINOL, V28, P925, DOI 10.1210/me.2013-1225; Guise TA, 2002, BONE, V30, P670, DOI 10.1016/S8756-3282(02)00685-3; Guise TA, 1997, CANCER-AM CANCER SOC, V80, P1572, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.3.CO;2-D; Helfrich M.H., 2003, BONE RES PROTOCOLS; Hodde JP, 2004, J SURG RES, V120, P189, DOI 10.1016/j.jss.2003.10.022; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Ibaragi S, 2010, ANTICANCER RES, V30, P5029; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Katafuchi T, 2015, CELL METAB, V21, P898, DOI 10.1016/j.cmet.2015.05.004; Kawashima-Ohya Y, 1998, ENDOCRINOLOGY, V139, P2120, DOI 10.1210/en.139.4.2120; Krane SM, 2008, BONE, V43, P7, DOI 10.1016/j.bone.2008.03.020; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lopez-Otin C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228; Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670; Lynch CC, 2005, CANCER CELL, V7, P485, DOI 10.1016/j.ccr.2005.04.013; Lynch CC, 2011, BONE, V48, P44, DOI 10.1016/j.bone.2010.06.007; Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047; MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054; Mak IWY, 2013, BONE, V55, P198, DOI 10.1016/j.bone.2013.02.020; Martin TJ, 2016, PHYSIOL REV, V96, P831, DOI 10.1152/physrev.00031.2015; Martin TJ, 2005, J CLIN INVEST, V115, P2322, DOI 10.1172/JCI26239; McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617; Miao DS, 2004, ENDOCRINOLOGY, V145, P3554, DOI 10.1210/en.2003-1695; Miao DS, 2005, J CLIN INVEST, V115, P2402, DOI 10.1172/JCI24918; Mohammad Khalid S., 2008, V455, P37, DOI 10.1007/978-1-59745-104-8_3; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; Park HJ, 2015, J CELL PHYSIOL, V230, P667, DOI 10.1002/jcp.24790; Pettway GJ, 2005, BONE, V36, P959, DOI 10.1016/j.bone.2005.02.015; Pezzato E, 2004, INT J CANCER, V112, P787, DOI 10.1002/ijc.20460; Philbrick W, 2001, PARATHYROIDBASIC C, P881; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; Remily-Wood ER, 2011, PROTEOM CLIN APPL, V5, P383, DOI 10.1002/prca.201000115; Ruchon AF, 2000, J BONE MINER RES, V15, P1266, DOI 10.1359/jbmr.2000.15.7.1266; Schluter KD, 2001, BRIT J PHARMACOL, V132, P427, DOI 10.1038/sj.bjp.0703830; Stewart AF, 1996, BONE, V19, P303, DOI 10.1016/S8756-3282(96)00221-9; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TAKUWA Y, 1989, AM J PHYSIOL, V257, pE797, DOI 10.1152/ajpendo.1989.257.6.E797; Thiolloy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029862; Valin A, 1997, J CELL PHYSIOL, V170, P209, DOI 10.1002/(SICI)1097-4652(199702)170:2<209::AID-JCP13>3.3.CO;2-Y; Washam CL, 2013, CANCER EPIDEM BIOMAR, V22, P972, DOI 10.1158/1055-9965.EPI-12-1318-T; Winding B, 2002, CLIN CANCER RES, V8, P1932; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406; Yoon H, 2013, BIOL CHEM, V394, P137, DOI 10.1515/hsz-2012-0249; Zhao WG, 1999, J CLIN INVEST, V103, P517, DOI 10.1172/JCI5481	63	6	7	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4498	4507		10.1038/onc.2017.70	http://dx.doi.org/10.1038/onc.2017.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368420	Green Accepted			2022-12-17	WOS:000406806000011
J	Zhang, HR; Wang, XD; Yang, X; Chen, D; Hao, J; Cao, R; Wu, XZ				Zhang, H-R; Wang, X-D; Yang, X.; Chen, D.; Hao, J.; Cao, R.; Wu, X-Z			An FGFR inhibitor converts the tumor promoting effect of TGF-beta by the induction of fibroblast-associated genes of hepatoma cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; HEPATOCELLULAR-CARCINOMA; CANCER; PROGRESSION; EXPRESSION; ACTIVATION; AZD4547	Tumors consistently mimic wound-generating chronic inflammation; however, why they do not heal like wounds with fibrotic scars remains unknown. The components of the tumor microenvironment, such as transforming growth factor beta (TGF-beta) and fibroblast growth factors (FGFs), may account for this phenomenon. Tumor formation involves continuous activation of the FGF pathway, whereas the repair of tissue injury is a self-limiting process accompanied with controlled activation of the FGF pathway. In the tumor microenvironment TGF-beta increases the secretion of FGFs, further promoting the malignant biological properties of tumors. However, during wound healing, sufficient TGF-beta together with moderate FGFs lead to matrix deposition and the formation of fibrotic scars. In the present study, TGF-beta 1 combined with AZD4547, an FGF receptor (FGFR) inhibitor, transformed hepatoma cells into less malignant fibroblast-like cells with respect to morphology, physiological properties, and gene expression profiles. In vivo experiments showed that TGF-beta 1 combined with AZD4547 not only inhibited tumor growth but also promoted tumor parenchyma fibrosis. Our results indicate that FGFR inhibitor treatment converts the effect of TGF-beta on the hepatocellular carcinoma cells from tumor promotion into tumor inhibition by enhancing the induction effect of TGF-beta on some fibroblast-associated genes. Converting human liver cancer cells into less malignant fibroblast-like cells and inducing tumor parenchyma cell fibrosis provides an alternative strategy for limiting tumor progression.	[Zhang, H-R; Yang, X.; Hao, J.; Cao, R.; Wu, X-Z] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjin, Peoples R China; [Zhang, H-R; Yang, X.; Hao, J.; Cao, R.; Wu, X-Z] Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China; [Zhang, H-R; Yang, X.; Hao, J.; Cao, R.; Wu, X-Z] Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China; [Wang, X-D] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China; [Chen, D.] Tianjin Med Univ, Sch Basic Med Sci, Dept Pharmacol, Tianjin, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin Medical University	Wu, XZ (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Zhong Shan Men Inpatient Dept, Huan Hu Xi Rd, Tianjin 300060, Peoples R China.	wuxiongzhi@163.com	Wu, Xiong-Zhi/P-4045-2019		National Natural Science Foundation of China [81473441]; Program for New Century Excellent Talents in University [NCET-11-1068]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This work was supported by the National Natural Science Foundation of China (81473441) and the Program for New Century Excellent Talents in University (NO. NCET-11-1068).	Abolhassani A, 2014, J CANCER, V5, P537, DOI 10.7150/jca.7797; Arwert EN, 2012, NAT REV CANCER, V12, P170, DOI 10.1038/nrc3217; Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987; Dooley S, 2012, CELL TISSUE RES, V347, P245, DOI 10.1007/s00441-011-1246-y; El-Assal ON, 2001, CLIN CANCER RES, V7, P1299; Gaarenstroom T, 2014, SEMIN CELL DEV BIOL, V32, P107, DOI 10.1016/j.semcdb.2014.01.009; Gavine PR, 2012, CANCER RES, V72, P2045, DOI 10.1158/0008-5472.CAN-11-3034; Gupta EK, 2014, CANCER GROWTH METAST, V7, P1, DOI 10.4137/CGM.S14205; Islam SS, 2014, J CELL COMMUN SIGNAL, V8, P39, DOI 10.1007/s12079-013-0216-4; Jia LZ, 2012, CANCER LETT, V326, P176, DOI 10.1016/j.canlet.2012.08.004; Jiang WN, 2010, INT J MOL MED, V26, P571, DOI 10.3892/ijmm_00000501; Kajdaniuk D, 2013, ENDOKRYNOL POL, V64, P384, DOI 10.5603/EP.2013.0022; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Krisanaprakornkit S, 2013, ARCH ORAL BIOL, V58, P82, DOI 10.1016/j.archoralbio.2012.06.011; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Miyazono K, 2012, UPSALA J MED SCI, V117, P143, DOI 10.3109/03009734.2011.638729; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Sandhu DS, 2014, HEPATOLOGY, V59, P1166, DOI 10.1002/hep.26679; Schafer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455; Schulte J, 2012, HISTOCHEM CELL BIOL, V138, P847, DOI 10.1007/s00418-012-0998-0; Senturk S, 2010, HEPATOLOGY, V52, P966, DOI 10.1002/hep.23769; Seol Ho Jun, 2012, Genes Cancer, V3, P535, DOI 10.1177/1947601912473603; Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351; Spyrou GE, 2002, BRIT J PLAST SURG, V55, P275, DOI 10.1054/bjps.2002.3831; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Vasdev Nandini, 2003, Indian J Pathol Microbiol, V46, P625	30	6	6	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3831	3841		10.1038/onc.2016.512	http://dx.doi.org/10.1038/onc.2016.512			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263980				2022-12-17	WOS:000404848200004
J	Wang, GY; Wood, CN; Dolorito, JA; Libove, E; Epstein, EH				Wang, G. Y.; Wood, C. N.; Dolorito, J. A.; Libove, E.; Epstein, E. H., Jr.			Differing tumor-suppressor functions of Arf and p53 in murine basal cell carcinoma initiation and progression	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; DEFICIENT MICE; IN-VIVO; EXPRESSION; SKIN; TUMORIGENESIS; MUTATIONS; HEDGEHOG; GROWTH; GENES	Human basal cell carcinomas (BCCs) very frequently carry p53 mutations, and p53 loss markedly accelerates murine BCC carcinogenesis. We report here our studies of the mechanism by which p53 is activated to suppress BCC carcinogenesis. We find that aberrant hedgehog signaling in microscopic BCCs activates p53 in part via Arf (that is, the oncogene-induced stress pathway) but not via the DNA damage response pathway. However, Arf loss and p53 loss produce differing outcomes-loss of p53 promotes both tumor initiation and progression; loss of Arf promotes tumor progression but not initiation. Intriguingly, increased expression of Arf in tumor stromal cells, as in tumor keratinocytes themselves, contributes to suppression of BCC carcinogenesis.	[Wang, G. Y.; Wood, C. N.; Dolorito, J. A.; Libove, E.; Epstein, E. H., Jr.] Childrens Hosp Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA	Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Wang, GY; Epstein, EH (corresponding author), Childrens Hosp Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	gwang@chori.org; eepstein@chori.org		Wood, Carla/0000-0002-6813-7981	NIH [R01CA163611]; American Skin Association; Skin Cancer Foundation; NATIONAL CANCER INSTITUTE [R01CA163611] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Skin Association; Skin Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Peter Lamb at Exelixis for providing XL-139 and Charles Sherr for both providing mice carrying the Arf-GFP allele and for wise, ongoing counsel. This work was supported by NIH grant # R01CA163611 (PI: EHE), the American Skin Association (PI: GYW) and the Skin Cancer Foundation (PI: GYW).	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Abulaiti A, 2006, CANCER RES, V66, P10505, DOI 10.1158/0008-5472.CAN-06-2351; Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Busch SE, 2014, ONCOGENE, V33, P2665, DOI 10.1038/onc.2013.208; Campaner S, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-6; Carbonneau CL, 2012, BLOOD, V119, P717, DOI 10.1182/blood-2011-06-361626; Chen DL, 2013, MOL CELL, V51, P46, DOI 10.1016/j.molcel.2013.05.006; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Herranz S, 2012, ONCOIMMUNOLOGY, V1, P1227, DOI 10.4161/onci.21207; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Ismail F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021271; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1999, CANCER RES, V59, P2464; Kanellou P, 2009, BRIT J DERMATOL, V160, P1215, DOI 10.1111/j.1365-2133.2009.09079.x; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Konig S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093555; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; Lacour JP, 2002, BRIT J DERMATOL, V146, P17, DOI 10.1046/j.1365-2133.146.s61.5.x; LEWIS JG, 1987, CARCINOGENESIS, V8, P889, DOI 10.1093/carcin/8.7.889; Li ZJ, 2014, ONCOGENE, V33, P2674, DOI 10.1038/onc.2013.212; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Nitzki F, 2010, CANCER RES, V70, P2739, DOI 10.1158/0008-5472.CAN-09-3743; Orlando G, 2014, NUCLEIC ACIDS RES, V42, P2320, DOI 10.1093/nar/gkt1185; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Saridaki Z, 2000, J INVEST DERMATOL, V115, P719, DOI 10.1046/j.1523-1747.2000.00098.x; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Wang GY, 2011, J INVEST DERMATOL, V131, P2298, DOI 10.1038/jid.2011.204; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Wang Y, 2003, CANCER RES, V63, P4389; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Wetmore C, 2001, CANCER RES, V61, P513; Young NP, 2011, CANCER RES, V71, P4040, DOI 10.1158/0008-5472.CAN-10-4563; Zerrouqi A, 2012, J CLIN INVEST, V122, P1283, DOI 10.1172/JCI38596; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	47	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3772	3780		10.1038/onc.2017.12	http://dx.doi.org/10.1038/onc.2017.12			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28263978				2022-12-17	WOS:000404349700012
J	Zahavi, T; Maimon, A; Kushnir, T; Lange, R; Berger, E; Kornspan, D; Grossman, R; Anzi, S; Shaulian, E; Karni, R; Nechushtan, H; Paroush, Z				Zahavi, T.; Maimon, A.; Kushnir, T.; Lange, R.; Berger, E.; Kornspan, D.; Grossman, R.; Anzi, S.; Shaulian, E.; Karni, R.; Nechushtan, H.; Paroush, Z.			Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function	ONCOGENE			English	Article							GROUCHO-MEDIATED REPRESSION; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; CO-REPRESSORS; TRANSCRIPTION FACTORS; BREAST-CANCER; IN-VIVO; DROSOPHILA; PATHWAYS	Signaling mediated by the Ras-extracellular signal-regulated kinase (Erk) pathway often leads to the phosphorylation of transcriptional regulators, thereby modulating their activity and causing concerted changes in gene expression. In Drosophila, the induction of multiple Ras-Erk pathway target genes depends on prior phosphorylation of the general co-repressor Groucho, a modification that downregulates its repressive function. Here, we show that TLE1, one of the four human Groucho orthologs, is similarly phosphorylated in response to Ras-Erk pathway activation, and that this modification attenuates its capacity to repress transcription. Specifically, unphosphorylated TLE1 dominantly suppresses the induction of Ras-Erk pathway target genes in cultured human cells, and the expression of an unphosphorylatable TLE1 derivative causes severe phenotypes in a transgenic Drosophila model system, whereas a phosphomimetic variant of TLE1 exerts only negligible effects. We present data indicating that TLE1 is rapidly excluded from the nucleus following epidermal growth factor receptor pathway activation, an effect that likely accounts for its inability to mediate effective repression under such conditions. Significantly, we find that unphosphorylated TLE1 blocks oncogenic phenotypes induced by mutated H-Ras in human mammary cells, both in vitro and following their implantation in mice. Collectively, our data strongly indicate that phosphorylation of TLE family members and the consequent downregulation of their repressor function is a key conserved step in the transcriptional responses to Ras-Erk signaling, and possibly a critical event in the tumorigenic effects caused by excessive Ras-Erk pathway activity.	[Zahavi, T.; Kushnir, T.; Lange, R.; Berger, E.; Kornspan, D.; Grossman, R.; Paroush, Z.] Hebrew Univ Jerusalem, Fac Med, IMRIC, Dept Dev Biol & Canc Res, POB 12272, IL-91120 Jerusalem, Israel; [Maimon, A.; Anzi, S.; Shaulian, E.; Karni, R.] Hebrew Univ Jerusalem, Fac Med, IMRIC, Dept Biochem & Mol Biol, Jerusalem, Israel; [Kornspan, D.; Nechushtan, H.] Hadassah Hebrew Univ, Med Ctr, Sharett Inst Oncol, Dept Oncol, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center	Paroush, Z (corresponding author), Hebrew Univ Jerusalem, Fac Med, IMRIC, Dept Dev Biol & Canc Res, POB 12272, IL-91120 Jerusalem, Israel.	zparoush@cc.huji.ac.il	nechushtan, hovav/Z-3564-2019	Shaulian, Eitan/0000-0001-6242-6849; Kornspan, David/0000-0001-6848-2323	Israel Cancer Research Fund; Israel Science Foundation [1772/13, 1552/16]; Jan M and Eugenia Krol Charitable Foundation; Israel Cancer Association; Tsipora and Moshe Levin Foundation; Carole Annette Stevens-Walvish Postdoctoral Fellowship in Cancer Research; Lady Davis Postdoctoral Fellowship; Israel Cancer Research Fund Booster Fellowship	Israel Cancer Research Fund; Israel Science Foundation(Israel Science Foundation); Jan M and Eugenia Krol Charitable Foundation; Israel Cancer Association; Tsipora and Moshe Levin Foundation; Carole Annette Stevens-Walvish Postdoctoral Fellowship in Cancer Research; Lady Davis Postdoctoral Fellowship; Israel Cancer Research Fund Booster Fellowship	We thank members of our laboratory for continued help and encouragement during this project; David Engelberg, Shulamit Katzav, Oded Meyuhas, Joel Yisraeli and, particularly, Gerardo Jimenez for their insightful comments on the manuscript; Yosef Yarden and Stefano Stifani for providing us with DNA constructs and reagents; Konstantin Kogan, Vered Levin-Salomon and David Engelberg for their assistance with the Erk2 in vitro kinase assays and for contributing recombinant activated Erk2; Ahmad Mreisat for technical help; and Amir Orian for hosting TZ in his laboratory for some of her experiments. Work was supported by grants from the Israel Cancer Research Fund (Project Grant), Israel Science Foundation (Center of Excellence 1772/13 and 1552/16), and the Jan M and Eugenia Krol Charitable Foundation to ZP; and by the Israel Cancer Association to HN. TK received a Doctoral Fellowship from the Tsipora and Moshe Levin Foundation. DK is a recipient of a Carole Annette Stevens-Walvish Postdoctoral Fellowship in Cancer Research, a Lady Davis Postdoctoral Fellowship and an Israel Cancer Research Fund Booster Fellowship. ZP is an incumbent of the Lady Davis Professorship in Experimental Medicine and Cancer Research.	Agarwal M, 2015, IUBMB LIFE, V67, P472, DOI 10.1002/iub.1395; Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Barker N, 2000, ADV CANCER RES, V77, P1; Beagle B, 2010, DEV DYNAM, V239, P2795, DOI 10.1002/dvdy.22439; Ben-Hur V, 2013, CELL REP, V3, P103, DOI 10.1016/j.celrep.2012.11.020; Bezniakow Natalia, 2014, Dev Period Med, V18, P285; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Buscarlet M, 2007, TRENDS CELL BIOL, V17, P353, DOI 10.1016/j.tcb.2007.07.002; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Cinnamon E, 2008, DEVELOPMENT, V135, P829, DOI 10.1242/dev.015206; Cinnamon E, 2008, CURR OPIN GENET DEV, V18, P435, DOI 10.1016/j.gde.2008.07.010; Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; Dayyani F, 2008, BLOOD, V111, P4338, DOI 10.1182/blood-2007-07-103291; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DELIDAKIS C, 1991, GENETICS, V129, P803; Gasperowicz M, 2005, J CELL BIOCHEM, V95, P670, DOI 10.1002/jcb.20476; Goldstein RE, 2005, MOL CELL BIOL, V25, P10711, DOI 10.1128/MCB.25.24.10711-10720.2005; Hasson P, 2006, BRIT J CANCER, V94, P771, DOI 10.1038/sj.bjc.6603019; Hasson P, 2005, NAT GENET, V37, P101, DOI 10.1038/ng1486; Hasson P, 2001, EMBO J, V20, P5725, DOI 10.1093/emboj/20.20.5725; Helman A, 2012, DEVELOPMENT, V139, P3032, DOI 10.1242/dev.075812; Helman A, 2011, CURR BIOL, V21, P1102, DOI 10.1016/j.cub.2011.05.043; Jennings BH, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-205; Johnston MJ, 2016, DEVELOPMENT, V143, P4631, DOI 10.1242/dev.143263; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim Y, 2010, CURR BIOL, V20, P446, DOI 10.1016/j.cub.2010.01.019; Kwong PN, 2015, J BIOL CHEM, V290, P30119, DOI 10.1074/jbc.M115.681171; Lee S, 2010, MOL CELL BIOL, V30, P2621, DOI 10.1128/MCB.00782-09; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li Z, 2016, CELL DEATH DIFFER, V23, P583, DOI 10.1038/cdd.2015.125; Lien WH, 2014, NAT CELL BIOL, V16, P179, DOI 10.1038/ncb2903; Maimon A, 2014, CELL REP, V7, P501, DOI 10.1016/j.celrep.2014.03.041; McCurrach ME, 2001, METHOD CELL BIOL, V66, P197; McKay MM, 2007, ONCOGENE, V26, P3113, DOI 10.1038/sj.onc.1210394; Mrozek K, 2008, CURR OPIN ONCOL, V20, P711, DOI 10.1097/CCO.0b013e32831369df; Paroush Z, 1997, DEVELOPMENT, V124, P3827; Plotnikov A, 2011, BBA-MOL CELL RES, V1813, P1619, DOI 10.1016/j.bbamcr.2010.12.012; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Turki-Judeh W, 2012, CURR TOP DEV BIOL, V98, P65, DOI 10.1016/B978-0-12-386499-4.00003-3; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Whitmarsh AJ, 2007, BBA-MOL CELL RES, V1773, P1285, DOI 10.1016/j.bbamcr.2006.11.011; Yang SH, 2013, GENE, V513, P1, DOI 10.1016/j.gene.2012.10.033; Yogev O, 2008, CANCER RES, V68, P1398, DOI 10.1158/0008-5472.CAN-07-2865	47	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3729	3739		10.1038/onc.2016.517	http://dx.doi.org/10.1038/onc.2016.517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192406				2022-12-17	WOS:000404349700008
J	Pomeroy, EJ; Lee, LA; Lee, RDW; Schirm, DK; Temiz, NA; Ma, J; Gruber, TA; Diaz-Flores, E; Moriarity, BS; Downing, JR; Shannon, KM; Largaespada, DA; Eckfeldt, CE				Pomeroy, E. J.; Lee, L. A.; Lee, R. D. W.; Schirm, D. K.; Temiz, N. A.; Ma, J.; Gruber, T. A.; Diaz-Flores, E.; Moriarity, B. S.; Downing, J. R.; Shannon, K. M.; Largaespada, D. A.; Eckfeldt, C. E.			Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia	ONCOGENE			English	Article							PANCREATIC-CANCER GROWTH; TYROSINE KINASE; MEK INHIBITION; TARGETING RAS; SELF-RENEWAL; RESISTANCE; MELANOMA; CELLS; KRAS; BRAF	Somatic mutations that lead to constitutive activation of NRAS and KRAS proto-oncogenes are among the most common in human cancer and frequently occur in acute myeloid leukemia (AML). An inducible NRAS(V12)-driven AML mouse model has established a critical role for continued NRAS(V12) expression in leukemia maintenance. In this model genetic suppression of NRAS(V12) expression results in rapid leukemia remission, but some mice undergo spontaneous relapse with NRAS(V12)-independent (NRI) AMLs providing an opportunity to identify mechanisms that bypass the requirement for Ras oncogene activity and drive leukemia relapse. We found that relapsed NRI AMLs are devoid of NRAS(V12) expression and signaling through the major oncogenic Ras effector pathways, phosphatidylinositol-3-kinase and mitogen-activated protein kinase, but express higher levels of an alternate Ras effector, Ralb, and exhibit NRI phosphorylation of the RALB effector TBK1, implicating RALB signaling in AML relapse. Functional studies confirmed that inhibiting CDK5-mediated RALB activation with a clinically relevant experimental drug, dinaciclib, led to potent RALB-dependent antileukemic effects in human AML cell lines, induced apoptosis in patient-derived AML samples in vitro and led to a 2-log reduction in the leukemic burden in patient-derived xenograft mice. Furthermore, dinaciclib potently suppressed the clonogenic potential of relapsed NRI AMLs in vitro and prevented the development of relapsed AML in vivo. Our findings demonstrate that Ras oncogene-independent activation of RALB signaling is a therapeutically targetable mechanism of escape from NRAS oncogene addiction in AML.	[Pomeroy, E. J.; Lee, L. A.; Lee, R. D. W.; Schirm, D. K.; Eckfeldt, C. E.] Univ Minnesota, Sch Med, Div Hematol Oncol & Transplantat, Dept Med, 420 Delaware St SE,MMC 480,PWB 14-242, Minneapolis, MN 55455 USA; [Temiz, N. A.; Moriarity, B. S.; Largaespada, D. A.; Eckfeldt, C. E.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Ma, J.; Gruber, T. A.; Downing, J. R.] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Gruber, T. A.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA; [Diaz-Flores, E.; Shannon, K. M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Moriarity, B. S.; Largaespada, D. A.] Dept Pediat, Div Hematol & Oncol, Minneapolis, MN USA; [Largaespada, D. A.] Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities	Eckfeldt, CE (corresponding author), Univ Minnesota, Sch Med, Div Hematol Oncol & Transplantat, Dept Med, 420 Delaware St SE,MMC 480,PWB 14-242, Minneapolis, MN 55455 USA.	eckf0002@umn.edu	Gruber, Tanja/AAH-1248-2021; Downing, James R./N-8102-2018	Eckfeldt, Craig/0000-0003-2834-0421; Lee, Lindsey/0000-0002-7082-5484; Pomeroy, Emily/0000-0001-7690-3570	University of Minnesota Masonic Cancer Center; National Cancer Institute [P30CA77598]; Minnesota Masonic Charities; Killebrew-Thompson Memorial Fund; University of Minnesota Department of Medicine, Division of Hematology Oncology and Transplantation; University of Minnesota Foundation (CEE); Leukemia and Lymphoma Society of America Specialized Center of Research [LLS7019-04]; National Heart Lung and Blood Institute [T32HL007062]; NATIONAL CANCER INSTITUTE [P30CA077598, P30CA016672] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007062] Funding Source: NIH RePORTER	University of Minnesota Masonic Cancer Center; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Minnesota Masonic Charities; Killebrew-Thompson Memorial Fund; University of Minnesota Department of Medicine, Division of Hematology Oncology and Transplantation; University of Minnesota Foundation (CEE); Leukemia and Lymphoma Society of America Specialized Center of Research(Leukemia and Lymphoma Society); National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by funding from the University of Minnesota Masonic Cancer Center and Academic Health Center Flow Cytometry Resource, Research Animal Resources, Heme Malignancy Tissue Bank and Imaging Center that are supported by the National Cancer Institute (P30CA77598), Minnesota Masonic Charities and the Killebrew-Thompson Memorial Fund; the University of Minnesota Department of Medicine, Division of Hematology Oncology and Transplantation and the University of Minnesota Foundation (CEE); Leukemia and Lymphoma Society of America Specialized Center of Research LLS7019-04 (DAL); National Heart Lung and Blood Institute T32HL007062 (CEE). DAL and KMS are American Cancer Society Research Professors.	Baker A, 2016, CANCER RES, V76, P1158, DOI 10.1158/0008-5472.CAN-15-1070; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Berns K, 2012, DRUG RESIST UPDATE, V15, P268, DOI 10.1016/j.drup.2012.10.002; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; Braun BS, 2008, CLIN CANCER RES, V14, P2249, DOI 10.1158/1078-0432.CCR-07-1005; Braun BS, 2004, P NATL ACAD SCI USA, V101, P597, DOI 10.1073/pnas.0307203101; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Collins CT, 2016, ONCOGENE, V35, P1090, DOI 10.1038/onc.2015.174; Collins C, 2014, P NATL ACAD SCI USA, V111, P9899, DOI 10.1073/pnas.1402238111; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eckfeldt CE, 2016, RALB PROVIDES CRITIC; Feldmann G, 2011, CANCER BIOL THER, V12, P598, DOI 10.4161/cbt.12.7.16475; Feldmann G, 2010, CANCER RES, V70, P4460, DOI 10.1158/0008-5472.CAN-09-1107; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Frohling S, 2005, J CLIN ONCOL, V23, P6285, DOI 10.1200/JCO.2005.05.010; Gu TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019169; Huw LY, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.46; Iyengar S, 2013, BLOOD, V121, P2274, DOI 10.1182/blood-2012-10-460832; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim WI, 2009, BLOOD, V113, P1086, DOI 10.1182/blood-2008-01-132316; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li Q, 2011, BLOOD, V117, P2022, DOI 10.1182/blood-2010-04-280750; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Martelli AM, 2006, LEUKEMIA, V20, P911, DOI 10.1038/sj.leu.2404245; Patel JP, 2012, HEMATOL-AM SOC HEMAT, P28, DOI 10.1182/asheducation-2012.1.28; Peschard P, 2012, CURR BIOL, V22, P2063, DOI 10.1016/j.cub.2012.09.013; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rahrmann EP, 2014, AM J PATHOL, V184, P2082, DOI 10.1016/j.ajpath.2014.04.006; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Ricciardi MR, 2005, LEUKEMIA, V19, P1543, DOI 10.1038/sj.leu.2403859; Rushworth SA, 2014, BLOOD, V123, P1229, DOI 10.1182/blood-2013-06-511154; Sachs Z, 2014, BLOOD, V124, P3274, DOI 10.1182/blood-2013-08-521708; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Van Meter MEM, 2007, BLOOD, V109, P3945, DOI 10.1182/blood-2006-09-047530; Vigil D, 2010, J BIOL CHEM, V285, P34729, DOI 10.1074/jbc.M110.116756; Yan C, 2014, NATURE, V515, P443, DOI 10.1038/nature13713; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710; Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646	52	6	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3263	3273		10.1038/onc.2016.471	http://dx.doi.org/10.1038/onc.2016.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	27991934	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000402869800006
J	Palacio, L; Krishnan, V; Le, NLO; Sharpless, NE; Beausejour, CM				Palacio, L.; Krishnan, V.; Le, N. L. O.; Sharpless, N. E.; Beausejour, C. M.			Sustained p16(INK4a) expression is required to prevent IR-induced tumorigenesis in mice	ONCOGENE			English	Article							HEMATOPOIETIC STEM-CELLS; SENESCENT CELLS; CELLULAR SENESCENCE; TUMOR SUPPRESSION; DNA-DAMAGE; LIFE-SPAN; IN-VIVO; P53; FIBROBLASTS; PROGRESSION	Exposure of murine and human tissues to ionizing radiation (IR) induces the expression of p16(INK4a), a tumor suppressor gene and senescence/aging biomarker. Increased p16(INK4a) expression is often delayed several weeks post exposure to IR. In this context, it remains unclear if it occurs to suppress aberrant cellular growth of potentially transformed cells or is simply a result of IR-induced loss of tissue homeostasis. To address this question, we used a conditional p16(INK4a) null mouse model and determined the impact of p16(INK4a) inactivation long-term post exposure to IR. We found that, in vitro, bone marrow stromal cells exposed to IR enter DNA replication following p16(INK4a) inactivation. However, these cells did not resume growth; instead, they mostly underwent cell cycle arrest in G2. Similarly, delayed inactivation of p16(INK4a) in mice several weeks post exposure to IR resulted in increased BrdU incorporation and cancer incidence. In fact, we found that the onset of tumorigenesis was similar whether p16(INK4a) was inactivated before or after exposure to IR. Overall, our results suggest that IR-induced p16(INK4a) dependent growth arrest is reversible in mice and that sustained p16(INK4a) expression is necessary to protect against tumorigenesis.	[Palacio, L.; Krishnan, V.; Le, N. L. O.; Beausejour, C. M.] Ctr Hosp Univ Ste Justine, Ctr Rech, Montreal, PQ, Canada; [Palacio, L.; Krishnan, V.; Beausejour, C. M.] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada; [Sharpless, N. E.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA; [Sharpless, N. E.] Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC USA	Universite de Montreal; Universite de Montreal; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Beausejour, CM (corresponding author), Ctr Hosp Univ Ste Justine, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.	christian.beausejour@recherche-ste-justine.qc.ca	Krishnan, Vimal/AAP-1616-2020		Canadian Institute of Health Research [MOP-341566]; Fondation des Etoiles; Fonds de recherche du Quebec - Sante; NATIONAL INSTITUTE ON AGING [R01AG024379] Funding Source: NIH RePORTER	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Fondation des Etoiles; Fonds de recherche du Quebec - Sante(Fonds de la Recherche en Sante du Quebec); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to the members of Dr Elie Haddad's laboratory, flow cytometry and animal facility for providing technical support. We also would like to thank Dr Francis Rodier and Mohamad El-Ariss for the critical reading of the manuscript. This work was supported by a grant from the Canadian Institute of Health Research #MOP-341566 to CMB LP has been supported by a student fellowship from the Fondation des Etoiles. CMB is supported by a scientist award from the Fonds de recherche du Quebec - Sante.	Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Burd CE, 2013, CELL, V152, P340, DOI 10.1016/j.cell.2012.12.010; Carbonneau CL, 2012, BLOOD, V119, P717, DOI 10.1182/blood-2011-06-361626; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Hinkal G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006654; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Johmura Y, 2014, MOL CELL, V55, P73, DOI 10.1016/j.molcel.2014.05.003; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Le ONL, 2010, AGING CELL, V9, P398, DOI 10.1111/j.1474-9726.2010.00567.x; Marcoux S, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-252; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Sanoff HK, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju057; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sorrentino JA, 2014, J CLIN INVEST, V124, P169, DOI 10.1172/JCI70960; Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013; Stein GH, 1999, MOL CELL BIOL, V19, P2109; van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193; Wang Y, 2006, BLOOD, V107, P358, DOI 10.1182/blood-2005-04-1418; Yamakoshi K, 2009, J CELL BIOL, V186, P393, DOI 10.1083/jcb.200904105; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	33	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1309	1314		10.1038/onc.2016.298	http://dx.doi.org/10.1038/onc.2016.298			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27568978	Green Accepted, Green Submitted			2022-12-17	WOS:000395861300014
J	Tang, W; Wang, H; Ha, HL; Tassi, I; Bhardwaj, R; Claudio, E; Siebenlist, U				Tang, W.; Wang, H.; Ha, H. L.; Tassi, I.; Bhardwaj, R.; Claudio, E.; Siebenlist, U.			The B-cell tumor promoter Bcl-3 suppresses inflammation associated colon tumorigenesis in epithelial cells	ONCOGENE			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; MICE DEFICIENT; COLITIS; ONCOPROTEIN; EXPRESSION; SURVIVAL; SODIUM; STAT3	Bcl-3 is an atypical member of the inhibitor of kappa light polypeptide gene enhancer in B-cells (I.B) family. It associates with p50/nuclear factor-kappa B1 (NF-kappa B1) and p52/NF-kappa B2 homodimers in nuclei where it modulates transcription in a context-dependent manner. A subset of B-cell tumors exhibits recurrent translocations of Bcl-3, resulting in overexpression. Elevated expression without translocations is also observed in various B-cell lymphomas and even some solid tumors. Here we investigated the role of Bcl-3 in azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colon tumors, a mouse model for colitis-associated colorectal cancers in humans. Contrary to expectations, Bcl-3 suppressed colorectal tumor formation: Bcl-3-deficient mice were relatively protected from DSS-induced epithelial damage and developed more polyps after AOM/DSS treatment, although polyp size was unaffected. DSSchallenged mutant mice exhibited increased recruitment of myeloid-derived suppressor cells, consistent with protection of the epithelium. Loss of Bcl-3 in intestinal epithelial cells was sufficient to increase tumorigenesis. The added tumor burden in mutant mice was dependent on tumor necrosis factor-a (TNF alpha), a tumorigenic, NF-kappa B-mediated signaling pathway that was dampened by Bcl-3. These findings reveal a tumor-suppressive role for Bcl-3 in this inflammation-associated cancer model. Bcl-3 thus functions as a tumor promoter or suppressor, depending on the cellular and environmental context.	[Tang, W.; Wang, H.; Ha, H. L.; Tassi, I.; Bhardwaj, R.; Claudio, E.; Siebenlist, U.] NIAID, Lab Mol Immunol, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Siebenlist, U (corresponding author), NIH, Bldg 10,Room 11N210, Bethesda, MD 20892 USA.	usiebenlist@niaid.nih.gov		tassi, ilaria/0000-0002-5803-9499	Intramural Research Program of NIAID, NIH; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000722] Funding Source: NIH RePORTER	Intramural Research Program of NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We greatly appreciate the constructive inputs provided by all members of the Siebenlist laboratory. This research was supported by the Intramural Research Program of NIAID, NIH.	Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Burkitt MD, 2015, J PATHOL, V236, P326, DOI 10.1002/path.4527; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Diaz-Montero CM, 2014, SEMIN ONCOL, V41, P174, DOI 10.1053/j.seminoncol.2014.02.003; Eigenbrod T, 2013, J IMMUNOL, V190, P6533, DOI 10.4049/jimmunol.1300324; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hinz M, 2012, IMMUNOL REV, V246, P59, DOI 10.1111/j.1600-065X.2012.01102.x; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Liu ZJ, 2013, J MOL CELL BIOL, V5, P280, DOI 10.1093/jmcb/mjt020; Maldonado V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-152; Manjili MH, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00303; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Naito Y, 2003, J GASTROEN HEPATOL, V18, P560, DOI 10.1046/j.1440-1746.2003.03034.x; Nielsen OH, 2014, FRONT MED-LAUSANNE, V1, DOI 10.3389/fmed.2014.00003; Onizawa M, 2009, AM J PHYSIOL-GASTR L, V296, pG850, DOI 10.1152/ajpgi.00071.2008; Palmer S, 2008, IMMUNOL RES, V42, P210, DOI 10.1007/s12026-008-8075-4; Pasparakis M, 2012, IMMUNOL REV, V246, P346, DOI 10.1111/j.1600-065X.2012.01109.x; Pene F, 2011, J IMMUNOL, V186, P2412, DOI 10.4049/jimmunol.1001331; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Schuster M, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-23; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Tang WH, 2014, IMMUNITY, V41, P555, DOI 10.1016/j.immuni.2014.09.017; Tassi I, 2015, EUR J IMMUNOL, V45, P1059, DOI 10.1002/eji.201444994; Tassi I, 2014, J IMMUNOL, V193, P4303, DOI 10.4049/jimmunol.1401505; Wakefield A, 2013, CANCER RES, V73, P745, DOI 10.1158/0008-5472.CAN-12-1321; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003	34	6	7	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6203	6211		10.1038/onc.2016.152	http://dx.doi.org/10.1038/onc.2016.152			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27132515	Green Accepted			2022-12-17	WOS:000388857700005
J	Ko, C; Kim, YG; Le, TP; Choi, KW				Ko, C.; Kim, Y-G; Le, T. P.; Choi, K-W			Twinstar/cofilin is required for regulation of epithelial integrity and tissue growth in Drosophila	ONCOGENE			English	Article							ACTIN-CAPPING-PROTEIN; HIPPO PATHWAY; CELL POLARITY; F-ACTIN; SIGNALING PATHWAYS; COFILIN; APOPTOSIS; SLINGSHOT; MIGRATION; PROLIFERATION	Regulation of actin assembly and depolymerization is important for the organization of epithelia. Recent studies have shown that the actin-capping proteins are required to prevent cell extrusion and inappropriate activation of Yorkie (Yki) activity in Drosophila, implicating the importance of actin regulation for epithelial integrity and Yki-dependent tissue growth. However, the role of Twinstar (Tsr), the Drosophila homolog for cofilin/actin depolymerization factor (ADF), in epithelial integrity and Hippo signaling is unknown. Here we demonstrate that reduction of Tsr by RNA interference (RNAi) or mutant clones in wing imaginal disc induces not only F-actin accumulation but also ectopic expression of Wingless (Wg) and Yki target gene expanded (ex). Knockdown of Yki in Tsr-depleted cells reduced the level of ectopic Wg expression. Reduced Tsr also led to downregulation of cell junction proteins and extrusion of affected cells from the basal part of the epithelium. Rho GTPase 1 was upregulated in Tsr-depleted tissue, supporting the Tsr function in the inhibition of cell extrusion from the epithelium. Tsr is also required for blocking cell death and c-Jun N-terminal kinase (JNK) signaling. Ectopic JNK activation induced caspase activation but did not cause cell extrusion. Further, the invasiveness of Tsr-depleted cells was not suppressed by inhibition of cell death or JNK signaling. In contrast, Yki upregulation was significantly suppressed by cell death inhibition. Taken together, our data suggest that Tsr is required for cell survival and tissue growth by regulating JNK and Yki signaling while maintaining the epithelial integrity by controlling cell junctions. This study provides an insight into potential roles of ADF/cofilin in invasive cell migration and tumor suppression in higher animals.	[Ko, C.; Kim, Y-G; Le, T. P.; Choi, K-W] Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Choi, KW (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Taejon 305701, South Korea.	kchoi100@kaist.ac.kr	Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065	National Research Foundation of Korea - Korean, Ministry of Education, Science and Technology [NRF-2011-0028326, 2014K1A1A2042982]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084947] Funding Source: NIH RePORTER	National Research Foundation of Korea - Korean, Ministry of Education, Science and Technology; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Drs David Helfman and Kyung-Ok Cho for critical comments on the manuscript. We thank Drs Florence Janody, Jongkyeong Chung and Kenneth Irvine for providing flies and antibodies mentioned in the text. We acknowledge the Bloomington Drosophila Stock Center, DGGC, the NIG-Fly Stock Center and the Developmental Studies Hybridoma Bank for fly stocks and antibodies. We thank the TRiP at Harvard Medical School (NIH/NIGMS R01-GM084947) for providing transgenic RNAi fly stocks. This research was supported by a National Research Laboratory Grant (NRF-2011-0028326) and a Global Research Laboratory Grant (2014K1A1A2042982) through the National Research Foundation of Korea, funded by the Korean, Ministry of Education, Science and Technology.	Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Blair A, 2006, DEVELOPMENT, V133, P1789, DOI 10.1242/dev.02320; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Chen J, 2001, NAT CELL BIOL, V3, P204, DOI 10.1038/35055120; Cho E, 2004, DEVELOPMENT, V131, P4489, DOI 10.1242/dev.01315; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; Fernandez BG, 2011, DEVELOPMENT, V138, P2337, DOI 10.1242/dev.063545; Genevet A, 2011, BIOCHEM J, V436, P213, DOI 10.1042/BJ20110217; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Hsu FF, 2010, ONCOGENE, V29, P2864, DOI 10.1038/onc.2010.40; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Janody F, 2006, DEVELOPMENT, V133, P3349, DOI 10.1242/dev.02511; Jezowska B, 2011, DEV BIOL, V360, P143, DOI 10.1016/j.ydbio.2011.09.016; Lee YJ, 2005, CELL BIOL INT, V29, P877, DOI 10.1016/j.cellbi.2005.07.005; Lee YS, 2003, METHODS, V30, P322, DOI 10.1016/S1046-2023(03)00051-3; Lin CM, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-46; Liu XF, 2000, DEV BIOL, V228, P287, DOI 10.1006/dbio.2000.9939; Maloney MT, 2007, MOL NEUROBIOL, V35, P21, DOI 10.1007/BF02700622; Miles WO, 2011, DIS MODEL MECH, V4, P753, DOI 10.1242/dmm.006908; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Nakajima Y, 2013, NATURE, V500, P359, DOI 10.1038/nature12335; Neumann CJ, 1996, DEVELOPMENT, V122, P1781; Ng JL, 2004, NEURON, V44, P779, DOI 10.1016/j.neuron.2004.11.014; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Pham H, 2008, DEV BIOL, V318, P82, DOI 10.1016/j.ydbio.2008.03.006; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Rogers EM, 2005, MECH DEVELOP, V122, P1194, DOI 10.1016/j.mod.2005.07.002; Rudrapatna VA, 2014, ONCOGENE, V33, P2801, DOI 10.1038/onc.2013.232; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; Schlote, 1984, DROS INFORM SERV, V60, P210; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Sun GP, 2011, DEV BIOL, V350, P139, DOI 10.1016/j.ydbio.2010.11.036; Tahtamouni LH, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-45; Tsai CH, 2009, CELL CYCLE, V8, P2365, DOI 10.4161/cc.8.15.9072; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; XU T, 1993, DEVELOPMENT, V117, P1223	40	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5144	5154		10.1038/onc.2016.46	http://dx.doi.org/10.1038/onc.2016.46			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27041568				2022-12-17	WOS:000384433000006
J	Laugier, F; Delyon, J; Andre, J; Bensussan, A; Dumaz, N				Laugier, F.; Delyon, J.; Andre, J.; Bensussan, A.; Dumaz, N.			Hypoxia and MITF regulate KIT oncogenic properties in melanocytes	ONCOGENE			English	Article							STEM-CELL FACTOR; HUMAN-MELANOMA CELLS; METASTATIC MELANOMA; SIGNAL-TRANSDUCTION; OXYGEN; SKIN; ACTIVATION; EXPRESSION; SURVIVAL; IMATINIB	KIT mutations are frequent in acral, mucosal and chronic sun-damage (CSD) melanoma, but little is known about the mechanisms driving the transformation of KIT-mutated melanocytes into melanoma cells. We showed that exposition of melanocytes harboring the L576PKIT mutation to a hypoxic environment induced their transformation into malignant cells. Transformed L576PKIT melanocytes showed downregulation of MITF expression characteristic of melanoma initiating cells (MICs). In agreement, these cells were able to form spheres in neural crest cell medium and low-adherence conditions, also a characteristic of MICs. Downregulation of MITF by RNA interference induced transformation of KIT-mutated melanocytes in normoxia and acquisition of a MIC phenotype by these cells. Hence, low level of MITF cooperates with oncogenic KIT to transform melanocytes. Activation of the cAMP pathway in transformed L576PKIT melanocytes stimulated MITF expression, and reduced cellular proliferation and sphere formation. These findings highlight the essential role of MITF in revealing the oncogenic activity of KIT in melanocytes and suggest that the cAMP pathway is a therapeutic target in KIT-mutated melanoma.	[Laugier, F.; Delyon, J.; Andre, J.; Bensussan, A.; Dumaz, N.] Hop St Louis, Ctr Rech Peau, INSERM, U976, Paris, France; [Laugier, F.; Delyon, J.; Andre, J.; Bensussan, A.; Dumaz, N.] Univ Paris Diderot, Sorbonne Paris Cite, UMRS976, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Dumaz, N (corresponding author), Hop St Louis, U976, INSERM, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	nicolas.dumaz@inserm.fr	Bensussan, Armand/E-5434-2017; Delyon, Julie/O-5147-2019; Dumaz, Nicolas/B-5907-2008	Delyon, Julie/0000-0002-4557-3377; Dumaz, Nicolas/0000-0003-3511-2160; Bensussan, Armand/0000-0002-0409-2497	L'Oreal Research Innovation; INSERM; Universite Paris Diderot; Fondation ARC pour la Recherche sur le Cancer	L'Oreal Research Innovation; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite Paris Diderot; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer)	We thank Pr Antoni Ribas for the M230 melanoma cell line. This work was funded by L'Oreal Research & Innovation, INSERM, Universite Paris Diderot and Fondation ARC pour la Recherche sur le Cancer. FL was supported by L'Oreal Research & Innovation.	Bastian BC, 2013, J CLIN ONCOL, V31, P3288, DOI 10.1200/JCO.2013.50.3227; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bedogni B, 2009, PIGM CELL MELANOMA R, V22, P166, DOI 10.1111/j.1755-148X.2009.00553.x; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bourillon A, 2013, PIGM CELL MELANOMA R, V26, P88, DOI 10.1111/pcmr.12032; Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dumaz N, 2015, MELANOMA RES, V25, P88, DOI 10.1097/CMR.0000000000000116; Evans SM, 2006, J INVEST DERMATOL, V126, P2596, DOI 10.1038/sj.jid.5700451; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Feige E, 2011, P NATL ACAD SCI USA, V108, pE924, DOI 10.1073/pnas.1106351108; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garrido MC, 2010, J INVEST DERMATOL, V130, P20, DOI 10.1038/jid.2009.334; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; Hamai A, 2006, ONCOGENE, V25, P7618, DOI 10.1038/sj.onc.1209738; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; HORIKOSHI T, 1991, J INVEST DERMATOL, V96, P841, DOI 10.1111/1523-1747.ep12474550; Huang SY, 1996, ONCOGENE, V13, P2339; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; LASSAM N, 1992, ONCOGENE, V7, P51; Liang RX, 2011, PIGM CELL MELANOMA R, V24, P714, DOI 10.1111/j.1755-148X.2011.00870.x; Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Ohanna M, 2013, ONCOTARGET, V4, P2212, DOI 10.18632/oncotarget.1143; Park E, 2012, AM J DERMATOPATH, V34, P41, DOI 10.1097/DAD.0b013e31821ec0ef; Ramgolam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018784; Rezvani HR, 2011, J INVEST DERMATOL, V131, P1793, DOI 10.1038/jid.2011.141; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Todd JR, 2014, ONCOGENE, V33, P236, DOI 10.1038/onc.2012.562; von Euw E, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-22; Young SM, 2007, CELL SIGNAL, V19, P2572, DOI 10.1016/j.cellsig.2007.08.004	39	6	7	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5070	5077		10.1038/onc.2016.39	http://dx.doi.org/10.1038/onc.2016.39			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	26973244				2022-12-17	WOS:000383965300010
J	Kumar, A; Singhal, M; Chopra, C; Srinivasan, S; Surabhi, RP; Kanumuri, R; Tentu, S; Jagadeeshan, S; Sundaram, S; Ramanathan, K; Pitani, RS; Muthuswamy, B; Abhijit, S; Nair, AS; Venkatraman, G; Rayala, SK				Kumar, A.; Singhal, M.; Chopra, C.; Srinivasan, S.; Surabhi, R. P.; Kanumuri, R.; Tentu, S.; Jagadeeshan, S.; Sundaram, S.; Ramanathan, K.; Pitani, R. Shankar; Muthuswamy, B.; Abhijit, S.; Nair, A. S.; Venkatraman, G.; Rayala, S. K.			Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; PROMOTER HYPERMETHYLATION; PROTEIN MISLOCALIZATION; GASTRIC-CANCER; EXPRESSION; FAMILY	P21 Activated Kinase 1 (Pak1), an oncogenic serine/threonine kinase, is known to have a significant role in the regulation of cytoskeleton and cellular morphology. Runx3 was initially known for its role in tumor suppressor function, but recent studies have reported the oncogenic role of Runx3 in various cancers. However, the mechanism that controls the paradoxical functions of Runx3 still remains unclear. In this study, we show that Runx3 is a physiologically interacting substrate of Pak1. We identified the site of phosphorylation in Runx3 as Threonine 209 by mass spectrometry analysis and site-directed mutagenesis, and further confirmed the same with a site-specific antibody. Results from our functional studies showed that Threonine 209 phosphorylation in Runx3 alters its subcellular localization by protein mislocalization from the nucleus to the cytoplasm and subsequently converses its biological functions. This was further supported by in vivo tumor xenograft studies in nude mouse models which clearly demonstrated that PANC-28 cells transfected with the Runx3-T209E clone showed high tumorigenic potential as compared with other clones. Our results from clinical samples also suggest that Threonine 209 phosphorylation by Pak1 could be a potential therapeutic target and of great clinical relevance with implications for Runx3 inactivation in cancer cells where Runx3 is known to be oncogenic. The findings presented in this study provide evidence of Runx3-Threonine 209 phosphorylation as a molecular switch in dictating the tissue-specific dualistic functions of Runx3 for the first time.	[Kumar, A.; Singhal, M.; Chopra, C.; Srinivasan, S.; Surabhi, R. P.; Kanumuri, R.; Tentu, S.; Jagadeeshan, S.; Rayala, S. K.] IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India; [Sundaram, S.; Ramanathan, K.] Sri Ramachandra Univ, Dept Pathol, Madras, Tamil Nadu, India; [Pitani, R. Shankar] Sri Ramachandra Univ, Dept Community Med, Madras, Tamil Nadu, India; [Muthuswamy, B.; Abhijit, S.] MDRF, Madras, Tamil Nadu, India; [Nair, A. S.] RGCB, Thiruvananthapuram, Kerala, India; [Venkatraman, G.] Sri Ramachandra Univ, Dept Human Genet, Madras, Tamil Nadu, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; Sri Ramachandra Institute of Higher Education & Research; Sri Ramachandra Institute of Higher Education & Research; Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Sri Ramachandra Institute of Higher Education & Research	Rayala, SK (corresponding author), IITM, Dept Biotechnol, Madras 600036, Tamil Nadu, India.; Venkatraman, G (corresponding author), Sri Ramachandra Univ, Dept Human Genet, Madras, Tamil Nadu, India.	ganeshv@sriramachandra.edu.in; rayala@iitm.ac.in	Singhal, Mahak/V-4017-2019; Gampala, Silpa/AAL-7982-2020; CHELLUBOYINA, ARUNA KUMAR/GXG-8165-2022; GAMPALA, SILPA/A-1541-2019; CHELLUBOYINA, ARUNA KUMAR/GZL-7536-2022; Venkatraman, Ganesh/AAB-1467-2020; Kanumuri, Rahul Sankrityayan/AGF-8012-2022; JAGADEESHAN, SANKAR/S-8384-2019	Singhal, Mahak/0000-0002-7303-9585; Gampala, Silpa/0000-0001-9928-3941; CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; CHELLUBOYINA, ARUNA KUMAR/0000-0001-7201-3810; Venkatraman, Ganesh/0000-0003-0179-9785; Kanumuri, Rahul Sankrityayan/0000-0001-6039-461X; JAGADEESHAN, SANKAR/0000-0002-3778-8757; Rayala, Suresh/0000-0003-4394-4450; Chopra, Chirag/0000-0002-7239-709X	DAE-BRNS Government of India [35/14/41/2014-BRNS-RTAC]; DBT Government of India [BT/PR14340/NNT/28/860/2015]	DAE-BRNS Government of India(Department of Atomic Energy (DAE)Board of Research in Nuclear Sciences (BRNS)); DBT Government of India(Department of Biotechnology (DBT) India)	We thank Prof Yoshiaki Ito, Cancer Science Institute of Singapore, Singapore, for providing us the Runx3 constructs. We profusely thank Prof Susanne M Gollin, University of Pittsburgh, for providing us with SCC-131 cells. We thank Dr Marsha Fraizer (University of Texas, M. D. Anderson Cancer Center, USA); for providing MDA Panc 28 cells. We thank Dr Rajeshwari, Bioklone, Chennai, for generating polyclonal Runx3-Threonine 209 phospho antibody. We thank DAE-BRNS (Grant # 35/14/41/2014-BRNS-RTAC), DBT (BT/PR14340/NNT/28/860/2015) Government of India for financial support to SKR and the Department of Biotechnology, Indian Institute of Technology Madras (IITM) for infrastructural facilities. We thank Mr Balabhaskara Rao and Ms Lakshmi Arivazhagan for the initial help with protein expression studies and Runx3 clones. We thank Professor SP Thyagarajan, Dean Research and Management of SRU for Support and encouragement.	Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017; Bae SC, 2004, ONCOGENE, V23, P4336, DOI 10.1038/sj.onc.1207286; Baross JA, 2015, CELL, V162, P13, DOI 10.1016/j.cell.2015.06.038; Chauang LS, 2013, INT J CANCER, V15, P1260; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Chuang LSH, 2013, INT J CANCER, V132, P1260, DOI 10.1002/ijc.27964; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Kudo Y, 2011, J CELL BIOCHEM, V112, P387, DOI 10.1002/jcb.22967; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee CWL, 2011, GYNECOL ONCOL, V122, P410, DOI 10.1016/j.ygyno.2011.04.044; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Tsang YHN, 2013, ONCOGENE, V32, P1488, DOI 10.1038/onc.2012.178; Tsunematsu T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005892; Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x	19	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4857	4865		10.1038/onc.2016.18	http://dx.doi.org/10.1038/onc.2016.18			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26898755				2022-12-17	WOS:000383330700004
J	Bernaudo, S; Salem, M; Qi, X; Zhou, W; Zhang, C; Yang, W; Rosman, D; Deng, Z; Ye, G; Yang, BB; Vanderhyden, B; Wu, Z; Peng, C				Bernaudo, S.; Salem, M.; Qi, X.; Zhou, W.; Zhang, C.; Yang, W.; Rosman, D.; Deng, Z.; Ye, G.; Yang, B. B.; Vanderhyden, B.; Wu, Z.; Peng, C.			Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/beta-catenin signalling (vol 35, pg 4816, 2016)	ONCOGENE			English	Correction																		Bernaudo S, 2016, ONCOGENE, V35, P4816, DOI 10.1038/onc.2016.15	1	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4828	4828		10.1038/onc.2016.65	http://dx.doi.org/10.1038/onc.2016.65			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	27477697	hybrid, Green Published			2022-12-17	WOS:000383324700015
J	Nitzki, F; Cuvelier, N; Drager, J; Schneider, A; Braun, T; Hahn, H				Nitzki, F.; Cuvelier, N.; Draeger, J.; Schneider, A.; Braun, T.; Hahn, H.			Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells	ONCOGENE			English	Article							WNT INHIBITORY FACTOR-1; EMBRYONAL RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; SKELETAL MYOGENESIS; MOUSE MODEL; GENE; EXPRESSION; PATHWAY; GLI; PROTEINS	Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma. In children, the 2 major RMS subtypes are alveolar and embryonal RMS. Aberrant Hedgehog/Patched1 (Hh/Ptch) signaling is a hallmark of embryonal RMS. We demonstrate that mice carrying a Ptch mutation in mesodermal Delta1-expressing cells develop embryonal-like RMS at a similar rate as mice harboring a Ptch mutation in the germline or the brachury-expressing mesoderm. The tumor incidence decreases dramatically when Ptch is mutated in Myf5- or Pax3-expressing cells. No RMS develop from Myogenin/Mef2c-expressing cells. This suggests that Hh/Ptch-associated RMS are derived from Delta1-positive, Myf5-negative, Myogenin-negative and Pax3-negative mesodermal progenitors that can undergo myogenic differentiation but lack stable lineage commitment. Additional preliminary genetic data and data on mesodermal progenitors further imply an interplay of Hh/Ptch and Delta/Notch signaling activity during RMS initiation. In contrast, Wnt signals supposedly suppress RMS formation because RMS multiplicity decreases after inactivation of the Wnt-inhibitor Wif1. Finally, our results strongly suggest that the tumor-initiating event determines the lineage of RMS origin.	[Nitzki, F.; Cuvelier, N.; Draeger, J.; Hahn, H.] Univ Med Ctr Goettingen, Dept Human Genet, Heinrich Dueker Weg 12, D-37073 Gottingen, Germany; [Schneider, A.; Braun, T.] Max Planck Inst Heart & Lung Res, Dept Cardiac Dev & Remodelling, Bad Nauheim, Germany	University of Gottingen; Max Planck Society	Hahn, H (corresponding author), Univ Med Ctr Goettingen, Dept Human Genet, Heinrich Dueker Weg 12, D-37073 Gottingen, Germany.	hhahn@gwdg.de	Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	DFG [HA2197/7-1]	DFG(German Research Foundation (DFG))	We thank Lars Wittler and Ludger Hartmann for Wnt<SUP>vt/vt</SUP> mice, Walter Birchmeier and Felix Brembeck for beta-cat<SUP>flox/flox</SUP> mice and Christoph Englert and David Thomas for Wif1<SUP>-/-</SUP> mice. We are grateful to Susan Peter and Stefan Wolf for excellent animal care. We thank Anke Frommhold, Ina Hess and Tobias Goldak for technical assistance and Walter Schulz-Schaeffer (Institute of Neuropathology, University Medical Center Gottingen) and Ilona Skerjanc for useful advice. This work was supported by the DFG Grant HA2197/7-1 to HH.	Abraham J, 2014, GENE DEV, V28, P1578, DOI 10.1101/gad.238733.114; Beckers J, 2000, MECH DEVELOP, V95, P23, DOI 10.1016/S0925-4773(00)00322-1; Belyea Brian, 2012, Sarcoma, V2012, P406239, DOI 10.1155/2012/406239; Benito-Gonzalez A, 2014, J NEUROSCI, V34, P12865, DOI 10.1523/JNEUROSCI.1494-14.2014; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; Dequeant ML, 2008, NAT REV GENET, V9, P370, DOI 10.1038/nrg2320; Diaconescu S, 2013, ROM J MORPHOL EMBRYO, V54, P531; Ecke I, 2008, MOL CARCINOGEN, V47, P361, DOI 10.1002/mc.20394; Engleka KA, 2005, DEV BIOL, V280, P396, DOI 10.1016/j.ydbio.2005.02.002; Feller J, 2008, GENE DEV, V22, P2166, DOI 10.1101/gad.480408; Gianakopoulos PJ, 2011, J BIOL CHEM, V286, P2517, DOI 10.1074/jbc.M110.163709; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; Gurney JG, 1999, CANC INCIDENCE SURVI, P111; Hahn H, 2004, GENOMICS, V84, P853, DOI 10.1016/j.ygeno.2004.07.002; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Ji SJ, 2006, DEV BIOL, V297, P249, DOI 10.1016/j.ydbio.2006.05.015; Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Parker MH, 2003, NAT REV GENET, V4, P497, DOI 10.1038/nrg1109; Petropoulos H, 2004, J BIOL CHEM, V279, P23874, DOI 10.1074/jbc.M312612200; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Rajurkar M, 2014, ONCOGENE, V33, P5370, DOI 10.1038/onc.2013.480; Roma J, 2011, CLIN CANCER RES, V17, P505, DOI 10.1158/1078-0432.CCR-10-0166; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Sanchez-Gurmaches J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5099; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sebire NJ, 2003, J CLIN PATHOL, V56, P412, DOI 10.1136/jcp.56.6.412; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sprinzak D, 2010, NATURE, V465, P86, DOI 10.1038/nature08959; Stock M, 2013, ARTHRITIS RHEUM-US, V65, P2310, DOI 10.1002/art.38054; Surmann-Schmitt C, 2009, J CELL SCI, V122, P3627, DOI 10.1242/jcs.048926; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tamplin OJ, 2011, DEV BIOL, V360, P415, DOI 10.1016/j.ydbio.2011.10.002; Tews D, 2011, HORM RES PAEDIAT, V75, P231, DOI 10.1159/000324806; Uhmann A, 2007, BLOOD, V110, P1814, DOI 10.1182/blood-2007-02-075648; von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Zibat A, 2010, ONCOGENE, V29, P6323, DOI 10.1038/onc.2010.368; Zibat A, 2009, CARCINOGENESIS, V30, P918, DOI 10.1093/carcin/bgp068	57	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2923	2931		10.1038/onc.2015.346	http://dx.doi.org/10.1038/onc.2015.346			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26387541				2022-12-17	WOS:000377473700012
J	Naik, RR; Singh, AK; Mali, AM; Khirade, MF; Bapat, SA				Naik, R. R.; Singh, A. K.; Mali, A. M.; Khirade, M. F.; Bapat, S. A.			A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses	ONCOGENE			English	Article							STEM-CELLS; CANCER; HETEROGENEITY; CONTRIBUTE; ANEUPLOIDY	Tumor heterogeneity and the presence of drug-sensitive and refractory populations within the same tumor are almost never assessed in the drug discovery pipeline. Such incomplete assessment of drugs arising from spatial and temporal tumor cell heterogeneity reflects on their failure in the clinic and considerable wasted costs in the drug discovery pipeline. Here we report the derivation of a flow cytometry-based tumor deconstruction platform for resolution of at least 18 discrete tumor cell fractions. This is achieved through concurrent identification, quantification and analysis of components of cancer stem cell hierarchies, genetically instable clones and differentially cycling populations within a tumor. We also demonstrate such resolution of the tumor cytotype to be a potential value addition in drug screening through definitive cell target identification. Additionally, this real-time definition of intra-tumor heterogeneity provides a convenient, incisive and analytical tool for predicting drug efficacies through profiling perturbations within discrete tumor cell subsets in response to different drugs and candidates. Consequently, possible applications in informed therapeutic monitoring and drug repositioning in personalized cancer therapy would complement rational design of new candidates besides achieving a re-evaluation of existing drugs to derive non-obvious combinations that hold better chances of achieving remission.	[Naik, R. R.; Singh, A. K.; Mali, A. M.; Khirade, M. F.; Bapat, S. A.] Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Bapat, SA (corresponding author), Natl Ctr Cell Sci, NCCS Complex, Pune 411007, Maharashtra, India.	sabapat@nccs.res.in	Bapat, Sharmila/AGU-4130-2022	Bapat, Sharmila/0000-0002-9557-2233	NCCS	NCCS	We appreciate the efforts of Dr Mrunalini Moghe (Deenanath Mangeshkar Hospital, Pune) and Dr Anjali Kusumbe in karyotyping, Mr Swapnil Kamble in cryosectioning and thank Dr Shona Nag (Jehangir Hospital, Pune) for providing gemcitabine. This research is supported by NCCS intra-mural grants to SAB.	Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Bian ML, 2010, SCI CHINA LIFE SCI, V53, P1322, DOI 10.1007/s11427-010-4086-1; Bouchet BP, 2007, BRIT J CANCER, V97, P1218, DOI 10.1038/sj.bjc.6603936; Cavanagh BL, 2011, MOLECULES, V9, P7980; Centenera MM, 2013, NAT REV UROL, V10, P483, DOI 10.1038/nrurol.2013.126; Chiang YP, 1996, BBA-MOL CELL RES, V1313, P295, DOI 10.1016/0167-4889(96)00103-6; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Cree IA, 2010, CURR OPIN PHARMACOL, V10, P375, DOI 10.1016/j.coph.2010.05.001; Diaz-Cano SJ, 2012, INT J MOL SCI, V13, P1951, DOI 10.3390/ijms13021951; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kunos CA, 2011, RADIAT RES, V176, P425, DOI 10.1667/RR2556.1; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Kusumbe AP, 2009, STEM CELLS, V27, P498, DOI 10.1634/stemcells.2008-0868; Li B, 2012, CLIN CANCER RES, V18, P5595, DOI 10.1158/1078-0432.CCR-12-1427; Lin D, 2014, ASIAN J ANDROL, V16, P407, DOI 10.4103/1008-682X.125394; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; Natrajan R, 2013, CANCER RES, V73, P3483, DOI 10.1158/0008-5472.CAN-12-4717; Navin NE, 2010, MOL ONCOL, V4, P267, DOI 10.1016/j.molonc.2010.04.010; Niu DD, 2009, PROTEOMICS, V9, P3856, DOI 10.1002/pmic.200900071; Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schoenborn JR, 2013, CLIN CANCER RES, V19, P4058, DOI 10.1158/1078-0432.CCR-12-3606; Shan-Cheng R, 2013, ASIAN J ANDROL, V15, P729; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Wang B, 2010, EXPERT OPIN DRUG DEL, V7, P1159, DOI 10.1517/17425247.2010.513968; Wani AA, 2006, ONCOGENE, V25, P6336, DOI 10.1038/sj.onc.1209649; Ye Neng-Sheng, 2006, Genomics Proteomics & Bioinformatics, V4, P18, DOI 10.1016/S1672-0229(06)60012-0	33	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					727	737		10.1038/onc.2015.130	http://dx.doi.org/10.1038/onc.2015.130			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	25915841				2022-12-17	WOS:000370331300006
J	Ohno, S; Naito, Y; Mukai, S; Yabuta, N; Nojima, H				Ohno, S.; Naito, Y.; Mukai, S.; Yabuta, N.; Nojima, H.			ELAS1-mediated inhibition of the cyclin G1-B 'gamma interaction promotes cancer cell apoptosis via stabilization and activation of p53	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; DNA-DAMAGE; PHOSPHOINOSITIDE 3-KINASE; COLORECTAL-CANCER; MEDIATED TRANSFER; G2 EXPRESSION; TUMOR-GROWTH; G1; ARREST; PHOSPHORYLATION	Radiation therapy (RT) is useful for selectively killing cancer cells. However, because high levels of ionizing radiation (IR) are toxic to normal cells, RT cannot be applied repeatedly to cancer patients. Therefore, novel chemicals that enhance the efficacy of chemoradiotherapy (CRT) would be valuable. Here, we report that ELAS1, a peptide corresponding to the protein phosphatase 2A (PP2A) association domain of cyclin G1 (CycG1), can enhance the efficacy of CRT. ELAS1 interacts with the PP2A B'gamma-subunit and competitively inhibits association with CycG1, thereby preventing the PP2A holoenzyme from dephosphorylating target proteins, Mdm2 (pT218) and p53 (pS46), following DNA double-strand break (DSB) insults. Doxycycline (Dox)-induced overexpression of Myc-ELAS1 caused.-irradiation to induce apoptosis in human osteosarcoma (U2OS) cells, at 1/10th the effective dosage of.-irradiation required for apoptosis in Myc-vector-expressing cells; ELAS1 peptide incorporation into U2OS cells also showed similar apoptotic effects. Moreover, administration of DSB-inducing chemicals, camptothecin (CPT) or irinotecan, to Myc-ELAS1-expressing U2OS cells also induced efficient apoptosis with only 1/100th (CPT) or 1/5th (irinotecan) of the amounts of drugs required for this effect in Myc-vector-expressing cells. Taken together, ELAS1 may be important for the design of ELAS1-mimetic compounds to improve CRT efficacy.	[Ohno, S.; Naito, Y.; Mukai, S.; Yabuta, N.; Nojima, H.] Osaka Univ, Microbial Dis Res Inst, Dept Mol Genet, Suita, Osaka 5650871, Japan	Osaka University	Nojima, H (corresponding author), Osaka Univ, Reasearch Inst Microbial Dis, Dept Mol Genet, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	snj-0212@biken.osaka-u.ac.jp			Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan [23370086]	Osaka University; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Patrick Hughes for critically reading the manuscript and Ms Yuki Ozaki for technical assistance. This work was supported by the Drug Discovery Gap Fund from Osaka University (to HN) and Grants-in-aid for Scientific Research (to HN) (No. 23370086) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Baek WK, 2003, AM J OBSTET GYNECOL, V188, P634, DOI 10.1067/mob.2003.140; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Chen DS, 1997, HUM GENE THER, V8, P1667, DOI 10.1089/hum.1997.8.14-1667; Chen WB, 2013, GASTROENT RES PRACT, V2013, DOI 10.1155/2013/675429; Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351; Craik DJ, 2013, CHEM BIOL DRUG DES, V81, P136, DOI 10.1111/cbdd.12055; Fu G, 2011, ONCOGENE, V30, P3953, DOI 10.1038/onc.2011.127; Gordon EM, 2000, CANCER RES, V60, P3343; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Ito Y, 2003, ANTICANCER RES, V23, P2335; Jensen MR, 2003, HEPATOLOGY, V37, P862, DOI 10.1053/jhep.2003.50137; Kalev P, 2011, ANTI-CANCER AGENT ME, V11, P38, DOI 10.2174/187152011794941172; Kampmeier J, 2000, HUM GENE THER, V11, P1, DOI 10.1089/10430340050016102; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kimura SH, 2001, ONCOGENE, V20, P3290, DOI 10.1038/sj.onc.1204270; Le XF, 2007, MOL CANCER THER, V6, P2843, DOI 10.1158/1535-7163.MCT-07-0109; Liu C, 2014, NUCLEIC ACIDS RES, V42, P6106, DOI 10.1093/nar/gku284; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; Mi J, 2009, MOL CANCER THER, V8, P135, DOI 10.1158/1535-7163.MCT-08-0457; Naito Y, 2013, CELL CYCLE, V12, P1773, DOI 10.4161/cc.24878; Naito Y, 2012, CELL CYCLE, V11, P604, DOI 10.4161/cc.11.3.19114; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Park IJ, 2014, WORLD J GASTROENTERO, V20, P2023, DOI 10.3748/wjg.v20.i8.2023; Peng A, 2010, ONCOGENE, V29, P5977, DOI 10.1038/onc.2010.371; Perez R, 2003, J GASTROINTEST SURG, V7, P884, DOI 10.1016/j.gassur.2003.08.001; Piscopo DM, 2008, CANCER RES, V68, P5581, DOI 10.1158/0008-5472.CAN-07-6346; Ragel BT, 2007, NEUROSURG REV, V30, P181, DOI 10.1007/s10143-007-0070-z; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; Shimizu A, 1998, BIOCHEM BIOPH RES CO, V242, P529, DOI 10.1006/bbrc.1997.8004; SKOTZKO M, 1995, CANCER RES, V55, P5493; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; TAMURA K, 1993, ONCOGENE, V8, P2113; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Tomicic MT, 2013, BBA-REV CANCER, V1835, P11, DOI 10.1016/j.bbcan.2012.09.002; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Wen W, 2012, HEPATOLOGY, V55, P1787, DOI 10.1002/hep.25596; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yang J, 2010, LIFE SCI, V87, P659, DOI 10.1016/j.lfs.2010.10.003; Zhang Qingxiu, 2012, Enzyme Res, V2012, P659649, DOI 10.1155/2012/659649; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200; Zhao L, 2003, MOL CANCER RES, V1, P195; Zimmermann M, 2012, J BIOL CHEM, V287, P22838, DOI 10.1074/jbc.M112.376855	48	6	6	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5983	5996		10.1038/onc.2015.47	http://dx.doi.org/10.1038/onc.2015.47			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25915850				2022-12-17	WOS:000366113500005
J	He, Y; Chen, D; Zheng, W				He, Y.; Chen, D.; Zheng, W.			An enhanced functional interrogation/manipulation of intracellular signaling pathways with the peptide 'stapling' technology	ONCOGENE			English	Review							STABILIZED ALPHA-HELICES; BCL-2 FAMILY; BH3 HELIX; PROTEINS; ACTIVATION; DESIGN; P53; INHIBITOR; BINDING; CANCER	Specific protein-protein interactions (PPIs) constitute a key underlying mechanism for the presence of a multitude of intracellular signaling pathways, which are essential for the survival of normal and cancer cells. Specific molecular blockers for a crucial PPI would therefore be invaluable tools for an enhanced functional interrogation of the signaling pathway harboring this particular PPI. On the other hand, if a particular PPI is essential for the survival of cancer cells but is absent in or dispensable for the survival of normal cells, its specific molecular blockers could potentially be developed into effective anticancer therapeutics. Due to the flat and extended PPI interface, it would be conceivably difficult for small molecules to achieve an effective blockade, a problem which could be potentially circumvented with peptides or proteins. However, the well-documented proteolytic instability and cellular impermeability of peptides and proteins in general would make their developing into effective intracellular PPI blockers quite a challenge. With the advent of the peptide 'stapling' technology which was demonstrated to be able to stabilize the a-helical conformation of a peptide via bridging two neighboring amino-acid side chains with a 'molecular staple', a linear parent peptide could be transformed into a stronger PPI blocker with enhanced proteolytic stability and cellular permeability. This review will furnish an account on the peptide 'stapling' technology and its exploitation in efforts to achieve an enhanced functional interrogation or manipulation of intracellular signaling pathways especially those that are cancer relevant.	[He, Y.; Chen, D.; Zheng, W.] Jiangsu Univ, Sch Pharm, Zhenjiang 212013, Peoples R China	Jiangsu University	Zheng, W (corresponding author), Jiangsu Univ, Sch Pharm, 301 Xuefu Rd, Zhenjiang 212013, Peoples R China.	wzheng@ujs.edu.cn			Jiangsu provincial 'innovation and venture talents' award plan	Jiangsu provincial 'innovation and venture talents' award plan	WZ is a Jiangsu provincial specially appointed professor and a recipient of the Jiangsu provincial 'innovation and venture talents' award plan, and the associated financial supports to the completion of this manuscript are appreciated.	Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587; Bernal F, 2014, METHODS MOL BIOL, V1176, P107, DOI 10.1007/978-1-4939-0992-6_9; Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bird GH, 2014, ACS CHEM BIOL, V9, P831, DOI 10.1021/cb4003305; Bird GH, 2008, METHOD ENZYMOL, V446, P369, DOI 10.1016/S0076-6879(08)01622-4; Bird Gregory H, 2011, Curr Protoc Chem Biol, V3, P99, DOI 10.1002/9780470559277.ch110042; Blackwell HE, 1998, ANGEW CHEM INT EDIT, V37, P3281, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3281::AID-ANIE3281>3.0.CO;2-V; BRACKEN C, 1994, J AM CHEM SOC, V116, P6431, DOI 10.1021/ja00093a052; Brown CJ, 2013, ACS CHEM BIOL, V8, P506, DOI 10.1021/cb3005148; Cantel S, 2008, J ORG CHEM, V73, P5663, DOI 10.1021/jo800142s; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Choi YS, 2014, CURR PHARM BIOTECHNO, V15, P192, DOI 10.2174/1389201015666140617093331; Danial NN, 2008, NAT MED, V14, P144, DOI 10.1038/nm1717; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Edwards AL, 2013, CHEM BIOL, V20, P888, DOI 10.1016/j.chembiol.2013.06.007; Flint DG, 2002, CHEM BIOL, V9, P391, DOI 10.1016/S1074-5521(02)00109-6; Frank AO, 2014, J MED CHEM, V57, P2455, DOI 10.1021/jm401730y; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Gavathiotis E, 2010, MOL CELL, V40, P481, DOI 10.1016/j.molcel.2010.10.019; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; Goodman M., 1995, BURGERS MED CHEM DRU, VI, P803; Grossmann TN, 2012, P NATL ACAD SCI USA, V109, P17942, DOI 10.1073/pnas.1208396109; Guo ZJ, 2010, CHEM BIOL DRUG DES, V75, P348, DOI 10.1111/j.1747-0285.2010.00951.x; Haney CM, 2011, CHEM COMMUN, V47, P10915, DOI 10.1039/c1cc12010g; Hao YJ, 2013, CANCER CELL, V23, P583, DOI 10.1016/j.ccr.2013.03.021; JACKSON DY, 1991, J AM CHEM SOC, V113, P9391, DOI 10.1021/ja00024a067; Joseph TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043985; Joseph TL, 2010, CELL CYCLE, V9, P4560, DOI 10.4161/cc.9.22.13816; Karle IL, 2001, BIOPOLYMERS, V60, P351, DOI 10.1002/1097-0282(2001)60:5<351::AID-BIP10174>3.0.CO;2-U; Kaul R, 1999, BIOORGAN MED CHEM, V7, P105, DOI 10.1016/S0968-0896(98)00221-1; Kawamoto SA, 2012, J MED CHEM, V55, P1137, DOI 10.1021/jm201125d; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Kim YW, 2011, NAT PROTOC, V6, P761, DOI 10.1038/nprot.2011.324; LaBelle JL, 2012, J CLIN INVEST, V122, P2018, DOI 10.1172/JCI46231; Lama D, 2013, SCI REP-UK, V3, DOI 10.1038/srep03451; Lau YH, 2014, ORG BIOMOL CHEM, V12, P4074, DOI 10.1039/c4ob00742e; Lau YH, 2014, CHEM SCI, V5, P1804, DOI 10.1039/c4sc00045e; Leshchiner ES, 2013, P NATL ACAD SCI USA, V110, pE986, DOI 10.1073/pnas.1214313110; Madden MM, 2011, BIOORG MED CHEM LETT, V21, P1472, DOI 10.1016/j.bmcl.2011.01.004; McCrudden MTC, 2013, THER DELIV, V4, P593, DOI [10.4155/tde.13.31, 10.4155/TDE.13.31]; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Moldoveanu T, 2013, NAT STRUCT MOL BIOL, V20, P589, DOI 10.1038/nsmb.2563; Muppidi A, 2014, BIOORG MED CHEM LETT, V24, P1748, DOI 10.1016/j.bmcl.2014.02.038; Muppidi A, 2012, J AM CHEM SOC, V134, P14734, DOI 10.1021/ja306864v; Muppidi A, 2011, CHEM COMMUN, V47, P9396, DOI 10.1039/c1cc13320a; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Phelan JC, 1997, J AM CHEM SOC, V119, P455, DOI 10.1021/ja9611654; Phillips C, 2011, J AM CHEM SOC, V133, P9696, DOI 10.1021/ja202946k; Pitter K, 2008, METHOD ENZYMOL, V446, P387, DOI 10.1016/S0076-6879(08)01623-6; Ramos YFM, 2001, CANCER RES, V61, P1839; Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a; Shim SY, 2013, CHEM BIOL DRUG DES, V82, P635, DOI 10.1111/cbdd.12231; Simerska P, 2011, MED RES REV, V31, P520, DOI 10.1002/med.20191; Sinclair JKL, 2014, J AM CHEM SOC, V136, P11232, DOI 10.1021/ja504076t; Spiegel J, 2014, ANGEW CHEM INT EDIT, V53, P2498, DOI 10.1002/anie.201308568; Stewart ML, 2010, NAT CHEM BIOL, V6, P595, DOI [10.1038/NCHEMBIO.391, 10.1038/nchembio.391]; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Thomas S, 2013, EXPERT OPIN THER TAR, V17, P61, DOI 10.1517/14728222.2013.733001; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; URNES P, 1961, ADV PROTEIN CHEM, V16, P401; Verdine GL, 2007, CLIN CANCER RES, V13, P7264, DOI 10.1158/1078-0432.CCR-07-2184; Verdine GL, 2012, METHOD ENZYMOL, V503, P3, DOI 10.1016/B978-0-12-396962-0.00001-X; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Walensky LD, 2014, J MED CHEM, V57, P6275, DOI 10.1021/jm4011675; Wang YX, 2014, ACS CHEM BIOL, V9, P635, DOI 10.1021/cb400900r; Wei SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081068; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	73	6	6	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5685	5698		10.1038/onc.2015.37	http://dx.doi.org/10.1038/onc.2015.37			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25798838				2022-12-17	WOS:000364594600001
J	Kim, RK; Suh, Y; Hwang, E; Yoo, KC; Choi, KS; An, S; Hwang, SG; Kim, IG; Kim, MJ; Lee, HJ; Lee, SJ				Kim, R-K; Suh, Y.; Hwang, E.; Yoo, K-C; Choi, K-S; An, S.; Hwang, S-G; Kim, I-G; Kim, M-J; Lee, H-J; Lee, S-J			PKC delta maintains phenotypes of tumor initiating cells through cytokine-mediated autocrine loop with positive feedback	ONCOGENE			English	Article							PROTEIN-KINASE-C; CANCER STEM-CELLS; GROWTH-FACTOR; GLIOMA; BRAIN; ACTIVATION; SURVIVAL; PATHWAY; IDENTIFICATION; POPULATION	The existence of tumor initiating cells (TICs) has been emerged as a good therapeutic target for treatment of glioblastoma that is the most aggressive brain tumor with poor prognosis. However, the molecular mechanisms that regulate the phenotypes of TICs still remain obscure. In this study, we found that PKC delta, among PKC isoforms, is preferentially activated in TICs and acts as a critical regulator for the maintenance of TICs in glioblastoma. By modulating the expression levels or activity of PKC delta, we demonstrated that PKC delta promotes self-renewal and tumorigenic potentials of TICs. Importantly, we found that the activation of PKC delta persists in TICs through an autocrine loop with positive feedback that was driven by PKC delta/STAT3/IL-23/JAK signaling axis. Moreover, for phenotypes of TICs, we showed that PKC delta activates AKT signaling component by phosphorylation specifically on Ser473. Taken together, we proposed that TICs regulate their own population in glioblastoma through an autocrine loop with positive feedback that is driven by PKC delta-dependent secretion of cytokines.	[Kim, R-K; Suh, Y.; Hwang, E.; Yoo, K-C; Kim, M-J; Lee, S-J] Hanyang Univ, Lab Mol Biochem, Dept Life Sci, Res Inst Nat Sci, Seoul 133791, South Korea; [Choi, K-S] Sungkyunkwan Univ, Mol & Cellular Imaging Ctr, Samsung Biomed Res Inst, Sch Med, Seoul, South Korea; [An, S.] Konkuk Univ, Funct Genoproteome Res Ctr, Seoul, South Korea; [Hwang, S-G] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul, South Korea; [Kim, I-G] Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Taejon, South Korea; [Kim, M-J] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul, South Korea; [Lee, H-J] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul, South Korea	Hanyang University; Sungkyunkwan University (SKKU); Samsung Medical Center; Konkuk University; Korea Institute of Radiological & Medical Sciences; Korea Atomic Energy Research Institute (KAERI); Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences	Lee, SJ (corresponding author), Hanyang Univ, Lab Mol Biochem, Dept Life Sci, Res Inst Nat Sci, 17 Haengdang Dong, Seoul 133791, South Korea.	sj0420@hanyang.ac.kr			National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean government, through its National Nuclear Technology Program [NRF-2012M2B2B1055639, NRF-2013M2A2A7066345]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean government, through its National Nuclear Technology Program	We thank Dr Akio Soeda (Department of Neurological Surgery, University of Virginia, USA) for providing patient-derived glioma cells. This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean government, through its National Nuclear Technology Program (NRF-2012M2B2B1055639 and NRF-2013M2A2A7066345).	Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107; Basu A, 2003, J CELL MOL MED, V7, P341, DOI 10.1111/j.1582-4934.2003.tb00237.x; Basu A, 2010, THESCIENTIFICWORLDJO, V10, P2272, DOI 10.1100/tsw.2010.214; Behin A, 2003, LANCET, V361, P323, DOI 10.1016/S0140-6736(03)12328-8; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Black JD, 2000, FRONT BIOSCI-LANDMRK, V5, pD406, DOI 10.2741/Black; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Brescia P, 2013, STEM CELLS, V31, P857, DOI 10.1002/stem.1317; Carrillo-Garcia C, 2010, MOL CELL NEUROSCI, V44, P318, DOI 10.1016/j.mcn.2010.04.003; Chen ZH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-90; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dirks PB, 2008, J CLIN ONCOL, V26, P2916, DOI 10.1200/JCO.2008.17.6792; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Duan ZF, 2006, CLIN CANCER RES, V12, P6844, DOI 10.1158/1078-0432.CCR-06-1330; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hernandez-Maqueda JG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058540; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Inagaki A, 2007, BIOCHEM BIOPH RES CO, V361, P586, DOI 10.1016/j.bbrc.2007.07.037; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Kim NH, 2013, BMB REP, V46, P59, DOI 10.5483/BMBRep.2013.46.1.123; Laperriere N, 2002, RADIOTHER ONCOL, V64, P259, DOI 10.1016/S0167-8140(02)00078-6; Lu F, 2005, RADIAT RES, V163, P63, DOI 10.1667/RR3285; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Mandil R, 2001, CANCER RES, V61, P4612; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Nakashima S, 2002, J BIOCHEM, V132, P669, DOI 10.1093/oxfordjournals.jbchem.a003272; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Ohgaki H, 2005, J NEUROPATH EXP NEUR, V64, P479, DOI 10.1093/jnen/64.6.479; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Salmaggi A, 2006, GLIA, V54, P850, DOI 10.1002/glia.20414; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Soeda A, 2008, J BIOL CHEM, V283, P10958, DOI 10.1074/jbc.M704205200; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Suh Y, 2009, MOL CELL NEUROSCI, V42, P308, DOI 10.1016/j.mcn.2009.08.003; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhou YH, 2003, CLIN CANCER RES, V9, P3369	57	6	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2015	34	46					5749	5759		10.1038/onc.2015.29	http://dx.doi.org/10.1038/onc.2015.29			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GC	25746003				2022-12-17	WOS:000364594600007
J	Zhang, X; Pageon, L; Post, SM				Zhang, X.; Pageon, L.; Post, S. M.			Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; SINGLE NUCLEOTIDE POLYMORPHISM; ACCELERATES TUMOR-FORMATION; MDM2 GENE; TRANSCRIPTIONAL ACTIVITY; DIFFERENTIAL REGULATION; P53; PROMOTER; CELL; EXPRESSION	A single-nucleotide polymorphism (SNP) in the promoter of the Mdm2 gene (Mdm2(SNP309-G)) results in an increased Mdm2 expression, partial attenuation of the p53 pathway and accelerated tumor development. Clinical case-control studies indicate the Mdm2(SNP309-G) allele associates with a significant increase in colorectal cancer (CRC) risk that is heightened in women, but the biological significance of this polymorphism has never been directly evaluated. To examine whether the Mdm2(SNP309-G) allele contributes to colorectal cancer, we generated cohorts of mice harboring either the G (minor allelic variant) or T (major allelic variant) allele and treated them with azoxymethane (AOM), a carcinogen that induces sporadic colorectal cancer. Mdm2(SNP309-G/G) mice displayed a significant reduction in survival following AOM treatment with more colonic lesions in a wider distribution throughout the lower and upper colon and an attenuated apoptotic response following exposure. AOM did not significantly induce stabilization of wild-type p53 or activate p53 downstream targets following AOM treatment, regardless of the genotype. Instead, Mdm2(SNP309-G/G) colons had significant changes in the expression of genes that regulate Mdm2 transcription (ERa and Sp1) as well as downstream targets of Mdm2. Together these results suggest the Mdm2(SNP309-G) allele significantly impacts CRC through mechanisms outside the p53 pathway.	[Zhang, X.; Post, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Pageon, L.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Post, SM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.	spost@mdanderson.org			Cancer Center [CA016672]; Center for Genetics and Genomics; MDACC; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Cancer Center; Center for Genetics and Genomics; MDACC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Maurisa Flynn-Croce and Brittany N Kleb for reviewing and editing the manuscript. These studies were supported by Cancer Center support grant CA016672 and funding from the Center for Genetics and Genomics and MDACC start-up funds to (SMP).	Abdel-Fattah G, 2000, J GASTROINTEST SURG, V4, P109, DOI 10.1016/S1091-255X(00)80041-4; Armstrong CM, 2013, ENDOCR-RELAT CANCER, V20, P515, DOI 10.1530/ERC-12-0308; Barboza JA, 2008, MOL CANCER RES, V6, P947, DOI 10.1158/1541-7786.MCR-07-2079; Bissahoyo A, 2005, TOXICOL SCI, V88, P340, DOI 10.1093/toxsci/kfi313; Bond GL, 2006, J MED GENET, V43, P950, DOI 10.1136/jmg.2006.043539; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brekman A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2804; Brendel A, 2013, RESTOR NEUROL NEUROS, V31, P199, DOI 10.3233/RNN-120272; Chaar I, 2012, EUR J GASTROEN HEPAT, V24, P320, DOI 10.1097/MEG.0b013e32834bdf84; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105; Ferreira KS, 2012, APOPTOSIS, V17, P503, DOI 10.1007/s10495-011-0691-0; Ferriere F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069081; Firoz EF, 2009, CLIN CANCER RES, V15, P2573, DOI 10.1158/1078-0432.CCR-08-2678; Fu W, 2009, J BIOL CHEM, V284, P13987, DOI 10.1074/jbc.M901758200; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Heijmans J, 2014, GUT, V63, P310, DOI 10.1136/gutjnl-2012-304216; Hu WW, 2007, CANCER RES, V67, P2757, DOI 10.1158/0008-5472.CAN-06-2656; Hu Y, 2005, INT J CANCER, V115, P561, DOI 10.1002/ijc.20876; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Itoh Y, 2007, J IMMUNOL, V178, P3059, DOI 10.4049/jimmunol.178.5.3059; James AW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007120; Jin J, 2014, J RADIAT RES, V55, P443, DOI 10.1093/jrr/rrt132; Kim K, 2011, J MOL ENDOCRINOL, V46, P67, DOI 10.1677/JME-10-0110; Knappskog S, 2012, EUR J CANCER, V48, P1988, DOI 10.1016/j.ejca.2011.10.024; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lind H, 2006, INT J CANCER, V119, P718, DOI 10.1002/ijc.21872; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nambiar PR, 2002, CANCER RES, V62, P3667; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Post SM, 2010, ONCOGENE, V29, P1260, DOI 10.1038/onc.2009.423; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Qin X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076031; Riley Maurisa F, 2012, Genes Cancer, V3, P226, DOI 10.1177/1947601912455322; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Spandidos A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-633; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; Tien JCY, 2012, EXPERT OPIN THER TAR, V16, P1085, DOI 10.1517/14728222.2012.718330; U.S. Department of Health and Human Services, 1999, US CANC STAT 1999 20; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WZ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04851	48	6	6	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4412	4420		10.1038/onc.2014.377	http://dx.doi.org/10.1038/onc.2014.377			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25435368				2022-12-17	WOS:000359494400012
J	Ren, Z; Aerts, JL; Pen, JJ; Heirman, C; Breckpot, K; De Greve, J				Ren, Z.; Aerts, J. L.; Pen, J. J.; Heirman, C.; Breckpot, K.; De Greve, J.			Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer	ONCOGENE			English	Article							NUCLEOLAR PROTEIN B23; NUCLEAR IMPORT; TYROSINE PHOSPHORYLATION; LOCALIZATION SIGNALS; CELL-DEATH; NUCLEOPHOSMIN; IDENTIFICATION; ACTIVATION; P53; INFLAMMATION	The signal transducer and activator of transcription 3 (STAT3) can be activated by the tyrosine kinase domain of the chimeric protein nucleophosmin/anaplastic lymphoma kinase (NPM/ALK), and has a pivotal role in mediating NPM/ALK-related malignant cell transformation. Although the role of STAT3 and wild-type NPM in oncogenesis has been extensively investigated, the relationship between both molecules in cancer remains poorly understood. In the present study, we first demonstrate that STAT3 phosphorylation at tyrosine 705 is accompanied by a concomitant increase in the expression level of NPM. Nuclear co-translocation of phosphorylated STAT3 with NPM can be triggered by interferon-alpha (IFN-alpha) stimulation of Jurkat cells and phosphorylated STAT3 co-localizes with NPM in cancer cells showing constitutive STAT3 activation. We further demonstrate that STAT3 phosphorylation can transcriptionally mediate NPM upregulation in IFN-alpha-stimulated Jurkat cells and is responsible for maintaining its expression in cancer cells showing constitutive STAT3 activation. Inhibition of STAT3 phosphorylation or knockdown of NPM expression abrogates their simultaneous transnuclear movements. Finally, we found evidence for a physical interaction between NPM and STAT3 in conditions of STAT3 activation. In conclusion, NPM is a downstream effector of the STAT3 signaling, and can facilitate the nuclear entry of phosphorylated STAT3. These observations might open novel opportunities for targeting the STAT3 pathway in cancer.	[Ren, Z.; De Greve, J.] Vrije Univ Brussel, UZ Brussel, Dept Med Oncol, LMMO, B-1090 Brussels, Belgium; [Ren, Z.] Shanghai Jiao Tong Univ, Peoples Hosp Shanghai 1, Dept Gen Surg, Shanghai 200030, Peoples R China; [Ren, Z.; Pen, J. J.; De Greve, J.] Vrije Univ Brussel, UZ Brussel, Ctr Oncol, Dept Med Oncol, B-1090 Brussels, Belgium; [Aerts, J. L.; Pen, J. J.; Heirman, C.; Breckpot, K.] Vrije Univ Brussel, Dept Immunol Physiol, B-1090 Brussels, Belgium	University Hospital Brussels; Vrije Universiteit Brussel; Shanghai Jiao Tong University; University Hospital Brussels; Vrije Universiteit Brussel; Vrije Universiteit Brussel	De Greve, J (corresponding author), Vrije Univ Brussel, UZ Brussel, Ctr Oncol, Dept Med Oncol, Laarbeeklaan 101, B-1090 Brussels, Belgium.	jacques.degreve@uzbrussel.be	De Greve, Jacques/J-4939-2012; Breckpot, Karine RP/A-4298-2008; Aerts, Joeri/J-6957-2014; Pen, Joeri/AAO-5644-2020	De Greve, Jacques/0000-0002-2389-0742; Breckpot, Karine RP/0000-0003-4331-3480; Aerts, Joeri/0000-0002-9902-3696; 	Stichting Tegen Kanker Belgium; FWO-Vlaanderen [FWOAL335, FWOAL455, FWOWO35]; VUB [OZR1144]; Chinese Scholarship Council (CSC)-VUB joint scholarship	Stichting Tegen Kanker Belgium; FWO-Vlaanderen(FWO); VUB; Chinese Scholarship Council (CSC)-VUB joint scholarship	We gratefully acknowledge technical and administrative assistance from Dr Erik Teugels, Dr Zhihai Peng, Eddy Himpe, Bill Roskams, Geert Stange, Petra Roman, Elsy Vaeremans, Cleo Goyvaerts. We sincerely thank Dr Jacqueline Bromberg, Dr Dorothee Herlyn, Dr Pravin Sehgal, Dr Qishen Pang for their provision of shSTAT3, shNPM, GFP-STAT3 Y705A, and NPM promoter vectors. We also express our gratitude to Dr Georges De Bruyne and Dr Peter de Witte for providing MDA-MB-231, MDA-MB-435 and MDA-MB-468 cell lines. This work was supported by the Stichting Tegen Kanker Belgium, FWO-Vlaanderen (FWOAL335, FWOAL455 and FWOWO35) and the VUB (OZR1144). ZR is a Ph. D student supported by Chinese Scholarship Council (CSC)-VUB joint scholarship. JLA and KB are postdoctoral fellows of the Foundation of Scientific Research Flanders (FWO-V).	Berishaj M, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1680; Bhat UG, 2011, J BIOL CHEM, V286, P41425, DOI 10.1074/jbc.M111.270843; Brady SN, 2009, ONCOGENE, V28, P3209, DOI 10.1038/onc.2009.178; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Cimica V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020188; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Falini B, 2009, LEUKEMIA, V23, P1731, DOI 10.1038/leu.2009.124; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Herrmann A, 2004, J CELL SCI, V117, P339, DOI 10.1242/jcs.00833; Kasprzycka M, 2006, P NATL ACAD SCI USA, V103, P9964, DOI 10.1073/pnas.0603507103; Kelley JB, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-63; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Lee H, 2010, NAT MED, V16, P1421, DOI 10.1038/nm.2250; Leslie K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2725; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li YP, 1996, EUR J BIOCHEM, V237, P153, DOI 10.1111/j.1432-1033.1996.0153n.x; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Pranada AL, 2004, J BIOL CHEM, V279, P15114, DOI 10.1074/jbc.M312530200; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Su L, 2000, J BIOL CHEM, V275, P12661, DOI 10.1074/jbc.275.17.12661; Swaminathan V, 2005, MOL CELL BIOL, V25, P7534, DOI 10.1128/MCB.25.17.7534-7545.2005; Swoboda RK, 2010, INT J CANCER, V127, P1124, DOI 10.1002/ijc.25133; Szebeni A, 1997, BIOCHEMISTRY-US, V36, P3941, DOI 10.1021/bi9627931; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; Vallania F, 2009, P NATL ACAD SCI USA, V106, P5117, DOI 10.1073/pnas.0900473106; Vassiliou GS, 2011, NAT GENET, V43, P470, DOI 10.1038/ng.796; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zheng P, 2012, J PROTEOMICS, V75, P1055, DOI 10.1016/j.jprot.2011.10.020; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	42	6	6	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1650	1657		10.1038/onc.2014.109	http://dx.doi.org/10.1038/onc.2014.109			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24793791				2022-12-17	WOS:000351848400005
J	Feuerborn, A; Mathow, D; Srivastava, PK; Gretz, N; Grone, HJ				Feuerborn, A.; Mathow, D.; Srivastava, P. K.; Gretz, N.; Groene, H-J			Basonuclin-1 modulates epithelial plasticity and TGF-beta 1-induced loss of epithelial cell integrity	ONCOGENE			English	Article							BREAST-CANCER CELLS; TGF-BETA; MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR; E-CADHERIN; GENE-EXPRESSION; GROWTH; METASTASIS; SUPPRESSOR; PROTEINS	Transforming growth factor-alpha 1 (TGF-beta 1) is a multifunctional cytokine and critically involved in the progression of a variety of cancers. TGF-beta 1 signaling can impair tumor development by its anti-proliferative and pro-apoptotic features. In contrast, it may actively promote tumor progression and cancer cell dissemination by inducing a gradual switch from epithelial towards mesenchymal-like cell features (EMT-like), including decreased intercellular adhesion. Here, we show that expression of the transcription factor Basonuclin-1 (Bnc1) modulates TGF-beta 1-induced epithelial dedifferentiation of mammary epithelial cells. RNAi-mediated repression of Bnc1 resulted in enhanced intercellular adhesion and strongly impaired TGF-beta 1-dependent sheet disintegration and cell scattering. In contrast, forced expression of Bnc1 modifies plasma membrane/cytoskeletal dynamics and seemingly interferes with the initiation of sustainable cell-cell contacts. Follow-up analyses revealed that Bnc1 affects the expression of numerous TGF-beta 1-responsive genes including distinct EMT-related transcription factors, some of which modulate the expression of Bnc1 themselves. These results suggest that Bnc1 is part of a transcription factor network related to epithelial plasticity with reciprocal feedback-loop connections on which Smad-factors integrate TGF-beta 1 signaling. Our study demonstrates that Bnc1 regulates epithelial plasticity of mammary epithelial cells and influences outcome of TGF-beta 1 signaling.	[Feuerborn, A.; Mathow, D.; Groene, H-J] German Canc Res Ctr, Dept Cellular & Mol Pathol, Heidelberg, Germany; [Srivastava, P. K.] Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci, London, England; [Gretz, N.] Heidelberg Univ, Med Res Ctr ZMF, Fac Med, Dept Med Res, Mannheim, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Imperial College London; Ruprecht Karls University Heidelberg	Feuerborn, A (corresponding author), German Canc Res Ctr, Dept Cellular & Mol Pathol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	alexander.feuerborn@path.ox.ac.uk; h.-j.groene@dkfz.de			DFG [SFB-938]	DFG(German Research Foundation (DFG))	We kindly acknowledge Peter ten Dijke, David Danielpour, Sebastian Diecke and Roderick Beijersbergen for generously providing cells and plasmids. Support by the DKFZ Light Microscopy Facility is gratefully acknowledged. We thank Maria Muciek for excellent assistance with regard to microarray expression profiling and Ann Na Tan for excellent technical support. This study was supported by a grant of the DFG (SFB-938) to HJG.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Aigner K, 2007, FEBS LETT, V581, P1617, DOI 10.1016/j.febslet.2007.03.026; Boldrup L, 2012, EUR J CANCER, V48, P1401, DOI 10.1016/j.ejca.2011.06.032; Brena RM, 2006, PLOS MED, V3, P2184, DOI 10.1371/journal.pmed.0030479; Capaldo CT, 2007, MOL BIOL CELL, V18, P189, DOI 10.1091/mbc.E06-05-0471; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Cui CH, 2004, CANCER RES, V64, P5651, DOI 10.1158/0008-5472.CAN-04-0801; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; de Rooij J, 2005, J CELL BIOL, V171, P153, DOI 10.1083/jcb.200506152; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Feuerborn A, 2011, J CELL PHYSIOL, V226, P710, DOI 10.1002/jcp.22385; Feuerborn A, 2011, CELL CYCLE, V10, P2454, DOI 10.4161/cc.10.15.16306; Garber M, 2012, MOL CELL, V47, P810, DOI 10.1016/j.molcel.2012.07.030; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gervasi M, 2012, J CELL BIOL, V196, P589, DOI 10.1083/jcb.201109045; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Guo LX, 2011, AM J PATHOL, V178, P2357, DOI 10.1016/j.ajpath.2011.01.047; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kenzelmann M, 2007, P NATL ACAD SCI USA, V104, P6164, DOI 10.1073/pnas.0610439104; Koinuma D, 2009, CANCER SCI, V100, P2133, DOI 10.1111/j.1349-7006.2009.01299.x; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Kumper S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011801; Kwon AT, 2012, G3-GENES GENOM GENET, V2, P987, DOI 10.1534/g3.112.003202; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loerke D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002677; Ma J, 2006, DEVELOPMENT, V133, P2053, DOI 10.1242/dev.02371; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; Mahoney MG, 1998, BIOL REPROD, V59, P388, DOI 10.1095/biolreprod59.2.388; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Morikawa M, 2013, ONCOGENE, V32, P1609, DOI 10.1038/onc.2012.191; Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nakahata S, 2010, ONCOGENE, V29, P4157, DOI 10.1038/onc.2010.172; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Papantonis A, 2012, EMBO J, V31, P4404, DOI 10.1038/emboj.2012.288; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Qiao YY, 2011, CANCER RES, V71, P3076, DOI 10.1158/0008-5472.CAN-10-2787; Redmer T, 2011, EMBO REP, V12, P720, DOI 10.1038/embor.2011.88; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Suzuki H, 2009, NAT GENET, V41, P553, DOI 10.1038/ng.375; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Tseng H, 1999, DIFFERENTIATION, V65, P221, DOI 10.1046/j.1432-0436.1999.6540221.x; Tseng H, 1998, FRONT BIOSCI, V3, pD985; Tsunoda T, 1999, BIOINFORMATICS, V15, P622, DOI 10.1093/bioinformatics/15.7.622; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanhoutteghem A, 2011, BIOCHIMIE, V93, P127, DOI 10.1016/j.biochi.2010.09.010; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Wang JW, 2006, BIOCHEM BIOPH RES CO, V348, P1261, DOI 10.1016/j.bbrc.2006.07.198; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang SL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000902; Zhang XH, 2012, GENESIS, V50, P517, DOI 10.1002/dvg.22014; Zhang XH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001087	62	6	6	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1185	1195		10.1038/onc.2014.54	http://dx.doi.org/10.1038/onc.2014.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662832				2022-12-17	WOS:000350122100011
J	Greenow, KR; Clarke, AR; Williams, GT; Jones, R				Greenow, K. R.; Clarke, A. R.; Williams, G. T.; Jones, R.			Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency	ONCOGENE			English	Article						Chk1; Apc; genomic instability; small intestine; apoptosis	DNA-DAMAGE RESPONSE; ANTICANCER BARRIER; COLORECTAL-CANCER; INSTABILITY; GENE; INHIBITION; CHECKPOINT; EXPRESSION; APOPTOSIS; STRESS	Chk1 is essential in maintaining genomic stability due to its role in cell cycle regulation. Several recent studies have indicated that the abrogation of checkpoints in tumourigenesis through the inhibition of Chk1 may be of therapeutic value. To further investigate the role of Chk1 in the mouse small intestine and its potential role as a therapy for colorectal cancer, we simultaneously deleted Chk1 and Apc in the mouse small intestine. We found that homozygous loss of Chk1 is not compatible with Wnt-driven proliferation and resulted in the suppression of Wnt-driven tumourigenesis in the mouse small intestine. In contrast, heterozygous loss of Chk1 in a Wnt-driven background resulted in an increase in DNA damage and apoptosis and accelerated both tumour development and progression.	[Greenow, K. R.; Clarke, A. R.; Jones, R.] Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3AX, S Glam, Wales; [Williams, G. T.] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales	Cardiff University; Cardiff University	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3AX, S Glam, Wales.	clarkeAR@cardiff.ac.uk	clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X	Cancer Research UK; Cancer Research UK [15937] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	This work was supported by Cancer Research UK. Particular thanks go to Mark Bishop, Lucie Pietzka and Derek Scarborough for technical assistance. The authors declare no conflicts of interest.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartek J, 2012, NAT STRUCT MOL BIOL, V19, P5, DOI 10.1038/nsmb.2220; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Fishler T, 2010, ONCOGENE, V29, P4007, DOI 10.1038/onc.2010.163; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Greenow KR, 2009, ONCOGENE, V28, P1443, DOI 10.1038/onc.2008.482; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Liu QH, 2000, GENE DEV, V14, P1448; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Montano R, 2012, MOL CANCER THER, V11, P427, DOI 10.1158/1535-7163.MCT-11-0406; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Plummer R, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2877; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; SALHAB N, 1989, DIS COLON RECTUM, V32, P659, DOI 10.1007/BF02555769; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Soreide K, 2006, BRIT J SURG, V93, P395, DOI 10.1002/bjs.5328; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tho LM, 2012, ONCOGENE, V31, P1366, DOI 10.1038/onc.2011.326; Venkatesha VA, 2012, NEOPLASIA, V14, P519, DOI 10.1593/neo.12538; Zaugg K, 2007, P NATL ACAD SCI USA, V104, P3805, DOI 10.1073/pnas.0611584104	27	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4089	4096		10.1038/onc.2013.371	http://dx.doi.org/10.1038/onc.2013.371			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24037525				2022-12-17	WOS:000340595300008
J	Kai, K; Iwamoto, T; Kobayashi, T; Arima, Y; Takamoto, Y; Ohnishi, N; Bartholomeusz, C; Horii, R; Akiyama, F; Hortobagyi, GN; Pusztai, L; Saya, H; Ueno, NT				Kai, K.; Iwamoto, T.; Kobayashi, T.; Arima, Y.; Takamoto, Y.; Ohnishi, N.; Bartholomeusz, C.; Horii, R.; Akiyama, F.; Hortobagyi, G. N.; Pusztai, L.; Saya, H.; Ueno, N. T.			Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells	ONCOGENE			English	Article						Ink4a/Arf; HRAS(G12V); Triple-negative breast cancer; Intratumoral heterogeneity; Tumor-initiating cell	TUMOR-INITIATING CELLS; HEPATIC STELLATE CELLS; GENE-EXPRESSION; STEM-CELLS; MOLECULAR CHARACTERIZATION; MESENCHYMAL TRANSITION; RAS ACTIVATION; CLAUDIN-LOW; IDENTIFICATION; MODEL	Intratumoral heterogeneity within individual breast tumors is a well-known phenomenon that may contribute to drug resistance. This heterogeneity is dependent on several factors, such as types of oncogenic drivers and tumor precursor cells. The purpose of our study was to engineer a mouse mammary tumor model with intratumoral heterogeneity by using defined genetic perturbations. To achieve this, we used mice with knockout (-/-) of Ink4a/Arf, a tumor suppressor locus; these mice are known to be susceptible to non-mammary tumors such as fibrosarcoma. To induce mammary tumors, we retrovirally introduced an oncogene, HRAS(G12V), into Ink4a/Arf(-/-) mammary cells in vitro, and those cells were inoculated into syngeneic mice mammary fat pads. We observed 100% tumorigenesis. The tumors formed were negative for estrogen receptor, progesterone receptor and HER2. Further, they had pathological features similar to those of human triple-negative breast cancer (TNBC) (for example, pushing borders, central necrosis). The tumors were found to be heterogeneous and included two subpopulations: CD49f(-) quiescent cells and CD49f(-) cells. Contrary to our expectation, CD49f(-) quiescent cells had high tumor-initiating potential and CD49f(-) cells had relatively low tumor-initiating potential. Gene expression analysis revealed that CD49f(-) quiescent cells overexpressed epithelial-to-mesenchymal transition-driving genes, reminiscent of tumor-initiating cells and claudin-low breast cancer. Our animal model with intratumoral heterogeneity, derived from defined genetic perturbations, allows us to test novel molecular targeted drugs in a setting that mimics the intratumoral heterogeneity of human TNBC.	[Kai, K.; Bartholomeusz, C.; Pusztai, L.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Houston, TX 77030 USA; [Kai, K.; Iwamoto, T.; Bartholomeusz, C.; Hortobagyi, G. N.; Pusztai, L.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Kai, K.; Kobayashi, T.; Arima, Y.; Takamoto, Y.; Ohnishi, N.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan; [Horii, R.; Akiyama, F.] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo 170, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Keio University; Japanese Foundation for Cancer Research	Saya, H (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan.	hsaya@a5.keio.jp; nueno@mdanderson.org	Saya, Hideyuki/J-4325-2013; Pusztai, Lajos/AAB-2901-2019	Saya, Hideyuki/0000-0001-6610-1902	Japan Society for the Promotion of Science, Japan; Ministry of Education, Culture, Sports, Science and Technology, Japan; US National Institutes of Health through MD Anderson's Cancer Center Support Grant [5 P30 CA016672-36, R01 CA123318-01A1]; Nellie B Connally Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA123318] Funding Source: NIH RePORTER	Japan Society for the Promotion of Science, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); US National Institutes of Health through MD Anderson's Cancer Center Support Grant; Nellie B Connally Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank N Suzuki, Y Ito and S Hayashi for excellent animal husbandry, I Ishimatsu for expert assistance with histology and K Hashimoto for expert help in the flow cytometry lab. We thank T Suda and MC Hung for invaluable discussions. Thanks are also owed to M Fujiwara for expert help with microarray analysis, T Ishimoto for technical help with confocal microscopy and SC Patterson for editorial assistance. This work was supported by grants from the Japan Society for the Promotion of Science, Japan (to KK and HS). KK was supported by the program 'Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation' by the Ministry of Education, Culture, Sports, Science and Technology, Japan. This research was also supported in part by the US National Institutes of Health through MD Anderson's Cancer Center Support Grant (5 P30 CA016672-36), grant R01 CA123318-01A1 (to NTU) and by the Nellie B Connally Breast Cancer Research Fund and a donation from Mr and Mrs Sidney J Jansma, Jr.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bartholomeusz C, 2012, MOL CANCER THER, V11, P360, DOI 10.1158/1535-7163.MCT-11-0400; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Cho JJ, 2000, GASTROENTEROLOGY, V118, P1169, DOI 10.1016/S0016-5085(00)70370-2; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; Debies MT, 2008, J CLIN INVEST, V118, P51, DOI 10.1172/JCI33320; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Iwamoto T, 2011, J NATL CANCER I, V103, P264, DOI 10.1093/jnci/djq524; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Kai K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-262; Kai K, 2009, CANCER SCI, V100, P2275, DOI 10.1111/j.1349-7006.2009.01318.x; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2003, CANCER RES, V63, P5821; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Sugihara E, 2012, ONCOGENE, V31, P2849, DOI 10.1038/onc.2011.462; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Zhang DW, 2009, CLIN CANCER RES, V15, P6639, DOI 10.1158/1078-0432.CCR-09-0951; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	47	6	6	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					440	448		10.1038/onc.2012.609	http://dx.doi.org/10.1038/onc.2012.609			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23376849	Green Accepted			2022-12-17	WOS:000330214600005
J	Bohringer, M; Obermeier, K; Griner, N; Waldraff, D; Dickinson, E; Eirich, K; Schindler, D; Hagen, M; Jerry, DJ; Wiesmuller, L				Boehringer, M.; Obermeier, K.; Griner, N.; Waldraff, D.; Dickinson, E.; Eirich, K.; Schindler, D.; Hagen, M.; Jerry, D. J.; Wiesmueller, L.			siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/ - with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors	ONCOGENE			English	Article						crosslink repair; Fanconi anemia; modifier of breast cancer susceptibility; Li-Fraumeni mouse model; p53	STRAND BREAK-REPAIR; HOMOLOGOUS RECOMBINATION; CANCER-RISK; DNA-DAMAGE; GENOMIC INSTABILITY; GERMLINE MUTATIONS; P53; BRCA2; GENE; CELLS	BALB/c mice heterozygous for Trp53 develop a high proportion of spontaneous mammary tumors, a phenotype distinct from other mouse strains. BALB/c-Trp53 + /- female mice, thus, resemble the hereditary Li-Fraumeni syndrome (LFS) characterized by earlyonset of breast cancer, even though LFS involves TP53 mutations, which may involve not only loss-but also gain-of-function. Previous analysis of tumors in BALB/c-Trp53 + /- females showed frequent loss of heterozygosity involving the wild-type allele of Trp53 and displayed characteristics indicative of mitotic recombination. Critical involvement of DNA double-strand break (DSB) repair dysfunction, particularly of homologous recombination (HR), was also noticed in the etiology of human breast cancer. To better define functional alterations in BALB/c-Trp53+ /- mice, we applied a fluorescence-based DSB repair assay on mouse embryonic fibroblasts (MEFs) from BALB/c-Trp53 + /- versus C57BL/6J-Trp53 + / - mice. This approach revealed deregulation of HR but not non-homologous end-joining (NHEJ) in BALB/c-Trp53 + /- which was further confirmed for mammary epithelial cells. Screening of a small interfering RNA-library targeting DSB repair, recombination, replication and signaling genes, identified 25 genes causing differences between homologous DSB repair in the two strains upon silencing. Interactome analysis of the hits revealed clustering of replication-related and fanconi anemia (FA)/breast cancer susceptibility (BRCA) genes. Further dissection of the functional change in BALB/c-Trp53_/ +- by immunofluorescence microscopy of nuclear 53BP1, Replication protein A (RPA) and Rad51 foci uncovered differences in crosslink and replication-associated repair. Chromosome breakage, G2 arrest and biochemical analyses indicated a FA pathway defect downstream of FancD2 associated with reduced levels of BRCA2. Consistent with polygenic models for BRCA, mammary carcinogenesis in BALB/c-Trp53+ /- mice may, therefore, be promoted by a BRCA modifier allele in the FA pathway in the context of partial p53 loss-of-function.	[Boehringer, M.; Obermeier, K.; Waldraff, D.; Wiesmueller, L.] Univ Ulm, Dept Obstet & Gynecol, D-89075 Ulm, Germany; [Griner, N.; Dickinson, E.; Hagen, M.; Jerry, D. J.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; [Eirich, K.; Schindler, D.] Univ Wurzburg, Dept Human Genet, Wurzburg, Germany	Ulm University; University of Massachusetts System; University of Massachusetts Amherst; University of Wurzburg	Wiesmuller, L (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@uni-ulm.de		Bohringer, Michael/0000-0001-9150-122X	Foundation of the State Baden-Wurttemberg Germany [10-1907Wi 2]; Ministry for Education and Research, Germany (BMBF) [012P0505]; German Research Foundation (DFG) [WI 3099/7-1, WI 3099/7-2]; National Cancer Institute [R01CA105452]; NATIONAL CANCER INSTITUTE [R01CA105452] Funding Source: NIH RePORTER	Foundation of the State Baden-Wurttemberg Germany; Ministry for Education and Research, Germany (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation (DFG)(German Research Foundation (DFG)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Bing Xia, The Cancer Institute of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA, for the generous gift of EUFA1341 cells and expression plasmid for human PALB2, POZ-PALB2. Jeffrey Kane, Amherst, provided assistance with the cloning of mouse Palb2. We cordially thank Marlen Keimling, Ulm, for experimental help during the initial phase of the project and Richard Friedl, Wurzburg, for expert flow cytometry. The drugs KU-55933 and NU7441 were kindly provided by KuDOS Pharmaceuticals Ltd. This work was supported by grants to LW by the Foundation of the State Baden-Wurttemberg Germany (10-1907Wi 2), the Ministry for Education and Research, Germany (BMBF, 012P0505), and the German Research Foundation (DFG, WI 3099/7-1 and -2), as well as to DJJ by the National Cancer Institute (R01CA105452).	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; AUERBACH AD, 1989, BLOOD, V73, P391; Bahassi EM, 2008, ONCOGENE, V27, P3977, DOI 10.1038/onc.2008.17; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; Blackburn AC, 2003, CANCER RES, V63, P2364; Blackburn AC, 2007, AM J PATHOL, V170, P2030, DOI 10.2353/ajpath.2007.060512; Chompret A, 2000, BRIT J CANCER, V82, P1932; Cordelli E, 2004, MUTAT RES-FUND MOL M, V550, P133, DOI 10.1016/j.mrfmmm.2004.02.012; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Francis R, 2007, GENE DEV, V21, P1064, DOI 10.1101/gad.1522807; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Gohler T, 2008, DNA REPAIR, V7, P775, DOI 10.1016/j.dnarep.2008.02.001; Gutekunst M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019198; Hamimes S, 2005, J BIOL CHEM, V280, P9225, DOI 10.1074/jbc.M412874200; Hayakawa T, 2010, J CELL SCI, V123, P1124, DOI 10.1242/jcs.060178; He XF, 2012, MOL BIOL REP, V39, P5125, DOI 10.1007/s11033-011-1308-y; Heacock ML, 2010, DNA REPAIR, V9, P929, DOI 10.1016/j.dnarep.2010.05.007; Ho V, 2010, ENVIRON MOL MUTAGEN, V51, P552, DOI 10.1002/em.20573; Huertas P, 2010, NAT STRUCT MOL BIOL, V17, P11, DOI 10.1038/nsmb.1710; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Kavitha CV, 2010, BIOCHEM BIOPH RES CO, V399, P575, DOI 10.1016/j.bbrc.2010.07.117; Keimling M, 2012, FASEB J, V26, P2094, DOI 10.1096/fj.11-200790; Keimling M, 2011, FASEB J, V25, P3849, DOI 10.1096/fj.11-185546; Koch JG, 2007, MAMM GENOME, V18, P300, DOI 10.1007/s00335-007-9028-2; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lin WY, 2011, J MED GENET, V48, P477, DOI 10.1136/jmedgenet-2011-100018; Lu XB, 2003, MUTAT RES-FUND MOL M, V522, P69, DOI 10.1016/S0027-5107(02)00261-0; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Maloisel L, 2008, MOL CELL BIOL, V28, P1373, DOI 10.1128/MCB.01651-07; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Mitchell J, 2009, INT J RADIAT ONCOL, V75, P1520, DOI 10.1016/j.ijrobp.2009.07.1722; Okayasu R, 2000, CANCER RES, V60, P4342; Ralhan R, 2007, CANCER LETT, V248, P1, DOI 10.1016/j.canlet.2006.06.004; Schild D, 2010, NUCLEIC ACIDS RES, V38, P1061, DOI 10.1093/nar/gkp1063; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shamseldin HE, 2012, J MED GENET, V49, P184, DOI 10.1136/jmedgenet-2011-100585; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shevelev Igor V., 2002, TheScientificWorldJOURNAL, V2, P275; Shlien A, 2008, P NATL ACAD SCI USA, V105, P11264, DOI 10.1073/pnas.0802970105; Sy SMH, 2009, J BIOL CHEM, V284, P21127, DOI 10.1074/jbc.C109.023937; Szpirer C, 2007, MAMM GENOME, V18, P817, DOI 10.1007/s00335-007-9073-x; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; Tchatchou S, 2010, HUM MUTAT, V31, P60, DOI 10.1002/humu.21134; Thompson LH, 2009, MUTAT RES-FUND MOL M, V668, P54, DOI 10.1016/j.mrfmmm.2009.02.003; Toyota M, 2010, ADV GENET, V70, P309, DOI [10.1016/B978-0-12-380866-0.60011-3, 10.1016/S0065-2660(10)70011-0]; Varadi V, 2011, BREAST CANCER RES TR, V129, P235, DOI 10.1007/s10549-011-1460-z; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Villani G, 2011, J BIOL CHEM, V286, P32094, DOI 10.1074/jbc.M111.246611; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	56	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5458	5470		10.1038/onc.2013.38	http://dx.doi.org/10.1038/onc.2013.38			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23435420	hybrid, Green Published			2022-12-17	WOS:000327780800003
J	Landman, AS; Danielian, PS; Lees, JA				Landman, A. S.; Danielian, P. S.; Lees, J. A.			Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation	ONCOGENE			English	Article						pRB; p107; Prx1-Cre; cartilage; chondrocytes; enchondroma	RETINOBLASTOMA PROTEIN; CELL-CYCLE; TUMOR-SUPPRESSOR; BONE-DEVELOPMENT; RB-LOSS; EXPRESSION; DEFICIENT; MUTATION; GENE; DIFFERENTIATION	The pocket proteins pRB, p107 and p130 have established roles in regulating the cell cycle through the control of E2F activity. The pocket proteins regulate differentiation of a number of tissues in both cell cycle-dependent and -independent manners. Prior studies showed that mutation of p107 and p130 in the mouse leads to defects in cartilage development during endochondral ossification, the process by which long bones form. Despite evidence of a role for pRB in osteoblast differentiation, it is unknown whether it functions during cartilage development. Here, we show that mutation of Rb in the early mesenchyme of p107-mutant mice results in severe cartilage defects in the growth plates of long bones. This is attributable to inappropriate chondrocyte proliferation that persists after birth and leads to the formation of enchondromas in the growth plates as early as 8 weeks of age. Genetic crosses show that development of these tumorigenic lesions is E2f3 dependent. These results reveal an overlapping role for pRB and p107 in cartilage development, endochondral ossification and enchondroma formation that reflects their coordination of cell-cycle exit at appropriate developmental stages.	[Landman, A. S.; Danielian, P. S.; Lees, J. A.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave,Bldg 76-461B, Cambridge, MA 02139 USA.	jalees@mit.edu		Danielian, Paul/0000-0003-2651-0386	National Cancer Institute [CA121921]; Ludwig Graduate Fellowship; NATIONAL CANCER INSTITUTE [R01CA121921] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ludwig Graduate Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Rbc/c, p107<SUP>-/-</SUP> and Rosa26-LSL-LacZ transgenic mice were kindly provided by Tyler Jacks (MIT). We are grateful to Seth Berman for initial mouse colony generation, and Julie West for immuno-histochemistry assistance, as well as all members of the Lees laboratory for helpful discussions throughout this work. We thank MIT Swanson Biotechnology Center members Eliza Vasile for assistance with mCT data collection and analysis and Alicia Caron for histological sectioning and H&E staining. We also thank Roderick Bronson for histopathological analyses and advice. This work was supported by a grant to JAL from the National Cancer Institute (CA121921), and a Ludwig Graduate Fellowship to ASL. JAL is a Ludwig Scholar.	Asp J, 2001, J ORTHOPAED RES, V19, P149, DOI 10.1016/S0736-0266(00)00022-X; Asp J, 2000, INT J CANCER, V85, P782, DOI 10.1002/(SICI)1097-0215(20000315)85:6<782::AID-IJC7>3.0.CO;2-O; Berman SD, 2008, MOL CANCER RES, V6, P1440, DOI 10.1158/1541-7786.MCR-08-0176; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Berman SD, 2009, P NATL ACAD SCI USA, V106, P14932, DOI 10.1073/pnas.0902408106; Boeuf S, 2008, J PATHOL, V216, P158, DOI 10.1002/path.2389; Bovee JVMG, 2010, NAT REV CANCER, V10, P481, DOI 10.1038/nrc2869; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Danielian PS, 2008, ONCOGENE, V27, P6561, DOI 10.1038/onc.2008.253; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Dirlam A, 2007, MOL CELL BIOL, V27, P8713, DOI 10.1128/MCB.01118-07; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Miller MD, 2004, REV ORTHOPAEDICS, Vxv; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Politi K, 2004, AM J PATHOL, V164, P325, DOI 10.1016/S0002-9440(10)63122-7; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ropke M, 2006, ONCOL REP, V15, P89; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage C, 2006, P NATL ACAD SCI USA, V103, P7345, DOI 10.1073/pnas.0510631103; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Schrage YM, 2009, AM J PATHOL, V174, P979, DOI 10.2353/ajpath.2009.080623; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Tsai SY, 2008, NATURE, V454, P1137, DOI 10.1038/nature07066; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wenzel PL, 2007, GENE DEV, V21, P85, DOI 10.1101/gad.1485307; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Yamaguchi T, 1996, ANTICANCER RES, V16, P2009; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zheng QP, 2009, J BONE MINER RES, V24, P1022, DOI [10.1359/JBMR.081249, 10.1359/jbmr.081249]; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	51	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4798	4805		10.1038/onc.2012.496	http://dx.doi.org/10.1038/onc.2012.496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146901	Green Accepted, Green Submitted			2022-12-17	WOS:000325274700008
J	Katz, SG; Fisher, JK; Correll, M; Bronson, RT; Ligon, KL; Walensky, LD				Katz, S. G.; Fisher, J. K.; Correll, M.; Bronson, R. T.; Ligon, K. L.; Walensky, L. D.			Brain and testicular tumors in mice with progenitor cells lacking BAX and BAK	ONCOGENE			English	Article						BAX; BAK; neural progenitor cell; apoptosis; tumorigenesis	NEURAL STEM-CELLS; ABUNDANT NEUROPIL; MALIGNANT GLIOMA; TRANSGENIC MICE; NERVOUS-SYSTEM; EMBRYONIC STEM; TRUE ROSETTES; LEYDIG-CELLS; MOUSE MODEL; IN-VIVO	The proapoptotic BCL-2 family proteins BAX and BAK serve as essential gatekeepers of the intrinsic apoptotic pathway and, when activated, transform into pore-forming homo-oligomers that permeabilize the mitochondrial outer membrane. Deletion of Bax and Bak causes marked resistance to death stimuli in a variety of cell types. Bax(-/-) Bak(-/-) mice are predominantly non-viable and survivors exhibit multiple developmental abnormalities characterized by cellular excess, including accumulation of neural progenitor cells in the periventricular, hippocampal, cerebellar and olfactory bulb regions of the brain. To explore the long-term pathophysiological consequences of BAX/BAK deficiency in a stem cell niche, we generated Bak(-/-) mice with conditional deletion of Bax in Nestin-positive cells. Aged Nestin(Cre)Bax(fl/fl)Bak(-/-) mice manifest progressive brain enlargement with a profound accumulation of NeuN- and Sox2-positive neural progenitor cells within the subventricular zone (SVZ). One-third of the mice develop frank masses comprised of neural progenitors, and in 20% of these cases, more aggressive, hypercellular tumors emerged. Unexpectedly, 60% of Nestin(Cre)Bax(fl/fl)Bak(-/-) mice harbored high-grade tumors within the testis, a peripheral site of Nestin expression. This in vivo model of severe apoptotic blockade highlights the constitutive role of BAX/BAK in long-term regulation of Nestin-positive progenitor cell pools, with loss of function predisposing to adult-onset tumorigenesis.	[Katz, S. G.; Fisher, J. K.; Walensky, L. D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA; [Katz, S. G.; Fisher, J. K.; Walensky, L. D.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02215 USA; [Katz, S. G.; Ligon, K. L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Correll, M.] Dana Farber Canc Inst, Boston, MA 02215 USA; [Bronson, R. T.; Ligon, K. L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Ligon, K. L.] Harvard Univ, Sch Med, Dept Med Oncol, Boston, MA USA; [Ligon, K. L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Walensky, LD (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave,Mayer 664, Boston, MA 02215 USA.	Loren_Walensky@dfci.harvard.edu			NIH [5R01CA050239, 1P01CA142536, 5K08HL103847]; Todd J Schwartz Memorial Fund; NATIONAL CANCER INSTITUTE [R01CA050239, P01CA142536] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL103847] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Todd J Schwartz Memorial Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank E Smith for editorial and graphics assistance, R Segal, R Folkerth and C Stiles for helpful discussions, and S Rodig and the Harvard Medical School Rodent Histopathology and Brigham and Women's Hospital, Specialized Histopathology cores for technical support. This work was supported by NIH Grants 5R01CA050239 and 1P01CA142536 to LDW, NIH Grant 5K08HL103847 to SGK and the Todd J Schwartz Memorial Fund.	ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; Amoh Y, 2005, CANCER RES, V65, P5352, DOI 10.1158/0008-5472.CAN-05-0821; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Burness ML, 2010, SEMIN CANCER BIOL, V20, P107, DOI 10.1016/j.semcancer.2010.05.006; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Carvalho BS, BIOINFORMATICS, V26, P2363; Culhane AC, 2012, NUCLEIC ACIDS RES, V40, pD1060, DOI 10.1093/nar/gkr901; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Davidoff MS, 2004, J CELL BIOL, V167, P935, DOI 10.1083/jcb.200409107; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Dubois NC, 2006, GENESIS, V44, P355, DOI 10.1002/dvg.20226; Eberhart CG, 2000, PEDIATR DEVEL PATHOL, V3, P346, DOI 10.1007/s100249910049; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gessi M, 2009, AM J SURG PATHOL, V33, P211, DOI 10.1097/PAS.0b013e318186235b; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Lindsten T, 2003, J NEUROSCI, V23, P11112; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lobo MVT, 2004, CELL TISSUE RES, V316, P369, DOI 10.1007/s00441-003-0848-4; McCall MN, 2011, NUCLEIC ACIDS RES, V39, pD1011, DOI 10.1093/nar/gkq1259; Mehta S, 2011, CANCER CELL, V19, P359, DOI 10.1016/j.ccr.2011.01.035; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Preusser M, 2003, ACTA NEUROPATHOL, V106, P506, DOI 10.1007/s00401-003-0758-2; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reyes NA, 2010, J CLIN INVEST, V120, P3673, DOI 10.1172/JCI42986; Sauvageot CM, 2007, NEUROL CLIN, V25, P891, DOI 10.1016/j.ncl.2007.07.014; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Takeuchi O, 2005, P NATL ACAD SCI USA, V102, P11272, DOI 10.1073/pnas.0504783102; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	42	6	6	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4078	4085		10.1038/onc.2012.421	http://dx.doi.org/10.1038/onc.2012.421			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	22986529	Green Accepted			2022-12-17	WOS:000323748500003
J	Wolf, S; Rudolph, C; Morgan, M; Busche, G; Salguero, G; Stripecke, R; Schlegelberger, B; Baum, C; Modlich, U				Wolf, S.; Rudolph, C.; Morgan, M.; Buesche, G.; Salguero, G.; Stripecke, R.; Schlegelberger, B.; Baum, C.; Modlich, U.			Selection for Evi1 activation in myelomonocytic leukemia induced by hyperactive signaling through wild-type NRas	ONCOGENE			English	Article						NRas; myelomonocytic leukemia; malignant histiocytosis; murine BMT model; retroviral vector; Evi1	ACUTE MYELOID-LEUKEMIA; N-RAS PROTOONCOGENE; HEMATOPOIETIC-CELLS; DENDRITIC CELLS; RETROVIRAL VECTORS; TRANSGENIC MICE; DOWN-REGULATION; TARGETING RAS; MOUSE MODEL; MUTATIONS	Activation of NRas signaling is frequently found in human myeloid leukemia and can be induced by activating mutations as well as by mutations in receptors or signaling molecules upstream of NRas. To study NRas-induced leukemogenesis, we retrovirally overexpressed wild-type NRas in a murine bone marrow transplantation (BMT) model in C57BL/6J mice. Overexpression of wild-type NRas caused myelomonocytic leukemias similar to 3 months after BMT in the majority of mice. A subset of mice (30%) developed malignant histiocytosis similar to mice that received mutationally activated NRas(G12D)-expressing bone marrow. Aberrant Ras signaling was demonstrated in cells expressing mutationally active or wild-type NRas, as increased activation of Erk and Akt was observed in both models. However, more NRas(G12D) were found to be in the activated, GTP-bound state in comparison with wild-type NRas. Consistent with observations reported for primary human myelomonocytic leukemia cells, Stat5 activation was also detected in murine leukemic cells. Furthermore, clonal evolution was detected in NRas wild-type-induced leukemias, including expansion of clones containing activating vector insertions in known oncogenes, such as Evi1 and Prdm16. In vitro cooperation of NRas and Evi1 improved long-term expansion of primary murine bone marrow cells. Evi1-positive cells upregulated Bcl-2 and may, therefore, provide anti-apoptotic signals that collaborate with the NRas-induced proliferative effects. As activation of Evi1 has been shown to coincide with NRAS mutations in human acute myeloid leukemia, our murine model recapitulates crucial events in human leukemogenesis.	[Wolf, S.; Baum, C.; Modlich, U.] Hannover Med Sch, Inst Expt Hematol, D-30625 Hannover, Germany; [Rudolph, C.; Schlegelberger, B.] Hannover Med Sch, Inst Cell & Mol Pathol, D-30625 Hannover, Germany; [Morgan, M.; Salguero, G.; Stripecke, R.] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, D-30625 Hannover, Germany; [Buesche, G.] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School; Hannover Medical School	Modlich, U (corresponding author), Hannover Med Sch, Inst Expt Hematol, OE6960,Carl Neuberg Str 1, D-30625 Hannover, Germany.	modlich.ute@mh-hannover.de	Stripecke, Renata/G-3252-2013	Modlich, Ute/0000-0001-8018-4118; Wolf, Susanne/0000-0003-0922-8418; Salguero, Gustavo/0000-0002-5018-9927	Deutsche Forschungsgemeinschaft [DFG RU- 1476]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Hans Grundtke, Jorg Fruhauf and Martin Werner (Radiotherapy) for irradiation of the mice, Sabine Knoss, Johanna Krause (Institute of Experimental Hematology) and Andrea Schienke (Institute of Cell and Molecular Pathology) for their excellent technical help, Axel Schambach (Institute of Experimental Hematology) for providing the vector backbone and Sandra Liessem (Institute of Pathology) for help with the immunohistochemistry (all Hannover Medical School). This study was supported by grants from the Deutsche Forschungsgemeinschaft (DFG RU- 1476 and Excellence Cluster REBIRTH).	Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Arico M, 1997, BLOOD, V90, P479, DOI 10.1182/blood.V90.2.479.479_479_488; Bacher U, 2006, BLOOD, V107, P3847, DOI 10.1182/blood-2005-08-3522; BAUM C, 1995, J VIROL, V69, P7541, DOI 10.1128/JVI.69.12.7541-7547.1995; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Braun BS, 2008, CLIN CANCER RES, V14, P2249, DOI 10.1158/1078-0432.CCR-07-1005; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Calmels B, 2005, BLOOD, V106, P2530, DOI 10.1182/blood-2005-03-1115; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CLINE MJ, 1994, BLOOD, V84, P2840; Cuenco GM, 2004, ONCOGENE, V23, P569, DOI 10.1038/sj.onc.1207143; De Weer A, 2011, BRIT J HAEMATOL, V154, P337, DOI 10.1111/j.1365-2141.2011.08737.x; Diaz R, 2004, CARCINOGENESIS, V25, P535, DOI 10.1093/carcin/bgh026; Diaz R, 2002, CANCER RES, V62, P4514; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Du Y, 2005, BLOOD, V106, P3932, DOI 10.1182/blood-2005-03-1113; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gomez-Benito M, 2002, BRIT J CANCER, V103, P1292; Haferlach C, 2011, LEUKEMIA, V25, P874, DOI 10.1038/leu.2011.5; Hao X, 2010, VET PATHOL, V47, P434, DOI 10.1177/0300985810363705; HAUPT Y, 1992, ONCOGENE, V7, P981; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; Kohlmann A, 2010, J CLIN ONCOL, V28, P3858, DOI 10.1200/JCO.2009.27.1361; Koike K, 2008, BRIT J HAEMATOL, V141, P567, DOI 10.1111/j.1365-2141.2008.07104.x; Konrad TA, 2009, J LEUKOCYTE BIOL, V86, P813, DOI 10.1189/jlb.0109042; Kotecha N, 2008, CANCER CELL, V14, P335, DOI 10.1016/j.ccr.2008.08.014; Kustikova O, 2005, SCIENCE, V308, P1171, DOI 10.1126/science.1105063; Kustikova Olga S., 2009, V506, P373, DOI 10.1007/978-1-59745-409-4_25; Laricchia-Robbio L, 2009, CANCER RES, V69, P1633, DOI 10.1158/0008-5472.CAN-08-2562; Leenen PJM, 2010, J LEUKOCYTE BIOL, V87, P949, DOI 10.1189/jlb.0609432; LEENEN PJM, 1990, EUR J IMMUNOL, V20, P27, DOI 10.1002/eji.1830200105; Li Q, 2011, BLOOD, V117, P2022, DOI 10.1182/blood-2010-04-280750; Loh ML, 2009, BLOOD, V114, P1859, DOI 10.1182/blood-2009-01-198416; LOHLER J, 1987, LEUKEMIA, V1, P58; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; Lugthart S, 2010, J CLIN ONCOL, V28, P3890, DOI 10.1200/JCO.2010.29.2771; MacKenzie KL, 1999, BLOOD, V93, P2043, DOI 10.1182/blood.V93.6.2043.406k17_2043_2056; MANGUES R, 1994, CANCER RES, V54, P6395; Mangues R, 1996, ONCOGENE, V13, P1053; MANGUES R, 1992, ONCOGENE, V7, P2073; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Modlich U, 2008, LEUKEMIA, V22, P1519, DOI 10.1038/leu.2008.118; Modlich U, 2006, BLOOD, V108, P2545, DOI 10.1182/blood-2005-08-024976; Modlich U, 2009, MOL THER, V17, P1919, DOI 10.1038/mt.2009.179; Morgan MA, 2003, LEUKEMIA, V17, P1482, DOI 10.1038/sj.leu.2403024; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Omidvar N, 2007, CANCER RES, V67, P11657, DOI 10.1158/0008-5472.CAN-07-0196; Parikh C, 2006, BLOOD, V108, P2349, DOI 10.1182/blood-2004-08-009498; Pileri SA, 2002, HISTOPATHOLOGY, V41, P1, DOI 10.1046/j.1365-2559.2002.01418.x; Pradhan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025370; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; Schambach A, 2006, GENE THER, V13, P1524, DOI 10.1038/sj.gt.3302807; Schlenk RF, 2008, NEW ENGL J MED, V358, P1909, DOI 10.1056/NEJMoa074306; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shing DC, 2007, J CLIN INVEST, V117, P3696, DOI 10.1172/JCI32390; Steinemann D, 2010, HAEMATOL-HEMATOL J, V95, P320, DOI 10.3324/haematol.2009.010355; Takaoka M, 2004, ONCOGENE, V23, P6760, DOI 10.1038/sj.onc.1207923; Vazquez I, 2011, HAEMATOL-HEMATOL J, V96, P1448, DOI 10.3324/haematol.2011.040535; Wahlers A, 2002, MOL THER, V6, P313, DOI 10.1006/mthe.2002.0671; Wahlers A, 2002, J VIROL, V76, P303, DOI 10.1128/JVI.76.1.303-312.2002; Wang JY, 2010, BLOOD, V116, P5991, DOI 10.1182/blood-2010-04-281527; Wiesner SM, 2005, BLOOD, V106, P1054, DOI 10.1182/blood-2004-08-3306	66	6	7	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2013	32	25					3028	3038		10.1038/onc.2012.329	http://dx.doi.org/10.1038/onc.2012.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22847614				2022-12-17	WOS:000320705700003
J	Kuroda, I; Inukai, T; Zhang, X; Kikuchi, J; Furukawa, Y; Nemoto, A; Akahane, K; Hirose, K; Honna-Oshiro, H; Goi, K; Kagami, K; Yagita, H; Tauchi, T; Maeda, Y; Sugita, K				Kuroda, I.; Inukai, T.; Zhang, X.; Kikuchi, J.; Furukawa, Y.; Nemoto, A.; Akahane, K.; Hirose, K.; Honna-Oshiro, H.; Goi, K.; Kagami, K.; Yagita, H.; Tauchi, T.; Maeda, Y.; Sugita, K.			BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia	ONCOGENE			English	Article						Philadelphia chromosome-positive leukemia; tumor necrosis factor-related apoptosis-inducing ligand; BCR-ABL	ACUTE LYMPHOBLASTIC-LEUKEMIA; STEM-CELL TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE; IMATINIB; INHIBITOR; SURVEILLANCE; METASTASIS; MECHANISMS; INITIATION	Allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for chronic myeloid leukemia and Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia, and the graft-vs-leukemia (GVL) effect can eradicate residual leukemia after allo-SCT. Ph(+) leukemia cells frequently express death-inducing receptors (DR4 and DR5) for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is one of the cytotoxic ligands expressed on cytotoxic T cells and natural killer cells mediating the GVL effect. Here we demonstrate that imatinib specifically downregulated DR4 and DR5 expression in cell lines and clinical samples of Ph(+) leukemia. Second-generation tyrosine kinase inhibitors (dasatinib and nilotinib) and short hairpin RNA against bcr-abl also downregulated DR4 and DR5 expression in Ph(+) leukemia cells, and transfection of bcr-abl into a Ph(-) leukemia cell line induced DR4 and DR5 expression, which was abrogated by imatinib treatment. Accordingly, Ph(+) leukemia cells that had been pretreated with imatinib showed resistance to the pro-apoptotic activity of recombinant human soluble TRAIL. These observations demonstrate that BCR-ABL is critically involved in the leukemia-specific expression of DR4 and DR5 and in the susceptibility of Ph(+) leukemia to TRAIL-mediated anti-leukemic activity, providing new insight into the mechanisms of the tumor-specific cytotoxic activities of TRAIL. Oncogene (2013) 32, 1670-1681; doi:10.1038/onc.2012.186; published online 4 June 2012	[Kuroda, I.; Inukai, T.; Zhang, X.; Nemoto, A.; Akahane, K.; Hirose, K.; Honna-Oshiro, H.; Goi, K.; Kagami, K.; Sugita, K.] Univ Yamanashi, Dept Pediat, Sch Med, Chuo, Yamanashi 4093898, Japan; [Kikuchi, J.; Furukawa, Y.] Jichi Med Sch, Ctr Mol Med, Simotsuke, Tochigi, Japan; [Yagita, H.] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; [Tauchi, T.] Tokyo Med Univ, Dept Internal Med 1, Tokyo 1608402, Japan; [Maeda, Y.] Kinki Univ, Sch Med, Div Hematol, Dept Internal Med, Osaka 589, Japan	University of Yamanashi; Juntendo University; Tokyo Medical University; Kindai University (Kinki University)	Inukai, T (corresponding author), Univ Yamanashi, Dept Pediat, Sch Med, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan.	tinukai@yamanashi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	Ministry of Education, Science and Culture, Japan	Ministry of Education, Science and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	The authors thank technological supports by Masako Abe. This work was supported in part by research grants from the Ministry of Education, Science and Culture, Japan.	Akahane K, 2010, EXP HEMATOL, V38, P885, DOI 10.1016/j.exphem.2010.06.014; Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Carpenter PA, 2007, BLOOD, V109, P2791, DOI 10.1182/blood-2006-04-019836; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fielding AK, 2010, BLOOD, V116, P3409, DOI 10.1182/blood-2010-01-242750; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Hess G, 2005, J CLIN ONCOL, V23, P7583, DOI 10.1200/JCO.2005.01.3110; Hirase C, 2009, LEUKEMIA RES, V33, P450, DOI 10.1016/j.leukres.2008.07.023; Hirose K, 2010, BLOOD, V116, P962, DOI 10.1182/blood-2009-09-244673; INUKAI T, 1993, BRIT J HAEMATOL, V85, P823; Jabbour E, 2010, LEUKEMIA, V24, P6, DOI 10.1038/leu.2009.193; Jabbour E, 2011, BLOOD, V117, P1822, DOI 10.1182/blood-2010-07-293977; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Kolb HJ, 2008, BLOOD, V112, P4371, DOI 10.1182/blood-2008-03-077974; Kolb HJ, 2004, BLOOD, V103, P767, DOI 10.1182/blood-2003-02-0342; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Nimmanapalli R, 2001, CLIN CANCER RES, V7, P350; Olavarria E, 2007, BLOOD, V110, P4614, DOI 10.1182/blood-2007-04-082990; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PRETI HA, 1994, AM J MED, V97, P60, DOI 10.1016/0002-9343(94)90049-3; Quintas-Cardama A, 2009, BLOOD, V113, P1619, DOI 10.1182/blood-2008-03-144790; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Savani BN, 2005, BONE MARROW TRANSPL, V36, P1009, DOI 10.1038/sj.bmt.1705167; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2007, ONCOGENE, V26, P3745, DOI 10.1038/sj.onc.1210374; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tiribelli M, 2009, LEUKEMIA RES, V33, P174, DOI 10.1016/j.leukres.2008.03.031; Uckun FM, 1998, CANCER-AM CANCER SOC, V83, P2030, DOI 10.1002/(SICI)1097-0142(19981101)83:9<2030::AID-CNCR21>3.0.CO;2-Q; Uno K, 2003, BLOOD, V101, P3658, DOI 10.1182/blood-2002-06-1770; Yoshida T, 2001, FEBS LETT, V507, P381, DOI 10.1016/S0014-5793(01)02947-7; Yoshimitsu M, 2008, INT J HEMATOL, V88, P331, DOI 10.1007/s12185-008-0150-z; Zhang XC, 2011, LEUKEMIA RES, V35, P940, DOI 10.1016/j.leukres.2011.03.016	41	6	8	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2013	32	13					1670	1681		10.1038/onc.2012.186	http://dx.doi.org/10.1038/onc.2012.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22665066				2022-12-17	WOS:000316855800007
J	Morancho, B; Parra-Palau, JL; Ibrahim, YH; Morales, CB; Peg, V; Bech-Serra, JJ; Pandiella, A; Canals, F; Baselga, J; Rubio, I; Arribas, J				Morancho, B.; Parra-Palau, J. L.; Ibrahim, Y. H.; Bernado Morales, C.; Peg, V.; Bech-Serra, J. J.; Pandiella, A.; Canals, F.; Baselga, J.; Rubio, I.; Arribas, J.			A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers	ONCOGENE			English	Article						HER2; ErbB2; breast cancer	RECEPTOR; CLEAVAGE; ERBB-2; GELDANAMYCIN; IDENTIFICATION; TRASTUZUMAB; DEGRADATION; EFFECTOR; P95HER2; GROWTH	The transmembrane tyrosine kinase HER2 (ErbB2, neu) is a prototypical biomarker for breast cancers and a therapeutic target. Although anti-HER2 therapies are remarkably effective, HER2-positive tumors are heterogeneous and some subtypes do not respond or develop resistance to these therapies. Here we show that H2NTF, a novel N-terminal fragment of HER2, is expressed at variable levels in 60% of the breast cancer samples analyzed. Characterization of H2NTF shows that it is devoid of the tyrosine kinase domain but it readily interacts with full-length HER2 and other HER receptors. As a consequence, H2NTF acts as a dominant-negative, attenuating the signaling triggered by full-length HER receptors. Expression of H2NTF results in resistance to the treatment with low concentrations of trastuzumab in vitro. However, cells expressing H2NTF and non-expressing cells have similar sensitivity to trastuzumab in vivo, indicating that H2NTF/trastuzumab complexes trigger antibody-dependent cell-mediated cytotoxicity. Oncogene (2013) 32, 1452-1459; doi:10.1038/onc.2012.152; published online 28 May 2012	[Morancho, B.; Parra-Palau, J. L.; Ibrahim, Y. H.; Bernado Morales, C.; Bech-Serra, J. J.; Canals, F.; Baselga, J.; Arribas, J.] Vall dHebron Inst Oncol VHIO, Preclin Res Program, Barcelona 08035, Spain; [Peg, V.] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Dept Pathol, Bellaterra, Spain; [Peg, V.] Univ Autonoma Barcelona, Dept Morphol Sci, Bellaterra, Spain; [Pandiella, A.] Univ Salamanca, CSIC, Inst Biol Mol Celular & Celular Canc, E-37008 Salamanca, Spain; [Baselga, J.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA; [Rubio, I.] Vall dHebron Univ Hosp, Breast Canc Ctr, Barcelona, Spain; [Arribas, J.] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Arribas, J.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Harvard University; Harvard Medical School; Massachusetts General Hospital; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; ICREA	Arribas, J (corresponding author), Vall dHebron Inst Oncol VHIO, Preclin Res Program, Psg Vall dHebron 119-129, Barcelona 08035, Spain.	jarribas@vhio.net	rubio, isabel/U-4259-2018; Arribas, Joaquin/M-4482-2014; Morancho, Beatriz/AAD-3540-2021; Pandiella, Atanasio/O-5180-2014; Bech-Serra, Joan Josep/AAA-2330-2020; Peg., Vicente/AAC-9447-2020; Peg, Vicente/E-9160-2018	rubio, isabel/0000-0003-0035-0679; Arribas, Joaquin/0000-0002-0504-0664; Morancho, Beatriz/0000-0003-3369-8647; Pandiella, Atanasio/0000-0002-4704-8971; Bech-Serra, Joan Josep/0000-0003-3486-781X; Peg., Vicente/0000-0002-5203-6166; Peg, Vicente/0000-0002-5203-6166; Bernado Morales, Cristina/0000-0003-1376-0407	Instituto de Salud Carlos III (Intrasalud) [PI081154, PI11/02496]; Instituto de Salud Carlos III (network of cooperative cancer research) [RTICC-RD06/0020/0022, RTICC-RD06/0020/0041]; GlaxoSmithKline; Breast Cancer Research Foundation (BCRF); ICREA Funding Source: Custom	Instituto de Salud Carlos III (Intrasalud); Instituto de Salud Carlos III (network of cooperative cancer research); GlaxoSmithKline(GlaxoSmithKline); Breast Cancer Research Foundation (BCRF); ICREA(ICREA)	This work was supported by Instituto de Salud Carlos III (Intrasalud PI081154, PI11/02496 and the network of cooperative cancer research (RTICC-RD06/0020/0022 and RTICC-RD06/0020/0041)), GlaxoSmithKline and the Breast Cancer Research Foundation (BCRF).	Abramson V, 2011, CLIN CANCER RES, V17, P952, DOI 10.1158/1078-0432.CCR-09-1947; Anelli T, 2008, EMBO J, V27, P315, DOI 10.1038/sj.emboj.7601974; Arribas J, 2011, CANCER RES, V71, P1515, DOI 10.1158/0008-5472.CAN-10-3795; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Benoit V, 2004, CANCER RES, V64, P2684, DOI 10.1158/0008-5472.CAN-03-2914; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; HASUI M, 1989, CELL IMMUNOL, V120, P230, DOI 10.1016/0008-8749(89)90190-1; Kulkarni S, 2010, ONCOGENE, V29, P1339, DOI 10.1038/onc.2009.422; Parra-Palau JL, 2010, CANCER RES, V70, P8537, DOI 10.1158/0008-5472.CAN-10-1701; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Ryan Q, 2008, ONCOLOGIST, V13, P1114, DOI 10.1634/theoncologist.2008-0816; Sanchez-Martin M, 2012, INT J CANCER, V131, P244, DOI 10.1002/ijc.26358; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Sibilia M, 2007, DIFFERENTIATION, V75, P770, DOI 10.1111/j.1432-0436.2007.00238.x; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Sperinde J, 2010, CLIN CANCER RES, V16, P4226, DOI 10.1158/1078-0432.CCR-10-0410; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Tikhomirov O, 2005, ONCOGENE, V24, P3906, DOI 10.1038/sj.onc.1208534; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Tompa P, 2004, J BIOL CHEM, V279, P20775, DOI 10.1074/jbc.M313873200	23	6	6	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1452	1459		10.1038/onc.2012.152	http://dx.doi.org/10.1038/onc.2012.152			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22641219				2022-12-17	WOS:000316455600011
J	Lo, PK; Chen, H				Lo, P-K; Chen, H.			Cancer stem cells and cells of origin in MMTV-Her2/neu-induced mammary tumorigenesis	ONCOGENE			English	Letter							NEU TRANSGENIC MICE; EPITHELIAL-CELLS; KINASE-ACTIVITY; GLAND; PROGENITOR; MORPHOGENESIS; EXPRESSION		[Lo, P-K] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Lo, PK (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.							Andrechek ER, 2005, ONCOGENE, V24, P932, DOI 10.1038/sj.onc.1208230; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Booth BW, 2007, J CELL PHYSIOL, V212, P729, DOI 10.1002/jcp.21071; Boulanger CA, 2005, ONCOGENE, V24, P552, DOI 10.1038/sj.onc.1208185; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Jackson-Fisher AJ, 2004, P NATL ACAD SCI USA, V101, P17138, DOI 10.1073/pnas.0407057101; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Matulka LA, 2007, DEV BIOL, V303, P29, DOI 10.1016/j.ydbio.2006.12.017; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2011, EMBO J, V30, P4858, DOI 10.1038/emboj.2011.415; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509	24	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1338	1340		10.1038/onc.2012.456	http://dx.doi.org/10.1038/onc.2012.456			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	23045276				2022-12-17	WOS:000316454500015
J	Halder, G; Mills, GB				Halder, G.; Mills, G. B.			Drosophila in cancer research: to boldly go where no one has gone before	ONCOGENE			English	Editorial Material							TRANSGENIC RNAI; GENOME; GENE; SCREEN; GROWTH; MORPHOGENESIS; MELANOGASTER; MOSAICS; NOTCH	Transformation and metastasis are complex processes that depend on integration of effects from multiple mutations. Modeling this complexity requires manipulating multiple genes in particular sub-populations of cells in vivo. This is technically challenging in mammalian model systems and has limited the rate of progress in understanding the effects of the complex aberrations present in cancer cells. In contrast, powerful genetic methods in the fruit fly Drosophila allow efficient generation and analysis of complex genotypes in defined cell populations. These methods are already fruitful in exploring the interactions among cancer mutations, and between cell populations that mimic the tumor micro-environment. In this issue of Oncogene, Willecke et al. (2011) describe the implementation of a novel genetic screen in Drosophila to identify genes required for tumor growth in vivo. This report illustrates the power of using Drosophila to perform systematic genome-wide genetic screens in complex genetic backgrounds and for the resulting data to inform our understanding of transformation and metastasis in human systems. Oncogene (2011) 30, 4063-4066; doi:10.1038/onc.2011.128; published online 18 April 2011	[Halder, G.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Halder, G.] Univ Texas MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA; [Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Chair Syst Biol, Houston, TX 77030 USA; [Halder, G.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Halder, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	ghalder@mdanderson.org	Halder, Georg/F-2966-2015	Halder, Georg/0000-0001-7580-3236				Baker NE, 2007, CURR OPIN GENET DEV, V17, P287, DOI 10.1016/j.gde.2007.05.005; Bier E, 2005, NAT REV GENET, V6, P9, DOI 10.1038/nrg1503; Blair SS, 2003, DEVELOPMENT, V130, P5065, DOI 10.1242/dev.00774; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Dietzl G, 2007, NATURE, V448, P151, DOI 10.1038/nature05954; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Fortini ME, 2000, J CELL BIOL, V150, pF23, DOI 10.1083/jcb.150.2.F23; Grewal SS, 2009, INT J BIOCHEM CELL B, V41, P1006, DOI 10.1016/j.biocel.2008.10.010; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Mummery-Widmer JL, 2009, NATURE, V458, P987, DOI 10.1038/nature07936; Neely GG, 2010, CELL, V143, P628, DOI 10.1016/j.cell.2010.09.047; Neely GG, 2010, CELL, V141, P142, DOI 10.1016/j.cell.2010.02.023; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pospisilik JA, 2010, CELL, V140, P148, DOI 10.1016/j.cell.2009.12.027; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Schnorrer F, 2010, NATURE, V464, P287, DOI 10.1038/nature08799; St Johnston D, 2002, NAT REV GENET, V3, P176, DOI 10.1038/nrg751; Willecke M, 2011, ONCOGENE, V30, P4067, DOI 10.1038/onc.2011.125; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; XU T, 1993, DEVELOPMENT, V117, P1223	27	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	39					4063	4066		10.1038/onc.2011.128	http://dx.doi.org/10.1038/onc.2011.128			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21499298				2022-12-17	WOS:000295357500001
J	Schwarze, F; Meraner, J; Lechner, M; Loidl, A; Stasyk, T; Laich, A; Loidl, P				Schwarze, F.; Meraner, J.; Lechner, M.; Loidl, A.; Stasyk, T.; Laich, A.; Loidl, P.			Cell cycle-dependent acetylation of Rb2/p130 in NIH3T3 cells	ONCOGENE			English	Article						Rb2/p130; cell cycle; acetylation; p300; posttranslational modification	RETINOBLASTOMA TUMOR-SUPPRESSOR; FAMILY PROTEINS; POCKET PROTEINS; P130; PHOSPHORYLATION; RB	The retinoblastoma protein (pRb) and the pRb-related proteins, p130 and p107, form the 'pocket protein' family of cell cycle regulatory factors. A well characterized function of these proteins is the cell cycle-dependent regulation of E2F-responsive genes. The biological activity of pocket proteins is regulated by phosphorylation and for the founding member pRb it has been shown that acetylation also has an important role in modulating its function during the cell cycle. Here, we show that hyperphosphorylated retinoblastoma 2 (Rb2)/p130 also exists in an acetylated form in NIH3T3 cells. Acetylated p130 is present in the nucleus but not in the cytoplasm. Acetylation is cell cycle dependent, starting in S-phase and persisting until late G(2)-period. Using recombinant p130 and truncated forms for in vitro acetylation by the acetyltransferase p300, we could identify K1079 in the C-terminal part as the major acetylation site by mass spectrometry. Minor acetylation sites were pinpointed to K1068 and K1111 in the C-terminus, and K128 and K130 in the N-terminus. The human papilloma virus 16 protein-E7 preferentially binds to acetylated p130 and significantly increases in vitro p130 acetylation by p300. Oncogene (2010) 29, 5755-5760; doi:10.1038/onc.2010.311; published online 2 August 2010	[Schwarze, F.; Meraner, J.; Lechner, M.; Loidl, A.; Loidl, P.] Innsbruck Med Univ, Div Mol Biol, Bioctr, A-6020 Innsbruck, Austria; [Stasyk, T.] Innsbruck Med Univ, Div Cell Biol, Bioctr, A-6020 Innsbruck, Austria; [Laich, A.] Tyrolean Canc Res Inst, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Loidl, P (corresponding author), Innsbruck Med Univ, Div Mol Biol, Bioctr, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Peter.Loidl@i-med.ac.at	Loidl, Alois/L-8199-2015	Loidl, Alois/0000-0002-5579-0746; Schwarze, Florian/0000-0002-1334-1301; Stasyk, Taras/0000-0003-0568-6841	Tyrolean Science Foundation	Tyrolean Science Foundation	We thank A Giordano for providing a p130 plasmid, J Kadonaga for a p300 vector, F Marx-Ladurner for PAF, G Bonn for mass spectrometry facilities and L Huber, A Lusser and M Saeed for valuable discussions. This work was supported by a grant of the Tyrolean Science Foundation to JM.	Brosch G, 2008, FEMS MICROBIOL REV, V32, P409, DOI 10.1111/j.1574-6976.2007.00100.x; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Choi CH, 2003, NATURE, V424, P965, DOI 10.1038/nature01899; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio P, 2002, GENOME BIOL, V3; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hansen K, 1999, ELECTROPHORESIS, V20, P372, DOI 10.1002/(SICI)1522-2683(19990201)20:2<372::AID-ELPS372>3.0.CO;2-R; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mayol X, 1996, ONCOGENE, V13, P237; Meraner J, 2006, NUCLEIC ACIDS RES, V34, P1798, DOI 10.1093/nar/gkl101; Nelson CJ, 2006, CELL, V126, P905, DOI 10.1016/j.cell.2006.07.026; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Popov B, 2005, BIOCHEM BIOPH RES CO, V336, P762, DOI 10.1016/j.bbrc.2005.08.163; Roman A, 2006, CELL CYCLE, V5, P567, DOI 10.4161/cc.5.6.2571; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; White MK, 2006, ONCOGENE, V25, P5286, DOI 10.1038/sj.onc.1209618; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	29	6	7	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	42					5755	5760		10.1038/onc.2010.311	http://dx.doi.org/10.1038/onc.2010.311			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	668IT	20676144	Green Published, hybrid			2022-12-17	WOS:000283262500011
J	Mull, BB; Cox, J; Bui, T; Keyomarsi, K				Mull, B. B.; Cox, J.; Bui, T.; Keyomarsi, K.			Post-translational modification and stability of low molecular weight cyclin E	ONCOGENE			English	Article						cyclin E; phosphorylation; low molecular weight form; stability; cell cycle	BREAST-CANCER; UBIQUITIN LIGASE; TRANSGENIC MICE; IN-VIVO; PHOSPHORYLATION; INSTABILITY; CELLS; FORMS; CDK2; TUMORIGENESIS	Our laboratory has previously described the presence of five tumor-specific low molecular weight isoforms of cyclin E in both tumor cell lines and breast cancer patient biopsies. We have also shown that one of these low forms arises from an alternate start site, whereas the other four appear as two sets of doublets following cleavage through an elastase-like enzyme. However, the origin of both sets of doublets was unknown. Here, we demonstrate that the larger isoform of each doublet is the result of phosphorylation at a key degradation site. Through site-directed mutagenesis of different phosphorylation sites within the cyclin E protein, we discovered that phosphorylation of threonine 395 is responsible for generating the larger isoform of each doublet. Because phosphorylation of threonine 395 has been linked to the proteasome-mediated degradation of full length cyclin E, we examined the stability of T395A phospho-mutants in both non-tumorigenic mammary epithelial cells and tumor cells. The results revealed that the low molecular weight isoforms appear to be stable in both a tumor cell line and a non-tumor forming cell line regardless of the presence of this critical phosphorylation site. The stability of low molecular weight cyclin E may have implications for both tumorigenesis and treatment of tumors expressing them. Oncogene (2009) 28, 3167-3176; doi: 10.1038/onc.2009.182; published online 29 June 2009	[Keyomarsi, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 0066, Houston, TX 77030 USA; [Mull, B. B.; Keyomarsi, K.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Keyomarsi, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 0066, 1515 Holcombe Blvd, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Keyomarsi, Khandan/H-2716-2016	Keyomarsi, Khandan/0000-0002-5440-0849; Mull, Benjamin/0000-0001-8379-873X	National Institutes of Health [CA87458]; National Cancer Institute [P50CA116199]; Clayton Foundation [W81XWH-05-1-0255 03]; NATIONAL CANCER INSTITUTE [P50CA116199] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Clayton Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was funded in part by the following grants: National Institutes of Health CA87458 (to K Keyomarsi); National Cancer Institute P50CA116199 (project 2 to K Keyomarsi); Clayton Foundation (to K Keyomarsi) Department of Defense W81XWH-05-1-0255 03 (to B Mull).	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Akli S, 2007, CANCER RES, V67, P7212, DOI 10.1158/0008-5472.CAN-07-0599; Bales E, 2005, CANCER RES, V65, P692; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Delk NA, 2009, CANCER RES, V69, P2817, DOI 10.1158/0008-5472.CAN-08-4182; Harwell RM, 2000, CANCER RES, V60, P481; Honda R, 2005, EMBO J, V24, P452, DOI 10.1038/sj.emboj.7600554; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Loeb KR, 2005, CANCER CELL, V8, P35, DOI 10.1016/j.ccr.2005.06.010; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Nguyen HH, 2008, P NATL ACAD SCI USA, V105, P19750, DOI 10.1073/pnas.0806581105; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Smith APL, 2006, ONCOGENE, V25, P7245, DOI 10.1038/sj.onc.1209713; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Wingate H, 2005, J BIOL CHEM, V280, P15148, DOI 10.1074/jbc.M409789200; Wingate H, 2003, CELL CYCLE, V2, P461, DOI 10.4161/cc.2.5.464; Wingate H, 2009, CELL CYCLE, V8, P1062, DOI 10.4161/cc.8.7.8119; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Ye X, 2004, J BIOL CHEM, V279, P50110, DOI 10.1074/jbc.M409226200	29	6	7	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3167	3176		10.1038/onc.2009.182	http://dx.doi.org/10.1038/onc.2009.182			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19561641	Bronze			2022-12-17	WOS:000269515100008
J	Sun, TP; Shieh, SY				Sun, T-P; Shieh, S-Y			Human FEM1B is required for Rad9 recruitment and CHK1 activation in response to replication stress	ONCOGENE			English	Article						CHK1; FEM1B; replication stress	DNA-DAMAGE CHECKPOINTS; SEX-DETERMINATION; STRUCTURAL BASIS; GENE FAMILY; ATR; CLASPIN; PROTEIN; PHOSPHORYLATION; BINDING; P53	Human checkpoint kinase 1 (CHK1) is an essential kinase required to preserve genome stability, and is activated by DNA replication blockage through the ataxia-telangiectasia-mutated-and-Rad3-related (ATR)/ATRIP-signaling pathway. In this report, we show that a novel CHK1-interacting protein, FEM1B ( human homologue of the Caenorhabditis elegans sex determination fem1 protein), identified by a yeast two-hybrid screen, is involved in the activation of CHK1 by replication stress. Depletion of FEM1B by small interfering RNA in cancer cells impairs the activation of CHK1 kinase activity and attenuates the induction of CHK1 Ser345 phosphorylation upon replication interference. It is to be noted that, CHK2 Thr68 phosphorylation is not altered by FEM1B downregulation. By fractionation, we further demonstrated that FEM1B is able to associate with chromatin, and such association facilitates chromatin loading of the Rad9 protein. Consistently, ATR activity is poorly maintained in FEM1B knockdown cells; and FEM1B-ablated cells are as sensitive to replication block as CHK1-depleted cells. Our study has uncovered an adaptor protein FEM1B, which acts as a bridge linking CHK1 and Rad9, thus facilitating checkpoint signaling induced by replication stress. Oncogene (2009) 28, 1971-1981; doi:10.1038/onc.2009.58; published online 30 March 2009	[Sun, T-P; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Sun, T-P] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sec 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	Academia Sinica, Taiwan	Academia Sinica, Taiwan(Academia Sinica - Taiwan)	We thank Shiaw-Wei Tyan for his assistance with yeast library screening. We are also grateful to Drs Hsiu-Ming Shih for the human testis cDNA library; Victor Yu for pXJ-HA-F1Aa; Carol Prives for GST-Cdc25C<INF>200-256</INF>; Howard Lieberman for Rad9 cDNA; Randal Tibbetts and Robert Abraham for FlagATR. This study was supported by funds from Academia Sinica, Taiwan to S-Y Shieh.	Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Chini C, 2006, ONCOGENE, V25, P4165, DOI 10.1038/sj.onc.1209447; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Gaudet J, 1996, MOL BIOL CELL, V7, P1107, DOI 10.1091/mbc.7.7.1107; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Jamil S, 2008, MOL BIOL CELL, V19, P3212, DOI 10.1091/mbc.E07-11-1171; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Krakow D, 2001, GENE, V279, P213, DOI 10.1016/S0378-1119(01)00756-9; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(05)00092-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; Kumagai A, 2004, J BIOL CHEM, V279, P49599, DOI 10.1074/jbc.M408353200; Lee J, 2007, J BIOL CHEM, V282, P28036, DOI 10.1074/jbc.M704635200; Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q; Lu DY, 2005, MOL CELL BIOL, V25, P6570, DOI 10.1128/MCB.25.15.6570-6577.2005; Machida YJ, 2005, J BIOL CHEM, V280, P6253, DOI 10.1074/jbc.R400037200; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Ou YH, 2007, EMBO J, V26, P3968, DOI 10.1038/sj.emboj.7601825; Rodriguez R, 2006, MOL BIOL CELL, V17, P402, DOI 10.1091/mbc.E05-07-0594; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Shieh SY, 2000, GENE DEV, V14, P289; Ventura-Holman T, 2003, GENE, V314, P133, DOI 10.1016/S0378-1119(03)00712-1; Ventura-Holman T, 1998, GENOMICS, V54, P221, DOI 10.1006/geno.1998.5569; Ventura-Holman T, 2000, BIOCHEM BIOPH RES CO, V267, P317, DOI 10.1006/bbrc.1999.1942; Wang X, 2006, MOL CELL, V23, P331, DOI 10.1016/j.molcel.2006.06.022; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Yoo HY, 2006, GENE DEV, V20, P772, DOI 10.1101/gad.1398806; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	38	6	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1971	1981		10.1038/onc.2009.58	http://dx.doi.org/10.1038/onc.2009.58			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19330022				2022-12-17	WOS:000265820900004
J	Shiono, M; Kobayashi, T; Takahashi, R; Sun, G; Abe, M; Zhang, D; Wang, L; Piao, X; Takagi, Y; Mineki, R; Taka, H; Tada, N; Sonobe, S; Momose, S; Ueda, M; Hino, O				Shiono, M.; Kobayashi, T.; Takahashi, R.; Sun, G.; Abe, M.; Zhang, D.; Wang, L.; Piao, X.; Takagi, Y.; Mineki, R.; Taka, H.; Tada, N.; Sonobe, S.; Momose, S.; Ueda, M.; Hino, O.			The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition	ONCOGENE			English	Article						tuberous sclerosis; tumor suppressor gene; Tsc2; transgenic rat; mTOR	RAPAMYCIN ANALOG CCI-779; RENAL-CARCINOMA; MOUSE MODEL; TSC2; PHOSPHORYLATION; COMPLEX; GENE; HAMARTIN; TARGET; GAP	Tuberin, a tumor-suppressor protein produced by the tuberous sclerosis gene TSC2, downregulates the Rheb-mTOR-S6K pathway (mTOR axis). Comparison of the effects of human tuberin mutations, such as G1556S, suggests that pathways other than the mTOR axis might also be involved in the pathogenesis of tuberous sclerosis. Here we test this possibility using the rat G1556S-type mutation (GSM) and a transgenic Eker (Tsc2 mutant) rat system. Cells expressing GSM-tuberin failed to downregulate the mTOR axis. GSM-tuberin had an altered localization, which underlie its reduced ability to form a complex with hamartin, and a site-specific alteration in phosphorylation status indicating diverse regulation by Akt. GSM-transgenic (GSM-Tg) rats exhibited suppression of macroscopic renal tumors following N-ethyl-N-nitrosourea treatment. Intriguingly, rats with weaker GSM-Tg expression showed microscopic cystic and pre-tumorous lesions that were restricted in size and expansion, although they had hyper-phosphorylation of ribosomal protein S6. These results highlight a novel pathway involving tuberin that regulates tumor suppression independently of the mTOR inhibitory function. Identification of such a novel pathway will provide clear implications for generation of new therapeutic targets in the treatment of these tumors.	[Hino, O.] Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, Tokyo 1138421, Japan; [Mineki, R.; Taka, H.] Juntendo Univ, Sch Med, Div Prote & BioMol Sci, Tokyo 1138421, Japan; [Tada, N.] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 1138421, Japan; [Sonobe, S.] Juntendo Univ, Sch Med, Dept Gen Thorac Surg, Tokyo 1138421, Japan; [Momose, S.] Saitama Med Univ, Saitama Med Ctr, Dept Pathol, Saitama, Japan	Juntendo University; Juntendo University; Juntendo University; Juntendo University; Saitama Medical University	Hino, O (corresponding author), Juntendo Univ, Sch Med, Dept Pathol & Oncol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	ohino@juntendo.ac.jp	Warfield, Simon/B-3352-2009	Warfield, Simon/0000-0002-7659-3880	Ministry of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science; Ministry of Health, Labour and Welfare of Japan	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labour and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan)	This research was supported by a Grant-in-aid for Cancer Research from the Ministry of Education, Culture, Sports, Science and Technology and Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science and the Ministry of Health, Labour and Welfare of Japan. We also thank Ms N Otsuji (Department of Pathology and Oncology), Mr R Tsukada, Mr F Kanai, Ms T Hidano ( Center for Biomedical Research Resources), Mr M Yoshida, Mr J Nakamoto ( Division of Ultrastructural Research), Mr Y Watanabe, Mr K Matsunami, Ms K Ochiai ( Division of Radioisotope Research), Dr T Fujimura ( Division of Proteomics and BioMolecular Science), Ms Y Kojima, Dr H Kurihara ( Division of Biomedical Imaging Research), Dr T Seki ( Department of Developmental Neurobiology), Dr T Ueno and Dr E Kominami ( Department of Biochemistry), all of Juntendo University, for their support.	Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dancey JE, 2006, NAT REV DRUG DISCOV, V5, P649, DOI 10.1038/nrd2089; Davies DM, 2008, NEW ENGL J MED, V358, P200, DOI 10.1056/NEJMc072500; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062; Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784; Fukuda T, 1998, JPN J CANCER RES, V89, P1104, DOI 10.1111/j.1349-7006.1998.tb00503.x; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Granville CA, 2006, CLIN CANCER RES, V12, P679, DOI 10.1158/1078-0432.CCR-05-1654; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1994, BIOCHEM BIOPH RES CO, V203, P1302, DOI 10.1006/bbrc.1994.2324; HINO O, 1993, CANCER RES, V53, P5856; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jansen AC, 2006, ANN NEUROL, V60, P528, DOI 10.1002/ana.21037; Kenerson H, 2005, PEDIATR RES, V57, P67, DOI 10.1203/01.PDR.0000147727.78571.07; Kenerson HL, 2002, CANCER RES, V62, P5645; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P3990, DOI 10.1073/pnas.94.8.3990; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Kobayashi T, 2003, P JPN ACAD B-PHYS, V79, P22, DOI 10.2183/pjab.79B.22; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lee L, 2006, GENE CHROMOSOME CANC, V45, P933, DOI 10.1002/gcc.20357; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Mayer K, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.010835; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Nellist M, 2005, EUR J HUM GENET, V13, P59, DOI 10.1038/sj.ejhg.5201276; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Niida Y, 1999, HUM MUTAT, V14, P412, DOI 10.1002/(SICI)1098-1004(199911)14:5<412::AID-HUMU7>3.0.CO;2-K; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Shah OJ, 2004, J BIOL CHEM, V279, P20816, DOI 10.1074/jbc.M400957200; Sun GD, 2007, BIOCHEM BIOPH RES CO, V360, P181, DOI 10.1016/j.bbrc.2007.06.021; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	41	6	6	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2008	27	52					6690	6697		10.1038/onc.2008.283	http://dx.doi.org/10.1038/onc.2008.283			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368QY	18695678				2022-12-17	WOS:000260638800007
J	Impera, L; Albano, F; Lo Cunsolo, C; Funes, S; Iuzzolino, P; Laveder, F; Panagopoulos, I; Rocchi, M; Storlazzi, CT				Impera, L.; Albano, F.; Lo Cunsolo, C.; Funes, S.; Iuzzolino, P.; Laveder, F.; Panagopoulos, I.; Rocchi, M.; Storlazzi, C. T.			A novel fusion 5 ' AFF3/3 ' BCL2 originated from a t(2;18)(q11.2;q21.33) translocation in follicular lymphoma	ONCOGENE			English	Article						AFF3; BCL2; fusion gene; follicular lymphoma; translocation	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENE; BREAKPOINTS; BCL2; LAF4; MLL	Follicular lymphoma is the second most frequent type of non-Hodgkin's lymphoma in adults. The basic molecular defect consists of the t(14;18)(q32;q21) translocation, juxtaposing the B-cell lymphoma protein 2 gene BCL2 to the immunoglobulin heavy chain locus IGH@, and leading to the antiapoptotic BCL2 protein overproduction. Variations in the t(14;18) are rare and can be classified into two categories: (i) simple variants, involving chromosomes 18 and 2, or 22, in which the fusion partner of BCL2 is the light-chain IGK@ or IGL@; (ii) complex variant translocations occurring among chromosomes 14, 18 and other chromosomes. We report a follicular lymphoma case showing BCL2 overexpression, detected by immunohistochemistry and real-time quantitative PCR, consequently to the formation of a novel fusion gene between the 5' of the lymphoid nuclear transcriptional activator gene AFF3 at 2q11.2, and the 3' of BCL2. This case shows evidence, for the first time, of BCL2 overexpression consequently to the fusion of BCL2 to a non-IG partner locus.	[Impera, L.; Rocchi, M.; Storlazzi, C. T.] Univ Bari, Dept Genet & Microbiol, I-70126 Bari, Italy; [Albano, F.] Univ Bari, Sect Hematol, Dept Pathol, I-70126 Bari, Italy; [Lo Cunsolo, C.; Funes, S.; Iuzzolino, P.] Osped San Martino Genova, Dipartimento Med Lab, Belluno, Italy; [Laveder, F.] Osped San Martino Genova, Dipartimento Discipline Med, Belluno, Italy; [Panagopoulos, I.] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; ULSS 1 Dolomiti; Ospedale di Belluno; University of Genoa; IRCCS AOU San Martino IST; ULSS 1 Dolomiti; Ospedale di Belluno; University of Genoa; IRCCS AOU San Martino IST; Lund University; Skane University Hospital	Storlazzi, CT (corresponding author), Univ Bari, Dept Genet & Microbiol, Via Amendola 165-A, I-70126 Bari, Italy.	c.storlazzi@biologia.uniba.it	Albano, Francesco/J-2352-2016	Albano, Francesco/0000-0001-7926-6052; Rocchi, Mariano/0000-0002-9451-5616; Storlazzi, Clelia Tiziana/0000-0002-1696-0028; Panagopoulos, Ioannis/0000-0003-2159-5341	AIRC (Associazione Italiana per la Ricerca sul Cancro); MiUR (Ministero dell'Istruzione, dell'Universita e della Ricerca)	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); MiUR (Ministero dell'Istruzione, dell'Universita e della Ricerca)(Ministry of Education, Universities and Research (MIUR))	We thank Dr Maria Corsignano Guastadisegni for her contribution to the study, and Professor Roscoe Stanyon for language revision of an earlier version. This study has been supported by the AIRC (Associazione Italiana per la Ricerca sul Cancro), and the MiUR (Ministero dell'Istruzione, dell'Universita e della Ricerca).	Bentley G, 2005, CANCER GENET CYTOGEN, V157, P12, DOI 10.1016/j.cancergencyto.2004.05.012; Chinen Y, 2008, ONCOGENE, V27, P2249, DOI 10.1038/sj.onc.1210857; de Jong D, 2005, J CLIN ONCOL, V23, P6358, DOI 10.1200/JCO.2005.26.856; Hiwatari M, 2003, ONCOGENE, V22, P2851, DOI 10.1038/sj.onc.1206389; Mahmoodi M, 2004, CANCER GENET CYTOGEN, V154, P160, DOI 10.1016/j.cancergencyto.2004.02.008; Storlazzi CT, 2007, LEUKEMIA, V21, P2221, DOI 10.1038/sj.leu.2404784; Weinberg OK, 2007, J MOL DIAGN, V9, P530, DOI 10.2353/jmoldx.2007.070038; Yonetani N, 2001, JPN J CANCER RES, V92, P933, DOI 10.1111/j.1349-7006.2001.tb01183.x	8	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6187	6190		10.1038/onc.2008.214	http://dx.doi.org/10.1038/onc.2008.214			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18622426	Green Submitted			2022-12-17	WOS:000260083100011
J	Hara, T; Schwieger, M; Kazama, R; Okamoto, S; Minehata, K; Ziegler, M; Lohler, J; Stocking, C				Hara, T.; Schwieger, M.; Kazama, R.; Okamoto, S.; Minehata, K.; Ziegler, M.; Loehler, J.; Stocking, C.			Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells	ONCOGENE			English	Article						Meis1; Meis3; Icsbp; AML	SEQUENCE-BINDING-PROTEIN; HUMAN MYELOID LEUKEMIAS; TRANSCRIPTION FACTOR; HEMATOPOIETIC STEM; HOMEOBOX GENES; BXH-2 MICE; TRANSFORMATION; NUP98-HOXD13; COEXPRESSION; MUTATION	Identifying genetic pathways that cooperate in leukemo-genesis facilitates our understanding of the molecular mechanisms at play. Interferon consensus sequence-binding protein ( ICSBP) is a tumor suppressor, whose downregulation cooperates with BCR-ABL and NUP98-TOP1 gene products to accelerate leukemia induction in mouse models. Similarly, Meis1 synergizes with HoxA9 or NUP98-HOX ( but not NUP98-TOP1) fusion genes to promote the early onset of leukemia. To investigate whether Icsbp deficiency interacts with Meis1 or its family member Meis3, we transplanted Icsbp -/- bone marrow ( BM) cells after transduction with Meis1 or Meis3 retroviral vectors. Here, we show that enforced expression of Meis1 or Meis3 in Icsbp -/- BM cells induces a fatal, invasive myeloproliferative disease. Secondary mutations, such as activation of Mn1, led to the progression to acute myeloid leukemia in a few mice. Interestingly, expression of endogenous Meis1 and Meis3 mRNAs was repressed in the granulocytic progenitor population of Icsbp -/- mice. These results reveal a novel collaboration between Icsbp deficiency and Meis1/Meis3 in the acceleration of chronic myeloid leukemia-like disease.	[Hara, T.] Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Stem Cell Project Grp, Bunkyo Ku, Tokyo 1138613, Japan; [Schwieger, M.; Ziegler, M.; Loehler, J.; Stocking, C.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Mol Pathol Grp, D-2000 Hamburg, Germany	Tokyo Metropolitan Institute of Medical Science; Heinrich Pette Institute; University of Hamburg	Hara, T (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Metropolitan Inst Med Sci, Stem Cell Project Grp, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	thara@rinshoken.or.jp	Okamoto, Shiki/X-7274-2018	Okamoto, Shiki/0000-0002-2802-0527				Burchert A, 2004, BLOOD, V103, P3480, DOI 10.1182/blood-2003-08-2970; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Gurevich RM, 2006, EXP HEMATOL, V34, P1192, DOI 10.1016/j.exphem.2006.04.020; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Pineault N, 2004, MOL CELL BIOL, V24, P1907, DOI 10.1128/MCB.24.5.1907-1917.2004; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schmidt M, 2004, BLOOD, V103, P4142, DOI 10.1182/blood-2003-01-0285; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schmidt M, 2001, BLOOD, V97, P3648, DOI 10.1182/blood.V97.11.3648; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Serrano E, 2006, ACTA HAEMATOL-BASEL, V116, P77, DOI 10.1159/000093636; Slape C, 2007, CANCER RES, V67, P5148, DOI 10.1158/0008-5472.CAN-07-0075; Turcotte K, 2005, J EXP MED, V201, P881, DOI 10.1084/jem.20042170; Wang GG, 2006, MOL CELL BIOL, V26, P3902, DOI 10.1128/MCB.26.10.3902-3916.2006; Zhu CL, 2004, J BIOL CHEM, V279, P50874, DOI 10.1074/jbc.M405736200	25	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3865	3869		10.1038/sj.onc.1211043	http://dx.doi.org/10.1038/sj.onc.1211043			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18223676				2022-12-17	WOS:000256904700010
J	Blouw, B; Haase, VH; Song, H; Bergers, G; Johnson, RS				Blouw, B.; Haase, V. H.; Song, H.; Bergers, G.; Johnson, R. S.			Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene	ONCOGENE			English	Article						hypoxia; angiogenesis; HIF-1; VEGF; tumor	RENAL-CELL-CARCINOMA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECEPTOR; VEGF; PVHL; TUMORIGENESIS; INACTIVATION; HIF-1-ALPHA; ACTIVATION; INDUCTION	Individuals bearing germ line mutations in the Von Hippel-Lindau (VHL) tumor suppressor gene are predisposed to the development of highly angiogenic tumors. This is correlated with an increased expression of the angiogenic factor vascular endothelial growth factor (VEGF) in these tumors, which is in part caused by elevated expression of the HIF-1 hypoxia inducible transcription factors. We created malignant astrocytes with genetic deletions of the VHL gene and implanted them in subcutaneous and intracranial sites; these sites are respectively vessel poor and vessel-rich tissues. When grown in a vessel poor site, VEGF expression in VHL null cells was important for both vascularization and tumor growth. However, when the same cells are grown in the vessel-rich intracranial environment, loss of VEGF expression reduces vascularization, but does not affect tumor growth. This indicates that antiangiogenic therapies for tumors that express high levels of angiogenic factors such as VEGF may vary in their efficacy, with potentially lowered effectiveness in sites, such as the brain, that are inherently vessel rich.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, Dept Neurosurg, San Francisco, CA USA	University of California System; University of California San Diego; University of Pennsylvania; University of California System; University of California San Francisco	Johnson, RS (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr,Nat Sci Bldg Rm 5328, La Jolla, CA 92093 USA.	rjohnson@biomail.ucsd.edu	Haase, Volker Hans/A-6758-2013; Bergers, Gabriele/AAJ-5535-2020; Haase, Volker Hans/AAJ-5061-2021; Johnson, Randall/AAM-1189-2021	Haase, Volker Hans/0000-0002-7051-8994; Johnson, Randall/0000-0002-4084-6639; Bergers, Gabriele/0000-0003-3545-5171	NATIONAL CANCER INSTITUTE [R01CA082515, R01CA100787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK062060, K08DK002668] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100787, CA082515, CA 100787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Grunstein J, 1999, CANCER RES, V59, P1592; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hansel DE, 2006, HISTOL HISTOPATHOL, V21, P437, DOI 10.14670/HH-21.437; Harris A L, 2000, Oncologist, V5 Suppl 1, P32; Hasselblatt M, 2005, NEUROPATH APPL NEURO, V31, P618, DOI 10.1111/j.1365-2990.2005.00669.x; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Los M, 1999, CANCER RES, V59, P4440; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Rankin EB, 2005, MOL CELL BIOL, V25, P3163, DOI 10.1128/MCB.25.8.3163-3172.2005; Rathmell WK, 2004, ANTICANCER RES, V24, P167; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tang N, 2006, MOL CELL BIOL, V26, P2519, DOI 10.1128/MCB.26.7.2519-2530.2006; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W	30	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4531	4540		10.1038/sj.onc.1210249	http://dx.doi.org/10.1038/sj.onc.1210249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297464				2022-12-17	WOS:000247836100007
J	Shimanuki, T; Hara, T; Furuya, T; Imamura, T; Miyazono, K				Shimanuki, T.; Hara, T.; Furuya, T.; Imamura, T.; Miyazono, K.			Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling	ONCOGENE			English	Article						tGF-beta; TGF-beta receptor; homology modeling; antagonist	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; SMAD PROTEINS; ACTIVIN; COMPLEX; SUPERFAMILY; FLAVOPIRIDOL; MEMBRANE	Transforming growth factor-beta (TGF-beta) binds to two different types of serine/threonine kinase receptors termed type II (T beta R-II) and type I (T beta R-I). TGF-beta is unable to bind to T beta R-I in the absence of T beta R-II, and initiates receptor assembly by binding with high affinity to T beta beta R-II. Previous structural analysis of the TGF-beta 3-T beta R-II complex has suggested that two charged amino acid residues, D55 and E142 of T beta R-II, are binding sites of TGF-beta. In the present study, we have shown that mutations of the amino-acid residues, D55 and E142 of T beta R-II, resulted in loss of TGF-beta binding and downstream signaling activity. Moreover, we found that 3,5,7,2',4'-pentahydroxyflavone (Morin) inhibits TGF-beta binding to T beta R-II, and suppresses phosphorylation of Smad2 and expression of a TGF-beta target gene Smad7 induced by TGF-beta. Our findings may thus provide useful information for designing therapeutic agents for various diseases induced by TGF-beta, including advanced cancers.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; JFCR, Canc Inst, Koto Ku, Tokyo, Japan; POLA Chem Inst Ltd, Cutaneous Drug Res, Totsuka Ku, Kanagawa, Japan; PharmaDesign Inc, Chuo Ku, Tokyo, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research; Pola Chemical Industries Inc.	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp						Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103; Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BIRT DF, 1990, CHEMOPREVENTION NONN, P221; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DE AWJ, 1996, P NATL ACAD SCI USA, V93, P2735; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 1999, J CELL SCI, V112, P3519; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; EWING T, 1998, DOCK VERSION 4 0 REF; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Hsiang CY, 2005, BIOCHEM PHARMACOL, V69, P1603, DOI 10.1016/j.bcp.2005.03.008; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oeda E, 1998, J BIOL CHEM, V273, P9353, DOI 10.1074/jbc.273.16.9353; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Qian SW, 1999, GROWTH FACTORS, V17, P63, DOI 10.3109/08977199909001063; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	39	6	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3311	3320		10.1038/sj.onc.1210123	http://dx.doi.org/10.1038/sj.onc.1210123			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146441				2022-12-17	WOS:000246579600001
J	Wang, H; Yan, C; Asangani, I; Allgayer, H; Boyd, DD				Wang, H.; Yan, C.; Asangani, I.; Allgayer, H.; Boyd, D. D.			Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression	ONCOGENE			English	Article						urokinase receptor; enhancer; gene expression	PLASMINOGEN-ACTIVATOR RECEPTOR; TRANSCRIPTION FACTOR-BINDING; IV COLLAGENASE EXPRESSION; INVASIVE COLON-CANCER; GENE-EXPRESSION; IN-VIVO; COLORECTAL-CANCER; CELL-MIGRATION; PROTEIN-KINASE; POSTTRANSCRIPTIONAL REGULATION	The transcriptionally regulated urokinase-type plasminogen activator receptor (u-PAR) contributes to cancer progression. Although previous studies have identified multiple 50 regulatory elements, these cis motifs cannot fully account for u-PAR expression prompting a search for hitherto uncharacterized regulatory elements. DNase I hypersensitivity and chromatin immunoprecipitation assays using u-PAR-expressing colon cancer cells indicated a hypersensitive region (+665/+2068) in intron 1 enriched with acetylated histone 3 (H3) and H3 methylated at lysine 4, markers of regulatory regions. The +665/+2068 region increased transcription from a u-PAR-promoter in an orientation- and distance-independent manner fulfilling the criteria of an enhancer. Optimal stimulation of the u-PAR promoter by phorbol ester required this enhancer. Systematic truncations combined with DNase I footprinting revealed two protected regions (+1060/+1099 and +1123/+1134) with deletion of the latter practically abolishing enhancer activity. The +1123/+1134 region harbored non-consensus activator protein-1 and Ets1 binding sites bound with c-Jun (and/or the related JunD/JunB) and c-Fos (and/or the related FosB/Fra-1/Fra-2) as revealed with chromatin immunoprecipitation. Further, nuclear extract from resected colon cancers showed elevated protein binding to a +1123/_1134- spanning probe coordinate with elevated u-PAR protein. Thus, we have defined a novel intragenic enhancer in the u-PAR gene required for constitutive and inducible expression.	MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Heidelberg, Dept Expt Mol Surg, D-6900 Heidelberg, Germany	University of Texas System; UTMD Anderson Cancer Center; Ruprecht Karls University Heidelberg	Boyd, DD (corresponding author), MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org		asangani, irfan/0000-0001-5381-1702; Yan, Chunhong/0000-0002-3974-7991	NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ahnen DJ, 1998, CANCER RES, V58, P1149; Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Bass R, 2005, J BIOL CHEM, V280, P14811, DOI 10.1074/jbc.M414189200; BOS JL, 1989, CANCER RES, V49, P4682; CASEY JR, 1994, BLOOD, V84, P1151; DeLong CJ, 2005, BIOCHEM BIOPH RES CO, V338, P53, DOI 10.1016/j.bbrc.2005.07.184; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Ibanez-Tallon I, 1999, ONCOGENE, V18, P2836, DOI 10.1038/sj.onc.1202644; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; JONES LG, 1994, J BIOL CHEM, V269, P23790; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Lakka SS, 2003, CANCER RES, V63, P2454; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Lin CY, 2004, GENE, V334, P63, DOI 10.1016/j.gene.2004.03.016; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Nair RR, 2005, ONCOL RES, V15, P265, DOI 10.3727/096504005776404571; Nestl A, 2001, CANCER RES, V61, P1569; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 2002, CANCER RES, V62, P2390; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; REITER LS, 1993, INT J CANCER, V53, P444, DOI 10.1002/ijc.2910530316; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279; Schewe DM, 2003, CLIN CANCER RES, V9, P2267; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Shetty S, 2005, MOL CELL BIOCHEM, V272, P107, DOI 10.1007/s11010-005-7644-2; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Shitoh K, 2001, GENE CHROMOSOME CANC, V30, P32, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1065>3.0.CO;2-I; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; SOZERI O, 1992, ONCOGENE, V7, P2259; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; Suzuki S, 1998, GUT, V43, P798, DOI 10.1136/gut.43.6.798; Trisciuoglio D, 2004, J BIOL CHEM, V279, P6737, DOI 10.1074/jbc.M308938200; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	66	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2058	2070		10.1038/sj.onc.1210003	http://dx.doi.org/10.1038/sj.onc.1210003			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001307				2022-12-17	WOS:000245313400008
J	Wang, DM; Sevcikova, S; Wen, H; Roberts, S; Lipsick, JS				Wang, D-M; Sevcikova, S.; Wen, H.; Roberts, S.; Lipsick, J. S.			v-Myb represses the transcription of Ets-2	ONCOGENE			English	Article						Myb; Ets; repression	MYELOMONOCYTIC GROWTH-FACTOR; AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING ACTIVITY; C-MYB; TARGET GENE; TRANS-ACTIVATION; ONCOGENE PRODUCT; E26 VIRUS; B-MYB; EXPRESSION	The v-Myb oncogene causes monoblastic leukemia and transforms only myelomonocytic cells in culture. The vMyb protein is nuclear and binds to specific DNA sequences. To identify genes regulated by v-Myb, we utilized primary cells transformed by a retrovirus encoding a v-Myb-estrogen receptor (ER) fusion protein. The Ets-2 gene was not expressed in v-Myb-ER transformed cells in the presence of estradiol, but was expressed within 4 h after estradiol withdrawal. The expression of Ets-2 also increased dramatically following phorbol ester-induced differentiation of the v-Myb-transformed BM2 cell line. Conversely, CRYP-alpha, encoding a transmembrane tyrosine phosphatase, was expressed in the presence but not the absence of estradiol in v-Myb-ER transformed cells. CRYP-alpha was downregulated during the phorbol ester-induced differentiation of BM2 cells. Although LIM-3 expression was estradiol-inducible in v-Myb-ER transformed monoblasts, LIM-3 was expressed neither in primary yolk sac cells transformed by unfused v-Myb nor in BM2 cells. We conclude that although v-Myb has been intensively studied as a transcriptional activator, v-Myb can repress biologically relevant genes such as Ets-2, which promotes macrophage differentiation. In addition, we have shown that some genes that are regulated by a v-Myb-ER fusion protein may not be relevant to the biological function of the unfused v-Myb protein.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	lipsick@stanford.edu	Sevcikova, Sabina/AAB-4267-2021	Wen, Hong/0000-0001-8739-4572	NATIONAL CANCER INSTITUTE [T32CA009151, R01CA043592] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA43592, T32 CA09151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aperlo C, 1996, MOL CELL BIOL, V16, P6851; Bartley PA, 2003, ONCOGENE, V22, P7570, DOI 10.1038/sj.onc.1207136; Begue A, 1997, GENE EXPRESSION, V6, P333; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; Braas D, 2004, NUCLEIC ACIDS RES, V32, P4750, DOI 10.1093/nar/gkh808; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Chen J, 2002, ONCOGENE, V21, P1859, DOI 10.1038/sj.onc.1205003; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; Ferrao P, 1997, BLOOD, V90, P4539; GARCIA A, 1991, ONCOGENE, V6, P265; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KU DH, 1993, J BIOL CHEM, V268, P2255; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Lisitsyn N A, 1993, Mol Gen Mikrobiol Virusol, P26; Liu F, 2006, ONCOGENE, V25, P795, DOI 10.1038/sj.onc.1209105; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PESSANO S, 1979, NEW MICROBIOL, V2, P379; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179	42	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1238	1244		10.1038/sj.onc.1209868	http://dx.doi.org/10.1038/sj.onc.1209868			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16909100				2022-12-17	WOS:000244406400014
J	Hutvagner, G				Hutvagner, G.			MicroRNAs and cancer: issue summary	ONCOGENE			English	Editorial Material									Univ Dundee, Div Gene Regulat & Express, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Hutvagner, G (corresponding author), Univ Dundee, Div Gene Regulat & Express, Coll Life Sci, Dow St, Dundee DD1 5EH, Scotland.	g.hutvagner@dundee.ac.uk		Hutvagner, Gyorgy/0000-0002-7231-9446					0	6	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2006	25	46					6154	6155		10.1038/sj.onc.1209917	http://dx.doi.org/10.1038/sj.onc.1209917			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL					2022-12-17	WOS:000241158900002
J	Cotroneo, MS; Merry, GM; Haag, JD; Lan, H; Shepel, LA; Gould, MN				Cotroneo, M. S.; Merry, G. M.; Haag, J. D.; Lan, H.; Shepel, L. A.; Gould, M. N.			The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance	ONCOGENE			English	Article						breast cancer; animal models; loss of heterozygosity (LOH); genotype/phenotype correlation	BREAST-CANCER; TUMOR SUSCEPTIBILITY; MULTIPLE LOCI; GENE; HETEROZYGOSITY; CARCINOMAS; CARCINOGENESIS; CHROMOSOME-10; NEUROBLASTOMA; SCHWANNOMAS	Identification of high-penetrance breast cancer genes such as Brca1 has been accomplished by analysing familial cases. However, these genes occur at low frequency and do not account for the majority of genetic risk. Identification of low-penetrance alleles that occur commonly in populations may benefit from unbiased genome-wide screening. One such approach uses linkage studies in rodent models to identify homologous human candidates. The Wistar Kyoto (WKy) rat is resistant to mammary carcinomas induced with 7,12-dimethybenz[a]anthracene (DMBA), whereas the Wistar Furth (WF) strain is susceptible. Previous genome-wide linkage studies in crosses of these strains identified three WKy resistance quantitative trait loci, Mcs5, Mcs6 and Mcs8, and one predicted to increase susceptibility, Mcs7. The Mcs7 region on rat chromosome 10 (RNO10) is orthologous to human 17q, a common site of genetic aberrations in breast cancer. Here, we establish the independent phenotype conferred by Mcs7 using congenic rats carrying the WKy Mcs7 locus on a WF background. Tumor multiplicity was significantly higher (similar to 50%) in DMBA-treated congenics homozygous and heterozygous for the WKy allele at the Mcs7 locus, compared to controls. We also investigated allelic imbalance (AI) in mammary carcinomas from (WKy x WF)F1 rats and Mcs7 heterozygous congenics. Of the four known WKy Mcs loci tested, only Mcs7 displayed AI. The pattern of AI in carcinomas from both F1 and Mcs7 congenic rats was similar, suggesting a WF allelic loss. Together, these data suggest that one or more breast cancer-related genes are located within the dominantly acting WKy allele at the Mcs7 locus.	Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cotroneo, MS (corresponding author), Univ Wisconsin, Dept Oncol, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	cotroneo@oncology.wisc.edu	Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R01CA077494] Funding Source: NIH RePORTER; NCI NIH HHS [CA77494] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CALLAHAN R, 1993, J CELL BIOCHEM, P167; Chen KS, 1996, CARCINOGENESIS, V17, P1561, DOI 10.1093/carcin/17.8.1561; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6; Haag JD, 2003, CANCER RES, V63, P5808; Haag JD, 1996, MOL CARCINOGEN, V17, P134, DOI 10.1002/(SICI)1098-2744(199611)17:3<134::AID-MC5>3.3.CO;2-N; Haag JD, 1999, MOL CARCINOGEN, V24, P47, DOI 10.1002/(SICI)1098-2744(199901)24:1<47::AID-MC7>3.0.CO;2-B; Hino O, 2001, MUTAT RES-FUND MOL M, V477, P155, DOI 10.1016/S0027-5107(01)00116-6; Kindler-Rohrborn A, 1999, CANCER RES, V59, P1109; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Koelsch BU, 2002, CARCINOGENESIS, V23, P1033, DOI 10.1093/carcin/23.6.1033; Lan H, 1999, MAMM GENOME, V10, P687, DOI 10.1007/s003359901071; Lan H, 2001, GENETICS, V157, P331; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lastowska M, 2004, GENE CHROMOSOME CANC, V40, P158, DOI 10.1002/gcc.20031; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lesueur F, 2005, HUM MOL GENET, V14, P2349, DOI 10.1093/hmg/ddi237; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Newton MA, 2000, BIOMETRICS, V56, P1088, DOI 10.1111/j.0006-341X.2000.01088.x; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NORLANDER C, 2005, CANCER GENET CYTOGEN, V156, P158; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Peto R, 2000, NEW ENGL J MED, V343, P1495; Phelan CM, 1998, CANCER RES, V58, P1004; Ponder BAJ, 2005, BREAST CANCER RES, V7, pS14, DOI 10.1186/bcr1083; Samuelson DJ, 2005, CANCER RES, V65, P9637, DOI 10.1158/0008-5472.CAN-05-1498; Samuelson DJ, 2003, CARCINOGENESIS, V24, P1455, DOI 10.1093/carcin/bgg112; Shepel LA, 1998, GENETICS, V149, P289; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Toyota M, 1996, MOL CARCINOGEN, V15, P176, DOI 10.1002/(SICI)1098-2744(199603)15:3<176::AID-MC3>3.0.CO;2-G; Yu MS, 2000, MOL CARCINOGEN, V27, P76, DOI 10.1002/(SICI)1098-2744(200002)27:2<76::AID-MC3>3.0.CO;2-7	32	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5011	5017		10.1038/sj.onc.1209506	http://dx.doi.org/10.1038/sj.onc.1209506			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568087				2022-12-17	WOS:000239921300006
J	Uenoyama, Y; Seno, H; Fukuda, A; Sekikawa, A; Nanakin, A; Sawabu, T; Kawada, M; Kanda, N; Suzuki, K; Yada, N; Fukui, H; Chiba, T				Uenoyama, Y.; Seno, H.; Fukuda, A.; Sekikawa, A.; Nanakin, A.; Sawabu, T.; Kawada, M.; Kanda, N.; Suzuki, K.; Yada, N.; Fukui, H.; Chiba, T.			Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway	ONCOGENE			English	Article						colorectal tumor; fibroblast; cell density	EPIDERMAL-GROWTH-FACTOR; NF-KAPPA-B; PROSTAGLANDIN E-2; GENE-EXPRESSION; UP-REGULATION; CANCER CELLS; COLORECTAL ADENOMAS; SIGNALING PATHWAYS; C-JUN; ANGIOGENESIS	Cyclooxygenase-2 (COX-2) plays important roles in tumor development. Especially in the early-stage colorectal tumors, COX-2 expression is often observed in the tumor stroma. However, the mechanism regulating such stromal expression of COX-2 remains unknown. In the present study, we simulated the indirect interaction between epithelial cells and stromal cells in the process of colorectal tumor development using an in vitro co-culture model in which NIH3T3 fibroblasts were co-cultured with 'sparsely' or 'densely' populated intestinal epithelial cells, Intestine-407 as a model of premalignant or benign intestinal epithelial cells, and DLD-1 and Caco-2 as models of malignant epithelial cells. COX-2 expression in NIH3T3 fibroblasts was upregulated when co-cultured with the 'dense' epithelial cells regardless of their character. Interestingly, there was pericellular hypoxia in the vicinity of NIH3T3 fibroblasts when cocultured with 'dense' epithelial cells, and the recovery of the partial pressure of oxygen level resulted in the reduction of enhanced COX-2 expression only in NIH3T3 fibroblasts co-cultured with 'dense' Intestine-407 cells. Furthermore, COX-2 expression was also reduced by the inhibition of transcription factor AP-1. Thus, pericellular hypoxia of the stromal cells caused by densely populated epithelial cells may be one of the potent COX-2 enhancers before completion of malignant transformation during intestinal tumor development.	Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Seno, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin Kawara Cho 54, Kyoto 6068507, Japan.	seno@kuhp.kyoto-u.ac.jp		Seno, Hiroshi/0000-0002-8509-8128				BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Boman BM, 2004, AM J PATHOL, V165, P1489, DOI 10.1016/S0002-9440(10)63407-4; Chapple KS, 2002, J PATHOL, V198, P435, DOI 10.1002/path.1223; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Fujita T, 1998, CANCER RES, V58, P4823; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Han C, 2004, J BIOL CHEM, V279, P44344, DOI 10.1074/jbc.M404852200; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; Jobin C, 1997, J IMMUNOL, V158, P226; Kawada M, 2003, DIGESTION, V67, P20, DOI 10.1159/000069708; Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200; Kim HJ, 2004, J INVEST DERMATOL, V123, P547, DOI 10.1111/j.0022-202X.2004.23317.x; Ko SC, 2002, ONCOGENE, V21, P7175, DOI 10.1038/sj.onc.1205869; Kondoh N, 1999, CANCER RES, V59, P4990; Li QF, 2004, CANCER RES, V64, P7078, DOI 10.1158/0008-5472.CAN-04-1152; Liu WV, 2003, CANCER RES, V63, P3632; LU YP, 1994, CARCINOGENESIS, V15, P2363, DOI 10.1093/carcin/15.10.2363; Masferrer JL, 2000, CANCER RES, V60, P1306; Montano X, 2004, FEBS LETT, V571, P1, DOI 10.1016/j.febslet.2004.06.088; Nordsmark M, 1996, RADIOTHER ONCOL, V41, P31, DOI 10.1016/S0167-8140(96)91811-3; Oshima M, 2005, BIOCHEM BIOPH RES CO, V330, P928, DOI 10.1016/j.bbrc.2005.03.060; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park CH, 2005, J BIOCHEM MOL BIOL, V38, P474; Preston SL, 2003, CANCER RES, V63, P3819; Ricchi P, 2003, BRIT J CANCER, V88, P803, DOI 10.1038/sj.bjc.6600829; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Seno H, 2002, CANCER RES, V62, P506; Sheares KKK, 2004, AM J PHYSIOL-LUNG C, V287, pL919, DOI 10.1152/ajplung.00012.2004; Sheta EA, 2001, ONCOGENE, V20, P7624, DOI 10.1038/sj.onc.1204972; Slice LW, 2005, J BIOL CHEM, V280, P1582, DOI 10.1074/jbc.M408172200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sol VVD, 2005, J IMMUNOL, V174, P2825, DOI 10.4049/jimmunol.174.5.2825; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Tanaka Y, 2004, J BIOL CHEM, V279, P8567, DOI 10.1074/jbc.M309131200; Tokuda Y, 2000, J CELL PHYSIOL, V182, P414, DOI 10.1002/(SICI)1097-4652(200003)182:3<414::AID-JCP12>3.0.CO;2-5; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wu GF, 2003, AM J PHYSIOL-HEART C, V285, pH2420, DOI 10.1152/ajpheart.00187.2003; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang KX, 2004, MOL CANCER RES, V2, P242	47	6	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3277	3285		10.1038/sj.onc.1209359	http://dx.doi.org/10.1038/sj.onc.1209359			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16407821	Green Submitted			2022-12-17	WOS:000237951200006
J	Heyninck, K; Beyaert, R				Heyninck, K; Beyaert, R			A novel link between Lck, Bak expression and chemosensitivity	ONCOGENE			English	Editorial Material						apoptosis; chemotherapy; Bcl-2 family; Lck	TYROSINE KINASE LCK; NF-KAPPA-B; APOPTOSIS; INVOLVEMENT; ACTIVATION; P56(LCK); LIGAND; GENE; P53	Protein kinases are critically involved in signaling pathways that regulate cell growth, differentiation, activation, and survival. Lck, a member of the Src family of protein tyrosine kinases, plays a key role in T-lymphocyte activation and differentiation. However, under certain conditions Lck is also involved in the induction of apoptosis. In Oncogene volume 25 pages 186 - 197, Samraj et al. used the Lck-defective JCaM1.6 cell line to demonstrate the critical role of Lck in the apoptotic response of T-cell leukemia cells to several chemotherapeutic drugs. They further showed that Lck controls the mitochondrial death pathway by regulating proapoptotic Bak expression. This chemosensitizing effect of Lck is independent of T-cell receptor signaling and does not require the kinase activity of Lck. These findings demonstrate that Lck might be part of two independent signaling pathways leading to either cell proliferation or apoptosis, and reveal a hitherto unrecognized link between Lck, Bak, and chemosensitivity of human leukemic cells.	State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University	Beyaert, R (corresponding author), State Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, Technol Pk 927, B-9052 Ghent, Belgium.	rudi.beyaert@dmbr.ugent.be	Beyaert, Rudi/B-2589-2009	Beyaert, Rudi/0000-0002-5704-582X				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hur YG, 2004, J IMMUNOL, V172, P79, DOI 10.4049/jimmunol.172.1.79; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; Manna SK, 2000, J BIOL CHEM, V275, P13297, DOI 10.1074/jbc.275.18.13297; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; Rouer E, 1999, ONCOGENE, V18, P4262, DOI 10.1038/sj.onc.1202720; Samraj AK, 2006, ONCOGENE, V25, P186, DOI 10.1038/sj.onc.1209034; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060	20	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1693	1695		10.1038/sj.onc.1209157	http://dx.doi.org/10.1038/sj.onc.1209157			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16186791				2022-12-17	WOS:000236013700001
J	Godon, C; Coullet, S; Baus, B; Alonso, B; Davin, AH; Delcuze, Y; Marchetti, C; Hainaut, P; Kazmaier, M; Quemeneur, E				Godon, C; Coullet, S; Baus, B; Alonso, B; Davin, AH; Delcuze, Y; Marchetti, C; Hainaut, P; Kazmaier, M; Quemeneur, E			Quantitation of p53 nuclear relocation in response to stress using a yeast functional assay: effects of irradiation and modulation by heavy metal ions	ONCOGENE			English	Article						p53; genotoxic stress; nuclear relocation	TUMOR-SUPPRESSOR PROTEIN; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; EXPORT SIGNAL; DNA-DAMAGE; IN-VIVO; LOCALIZATION; ACTIVATION; GENE; YAP1	Many regulatory proteins undergo transient nuclear relocation under physical or chemical stress. This phenomenon is, however, difficult to assess due to the lack of sensitive and standardized biological assays. Here, we describe a new quantitative nuclear relocation assay (QNR), based on expression in yeasts of chimeric proteins in which an artificial transcription factor is fused to a target protein acting as driver for relocation. This assay combines the experimental versatility of yeast with quantitation of nuclear relocation at low levels of protein expression. We have assessed the nuclear relocation of yeast Yap1 and human p53, two transcription factors that relocate to the nucleus in response to oxidative-stress and DNA damage, respectively. We show that p53 efficiently drives the relocation of the chimeric reporter in response to irradiation and that this process requires the C-terminal nuclear export signal (NES). Cd2+ and Hg2+, two metal ions inducing DNA damage as well as conformational changes in p53, have opposite effects on p53 relocation in response to DNA damage. Whereas Hg2+ effects are synergistic to DNA damage, Cd2+ inhibits relocation and sequesters p53 into the cytoplasm. These results demonstrate the effectiveness of QNR to investigate the regulation of p53 shuttling in response to stress signals including suspected environmental carcinogens.	CEA Valrho, DSV, DIEP, SBTN, F-30207 Bagnols Sur Ceze, France; CEN Cadarache, DSV, DEVM, LBC, F-13108 St Paul Les Durance, France; IARC Lyon, Unit Mol Carcinogenesis, F-69372 Lyon, France	CEA; CEA; World Health Organization; International Agency for Research on Cancer (IARC)	Godon, C (corresponding author), CEA Valrho, DSV, DIEP, SBTN, F-30207 Bagnols Sur Ceze, France.	christian.godon@cea.fr	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Delaunay A, 2002, CELL, V111, P471, DOI 10.1016/S0092-8674(02)01048-6; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FRITSCHE M, 1993, ONCOGENE, V8, P307; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kitagawa K, 2002, BIOTECHNIQUES, V33, P288, DOI 10.2144/02332bm07; Klibanov SA, 2001, J CELL SCI, V114, P1867; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kungolos A, 1999, ECOTOX ENVIRON SAFE, V43, P149, DOI 10.1006/eesa.1999.1767; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; O'Keefe K, 2003, MOL CELL BIOL, V23, P6396, DOI 10.1128/MCB.23.18.6396-6405.2003; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sutton DJ, 2002, INT J MOL SCI, V3, P965, DOI 10.3390/i3090965; Waalkes MP, 2003, MUTAT RES-FUND MOL M, V533, P107, DOI 10.1016/j.mrfmmm.2003.07.011; WU AL, 1993, J BIOL CHEM, V268, P18850; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	28	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 22	2005	24	42					6459	6464		10.1038/sj.onc.1208785	http://dx.doi.org/10.1038/sj.onc.1208785			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007197				2022-12-17	WOS:000232038200013
J	Tamguney, G; Van Snick, J; Fickenscher, H				Tamguney, G; Van Snick, J; Fickenscher, H			Autocrine stimulation of rhadinovirus-transformed T cells by the chemokine CCL1/I-309	ONCOGENE			English	Article						autocrine loop; growth transformation; rhadinovirus; suppressive subtractive hybridization T lymphocyte	VIRUS TYPE-I; DEXAMETHASONE-INDUCED APOPTOSIS; SAIMIRI PROTEIN TIP; SUBGROUP-C STRAINS; HERPESVIRUS-SAIMIRI; MOLECULAR-CLONING; RECEPTOR CCR8; MONOCYTE CHEMOATTRACTANT; GROWTH TRANSFORMATION; ONCOPROTEIN STP-C488	The rhadinovirus herpesvirus saimiri transforms human T lymphocytes to stable growth in culture. Besides the viral oncogenes stpC and tip, little is understood about the transformation process at the cellular level. To identify cellular factors that might contribute to growth transformation, we compared cellular gene expression in pairs of herpesvirus saimiri-transformed and nontransformed human T-cell clones. Using cDNA arrays and suppressive subtractive hybridization, we were able to identify the chemokine CCL1/I-309 as one of the few cellular genes that are strongly overexpressed in T cells after growth transformation with herpesvirus saimiri. The transformed T cells expressed CCR8, the receptor for CCL1, which rapidly induced intracellular calcium ion levels. Neutralizing antibodies to CCL1 led to reduced secretion of interferon-gamma and tumor necrosis factor-alpha as well as to reduced proliferation rates in transformed T cells. Thus, we propose that growth transformation of human T cells with herpesvirus saimiri gives rise to an autocrine loop where the proliferation of transformed T cells is supported by the endogenous production of the chemokine CCL1.	Univ Heidelberg, Dept Virol, D-69120 Heidelberg, Germany; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Catholique Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Univ Catholique Louvain, Expt Med Unit, B-1200 Brussels, Belgium	Ruprecht Karls University Heidelberg; University of California System; University of California San Francisco; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain	Fickenscher, H (corresponding author), Univ Heidelberg, Dept Virol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	helmut.fickenscher@med.uni-heidelberg.de	Fickenscher, Helmut/A-3004-2010; Tamgüney, Gültekin/T-6333-2019; Fickenscher, Helmut/J-9655-2019	Tamgüney, Gültekin/0000-0002-6933-5154; Fickenscher, Helmut/0000-0003-0043-1153				BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BROKER BM, 1993, J IMMUNOL, V151, P1184; BURD PR, 1987, J IMMUNOL, V139, P3126; Colantonio L, 2002, EUR J IMMUNOL, V32, P3506, DOI 10.1002/1521-4141(200212)32:12<3506::AID-IMMU3506>3.0.CO;2-#; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; DECARLI M, 1993, J IMMUNOL, V151, P5022; DELPRETE G, 1994, J IMMUNOL, V153, P4872; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duboise SM, 1998, J VIROL, V72, P1308, DOI 10.1128/JVI.72.2.1308-1313.1998; Fickenscher H, 2002, METHOD MICROBIOL, V32, P657; Fickenscher H, 1997, J VIROL, V71, P2252, DOI 10.1128/JVI.71.3.2252-2263.1997; Fickenscher H, 1996, J VIROL, V70, P6012, DOI 10.1128/JVI.70.9.6012-6019.1996; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; Goya I, 1998, J IMMUNOL, V160, P1975; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Hartley DA, 2000, J BIOL CHEM, V275, P16925, DOI 10.1074/jbc.M000709200; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; INATSUKI A, 1989, J IMMUNOL, V143, P1327; Inngjerdingen M, 2000, J IMMUNOL, V164, P4048, DOI 10.4049/jimmunol.164.8.4048; JUNG JU, 1991, J VIROL, V65, P6953, DOI 10.1128/JVI.65.12.6953-6960.1991; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1995, MOL CELL BIOL, V15, P6506; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Knappe A, 1997, J VIROL, V71, P9124, DOI 10.1128/JVI.71.12.9124-9133.1997; Kraft MS, 1998, J VIROL, V72, P3138, DOI 10.1128/JVI.72.4.3138-3145.1998; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; Louahed J, 2003, EUR J IMMUNOL, V33, P494, DOI 10.1002/immu.200310025; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Mackewicz CE, 1997, CLIN IMMUNOL IMMUNOP, V82, P274, DOI 10.1006/clin.1996.4292; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; MITTRUCKER HW, 1992, J EXP MED, V176, P909, DOI 10.1084/jem.176.3.909; MURPHY C, 1994, ONCOGENE, V9, P221; Napolitano M, 1996, J IMMUNOL, V157, P2759; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; Samson M, 1996, EUR J IMMUNOL, V26, P3021, DOI 10.1002/eji.1830261230; Schrum S, 1996, J IMMUNOL, V157, P3598; Sebastiani S, 2001, J IMMUNOL, V166, P996, DOI 10.4049/jimmunol.166.2.996; Spinetti G, 2003, J LEUKOCYTE BIOL, V73, P201, DOI 10.1189/jlb.0302105; VanSnick J, 1996, J IMMUNOL, V157, P2570; Wehner LE, 2001, DNA CELL BIOL, V20, P81, DOI 10.1089/104454901750070283; Wiese N, 1996, J BIOL CHEM, V271, P847, DOI 10.1074/jbc.271.2.847; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YASUKAWA M, 1995, J VIROL, V69, P8114, DOI 10.1128/JVI.69.12.8114-8117.1995; YSSEL H, 1989, J IMMUNOL, V142, P2279; Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595; Zingoni A, 1998, J IMMUNOL, V161, P547	56	6	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8475	8485		10.1038/sj.onc.1207903	http://dx.doi.org/10.1038/sj.onc.1207903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15378023				2022-12-17	WOS:000224870700008
J	Ishii, H; Vecchione, A; Furukawa, Y; Croce, CM; Huebner, K; Fong, LYY				Ishii, H; Vecchione, A; Furukawa, Y; Croce, CM; Huebner, K; Fong, LYY			Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats	ONCOGENE			English	Article						esophagus; apoptosis; gene expression analysis; zinc replenishment	CELL-PROLIFERATION; N-NITROSOMETHYLBENZYLAMINE; CANCER; INDUCTION; CARCINOGENESIS; PROGRESSION; METABOLISM; ALCOHOL; DEATH; LINE	Zinc deficiency (ZD) in rats increases esophageal cell proliferation and the incidence of N-nitrosomethylbenzylamine-induced esophageal tumors. Conversely, zinc replenishment (ZR) rapidly induces apoptosis in esophageal epithelia and reverses cancer development. We investigated gene expression changes in ZR versus ZD esophageal epithelia to identify differentially expressed genes associated with the antitumor effect of ZR. Weanling rats were fed a ZD diet for 6 weeks to establish esophageal cell proliferation or a zinc-sufficient (ZS) diet. Then, 10 ZD rats were treated with zinc gluconate intragastrically and switched to ZS diet; the remaining 10 ZD and ZS animals were treated with saline. All animals were killed 26-28 h later. Using cDNA microarrays, real-time polymerase chain reaction amplification and RNA hybridization techniques, we identified novel differentially expressed genes, including a RNA-binding protein with two RNA recognition motifs and a zinc knuckle (ZD7), and a DNA/RNA helicase with a DEAD box (ZD10) with two splice variants, ZD10a and ZD10b. In situ hybridization detected increased mRNA expression of ZD7, ZD10a and ZD10b in ZR esophageal epithelia, which displayed markedly increased occurrence of apoptotic cells, relative to ZD epithelia. Overexpression of ZD7 in human esophageal cancer cells resulted in induction of apoptosis and activation of caspase-3 and -7, activities that were inhibited by caspase-specific inhibitors. In addition, ZD7 mRNA levels and zinc-induced apoptosis in rat squamous carcinoma cells were reduced by specific small interfering ribonucleic acids. Thus, ZR rapidly induces ZD7 and ZD10 expression, which in turn stimulates apoptosis. These results provide the beginnings of a molecular pathway for zinc-induced apoptosis under conditions that reverse esophageal tumor initiation.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Jichi Med Sch, Ctr Mol Med, Minami Kawachi, Tochigi 3290498, Japan	Jefferson University; Jichi Medical University	Fong, LYY (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, 1020 Locust St, Philadelphia, PA 19107 USA.	L_Fong@mail.jci.tju.edu	Furukawa, Yusuke/Y-1342-2018; Young, Richard A/F-6495-2012	Furukawa, Yusuke/0000-0002-7249-6418; Young, Richard A/0000-0001-8855-8647; Vecchione, Andrea/0000-0002-5497-6856; Fong, Louise/0000-0001-7654-7035	NCI NIH HHS [CA56036, CA77738] Funding Source: Medline; NIDCR NIH HHS [P01 DE12467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BARCH DH, 1984, CANCER RES, V44, P5629; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Cintorino M, 2001, ANTICANCER RES, V21, P4195; COIA LR, 1994, CURR PROB CANCER, V18, P189; Cousins RJ, 2003, J NUTR, V133, p1521S, DOI 10.1093/jn/133.5.1521S; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; Didenko Vladimir V, 2002, Methods Mol Biol, V203, P143; Didenko VV, 1998, AM J PATHOL, V152, P897; Dieck HT, 2003, J NUTR, V133, P1004, DOI 10.1093/jn/133.4.1004; Fong LYY, 1999, CANCER LETT, V143, P63, DOI 10.1016/S0304-3835(99)00191-3; Fong LYY, 2003, CANCER RES, V63, P186; Fong LYY, 2001, JNCI-J NATL CANCER I, V93, P1525, DOI 10.1093/jnci/93.20.1525; Fong LYY, 1996, CARCINOGENESIS, V17, P1841, DOI 10.1093/carcin/17.9.1841; FONG LYY, 1978, J NATL CANCER I, V61, P145, DOI 10.1093/jnci/61.1.145; Fong LYY, 2000, CANCER RES, V60, P4589; Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229, DOI 10.3181/00379727-215-44132; GABRIAL GN, 1982, J NATL CANCER I, V68, P785; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Ishii H, 2001, CANCER RES, V61, P1578; Kadkol Shrihari, 2003, Methods Mol Biol, V223, P51; Kindermann B, 2004, J NUTR, V134, P57, DOI 10.1093/jn/134.1.57; Lu S H, 1991, IARC Sci Publ, P11; LU SH, 1986, J CELL PHYSIOL, P51; MAGEE PN, 1989, CANCER SURV, V8, P207; Moore JB, 2003, P NATL ACAD SCI USA, V100, P3883, DOI 10.1073/pnas.0330670100; Newberne PM, 1997, PATHOBIOLOGY, V65, P39, DOI 10.1159/000164101; Nodera M, 2001, LIFE SCI, V69, P1639, DOI 10.1016/S0024-3205(01)01252-8; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; SUNDERMAN FW, 1995, ANN CLIN LAB SCI, V25, P134; Truong-Tran AQ, 2000, J NUTR, V130, p1459S, DOI 10.1093/jn/130.5.1459S; VANRENSBURG SJ, 1981, J NATL CANCER I, V67, P243; YANG CS, 1980, CANCER RES, V40, P2633	33	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8040	8048		10.1038/sj.onc.1207974	http://dx.doi.org/10.1038/sj.onc.1207974			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361827				2022-12-17	WOS:000224692500002
J	Walters, DK; Jelinek, DF				Walters, DK; Jelinek, DF			A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells	ONCOGENE			English	Article						Jak1; Tyk2; ErbB3; interferon-alpha; multiple myeloma	TYROSINE KINASE; BREAST-CANCER; MULTIPLE-MYELOMA; RECEPTOR; EXPRESSION; LEUKEMIA; OVEREXPRESSION; INTERLEUKIN-6; ACTIVATION; RESPONSES	Receptor crosstalk is an emerging and recurrent theme in cytokine and growth factor signaling; however, insight into the mechanism(s) underlying these interactions remains limited. Recently, we reported that crosstalk occurs between ErbB3 and the interferon alpha (IFN-alpha) signaling complex in the myeloma cell line KAS-6/1 and that this crosstalk contributes to the regulation of cell proliferation. In this study, we examined the mechanism underlying the transactivation of ErbB3 in the IFN-alpha growth-responsive KAS-6/1 cells. The examination of IFN-alpha receptor 1 and 2 (IFNAR1 and IFNAR2) levels revealed that the KAS-6/1 cell line overexpresses IFNAR1 relative to other myeloma cell lines that are growth arrested by IFN-alpha. Subsequent investigation of Tyk2, which is constitutively associated with IFNAR1, demonstrated that Tyk2 activation is uniquely sustained in the KAS-6/1 cell line following IFN-alpha stimulation. Interestingly, silencing of Tyk2 expression via siRNA resulted in attenuation of ErbB3 transactivation. However, inhibit ion of Jak1 expression also decreased IFN-alpha-induced tyrosine phosphorylation of ErbB3. Finally, siRNA downregulation of Tyk2 and Jak1 was found to decrease IFN-alpha-stimulated proliferation. These findings validate our previous report of ErbB3 involvement in IFN-alpha-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Jelinek, DF (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	jelinek.diane@mayo.edu			NCI NIH HHS [CA62228, CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062228, R55CA062228, P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arora T, 1999, J IMMUNOL, V162, P3289; BLADE J, 1991, BRIT J HAEMATOL, V79, P523, DOI 10.1111/j.1365-2141.1991.tb08068.x; BOUNDY V, 2002, NEOPLASMA, V49, P349; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; BUHRING HJ, 1995, BLOOD, V86, P1916, DOI 10.1182/blood.V86.5.1916.bloodjournal8651916; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DiGiovanna MP, 2002, CANCER RES, V62, P6667; Dondi E, 2001, J BIOL CHEM, V276, P47004, DOI 10.1074/jbc.M104316200; Dumont JE, 2001, CELL SIGNAL, V13, P457, DOI 10.1016/S0898-6568(01)00168-1; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; JELINEK DF, 2003, HEMATOL J, V4, pS37; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Kuhn DJ, 2003, J CELL BIOCHEM, V89, P824, DOI 10.1002/jcb.10557; Long IS, 2003, MOL CANCER RES, V1, P393; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; SAWAMURA M, 1992, BRIT J HAEMATOL, V82, P631, DOI 10.1111/j.1365-2141.1992.tb06484.x; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Walters DK, 2003, ONCOGENE, V22, P3598, DOI 10.1038/sj.onc.1206512; Walters DK, 2002, ANTISENSE NUCLEIC A, V12, P411, DOI 10.1089/108729002321082483; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	30	6	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1197	1205		10.1038/sj.onc.1207203	http://dx.doi.org/10.1038/sj.onc.1207203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647450				2022-12-17	WOS:000188892200003
J	Debruyne, PR; Vermeulen, SJ; Berx, G; Pocard, M; da Rocha, ASC; Li, XD; Cirnes, L; Poupon, MF; van Roy, FM; Mareel, MM				Debruyne, PR; Vermeulen, SJ; Berx, G; Pocard, M; da Rocha, ASC; Li, XD; Cirnes, L; Poupon, MF; van Roy, FM; Mareel, MM			Functional and molecular characterization of the epithelioid to round transition in human colorectal cancer LoVo cells	ONCOGENE			English	Article						colorectal cancer; E-cadherin/catenin complex; invasion; morphotype	INVASION-SUPPRESSOR GENE; E-CADHERIN EXPRESSION; ALPHA-CATENIN; BETA-CATENIN; CPG ISLAND; ADHESION; GROWTH; METHYLATION; ACTIVATION; DIFFERENTIATION	In subclones of the human colon cancer LoVo cell line, there is a reproducible spontaneous transition from an epithelioid (E) to a round (R) morphotype. The E to R transition is associated with increased cell growth, absence of E-cadherin-dependent compaction in a slow aggregation assay, loss of contact inhibition of motility and directional migration in a wound filling motility assay. Furthermore, none of the E subclones from LoVo was invasive into chick heart fragments. This is in contrast to the R subclones that were either nonadherent or adherent and invasive. Macroarray analysis demonstrated transcriptional downregulation of plakoglobin in R type LoVo cells and this was confirmed at the level of the mRNA by quantitative RT-PCR. Western blotting showed lower expression of all components of the E-cadherin/catenin complex in R subclones. Interestingly, treatment of R subclones with the demethylating agent 5-aza-2'-deoxycytidine resulted in restoration of the E morphotype, higher expression of E-cadherin, but not plakoglobin mRNA, and higher expression of E-cadherin and plakoglobin at the protein level.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; VIB Univ Ghent, Dept Mol Biol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Inst Curie, CNRS, UMR Cytogenet Mol & Oncol 147, Sect Rech, F-75231 Paris 05, France; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal	Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Ghent University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universidade do Porto	Mareel, MM (corresponding author), Ghent Univ Hosp 1P7, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	marc.mareel@rug.ac.be	van Roy, Frans M/C-6123-2009; Debruyne, Philip/AAU-6685-2021	van Roy, Frans M/0000-0003-4358-1039; Debruyne, Philip/0000-0001-5438-9697; Berx, Geert/0000-0001-5770-2458				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; AZNAVOORIAN S, 1990, J NATL CANCER I, V82, P1485, DOI 10.1093/jnci/82.18.1485; Bieche I, 1999, CANCER RES, V59, P2759; Boterberg T, 2001, Methods Mol Med, V58, P33, DOI 10.1385/1-59259-137-X:033; BOUKAMP P, 1993, J CELL BIOL, V120, P981, DOI 10.1083/jcb.120.4.981; Bracke M E, 2001, Methods Mol Med, V58, P91, DOI 10.1385/1-59259-137-X:091; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Chen HY, 1997, J CELL SCI, V110, P345; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cowell HE, 1999, INT J CANCER, V80, P455; Daemi N, 2000, INT J CANCER, V85, P850, DOI 10.1002/(SICI)1097-0215(20000315)85:6<850::AID-IJC19>3.0.CO;2-B; Daemi N, 1995, INVAS METAST, V15, P103; DREWINKO B, 1976, CANCER RES, V36, P467; Dumortier J, 1998, DIFFERENTIATION, V63, P141, DOI 10.1046/j.1432-0436.1998.6330141.x; FISH EM, 1994, NEW ENGL J MED, V330, P1580; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KINSELLA AR, 1994, CLIN EXP METASTAS, V12, P335, DOI 10.1007/BF01753841; Lehmann M, 1998, ENDOCRINOLOGY, V139, P3763, DOI 10.1210/en.139.9.3763; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Leroy A, 2000, FASEB J, V14, P1139, DOI 10.1096/fasebj.14.9.1139; MAREEL M, 1981, CELL BIOL INT REP, V5, P921, DOI 10.1016/0309-1651(81)90207-1; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; MAREEL MM, 1986, NEW FRONTIERS MAMMAR, P351; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Orsulic S, 2000, J CELL SCI, V113, P1793; Pocard M, 2001, DIS COLON RECTUM, V44, P1106, DOI 10.1007/BF02234630; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; REMY L, 1992, INT J CANCER, V51, P204, DOI 10.1002/ijc.2910510207; Sgambato A, 1998, CANCER RES, V58, P3448; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TOMITA N, 1992, CANCER RES, V52, P6840; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Van Hoorde L, 2000, INT J CANCER, V88, P751, DOI 10.1002/1097-0215(20001201)88:5<751::AID-IJC11>3.0.CO;2-B; VandenBroecke C, 1996, CLIN EXP METASTAS, V14, P282, DOI 10.1007/BF00053902; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; Vermeulen SJ, 1999, CLIN EXP METASTAS, V17, P663, DOI 10.1023/A:1006724300022; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	48	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7199	7208		10.1038/sj.onc.1206628	http://dx.doi.org/10.1038/sj.onc.1206628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562048				2022-12-17	WOS:000185955000011
J	Kovalchuk, AL; Kim, JS; Janz, S				Kovalchuk, AL; Kim, JS; Janz, S			E mu/S mu transposition into Myc is sometimes a precursor for T(12;15) translocation in mouse B cells	ONCOGENE			English	Article						genetic transposition; immunoglobulin heavy-chain locus; intronic heavy-chain enhancer; immunoglobulin switch region; chromosomal translocation	CLASS-SWITCH RECOMBINATION; HEAVY-CHAIN GENE; VISIBLE CHROMOSOMAL TRANSLOCATIONS; C-MYC; MURINE PLASMACYTOMA; MULTIPLE-MYELOMA; ABERRANT REARRANGEMENT; IMMUNOGLOBULIN; REGION; ENHANCER	Misguided immunoglobulin (Ig) class switch recombination (CSR) has been implicated in the origin of Myc-activating chromosomal translocations, T(12;15), in BALB/c mouse plasmacytomas (PCTs). CSR has also been involved in the progression of T(12;15); for example, the approximation of Myc to the 3'-Calpha enhancer. This study provides evidence for an additional mechanism by which aberrant CSR may facilitate T(12;15): transposition of Ig heavy-chain (IgH) sequences to Myc. Five IgH transposons containing the intronic heavy-chain enhancer, Emu, and a truncated switch mu region, Smu, were found in the first intron of Myc in lymph node cells of IL-6 transgenic BALB/c mice. In two cases Emu/Smu transposition primed Myc to get involved in apparent trans-chromosomal CSR to Cgamma1, presumably leading to T(12;15). Translocations preceded by Emu/Smu transposition can sometimes be distinguished from de novo translocations by molecular fingerprints in translocation breakpoint regions (Ig switch region [S] inversions and unusual gene orders in composite S regions). The presence of such fingerprints in some PCTs suggests that the tumors sometimes evolve from transposition-bearing precursors. We propose that Emu/Smu transposition to Myc may facilitate plasmacytomagenesis by sensitizing Myc to undergo T(12;15) translocation. T(12;15), in turn, juxtaposes Myc to the 3'-Calpha enhancer, which appears to be required for deregulating Myc in a manner that is conducive to PCT development.	NCI, Genet Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Genet Lab, Ctr Canc Res, NIH, Bldg 37,Room 2B10, Bethesda, MD 20892 USA.			Kovalchuk, Alexander/0000-0003-2761-0442	DIVISION OF BASIC SCIENCES - NCI [Z01BC010024] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUILERA RJ, 1985, EMBO J, V4, P3689, DOI 10.1002/j.1460-2075.1985.tb04136.x; AXELSON H, 1991, ONCOGENE, V6, P2263; Bakkus MHC, 2001, LEUKEMIA, V15, P1127, DOI 10.1038/sj.leu.2402164; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; Chen C, 1995, IMMUNITY, V3, P747, DOI 10.1016/1074-7613(95)90064-0; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; Crossen PE, 1998, LEUKEMIA LYMPHOMA, V31, P559, DOI 10.3109/10428199809057615; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; Gabrea A, 1999, MOL CELL, V3, P119, DOI 10.1016/S1097-2765(00)80180-X; Geltinger C, 1996, GENE EXPRESSION, V6, P113; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; GREENBERG R, 1982, NUCLEIC ACIDS RES, V10, P7751, DOI 10.1093/nar/10.23.7751; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; JANZ S, 1993, P NATL ACAD SCI USA, V90, P7361, DOI 10.1073/pnas.90.15.7361; Janz S, 1995, Curr Top Microbiol Immunol, V194, P373; Kovalchuk AL, 2000, LEUKEMIA, V14, P1127, DOI 10.1038/sj.leu.2401767; Kovalchuk AL, 1997, ONCOGENE, V15, P2369, DOI 10.1038/sj.onc.1201409; Kovalchuk AL, 2000, LEUKEMIA, V14, P909, DOI 10.1038/sj.leu.2401676; Kovalchuk AL, 2002, P NATL ACAD SCI USA, V99, P1509, DOI 10.1073/pnas.022643999; Kovalchuk AL, 2001, GENE CHROMOSOME CANC, V30, P283, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1094>3.0.CO;2-I; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LAFFAN M, 1992, J CLIN INVEST, V90, P2299, DOI 10.1172/JCI116117; Lee CG, 1998, CURR BIOL, V8, P227, DOI 10.1016/S0960-9822(98)70087-9; Luby TM, 2001, J EXP MED, V193, P159, DOI 10.1084/jem.193.2.159; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muller JR, 1996, CANCER RES, V56, P419; Muller JR, 1997, BLOOD, V89, P291, DOI 10.1182/blood.V89.1.291.291_291_296; MULLER JR, 1995, CANCER RES, V55, P5012; MULLER JR, 1994, P NATL ACAD SCI USA, V91, P12066, DOI 10.1073/pnas.91.25.12066; MURAMATSU M, 2000, CELL, DOI UNSP 102553; Nardini E, 2000, BLOOD, V95, P1032, DOI 10.1182/blood.V95.3.1032.003k38_1032_1038; OHNO S, 1989, ONCOGENE, V4, P1513; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Papavasiliou FN, 2002, CELL, V109, pS35, DOI 10.1016/S0092-8674(02)00706-7; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; PEAR WS, 1986, IMMUNOGENETICS, P23393; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Pratt G, 2001, BRIT J HAEMATOL, V112, P388, DOI 10.1046/j.1365-2141.2001.02588.x; Proffitt J, 1999, LEUKEMIA, V13, P1100, DOI 10.1038/sj.leu.2401465; RAYNAL MC, 1989, P NATL ACAD SCI USA, V86, P8024, DOI 10.1073/pnas.86.20.8024; Roschke V, 1997, ONCOGENE, V14, P3011, DOI 10.1038/sj.onc.1201156; SHAPIRO MA, 1987, MOL CELL BIOL, V7, P4130, DOI 10.1128/MCB.7.11.4130; SHAUGHNESSY JD, 1993, ONCOGENE, V8, P3111; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; Vaandrager JW, 2000, BLOOD, V96, P1947, DOI 10.1182/blood.V96.5.1947.h8001947_1947_1952; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; ZHANG K, 1995, J IMMUNOL, V154, P2237	53	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2842	2850		10.1038/sj.onc.1206345	http://dx.doi.org/10.1038/sj.onc.1206345			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743607				2022-12-17	WOS:000182569300015
J	Gingras, B; Rodier, G; Giasson, E; Coulombe, P; Chassagne, C; Meloche, S				Gingras, B; Rodier, G; Giasson, E; Coulombe, P; Chassagne, C; Meloche, S			Expression of angiotensin type II receptor downregulates Cdk4 synthesis and inhibits cell-cycle progression	ONCOGENE			English	Article						angiotensin receptor; cell proliferation; cell cycle; CDK4	GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; PHOSPHORYLATION; PROLIFERATION; FIBROBLASTS; ACTIVATION; CLONING	Accumulating evidence suggests that angiotensin II type II (AT(2)) receptor subtype negatively regulates cell proliferation in pathophysiological conditions associated with tissue remodeling. However, the mechanisms through which AT(2) receptor achieves this effect remain poorly understood. In this study, we demonstrate that expression of AT(2) receptor inhibits the proliferation of rat fibroblasts in a ligand-independent manner. The antiproliferative action of AT(2) is dependent on the density of surface receptors. We show that AT(2) receptor expression negatively regulates G1 phase progression in both cycling cells and G0-arrested cells stimulated to re-enter the cell cycle, but has no detectable effect on apoptosis. The delay in cell-cycle progression of AT(2)-expressing cells is associated with downregulation of cyclin E expression, decreased assembly of cyclin E-Cdk2 complexes, and the resulting attenuation of Cdk2 activation. The induction of Cdk4 expression and activity is also markedly attenuated, which likely contributes to the inhibition of cyclin E expression. Ectopic expression of Cdk4 alleviates the proliferation defect of AT2-expressing cells. These findings suggest that the growth-inhibitory effects of the AT(2) receptor are attributable in part to its spontaneous inhibitory action on the cell cycle machinery.	Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada; Univ Paris 07, Hop Lariboisiere, Inst Federat Rech Circulat Paris 7, INSERM,U127, Paris, France	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Meloche, S (corresponding author), Inst Rech Clin Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	melochs@ircm.qc.ca	GIASSON, ELVIO/J-3623-2012	GIASSON, ELVIO/0000-0003-3659-6873; COULOMBE, Philippe/0000-0002-4638-9694; RODIER, Genevieve/0000-0002-9901-639X				Akishita M, 1999, J CLIN INVEST, V103, P63, DOI 10.1172/JCI5182; Allan LA, 2000, MOL CELL BIOL, V20, P1291, DOI 10.1128/MCB.20.4.1291-1298.2000; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Blume A, 2001, CURR OPIN NEPHROL HY, V10, P239, DOI 10.1097/00041552-200103000-00013; BOND RA, 1998, DRUGS PHARM SCI, V89, P363; CHAASSAGNE C, 1995, GENOMICS, V25, P601, DOI 10.1016/0888-7543(95)80072-T; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUDLEY DT, 1993, REGUL PEPTIDES, V44, P199, DOI 10.1016/0167-0115(93)90243-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ewen ME, 2000, GENE DEV, V14, P2265, DOI 10.1101/gad.842100; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Goto M, 1997, HYPERTENSION, V30, P358, DOI 10.1161/01.HYP.30.3.358; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Horiuchi M, 1999, HYPERTENSION, V33, P613, DOI 10.1161/01.HYP.33.2.613; Huang XC, 1996, J BIOL CHEM, V271, P15635, DOI 10.1074/jbc.271.26.15635; Hutchinson HG, 1999, CARDIOVASC RES, V41, P689, DOI 10.1016/S0008-6363(98)00267-3; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Kim S, 2000, PHARMACOL REV, V52, P11; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LAMBERT C, 1995, CIRC RES, V77, P1001, DOI 10.1161/01.RES.77.5.1001; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Maric C, 1998, KIDNEY INT, V53, P92, DOI 10.1046/j.1523-1755.1998.00749.x; Masaki H, 1998, J CLIN INVEST, V101, P527, DOI 10.1172/JCI1885; Matsubara H, 1998, CIRC RES, V83, P1182, DOI 10.1161/01.RES.83.12.1182; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; MELOCHE S, 1986, MOL PHARMACOL, V30, P537; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Miller SJ, 2000, MOL CELL BIOL, V20, P8420, DOI 10.1128/MCB.20.22.8420-8431.2000; Miura SI, 2000, EMBO J, V19, P4026, DOI 10.1093/emboj/19.15.4026; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Nouet S, 2000, TRENDS ENDOCRIN MET, V11, P1, DOI 10.1016/S1043-2760(99)00205-2; Ohkubo N, 1997, CIRCULATION, V96, P3954; Reed SI, 1997, CANCER SURV, V29, P7; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	53	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2633	2642		10.1038/sj.onc.1206346	http://dx.doi.org/10.1038/sj.onc.1206346			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730677				2022-12-17	WOS:000182569000011
J	Feuillet, V; Semichon, M; Restouin, A; Harriague, J; Janzen, J; Magee, A; Collette, Y; Bismuth, G				Feuillet, V; Semichon, M; Restouin, A; Harriague, J; Janzen, J; Magee, A; Collette, Y; Bismuth, G			The distinct capacity of Fyn and Lck to phosphorylate Sam68 in T cells is essentially governed by SH3/SH2-catalytic domain linker interactions	ONCOGENE			English	Article						Fyn; Lck; substrate specificity; T cells; Sam68	PROTEIN-TYROSINE KINASE; SH3 DOMAIN; MICE LACKING; LIPID RAFTS; C-SRC; CRYSTAL-STRUCTURE; BINDING-PROTEIN; KH-DOMAIN; ACTIVATION; FAMILY	Sam68 phosphorylation correlates with Fyn but not Lck expression in T cells. This substrate has been used here to explore the possible basis of the specificity of Fyn versus Lck. We show that this specificity is not based on a spatial segregation of the two kinases, since a chimeric Lck molecule containing the membrane anchoring domain of Fyn does not phosphorylate Sam68. Moreover, a Sam68 molecule targeted to the plasma membrane by the farnesylation signal of c-Ha-Ras remains poorly phosphorylated by Lck. In T cells, Fyn appears to be the active Src kinase in rafts, but Sam68 is not expressed in rafts, and its distinct phosphorylation by Fyn and Lck is not affected by raft dispersion. The Fyn/Lck specificity does not reflect a higher kinase activity of Fyn in general, as both Fyn and Lck are similarly recognized by an anti-active Src antibody. Both also strongly phosphorylate another Src substrate in vivo. Mainly, Lck phosphorylates Sam68 when the interaction between the SH3 domain and the SH2-catalytic domain linker is altered in heterologous Src molecules or after mutating key residues in the linker that increase the accessibility of the SH3 domain. Thus, the distinct potential of Fyn and Lck to phosphorylate Sam68 is likely controlled by the interaction of the kinase SH3 domain with the linker and Sam68, possibly on a competitive binding basis.	Univ Paris 05, Dept Biol Cellulaire, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France; Inst J Paoli I Calmettes, Lab Labellise Ligue Natl Contre Canc, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM U119, F-13009 Marseille, France; Univ London Imperial Coll Sci Technol & Med, Sect Cell & Mol Biol, Div Biomed Sci, Fac Med, London SW7 2AZ, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Imperial College London	Bismuth, G (corresponding author), Univ Paris 05, Dept Biol Cellulaire, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France.		Feuillet, Vincent/P-4988-2017; COLLETTE, Yves/F-2270-2013	Feuillet, Vincent/0000-0003-1898-2527; COLLETTE, Yves/0000-0001-5359-7099; Harriague, Julie/0000-0001-6824-9169				ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; Hiroaki H, 1996, J BIOMOL NMR, V8, P105; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Jabado N, 1998, J IMMUNOL, V161, P2798; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lang V, 1997, EUR J IMMUNOL, V27, P3360, DOI 10.1002/eji.1830271235; Lang V, 1999, J IMMUNOL, V162, P7224; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607	58	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7205	7213		10.1038/sj.onc.1205929	http://dx.doi.org/10.1038/sj.onc.1205929			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370810				2022-12-17	WOS:000178504600008
J	Mey, A; Gandrillon, O; McNagny, KM; Clegg, DO; Samarut, J				Mey, A; Gandrillon, O; McNagny, KM; Clegg, DO; Samarut, J			The v-erbA oncogene blocks expression of alpha 2/beta 1 integrin a normal inhibitor of erythroid progenitor proliferation	ONCOGENE			English	Article						erythropoiesis; self-renewal; oncogene; v-erbA; VLA-2	MARROW STROMAL CELLS; GROWTH-FACTOR-BETA; HORMONE-RECEPTOR; HEMATOPOIETIC PROGENITORS; MONOCLONAL-ANTIBODIES; EXTRACELLULAR-MATRIX; ADHERENT CELLS; SELF-RENEWAL; ADHESION; COLLAGEN	T2EC are chicken erythrocytic progenitors that balance between self-renewal and differentiation as a function of response to specific growth factors. Their transformation by the v-erbA oncogene locks them into the self-renewal program. We show here that the expression of the VLA-2 integrin alpha2 subunit mRNA is downregulated by v-erbA and that VLA-2 engagement and clustering, brought about by treatment with an alpha-specific antibody or by culture on the VLA-2 ligand collagen I, inhibits T2EC proliferation. From competition studies using antibodies, VLA-2 was shown to be involved in the collagen-induced response. While engagement of VLA-2 inhibited proliferation, it was not sufficient to induce differentiation. The transformation of T2EC by v-erbA decreased their interaction with collagen I and the VLA-2 brake on cell proliferation, which may account for the increased proliferation potential of transformed erythrocytic progenitors and for their shedding into the blood of infected chickens. Our data suggest that the interaction between erythroid progenitors and collagen, mediated by VLA-2, play a major role in the control of erythropoiesis in vitro and that this pathway is a target of the v-erbA oncogene.	Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, F-69008 Lyon, France; Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, UMR 5534, F-69622 Villeurbanne, France; Univ British Columbia, Dept Med Genet, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of British Columbia; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Samarut, J (corresponding author), Ecole Normale Super Lyon, Biol Cellulaire & Mol Lab, CNRS, UMR 5665, 46 Allee Italie, F-69008 Lyon, France.	Jacques.Samarut@ens-lyon.fr	McNagny, Kelly/P-5239-2014; Samarut, Jacques/AAD-2587-2019	McNagny, Kelly/0000-0003-4737-3499; MEY, Anne/0000-0002-2643-5702	NEI NIH HHS [EY 09736] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009736] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arroyo AG, 1999, IMMUNITY, V11, P555, DOI 10.1016/S1074-7613(00)80131-4; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENTLEY SA, 1982, BRIT J HAEMATOL, V50, P491, DOI 10.1111/j.1365-2141.1982.tb01945.x; BENTLEY SA, 1980, BLOOD, V56, P1006; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; BOUCHER P, 1988, J VIROL, V62, P534, DOI 10.1128/JVI.62.2.534-544.1988; BRADSHAW AD, 1995, DEVELOPMENT, V121, P3593; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; Cann GM, 1996, DEV BIOL, V180, P82, DOI 10.1006/dbio.1996.0286; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; Coulombel L, 1997, ACTA HAEMATOL-BASEL, V97, P13, DOI 10.1159/000203655; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DINNEN RD, 1994, CELL GROWTH DIFFER, V5, P855; DORSHKIND K, 1990, ANNU REV IMMUNOL, V8, P111, DOI 10.1146/annurev.iy.08.040190.000551; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; Goltry KL, 1997, BLOOD, V90, P138; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; Hamamura K, 1996, BLOOD, V87, P2513, DOI 10.1182/blood.V87.6.2513.bloodjournal8762513; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; KERST JM, 1993, BLOOD, V81, P344; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KOENIGSMANN M, 1992, BLOOD, V79, P657; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lemischka IR, 1997, STEM CELLS, V15, P63, DOI 10.1002/stem.5530150810; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; Mey A, 1998, INFECT IMMUN, V66, P2547, DOI 10.1128/IAI.66.6.2547-2552.1998; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHMIDT JA, 1986, LEUKEMIA RES, V10, P257, DOI 10.1016/0145-2126(86)90023-8; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SPOONCER E, 1983, J CELL BIOL, V96, P510, DOI 10.1083/jcb.96.2.510; STONE EM, 1985, P NATL ACAD SCI USA, V82, P1628, DOI 10.1073/pnas.82.6.1628; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; Whetton AD, 1998, CURR OPIN CELL BIOL, V10, P721, DOI 10.1016/S0955-0674(98)80113-0; WILLIAMS DA, 1991, NATURE, V352, P438, DOI 10.1038/352438a0; YANAI N, 1994, BLOOD, V83, P2844, DOI 10.1182/blood.V83.10.2844.2844; YODER MC, 1995, EXP HEMATOL, V23, P961; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZUCKERMAN KS, 1983, BLOOD, V61, P540	51	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2864	2872		10.1038/sj.onc.1205411	http://dx.doi.org/10.1038/sj.onc.1205411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973646				2022-12-17	WOS:000175063700011
J	Nomoto, M; Yamaguchi, R; Kohno, K; Kasai, H				Nomoto, M; Yamaguchi, R; Kohno, K; Kasai, H			Relations between clusters of oxidatively damaged nucleotides and active or open nucleosomes in the rat Nth 1 gene	ONCOGENE			English	Article						nucleotide damage; 8-hydroxyguanine; micrococcal nuclease; active or open nucleosomes; Nth 1 gene	POLYCYSTIC KIDNEY-DISEASE; SITE-SPECIFIC MUTAGENESIS; DNA-DAMAGE; FERRIC NITRILOTRIACETATE; TRANSCRIPTION FACTORS; IONIZING-RADIATION; RENAL CARCINOGEN; HUMAN HOMOLOG; 8-HYDROXYGUANINE; REPAIR	The distribution of oxidative damage to bases such as 8-hydroxyguanine (8-OH-Gua), was determined at the nucleotide level of resolution using the ligation-mediated PCR technique. Administration of a renal carcinogen, ferric nitrilotriacetate (Fe-NTA), is known to induce oxidative stress and subsequent formation of 8-OH-Gua in the kidney. Whole genomic DNA was isolated from the rat kidney with or without Fe-NTA treatment and then digested with formamidopyrimidine-DNA glycosylase (Fpg). As a target, we focused on the gene of a DNA repair enzyme for thymine glycol, Nth 1. Cleaved signals were found in exon 1 and exon 3, but not exon 5. Nucleosomes in these regions, enriched in damaged nucleotides, were highly accessible to micrococcal nuclease, especially in the kidney. Taking into account the function of the protein segment encoded by these regions, we discussed the molecular mechanism of the restricted formation of the damaged nucleotides.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Urol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Inst Ind Ecol Sci, Dept Environm Oncol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Nomoto, M (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahata Nishi Ku, Kitakyushu, Fukuoka 8078555, Japan.	m-nomoto@med.uoeh-u.ac.jp						AKMAN SA, 1991, MUTAT RES, V261, P123, DOI 10.1016/0165-1218(91)90058-T; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; AWAI M, 1979, AM J PATHOL, V95, P663; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; Burn TC, 1996, GENOME RES, V6, P525, DOI 10.1101/gr.6.6.525; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; CHENG KC, 1992, J BIOL CHEM, V267, P166; CHUNG MH, 1992, BIOCHEM BIOPH RES CO, V188, P1, DOI 10.1016/0006-291X(92)92341-T; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; EBINA Y, 1986, J NATL CANCER I, V76, P107; FEIG DI, 1994, P NATL ACAD SCI USA, V91, P6609, DOI 10.1073/pnas.91.14.6609; Floyd R A, 1986, Free Radic Res Commun, V1, P163, DOI 10.3109/10715768609083148; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KASAI H, 1993, ADV MUT RES, V4, P31; Kato K, 2000, BBA-GENE STRUCT EXPR, V1493, P91, DOI 10.1016/S0167-4781(00)00168-8; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Kobayashi T, 1999, CANCER RES, V59, P1206; KONISHI T, 1995, J BIOCHEM-TOKYO, V118, P1021, DOI 10.1093/jb/118.5.1021; LOEB LA, 1988, P NATL ACAD SCI USA, V85, P3918, DOI 10.1073/pnas.85.11.3918; MACCABEE M, 1994, J MOL BIOL, V236, P514, DOI 10.1006/jmbi.1994.1162; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUELLER PR, 1991, CURRENT PROTOCOLS S, V14; NAKAE D, 1995, CANCER LETT, V97, P233, DOI 10.1016/0304-3835(95)03980-B; NELLIST M, 1993, CELL, V75, P1305; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOMOTO M, 1995, BBA-GENE STRUCT EXPR, V1264, P35, DOI 10.1016/0167-4781(95)00158-D; Nomoto M, 1999, CARCINOGENESIS, V20, P837, DOI 10.1093/carcin/20.5.837; OKADA S, 1987, BIOCHIM BIOPHYS ACTA, V922, P28, DOI 10.1016/0005-2760(87)90241-4; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; TATA JR, 1978, J MOL BIOL, V118, P249, DOI 10.1016/0022-2836(78)90227-9; TCHOU J, 1994, J BIOL CHEM, V269, P15318; TKESHELASHVILI LK, 1991, J BIOL CHEM, V266, P6401; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; Tu YQ, 1997, J BIOL CHEM, V272, P20747, DOI 10.1074/jbc.272.33.20747; UMEMURA T, 1990, CARCINOGENESIS, V11, P345, DOI 10.1093/carcin/11.2.345; WEITZMAN SA, 1990, BLOOD, V76, P655; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yamaguchi R, 1996, CARCINOGENESIS, V17, P2419, DOI 10.1093/carcin/17.11.2419	52	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1649	1657		10.1038/sj.onc.1205237	http://dx.doi.org/10.1038/sj.onc.1205237			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896596				2022-12-17	WOS:000174214200003
J	Wang, DM; Lipsick, JS				Wang, DM; Lipsick, JS			Mutational analysis of the transcriptional activation domains of v-Myb	ONCOGENE			English	Article						v-Myb; transcriptional activation; transformation; leukemia; oncogene	TRANSFORMATION; TRANSACTIVATION; COACTIVATOR; ONCOGENE; CBP	A minimal transcription activation domain of the v-Myb oncoprotein was initially mapped to a central cluster of charged residues using GAL4-Myb fusion proteins. This region has been proposed to interact directly with the CBP co-activator in animal cells. Regions flanking this central domain of v-Myb are required for transcriptional activation by the native, unfused protein in both mammalian cells and in budding yeast. To identify the critical residues for transcriptional activation, we have now subjected the minimal activation domain and flanking regions including the heptad leucine repeat to random PCR-mediated mutagenesis. We found that the entire region examined can endure extensive substitutions without affecting transcriptional activation by v-Myb in budding yeast. The few mutations that did affect transcriptional activation altered acidic residues within the minimal activation domain or the heptad leucine repeat region, rather than leucine residues. Remarkably, there was a strong concordance between transcriptional activation in animal cells and in budding yeast, even though budding yeast have no known homologue of CBP or related co-activators. In contrast, there was not a strong correlation between transcriptional activation and oncogenic transformation.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	lipsick@stanford.edu			NATIONAL CANCER INSTITUTE [T32CA009151, R01CA043592] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09151, R01 CA43592] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Leung DW, 1989, TECHNIQUE, V1, P11; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	14	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1611	1615		10.1038/sj.onc.1205236	http://dx.doi.org/10.1038/sj.onc.1205236			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896590				2022-12-17	WOS:000173956800017
J	Li, H; Myeroff, L; Kasturi, L; Krumroy, L; Schwartz, S; Willson, JKV; Stanbridge, E; Casey, G; Markowitz, S				Li, H; Myeroff, L; Kasturi, L; Krumroy, L; Schwartz, S; Willson, JKV; Stanbridge, E; Casey, G; Markowitz, S			Chromosomal autonomy of hMLH1 methylation in colon cancer	ONCOGENE			English	Article						colon cancer; methylation; hMLH1	DNA METHYLATION; FUNCTIONAL EVIDENCE; SUPPRESSOR GENE; PROMOTER; INACTIVATION; EXPRESSION	Silencing of hMLH1 expression by aberrant hMLH1 promoter methylation accounts for the majority of sporadic colon cancers with microsatellite instability. We have previously shown hMLH1 silencing is biallelic and actively maintained. To study the mechanism of aberrant hMLH1 methylation, we assayed whether an hMLH1 methylated cell could transfer methylation and silencing to an exogenous hMLH1 promoter in somatic cell hybrids between hMLH1 methylated-silenced and hMLH1 unmethylated-expressing colon cancer cells. Conversely, we assayed whether these hybrids could reactivate expression of initially methylated and silenced hMLH1 alleles. Compellingly, within the hybrids each hMLH1 allele remained unchanged, retaining the expression status of its parental cell of origin. This chromosomal autonomy may not be simply determined by DNA methylation, as it is reasserted after experimentally forced demethylation of all hMLH1 alleles in the hybrids. Confirming findings included hMLH1 methylated cells being unable to methylate single transferred exogenous hMLH1 expressing chromosomes or transfected hMLH1 reporter constructs. hMLH1 silencing does not conform to either a dominant or recessive model, and is not determined by trans-acting factors differing between hMLH1 expressing or silenced genomes. We posit that hMLH1 methylation is dependent on and maintained by cis chromosomal marks, whose nature remains to be elucidated.	Case Western Reserve Univ, Dept Microbiol & Mol Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Canc Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; Univ Calif Irvine, Irvine, CA 92697 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; University Hospitals of Cleveland; Howard Hughes Medical Institute; Cleveland Clinic Foundation; Case Western Reserve University; University of California System; University of California Irvine	Markowitz, S (corresponding author), Case Western Reserve Univ, Dept Microbiol & Mol Biol, 2 Rm 200 11001 Cedar Rd, Cleveland, OH 44106 USA.	sxm10@po.cwru.edu			NCI NIH HHS [P30 CA43703, R01 CA67409, R01 CA72160] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067409, P30CA043703, R01CA072160] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arad U, 1998, BIOTECHNIQUES, V24, P760, DOI 10.2144/98245bm14; Baylin SB, 1998, ADV CANCER RES, V72, P141; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Deng GR, 1999, CANCER RES, V59, P2029; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; GEISER AG, 1989, CANCER RES, V49, P1572; Grady WM, 2001, CANCER RES, V61, P900; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hsieh CL, 2000, CURR OPIN GENET DEV, V10, P224, DOI 10.1016/S0959-437X(00)00064-2; Issa JP, 2000, ANN NY ACAD SCI, V910, P140; Ito E, 1999, BIOCHEM BIOPH RES CO, V256, P488, DOI 10.1006/bbrc.1999.0368; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Kane MF, 1997, CANCER RES, V57, P808; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Kuzmin I, 1999, ONCOGENE, V18, P5672, DOI 10.1038/sj.onc.1202959; LEE YW, 1995, MOL CELL BIOL, V15, P2547; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wiesner GL, 2001, J NATL CANCER I, V93, P635, DOI 10.1093/jnci/93.8.635; WILLSON JKV, 1987, CANCER RES, V47, P2704	26	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1443	1449		10.1038/sj.onc.1205247	http://dx.doi.org/10.1038/sj.onc.1205247			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857087				2022-12-17	WOS:000173861000014
J	Oelgeschlager, M; Kowenz-Leutz, E; Schreek, S; Leutz, A; Luscher, B				Oelgeschlager, M; Kowenz-Leutz, E; Schreek, S; Leutz, A; Luscher, B			Tumorigenic N-terminal deletions of c-Myb modulate DNA binding, transactivation, and cooperativity with C/EBP	ONCOGENE			English	Article						oncogene; transcription; hematopoiesis; differentiaion; leukemia	AVIAN MYELOMONOCYTIC CELLS; V-MYB; PROMONOCYTIC LEUKEMIAS; RAPID INDUCTION; LEUCINE-ZIPPER; MYELOID GENES; MIM-1 GENE; ACTIVATION; BETA; MUTATIONS	Oncogenic activation of c-myb by retroviral insertion has been implicated fit tumor formation in chicken and mice. These genetic alterations result in deregulated expression of the: c-myb gene and frequently in, N-terminal truncation of the c-Myb: protein. We demonstrate that truncation of the c-Myb N-terminus affects DNA binding and reporter activation. However, all three mutants, Myb Delta N20, Myb Delta N47 and Myb Delta N71 cooperated with C/EBP beta in reporter assays. In contrast to Myb Delta N20 and Myb Delta N47, however, the Myb Delta N71 mutant failed to activate the chromatin, embedded endogenous mim-1 gene together with C/EBP beta. This suggests that an N-terminal region (amino acids 47-71) within repeat 1 (R1), of the murine c-Myb DNA binding domain affects activation of chromosomal target genes in collaboration with C/EBP beta.	Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Hannover Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Luscher, B (corresponding author), Rhein Westfal TH Aachen Klinikum, Inst Biochem, Abt Biochem & Mol Biol, Pauwels Str 30, D-52057 Aachen, Germany.	luescher@rwth-aachen.de	Leutz, Achim/K-9643-2013; Luscher, Bernhard/A-7330-2011	Leutz, Achim/0000-0001-8259-927X; Luscher, Bernhard/0000-0002-9622-8709				Brendeford EM, 1997, J BIOL CHEM, V272, P4436, DOI 10.1074/jbc.272.7.4436; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; Jiang WP, 1997, J VIROL, V71, P6526, DOI 10.1128/JVI.71.9.6526-6533.1997; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEG J, 1995, ONCOGENE, V10, P2221; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NAKANO T, 1992, ONCOGENE, V7, P527; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60	35	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7420	7424		10.1038/sj.onc.1204922	http://dx.doi.org/10.1038/sj.onc.1204922			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704872				2022-12-17	WOS:000171894200015
J	Gual, P; Giordano, S; Anguissola, S; Comoglio, PM				Gual, P; Giordano, S; Anguissola, S; Comoglio, PM			Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness	ONCOGENE			English	Article						Met; C-terminal domain; regulatory domain; kinase activity; cell transformation; invasiveness	HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; TYROSINE KINASE DOMAIN; HGF-RECEPTOR; CONSTITUTIVE ACTIVATION; FACTOR/SCATTER FACTOR; RET PROTOONCOGENE; CRYSTAL-STRUCTURE; ADAPTER PROTEINS; INSULIN-RECEPTOR	Biological responses to Hepatocyte Growth Factor are mediated by the tyrosine kinase receptor encoded by the Met oncogene. Under physiological conditions, Met triggers a multi-step genetic program called 'invasive growth' including cell-dissociation, invasion of extracellular matrices and growth. When constitutively activated, Met can induce cell transformation and metastasis. Phosphorylation of two docking tyrosines in the receptor tail is essential for all biological responses. To investigate the role of the C-terminal part of Met, we have generated mutants lacking either the last 26 or 47 amino acids. As expected, mutants lacking the docking sites fail to mediate cell transformation and invasion. Interestingly, while Met Delta 26 can mediate invasion, its transforming ability is severely impaired. Moreover, the lack of the last 26 amino acids strongly reduces Met ability to phosphorylate substrates in vitro and in vivo. These data indicate that the last 26 amino acids are required to confer the kinase its full enzymatic activity, which is critical for cell transformation but dispensable for invasive properties. Finally, we also show that upregulation of Met enzymatic activity by insertion of a point mutation in the kinase domain (M1250T) overcomes the regulatory role played by the last 26 amino acids of the tail. It is concluded that the C-terminal domain of Met is crucial not only for recruitment of transducers but also for regulation of receptor enzymatic activity.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Giordano, S (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Giordano, Silvia/J-9858-2018; Gual, Philippe/P-9833-2019; Comoglio, Paolo/G-6323-2011	Giordano, Silvia/0000-0003-1854-1086; Gual, Philippe/0000-0001-7393-8356; Comoglio, Paolo/0000-0002-7056-5328				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bardelli A, 1999, J BIOL CHEM, V274, P29274, DOI 10.1074/jbc.274.41.29274; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Borrello MG, 1995, ONCOGENE, V11, P2419; Comoglio PM, 1999, EXP CELL RES, V253, P88, DOI 10.1006/excr.1999.4684; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FERRACINI R, 1995, ONCOGENE, V10, P739; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Giordano S, 2000, FASEB J, V14, P399, DOI 10.1096/fasebj.14.2.399; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Iwashita T, 1996, ONCOGENE, V12, P481; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; LONGATI P, 1994, ONCOGENE, V9, P49; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1994, COLD SPRING HARB SYM, V59, P629, DOI 10.1101/SQB.1994.059.01.072; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1998, CANCER RES, V58, P1719; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; Xiao ZQ, 2000, BIOCHEM BIOPH RES CO, V267, P669, DOI 10.1006/bbrc.1999.2011; ZHEN Z, 1994, ONCOGENE, V9, P1691	53	6	7	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 6	2001	20	39					5493	5502		10.1038/sj.onc.1204713	http://dx.doi.org/10.1038/sj.onc.1204713			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571647				2022-12-17	WOS:000170781100010
J	Le Scolan, E; Wendling, F; Barnache, S; Denis, N; Tulliez, M; Vainchenker, W; Moreau-Gachelin, F				Le Scolan, E; Wendling, F; Barnache, S; Denis, N; Tulliez, M; Vainchenker, W; Moreau-Gachelin, F			Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts	ONCOGENE			English	Article						erythroleukemia; Spi-1/PU.1; p53; p2l(Cip1/Waf1); transgenic mice	WILD-TYPE P53; VIRUS-INDUCED ERYTHROLEUKEMIA; TRANSCRIPTION FACTOR PU.1; LONG TERMINAL REPEAT; DNA-BINDING PROTEIN; FRIEND-VIRUS; ERYTHROPOIETIN RECEPTOR; CELL-DIFFERENTIATION; HEMATOPOIETIC-CELLS; MICE DEFICIENT	Activation of the spi-1/PU.1 proto-oneogene and loss of p53 function are genetic alterations associated with the emergence of Friend malignant erythroleukemic cells. To address the role of p53 during erythroleukemogenesis, spi-1 transgenic mice (spi-1-Tg) which develop erythroleukemia were bred with p53-deficient mice. Three classes of spi-1 transgenic mice differing in their p53 functional status (p53(+/+), p53(+/-) and p53(-/-)) were generated. These mice developed a unique pattern of erythroleukemia. In wild-type p53 spi-1-Tg mice, none of the primary erythroleukemic spleen cells displayed autonomous growth in vitro and in vivo. In contrast, in p53(+/-) spi-1-Tg mice, erythroleukemic cells gave rise to growth factor-independent cell lines and generated tumors in vivo. Malignancy was associated with loss of the wild-type p53 allele. The p53(-/-) spi-1-Tg mice developed erythroleukemia with a total incidence and a reduced latency compared to the two other genotypes. Unexpectedly, 50% of p53(-/-) spi-1-Tg erythroleukemic spleens generated cell lines that were strictly dependent upon erythropoietin (Epo) for proliferation, whereas the remainder proliferated independently of cytokines. Moreover, only 70% of these spleen cells were tumorigenic. These findings indicate that p53 germ-line deletion did not confer malignancy to spi-1-transgenic proerythroblasts. Moreover Epo independence and tumorigenicity appear as separable phenotypic characteristics revealing that the spi-1-Tg proerythroblasts progress towards malignancy through multiple oncogenic events.	Inst Curie, INSERM, U528, F-75005 Paris, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Hop Cochin, Lab Anat, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Moreau-Gachelin, F (corresponding author), Inst Curie, INSERM, U528, 26 Rue Ulm, F-75005 Paris, France.	framoreau@curie.fr		Vainchenker, William/0000-0003-4705-202X				AIZAWA S, 1990, EMBO J, V9, P2107, DOI 10.1002/j.1460-2075.1990.tb07379.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BLYTH K, 1995, ONCOGENE, V10, P1717; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; DAVID YB, 1988, ONCOGENE, V3, P179; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELSON A, 1995, ONCOGENE, V11, P181; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LACOMBE C, 1991, J BIOL CHEM, V266, P6952; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MIYASHITA T, 1995, CELL, V80, P293; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1983, BIOCHIMIE, V65, P259, DOI 10.1016/S0300-9084(83)80277-6; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; PURDIE CA, 1994, ONCOGENE, V9, P603; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SITBON M, 1986, CELL, V47, P851, DOI 10.1016/0092-8674(86)90800-7; Tang PP, 2000, LEUKEMIA, V14, P1292, DOI 10.1038/sj.leu.2401823; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	57	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2001	20	39					5484	5492		10.1038/sj.onc.1204708	http://dx.doi.org/10.1038/sj.onc.1204708			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468WL	11571646				2022-12-17	WOS:000170781100009
J	Song, Y; Cohler, AN; Weinstein, DC				Song, Y; Cohler, AN; Weinstein, DC			Regulation of Laloo by the Xenopus C-terminal Src kinase (Xcsk) during early vertebrate development	ONCOGENE			English	Article						Laloo; Csk; Fyn; Src; Xenopits; mesoderm	MESODERM INDUCTION; TYROSINE KINASES; MAP KINASE; EMBRYOS; EXPRESSION; LAEVIS; FGF; CSK; INHIBITION; XWNT-8	Mesoderm formation in the frog, Xenopus laevis, is dependent on the activity of one or more members of the Src family kinases; the molecular interactions underlying this requirement are not well understood. The C-terminal Src Kinase (Csk) is a potent inhibitor of Src activity, and is required for normal mammalian development; here we report the characterization of Xenopus Csk (Xcsk). Xcsk is widely expressed during early development, physically interacts with the Src kinase Laloo, and inhibits the generation of mesoderm by the Src kinases. Xcsk activity requires a functional kinase domain; furthermore, a kinase-inactive Xcsk mutant potently synergizes with Laloo during early vertebrate development, suggesting a fundamental role for the Src kinase-Csk regulatory circuit during mesoderm induction, in vivo.	Mt Sinai Sch Med, Dept Pharmacol, New York, NY USA	Icahn School of Medicine at Mount Sinai	Weinstein, DC (corresponding author), Mt Sinai Sch Med, Dept Pharmacol, New York, NY USA.			Weinstein, Daniel/0000-0001-7832-9285				BASSEZ T, 1990, DEVELOPMENT, V110, P955; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; Curran KL, 2000, DEV BIOL, V228, P41, DOI 10.1006/dbio.2000.9917; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LaBonne C, 1997, DEV BIOL, V183, P9, DOI 10.1006/dbio.1996.8497; Miller MA, 2000, ONCOGENE, V19, P3925, DOI 10.1038/sj.onc.1203714; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; STEELE RE, 1990, ONCOGENE, V5, P369; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; Weinstein DC, 2001, DEV DYNAM, V220, P163, DOI 10.1002/1097-0177(2000)9999:9999<1::AID-DVDY1098>3.0.CO;2-5; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0	21	6	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 23	2001	20	37					5210	5214		10.1038/sj.onc.1204672	http://dx.doi.org/10.1038/sj.onc.1204672			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	463EN	11526510				2022-12-17	WOS:000170464000015
J	Purrello, M; Di Pietro, C; Rapisarda, A; Amico, V; Giunta, V; Engel, H; Stevens, S; Hsieh, YJ; Teichman, M; Wang, ZX; Sichel, G; Roeder, R; Grzeschik, KH				Purrello, M; Di Pietro, C; Rapisarda, A; Amico, V; Giunta, V; Engel, H; Stevens, S; Hsieh, YJ; Teichman, M; Wang, ZX; Sichel, G; Roeder, R; Grzeschik, KH			Genes for human general transcription initiation factors TFIIIB, TFIIIB-associated proteins, TFIIIC2 and PTF/SNAPC: functional and positional candidates for tumour predisposition or inherited genetic diseases?	ONCOGENE			English	Article						Cancer Genome Anatomy Project; oncogenesis; human general transcription factors; regulation of gene expression; cell proliferation, differentiation and apoptosis	RNA-POLYMERASE-III; TATA-BINDING PROTEIN; OVARIAN-TUMORS; CLONING; SUBUNIT; ACTIVATION; COMPLEX; SIMIAN-VIRUS-40; INVOLVEMENT; INTERACTS	TFIIIB, TFIIIC2, and PTF/SNAPC are heteromultimeric general transcription factors (GTFs) needed for expression of genes encoding small cytoplasmic (scRNAs) and small nuclear RNAs (snRNAs). Their activity is stimulated by viral oncogenes, such as SV40 large T antigen and Adenovirus EIA, and is repressed by specific transcription factors (STFs) acting as antioncogenes, such as p53 and pRb. GTFs role as final targets of critical signal transduction pathways, that control cell proliferation and differentiation, and their involvement in gene expression regulation suggest that the genes encoding them are potential proto-oncogenes or anti-oncogenes or may be otherwise involved in the pathogenesis of inherited genetic diseases. To test our hypothesis through the positional candidate gene approach, we have determined the physical localization in the human genome of the 11 genes, encoding the subunits of these GTFs, and of three genes for proteins associated with TFIIIB (GTF3BAPs). Our data, obtained by chromosomal in situ hybridization, radiation hybrids and somatic cell hybrids analysis, demonstrate that these genes are present in the human genome as single copy sequences and that some cluster to the same cytogenetic band, alone or in combination with class II GTFs. Intriguingly, some of them are localized within chromosomal regions where recurrent, cytogenetically detectable mutations are seen in specific neoplasias, such as neuroblastoma, uterine leyomioma, mucoepidermoid carcinoma of the salivary glands and hemangiopericytoma, or where mutations causing inherited genetic diseases map, such as Peutz-Jeghers syndrome. Their molecular function and genomic position make these GTF genes interesting candidates for causal involvement in oncogenesis or in the pathogenesis of inherited genetic diseases.	Univ Catania, Dipartimento Sci Biomed, Sez Biol Gen Cellulare & Genet Mol, I-95124 Catania, Italy; Univ Marburg, Zentrum Humangenet, D-35037 Marburg, Germany; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	University of Catania; Philipps University Marburg; Rockefeller University	Purrello, M (corresponding author), Univ Catania, Dipartimento Sci Biomed, Sez Biol Gen Cellulare & Genet Mol, I-95124 Catania, Italy.		Teichmann, Martin/M-7407-2014	Teichmann, Martin/0000-0002-5257-0510; DI PIETRO, Cinzia Santa/0000-0002-6036-4469				Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; Bai L, 1996, MOL CELL BIOL, V16, P5419; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Pedeutour F, 2000, GENE CHROMOSOME CANC, V27, P209, DOI 10.1002/(SICI)1098-2264(200002)27:2<209::AID-GCC14>3.3.CO;2-L; Purrello M, 1998, ONCOGENE, V16, P1633, DOI 10.1038/sj.onc.1201673; PURRELLO M, 1995, CYTOGENET CELL GENET, V69, P75, DOI 10.1159/000133942; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; White RJ, 1998, INT J ONCOL, V12, P741; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; Yoon JB, 1996, MOL CELL BIOL, V16, P1	25	6	6	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4877	4883		10.1038/sj.onc.1204604	http://dx.doi.org/10.1038/sj.onc.1204604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521199				2022-12-17	WOS:000170271800012
J	Codony, C; Guil, S; Caudevilla, C; Serra, D; Asins, G; Graessmann, A; Hegardt, FG; Bach-Elias, M				Codony, C; Guil, S; Caudevilla, C; Serra, D; Asins, G; Graessmann, A; Hegardt, FG; Bach-Elias, M			Modulation in vitro of H-ras oncogene expression by trans-splicing	ONCOGENE			English	Article						splicing; c-H-ras; trans-splicing	MESSENGER-RNA; MAMMALIAN-CELLS; EXON; GENE; LIVER; ENHANCER	In man, activated N-, K- and H-ras oncogenes have been found in around 30% of the solid tumours tested, An exon known as IDX, which has been described previously and is located between exon 3 and exon 4A of the c-H-ras pre-mRNA, allows an alternative splicing process that results in the synthesis of the mRNA of a putative protein named p19, It has been suggested that this alternative pathway is less tumorigenic than that which results in the activation of p21, We have used the mammalian trans-splicing mechanism as a tool with which to modulate this particular pre-mRNA processing to produce mRNA similar to that of mature p19 RNA. The E4A exon of the activated H-vas gene was found to be a good target for external trans-splicing. We reprogrammed the rat carnitine octanoyltransferase exon 2 to specifically invade the terminal region of H-ras. Assays performed with this reprogrammed trans-exon showed that the trans-splicing product was obtained in competition with cis-splicing of the D intron of the H-ras gene, and was associated with concomitant downmodulation of D intron cis-splicing. We also found that the exon 4A of the human c-H-ras gene underwent successive trans-splicing rounds with an external exon.	CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, ES-08034 Barcelona, Spain; Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08007 Barcelona, Spain; Free Univ Berlin, Inst Molekularbiol & Biochim, D-14195 Berlin, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Free University of Berlin	Bach-Elias, M (corresponding author), CSIC, IIBB, Dept PMT, Unidad Biol & Farmacol Mol Canc, C Jorge Girona Salgado 18-26, ES-08034 Barcelona, Spain.		Guil, Sonia/M-8036-2015; Serra, Dolors/L-3657-2014	Guil, Sonia/0000-0002-2257-3331; Serra, Dolors/0000-0002-4936-4206; Codony Servat, Carles/0000-0001-8928-2312				Akopian AN, 1999, FEBS LETT, V445, P177, DOI 10.1016/S0014-5793(99)00126-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Breen MA, 1997, FEBS LETT, V409, P375, DOI 10.1016/S0014-5793(97)00555-3; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Cicarelli RMB, 1998, BIOCHEM BIOPH RES CO, V247, P204, DOI 10.1006/bbrc.1998.8771; COHEN JB, 1993, MOL CELL BIOL, V13, P2666, DOI 10.1128/MCB.13.5.2666; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; EUL J, 1995, EMBO J, V14, P3226, DOI 10.1002/j.1460-2075.1995.tb07325.x; Frantz SA, 1999, P NATL ACAD SCI USA, V96, P5400, DOI 10.1073/pnas.96.10.5400; Huang MY, 1997, ONCOL RES, V9, P611; Kawasaki T, 1999, PLANT J, V18, P625, DOI 10.1046/j.1365-313x.1999.00493.x; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mansfield SG, 2000, GENE THER, V7, P1885, DOI 10.1038/sj.gt.3301307; Puttaraju M, 1999, NAT BIOTECHNOL, V17, P246, DOI 10.1038/6986; SHIMIZU A, 1993, FASEB J, V7, P149, DOI 10.1096/fasebj.7.1.7916698; SULLIVAN PM, 1991, J BIOL CHEM, V266, P143; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; Zaphiropoulos PG, 1999, NUCLEIC ACIDS RES, V27, P2585, DOI 10.1093/nar/27.13.2585	24	6	6	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3683	3694		10.1038/sj.onc.1204473	http://dx.doi.org/10.1038/sj.onc.1204473			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439331				2022-12-17	WOS:000169400200009
J	Yamane, K; Katayama, E; Tsuruo, T				Yamane, K; Katayama, E; Tsuruo, T			p53 contains a DNA break-binding motif similar to the functional part of BRCT-related region of Rb	ONCOGENE			English	Article						DNA damage; tumor suppressor; Nijmegen breakage syndrome; DNA double-strand breaks; DNA end binding	C-TERMINAL DOMAIN; OLIGOMERIZATION DOMAIN; LI-FRAUMENI; PROTEIN; CHECKPOINT; APOPTOSIS; DAMAGE; REPAIR; TRANSFORMATION; LOCALIZATION	The BRCT regions are two repeating structures at BRCA1 carboxyl-terminus and are ubiquitous in some proteins involved in DNA repair and cell cycle checkpoints. It was shown that BRCTs of TopBP1, BRCA1, and BRCT-Ws of Rb hound DNA ends and breaks. We indicate here that the C-terminus of p53 tumor suppressor contains a DNA binding motif (residues 327-333 in human), whose features are similar to those of the part of BRCT-W in Rb with DNA binding activity. The short motif was required for the gel retardation activity of DNA fragments, since residues 311-333 show cd the activity while residues 311-326 showed no activity. Significant numbers of total p53 and its fragments with the motif formed multimerizing complexes and associated with DNA ends and breaks, These results suggest the common presence of DNA binding motifs that can recognize DNA ends or damages in major tumor suppressors, Rb, BRCA1 and p53. The oncogenic activity of p53 C-terminus (residues 311-393) required both the DNA damage recognition motif and the repair enzyme-associating domain. Oncogene (2001) 20, 2859-2867.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Japan Sci & Technol Corp, Div Biomol Imaging, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japanese Foundation for Cancer Research; Japan Science & Technology Agency (JST); University of Tokyo	Yamane, K (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Guggenheim Bldg,Room 1306,200 1st St SW, Rochester, MN 55905 USA.							Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIMORI T, 1986, J BIOL CHEM, V261, P375; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamane K, 2000, ONCOGENE, V19, P1982, DOI 10.1038/sj.onc.1203528; Yamane K, 2000, BIOCHEM BIOPH RES CO, V279, P678, DOI 10.1006/bbrc.2000.3983; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	38	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2001	20	23					2859	2867		10.1038/sj.onc.1204408	http://dx.doi.org/10.1038/sj.onc.1204408			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420698				2022-12-17	WOS:000168901800001
J	Daniel, R; Chung, SW; Eisenstein, TK; Sultzer, BM; Wong, PMC				Daniel, R; Chung, SW; Eisenstein, TK; Sultzer, BM; Wong, PMC			Specific association of type I c-abl with ran GTPase in lipopolysaccharide-mediated differentiation	ONCOGENE			English	Article						Ran; LPS; endotoxin; sepsis; c-Abl isoform	TYROSINE KINASE INHIBITORS; TUMOR-NECROSIS-FACTOR; 3' UNTRANSLATED REGION; ALPHA MESSENGER-RNA; CELL-CYCLE; ANTISENSE SEQUENCES; RETROVIRAL TRANSFER; MURINE MACROPHAGES; PROTEIN; BINDING	Each of several isoforms of c-Abl may be involved in different biological functions. Type I c-Abl has been shown to be involved in LPS-induced differentiation and Type IV c-Abl, apoptosis, Ran has recently been shown to be involved in LPS endotoxin signal transduction, Here we show that Type I c-Abl associates with Ran. Formation of this complex is specific, as Ran did not associate with the highly homologous Type IV c-Abl isoform, In non-stimulated lymphoid B cells, Type I c-Abl tyrosine kinase is inactive, whereas Type IV kinase is active. Formation of Type I c-Abl/Ran complex and activation of Type I c-Abl kinase activity are LPS dose-dependent. This complex is detectable in B cells of endotoxin-sensitive inbred mice but absent in B cells of endotoxin-resistant mice. These findings therefore suggest that Type I c-Abl and Ran are important targets in lipopolysaccharide-induced biological responses of hematopoietic cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Stem Cell Therapeut, King Of Prussia, PA 19406 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Wong, PMC (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Pathol & Lab Med, Philadelphia, PA 19140 USA.			Daniel, Rene/0000-0002-3876-6242	NCI NIH HHS [R01CA70854] Funding Source: Medline; NIAID NIH HHS [R01AI39159] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Belasco J.G., 2012, CONTROL MESSENGER RN; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; Daniel R, 1996, CELL GROWTH DIFFER, V7, P1141; Daniel R, 1998, J BIOMED SCI, V5, P383; DANIEL R, 1995, ONCOGENE, V10, P1607; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; DONG ZY, 1993, J IMMUNOL, V151, P2717; Dorsch M, 1996, P NATL ACAD SCI USA, V93, P13131, DOI 10.1073/pnas.93.23.13131; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Goldfield EM, 1997, CHEM PHYS LETT, V276, P1, DOI 10.1016/S0009-2614(97)00818-X; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; Hel Z, 1996, MOL CELL BIOL, V16, P5579; Hel Z, 1998, NUCLEIC ACIDS RES, V26, P2803, DOI 10.1093/nar/26.11.2803; Kang AD, 1996, INFECT IMMUN, V64, P4612, DOI 10.1128/IAI.64.11.4612-4617.1996; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Le Q, 1998, J IMMUNOL, V160, P3330; Moore MS, 1996, SCIENCE, V272, P47, DOI 10.1126/science.272.5258.47; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Orlicek SL, 1996, J INFECT DIS, V174, P638, DOI 10.1093/infdis/174.3.638; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SULTZER BM, 1972, INFECT IMMUN, V5, P107, DOI 10.1128/IAI.5.1.107-113.1972; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wong HW, 1999, DUKE MATH J, V96, P1, DOI 10.1215/S0012-7094-99-09601-1; WONG KK, 1995, ONCOGENE, V10, P705; Wong PMC, 2000, SCAND J IMMUNOL, V51, P123; Wong PMC, 2000, J HEMATOTH STEM CELL, V9, P629, DOI 10.1089/15258160050196669; Yuan Q, 2000, P NATL ACAD SCI USA, V97, P2852, DOI 10.1073/pnas.040567797; ZHAO F, 2001, IN PRESS J ENDO RES	50	6	7	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2618	2625		10.1038/sj.onc.1204361	http://dx.doi.org/10.1038/sj.onc.1204361			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420673				2022-12-17	WOS:000168652600002
J	Gagliardi, M; Maynard, S; Bojovic, B; Bedard, PA				Gagliardi, M; Maynard, S; Bojovic, B; Bedard, PA			The constitutive activation of the CEF-4/9E3 chemokine gene depends on C/EBP beta in v-src transformed chicken embryo fibroblasts	ONCOGENE			English	Article						CEF-4/9E3 chemokine; C/EBP beta; pp60(v-src)	ROUS-SARCOMA VIRUS; NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; EFII ENHANCER SEQUENCE; BINDING-PROTEIN-BETA; LONG TERMINAL REPEAT; KINASE-C SUBSTRATE; TRANSCRIPTION FACTOR; CELLULAR-TRANSFORMATION	The CEF-4/9E3 chemokine gene is expressed constitutively in chicken embryo fibroblasts (CEF) transformed by the Rous sarcoma virus (RSV), This aberrant induction is controlled at the transcriptional and posttranscriptional Levels. Transcriptional activation depends on multiple elements of the CEF-4 promoter composing a Src-responsive-Unit or SRU, The SRU includes a TPA responsive element, a PRDII/kappaB domain and a CAAT box. In this report, we identify C/EBP beta as a component of the trans-acting factor interacting with the CAAT box of the CEF-4 promoter. In addition, we show that CI EBP beta binds to a second element located in proximity of the TRE, A mutation of this distal CAAT box impaired the activation of the CEF-4 promoter by pp60(v-src) indicating that this element is also part of the SRU, Using the RCASBP retroviral vector, we expressed a dominant negative mutant of C/EBP beta (designated Delta 184-C/EBP beta) in RSV-transformed CEF, Delta 184-C/EBP beta decreased the accumulation of the CEF-4 mRNA and activation of the CEF-4 promoter by pp60(v-src). The induction of the Cox-2 gene (CEF-147) was also reduced by Delta 184-C/EBP beta. The effect of the dominant negative mutant was observed within 1 h of the activation of a thermolabile pp60(v-src) suggesting that C/EBP beta is an early target of v-src transformation. The dominant negative mutant did not inhibit the transformation of CEF by RSV and in fact accentuated the transformed cell phenotype, Therefore, the activation of C/EBP beta is important for the expression of v-src regulated genes but is not required for the in vitro transformation of CEF by pp60(v-src).	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	York University - Canada; McMaster University	Bedard, PA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.			Maynard, Scott/0000-0001-5625-936X				Arenberg DA, 1996, J CLIN INVEST, V97, P2792, DOI 10.1172/JCI118734; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; CALKHOVEN CF, 1994, NUCLEIC ACIDS RES, V22, P5540, DOI 10.1093/nar/22.25.5540; Calkhoven CF, 2000, GENE DEV, V14, P1920; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Greenbaum LE, 1998, J CLIN INVEST, V102, P996, DOI 10.1172/JCI3135; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; Kim S, 1999, MOL CELL BIOL, V19, P5718; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; Lin X, 1997, CANCER RES, V57, P3068; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; Lin XY, 1998, CANCER RES, V58, P1770; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Mangeney M, 1996, ONCOGENE, V13, P1441; MAO PL, 1993, J BIOL CHEM, V268, P8131; Martins-Green M., 1997, Cytokine and Growth Factor Reviews, V8, P221, DOI 10.1016/S1359-6101(97)00016-6; Martins-Green M, 1998, CYTOKINE, V10, P522, DOI 10.1006/cyto.1997.0311; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Raught B, 1996, CANCER RES, V56, P4382; RICHMOND A, 1988, EMBO J, V7, P2025, DOI 10.1002/j.1460-2075.1988.tb03042.x; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SCHADENDORF, 1994, J IMMUNOL, V153, P3360; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Seagroves TN, 2000, MOL ENDOCRINOL, V14, P359, DOI 10.1210/me.14.3.359; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; SEARS RC, 1994, MOL CELL BIOL, V14, P5617; SEARS RC, 1992, J VIROL, V66, P6338, DOI 10.1128/JVI.66.11.6338-6352.1992; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P4517, DOI 10.1093/nar/27.22.4517; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wakabayashi Y, 1995, JPN J CANCER RES, V86, P1189, DOI 10.1111/j.1349-7006.1995.tb03314.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	71	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2301	2313		10.1038/sj.onc.1204354	http://dx.doi.org/10.1038/sj.onc.1204354			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402325				2022-12-17	WOS:000168404500012
J	Beadling, C; Cereseto, A; Fan, W; Naramura, M; Smith, KA				Beadling, C; Cereseto, A; Fan, W; Naramura, M; Smith, KA			Cytokine response gene 8 (CR8) regulates the cell cycle G1-S phase transition and promotes cellular survival	ONCOGENE			English	Article						basic helix-loop-helix; G1 progression; survival	LOOP-HELIX PROTEINS; ID PROTEINS; EXPRESSION; GROWTH; TRANSCRIPTION; PROGRESSION; APOPTOSIS; DIFFERENTIATION; ENHANCER; ARREST	Cellular proliferation and survival are modulated by the expression of specific genes. Cytokine response gene 8 (CR8), which was originally cloned as an IL-2-induced gene in human T lymphocytes, encodes a basic helix-loop-helix (bHLH) transcription factor, The CR8 gene product is highly conserved among human, mouse and rat, and contains sequence motifs that distinguish it from other bHLH families, The CR8 gene is ubiquitously expressed, and CR8 gene expression is induced by both growth-promoting as well as growth-inhibitory stimuli. As bHLH proteins have been found to regulate both the G1-S phase cell cycle transition, as well as cellular survival, the effects of CR8 on these processes were investigated. Ectopic CR8 expression in asynchronous U2OS cell cultures reduces the percentage of cells in the cell cycle S phase, and also slows the entry of G1-synchronized cells into S phase. The prolonged G1 interval correlates with impaired elevation of cyclin E protein and prolonged p21 protein expression in G1, CR8 expression also protects U2OS cells from serum-withdrawal induced apoptosis, These results indicate that CR8 is an important modulator of both the G1-S phase cell cycle transition, and cellular survival.	New York Presbyterian Cornell Med Ctr, Div Immunol, Dept Med, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Weill Med Coll, New York, NY 10021 USA; New York Presbyterian Cornell Med Ctr, Grad Sch Med Sci, New York, NY 10021 USA	Cornell University	Smith, KA (corresponding author), New York Presbyterian Cornell Med Ctr, Div Immunol, Dept Med, 1300 York Ave, New York, NY 10021 USA.			Cereseto, Anna/0000-0003-4453-2597; Naramura, Mayumi/0000-0003-3658-0767	NIAID NIH HHS [1RO1 AI44207-O1A1, R01 AI 32031-24] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032031, R01AI044207] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; Darzynkiewicz Z, 1996, CYTOMETRY, V25, P1; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Fan W, 1999, ONCOGENE, V18, P6573, DOI 10.1038/sj.onc.1203054; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; GONG J, 1994, CELL PROLIFERAT, V27, P357, DOI 10.1111/j.1365-2184.1994.tb01469.x; GONG JP, 1993, INT J ONCOL, V3, P1037; GULLBERG M, 1986, J EXP MED, V163, P270, DOI 10.1084/jem.163.2.270; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297	34	6	6	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1771	1783		10.1038/sj.onc.1204212	http://dx.doi.org/10.1038/sj.onc.1204212			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313924				2022-12-17	WOS:000167750900010
J	Michael, D; Rajewsky, MF				Michael, D; Rajewsky, MF			Induction of the common fragile site FRA3B does not affect FHIT expression	ONCOGENE			English	Article						FHIT gene; FRA3B; fragile sites; human chromosome 3	CANCER; GENE; TUMORIGENICITY; PROTEIN; CELLS; REPLICATION; 3P14.2; P53	A long-standing issue concerns the extent to which fragile sites predispose to cancer-associated chromosomal rearrangements. The FHIT gene at chromosome 3p14.2 spans the most common fragile site, FRA3B, in the human genome. Although the FHIT gene is altered in many human cancers, its status as a tumor suppressor gene has remained controversial, particularly since functional studies provided contradictory results. It had been suggested the FHIT alterations result from FRA3B induction promoted by the interference of carcinogens with DNA replication. Here we investigated the effect of FRA3B induction on FHIT expression. Common fragile sites were induced by treatment with aphidicolin and scored cytogenetically, FHIT transcription was analysed by RT-PCR and RNase protection analysis. Unexpectedly, FHIT transcription proceeded unchanged after fragile site induction. Aberrant FHIT transcripts lacking one or more exons were not observed. Morevover, Western blots revealed that the levels of FHIT prior to and following fragile site induction was unchanged, whereas p53 was found at elevated levels after induction. FRA3B induction thus has no direct effect on FHIT transcription and translation.	Univ Essen, Sch Med, Inst Cell Biol Canc Res, D-45122 Essen, Germany; Univ Essen, Sch Med, Dept Internal Med Canc Res, D-45122 Essen, Germany; W German Canc Ctr, D-45122 Essen, Germany	University of Duisburg Essen; University of Duisburg Essen	Michael, D (corresponding author), Univ Essen, Sch Med, Inst Cell Biol Canc Res, Hufeland Str 55, D-45122 Essen, Germany.							Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; GILMANN M, 1993, CURRENT PROTOCOLS MO; GLOVER TW, 1987, AM J HUM GENET, V41, P882; Gustashaw KM., 1991, ACT CYTOGENETICS LAB, V2; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; MOSNER J, 1994, ONCOGENE, V9, P3321; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Thiagalingam S, 1996, CANCER RES, V56, P2936; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; WENGER SL, 1987, AM J MED GENET, V26, P909, DOI 10.1002/ajmg.1320260419; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; YUNIS JJ, 1987, ONCOGENE, V1, P59; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	24	6	6	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1798	1801		10.1038/sj.onc.1204243	http://dx.doi.org/10.1038/sj.onc.1204243			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313927				2022-12-17	WOS:000167750900013
J	Dhanasekaran, N; Gutkind, JS				Dhanasekaran, N; Gutkind, JS			Signaling by G protein coupled receptors and G proteins: a perspective	ONCOGENE			English	Editorial Material						G proteins; signal transduction; oncogene; GTPases; kinases			Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NIH, Oral & Pharyngeal Canc Branch, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 					0	6	6	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	2001	20	13					1530	1531		10.1038/sj.onc.1204273	http://dx.doi.org/10.1038/sj.onc.1204273			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX					2022-12-17	WOS:000168089800001
J	Rodier, F; Bertrand, R; Bossolasco, M; Mes-Masson, AM				Rodier, F; Bertrand, R; Bossolasco, M; Mes-Masson, AM			Polyomavirus large T-antigen protects mouse cells from Fas-, TNF-alpha- and taxol-induced apoptosis	ONCOGENE			English	Review						apoptosis; polyomavirus large T-antigen; Fas receptor; caspase-8; caspase-3	CHEMOTHERAPY-INDUCED APOPTOSIS; INTERLEUKIN-1-BETA CONVERTING-ENZYME; HEAT-SHOCK PROTEINS; RETINOBLASTOMA PROTEIN; MEDIATED APOPTOSIS; EXPRESSING MYOBLASTS; INTERACTING PROTEIN; TRANSGENIC MICE; DEATH RECEPTORS; MAMMALIAN-CELL	Polyomavirus large T-antigen (PyLT-Ag), a nucleophosphoprotein essential for regulating viral gene expression, modulates the cell cycle by binding to the Rb tumor suppressor gene product. PyLT-Ag/Rb binding is essential for in vitro immortalization. However, the effect of PyLT-Ag on apoptosis has not been extensively studied, We have previously reported that FasR agonist antibodies (FasR(Ab)) treatment of Sertoli cells derived from transgenic mice expressing PyLT-Ag induces the cells without concomitant apoptosis, Here we show that stable expression of PyLT-Ag in murine Sertoli TM4 and hybridoma NSO cell lines confers protection from FasR(Ab)-induced apoptosis, The protection was maintained up to 48 h when cells were grown continuously in the presence of FasR(Ab), Removal of the death stimulus after 24 h exposure was sufficient to allow full recovery of the PyLT-Ag expressing cells. The protective effect conferred by PyLT-Ag was associated with a delay in the sequential activation of caspase-8 and -3 after FasR(Ab) treatment. PyLT-Ag co-precipitated following immunoprecipitation of caspase-8 or FADD, both components of; the DISC, Based on these results we suggest that PyLT-Ag directly impedes the recruitment or activation of caspase-8 by the FasR, PyLT-Ag expression in TM4 cells was also associated with protection from TNF-chi -and taxol-induced apoptosis, In contrast, PyLT-Ag expression was not sufficient to confer protection from captothecin-induced apoptosis, Taken together, these results indicate that PyLT-Ag can be a potent inhibitor of Fas(R)(Ab)-, TNF-chi- and taxol-induced apoptosis.	CHUM, Ctr Rech, Hop Notre Dame, Montreal, PQ H2L 4M1, Canada; Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Mes-Masson, AM (corresponding author), CHUM, Ctr Rech, Hop Notre Dame, 1560 Rue Sherbrooke Est, Montreal, PQ H2L 4M1, Canada.			Rodier, Francis/0000-0003-2523-309X; Mes-Masson, Anne-Marie/0000-0002-6498-266X				Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Arrigo AP, 1998, BIOL CHEM, V379, P19; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BERTRAND R, 1995, DRUG DEVELOP RES, V34, P138, DOI 10.1002/ddr.430340206; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Chinnaiyan A M, 1997, Semin Immunol, V9, P69, DOI 10.1006/smim.1996.0055; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Decaudin D, 1998, INT J ONCOL, V12, P141; DOLE MG, 1995, CANCER RES, V55, P2576; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Endo T, 1998, J CELL SCI, V111, P1081; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Fimia GM, 1998, MOL BIOL CELL, V9, P1449, DOI 10.1091/mbc.9.6.1449; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Gottifredi V, 1999, J CELL SCI, V112, P2397; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Hohfeld J, 1998, BIOL CHEM, V379, P269; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jung YK, 1997, ONCOGENE, V14, P1207, DOI 10.1038/sj.onc.1200943; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; KHANDJIAN EW, 1992, ONCOGENE, V7, P909; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; LAROSE A, 1990, VIROLOGY, V176, P98, DOI 10.1016/0042-6822(90)90234-I; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Lebel M, 1996, ONCOGENE, V12, P1127; LEBEL M, 1994, EXP CELL RES, V213, P12, DOI 10.1006/excr.1994.1167; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mountz JD, 1997, IMMUNOL REV, V160, P19, DOI 10.1111/j.1600-065X.1997.tb01024.x; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Oyaizu H, 1999, Mol Cell Biol Res Commun, V2, P36, DOI 10.1006/mcbr.1999.0146; Perkins CL, 2000, CANCER RES, V60, P1645; Pilon AA, 1996, J VIROL, V70, P4457, DOI 10.1128/JVI.70.7.4457-4465.1996; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RASSSOULZADEGAN M, 1983, P NATL ACAD SCI USA, V82, P4354; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Reed JC, 1997, SEMIN HEMATOL, V34, P9; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; Riley MI, 1997, J VIROL, V71, P6068, DOI 10.1128/JVI.71.8.6068-6074.1997; ROUQUET N, 1995, ONCOGENE, V11, P1061; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1998, CELL STRESS CHAPERON, V3, P228, DOI 10.1054/csac.1998.0129; Sambrook J, 1989, MOL CLONING LAB MANU; Sane AT, 1999, CANCER RES, V59, P3565; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schett G, 1999, FASEB J, V13, P833, DOI 10.1096/fasebj.13.8.833; Schmitt E, 1998, EXP CELL RES, V240, P107, DOI 10.1006/excr.1998.4003; Schmitt E, 1999, DRUG RESIST UPDATE, V2, P21, DOI 10.1054/drup.1999.0065; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Siegel RM, 1999, J ALLERGY CLIN IMMUN, V103, P729, DOI 10.1016/S0091-6749(99)70412-4; SILVER J, 1978, CELL, V15, P485, DOI 10.1016/0092-8674(78)90018-1; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Slinskey A, 1999, J VIROL, V73, P6791, DOI 10.1128/JVI.73.8.6791-6799.1999; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAKAHASHI H, 1995, J INVEST DERMATOL, V105, P810, DOI 10.1111/1523-1747.ep12326577; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Vayssier M, 1998, CELL STRESS CHAPERON, V3, P221, DOI 10.1379/1466-1268(1998)003<0221:HSPCLA>2.3.CO;2; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Weigel TL, 2000, J THORAC CARDIOV SUR, V119, P795, DOI 10.1016/S0022-5223(00)70016-X; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Young LS, 1997, BRIT MED BULL, V53, P509; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHENG DQ, 1994, ONCOGENE, V9, P3345; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	92	6	7	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6261	6270		10.1038/sj.onc.1204015	http://dx.doi.org/10.1038/sj.onc.1204015			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175340				2022-12-17	WOS:000166210500009
J	Pereira, R; Raingeaud, J; Pironin, M; Ghysdael, J; Quang, CT				Pereira, R; Raingeaud, J; Pironin, M; Ghysdael, J; Quang, CT			SPI-1 transforming properties depend upon specifically activated forms of the EPOR	ONCOGENE			English	Article						friend erythroleukemia; SPI-1/PU.1; SFFV GP55; erythropoietin receptor; oncogene cooperation	ERYTHROID PROGENITOR CELLS; PU.1 TRANSCRIPTION FACTOR; ERYTHROPOIETIN RECEPTOR; PRIMARY ERYTHROBLASTS; DIFFERENTIATION; PROLIFERATION; ERYTHROLEUKEMIA; PHOSPHORYLATION; EXPRESSION; KINASE	Friend erythroleukemia induced in mice by the spleen focus forming virus (SFFV) is a multi-step process, The pre-leukemic phase of the disease results from the abnormal activation of the Erythropoietin (Epo) receptor by the gp55 env gene product of SFFV, Later in disease progression, the emergence of leukemic clones is associated with recurrent genetic events, in particular the activation of the expression of SPI-1, an ETS family transcriptional regulator. We show here that the expression of either SPI-1 or GP55 with the mouse EPOR in arian primary erythroblasts only marginally affects their normal Epo-induced terminal differentiation. In contrast, the co-expression of GP55 and SPI-1 resulted in inhibition of Epo-induced differentiation of EPOR-expressing erythroblasts, promoting instead their proliferation. Co-expression of SPI-1 and GP55 also inhibited the apoptotic cell. death program normally induced in response to Epo withdrawal. This cooperation between SPI-1 and GP55 to induce primary erythroblast transformation suggests that progression of Friend erythroleukemia critically depends upon inter-dependent interactions between the molecular events specific of the early and late phase of the disease.	Ctr Univ Orsay, Inst Curie, CNRS, UMR146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Ghysdael, J (corresponding author), Ctr Univ Orsay, Inst Curie, CNRS, UMR146, Bat 110, F-91405 Orsay, France.		GHYSDAEL, Jacques/F-3377-2013; QUANG, christine TRAN/G-7508-2016					Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Constantinescu SN, 1998, BLOOD, V91, P1163, DOI 10.1182/blood.V91.4.1163; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; HANKINS WD, 1980, CELL, V22, P693; Klingmuller U, 1997, EUR J BIOCHEM, V249, P637, DOI 10.1111/j.1432-1033.1997.t01-1-00637.x; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Pereira R, 1999, ONCOGENE, V18, P1597, DOI 10.1038/sj.onc.1202534; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; Tamir A, 1999, MOL CELL BIOL, V19, P4452; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	23	6	6	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5106	5110		10.1038/sj.onc.1203886	http://dx.doi.org/10.1038/sj.onc.1203886			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042699				2022-12-17	WOS:000089930100008
J	Basso, J; Briggs, J; Findlay, C; Bos, T				Basso, J; Briggs, J; Findlay, C; Bos, T			Directed mutation of the basic domain of v-Jun alters DNA binding specificity and abolishes its oncogenic activity in chicken embryo fibroblasts	ONCOGENE			English	Article						v-Jun; chicken; binding mutants	MOUSE C-JUN; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; TRANSCRIPTION FACTORS; CELL-TRANSFORMATION; NUCLEAR-PROTEIN; LEUCINE ZIPPER; BZIP PROTEINS; TARGET GENE; FOS	Overexpression of v-Jun in chicken embryo fibroblasts (CEF) leads to oncogenic transformation phenotypically characterized by anchorage independent growth and release from contact inhibition (focus formation). The mechanisms involved in this oncogenic conversion however, are not yet clear. Because Jun is a transcription factor, it has been assumed that oncogenic transformation results directly from deregulated AP-1 target gene expression. However, a number of experimental observations in avian cell culture models fail to correlate oncogenesis with AP-I activity suggesting that transformation induced by v-Jun may occur through an indirect mechanism, To test this possibility, we introduced point mutations into the basic DNA binding domain of v-Jun and created mutants that exhibit altered binding specificity, When expressed in CEF, these mutants fail to deregulate three known v-Jun target genes (JTAP-1, apolipoprotein Al,: c-Jun) thus demonstrating in vivo specificity changes, Each of the binding specificity mutants was also tested for its ability to induce oncogenic transformation. Interestingly, expression of these mutants in CEF results in a phenotype indistinguishable from the vector control with respect to growth rate, focus formation and the ability to form colonies in soft agar, These results are consistent with a model requiring direct AP-1 target deregulation as a prerequisite of v-Jun induced cell transformation. With this in mind, we generated a series of additional mutants that retain the ability to bind AP-1 sequence elements, but vary in their oncogenic potential. We demonstrate the use of these mutants to screen v-Jun induced gene targets for a functional role in cell transformation.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, T (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1993, ONCOGENE, V8, P877; CASTELLAZZI M, 1993, ONCOGENE, V8, P1149; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Goller ME, 1998, ONCOGENE, V16, P2945, DOI 10.1038/sj.onc.1201819; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1998, ONCOGENE, V16, P655, DOI 10.1038/sj.onc.1201574; Hadman M, 1996, ONCOGENE, V12, P135; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; METIVIER C, 1993, ONCOGENE, V8, P2311; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUCKOW M, 1993, EMBO J, V12, P1193, DOI 10.1002/j.1460-2075.1993.tb05760.x; TOURAY M, 1991, ONCOGENE, V6, P1227; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; VOGT PK, 1990, CANCER BIOL, V1, P27; WONG WY, 1992, ONCOGENE, V7, P2077; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206	50	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4876	4885		10.1038/sj.onc.1203863	http://dx.doi.org/10.1038/sj.onc.1203863			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039905				2022-12-17	WOS:000089757800010
J	Sengupta, S; Ralhan, R; Wasylyk, B				Sengupta, S; Ralhan, R; Wasylyk, B			Tumour regression in a ligand inducible manner mediated by a chimeric tumour suppressor derived from p53	ONCOGENE			English	Article						head and neck cancer; apoptosis; tamoxifen; oestrogen receptor; gene therapy	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; SQUAMOUS-CELL CARCINOMAS; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSFER; IN-VIVO; MUTANT P53; GROWTH SUPPRESSION; ESTROGEN-RECEPTOR	The p53 tumour suppressor induces cell cycle arrest and apoptosis in response to cellular stresses. p53 is inactivated by various cellular and viral factors. We set out to generate regulatable p53 derivatives that are highly inducible by synthetic ligands, escape inactivation and efficiently induce apoptosis. We have generated Ligand Inducible Chimeric Tumour Suppressors (LICTS), that are inactive unless provided with artificial ligands. They are resistant to inactivation, due to the replacement of domains that mediate p53 inhibition by heterologous sequences. LICTS are activated by micromolar concentrations of ligand in a variety of cell lines. Following ligand addition, they translocate to the nucleus, activate p53 inducible genes and induce apoptosis. We have established human head and neck squamous cell carcinoma lines that stably express LICTS, which are inducible. These lines form tumours in nude mice in the absence of ligand. Addition of ligand inhibits tumour formation, and moreover, regresses established tumours by apoptosis. Although regulatable p53 expression has been achieved previously, our study provides the first demonstration of regulatable in vivo regression of tumours in a p53 based approach. Regulated inhibition and regression of tumours with a ligand inducible chimeric tumour suppressor could provide a novel approach to p53 based gene therapy.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; All India Inst Med Sci, New Delhi 110029, India	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; All India Institute of Medical Sciences (AIIMS) New Delhi	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.		Wasylyk, Bohdan/ABG-6778-2020; Sengupta, Sagar/AGR-1063-2022	Wasylyk, Bohdan/0000-0002-1718-1237; Sengupta, Sagar/0000-0002-6365-1770				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bond J, 1996, ONCOGENE, V13, P2097; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Brachmann RK, 1998, EMBO J, V17, P1847, DOI 10.1093/emboj/17.7.1847; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burcin MM, 1999, P NATL ACAD SCI USA, V96, P355, DOI 10.1073/pnas.96.2.355; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Ford LG, 1997, PROG CLIN BIOL RES, V396, P271; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gallardo D, 1996, CANCER RES, V56, P4891; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GomezManzano C, 1996, CANCER RES, V56, P694; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JIANG D, 1993, ONCOGENE, V8, P2805; JUVEN T, 1993, ONCOGENE, V8, P3411; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LE GLS, 1993, SCIENCE, V259, P988; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; LIU TJ, 1994, CANCER RES, V54, P3662; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; MOMOSE F, 1989, J ORAL PATHOL MED, V18, P391, DOI 10.1111/j.1600-0714.1989.tb01570.x; Mukhopadhyay T, 1998, ONCOGENE, V17, P241, DOI 10.1038/sj.onc.1201909; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Pirollo KF, 1997, ONCOGENE, V14, P1735, DOI 10.1038/sj.onc.1201116; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SAKAI E, 1992, ONCOGENE, V7, P927; Sankaranarayanan R, 1998, ANTICANCER RES, V18, P4779; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schuler M, 1998, HUM GENE THER, V9, P2075, DOI 10.1089/hum.1998.9.14-2075; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; SHAH JP, 1995, CA-CANCER J CLIN, V45, P352, DOI 10.3322/canjclin.45.6.352; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Treinies I, 1999, MOL CELL BIOL, V19, P321; Vater CA, 1996, ONCOGENE, V13, P739; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WAKELING AE, 1995, BIOCHEM PHARMACOL, V49, P1545, DOI 10.1016/0006-2952(94)00528-T; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Xu GW, 1996, HEPATOLOGY, V24, P1264; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	100	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					337	350		10.1038/sj.onc.1203256	http://dx.doi.org/10.1038/sj.onc.1203256			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656680				2022-12-17	WOS:000084873700003
J	Bell, MV; Frampton, J				Bell, MV; Frampton, J			v-Myb can transform and regulate the differentiation of melanocyte precursors	ONCOGENE			English	Article						Myb; progenitor; melanocyte; differentiation	MULTIPOTENT HEMATOPOIETIC PROGENITORS; CREST CELL-CULTURES; E26 LEUKEMIA-VIRUS; C-MYB; NEURAL CREST; NEURORETINA CELLS; MONOCLONAL-ANTIBODIES; WAARDENBURG-SYNDROME; MALIGNANT-MELANOMA; LINEAGE COMMITMENT	The activity of the c-Myb transcription factor is essential for the development of definitive multi- and uni-lineage progenitors of the haemopoietic system. Reflecting this requirement, c-Myb has been oncogenically activated by transduction in the E26 avian retrovirus which elicits an acute leukaemia by transforming haemopoietic progenitors, Here, we report the novel finding that Myb in cooperation with EGF receptor signalling can be used to generate clonally expanded populations of transformed cells which have the phenotype of melanocyte precursors. Through the use of a conditional temperature sensitive mutant of Myb, we show that in the transformed cells Myb regulates commitment to melanocyte differentiation and possibly proliferation. These results add to our understanding of the roles of c-Myb beyond the haemopoietic system and to our knowledge and means of investigating the importance of transcription factors in the melanocyte linage.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford	Frampton, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO T, 1981, J IMMUNOL, V127, P1024; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; BROWN KE, 1992, J BIOL CHEM, V267, P4625; DASGUPTA P, 1989, ONCOGENE, V4, P1201; Eisen TG, 1996, MELANOMA RES, V6, P277, DOI 10.1097/00008390-199608000-00001; Ess KC, 1999, ONCOGENE, V18, P1103, DOI 10.1038/sj.onc.1202387; FRAMPTON J, 1995, EMBO J, V14, P2866, DOI 10.1002/j.1460-2075.1995.tb07286.x; Frampton J, 1997, MOL B INT U, P287; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; Gadson PF, 1997, EXP CELL RES, V230, P169, DOI 10.1006/excr.1996.3398; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HORTON MA, 1985, CANCER RES, V45, P5663; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; LAHAV R, 1994, DIFFERENTIATION, V58, P133; Lecoin L, 1998, P NATL ACAD SCI USA, V95, P3024, DOI 10.1073/pnas.95.6.3024; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Li M, 1998, INT J CANCER, V76, P430; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; McNagny KM, 1996, BLOOD, V87, P1343, DOI 10.1182/blood.V87.4.1343.bloodjournal8741343; Miglarese MR, 1997, CELL GROWTH DIFFER, V8, P1199; MOCHII M, 1988, CELL DIFFER DEV, V24, P67, DOI 10.1016/0045-6039(88)90087-5; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NATAF V, 1993, EXP CELL RES, V207, P171, DOI 10.1006/excr.1993.1177; NATAF V, 1995, EXP CELL RES, V218, P394, DOI 10.1006/excr.1995.1171; Nerlov C, 1998, GENE DEV, V12, P2403, DOI 10.1101/gad.12.15.2403; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; Rossi F, 1996, EMBO J, V15, P1894, DOI 10.1002/j.1460-2075.1996.tb00540.x; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; TRENT JM, 1989, CANCER RES, V49, P420; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655; VINCENT M, 1984, DEV BIOL, V103, P468, DOI 10.1016/0012-1606(84)90334-8; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874	52	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7226	7233		10.1038/sj.onc.1203161	http://dx.doi.org/10.1038/sj.onc.1203161			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602476				2022-12-17	WOS:000084119400006
J	Courtemanche, C; Anderson, A				Courtemanche, C; Anderson, A			The p53 tumor suppressor protein reduces point mutation frequency of a shuttle vector modified by the chemical mutagens (+/-)7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene, aflatoxin B-1 and meta-chloroperoxybenzoic acid	ONCOGENE			English	Article						p53; mutation frequency; shuttle vector	WILD-TYPE P53; HUMAN OSTEOSARCOMA CELLS; UV-INDUCED MUTATIONS; EXPRESSING CYTOCHROME-P450IA2 CDNA; DOSE-DEPENDENT DIFFERENCES; DNA-DAMAGE; P53-DEFICIENT MICE; EMBRYO FIBROBLASTS; MOUSE CELLS; SEQUENCE SPECIFICITY	p53 has been postulated to be the guardian of the genome. However, results supporting the prediction that point mutation frequencies are elevated in p53-deficient cells either have not been forthcoming or have been equivocal, To analyse the effect of p53 on point mutation frequency, we used the supF gene of the pYZ289 shuttle vector as a mutagenic target. pYZ289 was treated in vitro by ultraviolet irradiation, aflatoxin B-1, (+/-)7,8-dihy droxy-9, 10-epoxy-7,8,9, 10-tetrahydrobenzo/a/pyrene and meta-chloroperoxybenzoic acid and then transfected into p53-deficient cells with or without a p53 expression, vector. p,53 reduced the mutant frequency up to fivefold when pYZ289 was treated with aflatoxin B-1, (+/-)7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo/a/ or meta-chloroperoxybenzoic acid but not when it was ultraviolet-irradiated. The p53-dependent mutation frequency reduction was higher at a higher level of premutational lesions for aflatoxin B-1 and (+/-)7,8-dihydroxy-9, 10-epoxy-7,8,9, 10-tetrahydrobenzo/a/pyrene and at a lower level of lesions for meta-chloroperoxybenzoic acid. This suggests that the chemical mutagens produce, in a dose-dependent fashion, two kinds of DNA damage, one subject to p53-dependent mutation frequency reduction and the other not. These results indicate that p53 can reduce the point mutation frequency in a shuttle vector treated by chemical mutagens and suggest that p53 can act as guardian of the genome for at least some kinds of point mutations.	Univ Laval, CHU Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Dept Biol, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Anderson, A (corresponding author), Hop Hotel Dieu, Ctr Rech, 11 Cote Palais, Quebec City, PQ G1R 2J6, Canada.							AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; COURTEMANCHE C, 1994, MUTAT RES, V306, P143, DOI 10.1016/0027-5107(94)90025-6; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FOSTER PL, 1983, P NATL ACAD SCI-BIOL, V80, P2695, DOI 10.1073/pnas.80.9.2695; FREBOURG T, 1992, J CLIN INVEST, V90, P1637, DOI 10.1172/JCI116034; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, ONCOGENE, V8, P2457; HAVRE PA, 1995, CANCER RES, V55, P4420; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Ishizaki K, 1996, MUTAT RES-DNA REPAIR, V364, P43, DOI 10.1016/0921-8777(96)00020-1; JACOBSEN JS, 1986, CARCINOGENESIS, V7, P491, DOI 10.1093/carcin/7.3.491; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAPP LN, 1974, BIOCHIM BIOPHYS ACTA, V361, P140, DOI 10.1016/0005-2787(74)90341-4; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane D, 1998, NATURE, V394, P616, DOI 10.1038/29166; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY DD, 1992, CANCER RES, V52, P5668; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARIEN K, 1987, J BIOL CHEM, V262, P7455; MORIWAKI S, 1991, CANCER RES, V51, P6219; MUENCH KF, 1983, P NATL ACAD SCI-BIOL, V80, P6, DOI 10.1073/pnas.80.1.6; MURNANE JP, 1993, NATURE, V365, P22, DOI 10.1038/365022a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHINO H, 1995, ONCOGENE, V11, P263; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PEDEN KWC, 1980, SCIENCE, V209, P1392, DOI 10.1126/science.6251547; ROSENTHAL A, 1990, BIOCHEM BIOPH RES CO, V173, P272, DOI 10.1016/S0006-291X(05)81052-6; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; Smith ML, 1996, AM J PATHOL, V148, P1019; TROTTIER Y, 1992, MUTAT RES, V281, P39, DOI 10.1016/0165-7992(92)90034-F; TROTTIER Y, 1992, MOL CARCINOGEN, V6, P140, DOI 10.1002/mc.2940060209; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; Yagi T, 1998, CANCER LETT, V123, P71, DOI 10.1016/S0304-3835(97)00406-0; Yamagishi N, 1997, CARCINOGENESIS, V18, P695, DOI 10.1093/carcin/18.4.695; Yamagishi N, 1997, MUTAGENESIS, V12, P191, DOI 10.1093/mutage/12.3.191; YANG JL, 1987, P NATL ACAD SCI USA, V84, P3787, DOI 10.1073/pnas.84.11.3787; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295	59	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	1999	18	33					4672	4680		10.1038/sj.onc.1202805	http://dx.doi.org/10.1038/sj.onc.1202805			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	228UQ	10467414				2022-12-17	WOS:000082154400004
J	Cook, JL; Zhang, Z; Alam, J; Re, RN				Cook, JL; Zhang, Z; Alam, J; Re, RN			Effects of chromosomal integration site upon p53 interactions with DNA consensus sequence homologies	ONCOGENE			English	Article						p53; consensus sequence; chromatin; stable transfection	GENE-EXPRESSION; BINDING-SITE; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; MCK PROMOTER; CELL-LINES; REPRESSION	In the present study, we report that, despite the presence of one perfect p53 consensus sequence homology (designated SCL CS) and four half-sites within the 3'-untranslated region of the stem cell leukemia (SCL) gene, the native endogenous gene is not regulated by p53, We employ a tet-repressible system to show that, under conditions in which the WAF1 mRNA steady-state level is upregulated fourfold by p53, the SCL mRNA level is not altered, In a previous report, ne demonstrated that p53 interactions with the SCL CS can upregulate downstream reporter gene activity 43-fold in transient reporter assays, This disparity prompted us to explore the differences between p53 regulation of SCL CS activity in organized (chromosomally integrated) and disorganized (non-replicating episomal plasmid) chromatin. We show that p53 can increase (between 3-80-fold), decrease (between 5-33-fold) or have no effect upon transactivation of an SCL CS/reporter fusion gene depending upon chromosomal integration site. Most studies used to characterize p53 binding sites employ transient transfection assays. Our results suggest that characterization of consensus sequence homologies by assay of transiently transfected cells mag be inaccurate.	Alton Ochsner Med Fdn & Ochsner Clin, Div Res, New Orleans, LA 70121 USA	Ochsner Health System	Cook, JL (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Div Res, 1516 Jefferson Hwy, New Orleans, LA 70121 USA.		Alam, Jawed/F-2596-2010	Alam, Jawed/0000-0001-6520-482X				ACKLANDBERGLUND CE, 1995, BIOTECHNIQUES, V18, P196; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BI SC, 1994, CANCER RES, V54, P582; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COOK JL, 1995, ONCOGENE, V11, P723; DEB SP, 1994, ONCOGENE, V9, P1341; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOWE JR, 1995, J BIOL CHEM, V270, P14168, DOI 10.1074/jbc.270.23.14168; Jackson P, 1997, FEBS LETT, V406, P271, DOI 10.1016/S0014-5793(97)00283-4; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Kristjuhan A, 1995, EUR J BIOCHEM, V234, P827, DOI 10.1111/j.1432-1033.1995.827_a.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Metcalfe AMJ, 1997, NUCLEIC ACIDS RES, V25, P983, DOI 10.1093/nar/25.5.983; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARK DJ, 1994, ONCOGENE, V9, P1899; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; RAIMOND J, 1995, FEBS LETT, V363, P165, DOI 10.1016/0014-5793(95)00310-6; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	28	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2373	2379		10.1038/sj.onc.1202566	http://dx.doi.org/10.1038/sj.onc.1202566			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327058				2022-12-17	WOS:000079595500010
J	Zwicker, J; Korner, K; Muller, R				Zwicker, J; Korner, K; Muller, R			The SV40 large T oncoprotein disrupts DNA-binding of the cell cycle-regulated transcriptional repressor CDF	ONCOGENE			English	Article						cell cycle; repression; transcriptional regulation; viral oncoproteins; SV40; cyclin A; cdc25C	CDC25C TRANSCRIPTION; GENE; PROTEIN; EXPRESSION; ANTIGEN; E2F; MODULATION; PATHWAY; PRODUCT; ELEMENT	A hallmark of neoplastic transformation by DNA tumor viruses is the deregulation of cell cycle genes. At least in some genes, this deregulation appears to be due to the oncoprotein-mediated disruption of complexes between E2F and pocket proteins and the ensuing generation of transcriptionally active free E2F. In the present study, we have analysed the effect of the SV40 large T oncoprotein (SV-LT) on the function of a different cell cycle-regulated transcriptional repressor, CDF, which is the principal regulator of the cdc25C, cyclin A and cdc2 genes, As shown by genomic footprinting of sorted G(1) and G(2) cell populations, transformation by SV-LT completely abrogated protection of the CDF binding site (CDE-CHR) in the cdc25C promoter. In agreement with this observation, expression of the SV-LT in fibroblasts led to a dramatic up-regulation of the cdc25C promoter in cells synchronized in G(0). These findings indicate that the oncoprotein-mediated dissociation of the CDF repressor protein from its cognate DNA-binding site is a major mechanism in virus-induced transcriptional deregulation.	Univ Marburg, IMT, D-35033 Marburg, Germany	Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, IMT, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Boyer SN, 1996, CANCER RES, V56, P4620; BUCHOU T, 1993, ONCOGENE, V8, P1765; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; NEVINS JR, 1992, SCIENCE, V258, P424; OSHIMA J, 1993, ONCOGENE, V8, P2987; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	19	6	6	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					2023	2025		10.1038/sj.onc.1202063	http://dx.doi.org/10.1038/sj.onc.1202063			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208424				2022-12-17	WOS:000079191300012
J	Martincic, D; Koury, MJ; Gale, K; Whitlock, JA				Martincic, D; Koury, MJ; Gale, K; Whitlock, JA			Detection of mutations by automated fluorescence/RNA-based dideoxy fingerprinting (ARddF)	ONCOGENE			English	Article						dideoxyfingerprinting (ddF); mutation detection; p53 gene; automated sequencing	SEVERE COMBINED IMMUNODEFICIENCY; P53 GENE; DNA; DDF; POLYMORPHISMS; SEQUENCE	Dideoxy fingerprinting (ddF) is a hybrid technique which combines aspects of single strand conformational polymorphism (SSCP) and dideoxy sequencing to detect the presence of single base changes in a defined fragment of nucleic acid, ddF is no more technically demanding than SSCP, yet it is more sensitive in detecting point mutations. We describe here the adaptation of conventional ddF to an automated sequencing system using fluorescent Cy5 labeled primers. We show that automated RNA-based ddF (ARddF) has several advantages over conventional radioisotope-based ddF, including: (1) analysis of larger nucleic acid fragments (up to 10(3) bp), due to the ability to continuously analyse and compile sequencing information; (2) greater reliability for distinguishing mutant sequences from wild type sequences (particularly when the mutation leads to gain or loss of a dideoxy termination segment); (3) the use of fluorescent labeled primers, making ARddF less hazardous than methods requiring radionucleotides, The use of ARddF in conjunction with new methods for isolating RNA from nine small number of cells facilitates mutational analysis of small tissue biopsies and other limited samples, and will allow more widespread application of mutational screening in the setting of clinical diagnostic laboratories.	Vanderbilt Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Internal Med, Div Hematol, Nashville, TN 37232 USA; Vet Adm Med Ctr, Nashville, TN 37232 USA; Amersham Pharm Biotech, Piscataway, NJ 08854 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Martincic, D (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Div Pediat Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37232 USA.			Whitlock, James/0000-0002-7887-0634	NCI NIH HHS [1P30CA68485] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; Chen HL, 1997, MOL MED TODAY, V3, P160, DOI 10.1016/S1357-4310(97)01003-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVID YB, 1988, ONCOGENE, V3, P179; Durocher F, 1996, J MED GENET, V33, P814, DOI 10.1136/jmg.33.10.814; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; Koury MJ, 1997, BLOOD, V90, P4054, DOI 10.1182/blood.V90.10.4054; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LIU Q, 1992, HUM MOL GENET, V5, P107; Martincic D, 1996, ONCOGENE, V13, P2039; MARTINCIC D, 1998, IN PRESS BLOOD; Miyata I, 1997, ENDOCR J, V44, P149, DOI 10.1507/endocrj.44.149; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Olsen LS, 1996, PHARMACOL TOXICOL, V78, P364, DOI 10.1111/j.1600-0773.1996.tb00220.x; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; *PHARM BIOT, 1996, ALF EXPR DNA SEQ US; Puck JM, 1997, BLOOD, V89, P1968; Puck JM, 1997, HUM GENET, V99, P628, DOI 10.1007/s004390050418; QUIANG L, 1995, AM J MED GENET, V60, P165; QUIANG L, 1994, PCR METH APPL, V4, P97; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1992, NUCLEIC ACIDS RES, V20, P871, DOI 10.1093/nar/20.4.871; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Scriver C.R., 1995, METABOLIC MOL BASES, P1; Sobell JL, 1997, AM J MED GENET, V74, P44, DOI 10.1002/(SICI)1096-8628(19970221)74:1<44::AID-AJMG10>3.0.CO;2-R; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; ZAHURAK M, 1996, J NATL CANCER I, V88, P1580; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155	31	6	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	1999	18	3					617	621		10.1038/sj.onc.1202295	http://dx.doi.org/10.1038/sj.onc.1202295			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989811				2022-12-17	WOS:000078394400006
J	Wu, RC; Hohenstein, A; Park, JM; Qiu, XB; Mueller, S; Cadenas, E; Schonthal, AH				Wu, RC; Hohenstein, A; Park, JM; Qiu, XB; Mueller, S; Cadenas, E; Schonthal, AH			Role of p53 in aziridinylbenzoquinone-induced p21(waf1) expression	ONCOGENE			English	Article						p21; p53; quinones; aziridinylbenzoquinones	CYCLIN-DEPENDENT KINASES; DT-DIAPHORASE; P53-INDEPENDENT PATHWAY; ANTICANCER AGENTS; DNA-DAMAGE; OXIDATIVE STRESS; CELL-GROWTH; P21; SENSITIVITY; METABOLISM	Quinones are the second largest family of anticancer drugs clinically used in the United States. However, their exact mode of action at the cellular and molecular level is not completely understood. We have shown earlier that the quinone 3,6-diaziridinyl-1,4-benzoquinone (DZQ) leads to the increased expression of p21(waf1/cip/sdi1) protein, an inhibitor of cyclin-dependent kinases, Because p21 has been established as an important negative regulator of the cell cycle, we further investigated the molecular basis of p21 induction by DZQ. Here we report that the induction of p21 by DZQ is regulated at the transcriptional level, and requires the activation of p53, a tumor suppressor protein. In cells that lack functional p53 protein, DZQ-mediated p21 induction is greatly diminished. However, the introduction of a wild type p53 gene into p53-negative cells restores the strong DZQ-inducibility of p21. Restoration of wild type p53 status in HL60 myeloid leukemia cells significantly increases the cells' sensitivity to the cytotoxic effects of DZQ. Thus, our results indicate that the p53-p21 pathway may play a central role in mediating the gene-regulatory and cytotoxic effects of aziridinylbenzoquinones.	Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California	Schonthal, AH (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, 2011 Zonal Ave,HMR-405, Los Angeles, CA 90033 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653; Qiu, Xiao-Bo/0000-0003-2608-9376	NCI NIH HHS [R29CA74278-01] Funding Source: Medline; NHLBI NIH HHS [R01HL53467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Coursen JD, 1997, MOL CARCINOGEN, V19, P191; CRESTEIL T, 1991, BIOCHEM PHARMACOL, V42, P1021, DOI 10.1016/0006-2952(91)90284-C; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; GIBSON NW, 1992, MOL PHARMACOL, V42, P531; GUTIERREZ PL, 1989, FREE RADICAL BIO MED, V6, P405, DOI 10.1016/0891-5849(89)90087-7; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hawkins DS, 1996, CANCER RES, V56, P892; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; LEE CS, 1992, BIOCHEMISTRY-US, V31, P3019, DOI 10.1021/bi00126a025; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Liu Y, 1996, CANCER RES, V56, P31; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martinez JD, 1997, CELL GROWTH DIFFER, V8, P941; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OConnor PM, 1997, CANCER RES, V57, P4285; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POWIS G, 1987, PHARMACOL THERAPEUT, V35, P57, DOI 10.1016/0163-7258(87)90105-7; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QIU X, 1997, IN PRESS FREE RADIC; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Renzing J, 1996, J CELL SCI, V109, P1105; ROSS D, 1996, COMPREHENSIVE TOXICO; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITSKAMPWILMS E, 1995, BRIT J CANCER, V72, P917, DOI 10.1038/bjc.1995.433; Vile GF, 1997, FEBS LETT, V412, P70, DOI 10.1016/S0014-5793(97)00748-5; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	50	6	6	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 23	1998	17	3					357	365		10.1038/sj.onc.1201930	http://dx.doi.org/10.1038/sj.onc.1201930			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	102VV	9690517				2022-12-17	WOS:000074947500010
J	Schiemann, WP; Nathanson, NM				Schiemann, WP; Nathanson, NM			Raf-1 independent stimulation of mitogen-activated protein kinase by leukemia inhibitory factor in 3T3-L1 cells	ONCOGENE			English	Article						cytokine; leukemia inhibitory factor; MAP kinase; signal transduction	TRANSDUCING RECEPTOR COMPONENT; SIGNAL-REGULATED KINASE-2; EPIDERMAL GROWTH-FACTOR; MAP KINASE; PC12 CELLS; SERINE PHOSPHORYLATION; C-RAF; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA	We show here that treatment of 3T3-L1 cells with leukemia inhibitory factor (LIF) stimulated Raf-l activity in a time-and dose-dependent manner, Although phorbol ester failed to activate Raf-l directly, a protein kinase C-stimulated signal was found to be necessary, but not sufficient, for LIF-mediated activation of Raf-l, Elevation of intracellular cAMP levels completely blocked Raf-l activation by LIF, but was without effect on the magnitude of mitogen-activated protein kinase (MAPK) stimulation by the cytokine, suggesting the presence of a Raf-l-independent, cAMP-insensitive MAPK kinase kinase (MAPKKK) pathway in 3T3-L1 cells, Mono Q-fractionation of LIF-stimulated 3T3-L1 extracts identified a single peak of MAPKKK activity that was largely insensitive to elevated intracellular levels of cAMP, and that failed to correlate with stimulation of either Raf-l or MEKK1 protein kinases, Our results demonstrate that LIF-mediated activation of the MAP kinase cascade in 3T3-L1 cells proceeds through both Raf-l-dependent and -independent pathways which differ in their sensitivity to inhibition by intracellular cAMP.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Nathanson, NM (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007750] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07750] Funding Source: Medline; NINDS NIH HHS [NS30410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUMANN H, 1992, J BIOL CHEM, V267, P19744; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRUNET A, 1994, FEBS LETT, V346, P299, DOI 10.1016/0014-5793(94)00475-7; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; FAURE M, 1994, J BIOL CHEM, V269, P7851; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GARDNER AM, 1994, MEHTODS ENZYMOL, V238, P528; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; ICHIKAWA Y, 1970, J CELL PHYSIOL, V76, P175, DOI 10.1002/jcp.1040760207; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Keller JR, 1996, CURR TOP MICROBIOL, V211, P43; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRYIAKIS JM, 1992, NATURE, V358, P417; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; METCALF D, 1991, INT J CELL CLONING, V9, P95, DOI 10.1002/stem.5530090201; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; PORRAS A, 1994, J BIOL CHEM, V269, P12741; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; SOZERI O, 1992, ONCOGENE, V7, P2259; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; SVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Taga T, 1996, J NEUROCHEM, V67, P1; THOMA B, 1994, J BIOL CHEM, V269, P6215; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YIN TG, 1994, J BIOL CHEM, V269, P3731; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	54	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2671	2679		10.1038/sj.onc.1201800	http://dx.doi.org/10.1038/sj.onc.1201800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632143				2022-12-17	WOS:000073698200011
J	Waddell, S; Jenkins, JR				Waddell, S; Jenkins, JR			Defining the minimal requirements for papilloma viral E6-mediated inhibition of human p53 activity in fission yeast	ONCOGENE			English	Article						p53; E6; E6-AP; Schizosaccharomyces pombe	CARCINOMA CELL-LINES; UBIQUITIN-CONJUGATING ENZYMES; TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; SCHIZOSACCHAROMYCES-POMBE; E6 ONCOPROTEIN; SV40-TRANSFORMED CELLS; RETINOBLASTOMA GENES; MUTATIONAL ANALYSIS; TRANSFORMED-CELLS	The majority of human anogenital carcinomas show evidence of papillomavirus infection. To facilitate viral replication, viruses disable key cellular responses which would otherwise precipitate cell suicide. An obligate factor in one such response is the p53 tumour suppressor protein, p53 gene mutation is an infrequent event in anogenital cancer, apparently due to the action of HPV E6 protein, which inhibits mild-type p53 function by stimulating the degradation of p53 protein, p53 is required for the apoptotic response that is triggered in untransformed cells following inappropriate cell-cycling, E6 directed inhibition of p53 function thus facilitates the survival of transformed cells, We have developed a genetically tractable model that reports E6 protein-mediated human p53 inactivation in the fission yeast Schizosaccharomyces pombe. Functional dissection of the requirements for E6 directed inhibition in this system reveal an absolute requirement for the presence of both E6 protein and the human E3 ubiquitin ligase, E6-AP. Using a defined set of E6 mutants we show that degradation of p53 protein rather than E6/p53 association is Likely required for E6-mediated inhibition, This S, pombe based system represents a candidate screen for novel antiviral agents that act by disrupting the E6/E6-AP/p53 interaction.	Marie Curie Res Inst, Cell Proliferat Lab, Surrey RH8 0TL, England		Jenkins, JR (corresponding author), Marie Curie Res Inst, Cell Proliferat Lab, Surrey RH8 0TL, England.			Waddell, Scott/0000-0003-4503-6229				BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; BERBERICH S, 1994, ONCOGENE, V9, P1469; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HOWES KA, 1994, GENE DEV, V8, P1738; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KEEN N, 1994, ONCOGENE, V9, P1493; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIM D, 1994, ONCOGENE, V9, P1869; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; TARUNINA M, 1993, ONCOGENE, V8, P3165; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; VANHUFFEL C, 1992, EUR J BIOCHEM, V205, P33; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WADDELL S, 1995, NUCLEIC ACIDS RES, V23, P1836, DOI 10.1093/nar/23.10.1836; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	47	6	7	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	1998	16	13					1759	1765		10.1038/sj.onc.1201848	http://dx.doi.org/10.1038/sj.onc.1201848			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582024				2022-12-17	WOS:000072807600014
J	Gritti, C; Choukroun, V; Soulier, J; Madani, A; Dastot, H; Leblond, V; RadfordWeiss, I; Valensi, F; Varet, B; Sigaux, F; Stern, MH				Gritti, C; Choukroun, V; Soulier, J; Madani, A; Dastot, H; Leblond, V; RadfordWeiss, I; Valensi, F; Varet, B; Sigaux, F; Stern, MH			Alternative origin of p13(MTCP1)-encoding transcripts in mature T-cell proliferations with t(X;14) translocations	ONCOGENE			English	Article						MTCP1; TCL1; alternative promoter T-cell prolymphocytic leukemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; ATAXIA-TELANGIECTASIA; PROLYMPHOCYTIC LEUKEMIA; GENE; CHROMOSOME; EXPRESSION; ONCOGENE; MTCP-1; ABNORMALITIES; MALIGNANCIES	The MTCP1 gene is involved in the t(X;14)(q28;q11) translocation associated with T-cell prolymphocytic leukemia and related conditions. This gene is unusual in that it codes for two distinct proteins: a small mitochondrial protein, p8(MTCP1), putative oncogenic protein, p13(MTCP1). Scarcity of material from t(X;14)-associated proliferations and very low levels of mRNA expression have so far prevented a thorough description of p13(MTCP1)-encoding transcripts. Here, we characterize two additional t(X;14) bearing leukemias allowing this analysis. In one case, with a breakpoint located 5' to the MTCP1 gene, the level of transcription of previously described p13(MTCP1)-encoding transcripts is enhanced. In the second case, with a breakpoint within the MTCP1 intron I, an alternative transcription initiation site is demonstrated in the tumor cells at 229 bp upstream to exon II. The identification of this internal promoter, together with the similarity between TCL1 and MTCP1 genomic structures, allow us to propose a model in which the duplication of an ancestral gene was followed by the insertion of one copy within the intron of a p8-encoding gene, accounting for the unusual feature of the MTCP1 gene.	HOP ST LOUIS, INSERM U462, CTR HAYEM, F-75475 PARIS 10, FRANCE; HOP LA PITIE SALPETRIERE, DEPT HEMATOL, F-75631 PARIS 13, FRANCE; HOP NECKER ENFANTS MALAD, DEPT HEMATOL, F-75743 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite			Stern, Marc-Henri/A-2728-2011	Stern, Marc-Henri/0000-0002-8100-2272				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BEATTY DW, 1986, S AFR MED J, V69, P115; CANKI N, 1983, ZDRAV VESTN, V52, P567; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DALLAPICCOLA B, 1984, INT J CANCER, V34, P171, DOI 10.1002/ijc.2910340206; DURO D, 1995, ONCOGENE, V11, P21; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FISCH P, 1993, ONCOGENE, V8, P3271; FU TB, 1994, CANCER RES, V54, P6297; GOYNS MH, 1993, LEUKEMIA, V7, P848; LABARRIERE N, 1995, J BIOL CHEM, V270, P19205, DOI 10.1074/jbc.270.33.19205; MADANI A, 1995, ONCOGENE, V10, P2259; Madani A, 1996, BLOOD, V87, P1923; QUELLE DE, 1995, CELL, V83, P993; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOULIER J, 1994, ONCOGENE, V9, P3565; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1981, INT J CANCER, V27, P311, DOI 10.1002/ijc.2910270309; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; THICK J, 1994, LEUKEMIA, V8, P564; Thick J, 1996, ONCOGENE, V12, P379; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; WITZIG TE, 1986, AM J HEMATOL, V21, P139, DOI 10.1002/ajh.2830210204	26	6	6	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1329	1335		10.1038/sj.onc.1201303	http://dx.doi.org/10.1038/sj.onc.1201303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315101				2022-12-17	WOS:A1997XV84500011
J	Sharma, SV; Boyajian, A; Myers, CD; Nakano, H				Sharma, SV; Boyajian, A; Myers, CD; Nakano, H			Specific changes in rasGAP-associated 62 kilodalton protein during integrin mediated cell-substrate interaction	ONCOGENE			English	Article						rasGAP; GAP associated-p62; cell-substrate interaction; integrins; transformation	GTPASE-ACTIVATING PROTEIN; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; SURFACE PROTEIN; TRANSFORMED-CELLS; HUMAN-PLATELETS; NUDE MICE; GENE	A cascade of signal transduction events is initiated when cells make contact with each other or with a substrate. The nature of these signal transduction pathways is beginning to be elucidated. In particular, adhesive interactions between cells and their substrate, mediated by cell-surface integrins and extracellular matrix proteins, appears to activate the MAP kinase pathway. Here we show that in mouse fibroblasts and rat epithelial cells, tyrosine phosphorylation of a 62 kilodalton rasGAP-associated protein (GAPa-p62) is decreased upon cell-substrate interaction. Interaction between fibroblasts and various extracellular matrices such as fibronectin, vitronectin and collagen IV, but not laminin, results in tyrosine dephosphorylation of GAPa-p62. Cell-substrate mediated tyrosine dephosphorylation of GAPa-p62 is defective in transformed cell lines, suggesting a possible role for p62 in tumorigenic transformation. These studies suggest that in fibroblasts, and perhaps even in epithelial cells, the signal transduction pathway(s) triggered by different integrin engagement events converge on the rasGAP protein and alter the tyrosine phosphorylation and/or association of GAPa-p62.	KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,MACHIDA,TOKYO 194,JAPAN	Kyowa Kirin Ltd	Sharma, SV (corresponding author), UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,858 MADISON AVE,MEMPHIS,TN 38163, USA.				NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER; NCI NIH HHS [CA55983] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BERNARDS A, 1995, BBA-REV CANCER, V1242, P43, DOI 10.1016/0304-419X(95)00003-X; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHAN BMC, 1991, SCIENCE, V251, P1600, DOI 10.1126/science.2011740; CHEN Q, 1994, J BIOL CHEM, V296, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HEMLER ME, 1993, GUIDEBOOK EXTRACELLU; HYNES RO, 1973, P NATL ACAD SCI USA, V70, P3170, DOI 10.1073/pnas.70.11.3170; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER, 1984, CELL CULTURE METHODS; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PIERSCHBACHER MD, 1987, J BIOL CHEM, V262, P17294; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; TODARO GJ, 1964, P NATL ACAD SCI USA, V51, P66, DOI 10.1073/pnas.51.1.66; TODARO GJ, 1966, VIROLOGY, V28, P756, DOI 10.1016/0042-6822(66)90261-3; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHAO JF, 1995, ONCOGENE, V11, P161; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	71	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2641	2649		10.1038/sj.onc.1201115	http://dx.doi.org/10.1038/sj.onc.1201115			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178762				2022-12-17	WOS:A1997XB97800003
J	Felts, SJ; Stang, MT; Getz, MJ				Felts, SJ; Stang, MT; Getz, MJ			A c-Fos- and E1A-interacting component of the tissue factor basal promoter complex mediates synergistic activation of transcription by transforming growth factor-beta 1	ONCOGENE			English	Article						tissue factor; TGF-beta 1; c-Fos; transcriptional coactivators	NUCLEAR-PROTEIN CBP; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; BINDING-PROTEIN; E1A; COACTIVATOR; FAMILY; CREB; STIMULATION; COAGULATION	Stimulation of quiescent mouse fibroblasts with TGF-beta 1 and certain other growth factors result in cooperative activation of tissue factor (TF) gene transcription, an event accompanied by the rapid entry of c-Fos into specific AP-1 DNA-binding complexes (Felts et al, (1995) Biochemistry 34, 12355-12362), Here, we demonstrate that the ability of TGF-beta 1 to synergistically activate TF transcription in serum-stimulated fibroblasts is dependent upon both c-Fos and a promoter-specific factor with functional properties characteristic of transcriptional coactivators. Inhibition of TF promoter activity by an adenovirus E1A mutant deleted in an essential CREB binding protein (CBP) interaction domain suggests that this factor is distinct from the CBP/p300 family of transcriptional coactivators. Importantly, the ability of this factor to mediate molecular interactions with c-Fos required for transcriptional synergism is directly linked to TGF-beta 1 signaling. These data suggest a model in which a component of the TF basal transcription complex functions to integrate multiple signaling pathways required for full transcriptional activation of TF in fibroblasts.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,PROGRAM TUMOR BIOL,ROCHESTER,MN 55905	Mayo Clinic					NCI NIH HHS [CA65800-01E] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BARBEAU D, 1994, ONCOGENE, V9, P359; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KRAMER IM, 1991, EMBO J, V10, P1083, DOI 10.1002/j.1460-2075.1991.tb08048.x; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACKMAN N, 1992, ARTERIOSCLER THROMB, V12, P474, DOI 10.1161/01.ATV.12.4.474; Martin ML, 1996, MOL CELL BIOL, V16, P2110; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; RANGANATHAN G, 1990, J BIOL CHEM, V265, P3001; RANGANATHAN G, 1991, J BIOL CHEM, V266, P496; RAO LVM, 1992, CANCER METAST REV, V11, P249; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Vrana JA, 1996, CANCER RES, V56, P5063; WARR TA, 1990, BLOOD, V75, P1481; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	45	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1679	1685		10.1038/sj.onc.1201006	http://dx.doi.org/10.1038/sj.onc.1201006			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135069				2022-12-17	WOS:A1997WR89300006
J	Ribeiro, JCC; Hanley, JR; Russell, PJ				Ribeiro, JCC; Hanley, JR; Russell, PJ			Studies of X-irradiated bladder cancer cell lines showing differences in p53 status: Absence of a p53-dependent cell cycle checkpoint pathway	ONCOGENE			English	Article						p53; bladder cancer; cell lines; ionising irradiation; cell cycle; flow cytometry	WILD-TYPE P53; ATAXIA-TELANGIECTASIA CELLS; BRONCHIAL EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; KINASE INHIBITOR P21; DNA-DAMAGE; G(1) ARREST; NASOPHARYNGEAL CARCINOMA; P53-INDEPENDENT PATHWAY; IONIZING-RADIATION	Cell growth arrest is a common response to DNA damage by ionising irradiation and the p53 gene has been shown to play an important role in this mechanism, possibly in a tissue-specific manner. Mutations in the p53 gene are frequent in invasive bladder cancers, which are often treated by radiotherapy. In this paper we have investigated the growth response to X-irradiation of three bladder cancer cell lines with differing p53 status: UCRU-BL-17 overexpresses mutant p53, while UCRU-BL-13 and UCRU-BL-28 contain wt p53. We have also examined the expression of proteins reported to be part of the p53 control pathway in response to irradiation-induced DNA damage. No G1 arrest was detectable in any of the cell lines after ionising irradiation; furthermore, in a downstream event reported to be correlated with p53 function there was no increase in WAF-1 protein levels regardless of p53 status. Rather, ionising irradiation resulted in G2 arrest, but the extent of this was not related to p53 status. p16 levels were also not affected by irradiation, Our results suggest that the UCRU-BL-28 cell line may have a defect in the p53-cell control pathway upstream of p53, while UCRU-BL-13 cells may have a defect downstream between p53 and WAF-1.			Ribeiro, JCC (corresponding author), PRINCE WALES HOSP,ONCOL RES CTR,VILLA 1,HIGH ST,RANDWICK,NSW 2031,AUSTRALIA.		Russell, Pamela J/G-1685-2010; Russell, Pamela/O-8504-2019	Russell, Pamela J/0000-0002-3995-1239; 				AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bernhard E. J., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P602; CAAMANO J, 1991, AM J PATHOL, V139, P839; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EBLEN ST, 1995, CANCER RES, V55, P1994; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESRIG D, 1993, AM J PATHOL, V143, P1389; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GIRINSKY T, 1995, CANCER RES, V55, P3726; GONG JP, 1993, CANCER RES, V53, P5096; GONG JP, 1994, CANCER RES, V54, P4285; GOZY M, 1993, INT J RADIAT ONCOL, V27, P83, DOI 10.1016/0360-3016(93)90424-T; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAIN J, 1993, CANCER RES, V53, P1507; HARPER JW, 1993, CELL, V75, P805; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LI CY, 1995, ONCOGENE, V11, P1885; LI Y, 1994, ONCOGENE, V9, P2261; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLINARI M, 1995, ONCOGENE, V10, P1849; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NASRIN N, 1994, CANCER GENET CYTOGEN, V77, P14, DOI 10.1016/0165-4608(94)90142-2; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAULES RS, 1995, CANCER RES, V55, P1763; PODUST N, 1995, CANCER RES, V34, P8869; PRICE BD, 1994, CANCER RES, V54, P896; REDDEL RR, 1988, CANCER RES, V48, P1904; RIBEIRO JC, 1994, J CELL BIOCHEM, V18, P196; RUSSELL PJ, 1988, INT J CANCER, V41, P74, DOI 10.1002/ijc.2910410115; RUSSELL PJ, 1989, INT J CANCER, V44, P276, DOI 10.1002/ijc.2910440216; RUSSELL PJ, 1993, J UROLOGY, V150, P1038, DOI 10.1016/S0022-5347(17)35682-3; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIMMEL A, 1994, ONCOGENE, V9, P995; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; ZHAN QM, 1994, CANCER RES, V54, P2755	62	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1269	1278						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808701				2022-12-17	WOS:A1996VJ20200018
J	SunHoffman, L; Aurigemma, RE; Sun, B; Ruscetti, SK				SunHoffman, L; Aurigemma, RE; Sun, B; Ruscetti, SK			Transactivation of the GATA-1 promoter by a myb-ets-containing mouse retrovirus is mediated by CACCC elements	ONCOGENE			English	Article						ME26 virus; GATA-1 transactivation; CACCC element; Sp1	TRANSCRIPTION FACTOR GATA-1; ERYTHROPOIETIN RECEPTOR GENE; LEUKEMIA-VIRUS; FACTOR SP1; BINDING; CELLS; PROTEINS; E26	The myb-ets-containing ME26 virus causes erythroleukemia in mice by a novel mechanism involving the inappropriate activation of erythroid-specific genes in hematopoietic precursor cells, We have previously shown that the ME26 viral protein can transactivate the GATA-1 promoter in transient transactivation assays carried out in mouse fibroblasts. The mouse GATA-1 promoter, whose activity is regulated by the GATA-1 protein itself, contains a double GATA consensus sequence at its 5' end and two CACCC elements at its 3' end, both of which are crucial for promoter activity in erythroid cells, as well as a nonconsensus GATA sequence and several putative c-myb and c-ets binding sites, In order to determine which sequences in the GATA-1 promoter are crucial for activation by the ME26 viral protein, we made deletions of the promoter, cloned them into a luciferase expression vector and tested their activity in mouse fibroblasts, which do not express GATA-1, Our results indicate that sequences in the 3' end of the GATA-1 promoter, which include two CACCC elements, are essential for transactivation by ME26 virus, while other upstream sites contribute to full activation by the virus, Mutation of the CACCC sites abolishes ME26 viral transactivation. The interaction of cell extracts containing ME26 viral protein and the GATA-1 promoter fragment containing the two CACCC elements was examined by electrophoretic mobility shift analysis (EMSA) and the results showed no direct interaction between the two, However, we could detect the ubiquitous transcription factor Spl bound to this sequence, These data demonstrate that the CACCC element is necessary for GATA-1 promoter transactivation by ME26 virus and that the viral protein may indirectly transactivate the promoter by binding to Sp1.	NCI,MOL ONCOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BRADY HJM, 1989, FEBS LETT, V257, P451, DOI 10.1016/0014-5793(89)81594-7; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; FISCHER KD, 1993, J BIOL CHEM, V268, P23195; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GREGORY RC, 1996, BLOOD, V5, P1793; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Ren SC, 1996, NUCLEIC ACIDS RES, V24, P342, DOI 10.1093/nar/24.2.342; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	22	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1037	1042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806693				2022-12-17	WOS:A1996VG76600017
J	Kanazawa, S; Ilic, D; Hashiyama, M; Okada, M; Noumura, T; Aizawa, S; Suda, T				Kanazawa, S; Ilic, D; Hashiyama, M; Okada, M; Noumura, T; Aizawa, S; Suda, T			Impaired development of CD4(+) CD8(+) thymocytes by csk-(knock-in) into fyn locus	ONCOGENE			English	Article						p59(fyn); p50(csk); p56(lck); knock-in; thymocytes; T cell development	PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; SRC FAMILY KINASES; CROSS-LINKING; MICE LACKING; MUTANT MICE; ACTIVATION; ASSOCIATION; P56(LCK); ZAP-70	p59(fyn) is one of the Src-family kinases thought to play an important role in signaling through T cell receptor, However, Fyn deficiency has caused no overt defects in vivo on T cell development, nor has it caused any changes in the phosphorylation status of molecules such as ZAP-70 which have been proposed as p59(fyn) substrates, This could be explained as being due to compensation of Fyn deficiency by other Src-family kinases, Here, we have 'knocked-in' the csk gene, a negative regulator of Src-family kinases, into fyn locus to challenge the problem of redundant functions among Src-family kinases, The csk-'knock-in' mice displayed atrophy of the thymic cortex and impaired development of CD4(+) CD8(+) thymocytes, This was concomitant with decrease in tyrosine phosphorylation of ZAP-70 and p120(cbl).	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; SAITAMA UNIV,GRAD SCH ENGN SCI,URAWA,SAITAMA 338,JAPAN; OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN	Kumamoto University; Kumamoto University; Saitama University; Osaka University			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771; ILIC, DUSKO/0000-0003-1647-0026				ALLAND L, 1994, J BIOL CHEM, V269, P16701; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BLACK TJ, 1993, EMBO J, V12, P2017; BOLEN JB, 1993, ONCOGENE, V8, P2025; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; IMAMOTO A, 1993, CELL, V73, P117; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEVIN SD, 1993, J EXP MED, V178, P245, DOI 10.1084/jem.178.1.245; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKADA S, 1993, BLOOD, V81, P1720; OLSZOWY MW, 1995, J IMMUNOL, V155, P4236; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TAMURA T, 1993, J IMMUNOL, V151, P6051; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAGI T, 1994, ONCOGENE, V9, P2433	43	6	6	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					199	204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700547				2022-12-17	WOS:A1996UX31900023
J	FUKASAWA, K; ZHOU, RP; MATTEN, WT; ARMSTRONG, AJ; DAAR, I; OSKARSSON, M; SATHYANARAYANA, BK; MACLVOR, L; WOOD, TG; VANDEWOUDE, GF				FUKASAWA, K; ZHOU, RP; MATTEN, WT; ARMSTRONG, AJ; DAAR, I; OSKARSSON, M; SATHYANARAYANA, BK; MACLVOR, L; WOOD, TG; VANDEWOUDE, GF			MUTAGENIC ANALYSIS OF FUNCTIONAL DOMAINS OF THE MOS PROTOONCOGENE AND IDENTIFICATION OF THE SITES IMPORTANT FOR MAPK ACTIVATION AND DNA-BINDING	ONCOGENE			English	Article						MOS; MAP KINASE; TRANSFORMATION; OOCYTE MATURATION	XENOPUS-OOCYTES; V-MOS; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; KINASE-ACTIVITY; MEIOSIS-II; TUBULIN; INVITRO; CELLS; TRANSFORMATION	We constructed in-frame deletion/replacement mutations in the Xenopus mos proto-oncogene that lie within conserved Mos-specific codons, but outside of the regions that are conserved among the src kinase family of genes, All gene products were assayed in vine for kinase activity and in vivo for their ability to induce oocyte maturation, embryonic cleavage arrest and cellular transformation, Most mutations in Mos eliminated both kinase and biological activity, However, a mutation in Mos that removed two basic amino acid residues (R94 and K97) downstream from the lysine at the ATP binding site (K90) markedly enhanced autophosphorylation activity, Moreover, this mutant displayed markedly reduced biological activity, lacked transforming activity, and failed to activate mitogen activated protein kinase (MAPK), A second mutant Mos product, lacking amino acids R45-A54, displayed a five-fold increase in cellular transforming activity, This Mos mutant specifically localized to the cytoplasm; in contrast to wild-type (wt) Mos that localized to both the nucleus and the cytoplasm, These data indicate that Mos transforming activity is mediated via signalling exerted in the cytoplasm, presumably through MAPK, and that nuclear localization of the oncogene product interferes with transforming activity, We also show that amino acids R45-A54 are important for Mos DNA binding activity.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702; UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,RECOMBINANT DNA LAB,GALVESTON,TX 77555	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Texas System; University of Texas Medical Branch Galveston			Wood, Thomas/B-6172-2012; Wood, Thomas/GWZ-2481-2022	Wood, Thomas/0000-0001-8962-8571; Daar, Ira/0000-0003-2657-526X				BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKASAWA K, 1995, ONCOGENE, V10, P1; FUKASAWA K, 1995, P NATL ACAD SCI USA, V92, P3430, DOI 10.1073/pnas.92.8.3430; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUCHON D, 1981, REPROD NUTR DEV, V21, P135, DOI 10.1051/rnd:19810112; JESSUS C, 1986, BIOL CELL, V56, P113, DOI 10.1111/j.1768-322X.1986.tb00448.x; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; OKAZAKI K, 1995, JPN J CANCER RES, P1149; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; RIEDER CL, 1993, MORPHOGENESIS MITOTI, P183; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1987, P NATL ACAD SCI USA, V84, P3560, DOI 10.1073/pnas.84.11.3560; SETH A, 1988, LOCALIZATION NUCLEIC, P82; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WANG XM, 1994, P NATL ACAD SCI USA, V91, P8329, DOI 10.1073/pnas.91.18.8329; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	52	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1447	1457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478569				2022-12-17	WOS:A1995TC53500003
J	TIKHONENKO, AT; BLACK, DJ; LINIAL, ML				TIKHONENKO, AT; BLACK, DJ; LINIAL, ML			V-MYC IS INVARIABLY REQUIRED TO SUSTAIN RAPID PROLIFERATION OF INFECTED-CELLS BUT IN STABLE CELL-LINES BECOMES DISPENSABLE FOR OTHER TRAITS OF THE TRANSFORMED PHENOTYPE	ONCOGENE			English	Article						MYC; GLUCORTICOID RECEPTOR; TRANSFORMATION; PROLIFERATION	HUMAN C-MYC; AVIAN LEUKEMIA VIRUSES; EMBRYO FIBROBLASTS; DNA-BINDING; GLUCOCORTICOID RECEPTOR; N-MYC; NUCLEAR-LOCALIZATION; GENE; CHICKEN; EXPRESSION	The v-myc-containing retrovirus MC29 induces neoplastic transformation of avian embryo cells. To determine which traits of the transformed phenotype are directly controlled by v-Myc, we engineered a conditional MC29 mutant (GRIM) expressing v-Myc as a fusion protein with the glucocorticoid receptor and the retroviral Gag polyprotein. Only in the presence of glucocorticoids such as dexamethasone is GRIM capable of transforming embryo cells, from which six stable GRIM-lines have been derived. Although their survival in culture no longer requires functional v-Myc, hormone deprivation causes all six GRIM clones as web as acutely infected fibroblast cultures to either withdraw from cell cycle completely or to grow much more slowly and to much lower densities. However, removal of dexamethasone does not allow GRIM-transformed mass cultures and most of the clones to revert to normal shapes or to reconstruct actin cables. Furthermore, most clones do not require the hormone sustain anchorage-independent growth. We propose that certain secondary events have let the GRIM-clones sustain immortality, transformed morphology, and anchorage-independent growth independently of v-Myc. None of these events, however, has obliterated the requirement for v-Myc in cell division control. We thus conclude that enhanced proliferation is the primary effect of v-Myc expression.			TIKHONENKO, AT (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.		Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206	NCI NIH HHS [CA58809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKER D, 1977, J VIROL, V21, P1042, DOI 10.1128/JVI.21.3.1042-1055.1977; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIEGALKE BJ, 1987, J VIROL, V61, P2138, DOI 10.1128/JVI.61.7.2138-2142.1987; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CROUCH DH, 1990, ONCOGENE, V5, P683; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DEHM P, 1971, BIOCHIM BIOPHYS ACTA, V240, P358, DOI 10.1016/0005-2787(71)90529-6; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; MA A, 1993, ONCOGENE, V8, P1093; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; OLSON WC, 1990, HYBRIDOMA, V9, P331, DOI 10.1089/hyb.1990.9.331; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SYMONDS G, 1989, ONCOGENE, V4, P285; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1993, MOL CELL BIOL, V13, P3623, DOI 10.1128/MCB.13.6.3623; ULRICH E, 1992, GENE DEV, V6, P876, DOI 10.1101/gad.6.5.876; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG E, 1976, P NATL ACAD SCI USA, V73, P4065, DOI 10.1073/pnas.73.11.4065; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	52	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1499	1508						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478574				2022-12-17	WOS:A1995TC53500008
J	BIA, B; COWELL, JK				BIA, B; COWELL, JK			INDEPENDENT CONSTITUTIONAL GERMLINE MUTATIONS OCCURRING IN THE RB1 GENE IN COUSINS WITH BILATERAL RETINOBLASTOMA	ONCOGENE			English	Note						RB1 GENE; MUTATIONS	ONCOGENIC POINT MUTATIONS; HEREDITARY RETINOBLASTOMA; LOW-PENETRANCE; MECHANISMS; PEDIGREES	The inheritance of a genetic susceptibility to the development of retinoblastoma generally follows an autosomal mode of inheritance with high penetrance. Rare families, however, show evidence of incomplete penetrance where individuals can transmit the mutant gene without being affected themselves. In these families formal proof of this dogma requires the identification of the predisposing mutation. In this study we have identified the mutations in cousins with bilateral (hereditary) disease. Using SSCP and DNA sequencing, different constitutional mutations were detected in the affected cousins in this pedigree. One cousin carries a C-->T mutation in exon 8 generating a stop codon directly which was also present in his affected mother whereas the other cousin carries an 8 base pair deletion in exon 20. Neither half of the family carried the same mutation as the other. The mother of the patient with the 8 bp deletion carried neither of the mutations. Thus, we have demonstrated that the retinoblastomas in this family have developed as a result of independent, sporadic genetic events which occurred coincidentally in the same extended family rather than being due to a common mutation which manifests as incompletely penetrant, These observations have important implications for genetic counselling in this type of family.	INST CHILD HLTH,IMPERIAL CANC RES FUND,ONCOL GRP,HEMATOL ONCOL UNIT,LONDON WC1,ENGLAND					Cowell, John/0000-0002-2079-5950				BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; GALLIE BL, 1982, BRIT J CANCER, V45, P513, DOI 10.1038/bjc.1982.87; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; KATO MV, 1994, HUM MUTAT, V3, P44, DOI 10.1002/humu.1380030108; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MATSUNAGA E, 1978, AM J HUM GENET, V30, P406; MUNIER FL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1507, DOI 10.1001/archopht.1993.01090110073028; NAUMOVA A, 1994, AM J HUM GENET, V54, P264; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1991, BRIT J OPHTHALMOL, V75, P147, DOI 10.1136/bjo.75.3.147; ONADIM Z, 1993, BRIT J CANCER, V68, P958, DOI 10.1038/bjc.1993.461; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; VOGEL F, 1979, HUM GENET, V52, P1; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	20	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					977	979						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675457				2022-12-17	WOS:A1995RU79800019
J	VELASCO, JA; RAMSAMOOJ, P; THRAVES, PJ; EVA, A; DRITSCHILO, A; NOTARIO, V				VELASCO, JA; RAMSAMOOJ, P; THRAVES, PJ; EVA, A; DRITSCHILO, A; NOTARIO, V			COREGULATED EXPRESSION OF DBL AND POLY(ADP-RIBOSE) POLYMERASE IN EWINGS-SARCOMA CELLS AND DBL-TRANSFORMED NIH3T3 FIBROBLASTS	ONCOGENE			English	Note						EWINGS SARCOMA; GENE EXPRESSION; DBL ONCOGENE; POLY(ADP-RIBOSE) POLYMERASE; NIH3T3 FIBROBLASTS	PROTO-ONCOGENE; DNA; PROTOONCOGENE; CLONING; PRODUCT; ORIGIN; CDNA; GENE	Poly(ADP-ribose) polymerase (PADPRP) is a ubiquitous enzyme constitutively expressed at low levels in the majority of eukaryotic cells, including most mammalian tumors and tumor-derived cell lines. Overexpression of PADPRP following the introduction of cDNA recombinant constructs into various cell types results in cell death. An exception to this effect are Ewing's sarcoma (ES) cells, which have been shown to contain elevated steady-state levels of PADPRP mRNA and high constitutive levels of protein and polymerase activity. In fact, this excess of PADPRP has been suggested to participate in the intrinsic radiosensitivity of Ewing's sarcomas, a highly malignant childhood bone tumor frequently curable with radiotherapy. It appears that ES cells might possess a hitherto unknown mechanism(s) by which PADPRP overexpression is controlled and made compatible with cell survival and proliferation. In order to investigate the contribution of other genetic alterations to PADPRP regulation in ES cells, we analysed the expression levels of PADPRP and of other genes, such as oncogenes and tumor suppressor genes, which may enhance the proliferative potential of ES cells. We have detected a positive correlation between the expression levels of the DNA-repair enzyme poly(ADP-ribose) polymerase and the dbl proto-oncogene in Ewing's sarcoma cells. The co-regulated expression of these genes has been established in NIH3T3 cells transformed by the human dbl oncogene or by overexpression of the dbl proto-oncogene. In both instances, the increase in dbl expression resulted in elevated levels of PADPRP mRNA and polymerase activity. The dbl oncogene was more efficient than the proto-oncogene in upregulating PADPRP expression. The inability of other oncogenes to upregulate PADPRP upon transformation of NIH3T3 cells demonstrated the specificity of the dbl in the process. Transfection of dbl-transformed NIH3T3 cells with retroviral PADPRP vectors resulted in the establishment of clones with PADPRP levels higher than those detectable in untransformed NIH3T3 cells transfected with the same retroviral constructs. These results suggest that dbl plays a role in the mechanism by which mammalian cells autoregulate their endogenous levels of PADPRP. Post-translational modification of the dbl or proto-dbl proteins by cytoplasmic PADPRP does not participate in the mechanism(s) underlying the observed PADPRP/dbl co-regulation.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; Eva, Alessandra/J-8268-2016; /AAB-6461-2022	Eva, Alessandra/0000-0003-2949-078X; 	NATIONAL CANCER INSTITUTE [R01CA058986] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA58986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BHATIA K, 1990, J CELL PHYSIOL, V144, P345, DOI 10.1002/jcp.1041440221; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DEFRANCISCIS V, 1991, CANCER RES, V51, P4234; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GRAZIANI G, 1989, ONCOGENE, V4, P823; HUPPI K, 1989, NUCLEIC ACIDS RES, V17, P3387, DOI 10.1093/nar/17.9.3387; IKAI K, 1980, P NATL ACAD SCI-BIOL, V77, P3682, DOI 10.1073/pnas.77.6.3682; JORGENSEN TJ, 1993, RADIAT ONCOL INVEST, V1, P189; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; NOTARIO V, 1990, ONCOGENE, V5, P1425; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; Prasad Sarada, 1994, Applied and Theoretical Electrophoresis, V4, P3; PRASAD SC, 1990, CANCER RES, V50, P38; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; THOMASSIN H, 1985, BIOCHEM BIOPH RES CO, V133, P654, DOI 10.1016/0006-291X(85)90955-6; VECCHIO G, 1989, ONCOGENE, V4, P897; VELASCO JA, 1994, ONCOGENE, V9, P2065; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	25	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 1	1995	10	11					2253	2258						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784072				2022-12-17	WOS:A1995RB70300023
J	DAS, GC; SHIVAKUMAR, CV; TODD, SD				DAS, GC; SHIVAKUMAR, CV; TODD, SD			CELL-SPECIFIC MODULATION OF THE PAPOVAVIRUS PROMOTERS BY TUMOR-SUPPRESSOR PROTEIN P53 IN THE ABSENCE OF LARGE T-ANTIGEN	ONCOGENE			English	Article						P53; TUMOR-SUPPRESSOR PROTEIN; PAPOVAVIRUS PROMOTERS; TRANSACTIVATION; GENE REGULATION BY P53	WILD-TYPE P53; EMBRYONAL CARCINOMA-CELLS; POLYOMAVIRUS BK INVITRO; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; SV40-TRANSFORMED CELLS; IDENTIFICATION; SEQUENCES; INDUCTION; ENHANCER	The oncoproteins from several DNA tumor viruses form a complex with p53 and inactivate its function. Wild-type p53 is a transcription factor and can regulate eukaryotic promoters both positively and negatively. To elucidate the basis of the opposing functions and to understand whether and how oncoprotein synthesis in papovaviruses is regulated by p53, we studied modulation of the early promoters of SV40, polyomavirus and BK virus in the absence of the interfering effect of viral large T antigens. We here show that murine p53 can regulate the viral promoters either positively or negatively depending on the cell type. A temperature-sensitive mutant p53, 135 Val, at 37 degrees C also showed a cell-specific effect. These results suggest that promoter activation by p53 is not solely determined by p53 binding site, but host factors modulate p53's transactivation function. A TATA-less polyomavirus Late promoter was also repressed in HeLa cells and the level of repression was much less in the presence of active early promoter. As p53 and 135 Val were overexpressed to similar extent in different transfected cell Lines, variation in transactivation function is not due to the difference in the level of expressed protein. Our observations thus suggest that p53 interactions with cellular factors in addition to the TATA binding protein (TBP) are important for activator and repressor functions of p53. Well-defined viral promoters could thus provide us with an important tool for the identification and characterization of cellular factors that modulate p53-binding dependent gene regulation in animal cells.			DAS, GC (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MOLEC BIOL,POB 2003,TYLER,TX 75710, USA.				NCI NIH HHS [CA 47611] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABORTY T, 1989, MOL CELL BIOL, V9, P3821, DOI 10.1128/MCB.9.9.3821; CHAKRABORTY T, 1991, J GEN VIROL, V72, P1935, DOI 10.1099/0022-1317-72-8-1935; CHEN JY, 1993, ONCOGENE, V8, P2159; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DASGUPTA S, 1993, J GEN VIROL, V74, P597, DOI 10.1099/0022-1317-74-4-597; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEYERLE KL, 1987, J VIROL, V62, P3378; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1049; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1991, SCIENCE, V256, P827; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MEITZ JA, 1992, EMBO J, V11, P5013; MICHALOVITZ D, 1990, CURR OPIN CELL BIOL, V3, P282; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAGIMOV N, 1992, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMBROOK J, 1993, MOL CLONING LABORATO; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P10277; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEGHAL PB, 1993, ONCOGENE, V8, P3417; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIVAKUMAR CV, 1994, J GEN VIROL, V75, P1281, DOI 10.1099/0022-1317-75-6-1281; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSENG RW, 1988, J VIROL, V62, P2896, DOI 10.1128/JVI.62.8.2896-2902.1988; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; ZAMBETTI ZP, 1992, GENE DEV, V6, P1131	58	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					449	455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845669				2022-12-17	WOS:A1995QF64800005
J	CHUNG, SW; CAI, YL; NYEIN, R; BRIZZOLARA, E; DERIEL, K; WONG, PMC				CHUNG, SW; CAI, YL; NYEIN, R; BRIZZOLARA, E; DERIEL, K; WONG, PMC			ENDOGENOUS GROWTH-FACTOR PATTERNS MODULATE HEMATOPOIETIC LINEAGE DEVELOPMENT	ONCOGENE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; CHRONIC MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; ABL TYROSINE KINASE; ABELSON VIRUS; C-ABL; AUTOCRINE GROWTH; STEM-CELLS; V-ABL; MYELOPROLIFERATIVE DISEASE	Hemopoietic growth factors play an important role during stem cell differentiation, and multipotent hemopoietic cells expressing abl oncogenes can cause stem cell diseases in mice. To further elucidate the mechanism of disease development, we examined the initial changes of normal and abl-transduced progenitor cells early in culture, including the endogenous production of growth factors. From 2-3 days methycellulose cultures, we isolated colonies of early cells and subjected them to RT-PCR analysis. They were found to produce endogenous IL-1 alpha and IL-4. Treatment of these early cells with the antisense oligonucleotides directed against the mRNA of the growth factors did not prevent colony formation. However, the percentage of pure macrophage colonies in cultures containing the antisense IL-1 alpha was increased from 26-60%. This effect was not observed when the antisense oligomers were added 2 days after initiation of culture. We also transduced the progenitor cells with retrovirus vectors carrying either a neo(r) gene (N2) or a v-abl oncogene (A-MuLV or NSabl). After their culture in methylcellulose, we examined the types of colonies developed, growth factor expression by the early cells and their proliferation rate. While the ratio of erythroid to non-erythroid hemopoietic colonies in uninfected culture and N2-infected culture was 0.8, the ratio in A-MuLV-infected culture was 6.0, and in NSabl-infected culture, 3.1. RT-PCR analysis on colonies of abl-transduced cells from 2-3 day cultures indicated a reduction of IL-4 and IL-1 alpha in these cells, and they entered cell division sooner. Our data suggest that hematopoietic lineage development may be a function of the pattern of endogenous as well as exogenous growth factors, and alteration of this pattern either through antisense treatment or v-abl transduction affects the hemopoietic differentiation program.	TEMPLE UNIV, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, DEPT IMMUNOL & MICROBIOL, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	CHUNG, SW (corresponding author), SUNY HLTH SCI CTR, MORSE INST MOLEC GENET, DEPT MICROBIOL & IMMUNOL, BROOKLYN, NY 11203 USA.				NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA12227] Funding Source: Medline; NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; CHEN YY, 1992, P NATL ACAD SCI USA, V89, P6683, DOI 10.1073/pnas.89.15.6683; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1987, RECENT ADV LEUKEMIA, V61, P181; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HERMINE O, 1991, BLOOD, V78, P2253; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; JEAN JYW, 1993, CURR BIOL, V3, P35; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JURGENSEN CH, 1986, J IMMUNOL, V136, P4542; KATAYAMA N, 1993, BLOOD, V81, P610; KELLER G, 1989, GENE DEV, V3, P827, DOI 10.1101/gad.3.6.827; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KISHI K, 1989, J CELL PHYSIOL, V139, P463, DOI 10.1002/jcp.1041390303; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MURAGUCHI A, 1986, J IMMUNOL, V137, P179; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PECH N, 1993, BLOOD, V82, P1502; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; RAMBALDI A, 1987, BLOOD, V69, P1409; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; SIRARD C, 1994, BLOOD, V83, P1575; SMITH KA, 1980, J EXP MED, V151, P1551, DOI 10.1084/jem.151.6.1551; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; WANECK GL, 1986, CELL, V44, P337, DOI 10.1016/0092-8674(86)90768-3; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG PMC, 1987, EXP HEMATOL, V15, P280; WONG PMC, 1988, EXP HEMATOL, V16, P5; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; WONG PMC, 1982, P NATL ACAD SCI-BIOL, V79, P2952, DOI 10.1073/pnas.79.9.2952; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; ZUBIAGA AM, 1991, J IMMUNOL, V146, P3849	49	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3527	3533						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970713				2022-12-17	WOS:A1994PT39200015
J	WIEST, JS; BURNETT, VL; ANDERSON, MW; REYNOLDS, SH				WIEST, JS; BURNETT, VL; ANDERSON, MW; REYNOLDS, SH			A NOVEL MECHANISM OF IN-VIVO RAS GENE ACTIVATION INVOLVING TANDEM DUPLICATION OF CODING SEQUENCES	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; P21 TRANSFORMING PROTEIN; POINT MUTATION; GTP HYDROLYSIS; HAMSTER-CELLS; APRT LOCUS; K-RAS; ONCOGENE; MOUSE; DNA	A series of weakly transforming c-K-ras genes have been detected in spontaneously occurring and chemically induced mouse adenomas. DNA sequence analysis of these weakly transforming ras oncogenes showed that activation occurred by a novel mechanism involving duplication of nine or ten codon segments flanking codon 61 in exon 2. The codon repetitions in exon 2 are directly preceded by a number of potentially recombinogenic DNA sequences which may have been involved in the genesis of the codon repetitions through mechanisms involving recombination or DNA slippage. Duplication of DNA sequences such as those observed in the mouse c-K-ras gene may represent a new mechanism for both tumor suppressor gene inactivation and proto-oncogene activation.	NIEHS,CELLULAR & MOLEC PHARMACOL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	WIEST, JS (corresponding author), NIEHS,MOLEC TOXICOL LAB,RES TRIANGLE PK,NC 27709, USA.							BARACID M, 1987, AM REV BIOCH, V56, P779; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; COHEN JB, 1983, NATURE, V306, P797, DOI 10.1038/306797a0; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; ELLIS RW, 1982, MOL CELL BIOL, V2, P1339, DOI 10.1128/MCB.2.11.1339; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HIGINBOTHAM KG, 1992, MOL CARCINOGEN, V5, P136, DOI 10.1002/mc.2940050209; HIGINBOTHAM KG, 1994, UNPUB; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEFFREYS AJ, 1987, NUCLEIC ACIDS RES, V15, P2823, DOI 10.1093/nar/15.7.2823; KROWCZYNSKA AM, 1990, NUCLEIC ACIDS RES, V18, P1121, DOI 10.1093/nar/18.5.1121; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; NALBANTOGLU J, 1988, J MOL BIOL, V200, P449, DOI 10.1016/0022-2836(88)90535-9; NALBANTOGLU J, 1987, MOL CELL BIOL, V7, P1445, DOI 10.1128/MCB.7.4.1445; ORITA S, 1991, VIRUS GENES, V5, P75, DOI 10.1007/BF00571733; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATEL G, 1992, ONCOGENE, V7, P283; PICOLLI SP, 1984, NATURE, V310, P327; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIH TY, 1979, VIROLOGY, V93, P64; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SLOAN SR, 1990, MOL CELL BIOL, V10, P405, DOI 10.1128/MCB.10.1.405; SMITH GR, 1983, CELL, V34, P709, DOI 10.1016/0092-8674(83)90525-1; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	39	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2449	2454						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058307				2022-12-17	WOS:A1994PC05400003
J	DEHBI, M; BEAULIEU, S; COHEN, EA; BEDARD, PA				DEHBI, M; BEAULIEU, S; COHEN, EA; BEDARD, PA			ACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS-1 GENE-EXPRESSION BY THE SRC ONCOPROTEIN	ONCOGENE			English	Note							NF-KAPPA-B; LONG TERMINAL REPEAT; T-CELLS; TRANSFORMED-CELLS; TRANSCRIPTION; PROMOTER; INDUCTION; ENHANCER; REPLICATION; PP60V-SRC	Several genes are induced constitutively in cells transformed by the v-src oncoprotein. This induction is generally dependent on the activation of transcription factors binding to src-responsive elements of the promoter. In previous studies, we showed that the induction of the CEF-4/9E3 cytokine gene by pp60(v-src) is dependent on the PRDII/kappa B domain of the promoter (Dehbi et al., 1992). In this investigation, we describe the activation of the HIV-1 LTR by pp60(v-src) and show that a region of 30 bp containing the two IVF-kappa B binding sites is critical for activation of the promoter. The induction was dependent on transformation since non-transforming forms of pp60(v-src) had little or no effect on the promoter. The expression of proviral DNA and the release of p24 antigen were also increased by v-src indicating that viral replication was stimulated in src-transformed cells. The effect of v-src on HIV-1 gene expression occurred in the presence or in the absence of the tat viral trans-activator, in fibroblasts and in Jurkat T lymphocytes. These results indicate that several promoters controlled by PRDII/kappa B may be activated constitutively in v-src transformed cells and suggest that oncogenic tyrosine kinases may play a role in the induction of viruses with a PRDII/kappa B-controlled promoter.	YORK UNIV, DEPT BIOL, N YORK M3J 1P3, ON, CANADA; UNIV MONTREAL, DEPT BIOCHIM, MONTREAL H3C 3J7, PQ, CANADA; UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, PQ, CANADA	York University - Canada; Universite de Montreal; Universite de Montreal								ARENZANASEISDEDOS F, 1989, ONCOGENE, V4, P1359; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUTTA A, 1990, P NATL ACAD SCI USA, V87, P608, DOI 10.1073/pnas.87.2.608; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; KIM YS, 1993, J VIROL, V67, P239, DOI 10.1128/JVI.67.1.239-248.1993; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; LACOSTE J, 1991, VIROLOGY, V184, P553, DOI 10.1016/0042-6822(91)90425-B; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LIN G, 1990, DEV BIOL, V139, P186, DOI 10.1016/0012-1606(90)90287-S; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; MARONEY AC, 1992, ONCOGENE, V7, P1207; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; RAZIUDDIN, 1991, P NATL ACAD SCI USA, V88, P9426, DOI 10.1073/pnas.88.21.9426; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P3857, DOI 10.1073/pnas.86.10.3857; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; WELHAM MJ, 1990, ONCOGENE, V5, P161; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	28	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1994	9	8					2399	2403						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036024				2022-12-17	WOS:A1994NX62900035
J	KRAUZEWICZ, N; ELLIOTT, J; GRIFFIN, BE				KRAUZEWICZ, N; ELLIOTT, J; GRIFFIN, BE			CELL FRACTIONATION IN NONIONIC DETERGENT DISTINGUISHES SUBPOPULATIONS OF POLYOMA-VIRUS MIDDLE T-ANTIGEN AND REVEALS A NOVEL FORM	ONCOGENE			English	Article							TUMOR-ANTIGEN; MONOCLONAL-ANTIBODIES; KINASE-ACTIVITY; EARLY REGION; PROTEIN; PP60C-SRC; TRANSFORMATION; ASSOCIATION; COMPLEX; BINDING	The transforming function of polyoma virus, middle T antigen (MT), interacts with several cellular enzymes, essential to its oncogenic activity. We have used cell fractionation to study the various MT/cellular protein complexes. We demonstrate that MT can be separated into three sub-species, dependent upon extraction in two buffers that we designate A and B: Antigen extracted from whole cells by both buffers (called MT(1)) is associated with most of the phosphorylated phosphatidylinositol kinase 85 kD subunit, pp85, and protein phosphatase 2A. Antigen (MT(2)), associated with the greater portion of pp60c-src, is extracted by buffer B, but not buffer A. A third population (MT(3)), resistant to extraction by either buffer, is not detectably associated with protein phosphatase 2A or pp85. It is, however, associated with a low level kinase activity. The interaction between pp60c-src and MT appears to influence the formation of both MT(2) and MT(3). MT(2) fractionates with the cellular microtubule network, but does not appear to be directly associated with it. MT(3), a previously undescribed population, comprises about one third of MT in wild type antigen-containing cells. It is missing in mutants incapable of interacting with pp60c-src, but exists in the absence of an interaction with pp85. We suggest that MT(3) may be an intermediate in, or product of, one of the MT/pp60c-src signalling pathways, distinct from that involving pp85.	ROYAL POSTGRAD MED SCH,DEPT VIROL,LONDON W12 0NN,ENGLAND	Imperial College London								ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BOLEN JB, 1985, J VIROL, V53, P114, DOI 10.1128/JVI.53.1.114-119.1985; BOLEN JB, 1987, J VIROL, V61, P3299, DOI 10.1128/JVI.61.10.3299-3305.1987; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHENG SH, 1986, EMBO J, V5, P325, DOI 10.1002/j.1460-2075.1986.tb04216.x; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; GORGA FR, 1990, J VIROL, V64, P105, DOI 10.1128/JVI.64.1.105-112.1990; GRIFFIN BE, 1979, J VIROL, V31, P645, DOI 10.1128/JVI.31.3.645-656.1979; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GRUSSENMEYER T, 1987, J VIROL, V61, P3902, DOI 10.1128/JVI.61.12.3902-3909.1987; HOFER KB, 1988, ONCOGENE, V3, P365; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KRAUZEWICZ J, 1992, THESIS LONDON U; KRAUZEWICZ N, 1993, ELECTROPHORESIS, V15, P491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENSTRA JA, 1983, EUR J BIOCHEM, V135, P413, DOI 10.1111/j.1432-1033.1983.tb07668.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAGNUSSON G, 1979, J VIROL, V32, P523, DOI 10.1128/JVI.32.2.523-529.1979; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; OSBORN M, 1977, EXP CELL RES, V106, P339, DOI 10.1016/0014-4827(77)90179-3; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; PONTEN J, 1971, VIROL MONOGR, P45; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SMITH AE, 1979, CELL, V18, P915, DOI 10.1016/0092-8674(79)90204-6; SMITH AE, 1980, COLD SPRING HARB SYM, V1, P141; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; STREULI CH, 1990, J VIROL, V64, P3570, DOI 10.1128/JVI.64.8.3570-3580.1990; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; WALTER G, 1982, P NATL ACAD SCI-BIOL, V79, P4025, DOI 10.1073/pnas.79.13.4025; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	49	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2283	2291						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518577				2022-12-17	WOS:A1994NX62900021
J	SCHWARTEWALDHOFF, I; MARTIN, W; WILLECKE, K; SCHAFER, R				SCHWARTEWALDHOFF, I; MARTIN, W; WILLECKE, K; SCHAFER, R			FUNCTIONAL IDENTIFICATION AND MOLECULAR-CLONING OF A RAT GENE MEDIATING GROWTH-INHIBITION AND PROGRAMMED CELL-DEATH IN NORMAL AND TRANSFORMED RAT-CELL LINES	ONCOGENE			English	Article							WILD-TYPE P53; TUMOR SUPPRESSOR GENES; HIGHER EUKARYOTIC CELLS; C-MYC EXPRESSION; RB GENE; EMBRYONIC FIBROBLASTS; ONCOGENE EXPRESSION; EPITHELIAL-CELLS; CARCINOMA-CELLS; HAMSTER-CELLS	We wished to identify DNA sequences conferring suppression of proliferation and transformed phenotypes. Thus, we have transfected DNA from normal rat cells, covalently linked to neo DNA coding for neomycin resistance into a tumorigenic, HRAS transformed rat cell line. Phenotypic revertants were selected after the first cycle of transfection by enrichment procedures that served to eliminate transformed cells. The revertant clones continued to express the HRAS oncogene, but exhibited a lower tumorigenicity, loss of anchorage-independent proliferation, flat morphology, and retardation of growth in monolayer culture. The reverted phenotype could be transferred in a second cycle of transfection into the HRAS transformed rat cells. Neo DNA ligated to genomic donor DNA was used as a tagging sequence to molecularly clone the transferred DNA sequence in a recombinant phage. Fragments of the cloned DNA detect a 2.5 kb transcript in parental cells and revertants. Thus, the recombinant phage harbors a putative growth inhibitory gene, designated trg, that is expressed at a higher level in rat embryo fibroblasts and in the REF52 cell line. Introduction of recombinant phage DNA into established 208F and Rat-2 cells and into HRAS-, v-fgr-, v-fms- and v-raf-transformed rat cell lines resulted in inhibition of growth and induction of programmed cell death.	UNIV ZURICH,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND	University of Zurich	SCHWARTEWALDHOFF, I (corresponding author), UNIV BONN,INST GENET,DIV MOLEC GENET,MOLEK GENET ABT,ROMERSTR 164,D-53117 BONN,GERMANY.		Schäfer, Reinhold/AAB-5110-2021					ASKEW DS, 1991, ONCOGENE, V6, P1915; BAKER RF, 1983, P NATL ACAD SCI-BIOL, V80, P1174, DOI 10.1073/pnas.80.5.1174; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASSIN RH, 1984, CANCER CELL, V2, P463; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRADY G, 1985, EMBO J, V4, P2583, DOI 10.1002/j.1460-2075.1985.tb03974.x; BRADY G, 1984, GENE, V27, P223, DOI 10.1016/0378-1119(84)90143-4; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GEISER A G, 1989, Critical Reviews in Oncogenesis, V1, P261; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HARRIS H, 1988, CANCER RES, V48, P3302; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLINGER HP, 1983, JNCI-J NATL CANCER I, V71, P559; KRZYZOSIAK WJ, 1992, P NATL ACAD SCI USA, V89, P4879, DOI 10.1073/pnas.89.11.4879; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTIN W, 1992, EXP CELL RES, V200, P41, DOI 10.1016/S0014-4827(05)80069-2; MERCER WE, 1990, ONCOGENE, V5, P973; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P9613, DOI 10.1073/pnas.88.21.9613; NAGY A, 1987, J CELL SCI, V87, P651; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PADMANABHAN R, 1987, MOL CELL BIOL, V7, P1894, DOI 10.1128/MCB.7.5.1894; PHILIPSON L, 1991, J CELL BIOCHEM, V46, P95, DOI 10.1002/jcb.240460202; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAGER R, 1986, CANCER RES, V46, P1573; SCHAEFER R, 1988, P NATL ACAD SCI USA, V85, P1590, DOI 10.1073/pnas.85.5.1590; SCHAFER R, 1983, CANCER RES, V43, P2240; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; Smith J R, 1990, Adv Cancer Res, V54, P63, DOI 10.1016/S0065-230X(08)60808-8; SORRENTINO V, 1989, ANTICANCER RES, V9, P1925; SORRENTINO V, 1989, ONCOGENE, V4, P569; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STEINBERG B, 1978, CELL, V13, P300; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	78	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					899	909						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108134				2022-12-17	WOS:A1994MW55100027
J	INUZUKA, M; ISHIKAWA, H; KUMAR, S; GELINAS, C; ITO, Y				INUZUKA, M; ISHIKAWA, H; KUMAR, S; GELINAS, C; ITO, Y			THE VIRAL AND CELLULAR REL ONCOPROTEINS INDUCE THE DIFFERENTIATION OF P19 EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							CHICKEN SPLEEN-CELLS; NF-KAPPA-B; V-REL; RETICULOENDOTHELIOSIS VIRUS; C-JUN; PROTEINS; EXPRESSION; ONCOGENE; F9; TRANSFORMATION	Rel proteins have been implicated in the differentiation and transformation of lymphoid cells. Despite their significant sequence homology to the Drosophila Dorsal morphogen, a functional role for Rel proteins in early development has yet to be established. Here we show that expression of the v- or c-rel genes in P19 embryonal carcinoma (EC) cells leads to drastic morphological changes accompanied by the expression of several differentiation-specific antigens. In contrast, v-Rel mutants defective for DNA-binding as well as those lacking the F9 cell-specific transcription activation region of v-Rel were equally unable to promote P19 cell differentiation. Our results demonstrate that transcriptional activation by Rel proteins correlates with Rel-induced differentiation of EC cells, and raise the intriguing possibility that Rel proteins may play an important role in early developmental processes.	KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Kyoto University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center								ADAMSON ED, 1984, DIFFERENTIATION, V27, P152, DOI 10.1111/j.1432-0436.1984.tb01421.x; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRAVO R, 1988, QUANT BIOL, P901; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; Graham C.F, 1977, CONCEPTS MAMMALIAN E, P315; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; ISHIKAWA H, 1993, IN PRESS ONCOGENE; KAHAN B, 1983, CELL PROLIFERAT, V10, P131; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T, 1989, DECONTAMINATION DILU; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SHIBUYA T, 1982, CANCER RES, V42, P2722; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	33	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					133	140						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302572				2022-12-17	WOS:A1994MW24700016
J	KUBOTA, S; FURUTA, R; MAKI, M; SIOMI, H; HATANAKA, M				KUBOTA, S; FURUTA, R; MAKI, M; SIOMI, H; HATANAKA, M			LONG CELLULAR REPEATS FLANKING A DEFECTIVE HTLV-I PROVIRUS - IMPLICATION FOR SITE-TARGETED INTEGRATION	ONCOGENE			English	Note							DNA; GENE; TRANSFORMATION; LEUKEMIA; INVITRO	Retroviruses generally integrate as proviruses which are flanked by long-terminal repeats (LTRs) on both 5' and 3' ends. Since these LTRs are required for the efficient integration mediated by the viral integrase, it is believed that defective proviruses with a single LTR are normally formed by deletion after integration. However, we found no deletion of cellular sequences around the integration site of such a defective HTLV-1. Rather, we identified 99 bp-long direct repeats adjacent to both ends of the defective provirus. The repeated cellular sequences contained a potential poly(A) signal followed by a retroviral primer-binding-site-like sequence. The presence of the direct repeats of cellular sequences can be explained by the integration of the defective virus through homologous recombination between cellular and viral read-through sequences.	KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University			Maki, Masatoshi/AAM-6839-2021; Siomi, Haruhiko/A-7020-2015	Maki, Masatoshi/0000-0001-9144-5491; Siomi, Haruhiko/0000-0001-8690-3822				CAMPBELL C R, 1989, New Biologist, V1, P223; Coffin J. M., 1990, VIROLOGY, P1437; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Konishi H, 1984, Mol Biol Med, V2, P273; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; SINGH MK, 1982, VIROLOGY, V188, P451; SIOMI H, 1988, VIRUS GENES, V1, P373; SPIRNZL M, 1989, NUCLEIC ACIDS RES, V17, pR1; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992	18	6	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2873	2877						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378096				2022-12-17	WOS:A1993LX34300033
J	BRYCE, DM; LIU, QR; KHOO, W; TSUI, LC; BREITMAN, ML				BRYCE, DM; LIU, QR; KHOO, W; TSUI, LC; BREITMAN, ML			PROGRESSIVE AND REGRESSIVE FATE OF LENS TUMORS CORRELATES WITH SUBTLE DIFFERENCES IN TRANSGENE EXPRESSION IN GAMMA-F-CRYSTALLIN-SV40 T-ANTIGEN TRANSGENIC MICE	ONCOGENE			English	Article							GAMMA-CRYSTALLIN GENES; MOUSE LENS; EYE LENS; REGULATORY ELEMENTS; CELL ELONGATION; RAT LENS; PROMOTER; DIFFERENTIATION; MORPHOGENESIS; ENHANCER	Regulatory elements of the mouse gammaF-crystallin gene were used to derive transgenic mice expressing SV40 large T antigen in terminally differentiating fiber cells of the ocular lens. The resulting gammaF-crystallin-T antigen mice developed either malignant or regressive lens tumors in a strain-dependent fashion. Developmental and RNA analyses revealed that in both 'tumor-progressing' and 'tumor-regressing' mouse strains expression of the transgene blocked morphological differentiation of lens fibers without appreciably affecting gamma-crystallin gene expression, a marker of terminal lens fiber cell differentiation. Strain-dependent differences in tumorigenic outcome could be correlated with both subtle differences in transgene expression and the ability of tumor cells to escape from the normal confines of the lens. The results implicate the importance of cellular environment to malignant tumor development and provide insight into those features of normal lens ontogeny that may render the lens refractory to the development of spontaneous tumors.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL 600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Tsui, Lap-chee/A-1081-2010	Bryce, Dawn/0000-0002-7403-2940				BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1989, DEVELOPMENT, V106, P457; BREITMAN ML, 1984, P NATL ACAD SCI-BIOL, V81, P7762, DOI 10.1073/pnas.81.24.7762; CHEPELINSKY AB, 1987, MOL CELL BIOL, V7, P1807, DOI 10.1128/MCB.7.5.1807; COUNIS MF, 1989, INT J BIOCHEM, V21, P235, DOI 10.1016/0020-711X(89)90181-X; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; GORING DR, 1992, EXP EYE RES, V54, P785, DOI 10.1016/0014-4835(92)90034-P; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; LIU QR, 1991, MOL CELL BIOL, V11, P1531, DOI 10.1128/MCB.11.3.1531; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MATSUO I, 1991, DEVELOPMENT, V113, P539; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V45, P271; MCAVOY JW, 1980, DIFFERENTIATION, V17, P137, DOI 10.1111/j.1432-0436.1980.tb01091.x; MEAKIN SO, 1989, EXP EYE RES, V48, P131, DOI 10.1016/0014-4835(89)90026-2; MURERORLANDO M, 1987, DEV BIOL, V119, P260, DOI 10.1016/0012-1606(87)90227-2; NAKAMURA T, 1989, New Biologist, V1, P193; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PEEK R, 1990, NUCLEIC ACIDS RES, V18, P1189, DOI 10.1093/nar/18.5.1189; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; SACHS E, 1948, AM J OPHTHALMOL, V31, P561, DOI 10.1016/0002-9394(48)90558-3; SIEZEN RJ, 1988, J MOL BIOL, V199, P475, DOI 10.1016/0022-2836(88)90619-5; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI Y, 1988, DEVELOPMENT, V102, P259; VANLEEN RW, 1987, DEV BIOL, V120, P457, DOI 10.1016/0012-1606(87)90249-1; YU CCK, 1990, DEVELOPMENT, V110, P131	30	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1611	1620						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8389033				2022-12-17	WOS:A1993LE06400025
J	MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B				MAZARS, GR; PORTIER, M; ZHANG, XG; JOURDAN, M; BATAILLE, R; THEILLET, C; KLEIN, B			MUTATIONS OF THE P53-GENE IN HUMAN MYELOMA CELL-LINES (VOL 7, PG 1015, 1992)	ONCOGENE			English	Correction, Addition									INSERM,U291,F-34100 MONTPELLIER,FRANCE; CTR GUI DE CHAULIAC,F-34059 MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	MAZARS, GR (corresponding author), UNIV MONTPELLIER 2,GENET MOLEC LAB,CNRS,URA 1191,F-34095 MONTPELLIER 5,FRANCE.		Theillet, Charles/O-7634-2018	Theillet, Charles/0000-0001-5555-2759				MAZARS GR, 1992, ONCOGENE, V7, P1015	1	6	6	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1107	1107						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220					2022-12-17	WOS:A1993KT22000040
J	KUMAR, G; SHARMA, AK; JAYARAMAN, K				KUMAR, G; SHARMA, AK; JAYARAMAN, K			INCORPORATION OF BRDU IN A DNA FRAGMENT MAY AFFECT PROTEIN DNA INTERACTIONS IN A SITE-DEPENDENT MANNER	ONCOGENE			English	Article							BINDING	DNA in which BrdU has been randomly incorporated is used to identify specific DNA-binding proteins. We show here that the location of BrdU incorporation in a DNA fragment can significantly affect specific protein-DNA interactions and thereby identification of DNA-binding proteins. We suggest that a radioactive labeled unmodified DNA, rather than BrdU-incorporated DNA, be used for identifying DNA-binding proteins by UV cross-linking.	WAYNE STATE UNIV,SCH MED,CTR MOLEC BIOL,DETROIT,MI 48201; EASTMAN KODAK CO,RES LABS,NEW YORK,NY 14601	Wayne State University; Eastman Kodak	KUMAR, G (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,540 E CANFIELD,DETROIT,MI 48201, USA.			Sharma, Arun/0000-0002-2777-8731	NIGMS NIH HHS [GM 38228, GM 08167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN JK, 1989, J VIROL, V63, P5425, DOI 10.1128/JVI.63.12.5425-5439.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; KUMAR G, 1984, J ORG CHEM, V49, P4905, DOI 10.1021/jo00199a032; SHARMA AK, 1991, FEBS LETT, V281, P272, DOI 10.1016/0014-5793(91)80409-V	7	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1453	1455						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320247				2022-12-17	WOS:A1992HZ97100027
J	DELMAS, V; ANDRE, CD; GARDES, M; GOUTEBROZE, L; FEUNTEUN, J				DELMAS, V; ANDRE, CD; GARDES, M; GOUTEBROZE, L; FEUNTEUN, J			EARLY GENE-EXPRESSION IN LYMPHOMA-ASSOCIATED HAMSTER POLYOMAVIRUS VIRAL GENOMES	ONCOGENE			English	Article							EMBRYONAL CARCINOMA-CELLS; MIDDLE-T-ANTIGEN; TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; PROTEIN PHOSPHATASE-2A; NONCODING SEQUENCES; MAMMALIAN-CELLS; LATE PROMOTER; REPLICATION; MICE	Hamster polyomavirus (HaPV) is the causal agent of hair follicle epithelioma in hamsters belonging to a colony bred in Berlin-Buch. These tumors shed virus particles that are assembled in the keratinized layer of the epidermis. By contrast, HaPV induces lymphomas after inoculation into newborn hamsters from a distinct colony bred in Potsdam. These lymphoid tumors accumulate massive amounts of episomal viral genomes characterized by deletions that alter specifically the regulatory and the late coding sequences. Assuming that these alterations of the regulatory region may affect the transcription of the viral oncogenes in the tumor cells, the transcriptional activity of the wild-type and deleted early promoters have been studied in vitro in transient chloramphenicol acetyltransferase (CAT) expression assays. These assays performed in various cell types demonstrate that both versions of the HaPV early promoter carry a weak constitutive activity. Simultaneous expression of the HaPV early gene products leads to a strong stimulation of CAT activity with a concomitant activation of the replication of the plasmid constructs. The results obtained with origin-defective CAT vectors indicate that the replication contributes significantly to the stimulating effect of the early gene products. Indeed, transfection of massive amounts of CAT vectors that are unable to replicate can simulate the dosage effect of replication and also leads to measurable CAT activities. Under these conditions, the wild-type promoter is more active than the deleted version, indicating that sequences within the deletion carry a distinct stimulatory effect on transcription. This conclusion is supported by the observation that the lymphoma cells contain a low level of early transcripts, indicating that the deleted episomal viral templates accumulated in these tumors carry a weak transcriptional activity.	INST GUSTAVE ROUSSY, ONCOL MOLEC LAB, F-94805 VILLEJUIF, FRANCE	UNICANCER; Gustave Roussy			Goutebroze, Laurence/H-3543-2016; Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189; Delmas, veronique/0000-0001-7368-3664; Goutebroze, laurence/0000-0002-8712-000X				ANDRE CDS, 1990, VIROLOGY, V177, P532, DOI 10.1016/0042-6822(90)90518-V; BASTIEN C, 1988, ONCOGENE, V2, P129; BEREBBI M, 1988, ONCOGENE, V2, P149; BOVI PD, 1984, J VIROL, V49, P566, DOI 10.1128/JVI.49.2.566-571.1984; BRADY J, 1984, P NATL ACAD SCI-BIOL, V81, P2040, DOI 10.1073/pnas.81.7.2040; CAHILL KB, 1990, J VIROL, V64, P992, DOI 10.1128/JVI.64.3.992-1001.1990; CAMPBELL BA, 1986, MOL CELL BIOL, V6, P2068, DOI 10.1128/MCB.6.6.2068; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEPAMPHILIS ML, 1986, VIRUSES PAPOVAVIRIDA, P99; DIAMANDOPOULOS GT, 1983, J NATL CANCER I, V71, P1319; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; FREUND R, 1988, J VIROL, V62, P3896, DOI 10.1128/JVI.62.10.3896-3899.1988; FREUND R, 1987, J VIROL, V61, P2232, DOI 10.1128/JVI.61.7.2232-2239.1987; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAFFI A, 1969, P NATL ACAD SCI USA, V64, P1172, DOI 10.1073/pnas.64.4.1172; GRAFFI A, 1968, J NATL CANCER I, V40, P867; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KELLY JJ, 1989, J VIROL, V63, P383, DOI 10.1128/JVI.63.1.383-391.1989; KERN FG, 1986, J VIROL, V60, P275, DOI 10.1128/JVI.60.1.275-285.1986; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KUSANO T, 1987, P NATL ACAD SCI USA, V84, P1789, DOI 10.1073/pnas.84.7.1789; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEWIS AM, 1979, J NATL CANCER I, V63, P695, DOI 10.1093/jnci/63.3.695; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MAIONE R, 1985, EMBO J, V4, P3215, DOI 10.1002/j.1460-2075.1985.tb04068.x; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PANUTTI A, 1987, J VIROL, V61, P1296; ROCHFORD R, 1990, J VIROL, V64, P476, DOI 10.1128/JVI.64.2.476-485.1990; SAINTANDRE CD, 1989, ICN UCI C V, P225; SALZMAN NP, 1986, VIRUSES PAPOVAVIRIDA, V1, P27; SCHERNECK S, 1987, J VIROL, V61, P3992, DOI 10.1128/JVI.61.12.3992-3998.1987; SEKIKAWA K, 1981, P NATL ACAD SCI-BIOL, V78, P1100, DOI 10.1073/pnas.78.2.1100; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	45	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					295	302						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312694				2022-12-17	WOS:A1992HG98200014
J	GRAZIANI, G; NEBREDA, AR; SRIVASTAVA, S; SANTOS, E; EVA, A				GRAZIANI, G; NEBREDA, AR; SRIVASTAVA, S; SANTOS, E; EVA, A			INDUCTION OF XENOPUS OOCYTE MEIOTIC MATURATION BY THE DBL ONCOGENE PRODUCT	ONCOGENE			English	Article							CDC2 PROTEIN-KINASE; H-1 HISTONE KINASE; CELL-CYCLE; PROMOTING FACTOR; M-PHASE; MOLECULAR-CLONING; PHOSPHOLIPASE-C; RAS PROTEINS; GENE-PRODUCT; EXPRESSION	The dbl oncogene was originally identified by transfection of NIH3T3 cells with DNA from a human diffuse B-cell lymphoma. The dbl oncogene product is a cytoplasmic phosphoprotein distributed between the cytosolic and cytoskeletal matrix-associated membrane fractions. Nucleotide sequence analysis has indicated that the predicted dbl product is very hydrophilic with no detectable similarity to known oncogene products. We have more recently discovered that a region of dbl essential for its transforming activity shows significant sequence similarity to a yeast cell cycle gene, CDC24, which is involved in cell polarity and bud formation in the division cycle of Saccharomyces cerevisiae. This sequence similarity suggests a possible role for dbl in cell division. We report here that the dbl oncogene product is able to induce maturation of Xenopus oocytes. Germinal vesicle breakdown (GVBD) was observed when oocytes were microinjected with the soluble fraction of SF9 insect cells infected with a dbl recombinant baculovirus as well as with the in vitro-transcribed dbl mRNA. Moreover, extracts of oocytes microinjected with dbl mRNA showed activation of H1 histone kinase activity. These findings define a new biologic activity of the dbl product and provide the opportunity to analyse dbl interactions with other components of signaling pathways involved in oocyte maturation.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL & SURG,BETHESDA,MD 20814; NIAID,MOLEC MICROBIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Nebreda, Angel Rodriguez/R-9594-2019; Eva, Alessandra/J-8268-2016; Graziani, Grazia/G-5747-2012	Eva, Alessandra/0000-0003-2949-078X; Graziani, Grazia/0000-0002-0221-768X	NCI NIH HHS [CA-46455] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046455] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GRAZIANI G, 1989, ONCOGENE, V4, P823; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; Masui Y., 1987, MOL REGULATION NUCLE, P1; MIYAMOTO C, 1985, MOL CELL BIOL, V5, P2860, DOI 10.1128/MCB.5.10.2860; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OLLO R, 1987, P NATL ACAD SCI USA, V84, P5700, DOI 10.1073/pnas.84.16.5700; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PRINGLE JR, 1986, UCLA S MOL CELL BIOL, V33, P47; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; RON D, 1989, ONCOGENE, V4, P1067; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SANTOS E, 1988, J BIOL CHEM, V263, P9853; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TRONICK SR, 1989, GENOMICS, V5, P546, DOI 10.1016/0888-7543(89)90022-0	45	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1992	7	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312693				2022-12-17	WOS:A1992HG98200004
J	WHEELER, TT; XIAO, JP; DOWDY, SF; STANBRIDGE, EJ; YOUNG, DA				WHEELER, TT; XIAO, JP; DOWDY, SF; STANBRIDGE, EJ; YOUNG, DA			SUPPRESSION OF TUMORIGENICITY OF A WILMS-TUMOR CELL-LINE IS ASSOCIATED WITH A DECREASE IN SYNTHESIS OF 2 PROTEINS	ONCOGENE			English	Note							FAMILIAL PREDISPOSITION; HUMAN CHROMOSOME-11; SHORT ARM; GENE; 11P13; MAP; EXPRESSION; DELETION; LOCUS; ACID	Wilms' tumor has been associated with deletions in two loci on chromosome 11, and the introduction of a translocated human chromosome [t(X;11)] into a Wilms' tumor cell line (G401.6TG.6) by microcell hybridization suppresses tumor formation in nude mice. The tumorigenic phenotype is restored in segregants of these microcell hybrids, in which the introduced chromosome is lost. We have used ultrahigh-resolution 'giant' two-dimensional gel electrophoresis of metabolically labeled cellular proteins and in vitro translation products of isolated mRNA to identify changes in cellular gene expression that occur in these cell lines. The changes in gene expression associated with these chromosomal manipulations per se are quite minimal. However, we have identified two proteins (p16 and p28) whose synthesis is consistently decreased in three non-tumorigenic (suppressed) microcell hybrid clones relative to parental and segregant tumorigenic lines. They are also decreased at the level of mRNA in at least two of the non-tumorigenic clones. The decrease of these proteins represents markers of the suppressed phenotype, and their down-regulation may conceivably mediate the suppression of tumorigenicity.	E HENRY KEUTMANN LAB,DEPT MED,ENDOCRINE METAB UNIT,ROCHESTER,NY 14642; E HENRY KEUTMANN LAB,DEPT RADIAT BIOL & BIOPHYS,ENDOCRINE METAB UNIT,ROCHESTER,NY 14642; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					NATIONAL CANCER INSTITUTE [R01CA047650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER; NCI NIH HHS [CA194104, CA47650] Funding Source: Medline; NIDDK NIH HHS [DK16177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLBERT RA, 1989, J BIOL CHEM, V261, P14733; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVENSON RM, 1989, VIROLOGY, V172, P170, DOI 10.1016/0042-6822(89)90118-9; LEVENSON RM, 1987, CANCER CELLS, V5, P137; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; VANKEUREN ML, 1982, ANN NY ACAD SCI, V396, P55; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190; YOUNG DA, 1984, CLIN CHEM, V30, P2104	17	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1903	1907						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656366				2022-12-17	WOS:A1991GX11800026
J	JEYAPAUL, J; SESHAMMA, T; KHAN, SA				JEYAPAUL, J; SESHAMMA, T; KHAN, SA			SYNTHETIC HIV-1 TAT CAN DISSOCIATE HELA NUCLEAR-PROTEIN TAR RNA COMPLEXES INVITRO - A NOVEL TAT-NUCLEAR PROTEIN-INTERACTION	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANS-ACTIVATOR GENE; MUTATIONAL ANALYSIS; TRANSCRIPTIONAL ACTIVATION; RESPONSIVE SEQUENCE; FUNCTIONAL DOMAINS; LOOP SEQUENCE; NASCENT RNA; TYPE-1	Multiple binding of Tat and nuclear protein(s) to HIV-1 TAR RNA appears to be essential for the Tat-mediated trans-activation. As synthetic Tat-(1-47), which lacks the basic domain and does not bind TAR RNA in vitro, efficiently transactivated HIV-1 LTR in HeLa nuclear extracts, we hypothesized that Tat might trans-activate by interaction with TAR RNA via a host nuclear protein. The role of nuclear proteins in Tat-TAR interaction was examined through evaluation of several synthetic Tat peptides for ability to bind TAR RNA in vitro both in the presence and in the absence of HeLa nuclear proteins. Our data show that both Tat-(1-47) and Tat-(1-86) interact with TAR RNA-bound nuclear proteins, leading to dissociation of the nuclear protein-TAR RNA complexes; the N-terminal sequence of Tat appears to be involved in this interaction. Thus, after binding to TAR RNA, Tat can interact with a proximal TAR-bound nuclear protein and the resulting Tat-nuclear protein complex, now displaced from TAR, may initiate a facile and rapid assembly of the RNA polymerase II transcription complex. This study thus recognizes a novel interaction between Tat and a nuclear protein(s). Here we propose that the interaction of Tat with a nuclear protein(s) occurring on TAR RNA may be one of several steps in the mechanism of Tat-mediated trans-activation of the HIV-1 LTR.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NIAID NIH HHS [AI27422, AI25380] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027422, P01AI025380] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1990, CELL, V62, P1123, DOI 10.1016/0092-8674(90)90389-V; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; DINGWALL C, 1989, CELL, V57, P1155; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAPPAPORT J, 1989, New Biologist, V1, P101; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; RUBEN S, 1989, J VIROL, V63, P1; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SENGUPTA DN, 1990, P NATL ACAD SCI USA, V87, P7492, DOI 10.1073/pnas.87.19.7492; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002	48	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1507	1513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923518				2022-12-17	WOS:A1991GX27400003
J	GISHIZKY, ML; MCLAUGHLIN, J; PENDERGAST, AM; WITTE, ON				GISHIZKY, ML; MCLAUGHLIN, J; PENDERGAST, AM; WITTE, ON			THE 5' NONCODING REGION OF THE BCR/ABL ONCOGENE AUGMENTS ITS ABILITY TO STIMULATE THE GROWTH OF IMMATURE LYMPHOID-CELLS	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL ONCOGENE; PHILADELPHIA-CHROMOSOME; BONE-MARROW; V-ABL; FUSED TRANSCRIPT; TRANSGENIC MICE	The Philadelphia chromosome (Ph1, t9: 22; 34:q11) is a reciprocal translocation between chromosome 22 and chromosome 9 which results in the formation of the chimeric BCR/ABL oncogene. Alternative forms of BCR/ABL are produced by splicing different sets of exons of the BCR gene to a common set of c-ABL sequences. This results in the formation of an 8.7 kilobase mRNA that encodes the P210 BCR/ABL gene product or a 7.0 kilobase mRNA that encodes the P185 BCR/ABL gene product. Both BCR/ABL transcripts derive their 5' non-coding sequences from the BCR gene locus. This 5' region is over 500 nucleotides in length, has a GC content > 75% and has a short open reading frame. To determine if this unusual 5' non-coding region plays a role in BCR/ABL transformation, we prepared retroviral vectors containing identical BCR/ABL coding regions but differing in the length of the BCR 5' non-coding region. Matched viral stocks were evaluated for their ability to transform bone marrow in vitro and for their ability to cause tumors when inoculated into 3- to 4-week-old mice. In this report we present the unexpected finding that the BCR/ABL 5' non-coding region augments the transforming activity of both P210 and P185 BCR/ABL in vitro. In vivo, BCR/ABL is a weak tumorigenic agent and its potency is enhanced by the presence of the 5' non-coding region.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Pendergast, Ann Marie/0000-0002-1250-6880				ABELSON HT, 1970, CANCER RES, V30, P2208; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CLARK SS, 1989, ANNU REV MED, V40, P113; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LANDAU NR, 1984, P NATL ACAD SCI-BIOL, V81, P5836, DOI 10.1073/pnas.81.18.5836; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MELTON DA, 1989, CIBA F SYMP, V144, P16; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG N, 1978, J EXP MED, V147, P1126, DOI 10.1084/jem.147.4.1126; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SHEN FW, 1985, P NATL ACAD SCI USA, V82, P7360, DOI 10.1073/pnas.82.21.7360; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608	50	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1299	1306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886706				2022-12-17	WOS:A1991GX27200001
J	BAIRD, P; WADEY, R; COWELL, J				BAIRD, P; WADEY, R; COWELL, J			LOSS OF HETEROZYGOSITY FOR CHROMOSOME REGION 11P15 IN WILMS-TUMORS IS NOT RELATED TO HRAS GENE TRANSFORMING MUTATIONS	ONCOGENE			English	Note							BECKWITH-WIEDEMANN SYNDROME; TUMORS; EXPRESSION; CARCINOMA; DELETION; ANIRIDIA; ALLELES; ASSOCIATION; ONCOGENE; LOCUS	Although a candidate Wilms' tumour gene-WT1-has been identified in chromosome region 11p13, there is strong evidence from loss of heterozygosity studies suggesting that a second relevant gene is present in region 11p15. The Harvey-Ras proto-oncogene also lies in this region. In other types of tumours mutations in RAS genes have been associated with the development and/or progression of a number of tumour types. We therefore analysed the sequence of the Ras oncogene for possible mutations in six Wilms' tumours showing loss of heterozygosity for chromosome region 11p15. No tumour analysed showed HRAS sequence mutations. We conclude that loss of heterozygosity at 11p15 does not implicate HRAS mutations in the molecular pathogenesis of Wilms' tumour.			BAIRD, P (corresponding author), INST CHILD HLTH,DEPT HAEMATOL & ONCOL,IMPERIAL CANC RES FUND,MOLEC GENET LAB,LONDON WC1N 1EH,ENGLAND.			Cowell, John/0000-0002-2079-5950; Baird, Paul/0000-0002-1305-3502				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1990, ONCOGENE, V5, P893; Beckwith JB, 1963, W SOC PEDIAT RES; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; JEANPIERRE C, 1990, GENOMICS, V7, P434, DOI 10.1016/0888-7543(90)90179-X; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; Maniatis T., 1982, MOL CLONING; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MATSUNAGA E, 1981, HUM GENET, V57, P231; NARAHARA K, 1984, HUM GENET, V66, P181, DOI 10.1007/BF00286597; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; TURLEAU C, 1984, HUM GENET, V67, P219, DOI 10.1007/BF00273006; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WADEY RB, 1990, ONCOGENE, V5, P901; WAZIRI M, 1983, J PEDIATR-US, V102, P873, DOI 10.1016/S0022-3476(83)80014-6; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WIEDEMANN H. R., 1964, J GENET HUM, V13, P223; WIEDEMANN HR, 1983, EUR J PEDIATR, V141, P129, DOI 10.1007/BF00496807	29	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1147	1149						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861864				2022-12-17	WOS:A1991GV26000008
J	KAWATA, M; KAWAHARA, Y; SUNAKO, M; ARAKI, S; KOIDE, M; TSUDA, T; FUKUZAKI, H; TAKAI, Y				KAWATA, M; KAWAHARA, Y; SUNAKO, M; ARAKI, S; KOIDE, M; TSUDA, T; FUKUZAKI, H; TAKAI, Y			THE MOLECULAR HETEROGENEITY OF THE SMG-21 KREV-1 RAP1 PROTEINS, A GTP-BINDING PROTEIN HAVING THE SAME EFFECTOR DOMAIN AS RAS P21S, IN BOVINE AORTIC SMOOTH-MUSCLE MEMBRANES	ONCOGENE			English	Article							GENE-PRODUCT; ACTIVATING PROTEIN; HUMAN-PLATELETS; BRAIN MEMBRANES; CARBOXYL-METHYLATION; RAS-P21 GTPASE; PURIFICATION; IDENTIFICATION; PHOSPHORYLATION; KINASE	smg p21 is a member of the ras p21/ras p21-like small GTP-binding protein (G protein) superfamily, having the same putative effector domain as ras p21s. In the preceding report, we showed that smg p21 was a major G protein in bovine aortic smooth muscle membranes. Recently, two different smg p21 cDNA clones, designated smg-21A and -B, were isolated from a bovine brain cDNA library. In the present studies, we resolved the bovine aortic smg p21 fraction into two distinct G protein fractions on hydroxyapatite column chromatography and purified them separately to near homogeneity (22K G1 and -2). Both 22K G1 and -2 were specifically recognized by an anti-smg p21 polyclonal antibody. 22K G1 and -2 were identified as smg p21B and -A, respectively, by peptide map and amino acid sequence analyses. Purified smg p21A and -B showed GDP/GTP-binding and GTPase activities similar to each other. The GTPase activities of smg p21A and -B were equally stimulated by smg p21 GTPase activating protein 1 and -2. Moreover, both smg p21A and -B were phosphorylated by cyclic AMP-dependent protein kinase with a stoichiometry of one phosphate/molecule of protein. These results indicate that smg p21A and -B coexist in bovine aortic smooth muscle membranes and suggest that smg p21A and -B may serve as intermediates for cyclic AMP actions.	KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University; Kobe University	KAWAHARA, Y (corresponding author), KOBE UNIV,SCH MED,DEPT INTERNAL MED,DIV 1,KOBE 650,JAPAN.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FISCHER TH, 1987, BIOCHEM BIOPH RES CO, V149, P700, DOI 10.1016/0006-291X(87)90424-4; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; Haslam R J, 1978, Adv Cyclic Nucleotide Res, V9, P533; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROYOSHI M, 1991, IN PRESS J BIOL CHEM; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KASERGLANZMANN R, 1979, BIOCHIM BIOPHYS ACTA, V558, P344, DOI 10.1016/0005-2736(79)90271-2; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1989, BIOCHEM BIOPH RES CO, V163, P1418, DOI 10.1016/0006-291X(89)91137-6; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOESBERG C, 1985, EXP CELL RES, V160, P117, DOI 10.1016/0014-4827(85)90241-1; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NAGATA K, 1989, BIOCHEM BIOPH RES CO, V160, P235, DOI 10.1016/0006-291X(89)91646-X; NILLSON J, 1984, ATHEROSCLEROSIS, V53, P77; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; TADA M, 1975, J BIOL CHEM, V250, P2640; TAKAI Y, 1984, ADV CYCLIC NUCL PROT, V18, P119; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YOSHIDA K, 1988, CANCER RES, V48, P5503	49	6	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					841	848						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1646988				2022-12-17	WOS:A1991GT82500021
J	PIM, D; BANKS, L				PIM, D; BANKS, L			LOSS OF HPV-16 E7 DEPENDENCE IN CELLS TRANSFORMED BY HPV-16 E7 PLUS EJ-RAS CORRELATES WITH INCREASED C-MYC EXPRESSION	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; CERVICAL-CARCINOMA; ADENOVIRUS E1A; ACTIVATED RAS; MOUSE CELLS; DNA; PROTEIN; ONCOGENE; SEQUENCES	We have previously shown that continued expression of the HPV-16 E7 gene was required to maintain the transformed phenotype of primary baby rat kidney cells transformed by HPV-16 E7 plus EJ-ras. In this study we aimed to investigate the possible mechanisms by which cells could overcome this continued requirement for E7 expression. Using an inducible system for expression of the E7 gene we were able to generate cell lines no longer dependent on continued E7 expression. All such lines were still fully transformed, maintained inducible E7 expression and showed increased proliferative activity in the presence of HPV-16 E7 gene product. Further analysis has demonstrated a marked increase in the presence of c-myc protein in these cell lines when compared with the parental cells, suggesting a possible mechanism by which E7 dependence can be overcome.	INT CTR GENET ENGN & BIOTECHNOL, PADRICIANO 99, I-34012 TRIESTE, ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)								ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CROOK T, 1989, P NATL ACAD SCI USA, V86, P5713, DOI 10.1073/pnas.86.15.5713; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; CROOK T, 1989, MOL CARCINOGEN, V2, P308, DOI 10.1002/mc.2940020605; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GLOSS B, 1987, EMBO J, V6, P3735, DOI 10.1002/j.1460-2075.1987.tb02708.x; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEES E, 1990, J GEN VIROL, V71, P183, DOI 10.1099/0022-1317-71-1-183; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MUNGER K, 1989, J VIROL, V63, P4417; OCADIZ R, 1987, CANCER RES, V47, P4173; PATER MM, 1988, NATURE, V335, P832, DOI 10.1038/335832a0; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; RIOU G, 1987, LANCET, V1, P761; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCE RP, 1988, CANCER RES, V48, P324; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	34	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					589	594						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	2030911				2022-12-17	WOS:A1991FR93900013
J	WERNER, S; VIEHWEGER, P; HOFSCHNEIDER, PH; ROTH, WK				WERNER, S; VIEHWEGER, P; HOFSCHNEIDER, PH; ROTH, WK			LOW MITOGENIC RESPONSE TO EGF AND TGF-ALPHA - A CHARACTERISTIC FEATURE OF CULTURED KAPOSIS-SARCOMA DERIVED CELLS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; LONG-TERM CULTURE; HUMAN-FIBROBLASTS; PREREPLICATIVE PHASE; BINDING; INVITRO; ACID	We have investigated the mitogenicity of Epidermal Growth Factor (EGF) and Transforming Growth Factor alpha (TGF-alpha) for cultured Kaposi's sarcoma derived cells (KS cells). In contrast to control fibroblasts from the same patients, KS cells revealed only a weak mitogenic response to these growth factors. Neither EGF nor TGF-alpha were able to substitute for Platelet-derived growth factor (PDGF) when KS cells were grown in PDGF-depleted Platelet-Poor-Plasma serum (PPPS)-supplemented medium. The low mitogenicity of EGF and TGF-alpha for KS cells is not based upon a reduced expression of EGF receptor mRNA and protein in KS cells. However, the binding of EGF to KS cells is about 50% lower than that to fibroblasts. This reduced binding is not due to an occupation of the receptors by TGF-alpha since the expression level of this mitogen in different KS cell lines does not correlate with their capacity to bind EGF. In contrast, the low EGF binding seems to be an intrinsic feature of the EGF receptors of KS cells. In spite of the low mitogenicity of EGF for the tumor cells, the expression of c-myc, PDGF-A and Fibroblast growth factor 5 (FGF-5) mRNA is equally induced by purified EGF in KS cells and fibroblasts. This shows that at least the signal transduction pathways which lead to the expression of these genes are functional in KS cells.	MAX PLANCK INST BIOCHEM,DEPT VIRUS RES,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY	Max Planck Society				Werner, Sabine/0000-0001-7397-8710				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOVI PD, 1986, CANCER RES, V46, P6333; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; CARPENTER G, 1975, J BIOL CHEM, V250, P4297; CARPENTER G, 1990, GROWTH REGULATORY PE, P69; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DERYNCK R, 1985, CANCER CELL, V3, P79; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; KATOH M, 1990, BIOCHEM BIOPH RES CO, V167, P1065, DOI 10.1016/0006-291X(90)90631-V; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; ROTHWK, 1989, ONCOGENE, V4, P483; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SCHIRREN CG, 1990, BRIT J DERMATOL, V123, P373; SNOVER DC, 1985, CLIN BIOCH ANAL, V20, P181; WERNER S, 1990, EXP CELL RES, V187, P98, DOI 10.1016/0014-4827(90)90122-Q; WERNER S, 1989, INT J CANCER, V6, P1137; WESTERMARK B, 1985, J CELL PHYSIOL, V124, P43, DOI 10.1002/jcp.1041240108; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	25	6	6	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					59	64						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992446				2022-12-17	WOS:A1991EY03900008
J	BOEUF, H; JANSENDURR, P; KEDINGER, C				BOEUF, H; JANSENDURR, P; KEDINGER, C			EIA-MEDIATED TRANSACTIVATION OF THE ADENOVIRUS EIIA EARLY PROMOTER IS RESTRICTED IN UNDIFFERENTIATED F9 CELLS	ONCOGENE			English	Article									FAC MED STRASBOURG,CNRS,GENET MOLEC LAB,INSERM,U184,UNITE BIOL MOLEC & GENIE GENET,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429				BABISS LE, 1989, J VIROL, V63, P2709, DOI 10.1128/JVI.63.6.2709-2717.1989; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BOEUF H, 1987, NUCLEIC ACIDS RES, V15, P509, DOI 10.1093/nar/15.2.509; BOEUF H, 1990, IN PRESS P NATL ACAD; BOHLER K, 1983, COLD SPRING HARBOR C, V10, P39; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CHENG C, 1982, VIROLOGY, V123, P45, DOI 10.1016/0042-6822(82)90293-8; GODING C, 1985, EMBO J, V4, P1523, DOI 10.1002/j.1460-2075.1985.tb03812.x; HANAUER A, 1984, EMBO J, V3, P2627, DOI 10.1002/j.1460-2075.1984.tb02185.x; HARDY S, 1989, MOL CELL BIOL, V9, P4495, DOI 10.1128/MCB.9.10.4495; HARDY S, 1989, GENE DEV, V3, P1062, DOI 10.1101/gad.3.7.1062; HOGAN BLM, 1986, LABORATORY MANUAL, P262; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; IMPERIALE MJ, 1984, MOL CELL BIOL, V4, P867, DOI 10.1128/MCB.4.5.867; JALINOT P, 1987, MOL CELL BIOL, V7, P3806, DOI 10.1128/MCB.7.10.3806; JANSENDURR P, 1988, NUCLEIC ACIDS RES, V16, P3771, DOI 10.1093/nar/16.9.3771; JANSENDURR P, 1989, EMBO J, V8, P3365, DOI 10.1002/j.1460-2075.1989.tb08499.x; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KELLY F, 1976, NATURE, V262, P409, DOI 10.1038/262409a0; KEMLER R, 1981, IMMUNE SYSTEM, V1, P102; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1988, TRANSCRIPTION SPLICI, P1; LEONG K, 1986, P NATL ACAD SCI USA, V83, P5844, DOI 10.1073/pnas.83.16.5844; LEWIS ED, 1985, MOL CELL BIOL, V5, P2433, DOI 10.1128/MCB.5.9.2433; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; REICHEL R, 1989, J VIROL, V63, P3643, DOI 10.1128/JVI.63.9.3643-3650.1989; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SASSONECORSI P, 1985, COLD SPRING HARB SYM, V50, P747, DOI 10.1101/SQB.1985.050.01.092; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; STAFFORD J, 1983, NATURE, V306, P77, DOI 10.1038/306077a0; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUEMORI H, 1988, MOL CELL BIOL, V8, P3553, DOI 10.1128/MCB.8.8.3553; THOMAS GP, 1980, CELL, V22, P523; ZAJCHOWSKI DA, 1987, GENE, V58, P243, DOI 10.1016/0378-1119(87)90379-9; ZAJCHOWSKI DA, 1985, EMBO J, V4, P1293, DOI 10.1002/j.1460-2075.1985.tb03775.x	43	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					691	699						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2161097				2022-12-17	WOS:A1990DG37400009
J	WAGNER, HE; JOYCE, AD; BEATRICE, K; SUMMERHAYES, IC				WAGNER, HE; JOYCE, AD; BEATRICE, K; SUMMERHAYES, IC			RAS INDUCED LESIONS IN A HETEROTOPIC MOUSE BLADDER	ONCOGENE			English	Article									NEW ENGLAND DEACONESS HOSP, CANC BIOL LAB, 50 BINNEY ST, BOSTON, MA 02215 USA						NATIONAL CANCER INSTITUTE [R23CA042944, P01CA044704, R01CA042944] Funding Source: NIH RePORTER; NCI NIH HHS [CA42944, CA44704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; EDWARDS PAW, 1988, ONCOGENE, V2, P407; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; HICKS RM, 1975, BIOL REV, V50, P215, DOI 10.1111/j.1469-185X.1975.tb01057.x; JOYCE AD, 1988, J UROLOGY, V140, P1067, DOI 10.1016/S0022-5347(17)41928-8; JOYCE AD, 1989, LAB INVEST, V61, P212; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; NADAKAVUKAREN KK, 1984, DIFFERENTIATION, V27, P209, DOI 10.1111/j.1432-0436.1984.tb01431.x; OHTANI M, 1986, CANCER RES, V46, P2001; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUAREZ HG, 1988, ONCOGENE, V2, P403; SUMMERHAYES IC, 1988, J UROLOGY, V139, P405, DOI 10.1016/S0022-5347(17)42444-X; SUMMERHAYES IC, 1982, CANCER RES, V42, P4098; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	32	6	6	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					557	563						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183157				2022-12-17	WOS:A1990DB85300015
J	YUASA, Y; KAMIYAMA, T; KATO, M; IWAMA, T; IKEUCHI, T; TONOMURA, A				YUASA, Y; KAMIYAMA, T; KATO, M; IWAMA, T; IKEUCHI, T; TONOMURA, A			TRANSFORMING GENES FROM FAMILIAL ADENOMATOUS POLYPOSIS PATIENT CELLS DETECTED BY A TUMORIGENICITY ASSAY	ONCOGENE			English	Article									TOKYO MED & DENT UNIV, SCH MED, DEPT SURG 2, TOKYO 113, JAPAN; TOKYO MED & DENT UNIV, MED RES INST, TOKYO 113, JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	YUASA, Y (corresponding author), TOKYO MED & DENT UNIV, DEPT HYG & ONCOL, BUNKYO KU, TOKYO 113, JAPAN.							BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; JELINEK WR, 1980, P NATL ACAD SCI-BIOL, V77, P1398, DOI 10.1073/pnas.77.3.1398; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KRONTIRIS TG, 1981, P NATL ACAD SCI-BIOL, V78, P1181, DOI 10.1073/pnas.78.2.1181; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; Maniatis T., 1982, MOL CLONING; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NEEDLEMAN SW, 1983, SCIENCE, V222, P173, DOI 10.1126/science.6623066; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAMAMOTO A, 1989, BIOCHEM BIOPH RES CO, V159, P1100, DOI 10.1016/0006-291X(89)92222-5; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YUASA Y, 1986, JPN J CANCER RES, V77, P901; YUASA Y, 1987, JPN J CANCER RES, V78, P1036; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0	24	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					589	596						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1970154				2022-12-17	WOS:A1990DB85300020
J	POPESCU, NC; MARK, GE				POPESCU, NC; MARK, GE			LOCALIZATION OF THE PKS GENE, A RAF RELATED SEQUENCE ON HUMAN CHROMOSOME-X AND CHROMOSOME-7	ONCOGENE			English	Note									MERCK SHARP & DOHME RES LABS,RAHWAY,NJ 07065	Merck & Company	POPESCU, NC (corresponding author), NCI,DIV CANC ETIOL,BIOL LAB,BETHESDA,MD 20892, USA.							BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLEEKERWAGEMAKERS LM, 1985, HUM GENET, V71, P211, DOI 10.1007/BF00284575; BONNER T, 1984, SCIENCE, V223, P71, DOI 10.1126/science.6691137; CROCE CM, 1985, BLOOD, V65, P1; DEGROUCHY J, 1985, ANN GENET-PARIS, V28, P86; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; GAL A, 1985, CLIN GENET, V27, P282; GILGENKRANTZ S, 1985, ANN GENET-PARIS, V28, P90; GRIFFIN CA, 1987, CANCER GENET CYTOGEN, V26, P181, DOI 10.1016/0165-4608(87)90148-8; HAMEISTER H, 1986, HUM GENET, V72, P241, DOI 10.1007/BF00291886; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; HUEBNER K, 1986, AM J HUM GENET, V38, P819; LYON MF, 1970, NATURE, V227, P1217, DOI 10.1038/2271217a0; MARK GE, 1986, P NATL ACAD SCI USA, V83, P6312, DOI 10.1073/pnas.83.17.6312; MENKES JH, 1962, PEDIATRICS, V29, P764; MIGEON BR, 1981, P NATL ACAD SCI-BIOL, V78, P6339, DOI 10.1073/pnas.78.10.6339; MITCHELL G, 1986, American Journal of Human Genetics, V39, pA163; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; PEACOCKE M, 1987, P NATL ACAD SCI USA, V84, P3430, DOI 10.1073/pnas.84.10.3430; POPESCU NC, 1985, CYTOGENET CELL GENET, V39, P73, DOI 10.1159/000132107; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; RAMESH V, 1987, HUM GENET, V76, P121, DOI 10.1007/BF00284906; ROWLEY JD, 1984, CANCER RES, V44, P3159; SANDBERG AA, 1980, CHROMOSOMES HUMAN CA; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; SPURR NK, 1987, ANN HUM GENET, V51, P189, DOI 10.1111/j.1469-1809.1987.tb00870.x; TEMIN HM, 1986, GENETIC REARRANGEMEN, P136; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WIEACKER P, 1987, HUM GENET, V76, P248; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P8679, DOI 10.1073/pnas.83.22.8679	31	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					517	519						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2717185				2022-12-17	WOS:A1989U567700018
J	BARNES, D; CLAYTON, L; CHUMBLEY, G; MACLEOD, AR				BARNES, D; CLAYTON, L; CHUMBLEY, G; MACLEOD, AR			ACTIVATION OF THE TRK ONCOGENE BY ALTERNATIVELY SPLICED MUSCLE AND NON-MUSCLE TROPOMYOSIN SEQUENCES	ONCOGENE			English	Note									UNIV CAMBRIDGE,DEPT ANAT,DOWNING ST,CAMBRIDGE CB2 3DY,ENGLAND; MRC,LUDWIG INST CANC RES,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge; Ludwig Institute for Cancer Research; University of Cambridge								BLAIR DG, 1982, SCIENCE, V218, P112; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FIERS W, 1978, NATURE, V273, P113, DOI 10.1038/273113a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JEFFREYS AJ, 1977, CELL, V12, P1097, DOI 10.1016/0092-8674(77)90172-6; KOSMA SC, 1988, EMBO J, V7, P147; KREIG PA, 1984, NUCLEIC ACIDS RES, V12, P7057; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MITRA G, 1987, P NATL ACAD SCI USA, V84, P6707, DOI 10.1073/pnas.84.19.6707; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; REINACH FC, 1986, NATURE, V322, P648, DOI 10.1038/322648a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	19	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1989	4	2					259	262						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5675	2927948				2022-12-17	WOS:A1989U567500020
J	Somatilaka, BN; Sadek, A; McKay, RM; Le, LQ				Somatilaka, Bandarigoda N.; Sadek, Ali; McKay, Renee M.; Le, Lu Q.			Malignant peripheral nerve sheath tumor: models, biology, and translation	ONCOGENE			English	Review							SOFT-TISSUE SARCOMA; FARNESYLTRANSFERASE INHIBITOR TIPIFARNIB; RECEPTOR TYROSINE KINASES; NEUROFIBROMATOSIS TYPE-I; CANCER STEM-CELL; SCHWANN-CELLS; MOUSE MODELS; PHASE-II; MOLECULAR CHARACTERIZATION; PLEXIFORM NEUROFIBROMAS	Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive, invasive cancer that comprise around 10% of all soft tissue sarcomas and develop in about 8-13% of patients with Neurofibromatosis Type 1. They are associated with poor prognosis and are the leading cause of mortality in NF1 patients. MPNSTs can also develop sporadically or following exposure to radiation. There is currently no effective targeted therapy to treat MPNSTs and surgical removal remains the mainstay treatment. Unfortunately, surgery is not always possible due to the size and location of the tumor, thus, a better understanding of MPNST initiation and development is required to design novel therapeutics. Here, we provide an overview of MPNST biology and genetics, discuss findings regarding the developmental origin of MPNST, and summarize the various model systems employed to study MPNST. Finally, we discuss current management strategies for MPNST, as well as recent developments in translating basic research findings into potential therapies.	[Somatilaka, Bandarigoda N.; Sadek, Ali; McKay, Renee M.; Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA; [Le, Lu Q.] Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, UTSW Comprehens Neurofibromatosis Clin, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Hamon Ctr Regenerat Sci & Med, Dallas, TX 75390 USA.; Le, LQ (corresponding author), Univ Texas Southwestern Med Ctr Dallas, ODonnell Brain Inst, Dallas, TX 75390 USA.	lu.le@utsouthwestern.edu		Somatilaka, Bandarigoda Nipunika/0000-0003-4366-9153; McKay, Renee/0000-0001-5976-1996; Le, Lu/0000-0003-2817-5382	Burroughs Wellcome Fund; US Department of Defense [NF210010]; National Cancer Institute of the NIH [R01 CA166593]; Developmental and Hyperactive RAS Tumor SPORE [U54 CA196519]; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	Burroughs Wellcome Fund(Burroughs Wellcome Fund); US Department of Defense(United States Department of Defense); National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental and Hyperactive RAS Tumor SPORE; Neurofibromatosis Therapeutic Acceleration Program; NF1 Research Consortium Fund; Giorgio Foundation	LQL held a Career Award for Medical Scientists from the Burroughs Wellcome Fund and is the Thomas L. Shield, M.D. endowed Professor in Dermatology. He is supported by funding from the US Department of Defense (NF210010), the National Cancer Institute of the NIH (R01 CA166593), and the Developmental and Hyperactive RAS Tumor SPORE (U54 CA196519); the Neurofibromatosis Therapeutic Acceleration Program; the NF1 Research Consortium Fund; and the Giorgio Foundation.	Ahlawat S, 2020, SKELETAL RADIOL, V49, P199, DOI 10.1007/s00256-019-03290-1; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Albers AC, 2009, EXPERT REV NEUROTHER, V9, P535, DOI [10.1586/ern.09.4, 10.1586/ERN.09.4]; Albritton KH, 2006, J CLIN ONCOL, V24, p524S; Ambrosini G, 2008, MOL CANCER THER, V7, P890, DOI 10.1158/1535-7163.MCT-07-0518; Anastasaki C, 2020, STEM CELL REP, V14, P541, DOI 10.1016/j.stemcr.2020.03.007; Arshi A, 2015, ORAL ONCOL, V51, P1088, DOI 10.1016/j.oraloncology.2015.08.012; Astone M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145178; Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; Bates JE, 2014, PEDIATR BLOOD CANCER, V61, P1955, DOI 10.1002/pbc.25149; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Berner JM, 1999, GENE CHROMOSOME CANC, V26, P151, DOI 10.1002/(SICI)1098-2264(199910)26:2<151::AID-GCC7>3.3.CO;2-1; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhatia S, 2019, J CLIN ONCOL, V37, P3050, DOI 10.1200/JCO.19.00114; Bhola P, 2010, INT J CANCER, V126, P563, DOI 10.1002/ijc.24783; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Bottillo I, 2009, J PATHOL, V217, P693, DOI 10.1002/path.2494; Boyd KP, 2009, J AM ACAD DERMATOL, V61, P1, DOI 10.1016/j.jaad.2008.12.051; Bradtmoller M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047595; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brohl AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15183-1; Brosseau JP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07452-y; Buchanan ME, 2010, J NEUROSCI, V30, P10135, DOI 10.1523/JNEUROSCI.0283-10.2010; Butti R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0797-x; Byer SJ, 2011, NEURO-ONCOLOGY, V13, P28, DOI 10.1093/neuonc/noq146; Carli M, 2005, J CLIN ONCOL, V23, P8422, DOI 10.1200/JCO.2005.01.4886; Carrio M, 2019, STEM CELL REP, V12, P411, DOI 10.1016/j.stemcr.2019.01.001; Carroll SL, 2016, AM J PATHOL, V186, P464, DOI 10.1016/j.ajpath.2015.10.023; Carroll SL, 2012, ACTA NEUROPATHOL, V123, P321, DOI 10.1007/s00401-011-0928-6; Castells-Roca L, 2021, CANCERS, V13, DOI 10.3390/cancers13071591; Castellsague J, 2015, EMBO MOL MED, V7, P608, DOI 10.15252/emmm.201404430; Chamseddin BH., 2020, NEUROONCOL ADV, V2, pi107; Chaney KE, 2020, CANCER RES, V80, P4720, DOI 10.1158/0008-5472.CAN-19-1429; Chau V, 2014, CANCER RES, V74, P586, DOI 10.1158/0008-5472.CAN-13-1934; Chen ZG, 2014, CANCER CELL, V26, P695, DOI 10.1016/j.ccell.2014.09.009; Chou D, 2017, J NEUROSURG-SPINE, V26, P291, DOI 10.3171/2016.8.SPINE151548; Chugh R, 2009, J CLIN ONCOL, V27, P3148, DOI 10.1200/JCO.2008.20.5054; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Cleven AHG, 2016, MODERN PATHOL, V29, P582, DOI 10.1038/modpathol.2016.45; Cooper JM, 2019, CLIN CANCER RES, V25, P3404, DOI 10.1158/1078-0432.CCR-18-2437; Cox Adrienne D, 2010, Small GTPases, V1, P2; DAHLBERG WK, 1993, INT J RADIAT BIOL, V63, P191, DOI 10.1080/09553009314550251; Dang I, 2005, J NEUROSCI RES, V79, P318, DOI 10.1002/jnr.20334; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; Dehner C, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146351; Demestre M, 2013, J NEURO-ONCOL, V115, P391, DOI 10.1007/s11060-013-1252-x; Deyle DR, 2015, GENE, V565, P140, DOI 10.1016/j.gene.2015.04.001; Dodd RD, 2017, CANCER RES, V77, P4486, DOI 10.1158/0008-5472.CAN-16-2643; Dodd RD, 2013, MOL CANCER THER, V12, P1906, DOI 10.1158/1535-7163.MCT-13-0189; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Dunn GP, 2013, J NEUROSURG, V118, P142, DOI 10.3171/2012.9.JNS101610; Ebben JD, 2010, EXPERT OPIN THER TAR, V14, P621, DOI 10.1517/14712598.2010.485186; Eckert JM, 2009, GLIA, V57, P1501, DOI 10.1002/glia.20866; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Fang YQ, 2009, ANTICANCER RES, V29, P1255; Farid M, 2014, ONCOLOGIST, V19, P193, DOI 10.1634/theoncologist.2013-0328; Ferner RE, 2008, ANN ONCOL, V19, P390, DOI 10.1093/annonc/mdm450; Ferner RE, 2000, J NEUROL NEUROSUR PS, V68, P353, DOI 10.1136/jnnp.68.3.353; Ferner RE, 2002, CANCER RES, V62, P1573; Ferner RE, 2007, LANCET NEUROL, V6, P340, DOI 10.1016/S1474-4422(07)70075-3; Ferrari A, 2011, EUR J CANCER, V47, P724, DOI 10.1016/j.ejca.2010.11.013; Fisher MJ, 2012, NEURO-ONCOLOGY, V14, P790, DOI 10.1093/neuonc/nos076; Fuchs Bruno, 2005, J Surg Orthop Adv, V14, P168; Gachiani John, 2007, Neurosurg Focus, V22, pE13; Garozzo D, 2019, NEUROL INDIA, V67, pS38, DOI 10.4103/0028-3886.250697; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; Gouzi JY, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002281; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gregorian C, 2009, P NATL ACAD SCI USA, V106, P19479, DOI 10.1073/pnas.0910398106; Gross AM, 2020, NEW ENGL J MED, V382, P1430, DOI 10.1056/NEJMoa1912735; Guo HF, 2000, NATURE, V403, P895, DOI 10.1038/35002593; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; Guo JM, 2020, AM J CANCER RES, V10, P856; Guo JM, 2017, AM J CANCER RES, V7, P923; Gupta G, 2008, NEUROSURG CLIN N AM, V19, P533, DOI 10.1016/j.nec.2008.07.004; Gutmann DH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.4; Hakozaki M, 2009, VIRCHOWS ARCH, V455, P517, DOI 10.1007/s00428-009-0848-1; Harachi M, 2021, METABOLITES, V11, DOI 10.3390/metabo11040216; Higham Christine S., 2017, Sarcoma, V2017, P8685638, DOI 10.1155/2017/8685638; Hirbe AC, 2016, ONCOTARGET, V7, P7403, DOI 10.18632/oncotarget.7232; Hirbe AC, 2014, NEURO-ONCOLOGY, V16, P466, DOI 10.1093/neuonc/not248; Hirokowa Y, 2005, CANCER BIOL THER, V4, P379; Ho IS, 2007, J NEUROSCI, V27, P6852, DOI 10.1523/JNEUROSCI.0933-07.2007; HOLT GR, 1987, OTOLARYNG CLIN N AM, V20, P179; Holtkamp N, 2006, CARCINOGENESIS, V27, P664, DOI 10.1093/carcin/bgi273; Holtkamp N, 2008, NEURO-ONCOLOGY, V10, P946, DOI 10.1215/15228517-2008-053; Hubbard SR, 2007, CURR OPIN CELL BIOL, V19, P117, DOI 10.1016/j.ceb.2007.02.010; Huijbregts RPH, 2003, J NEUROSCI, V23, P7269; Imaizumi S, 1998, VIRCHOWS ARCH, V433, P435, DOI 10.1007/s004280050271; Inoue A, 2019, CANCERS, V11, DOI 10.3390/cancers11091321; Isfort I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56247-8; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Jia LQ, 1997, MOL CARCINOGEN, V19, P243, DOI 10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johannessen CM, 2008, CURR BIOL, V18, P56, DOI 10.1016/j.cub.2007.11.066; Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Jouhilahti EM, 2011, AM J PATHOL, V178, P1932, DOI 10.1016/j.ajpath.2010.12.056; Kahen Elliot John, 2018, Oncotarget, V9, P22571, DOI 10.18632/oncotarget.25181; Kahn J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00324; Kaplan HG, 2018, J NATL COMPR CANC NE, V16, P967, DOI 10.6004/jnccn.2018.7033; Kar Madhabananda, 2006, World J Surg Oncol, V4, P55, DOI 10.1186/1477-7819-4-55; Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129; Kazmi SJ, 2013, AM J PATHOL, V182, P646, DOI 10.1016/j.ajpath.2012.11.017; Keng Vincent W., 2012, Sarcoma, V2012, P620834, DOI 10.1155/2012/620834; Keng VW, 2012, CANCER RES, V72, P3405, DOI 10.1158/0008-5472.CAN-11-4092; Ki DH, 2017, ONCOGENE, V36, P1058, DOI 10.1038/onc.2016.269; Ki DH, 2019, ONCOGENE, V38, P6585, DOI 10.1038/s41388-019-0965-5; Kim AeRang, 2020, Sarcoma, V2020, P5784876, DOI 10.1155/2020/5784876; Kim AeRang, 2017, Sarcoma, V2017, P7429697, DOI 10.1155/2017/7429697; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Koelsche C, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-33; Kohlmeyer JL, 2020, CLIN CANCER RES, V26, P2997, DOI 10.1158/1078-0432.CCR-19-2706; Kolberg M, 2017, MOL ONCOL, V11, P1156, DOI 10.1002/1878-0261.12086; Kolberg M, 2013, NEURO-ONCOLOGY, V15, P135, DOI 10.1093/neuonc/nos287; Kraniak JM, 2018, EXP NEUROL, V299, P289, DOI 10.1016/j.expneurol.2017.10.012; Kumari Rashmi, 2018, Oncotarget, V9, P23494, DOI 10.18632/oncotarget.25236; LaFemina J, 2013, ANN SURG ONCOL, V20, P66, DOI 10.1245/s10434-012-2573-2; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laycock-van Spyk Sebastian, 2011, Human Genomics, V5, P623; Lee PR, 2004, NEURON GLIA BIOL, V1, P135, DOI 10.1017/S1740925X04000274; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405; Lemberg KM, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060691; Levi AD, 2010, NEUROSURGERY, V66, P833, DOI 10.1227/01.NEU.0000367636.91555.70; Li H, 2016, LAB INVEST, V96, P1105, DOI 10.1038/labinvest.2016.88; Li HZ, 2002, CANCER RES, V62, P4507; Li YW, 2004, ONCOGENE, V23, P1146, DOI 10.1038/sj.onc.1207068; Lock R, 2016, J CLIN INVEST, V126, P2181, DOI 10.1172/JCI85183; Longo JF, 2018, ADV ANAT PATHOL, V25, P353, DOI 10.1097/PAP.0000000000000197; Longo JF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85055-2; Lopez G, 2011, CANCER RES, V71, P185, DOI 10.1158/0008-5472.CAN-10-2799; Luscan A, 2014, CLIN CANCER RES, V20, P358, DOI 10.1158/1078-0432.CCR-13-0780; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Mak IWY, 2014, AM J TRANSL RES, V6, P114; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Maldonado AR, 2010, J GENE MED, V12, P613, DOI 10.1002/jgm.1479; Malone CF, 2017, CANCER DISCOV, V7, P1450, DOI 10.1158/2159-8290.CD-17-0177; Malone CF, 2014, CANCER DISCOV, V4, P1062, DOI 10.1158/2159-8290.CD-14-0159; Mantripragada KK, 2008, CLIN CANCER RES, V14, P1015, DOI 10.1158/1078-0432.CCR-07-1305; Markham A, 2020, DRUGS, V80, P931, DOI 10.1007/s40265-020-01331-x; Martin E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28138; Mashour GA, 2005, ONCOGENE, V24, P2367, DOI 10.1038/sj.onc.1208425; Mattingly RR, 2006, J PHARMACOL EXP THER, V316, P456, DOI 10.1124/jpet.105.091454; Mautner VF, 2003, NEURORADIOLOGY, V45, P618, DOI 10.1007/s00234-003-0964-6; MERTENS F, 1995, INT J CANCER, V61, P793, DOI 10.1002/ijc.2910610609; Miettinen MM, 2017, HUM PATHOL, V67, P1, DOI 10.1016/j.humpath.2017.05.010; Miller DT, 2020, GENES-BASEL, V11, DOI 10.3390/genes11040387; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Misra JR, 2018, ANNU REV GENET, V52, P65, DOI 10.1146/annurev-genet-120417-031621; Mo J, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI139807; Mo W, 2013, CELL, V152, P1077, DOI 10.1016/j.cell.2013.01.053; Moll C, 2013, JOVE-J VIS EXP, DOI 10.3791/50460; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Morrison Deborah K, 2012, Cold Spring Harb Perspect Biol, V4, DOI 10.1101/cshperspect.a011254; Muir D, 2001, AM J PATHOL, V158, P501, DOI 10.1016/S0002-9440(10)63992-2; Nagabushan S, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00145-8; NAGASHIMA Y, 1990, VIRCHOWS ARCH B, V59, P321, DOI 10.1007/BF02899420; Nakamura JL, 2011, CANCER RES, V71, P106, DOI 10.1158/0008-5472.CAN-10-2732; O'Sullivan B, 2002, LANCET, V359, P2235, DOI 10.1016/S0140-6736(02)09292-9; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohishi J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-224; Oppel F, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008039; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Patel AJ, 2014, CELL REP, V6, P81, DOI 10.1016/j.celrep.2013.12.001; Patwardhan PP, 2014, CLIN CANCER RES, V20, P3146, DOI 10.1158/1078-0432.CCR-13-2576; Peacock JD, 2018, CANCER RES, V78, P3672, DOI 10.1158/0008-5472.CAN-17-3167; Pekmezci M, 2015, MODERN PATHOL, V28, P187, DOI 10.1038/modpathol.2014.109; Pemov Alexander, 2020, Neurooncol Adv, V2, pi50, DOI 10.1093/noajnl/vdz049; Pemov A, 2019, NEURO-ONCOLOGY, V21, P981, DOI 10.1093/neuonc/noz028; Perrin GQ, 2007, LAB INVEST, V87, P1092, DOI 10.1038/labinvest.3700675; Pollard K, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0508-5; Rad E, 2016, SEMIN CELL DEV BIOL, V52, P39, DOI 10.1016/j.semcdb.2016.02.007; Rahrmann EP, 2014, AM J PATHOL, V184, P2082, DOI 10.1016/j.ajpath.2014.04.006; Rahrmann EP, 2013, NAT GENET, V45, P756, DOI 10.1038/ng.2641; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Regad T, 2015, CANCERS, V7, P1758, DOI 10.3390/cancers7030860; Reilly KM, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx124; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Reuss DE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057152; Rhodes SD, 2019, HUM MOL GENET, V28, P2752, DOI 10.1093/hmg/ddz095; Rosenbaum T, 2014, KLIN PADIATR, V226, P309, DOI 10.1055/s-0034-1382021; RYAN JJ, 1994, J NEUROSCI RES, V37, P415, DOI 10.1002/jnr.490370314; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Scaife Courtney L, 2003, Surg Oncol Clin N Am, V12, P355, DOI 10.1016/S1055-3207(03)00003-6; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt H, 2001, CANCER GENET CYTOGEN, V128, P14, DOI 10.1016/S0165-4608(01)00393-4; Schuetze SM, 2016, CANCER-AM CANCER SOC, V122, P868, DOI 10.1002/cncr.29858; Semenova G, 2017, BIOCHIMIE, V135, P1, DOI 10.1016/j.biochi.2017.01.001; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Singh SK, 2003, CANCER RES, V63, P5821; Sonobe H, 2000, INT J ONCOL, V17, P347; Spyra M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021099; Stalnecker CA, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay6013; Subramanian S, 2010, J PATHOL, V220, P58, DOI 10.1002/path.2633; Sun DC, 2021, CELL STEM CELL, V28, P1397, DOI 10.1016/j.stem.2021.04.029; Sun Daochun, 2012, Transl Oncogenomics, V5, P1, DOI 10.4137/TOG.S8830; Suratwala SJ, 2020, SPINE DEFORM, V8, P333, DOI 10.1007/s43390-019-00013-3; Szymanski JJ, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003734; Tabone-Eglinger Severine, 2008, Sarcoma, V2008, P1, DOI 10.1155/2008/849156; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TAKAMIYA Y, 1993, J NEUROSURG, V78, P470, DOI 10.3171/jns.1993.78.3.0470; Teicher BA, 2015, MOL CANCER THER, V14, P2452, DOI 10.1158/1535-7163.MCT-15-0074; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Theos A, 2006, ANN INTERN MED, V144, P842, DOI 10.7326/0003-4819-144-11-200606060-00010; Thomson CS, 2021, ONCOGENE, V40, P4229, DOI 10.1038/s41388-021-01773-x; Tierney JF, 1997, LANCET, V350, P1647; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Torres KE, 2011, CLIN CANCER RES, V17, P3943, DOI 10.1158/1078-0432.CCR-11-0193; Tovmassian D, 2016, INT J SURG ONCOL, V2016, DOI 10.1155/2016/6162182; van der Voet M, 2016, MOL PSYCHIATR, V21, P565, DOI 10.1038/mp.2015.55; Varin J, 2016, ONCOTARGET, V7, P35753, DOI 10.18632/oncotarget.7099; Verdijk RM, 2010, J NEUROPATH EXP NEUR, V69, P16, DOI 10.1097/NEN.0b013e3181c55d55; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Walker JA, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003958; Wang W, 2012, J INT MED RES, V40, P2284, DOI 10.1177/030006051204000626; Watson AL, 2014, ONCOTARGET, V5, P1502, DOI 10.18632/oncotarget.1609; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Wegscheid ML, 2018, EXP NEUROL, V299, P270, DOI 10.1016/j.expneurol.2017.04.001; Weiss B, 2015, NEURO-ONCOLOGY, V17, P596, DOI 10.1093/neuonc/nou235; Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638; Widemann Brigitte C., 2019, Sarcoma, V2019, P7656747, DOI 10.1155/2019/7656747; Widemann BC, 2018, J CLIN ONCOL, V36, P160, DOI 10.1200/JCO.2017.75.3467; Widemann BC, 2014, NEURO-ONCOLOGY, V16, P707, DOI 10.1093/neuonc/nou004; Williams JA, 2001, SCIENCE, V293, P2251, DOI 10.1126/science.1063097; Williams KB, 2020, GENES-BASEL, V11, DOI 10.3390/genes11050477; Williams KB, 2017, MOL CANCER THER, V16; Wojtkowiak JW, 2008, J PHARMACOL EXP THER, V326, P1, DOI 10.1124/jpet.107.135830; Wood M, 2011, MOL CANCER THER, V10, P1740, DOI 10.1158/1535-7163.MCT-11-0309; Wu J, 2014, ONCOGENE, V33, P173, DOI 10.1038/onc.2012.579; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Wu LMN, 2018, CANCER CELL, V33, P292, DOI 10.1016/j.ccell.2018.01.005; Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y; YAN N, 1995, CANCER RES, V55, P3569; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yang JC, 1998, J CLIN ONCOL, V16, P197, DOI 10.1200/JCO.1998.16.1.197; Yang JL, 2011, CLIN CANCER RES, V17, P7563, DOI 10.1158/1078-0432.CCR-11-1707; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yoshida GJ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0829-z; Zhang M, 2014, NAT GENET, V46, P1170, DOI 10.1038/ng.3116; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; Zou CY, 2009, ANN SURG, V249, P1014, DOI 10.1097/SLA.0b013e3181a77e9a	254	5	5	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2405	2421		10.1038/s41388-022-02290-1	http://dx.doi.org/10.1038/s41388-022-02290-1		APR 2022	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35393544	Green Accepted			2022-12-17	WOS:000779227700003
J	Zou, HL; Luo, J; Guo, YB; Liu, YH; Wang, Y; Deng, L; Li, P				Zou, Hailin; Luo, Juan; Guo, Yibo; Liu, Yuhong; Wang, Yun; Deng, Liang; Li, Peng			RNA-binding protein complex LIN28/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7	ONCOGENE			English	Article							BREAST-CANCER; EXPRESSION; PATHWAY; TAZ; MICRORNA; LIN28A; YAP; TRANSFORMATION; PROLIFERATION; PLURIPOTENCY	The RNA binding protein LIN28 directly modulates the stability and translation of target mRNAs independently of Let-7; however, the key downstream targets of LIN28 in this process are largely unknown. Here, we revealed that Hippo signaling effector YAP1 functioned as a key downstream regulator of LIN28 to modulate the cancer stem cell (CSC)-like properties and tumor progressions in triple negative breast cancer (TNBC). LIN28 was overexpressed in BC tissues and cell lines, and significantly correlated with poorer overall survivals in patients. Ectopic LIN28 expression enhanced, while knockdown of LIN28A inhibited the CSC-like properties, cell growth and invasive phenotypes of TNBC cells in vitro and in vivo. Transcriptome analysis demonstrated LIN28 overexpression significantly induced the expressions of YAP1 downstream genes, while reduced the transcripts of YAP1 upstream kinases, such as MST1/2 and LATS1/2, and knockdown of LIN28A exhibited the opposite effects. Furthermore, constitutive activation of YAP1 in LIN28 knockdown TNBC cells could rescue the cell growth and invasive phenotypes in vitro and in vivo. Mechanistically, instead of the dependence of Let-7, LIN28 recruited RNA binding protein MSI2 in a manner dependent on the LIN28 CSD domain and MSI2 RRM domain, to directly induce the mRNA decay of YAP1 upstream kinases, leading to the inhibition of Hippo pathway and activation of YAP1, which eventually gave rise to increased CSC populations, enhanced tumor cell growth and invasive phenotypes. Accordingly, co-upregulations of LIN28 and MSI2 in TNBC tissues were strongly associated with YAP1 protein level and tumor malignance. Taken together, our findings unravel a novel LIN28/MSI2-YAP1 regulatory axis to induce the CSC-like properties, tumor growth and metastasis, independently of Let-7, which may serve as a potential therapeutic strategy for the treatment of a subset of TNBC with LIN28 overexpression.	[Zou, Hailin; Luo, Juan; Guo, Yibo; Wang, Yun; Li, Peng] Sun Yat Sen Univ, Sci Res Ctr, Affiliated Hosp 7, Shenzhen 518107, Guangdong, Peoples R China; [Liu, Yuhong; Deng, Liang] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Gen Surg, Shenzhen 518107, Guangdong, Peoples R China; [Li, Peng] Sun Yat Sen Univ, Affiliated Hosp 7, Guangdong Prov Key Lab Digest Canc Res, 628 Zhenyuan Rd, Shenzhen 518107, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, P (corresponding author), Sun Yat Sen Univ, Sci Res Ctr, Affiliated Hosp 7, Shenzhen 518107, Guangdong, Peoples R China.; Li, P (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Guangdong Prov Key Lab Digest Canc Res, 628 Zhenyuan Rd, Shenzhen 518107, Guangdong, Peoples R China.	lipeng56@mail.sysu.edu.cn	Deng, Liang/GXH-6710-2022	Li, Peng/0000-0001-7226-4214	Shenzhen Science and Technology Innovation Commission [JCYJ20210324120409026]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110285]; National Natural Science Foundation of China [32000679, 82072901]; Fundamental Research Funds for the Central Universities [20ykzd02]; Guangdong Provincial Key Laboratory of Digestive Cancer Research [2021B1212040006]	Shenzhen Science and Technology Innovation Commission; Guangdong Basic and Applied Basic Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Guangdong Provincial Key Laboratory of Digestive Cancer Research	This work was supported by Shenzhen Science and Technology Innovation Commission (JCYJ20210324120409026 to PL), Guangdong Basic and Applied Basic Research Foundation (Grant No. 2021A1515111052 to JL), National Natural Science Foundation of China (Grant No. 32000679 and 82072901 to PL), the Fundamental Research Funds for the Central Universities (Grant No. 20ykzd02 to PL), Guangdong Basic and Applied Basic Research Foundation (Grant No. 2019A1515110285 to PL), and the Guangdong Provincial Key Laboratory of Digestive Cancer Research (No. 2021B1212040006).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ali MA, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103197; Balzeau J, 2017, FRONT GENET, V8, P1, DOI 10.3389/fgene.2017.00031; Balzer E, 2010, DEVELOPMENT, V137, P891, DOI 10.1242/dev.042895; Beachy SH, 2012, BLOOD, V120, P1048, DOI 10.1182/blood-2012-01-401760; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Borah A, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.35; Choi YM, 2017, ONCOGENE, V36, P2802, DOI 10.1038/onc.2016.441; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Farzaneh M, 2017, CELL REPROGRAM, V19, P289, DOI 10.1089/cell.2017.0015; Feng C, 2012, CELL CYCLE, V11, P2486, DOI 10.4161/cc.20893; Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Jin JY, 2011, NUCLEIC ACIDS RES, V39, P3724, DOI 10.1093/nar/gkq1350; Kang MH, 2017, ONCOGENE, V36, P1745, DOI 10.1038/onc.2016.327; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Kudinov AE, 2017, CLIN CANCER RES, V23, P2143, DOI 10.1158/1078-0432.CCR-16-2728; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li MX, 2019, ORAL ONCOL, V98, P92, DOI 10.1016/j.oraloncology.2019.09.024; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Luo J, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/6674283; Maugeri-Sacca M, 2016, CRIT REV ONCOL HEMAT, V99, P115, DOI 10.1016/j.critrevonc.2015.12.004; Mo HN, 2021, FRONT MED-PRC, V15, P1, DOI 10.1007/s11684-020-0741-5; Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436; Moss EG, 2003, DEV BIOL, V258, P432, DOI 10.1016/S0012-1606(03)00126-X; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Park JH, 2018, MOL CELLS, V41, P83, DOI 10.14348/molcells.2018.2242; Peng F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.438; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Reggiani F, 2021, TRENDS BIOCHEM SCI, V46, P154, DOI 10.1016/j.tibs.2020.08.012; Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005; Thompson BJ, 2020, BIOESSAYS, V42, DOI 10.1002/bies.201900162; Tu HC, 2015, GENE DEV, V29, P1074, DOI 10.1101/gad.256693.114; Vadla B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002588; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang LF, 2018, CELL REP, V23, P3091, DOI 10.1016/j.celrep.2018.04.116; Wang LF, 2017, CELL REP, V18, P2664, DOI 10.1016/j.celrep.2017.02.044; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Wu ZM, 2021, TRENDS BIOCHEM SCI, V46, P51, DOI 10.1016/j.tibs.2020.08.008; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Yang HY, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-01384-8; Yang J, 2015, MOL CELL BIOL, V35, P3225, DOI 10.1128/MCB.00426-15; Zeng YX, 2016, MOL CELL, V61, P153, DOI 10.1016/j.molcel.2015.11.020; Zhang K, 2015, BIOCHEMISTRY-US, V54, P6555, DOI 10.1021/acs.biochem.5b01014; Zhang R, 2022, SEMIN CANCER BIOL, V82, P11, DOI 10.1016/j.semcancer.2021.03.008; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou JB, 2013, INT J BIOCHEM CELL B, V45, P973, DOI 10.1016/j.biocel.2013.02.006	52	5	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2022	41	11					1657	1672		10.1038/s41388-022-02198-w	http://dx.doi.org/10.1038/s41388-022-02198-w		JAN 2022	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ8WH	35102250	Green Published, hybrid			2022-12-17	WOS:000750409400001
J	Fan, M; Sun, WK; Gu, XF; Lu, SS; Shen, Q; Liu, X; Zhang, XW				Fan, Meng; Sun, Weikuan; Gu, Xiaofan; Lu, Shanshan; Shen, Qiang; Liu, Xuan; Zhang, Xiongwen			The critical role of STAT3 in biogenesis of tumor-derived exosomes with potency of inducing cancer cachexia in vitro and in vivo	ONCOGENE			English	Article							SNARE COMPLEXES; IL-6; INHIBITION; GLYCOLYSIS; ACTIVATION; PATHWAY; PKM2; MICROENVIRONMENT; PROLIFERATION; TRANSCRIPTION	Tumor-derived exosomes are emerging mediators of cancer cachexia. Clarifying the regulation of exosome biogenesis and finding possible targets for cancer cachexia therapy are important and necessary. In the present study, systemic analysis of the roles of STAT3 in controlling exosome biogenesis of murine C26 colon tumor cells and its contribution to the development of cancer cachexia is conducted. The genetic manipulation of STAT3 expression, STAT3 knockout (KO) or overexpression (OE), significantly affected the exosome biogenesis and also the potency of C26 conditioned medium (CM) in inducing muscle atrophy and lipolysis in vitro. The genetic manipulation of STAT3 expression caused change in phosphorylation of PKM2 and glycolysis. PKM2/SNAP23 pathway was involved in regulation of exosome biogenesis by STAT3 genetic manipulation as well as by STAT3 inhibitors in C26 cells. Mice inoculated with STAT3 knockout or overexpression C26 cells exhibited ameliorated or aggravated cancer cachexia symptoms, with a positive correlation with the serum exosome and IL-6 levels. The STAT3/PKM2/SNAP23 pathway was affected in C26 tumor tissues with genetic manipulation of STAT3 expression. The capacity of exosome biogenesis of different human cancer cells also exhibited a positive correlation with the activation of STAT3/PKM2/SNAP23 pathway. The research presented here confirms that STAT3 plays a critical role in regulating biogenesis of tumor-derived exosomes which could contribute to cancer cachexia development.	[Fan, Meng; Sun, Weikuan; Gu, Xiaofan; Lu, Shanshan; Zhang, Xiongwen] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai, Peoples R China; [Shen, Qiang; Liu, Xuan] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China	East China Normal University; Shanghai University of Traditional Chinese Medicine	Zhang, XW (corresponding author), East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai, Peoples R China.; Liu, X (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China.	xuanliu@shutcm.edu.cn; xwzhang@sat.ecnu.edu.cn		Liu, Xuan/0000-0002-7356-7898; Gu, Xiaofan/0000-0002-2441-3489; Fan, Meng/0000-0002-3761-4431	National Nature Science Foundation of China [81872496, 81873056]; Science and Technology Commission of Shanghai Municipality [20S11902200, 16DZ2280100]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This work was supported by National Nature Science Foundation of China (No. 81872496 and 81873056), and the Science and Technology Commission of Shanghai Municipality (20S11902200 and 16DZ2280100).	Altenberg B, 2004, GENOMICS, V84, P1014, DOI 10.1016/j.ygeno.2004.08.010; Damasceno LEA, 2020, J EXP MED, V217, DOI 10.1084/jem.20190613; Arora Gurpreet, 2020, JCSM Rapid Commun, V3, P115, DOI 10.1002/rco2.24; Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105; Bi YH, 2019, WORLD J GASTROENTERO, V25, P1936, DOI 10.3748/wjg.v25.i16.1936; Bian ZH, 2018, CLIN CANCER RES, V24, P4808, DOI 10.1158/1078-0432.CCR-17-2967; Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012; Chai EZP, 2016, PHARMACOL THERAPEUT, V162, P86, DOI 10.1016/j.pharmthera.2015.10.004; Chaneton B, 2012, TRENDS BIOCHEM SCI, V37, P309, DOI 10.1016/j.tibs.2012.04.003; Chen LL, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113066; Chen LL, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104871; Chitti SV, 2018, BIOCHEM SOC T, V46, P1129, DOI 10.1042/BST20180213; D'Souza-Schorey C, 2012, GENE DEV, V26, P1287, DOI 10.1101/gad.192351.112; Demaria Marco, 2012, JAKSTAT, V1, P194, DOI 10.4161/jkst.20662; Dorayappan KDP, 2018, ONCOGENE, V37, P3806, DOI 10.1038/s41388-018-0189-0; Eskiler GG, 2019, BRATISL MED J, V120, P819, DOI 10.4149/BLL_2019_136; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011; Fu XQ, 2018, EXP DERMATOL, V27, P201, DOI 10.1111/exd.13454; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gao SM, 2019, J CELL BIOCHEM, V120, P1193, DOI 10.1002/jcb.26915; Gao XH, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12060; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Harada Y, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108261; Hu WJ, 2018, BIOCHEM BIOPH RES CO, V506, P122, DOI 10.1016/j.bbrc.2018.09.139; Jaskiewicz A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218261; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kalra H, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020170; Kim NH, 2020, BIOCHEM BIOPH RES CO, V533, P1378, DOI 10.1016/j.bbrc.2020.10.025; Kosgodage US, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00889; Kroon P, 2013, CANCER RES, V73, P5288, DOI 10.1158/0008-5472.CAN-13-0874; Kunou S, 2021, ONCOGENE, V40, P3989, DOI 10.1038/s41388-021-01829-y; Li M, 2017, ONCOTARGET, V8, P24777, DOI 10.18632/oncotarget.15801; Li YX, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00273; Liu Y, 2008, EVID-BASED COMPL ALT, V5, P337, DOI 10.1093/ecam/nem031; Lu SS, 2021, J CACHEXIA SARCOPENI, V12, P779, DOI 10.1002/jcsm.12710; Marinho R, 2018, FRONT NUTR, V4, DOI 10.3389/fnut.2017.00069; Marrocco I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091048; McAndrews KM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0963-9; Miao CX, 2021, MOL THER-NUCL ACIDS, V24, P923, DOI 10.1016/j.omtn.2021.04.015; Miller A, 2017, ONCOGENE, V36, P3059, DOI 10.1038/onc.2016.437; Ou BC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1418-2; Palsson-McDermott EM, 2013, BIOESSAYS, V35, P965, DOI 10.1002/bies.201300084; Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358; Prado BL, 2019, ANN PALLIAT MED, V8, P67, DOI 10.21037/apm.2018.07.06; Puckett DL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031171; Puri N, 2006, TRAFFIC, V7, P1482, DOI 10.1111/j.1600-0854.2006.00490.x; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Ren RX, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0325-8; Rice GE, 2015, J CLIN ENDOCR METAB, V100, pE1280, DOI 10.1210/jc.2015-2270; Rodriguez-Barrueco R, 2015, GENE DEV, V29, P1631, DOI 10.1101/gad.262642.115; Silva KAS, 2015, J BIOL CHEM, V290, P11177, DOI 10.1074/jbc.M115.641514; Seto DN, 2015, J BIOL CHEM, V290, P19976, DOI 10.1074/jbc.M115.638411; Shin MK, 2021, BIOL PHARM BULL, V44, P686, DOI 10.1248/bpb.b20-01032; Shirai T, 2016, J EXP MED, V213, P337, DOI 10.1084/jem.20150900; Shouda T, 2006, CANCER LETT, V231, P176, DOI 10.1016/j.canlet.2005.01.042; Simon T, 2020, ONCOGENE, V39, P4477, DOI 10.1038/s41388-020-1308-2; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; Sun L, 2015, NUTR CANCER, V67, P1056, DOI 10.1080/01635581.2015.1073753; Suzuki T, 2020, EXPERT OPIN DRUG DIS, V15, P627, DOI 10.1080/17460441.2020.1724954; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Valle-Mendiola A, 2020, CANCERS, V12, DOI 10.3390/cancers12010124; Vallee A, 2018, REV NEUROSCIENCE, V29, P71, DOI 10.1515/revneuro-2017-0032; Vaupel P, 2021, J PHYSIOL-LONDON, V599, P1745, DOI 10.1113/JP278810; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wendler F, 2017, ONCOGENE, V36, P877, DOI 10.1038/onc.2016.253; Wu Q, 2019, ADIPOCYTE, V8, P31, DOI 10.1080/21623945.2018.1551688; Wu Q, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0899-5; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yang M, 2017, CELL PHYSIOL BIOCHEM, V44, P293, DOI 10.1159/000484885; Yang X, 2021, ONCOGENE, V40, P4307, DOI 10.1038/s41388-021-01837-y; Yoon YJ, 2018, CANCER LETT, V434, P42, DOI 10.1016/j.canlet.2018.07.015; Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159; Zhang GH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00726-x; Zhang QQ, 2021, J CANCER, V12, P4830, DOI 10.7150/jca.58494; Zhang WL, 2020, ACTA PHARMACOL SIN, V41, P237, DOI 10.1038/s41401-019-0275-z; Zhao WN, 2013, INT J MOL SCI, V14, P13577, DOI 10.3390/ijms140713577; Zhou L, 2021, SKELET MUSCLE, V11, DOI 10.1186/s13395-021-00274-5; Zhu B, 2018, J ETHNOPHARMACOL, V226, P143, DOI 10.1016/j.jep.2018.08.023; Zimmers TA, 2016, SEMIN CELL DEV BIOL, V54, P28, DOI 10.1016/j.semcdb.2016.02.009	80	5	5	7	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1050	1062		10.1038/s41388-021-02151-3	http://dx.doi.org/10.1038/s41388-021-02151-3		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	35034093				2022-12-17	WOS:000742810100001
J	He, DD; Shang, XY; Wang, N; Wang, GX; He, KY; Wang, L; Han, ZG				He, Dan-Dan; Shang, Xue-Ying; Wang, Na; Wang, Guang-Xing; He, Kun-Yan; Wang, Lan; Han, Ze-Guang			BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage	ONCOGENE			English	Article							INACTIVATING MUTATIONS; SWI/SNF COMPLEXES; REPAIR; ARID2; CANCER; CELLS; VULNERABILITIES; RESISTANCE; BREAKS; ROLES	Hepatocellular carcinoma (HCC) has emerged as the third cause of cancer-related death owing to lacking effective systemic therapies. Genomic DNA sequencing revealed the high frequency of loss-of-function mutations in ARID2, which encodes a subunit of SWI/SNF chromatin remodeling complex, however, the therapeutic strategy for the HCC patients with ARID2 mutations is still completely unclear. In this study, we first performed a high-throughput screening approach using a compound library consisting of 2 180 FDA-approved drugs and other compounds, to elicit the potential drugs for synthetic lethality to target ARID2-deficient HCC cells. Interestingly, JQ1, a selective inhibitor of bromodomain protein BRD4, uniquely suppressed the growth of ARID2- deficient HCC cells. Next JQ1 is further confirmed to predominantly induce cell lethality upon ARID2 depletion through exacerbating DNA damage, especially double strand breaks (DSBs). Functional assays demonstrated that both BRD4 inhibition and ARID2 deficiency synergistically impede two main DNA damage repair pathways, homologous recombination (HR) and non-homologous end-joining (NHEJ), through attenuating the transcription of BRCA1, RAD51, and 53BP1, which encode the core molecules responsible for DSB repair. Mechanistically, both ARID2 and BRD4 exert a synergistic effect for maintaining transcriptional enhancer-promoter loops of these genes within chromatin conformation. However, as both ARID2 and BRD4 are disrupted, the expression of these DNA repair-related genes in response to DNA damage are hindered, resulting in DSB accumulation and cell apoptosis. Taken together, this study discloses that BRD4 inhibition may induce synthetic lethality in ARID2-deficient HCC cells, which might provide a potential therapeutic strategy for HCC patients with ARID2 mutations.	[He, Dan-Dan; Shang, Xue-Ying; Wang, Na; Wang, Guang-Xing; He, Kun-Yan; Wang, Lan; Han, Ze-Guang] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai 200240, Peoples R China; [Han, Ze-Guang] Hangzhou Innovat Inst Syst Oncol HIISCO, 3F Bldg 1,2636 Yuhangtang Rd, Hangzhou 311121, Zhejiang, Peoples R China	Shanghai Jiao Tong University	Han, ZG (corresponding author), Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai 200240, Peoples R China.; Han, ZG (corresponding author), Hangzhou Innovat Inst Syst Oncol HIISCO, 3F Bldg 1,2636 Yuhangtang Rd, Hangzhou 311121, Zhejiang, Peoples R China.	hanzg@sjtu.edu.cn		Han, Ze-Guang/0000-0002-1018-1752	National Natural Science Foundation of China [82073116, 81672772]; National Key Research and Development Program of China [2020YFC2002705]; Natural Science Foundation of Shanghai [19140902500]; National Science and Technology Major Project [2017ZX10203207]; Shanghai Jiao Tong University Scientific and Technological Innovation Funds [2019TPA09, ZH2018ZDA33]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai); National Science and Technology Major Project; Shanghai Jiao Tong University Scientific and Technological Innovation Funds	We thank all members of Han Lab for helpful discussions on the project. This work was supported by Grants from the National Natural Science Foundation of China (82073116 and 81672772 to ZH), National Key Research and Development Program of China (2020YFC2002705 to ZH), Natural Science Foundation of Shanghai (19140902500 to ZH), National Science and Technology Major Project (2017ZX10203207 to ZH) and Shanghai Jiao Tong University Scientific and Technological Innovation Funds (2019TPA09 and ZH2018ZDA33 to ZH).	Arnoult N, 2017, NATURE, V549, P548, DOI 10.1038/nature24023; Berns K, 2018, ONCOGENE, V37, P4611, DOI 10.1038/s41388-018-0300-6; Bhagwat AS, 2016, CELL REP, V15, P519, DOI 10.1016/j.celrep.2016.03.054; Bitler BG, 2017, NAT CELL BIOL, V19, P962, DOI 10.1038/ncb3582; Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Caruso S, 2019, GASTROENTEROLOGY, V157, P760, DOI 10.1053/j.gastro.2019.05.001; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Centore RC, 2020, TRENDS GENET, V36, P936, DOI 10.1016/j.tig.2020.07.011; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; de Castro RO, 2017, J BIOL CHEM, V292, P8459, DOI 10.1074/jbc.M117.778183; de la Cruz FF, 2015, ANNU REV PHARMACOL, V55, P513, DOI 10.1146/annurev-pharmtox-010814-124511; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deribe YL, 2018, NAT MED, V24, P1627, DOI 10.1038/s41591-018-0173-9; Devaiah BN, 2016, NAT STRUCT MOL BIOL, V23, P540, DOI 10.1038/nsmb.3228; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008; Eustermann S, 2015, MOL CELL, V60, P742, DOI 10.1016/j.molcel.2015.10.032; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Friend SH, 1998, NEW ENGL J MED, V338, P125, DOI 10.1056/NEJM199801083380211; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Gao QZ, 2017, CANCER SCI, V108, P1328, DOI 10.1111/cas.13277; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; He S, 2020, SCIENCE, V367, P875, DOI 10.1126/science.aaz9761; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z; Jiang H, 2020, P NATL ACAD SCI USA, V117, P4770, DOI 10.1073/pnas.1914937117; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kakarougkas A, 2014, MOL CELL, V55, P723, DOI 10.1016/j.molcel.2014.06.028; Kurimchak AM, 2016, CELL REP, V16, P1273, DOI 10.1016/j.celrep.2016.06.091; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Li SJ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00358-6; Li XY, 2018, CELL REP, V22, P796, DOI 10.1016/j.celrep.2017.12.078; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Loesch R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102152; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Michel BC, 2018, NAT CELL BIOL, V20, P1410, DOI 10.1038/s41556-018-0221-1; Mittal P, 2020, NAT REV CLIN ONCOL, V17, P435, DOI 10.1038/s41571-020-0357-3; Nagarajan S, 2020, NAT GENET, V52, P187, DOI 10.1038/s41588-019-0541-5; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Oba A, 2017, J HEPATOL, V66, P942, DOI 10.1016/j.jhep.2016.12.026; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Schulze K, 2016, J HEPATOL, V65, P1031, DOI 10.1016/j.jhep.2016.05.035; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shen JF, 2015, CANCER DISCOV, V5, P752, DOI 10.1158/2159-8290.CD-14-0849; Shu SK, 2020, MOL CELL, V78, P1096, DOI 10.1016/j.molcel.2020.04.027; Slaughter MJ, 2018, J BIOL CHEM, V293, P13592, DOI 10.1074/jbc.RA118.003381; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Tai Y, 2018, INT J CLIN EXP PATHO, V11, P2931; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645	65	5	5	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2022	41	10					1397	1409		10.1038/s41388-022-02176-2	http://dx.doi.org/10.1038/s41388-022-02176-2		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN2JO	35017665				2022-12-17	WOS:000741240600001
J	Kan, TT; Zhang, SP; Zhou, ST; Zhang, Y; Zhao, Y; Gao, YH; Zhang, T; Gao, F; Wang, X; Zhao, LJ; Yang, MS				Kan, Tongtong; Zhang, Shupeng; Zhou, Shengtao; Zhang, Ya; Zhao, Yun; Gao, Yinghua; Zhang, Tao; Gao, Feng; Wang, Xin; Zhao, Linjie; Yang, Mengsu			Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence	ONCOGENE			English	Article							GENE-EXPRESSION PROFILES; STEM-CELLS; HETEROGENEITY; MECHANISMS; GROWTH; PROGRESSION; RESISTANCE; CYR61	Epithelial ovarian cancers (EOCs) are sensitive to chemotherapy but will ultimately relapse and develop drug resistance. The origin of EOC recurrence has been elusive due to intra-tumor heterogeneity. Here we performed single-cell RNA sequencing (scRNA-seq) in 13,369 cells from primary, untreated peritoneal metastasis, and relapse tumors. We used time-resolved analysis to chart the developmental sequence of cells from the metastatic tumors, then traced the earliest replanting cells back to the primary tumors. We discovered seven distinct subpopulations in primary tumors where the CYR61(+) "stress" subpopulation was identified as the relapse-initiators. Furthermore, a subpopulation of RGS5(+) cancer-associated fibroblasts (CAFs) was found to strongly support tumor metastasis. The combined CYR61/RGS5 expression scores significantly correlated with the relapse-free-survival of EOC patients and can be used as predictors of EOC recurrence. Our study provides insights into the mechanism of EOC recurrence and presents CYR61(+) relapse-initiating cells as potential therapeutic targets to prevent EOC relapse.	[Kan, Tongtong; Gao, Feng; Wang, Xin; Yang, Mengsu] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China; [Kan, Tongtong] Beijing Inst Basic Med Sci, Beijing, Peoples R China; [Zhang, Shupeng; Zhang, Ya; Gao, Yinghua] Shandong First Med Univ, Affiliated Hosp 2, Dept Pathol, Tai An, Shandong, Peoples R China; [Zhou, Shengtao; Zhao, Linjie] Sichuan Univ, West China Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Minist Educ,Dept Obstet & Gynecol,West China Hosp, Chengdu, Peoples R China; [Zhou, Shengtao; Zhao, Linjie] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr, State Key Lab Biotherapy, Chengdu, Peoples R China; [Zhao, Yun] Taian Tumor Prevent & Treatment Hosp, Dept Pathol, Tai An, Shandong, Peoples R China; [Zhang, Tao] Shandong Univ, Sch Publ Hlth, Dept Biostat, Jinan, Peoples R China; [Yang, Mengsu] City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China	City University of Hong Kong; Academy of Military Medical Sciences - China; Shandong First Medical University & Shandong Academy of Medical Sciences; Sichuan University; Sichuan University; Shandong University; City University of Hong Kong	Kan, TT; Yang, MS (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.; Kan, TT (corresponding author), Beijing Inst Basic Med Sci, Beijing, Peoples R China.; Yang, MS (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Key Lab Biochip Technol, Shenzhen, Peoples R China.	tongtongkan@hotmail.com; bhmyang@cityu.edu.hk		Wang, Xin/0000-0002-5122-2418; Gao, Feng/0000-0002-0500-5527; Zhou, Shengtao/0000-0001-8322-5536	General Research Fund [CityU_11319516]; Research Impact Fund of Hong Kong Research Grant Council [R1020-18F]; Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China [2017B020226001]; Knowledge Innovation Program of Shenzhen Municipality, PR China [JCYJ20170818095453642, JCYJ20180307123759162]	General Research Fund; Research Impact Fund of Hong Kong Research Grant Council; Guangdong Frontier and Key Technology Development Fund of Guangdong Province, PR China; Knowledge Innovation Program of Shenzhen Municipality, PR China	We thank Dr Junhai Wang from Taian Tumor Prevention and Treatment Hospital for assistance with IHC. This work was supported by grants from the General Research Fund (CityU_11319516) and the Research Impact Fund (R1020-18F) of Hong Kong Research Grant Council, the Guangdong Frontier and Key Technology Development Fund (2017B020226001) of Guangdong Province, PR China, and the Knowledge Innovation Program (JCYJ20170818095453642 and JCYJ20180307123759162) of Shenzhen Municipality, PR China.	Abal M, 2003, CURR CANCER DRUG TAR, V3, P193, DOI 10.2174/1568009033481967; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; Corrado G, 2017, EXPERT REV ANTICANC, V17, P1147, DOI 10.1080/14737140.2017.1398088; CRICK F H, 1958, Symp Soc Exp Biol, V12, P138; Dan S, 2002, CANCER RES, V62, P1139; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231; Goveia J, 2020, CANCER CELL, V37, P21, DOI 10.1016/j.ccell.2019.12.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hellinger JW, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01074; Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6; Hoang-Minh LB, 2018, EMBO J, V37, DOI 10.15252/embj.201798772; Hyun HB, 2018, MOLECULES, V23, DOI 10.3390/molecules23020209; Kan TT, 2020, ONCOGENE, V39, P4227, DOI 10.1038/s41388-020-1288-2; Khalique L, 2007, J PATHOL, V211, P286, DOI 10.1002/path.2112; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Klein CA, 2011, CURR OPIN GENET DEV, V21, P42, DOI 10.1016/j.gde.2010.10.011; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lau LF, 2011, CELL MOL LIFE SCI, V68, P3149, DOI 10.1007/s00018-011-0778-3; Li XP, 2018, EXP THER MED, V16, P730, DOI 10.3892/etm.2018.6274; Lin JPA, 2012, CANCER IMMUNOL IMMUN, V61, P677, DOI 10.1007/s00262-011-1135-y; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Maity G, 2019, MOL CANCER THER, V18, P788, DOI 10.1158/1535-7163.MCT-18-0899; Martz CA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.aaa1877; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Pantel Klaus, 2014, Bonekey Rep, V3, P584, DOI 10.1038/bonekey.2014.79; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Tirosh I, 2016, NATURE, V539, P309, DOI 10.1038/nature20123; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Vasey PA, 2003, BRIT J CANCER, V89, pS23, DOI 10.1038/sj.bjc.6601497; Vladoiu MC, 2019, NATURE, V572, P67, DOI 10.1038/s41586-019-1158-7; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Zembutsu H, 2002, CANCER RES, V62, P518; Zhang YQ, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.057; Zlobec I, 2007, J CLIN PATHOL, V60, P1112, DOI 10.1136/jcp.2006.044537	50	5	5	6	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					895	906		10.1038/s41388-021-02139-z	http://dx.doi.org/10.1038/s41388-021-02139-z		JAN 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34992217				2022-12-17	WOS:000739823800001
J	Nicosia, L; Boffo, FL; Ceccacci, E; Conforti, F; Pallavicini, I; Bedin, F; Ravasio, R; Massignani, E; Somervaille, TCP; Minucci, S; Bonaldi, T				Nicosia, Luciano; Boffo, Francesca Ludovica; Ceccacci, Elena; Conforti, Fabio; Pallavicini, Isabella; Bedin, Fabio; Ravasio, Roberto; Massignani, Enrico; Somervaille, Tim C. P.; Minucci, Saverio; Bonaldi, Tiziana			Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML	ONCOGENE			English	Article							DEMETHYLASE; GENE	The histone demethylase LSD1 is over-expressed in hematological tumors and has emerged as a promising target for anticancer treatment, so that several LSD1 inhibitors are under development and testing, in preclinical and clinical settings. However, the complete understanding of their complex mechanism of action is still unreached. Here, we unraveled a novel mode of action of the LSD1 inhibitors MC2580 and DDP-38003, showing that they can induce differentiation of AML cells through the downregulation of the chromatin protein GSE1. Analysis of the phenotypic effects of GSE1 depletion in NB4 cells showed a strong decrease of cell viability in vitro and of tumor growth in vivo. Mechanistically, we found that a set of genes associated with immune response and cytokine-signaling pathways are upregulated by LSD1 inhibitors through GSE1-protein reduction and that LSD1 and GSE1 colocalize at promoters of a subset of these genes at the basal state, enforcing their transcriptional silencing. Moreover, we show that LSD1 inhibitors lead to the reduced binding of GSE1 to these promoters, activating transcriptional programs that trigger myeloid differentiation. Our study offers new insights into GSE1 as a novel therapeutic target for AML.	[Nicosia, Luciano; Boffo, Francesca Ludovica; Ceccacci, Elena; Conforti, Fabio; Pallavicini, Isabella; Bedin, Fabio; Ravasio, Roberto; Massignani, Enrico; Minucci, Saverio; Bonaldi, Tiziana] European Inst Oncol IRCCS, Dept Expt Oncol, IEO, I-20139 Milan, Italy; [Nicosia, Luciano; Somervaille, Tim C. P.] Univ Manchester, ItalyLeukaemia Biol Lab, Canc Res UK Manchester Inst, Oglesby Canc Res Ctr Bldg, Manchester M20 4GJ, Lancs, England; [Minucci, Saverio] Univ Milan, Dept Biosci, I-20133 Milan, Italy; [Bonaldi, Tiziana] Univ Milan, Dept Oncol & Haematooncol, I-20133 Milan, Italy	IRCCS European Institute of Oncology (IEO); Cancer Research UK; University of Manchester; University of Milan; University of Milan	Bonaldi, T (corresponding author), European Inst Oncol IRCCS, Dept Expt Oncol, IEO, I-20139 Milan, Italy.; Bonaldi, T (corresponding author), Univ Milan, Dept Oncol & Haematooncol, I-20133 Milan, Italy.	tiziana.bonaldi@ieo.it	Ravasio, Roberto/AAP-8901-2020	Ravasio, Roberto/0000-0002-3144-0514; Ceccacci, Elena/0000-0002-2285-8994; Nicosia, Luciano/0000-0003-3016-931X; Somervaille, Tim/0000-0002-9188-4379	Italian Association for Cancer Research [15741]; EPIC-XS - Horizon 2020 programme of the European Union [823839]; European Institute of Oncology Foundation (FIEO); Italian Foundation for Cancer Research (FIRC); Italian Association for Cancer Research (AIRC) [24944]; Cancer Research UK [C5759/A20971]	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); EPIC-XS - Horizon 2020 programme of the European Union; European Institute of Oncology Foundation (FIEO); Italian Foundation for Cancer Research (FIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Cancer Research UK(Cancer Research UK)	T.B. research activity is supported by grants from the Italian Association for Cancer Research (grant#15741) and by EPIC-XS, project number 823839, funded by the Horizon 2020 programme of the European Union; L.N. was supported by a Fellowship of the European Institute of Oncology Foundation (FIEO) and was a PhD student within the European School of Molecular Medicine (SEMM); E.M. is supported by a fellowship of the Italian Foundation for Cancer Research (FIRC) and is a PhD student within the European School of Molecular Medicine (SEMM); S.M. is supported by the Italian Association for Cancer Research (AIRC, grant#24944); T.S. is supported by Cancer Research UK grant number C5759/A20971.	Abdel-Aziz AK, 2020, HAEMATOLOGICA, V105, P2105, DOI 10.3324/haematol.2019.224501; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Bamodu OA, 2021, CANCERS, V13, DOI 10.3390/cancers13163959; Binda C, 2010, J AM CHEM SOC, V132, P6827, DOI 10.1021/ja101557k; Blagosklonny MV, 2003, SEMIN CANCER BIOL, V13, P97, DOI 10.1016/S1044-579X(02)00127-X; Blecher-Gonen R, 2013, NAT PROTOC, V8, P539, DOI 10.1038/nprot.2013.023; Carnesecchi J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188871; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chai P, 2016, BIOCHEM BIOPH RES CO, V471, P123, DOI 10.1016/j.bbrc.2016.01.168; Chao A, 2017, ONCOTARGET, V8, P74434, DOI 10.18632/oncotarget.20158; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen YW, 2012, CRIT REV EUKAR GENE, V22, P53, DOI 10.1615/CritRevEukarGeneExpr.v22.i1.40; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Ding KS, 2018, J BIOL CHEM, V293, P3949, DOI 10.1074/jbc.RA117.001103; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Duan YC, 2017, EUR J MED CHEM, V140, P392, DOI 10.1016/j.ejmech.2017.09.038; Fang JW, 2017, ONCOTARGET, V8, P85085, DOI 10.18632/oncotarget.18564; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; Huang M, 2019, CELL STEM CELL, V25, P433, DOI 10.1016/j.stem.2019.05.013; Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200; Ishikawa Y, 2017, MOL CANCER THER, V16, P273, DOI 10.1158/1535-7163.MCT-16-0471; Kim SA, 2020, MOL CELL, V78, P903, DOI 10.1016/j.molcel.2020.04.019; Lan HY, 2019, P NATL ACAD SCI USA, V116, P12311, DOI 10.1073/pnas.1902012116; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lanneau D, 2007, PRION, V1, P53, DOI 10.4161/pri.1.1.4059; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li Y, 2019, CANCER LETT, V454, P179, DOI 10.1016/j.canlet.2019.03.052; Liang XQ, 2013, BIOTECHNIQUES, V55, P267, DOI 10.2144/000114101; Lillico R, 2016, FUTURE MED CHEM, V8, P879, DOI 10.4155/fmc-2016-0021; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lokken AA, 2012, CANCER CELL, V21, P451, DOI 10.1016/j.ccr.2012.03.027; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maiques-Diaz A, 2018, CELL REP, V22, P3641, DOI 10.1016/j.celrep.2018.03.012; McClellan D, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00020-19; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Perillo B, 2020, EXP MOL MED, V52, P1936, DOI 10.1038/s12276-020-00542-2; Ravasio R, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2746; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Sehrawat A, 2018, P NATL ACAD SCI USA, V115, pE4179, DOI 10.1073/pnas.1719168115; Seiler CY, 2014, NUCLEIC ACIDS RES, V42, pD1253, DOI 10.1093/nar/gkt1060; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song P, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00444-9; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; Vianello P, 2016, J MED CHEM, V59, P1501, DOI 10.1021/acs.jmedchem.5b01209; Wang J, 2017, NUCLEIC ACIDS RES, V45, pW130, DOI 10.1093/nar/gkx356; Wang WB, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8834923; Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wiemann S, 2016, NAT METHODS, V13, P191, DOI 10.1038/nmeth.3776; Yamamoto Ryusuke, 2018, Oncotarget, V9, P21007, DOI 10.18632/oncotarget.24774; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zhang XF, 2018, NAT PROTOC, V13, P530, DOI 10.1038/nprot.2017.147; Zhang XL, 2019, DRUG DES DEV THER, V13, P3037, DOI 10.2147/DDDT.S209219; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x; Zheng YC, 2016, EPIGENOMICS-UK, V8, P651, DOI 10.2217/epi-2015-0002; Zheng YC, 2015, MED RES REV, V35, P1032, DOI 10.1002/med.21350; Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237	72	5	5	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					878	894		10.1038/s41388-021-02123-7	http://dx.doi.org/10.1038/s41388-021-02123-7		DEC 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34862459	Green Published, hybrid			2022-12-17	WOS:000725939000002
J	Lee, YC; Lin, SC; Yu, GY; Zhu, M; Song, JH; Rivera, K; Pappin, D; Logothetis, CJ; Panaretakis, T; Wang, GC; Yu-Lee, LY; Lin, SH				Lee, Yu-Chen; Lin, Song-Chang; Yu, Guoyu; Zhu, Ming; Song, Jian H.; Rivera, Keith; Pappin, Darryl; Logothetis, Christopher J.; Panaretakis, Theocharis; Wang, Guocan; Yu-Lee, Li-Yuan; Lin, Sue-Hwa			Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition	ONCOGENE			English	Article							BONE; CELLS; EXPRESSION; GROWTH; PROGRESSION; RECEPTOR; INTEGRIN; LNCAP; PHOSPHORYLATION; ACTIVATION	Metastatic prostate cancer (PCa) in bone induces bone-forming lesions that enhance PCa progression. How tumor-induced bone formation enhances PCa progression is not known. We have previously shown that PCa-induced bone originates from endothelial cells (ECs) that have undergone endothelial-to-osteoblast (EC-to-OSB) transition by tumor-secreted bone morphogenetic protein 4 (BMP4). Here, we show that EC-to-OSB transition leads to changes in the tumor microenvironment that increases the metastatic potential of PCa cells. We found that conditioned medium (CM) from EC-OSB hybrid cells increases the migration, invasion, and survival of PC3-mm2 and C4-2B4 PCa cells. Quantitative mass spectrometry (Isobaric Tags for Relative and Absolute Quantitation) identified Tenascin C (TNC) as one of the major proteins secreted from EC-OSB hybrid cells. TNC expression in tumor-induced OSBs was confirmed by immunohistochemistry of MDA PCa-118b xenograft and human bone metastasis specimens. Mechanistically, BMP4 increases TNC expression in EC-OSB cells through the Smad1-Notch/Hey1 pathway. How TNC promotes PCa metastasis was next interrogated by in vitro and in vivo studies. In vitro studies showed that a TNC-neutralizing antibody inhibits EC-OSB-CM-mediated PCa cell migration and survival. TNC knockdown decreased, while the addition of recombinant TNC or TNC overexpression increased migration and anchorage-independent growth of PC3 or C4-2b cells. When injected orthotopically, PC3-mm2-shTNC clones decreased metastasis to bone, while C4-2b-TNC-overexpressing cells increased metastasis to lymph nodes. TNC enhances PCa cell migration through alpha 5 beta 1 integrin-mediated YAP/TAZ inhibition. These studies elucidate that tumor-induced stromal reprogramming generates TNC that enhances PCa metastasis and suggest that TNC may be a target for PCa therapy.	[Lee, Yu-Chen; Lin, Song-Chang; Yu, Guoyu; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Zhu, Ming; Song, Jian H.; Logothetis, Christopher J.; Panaretakis, Theocharis; Wang, Guocan; Lin, Sue-Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Rivera, Keith; Pappin, Darryl] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Yu-Lee, Li-Yuan] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Cold Spring Harbor Laboratory; Baylor College of Medicine; Baylor College of Medicine	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.; Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.	slin@mdanderson.org			NIH [R01CA174798, 5P50CA140388, P30CA16672]; Cancer Prevention Research Institute of Texas grants [RP150179, RP190252]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas grants	This work was supported by grants from the NIH R01CA174798 (to S-HL, L-YY-L), NIH 5P50CA140388 (to CJL, S-HL), NIH P30CA16672 Core grant to MD Anderson Cancer Center, and Cancer Prevention Research Institute of Texas grants RP150179 and RP190252 (to S-HL and L-YY-L).	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Carey WA, 2010, AM J PHYSIOL-LUNG C, V299, pL785, DOI 10.1152/ajplung.00385.2009; CHIQUETEHRISMANN R, 1986, CELL, V47, P131, DOI 10.1016/0092-8674(86)90374-0; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Conklin MW, 2012, CELL ADHES MIGR, V6, P249, DOI 10.4161/cam.20567; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Fischer A, 2005, MOL CELL BIOL, V25, P8960, DOI 10.1128/MCB.25.20.8960-8970.2005; Grahovac J, 2013, J INVEST DERMATOL, V133, P210, DOI 10.1038/jid.2012.263; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Heindryckx F, 2015, WORLD J HEPATOL, V7, P165, DOI 10.4254/wjh.v7.i2.165; Herold-Mende C, 2002, INT J CANCER, V98, P362, DOI 10.1002/ijc.10233; Hong CC, 2009, CYTOKINE GROWTH F R, V20, P409, DOI 10.1016/j.cytogfr.2009.10.021; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008-5472.CAN-09-3016; Jachetti E, 2015, CANCER RES, V75, P2095, DOI 10.1158/0008-5472.CAN-14-2346; Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Katoh D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.27; Lee YC, 2018, J PROTEOME RES, V17, P348, DOI 10.1021/acs.jproteome.7b00599; Lee YC, 2015, CANCER RES, V75, P4949, DOI 10.1158/0008-5472.CAN-15-1215; Lee YC, 2013, MOL CANCER RES, V11, P1401, DOI 10.1158/1541-7786.MCR-13-0108; Lee YC, 2013, MOL CANCER RES, V11, P405, DOI 10.1158/1541-7786.MCR-12-0551; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lin SC, 2017, DEV CELL, V41, P467, DOI 10.1016/j.devcel.2017.05.005; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Martin RS, 2017, CANCER RES, V77, P5977, DOI 10.1158/0008-5472.CAN-17-0064; Midwood KS, 2016, J CELL SCI, V129, P4321, DOI 10.1242/jcs.190546; Miroshnikova YA, 2016, NAT CELL BIOL, V18, P1336, DOI 10.1038/ncb3429; Morrissey C, 2010, NEOPLASIA, V12, P192, DOI 10.1593/neo.91836; Mutvei AP, 2018, ONCOGENE, V37, P6083, DOI 10.1038/s41388-018-0400-3; Nagaharu K, 2011, AM J PATHOL, V178, P754, DOI 10.1016/j.ajpath.2010.10.015; Ni WD, 2017, BIOCHEM BIOPH RES CO, V486, P607, DOI 10.1016/j.bbrc.2017.03.021; Nordstrand A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041223; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Qiang L, 2012, CELL DEATH DIFFER, V19, P284, DOI 10.1038/cdd.2011.95; Riedel A, 2016, NAT IMMUNOL, V17, P1118, DOI 10.1038/ni.3492; Sarkar S, 2017, CANCER RES, V77, P3231, DOI 10.1158/0008-5472.CAN-16-2171; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Sun Z, 2018, CANCER RES, V78, P950, DOI 10.1158/0008-5472.CAN-17-1597; Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008-5472.CAN-08-2492; Takada Y, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-215; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Totaro A, 2018, NAT CELL BIOL, V20, P888, DOI 10.1038/s41556-018-0142-z; Tu Shi-Ming, 2004, Cancer Treat Res, V118, P23; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Ye XC, 2012, PROSTATE, V72, P291, DOI 10.1002/pros.21431; Yu G, 2021, ISCIENCE, V24; Yu G, 2015, MOL CANCER RES, V13, P348, DOI 10.1158/1541-7786.MCR-14-0384-T; Yu-Lee LY, 2018, CANCER RES, V78, P2911, DOI 10.1158/0008-5472.CAN-17-1051; Zhu M, 2021, ONCOGENE, V40, P6049, DOI 10.1038/s41388-021-02000-3	55	5	6	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					757	769		10.1038/s41388-021-02131-7	http://dx.doi.org/10.1038/s41388-021-02131-7		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34845375	Green Submitted, Green Accepted			2022-12-17	WOS:000723571700003
J	Ma, L; Lin, Y; Sun, SW; Xu, J; Yu, T; Chen, WL; Zhang, LH; Guo, YC; Wang, YW; Chen, T; Wei, JF; Zhu, LJ				Ma, Ling; Lin, Yu; Sun, Shan-Wen; Xu, Jun; Yu, Ting; Chen, Wen-Long; Zhang, Liang-Hui; Guo, Yu-Chen; Wang, Yi-Wen; Chen, Tao; Wei, Ji-Fu; Zhu, Ling-Jun			KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner	ONCOGENE			English	Article							BUTYRATE; CARCINOMA	N6-methyladenosine (m6A), the most abundant mRNA modification in mammals, is involved in the metabolism of mRNA. KIAA1429 is regarded as the largest m6A methyltransferase and plays an important role in m6A modification. However, the prognostic value and function of KIAA1429 in colorectal cancer (CRC) are unclear. Quantitative real-time PCR and immunohistochemical assays were performed to evaluate the expression of KIAA1429 in CRC tissues. Kaplan-Meier survival curves and log-rank tests were used to assess the association between KIAA1429 expression and the prognosis of patients with CRC. CCK-8 assays, colony formation assays, cell cycle assays, and xenograft experiments were performed to investigate the effect of KIAA1429 on cell proliferation. RNA immunoprecipitation, methylated RNA immunoprecipitation assays, and RNA stability assays were conducted to explore the underlying mechanism. KIAA1429 was significantly upregulated in CRC tissues compared with adjacent normal tissues. Patients with higher expression of KIAA1429 had shorter overall survival than those with lower expression. Functionally, KIAA1429 promoted CRC cell proliferation in vitro and in vivo. Mechanistically, KIAA1429 negatively regulated the expression of WEE1 by decreasing its stability in an m6A-independent manner by binding to the third segment in the 3 '-UTR of WEE1 mRNA. Moreover, butyrate decreased the expression of KIAA1429 by downregulating the level of the transcription factor NF kappa B1. Our findings indicated that KIAA1429 plays an oncogenic role in CRC cells by inhibiting the expression of WEE1 in an m6A-independent manner and is associated with poor survival in CRC patients. These results suggested that KIAA1429 might be a potential prognostic marker for CRC.	[Ma, Ling; Lin, Yu; Sun, Shan-Wen; Xu, Jun; Yu, Ting; Zhang, Liang-Hui; Guo, Yu-Chen; Zhu, Ling-Jun] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China; [Chen, Wen-Long; Wang, Yi-Wen; Chen, Tao] Nanjing Med Univ, Dept Colorectal Surg, Affiliated Hosp 1, Nanjing, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Res Div Clin Pharmacol, Affiliated Hosp 1, Nanjing, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Dept Pharm, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China; [Wei, Ji-Fu] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China; [Zhu, Ling-Jun] Nanjing Med Univ, Dept Oncol, Sir Run Run Hosp, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Zhu, LJ (corresponding author), Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, Nanjing, Peoples R China.; Chen, T (corresponding author), Nanjing Med Univ, Dept Colorectal Surg, Affiliated Hosp 1, Nanjing, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Res Div Clin Pharmacol, Affiliated Hosp 1, Nanjing, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Dept Pharm, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China.; Wei, JF (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China.; Zhu, LJ (corresponding author), Nanjing Med Univ, Dept Oncol, Sir Run Run Hosp, Nanjing, Peoples R China.	ct55979@163.com; weijifu@njmu.edu.cn; zhulingjun@njmu.edu.cn		Ma, Ling/0000-0002-2960-1956; Zhu, Lingjun/0000-0001-8033-1528	Natural Science Foundation of Jiangsu Province [BK20201495]; Jiangsu Province's Key Provincial Talents Program [ZDRCA2016089]; National Natural Science Foundation of China [82102981]	Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Province's Key Provincial Talents Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from Natural Science Foundation of Jiangsu Province (BK20201495), Jiangsu Province's Key Provincial Talents Program (ZDRCA2016089), and the National Natural Science Foundation of China (No. 82102981).	Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; Bai Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00332; Barros-Silva D, 2020, CANCERS, V12, DOI 10.3390/cancers12040771; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai XL, 2018, CANCER LETT, V415, P11, DOI 10.1016/j.canlet.2017.11.018; Chen XX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01220-7; Chen XX, 2020, MOL THER, V28, P599, DOI 10.1016/j.ymthe.2019.11.016; Chen YH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1053-8; Cheng XY, 2019, ONCOTARGETS THER, V12, P3421, DOI 10.2147/OTT.S180954; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; Encarnacao JC, 2015, CANCER METAST REV, V34, P465, DOI 10.1007/s10555-015-9578-9; Ge XC, 2017, ONCOL LETT, V13, P4341, DOI 10.3892/ol.2017.5984; Goncalves P, 2013, CURR DRUG METAB, V14, P994; Lan T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1106-z; Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7; Li YS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1066-3; Liu Y, 2016, FOOD FUNCT, V7, P3772, DOI [10.1039/c6fo00856a, 10.1039/C6FO00856A]; Miao R, 2020, J CELL PHYSIOL, V235, P7420, DOI 10.1002/jcp.29645; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Nishizawa Yujiro, 2018, Oncotarget, V9, P7476, DOI 10.18632/oncotarget.23554; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002; Peng W, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1408-4; Qian JY, 2019, ONCOGENE, V38, P6123, DOI 10.1038/s41388-019-0861-z; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585-015-9719-0; Wang JJ, 2017, BRIT J PHARMACOL, V174, P3811, DOI 10.1111/bph.13976; Wang XY, 2019, CELL RES, V29, P167, DOI 10.1038/s41422-018-0127-2; Wang XY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01283-y; Wang YF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0957-7; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wu XQ, 2018, J CANCER, V9, P2510, DOI 10.7150/jca.25324; Yang PP, 2020, PATHOL ONCOL RES, V26, P1615, DOI 10.1007/s12253-019-00737-7; Yue B, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1065-4; Yue YA, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0019-0; Zhu W, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01868-1; Zhu W, 2020, J CELL MOL MED, V24, P3521, DOI 10.1111/jcmm.15042	39	5	5	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					692	703		10.1038/s41388-021-02066-z	http://dx.doi.org/10.1038/s41388-021-02066-z		NOV 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34819634				2022-12-17	WOS:000722084500001
J	McCann, JJ; Vasilevskaya, IA; McNair, C; Gallagher, P; Neupane, NP; de Leeuw, R; Shafi, AA; Dylgjeri, E; Mandigo, AC; Schiewer, MJ; Knudsen, KE				McCann, Jennifer J.; Vasilevskaya, Irina A.; McNair, Christopher; Gallagher, Peter; Neupane, Neermala Poudel; de Leeuw, Renee; Shafi, Ayesha A.; Dylgjeri, Emanuela; Mandigo, Amy C.; Schiewer, Matthew J.; Knudsen, Karen E.			Mutant p53 elicits context-dependent pro-tumorigenic phenotypes	ONCOGENE			English	Article							GAIN-OF-FUNCTION; MUTATIONAL LANDSCAPE; DRIVE CANCER; DNA-BINDING; COMBINATIONS; ANTAGONISTS; CHROMATIN; EVOLUTION; PATHWAYS; GENOMICS	The tumor suppressor gene TP53 is the most frequently mutated gene in numerous cancer types, including prostate cancer (PCa). Specifically, missense mutations in TP53 are selectively enriched in PCa, and cluster to particular "hot spots" in the p53 DNA binding domain with mutation at the R273 residue occurring most frequently. While this residue is similarly mutated to R273C-p53 or R273H-p53 in all cancer types examined, in PCa selective enrichment of R273C-p53 is observed. Importantly, examination of clinical datasets indicated that TP53 heterozygosity can either be maintained or loss of heterozygosity (LOH) occurs. Thus, to mimic tumor-associated mutant p53, R273C-p53 and R273H-p53 isogenic PCa models were developed in the presence or absence of wild-type p53. In the absence of wild-type p53, both R273C-p53 and R273H-p53 exhibited similar loss of DNA binding, transcriptional profiles, and loss of canonical tumor suppressor functions associated with wild-type p53. In the presence of wild-type p53 expression, both R273C-p53 and R273H-p53 supported canonical p53 target gene expression yet elicited distinct cistromic and transcriptional profiles when compared to each other. Moreover, heterozygous modeling of R273C-p53 or R273H-p53 expression resulted in distinct phenotypic outcomes in vitro and in vivo. Thus, mutant p53 acts in a context-dependent manner to elicit pro-tumorigenic transcriptional profiles, providing critical insight into mutant p53-mediated prostate cancer progression.	[McCann, Jennifer J.; Vasilevskaya, Irina A.; McNair, Christopher; Gallagher, Peter; Neupane, Neermala Poudel; de Leeuw, Renee; Shafi, Ayesha A.; Dylgjeri, Emanuela; Mandigo, Amy C.; Schiewer, Matthew J.; Knudsen, Karen E.] Sidney Kimmel Med Coll, Dept Canc Biol, Philadelphia, PA 19107 USA	Jefferson University	Knudsen, KE (corresponding author), Sidney Kimmel Med Coll, Dept Canc Biol, Philadelphia, PA 19107 USA.	karen.knudsen@jefferson.edu		Shafi, Ayesha/0000-0003-0335-638X; Dylgjeri, Emanuela/0000-0002-1784-634X	National Cancer Institute [F99CA212225, 5R01CA17640105, 5R01CA18256905, 5R01CA21732903]; Sidney Kimmel Cancer Center [5P30CA056036-17]; Laboratory Animals, MetaOmics, Translational Pathology shared resources; Prostate Cancer Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sidney Kimmel Cancer Center; Laboratory Animals, MetaOmics, Translational Pathology shared resources; Prostate Cancer Foundation	We gratefully thank all members of the Knudsen laboratory for their invaluable input and support. We also thank the institutions that supported this work: The National Cancer Institute (F99CA212225 JJM, 5R01CA17640105 KEK, 5R01CA18256905 KEK, 5R01CA21732903 KEK), the Sidney Kimmel Cancer Center (Support Grant 5P30CA056036-17), the Laboratory Animals, MetaOmics, Translational Pathology shared resources, as well as awards from the Prostate Cancer Foundation.	Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abida W, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00029; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Beltran H, 2016, NAT MED, V22, P298, DOI 10.1038/nm.4045; Boettcher S, 2019, SCIENCE, V365, P599, DOI 10.1126/science.aax3649; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; Comel A, 2014, FEBS LETT, V588, P2600, DOI 10.1016/j.febslet.2014.04.015; De Laere B, 2019, CLIN CANCER RES, V25, P1766, DOI 10.1158/1078-0432.CCR-18-1943; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Agostino S, 2016, EMBO REP, V17, P188, DOI 10.15252/embr.201540488; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hainaut P, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026179; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Henrich IC, 2021, CANCER RES, V81, P2171, DOI 10.1158/0008-5472.CAN-20-1458; Hieronymus H, 2014, P NATL ACAD SCI USA, V111, P11139, DOI 10.1073/pnas.1411446111; Joerger AC, 2016, ANNU REV BIOCHEM, V85, P375, DOI 10.1146/annurev-biochem-060815-014710; Junk DJ, 2008, NEOPLASIA, V10, P450, DOI 10.1593/neo.08120; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lehen'kyi V, 2007, ONCOGENE, V26, P7380, DOI 10.1038/sj.onc.1210545; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Liu Y, 2016, NATURE, V531, P471, DOI 10.1038/nature17157; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; McCann JJ, 2020, CANCER RES, V80, P430, DOI 10.1158/0008-5472.CAN-19-1033; McNair C, 2017, ONCOGENE, V36, P1655, DOI 10.1038/onc.2016.334; McNair C, 2018, J CLIN INVEST, V128, P341, DOI 10.1172/JCI93566; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; NGUYEN B, 2020, EUR UROL; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Reich NC, 2013, J INTERF CYTOK RES, V33, P199, DOI 10.1089/jir.2012.0159; Ren SC, 2018, EUR UROL, V73, P322, DOI 10.1016/j.eururo.2017.08.027; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sandy Z, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111557; Schrecengost RS, 2014, CANCER RES, V74, P272, DOI 10.1158/0008-5472.CAN-13-1954; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Shiota M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060602; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Stopsack KH, 2020, CLIN CANCER RES, V26, P3230, DOI 10.1158/1078-0432.CCR-20-0168; Tang QS, 2020, TRENDS CANCER, V6, P62, DOI 10.1016/j.trecan.2019.11.004; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023; Yamamoto S, 2019, CANCERS, V11, DOI 10.3390/cancers11010004; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	75	5	5	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					444	458		10.1038/s41388-021-01903-5	http://dx.doi.org/10.1038/s41388-021-01903-5		NOV 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34773073	Green Published, hybrid			2022-12-17	WOS:000717915200004
J	Zhang, BY; Zhang, MP; Yang, YJ; Li, Q; Yu, JP; Zhu, SM; Niu, YJ; Shang, ZQ				Zhang, Boya; Zhang, Mingpeng; Yang, Yanjie; Li, Qi; Yu, Jianpeng; Zhu, Shimiao; Niu, Yuanjie; Shang, Zhiqun			Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC	ONCOGENE			English	Article							RESISTANT PROSTATE-CANCER; ANDROGEN-RECEPTOR; PROTEASOMAL DEGRADATION; SPLICE VARIANTS; NONCODING RNA; PROGRESSION; MECHANISMS; EXPRESSION; THERAPY; GROWTH	Castration-resistant prostate cancer (CRPC) is a highly malignant type of advanced cancer resistant to androgen deprivation therapy. One of the important mechanisms for the development of CRPC is the persistent imbalanced regulation of AR and AR splice variants (AR/AR-Vs). In this study, we reported KDM4A-AS1, a recently discovered lncRNA, as a tumor promoter that was significantly increased in CRPC cell lines and cancer tissues. Depletion of KDM4A-AS1 significantly reduced cell viability, proliferation, migration in vitro, and tumor growth in vivo. We found that by binding to the NTD domain, KDM4A-AS1 enhances the stability of USP14-AR/AR-Vs complex, and promoted AR/AR-Vs deubiquitination to protect it from MDM2-mediated ubiquitin-proteasome degradation. Moreover, KDM4A-AS1 was found to enhance CRPC drug resistance to enzalutamide by repressing AR/AR-Vs degradation; antisense oligonucleotide drugs targeting KDM4A-AS1 significantly reduced the growth of tumors with enzalutamide resistance. Taken together, our results indicated that KDM4A-AS1 played an important role in the progression of CRPC and enzalutamide resistance by regulating AR/AR-Vs deubiquitination; targeting KDM4A-AS1 has broad clinical application potential.	[Zhang, Boya; Zhang, Mingpeng; Yang, Yanjie; Li, Qi; Yu, Jianpeng; Zhu, Shimiao; Niu, Yuanjie; Shang, Zhiqun] Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Tianjin 300211, Peoples R China	Tianjin Medical University	Shang, ZQ (corresponding author), Tianjin Med Univ, Hosp 2, Tianjin Inst Urol, Tianjin 300211, Peoples R China.	zhiqun_shang@tmu.edu.cn	zhang, boya/GRO-7325-2022; shang, zhiqun/N-9995-2015	shang, zhiqun/0000-0001-8263-707X	National Natural Science Foundation of China [81872100, 81772756]; Natural Science Foundation of Tianjin [18PTLCSY00030, 19JCYBJC24900]; Tianjin Research Innovation Project for Postgraduate Students	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Tianjin Research Innovation Project for Postgraduate Students	This work was supported by National Natural Science Foundation of China (grants 81872100 and 81772756), Natural Science Foundation of Tianjin (18PTLCSY00030 and 19JCYBJC24900), and Tianjin Research Innovation Project for Postgraduate Students.	Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005; Davey Rachel A, 2016, Clin Biochem Rev, V37, P3; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Grillone K, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01622-x; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kwegyir-Afful AK, 2015, ONCOTARGET, V6, P27440, DOI 10.18632/oncotarget.4578; Li B, 2014, PROSTATE, V74, P421, DOI 10.1002/pros.22763; Li YA, 2015, ONCOTARGET, V6, P33743, DOI 10.18632/oncotarget.5608; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95; Liao YN, 2018, ONCOGENE, V37, P1896, DOI 10.1038/s41388-017-0069-z; Liao YN, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.477; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Liu CF, 2019, MOL CANCER THER, V18, P1875, DOI 10.1158/1535-7163.MCT-18-1322; Liu CF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07178-x; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Muppirala UK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-489; Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Qi JF, 2013, CANCER CELL, V23, P332, DOI 10.1016/j.ccr.2013.02.016; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Sarkar S, 2014, ONCOGENE, V33, P26, DOI 10.1038/onc.2012.561; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Shang ZQ, 2019, NUCLEIC ACIDS RES, V47, P4211, DOI 10.1093/nar/gkz108; Shipley WU, 2017, NEW ENGL J MED, V376, P417, DOI 10.1056/NEJMoa1607529; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21601, 10.3322/caac.21590]; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Yang R, 2019, ONCOGENE, V38, P7133, DOI 10.1038/s41388-019-0909-0; Yin Y, 2017, CANCER RES, V77, P4745, DOI 10.1158/0008-5472.CAN-17-0164; Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939; Yoshida T, 2005, CANCER RES, V65, P9611, DOI 10.1158/0008-5472.CAN-05-0817; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928	49	5	5	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					387	399		10.1038/s41388-021-02103-x	http://dx.doi.org/10.1038/s41388-021-02103-x		NOV 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34759344	Green Published, hybrid			2022-12-17	WOS:000716867900002
J	Li, Y; Liu, HT; Chen, X; Wang, YW; Tian, YR; Ma, RR; Song, L; Zou, YX; Gao, P				Li, Yan; Liu, Hai-Ting; Chen, Xu; Wang, Ya-Wen; Tian, Ya-Ru; Ma, Ran-ran; Song, Lin; Zou, Yong-Xin; Gao, Peng			Aberrant promoter hypermethylation inhibits RGMA expression and contributes to tumor progression in breast cancer	ONCOGENE			English	Article							REPULSIVE GUIDANCE MOLECULE; DNA METHYLATION; APOPTOSIS; SURVIVAL; PROLIFERATION; INACTIVATION; RECEPTORS; ADHESION; GROWTH; CELLS	Breast cancer (BC) is the most common cancer in women worldwide, and the exploration of aberrantly expressed genes might clarify tumorigenesis and help uncover new therapeutic strategies for BC. Although RGMA was recently recognized as a tumor suppressor gene, its detailed biological function and regulation in BC remain unclear. Herein, we found that RGMA was downregulated in BC tissues compared with non-tumorous breast tissues, particularly in metastatic BC samples, and that patients with low RGMA expression manifested a poorer prognosis. Furthermore, DNMT1 and DNMT3A were found to be recruited to the RGMA promoter and induced aberrant hypermethylation, resulting in downregulation of RGMA expression in BC. In contrast, RGMA overexpression suppressed BC cell proliferation and colony-formation capabilities and increased BC cell apoptosis. Furthermore, RGMA knockdown accelerated BC cell proliferation and suppressed cellular apoptosis in vitro and in vivo. Reversal of RGMA promoter methylation with 5-Aza-CdR restored RGMA expression and blocked tumor growth. Overall, DNMT1- and DNMT3A-mediated RGMA promoter hypermethylation led to downregulation of RGMA expression, and low RGMA expression contributed to BC growth via activation of the FAK/Src/PI3K/AKT-signaling pathway. Our data thus suggested that RGMA might be a promising therapeutic target in BC.	[Li, Yan; Liu, Hai-Ting; Chen, Xu; Wang, Ya-Wen; Tian, Ya-Ru; Ma, Ran-ran; Song, Lin; Gao, Peng] Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China; [Li, Yan; Liu, Hai-Ting; Chen, Xu; Wang, Ya-Wen; Tian, Ya-Ru; Ma, Ran-ran; Song, Lin; Zou, Yong-Xin; Gao, Peng] Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Pathol, Jinan 250012, Shandong, Peoples R China; [Li, Yan] Shandong Univ, Qilu Hosp Qingdao, Dept Gastroenterol, Qingdao 266035, Shandong, Peoples R China	Shandong University; Shandong University; Shandong University	Gao, P (corresponding author), Shandong Univ, Dept Pathol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.; Zou, YX; Gao, P (corresponding author), Shandong Univ, Cheeloo Coll Med, Sch Basic Med Sci, Key Lab Expt Teratol,Minist Educ,Dept Pathol, Jinan 250012, Shandong, Peoples R China.	zouyongxin@sdu.edu.cn; gaopeng@sdu.edu.cn			National Natural Science Foundation of China [81872362, 82072665]; Taishan Scholars Program of Shandong Province [ts201511096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province	We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this paper. This study was supported by the National Natural Science Foundation of China (Grant No. 81872362 and 82072665) and the Taishan Scholars Program of Shandong Province (Grant No. ts201511096).	Abdel-Hafiz HA, 2015, EPIGENOMICS-UK, V7, P847, DOI 10.2217/epi.15.10; Bao RK, 2017, ENVIRON SCI POLLUT R, V24, P20342, DOI 10.1007/s11356-017-9422-6; Borges S, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3460; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Endo M, 2009, J NEUROSCI, V29, P6649, DOI 10.1523/JNEUROSCI.0927-09.2009; Feng FB, 2018, BIOMED PHARMACOTHER, V102, P1209, DOI 10.1016/j.biopha.2018.03.142; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Jia XQ, 2019, J BUON, V24, P1985; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Korecka JA, 2017, J NEUROSCI, V37, P9361, DOI 10.1523/JNEUROSCI.0084-17.2017; Ku JL, 2011, METHODS MOL BIOL, V791, P23, DOI 10.1007/978-1-61779-316-5_3; Li J, 2012, INT J ONCOL, V40, P544, DOI 10.3892/ijo.2011.1251; Li VSW, 2009, GASTROENTEROLOGY, V137, P176, DOI 10.1053/j.gastro.2009.03.005; Li Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.559486; Li Y, 2020, CLIN BREAST CANCER, V20, pE113, DOI 10.1016/j.clbc.2019.08.010; Liu H, 2020, CELL DEATH DIFFER, V27, P966, DOI 10.1038/s41418-019-0389-3; Lu YJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108608; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y; Niit Maximilian, 2015, BioMolecular Concepts, V6, P383, DOI 10.1515/bmc-2015-0022; O'Leary C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081711; Pathania R, 2016, CANCER RES, V76, P3224, DOI 10.1158/0008-5472.CAN-15-2249; Pathania R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7910; Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112; Schoeps A, 2014, GENET EPIDEMIOL, V38, P84, DOI 10.1002/gepi.21771; Siebold C, 2017, TRENDS CELL BIOL, V27, P365, DOI 10.1016/j.tcb.2016.11.009; Specht E, 2015, HISTOPATHOLOGY, V67, P368, DOI 10.1111/his.12662; Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080; Xiao B, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4314-9; Zhang G, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00504; Zhang Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00138; Zhao ZW, 2012, ONCOL REP, V27, P1653, DOI 10.3892/or.2012.1693	33	5	5	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2022	41	3					361	371		10.1038/s41388-021-02083-y	http://dx.doi.org/10.1038/s41388-021-02083-y		NOV 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YF8LK	34754080				2022-12-17	WOS:000716255200001
J	ter Steege, EJ; Bakker, ERM				ter Steege, Eline J.; Bakker, Elvira R. M.			The role of R-spondin proteins in cancer biology	ONCOGENE			English	Review							MAMMARY STEM-CELLS; APICAL ECTODERMAL RIDGE; WNT SIGNALING PATHWAY; BETA-CATENIN; WNT/BETA-CATENIN; COLORECTAL-CANCER; BREAST-CANCER; R-SPONDIN-4 RSPO4; EPIGENETIC INACTIVATION; PROGENITOR CELLS	R-spondin (RSPO) proteins constitute a family of four secreted glycoproteins (RSPO1-4) that have appeared as multipotent signaling ligands. The best-known molecular function of RSPOs lie within their capacity to agonize the Wnt/beta-catenin signaling pathway. As RSPOs act upon cognate receptors LGR4/5/6 that are typically expressed by stem cells and progenitor cells, RSPO proteins importantly potentiate Wnt/beta-catenin signaling especially within these proliferative stem cell compartments. Since multiple organs express LGR4/5/6 receptors and RSPO ligands within their stem cell niches, RSPOs can exert an influential role in stem cell regulation throughout the body. Inherently, over the last decade a multitude of reports implicated the deregulation of RSPOs in cancer development. First, RSPO2 and RSPO3 gene fusions with concomitant enhanced expression have been identified in colon cancer patients, and proposed as an alternative driver of Wnt/beta-catenin hyperactivation that earmarks cancer in the colorectal tract. Moreover, the causal oncogenic capacity of RSPO3 overactivation has been demonstrated in the mouse intestine. As a paradigm organ in this field, most of current knowledge about RSPOs in cancer is derived from studies in the intestinal tract. However, RSPO gene fusions as well as enhanced RSPO expression have been reported in multiple additional cancer types, affecting different organs that involve divergent stem cell hierarchies. Importantly, the emerging oncogenic role of RSPO and its potential clinical utility as a therapeutic target have been recognized and investigated in preclinical and clinical settings. This review provides a survey of current knowledge on the role of RSPOs in cancer biology, addressing the different organs implicated, and of efforts made to explore intervention opportunities in cancer cases with RSPO overrepresentation, including the potential utilization of RSPO as novel therapeutic target itself.	[ter Steege, Eline J.; Bakker, Elvira R. M.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Bakker, ERM (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.	e.r.m.bakker-8@umcutrecht.nl			Netherlands Organization for Scientific Research [NWO/ZonMW VENI 016.186.138]; Dutch Cancer Society [10957]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding)	This work was financially supported by the Netherlands Organization for Scientific Research (NWO/ZonMW VENI 016.186.138) and the Dutch Cancer Society (KWF Young Investigator Grant 10957).	Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198; Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Alexander CM, 2018, PROG MOL BIOL TRANSL, V153, P271, DOI 10.1016/bs.pmbts.2017.11.020; Aoki M, 2008, DEV GROWTH DIFFER, V50, P85, DOI 10.1111/j.1440-169x.2007.00978.x; Aoki M, 2007, DEV BIOL, V301, P218, DOI 10.1016/j.ydbio.2006.08.018; Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594; Bakker ERM, 2013, ONCOGENE, V32, P4579, DOI 10.1038/onc.2012.449; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bell SM, 2008, DEVELOPMENT, V135, P1049, DOI 10.1242/dev.013359; Bendell J, 2016, EUR J CANCER, V69, pS29, DOI 10.1016/S0959-8049(16)32668-5; Bergmann C, 2006, AM J HUM GENET, V79, P1105, DOI 10.1086/509789; Blaas L, 2016, NAT CELL BIOL, V18, P1346, DOI 10.1038/ncb3434; Blagodatski Artem, 2014, Mol Cell Ther, V2, P28, DOI 10.1186/2052-8426-2-28; Blaydon DC, 2006, NAT GENET, V38, P1245, DOI 10.1038/ng1883; Bruchle NO, 2008, J INVEST DERMATOL, V128, P791, DOI 10.1038/sj.jid.5701088; Cai CG, 2014, GENE DEV, V28, P2205, DOI 10.1101/gad.245142.114; Callahan R, 2012, ONCOTARGET, V3, P1320, DOI 10.18632/oncotarget.682; Carmon KS, 2014, P NATL ACAD SCI USA, V111, pE1221, DOI 10.1073/pnas.1323106111; Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108; Castillo-Azofeifa D, 2019, EMBO J, V38, DOI 10.15252/embj.201899984; Chadi S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162566; Chadi S, 2009, BIOCHEM BIOPH RES CO, V390, P1040, DOI 10.1016/j.bbrc.2009.10.104; Chartier C, 2016, CANCER RES, V76, P713, DOI 10.1158/0008-5472.CAN-15-0561; Chassot AA, 2008, HUM MOL GENET, V17, P1264, DOI 10.1093/hmg/ddn016; Chassot AA, 2012, DEVELOPMENT, V139, P4461, DOI 10.1242/dev.078972; Chassot AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025641; Chen JZ, 2002, MOL BIOL REP, V29, P287, DOI 10.1023/A:1020479301379; Chen PH, 2013, GENE DEV, V27, P1345, DOI 10.1101/gad.219915.113; Chen ZH, 2019, CARCINOGENESIS, V40, P360, DOI 10.1093/carcin/bgy140; Clements WM, 2002, CANCER RES, V62, P3503; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Colacino JA, 2018, STEM CELL REP, V10, P1596, DOI 10.1016/j.stemcr.2018.03.001; Conboy CB, 2019, HEPATOL COMMUN, V3, P1496, DOI 10.1002/hep4.1422; Coussy F, 2017, BRIT J CANCER, V116, P1595, DOI 10.1038/bjc.2017.131; Davis FM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13053; De Cian MC, 2017, ONCOGENE, V36, P208, DOI 10.1038/onc.2016.191; de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337; de Visser KE, 2012, J PATHOL, V228, P300, DOI 10.1002/path.4096; Dong XM, 2017, CANCER LETT, V402, P153, DOI 10.1016/j.canlet.2017.05.024; Dubey R, 2020, ELIFE, V9, DOI 10.7554/eLife.54469; Fischer AS, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7020044; Fischer M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02831-9; Francis JC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003180; Gaspar C, 2004, INT J DEV BIOL, V48, P377, DOI 10.1387/ijdb.041807cg; Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547; Gattelli A, 2006, J VIROL, V80, P11409, DOI 10.1128/JVI.00234-06; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175; Gong X, 2015, ONCOGENE, V34, P4692, DOI 10.1038/onc.2014.417; Greicius G, 2018, P NATL ACAD SCI USA, V115, pE3173, DOI 10.1073/pnas.1713510115; Han T, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms15945; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Harnack C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12349-5; Hashimoto T, 2019, HISTOPATHOLOGY, V75, P266, DOI 10.1111/his.13867; He YJ, 2014, MOL MED REP, V9, P137, DOI 10.3892/mmr.2013.1774; Hilkens J, 2017, GUT, V66, P1095, DOI 10.1136/gutjnl-2016-311606; Ilmer M, 2015, CANCER RES, V75, P1883, DOI 10.1158/0008-5472.CAN-14-1327; Ishii Y, 2008, J INVEST DERMATOL, V128, P867, DOI 10.1038/sj.jid.5701078; Jonsson M, 2000, EUR J CANCER, V36, P242, DOI 10.1016/S0959-8049(99)00276-2; Joshi PA, 2015, STEM CELL REP, V5, P31, DOI 10.1016/j.stemcr.2015.05.012; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kan ZY, 2013, GENOME RES, V23, P1422, DOI 10.1101/gr.154492.113; Kang E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152859; Karayiannakis AJ, 2001, EUR J SURG ONCOL, V27, P31, DOI 10.1053/ejso.1999.1017; Karthaus WR, 2014, CELL, V159, P163, DOI 10.1016/j.cell.2014.08.017; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kazanskaya O, 2008, DEVELOPMENT, V135, P3655, DOI 10.1242/dev.027284; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305; Klauzinska M, 2012, J CELL PHYSIOL, V227, P1960, DOI 10.1002/jcp.22924; Kleeman SO, 2020, CANCERS, V12, DOI 10.3390/cancers12113355; Kleeman SO, 2020, GUT, V69, P1092, DOI 10.1136/gutjnl-2019-319126; Klijn C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062113; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Koushyar S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113927; Kuchenbaecker KB, 2015, NAT GENET, V47, P164, DOI 10.1038/ng.3185; Lebensohn AM, 2018, ELIFE, V7, DOI 10.7554/eLife.33126; Lee H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19373-w; Li CL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22731-w; Li SG, 2014, TUMOR BIOL, V35, P7693, DOI 10.1007/s13277-014-1975-0; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Longerich T, 2019, GUT, V68, P1287, DOI 10.1136/gutjnl-2018-317632; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Lorenzi MV., PROC AACR IASLC JT C; Luo WJ, 2013, STEM CELLS, V31, P2492, DOI 10.1002/stem.1484; Maatouk DM, 2013, DEV BIOL, V383, P295, DOI 10.1016/j.ydbio.2013.08.026; Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280; Mehta V, 2011, DEV DYNAM, V240, P2548, DOI 10.1002/dvdy.22741; Mesci A, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1878-3; Mizuguchi Y, 2019, VIRCHOWS ARCH, V475, P659, DOI 10.1007/s00428-019-02604-x; Morgan RG, 2018, BRIT J CANCER, V118, P1410, DOI 10.1038/s41416-018-0118-6; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Mustata RC, 2011, EMBO REP, V12, P558, DOI 10.1038/embor.2011.52; Nam JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/jbc.M508324200; Nam JS, 2007, DEV BIOL, V311, P124, DOI 10.1016/j.ydbio.2007.08.023; Ohkawara B, 2011, DEV CELL, V20, P303, DOI 10.1016/j.devcel.2011.01.006; Ozaki S, 2005, ONCOL REP, V14, P1437; Park S, 2018, J BIOL CHEM, V293, P9759, DOI 10.1074/jbc.RA118.002743; Parma P, 2006, NAT GENET, V38, P1304, DOI 10.1038/ng1907; Peng WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083110; Picco G, 2017, EMBO MOL MED, V9, P293, DOI 10.15252/emmm.201606773; Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017; Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337; Planche A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018640; Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999; Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rocha AS, 2015, CELL REP, V13, P1757, DOI 10.1016/j.celrep.2015.10.049; Salik B, 2020, CANCER CELL, V38, P263, DOI 10.1016/j.ccell.2020.05.014; Santos AJM, 2018, TRENDS CELL BIOL, V28, P1062, DOI 10.1016/j.tcb.2018.08.001; Scheele CLGJ, 2017, NATURE, V542, P313, DOI 10.1038/nature21046; Schindler AJ, 2018, ONCOTARGET, V9, P1346, DOI 10.18632/oncotarget.20178; Sekine S, 2017, HISTOPATHOLOGY, V71, P601, DOI 10.1111/his.13265; Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shinmura K, 2014, MOL BIOL REP, V41, P5375, DOI 10.1007/s11033-014-3409-x; Sigal M, 2019, NAT CELL BIOL, V21, P812, DOI 10.1038/s41556-019-0339-9; Sigal M, 2017, NATURE, V548, P451, DOI 10.1038/nature23642; Simons BW, 2012, DEV BIOL, V371, P246, DOI 10.1016/j.ydbio.2012.08.016; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Storm EE, 2016, NATURE, V529, P97, DOI 10.1038/nature16466; Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259; Szenker-Ravi E, 2018, NATURE, V557, P564, DOI 10.1038/s41586-018-0118-y; Teeuwssen M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101658; Tharmapalan P, 2019, EMBO J, V38, DOI 10.15252/embj.2018100852; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Tocci JM, 2020, IUBMB LIFE, V72, P1546, DOI 10.1002/iub.2278; Tocci JM, 2018, CANCER RES, V78, P4497, DOI 10.1158/0008-5472.CAN-17-2676; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Tomizuka K, 2008, HUM MOL GENET, V17, P1278, DOI 10.1093/hmg/ddn036; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van Schie EH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00025; Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076; Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217; Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114; Wang DS, 2015, NATURE, V517, P81, DOI 10.1038/nature13851; Wang DL, 2013, GENE DEV, V27, P1339, DOI 10.1101/gad.219360.113; Wu CJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4149; Wuidart A, 2016, GENE DEV, V30, P1261, DOI 10.1101/gad.280057.116; Xie Y, 2013, EMBO REP, V14, P1120, DOI 10.1038/embor.2013.167; Xu K, 2013, STRUCTURE, V21, P1683, DOI 10.1016/j.str.2013.07.001; Yamada W, 2009, BIOCHEM BIOPH RES CO, V381, P453, DOI 10.1016/j.bbrc.2009.02.066; Yan KS, 2017, NATURE, V545, P238, DOI 10.1038/nature22313; Zebisch M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3787; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	150	5	5	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2021	40	47					6469	6478		10.1038/s41388-021-02059-y	http://dx.doi.org/10.1038/s41388-021-02059-y		OCT 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD3ZR	34663878	hybrid, Green Published			2022-12-17	WOS:000708355700003
J	Li, ZL; He, YX; Li, YJ; Li, J; Zhao, HZ; Song, GB; Miyagishi, M; Wu, SR; Kasim, V				Li, Zhuolin; He, Yuxin; Li, Yanjun; Li, Juan; Zhao, Hezhao; Song, Guanbing; Miyagishi, Makoto; Wu, Shourong; Kasim, Vivi			NeuroD1 promotes tumor cell proliferation and tumorigenesis by directly activating the pentose phosphate pathway in colorectal carcinoma	ONCOGENE			English	Article							CANCER; GENE; TRANSCRIPTION; METABOLISM; EXPRESSION; CONTRIBUTE; MIGRATION; RECEPTOR; DIFFERENTIATION; CHROMATIN	Tumor metabolic reprogramming ensures that cancerous cells obtain sufficient building blocks, energy, and antioxidants to sustain rapid growth and for coping with oxidative stress. Neurogenic differentiation factor 1 (NeuroD1) is upregulated in various types of tumors; however, its involvement in tumor cell metabolic reprogramming remains unclear. In this study, we report that NeuroD1 is positively correlated with glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway (PPP), in colorectal cancer cells. In addition, the regulation of G6PD by NeuroD1 alters tumor cell metabolism by stimulating the PPP, leading to enhanced production of nucleotides and NADPH. These, in turn, promote DNA and lipid biosynthesis in tumor cells, while decreasing intracellular levels of reactive oxygen species. Mechanistically, we showed that NeuroD1 binds directly to the G6PD promoter to activate G6PD transcription. Consequently, tumor cell proliferation and colony formation are enhanced, leading to increased tumorigenic potential in vitro and in vivo. These findings reveal a novel function of NeuroD1 as a regulator of G6PD, whereby its oncogenic activity is linked to tumor cell metabolic reprogramming and regulation of the PPP. Furthermore, NeuroD1 represents a potential target for metabolism-based anti-tumor therapeutic strategies.	[Li, Zhuolin; He, Yuxin; Li, Yanjun; Li, Juan; Song, Guanbing; Wu, Shourong; Kasim, Vivi] Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China; [Li, Zhuolin; He, Yuxin; Li, Yanjun; Li, Juan; Wu, Shourong; Kasim, Vivi] Chongqing Univ, Coll Bioengn, Project Lab Biomech & Tissue Repair 111, Chongqing 400044, Peoples R China; [Zhao, Hezhao] Chongqing Univ, Chongqing Univ Canc Hosp, Dept Gastrointestinal Surg, Chongqing 400030, Peoples R China; [Miyagishi, Makoto] Natl Inst Adv Ind Sci & Technol, Biomed Res Inst, Mol Composite Med Res Grp, Tsukuba, Ibaraki, Japan; [Wu, Shourong; Kasim, Vivi] Chongqing Univ, Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing 400030, Peoples R China	Chongqing University; Chongqing University; Chongqing University; National Institute of Advanced Industrial Science & Technology (AIST); Chongqing University	Wu, SR; Kasim, V (corresponding author), Chongqing Univ, Coll Bioengn, Minist Educ, Key Lab Biorheol Sci & Technol, Chongqing 400044, Peoples R China.; Wu, SR; Kasim, V (corresponding author), Chongqing Univ, Coll Bioengn, Project Lab Biomech & Tissue Repair 111, Chongqing 400044, Peoples R China.; Wu, SR; Kasim, V (corresponding author), Chongqing Univ, Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing 400030, Peoples R China.	shourongwu@cqu.edu.cn; vivikasim@cqu.edu.cn	Song, Guanbin/AFL-8473-2022	Wu, Shourong/0000-0001-9650-5465; Kasim, Vivi/0000-0001-9182-8230	National Natural Science Foundation of China [11832008, 31871367, 81872273]; Natural Science Foundation of Chongqing [cstc2018jcyjAX0411, cstc2018jcyjAX0374]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing)	We thank Dr. Bert Vogelstein (School of Medicine, Johns Hopkins University) for kindly providing wild-type and p53-null HCT116<SUP>p53null</SUP> cell lines. This work was supported by grants from the National Natural Science Foundation of China (11832008, 31871367, and 81872273); and the Natural Science Foundation of Chongqing (cstc2018jcyjAX0411 and cstc2018jcyjAX0374).	Almeida AS, 2018, REDOX BIOL, V17, P338, DOI 10.1016/j.redox.2018.05.004; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Borromeo MD, 2016, CELL REP, V16, P1259, DOI 10.1016/j.celrep.2016.06.081; Boulay G, 2017, CANCER DISCOV, V7, P288, DOI 10.1158/2159-8290.CD-16-0844; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chen L, 2019, NAT METAB, V1, P404, DOI 10.1038/s42255-019-0043-x; Cheng J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15819-3; Cheng Y, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107782; Cindolo L, 2007, EUR UROL, V52, P1365, DOI 10.1016/j.eururo.2006.11.030; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Enya M, 2008, HUM MUTAT, V29, pE271, DOI 10.1002/humu.20865; Gay CM, 2021, CANCER CELL, V39, P346, DOI 10.1016/j.ccell.2020.12.014; Giles ED, 2012, CANCER RES, V72, P6490, DOI 10.1158/0008-5472.CAN-12-1653; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang P, 2011, CANCER RES, V71, P2938, DOI 10.1158/0008-5472.CAN-10-3524; Ireland AS, 2020, CANCER CELL, V38, P60, DOI 10.1016/j.ccell.2020.05.001; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Kim JW, 2002, MOL ENDOCRINOL, V16, P1097, DOI 10.1210/me.16.5.1097; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Ku HC, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00556; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lei K, 2020, CANCER SCI, V111, P175, DOI 10.1111/cas.14233; Li QD, 2019, CELL METAB, V30, P157, DOI 10.1016/j.cmet.2019.05.009; Liu CL, 2020, MOL CELL ENDOCRINOL, V499, DOI 10.1016/j.mce.2019.110595; Liu YH, 2016, J NEURO-ONCOL, V126, P455, DOI 10.1007/s11060-015-2003-y; Lu FJ, 2015, CANCER SCI, V106, P390, DOI 10.1111/cas.12628; Ma XY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01647-5; Marsich E, 2003, BIOCHEM J, V376, P707, DOI 10.1042/BJ20031021; Martin CC, 2003, BIOCHEM J, V371, P675, DOI 10.1042/BJ20021585; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Moates JM, 2003, DIABETES, V52, P403, DOI 10.2337/diabetes.52.2.403; Osborne JK, 2014, MOL BIOL CELL, V25, P1782, DOI 10.1091/mbc.E13-06-0316; Osborne JK, 2013, P NATL ACAD SCI USA, V110, P6524, DOI 10.1073/pnas.1303932110; Owonikoko TK, 2021, J THORAC ONCOL, V16, P464, DOI 10.1016/j.jtho.2020.11.006; Pan N, 2009, CELL TISSUE RES, V337, P407, DOI 10.1007/s00441-009-0826-6; Pang ZPP, 2011, NATURE, V476, P220, DOI 10.1038/nature10202; Park AK, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5742-x; Pataskar A, 2016, EMBO J, V35, P24, DOI 10.15252/embj.201591206; Patra KC, 2014, TRENDS BIOCHEM SCI, V39, P347, DOI 10.1016/j.tibs.2014.06.005; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Reina-Campos M, 2019, CANCER CELL, V36, P218, DOI 10.1016/j.ccell.2019.07.010; Rotinen M, 2018, NAT MED, V24, P1887, DOI 10.1038/s41591-018-0241-1; Santana-Codina N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07472-8; Shan CL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1756-1; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Wang JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03201-6; Wang M, 2018, CLIN TRANSL ONCOL, V20, P906, DOI 10.1007/s12094-017-1805-0; Wang Y, 2014, CELL BIOCHEM BIOPHYS, V69, P487, DOI 10.1007/s12013-014-9822-x; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wu SR, 2018, CANCER RES, V78, P4549, DOI 10.1158/0008-5472.CAN-17-4047; Xu H, 2021, ONCOGENE, V40, P1555, DOI 10.1038/s41388-020-01587-3; Yang HC, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091055	59	5	5	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2021	40	50					6736	6747		10.1038/s41388-021-02063-2	http://dx.doi.org/10.1038/s41388-021-02063-2		OCT 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XP7IH	34657129				2022-12-17	WOS:000707687400001
J	Tong, JS; Tan, X; Risnik, D; Gao, M; Song, XP; Ermine, K; Shen, LF; Wang, SM; Yu, J; Zhang, L				Tong, Jingshan; Tan, Xiao; Risnik, Denise; Gao, Man; Song, Xiangping; Ermine, Kaylee; Shen, Liangfang; Wang, Shaomeng; Yu, Jian; Zhang, Lin			BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade	ONCOGENE			English	Article							BROMODOMAIN INHIBITORS; INDUCED APOPTOSIS; RECEPTOR 5; EXPRESSION; RESISTANCE; BRD4; STABILIZATION; SENSITIVITY; MECHANISMS; TUMORS	Bromodomain and extra-terminal domain (BET) family proteins are epigenetic readers that play a critical role in oncogenesis by controlling the expression of oncogenes such as c-Myc. Targeting BET family proteins has recently emerged as a promising anticancer strategy. However, the molecular mechanisms by which cancer cells respond to BET inhibition are not well understood. In this study, we found that inducing the degradation of BET proteins by the proteolysis targeting chimeras (PROTAC) approach potently suppressed the growth of colorectal cancer (CRC) including patient-derived tumors. Mechanistically, BET degradation transcriptionally activates Death Receptor 5 (DR5) to trigger immunogenic cell death (ICD) in CRC cells. Enhanced DR5 induction further sensitizes CRC cells with a mutation in Speckle-type POZ protein (SPOP). Furthermore, DR5 is indispensable for a striking antitumor effect of combining BET degradation and anti-PD-1 antibody, which was well tolerated in mice and almost eradicated syngeneic tumors. Our results demonstrate that BET degradation triggers DR5-mediated ICD to potently suppress CRC and potentiate immune checkpoint blockade. These results provide a rationale, mechanistic insights, and potential biomarkers for developing a precision CRC therapy by inducing BET protein degradation.	[Tong, Jingshan; Tan, Xiao; Risnik, Denise; Gao, Man; Song, Xiangping; Ermine, Kaylee; Yu, Jian; Zhang, Lin] UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Tong, Jingshan; Tan, Xiao; Risnik, Denise; Song, Xiangping; Ermine, Kaylee; Zhang, Lin] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15213 USA; [Tan, Xiao; Shen, Liangfang] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Gao, Man; Yu, Jian] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15213 USA; [Song, Xiangping] Cent South Univ, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha 410008, Hunan, Peoples R China; [Wang, Shaomeng] Univ Michigan, Dept Internal Med, Sch Med, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Central South University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Central South University; University of Michigan System; University of Michigan	Zhang, L (corresponding author), UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.; Zhang, L (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Sch Med, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Tong, Jingshan/0000-0003-1640-5769; Ermine, Kaylee/0000-0002-0870-7129; Risnik, Denise/0000-0001-8843-7968	U.S. National Institutes of Health [R01CA203028, R01CA217141, R01CA236271, R01CA247231, R01CA248112, R01CA215758, U19AI068021, R01CA215481, T32GM133332, P30CA047904]	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank our lab members for discussion and critical reading. This work was supported by the U.S. National Institutes of Health grants (R01CA203028, R01CA217141, R01CA236271, R01CA247231, and R01CA248112 to LZ; R01CA215758 to SW; U19AI068021 and R01CA215481 to JY; T32GM133332 to KE). This project used the Hillman Cancer Center Animal Facility, Cytometry Facility, and Tissue and Research Pathology Services, which are supported in part by P30CA047904.	An SA, 2018, EBIOMEDICINE, V36, P553, DOI 10.1016/j.ebiom.2018.09.005; Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637; Bai LC, 2017, CANCER RES, V77, P2476, DOI 10.1158/0008-5472.CAN-16-2622; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Bolden JE, 2014, CELL REP, V8, P1919, DOI 10.1016/j.celrep.2014.08.025; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chen DS, 2014, CLIN CANCER RES, V20, P3472, DOI 10.1158/1078-0432.CCR-13-2944; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Conery AR, 2016, CANCER RES, V76, P1313, DOI 10.1158/0008-5472.CAN-15-1458; Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/NCHEMBIO.2329, 10.1038/nchembio.2329]; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673; Han B, 2015, ONCOTARGET, V6, P17532, DOI 10.18632/oncotarget.3947; He K, 2016, ONCOGENE, V35, P148, DOI 10.1038/onc.2015.79; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928; Janouskova H, 2017, NAT MED, V23, P1046, DOI 10.1038/nm.4372; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee DU, 2016, TOXICOL APPL PHARM, V300, P47, DOI 10.1016/j.taap.2016.03.013; Leibowitz B, 2014, P NATL ACAD SCI USA, V111, P16520, DOI 10.1073/pnas.1415178111; Li J, 2015, CANCER RES, V75, P508, DOI 10.1158/0008-5472.CAN-14-1215; Li XY, 2017, ONCOTARGET, V8, P9280, DOI 10.18632/oncotarget.14063; Lin JJ, 2016, TRENDS CANCER, V2, P350, DOI 10.1016/j.trecan.2016.05.010; Lu J, 2015, CHEM BIOL, V22, P755, DOI 10.1016/j.chembiol.2015.05.009; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265; Oh YT, 2012, J BIOL CHEM, V287, P257, DOI 10.1074/jbc.M111.304006; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078; Selby MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161779; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Tan X, 2019, CANCER RES, V79, P1191, DOI 10.1158/0008-5472.CAN-18-3223; Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61; Togel L, 2016, MOL CANCER THER, V15, P1217, DOI 10.1158/1535-7163.MCT-15-0724; Tong JS, 2018, CANCER RES, V78, P4704, DOI 10.1158/0008-5472.CAN-18-0399; Tong JS, 2017, CANCER RES, V77, P2512, DOI 10.1158/0008-5472.CAN-16-3242; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wang YJ, 2018, GENES DIS, V5, P194, DOI 10.1016/j.gendis.2018.05.003; Winter GE, 2017, MOL CELL, V67, P5, DOI 10.1016/j.molcel.2017.06.004; Winter GE, 2015, SCIENCE, V348, P1376, DOI 10.1126/science.aab1433; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yao WL, 2015, ONCOTARGET, V6, P34669, DOI 10.18632/oncotarget.5785; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379; Zhou B, 2018, J MED CHEM, V61, P462, DOI 10.1021/acs.jmedchem.6b01816; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032	56	5	5	5	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2021	40	48					6566	6578		10.1038/s41388-021-02041-8	http://dx.doi.org/10.1038/s41388-021-02041-8		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XJ0UH	34615996	Green Accepted			2022-12-17	WOS:000705759400004
J	Zhang, WY; Pan, RL; Lu, M; Zhang, Q; Lin, ZQ; Qin, Y; Wang, ZY; Gong, SQ; Lin, H; Chong, SY; Lu, LT; Liao, WQ; Lu, XC				Zhang, Wenyi; Pan, Rulu; Lu, Mei; Zhang, Qian; Lin, Ziqi; Qin, Yuan; Wang, Zhanyu; Gong, Siqing; Lin, Huan; Chong, Shuyi; Lu, Liting; Liao, Wanqin; Lu, Xincheng			Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin beta 3/SRC pathway	ONCOGENE			English	Article							THYMIDYLATE SYNTHASE; DRUG-RESISTANCE; SRC ACTIVATION; C-SRC; CELLS; PROGRESSION; SUPPRESSES; MECHANISM; BCL-X(L); PROTEIN	The therapeutic efficacy of 5-fluorouracil (5-FU) is often reduced by the development of drug resistance. We observed significant upregulation of lipocalin 2 (LCN2) expression in a newly established 5-FU-resistant colorectal cancer (CRC) cell line. In this study, we demonstrated that 5-FU-treated CRC cells developed resistance through LCN2 upregulation caused by LCN2 promoter demethylation and that feedback between LCN2 and NF-kappa B further amplified LCN2 expression. High LCN2 expression was associated with poor prognosis in CRC patients. LCN2 attenuated the cytotoxicity of 5-FU by activating the SRC/AKT/ERK-mediated antiapoptotic program. Mechanistically, the LCN2-integrin beta 3 interaction enhanced integrin beta 3 stability, thus recruiting SRC to the cytomembrane for autoactivation, leading to downstream AKT/ERK cascade activation. Targeting LCN2 or SRC compromised the growth of CRC cells with LCN2-induced 5-FU resistance. Our findings demonstrate a novel mechanism of acquired resistance to 5-FU, suggesting that LCN2 can be used as a biomarker and/or therapeutic target for advanced CRC.	[Zhang, Wenyi; Pan, Rulu; Lu, Mei; Zhang, Qian; Lin, Ziqi; Qin, Yuan; Wang, Zhanyu; Gong, Siqing; Lin, Huan; Chong, Shuyi; Lu, Liting; Lu, Xincheng] Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou 325035, Peoples R China; [Zhang, Wenyi] Wenzhou Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Wenzhou, Peoples R China; [Liao, Wanqin] Foshan Univ, Dept Basic Med & Biomed Engn, Foshan 528200, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Foshan University	Lu, XC (corresponding author), Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou 325035, Peoples R China.	xinchenglu@yahoo.com		Lin, Ziqi/0000-0001-7949-2092	National Natural Science Foundation of China [81972765, 81772966]; Zhejiang Provincial Natural Science Foundation [LZ21H160007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation(Natural Science Foundation of Zhejiang Province)	This work was supported by National Natural Science Foundation of China (Grant Nos. 81972765 and 81772966) and Zhejiang Provincial Natural Science Foundation (No. LZ21H160007). The Superbiotek Inc. (Shanghai, China) provided CRC tissue microarray analysis. The authors also thank the Laboratory Animal Research Center in Wenzhou Medical University for technical assistance.	Abella V, 2015, BIOMARKERS, V20, P565, DOI 10.3109/1354750X.2015.1123354; Arachiche A, 2008, J BIOL CHEM, V283, P24406, DOI 10.1074/jbc.M709217200; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Belli S, 2020, CANCERS, V12, DOI 10.3390/cancers12061489; Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532; Borkham-Kamphorst E, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00426; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown R, 2014, NAT REV CANCER, V14, P747, DOI 10.1038/nrc3819; Chen LJ, 2015, NANOSCALE, V7, P14080, DOI 10.1039/c5nr03527a; Chen TK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03030-7; Chi Y, 2020, SCIENCE, V369, P276, DOI 10.1126/science.aaz2193; Conde J, 2016, J PHYSIOL-LONDON, V594, P6133, DOI 10.1113/JP272240; de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321; Desgrosellier JS, 2009, NAT MED, V15, P1163, DOI 10.1038/nm.2009; Dong XM, 2017, CANCER LETT, V402, P153, DOI 10.1016/j.canlet.2017.05.024; Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430; Gomez-Chou SB, 2017, CANCER RES, V77, P2647, DOI 10.1158/0008-5472.CAN-16-1986; Griffiths GJ, 2004, J BIOL CHEM, V279, P46113, DOI 10.1074/jbc.M408550200; Guo X, 2018, RECENT PAT ANTI-CANC, V13, P248, DOI 10.2174/1574892813666171221120504; Huang ZX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2177-x; Jin W, 2020, CANCERS, V12, DOI 10.3390/cancers12051339; Kim SL, 2018, INT J ONCOL, V53, P2789, DOI 10.3892/ijo.2018.4562; Leung L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046677; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Martinez-Perez J, 2017, HUM PATHOL, V67, P119, DOI 10.1016/j.humpath.2017.05.025; Meka Phanni bhushann, 2015, Asian Pac J Cancer Prev, V16, P4965; Miao Q, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5088; Ong KL, 2020, DIABETES RES CLIN PR, V169, DOI 10.1016/j.diabres.2020.108450; Perez M, 2016, ONCOTARGET, V7, P33111, DOI 10.18632/oncotarget.8880; Pothuraju R, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01156-y; Reinecke JB, 2014, J CELL SCI, V127, P1684, DOI 10.1242/jcs.133892; Rosenzweig SA, 2018, ADV CANCER RES, V138, P71, DOI 10.1016/bs.acr.2018.02.003; Roskoski R, 2015, PHARMACOL RES, V94, P9, DOI 10.1016/j.phrs.2015.01.003; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Santiago-Sanchez GS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124365; Sun Y, 2011, CLIN CANCER RES, V17, P4331, DOI 10.1158/1078-0432.CCR-11-0226; Tominaga T, 2010, INT J CANCER, V126, P1691, DOI 10.1002/ijc.24929; Tung MC, 2013, PROSTATE, V73, P1281, DOI 10.1002/pros.22670; Viau A, 2010, J CLIN INVEST, V120, P4065, DOI 10.1172/JCI42004; Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146; Wang H, 2020, CANCER SCI, V111, P84, DOI 10.1111/cas.14253; Wang QQ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02594; Wang TL, 2004, P NATL ACAD SCI USA, V101, P3089, DOI 10.1073/pnas.0308716101; Wang ZX, 2018, INT J ONCOL, V53, P2102, DOI 10.3892/ijo.2018.4521; Wilson BJ, 2011, CANCER RES, V71, P5307, DOI 10.1158/0008-5472.CAN-11-0221; Wu CJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4149; Xiao R, 2013, BLOOD, V121, P700, DOI 10.1182/blood-2012-07-440644; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang X, 2016, CANCER LETT, V381, P305, DOI 10.1016/j.canlet.2016.08.004; Zou ZW, 2016, MOL MED REP, V14, P4893, DOI 10.3892/mmr.2016.5812	50	5	5	3	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2021	40	45					6369	6380		10.1038/s41388-021-02029-4	http://dx.doi.org/10.1038/s41388-021-02029-4		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW1BA	34588619				2022-12-17	WOS:000701380400002
J	Labanca, E; Bizzotto, J; Sanchis, P; Anselmino, N; Yang, J; Shepherd, PDA; Paez, A; Antico-Arciuch, V; Lage-Vickers, S; Hoang, AG; Tang, XM; Raso, MG; Titus, M; Efstathiou, E; Cotignola, J; Araujo, J; Logothetis, C; Vazquez, E; Navone, N; Gueron, G				Labanca, Estefania; Bizzotto, Juan; Sanchis, Pablo; Anselmino, Nicolas; Yang, Jun; Shepherd, Peter D. A.; Paez, Alejandra; Antico-Arciuch, Valeria; Lage-Vickers, Sofia; Hoang, Anh G.; Tang, Ximing; Raso, Maria Gabriela; Titus, Mark; Efstathiou, Eleni; Cotignola, Javier; Araujo, John; Logothetis, Christopher; Vazquez, Elba; Navone, Nora; Gueron, Geraldine			Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel	ONCOGENE			English	Article							METABOLISM; PATHWAY; BODIES; DISCOVERY; RESPONSES; REVEALS; ENZYME; ATLAS	Prostate cancer (PCa) that progresses after androgen deprivation therapy (ADT) remains incurable. The underlying mechanisms that account for the ultimate emergence of resistance to ADT, progressing to castrate-resistant prostate cancer (CRPC), include those that reactivate androgen receptor (AR), or those that are entirely independent or cooperate with androgen signaling to underlie PCa progression. The intricacy of metabolic pathways associated with PCa progression spurred us to develop a metabolism-centric analysis to assess the metabolic shift occurring in PCa that progresses with low AR expression. We used PCa patient-derived xenografts (PDXs) to assess the metabolic changes after castration of tumor-bearing mice and subsequently confirmed main findings in human donor tumor that progressed after ADT. We found that relapsed tumors had a significant increase in fatty acids and ketone body (KB) content compared with baseline. We confirmed that critical ketolytic enzymes (ACAT1, OXCT1, BDH1) were dysregulated after castrate-resistant progression. Further, these enzymes are increased in the human donor tissue after progressing to ADT. In an in silico approach, increased ACAT1, OXCT1, BDH1 expression was also observed for a subset of PCa patients that relapsed with low AR and ERG (ETS-related gene) expression. Further, expression of these factors was also associated with decreased time to biochemical relapse and decreased progression-free survival. Our studies reveal the key metabolites fueling castration resistant progression in the context of a partial or complete loss of AR dependence.	[Labanca, Estefania; Anselmino, Nicolas; Yang, Jun; Shepherd, Peter D. A.; Hoang, Anh G.; Titus, Mark; Efstathiou, Eleni; Araujo, John; Logothetis, Christopher; Navone, Nora] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Labanca, Estefania; Anselmino, Nicolas; Yang, Jun; Shepherd, Peter D. A.; Hoang, Anh G.; Titus, Mark; Efstathiou, Eleni; Araujo, John; Logothetis, Christopher; Navone, Nora] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA; [Bizzotto, Juan; Sanchis, Pablo; Paez, Alejandra; Antico-Arciuch, Valeria; Lage-Vickers, Sofia; Cotignola, Javier; Vazquez, Elba; Gueron, Geraldine] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Lab Inflamac & Canc, Buenos Aires, DF, Argentina; [Bizzotto, Juan; Sanchis, Pablo; Paez, Alejandra; Antico-Arciuch, Valeria; Lage-Vickers, Sofia; Cotignola, Javier; Vazquez, Elba; Gueron, Geraldine] Univ Buenos Aires, CONICET, Inst Quim Biol, Fac Ciencias Exactas & Nat IQUIBIC, Buenos Aires, DF, Argentina; [Paez, Alejandra] Univ Buenos Aires, Inst Oncol Angel H Roffo, Unidad Transferencia Genet, Buenos Aires, DF, Argentina; [Tang, Ximing; Raso, Maria Gabriela] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires; University of Texas System; UTMD Anderson Cancer Center	Navone, N (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.; Navone, N (corresponding author), Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Houston, TX 77030 USA.; Vazquez, E; Gueron, G (corresponding author), Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, Lab Inflamac & Canc, Buenos Aires, DF, Argentina.; Vazquez, E; Gueron, G (corresponding author), Univ Buenos Aires, CONICET, Inst Quim Biol, Fac Ciencias Exactas & Nat IQUIBIC, Buenos Aires, DF, Argentina.	elba@qb.fcen.uba.ar; nnavone@mdanderson.org; ggueron@gmail.com	Bizzotto, Juan Antonio/AAZ-9350-2021	Bizzotto, Juan Antonio/0000-0002-7844-2162; Labanca, Estefania/0000-0003-3201-7790; Sanchis, Pablo Antonio/0000-0002-0243-8036; Anselmino, Nicolas/0000-0002-6482-2623; Paez, Alejandra/0000-0002-7715-7458				Abida W, 2019, P NATL ACAD SCI USA, V116, P11428, DOI 10.1073/pnas.1902651116; Abida W, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00029; Allen BG, 2013, CLIN CANCER RES, V19, P3905, DOI 10.1158/1078-0432.CCR-12-0287; Blighe K., 2018, ENHANCEDVOLCANO PUBL; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Budczies J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051862; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Chriett S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36941-9; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; Devic S, 2016, J CANCER, V7, P817, DOI 10.7150/jca.14274; Efstathiou E, 2015, EUR UROL, V67, P53, DOI 10.1016/j.eururo.2014.05.005; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Faria Michelle, 2018, Oncotarget, V9, P36273, DOI 10.18632/oncotarget.26345; Garcia-Bermudez J, 2016, MOL CELL, V64, P856, DOI 10.1016/j.molcel.2016.11.023; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Goveia J, 2016, EMBO MOL MED, V8, P1134, DOI 10.15252/emmm.201606798; Hakimi AA, 2016, CANCER CELL, V29, P104, DOI 10.1016/j.ccell.2015.12.004; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang D, 2016, CELL RES, V26, P1112, DOI 10.1038/cr.2016.109; Jaworski DM, 2016, J CELL BIOCHEM, V117, P574, DOI 10.1002/jcb.25305; Kassambara A., 2020, RSTATIX PIPE FRIENDL; Klement Rainer J, 2016, BMC Res Notes, V9, P143, DOI 10.1186/s13104-016-1959-9; Kolde Raivo, 2019, CRAN; Labanca E, 2020, ENDOCR-RELAT CANCER, V27, pR255, DOI 10.1530/ERC-19-0472; Li LK, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005070; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Lima AR, 2016, TRANSL ONCOL, V9, P357, DOI 10.1016/j.tranon.2016.05.004; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3956, DOI 10.4161/cc.22136; Mierziak J, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030402; Morscher RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129802; Nagarajan A, 2016, TRENDS CANCER, V2, P365, DOI 10.1016/j.trecan.2016.06.002; Navone NM, 2018, PROSTATE, V78, P1262, DOI 10.1002/pros.23701; Newman JC, 2014, TRENDS ENDOCRIN MET, V25, P42, DOI 10.1016/j.tem.2013.09.002; Palanisamy N, 2020, CLIN CANCER RES, V26, P4933, DOI 10.1158/1078-0432.CCR-20-0479; Poff AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065522; Puchalska P, 2017, CELL METAB, V25, P262, DOI 10.1016/j.cmet.2016.12.022; Rodrigues LM, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0166-z; Ross-Adams H, 2015, EBIOMEDICINE, V2, P1133, DOI 10.1016/j.ebiom.2015.07.017; Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161; Salameh A, 2015, P NATL ACAD SCI USA, V112, P8403, DOI 10.1073/pnas.1507882112; Saraon P, 2014, PROSTATE, V74, P372, DOI 10.1002/pros.22758; Saraon P, 2013, MOL CELL PROTEOMICS, V12, P1589, DOI 10.1074/mcp.M112.023887; Shukla SK, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-18; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017; THUMELIN S, 1993, BIOCHEM J, V292, P493, DOI 10.1042/bj2920493; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078-0432.CCR-11-1867; Varkaris A, 2016, CLIN CANCER RES, V22, P107, DOI 10.1158/1078-0432.CCR-15-0235; Vazquez ES., 2017, INT J SCI RES, V6, P614; Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332; Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yang J, 2001, CANCER RES, V61, P5652; Yoshii Y, 2015, CANCER LETT, V356, P211, DOI 10.1016/j.canlet.2014.02.019; Zhang DJ, 2011, AM J PHYSIOL-ENDOC M, V300, pE287, DOI 10.1152/ajpendo.00308.2010; Zhang J, 2018, J LIPID RES, V59, P625, DOI 10.1194/jlr.M082040; Zhang S, 2017, LIFE SCI, V183, P110, DOI 10.1016/j.lfs.2017.07.003; Zhang W, 2018, CLIN CANCER RES, V24, P696, DOI 10.1158/1078-0432.CCR-17-1872; Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06177-2	64	5	5	2	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6284	6298		10.1038/s41388-021-02008-9	http://dx.doi.org/10.1038/s41388-021-02008-9		SEP 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34584218	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000701638300004
J	Lee, CS; Siprashvili, Z; Mah, A; Bencomo, T; Elcavage, LE; Che, YL; Shenoy, RM; Aasi, SZ; Khavari, PA				Lee, Carolyn S.; Siprashvili, Zurab; Mah, Angela; Bencomo, Tomas; Elcavage, Lara E.; Che, Yonglu; Shenoy, Rajani M.; Aasi, Sumaira Z.; Khavari, Paul A.			Mutant collagen COL11A1 enhances cancerous invasion	ONCOGENE			English	Article							MATRIX METALLOPROTEINASES; SKIN-CANCER; MUTATIONS; GENE; SUBSTITUTION; PROGRESSION; METASTASIS; CARCINOMAS; NEOPLASIA; DIAGNOSIS	Collagens are the most abundant proteins in the body and comprise the basement membranes and stroma through which cancerous invasion occurs; however, a pro-neoplastic function for mutant collagens is undefined. Here we identify COL11A1 mutations in 66 of 100 cutaneous squamous cell carcinomas (cSCCs), the second most common U.S. cancer, concentrated in a triple helical region known to produce trans-dominant collagens. Analysis of COL11A1 and other collagen genes found that they are mutated across common epithelial malignancies. Knockout of mutant COL11A1 impairs cSCC tumorigenesis in vivo. Compared to otherwise genetically identical COL11A1 wild-type tissue, gene-edited mutant COL11A1 skin is characterized by induction of beta 1 integrin targets and accelerated neoplastic invasion. In mosaic tissue, mutant COL11A1 cells enhanced invasion by neighboring wild-type cells. These results suggest that specific collagens are commonly mutated in cancer and that mutant collagens may accelerate this process.	[Lee, Carolyn S.; Siprashvili, Zurab; Mah, Angela; Bencomo, Tomas; Elcavage, Lara E.; Che, Yonglu; Shenoy, Rajani M.; Aasi, Sumaira Z.; Khavari, Paul A.] Stanford Univ, Stanford Program Epithelial Biol, Stanford, CA 94305 USA; [Lee, Carolyn S.; Khavari, Paul A.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA; [Lee, Carolyn S.; Khavari, Paul A.] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA	Stanford University; Stanford Cancer Institute; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Lee, CS; Khavari, PA (corresponding author), Stanford Univ, Stanford Program Epithelial Biol, Stanford, CA 94305 USA.; Lee, CS; Khavari, PA (corresponding author), Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.; Lee, CS; Khavari, PA (corresponding author), Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA 94304 USA.	carilee@stanford.edu; khavari@stanford.edu		Elcavage, Lara/0000-0003-1457-2109; Bencomo, Tomas/0000-0001-6048-8843; Lee, Carolyn/0000-0002-6511-3757				Annunen S, 1999, AM J HUM GENET, V65, P974, DOI 10.1086/302585; [Anonymous], 2014, GENOME BIOL, DOI DOI 10.1186/S13059-014-0550-8; Bak RO, 2018, NAT PROTOC, V13, P358, DOI 10.1038/nprot.2017.143; Bak RO, 2017, ELIFE, V6, DOI 10.7554/eLife.27873.001; Benjamin, 2019, BIORXIV861054, DOI [10.1101/861054, DOI 10.1101/861054]; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Cathcart J, 2015, GENES DIS, V2, P26, DOI 10.1016/j.gendis.2014.12.002; Chen Y, 2021, CANCER CELL, V39, P548, DOI 10.1016/j.ccell.2021.02.007; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Chong IW, 2006, ONCOL REP, V16, P981; Cooper J, 2019, CANCER CELL, V35, P347, DOI 10.1016/j.ccell.2019.01.007; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Durinck S, 2011, CANCER DISCOV, V1, P137, DOI 10.1158/2159-8290.CD-11-0028; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Fritsch A, 2009, J BIOL CHEM, V284, P30248, DOI 10.1074/jbc.M109.045294; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; Hammami-Hauasli N, 1998, J BIOL CHEM, V273, P19228, DOI 10.1074/jbc.273.30.19228; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; Hida M, 2014, IN VITRO CELL DEV-AN, V50, P358, DOI 10.1007/s11626-013-9692-3; Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165; Jia DY, 2016, CANCER LETT, V382, P203, DOI 10.1016/j.canlet.2016.09.001; Karia PS, 2013, J AM ACAD DERMATOL, V68, P957, DOI 10.1016/j.jaad.2012.11.037; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn566; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Labun K, 2019, NUCLEIC ACIDS RES, V47, pW171, DOI 10.1093/nar/gkz365; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Lee CS, 2018, J INVEST DERMATOL, V138, P1445, DOI 10.1016/j.jid.2018.01.003; Lee CS, 2014, NAT GENET, V46, P1060, DOI 10.1038/ng.3091; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; MARINKOVICH MP, 1993, DEV DYNAM, V197, P255, DOI 10.1002/aja.1001970404; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; McLean WHI, 2011, HUM MOL GENET, V20, pR189, DOI 10.1093/hmg/ddr379; Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Raglow Z, 2015, CANCER LETT, V357, P448, DOI 10.1016/j.canlet.2014.12.011; Reuter JA, 2009, CANCER CELL, V15, P477, DOI 10.1016/j.ccr.2009.04.002; Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265; Rogers HW, 2015, JAMA DERMATOL, V151, P1081, DOI 10.1001/jamadermatol.2015.1187; Shen LH, 2016, ONCOL REP, V36, P877, DOI 10.3892/or.2016.4869; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sorushanova A, 2019, ADV MATER, V31, DOI 10.1002/adma.201801651; South AP, 2014, J INVEST DERMATOL, V134, P2630, DOI 10.1038/jid.2014.154; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15; Supp DM, 2019, CELL TRANSPLANT, V28, P1242, DOI 10.1177/0963689719857657; Tarpey PS, 2013, NAT GENET, V45, P923, DOI 10.1038/ng.2668; UITTO J, 1994, J INVEST DERMATOL, V103, pS39, DOI 10.1111/1523-1747.ep12398967; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; Wang NJ, 2011, P NATL ACAD SCI USA, V108, P17761, DOI 10.1073/pnas.1114669108; Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307; Zhang JY, 2007, CANCER RES, V67, P3827, DOI 10.1158/0008-5472.CAN-06-4017	55	5	5	3	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2021	40	44					6299	6307		10.1038/s41388-021-02013-y	http://dx.doi.org/10.1038/s41388-021-02013-y		SEP 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR3FG	34584216	Green Published, hybrid			2022-12-17	WOS:000701638300001
J	Ye, ZPP; Ai, XL; Zhao, LJ; Fei, F; Wang, P; Zhou, ST				Ye, Zengpanpan; Ai, Xiaolin; Zhao, Linjie; Fei, Fan; Wang, Ping; Zhou, Shengtao			Phenotypic plasticity of myeloid cells in glioblastoma development, progression, and therapeutics	ONCOGENE			English	Review							TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; SUPPRESSOR-CELLS; DENDRITIC CELLS; BRAIN-TUMORS; GLIOMA MICROENVIRONMENT; SURVIVAL ADVANTAGE; RESIDENT MICROGLIA; LYMPHOCYTE RATIO; DOWN-REGULATION	Glioblastoma (GBM) is the most common and malignant type of intracranial tumors with poor prognosis. Accumulating evidence suggests that phenotypic alterations of infiltrating myeloid cells in the tumor microenvironment are important for GBM progression. Conventional tumor immunotherapy commonly targets T-cells, while innate immunity as a therapeutic target is an emerging field. Targeting infiltrating myeloid cells that induce immune suppression in the TME provides a novel direction to improve the prognosis of patients with GBM. The factors released by tumor cells recruit myeloid cells into tumor bed and reprogram infiltrating myeloid cells into immunostimulatory/immunosuppressive phenotypes. Reciprocally, infiltrating myeloid cells, especially microglia/macrophages, regulate GBM progression and affect therapeutic efficacy. Herein, we revisited biological characteristics and functions of infiltrating myeloid cells and discussed the recent advances in immunotherapies targeting infiltrating myeloid cells in GBM. With an evolving understanding of the complex interactions between infiltrating myeloid cells and tumor cells in the tumor microenvironment, we will expand novel immunotherapeutic regimens targeting infiltrating myeloid cells in GBM treatment and improve the outcomes of GBM patients.	[Ye, Zengpanpan; Ai, Xiaolin; Wang, Ping; Zhou, Shengtao] Sichuan Univ, West China Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol,Minist Educ, Chengdu, Peoples R China; [Ye, Zengpanpan; Ai, Xiaolin; Wang, Ping; Zhou, Shengtao] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China; [Zhao, Linjie] Univ Calif San Diego, Dept Med, Div Regenerat Med, La Jolla, CA 92103 USA; [Fei, Fan] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Neurosurg, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China; [Fei, Fan] Univ Elect Sci & Technol China, Sch Med, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China	Sichuan University; Sichuan University; University of California System; University of California San Diego; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Wang, P; Zhou, ST (corresponding author), Sichuan Univ, West China Hosp 2, Key Lab Birth Defects & Related Dis Women & Child, Dept Obstet & Gynecol,Minist Educ, Chengdu, Peoples R China.; Wang, P; Zhou, ST (corresponding author), Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China.; Fei, F (corresponding author), Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Dept Neurosurg, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China.; Fei, F (corresponding author), Univ Elect Sci & Technol China, Sch Med, 32 West Second Sect,First Ring Rd, Chengdu 610072, Sichuan, Peoples R China.	917597029@qq.com; wangping_886@126.com; taotaovip2005@163.com		Zhou, Shengtao/0000-0001-8322-5536; Fei, Fan/0000-0003-4437-3186	National Natural Science Foundation of China [81822034, 81821002]; National Key Research and Development Program of China [2017YFA0106800, 2018YFA0109200]; Sichuan Science-Technology International Cooperation Project [2019YFH0144]; Sichuan Science-Technology Key Research and Development Program [2021YFS0015]; West China Second Hospital, Sichuan University [KS021, K1907]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Sichuan Science-Technology International Cooperation Project; Sichuan Science-Technology Key Research and Development Program; West China Second Hospital, Sichuan University	This work was supported by grants from National Natural Science Foundation of China (grant # 81822034 and grant # 81821002), National Key Research and Development Program of China (2017YFA0106800 and 2018YFA0109200), Sichuan Science-Technology International Cooperation Project (grant #2019YFH0144), Sichuan Science-Technology Key Research and Development Program (grant #2021YFS0015), Direct Scientific Research Grants from West China Second Hospital, Sichuan University (grant #KS021 and #K1907).	Adrover JM, 2016, TRENDS IMMUNOL, V37, P334, DOI 10.1016/j.it.2016.03.005; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Akasaki Y, 2004, J IMMUNOL, V173, P4352, DOI 10.4049/jimmunol.173.7.4352; Alban TJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01191; Alban TJ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122264; Albulescu R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/979748; Alfaro C, 2016, CLIN CANCER RES, V22, P3924, DOI 10.1158/1078-0432.CCR-15-2463; An ZY, 2018, CANCER RES, V78, P6785, DOI 10.1158/0008-5472.CAN-17-3551; Antunes ARP, 2020, ELIFE, V9, DOI 10.7554/eLife.52176; Aslan K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14642-0; Aspord C, 2013, CANCER IMMUNOL RES, V1, P402, DOI 10.1158/2326-6066.CIR-13-0114-T; Bah I, 2018, CELL IMMUNOL, V332, P32, DOI 10.1016/j.cellimm.2018.07.003; Bambury RM, 2013, J NEURO-ONCOL, V114, P149, DOI 10.1007/s11060-013-1164-9; Batich KA, 2017, CLIN CANCER RES, V23, P1898, DOI 10.1158/1078-0432.CCR-16-2057; Bayik D, 2020, CANCER DISCOV, V10, P1210, DOI 10.1158/2159-8290.CD-19-1355; Bertaut A, 2016, ONCOTARGET, V7, P70948, DOI 10.18632/oncotarget.10898; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Brandenburg S, 2016, ACTA NEUROPATHOL, V131, P365, DOI 10.1007/s00401-015-1529-6; Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245; da Fonseca ACC, 2014, J NEUROIMMUNOL, V274, P71, DOI 10.1016/j.jneuroim.2014.06.021; Castro BA, 2017, ONCOGENE, V36, P3749, DOI 10.1038/onc.2017.1; Chabot V, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0848-2; Chae M, 2015, NEURO-ONCOLOGY, V17, P978, DOI 10.1093/neuonc/nou343; Chai EQ, 2019, CANCER MANAG RES, V11, P7307, DOI 10.2147/CMAR.S210545; Chang AL, 2016, CANCER RES, V76, P5671, DOI 10.1158/0008-5472.CAN-16-0144; Chen PW, 2019, CANCER CELL, V35, P868, DOI 10.1016/j.ccell.2019.05.003; Chen XB, 2014, CANCER RES, V74, P7285, DOI 10.1158/0008-5472.CAN-14-1240; Chen ZH, 2019, P NATL ACAD SCI USA, V116, P14254, DOI 10.1073/pnas.1902366116; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Chio CC, 2001, BRIT J CANCER, V85, P1185, DOI 10.1054/bjoc.2001.2055; Cho HR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47438-4; Chonan M, 2015, NEURO-ONCOLOGY, V17, P1453, DOI 10.1093/neuonc/nov090; Cimino PJ, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0443-7; Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Delwar ZM, 2018, CANCER RES, V78, P718, DOI 10.1158/0008-5472.CAN-17-0599; Dey M, 2015, J IMMUNOL, V195, P367, DOI 10.4049/jimmunol.1401607; Dubinski D, 2016, NEURO-ONCOLOGY, V18, P807, DOI 10.1093/neuonc/nov280; Dumitru CA, 2013, SEMIN CANCER BIOL, V23, P141, DOI 10.1016/j.semcancer.2013.02.005; Fan YF, 2008, J CEREBR BLOOD F MET, V28, P90, DOI 10.1038/sj.jcbfm.9600509; Fiore A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07654-4; Friebel E, 2020, CELL, V181, P1626, DOI 10.1016/j.cell.2020.04.055; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gabrusiewicz K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85841; Galani V, 2017, J INTERF CYTOK RES, V37, P139, DOI 10.1089/jir.2016.0094; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Ghoochani A, 2016, ONCOGENE, V35, P6246, DOI 10.1038/onc.2016.160; Gielen PR, 2016, NEURO-ONCOLOGY, V18, P1253, DOI 10.1093/neuonc/now034; Ginhoux F, 2016, IMMUNITY, V44, P439, DOI 10.1016/j.immuni.2016.02.024; Gousias K, 2013, J NEUROIMMUNOL, V264, P84, DOI 10.1016/j.jneuroim.2013.09.001; Guneykaya D, 2018, CELL REP, V24, P2773, DOI 10.1016/j.celrep.2018.08.001; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; Hanamsagar R, 2017, GLIA, V65, P1504, DOI 10.1002/glia.23176; Hu CE, 2011, SCAND J GASTROENTERO, V46, P156, DOI 10.3109/00365521.2010.516450; Hu JM, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abc2511; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Huang YJ, 2017, J CLIN INVEST, V127, P1826, DOI 10.1172/JCI86443; Inoges S, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1202-z; Jego G, 2003, IMMUNITY, V19, P225, DOI 10.1016/S1074-7613(03)00208-5; Jung Y, 2018, CELL PHYSIOL BIOCHEM, V48, P1332, DOI 10.1159/000492092; Kamran N, 2018, CLIN IMMUNOL, V189, P34, DOI 10.1016/j.clim.2016.10.008; Kamran N, 2017, MOL THER, V25, P232, DOI 10.1016/j.ymthe.2016.10.003; Kees T, 2012, NEURO-ONCOLOGY, V14, P64, DOI 10.1093/neuonc/nor182; Klemm F, 2020, CELL, V181, P1643, DOI 10.1016/j.cell.2020.05.007; Kloepper J, 2016, P NATL ACAD SCI USA, V113, P4476, DOI 10.1073/pnas.1525360113; Kodama L, 2019, TRENDS MOL MED, V25, P741, DOI 10.1016/j.molmed.2019.05.001; Kwon HS, 2020, TRANSL NEURODEGENER, V9, DOI 10.1186/s40035-020-00221-2; Lamano JB, 2019, CLIN CANCER RES, V25, P3643, DOI 10.1158/1078-0432.CCR-18-2402; Laoui D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13720; Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5; Lee-Chang C, 2019, CANCER IMMUNOL RES, V7, P1928, DOI 10.1158/2326-6066.CIR-19-0240; Lehrer S, 2019, CLIN NEUROL NEUROSUR, V177, P63, DOI 10.1016/j.clineuro.2018.12.021; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Liang H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15015; Liang J, 2014, CLIN CANCER RES, V20, P187, DOI 10.1158/1078-0432.CCR-13-1279; Liau LM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1507-6; Liau LM., 2000, NEUROSURG FOCUS, V9, P8; Lin H, 2018, J CLIN INVEST, V128, P1708, DOI 10.1172/JCI120803; Liu CY, 2010, J CANCER RES CLIN, V136, P35, DOI 10.1007/s00432-009-0634-0; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Manda-Handzlik A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121477; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mao YM, 2014, CLIN CANCER RES, V20, P4096, DOI 10.1158/1078-0432.CCR-14-0635; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Mason M, 2017, J NEURO-ONCOL, V132, P463, DOI 10.1007/s11060-017-2395-y; Massara M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01349; Mattila S, 2009, NEUROPATHOLOGY, V29, P156, DOI 10.1111/j.1440-1789.2008.00963.x; Megjugorac NJ, 2004, J LEUKOCYTE BIOL, V75, P504, DOI 10.1189/jlb.0603291; Meng XQ, 2019, EBIOMEDICINE, V41, P185, DOI 10.1016/j.ebiom.2019.01.067; Mitchell DA, 2015, NATURE, V519, P366, DOI 10.1038/nature14320; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Muraoka D, 2019, J CLIN INVEST, V129, P1278, DOI 10.1172/JCI97642; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Osterberg N, 2016, NEURO-ONCOLOGY, V18, P939, DOI 10.1093/neuonc/now005; Ott M, 2020, CLIN CANCER RES, V26, P4983, DOI 10.1158/1078-0432.CCR-19-4092; Otvos B, 2016, STEM CELLS, V34, P2026, DOI 10.1002/stem.2393; Pallotta MT, 2011, NAT IMMUNOL, V12, P870, DOI 10.1038/ni.2077; Park JE, 2019, ONCOGENE, V38, P5158, DOI 10.1038/s41388-019-0782-x; Peereboom DM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130748; Pinton L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0536-x; Polajeva J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025222; Poli A, 2013, ONCOTARGET, V4, P1527, DOI 10.18632/oncotarget.1291; Poon CC, 2017, BRAIN, V140, P1548, DOI 10.1093/brain/aww355; Powell DR, 2016, TRENDS IMMUNOL, V37, P41, DOI 10.1016/j.it.2015.11.008; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian MY, 2020, ONCOGENE, V39, P428, DOI 10.1038/s41388-019-0996-y; Raber PL, 2014, INT J CANCER, V134, P2853, DOI 10.1002/ijc.28622; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Raychaudhuri B, 2015, J NEURO-ONCOL, V122, P293, DOI 10.1007/s11060-015-1720-6; Raychaudhuri B, 2011, NEURO-ONCOLOGY, V13, P591, DOI 10.1093/neuonc/nor042; Reap EA, 2018, CANCER RES, V78, P256, DOI 10.1158/0008-5472.CAN-17-0469; Ribechini E, 2017, BLOOD ADV, V1, P947, DOI 10.1182/bloodadvances.2017006858; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rodriguez PC, 2004, CANCER RES, V64, P5839, DOI 10.1158/0008-5472.CAN-04-0465; Roesch S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020436; Roy A, 2015, ONCOTARGET, V6, P23647, DOI 10.18632/oncotarget.4640; Sade-Feldman M, 2013, IMMUNITY, V38, P541, DOI 10.1016/j.immuni.2013.02.007; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Schernberg A, 2018, CLIN TRANSL RAD ONCO, V10, P47, DOI 10.1016/j.ctro.2018.04.002; Scholz A, 2016, EMBO MOL MED, V8, P39, DOI 10.15252/emmm.201505505; Schwarz JM, 2012, J NEUROCHEM, V120, P948, DOI 10.1111/j.1471-4159.2011.07630.x; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Shoji T, 2016, NEURO-ONCOLOGY, V18, P1120, DOI 10.1093/neuonc/now023; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Sippel TR, 2011, CLIN CANCER RES, V17, P6992, DOI 10.1158/1078-0432.CCR-11-1107; Soderberg SS, 2009, ANN NY ACAD SCI, V1176, P55, DOI 10.1111/j.1749-6632.2009.04569.x; Song LH, 2019, J CELL BIOCHEM, V120, P19518, DOI 10.1002/jcb.29259; Sorensen MD, 2018, NEUROPATH APPL NEURO, V44, P185, DOI 10.1111/nan.12428; Spiller KL, 2014, BIOMATERIALS, V35, P4477, DOI 10.1016/j.biomaterials.2014.02.012; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Takeda A, 2018, GLIA, V66, P2366, DOI 10.1002/glia.23475; Takenaka MC, 2019, NAT NEUROSCI, V22, P729, DOI 10.1038/s41593-019-0370-y; Tan AC, 2020, CA-CANCER J CLIN, V70, P299, DOI 10.3322/caac.21613; Tao WW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16827-z; Tel J, 2014, TRENDS IMMUNOL, V35, P38, DOI 10.1016/j.it.2013.10.007; Thaci B, 2014, CANCER GENE THER, V21, P38, DOI 10.1038/cgt.2013.81; Thion MS, 2018, CELL, V172, P500, DOI 10.1016/j.cell.2017.11.042; Thomas RP, 2019, CLIN CANCER RES, V25, P6948, DOI 10.1158/1078-0432.CCR-19-1421; Tomaszewski W, 2019, CLIN CANCER RES, V25, P4202, DOI 10.1158/1078-0432.CCR-18-1627; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ugolini A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138581; Vakilian A, 2017, NEUROCHEM INT, V103, P1, DOI 10.1016/j.neuint.2016.12.013; Van Acker HH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00658; Villa A, 2018, CELL REP, V23, P3501, DOI 10.1016/j.celrep.2018.05.048; Wainwright DA, 2012, CLIN CANCER RES, V18, P6110, DOI 10.1158/1078-0432.CCR-12-2130; Wang JL, 2017, EXP CELL RES, V360, P66, DOI 10.1016/j.yexcr.2017.07.031; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Wang QR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03050-0; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Wang ZL, 2019, CNS NEUROSCI THER, V25, P876, DOI 10.1111/cns.13120; Wei J, 2019, J CLIN INVEST, V129, P137, DOI 10.1172/JCI121266; Wen PY, 2019, CLIN CANCER RES, V25, P5799, DOI 10.1158/1078-0432.CCR-19-0261; Wildes TJ, 2018, CLIN CANCER RES, V24, P3955, DOI 10.1158/1078-0432.CCR-17-3061; Wu J, 2018, NEURO-ONCOLOGY, V20, P92, DOI 10.1093/neuonc/nox111; WU M, 2018, NAT COMMUN, V9; Xue JW, 2017, NAT NANOTECHNOL, V12, P692, DOI [10.1038/nnano.2017.54, 10.1038/NNANO.2017.54]; Yan J, 2021, CANCER LETT, V506, P83, DOI 10.1016/j.canlet.2021.02.021; Yan J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08770-5; Yee PP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19193-y; Yin JL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16789-2; Zeiner PS, 2019, BRAIN PATHOL, V29, P513, DOI 10.1111/bpa.12690; Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367; Zhang J, 2012, CARCINOGENESIS, V33, P312, DOI 10.1093/carcin/bgr289; Zhang P, 2019, P NATL ACAD SCI USA, V116, P23714, DOI 10.1073/pnas.1906346116; Zhang YJ, 2018, MOL CELL, V71, P201, DOI 10.1016/j.molcel.2018.06.023; Zhang ZP, 2020, CANCER IMMUNOL RES, V8, P966, DOI 10.1158/2326-6066.CIR-19-0759; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhu C, 2017, ONCOGENE, V36, P5356, DOI 10.1038/onc.2017.145	177	5	5	4	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6059	6070		10.1038/s41388-021-02010-1	http://dx.doi.org/10.1038/s41388-021-02010-1		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34556813				2022-12-17	WOS:000698556400001
J	Komura, K; Inamoto, T; Tsujino, T; Matsui, Y; Konuma, T; Nishimura, K; Uchimoto, T; Tsutsumi, T; Matsunaga, T; Maenosono, R; Yoshikawa, Y; Taniguchi, K; Tanaka, T; Uehara, H; Hirata, K; Hirano, H; Nomi, H; Hirose, Y; Ono, F; Azuma, H				Komura, Kazumasa; Inamoto, Teruo; Tsujino, Takuya; Matsui, Yusuke; Konuma, Tsuyoshi; Nishimura, Kazuki; Uchimoto, Taizo; Tsutsumi, Takeshi; Matsunaga, Tomohisa; Maenosono, Ryoichi; Yoshikawa, Yuki; Taniguchi, Kohei; Tanaka, Tomohito; Uehara, Hirofumi; Hirata, Koichi; Hirano, Hajime; Nomi, Hayahito; Hirose, Yoshinobu; Ono, Fumihito; Azuma, Haruhito			Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents	ONCOGENE			English	Article							FOXM1/BUB1B SIGNALING PATHWAY; CELL-LINE; BUBR1; ATM; BLADDER; TRANSCRIPTION; INHIBITOR; PLATFORM; REGIONS; APC/C	There has been accumulating evidence for the clinical benefit of chemoradiation therapy (CRT), whereas mechanisms in CRT-recurrent clones derived from the primary tumor are still elusive. Herein, we identified an aberrant BUB1B/BUBR1 expression in CRT-recurrent clones in bladder cancer (BC) by comprehensive proteomic analysis. CRT-recurrent BC cells exhibited a cell-cycle-independent upregulation of BUB1B/BUBR1 expression rendering an enhanced DNA repair activity in response to DNA double-strand breaks (DSBs). With DNA repair analyses employing the CRISPR/cas9 system, we revealed that cells with aberrant BUB1B/BUBR1 expression dominantly exploit mutagenic nonhomologous end joining (NHEJ). We further found that phosphorylated ATM interacts with BUB1B/BUBR1 after ionizing radiation (IR) treatment, and the resistance to DSBs by increased BUB1B/BUBR1 depends on the functional ATM. In vivo, tumor growth of CRT-resistant T24R cells was abrogated by ATM inhibition using AZD0156. A dataset analysis identified FOXM1 as a putative BUB1B/BUBR1-targeting transcription factor causing its increased expression. These data collectively suggest a redundant role of BUB1B/BUBR1 underlying mutagenic NHEJ in an ATM-dependent manner, aside from the canonical activity of BUB1B/BUBR1 on the G2/M checkpoint, and offer novel clues to overcome CRT resistance.	[Komura, Kazumasa; Inamoto, Teruo; Nishimura, Kazuki; Uchimoto, Taizo; Matsunaga, Tomohisa; Maenosono, Ryoichi; Yoshikawa, Yuki; Uehara, Hirofumi; Hirano, Hajime; Nomi, Hayahito; Azuma, Haruhito] Osaka Med & Pharmaceut Univ, Dept Urol, Osaka 5698686, Japan; [Komura, Kazumasa; Taniguchi, Kohei; Tanaka, Tomohito; Ono, Fumihito] Osaka Med & Pharmaceut Univ, Translat Res Program, Osaka 5698686, Japan; [Tsujino, Takuya; Tsutsumi, Takeshi] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Div Urol, Boston, MA 02115 USA; [Matsui, Yusuke] Nagoya Univ, Dept Integrated Hlth Sci, Biomed & Hlth Informat Unit, Grad Sch Med, Nagoya, Aichi 4618673, Japan; [Matsui, Yusuke] Nagoya Univ, Inst Glycocore Res iGCORE, Nagoya, Aichi 4618673, Japan; [Konuma, Tsuyoshi] Yokohama City Univ, Grad Sch Med Life Sci, Yokohama, Kanagawa 2300045, Japan; [Hirata, Koichi; Hirose, Yoshinobu] Osaka Med & Pharmaceut Univ, Dept Pathol, Osaka 5698686, Japan; [Ono, Fumihito] Osaka Med & Pharmaceut Univ, Dept Physiol, Osaka 5698686, Japan	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Nagoya University; Nagoya University; Yokohama City University	Komura, K (corresponding author), Osaka Med & Pharmaceut Univ, Dept Urol, Osaka 5698686, Japan.; Komura, K (corresponding author), Osaka Med & Pharmaceut Univ, Translat Res Program, Osaka 5698686, Japan.	kazumasa.komura@ompu.ac.jp	Hirose, Yoshinobu/AAW-9079-2020	Hirose, Yoshinobu/0000-0002-3860-0293; Nishimura, Kazuki/0000-0002-2878-7664; Konuma, Tsuyoshi/0000-0002-4412-2849	Japan Society for the Promotion of Science: JSPS [21H03070, 19K18624, 17K16821, 16K11033, 16K11034]; Uehara Memorial Foundation; NOVARTIS Foundation (Japan) for the Promotion of Science; Japan Research Foundation for Clinical Pharmacology; Yamaguchi Endocrine Disease Research Foundation; Takeda Science Foundation; Young Research Grant of Japanese Urological Association (JUA)	Japan Society for the Promotion of Science: JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Uehara Memorial Foundation(Uehara Memorial Foundation); NOVARTIS Foundation (Japan) for the Promotion of Science(Novartis); Japan Research Foundation for Clinical Pharmacology; Yamaguchi Endocrine Disease Research Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); Young Research Grant of Japanese Urological Association (JUA)	This work was partially supported by the Grant-in-Aid No. 21H03070, 19K18624, 17K16821, 16K11033, and 16K11034 (Japan Society for the Promotion of Science: JSPS), the Uehara Memorial Foundation, the NOVARTIS Foundation (Japan) for the Promotion of Science, Japan Research Foundation for Clinical Pharmacology, Yamaguchi Endocrine Disease Research Foundation, the Takeda Science Foundation, and Young Research Grant of Japanese Urological Association (JUA).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Balmus G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07729-2; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bergom C, 2019, INT J RADIAT ONCOL, V105, P698, DOI 10.1016/j.ijrobp.2019.07.026; Betermier M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004086; Bolanos-Garcia VM, 2011, TRENDS BIOCHEM SCI, V36, P141, DOI 10.1016/j.tibs.2010.08.004; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chai N, 2018, BIOCHEM BIOPH RES CO, V500, P924, DOI 10.1016/j.bbrc.2018.04.201; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Chao WCH, 2012, NATURE, V484, P208, DOI 10.1038/nature10896; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; Degorce SL, 2016, J MED CHEM, V59, P6281, DOI 10.1021/acs.jmedchem.6b00519; DINNEY CPN, 1995, J UROLOGY, V154, P1532, DOI 10.1016/S0022-5347(01)66923-4; Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620; Fang Y, 2006, ONCOGENE, V25, P3598, DOI 10.1038/sj.onc.1209392; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037; Guo T, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1518-x; Jette NR, 2019, BRIT J CANCER, V121, P600, DOI 10.1038/s41416-019-0565-8; Kapanidou M, 2015, TRENDS MOL MED, V21, P364, DOI 10.1016/j.molmed.2015.04.003; Karess RE, 2013, INT REV CEL MOL BIO, V306, P223, DOI 10.1016/B978-0-12-407694-5.00006-7; Kato-Inui T, 2018, NUCLEIC ACIDS RES, V46, P4677, DOI 10.1093/nar/gky264; Kirmitzoglou I, 2015, BIOINFORMATICS, V31, P2208, DOI 10.1093/bioinformatics/btv115; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lara-Gonzalez P, 2011, J CELL SCI, V124, P4332, DOI 10.1242/jcs.094763; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977; Ma Q, 2017, ONCOL REP, V38, P3367, DOI 10.3892/or.2017.6032; Mcree AJ, 2011, FUTURE ONCOL, V7, P409, DOI [10.2217/FON.11.7, 10.2217/fon.11.7]; Miyaoka Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep23549; MORITA T, 1995, UROL RES, V23, P143, DOI 10.1007/BF00389565; Myslinski E, 2007, NUCLEIC ACIDS RES, V35, P3453, DOI 10.1093/nar/gkm239; Randon G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39525-3; Riches LC, 2020, MOL CANCER THER, V19, P13, DOI 10.1158/1535-7163.MCT-18-1394; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sanders DA, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0696-z; Sanders DA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-1-r6; Shen MJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1161-8; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Thompson R, 2015, MOL CELL, V58, P767, DOI 10.1016/j.molcel.2015.03.034; Traven A, 2005, BIOESSAYS, V27, P397, DOI 10.1002/bies.20204; Wan XL, 2012, CANCER RES, V72, P5889, DOI 10.1158/0008-5472.CAN-12-1991; Wang C, 2017, TRANSL ONCOL, V10, P190, DOI 10.1016/j.tranon.2017.01.007; Weston VJ, 2010, BLOOD, V116, P4578, DOI 10.1182/blood-2010-01-265769; Zuiverloon TCM, 2018, BLADDER CANCER, V4, P169, DOI 10.3233/BLC-180167	51	5	5	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2021	40	43					6210	6222		10.1038/s41388-021-02021-y	http://dx.doi.org/10.1038/s41388-021-02021-y		SEP 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WO5HW	34545188	hybrid, Green Published			2022-12-17	WOS:000698130400002
J	Dewaele, S; Delhaye, L; De Paepe, B; de Bony, EJ; De Wilde, J; Vanderheyden, K; Anckaert, J; Yigit, N; Nuytens, J; Vanden Eynde, E; Smet, J; Verschoore, M; Nemati, F; Decaudin, D; Rodrigues, M; Zhao, PH; Jochemsen, A; Leucci, E; Vandesompele, J; Van Dorpe, J; Marine, JC; Van Coster, R; Eyckerman, S; Mestdagh, P				Dewaele, Shanna; Delhaye, Louis; De Paepe, Boel; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Smet, Joel; Verschoore, Maxime; Nemati, Fariba; Decaudin, Didier; Rodrigues, Manuel; Zhao, Peihua; Jochemsen, Aart; Leucci, Eleonora; Vandesompele, Jo; Van Dorpe, Jo; Marine, Jean-Christophe; Van Coster, Rudy; Eyckerman, Sven; Mestdagh, Pieter			The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival	ONCOGENE			English	Article							ESTABLISHMENT; GLYCYLCYCLINE; TIGECYCLINE; KI-67	Long non-coding RNAs (lncRNAs) can exhibit cell-type and cancer-type specific expression profiles, making them highly attractive as therapeutic targets. Pan-cancer RNA sequencing data revealed broad expression of the SAMMSON lncRNA in uveal melanoma (UM), the most common primary intraocular malignancy in adults. Currently, there are no effective treatments for UM patients with metastatic disease, resulting in a median survival time of 6-12 months. We aimed to investigate the therapeutic potential of SAMMSON inhibition in UM. Antisense oligonucleotide (ASO)-mediated SAMMSON inhibition impaired the growth and viability of a genetically diverse panel of uveal melanoma cell lines. These effects were accompanied by an induction of apoptosis and were recapitulated in two uveal melanoma patient derived xenograft (PDX) models through subcutaneous ASO delivery. SAMMSON pulldown revealed several candidate interaction partners, including various proteins involved in mitochondrial translation. Consequently, inhibition of SAMMSON impaired global, mitochondrial and cytosolic protein translation levels and mitochondrial function in uveal melanoma cells. The present study demonstrates that SAMMSON expression is essential for uveal melanoma cell survival. ASO-mediated silencing of SAMMSON may provide an effective treatment strategy to treat primary and metastatic uveal melanoma patients.	[Dewaele, Shanna; Delhaye, Louis; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Vandesompele, Jo; Mestdagh, Pieter] Univ Ghent, Ctr Med Genet CMGG, OncoRNALab, Ghent, Belgium; [Dewaele, Shanna; Delhaye, Louis; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Vandesompele, Jo; Van Dorpe, Jo; Eyckerman, Sven; Mestdagh, Pieter] Canc Res Inst Ghent CRIG, Ghent, Belgium; [Dewaele, Shanna; Delhaye, Louis; de Bony, Eric James; De Wilde, Jilke; Vanderheyden, Katrien; Anckaert, Jasper; Yigit, Nurten; Nuytens, Justine; Vanden Eynde, Eveline; Vandesompele, Jo; Eyckerman, Sven; Mestdagh, Pieter] Univ Ghent, Dept Biomol Med, Ghent, Belgium; [Delhaye, Louis; Eyckerman, Sven] VIB Ghent Univ, Ctr Med Biotechnol, Ghent, Belgium; [De Paepe, Boel; Smet, Joel; Verschoore, Maxime; Van Coster, Rudy] Ghent Univ Hosp, Dept Pediat, Div Pediat Neurol & Metab, Ghent, Belgium; [De Wilde, Jilke; Van Dorpe, Jo] Ghent Univ Hosp, Dept Pathol, Ghent, Belgium; [Nemati, Fariba; Decaudin, Didier] PSL Res Univ, Inst Curie, Lab Preclin Invest, Translat Res Dept, Paris, France; [Decaudin, Didier; Rodrigues, Manuel] PSL Res Univ, Inst Curie, Dept Med Oncol, Paris, France; [Rodrigues, Manuel] PSL Res Univ, Inserm U830, DNA Repair & Uveal Melanoma DRUM, Equipe Labellisee Ligue Natl Canc,Inst Curie, F-75005 Paris, France; [Zhao, Peihua] VIB KU Leuven Ctr Canc Biol, Ctr Med Biotechnol, Leuven, Belgium; [Zhao, Peihua; Leucci, Eleonora; Marine, Jean-Christophe] Katholieke Univ Leuven, Lab RNA Canc Biol, Dept Oncol, Leuven, Belgium; [Jochemsen, Aart] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, Leiden, Netherlands; [Leucci, Eleonora] LKI Leuven Canc Inst, TRACE, Leuven, Belgium	Ghent University; Ghent University; Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Flanders Institute for Biotechnology (VIB); KU Leuven; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Mestdagh, P (corresponding author), Univ Ghent, Ctr Med Genet CMGG, OncoRNALab, Ghent, Belgium.; Mestdagh, P (corresponding author), Canc Res Inst Ghent CRIG, Ghent, Belgium.; Mestdagh, P (corresponding author), Univ Ghent, Dept Biomol Med, Ghent, Belgium.	pieter.mestdagh@ugent.be	Leucci, Eleonora/G-4938-2011; Vandesompele, Jo/W-3411-2018; Rodrigues, Manuel/C-8506-2018; Marine, Jean-Christophe/K-3292-2016; De Paepe, Boel/B-7548-2013	Leucci, Eleonora/0000-0002-2898-748X; Vandesompele, Jo/0000-0001-6274-0184; Rodrigues, Manuel/0000-0002-5443-0802; Nuytens, Justine/0000-0002-4878-1200; De Wilde, Jilke/0000-0003-0392-7162; Delhaye, Louis/0000-0001-8876-7385; Vanden Eynde, Eveline/0000-0003-0454-4171; ANCKAERT, JASPER/0000-0001-8144-4639; Mestdagh, Pieter/0000-0001-7821-9684; de Bony, Eric James/0000-0002-1289-7199; Dewaele, Shanna/0000-0002-2219-8930; Marine, Jean-Christophe/0000-0003-2433-9837; De Paepe, Boel/0000-0001-9403-4401; Yigit, Nurten/0000-0003-1183-8688	Foundation Against Cancer grant (Stichting tegen Kanker); Standup Against Cancer grant (Kom op tegen Kanker); Ghent University Industrial Research Fund (IOF); Ghent University GOA research grant; Fund for Scientific Research Flanders (FWO Vlaanderen); Melanoma Research Alliance (MRA) Amanda; Jonathan Eilian young investigator award; Fund of Scientific Research Flanders (FWO Vlaanderen)	Foundation Against Cancer grant (Stichting tegen Kanker); Standup Against Cancer grant (Kom op tegen Kanker); Ghent University Industrial Research Fund (IOF); Ghent University GOA research grant; Fund for Scientific Research Flanders (FWO Vlaanderen)(FWO); Melanoma Research Alliance (MRA) Amanda; Jonathan Eilian young investigator award; Fund of Scientific Research Flanders (FWO Vlaanderen)(FWO)	We would like to thank the VIB proteomics core for performing LC-MS/MS analysis and Prof. Olivier De Wever for providing the CT5.3hTERT cell line. The authors would also like to thank the Animal PlatformCRP2-UMS 3612 CNRS-US25 Inserm-IRD (Faculty of Pharmacy, Paris University, Paris), and the Animal Platform of Institut Curie. They also thank Justine Fleury for her technical assistance (Laboratory of preclinical Investigation, Institut Curie). This work was supported by a Foundation Against Cancer grant (Stichting tegen Kanker), a Standup Against Cancer grant (Kom op tegen Kanker), a Ghent University Industrial Research Fund (IOF), a Ghent University GOA research grant and Fund for Scientific Research Flanders (FWO Vlaanderen). EL is the recipient of the Melanoma Research Alliance (MRA) Amanda and Jonathan Eilian young investigator award. SD, LD and JDW are recipients of a grant from the Fund of Scientific Research Flanders (FWO Vlaanderen).	Amirouchene-Angelozzi N, 2014, MOL ONCOL, V8, P1508, DOI 10.1016/j.molonc.2014.06.004; Bakalian S, 2008, CLIN CANCER RES, V14, P951, DOI 10.1158/1078-0432.CCR-06-2630; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Cheng Z, 2019, NUCLEIC ACIDS RES, V47, P5061, DOI 10.1093/nar/gkz231; Coyne LP, 2018, FEBS LETT, V592, P759, DOI 10.1002/1873-3468.12894; De Paepe B, 2012, PEDIATR RES, V72, P232, DOI 10.1038/pr.2012.84; DEWAARDSIEBINGA I, 1995, INT J CANCER, V62, P155, DOI 10.1002/ijc.2910620208; Doan TL, 2006, CLIN THER, V28, P1079, DOI 10.1016/j.clinthera.2006.08.011; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Helgadottir H, 2016, APPL CLIN GENET, V9, P147, DOI 10.2147/TACG.S69210; Hong D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5272; Khan MS, 2013, BRIT J CANCER, V108, P1838, DOI 10.1038/bjc.2013.156; Koripella RK, 2019, P NATL ACAD SCI USA, V116, P8283, DOI 10.1073/pnas.1815675116; Krantz BA, 2017, CLIN OPHTHALMOL, V11, P279, DOI 10.2147/OPTH.S89591; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Li XP, 2017, ONCOTARGET, V8, P103785, DOI 10.18632/oncotarget.21792; Lindahl L, 2020, BIORXIV2020202010153; Luyten GPM, 1996, INT J CANCER, V66, P380, DOI 10.1002/(SICI)1097-0215(19960503)66:3<380::AID-IJC19>3.0.CO;2-F; Matatall KA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-371; MOOY CM, 1990, OPHTHALMOLOGY, V97, P1275; Nareyeck G, 2005, EXP EYE RES, V81, P361, DOI 10.1016/j.exer.2005.04.018; Ni HZ, 2021, CELL MOL NEUROBIOL, V41, P79, DOI 10.1007/s10571-020-00833-2; Nicholas D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170975; Noskin GA, 2005, CLIN INFECT DIS, V41, pS303, DOI 10.1086/431672; OBRIEN TW, 1990, BIOCHIM BIOPHYS ACTA, V1050, P174, DOI 10.1016/0167-4781(90)90162-U; Papastefanou VP, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/573974; Park JJ, 2018, PIGM CELL MELANOMA R, V31, P661, DOI 10.1111/pcmr.12708; Richards JR, 2020, PIGM CELL MELANOMA R, V33, P264, DOI 10.1111/pcmr.12853; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Rodrigues M, 2020, JAMA OPHTHALMOL, V138, P182, DOI 10.1001/jamaophthalmol.2019.5403; Rodriguez A, 2016, MOL CLIN ONCOL, V5, P675, DOI 10.3892/mco.2016.1037; Roger AJ, 2017, CURR BIOL, V27, pR1177, DOI 10.1016/j.cub.2017.09.015; Rossi L, 2015, BRIT J CANCER, V113, P996, DOI 10.1038/bjc.2015.239; Saw PE, 2020, SCI CHINA LIFE SCI, V63, P485, DOI 10.1007/s11427-018-9438-y; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Shao L, 2020, IUBMB LIFE, V72, P237, DOI 10.1002/iub.2158; Sharma A, 2018, CLIN GENET, V93, P952, DOI 10.1111/cge.13136; Sugase T, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02377-x; Van Maerken T, 2009, JNCI-J NATL CANCER I, V101, P1562, DOI 10.1093/jnci/djp355; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Vendramin R, 2018, NAT STRUCT MOL BIOL, V25, P1035, DOI 10.1038/s41594-018-0143-4; Verma, 2018, ASTROCYTE, V5, P81, DOI [10.4103/astrocyte.astrocyte_55_18, DOI 10.4103/ASTROCYTE.ASTROCYTE_55_18]; Wang A, 2016, J CLIN PATHOL, V69, P750, DOI 10.1136/jclinpath-2016-203866; Wang YH, 2019, CLIN EXP PHARMACOL P, V46, P890, DOI 10.1111/1440-1681.13126; Xie JW, 2019, NEUROREPORT, V30, P817, DOI 10.1097/WNR.0000000000001278; Yang H, 2008, MELANOMA RES, V18, P95, DOI 10.1097/CMR.0b013e3282f628df; Yang SZ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190615; Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2; Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014	49	5	5	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2022	41	1					15	25		10.1038/s41388-021-02006-x	http://dx.doi.org/10.1038/s41388-021-02006-x		SEP 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA0OI	34508176	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000694774500001
J	Tan, P; Wang, ML; Zhong, AL; Wang, YY; Du, JJ; Wang, J; Qi, L; Bi, ZY; Zhang, P; Lin, TH; Zhang, JP; Yang, L; Chen, JY; Han, P; Gong, QY; Liu, Y; Chen, C; Wei, Q				Tan, Ping; Wang, Manli; Zhong, Ailing; Wang, Yiyun; Du, Jiajia; Wang, Jian; Qi, Lu; Bi, Zhanying; Zhang, Peng; Lin, Tianhai; Zhang, Jiapeng; Yang, Lu; Chen, Jingyao; Han, Ping; Gong, Qiyong; Liu, Yu; Chen, Chong; Wei, Qiang			SRT1720 inhibits the growth of bladder cancer in organoids and murine models through the SIRT1-HIF axis	ONCOGENE			English	Article							SIRTUIN 1; HYPOXIA; MECHANISMS; PROMOTER; CELLS	There are unmet clinical needs for novel therapeutic targets and drugs for bladder cancer. Majority of previous work relied on limited bladder cancer cell lines, which could not well represent the tumor heterogeneity and pathology of this disease. Recently, it has been shown that cancer organoids can recapitulate pathological and molecular properties of bladder cancer. Here, we report, by our knowledge, the first bladder cancer organoid-based small molecule screening for epigenetic drugs. We found that SRT1720, a Sirtuin 1 (SIRT1) activator, significantly inhibits the growth of both mouse and human bladder cancer organoids. And it also restrains the development of mouse in situ bladder cancer and human PDX bladder cancer. Mutation of Sirt1 promotes the growth of cancer organoids and decreases their sensitivity to SRT1720, which validate Sirt1 as the target of SRT1720 in bladder cancer. Mechanistically, SRT1720 treatment represses the hypoxia pathway through deacetylating HIF1 alpha by activating Sirt1. Genetic or pharmaceutic inhibitions of HIF mimic the anti-tumor effect of SRT1720. Furthermore, the SIRT1-repressed gene signature is associated with the hypoxia target gene signature and poor prognosis in human bladder cancers. Thus, our study demonstrates the power of cancer organoid-based drug discovery and, in principle, identifies SRT1720 as a new treatment for bladder cancer.	[Tan, Ping; Wang, Manli; Zhong, Ailing; Wang, Yiyun; Du, Jiajia; Wang, Jian; Qi, Lu; Bi, Zhanying; Zhang, Peng; Lin, Tianhai; Zhang, Jiapeng; Yang, Lu; Chen, Jingyao; Han, Ping; Gong, Qiyong; Liu, Yu; Chen, Chong; Wei, Qiang] Sichuan Univ, West China Hosp, Dept Urol, Inst Urol,Dept Thorac Oncol,State Key Lab Biother, Chengdu, Peoples R China; [Tan, Ping; Wang, Manli; Zhong, Ailing; Wang, Yiyun; Du, Jiajia; Wang, Jian; Qi, Lu; Bi, Zhanying; Zhang, Peng; Lin, Tianhai; Zhang, Jiapeng; Yang, Lu; Chen, Jingyao; Han, Ping; Gong, Qiyong; Liu, Yu; Chen, Chong; Wei, Qiang] Sichuan Univ, Canc Ctr, Huaxi MR Res Ctr HMRRC, Dept Radiol,West China Hosp, Chengdu, Peoples R China	Sichuan University; Sichuan University	Chen, C; Wei, Q (corresponding author), Sichuan Univ, West China Hosp, Dept Urol, Inst Urol,Dept Thorac Oncol,State Key Lab Biother, Chengdu, Peoples R China.; Chen, C; Wei, Q (corresponding author), Sichuan Univ, Canc Ctr, Huaxi MR Res Ctr HMRRC, Dept Radiol,West China Hosp, Chengdu, Peoples R China.	chongchen@scu.edu.cn; weiqiang@scu.edu.cn	Gong, Qiyong/W-3052-2019; Chen, Chong/AAR-4186-2021	Gong, Qiyong/0000-0002-5912-4871; Chen, Chong/0000-0002-6787-0495; Zhong, Ailing/0000-0002-8044-1222; TAN, PING/0000-0002-7445-3577	National Key R&D Program of China [2017YFA0505600]; National Natural Science Foundation of China [82002692]; 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University [ZYGD18011, ZY2016104]; Post-Doctor Research Project of Sichuan University [2021SCU12016]; Post-Doctor Research Project, West China Hospital, Sichuan University [19HXBH057]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University; Post-Doctor Research Project of Sichuan University; Post-Doctor Research Project, West China Hospital, Sichuan University	This work was supported by the National Key R&D Program of China (Grant No. 2017YFA0505600), National Natural Science Foundation of China (Grant No. 82002692), 1.3.5. Project for Disciplines of Excellence, West China Hospital, Sichuan University (Grant No. ZYGD18011 and ZY2016104), Post-Doctor Research Project of Sichuan University (Grant No. 2021SCU12016), and Post-Doctor Research Project, West China Hospital, Sichuan University (Grant No. 19HXBH057).	Berdik C, 2017, NATURE, V551, pS34, DOI 10.1038/551S34a; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Carafa V, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00038; Chen J, 2019, HUM CELL, V32, P193, DOI 10.1007/s13577-019-00237-5; Chen JY, 2021, CANCER GENE THER, V28, P112, DOI 10.1038/s41417-020-0190-y; Chen R, 2011, J BIOL CHEM, V286, P13869, DOI 10.1074/jbc.M110.175414; Chini CCS, 2016, CLIN CANCER RES, V22, P2496, DOI 10.1158/1078-0432.CCR-15-1760; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956; Drost J, 2017, DEVELOPMENT, V144, P968, DOI 10.1242/dev.140566; Dudziec E, 2011, CLIN CANCER RES, V17, P1287, DOI 10.1158/1078-0432.CCR-10-2017; Faleiro I, 2017, ONCOTARGET, V8, P12484, DOI 10.18632/oncotarget.14226; Farghali H, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8765954; Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697; Gillet JP, 2011, P NATL ACAD SCI USA, V108, P18708, DOI 10.1073/pnas.1111840108; Groselj B, 2013, RADIOTHER ONCOL, V108, P429, DOI 10.1016/j.radonc.2013.06.021; Hu QX, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3781904; Huch M, 2013, REGEN MED, V8, P385, DOI 10.2217/rme.13.39; Joo HY, 2015, BIOCHEM BIOPH RES CO, V462, P294, DOI 10.1016/j.bbrc.2015.04.119; Julien C, 2009, J NEUROPATH EXP NEUR, V68, P48, DOI 10.1097/NEN.0b013e3181922348; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Lahusen TJ, 2015, MOL CANCER THER, V14, P183, DOI 10.1158/1535-7163.MCT-14-0584; Lee James T, 2013, Genes Cancer, V4, P112, DOI 10.1177/1947601913484496; Lee SH, 2018, CELL, V173, P515, DOI 10.1016/j.cell.2018.03.017; Li HT, 2016, INT NEUROUROL J, V20, P84, DOI 10.5213/inj.1632752.376; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Loriot Y, 2019, NEW ENGL J MED, V381, P338, DOI 10.1056/NEJMoa1817323; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Mitchell SJ, 2014, CELL REP, V6, P836, DOI 10.1016/j.celrep.2014.01.031; Mullenders J, 2019, P NATL ACAD SCI USA, V116, P4567, DOI 10.1073/pnas.1803595116; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Shin DH, 2014, CANCER RES, V74, P298, DOI 10.1158/0008-5472.CAN-13-2620; Sussmuth SD, 2015, BRIT J CLIN PHARMACO, V79, P465, DOI 10.1111/bcp.12512; Sun J, 2018, CELL STEM CELL, V23, P355, DOI 10.1016/j.stem.2018.07.018; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; van der Meer AJ, 2015, CRIT CARE MED, V43, pE199, DOI 10.1097/CCM.0000000000000949; Vlachostergios PJ, 2018, NAT REV CLIN ONCOL, V15, P495, DOI 10.1038/s41571-018-0026-y; Wang Y, 2016, IMMUNITY, V44, P1337, DOI 10.1016/j.immuni.2016.05.009; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Willyard C, 2015, NATURE, V523, P520, DOI 10.1038/523520a; Wolff EM, 2005, NAT CLIN PRACT UROL, V2, P502, DOI 10.1038/ncpuro0318; Wu BH, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0040-2; Yang Z, 2017, CLIN CANCER RES, V23, P6673, DOI 10.1158/1078-0432.CCR-17-0882; Yates DR, 2007, CLIN CANCER RES, V13, P2046, DOI 10.1158/1078-0432.CCR-06-2476; Zeng L, 2009, GERIATR GERONTOL INT, V9, P7, DOI 10.1111/j.1447-0594.2008.00504.x; Zhao H, 2019, INT J ONCOL, V54, P893, DOI 10.3892/ijo.2019.4683	51	5	5	11	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6081	6092		10.1038/s41388-021-01999-9	http://dx.doi.org/10.1038/s41388-021-01999-9		SEP 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34471236				2022-12-17	WOS:000691942100002
J	Soshnikova, NV; Tatarskiy, EV; Tatarskiy, VV; Klimenko, NS; Shtil, AA; Nikiforov, MA; Georgieva, SG				Soshnikova, N. V.; Tatarskiy, E. V.; Tatarskiy, V. V.; Klimenko, N. S.; Shtil, A. A.; Nikiforov, M. A.; Georgieva, S. G.			PHF10 subunit of PBAF complex mediates transcriptional activation by MYC	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEXES; COACTIVATOR SAYP; SWI/SNF COMPLEX; C-MYC; PHD FINGER; MUTATIONS; INI1; IDENTIFICATION; HSNF5/INI1; PROTEINS	The PBAF complex, a member of SWI/SNF family of chromatin remodelers, plays an essential role in transcriptional regulation. We revealed a disease progression associated elevation of PHF10 subunit of PBAF in clinical melanoma samples. In melanoma cell lines, PHF10 interacts with MYC and facilitates the recruitment of PBAF complex to target gene promoters, therefore, augmenting MYC transcriptional activation of genes involved in the cell cycle progression. Depletion of either PHF10 or MYC induced G1 accumulation and a senescence-like phenotype. Our data identify PHF10 as a pro-oncogenic mechanism and an essential novel link between chromatin remodeling and MYC-dependent gene transcription.	[Soshnikova, N. V.; Tatarskiy, E. V.; Georgieva, S. G.] Russian Acad Sci, Inst Gene Biol, Dept Eukaryot Transcript Factors, Moscow, Russia; [Soshnikova, N. V.] Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia; [Tatarskiy, V. V.; Shtil, A. A.] Russian Acad Sci, Inst Gene Biol, Lab Mol Oncobiol, Moscow, Russia; [Klimenko, N. S.] Russian Acad Sci, Inst Gene Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia; [Nikiforov, M. A.] Wake Forest Univ, Dept Canc Biol, Winston Salem, NC 27101 USA; [Georgieva, S. G.] Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Transcript Factors, Moscow, Russia	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Wake Forest University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Soshnikova, NV; Georgieva, SG (corresponding author), Russian Acad Sci, Inst Gene Biol, Dept Eukaryot Transcript Factors, Moscow, Russia.; Soshnikova, NV (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Ctr Precis Genome Editing & Genet Technol Biomed, Moscow, Russia.; Georgieva, SG (corresponding author), Russian Acad Sci, Engelhardt Inst Mol Biol, Dept Transcript Factors, Moscow, Russia.	nsoshnikova@genebiology.ru; sofia.georgieva2021@gmail.com	Klimenko, Natalia/V-9017-2018	Klimenko, Natalia/0000-0001-9640-0102	Ministry of Science and Higher Education of the Russian Federation [075-15-2019-1661]	Ministry of Science and Higher Education of the Russian Federation	We thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine (Institute of Gene Biology) supported by Ministry of Science and Higher Education of the Russian Federation (075-15-2019-1661) for providing the equipment.	Alfert A, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0264-y; Anbunathan H, 2019, CLIN CANCER RES, V25, P5156, DOI 10.1158/1078-0432.CCR-18-3052; Bagnasco L, 2007, FASEB J, V21, P1256, DOI 10.1096/fj.06-7082com; Banga SS, 2009, CYTOGENET GENOME RES, V126, P227, DOI 10.1159/000251960; Biegel JA, 1999, CANCER RES, V59, P74; Brechalov AV, 2016, MOL BIOL+, V50, P278, DOI 10.1134/S0026893316010039; Brechalov AV, 2014, CELL CYCLE, V13, P1970, DOI 10.4161/cc.28922; Buscarlet M, 2014, BLOOD, V123, P1720, DOI 10.1182/blood-2013-02-483495; Centore RC, 2020, TRENDS GENET, V36, P936, DOI 10.1016/j.tig.2020.07.011; Chalkley GE, 2008, MOL CELL BIOL, V28, P2920, DOI 10.1128/MCB.02217-07; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Egorov AA, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2706-8; Garcia-Gutierrez L, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030244; Georgieva SG., 2020, TRANSFORMATION, V12, P115; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Ishizaka A, 2012, J BIOL CHEM, V287, P11924, DOI 10.1074/jbc.M111.322792; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Krasteva V, 2017, EXP HEMATOL, V48, P58, DOI 10.1016/j.exphem.2016.11.008; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Lu BJ, 2019, J CANCER, V10, P223, DOI 10.7150/jca.26978; Martin M, 2011, EMBNET J, V17, P1, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Mashtalir N, 2018, CELL, V175, P1272, DOI 10.1016/j.cell.2018.09.032; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; Middeljans E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033834; Mittal P, 2020, NAT REV CLIN ONCOL, V17, P435, DOI 10.1038/s41571-020-0357-3; Panov VV, 2012, NUCLEIC ACIDS RES, V40, P2445, DOI 10.1093/nar/gkr1165; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Poole CJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8050142; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Ribeiro-Silva C, 2019, DNA REPAIR, V77, P87, DOI 10.1016/j.dnarep.2019.03.007; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saladi SV, 2010, STEM CELL REV REP, V6, P62, DOI 10.1007/s12015-010-9120-y; Sammak S, 2018, FEBS J, V285, P4165, DOI 10.1111/febs.14660; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Shidlovskii YV, 2005, EMBO J, V24, P97, DOI 10.1038/sj.emboj.7600508; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Stojanova A, 2016, CELL CYCLE, V15, P1693, DOI 10.1080/15384101.2016.1146836; Trotter Kevin W, 2008, Nucl Recept Signal, V6, pe004, DOI 10.1621/nrs.06004; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Viryasova GM, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118525; Vorobyeva NE, 2012, NUCLEIC ACIDS RES, V40, P7319, DOI 10.1093/nar/gks472; Vorobyeva NE, 2009, P NATL ACAD SCI USA, V106, P11049, DOI 10.1073/pnas.0901801106; Zeng L, 2010, NATURE, V466, P258, DOI 10.1038/nature09139; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258	54	5	5	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2021	40	42					6071	6080		10.1038/s41388-021-01994-0	http://dx.doi.org/10.1038/s41388-021-01994-0		AUG 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK6OK	34465901	Green Accepted			2022-12-17	WOS:000691653200001
